PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hastak, K; Agarwal, MK; Mukhtar, H; Agarwal, ML				Hastak, K; Agarwal, MK; Mukhtar, H; Agarwal, ML			Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate	FASEB JOURNAL			English	Article						siRNA; G1 arrest; caspase activation; chemoprevention	CELL-CYCLE ARREST; GROWTH ARREST; P53; INHIBITOR; EXPRESSION; P21(WAF1); INDUCTION; KINASE; DEATH; BCL-2	Treatment with epigallocatechin-3-gallate (EGCG), a polyphenolic compound of green tea, results in activation of p53 and induction of apoptosis in prostate cancer LnCaP cells. However, no direct evidence has delineated the role of p53 and p53-dependent pathways in EGCG-mediated apoptosis. To understand the mechanism of negative growth regulation of prostate cancer cells by EGCG we undertook a genetic approach and generated an isogenic pair of prostate carcinoma cells PC3 (p53(-/-)) by stably introducing a cDNA encoding wild-type p53. Treatment of the resultant cells, PC3-p53, with EGCG led to, as reported earlier in LnCaP cells, an increase in p53 protein, which exacerbated both G1 arrest and apoptosis. This response was accompanied by an increase in the levels of p21 and Bax. The cells lacking p53 continued to cycle and did not undergo apoptosis upon treatment with similar concentrations of EGCG, thus establishing the action of EGCG in a p53-dependent manner. This observation was revalidated in another prostate cancer LNCaP cells harboring wild-type p53. Inactivation of p53 using small interfering RNA (siRNA) rendered these cells resistant to EGCG-mediated apoptosis. Because p53 activation led to increase in p21 and Bax, we investigated whether these two proteins are important in this process. Ablation of p21 protein by siRNA prevented G1 arrest and apoptosis in PC3-p53 cells. The p53-dependent increase in Bax expression altered the Bax/Bcl-2 ratio and paralleled the activation of caspase 9 and 3 and cleavage of PARP. Transfection of cells with Bax siRNA abolished these effects and inhibited apoptosis but did not affect the accumulation of the cells in G1. In summary, using isogenic cell lines and siRNA, we have clearly demonstrated that EGCG activates growth arrest and apoptosis primarily via p53-dependent pathway that involves the function of both p21 and Bax such that down-regulation of either molecule confers a growth advantage to the cells.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Cleveland Clin, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Dermatol, Madison, WI USA	Case Western Reserve University; Cleveland Clinic Foundation; University of Wisconsin System; University of Wisconsin Madison	Agarwal, ML (corresponding author), Case Western Reserve Univ, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.	munnaagarwal@hotmail.com			NATIONAL CANCER INSTITUTE [R01CA078809, R01CA098916] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA98916-02, R01 CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2003, J NUTR, V133, p2417S, DOI 10.1093/jn/133.7.2417S; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Chen TG, 2004, CANCER RES, V64, P7412, DOI 10.1158/0008-5472.CAN-04-2077; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Gartel AL, 2002, MOL CANCER THER, V1, P639; Grassilli E, 1999, CANCER RES, V59, P2451; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; HALDAR S, 1994, CANCER RES, V54, P2095; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kobayashi N, 2000, CYTOKINE, V12, P1745, DOI 10.1006/cyto.2000.0782; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; MIYASHITA T, 1995, CELL, V80, P293; Mukhtar H, 1999, TOXICOL SCI, V52, P111, DOI 10.1093/toxsci/52.2.111; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Shin BA, 2001, CELL GROWTH DIFFER, V12, P243; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Weisburger JH, 1999, P SOC EXP BIOL MED, V220, P271, DOI 10.1046/j.1525-1373.1999.d01-46.x; Wu Q, 2002, J BIOL CHEM, V277, P36329, DOI 10.1074/jbc.M204962200; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	37	123	127	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					789	+		10.1096/fj.04-2226fje	http://dx.doi.org/10.1096/fj.04-2226fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764647				2022-12-28	WOS:000227901300017
J	LeMaoult, J; Zafaranloo, K; Le Danff, C; Carosella, ED				LeMaoult, J; Zafaranloo, K; Le Danff, C; Carosella, ED			HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells	FASEB JOURNAL			English	Article						inhibitory receptors; immune cells; human leukocyte antigen	G MESSENGER-RNA; NATURAL-KILLER-CELLS; G EXPRESSION; CLASS-I; G MOLECULE; INHIBITORY RECEPTORS; PROLIFERATIVE RESPONSE; MYELOMONOCYTIC CELLS; HUMAN TROPHOBLASTS; DENDRITIC CELLS	The nonclassical HLA class I antigen HLA-G is an inhibitory molecule involved in immune tolerance and immune escape. HLA-G exerts its inhibitory functions via interaction with inhibitory receptors ILT2, ILT4, and KIR2DL4, differentially expressed by NK, T, and antigen-presenting cells. Cells expressing HLA-G and cells expressing its receptors are often found in the vicinity of each other, but the mechanisms responsible for this colocalization are still unknown. We report that ILT2, ILT3, ILT4, and KIR2DL4 expression is up-regulated by HLA-G in antigen-presenting cells, NK cells, and T cells. Because this up- regulation seems not to require antigenic costimulation, it might precede an immune response. Functionally, up- regulation of inhibitory receptors in immune cells before stimulation might increase their activation thresholds and participate in immune escape mechanisms.	Hop St Louis, Inst Univ Hematol, CEA DRM DSV, Serv Rech Hematoimmunol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite	Carosella, ED (corresponding author), Hop St Louis, Inst Univ Hematol, CEA DRM DSV, Serv Rech Hematoimmunol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	carosella@dsvidf.cea.fr	LeMaoult, Joel/E-9583-2011	LeMaoult, Joel/0000-0002-4513-9482				Allan DSJ, 1999, J EXP MED, V189, P1149, DOI 10.1084/jem.189.7.1149; Aractingi S, 2001, AM J PATHOL, V159, P71, DOI 10.1016/S0002-9440(10)61675-6; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Bukur J, 2003, CANCER RES, V63, P4107; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Colonna M, 1998, J IMMUNOL, V160, P3096; COLONNA M, 1997, J EXP MED, V186, P1803; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Costa P, 2001, AIDS, V15, P965, DOI 10.1097/00002030-200105250-00004; Creput C, 2003, J HEPATOL, V39, P587, DOI 10.1016/S0168-8278(03)00354-4; Crisa L, 1997, J EXP MED, V186, P289, DOI 10.1084/jem.186.2.289; ELLIS SA, 1986, IMMUNOLOGY, V59, P595; Fainardi E, 2003, J NEUROIMMUNOL, V142, P149, DOI 10.1016/S0165-5728(03)00266-2; FUJII T, 1994, J IMMUNOL, V153, P5516; Ibrahim EC, 2001, CANCER RES, V61, P6838; ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947; Khalil-Daher I, 1999, J REPROD IMMUNOL, V43, P175, DOI 10.1016/S0165-0378(99)00032-7; Khosrotehrani K, 2001, J INVEST DERMATOL, V117, P750, DOI 10.1046/j.0022-202x.2001.01487.x; KIRSZENBAUM M, 1994, P NATL ACAD SCI USA, V91, P4209, DOI 10.1073/pnas.91.10.4209; Le Discorde M, 2003, HUM IMMUNOL, V64, P1039, DOI 10.1016/j.humimm.2003.08.346; Le Gal FA, 1999, INT IMMUNOL, V11, P1351, DOI 10.1093/intimm/11.8.1351; Lefebvre S, 2002, J PATHOL, V196, P266, DOI 10.1002/path.1039; LeMaoult J, 2004, P NATL ACAD SCI USA, V101, P7064, DOI 10.1073/pnas.0401922101; Lila N, 2000, LANCET, V355, P2138, DOI 10.1016/S0140-6736(00)02386-2; Lila N, 2002, CIRCULATION, V105, P1949, DOI 10.1161/01.CIR.0000015075.89984.46; Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398; Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005; Manavalan JS, 2004, INT IMMUNOL, V16, P1055, DOI 10.1093/intimm/dxh107; Menier C, 2000, HUM IMMUNOL, V61, P1118, DOI 10.1016/S0198-8859(00)00194-4; MOREAU P, 1995, HUM IMMUNOL, V43, P231, DOI 10.1016/0198-8859(95)00009-S; Pangault C, 2002, HUM IMMUNOL, V63, P83, DOI 10.1016/S0198-8859(01)00373-1; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Paul P, 2000, HUM IMMUNOL, V61, P1138, DOI 10.1016/S0198-8859(00)00197-X; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; Riteau B, 2001, J IMMUNOL, V166, P5018, DOI 10.4049/jimmunol.166.8.5018; Riteau B, 1999, J REPROD IMMUNOL, V43, P203, DOI 10.1016/S0165-0378(99)00034-0; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P5249, DOI 10.1073/pnas.94.10.5249; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Urosevic M, 2001, AM J PATHOL, V159, P817, DOI 10.1016/S0002-9440(10)61756-7; UROSEVIC M, 2003, BLOOD; Vlad G, 2003, HUM IMMUNOL, V64, P483, DOI 10.1016/S0198-8859(03)00040-5; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2003, BRAIN, V126, P176, DOI 10.1093/brain/awg017; Wiendl H, 2002, J IMMUNOL, V168, P4772, DOI 10.4049/jimmunol.168.9.4772	45	225	242	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					662	+		10.1096/fj.04-1617fje	http://dx.doi.org/10.1096/fj.04-1617fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15670976				2022-12-28	WOS:000226576600010
J	Ndiaye, M; Chataigneau, M; Lobysheva, I; Chataigneau, T; Schini-Kerth, VB				Ndiaye, M; Chataigneau, M; Lobysheva, I; Chataigneau, T; Schini-Kerth, VB			Red wine polyphenols-induced, endothelium-dependent NO-mediated relaxation is due to the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of endothelial NO-synthase in the isolated porcine coronary artery	FASEB JOURNAL			English	Article						vasodilatation; endothelial cell; reactive oxygen species; nitric oxide	NITRIC-OXIDE SYNTHASE; INHIBIT PLATELET-FUNCTION; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; HYDROGEN-PEROXIDE; HYPERPOLARIZING FACTOR; FACTOR EXPRESSION; FRENCH PARADOX; NADPH OXIDASE; ACTIVATION	An enhanced endothelial formation of nitric oxide (NO) by red wine polyphenolic compounds (RWPs) has been involved in the protective effect of chronic intake of red wine on coronary diseases. However, the mechanism underlying the activation of endothelial NO synthase (eNOS) remains unclear. In the presence of indomethacin and charybdotoxin plus apamin to prevent the formation of prostanoids and endothelium-derived hyperpolarizing factor, respectively, RWPs caused pronounced endothelium-dependent relaxations in porcine coronary arteries. Relaxations to RWPs were abolished by N-omega-nitro-L-arginine (L-NA, a competitive inhibitor of NO synthase) and the membrane permeant analog of superoxide dismutase (SOD), MnTMPyP, and reduced by polyethylene glycol-SOD (PEG-SOD), PEG-catalase and inhibitors of PI3-kinase (wortmannin and LY294002). RWPs caused the L-NA-sensitive formation of NO, as assessed by electron spin resonance spectroscopy and the formation of cyclic guanosine monophosphate in coronary artery endothelial cells; these responses were reduced by MnTMPyP, PEG-catalase, and inhibitors of PI3-kinase. RWPs caused the sustained phosphorylation of Akt and eNOS at Ser1177 in endothelial cells, which were abolished by MnTMPyP and inhibitors of PI3-kinase. These data demonstrate that RWPs induce the redox-sensitive activation of the PI3-kinase/Akt pathway in endothelial cells which, in turn, causes phosphorylation of eNOS, resulting in an increased formation of NO.	Univ Louis Pasteur Strasbourg, Fac Pharm, CNRS, UMR 7034, 74 Route Rhin,BP 60024, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schini-Kerth, VB (corresponding author), Univ Louis Pasteur Strasbourg, Fac Pharm, CNRS, UMR 7034, 74 Route Rhin,BP 60024, F-67401 Illkirch Graffenstaden, France.	schini@aspirine.u-strasbg.fr						Andriambeloson E, 1997, BRIT J PHARMACOL, V120, P1053, DOI 10.1038/sj.bjp.0701011; Benito S, 2002, BRIT J PHARMACOL, V135, P910, DOI 10.1038/sj.bjp.0704534; BHARADWAJ L, 1995, MOL CELL BIOCHEM, V149, P267, DOI 10.1007/BF01076587; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; Brandes RP, 2001, THROMB HAEMOSTASIS, V85, P1104; Busse R, 2002, TRENDS PHARMACOL SCI, V23, P374, DOI 10.1016/S0165-6147(02)02050-3; Cai H, 2003, MOL PHARMACOL, V63, P325, DOI 10.1124/mol.63.2.325; Carluccio MA, 2003, ARTERIOSCL THROM VAS, V23, P622, DOI 10.1161/01.ATV.0000062884.69432.A0; CHANG WS, 1993, ANTICANCER RES, V13, P2165; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; David-Dufilho M, 2001, CLIN EXP PHARMACOL P, V28, P1015, DOI 10.1046/j.1440-1681.2001.03565.x; Diebolt M, 2001, HYPERTENSION, V38, P159, DOI 10.1161/01.HYP.38.2.159; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; Feng AN, 1999, CIRCULATION, V100, P2254, DOI 10.1161/01.CIR.100.22.2254; FITZPATRICK DF, 1993, AM J PHYSIOL, V265, pH774; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; FLESCH M, 1998, AM J PHYSIOL, V275, P1183; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; Freedman JE, 2001, CIRCULATION, V103, P2792, DOI 10.1161/01.CIR.103.23.2792; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gronbaek M, 2000, ANN INTERN MED, V133, P411, DOI 10.7326/0003-4819-133-6-200009190-00008; GRONBECK M, 1995, BRIT MED J, V310, P1169; Hashimoto M, 2001, AM J CARDIOL, V88, P1457, DOI 10.1016/S0002-9149(01)02137-3; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Iida Y, 2000, STROKE, V31, P2224, DOI 10.1161/01.STR.31.9.2224; Iijima K, 2000, CIRCULATION, V101, P805, DOI 10.1161/01.CIR.101.7.805; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Johnson DK, 2002, ENDOTHELIUM-J ENDOTH, V9, P191, DOI 10.1080/10623320213638; Kleschyov AL, 2002, METHOD ENZYMOL, V359, P42; Long LH, 2000, BIOCHEM BIOPH RES CO, V273, P50, DOI 10.1006/bbrc.2000.2895; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Matoba T, 2000, J CLIN INVEST, V106, P1521, DOI 10.1172/JCI10506; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miyagi Y, 1997, AM J CARDIOL, V80, P1627, DOI 10.1016/S0002-9149(97)00755-8; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; Ndiaye M, 2003, BIOCHEM BIOPH RES CO, V310, P371, DOI 10.1016/j.bbrc.2003.09.028; Oak MH, 2003, ARTERIOSCL THROM VAS, V23, P1001, DOI 10.1161/01.ATV.0000070101.70534.38; Orallo F, 2002, MOL PHARMACOL, V61, P294, DOI 10.1124/mol.61.2.294; Pendurthi UR, 1999, ARTERIOSCL THROM VAS, V19, P419, DOI 10.1161/01.ATV.19.2.419; Pignatelli P, 2000, AM J CLIN NUTR, V72, P1150; Renaud S, 1998, NOVART FDN SYMP, V216, P208; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; ROBAK J, 1988, BIOCHEM PHARMACOL, V37, P837, DOI 10.1016/0006-2952(88)90169-4; Roques SC, 2002, FREE RADICAL RES, V36, P593, DOI 10.1080/10715760290025979; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Ullrich V, 2000, BIOCHEM BIOPH RES CO, V278, P1, DOI 10.1006/bbrc.2000.3733; Vanin AF, 1999, METHOD ENZYMOL, V301, P269; Wang ZR, 2002, INT J MOL MED, V9, P77; Wollin SD, 2001, J NUTR, V131, P1401, DOI 10.1093/jn/131.5.1401; Wollny T, 1999, BRIT J PHARMACOL, V127, P747, DOI 10.1038/sj.bjp.0702586; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838; Ying CJ, 2003, HYPERTENS RES, V26, P823, DOI 10.1291/hypres.26.823; ZEMBOWICZ A, 1993, BRIT J PHARMACOL, V110, P151, DOI 10.1111/j.1476-5381.1993.tb13785.x	60	106	127	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15								10.1096/fj.04-2146fje	http://dx.doi.org/10.1096/fj.04-2146fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15623569				2022-12-28	WOS:000226091000006
J	Dhanasekaran, SM; Dash, A; Yu, JJ; Maine, IP; Laxman, B; Tomlins, SA; Creighton, CJ; Menon, A; Rubin, MA; Chinnaiyan, AM				Dhanasekaran, SM; Dash, A; Yu, JJ; Maine, IP; Laxman, B; Tomlins, SA; Creighton, CJ; Menon, A; Rubin, MA; Chinnaiyan, AM			Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty	FASEB JOURNAL			English	Article						BPH; microarray; androgen	IN-SITU HYBRIDIZATION; RAT VENTRAL PROSTATE; GROWTH-FACTOR-BETA; ANDROGEN RECEPTOR; CANCER CELLS; FINASTERIDE; HYPERPLASIA; MICROARRAY; STROMA; CARCINOGENESIS	Testosterone production surges during puberty and orchestrates massive growth and reorganization of the prostate gland, and this glandular architecture is maintained thereafter throughout adulthood. Benign prostatic hyperplasia (BPH) and prostate adenocarcinoma (PCA) are common diseases in adulthood that do not develop in the absence of androgens. Our objective was to gain insight into gene expression changes of the prostate gland at puberty, a crucial juncture in prostate development that is androgen dependent. Understanding the role played by androgens in normal prostate development may provide greater insight into androgen involvement in prostatic diseases. Benign prostate tissues obtained from pubertal and adult age group cadaveric organ donors were harvested and profiled using 20,000 element cDNA microarrays. Statistical analysis of the microarray data identified 375 genes that were differentially expressed in pubertal prostates relative to adult prostates including genes such as Nkx3.1, TMEPAI, TGFBR3, FASN, ANKH, TGFBR2, FAAH, S100P, HoxB13, fibronectin, and TSC2 among others. Comparisons of pubertal and BPH expression profiles revealed a subset of genes that shared the expression pattern between the two groups. In addition, we observed that several genes from this list were previously demonstrated to be regulated by androgen and hence could also be potential in vivo targets of androgen action in the pubertal human prostate. Promoter searches revealed the presence of androgen response elements in a cohort of genes including tumor necrosis factor-alpha induced adipose related protein, which was found to be induced by androgen. In summary, this is the first report that provides a comprehensive view of the molecular events that occur during puberty in the human prostate and provides a cohort of genes that could be potential in vivo targets of androgenic action during puberty.	Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Bioinformat Program, Ann Arbor, MI 48109 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Dept Pathol & Urol, Michigan Urol Ctr, MSI Rm 4237,1301 Catherine Rd, Ann Arbor, MI 48109 USA.	arul@umich.edu		Rubin, Mark/0000-0002-8321-9950; Tomlins, Scott/0000-0001-8661-9821; Dhanasekaran, saravana mohan/0000-0002-0489-2224	NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG022312] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA69568] Funding Source: Medline; NIA NIH HHS [U01 AG22312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aumuller G, 1998, ANAT EMBRYOL, V197, P199, DOI 10.1007/s004290050131; Aumuller G, 1990, Int Rev Cytol, V121, P127, DOI 10.1016/S0074-7696(08)60660-9; Averboukh L, 1996, PROSTATE, V29, P350; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bierhoff E, 1997, PROSTATE, V31, P234, DOI 10.1002/(SICI)1097-0045(19970601)31:4<234::AID-PROS4>3.0.CO;2-K; Bruskewitz R, 1999, UROLOGY, V54, P670, DOI 10.1016/S0090-4295(99)00209-5; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; DePrimo SE, 2002, GENOME BIOL, V3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DONJACOUR AA, 1988, DEV BIOL, V128, P1, DOI 10.1016/0012-1606(88)90260-6; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Farnsworth WE, 1999, PROSTATE, V38, P60; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gnanapragasam VJ, 2000, BJU INT, V86, P1001, DOI 10.1046/j.1464-410x.2000.00943.x; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; Hiort O, 2002, BEST PRACT RES CL EN, V16, P31, DOI 10.1053/beem.2002.0178; Holterhus PM, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-r37; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Luo J, 2003, PROSTATE, V57, P134, DOI 10.1002/pros.10284; Luo J, 2002, PROSTATE, V51, P189, DOI 10.1002/pros.10087; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Miller GJ, 2003, CANCER RES, V63, P5879; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nunes Fabio Daumas, 2003, Pesqui Odontol Bras, V17, P94; Onuma M, 2003, J BIOL CHEM, V278, P42660, DOI 10.1074/jbc.M304984200; PARTIN AWR, 2002, MOL BIOL ENDOCRINOLO; PEEHL DM, 1995, WORLD J UROL, V13, P306; Pfohler C, 1998, PROSTATE, V36, P143, DOI 10.1002/(SICI)1097-0045(19980801)36:3<143::AID-PROS1>3.0.CO;2-I; Podlasek CA, 1999, DEV BIOL, V209, P28, DOI 10.1006/dbio.1999.9229; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; Shapiro E, 1997, PROSTATE, V33, P177; Shen MM, 2003, DEV DYNAM, V228, P767, DOI 10.1002/dvdy.10397; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Warot X, 1997, DEVELOPMENT, V124, P4781; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399	48	76	88	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					243	+		10.1096/fj.04-2415fje	http://dx.doi.org/10.1096/fj.04-2415fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15548588	Green Published			2022-12-28	WOS:000225482100013
J	Granda, TG; Liu, XH; Smaaland, R; Cermakian, N; Filipski, E; Sassone-Corsi, P; Levi, F				Granda, TG; Liu, XH; Smaaland, R; Cermakian, N; Filipski, E; Sassone-Corsi, P; Levi, F			Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor	FASEB JOURNAL			English	Article						clock genes; mammary cancer; BCL-2; BAX	DNA-SYNTHESIS; CANCER-CELLS; CLOCK GENES; IN-VIVO; EXPRESSION; MICE; CHRONOTHERAPY; AGENTS; STAGE; P53	Proapoptotic drugs such as docetaxel displayed least toxicity and highest antitumor efficacy following dosing during the circadian rest phase in mice, suggesting that cell cycle and apoptotic processes could be regulated by the circadian clock. In study 1, mouse bone marrow and/or tumor were obtained every 4 h for 24 h in C3H/HeN mice with or without MA13/C mammary adenocarcinoma in order to determine the circadian patterns in cell-cycle phase distribution and BCL-2 anti-apoptotic protein expression. In study 2, mouse bone marrow from B6D2F(1) mice was sampled every 3 h for 24 h in order to confirm the BCL-2 rhythm and to study its relation with 24 h changes in the expression of proapoptotic BCL-2-associated X protein (BAX) protein and clock genes mPer2, mBmal1, mClock, and mTim mRNAs. The rhythms in G1-, S- or G2/M-phase cells were shifted in tumor compared with bone marrow. In the tumor, the mean proportion of G2/M-phase cells increased by 75% from late rest to late activity span ( P from cosinor = 0.001). No 24 h rhythm was found for BCL-2 in tumors. In contrast to this, in the bone marrow, mean BCL-2 expression varied 2.8-fold in B6D2F1 mice (P = 0.025) and 3- or 4.5-fold in tumor-bearing and nontumor-bearing C3H/HeN mice, with a peak during the early rest span (P = 0.024 and P < 0.001, respectively). BAX varied fivefold during the 24 h span with a major peak occurring near mid-activity (P = 0.007). The mean mRNAs of mPer2, mClock, and mBmal1 varied twofold to threefold over the 24 h, with high values during the activity span (P < 0.05). In the tumor, the circadian organization in cell-cycle phase distribution was shifted and BCL2 rhythm was ablated. Conversely, a molecular circadian clock likely regulated BCL-2 and BAX expression in the bone marrow, increasing cellular protection against apoptosis during the rest span.	Hop Paul Brousse, INSERM, E Chronotherapeut Canc 0354, F-94800 Villejuif, France; Univ Paris 11, Hop Paul Brousse, F-94800 Villejuif, France; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Haukeland Hosp, Dept Oncol & Med Phys, N-5021 Bergen, Norway	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Bergen; Haukeland University Hospital	Levi, F (corresponding author), Hop Paul Brousse, INSERM, E Chronotherapeut Canc 0354, 14 Ave PV Couturier, F-94800 Villejuif, France.	levi-f@vjf.inserm.fr	Smaaland, Rune/AAH-2149-2021	Granda, Teresa/0000-0002-7490-5932; Cermakian, Nicolas/0000-0003-4517-9131				Abrahamsen JF, 1997, EUR J HAEMATOL, V58, P333; Abrahamsen JF, 1998, EUR J HAEMATOL, V60, P7; Asainz R. M., 1999, FASEB J, V13, P1547; Backus HHJ, 2003, EUR J CANCER, V39, P1310, DOI 10.1016/S0959-8049(03)00204-1; Bjarnason G A, 2000, Prog Cell Cycle Res, V4, P193; Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canaple L, 2003, CANCER RES, V63, P7545; Cermakian N, 2000, NAT REV MOL CELL BIO, V1, P59, DOI 10.1038/35036078; Chen YG, 2000, BIOCHEM BIOPH RES CO, V276, P724, DOI 10.1006/bbrc.2000.3536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0; Ezzat A, 1997, ANN ONCOL, V8, P663, DOI 10.1023/A:1008228121390; Filipski E, 1999, J PHARMACOL EXP THER, V289, P231; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Granda TG, 2002, CHRONOBIOL INT, V19, P21, DOI 10.1081/CBI-120002589; Granda TG, 2001, CANCER RES, V61, P1996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1997, CANCER RES, V57, P229; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; KLEVECZ RR, 1987, CANCER RES, V47, P6267; Levi F, 1997, LANCET, V350, P681, DOI 10.1016/S0140-6736(97)03358-8; Levi F, 2001, LANCET ONCOL, V2, P307, DOI 10.1016/S1470-2045(00)00326-0; Li XM, 2000, AM J PHYSIOL-REG I, V278, pR924, DOI 10.1152/ajpregu.2000.278.4.R924; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Maestroni GJM, 1998, ANN NY ACAD SCI, V840, P411, DOI 10.1111/j.1749-6632.1998.tb09579.x; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; Mormont MC, 2003, CANCER-AM CANCER SOC, V97, P155, DOI 10.1002/cncr.11040; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Ohdo S, 1997, J PHARMACOL EXP THER, V283, P1383; Oishi K, 1998, BIOCHEM BIOPH RES CO, V253, P199, DOI 10.1006/bbrc.1998.9779; OLTVAI ZN, 1993, CELL, V74, P619; Osaki M, 1997, APOPTOSIS, V2, P221, DOI 10.1023/A:1026476801463; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; SCHEVING LE, 1984, CELL CYCLE CLOCKS, P455; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; SMAALAND R, 1993, CANCER RES, V53, P3129; SMAALAND R, 1992, BLOOD, V79, P2281; SMAALAND R, 1991, JNCI-J NATL CANCER I, V83, P1092, DOI 10.1093/jnci/83.15.1092; Tampellini M, 1998, CANCER RES, V58, P3896; Vijayalaxmi, 2002, J CLIN ONCOL, V20, P2575, DOI 10.1200/JCO.2002.11.004; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; Workman P, 1998, BRIT J CANCER, V77, P1; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; ZHANG RW, 1993, CANCER RES, V53, P2816	49	118	122	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					304	+		10.1096/fj.04-2665fje	http://dx.doi.org/10.1096/fj.04-2665fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545298				2022-12-28	WOS:000225482100018
J	Ji, LL; Gomez-Cabrera, MC; Steinhafel, N; Vina, J				Ji, LL; Gomez-Cabrera, MC; Steinhafel, N; Vina, J			Acute exercise activates nuclear factor (NF)-kappa B signaling pathway in rat skeletal muscle	FASEB JOURNAL			English	Article						ROS; nuclear protein kappa B; redox signaling	NF-KAPPA-B; DISMUTASE GENE-EXPRESSION; FREE-RADICAL GENERATION; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; PROTEIN-KINASE; TRANSCRIPTION FACTOR; REDOX REGULATION; ANTIOXIDANT; DAMAGE	Two studies were performed to investigate the effects of an acute bout of physical exercise on the nuclear protein kappaB (NF-kappaB) signaling pathway in rat skeletal muscle. In Study 1, a group of rats (n = 6) was run on the treadmill at 25 m/min, 5% grade, for 1 h or until exhaustion ( Ex), and compared with a second group ( n = 6) injected with two doses of pyrrolidine dithiocarbamate ( PDTC, 100 mg/kg, i.p.) 24 and 1 h prior to the acute exercise bout. Three additional groups of rats ( n = 6) were injected with either 8 mg/kg (i.p.) of lipopolysaccharide (LPS), 1 mmol/kg (i.p.) t-butylhydroperoxide (tBHP), or saline ( C) and killed at resting condition. Ex rats showed higher levels of NF-kappaB binding and P50 protein content in muscle nuclear extracts compared with C rats. Cytosolic IkappaBalpha and IkappaB kinase (IKK) contents were decreased, whereas phospho-IkappaBalpha and phospho-IKK contents were increased, comparing Ex vs. C. The exercise-induced activation of NF-kappaB signaling cascade was partially abolished by PDTC treatment. LPS, but not tBHP, treatment mimicked and exaggerated the effects observed in Ex rats. In Study 2, the time course of exercise-induced NF-kappaB activation was examined. Highest levels of NF-kappaB binding were observed at 2 h postexercise. Decreased cytosolic IkappaBalpha and increased phosphor-IkappaBalpha content were found 0 - 1 h postexercise whereas P65 reached peak levels at 2 - 4 h. These data suggest that the NF-kappaB signaling pathway can be activated in a redox-sensitive manner during muscular contraction, presumably due to increased oxidant production. The cascade of intracellular events may be the overture to elevated gene expression of manganese superoxide dismutase reported earlier Pfluegers Arch. 442, 426 - 434, 2001).	Univ Wisconsin, Biodynam Lab, Dept Kinesiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Univ Valencia, Sch Med, Valencia, Spain	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Valencia	Ji, LL (corresponding author), Univ Wisconsin, Biodynam Lab, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA.	ji@education.wisc.edu	Gomez-Cabrera, Maria Carmen/H-6911-2018; Gomez-Cabrera, Mari Carmen/O-3109-2019; Vina, Jose/AAB-3069-2021	Gomez-Cabrera, Maria Carmen/0000-0003-4000-1684; Gomez-Cabrera, Mari Carmen/0000-0003-4000-1684; Vina, Jose/0000-0001-9709-0089				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bejma J, 2000, ACTA PHYSIOL SCAND, V169, P343; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; BROOKS GA, 1978, J APPL PHYSIOL, V45, P1009, DOI 10.1152/jappl.1978.45.6.1009; Cannon JG, 1998, MOL CELL BIOCHEM, V179, P159, DOI 10.1023/A:1006828425418; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIGUCHI M, 1985, J GERONTOL, V40, P281, DOI 10.1093/geronj/40.3.281; Hollander J, 1999, AM J PHYSIOL-REG I, V277, pR856, DOI 10.1152/ajpregu.1999.277.3.R856; Hollander J, 2001, PFLUG ARCH EUR J PHY, V442, P426, DOI 10.1007/s004240100539; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JACKSON MJ, 1985, BIOCHIM BIOPHYS ACTA, V847, P185, DOI 10.1016/0167-4889(85)90019-9; Ji LL, 2002, ANN NY ACAD SCI, V959, P82, DOI 10.1111/j.1749-6632.2002.tb02085.x; Ji LL, 1999, P SOC EXP BIOL MED, V222, P283, DOI 10.1046/j.1525-1373.1999.d01-145.x; KAWAI M, 1995, J IMMUNOL, V154, P2333; LAUGHLIN MH, 1990, J APPL PHYSIOL, V68, P2337, DOI 10.1152/jappl.1990.68.6.2337; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Pedersen BK, 1998, CAN J PHYSIOL PHARM, V76, P505, DOI 10.1139/cjpp-76-5-505; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; Powers S. K., 1994, AM J PHYSIOL, V266, P375; Ramires P. R., 2000, Medicine and Science in Sports and Exercise, V32, pS106; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SEN CK, 1995, J APPL PHYSIOL, V79, P675, DOI 10.1152/jappl.1995.79.3.675; Smith JA, 1996, AM J PHYSIOL-REG I, V270, pR838, DOI 10.1152/ajpregu.1996.270.4.R838; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000	41	216	233	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1499	1506		10.1096/fj.04-1846com	http://dx.doi.org/10.1096/fj.04-1846com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466358				2022-12-28	WOS:000224849900033
J	Le Floch, N; Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Dale, T; Gespach, C				Le Floch, N; Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Dale, T; Gespach, C			The proinvasive activity of Wnt-2 is mediated through a noncanonical Wnt pathway coupled to GSK-3 beta and c-Jun/AP-1 signaling	FASEB JOURNAL			English	Article						axin; Dvl-2; sFRP-3; trefoil peptides; HGF; Rho GTPases; Rho-kinase; PI3-kinase; GSK-3 beta silencing RNAs; matrilysin	EPIDERMAL-GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; CARCINOMA-ASSOCIATED ANTIGEN; PROMOTES CELLULAR INVASION; MAMMARY EPITHELIAL-CELLS; F9 TERATOCARCINOMA CELLS; G-ALPHA-O; BETA-CATENIN; FACTOR-RECEPTOR; TYROSINE PHOSPHORYLATION	Inappropriate activation of the Wnt/APC/beta-catenin signaling pathways plays a critical role at early stages in a variety of human cancers. However, their respective implication in tumor cell invasion is still hypothetical. Here, we show that two activators of the canonical Wnt/beta-catenin transcription pathway, namely Dvl-2, the Axin 501-560 fragment binding glycogen synthase kinase -3beta (GSK-3beta), and the negative Wnt regulator wt-Axin did not alter cell invasion into type I collagen. In addition, both Dvl-2 and Axin 501-560 exerted a permissive action on the proinvasive activity of HGF and intestinal trefoil factor. Upstream activation of Wnt signaling by the Wnt-2 and Wnt-3a ligands, stable overexpression of Wnt-2, as well as GSK-3beta inhibition by lithium, SB216763, and GSK-3beta dominant negative forms (K85R and R96E) conferred the invasive phenotype through several proinvasive pathways. Induction of the matrix metalloprotease MMP-7 (matrilysin) gene and protein by Wnt-2 was abolished by inactivation of the AP-1 binding site in the promoter. Accordingly, invasion induced by Wnt-2 was prevented by soluble FRP-3 and FRP-1, sequestration of Gbetagamma subunits, depletion of the GSK-3beta protein by RNA interference, the c-Jun dominant negative mutant TAM67 and was not reversed by wt-Axin. Thus, the proinvasive activity of Wnt-2 is mediated by a noncanonical Wnt pathway using GSK-3beta and the AP-1 oncogene. Our data provide a potential clue for our understanding of the action and crosstalk between Wnt activators and other proinvasive pathways, in relation with matrix substrates and proteases in human cancers.	Hop St Antoine, INSERM, U Signal Transduct & Cellular Funct Diab & Digest, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Cardiff University	Gespach, C (corresponding author), Hop St Antoine, INSERM, U Signal Transduct & Cellular Funct Diab & Digest, 184 Rue Faubourt St Antoine, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	de wever, olivier/J-3094-2013; Dale, Trevor C/D-3749-2009; LE FLOCH, Nathalie/I-3415-2015	de wever, olivier/0000-0002-5453-760X; Dale, Trevor C/0000-0002-4880-9963; LE FLOCH, Nathalie/0000-0002-6411-7975				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; BARBIER M, 2000, NATURE, V406, P897; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dahmen RP, 2001, CANCER RES, V61, P7039; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DEGROOT RP, 1993, ONCOGENE, V8, P841; DEWEVER O, 2004, IN PRESS FASEB J; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; EMAMI S, 2004, IN PRESS PEPTIDES; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hao L, 2004, CIRC RES, V94, P68, DOI 10.1161/01.RES.0000109413.57726.91; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Howe LR, 1999, CANCER RES, V59, P1572; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu D, 1997, LAB INVEST, V77, P557; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Monga SPS, 2002, CANCER RES, V62, P2064; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Nagahata T, 2003, CANCER SCI, V94, P515, DOI 10.1111/j.1349-7006.2003.tb01475.x; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Polakis P, 2000, GENE DEV, V14, P1837; Regnauld K, 2002, ONCOGENE, V21, P4020, DOI 10.1038/sj.onc.1205498; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vider BZ, 1996, ONCOGENE, V12, P153; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	79	62	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					144	+		10.1096/fj.04-2373fje	http://dx.doi.org/10.1096/fj.04-2373fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15507471				2022-12-28	WOS:000224849900006
J	Madeddu, P; Emanueli, C; Pelosi, E; Salis, MB; Cerio, AM; Bonanno, G; Patti, M; Stassi, G; Condorelli, G; Peschle, C				Madeddu, P; Emanueli, C; Pelosi, E; Salis, MB; Cerio, AM; Bonanno, G; Patti, M; Stassi, G; Condorelli, G; Peschle, C			Transplantation of low dose CD34(+)Kdr(+) cells promotes vascular and muscular regeneration in ischemic limbs	FASEB JOURNAL			English	Article						endothelial progenitor cells; angiogenesis; vasculogenesis; ischemia; apoptosis; vascular endothelial growth factor	ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW CELLS; INFARCTED MYOCARDIUM; PRECURSOR CELLS; GENE-TRANSFER; NEOVASCULARIZATION; ANGIOGENESIS; CARDIOMYOCYTES; VASCULOGENESIS; REQUIREMENT	Hematopoietic progenitor cell transplantation can contribute to revascularization of ischemic tissues. Yet, the optimal cell population to be transplanted has yet to be determined. We have compared the therapeutic potential of two subsets of human cord blood CD34(+) progenitors, either expressing the VEGF-A receptor 2 (KDR) or not. In serum-free starvation culture, CD34(+)KDR(+) cells reportedly showed greater resistance to apoptosis and ability to release VEGF-A, as compared with CD34(+)KDR(-) cells. When injected into the hind muscles in immunodeficient SCIDbg mice subjected to unilateral ischemia, a low number ( 103) of CD34(+)KDR(+) cells improved limb salvage and hemodynamic recovery better than a larger dosage (10(4)) of CD34(+) KDR- cells. The neovascularization induced by KDR+ cells was significantly superior to that promoted by KDR- cells. Similarly, endothelial cell apoptosis and interstitial fibrosis were significantly attenuated by KDR+ cells, which differentiated into mature human endothelial cells and also apparently skeletal muscle cells. This study demonstrates that a low number of CD34(+)KDR(+) cells favors reparative neovascularization and possibly myogenesis in limb ischemia, suggesting the potential use of this cell population in regenerative medicine.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; INBB, Expt Med & Gene Therapy, Osilo and Alghero, Italy; Univ Sassari, Dept Internal Med, I-07100 Sassari, Italy; INBB, Mol & Cellular Med Lab, Alghero and Pula, Italy; Catholic Univ, Dept Obstet & Gynecol, Rome, Italy; Univ Palermo, Dept Surg & Oncol Sci, I-90133 Palermo, Italy; Mol Cardiol Lab, Rome, Italy	Jefferson University; University of Sassari; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Palermo	Madeddu, P (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Room 609,233 S 10th St, Philadelphia, PA 19107 USA.	madeddu@yahoo.com	Stassi, Giorgio/AAC-1175-2022; pelosi, elvira/J-7298-2016; Condorelli, Gerolama/AAC-3472-2022; Condorelli, Gianluigi/Q-6736-2017	pelosi, elvira/0000-0002-3043-6249; Condorelli, Gerolama/0000-0003-0177-8829; Condorelli, Gianluigi/0000-0003-0481-6843; Emanueli, Costanza/0000-0002-2392-0702	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063168] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL63168] Funding Source: Medline; Telethon [GP0300Y01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; BOTTA R, 2004, FASEB J         0701; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Emanueli C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8; Emanueli C, 2001, CIRCULATION, V103, P125; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gill M, 2001, CIRC RES, V88, P167; Grewal SS, 2004, BLOOD, V103, P1147, DOI 10.1182/blood-2003-02-0587; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Murohara T, 2001, TRENDS CARDIOVAS MED, V11, P303, DOI 10.1016/S1050-1738(01)00128-1; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pelosi E, 2002, BLOOD, V100, P3203, DOI 10.1182/blood-2002-05-1511; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	31	107	109	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1737	+		10.1096/fj.04-2192fje	http://dx.doi.org/10.1096/fj.04-2192fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345695				2022-12-28	WOS:000224243200048
J	Hwang, YYC; Kaneko, M; Bakr, S; Liao, H; Lu, Y; Lewis, ER; Yan, SD; Ii, S; Itakura, M; Rui, L; Skopicki, H; Homma, S; Schmidt, AM; Oates, PJ; Szabolcs, M; Ramasamy, R				Hwang, YYC; Kaneko, M; Bakr, S; Liao, H; Lu, Y; Lewis, ER; Yan, SD; Ii, S; Itakura, M; Rui, L; Skopicki, H; Homma, S; Schmidt, AM; Oates, PJ; Szabolcs, M; Ramasamy, R			Central role for aldose reductase pathway in myocardial ischemic injury	FASEB JOURNAL			English	Article						cytosolic redox state; glucose metabolism; ischemia-reperfusion injury	DIABETIC COMPLICATIONS; RAT HEARTS; REPERFUSION INJURY; GLUCOSE; INHIBITION; METABOLISM; PATHOGENESIS; SORBITOL; ACTIVATION; PROTECTS	Aldose reductase (AR), a member of the aldo-keto reductase family, has been implicated in the development of vascular and neurological complications of diabetes. Recently, we demonstrated that aldose reductase is a component of myocardial ischemic injury and that inhibitors of this enzyme protect rat hearts from ischemia-reperfusion injury. To rigorously test the effect of aldose reductase on myocardial ischemia-reperfusion injury, we used transgenic mice broadly overexpressing human aldose reductase (ARTg) driven by the major histocompatibility complex I promoter. Hearts from these ARTg or littermate mice (WT) ( n = 6 in each group) were isolated, perfused under normoxic conditions, then subjected to 50 min of severe low flow ischemia followed by 60 min of reperfusion. Creatine kinase (CK) release ( a marker of ischemic injury) was measured during reperfusion; left ventricular developed pressure (LVDP), end diastolic pressure (EDP), and ATP were measured throughout the protocol. CK release was significantly greater in ARTg mice compared with the WT mice. LVDP recovery was significantly reduced in ARTg mice compared with the WT mice. Furthermore, ATP content was higher in WT mice compared with ARTg mice during ischemia and reperfusion. Infarct size measured by staining techniques and myocardial damage evaluated histologically were also significantly worse in ARTg mice hearts than in controls. Pharmacological inhibition of aldose reductase significantly reduced ischemic injury and improved functional recovery in ARTg mice. These data strongly support key roles for AR in ischemic injury and impairment of functional and metabolic recovery after ischemia. We propose that interventions targeting AR may provide a novel adjunctive approach to protect ischemic myocardium.	Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci P&S 17 410, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Univ Tokushima, Tokushima, Japan; Pfizer Global Res & Dev, Groton, CT USA	Columbia University; Columbia University; Columbia University; Tokushima University; Pfizer	Ramasamy, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci P&S 17 410, 630 W 168th St, New York, NY 10032 USA.	rr260@columbia.edu	Skopicki, Hal/AAJ-9827-2021	Ramasamy, Ravichandran/0000-0002-3666-3346	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061783, R01HL068954] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL 61783, R01HL68954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano S, 2002, BIOCHEM BIOPH RES CO, V299, P183, DOI 10.1016/S0006-291X(02)02584-6; BERGMEYER HU, 1995, CARBOHYDRATES, V6, P570; Bhatnagar A, 1999, ADV EXP MED BIOL, V463, P223; BRODERICK TL, 1993, CIRCULATION, V87, P972, DOI 10.1161/01.CIR.87.3.972; Busik JV, 1997, J CLIN INVEST, V100, P1685, DOI 10.1172/JCI119693; Chung SSM, 2003, J AM SOC NEPHROL, V14, pS233, DOI 10.1097/01.ASN.0000077408.15865.06; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GREENE DA, 1993, DIABETES METAB REV, V9, P189, DOI 10.1002/dmr.5610090304; GREENE DA, 1987, NEW ENGL J MED, V316, P599; GREENE DA, 1985, DIABETES CARE, V8, P290, DOI 10.2337/diacare.8.3.290; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; Hwang YYC, 2003, FASEB J, V17, P2331, DOI 10.1096/fj.03-0128fje; KADOR PF, 1985, AM J MED, V79, P8, DOI 10.1016/0002-9343(85)90504-2; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; Keogh RJ, 1997, METABOLISM, V46, P41, DOI 10.1016/S0026-0495(97)90165-7; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; NISHIMURA C, 1990, J BIOL CHEM, V265, P9788; Obrosova IG, 2001, FASEB J, V15, P123, DOI 10.1096/fj.01-0603fje; Park JW, 1998, INT J CARDIOL, V65, P139, DOI 10.1016/S0167-5273(98)00117-X; Ramasamy R, 2001, AM J PHYSIOL-HEART C, V281, pH290, DOI 10.1152/ajpheart.2001.281.1.H290; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Ramasamy R, 1999, CARDIOVASC RES, V42, P130, DOI 10.1016/S0008-6363(98)00303-4; Ramasamy R, 1998, AM J PHYSIOL-HEART C, V275, pH195, DOI 10.1152/ajpheart.1998.275.1.H195; Schaefer S, 1997, CARDIOVASC RES, V35, P90, DOI 10.1016/S0008-6363(97)00087-4; Siegel TW, 2000, ANAL BIOCHEM, V280, P329, DOI 10.1006/abio.2000.4531; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; SRIVASTAVA SK, 1986, METABOLISM, V35, P114, DOI 10.1016/0026-0495(86)90199-X; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Taegtmeyer H, 1998, AM J CARDIOL, V82, p54K, DOI 10.1016/S0002-9149(98)00538-4; Takuma S, 2001, AM J PHYSIOL-HEART C, V280, pH2364, DOI 10.1152/ajpheart.2001.280.5.H2364; Tanimoto T, 1998, ANAL CHIM ACTA, V365, P285, DOI 10.1016/S0003-2670(97)00649-1; Tracey WR, 2000, AM J PHYSIOL-HEART C, V279, pH1447, DOI 10.1152/ajpheart.2000.279.4.H1447; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; Trueblood NA, 2000, AM J PHYSIOL-HEART C, V279, pH764, DOI 10.1152/ajpheart.2000.279.2.H764; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; YAMAOKA T, 1995, DIABETOLOGIA, V38, P255, DOI 10.1007/s001250050278	39	107	114	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1192	1199		10.1096/fj.03-1400com	http://dx.doi.org/10.1096/fj.03-1400com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15284219				2022-12-28	WOS:000223554900034
J	Delgado, M; Gonzalez-Rey, E; Ganea, D				Delgado, M; Gonzalez-Rey, E; Ganea, D			VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells	FASEB JOURNAL			English	Article						neuroimmunology; Th1/Th2 cells; cell migration; CXCL10; CCL22	VASOACTIVE-INTESTINAL-PEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; GAMMA-INDUCIBLE PROTEIN-10; T-CELLS; MULTIPLE-SCLEROSIS; INTERFERON-GAMMA; IN-VITRO; EXPRESSION; VIP; RECEPTOR	The neuropeptides vasoactive intestinal peptide ( VIP) and the structurally related pituitary adenylate cyclase-activating polypeptide ( PACAP) are potent immunomodulatory agents, acting as general anti-inflammatory factors. VIP, produced and secreted by Th2 cells following antigen stimulation, participates in a Th2 autoregulatory loop, promoting Th2-type responses through several nonexcluding mechanisms. VIP and PACAP affect the differentiation of CD4(+) T cells directly and indirectly through antigen-presenting cells and promote the proliferation and/or survival of the Th2 effectors. Th1 and Th2 effectors express different chemokine receptors that control migration in response to various chemokines. In this study, we investigated the effects of VIP/PACAP on the production of CXCL10 ( a Th1 chemokine) and of CCL22 ( a Th2 chemokine) by bone marrow-derived dendritic cells. We found that VIP and PACAP inhibit CXCL10, while promoting CCL22 production, and that the effects are mediated through the VPAC1 receptor and involve cAMP/PKA as intracellular messengers. The induction of CCL22 and the suppression of CXCL10 in VIP/PACAP-treated dendritic cells results in the preferential chemoattraction of Th2 effectors both in vivo and in vitro. This is in agreement with the general Th2 bias induced by the two neuropeptides and adds an important parameter to their immunomodulatory function. By promoting Th2 migration, and preventing or reducing Th1 infiltration in inflammatory foci and sites of antigen presentation, VIP and PACAP help in resolving acute inflammatory processes and contribute to the prevention of chronic inflammation.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Rutgers State University Newark; Rutgers State University New Brunswick; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	dganea@andromeda.rutgers.edu	Delgado, Mario/P-1524-2016; GONZALEZ-REY, ELENA/L-3296-2014	Delgado, Mario/0000-0003-1893-5982; GONZALEZ-REY, ELENA/0000-0003-3917-9020	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041786, R21AI041786, R01AI052306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52306-01, AI 041786-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrew DP, 1998, J IMMUNOL, V161, P5027; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bonecchi R, 1998, BLOOD, V92, P2668, DOI 10.1182/blood.V92.8.2668.420k39_2668_2671; Boorsma DM, 1999, CYTOKINE, V11, P469, DOI 10.1006/cyto.1998.0463; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 2004, J LEUKOCYTE BIOL, V75, P1122, DOI 10.1189/jlb.1203626; Delgado M, 2003, J BIOL CHEM, V278, P27620, DOI 10.1074/jbc.M303199200; Delgado M, 2002, FASEB J, V16, P1844, DOI 10.1096/fj.02-0248fje; Delgado M, 1999, J IMMUNOL, V162, P1200; Delgado M, 2001, J IMMUNOL, V166, P2907, DOI 10.4049/jimmunol.166.5.2907; Delgado M, 2003, TRENDS IMMUNOL, V24, P221, DOI 10.1016/S1471-4906(03)00069-3; Delgado M, 1999, J IMMUNOL, V163, P3629; DELGADO M, 2004, IN PRESS PHARM REV; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Ganea D, 2003, CELL MOL BIOL, V49, P127; Ganea D, 2003, CURR PHARM DESIGN, V9, P997, DOI 10.2174/1381612033455116; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Jiang XJ, 2002, J NEUROIMMUNOL, V133, P81, DOI 10.1016/S0165-5728(02)00365-X; Kuroda E, 2001, J IMMUNOL, V166, P1650, DOI 10.4049/jimmunol.166.3.1650; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Martinez C, 1999, J NEUROIMMUNOL, V93, P126, DOI 10.1016/S0165-5728(98)00216-1; Melter M, 2001, CIRCULATION, V104, P2558, DOI 10.1161/hc4601.098010; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Patel DD, 2001, CLIN IMMUNOL, V98, P39, DOI 10.1006/clim.2000.4957; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Singh UP, 2003, J IMMUNOL, V171, P1401, DOI 10.4049/jimmunol.171.3.1401; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Sozzani S, 1999, J LEUKOCYTE BIOL, V66, P1, DOI 10.1002/jlb.66.1.1; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; VANGURI P, 1990, J BIOL CHEM, V265, P15049; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; Vulcano M, 2001, EUR J IMMUNOL, V31, P812, DOI 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Yoneyama H, 2000, SPRINGER SEMIN IMMUN, V22, P329, DOI 10.1007/s002810000050; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	58	81	90	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1453	+		10.1096/fj.04-1548fje	http://dx.doi.org/10.1096/fj.04-1548fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231725				2022-12-28	WOS:000222979200021
J	Kim, HP; Wang, X; Galbiati, F; Ryter, SW; Choi, AMK				Kim, HP; Wang, X; Galbiati, F; Ryter, SW; Choi, AMK			Caveolae compartmentalization of heme oxygenase-1 in endothelial cells	FASEB JOURNAL			English	Article						HO-1; biliverdin reductase; HO activity	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; CARBON-MONOXIDE; BILIVERDIN REDUCTASE; SKELETAL-MUSCLE; EXPRESSION; RECEPTOR; STRESS; ALPHA; PALMITOYLATION	The heme oxygenase (HO) and nitric oxide synthase ( NOS) enzymes generate the gaseous signaling molecules carbon monoxide ( CO) and nitric oxide, respectively. Constitutive NOSs localize to caveolae, and their activities are modulated by caveolin-1. Nothing is known of the localization of the inducible heme oxygenase-1 (HO-1) in plasma membrane caveolae. Thus, we examined the distribution and subcellular localization of HO-1, biliverdin reductase (BVR), and NADPH: cytochrome P450 reductase (NPR) in pulmonary artery endothelial cells. Each of these proteins localized in part to plasma membrane caveolae in endothelial cells. Inducers of HO-1 or overexpression of HO-1 increased the content of this protein in a detergent-resistant fraction containing caveolin-1. Inducible HO activity appeared in plasma membrane, cytosol, and isolated caveolae. In addition, caveolae contained endogenous BVR activity, supporting the same compartmentalization of both enzymes. Caveolin-1 physically interacted with HO-1, as shown by coimmunoprecipitation studies. HO activity dramatically increased in cells expressing caveolin-1 antisense transcripts, suggesting a negative regulatory role for caveolin-1. Conversely, caveolin-1 expression attenuated LPS-inducible HO activity. Since their initial characterization in 1969, HO enzymes have been described as endoplasmic reticulum-associated proteins. We demonstrate for the first time the localization of heme degradation enzymes to plasma membrane caveolae, and present novel evidence that caveolin-1 interacts with and modulates HO activity.	Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, AMK (corresponding author), Dept Med, Div Pulm Allergy & Crit Care Med, MUH 628NW,3459 5th Ave, Pittsburgh, PA 15213 USA.	Choiam@msx.upmc.edu	Galbiati, Ferruccio/AAF-3527-2020		NHLBI NIH HHS [R01-HL60234, R01-HL55330] Funding Source: Medline; NIAID NIH HHS [R01-AI42365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234, R01HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Baranano DE, 2000, J BIOL CHEM, V275, P15166, DOI 10.1074/jbc.275.20.15166; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Baum O, 2000, ACTA HISTOCHEM, V102, P281, DOI 10.1078/S0065-1281(04)70036-7; Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209, DOI 10.1152/ajplung.2001.281.1.L209; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Goligorsky MS, 2002, AM J PHYSIOL-RENAL, V283, pF1, DOI 10.1152/ajprenal.00377.2001; Hartsfield C, 1999, AM J PHYSIOL-LUNG C, V277, pL1133, DOI 10.1152/ajplung.1999.277.6.L1133; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Ko YG, 1999, J IMMUNOL, V162, P7217; Kyokane T, 2001, GASTROENTEROLOGY, V120, P1227, DOI 10.1053/gast.2001.23249; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lei MG, 2000, INFECT IMMUN, V68, P5084, DOI 10.1128/IAI.68.9.5084-5089.2000; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Maines MD, 2001, ADV EXP MED BIOL, V502, P249; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Osada M, 2002, J BIOL CHEM, V277, P23367, DOI 10.1074/jbc.M112413200; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; Parfenova H, 2003, J CEREBR BLOOD F MET, V23, P190, DOI 10.1097/01.WCB.000004823561824.C4; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Ryter SW, 2000, METH MOL B, V99, P369; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Stolz DB, 2002, HEPATOLOGY, V36, P81, DOI 10.1053/jhep.2002.33716; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wang JL, 2003, J BIOL CHEM, V278, P20069, DOI 10.1074/jbc.M300989200; Weaver LK, 1999, CRIT CARE CLIN, V15, P297, DOI 10.1016/S0749-0704(05)70056-7; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7786; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	51	150	154	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1080	1089		10.1096/fj.03-1391com	http://dx.doi.org/10.1096/fj.03-1391com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15226268				2022-12-28	WOS:000222979200035
J	Ryten, M; Yang, SY; Dunn, PM; Goldspink, G; Burnstock, G				Ryten, M; Yang, SY; Dunn, PM; Goldspink, G; Burnstock, G			Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures	FASEB JOURNAL			English	Article						ATP; P2 receptor; myotube	LEUKEMIA INHIBITORY FACTOR; ACETYLCHOLINE-RECEPTOR; C2C12 MYOTUBES; MYOBLAST PROLIFERATION; NUCLEOTIDE RECEPTORS; GLYCOPROTEIN COMPLEX; SYMPATHETIC NEURONS; EXTRACELLULAR ATP; P2X(5) RECEPTOR; P2Y RECEPTORS	ATP is an important extracellular signaling molecule mediating its effects by activation of P2X and P2Y receptors. P2 receptors are expressed during muscle development, and recent findings demonstrate that ATP can regulate myoblast proliferation and differentiation in vitro. However, the role of purinergic signaling during regeneration of injured skeletal muscle has not been investigated. To examine this process in a clinically relevant system, we used the mouse model of muscular dystrophy (mdx), in which muscle degeneration is rapidly followed by regeneration. The latter process, in vivo muscle regeneration, was the focus of this study, and to study the cellular mechanisms involved in it, a parallel study on normal rat skeletal myoblast cultures was conducted. Using immunohistochemistry, RT-PCR, and electrophysiology, we investigated the expression of the P2X(1-7) receptor subtypes and the P2Y(1,2,4,6) receptors. Experiments in vitro and in vivo demonstrated the sequential expression of the P2X(5), P2Y(1), and P2X(2) receptors during the process of muscle regeneration. The P2X(5) and P2Y(1) receptors were expressed first on activated satellite cells, and the P2Y(1) receptor was also expressed on infiltrating immune cells. Subsequent P2X(2) receptor expression on newly formed myotubes showed significant colocalization with AChRs, suggesting a role in regulation of muscle innervation. Thus, this study provides the first evidence for a role for purinergic signaling in muscle regeneration and raises the possibility of new therapeutic strategies in the treatment of muscle disease.	UCL Royal Free & Univ Coll Med Sch, Auton Neurosci Inst, London NW3 2PF, England; Univ Coll, Royal Free & Univ Coll Med Sch, Dept Surg, Mol Tissue Repair Unit, London NW3 2PF, England	University of London; University College London; UCL Medical School; University of London; University College London	Burnstock, G (corresponding author), UCL Royal Free & Univ Coll Med Sch, Auton Neurosci Inst, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	g.burnstock@ucl.ac.uk						AUSTIN L, 1991, J NEUROL SCI, V101, P193, DOI 10.1016/0022-510X(91)90045-9; Bailey MA, 2001, J AM SOC NEPHROL, V12, P1640, DOI 10.1681/ASN.V1281640; Bailey MA, 2000, KIDNEY INT, V58, P1893, DOI 10.1111/j.1523-1755.2000.00361.x; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; BRAJASLOPEZ C, 1998, J PHYSL, V513, P671; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Carlson CG, 1999, PFLUG ARCH EUR J PHY, V437, P371, DOI 10.1007/s004240050791; Ceruti S, 2000, NEUROMUSCULAR DISORD, V10, P436, DOI 10.1016/S0960-8966(00)00118-8; Cheung KK, 2003, DEV DYNAM, V228, P254, DOI 10.1002/dvdy.10378; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 2003, J NEUROSCI, V23, P4445; CUNHA RA, 1993, PFLUG ARCH EUR J PHY, V424, P503, DOI 10.1007/BF00374914; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; De la Porte S, 1999, INT REV CYTOL, V191, P99, DOI 10.1016/S0074-7696(08)60158-8; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dunn PM, 1996, BRIT J PHARMACOL, V117, P35, DOI 10.1111/j.1476-5381.1996.tb15151.x; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hede SE, 1999, J BIOL CHEM, V274, P31784, DOI 10.1074/jbc.274.45.31784; Hellsten Y, 1998, CIRCULATION, V98, P6, DOI 10.1161/01.CIR.98.1.6; HENNING RH, 1992, BRIT J PHARMACOL, V106, P853, DOI 10.1111/j.1476-5381.1992.tb14424.x; HENNING RH, 1993, BRIT J PHARMACOL, V110, P747, DOI 10.1111/j.1476-5381.1993.tb13875.x; HENNING RH, 1993, BRIT J PHARMACOL, V110, P133, DOI 10.1111/j.1476-5381.1993.tb13782.x; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HUME RI, 1988, J PHYSIOL-LONDON, V406, P503, DOI 10.1113/jphysiol.1988.sp017393; HUME RI, 1986, J NEUROSCI, V6, P681; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Jin Y, 2000, ACTA NEUROPATHOL, V99, P619, DOI 10.1007/s004010051172; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; KOLB HA, 1983, NATURE, V303, P621, DOI 10.1038/303621a0; Kong JM, 1999, BRAIN RES, V839, P298, DOI 10.1016/S0006-8993(99)01737-0; Kurek JB, 1996, MUSCLE NERVE, V19, P1291, DOI 10.1002/(SICI)1097-4598(199610)19:10<1291::AID-MUS6>3.0.CO;2-9; Meyer MP, 1999, DEV DYNAM, V216, P442, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<442::AID-DVDY12>3.0.CO;2-Z; Meyer MP, 1999, DEV DYNAM, V214, P152, DOI 10.1002/(SICI)1097-0177(199902)214:2<152::AID-AJA5>3.0.CO;2-L; NAKAZAWA K, 1994, J NEUROSCI, V14, P740; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Ralevic V, 1998, PHARMACOL REV, V50, P413; REDMAN RS, 1994, J PHYSIOL-LONDON, V477, P117, DOI 10.1113/jphysiol.1994.sp020176; Ruppelt A, 2001, J NEUROCHEM, V77, P1256, DOI 10.1046/j.1471-4159.2001.00348.x; Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025; Ryten M, 2001, DEV DYNAM, V221, P331, DOI 10.1002/dvdy.1147; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Searl TJ, 1998, J PHYSIOL-LONDON, V510, P783, DOI 10.1111/j.1469-7793.1998.783bj.x; Shibuya I, 1999, J PHYSIOL-LONDON, V514, P351, DOI 10.1111/j.1469-7793.1999.351ae.x; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Silinsky EM, 1996, J PHYSIOL-LONDON, V492, P815, DOI 10.1113/jphysiol.1996.sp021348; SMITH DO, 1991, J PHYSIOL-LONDON, V432, P343, DOI 10.1113/jphysiol.1991.sp018388; Straub RH, 2002, J NEUROIMMUNOL, V125, P73, DOI 10.1016/S0165-5728(02)00035-8; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; THOMAS SA, 1991, BRIT J PHARMACOL, V103, P1963, DOI 10.1111/j.1476-5381.1991.tb12360.x; THOMAS SA, 1990, J GEN PHYSIOL, V95, P569, DOI 10.1085/jgp.95.4.569; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; Torres GE, 1999, J BIOL CHEM, V274, P22359, DOI 10.1074/jbc.274.32.22359; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014-5793(02)02918-6; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	60	41	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1404	+		10.1096/fj.03-1175fje	http://dx.doi.org/10.1096/fj.03-1175fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231720				2022-12-28	WOS:000222979200024
J	Sethi, N; Palefsky, J				Sethi, N; Palefsky, J			Transcriptional profiling of dysplastic lesions in K14-HPV16 transgenic mice using laser microdissection	FASEB JOURNAL			English	Article						HPV16 transgenic mice; HPV E2 transcripts; real-time PCR; functional genomics	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL INTRAEPITHELIAL NEOPLASIA; POLYMERASE-CHAIN-REACTION; CARCINOMA CELL-LINES; ACTIVE ANTIRETROVIRAL THERAPY; MESSENGER-RNAS; E2 PROTEIN; QUANTITATIVE DETECTION; EXPRESSION; GENE	In the K14-HPV16 transgenic mouse model of human papillomavirus (HPV)-associated squamous cell cancers, HPV16 E6 and E7 oncogenes and E1 and E2 regulatory genes are driven by the K14 keratinocyte-specific promoter. HPV transcription varies within the different layers of the epithelium. The correlation between HPV transcription patterns and disease pathogenesis is not well understood. Understanding these patterns is critical to designing and testing new HPV-specific therapeutic strategies. We examined HPV gene expression in homogenous populations of cells microdissected from the stratum basale, stratum spinosum, and stratum corneum of lesions from the transgenic mice using PALM microlaser technology. RNA extracted from each cell layer was subjected to two-step gene-specific RT-PCR and real-time quantitative nested PCR. To ensure specific amplification of spliced transcripts, the primers used for real-time nested PCR spanned the splice sites. High levels of E2 were detected in the basal and supra-basal layers of hyperplastic and dysplastic lesions. E7 and E6* levels increased significantly over time in stratum basale and stratum spinosum. E6** was expressed at much lower levels. We showed that the transgenic mice express correctly spliced E2 transcripts and are suitable as a preclinical model to test a therapeutic strategy using transcriptional regulation by the E2 protein.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Palefsky, J (corresponding author), Univ Calif San Francisco, Dept Med, Gen Clin Res Ctr, Box 0126,505 Parnassus Ave,Room 1203, San Francisco, CA 94143 USA.	joelp@medicine.ucsf.edu			NIDCR NIH HHS [DE CA1192] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alloul N, 1999, J GEN VIROL, V80, P2461, DOI 10.1099/0022-1317-80-9-2461; Alloul N, 1999, J GEN VIROL, V80, P29, DOI 10.1099/0022-1317-80-1-29; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Blackshaw SE, 2003, J NEUROBIOL, V55, P355, DOI 10.1002/neu.10214; Casas L, 1999, INT J CANCER, V83, P449, DOI 10.1002/(SICI)1097-0215(19991112)83:4&lt;449::AID-IJC3&gt;3.0.CO;2-0; Chang JT, 2002, CLIN BIOCHEM, V35, P591, DOI 10.1016/S0009-9120(02)00403-4; Coussens LM, 1996, AM J PATHOL, V149, P1899; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Holly EA, 2001, J NATL CANCER I, V93, P843, DOI 10.1093/jnci/93.11.843; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Jiang SS, 2004, CLIN INFECT DIS, V38, P293, DOI 10.1086/380841; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Lanham S, 2001, J CLIN PATHOL, V54, P304, DOI 10.1136/jcp.54.4.304; Maitland NJ, 1998, J PATHOL, V186, P275, DOI 10.1002/(SICI)1096-9896(1998110)186:3&lt;275::AID-PATH159&gt;3.0.CO;2-E; MATSUKURA T, 1986, J VIROL, V58, P979, DOI 10.1128/JVI.58.3.979-982.1986; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; O'Neill HJ, 2002, J CLIN VIROL, V25, P335, DOI 10.1016/S1386-6532(02)00124-5; O'Neill HJ, 2003, J MED VIROL, V71, P557, DOI 10.1002/jmv.10516; Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007; Palefsky JM, 2001, J ACQ IMMUN DEF SYND, V28, P422, DOI 10.1097/00042560-200112150-00003; Parhar IS, 2003, ENDOCRINOLOGY, V144, P3297, DOI 10.1210/en.2003-0386; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; Ratge D, 2002, J CLIN VIROL, V24, P161, DOI 10.1016/S1386-6532(01)00244-X; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Sethi N, 2003, HUM GENE THER, V14, P45, DOI 10.1089/10430340360464705; SHERMAN L, 1992, VIROLOGY, V191, P953, DOI 10.1016/0042-6822(92)90271-P; SHERMAN L, 1992, INT J CANCER, V50, P356, DOI 10.1002/ijc.2910500305; SHIRASAWA H, 1987, J GEN VIROL, V68, P583, DOI 10.1099/0022-1317-68-2-583; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stevenson M, 2000, J GEN VIROL, V81, P1825, DOI 10.1099/0022-1317-81-7-1825; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STOLER MH, 1986, HUM PATHOL, V17, P1250, DOI 10.1016/S0046-8177(86)80569-X; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	39	8	8	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1243	+		10.1096/fj.03-0946fje	http://dx.doi.org/10.1096/fj.03-0946fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180960				2022-12-28	WOS:000222327500036
J	Verdier-Sevain, S; Yaar, M; Cantatore, J; Traish, A; Gilchrest, BA				Verdier-Sevain, S; Yaar, M; Cantatore, J; Traish, A; Gilchrest, BA			Estradiol induces proliferation of keratinocytes via receptor-mediated mechanisms	FASEB JOURNAL			English	Article						estrogen receptor; mitogen-activated protein kinase; ERE	ACTIVATED PROTEIN-KINASE; MEMBRANE ESTROGEN-RECEPTOR; PITUITARY-TUMOR CELLS; NERVE GROWTH-FACTOR; PLASMA-MEMBRANE; PROGESTERONE-RECEPTORS; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; DOWN-REGULATION; SEX STEROIDS	In this study, we investigated the effects of estradiol on the proliferation of neonatal keratinocytes, the expression of estrogen receptor isoforms, and the signaling mechanisms by which estradiol mediates cell growth. We demonstrate that estradiol binds neonatal keratinocytes with high affinity (K-d=5.2nM) and limited capacity (B-max of 14.2fmol/mg of protein), confirming the presence of estrogen binding sites. Using specific antibodies, we demonstrate that keratinocytes express both estrogen receptor (ER)-alpha and ER-beta. At physiological concentrations, estradiol up-regulates the level of ER-alpha receptors in keratinocytes and induces keratinocyte proliferation. The proliferative effect of estradiol requires the availability of functional estrogen receptors, as it is abrogated by anti-estrogen administration. Estradiol effect on keratinocyte proliferation is most likely mediated in part by activation of a nongenomic, membrane-associated, signaling pathway involving activation of the extracellular signal regulated kinases 1 and 2 and in part by the genomic signaling pathway through activation of nuclear receptors.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu						ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Ashcroft GS, 1999, AM J PATHOL, V155, P1137, DOI 10.1016/S0002-9440(10)65217-0; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; BAYARD F, 1978, J CLIN ENDOCR METAB, V46, P635, DOI 10.1210/jcem-46-4-635; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Berard A, 2001, PHARMACOEPIDEM DR S, V10, P245, DOI 10.1002/pds.582; BESTBELPOMME M, 1975, EUR J BIOCHEM, V57, P537, DOI 10.1111/j.1432-1033.1975.tb02329.x; BLAUSTEIN JD, 1992, ENDOCRINOLOGY, V131, P1336, DOI 10.1210/en.131.3.1336; Brandenberger AW, 1997, J CLIN ENDOCR METAB, V82, P3509, DOI 10.1210/jc.82.10.3509; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; Calvin M, 1998, BRIT J OBSTET GYNAEC, V105, P223, DOI 10.1111/j.1471-0528.1998.tb10057.x; Chaturvedi K, 2004, ENDOCRINOLOGY, V145, P706, DOI 10.1210/en.2003-1063; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ERNST M, 1988, P NATL ACAD SCI USA, V85, P2307, DOI 10.1073/pnas.85.7.2307; Goukassian D, 2000, FASEB J, V14, P1325, DOI 10.1096/fj.14.10.1325; HASSELQUIST MB, 1980, J CLIN ENDOCR METAB, V50, P76, DOI 10.1210/jcem-50-1-76; HUETHUDSON YM, 1990, MOL ENDOCRINOL, V4, P510, DOI 10.1210/mend-4-3-510; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; Jisa E, 2003, J STEROID BIOCHEM, V84, P141, DOI 10.1016/S0960-0760(03)00023-2; JORGENSEN O, 1962, Acta Chir Scand, V124, P1; Kanda N, 2003, J INVEST DERMATOL, V120, P411, DOI 10.1046/j.1523-1747.2003.12066.x; Kanda N, 2003, J INVEST DERMATOL, V120, P420, DOI 10.1046/j.1523-1747.2003.12067.x; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lee YJ, 1998, MOL CELL ENDOCRINOL, V137, P85, DOI 10.1016/S0303-7207(97)00235-9; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; MAHEUX R, 1994, AM J OBSTET GYNECOL, V170, P642, DOI 10.1016/S0002-9378(94)70242-X; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; Margolis DJ, 2002, LANCET, V359, P675, DOI 10.1016/S0140-6736(02)07806-6; Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276; Marino M, 2002, MOL BIOL CELL, V13, P3720, DOI 10.1091/mbc.E02-03-0153; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Milner TA, 2001, J COMP NEUROL, V429, P355; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Muramatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P1, DOI 10.1006/bbrc.2000.2214; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; NAKAO J, 1981, ATHEROSCLEROSIS, V38, P75, DOI 10.1016/0021-9150(81)90105-2; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKEEFE JA, 1990, DEV BRAIN RES, V57, P119, DOI 10.1016/0165-3806(90)90191-Z; Oliveira Cleida A, 2003, Reprod Biol Endocrinol, V1, P75, DOI 10.1186/1477-7827-1-75; Onuma H, 2001, ARCH DERMATOL RES, V293, P133, DOI 10.1007/s004030000195; Powell CE, 2001, J STEROID BIOCHEM, V77, P97, DOI 10.1016/S0960-0760(01)00040-1; PUNNONEN R, 1971, ACTA OBSTET GYN SCAN, V50, P32; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REE AH, 1989, ENDOCRINOLOGY, V124, P2577, DOI 10.1210/endo-124-5-2577; Revelli A, 1998, GYNECOL ENDOCRINOL, V12, P61, DOI 10.3109/09513599809024971; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SCHMIDT JB, 1994, MATURITAS, V20, P25, DOI 10.1016/0378-5122(94)90097-3; Shah M G, 2001, Am J Clin Dermatol, V2, P143; Singh M, 1999, J NEUROSCI, V19, P1179; Singleton DW, 2003, ENDOCRINOLOGY, V144, P121, DOI 10.1210/en.2002-220625; Steinhoff M, 2001, CURR OPIN ALLERGY CL, V1, P469, DOI 10.1097/00130832-200110000-00014; TAMMI R, 1982, ACTA DERM-VENEREOL, V62, P107; Thornton MJ, 2003, EXP DERMATOL, V12, P181, DOI 10.1034/j.1600-0625.2003.120209.x; Thornton MJ, 2002, EXP DERMATOL, V11, P487, DOI 10.1034/j.1600-0625.2002.110601.x; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; TRAISH AM, 1986, STEROIDS, V47, P157, DOI 10.1016/0039-128X(86)90086-3; URANO R, 1995, J DERMATOL SCI, V9, P176, DOI 10.1016/0923-1811(94)00375-O; WAKELING AE, 1991, CANCER RES, V51, P3867; Watson CS, 2002, STEROIDS, V67, P429, DOI 10.1016/S0039-128X(01)00172-6; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WELSHONS WV, 1988, MOL CELL ENDOCRINOL, V57, P169, DOI 10.1016/0303-7207(88)90072-X; White RE, 2002, VASC PHARMACOL, V38, P73, DOI 10.1016/S0306-3623(02)00129-5; WOODLEY DT, 1993, DERMATOL CLIN, V11, P641, DOI 10.1016/S0733-8635(18)30217-1; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	77	80	85	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1252	+		10.1096/fj.03-1088fje	http://dx.doi.org/10.1096/fj.03-1088fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208259				2022-12-28	WOS:000222327500021
J	Chen, ZJJ; Vulevic, B; Ile, KE; Soulika, A; Davis, W; Reiner, PB; Connop, BP; Nathwan, P; Trojanowski, JQ; Tew, KD				Chen, ZJJ; Vulevic, B; Ile, KE; Soulika, A; Davis, W; Reiner, PB; Connop, BP; Nathwan, P; Trojanowski, JQ; Tew, KD			Association of ABCA2 expression with determinants of Alzheimer's disease	FASEB JOURNAL			English	Article						beta-amyloid; A beta precursor protein; AD	TRANSPORTER GENE; OXIDATIVE STRESS; PROTEIN; ESTRAMUSTINE; CASSETTE; CLONING; IDENTIFICATION; CELLS; BRAIN; NEURODEGENERATION	With the use of a novel method for detecting differential gene expression, alterations in functional gene clusters related to transport or oxidative stress response and beta-amyloid (Abeta) peptide metabolism were identified in a HEK293 cell line engineered to overexpress the human ATP binding cassette transporter ABCA2. These included fatty acid binding protein, phospholipid binding protein, phospholipid synthesis protein, transporter cofactors, seladin-1, Abeta precursor protein (APP), vimentin, and low-density lipoprotein receptor-related protein. ABCA2 was highly expressed in neuroblastoma cells and colocalized with Abeta and APP. Additionally, increased APP protein levels were detected within ABCA2/APP double-transfected cells, and increased Abeta was detected in the media of ABCA2-transfected cells relative to controls. The transporter was abundant in the temporal and frontal regions of both normal and Alzheimer's disease ( AD) brain but was detected at lower concentrations in the parietal, occipital, and cerebellar regions. The ABCA2 transfected cell line expressed resistance to a free radical initiator, confirming involvement in protection against reactive oxygen species and suggesting a further possible link to AD.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Act Pass Pharmaceut Inc, Vancouver, BC V5Z 4H5, Canada; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	Fox Chase Cancer Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Tew, KD (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29425 USA.	tewk@musc.edu			NCI NIH HHS [CA-06927, CA-83778, CA-10124] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083778, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; BUTTERFIELD DA, 1994, BIOCHEM BIOPH RES CO, V200, P710, DOI 10.1006/bbrc.1994.1508; Chen ZJJ, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.10.e46; Chen ZJJ, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-28; Choi J, 2003, BBA-MOL BASIS DIS, V1637, P135, DOI 10.1016/S0925-4439(02)00227-2; Connop BP, 1999, J NEUROCHEM, V72, P1457, DOI 10.1046/j.1471-4159.1999.721457.x; Dean M, 2001, J BIOENERG BIOMEMBR, V33, P475, DOI 10.1023/A:1012823120935; Dubin RL, 2001, BONE, V28, P617, DOI 10.1016/S8756-3282(01)00463-X; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; Greeve I, 2000, J NEUROSCI, V20, P7345; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; Hu JY, 2003, J NEUROSCI, V23, P1804; HUDES GR, 1992, J CLIN ONCOL, V10, P1754, DOI 10.1200/JCO.1992.10.11.1754; Iivonen S, 2002, NEUROSCIENCE, V113, P301, DOI 10.1016/S0306-4522(02)00180-X; Ile KE, 2004, BBA-GENE STRUCT EXPR, V1678, P22, DOI 10.1016/j.bbaexp.2004.01.007; Jagust WJ, 1997, ANN NY ACAD SCI, V826, P254, DOI 10.1111/j.1749-6632.1997.tb48477.x; Kaminski WE, 2001, BIOCHEM BIOPH RES CO, V281, P249, DOI 10.1006/bbrc.2001.4305; Laing N, 1997, BIOCHEMISTRY-US, V36, P871, DOI 10.1021/bi961445w; Laing NM, 1998, CANCER RES, V58, P1332; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Ma SL, 2002, NEUROSCI LETT, V332, P216, DOI 10.1016/S0304-3940(02)00942-4; Mahapatra NR, 2003, J BIOL CHEM, V278, P19986, DOI 10.1074/jbc.M207983200; Mairhofer M, 2002, BLOOD, V100, P897, DOI 10.1182/blood.V100.3.897; Mills J, 1997, J NEUROSCI, V17, P9415; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Petrella JR, 2003, RADIOLOGY, V226, P315, DOI 10.1148/radiol.2262011600; PUNZI JS, 1992, MOL PHARMACOL, V41, P569; Safieddine S, 2002, MOL CELL NEUROSCI, V20, P343, DOI 10.1006/mcne.2002.1120; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Schmidt ML, 2001, AM J PATHOL, V159, P937, DOI 10.1016/S0002-9440(10)61769-5; Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; STEARNS ME, 1985, P NATL ACAD SCI USA, V82, P8483, DOI 10.1073/pnas.82.24.8483; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; Vulevic B, 2001, CANCER RES, V61, P3339; Wang D, 2003, MOL PHARMACOL, V64, P905, DOI 10.1124/mol.64.4.905; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhao LX, 2000, BIOCHEM J, V350, P865, DOI 10.1042/0264-6021:3500865; Zhou CJ, 2002, J COMP NEUROL, V451, P334, DOI 10.1002/cne.10354	40	52	54	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1129	+		10.1096/fj.03-1490fje	http://dx.doi.org/10.1096/fj.03-1490fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155565				2022-12-28	WOS:000221883200004
J	Siu, PM; Bryner, RW; Martyn, JK; Alway, SE				Siu, PM; Bryner, RW; Martyn, JK; Alway, SE			Apoptotic adaptations from exercise training in skeletal and cardiac muscles	FASEB JOURNAL			English	Article						programmed cell death; DNA fragmentation; Bcl-2; Bax; caspase	CYTOCHROME-C RELEASE; HEAT-SHOCK PROTEINS; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; OXIDATIVE STRESS; CELL-DEATH; CROSS-TALK; ACTIVATION; EXPRESSION; DAMAGE; MITOCHONDRIA	The effect of exercise on apoptosis in postmitotic tissues is not known. In this study, we investigated the effect of regular moderate physical activity (i.e., exercise training) on the extent of apoptosis in rat skeletal and cardiac muscles. Adult Sprague Dawley rats were trained (TR) 5 days weekly for 8 wk on treadmill. Sedentary rats served as controls ( CON). An ELISA was used to detect mono- and oligonucleosome fragmentation as an indicator of apoptosis. Bcl-2, Bax, Apaf-1, AIF, cleaved PARP, cleaved caspase-3, cleaved/active caspase-9, heat shock protein (HSP) 70, Cu/Zn-SOD, and Mn-SOD protein levels were determined by Western analyses. Bcl-2 and Bax transcript contents were estimated by RT-PCR. A spectrofluorometric assay was used to determine caspase-3 activity. DNA fragmentation in ventricles of the TR group decreased by 15% whereas that in soleus of the TR group tended to decrease (P = 0.058) when compared with CON group. Protein contents of Bcl-2, HSP70, and Mn-SOD increased in both soleus and ventricle muscles of TR animals when compared with CON animals. Apaf-1 protein content in the soleus of TR animals was lower than that of CON animals. Bcl-2 mRNA levels increased in both ventricle and soleus muscles of TR animals, and Bax mRNA levels decreased in the soleus of TR animals when compared with CON animals. Furthermore, HSP70 protein content was negatively correlated to Bax mRNA content and was positively correlated to Bcl-2 protein and mRNA contents. Mn-SOD protein content was negatively correlated to the apoptotic index, and caspase-3 activity and was positively correlated to Bcl-2 transcript content and HSP70 protein content. These data suggest that exercise training attenuates the extent of apoptosis in cardiac and skeletal muscles.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Sch Med, Div Exercise Physiol,Lab Muscle Biol & Sarcopenia, Morgantown, WV 26506 USA	West Virginia University	Alway, SE (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Sch Med, Div Exercise Physiol,Lab Muscle Biol & Sarcopenia, Morgantown, WV 26506 USA.	salway@hsc.wvu.edu	Alway, Stephen E./AAF-8834-2020	Siu, Parco/0000-0002-3548-5058; Alway, Stephen/0000-0002-0378-4707	NATIONAL INSTITUTE ON AGING [R01AG021530] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021530, R01 AG021530-02, AG 021530] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams V, 1999, J AM COLL CARDIOL, V33, P959, DOI 10.1016/S0735-1097(98)00626-3; Adler CP, 1996, VIRCHOWS ARCH, V429, P159; Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; Alway SE, 2003, J GERONTOL A-BIOL, V58, P687; Alway SE, 2003, AM J PHYSIOL-REG I, V284, pR540, DOI 10.1152/ajpregu.00550.2002; Alway SE, 2002, AM J PHYSIOL-CELL PH, V283, pC66, DOI 10.1152/ajpcell.00598.2001; Alway SE, 1997, J GERONTOL A-BIOL, V52, pB203, DOI 10.1093/gerona/52A.4.B203; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Borisov AB, 2000, ANAT RECORD, V258, P305; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Dalla Libera L, 1999, AM J PHYSIOL-CELL PH, V277, pC982, DOI 10.1152/ajpcell.1999.277.5.C982; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Duke RC, 1996, SCI AM, V275, P80, DOI 10.1038/scientificamerican1296-80; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fluck M, 2003, REV PHYSIOL BIOCH P, V146, P159, DOI 10.1007/s10254-002-0004-7; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gorman AM, 1996, J NEUROL SCI, V139, P45, DOI 10.1016/0022-510X(96)00097-4; Gorman AM, 2000, DEV NEUROSCI-BASEL, V22, P348, DOI 10.1159/000017460; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Ji LL, 2002, ANN NY ACAD SCI, V959, P82, DOI 10.1111/j.1749-6632.2002.tb02085.x; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Locke M, 1997, Exerc Sport Sci Rev, V25, P105; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; NEUFER PD, 1993, AM J PHYSIOL, V265, pC1597; Nunes VA, 2003, BRAZ J MED BIOL RES, V36, P1047, DOI 10.1590/S0100-879X2003000800010; Phaneuf S, 2002, AM J PHYSIOL-REG I, V282, pR423, DOI 10.1152/ajpregu.00296.2001; Phaneuf S, 2001, MED SCI SPORT EXER, V33, P393, DOI 10.1097/00005768-200103000-00010; Podhorska-Okolow M, 1998, NEUROPATH APPL NEURO, V24, P518; Podhorska-Okolow M, 1999, FOLIA HISTOCHEM CYTO, V37, P127; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; Pollack M, 2001, J GERONTOL A-BIOL, V56, pB475, DOI 10.1093/gerona/56.11.B475; Powers SK, 2002, CURR OPIN CARDIOL, V17, P495, DOI 10.1097/00001573-200209000-00009; Powers SK, 2001, MED SCI SPORT EXER, V33, P386, DOI 10.1097/00005768-200103000-00009; Powers SK, 1999, MED SCI SPORT EXER, V31, P987, DOI 10.1097/00005768-199907000-00011; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rivello HG, 2001, CARDIOVASC PATHOL, V10, P53, DOI 10.1016/S1054-8807(01)00068-0; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samelman TR, 2000, EXP PHYSIOL, V85, P97, DOI 10.1111/j.1469-445X.2000.01894.x; Sandri M, 2001, J NEUROPATH EXP NEUR, V60, P302, DOI 10.1093/jnen/60.3.302; Sandri M, 1997, J NEUROPATH EXP NEUR, V56, P45, DOI 10.1097/00005072-199701000-00005; Sandri M, 1998, LAB INVEST, V78, P1005; Sandri M, 2002, CURR OPIN CLIN NUTR, V5, P249, DOI 10.1097/00075197-200205000-00003; SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R; Sharov VG, 1996, AM J PATHOL, V148, P141; Sinha-Hikim I, 2003, AM J PHYSIOL-ENDOC M, V285, pE197, DOI 10.1152/ajpendo.00370.2002; Siu PM, 2003, J APPL PHYSIOL, V94, P555, DOI 10.1152/japplphysiol.00821.2002; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki H, 1995, J CLIN INVEST, V96, P2892, DOI 10.1172/JCI118360; Suzuki K, 2000, BASIC RES CARDIOL, V95, P397, DOI 10.1007/s003950070039; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yuan J, 2003, BBA-MOL CELL RES, V1641, P35, DOI 10.1016/S0167-4889(03)00047-8; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	68	165	187	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1150	+		10.1096/fj.03-1291fje	http://dx.doi.org/10.1096/fj.03-1291fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132982				2022-12-28	WOS:000221883200017
J	Kim, HS; Skurk, C; Maatz, H; Shiojima, I; Ivashchenko, Y; Yoon, SW; Park, YB; Walsh, K				Kim, HS; Skurk, C; Maatz, H; Shiojima, I; Ivashchenko, Y; Yoon, SW; Park, YB; Walsh, K			Akt/FOXO3a signaling modulates the endothelial stress response through regulation of heat shock protein 70 expression	FASEB JOURNAL			English	Article						endothelial cells; apoptosis	TRANSCRIPTION FACTOR FOXO3A; ACTIVATED PROTEIN-KINASE; HEAT-SHOCK; CELL-SURVIVAL; AKT; ANGIOGENESIS; PHOSPHORYLATION; APOPTOSIS; FKHR-L1	To identify new antiapoptotic targets of the PI3K-Akt signaling pathway in endothelial cells, adenovirus-mediated Akt1 gene transfer and oligonucleotide microarrays were used to examine Akt-regulated transcripts. DNA microarray analysis revealed that HSP70 expression underwent the greatest fold activation of 12,532 transcripts examined in human umbilical vein endothelial cells (HUVEC) transduced with constitutively active Akt1. Akt1 gene transfer increased HSP70 transcript expression by 24.8-fold as determined by quantitative PCR and promoted a dose-dependent up-regulation of HSP70 protein as determined by Western immunoblot analysis. Gene transfer of FOXO3a, a downstream target of Akt in endothelial cells, significantly suppressed both basal and stress-induced HSP70 protein expression. FOX03a induced caspase-9-dependent apoptosis in HUVEC, and cotransduction with Ad-HSP70 rescued endothelial cells from FOXO3a-induced apoptosis under basal and stress conditions. Our results identify HSP70 as a new antiapoptotic target of Akt-FOXO3a signaling in endothelial cells that controls viability through modulation of the stress-induced intrinsic cell death pathway.	Boston Univ, Sch Med, Mol Cardiol Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; AVENTIS Pharma, Cardiovasc Dis Grp, Frankfurt, Germany	Boston University; Seoul National University (SNU); Sanofi-Aventis	Walsh, K (corresponding author), Boston Univ, Sch Med, Mol Cardiol Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu	Kim, Hyo Soo/J-2753-2012	Youn, Seock-Won/0000-0003-3275-2170	NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG17241, AG15052] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017241, R37AG015052, R01AG015052] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nollen EAA, 2002, J CELL SCI, V115, P2809; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Semenza GL, 2000, GENE DEV, V14, P1983; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	33	48	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1042	+		10.1096/fj.04-2841fje	http://dx.doi.org/10.1096/fj.04-2841fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15784720				2022-12-28	WOS:000227901300008
J	Singh, A; Sowjanya, AP; Ramakrishna, G				Singh, A; Sowjanya, AP; Ramakrishna, G			The wild-type Ras: road ahead	FASEB JOURNAL			English	Article						Ras-GDP; Ras-GTP; mutant ras; cyclin-dependent kinase inhibitors (CDKIs)	NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; K-RAS; N-RAS; CELL-CYCLE; H-RAS; STIMULATED PROLIFERATION; ONCOGENIC RAS-P21; FREQUENT DELETION; DOWN-REGULATION	The cellular Ras is known to play an important role in cellular proliferation mediated by growth factor receptor. Evidence also points to its role in growth arrest. Substantiated proof for growth-suppressive activity of wild-type Ras comes from studies that showed 1) loss of wild-type ras allele in tumors, 2) suppression of growth in cells transformed by oncogenic ras upon overexpression of wild-type Ras, and 3) up-regulation of Ras expression during postnatal development and following growth arrest of untransformed cells in culture. To understand the mechanism by which the wild-type Ras brings about these diverse actions, we evaluated its well-known role in actively proliferating cells and its less understood role in growth arrest. This led to the proposal that wild-type Ras in either GDP GTP-bound state can antagonize the function of oncogenic Ras.	Ctr DNA Fingerprinting & Diagnost, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Ramakrishna, G (corresponding author), Ctr DNA Fingerprinting & Diagnost, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.	gayatri@cdfd.org.in			FIC NIH HHS [R01 TW006195, R01 TW006195-02] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006195] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Baccichet A, 1997, BRIT J HAEMATOL, V99, P107, DOI 10.1046/j.1365-2141.1997.3663180.x; BALTUS E, 1988, P NATL ACAD SCI USA, V85, P502, DOI 10.1073/pnas.85.2.502; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Chaturvedi V, 2003, AM J PATHOL, V162, P161, DOI 10.1016/S0002-9440(10)63807-2; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chen JM, 2002, J PROTEIN CHEM, V21, P349, DOI 10.1023/A:1019994302273; Chie L, 2003, J PROTEIN CHEM, V22, P625, DOI 10.1023/B:JOPC.0000008727.46554.9e; Chie L, 2003, ANN CLIN LAB SCI, V33, P200; CICHUTEK K, 1989, J VIROL, V63, P1377, DOI 10.1128/JVI.63.3.1377-1383.1989; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; Diaz R, 2004, CARCINOGENESIS, V25, P535, DOI 10.1093/carcin/bgh026; Diaz R, 2002, CANCER RES, V62, P4514; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fukuda M, 2003, J BIOL CHEM, V278, P15390, DOI 10.1074/jbc.M213090200; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; James RM, 2003, MOL CANCER RES, V1, P820; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kammouni W, 2002, CELL GROWTH DIFFER, V13, P441; Kanovsky M, 2003, CANCER CHEMOTH PHARM, V52, P202, DOI 10.1007/s00280-003-0639-3; KAPLAN JB, 1994, ONCOL RES, V6, P611; Kibel AS, 1998, CANCER RES, V58, P5652; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Li GP, 2004, J MOL BIOL, V340, P921, DOI 10.1016/j.jmb.2004.06.007; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; Lucas L, 2002, INT J ONCOL, V21, P477; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maruyama C, 2001, ONCOL REP, V8, P233; Matsui T, 2002, EMBO J, V21, P1021, DOI 10.1093/emboj/21.5.1021; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Park S., 1997, MATH SCI RES HOT LIN, V1, P1; Pells S, 1997, ONCOGENE, V15, P1781, DOI 10.1038/sj.onc.1201354; Perez de Castro I, 2003, CANCER RES, V63, P1615; Pfeifer GP, 2001, NAT GENET, V29, P3, DOI 10.1038/ng0901-3; Pils B, 2004, J MOL BIOL, V340, P399, DOI 10.1016/j.jmb.2004.04.063; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Ramakrishna G, 2000, EXP LUNG RES, V26, P659, DOI 10.1080/01902140150216747; Ranginwale M, 2001, EXP CELL RES, V269, P162, DOI 10.1006/excr.2001.5311; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Sharpe CC, 2000, J AM SOC NEPHROL, V11, P1600, DOI 10.1681/ASN.V1191600; Sharpe CC, 1999, J AM SOC NEPHROL, V10, P1186; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; Sithanandam G, 1998, ONCOGENE, V17, P493, DOI 10.1038/sj.onc.1201958; Sourvinos G, 1997, TUMOR BIOL, V18, P157, DOI 10.1159/000218026; SPANDIDOS A, 1988, BRIT J CANCER, V58, P67; Spandidos DA, 2002, INT J ONCOL, V21, P237; SPANDIDOS DA, 1990, ANTICANCER RES, V10, P1543; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; TAKEUCHI S, 1996, CANCER RES, V56, P38; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thrane EV, 1997, EXP LUNG RES, V23, P35, DOI 10.3109/01902149709046046; Tian DH, 2002, MOL CELL BIOL, V22, P2650, DOI 10.1128/MCB.22.8.2650-2662.2002; TSUNEMATSU S, 1994, INT J CANCER, V59, P554, DOI 10.1002/ijc.2910590420; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Uchiyama M, 2003, INT J CANCER, V107, P962, DOI 10.1002/ijc.11493; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	87	38	38	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					161	169		10.1096/fj.04-2584hyp	http://dx.doi.org/10.1096/fj.04-2584hyp			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677339				2022-12-28	WOS:000227591900020
J	Reagan-Shaw, S; Ahmad, N				Reagan-Shaw, S; Ahmad, N			Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer	FASEB JOURNAL			English	Article						cell cycle; cytokinesis; centrosome	DOWN-REGULATION; PLK1; INHIBITION; CENTROSOME; EXPRESSION; TARGET	Prostate cancer (PCa) is one of the most common cancers in men. Each year similar to 543,000 new cases are reported worldwide, and the disease kills 200,000 ( mostly older men) in developed countries. The existing treatment approaches and surgical intervention have not been able to effectively manage this dreaded cancer and, therefore, continuing efforts are ongoing to explore novel targets and strategies for the management of PCa. The activity of polo-like kinase 1 (Plk1) is elevated in tissues and cells with a high mitotic index, including cancer cells. An increasing body of evidence suggests that the level of Plk1 expression has prognostic value for predicting outcomes in patients with some cancers. A close correlation between Plk1 expression and carcinogenesis has been documented. However, the role of Plk1 in PCa is not known. We propagated a hypothesis that Plk1 inhibition will result in elimination of human PCa cells via a mitotic arrest followed by apoptosis ( 1). To define the role of Plk1 in PCa, we used the technique of RNA silencing via small interfering RNA ( siRNA). First, using a series of human prostate carcinoma cells and normal human prostate epithelial (PrEC) cells, we assessed Plk1 levels in PCa. Immunoblot analyses clearly showed a significant expression of Plk1 in LNCaP, DU145, and PC3 human PCa cells. Interestingly, Plk1 was not detectable in normal PrEC cells. Next, we transfected the PCa cells with Plk 1 siRNA, which resulted in a significant inhibition in Plk1 protein in all PCa cells. Plk1 depletion resulted in a decrease in cell viability and induction of apoptosis in PCa cells but had no appreciable effect in normal PrEC cells. Our data also demonstrated that Plk1 siRNA transfection of PCa cells resulted in 1) a mitotic cell cycle arrest, 2) failure of cytokinesis, and 3) defects in centrosome integrity and maturation. Thus, our study suggested that 1) Plk1 plays a critical role in the process of PCa development and 2) gene therapeutic approaches aimed at Plk1 or the pharmacological inhibitors of Plk1 may be developed for the management of PCa.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, 1300 Univ Ave,MSC 25B, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Ahmad N, 2004, FASEB J, V18, P5, DOI 10.1096/fj.03-0848hyp; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Donaldson MM, 2001, J CELL SCI, V114, P2357; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Masuda Y, 2003, ONCOGENE, V22, P1012, DOI 10.1038/sj.onc.1206200; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Pereira G, 2001, CURR OPIN CELL BIOL, V13, P762, DOI 10.1016/S0955-0674(00)00281-7; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Yuan JP, 2002, CANCER RES, V62, P4186	23	117	132	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					611	+		10.1096/fj.04-2910fje	http://dx.doi.org/10.1096/fj.04-2910fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15661849				2022-12-28	WOS:000226576600018
J	Motterlini, R; Sawle, P; Bains, S; Hammad, J; Alberto, R; Foresti, R; Green, CJ				Motterlini, R; Sawle, P; Bains, S; Hammad, J; Alberto, R; Foresti, R; Green, CJ			CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule	FASEB JOURNAL			English	Article						sodium boranocarbonate; CO electrode; vascular tone; blood pressure; heme oxygenase-1	HEME OXYGENASE-1; SMOOTH-MUSCLE; NITRIC-OXIDE; VASOACTIVE PROPERTIES; CO; SUPPRESSES; INDUCTION; CELLS; INHIBITION; REJECTION	Carbon monoxide (CO) is emerging as an important and versatile mediator of physiological processes to the extent that treatment of animals with exogenous CO gas has beneficial effects in a range of vascular- and inflammatory-related disease models. The recent discovery that certain transition metal carbonyls function as CO-releasing molecules (CO-RMs) in biological systems highlighted the potential of exploiting this and similar classes of compounds as a stratagem to deliver CO for therapeutic purposes. Here we describe the biochemical features and pharmacological actions of a newly identified water-soluble CO releaser (CORM-A1) that, unlike the first prototypic molecule recently described (CORM-3), does not contain a transition metal and liberates CO at a much slower rate under physiological conditions. Using a myoglobin assay and an amperometric CO electrode, we demonstrated that the release of CO from CORM-A1 is both pH- and temperature-dependent with a half-life of similar to21 min at 37degreesC and pH 7.4. In isolated aortic rings, CORM-A1 promoted a gradual but profound concentration-dependent vasorelaxation over time, which was highly amplified by YC-1 (1 muM) and attenuated by ODQ, a stimulator and inhibitor of guanylate cyclase, respectively. Similarly, administration of CORM-A1 (30 mumol/kg i.v.) in vivo produced a mild decrease in mean arterial pressure, which was markedly potentiated by pretreatment with YC-1 (1.2 mumol/kg i.v.). Interestingly, an inactive form of CORM-A1 that is incapable of releasing CO failed to promote both vasorelaxation and hypotension, thus directly implicating CO as the mediator of the observed pharmacological effects. Our results reveal that the bioactivities exerted by CORM-A1 reflect its intrinsic biochemical behavior of a slow CO releaser, which may be advantageous in the treatment of chronic conditions that require CO to be delivered in a carefully controlled manner.	Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow, Middx, England; Univ Zurich, Dept Chem, CH-8006 Zurich, Switzerland	Imperial College London; University of Zurich	Motterlini, R (corresponding author), Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow, Middx, England.	r.motterlini@imperial.ac.uk	Alberto, Roger/S-6405-2019; Motterlini, Roberto/G-2489-2013; Motterlini, Roberto/Q-1890-2019	Alberto, Roger/0000-0001-5978-3394; Motterlini, Roberto/0000-0003-2684-2612; Motterlini, Roberto/0000-0003-2684-2612; foresti, roberta/0000-0002-0836-7937				Alberto R, 1998, J AM CHEM SOC, V120, P7987, DOI 10.1021/ja980745t; Alberto R, 2001, J AM CHEM SOC, V123, P3135, DOI 10.1021/ja003932b; Arregui B, 2004, KIDNEY INT, V65, P564, DOI 10.1111/j.1523-1755.2004.00409.x; Bak I, 2003, FASEB J, V17, P2133, DOI 10.1096/fj.03-0032fje; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209, DOI 10.1152/ajplung.2001.281.1.L209; Chatterjee PK, 2004, BRIT J PHARMACOL, V142, P391, DOI 10.1038/sj.bjp.0705826; Choi BM, 2003, FREE RADICAL BIO MED, V34, P1136, DOI 10.1016/S0891-5849(03)00064-9; Choi BM, 2003, HEPATOLOGY, V37, P810, DOI 10.1053/jhep.2003.50114; Clark JE, 2003, CIRC RES, V93, pE2, DOI 10.1161/01.RES.0000084381.86567.08; Fiumana E, 2003, AM J PHYSIOL-HEART C, V284, pH1073, DOI 10.1152/ajpheart.00881.2002; Foresti R, 2004, BIOCHEM SOC SYMP, V71, P177, DOI 10.1042/bss0710177; Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Guo YR, 2004, AM J PHYSIOL-HEART C, V286, pH1649, DOI 10.1152/ajpheart.00971.2003; Johnson TR, 2003, ANGEW CHEM INT EDIT, V42, P3722, DOI 10.1002/anie.200301634; Jozkowicz A, 2003, ANTIOXID REDOX SIGN, V5, P155, DOI 10.1089/152308603764816514; Koneru P, 2004, AM J PHYSIOL-HEART C, V286, pH304, DOI 10.1152/ajpheart.00810.2003; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; Motterlini R, 2002, BIOMED PHARMACOTHER, V56, P349; Motterlini R, 2003, CURR PHARM DESIGN, V9, P2525, DOI 10.2174/1381612033453785; Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530; Motterlini R, 2002, ANTIOXID REDOX SIGN, V4, P615, DOI 10.1089/15230860260220111; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Motterlini R, 1998, CIRC RES, V83, P568, DOI 10.1161/01.RES.83.5.568; Motterlini R., 2002, CARBON MONOXIDE CARD, P249; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Rattan S, 2004, AM J PHYSIOL-GASTR L, V287, pG605, DOI 10.1152/ajpgi.00070.2004; RYTER SW, 2004, SCI STKE, pRE6; Sacerdoti D, 2004, J PHARMACOL EXP THER, V308, P636, DOI 10.1124/jpet.103.057315; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Stanford SJ, 2003, EUR J PHARMACOL, V473, P135, DOI 10.1016/S0014-2999(03)02001-6; Tongers J, 2004, CARDIOVASC RES, V63, P545, DOI 10.1016/j.cardiores.2004.04.015; Vannacci A, 2004, INFLAMM RES, V53, pS9, DOI 10.1007/s00011-003-0303-8; Waibel R, 1999, NAT BIOTECHNOL, V17, P897, DOI 10.1038/12890; Wakabayaski Y, 1999, AM J PHYSIOL-GASTR L, V277, pG1088, DOI 10.1152/ajpgi.1999.277.5.G1088; Wang R, 1998, CAN J PHYSIOL PHARM, V76, P1; Wang R, 1997, BRIT J PHARMACOL, V121, P927, DOI 10.1038/sj.bjp.0701222; Xi Q, 2004, AM J PHYSIOL-HEART C, V286, pH610, DOI 10.1152/ajpheart.00782.2003	49	334	353	1	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					284	+		10.1096/fj.04-2169fje	http://dx.doi.org/10.1096/fj.04-2169fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15556971	Green Accepted			2022-12-28	WOS:000225482100006
J	Cantara, S; Donnini, S; Morbidelli, L; Giachetti, A; Schulz, R; Memo, M; Ziche, M				Cantara, S; Donnini, S; Morbidelli, L; Giachetti, A; Schulz, R; Memo, M; Ziche, M			Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2	FASEB JOURNAL			English	Article						angiogenesis; endothelial cells; beta-amyloid; basic fibroblast growth factor; Alzheimer's disease	FIBROBLAST-GROWTH-FACTOR; NITRIC-OXIDE; ENDOTHELIAL-CELLS; ALZHEIMERS-DISEASE; RELEASE; PATHWAYS; DYSFUNCTION; ACTIVATION; MECHANISMS; INTEGRINS	Amyloid beta peptides (Abeta) form insoluble aggregates in Alzheimer's disease. Accumulation of misfolded amyloid fibrils is generally believed to be a key pathogenic event in several brain disorders. Here we show that small amounts of Abeta peptides activate angiogenesis by promoting endothelial cell proliferation and migration as well as pseudocapillary formation. Abeta peptides functionally synergize with fibroblast growth factor (FGF-2) to promote c-Raf and ERK1/2 activation and angiogenesis in vivo. Thus, Abeta peptides at nanomolar concentrations prime FGF-2 effects on the endothelium, enhancing survival and sustaining angiogenesis. The angiogenesis promoted by Abeta peptides via FGF-2 might have implications for understanding the initial stages of Alzheimer's disease and for the design of therapies targeting beta amyloid.	Univ Siena, Dept Mol Biol, Pharmacol Sect, I-53100 Siena, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, I-25121 Brescia, Italy	University of Siena; University of Brescia	Ziche, M (corresponding author), Univ Siena, Dept Mol Biol, Pharmacol Sect, Via A Moro 2, I-53100 Siena, Italy.	ziche@unisi.it	Schulz, Richard/M-3518-2019; Cantara, Silvia/J-8808-2016; Schulz, Richard/A-8739-2012; Donnini, Sandra/K-9252-2019; Memo, Maurizio/C-2555-2011; Morbidelli, Lucia/K-4053-2016; Memo, Maurizio/AAK-7197-2020; Morbidelli, Lucia/AAC-7858-2020	Schulz, Richard/0000-0002-5045-3193; Schulz, Richard/0000-0002-5045-3193; Donnini, Sandra/0000-0001-6617-1644; Morbidelli, Lucia/0000-0001-8148-7049; MEMO, Maurizio/0000-0002-7543-0289				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; Barillari G, 1999, BLOOD, V94, P663; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Esteban JA, 2004, TRENDS NEUROSCI, V27, P1, DOI 10.1016/j.tins.2003.10.008; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; Genersch E, 2000, J CELL SCI, V113, P4319; HAASS C, 1992, NATURE, V359, P325; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; Li QX, 1998, LAB INVEST, V78, P461; Lindahl B, 1999, J BIOL CHEM, V274, P30631, DOI 10.1074/jbc.274.43.30631; Mandriota SJ, 1997, J CELL SCI, V110, P2293; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; Morbidelli L, 2003, CLIN CANCER RES, V9, P5358; MORBIDELLI L, 1996, AM J PHYSIOL, V270, P411; Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Price JM, 2001, NEUROL RES, V23, P506, DOI 10.1179/016164101101198758; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Taraboletti G, 2000, FASEB J, V14, P1674; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Xu J, 2001, J CEREBR BLOOD F MET, V21, P702, DOI 10.1097/00004647-200106000-00008; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	40	47	49	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1943	+		10.1096/fj.04-2114fje	http://dx.doi.org/10.1096/fj.04-2114fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15448110				2022-12-28	WOS:000224243200011
J	Gragasin, FS; Michelakis, ED; Hogan, A; Moudgil, R; Hashimoto, K; Wu, XC; Bonnet, S; Haromy, A; Archer, SL				Gragasin, FS; Michelakis, ED; Hogan, A; Moudgil, R; Hashimoto, K; Wu, XC; Bonnet, S; Haromy, A; Archer, SL			The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels	FASEB JOURNAL			English	Article						laser capture microdissection; protein kinase G; electrical field stimulation; sildenafil; phosphodiesterase 5; nitric oxide electrode	FEMALE SEXUAL DYSFUNCTION; CAVERNOSUM SMOOTH-MUSCLE; DEPENDENT PROTEIN-KINASE; GENE-TRANSFER; CORPUS CAVERNOSUM; BLOOD-FLOW; TYPE-5 PHOSPHODIESTERASE; PULMONARY-HYPERTENSION; CORPORA CAVERNOSA; DUCTUS-ARTERIOSUS	Female sexual function is under-studied, and mechanisms of clitoral engorgement-relaxation are incompletely understood. Penile erection results from nitric oxide (NO)-induced cyclic guanosine monophosphate (cGMP) accumulation. cGMP-dependent protein kinase (PKG) activates large-conductance, calcium- activated potassium channels (BKCa), thereby hyperpolarizing and relaxing vascular and trabecular smooth muscle cells, allowing engorgement. We hypothesize rat clitorises relax by a similar mechanism. Rat clitorises express components of the proposed pathway: neuronal and endothelial NO synthases, soluble guanylyl cyclase (sGC), type 5 phosphodiesterase (PDE-5), and BKCa channels. The NO donor diethylamine NONOate ( DEANO), the PKG activator 8-pCPT-cGMP, and the PDE-5 inhibitor sildenafil, cause dose-dependent clitoral relaxation that is inhibited by antagonists of PKG (Rp-8-Br-cGMPS) or BKCa channels (iberiotoxin). Electrical field stimulation induces tetrodotoxin- sensitive NO release and relaxation that is inhibited by the Na+ channel blocker tetrodotoxin or sGC inhibitor H-1-(1,2,4) oxadiozolo(4,3-a) quinoxalin-1-one. Human BKCa channels, transferred to Chinese hamster ovary cells via an adenoviral vector, and endogenous rat clitoral smooth muscle K+ current are activated by this PKG-dependent mechanism. Laser confocal microscopy reveals protein expression of BKCa channels on clitoral smooth muscle cells; these cells exhibit BKCa channel activity that is activated by both DEANO and sildenafil. We conclude that neurovascular derived NO causes clitoral relaxation via a PKG-dependent activation of BKCa channels. The BKCa channel is an appealing target for drug therapy of female erectile dysfunction.	Univ Alberta, Div Cardiol, Dept Med, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Vasc Biol Grp, Edmonton, AB T6G 2B7, Canada	University of Alberta; University of Alberta	Archer, SL (corresponding author), Univ Alberta, Div Cardiol, Dept Med, WMC 2C-36,8440 112th St, Edmonton, AB T6G 2B7, Canada.	sarcher@cha.ab.ca	Archer, Stephen L/C-3621-2013		NHLBI NIH HHS [R01-HL071115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angulo J, 2003, INT J IMPOT RES, V15, P137, DOI 10.1038/sj.ijir.3900985; Archer SL, 2003, CIRCULATION, V107, P769, DOI 10.1161/01.CIR.0000047278.28407.C2; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; Avis N E, 2000, J Gend Specif Med, V3, P37; Bechara AJ, 2003, INT J IMPOT RES, V15, P166, DOI 10.1038/sj.ijir.3900982; Berman JR, 2001, J SEX MARITAL THER, V27, P411, DOI 10.1080/713846815; Berman JR, 1999, INT J IMPOT RES, V11, pS31, DOI 10.1038/sj.ijir.3900468; Bivalacqua TJ, 2000, INT J IMPOT RES, V12, pS8, DOI 10.1038/sj.ijir.3900556; Bivalacqua TJ, 2003, J UROLOGY, V169, P1911, DOI 10.1097/01.ju.0000051881.14239.4a; Bivalacqua TJ, 2003, AM J PHYSIOL-HEART C, V284, pH1408, DOI 10.1152/ajpheart.00770.2002; Burchardt T, 2000, J UROLOGY, V164, P1807, DOI 10.1016/S0022-5347(05)67111-X; Burnett AL, 1997, J UROLOGY, V158, P75, DOI 10.1097/00005392-199707000-00020; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; Cellek S, 1998, BRIT J PHARMACOL, V125, P1627, DOI 10.1038/sj.bjp.0702278; Champion HC, 1999, P NATL ACAD SCI USA, V96, P11648, DOI 10.1073/pnas.96.20.11648; Christ GJ, 1998, AM J PHYSIOL-HEART C, V275, pH600, DOI 10.1152/ajpheart.1998.275.2.H600; D'amati G, 2002, UROLOGY, V60, P191, DOI 10.1016/S0090-4295(02)01663-1; GILLAN P, 1979, PSYCHOPHYSIOLOGY, V16, P471, DOI 10.1111/j.1469-8986.1979.tb01507.x; Gragasin FS, 2003, ARTERIOSCL THROM VAS, V23, P38, DOI 10.1161/01.ATV.0000047868.93732.B7; Haas CA, 1998, UROLOGY, V51, P516, DOI 10.1016/S0090-4295(97)00715-2; Hampl V, 1996, CARDIOVASC RES, V31, P55, DOI 10.1016/0008-6363(95)00172-7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; Holdiman AJ, 2002, MOL CELL ENDOCRINOL, V192, P1, DOI 10.1016/S0303-7207(02)00136-3; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1; Kim Young Chan, 1994, Yonsei Medical Journal, V35, P308; LEVIN RJ, 1980, CLIN OBSTET GYNAECOL, V7, P213; Lin JSN, 2001, UROLOGY, V57, P837, DOI 10.1016/S0090-4295(00)01097-9; MacRitchie AN, 1997, CIRC RES, V81, P355, DOI 10.1161/01.RES.81.3.355; Michelakis ED, 2002, CIRC RES, V90, P1307, DOI 10.1161/01.RES.0000024689.07590.C2; Michelakis ED, 2002, CIRC RES, V91, P478, DOI 10.1161/01.RES.0000035057.63303.D1; MORLEY D, 1993, J CARDIOVASC PHARM, V22, pS3, DOI 10.1097/00005344-199306227-00003; Munarriz R, 2003, J UROLOGY, V170, pS40, DOI 10.1097/01.ju.0000075352.03144.15; NAKAZAWA M, 1994, EUR J PHARMACOL, V253, P179; Node K, 1997, FASEB J, V11, P793, DOI 10.1096/fasebj.11.10.9271364; Park JK, 2002, EXP BIOL MED, V227, P1022, DOI 10.1177/153537020222701111; Park K, 2000, INT J IMPOT RES, V12, P111, DOI 10.1038/sj.ijir.3900514; Park K, 1997, INT J IMPOT RES, V9, P27, DOI 10.1038/sj.ijir.3900258; Park K, 2002, J UROLOGY, V168, P1269, DOI 10.1016/S0022-5347(05)64638-1; Park K, 1998, BIOCHEM BIOPH RES CO, V249, P612, DOI 10.1006/bbrc.1998.9206; Park K, 2001, INT J IMPOT RES, V13, P116, DOI 10.1038/sj.ijir.3900655; Pozeg ZI, 2003, CIRCULATION, V107, P2037, DOI 10.1161/01.CIR.0000062688.76508.B3; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Rosenfeld CR, 2002, VASC PHARMACOL, V38, P115, DOI 10.1016/S0306-3623(02)00135-0; Seftel AD, 1997, UROLOGY, V50, P1016, DOI 10.1016/S0090-4295(97)00512-8; Shen WW, 1999, J REPROD MED, V44, P535; Sipski ML, 2000, UROLOGY, V55, P812, DOI 10.1016/S0090-4295(00)00493-3; Thebaud B, 2002, PEDIATR RES, V52, P19, DOI 10.1203/00006450-200207000-00006; Tristani-Firouzi M, 1998, J LAB CLIN MED, V131, P281, DOI 10.1016/S0022-2143(98)90101-9; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; Vachon P, 2000, INT J IMPOT RES, V12, P53, DOI 10.1038/sj.ijir.3900480; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Vemulapalli S, 2000, LIFE SCI, V67, P23, DOI 10.1016/S0024-3205(00)00596-8; WAGNER G, 1992, SEMIN NEUROL, V12, P87, DOI 10.1055/s-2008-1041161; Wallis RM, 1999, AM J CARDIOL, V83, p3C; Wei JY, 1998, J MOL NEUROSCI, V10, P53, DOI 10.1007/BF02737085	57	67	70	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1382	1391		10.1096/fj.04-1978com	http://dx.doi.org/10.1096/fj.04-1978com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333581				2022-12-28	WOS:000224243200057
J	Tschope, C; Spillmann, F; Rehfeld, U; Koch, M; Westermann, D; Altmann, C; Dendorfer, A; Walther, T; Bader, M; Paul, M; Schultheiss, HP; Vetter, R				Tschope, C; Spillmann, F; Rehfeld, U; Koch, M; Westermann, D; Altmann, C; Dendorfer, A; Walther, T; Bader, M; Paul, M; Schultheiss, HP; Vetter, R			Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene	FASEB JOURNAL			English	Article						bradykinin; cardiomyopathy; diabetes mellitus; phospholamban phosphorylation	CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; CALCIUM-TRANSPORT; DEPENDENT PHOSPHORYLATION; MYOCARDIAL-INFARCTION; CARDIAC MYOCYTES; BRADYKININ; PHOSPHOLAMBAN; CARDIOMYOPATHY; DYSFUNCTION; CA2+-ATPASE	The bradykinin-forming enzyme kallikrein-1 is expressed in the heart. To examine whether contractile performance and sarcoplasmic reticulum Ca2+ transport of the diabetic heart can be rescued by targeting the kallikrein-kinin system, we studied left ventricular function and sarcoplasmic reticular Ca2+ uptake after induction of streptozotocin-induced diabetes mellitus in transgenic rats expressing the human tissue kallikrein-1 gene. Six weeks after a single injection of either streptozotocin ( 70 mg/kg ip) or vehicle, left ventricular performance was determined using a Millar-Tip catheter system. The Ca2+-transporting activity of reticulum-derived membrane vesicles was determined in left ventricular homogenates as oxalate-supported Ca-45(2+) uptake. Western blot analysis was used to quantify the reticular Ca2+-ATPase SERCA2a, phospholamban, and the phosphorylation status of the latter. Contractile performance and Ca2+ uptake activity were similar in nondiabetic wild-type and transgenic rats. Severely diabetic wild-type animals exhibited impaired left ventricular performance and decreased reticular Ca2+ uptake (-39% vs. wild-type rats, P<0.05, respectively). These changes were attenuated in diabetic transgenic rats that, in addition, exhibited a markedly increased phospholamban phosphorylation at the Ca2+/calmodulin kinase-specific site threonine17 (2.2-fold vs. diabetic wild-type rats, P<0.05). These transgene-related effects were abolished after treatment with the bradykinin B-2 receptor antagonist icatibant (Hoe 140). The SERCA2-to-phospholamban ratio, phosphoserine(16)-phospholamban levels, and the apparent affinity for Ca2+ of the uptake reaction did not differ between the groups. Increasing the activity of the kallikrein-kinin system by expressing a human kallikrein-1 transgene protects rat heart against diabetes-induced contractile and reticular Ca2+ transport dysfunctions. An increased phosphorylation of the SERCA2 regulatory protein phospholamban at threonine(17) via a B-2 receptor-mediated mechanism is thereby involved.	Charite Univ Med Berlin, Dept Cardiol & Pneumol, D-12220 Berlin, Germany; Charite Univ Med Berlin, Inst Clin Pharmacol & Toxicol, D-12220 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Med Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, D-23538 Lubeck, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Lubeck	Tschope, C (corresponding author), Charite Univ Med Berlin, Dept Cardiol & Pneumol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12220 Berlin, Germany.	ctschoepe@yahoo.com	Paul, Martin/K-5425-2015; Bader, Michael/K-2124-2013; Westermann, Dirk/D-1344-2011	Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164; Spillmann, Frank/0000-0003-0002-5745; Westermann, Dirk/0000-0002-7542-1956				Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; Bidasee KR, 2004, DIABETES, V53, P463, DOI 10.2337/diabetes.53.2.463; Bischoff A, 1999, PFLUG ARCH EUR J PHY, V438, P797, DOI 10.1007/s004240051109; DHALLA NS, 1992, MOL CELL BIOCHEM, V116, P3, DOI 10.1007/BF01270562; DIXON IMC, 1990, MOL CELL BIOCHEM, V99, P125; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; Emanueli C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8; Fujii M, 2002, HYPERTENSION, V39, P952, DOI 10.1161/01.HYP.0000015613.78314.9E; GANGULY PK, 1983, AM J PHYSIOL, V244, pE528, DOI 10.1152/ajpendo.1983.244.6.E528; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; KAWAGUCHI H, 1993, CIRC RES, V72, P966, DOI 10.1161/01.RES.72.5.966; Koch M, 2003, AM J PHYSIOL-HEART C, V285, pH418, DOI 10.1152/ajpheart.00677.2002; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Kotsanas G, 2000, CARDIOVASC RES, V46, P450, DOI 10.1016/S0008-6363(00)00062-6; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; Kudoh A, 2002, J CARDIOVASC PHARM, V39, P621, DOI 10.1097/00005344-200205000-00001; Kuwahara Y, 1997, BASIC RES CARDIOL, V92, P214, DOI 10.1007/BF00788516; Maier LS, 2002, J MOL CELL CARDIOL, V34, P919, DOI 10.1006/jmcc.2002.2038; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; Netticadan T, 2001, DIABETES, V50, P2133, DOI 10.2337/diabetes.50.9.2133; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; PENPARGKUL S, 1981, J MOL CELL CARDIOL, V13, P303, DOI 10.1016/0022-2828(81)90318-7; PENPARGKUL S, 1980, CIRC RES, V47, P911, DOI 10.1161/01.RES.47.6.911; Pierce GN, 1997, CARDIOVASC RES, V34, P41, DOI 10.1016/S0008-6363(97)00010-2; PIERCE GN, 1983, P NATL ACAD SCI-BIOL, V80, P5412, DOI 10.1073/pnas.80.17.5412; Pinto YM, 2000, FASEB J, V14, P1861; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; Rett K, 1997, AM J CARDIOL, V80, pA143, DOI 10.1016/S0002-9149(97)00470-0; Schannwell CM, 2002, CARDIOLOGY, V98, P33, DOI 10.1159/000064682; Sharma JN, 1996, IMMUNOPHARMACOLOGY, V33, P341, DOI 10.1016/0162-3109(96)00104-X; Sharma JN, 1998, INT J CARDIOL, V63, P229, DOI 10.1016/S0167-5273(97)00329-X; Shiuchi T, 2002, HYPERTENSION, V40, P329, DOI 10.1161/01.HYP.0000028979.98877.0C; Silva JA, 2000, FASEB J, V14, P1858; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Spillmann F, 2002, INT IMMUNOPHARMACOL, V2, P1823, DOI 10.1016/S1567-5769(02)00174-1; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; Tschope C, 2004, FASEB J, V18, P828, DOI 10.1096/fj.03-0736com; Tschope C, 2004, CARDIOVASC RES, V61, P559, DOI 10.1016/j.cardiores.2003.10.018; Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P35, DOI 10.1016/S0162-3109(99)00109-5; Vetter R, 2002, FASEB J, V16, P1657, DOI 10.1096/fj.01-1019fje; Vetter R, 1998, MOL CELL BIOCHEM, V188, P177, DOI 10.1023/A:1006850724830; Vittone L, 1998, J BIOL CHEM, V273, P9804, DOI 10.1074/jbc.273.16.9804; XU A, 1993, J BIOL CHEM, V268, P8394; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25	45	27	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1967	+		10.1096/fj.04-1614fje	http://dx.doi.org/10.1096/fj.04-1614fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15448111				2022-12-28	WOS:000224243200012
J	Hong, YK; Lange-Asschenfeldt, B; Velasco, P; Hirakawa, S; Kunstfeld, R; Brown, LF; Bohlen, P; Senger, DR; Detmar, M				Hong, YK; Lange-Asschenfeldt, B; Velasco, P; Hirakawa, S; Kunstfeld, R; Brown, LF; Bohlen, P; Senger, DR; Detmar, M			VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha 1 beta 1 and alpha 2 beta 1 integrins	FASEB JOURNAL			English	Article						VEGF; lymphangiogenesis; wound healing; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; LYMPHANGIOGENESIS; ANGIOGENESIS; MECHANISMS; SKIN; KERATINOCYTES; EXPRESSION; DELIVERY; RECEPTOR; WOUNDS	Vascular endothelial growth factor-A (VEGF-A) is strongly up-regulated in wounded cutaneous tissue and promotes repair-associated angiogenesis. However, little is known about its role in lymphatic regeneration of the healing skin. We studied wound healing in transgenic mice that overexpress VEGF-A specifically in the epidermis and in wild-type mice in the absence or presence of inhibitors of VEGF-A signaling. Surprisingly, transgenic overexpression of VEGF-A in the skin promoted lymphangiogenesis at the wound healing site, whereas systemic blockade of VEGFR-2 prevented lymphatic vessel formation. Studies in cultured lymphatic endothelial cells revealed that VEGF-A induced expression of the alpha1 and alpha2 integrins, which promoted their in vitro tube formation and their haptotactic migration toward type I collagen. VEGF-A-induced lymphatic endothelial cord formation and haptotactic migration were suppressed by anti-alpha1 and anti-alpha2 integrin blocking antibodies, and systemic blockade of the alpha1 and alpha2 integrins inhibited VEGF-A-driven lymphangiogenesis in vivo. We propose that VEGF-A promotes lymphatic vasculature formation via activation of VEGFR-2 and that lineage-specific differences of integrin receptor expression contribute to the distinct dynamics of wound-associated angiogenesis and lymphangiogenesis.	Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA; ImClone Syst Inc, New York, NY USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Eli Lilly	Detmar, M (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	michael.detmar@cbrc2.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410, P01CA092644, R01CA077357] Funding Source: NIH RePORTER; NCI NIH HHS [CA92644, CA86410, CA77357, CA69184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; ARNOLD F, 1991, PHARMACOL THERAPEUT, V52, P407, DOI 10.1016/0163-7258(91)90034-J; BELLMAN S, 1959, Acta Chir Scand, V116, P99; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Hawighorst T, 2002, ONCOGENE, V21, P7945, DOI 10.1038/sj.onc.1205956; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Inoue K, 2000, CLIN CANCER RES, V6, P2635; Jacobi J, 2004, GENE THER, V11, P302, DOI 10.1038/sj.gt.3302162; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nissen NN, 1998, AM J PATHOL, V152, P1445; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Tsou R, 2002, WOUND REPAIR REGEN, V10, P222, DOI 10.1046/j.1524-475X.2002.10405.x; Whelan MC, 2003, J BIOL CHEM, V278, P327, DOI 10.1074/jbc.M207554200; Witte MH, 2001, MICROSC RES TECHNIQ, V55, P122, DOI 10.1002/jemt.1163; Xia YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood-2002-12-3793; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317	31	230	253	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1111	+		10.1096/fj.03-1179fje	http://dx.doi.org/10.1096/fj.03-1179fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132990				2022-12-28	WOS:000221883200026
J	Suzuki, K; Murtuza, B; Beauchamp, JR; Smolenski, RT; Varela-Carver, A; Fukushima, S; Coppen, SR; Partridge, TA; Yacoub, MH				Suzuki, K; Murtuza, B; Beauchamp, JR; Smolenski, RT; Varela-Carver, A; Fukushima, S; Coppen, SR; Partridge, TA; Yacoub, MH			Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart	FASEB JOURNAL			English	Article						myeloperoxidase; Smcy gene; [C-14] thymidine	CELL TRANSPLANTATION; SKELETAL-MUSCLE; SURVIVAL; MYOCARDIUM; ANTIGEN; SYSTEM; MODEL	Survival and proliferation of skeletal myoblasts within the cardiac environment are crucial to the therapeutic efficacy of myoblast transplantation to the heart. We have analyzed the early dynamics of myoblasts implanted into the myocardium and investigated the mechanisms underlying graft attrition. At 10 min after implantation of [C-14] thymidine-labeled male myoblasts into female mice hearts, C-14 measurement showed that 39.2 +/- 3.0% of the grafted cells survived, and this steadily decreased to 16.0 +/- 1.7% by 24 h and to 7.4 +/- 0.9% by 72 h. PCR of male-specific Smcy gene calculated that the total ( surviving plus proliferated) number of donor-derived cells was 18.3 +/- 1.6 and 23.3 +/- 1.3% at 24 and 72 h, respectively, indicating that proliferation of the surviving cells began after 24 h. Acute inflammation became prominent by 24 h and was reduced by 72 h as indicated by myeloperoxidase activity and histological findings. Multiplex RT-PCR revealed corresponding changes in IL-1beta, TGF-beta, IL-6, and TNF-alpha expression. Treatment with CuZn-superoxide dismutase attenuated the initial rapid death and resulted in enhanced cell numbers afterward, giving a twofold increased total number at 72 h compared with the nontreatment. This effect was associated with reduced inflammatory response, suggesting a causative role for superoxide in the initial rapid graft death and subsequent inflammation. These data describe the early dynamics of myoblasts implanted into the myocardium and suggest that initial oxidative stress and following inflammatory response may be important mechanisms contributing to acute graft attrition, both of which could be potential therapeutic targets to improve the efficiency of cell transplantation to the heart.	Natl Heart & Lung Inst, Harefield Heart Sci Ctr, Cell & Gene Therapy Grp, Harefield UB9 6JH, Middx, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, MRC,Clin Sci Ctr,Muscle Cell Biol Grp, London SW7 2AZ, England	Imperial College London; Imperial College London	Suzuki, K (corresponding author), Natl Heart & Lung Inst, Harefield Heart Sci Ctr, Cell & Gene Therapy Grp, Harefield UB9 6JH, Middx, England.	k.suzuki@ic.ac.uk	Smolenski, Ryszard T/B-9713-2013	Beauchamp, Jonathan/0000-0003-2067-3088; Smolenski, Ryszard/0000-0002-0190-9414	Medical Research Council [G116/158] Funding Source: Medline; MRC [G116/158] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agulnik AI, 1999, MAMM GENOME, V10, P926, DOI 10.1007/s003359901116; Barbero A, 2001, J CELL PHYSIOL, V186, P183, DOI 10.1002/1097-4652(200102)186:2<183::AID-JCP1020>3.3.CO;2-H; Beauchamp JR, 1997, TRANSPLANTATION, V63, P1794, DOI 10.1097/00007890-199706270-00015; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; BURTON KP, 1985, AM J PHYSIOL, V248, pH637, DOI 10.1152/ajpheart.1985.248.5.H637; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Hodgetts SI, 2003, TRANSPLANTATION, V75, P863, DOI 10.1097/01.TP.0000053754.33317.4B; Ing DJ, 1999, CIRC RES, V84, P21; Leobon B, 2003, P NATL ACAD SCI USA, V100, P7808, DOI 10.1073/pnas.1232447100; Marelli D, 1992, Cell Transplant, V1, P383; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Merly F, 1998, TRANSPLANTATION, V65, P793, DOI 10.1097/00007890-199803270-00005; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Muller-Ehmsen J, 2002, J MOL CELL CARDIOL, V34, P107, DOI 10.1006/jmcc.2001.1491; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; Murtuza B, 2004, P NATL ACAD SCI USA, V101, P4216, DOI 10.1073/pnas.0306205101; Pouzet B, 2001, ANN THORAC SURG, V71, P844, DOI 10.1016/S0003-4975(00)01785-9; Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0; Skuk D, 2002, CELL TRANSPLANT, V11, P671, DOI 10.3727/000000002783985378; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Suzuki K, 2000, CIRCULATION, V102, P359; Suzuki K, 2000, CIRCULATION, V102, P216; Suzuki K, 2002, TRANSPLANTATION, V73, P1398, DOI 10.1097/00007890-200205150-00007; Suzuki K, 2002, J THORAC CARDIOV SUR, V123, P984, DOI 10.1067/mtc.2002.121507; Suzuki K, 2001, CIRCULATION, V104, pI308; Suzuki K, 1999, ANN THORAC SURG, V68, P1266, DOI 10.1016/S0003-4975(99)00726-2; Suzuki K, 2001, CIRCULATION, V104, pI207; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929	31	136	143	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1153	+		10.1096/fj.03-1308fje	http://dx.doi.org/10.1096/fj.03-1308fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155562				2022-12-28	WOS:000221883200007
J	Zampetaki, A; Mitsialis, SA; Pfeilschifter, J; Kourembanas, S				Zampetaki, A; Mitsialis, SA; Pfeilschifter, J; Kourembanas, S			Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappa B: the prominent role of p42/p44 and PI3 kinase pathways	FASEB JOURNAL			English	Article						chemokines; signaling pathways	NECROSIS-FACTOR-ALPHA; RNA POLYMERASE-II; DEPENDENT TRANSCRIPTION; BETA ENHANCEOSOME; RELA/P65 SUBUNIT; LUNG INJURY; IN-VIVO; ACTIVATION; PHOSPHORYLATION; CHEMOKINES	We have previously reported that hypoxia induces a pronounced inflammatory response in the mouse lung associated with elevated levels of specific chemokines. To further explore the mechanisms involved in lung inflammation, we exposed RAW 264.7 cells as well as mouse primary macrophages to hypoxia and analyzed chemokine gene expression. Among the genes examined, macrophage inflammatory protein-2 (MIP-2) expression was prominently induced by hypoxia both at the mRNA and the protein level. When RAW 264.7 cells were transfected with a panel of plasmids harboring a luciferase marker gene under the control of wild-type or mutant variants of the MIP-2 gene promoter, a strong hypoxic induction of expression (9- to 17-fold) was observed. This induction was abolished by a mutation targeted to an NF-kappaB binding site in the MIP-2 promoter. Concordantly, specific NF-kappaB binding to the cognate sequence was enriched in nuclear extracts from hypoxic but not normoxic RAW 264.7 cells. The mechanism of MIP-2 gene induction by hypoxia was further characterized using inhibitors of signaling kinases. Inhibition of the p42/p44 and PI3 kinases but not p38 MAPK abolished the NF-kappaB-driven upregulation of MIP-2 gene expression by hypoxia. This attenuation of the NF-kappaB response to hypoxia did not involve decreased nuclear NF-kappaB abundance but correlated with diminished transactivation potential of the p65 subunit. Our results indicate that the hypoxic signal for induction of MIP-2 gene expression is implemented through enhanced NF-kappaB activity and transmitted along the p42/44 and PI3 kinase pathways.	Childrens Hosp, Dept Med, Div Newborn Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, D-6000 Frankfurt, Germany	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Kourembanas, S (corresponding author), Childrens Hosp, Dept Med, Div Newborn Med, 300 Longwood Ave,Enders 9, Boston, MA 02115 USA.	stella.kourembanas@childrens.Harvard.edu		Zampetaki, Anna/0000-0002-7257-8624; Mitsialis, S. Alex/0000-0001-8315-7828	NHLBI NIH HHS [R01 HL55454, 5P50 HL67669] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067669, R01HL055454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantrell DA, 2001, J CELL SCI, V114, P1439; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chandel NS, 2000, J IMMUNOL, V165, P1013, DOI 10.4049/jimmunol.165.2.1013; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Galindo M, 2001, CLIN EXP IMMUNOL, V123, P36, DOI 10.1046/j.1365-2249.2001.01412.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; KOONG AC, 1994, CANCER RES, V54, P5273; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Leeper-Woodford SK, 1999, AM J PHYSIOL-LUNG C, V276, pL909, DOI 10.1152/ajplung.1999.276.6.L909; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Madjdpour C, 2003, AM J PHYSIOL-LUNG C, V284, pL360, DOI 10.1152/ajplung.00158.2002; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Minamino T, 2001, P NATL ACAD SCI USA, V98, P8798, DOI 10.1073/pnas.161272598; Ozes ON, 1999, NATURE, V401, P82; Pearlstein DP, 2002, ARTERIOSCL THROM VAS, V22, P566, DOI 10.1161/01.ATV.0000012262.76205.6A; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmal H, 1996, J IMMUNOL, V156, P1963; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Shanley TP, 1997, J IMMUNOL, V158, P3439; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222; Strieter RM, 1999, CHEST, V116, p103S, DOI 10.1378/chest.116.suppl_1.103S; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Walpen S, 2001, FASEB J, V15, P571; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WIDMER U, 1993, J IMMUNOL, V150, P4996; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470; Xu L, 1999, CANCER RES, V59, P5822; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	67	72	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1090	+		10.1096/fj.03-0991fje	http://dx.doi.org/10.1096/fj.03-0991fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132979				2022-12-28	WOS:000221883200014
J	Jansen, R; Metzdorf, R; van der Roest, M; Fusani, L; ter Maat, A; Gahr, M				Jansen, R; Metzdorf, R; van der Roest, M; Fusani, L; ter Maat, A; Gahr, M			Melatonin affects the temporal organization of the song of the zebra finch	FASEB JOURNAL			English	Article						songbird; song system; RA	TAENIOPYGIA-GUTTATA; MOLECULAR-BIOLOGY; CIRCADIAN SYSTEM; POEPHILA-GUTTATA; GENE-EXPRESSION; CHICK BRAIN; BIRD SONG; RECEPTORS; NUCLEUS; HIPPOCAMPUS	In birds and mammals, including humans, melatonin-binding sites are abundant in brain areas that have no known clock function. Although the role of such binding sites is still unclear, it is assumed that these sites link neural functions to circadian or circannual demands of neuroendocrine homeostasis and reproduction. To investigate a possible direct role of melatonin in motor control, we studied the song and neural song system of the zebra finch. Neurons of two sensory-motor areas of the descending song control circuit that are crucial for the organization of the song pattern, the HVC and RA, express the melatonin-1B receptor (Mel(1B)), while the hypoglossal motor neurons of the song circuit express melatonin-1C receptors (Mel(1C)). Application of melatonin to brain slices decreases the firing-rate of RA-neurons. Systemic administration of a Mel1B antagonist at the beginning of the night shortens the song and motif length and affects the song syllable lengths produced the next day. The temporal pattern of the song, however, does not undergo daily changes. Thus, melatonin is likely to affect a non-circadian motor pattern by local modulation of song control neurons and in consequence alters a sexual signal, the song of the zebra finch.	Vrije Univ Amsterdam, Fac Earth & Life Sci, Inst Neurosci, Dept Dev & Behav Neurosci, NL-1081 HV Amsterdam, Netherlands; Univ Siena, Dipartimento Fisiol, Sez Neurosci & Fisiol Appl, I-53100 Siena, Italy	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; University of Siena	Gahr, M (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Inst Neurosci, Dept Dev & Behav Neurosci, 1087 De Boelelaan, NL-1081 HV Amsterdam, Netherlands.	Gahr@bio.vu.nl		Fusani, Leonida/0000-0001-8900-796X				Adachi A, 2002, GLIA, V39, P268, DOI 10.1002/glia.10109; Adret P, 2002, J COMP NEUROL, V454, P409, DOI 10.1002/cne.10459; Al-Ghoul WM, 1998, NEUROREPORT, V9, P4063, DOI 10.1097/00001756-199812210-00011; ARNOLD AP, 1975, J EXP ZOOL, V191, P309, DOI 10.1002/jez.1401910302; Aste N, 2001, MICROSC RES TECHNIQ, V55, P37, DOI 10.1002/jemt.1154; Ball GF, 2001, MICROSC RES TECHNIQ, V54, P327, DOI 10.1002/jemt.1146; Bentley GE, 2000, J NEUROENDOCRINOL, V12, P745, DOI 10.1046/j.1365-2826.2000.00523.x; Bentley GE, 1999, P NATL ACAD SCI USA, V96, P4674, DOI 10.1073/pnas.96.8.4674; Bentley GE, 2001, MICROSC RES TECHNIQ, V53, P63, DOI 10.1002/jemt.1069; Brainard MS, 2000, NAT REV NEUROSCI, V1, P31, DOI 10.1038/35036205; Brandstatter R, 2003, J NEUROENDOCRINOL, V15, P398, DOI 10.1046/j.1365-2826.2003.01003.x; Brotto LA, 2000, EUR J PHARMACOL, V402, P87, DOI 10.1016/S0014-2999(00)00491-X; Chi ZY, 2001, NEURON, V32, P899, DOI 10.1016/S0896-6273(01)00524-4; CLAYTON NS, 1990, PHILOS T R SOC B, V330, P351, DOI 10.1098/rstb.1990.0205; Cook T.C., 1979, QUASIEXPERIMENTATION; Dave AS, 2000, SCIENCE, V290, P812, DOI 10.1126/science.290.5492.812; Dave AS, 1998, SCIENCE, V282, P2250, DOI 10.1126/science.282.5397.2250; El-Sherif Y, 2003, J NEUROSCI RES, V72, P454, DOI 10.1002/jnr.10605; Fee MS, 1996, J NEUROSCI METH, V69, P175, DOI 10.1016/S0165-0270(96)00050-7; Fraschini F, 1999, BIOL SIGNAL RECEPT, V8, P111; Gahr M, 1996, J COMP NEUROL, V367, P308; Gahr M, 1999, J NEUROSCI, V19, P2628; GUPTA BBP, 1987, GEN COMP ENDOCR, V65, P451, DOI 10.1016/0016-6480(87)90131-6; Gwinner E, 1997, BRAIN RES BULL, V44, P439, DOI 10.1016/S0361-9230(97)00224-4; GWINNER E, 2000, DIVERSITY COMPLEXITY, P201; Hahnloser RHR, 2002, NATURE, V419, P65, DOI 10.1038/nature00974; HARDING CF, 1983, HORM BEHAV, V17, P111, DOI 10.1016/0018-506X(83)90021-1; Immelmann K., 1962, Zoologische Jahrbuecher Systematik, V90, P1; JANSEN RF, 1992, J NEUROSCI METH, V41, P123, DOI 10.1016/0165-0270(92)90055-I; Jarvis ED, 1998, NEURON, V21, P775, DOI 10.1016/S0896-6273(00)80594-2; Jin XW, 2003, MOL CELL BIOL, V23, P1054, DOI 10.1128/MCB.23.3.1054-1060.2003; Johnson F, 2002, BEHAV BRAIN RES, V131, P57, DOI 10.1016/S0166-4328(01)00374-6; Laurido C, 2002, NEUROREPORT, V13, P89, DOI 10.1097/00001756-200201210-00021; LIU F, 1995, FEBS LETT, V374, P273, DOI 10.1016/0014-5793(95)01129-3; Mazzucchelli C, 1996, MOL BRAIN RES, V39, P117, DOI 10.1016/0169-328X(96)00017-4; MOONEY R, 1992, J NEUROSCI, V12, P2464; Musshoff U, 2002, HIPPOCAMPUS, V12, P165, DOI 10.1002/hipo.1105; Neubauer RL, 1999, EVOL ECOL, V13, P365, DOI 10.1023/A:1006708826432; OLLASON JC, 1973, ANIM BEHAV, V21, P191, DOI 10.1016/S0003-3472(73)80059-4; Pevet P, 2003, J NEUROENDOCRINOL, V15, P422, DOI 10.1046/j.1365-2826.2003.01017.x; Podda MV, 2003, NEUROSCI LETT, V341, P209, DOI 10.1016/S0304-3940(03)00209-X; PROVE E, 1982, HORM BEHAV, V16, P121, DOI 10.1016/0018-506X(82)90013-7; Prove E., 1974, J ORNITHOLOGIE, V115, P338, DOI DOI 10.1007/BF01644328; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; Reppert SM, 1996, TRENDS PHARMACOL SCI, V17, P100, DOI 10.1016/0165-6147(96)10005-5; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Reppert SM, 1997, J BIOL RHYTHM, V12, P528, DOI 10.1177/074873049701200606; Riters LV, 1999, HORM BEHAV, V36, P276, DOI 10.1006/hbeh.1999.1549; RIVKEES SA, 1989, ENDOCRINOLOGY, V125, P363, DOI 10.1210/endo-125-1-363; Rozenboim I, 2002, POULTRY SCI, V81, P1354, DOI 10.1093/ps/81.9.1354; Savaskan E, 2002, J PINEAL RES, V32, P59, DOI 10.1034/j.1600-079x.2002.00841.x; SOSSINKA R, 1980, Z TIERPSYCHOL, V53, P123; Spiro JE, 1999, J NEUROPHYSIOL, V81, P3007, DOI 10.1152/jn.1999.81.6.3007; Thomas L, 2002, J PINEAL RES, V33, P218, DOI 10.1034/j.1600-079X.2002.02921.x; Uz T, 2003, NEUROPSYCHOPHARMACOL, V28, P2117, DOI 10.1038/sj.npp.1300254; Vanecek J, 1998, PHYSIOL REV, V78, P687, DOI 10.1152/physrev.1998.78.3.687; VantHof TJ, 1996, EXPERIENTIA, V52, P249, DOI 10.1007/BF01920717; von Gall C, 2002, CELL TISSUE RES, V309, P151, DOI 10.1007/s00441-002-0581-4; VU ET, 1994, J NEUROSCI, V14, P6924; WhitfieldRucker MG, 1996, HORM BEHAV, V30, P528, DOI 10.1006/hbeh.1996.0056; Wild JM, 1998, J NEUROBIOL, V36, P441, DOI 10.1002/(SICI)1097-4695(19980905)36:3<441::AID-NEU11>3.0.CO;2-E; Williams LM, 1999, J PINEAL RES, V26, P43, DOI 10.1111/j.1600-079X.1999.tb00565.x; Ying SW, 1996, EUR J PHARMACOL, V296, P33, DOI 10.1016/0014-2999(95)00684-2; Yu AC, 1996, SCIENCE, V273, P1871, DOI 10.1126/science.273.5283.1871	65	36	36	3	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					848	+		10.1096/fj.04-2874fje	http://dx.doi.org/10.1096/fj.04-2874fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746187				2022-12-28	WOS:000227901300028
J	Li, YP; Chen, YL; John, J; Moylan, J; Jin, BW; Mann, DL; Reid, MB				Li, YP; Chen, YL; John, J; Moylan, J; Jin, BW; Mann, DL; Reid, MB			TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle	FASEB JOURNAL			English	Article						tumor necrosis factor; muscle wasting; ubituitin conjugating activity	NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTORS; CONJUGATING ACTIVITY; OXIDATIVE STRESS; MESSENGER-RNAS; PROTEIN LOSS; ACTIVATION; PATHWAY; INHIBITOR; ATROGIN-1	Atrogin1/MAFbx is an ubiquitin ligase that mediates muscle atrophy in a variety of catabolic states. We recently found that H2O2 stimulates atrogin1/MAFbx gene expression. Since the cytokine tumor necrosis factor-alpha (TNF-alpha) stimulates both reactive oxygen production and general activity of the ubiquitin conjugating pathway, we hypothesized that TNF-alpha would also increase atrogin1/MAFbx gene expression. As with H2O2, we found that TNF-alpha exposure upregulates atrogin1/MAF-bx mRNA within 2 h in C2C12 myotubes. Intraperitoneal injection of TNF-alpha increased atrogin1/MAFbx mRNA in skeletal muscle of adult mice within 4 h. Exposing myotubes to either TNF-alpha or H2O2 also produced general activation of the mitogen-activated protein kinases (MAPKs): p38, ERK1/2, and JNK. The increase in atrogin1/MAFbx gene expression induced by TNF-alpha was not altered significantly by ERK inhibitor PD98059 or the JNK inhibitor SP600125. In contrast, atrogin1/MAFbx up-regulation and the associated increase in ubiquitin conjugating activity were both blunted by p38 inhibitors, either SB203580 or curcumin. These data suggest that TNF-alpha acts via p38 to increase atrogin1/MAFbx gene expression in skeletal muscle.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Kentucky, Coll Med, Dept Physiol, Med Ctr, Lexington, KY 40502 USA	Baylor College of Medicine; University of Kentucky	Li, YP (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	yiping@bcm.tmc.edu; michael.reid@uky.edu	Mann, Douglas Lowell/AAQ-3524-2021	Mann, Douglas/0000-0002-2516-0145	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061543, R01HL058081, R01HL059878, R01HL042250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059203] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59878, R01 HL058081, HL58081, R01 HL061543, HL42250-10/10, R01 HL059878, R01 HL042250] Funding Source: Medline; NIAMS NIH HHS [R01 AR049022-02, R01 AR049022, AR049022] Funding Source: Medline; NIGMS NIH HHS [GM59203] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1994, LIFE SCI, V55, P1383, DOI 10.1016/0024-3205(94)00752-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anker SD, 1999, CURR OPIN CARDIOL, V14, P211, DOI 10.1097/00001573-199905000-00004; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Carter Yvette, 2003, Surg Infect (Larchmt), V4, P17, DOI 10.1089/109629603764655245; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Childs TE, 2003, AM J PHYSIOL-CELL PH, V285, pC391, DOI 10.1152/ajpcell.00478.2002; Clanton TL, 1999, P SOC EXP BIOL MED, V222, P253, DOI 10.1046/j.1525-1373.1999.d01-142.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Di Giovanni S, 2004, ANN NEUROL, V55, P195, DOI 10.1002/ana.10811; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; KONDO H, 2000, HDB OXIDANTS ANTIOXI, P631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Li X, 2000, CIRCULATION, V102, P1690, DOI 10.1161/01.CIR.102.14.1690; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Li YP, 2001, CURR OPIN RHEUMATOL, V13, P483, DOI 10.1097/00002281-200111000-00005; LIU YC, 1990, BIOTECHNIQUES, V9, P558; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; Reid MB, 2001, ACTA PHYSIOL SCAND, V171, P225, DOI 10.1046/j.1365-201x.2001.00824.x; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Spiers S, 2000, ANN NY ACAD SCI, V908, P341; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; TESSITORE L, 1993, BRIT J CANCER, V67, P15, DOI 10.1038/bjc.1993.4; Tisdale MJ, 2000, SCIENCE, V289, P2293, DOI 10.1126/science.289.5488.2293; Tracey Kevin J, 2002, Sci STKE, V2002, ppe21; Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2	46	428	444	2	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					362	370		10.1096/fj.04-2364com	http://dx.doi.org/10.1096/fj.04-2364com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746179	Green Accepted			2022-12-28	WOS:000227901300036
J	Trauzold, A; Roder, C; Sipos, B; Karsten, K; Arlt, A; Jiang, P; Martin-Subero, JI; Siegmund, D; Muerkoster, S; Raluy, LP; Siebert, R; Wajant, H; Kalthoff, H				Trauzold, A; Roder, C; Sipos, B; Karsten, K; Arlt, A; Jiang, P; Martin-Subero, JI; Siegmund, D; Muerkoster, S; Raluy, LP; Siebert, R; Wajant, H; Kalthoff, H			CD95 and TRAF2 promote invasiveness of pancreatic cancer cells	FASEB JOURNAL			English	Article						apoptosis; invasion; uPA; MMP; IL-8	NF-KAPPA-B; CLASSICAL HODGKIN LYMPHOMA; PROTEIN-KINASE-C; CARCINOMA CELLS; CD95-MEDIATED APOPTOSIS; PLASMINOGEN-ACTIVATOR; ADENOCARCINOMA CELLS; FAS LIGAND; SIGNAL-TRANSDUCTION; MEDIATED APOPTOSIS	Pancreatic adenocarcinoma represents a tumor type with extremely poor prognosis. High apoptosis resistance and a strong invasive and early metastatic potential contribute to its highly malignant phenotype. Here we identified the death receptor adaptor molecule TRAF2 as a key player in pancreatic cancer pathophysiology. Using immunohistochemistry and Western blot analysis we found TRAF2 overexpressed in 34 of 36 pancreatic tumor samples as well as in pancreatic tumor cell lines resistant to CD95-mediated apoptosis. The high TRAF2 protein level was not related to chromosomal changes, as monitored by FISH analysis. Instead, the NF-kappaB- and MEK-signaling pathways were involved. Introduction of a TRAF2 expression vector in CD95-sensitive Colo357 cells resulted in (i) resistance to CD95-induced apoptosis; (ii) increased constitutive NF-kappaB and AP-1 activity; and (iii) higher basal secretion of matrix metalloproteinases ( MMPs), urokinase-type plasminogen activator (uPA), and IL-8, leading to increased invasiveness. High apoptosis resistance and uPA secretion could be reverted by TRAF2-specific siRNA. Stimulation of TRAF2-overexpressing cells with CD95 ligand led to induction of NF-kappaB and AP-1, enhanced IL-8- and uPA-secretion, and a further increased invasiveness. Thus, TRAF2 overexpression does not only block apoptosis induction by CD95 but also converts this death receptor into a mediator of invasiveness.	Univ Hosp Schleswig Holstein, Clin Gen Surg, Mol Oncol Unit, D-24105 Kiel, Germany; Univ Hosp Schleswig Holstein, Inst Pathol, D-24105 Kiel, Germany; Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, D-24105 Kiel, Germany; Univ Wurzburg, Dept Mol Internal Med, Med Polyclin, Wurzburg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Wurzburg	Kalthoff, H (corresponding author), Univ Hosp Schleswig Holstein, Clin Gen Surg, Mol Oncol Unit, Campus Kiel Arnold Heller Str 7, D-24105 Kiel, Germany.	hkalthoff@email.uni-kiel.de	Wajant, Harald/A-3020-2017; Sebens, Susanne/C-1222-2010; Trauzold, Anna/P-4398-2014; Roeder, Christian/F-1068-2010; Arlt, Alexander/G-7308-2019; Siebert, Reiner/A-8049-2010; Kalthoff, Holger/B-1618-2010	Wajant, Harald/0000-0002-2005-3949; Roeder, Christian/0000-0001-7881-9110; Arlt, Alexander/0000-0002-6160-1059; Martin-Subero, Jose Ignacio/0000-0001-8809-5195				Ademmer K, 1998, CLIN EXP IMMUNOL, V112, P21; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Bellone G, 2000, CLIN CANCER RES, V6, P2448; Butler LM, 1998, BRIT J CANCER, V77, P1454, DOI 10.1038/bjc.1998.239; Casey RC, 2003, CLIN EXP METASTAS, V20, P343, DOI 10.1023/A:1024009131191; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Chung JY, 2002, J CELL SCI, V115, P679; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Eggert A, 2001, CANCER RES, V61, P1314; Elnemr A, 2001, INT J ONCOL, V18, P311; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Harvey SR, 2003, CLIN CANCER RES, V9, P4935; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Irisarri M, 2000, LEUKEMIA, V14, P2149, DOI 10.1038/sj.leu.2401954; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jobin C, 1999, J IMMUNOL, V162, P4447; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Koshiba T, 1998, CANCER, V82, P642, DOI 10.1002/(SICI)1097-0142(19980215)82:4<642::AID-CNCR5>3.0.CO;2-N; Kuwada Y, 2003, INT J ONCOL, V22, P765; Loro LL, 1999, J ORAL PATHOL MED, V28, P82; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Martin-Subero JI, 2002, AM J PATHOL, V161, P413, DOI 10.1016/S0002-9440(10)64197-1; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Satoh K, 1999, PANCREAS, V19, P339, DOI 10.1097/00006676-199911000-00004; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Sliva D, 2002, BIOCHEM BIOPH RES CO, V290, P552, DOI 10.1006/bbrc.2001.6225; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Trauzold A, 2003, ONCOGENE, V22, P8939, DOI 10.1038/sj.onc.1207001; Trauzold A, 2003, BRIT J CANCER, V89, P1714, DOI 10.1038/sj.bjc.6601330; Ungefroren H, 2001, J CELL SCI, V114, P2735; Ungefroren H, 1998, CANCER RES, V58, P1741; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhu YM, 2003, J BIOL CHEM, V278, P29366, DOI 10.1074/jbc.M301785200	52	78	80	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					620	+		10.1096/fj.04-2984fje	http://dx.doi.org/10.1096/fj.04-2984fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15670977				2022-12-28	WOS:000226576600011
J	Cuthbertson, D; Smith, K; Babraj, J; Leese, G; Waddell, T; Atherton, P; Wackerhage, H; Taylor, PM; Rennie, MJ				Cuthbertson, D; Smith, K; Babraj, J; Leese, G; Waddell, T; Atherton, P; Wackerhage, H; Taylor, PM; Rennie, MJ			Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle	FASEB JOURNAL			English	Article						muscle protein synthesis; essential amino acids; sarcopenia; mTOR; p70(S6k)	HUMAN SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; WHOLE-BODY; TURNOVER; LEUCINE; AGE; AVAILABILITY; METABOLISM; HUMANS; YOUNG	The nature of the deficit underlying age-related muscle wasting remains controversial. To test whether it could be due to a poor anabolic response to dietary amino acids, we measured the rates of myofibrillar and sarcoplasmic muscle protein synthesis (MPS) in 44 healthy young and old men, of similar body build, after ingesting different amounts of essential amino acids (EAA). Basal rates of MPS were indistinguishable, but the elderly showed less anabolic sensitivity and responsiveness of MPS to EAA, possibly due to decreased intramuscular expression, and activation ( phosphorylation) after EAA, of amino acid sensing/signaling proteins ( mammalian target of rapamycin, mTOR; p70 S6 kinase, or p70(S6k); eukaryotic initiation factor [eIF] 4BP-1; and eIF2B). The effects were independent of insulin signaling since plasma insulin was clamped at basal values. Associated with the anabolic deficits were marked increases in NFkappaB, the inflammation-associated transcription factor. These results demonstrate first, EAA stimulate MPS independently of increased insulin availability; second, in the elderly, a deficit in MPS in the basal state is unlikely; and third, the decreased sensitivity and responsiveness of MPS to EAA, associated with decrements in the expression and activation of components of anabolic signaling pathways, are probably major contributors to the failure of muscle maintenance in the elderly. Countermeasures to maximize muscle maintenance should target these deficits.	Univ Nottingham, Sch Biomed Sci, City Hosp, Grad Entry Med Sch,Div Clin Physiol, Derby DE22 3DT, England; Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 4HN, Scotland; Ninewells Hosp & Med Sch, Tayside NHS Trust, Dept Med, Dundee DD1 9ST, Scotland; Univ Cent Lancashire, Dept Biol Sci, Preston PR1 2HE, Lancs, England	University of Nottingham; University of Dundee; University of Dundee; University of Central Lancashire	Rennie, MJ (corresponding author), Univ Nottingham, Sch Biomed Sci, City Hosp, Grad Entry Med Sch,Div Clin Physiol, Derby DE22 3DT, England.	michael.rennie@nottingham.ac.uk	Taylor, Peter M/A-4667-2010	Babraj, John/0000-0002-7427-7841; Smith, Ken/0000-0001-8971-6635; Cuthbertson, Daniel/0000-0002-6128-0822	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049869] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR49869] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENNET WM, 1991, DIABETIC MED, V8, P199, DOI 10.1111/j.1464-5491.1991.tb01572.x; BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; Bohe J, 2003, J PHYSIOL-LONDON, V552, P315, DOI 10.1113/jphysiol.2003.050674; Bohe J, 2001, J PHYSIOL-LONDON, V532, P575, DOI 10.1111/j.1469-7793.2001.0575f.x; Boirie Y, 1997, AM J CLIN NUTR, V65, P489; Bruunsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; Campbell WW, 2001, J GERONTOL A-BIOL, V56, pM373, DOI 10.1093/gerona/56.6.M373; Chevalier S, 2003, AM J CLIN NUTR, V78, P422; Chinkes D, 1996, AM J PHYSIOL-ENDOC M, V270, pE67, DOI 10.1152/ajpendo.1996.270.1.E67; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; Dangin M, 2003, J PHYSIOL-LONDON, V549, P635, DOI 10.1113/jphysiol.2002.036897; Dardevet D, 2000, J NUTR, V130, P2630, DOI 10.1093/jn/130.11.2630; DIETRICHSON P, 1987, J NEUROL NEUROSUR PS, V50, P1461, DOI 10.1136/jnnp.50.11.1461; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; Dorrens J, 2003, SCAND J MED SCI SPOR, V13, P26, DOI 10.1034/j.1600-0838.2003.00306.x; Esmarck B, 2001, J PHYSIOL-LONDON, V535, P301, DOI 10.1111/j.1469-7793.2001.00301.x; FRYBURG DA, 1994, AM J PHYSIOL, V267, pE331, DOI 10.1152/ajpendo.1994.267.2.E331; Gallagher D, 1997, J APPL PHYSIOL, V83, P229, DOI 10.1152/jappl.1997.83.1.229; Gallagher D, 2000, AM J PHYSIOL-ENDOC M, V279, pE124, DOI 10.1152/ajpendo.2000.279.1.E124; HARRIS T, 2003, SCI STKE, V212; Hughes LG, 2001, ANAESTHESIA, V56, P217; Kim J, 2002, AM J CLIN NUTR, V76, P378, DOI 10.1093/ajcn/76.2.378; Kimball SR, 2002, CURR OPIN CLIN NUTR, V5, P63, DOI 10.1097/00075197-200201000-00012; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Louis M, 2003, AM J PHYSIOL-ENDOC M, V284, pE764, DOI 10.1152/ajpendo.00338.2002; Millward DJ, 1997, AM J CLIN NUTR, V66, P774, DOI 10.1093/ajcn/66.4.774; MILLWARD DJ, 1978, FED PROC, V37, P2283; MITTENDORFER B, 2004, P PHYSL SOC P, V557, pC70; Morley JE, 1997, AM J CLIN NUTR, V66, P760, DOI 10.1093/ajcn/66.4.760; MUNRO HN, 1966, ANALYST, V91, P78, DOI 10.1039/an9669100078; NAIR KS, 1988, AM J PHYSIOL, V254, pE208, DOI 10.1152/ajpendo.1988.254.2.E208; Paddon-Jones D, 2004, AM J PHYSIOL-ENDOC M, V286, pE321, DOI 10.1152/ajpendo.00368.2003; Rennie MJ, 2004, ANNU REV PHYSIOL, V66, P799, DOI 10.1146/annurev.physiol.66.052102.134444; RENNIE MJ, 1985, BRIT MED BULL, V41, P257, DOI 10.1093/oxfordjournals.bmb.a072060; Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S; SMITH K, 1992, AM J PHYSIOL, V262, pE372, DOI 10.1152/ajpendo.1992.262.3.E372; Smith K, 1996, BAILLIERE CLIN ENDOC, V10, P469, DOI 10.1016/S0950-351X(96)80651-3; SMITH K, 1990, BAILLIERE CLIN ENDOC, V4, P461, DOI 10.1016/S0950-351X(05)80065-5; Taylor P, 1999, BIOMEMBRANE TRANSPOR, P295, DOI [DOI 10.1016/B978-012714510-5/50011-8, 10.1016/B978-012714510-5/50011-8]; Tipton KD, 1999, J NUTR BIOCHEM, V10, P89, DOI 10.1016/S0955-2863(98)00087-4; Tipton KD, 1999, AM J PHYSIOL-ENDOC M, V276, pE628, DOI 10.1152/ajpendo.1999.276.4.E628; Trappe T, 2004, J PHYSIOL-LONDON, V554, P803, DOI 10.1113/jphysiol.2003.051755; Vary T C, 1998, Curr Opin Clin Nutr Metab Care, V1, P217, DOI 10.1097/00075197-199803000-00013; Volpi E, 1998, J CLIN INVEST, V101, P2000, DOI 10.1172/JCI939; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Volpi E, 2000, J CLIN ENDOCR METAB, V85, P4481, DOI 10.1210/jc.85.12.4481; Volpi E, 1999, AM J PHYSIOL-ENDOC M, V277, pE513, DOI 10.1152/ajpendo.1999.277.3.E513; Waterlow J. C., 1978, PROTEIN TURNOVER MAM; WOLFE RR, 2001, HDB PHYSL 7, P735	51	837	862	4	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					422	+		10.1096/fj.04-2640fje	http://dx.doi.org/10.1096/fj.04-2640fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15596483				2022-12-28	WOS:000226091000020
J	Carmiel-Haggai, M; Cederbaum, AI; Nieto, N				Carmiel-Haggai, M; Cederbaum, AI; Nieto, N			A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats	FASEB JOURNAL			English	Article						oxidative stress; fa/fa	HIGH GLUCOSE; LIPID-PEROXIDATION; PROTEIN OXIDATION; ACTIVATION; EXPRESSION; OXIDASE; LEPTIN; STEATOHEPATITIS; PATHOGENESIS; GLUTATHIONE	Fatty livers of obese fa/fa rats are vulnerable to injury when challenged by insults such as endotoxin, ischemia-reperfusion or acute ethanol treatment. The objective of this study was to evaluate whether a high-fat diet can act as a "second hit" and cause progression to liver injury in obese fa/fa rats compared with lean Fa/? rats. Accordingly, obese fa/fa rats and their lean littermates were fed a diet low in fat (12% of total calories) or a diet with 60% calories as lard for 8 weeks. Hyperglycemia and steatohepatitis occurred in the fa/fa rats fed the high-fat diet. This was accompanied by liver injury as assessed by alanine aminotransferase, hematoxilin and eosin staining, increased TNFalpha and stellate cell-derived TGFbeta, collagen deposition, and up-regulation of alpha-smooth muscle actin. Active MMP13 decreased in fa/fa rats independently of the diet, and TIMP1 expression increased with the high-fat diet, especially in fa/fa rats. Although UCP2 expression was higher in fa/fa rats regardless of the diet, minor changes in ATP levels were observed. Oxidative stress occurred in the fa/fa rats fed the high-fat diet as lipid peroxidation and protein carbonyls were elevated, while glutathione and antioxidant enzymes were very low. Expression and activity of cytochrome P450 2E1 and xanthine oxidase activity were down-regulated in fa/fa compared with Fa/? rats, and no effect was seen by the high-fat diet. However, NADPH oxidase activity increased 2.5-fold in fa/fa rats fed with the high-fat diet. In summary, a high-fat diet induces liver injury in fa/fa rats leading to periportal fibrosis. A role for oxidative stress is suggested via increased NADPH oxidase activity, lipid peroxidation, protein carbonyl formation, and low antioxidant defense.	CUNY, Mt Sinai Med Ctr, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; CUNY, Mt Sinai Med Ctr, Div Liver Dis, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nieto, N (corresponding author), CUNY, Mt Sinai Med Ctr, Dept Pharmacol & Biol Chem, 1 Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	ny2000@hotmail.com			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA006610, R37AA006610, R01AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 06610, AA 03312] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Amet Y, 1995, BIOCHEM PHARMACOL, V50, P1775, DOI 10.1016/0006-2952(95)02040-3; Angulo P, 2002, J GASTROEN HEPATOL, V17, pS186, DOI 10.1046/j.1440-1746.17.s1.10.x; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bailey SM, 2001, ALCOHOL CLIN EXP RES, V25, P726, DOI 10.1111/j.1530-0277.2001.tb02273.x; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Carmiel-Haggai M, 2003, GASTROENTEROLOGY, V125, P1818, DOI 10.1053/j.gastro.2003.09.019; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; De Keulenaer GW, 1998, BIOCHEM J, V329, P653; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Enriquez A, 1999, BIOCHEM BIOPH RES CO, V255, P300, DOI 10.1006/bbrc.1999.0202; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hoffman BB, 1998, KIDNEY INT, V54, P1107, DOI 10.1046/j.1523-1755.1998.00119.x; Iredale JP, 1997, INT J BIOCHEM CELL B, V29, P43, DOI 10.1016/S1357-2725(96)00118-5; Jaeschke H, 2002, HEPATOLOGY, V36, P761, DOI 10.1053/jhep.2002.36038; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Lardinois OM, 1996, BBA-PROTEIN STRUCT M, V1298, P180, DOI 10.1016/S0167-4838(96)00130-6; Lardinois OM, 1996, BBA-PROTEIN STRUCT M, V1295, P222, DOI 10.1016/0167-4838(96)00043-X; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4; Lieber C S, 1997, Adv Pharmacol, V38, P601; Lieber CS, 2002, AM J CLIN NUTR, V76, p1183S, DOI 10.1093/ajcn/76.5.1183S; LOMBARDI B, 1966, LAB INVEST, V15, P1; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludwig J, 1997, J GASTROEN HEPATOL, V12, P398, DOI 10.1111/j.1440-1746.1997.tb00450.x; Maddox DA, 2002, KIDNEY INT, V62, P208, DOI 10.1046/j.1523-1755.2002.00412.x; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsuda S, 1999, KIDNEY INT, V56, pS150, DOI 10.1046/j.1523-1755.1999.07138.x; Nieto N, 1999, HEPATOLOGY, V30, P987, DOI 10.1002/hep.510300433; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Raner GM, 1997, BIOCHEMISTRY-US, V36, P4895, DOI 10.1021/bi9630568; Ratziu V, 2000, GASTROENTEROLOGY, V118, P1117, DOI 10.1016/S0016-5085(00)70364-7; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Robertson Graham, 2001, American Journal of Physiology, V281, pG1135; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tofovic SP, 2003, METH MOLEC MED, V86, P29; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; Woodcroft KJ, 1997, CHEM-BIOL INTERACT, V107, P75, DOI 10.1016/S0009-2797(97)00075-6; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yang SQ, 2001, AM J PHYSIOL-GASTR L, V281, pG382, DOI 10.1152/ajpgi.2001.281.2.G382	57	240	256	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					136	+		10.1096/fj.04-2291fje	http://dx.doi.org/10.1096/fj.04-2291fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522905				2022-12-28	WOS:000225482100027
J	Sharma, S; Adrogue, JV; Golfman, L; Uray, I; Lemm, J; Youker, K; Noon, GP; Frazier, OH; Taegtmeyer, H				Sharma, S; Adrogue, JV; Golfman, L; Uray, I; Lemm, J; Youker, K; Noon, GP; Frazier, OH; Taegtmeyer, H			Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart	FASEB JOURNAL			English	Article						triglyceride accumulation; contractile dysfunction; non-ischemic heart failure; lipotoxicity	TUMOR-NECROSIS-FACTOR; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; GENE-EXPRESSION; CONTRACTILE DYSFUNCTION; DILATED CARDIOMYOPATHY; ENERGY-METABOLISM; TRANSGENIC MICE; ADIPOSE-TISSUE; HUMAN OBESITY	In animal models of lipotoxicity, accumulation of triglycerides within cardiomyocytes is associated with contractile dysfunction. However, whether intramyocardial lipid deposition is a feature of human heart failure remains to be established. We hypothesized that intramyocardial lipid accumulation is a common feature of non-ischemic heart failure and is associated with changes in gene expression similar to those found in an animal model of lipotoxicity. Intramyocardial lipid staining with oil red O and gene expression analysis was performed on heart tissue from 27 patients (9 female) with non-ischemic heart failure. We determined intramyocardial lipid, gene expression, and contractile function in hearts from 6 Zucker diabetic fatty (ZDF) and 6 Zucker lean (ZL) rats. Intramyocardial lipid overload was present in 30% of non-ischemic failing hearts. The highest levels of lipid staining were observed in patients with diabetes and obesity (BMI>30). Intramyocardial lipid deposition was associated with an up-regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) -regulated genes, myosin heavy chain beta (MHC-beta), and tumor necrosis factor alpha (TNF-alpha). Intramyocardial lipid overload in the hearts of ZDF rats was associated with contractile dysfunction and changes in gene expression similar to changes found in failing human hearts with lipid overload. Our findings identify a subgroup of patients with heart failure and severe metabolic dysregulation characterized by intramyocardial triglyceride overload and changes in gene expression that are associated with contractile dysfunction.	Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cardiovasc Surg, Houston, TX 77030 USA; Texas Heart Inst, Houston, TX 77025 USA; St Lukes Episcopal Hosp, Houston, TX 77030 USA	University of Texas System; University of Texas System; Baylor College of Medicine; Texas Heart Institute; Saint Lukes Episcopal Hospital	Taegtmeyer, H (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, 6431 Fannin,MSB 1-246, Houston, TX 77030 USA.	Heinrich.Taegtmeyer@uth.tmc.edu		Youker, Keith/0000-0003-2535-7973	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007591, R01HL061483, R01HL073162] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL 07591, R01 HL073162-03, R01-HL073162-01, R01 HL073162, R01 HL061483, R01-HL/AG 61483] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barger PM, 2000, TRENDS CARDIOVAS MED, V10, P238, DOI 10.1016/S1050-1738(00)00077-3; Boden G, 2004, DIABETES MELLITUS FU, P979; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Cooney GJ, 2002, ANN NY ACAD SCI, V967, P196; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Finck BN, 2003, P NATL ACAD SCI USA, V100, P1226, DOI 10.1073/pnas.0336724100; Goodwin GW, 1998, J BIOL CHEM, V273, P29530, DOI 10.1074/jbc.273.45.29530; HOLUBARSCH C, 1985, CIRC RES, V56, P78, DOI 10.1161/01.RES.56.1.78; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hotamisligil GS, 2004, DIABETES MELLITUS FU, P953; KELLY DP, 1992, J INHERIT METAB DIS, V15, P171, DOI 10.1007/BF01799626; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; Listenberger LL, 2002, TRENDS CARDIOVAS MED, V12, P134, DOI 10.1016/S1050-1738(02)00152-4; Mann DL, 2002, J CARD FAIL, V8, pS379, DOI 10.1054/jcaf.2002.129253; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Nikolaidis LA, 2004, CARDIOVASC RES, V61, P297, DOI 10.1016/j.cardiores.2003.11.027; PAOLISSO G, 1991, METABOLISM, V40, P972, DOI 10.1016/0026-0495(91)90075-8; Razeghi P, 2003, CIRCULATION, V108, P2536, DOI 10.1161/01.CIR.0000096481.45105.13; Razeghi P, 2002, CIRCULATION, V106, P407, DOI 10.1161/01.CIR.0000026392.80723.DC; Razeghi P, 2001, CIRCULATION, V104, P2923, DOI 10.1161/hc4901.100526; RUPP H, 1995, AM J PHYSIOL-REG I, V269, pR630, DOI 10.1152/ajpregu.1995.269.3.R630; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Sivasubramanian N, 2001, CIRCULATION, V104, P826, DOI 10.1161/hc3401.093154; STEIN DT, 2004, DIABETES MELLITUS FU, P987; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P1828; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; Taegtmeyer H, 1994, CURR PROB CARDIOLOGY, V19, P57; Tardiff JC, 2000, AM J PHYSIOL-HEART C, V278, pH412, DOI 10.1152/ajpheart.2000.278.2.H412; Unger RH, 2003, ANNU REV PHYSIOL, V65, P333, DOI 10.1146/annurev.physiol.65.092101.142622; Young ME, 2002, DIABETES, V51, P2587, DOI 10.2337/diabetes.51.8.2587; Young ME, 2001, J BIOL CHEM, V276, P44390, DOI 10.1074/jbc.M103826200; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	35	546	559	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					1692	1700		10.1096/fj.04-2263com	http://dx.doi.org/10.1096/fj.04-2263com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522914				2022-12-28	WOS:000225482100037
J	Barkan, D; Hurgin, V; Dekel, N; Amsterdam, A; Rubinstein, M				Barkan, D; Hurgin, V; Dekel, N; Amsterdam, A; Rubinstein, M			Leptin induces ovulation in GnRH-deficient mice	FASEB JOURNAL			English	Article						gonadotropin-releasing hormone; progesterone; luteinizing hormone; ob/ob mice; hpg mice	GONADOTROPIN-RELEASING-HORMONE; CIRCULATING LEPTIN; FOLLICULAR DEVELOPMENT; LUTEINIZING-HORMONE; FEMALE MICE; IN-VITRO; RECEPTOR; OOCYTE; MOUSE; RAT	Leptin-deficient ob/ob mice have reduced gonadotropin-releasing hormone (GnRH) secretion, leading to gonadotropin deficiencies, hypogonadism, and anovulation, which are completely reversed following leptin administration. To determine whether the role of leptin in ovulation is mediated exclusively through GnRH, we studied leptin's action in GnRH-deficient (hpg) mice, as well as ob/ob mice and normal, prepubertal mice in which the GnRH axis was blocked with antide. Following pretreatment with pregnant mare serum gonadotropin, leptin induced ovulation in all three mouse models. Unlike mature normal mice, these ovulations were not triggered by a luteinizing hormone (LH) surge, as demonstrated by lack of increase in its surrogate marker progesterone. Rather, leptin induced hyperemia and leakage in the follicle, as well as the proteinase ADAMTS-1 (a disintegrin and metalloproteinase with a thrombospondin-like motif), which facilitates extrusion of the follicular content. These data show that on top of its role as an inducer of GnRH secretion, leptin may elicit an LH-independent ovulation.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Rubinstein, M (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	menachem.rubinstein@weizmann.ac.il	DEKEL, NAVA/R-8817-2019	Barkan, Dalit/0000-0003-4714-0580				Almog B, 2001, MOL CELL ENDOCRINOL, V183, P179, DOI 10.1016/S0303-7207(01)00543-3; AMSTERDAM A, 1987, ENDOCR REV, V8, P309, DOI 10.1210/edrv-8-3-309; Armstrong D T, 1968, Recent Prog Horm Res, V24, P255; Burgues S, 2001, HUM REPROD, V16, P2525, DOI 10.1093/humrep/16.12.2525; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; Chappell PE, 1997, ENDOCRINOLOGY, V138, P4147, DOI 10.1210/en.138.10.4147; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; CRAIG J, 2004, ENDOCRINOLOGY   0729; Duggal PS, 2000, ENDOCRINOLOGY, V141, P1971, DOI 10.1210/en.141.6.1971; EKHOLM C, 1981, ENDOCRINOLOGY, V108, P2022, DOI 10.1210/endo-108-5-2022; HALPIN DMG, 1986, J REPROD FERTIL, V77, P287, DOI 10.1530/jrf.0.0770287; Hardie L, 1997, CLIN ENDOCRINOL, V47, P101, DOI 10.1046/j.1365-2265.1997.2441017.x; HSUEH AJW, 1985, J STEROID BIOCHEM, V23, P757, DOI 10.1016/S0022-4731(85)80011-X; Kawahara M, 2002, THERIOGENOLOGY, V58, P1081, DOI 10.1016/S0093-691X(02)00939-1; KOHEN F, 1975, STEROID IMMUNOASSAY, P11; Lembo G, 2000, DIABETES, V49, P293, DOI 10.2337/diabetes.49.2.293; Licinio J, 1998, P NATL ACAD SCI USA, V95, P2541, DOI 10.1073/pnas.95.5.2541; Lim EA, 2004, J REPROD DEVELOP, V50, P179, DOI 10.1262/jrd.50.179; Matsuoka T, 1999, BIOCHEM BIOPH RES CO, V256, P480, DOI 10.1006/bbrc.1999.0365; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; Nagatani S, 1998, NEUROENDOCRINOLOGY, V67, P370, DOI 10.1159/000054335; Nothnick WB, 2003, ENDOCRINOLOGY, V144, P5, DOI 10.1210/en.2002-220963; Park JY, 2004, SCIENCE, V303, P682, DOI 10.1126/science.1092463; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; PHILLIPS A, 1988, LIFE SCI, V43, P883, DOI 10.1016/0024-3205(88)90263-9; Richards JS, 2002, RECENT PROG HORM RES, V57, P195, DOI 10.1210/rp.57.1.195; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Ryan NK, 2003, ENDOCRINOLOGY, V144, P5006, DOI 10.1210/en.2003-0584; Ryan NK, 2002, BIOL REPROD, V66, P1548, DOI 10.1095/biolreprod66.5.1548; Sainsbury A, 2002, GENE DEV, V16, P1077, DOI 10.1101/gad.979102; Smitz JEJ, 2002, REPRODUCTION, V123, P185, DOI 10.1530/rep.0.1230185; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; TIENHOVEN V, 1968, REPROD PHYSL VERTEBR; Watanobe H, 1999, BIOCHEM BIOPH RES CO, V263, P162, DOI 10.1006/bbrc.1999.1331; Yu WH, 1997, P NATL ACAD SCI USA, V94, P1023, DOI 10.1073/pnas.94.3.1023; Zachow RJ, 1997, ENDOCRINOLOGY, V138, P847, DOI 10.1210/en.138.2.847; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	38	47	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					133	+		10.1096/fj.04-2271fje	http://dx.doi.org/10.1096/fj.04-2271fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15629898				2022-12-28	WOS:000224849900009
J	Ventura, C; Maioli, M; Asara, Y; Santoni, D; Mesirca, P; Remondini, D; Bersani, F				Ventura, C; Maioli, M; Asara, Y; Santoni, D; Mesirca, P; Remondini, D; Bersani, F			Turning on stem cell cardiogenesis with extremely low frequency magnetic fields	FASEB JOURNAL			English	Article						gene expression; cardiac differentiation	PEPTIDE GENE-EXPRESSION; PROTEIN-KINASE-C; ELECTROMAGNETIC-FIELDS; TRANSCRIPTION; LYMPHOCYTES; MYOCYTES; CA2+; RAT	Modulation of stem cell differentiation is an important assignment for cellular engineering. Embryonic stem (ES) cells can differentiate into cardiomyocytes, but the efficiency is typically low. Here, we show that exposure of mouse ES cells to extremely low frequency magnetic fields triggered the expression of GATA-4 and Nkx-2.5, acting as cardiac lineage-promoting genes in different animal species, including humans. Magnetic fields also enhanced prodynorphin gene expression, and the synthesis and secretion of dynorphin B, an endorphin playing a major role in cardiogenesis. These effects occurred at the transcriptional level and ultimately ensued into a remarkable increase in the yield of ES-derived cardiomyocytes. These results demonstrate the potential use of magnetic fields for modifying the gene program of cardiac differentiation in ES cells without the aid of gene transfer technologies and may pave the way for novel approaches in tissue engineering and cell therapy.	Univ Bologna, S Orsola M Malpighi Hosp, Lab Mol Biol & Stem Cell Engn, Natl Inst Biostruct & Biosyst,Inst Cardiol, I-40138 Bologna, Italy; Univ Bologna, Dept Phys, ICEmB, I-40138 Bologna, Italy; Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna; University of Sassari	Ventura, C (corresponding author), Univ Bologna, S Orsola M Malpighi Hosp, Lab Mol Biol & Stem Cell Engn, Natl Inst Biostruct & Biosyst,Inst Cardiol, Pavil 21,Via Massarenti N 9, I-40138 Bologna, Italy.	cvent@libero.it	Mesirca, Pietro/X-4999-2019; Remondini, Daniel/ABA-9971-2020	Remondini, Daniel/0000-0003-3185-7456; Mesirca, Pietro/0000-0002-9538-3096; MAIOLI, Margherita/0000-0003-0187-4968				Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; CADOSSI R, 1992, FASEB J, V6, P2667, DOI 10.1096/fasebj.6.9.1612290; COSSARIZZA A, 1989, BIOCHEM BIOPH RES CO, V160, P692, DOI 10.1016/0006-291X(89)92488-1; COSSARIZZA A, 1993, EXP CELL RES, V204, P385, DOI 10.1006/excr.1993.1048; LAI H, 1993, BIOELECTROMAGNETICS, V14, P5, DOI 10.1002/bem.2250140104; LINTS TJ, 1993, DEVELOPMENT, V119, P419; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Thomas AW, 1997, PEPTIDES, V18, P703, DOI 10.1016/S0196-9781(97)00004-1; Ventura C, 2000, CIRC RES, V87, P189, DOI 10.1161/01.RES.87.3.189; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; Ventura C, 2000, CARDIOVASC RES, V45, P1054, DOI 10.1016/S0008-6363(99)00408-3; Ventura C, 2003, CIRC RES, V92, P623, DOI 10.1161/01.RES.0000065169.23780.0E; Ventura C, 2003, CIRC RES, V92, P617, DOI 10.1161/01.RES.0000065168.31147.5B; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; Vorobyov VV, 1998, BRAIN RES, V781, P182, DOI 10.1016/S0006-8993(97)01228-6	18	68	70	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					155	+		10.1096/fj.04-2695fje	http://dx.doi.org/10.1096/fj.04-2695fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15507470				2022-12-28	WOS:000224849900005
J	Ayub, K; Hallett, MB				Ayub, K; Hallett, MB			The mitochondrial ADPR link between Ca2+ store release and Ca2+ influx channel opening in immune cells	FASEB JOURNAL			English	Article						non-voltage-operated Ca2+; mitochondrial Ca2+; Ca2+ influx channels	ENDOPLASMIC-RETICULUM; T-LYMPHOCYTES; CALCIUM; ENTRY; DEPLETION; EXPRESSION; TRANSPORT; MESSENGER; NAD(+)	The regulation of non-voltage-operated Ca2+ channels in the plasma membrane remains unclear (1-3). However, there is often a link between the physiological release of Ca2+ from intracellular stores and opening of Ca2+ influx channels on the plasma membrane. This route has been referred to variously as store-operated Ca2+ entry (SOC), capacitative Ca2+ entry, and Ca2+ release-activated channel opening (CRAC), and often underlies the large changes in cytosolic free Ca2+ that accompany many stimuli in a wide variety of cell types (1-3). The linkage between Ca2+ store release and opening of Ca2+ channels on the plasma membrane has remained elusive for a number of years, perhaps in part because different mechanisms exist for this linkage, and are used to differing extents by different cells. We suggest here that one of the mechanisms that may operate in cells of the immune system, but that may be important elsewhere, involves the release of mitochondrial adenosine diphosphate ribose (ADPR) or nicotinamide adenine dinucleotide (NAD(+)). There is accumulating evidence to support each of the steps necessary for a complete description of this "Ca2+ store release to plasma membrane channel opening" link, but to our knowledge they have not been connected before to make a coherent model.	Cardiff Univ, Seutrophil Signalling Grp, Dept Surg, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Hallett, MB (corresponding author), Cardiff Univ, Seutrophil Signalling Grp, Dept Surg, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	hallettmb@cardiff.ac.uk	Hallett, Maurice/I-6866-2012	Hallett, Maurice/0000-0001-8197-834X				ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Conde M, 1996, J LEUKOCYTE BIOL, V60, P278, DOI 10.1002/jlb.60.2.278; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; DAVIES EV, 1995, BIOCHEM BIOPH RES CO, V206, P348, DOI 10.1006/bbrc.1995.1048; Davies-Cox EV, 2001, BIOCHEM J, V355, P139, DOI 10.1042/bj3550139; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FILIPPIN L, 2003, J BIOL CHEM, V31, P31; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; Haak LL, 2002, J NEUROCHEM, V80, P405, DOI 10.1046/j.0022-3042.2001.00727.x; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Scott SR, 1998, PFLUG ARCH EUR J PHY, V436, P928, DOI 10.1007/s004240050725; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	41	16	17	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1335	1338		10.1096/fj.04-1888hyp	http://dx.doi.org/10.1096/fj.04-1888hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333576				2022-12-28	WOS:000224243200052
J	Xu, WL; Kaneko, FT; Zheng, S; Comhair, SAA; Janocha, AJ; Goggans, T; Thunnissen, FBJM; Farver, C; Hazen, SL; Jennings, C; Dweik, RA; Arroliga, AC; Erzurum, SC				Xu, WL; Kaneko, FT; Zheng, S; Comhair, SAA; Janocha, AJ; Goggans, T; Thunnissen, FBJM; Farver, C; Hazen, SL; Jennings, C; Dweik, RA; Arroliga, AC; Erzurum, SC			Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension	FASEB JOURNAL			English	Article						arginine; lung; pulmonary vasodilation	NITRIC-OXIDE SYNTHASE; HUMAN AIRWAY EPITHELIUM; SMOOTH-MUSCLE-CELLS; HYDROXY-L-ARGININE; ALVEOLAR MACROPHAGES; MOLECULAR-MECHANISMS; GENE-EXPRESSION; INHIBITION; PURIFICATION; METABOLISM	Pulmonary arterial hypertension (PAH), a fatal disease of unknown etiology characterized by impaired regulation of pulmonary hemodynamics and vascular growth, is associated with low levels of pulmonary nitric oxide (NO). Based upon its critical role in mediating vasodilation and cell growth, decrease of NO has been implicated in the pathogenesis of PAH. We evaluated mechanisms for low NO and pulmonary hypertension, including NO synthases ( NOS) and factors regulating NOS activity, i.e. the substrate arginine, arginase expression and activity, and endogenous inhibitors of NOS in patients with PAH and healthy controls. PAH lungs had normal NOS I-III expression, but substrate arginine levels were inversely related to pulmonary artery pressures. Activity of arginase, an enzyme that regulates NO biosynthesis through effects on arginine, was higher in PAH serum than in controls, with high-level arginase expression localized by immunostaining to pulmonary endothelial cells. Further, pulmonary artery endothelial cells derived from PAH lung had higher arginase II expression and produced lower NO than control cells in vitro. Thus, substrate availability affects NOS activity and vasodilation, implicating arginase II and alterations in arginine metabolic pathways in the pathophysiology of PAH.	Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Canisius Wihelmina Ziekenhuis, Dept Pathol, Nijmegen, Netherlands	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Erzurum, SC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, 9500 Euclid Ave,NB40, Cleveland, OH 44195 USA.	erzurus@ccf.org	Arroliga, Alejandro/AAX-3933-2021; Hazen, Stanley L/ABD-5845-2021	Thunnissen, Erik/0000-0001-5355-8508	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL060917, P01HL076491, K24HL004265, R01HL060917] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR018390] Funding Source: Medline; NHLBI NIH HHS [HL 60917, HL076491, HL 04265] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albina JE, 2003, WOUND REPAIR REGEN, V11, P445, DOI 10.1046/j.1524-475X.2003.11619.x; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Archer S, 2000, CIRCULATION, V102, P2781, DOI 10.1161/01.CIR.102.22.2781; ARNAL JF, 1995, J CLIN INVEST, V95, P2565, DOI 10.1172/JCI117957; Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13; Arroliga AC, 2000, CLEV CLIN J MED, V67, P175, DOI 10.3949/ccjm.67.3.175; Azeka E, 2002, PEDIATR CARDIOL, V23, P20, DOI 10.1007/s00246-001-0006-2; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; Berkels R, 2001, J APPL PHYSIOL, V90, P317, DOI 10.1152/jappl.2001.90.1.317; Berkowitz DE, 2003, CIRCULATION, V108, P2000, DOI 10.1161/01.CIR.0000092948.04444.C7; Bogle RG, 1996, J PHYSIOL-LONDON, V490, P229, DOI 10.1113/jphysiol.1996.sp021138; Buga GM, 1996, AM J PHYSIOL-HEART C, V271, pH1988, DOI 10.1152/ajpheart.1996.271.5.H1988; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; Chang CI, 2000, J IMMUNOL, V165, P2134, DOI 10.4049/jimmunol.165.4.2134; Chicoine LG, 2004, AM J PHYSIOL-LUNG C, V287, pL60, DOI 10.1152/ajplung.00194.2003; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; Colleluori DM, 2001, ARCH BIOCHEM BIOPHYS, V389, P135, DOI 10.1006/abbi.2001.2324; Cooke JP, 1997, CIRCULATION, V96, P379; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; Dweik RA, 1999, LUNG BIOL HEALTH DIS, V131, P333; Dweik RA, 2001, AM J RESP CELL MOL, V24, P414, DOI 10.1165/ajrcmb.24.4.4127; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; ERZURUM SC, 1993, J APPL PHYSIOL, V75, P1256, DOI 10.1152/jappl.1993.75.3.1256; Fagan KA, 1999, AM J PHYSIOL-LUNG C, V277, pL472, DOI 10.1152/ajplung.1999.277.3.L472; Fagan KA, 2000, PHYSIOL RES, V49, P539; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Fishman AP, 2000, PHYSIOL RES, V49, P485; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; Ghamra Ziad W, 2003, Cleve Clin J Med, V70 Suppl 1, pS2; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gorenflo M, 2001, J CARDIOVASC PHARM, V37, P489, DOI 10.1097/00005344-200104000-00016; Gotoh T, 1997, BIOCHEM BIOPH RES CO, V233, P487, DOI 10.1006/bbrc.1997.6473; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HECKER M, 1995, FEBS LETT, V359, P251, DOI 10.1016/0014-5793(95)00039-C; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; Hey C, 1997, BRIT J PHARMACOL, V121, P395, DOI 10.1038/sj.bjp.0701143; Ignarro LJ, 2001, P NATL ACAD SCI USA, V98, P4202, DOI 10.1073/pnas.071054698; Jeffery TK, 2002, PROG CARDIOVASC DIS, V45, P173, DOI 10.1053/pcad.2002.130041; Kaneko FT, 1998, AM J RESP CRIT CARE, V158, P917, DOI 10.1164/ajrccm.158.3.9802066; Khangulov SV, 1998, BIOCHEMISTRY-US, V37, P8539, DOI 10.1021/bi972874c; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; Louis CA, 1998, AM J PHYSIOL-REG I, V274, pR775, DOI 10.1152/ajpregu.1998.274.3.R775; Mason NA, 1998, J PATHOL, V185, P313, DOI 10.1002/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8; MEHTA S, 1995, CIRCULATION, V92, P1539, DOI 10.1161/01.CIR.92.6.1539; Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169; Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200208-967OC; Nagaya N, 2001, AM J RESP CRIT CARE, V163, P887, DOI 10.1164/ajrccm.163.4.2007116; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; Ozkan M, 2001, LUNG, V179, P233, DOI 10.1007/s004080000064; Pauleau AL, 2004, J IMMUNOL, V172, P7565, DOI 10.4049/jimmunol.172.12.7565; Pearson DL, 2001, NEW ENGL J MED, V344, P1832, DOI 10.1056/NEJM200106143442404; Que LG, 1998, AM J PHYSIOL-LUNG C, V275, pL96, DOI 10.1152/ajplung.1998.275.1.L96; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Trummer G, 2002, ANN THORAC SURG, V73, P1299, DOI 10.1016/S0003-4975(01)03265-9; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; VALLANCE P, 1992, LANCET, V339, P572; Veyssier-Belot C, 1999, CARDIOVASC RES, V44, P274, DOI 10.1016/S0008-6363(99)00230-8; Wei LH, 2001, P NATL ACAD SCI USA, V98, P9260, DOI 10.1073/pnas.161294898; Wei LH, 2000, AM J PHYSIOL-CELL PH, V279, pC248, DOI 10.1152/ajpcell.2000.279.1.C248; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xu WL, 2003, AM J PHYSIOL-LUNG C, V285, pL137, DOI 10.1152/ajplung.00441.2002; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	74	282	294	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1746	+		10.1096/fj.04-2317fje	http://dx.doi.org/10.1096/fj.04-2317fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364894				2022-12-28	WOS:000224243200029
J	Block, ML; Wu, X; Pei, Z; Li, G; Wang, T; Qin, L; Wilson, B; Yang, J; Hong, JS; Veronesi, B				Block, ML; Wu, X; Pei, Z; Li, G; Wang, T; Qin, L; Wilson, B; Yang, J; Hong, JS; Veronesi, B			Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase	FASEB JOURNAL			English	Article						dopaminergic neurotoxicity; oxidative stress; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; ROTENONE-INDUCED DEGENERATION; IN-VITRO; PULMONARY INFLAMMATION; TETRAZOLIUM SALT; ACTIVATION; BRAIN; PARTICULATE; MECHANISMS; INHIBITION	The contributing role of environmental factors to the development of Parkinson's disease has become increasingly evident. We report that mesencephalic neuron-glia cultures treated with diesel exhaust particles (DEP; 0.22 muM) ( 5 - 50 mug/ml) resulted in a dose-dependent decrease in dopaminergic (DA) neurons, as determined by DA-uptake assay and tyrosine-hydroxylase immunocytochemistry (ICC). The selective toxicity of DEP for DA neurons was demonstrated by the lack of DEP effect on both GABA uptake and Neu-N immunoreactive cell number. The critical role of microglia was demonstrated by the failure of neuron-enriched cultures to exhibit DEP-induced DA neurotoxicity, where DEP-induced DA neuron death was reinstated with the addition of microglia to neuron-enriched cultures. OX-42 ICC staining of DEP treated neuronglia cultures revealed changes in microglia morphology indicative of activation. Intracellular reactive oxygen species and superoxide were produced from enriched-microglia cultures in response to DEP. Neuron-glia cultures from NADPH oxidase deficient (PHOX-/-) mice were insensitive to DEP neurotoxicity when compared with control mice (PHOX+/+). Cytochalasin D inhibited DEP-induced superoxide production in enriched-microglia cultures, implying that DEP must be phagocytized by microglia to produce superoxide. Together, these in vitro data indicate that DEP selectively damages DA neurons through the phagocytic activation of microglial NADPH oxidase and consequent oxidative insult.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA; NIEHS, Div Neurotoxicol, Off Res & Dev, US EPA, Res Triangle Pk, NC 27709 USA; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); United States Environmental Protection Agency; Dalian Medical University	Block, ML (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, MD F1-01,POB 12233, Res Triangle Pk, NC 27709 USA.	Block@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914				Boland S, 1999, AM J PHYSIOL-LUNG C, V276, pL604, DOI 10.1152/ajplung.1999.276.4.L604; Calderon-Garciduenas L, 2003, TOXICOL PATHOL, V31, P524, DOI 10.1080/01926230390226645; Calderon-Garciduenas L, 2002, TOXICOL PATHOL, V30, P373, DOI 10.1080/01926230252929954; Canudas AM, 2000, NEUROBIOL DIS, V7, P343, DOI 10.1006/nbdi.2000.0308; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cho BP, 2003, CELL MOL NEUROBIOL, V23, P551, DOI 10.1023/A:1025024129946; Finch GL, 2002, INHAL TOXICOL, V14, P1017, DOI 10.1080/08958370290084764; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; JEFFREY M, 1994, NEUROPATH APPL NEURO, V20, P535, DOI 10.1111/j.1365-2990.1994.tb01007.x; JENSEN L K, 1989, Ugeskrift for Laeger, V151, P2255; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649; KUMAGAI Y, 1995, FREE RADICAL BIO MED, V18, P365, DOI 10.1016/0891-5849(94)00125-4; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2001, J PHARMACOL EXP THER, V298, P1133; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.t01-1-00216.x; LOEFFLER DA, 1994, CLIN NEUROPHARMACOL, V17, P370, DOI 10.1097/00002826-199408000-00009; Ma JYC, 2002, J ENVIRON SCI HEAL C, V20, P117, DOI 10.1081/GNC-120016202; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Mitrasinovic OM, 2003, NEUROBIOL AGING, V24, P807, DOI 10.1016/S0197-4580(02)00237-3; Mitrasinovic OM, 2003, NEUROSCI LETT, V344, P185, DOI 10.1016/S0304-3940(03)00474-9; Nemmar A, 2003, TOXICOL APPL PHARM, V186, P38, DOI 10.1016/S0041-008X(02)00024-8; Oberdorster G, 1996, PARTICLE OVERLOAD IN THE RAT LUNG AND LUNG CANCER, P73; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; Sherer TB, 2003, NEUROSCI LETT, V341, P87, DOI 10.1016/S0304-3940(03)00172-1; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; Steerenberg PA, 1998, EXP LUNG RES, V24, P85, DOI 10.3109/01902149809046056; Sugama S, 2003, NEUROSCIENCE, V116, P925, DOI 10.1016/S0306-4522(02)00572-9; Takenaka S, 2001, ENVIRON HEALTH PERSP, V109, P547, DOI 10.2307/3454667; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Tao F, 2003, FREE RADICAL BIO MED, V35, P327, DOI 10.1016/S0891-5849(03)00280-6; Veronesi B, 2003, NEUROTOXICOLOGY, V24, P463, DOI 10.1016/S0161-813X(03)00022-6; Veronesi B, 2002, TOXICOL APPL PHARM, V178, P144, DOI 10.1006/taap.2001.9341; von Baumgarten F, 1980, Cell Tissue Res, V212, P279; WU X, IN PRESS ANTIOXID RE	45	269	280	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1618	+		10.1096/fj.04-1945fje	http://dx.doi.org/10.1096/fj.04-1945fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319363				2022-12-28	WOS:000223554900004
J	Casanova, ML; Bravo, A; Martinez-Palacio, J; Fernandez-Acenero, MJ; Villanueva, C; Larcher, F; Conti, CJ; Jorcano, JL				Casanova, ML; Bravo, A; Martinez-Palacio, J; Fernandez-Acenero, MJ; Villanueva, C; Larcher, F; Conti, CJ; Jorcano, JL			Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice	FASEB JOURNAL			English	Article						cutaneous cancer; epithelial dysplastic changes; ectopic keratin expression; neoplastic diseases	GROWTH-FACTOR RECEPTOR; SIMPLE EPITHELIAL KERATIN-8; INTERMEDIATE-FILAMENTS; CELL-PROLIFERATION; FACTOR-ALPHA; EXPRESSION; GENE; CYTOKERATINS; PROGRESSION; PAPILLOMAS	Keratins K8 and K18 are the major components of the intermediate filament cytoskeleton of simple epithelia. Increased levels of these keratins have been associated with invasive growth and progression to malignancy in different types of human and murine epithelial tumors ( including skin tumors), and even in tumors from nonepithelial origin. However, it has not yet clarified whether K8/K18 expression in tumors is cause or consequence of malignancy. Given the increasing incidence of epidermal cancer in humans (40% of all tumors diagnosed), we generated a mouse model to examine the role of simple epithelium keratins in the establishment and progression of human skin cancer. Transgenic mice expressing human K8 in the epidermis showed severe epidermal and hair follicle dysplasia with concomitant alteration in epidermal differentiation markers. The severity of the skin phenotype of these transgenic mice increases with age, leading to areas of preneoplastic transformation. Skin carcinogenesis assays showed a dramatic increase in the progression of papillomas toward malignancy in transgenic animals. These results support the idea that K8 alters the epidermal cell differentiation, favors the neoplastic transformation of cells, and is ultimately responsible of the invasive behavior of transformed epidermal cells leading of conversion of benign to malignant tumors.	CIEMAT, Epithelial Damage Repair & Tissue Engn, E-28040 Madrid, Spain; Univ Santiago de Compostela, Fac Vet, Dept Anim Pathol, Lugo, Spain; Univ Texas, MD Anderson Canc Ctr, Smithville, TX USA; Hosp Gen Mostoles, Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela; University of Texas System; UTMD Anderson Cancer Center	Casanova, ML (corresponding author), CIEMAT, Epithelial Damage Repair & Tissue Engn, Ave Complutense 22, E-28040 Madrid, Spain.	llanos.casanova@ciemat.es	Martinez, Jesus/M-3791-2014; Larcher, Fernando/J-1527-2016; Aceñero, M Jesús Fernández/ABC-5904-2020; Moral, Ana María Bravo/AAD-3339-2021	Martinez, Jesus/0000-0002-9521-8744; Larcher, Fernando/0000-0002-6771-3561; Aceñero, M Jesús Fernández/0000-0002-2439-3553; Moral, Ana María Bravo/0000-0002-5282-8921; Casanova, M. Llanos/0000-0001-7742-8265				ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; Ameen NA, 2001, J CELL SCI, V114, P563; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; CASANOVA L, 1995, J CELL SCI, V108, P811; Casanova ML, 2002, CANCER RES, V62, P3402; Casanova ML, 1999, J CLIN INVEST, V103, P1587, DOI 10.1172/JCI5343; CAULIN C, 1993, EXP CELL RES, V204, P11, DOI 10.1006/excr.1993.1003; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; CHENG C, 1990, MOL CARCINOGEN, V3, P363, DOI 10.1002/mc.2940030608; DIAZGUERRA M, 1992, CANCER RES, V52, P680; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; DuBowski A, 1998, CARCINOGENESIS, V19, P1141, DOI 10.1093/carcin/19.6.1141; EINARSSON R, 1995, SCAND J CLIN LAB INV, V55, P113, DOI 10.3109/00365519509090574; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HASHIDO K, 1991, EXP CELL RES, V192, P203, DOI 10.1016/0014-4827(91)90177-V; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HUNTS J, 1985, JPN J CANCER RES, V76, P663; Hutton E, 1998, J CELL BIOL, V143, P487, DOI 10.1083/jcb.143.2.487; Jaquemar D, 2003, J CELL BIOL, V161, P749, DOI 10.1083/jcb.200210004; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Lasota J, 1996, AM J SURG PATHOL, V20, P346, DOI 10.1097/00000478-199603000-00012; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Limmer B L, 2001, Tex Med, V97, P56; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; MARKEY AC, 1991, J INVEST DERMATOL, V97, P763, DOI 10.1111/1523-1747.ep12486607; McGowan K, 1998, Subcell Biochem, V31, P173; Moll I, 1996, J INVEST DERMATOL, V106, P281, DOI 10.1111/1523-1747.ep12340714; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; OGDEN GR, 1994, ORAL ONCOL, V30B, P405, DOI 10.1016/0964-1955(94)90020-5; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Porter RM, 2003, TRENDS GENET, V19, P278, DOI 10.1016/S0168-9525(03)00071-4; Relchelt J, 2002, J CELL SCI, V115, P2639; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; SCHAAFSMA HE, 1990, AM J PATHOL, V136, P329; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Toivola DM, 2001, HEPATOLOGY, V34, P1174, DOI 10.1053/jhep.2001.29374; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x	53	45	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1556	+		10.1096/fj.04-1683fje	http://dx.doi.org/10.1096/fj.04-1683fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319370				2022-12-28	WOS:000223554900015
J	Kaasik, A; Joubert, F; Ventura-Clapier, R; Veksler, V				Kaasik, A; Joubert, F; Ventura-Clapier, R; Veksler, V			A novel mechanism of regulation of cardiac contractility by mitochondrial functional state	FASEB JOURNAL			English	Article						myocardial contractility; mitochondria; myofibrils; potassium	RAT VENTRICULAR MYOCYTES; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; SARCOPLASMIC-RETICULUM; INORGANIC-PHOSPHATE; CATION-TRANSPORT; FORCE PRODUCTION; CREATINE-KINASE; MUSCLE-CELLS; K+ CHANNELS	It is generally considered that mitochondria regulate cardiac cell contractility by providing ATP for cellular ATPases and by participating in Ca2+ homeostasis. However, other possible mechanisms by which mitochondria can influence contractility have been largely overlooked. Here, we demonstrate that inhibition of the mitochondrial electron transport chain strongly increases Ca2+-dependent and independent isometric force development in rat ventricular fibers with selectively permeabilized sarcolemma. This effect is unrelated to the ATP-generating activity of mitochondria or Ca2+ homeostasis. Furthermore, various conditions that increase K+ accumulation in the mitochondrial matrix ( activation of ATP- or Ca2+-dependent K+ channels as well as inhibition of the K+ efflux pathway via the K+/H+ exchanger) induce a similar mechanical response. Modulators of mitochondrial function that augment isometric force also cause swelling of mitochondria in the vicinity of myofibrils in situ, as shown by confocal microscopy. Osmotic compression of intracellular structures abolishes the effect of mitochondria-induced force modulation, suggesting a mechanical basis for the interaction between the organelles. These findings suggest a novel mechanism for cellular regulation of myofibrillar function, whereby increases in mitochondrial volume can impose mechanical constraints inside the cell, leading to an increase in force developed by myofibrils.	Univ Paris Sud, Fac Pharm, Lab Cardiol Cellulaire & Mol, INSERM,U446, F-92296 Chatenay Malabry, France; Univ Tartu, Ctr Mol & Clin Med, Dept Pharmacol, Tartu, Estonia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Tartu	Veksler, V (corresponding author), Univ Paris Sud, Fac Pharm, Lab Cardiol Cellulaire & Mol, INSERM,U446, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	Vladimir.VEKSLER@cep.u-psud.fr	Kaasik, Allen/I-2738-2015	Joubert, Frederic/0000-0003-0239-1052; Kaasik, Allen/0000-0002-4850-3198; Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594				Andrienko T, 2003, J EXP BIOL, V206, P2059, DOI 10.1242/jeb.00242; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BEST PM, 1977, J PHYSIOL-LONDON, V265, P1; BRIERLEY GP, 1994, J BIOENERG BIOMEMBR, V26, P519, DOI 10.1007/BF00762736; Debska G, 2001, BRAIN RES, V892, P42, DOI 10.1016/S0006-8993(00)03187-5; DONALDSON SKB, 1978, PFLUG ARCH EUR J PHY, V376, P55; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; Fukuda N, 2000, CIRC RES, V86, pE1; Gao WH, 2001, J CELL SCI, V114, P2855; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HIBBERD MG, 1982, J PHYSIOL-LONDON, V329, P527, DOI 10.1113/jphysiol.1982.sp014317; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kaasik A, 2003, FASEB J, V17, DOI 10.1096/fj.02-0684fje; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; KENTISH JC, 1986, J PHYSIOL-LONDON, V370, P585, DOI 10.1113/jphysiol.1986.sp015952; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; MARBAN E, 1987, J GEN PHYSIOL, V90, P609, DOI 10.1085/jgp.90.5.609; MCDONALD KS, 1995, CIRC RES, V77, P199, DOI 10.1161/01.RES.77.1.199; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Moss RL, 2002, CIRC RES, V90, P11, DOI 10.1161/res.90.1.11; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Saks V, 2003, BIOPHYS J, V84, P3436, DOI 10.1016/S0006-3495(03)70065-4; Saks VA, 2001, BIOCHEM J, V356, P643, DOI 10.1042/0264-6021:3560643; SAKS VA, 1991, BIOCHIM BIOPHYS ACTA, V1074, P302, DOI 10.1016/0304-4165(91)90168-G; Sharma VK, 2000, J BIOENERG BIOMEMBR, V32, P97, DOI 10.1023/A:1005520714221; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; VENTURACLAPIER R, 1987, J GEN PHYSIOL, V89, P815, DOI 10.1085/jgp.89.5.815; Verde I, 1999, BRIT J PHARMACOL, V127, P65, DOI 10.1038/sj.bjp.0702506; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360	35	26	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1219	1227		10.1096/fj.04-1508com	http://dx.doi.org/10.1096/fj.04-1508com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15284222				2022-12-28	WOS:000223554900037
J	Zhang, HJ; Doctrow, SR; Xu, LJ; Oberley, LW; Beecher, B; Morrison, J; Oberley, TD; Kregel, KC				Zhang, HJ; Doctrow, SR; Xu, LJ; Oberley, LW; Beecher, B; Morrison, J; Oberley, TD; Kregel, KC			Redox modulation of the liver with chronic antioxidant enzyme mimetic treatment prevents age-related oxidative damage associated with environmental stress	FASEB JOURNAL			English	Article						free radicals; ROS; hyperthermia; lipid peroxidation; AP-1	SYNTHETIC SUPEROXIDE-DISMUTASE; GLUTATHIONE-S-TRANSFERASE; SALEN-MANGANESE COMPLEXES; CALORIC RESTRICTION; CATALASE MIMETICS; HEAT-WAVE; LIFE-SPAN; AP-1; EXTENSION; RESPONSES	A reduction in stress tolerance is a hallmark of the aging process, and the lowered functional capacity observed in aged organisms is associated with an increased rate of oxidative stress and a greater susceptibility of aged tissues to oxidative injury. In this report, we show that chronic systemic administration of a superoxide dismutase (SOD)/catalase mimetic (EUK-189), delivered over a 1 month period via osmotic pump, prevents heat stress-induced liver injury by dramatically decreasing oxidative damage in aged animals. Widespread liver injury was present in old but not young vehicle-treated rats in response to a 2 day heating protocol. However, SOD/catalase mimetic treatment markedly decreased the hyperthermia-induced liver injury associated in old animals. The reversal of damage with EUK-189 was associated with an improvement in intracellular redox status and a striking reduction in hepatocellular lipid peroxidation. EUK-189 treatment also blocked the activation of activator protein-1 (AP-1), which is a redox-sensitive early response transcription factor involved in the regulation of cellular stress responses. These results demonstrate that oxidative stress plays a unique role in age-related hyperthermic injury and suggest that therapeutic strategies aimed at improving redox potential, such as chronic SOD/catalase mimetic treatment, can prevent the oxidative-mediated damage associated with environmental stress.	Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; Eukarion Inc, Bedford, MA 01730 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA	University of Iowa; University of Iowa; University of Wisconsin System; University of Wisconsin Madison	Kregel, KC (corresponding author), Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, 532 FH, Iowa City, IA 52242 USA.	kevin-kregel@uiowa.edu		Doctrow, Susan/0000-0003-0628-9960	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012350, R29AG012350, R01AG014687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61389] Funding Source: Medline; NIA NIH HHS [AG-12350, AG-14687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; BAUDRY M, 1993, BIOCHEM BIOPH RES CO, V192, P964, DOI 10.1006/bbrc.1993.1509; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2; Doctrow S R, 1997, Adv Pharmacol, V38, P247; Doctrow SR, 2002, J MED CHEM, V45, P4549, DOI 10.1021/jm020207y; Dorozynski A, 2003, BRIT MED J, V327, P411, DOI 10.1136/bmj.327.7412.411; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; Hall DM, 2000, J APPL PHYSIOL, V89, P749, DOI 10.1152/jappl.2000.89.2.749; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jung CW, 2001, NEUROSCI LETT, V304, P157, DOI 10.1016/S0304-3940(01)01784-0; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEW M, 1970, AM J MED, V49, P192, DOI 10.1016/S0002-9343(70)80075-4; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; KREGEL KC, 1995, J APPL PHYSIOL, V79, P1673, DOI 10.1152/jappl.1995.79.5.1673; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Malfroy B, 1997, CELL IMMUNOL, V177, P62, DOI 10.1006/cimm.1997.1091; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Melov S, 2001, J NEUROSCI, V21, P8348, DOI 10.1523/JNEUROSCI.21-21-08348.2001; OBERLEY TD, 1991, AM J PATHOL, V139, P355; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; Pong K, 2001, EXP NEUROL, V171, P84, DOI 10.1006/exnr.2001.7747; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; RYAN AJ, 1995, J APPL PHYSIOL, V78, P38, DOI 10.1152/jappl.1995.78.1.38; Schar C, 2004, NATURE, V427, P332, DOI 10.1038/nature02300; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Van Remmen H, 2003, EXERC SPORT SCI REV, V31, P149, DOI 10.1097/00003677-200307000-00009; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7; Zhang HJ, 2003, FASEB J, V17, P2293, DOI 10.1096/fj.03-0139fje; Zhang HJ, 2002, J VIROL, V76, P355, DOI 10.1128/JVI.76.1.355-363.2002	39	55	55	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1547	+		10.1096/fj.04-1629fje	http://dx.doi.org/10.1096/fj.04-1629fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319374				2022-12-28	WOS:000223554900009
J	Yang, KT; Pan, SF; Chien, CL; Hsu, SM; Tseng, YZ; Wang, SM; Wu, ML				Yang, KT; Pan, SF; Chien, CL; Hsu, SM; Tseng, YZ; Wang, SM; Wu, ML			Mitochondrial Na+ overload is caused by oxidative stress and leads to activation of the caspase 3-dependent apoptotic machinery	FASEB JOURNAL			English	Article						Ca2+; mitochondria; apoptosis; cardiomyocyte	DEPENDENT ANION CHANNEL; HYDROGEN-PEROXIDE; PERMEABILITY TRANSITION; SIGNAL PROPAGATION; CALCIUM OVERLOAD; CA2+ UPTAKE; RADICALS; SODIUM; MECHANISMS; GENERATION	Oxidative stress is one of the major causes of cell death. Using time-lapse confocal recording of live cardiomyocytes, we showed that H2O2 (OH.) caused a marked increase in Na+ and Ca2+ levels in both the cytosol ([Na](cyt), [Ca](cyt)) and mitochondria ([Na](m), [Ca](m)). The H2O2-induced intracellular Na+ ([Na](i)) overload contributed to the H2O2-induced [Ca](cyt)/[Ca](m) overload via activation of the reverse mode of the Na-Ca exchanger. When myocytes were treated for 40 min with 100 muM H2O2 in normal medium, then returned to H2O2-free medium, the percentage of apoptotic cells increased from 4% at 0 h to 55 and 85% at 4.5 and 16 h, respectively. H2O2-induced apoptosis was completely prevented by using Na-free, but not Ca-free, medium. When a Na+ ionophore cocktail in Ca-free medium was used instead of H2O2 to increase the [Na](i) by more than 30 mM without any change in the [Ca](i), cytochrome c release and caspase 3-dependent apoptosis occurred, showing that [Na](i) overload per se induced apoptosis. We also showed that the increase in the mitochondrial, but not the cytosolic, Na+ levels resulted in the opening of the permeation transition pore, followed by cytochrome c release. Our findings therefore suggest that H2O2-induced [Na](m) overload is an important upstream signal for the apoptotic machinery, and the prevention of [Na](m) overload thus represents a particularly attractive target for strategies aimed at preventing oxidative stress-induced cell death.	Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Physiol, Taipei 10764, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Anat & Cell Biol, Taipei 10764, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10764, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10764, Taiwan; Ming Chuan Univ, Dept Biotechnol, Taoyuan, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Ming Chuan University	Wu, ML (corresponding author), Natl Taiwan Univ 1, Coll Med, Dept Physiol, Sec 1,Jen Ai Rd, Taipei, Taiwan.	mlw@ha.mc.ntu.edu.tw		CHIEN, CHUNG-LIANG/0000-0001-9806-486X				Akao M, 2003, CIRC RES, V92, P186, DOI 10.1161/01.RES.0000051861.21316.E9; BLAUSTEIN MP, 1991, ELECTROGENIC TRANSPO, P129; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; BOLLI R, 1989, CIRC RES, V65, P607, DOI 10.1161/01.RES.65.3.607; Chen WH, 2001, J PHYSIOL-LONDON, V537, P497, DOI 10.1111/j.1469-7793.2001.00497.x; Chen WH, 1999, J PHYSIOL-LONDON, V515, P133, DOI 10.1111/j.1469-7793.1999.133ad.x; Chen ZH, 2002, J BIOL CHEM, V277, P24653, DOI 10.1074/jbc.M111862200; CLAGUE JR, 1994, J MOL CELL CARDIOL, V26, P11, DOI 10.1006/jmcc.1994.1003; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Colucci WS, 1997, AM J CARDIOL, V80, pL15, DOI 10.1016/S0002-9149(97)00845-X; CORRETTI MC, 1991, J CLIN INVEST, V88, P1014, DOI 10.1172/JCI115361; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hool LC, 2002, CIRC RES, V91, P601, DOI 10.1161/01.RES.0000035528.00678.D5; Huang CS, 2002, CANCER RES, V62, P5689; Ide T, 2000, CIRC RES, V86, P152, DOI 10.1161/01.RES.86.2.152; Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; Kimura J, 1999, BRIT J PHARMACOL, V128, P969, DOI 10.1038/sj.bjp.0702869; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Park CO, 1999, AM J PHYSIOL-HEART C, V276, pH1581, DOI 10.1152/ajpheart.1999.276.5.H1581; Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9; PEETERS GA, 1989, AM J PHYSIOL, V256, pC351, DOI 10.1152/ajpcell.1989.256.2.C351; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; POWIS DA, 1994, CELL CALCIUM, V16, P377, DOI 10.1016/0143-4160(94)90031-0; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Saraste A, 1997, CIRCULATION, V95, P320; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wang SM, 1998, J CELL BIOCHEM, V71, P82, DOI 10.1002/(SICI)1097-4644(19981001)71:1<82::AID-JCB9>3.0.CO;2-Y; WENDTGALLITELLI MF, 1985, PFLUG ARCH EUR J PHY, V405, P310, DOI 10.1007/BF00595683; Wu ML, 2000, CIRC RES, V86, pE55	44	20	20	2	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1442	+		10.1096/fj.03-1038fje	http://dx.doi.org/10.1096/fj.03-1038fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231730	Green Submitted			2022-12-28	WOS:000222979200029
J	Cho, HY; Reddy, SPM; Yamamoto, M; Kleeberger, SR				Cho, HY; Reddy, SPM; Yamamoto, M; Kleeberger, SR			The transcription factor NRF2 protects against pulmonary fibrosis	FASEB JOURNAL			English	Article						bleomycin; reactive oxygen species; oxidative stress; lung; knockout mice; antioxidant	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INDUCED LUNG INJURY; GENE-EXPRESSION; ALVEOLAR BRONCHIOLIZATION; INTRATRACHEAL BLEOMYCIN; SUPEROXIDE-DISMUTASE; AIRWAY EPITHELIUM; OXIDATIVE STRESS; KNOCKOUT MICE; INDUCTION	The molecular mechanisms of pulmonary fibrosis are poorly understood, although reactive oxygen species are thought to have an important role. NRF2 is a transcription factor that protects cells and tissues from oxidative stress by activating protective antioxidant and detoxifying enzymes. We hypothesized that NRF2 protects lungs from injury and fibrosis induced by bleomycin, an anti-neoplastic agent that causes pulmonary fibrosis in susceptible patients. To test this hypothesis, mice with targeted deletion of Nrf2 (Nrf2(-/-)) and wild-type (Nrf2(+/+)) mice were treated with bleomycin or vehicle, and pulmonary injury and fibrotic responses were compared. Bleomycin-induced increases in lung weight, epithelial cell death, and inflammation were significantly greater in Nrf2(-/-) mice than in Nrf2(+/+) mice. Indices of lung fibrosis (hydroxyproline content, collagen accumulation, fibrotic score, cell proliferation) were significantly greater in bleomycin-treated Nrf2(-/-) mice, compared with Nrf2(+/+) mice. NRF2 expression and activity were elevated in Nrf2(+/+) mice by bleomycin. Bleomycin caused greater up-regulation of several NRF2-inducible antioxidant enzyme genes and protein products in Nrf2(+/+) mice compared with Nrf2(-/-) mice. Further, bleomycin-induced transcripts and protein levels of lung injury and fibrosis markers were significantly attenuated in Nrf2(+/+) mice compared with Nrf2(-/-) mice. Results demonstrated that NRF2 has a critical role in protection against pulmonary fibrosis, presumably through enhancement of cellular antioxidant capacity. This study has important implications for the development of intervention strategies against fibrosis.	NIEHS, Resp Biol Lab, Res Triangle Pk, NC 27709 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; University of Tsukuba; University of Tsukuba	Cho, HY (corresponding author), NIEHS, Resp Biol Lab, 111 TW Alexander Dr,Bd 101,MD D-201, Res Triangle Pk, NC 27709 USA.	cho2@niehs.nih.gov	Yamamoto, Masayuki/A-4873-2010; Kleeberger, Steven R/F-1807-2019	Yamamoto, Masayuki/0000-0002-9073-9436; Kleeberger, Steven R/0000-0003-2948-8452	NHLBI NIH HHS [HL-66109] Funding Source: Medline; NIEHS NIH HHS [ES-03819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES100513, P30ES003819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMSON IY, 1997, LAB INVEST, V36, P26; ADAMSON IYR, 1984, AM J PATHOL, V117, P37; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Arras M, 2001, AM J RESP CELL MOL, V24, P368, DOI 10.1165/ajrcmb.24.4.4249; ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467; Beeh KM, 2002, EUR RESPIR J, V19, P1119, DOI 10.1183/09031936.02.00262402; Betsuyaku T, 2000, AM J PATHOL, V157, P525, DOI 10.1016/S0002-9440(10)64563-4; Bowler RP, 2002, AM J PHYSIOL-LUNG C, V282, pL719, DOI 10.1152/ajplung.00058.2001; Buttner C, 2004, J CELL PHYSIOL, V198, P248, DOI 10.1002/jcp.10395; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; CHANG M, 1990, J BIOL CHEM, V265, P5418; Chen ES, 2001, AM J RESP CELL MOL, V24, P545, DOI 10.1165/ajrcmb.24.5.4064; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Daly HE, 1998, LAB INVEST, V78, P393; Day RM, 2002, AM J PHYSIOL-LUNG C, V282, pL1349, DOI 10.1152/ajplung.00338.2001; Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FANTONE JC, 1988, FREE RADICAL BIO MED, V4, P399, DOI 10.1016/0891-5849(88)90091-3; Gon Y, 2001, LIFE SCI, V68, P1877, DOI 10.1016/S0024-3205(01)00980-8; HECHT SM, 1986, FASEB J, V45, P2784; Hoshino T, 2003, AM J RESP CRIT CARE, V168, P1075, DOI 10.1164/rccm.200209-982OC; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; ISHIDA R, 1975, BIOCHEM BIOPH RES CO, V66, P1432, DOI 10.1016/0006-291X(75)90519-7; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Keane MP, 2001, AM J PHYSIOL-LUNG C, V281, pL92, DOI 10.1152/ajplung.2001.281.1.L92; Kunugi S, 2001, LAB INVEST, V81, P1309, DOI 10.1038/labinvest.3780344; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; LEDWOZYW A, 1991, ACTA VET HUNG, V39, P215; Liu JY, 2001, AM J RESP CELL MOL, V25, P3, DOI 10.1165/ajrcmb.25.1.4481; NETTESHEIM P, 1972, LAB INVEST, V26, P210; Poli P, 1999, MUTAGENESIS, V14, P233, DOI 10.1093/mutage/14.2.233; Sekhar KR, 2003, CANCER RES, V63, P5636; SELMAN M, 1989, EXP MOL PATHOL, V50, P147, DOI 10.1016/0014-4800(89)90027-0; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; TOH K, 1999, GENE DEV, V13, P76; White ES, 2003, J PATHOL, V201, P343, DOI 10.1002/path.1446; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	45	278	287	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1258	+		10.1096/fj.03-1127fje	http://dx.doi.org/10.1096/fj.03-1127fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208274				2022-12-28	WOS:000222327500020
J	Sheibanie, AF; Tadmori, I; Jing, H; Vassiliou, E; Ganea, D				Sheibanie, AF; Tadmori, I; Jing, H; Vassiliou, E; Ganea, D			Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells	FASEB JOURNAL			English	Article						PGE(2); inflammation; EP2/EP4 receptors	PROSTANOID RECEPTORS; IMMUNE-RESPONSES; IL-12; EXPRESSION; CYTOKINE; INTERLEUKIN-12; INFLAMMATION; DISTINCT; ACTIVATION; MATURATION	Interleukin-23, a recently described cytokine produced by activated antigen-presenting cells, including dendritic cells, is a p19/p40 heterodimer. The p40 subunit is shared with IL-12, the major Th1-driving cytokine, while p19 is distantly related to IL-12 p35. IL-23 has pro-inflammatory actions, inducing IL-17 secretion from activated CD4+ T cells, and stimulating the proliferation of memory CD4+ T cells. Here, we examined the effects of PGE(2), a well-known immunomodulator, on the production of IL-23 by bone marrow- derived dendritic cells (BM-DCs). Our results indicate that PGE(2) increases the production of functional IL-23 from immature BM-DCs in a time- and dose-dependent manner. PGE(2) induces both the expression of p19 and p40, without affecting p35 expression. The effect of PGE(2) is mediated through the specific receptors EP2/4 and is mimicked by cAMP-inducing agents, such as forskolin and dbcAMP. Although PGE(2) also induces IL-1beta and IL-6 expression in non-stimulated DCs, the stimulatory effect of PGE(2) on IL-23 production is not mediated through IL-1beta or IL-6. GM-CSF, the pro-inflammatory cytokine required for the generation of BM-DCs, amplifies the IL-23 inducing activity of PGE(2) in a synergistic manner. Recent studies described both pro- and anti-inflammatory effects of PGE(2), and our results suggest an additional mechanism for its pro-inflammatory role, particularly significant for autoimmune diseases, such as rheumatoid arthritis.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	dganea@andromeda.rutgers.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047325, R01AI052306, R56AI047325] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47325, AI052306] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Becker C, 2003, J CLIN INVEST, V112, P693, DOI 10.1172/JCI200317464; Belladonna ML, 2002, J IMMUNOL, V168, P5448, DOI 10.4049/jimmunol.168.11.5448; Brombacher F, 2003, TRENDS IMMUNOL, V24, P207, DOI 10.1016/S1471-4906(03)00067-X; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Harizi H, 2002, J IMMUNOL, V168, P2255, DOI 10.4049/jimmunol.168.5.2255; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Jefford M, 2003, BLOOD, V102, P1753, DOI 10.1182/blood-2002-12-3854; Jing H, 2003, J LEUKOCYTE BIOL, V74, P868, DOI 10.1189/jlb.0303116; Jozefowski S, 2003, INT IMMUNOPHARMACOL, V3, P865, DOI 10.1016/S1567-5769(03)00072-9; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Kalinski P, 1998, J IMMUNOL, V161, P2804; Kalinski P, 1997, J IMMUNOL, V159, P28; Kalinski P, 2001, BLOOD, V97, P3466, DOI 10.1182/blood.V97.11.3466; Lankford CSR, 2003, J LEUKOCYTE BIOL, V73, P49, DOI 10.1189/jlb.0602326; Lo CH, 2003, J IMMUNOL, V171, P600, DOI 10.4049/jimmunol.171.2.600; Luft T, 2002, BLOOD, V100, P1362, DOI 10.1182/blood-2001-12-0360; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Miossec P, 2003, ARTHRITIS RHEUM-US, V48, P594, DOI 10.1002/art.10816; Morelli AE, 2003, TRENDS IMMUNOL, V24, P108, DOI 10.1016/S1471-4906(03)00023-1; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Pirbonen J, 2002, J IMMUNOL, V169, P5673, DOI 10.4049/jimmunol.169.10.5673; Randolph GJ, 2001, SEMIN IMMUNOL, V13, P267, DOI 10.1006/smim.2001.0322; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Rieser C, 1997, J EXP MED, V186, P1603, DOI 10.1084/jem.186.9.1603; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; Tada Y, 2003, CANCER GENE THER, V10, P451, DOI 10.1038/sj.cgt.7700584; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; van Seventer JM, 2002, J NEUROIMMUNOL, V133, P60, DOI 10.1016/S0165-5728(02)00362-4; Vassiliou E, 2003, CELL IMMUNOL, V223, P120, DOI 10.1016/S0008-8749(03)00158-8; Wang YQ, 2003, INT J CANCER, V105, P820, DOI 10.1002/ijc.11160; Watford WT, 2003, NATURE, V421, P706, DOI 10.1038/421706a; Wiekowski MT, 2001, J IMMUNOL, V166, P7563, DOI 10.4049/jimmunol.166.12.7563; Zhang GX, 2003, J IMMUNOL, V171, P4485, DOI 10.4049/jimmunol.171.9.4485; Zhang GX, 2003, J IMMUNOL, V170, P2153, DOI 10.4049/jimmunol.170.4.2153	40	134	142	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1318	+		10.1096/fj.03-1367fje	http://dx.doi.org/10.1096/fj.03-1367fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180965				2022-12-28	WOS:000222327500025
J	Tschope, C; Walther, T; Koniger, J; Spillmann, F; Westermann, D; Escher, F; Pauschinger, M; Pesquero, JB; Bader, M; Schultheiss, HP; Noutsias, M				Tschope, C; Walther, T; Koniger, J; Spillmann, F; Westermann, D; Escher, F; Pauschinger, M; Pesquero, JB; Bader, M; Schultheiss, HP; Noutsias, M			Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene	FASEB JOURNAL			English	Article						diabetes mellitus; diabetic cardiomyopathy; kallikrein; pathogenesis; therapy; transgenic animal	ANGIOTENSIN-CONVERTING ENZYME; DELIVERY ATTENUATES HYPERTENSION; ENDOGENOUS BRADYKININ; CONNECTIVE-TISSUE; BLOOD-PRESSURE; RENAL INJURY; COLLAGEN; RECEPTOR; INHIBITION; GLUCOSE	Diabetic cardiomyopathy includes fibrosis. Kallikrein (KLK) can inhibit collagen synthesis and promote collagen breakdown. We investigated cardiac fibrosis and left ventricular (LV) function in transgenic rats (TGR) expressing the human kallikrein 1 (hKLK1) gene in streptozotocin (STZ) - induced diabetic conditions. Six weeks after STZ injection, LV function was determined in male Sprague-Dawley (SD) rats and TGR(hKLK1) (n = 10/group) by a Millar tip catheter. Total collagen content ( Sirius Red staining) and expression of types I, III, and VI collagen were quantified by digital image analysis. SD-STZ hearts demonstrated significantly higher total collagen amounts than normoglycemic controls, reflected by the concomitant increment of collagen types I, III, and VI. This correlated with a significant reduction of LV function vs. normoglycemic controls. In contrast, surface-specific content of the extracellular matrix, including collagen types I, III, and VI expression, was significantly lower in TGR( hKLK1)- STZ, not exceeding the content of SD and TGR( hKLK1) controls. This was paralleled by a preserved LV function in TGR( hKLK1)- STZ animals. The kallikrein inhibitor aprotinin and the bradykinin (BK) B2 receptor antagonist icatibant reduced the beneficial effects on LV function and collagen content in TGR( hKLK1)- STZ animals. Transgenic expression of hKLK1 counteracts the progression of LV contractile dysfunction and extracellular matrix remodeling in STZ-induced diabetic cardiomyopathy via a BK B2 receptor-dependent pathway.	Free Univ Berlin, Charite Univ Med, Dept Cardiol & Pneumonol, D-12220 Berlin, Germany; Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil; Max Delbruck Ctr Mol Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universidade Federal de Sao Paulo (UNIFESP); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Tschope, C (corresponding author), Free Univ Berlin, Charite Univ Med, Dept Cardiol & Pneumonol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12220 Berlin, Germany.	ctschoepe@yahoo.com	Pesquero, Joao/C-1470-2012; Bader, Michael/K-2124-2013; Westermann, Dirk/D-1344-2011; Noutsias, Michel/AAM-4006-2021	Pesquero, Joao/0000-0002-4507-632X; Westermann, Dirk/0000-0002-7542-1956; Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164; Noutsias, Michel/0000-0002-9066-5262; Escher, Felicitas/0000-0003-0678-5681; Spillmann, Frank/0000-0003-0002-5745				Cellier E, 2002, CAN J PHYSIOL PHARM, V80, P341, DOI 10.1139/Y02-033; Chao J, 1998, HUM GENE THER, V9, P21, DOI 10.1089/hum.1998.9.1-21; Cheng CP, 1998, J AM COLL CARDIOL, V31, P1679, DOI 10.1016/S0735-1097(98)00159-4; Clements J, 2001, BIOL CHEM, V382, P5, DOI 10.1515/BC.2001.002; Dostal DE, 2001, HYPERTENSION, V37, P841, DOI 10.1161/01.HYP.37.3.841; Douillet CD, 2000, AM J PHYSIOL-HEART C, V279, pH2829, DOI 10.1152/ajpheart.2000.279.6.H2829; Emanueli C, 2000, ARTERIOSCL THROM VAS, V20, P2379, DOI 10.1161/01.ATV.20.11.2379; Emanueli C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8; Emanueli C, 2001, CIRCULATION, V103, P125; Gallagher AM, 1998, HYPERTENSION, V32, P84, DOI 10.1161/01.HYP.32.1.84; GROVES P, 1995, CIRCULATION, V92, P3424, DOI 10.1161/01.CIR.92.12.3424; Hu K, 1998, CARDIOVASC RES, V39, P401, DOI 10.1016/S0008-6363(98)00090-X; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Kim NN, 1999, J MOL CELL CARDIOL, V31, P457, DOI 10.1006/jmcc.1998.0887; Kudoh A, 2000, HYPERTENSION, V36, P239, DOI 10.1161/01.HYP.36.2.239; Mayfield RK, 1996, DIABETES, V45, pS20, DOI 10.2337/diab.45.1.S20; Mizushige K, 2000, CIRCULATION, V101, P899, DOI 10.1161/01.CIR.101.8.899; MODRAK J, 1980, DIABETES, V29, P547, DOI 10.2337/diabetes.29.7.547; Noutsias M, 2002, MED SCI MONITOR, V8, pMT59; Pauschinger M, 1999, CIRCULATION, V99, P2750, DOI 10.1161/01.CIR.99.21.2750; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; Schanstra JP, 2002, J CLIN INVEST, V110, P371, DOI 10.1172/JCI200215493; SHANAHAN MF, 1989, ENDOCRINOLOGY, V125, P1074, DOI 10.1210/endo-125-2-1074; Sharma JN, 1996, IMMUNOPHARMACOLOGY, V33, P341, DOI 10.1016/0162-3109(96)00104-X; Shimizu M, 1993, Nihon Rinsho, V51, P1362; SHIMIZU M, 1993, J CLIN PATHOL, V46, P32, DOI 10.1136/jcp.46.1.32; Silva JA, 2000, FASEB J, V14, P1858; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Spillmann F, 2002, INT IMMUNOPHARMACOL, V2, P1823, DOI 10.1016/S1567-5769(02)00174-1; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; SPIRO MJ, 1993, DIABETOLOGIA, V36, P93, DOI 10.1007/BF00400687; Tschesche H, 1989, Adv Exp Med Biol, V247A, P545; Tschope C, 2002, J CARDIOVASC PHARM, V39, P478, DOI 10.1097/00005344-200204000-00003; Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P35, DOI 10.1016/S0162-3109(99)00109-5; Tschope C, 2000, J HYPERTENS, V18, P223, DOI 10.1097/00004872-200018020-00014; WANG C, 1995, J CLIN INVEST, V95, P1710, DOI 10.1172/JCI117847; WEBER KT, 1995, ANN NY ACAD SCI, V752, P286, DOI 10.1111/j.1749-6632.1995.tb17438.x; WEBER KT, 1995, J MOL CELL CARDIOL, V27, P107, DOI 10.1016/S0022-2828(08)80011-9; Wolf WC, 2000, KIDNEY INT, V58, P730, DOI 10.1046/j.1523-1755.2000.00219.x; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759; ZARICH SW, 1989, AM HEART J, V118, P1000, DOI 10.1016/0002-8703(89)90236-6	41	82	92	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					828	835		10.1096/fj.03-0736com	http://dx.doi.org/10.1096/fj.03-0736com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15117887				2022-12-28	WOS:000221883200031
J	Neels, JG; Thinnes, T; Loskutoff, DJ				Neels, JG; Thinnes, T; Loskutoff, DJ			Angiogenesis in an in vivo model of adipose tissue development	FASEB JOURNAL			English	Article						obesity; neovascularization; adipocytes; endothelial cells; progenitor cells	NECROSIS-FACTOR-ALPHA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ENDOTHELIAL-CELLS; INSULIN-RESISTANCE; PROGENITOR CELLS; FAT PADS; EXPRESSION; OBESITY; ADIPOCYTE; GROWTH	Obesity is associated with an increased risk for cardiovascular disease and cancer. Angiogenesis is a critical component of these pathological processes, and expanding adipose tissue represents one of the few sites of active angiogenesis in the adult. Despite the potential importance of angiogenesis in obesity, little is known about underlying mechanisms. This problem is magnified by the absence of useful quantitative model systems. In this report, we examine the angiogenic process using the 3T3-F442A model of adipose tissue development. In this model, 3T3-F442A preadipocytes are implanted subcutaneously into athymic Balb/c nude mice. We show that these cells develop into highly vascularized fat pads over the next 14-21 days, and that these fat pads are morphologically similar to normal subcutaneous adipose tissue. Histological studies demonstrate that a new microvasculature is evident as early as 5 days after cell implantation, and real-time quantitative RT-PCR analyses show that the expression of endothelial cell markers and adipogenesis markers increase in parallel during fat pad development. Finally, these preliminary studies suggest that the neovasculature originates by sprouting from larger, host-derived blood vessels that run parallel to peripheral nerves and that endothelial progenitor cells play little, if any, role in this process.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd,VB-3, La Jolla, CA 92037 USA.	loskutof@scripps.edu	Neels, Jaap G/F-5534-2010	Neels, Jaap G/0000-0002-5900-8395	NHLBI NIH HHS [HL59549] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki S, 2003, CELL STRUCT FUNCT, V28, P55; Asano A, 1997, BIOCHEM J, V328, P179, DOI 10.1042/bj3280179; BILLINGS E, 1989, PLAST RECONSTR SURG, V83, P368, DOI 10.1097/00006534-198902000-00033; Bouloumie A, 2002, ANN ENDOCRINOL-PARIS, V63, P91; BURNSTOCK G, 1994, BRIT J PLAST SURG, V47, P527, DOI 10.1016/0007-1226(94)90136-8; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P219, DOI 10.1097/00006534-199102000-00001; Fitzpatrick TE, 1998, EXP CELL RES, V245, P155, DOI 10.1006/excr.1998.4240; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; HAUSMAN GJ, 1991, MICROVASC RES, V41, P111, DOI 10.1016/0026-2862(91)90012-Z; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hutley LJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1037, DOI 10.1152/ajpendo.2001.281.5.E1037; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kawaguchi N, 1999, CYTOTECHNOLOGY, V31, P215, DOI 10.1023/A:1008198731341; Kral JG, 1999, PLAST RECONSTR SURG, V104, P1732, DOI 10.1097/00006534-199911000-00018; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300; Masuda H, 2003, CARDIOVASC RES, V58, P390, DOI 10.1016/S0008-6363(02)00785-X; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Patrick CW, 1999, TISSUE ENG, V5, P139, DOI 10.1089/ten.1999.5.139; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Ryan TJ, 1995, CLIN DERMATOL, V13, P493, DOI 10.1016/0738-081X(95)00092-T; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SCANNELL G, 1993, J SURG RES, V54, P281, DOI 10.1006/jsre.1993.1044; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Straczkowski M, 2002, J CLIN ENDOCR METAB, V87, P4602, DOI 10.1210/jc.2002-020135; Toriyama K, 2002, TISSUE ENG, V8, P157, DOI 10.1089/107632702753503144; VARZANEH FE, 1994, METABOLISM, V43, P906, DOI 10.1016/0026-0495(94)90275-5; Voswinckel R, 2003, CIRC RES, V93, P372, DOI 10.1161/01.RES.0000087643.60150.C2; Zangani D, 1999, DIFFERENTIATION, V64, P91, DOI 10.1046/j.1432-0436.1999.6420091.x	42	142	149	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					983	+		10.1096/fj.03-1101fje	http://dx.doi.org/10.1096/fj.03-1101fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084517				2022-12-28	WOS:000221108800006
J	van den Biggelaar, AHJ; de Craen, AJM; Gussekloo, J; Huizinga, TWJ; Heijmans, BT; Frolich, M; Kirkwood, TBL; Westendorp, RGJ				van den Biggelaar, AHJ; de Craen, AJM; Gussekloo, J; Huizinga, TWJ; Heijmans, BT; Frolich, M; Kirkwood, TBL; Westendorp, RGJ			Inflammation underlying cardiovascular mortality is a late consequence of evolutionary programming	FASEB JOURNAL			English	Article						ageing; pleiotropy; pro-inflammatory; anti-inflammatory	DENSITY-LIPOPROTEIN CHOLESTEROL; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; DISEASE; INTERLEUKIN-10; LONGEVITY; REPRODUCTION; POLYMORPHISM; IMMUNITY; BURDEN	With the increase in life expectancy, death from cardiovascular disease has risen greatly. There is increasing evidence that inflammation plays an important role in cardiovascular disease. We postulate that the development of cardiovascular disease in old age is a late consequence of evolutionary programming for a pro-inflammatory response to resist infections in early age. In 311 women, aged 85 yr old, the production of the pro- and anti-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-10 was determined in lipopolysaccharide-stimulated whole blood samples and studied prospectively in association with cardiovascular mortality. High TNF-alpha was a risk factor for death from cardiovascular disease (relative risk [RR] = 1.56; 95% confidence interval [CI]: 1-2.40), whereas high IL-10 was protective (RR = 0.58; 95% CI: 0.40-0.85). A genetic variant of the IL-10 gene promoter, which is associated with lower IL-10 production, was found to predispose to a 2.8-fold higher cardiovascular mortality risk ( 95% CI: 1.17-6.60). Reproductive success, which was studied as a measure of evolutionary programming because it trades off with early survival by pro- inflammatory resistance genes, was negatively associated with an increasing production of TNF-alpha (RR = 0.77; 95% CI: 0.68-0.88), while a positive association with IL-10 was found (RR = 1.22; 95% CI: 1.05-1.41). We suggest that cardiovascular mortality is a late consequence of evolutionary programming for a pro-inflammatory response.	Leiden Univ, Med Ctr, Dept Gen Internal Med, Sect Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Reumatol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Chem, NL-2300 RC Leiden, Netherlands; Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK	van den Biggelaar, AHJ (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, Sect Gerontol & Geriatr, C2-R,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	Biggelaar@lumc.nl	Gussekloo, Jacobijn/ABE-3879-2021	Gussekloo, Jacobijn/0000-0001-7186-8278	Biotechnology and Biological Sciences Research Council [BEP17042] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		[Anonymous], 1992, INT STAT CLASS DIS R, V1-3; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Bonow RO, 2002, CIRCULATION, V106, P1602, DOI 10.1161/01.CIR.0000035036.22612.2B; Bootsma-van der Wiel A, 2002, J CLIN EPIDEMIOL, V55, P1119, DOI 10.1016/S0895-4356(02)00505-X; DAY INM, 1994, ANAL BIOCHEM, V222, P389, DOI 10.1006/abio.1994.1507; Doblhammer G, 2003, P ROY SOC B-BIOL SCI, V270, P1541, DOI 10.1098/rspb.2003.2400; Haukim N, 2002, GENES IMMUN, V3, P313, DOI 10.1038/sj.gene.6363881; Hill JA, 1995, HUM REPROD, V10, P114, DOI 10.1093/humrep/10.suppl_2.114; Kirkwood TBL, 2002, NATURE, V419, P794, DOI 10.1038/419794a; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lowe PR, 2003, CRIT CARE MED, V31, P34, DOI 10.1097/00003246-200301000-00005; Makhseed M, 2003, AM J REPROD IMMUNOL, V49, P308, DOI 10.1034/j.1600-0897.2003.00038.x; Makhseed M, 2000, HUM REPROD, V15, P2011, DOI 10.1093/humrep/15.9.2011; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; Perkins DJ, 2000, J INFECT DIS, V182, P988, DOI 10.1086/315762; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rose MR, 2002, EVOLUTION, V56, P1982; Santos AR, 2002, J INFECT DIS, V186, P1687, DOI 10.1086/345366; Sgro CM, 2000, EVOLUTION, V54, P2152, DOI 10.1111/j.0014-3820.2000.tb01257.x; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Tong S, 2004, LANCET, V363, P129, DOI 10.1016/S0140-6736(03)15265-8; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; van den Biggelaar AHJ, 2002, J INFECT DIS, V186, P1474, DOI 10.1086/344352; van der Linden MW, 1998, J IMMUNOL METHODS, V218, P63, DOI 10.1016/S0022-1759(98)00108-2; van Exel E, 2002, STROKE, V33, P1135, DOI 10.1161/01.STR.0000014206.05597.9E; van Exel E, 2002, DIABETES, V51, P1088, DOI 10.2337/diabetes.51.4.1088; Westendorp RGJ, 1998, NATURE, V396, P743, DOI 10.1038/25519; Westendorp RGJ, 2001, NAT MED, V7, P873, DOI 10.1038/90868; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; Weverling-Rijnsburger AWE, 2003, ARCH INTERN MED, V163, P1549, DOI 10.1001/archinte.163.13.1549; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Yarnell J, 2003, INT J EPIDEMIOL, V32, P71, DOI 10.1093/ije/dyg038	37	40	41	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1022	+		10.1096/fj.03-1162fje	http://dx.doi.org/10.1096/fj.03-1162fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084512				2022-12-28	WOS:000221108800001
J	Slominski, A; Wortsman, J; Tobin, DJ				Slominski, A; Wortsman, J; Tobin, DJ			The cutaneous serotoninergic/melatoninergic system: securing a place under the sun	FASEB JOURNAL			English	Review						skin; melatonin; serotonin; N-acetylserotonin; endocrinology of the skin	SEROTONIN N-ACETYLTRANSFERASE; HYDROXYINDOLE-O-METHYLTRANSFERASE; CORTICOTROPIN-RELEASING HORMONE; HUMAN TRYPTOPHAN-HYDROXYLASE; HUMAN-MELANOMA CELLS; PINEALECTOMY-INDUCED ELEVATION; HUMAN SKIN FIBROBLASTS; MELATONIN RECEPTORS; MAST-CELL; HAIR-FOLLICLES	It was recently discovered that mammalian skin can produce serotonin and transform it into melatonin. Pathways for the biosynthesis and biodegradation of serotonin and melatonin have been characterized in human and rodent skin and in their major cellular populations. Moreover, receptors for serotonin and melatonin receptors are expressed in keratinocytes, melanocytes, and fibroblasts and these mediate phenotypic actions on cellular proliferation and differentiation. Melatonin exerts receptor-independent effects, including activation of pathways protective of oxidative stress and the modification of cellular metabolism. While serotonin is known to have several roles in skin - e.g., pro-edema, vasodilatory, proinflammatory, and pruritogenic - melatonin has been experimentally implicated in hair growth cycling, pigmentation physiology, and melanoma control. Thus, the widespread expression of a cutaneous seorotoninergic/melatoninergic system(s) indicates considerable selectivity of action to facilitate intra-, auto-, or paracrine mechanisms that define and influence skin function in a highly compartmentalized manner. Notably, the cutaneous melatoninergic system is organized to respond to continuous stimulation in contrast to the pineal gland, which ( being insulated from the external environment) responds to discontinuous activation by the circadian clock. Overall, the cutaneous serotoninergic/melatoninergic system could counteract or buffer external ( environmental) or internal stresses to preserve the biological integrity of the organ and to maintain its homeostasis.	Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Memphis, TN 38163 USA; So Illinois Univ, Dept Med, Springfield, IL USA; Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England	University of Tennessee System; University of Tennessee Health Science Center; Southern Illinois University System; Southern Illinois University; University of Bradford	Slominski, A (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Suite 599,930 Madison Ave, Memphis, TN 38163 USA.	aslominski@utmem.edu	; Tobin, Desmond/A-5228-2009	Slominski, Andrzej/0000-0001-8963-3995; Tobin, Desmond/0000-0003-4566-9392				Abe M, 1999, EXP EYE RES, V68, P255, DOI 10.1006/exer.1998.0601; ALLAIN D, 1980, REPROD NUTR DEV, V20, P197, DOI 10.1051/rnd:19800114; ALLAIN D, 1994, EUROPEAN FINE FIBRE, V2, P23; Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x; Allegra M, 2001, BIOCHEM BIOPH RES CO, V282, P380, DOI 10.1006/bbrc.2001.4582; ARENDT J, 1988, CLIN ENDOCRINOL, V29, P205, DOI 10.1111/j.1365-2265.1988.tb00263.x; AshkenazyShahar M, 1997, BIOCHEM MOL MED, V60, P187, DOI 10.1006/bmme.1996.2562; Balaskas EV, 1998, NEPHRON, V78, P395, DOI 10.1159/000044967; Bangha E, 1997, SKIN PHARMACOL, V10, P298; Bangha E, 1997, DERMATOLOGY, V195, P248, DOI 10.1159/000245953; Bardak Y, 2000, CURR EYE RES, V20, P225, DOI 10.1076/0271-3683(200003)20:3;1-9;FT225; BARTSCH H, 1986, NEUROENDOCRINOL LETT, V8, P289; Belmonte C., 1997, BIOMED PHARMACOTHER, V51, P187; BERNARD M, 1995, BRAIN RES, V696, P37, DOI 10.1016/0006-8993(95)00651-6; Bos JD, 1997, SKIN IMMUNE SYSTEM S; BOULARAND S, 1995, J BIOL CHEM, V270, P3748, DOI 10.1074/jbc.270.8.3748; BRANCHEK TA, 1988, J NEUROSCI, V8, P2582; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; Brydon L, 2001, ENDOCRINOLOGY, V142, P4264, DOI 10.1210/en.142.10.4264; Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919; Buznikov GA, 2001, CELL TISSUE RES, V305, P177, DOI 10.1007/s004410100408; CAHILL GM, 1989, P NATL ACAD SCI USA, V86, P1098, DOI 10.1073/pnas.86.3.1098; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Carlberg C, 2000, ANN NY ACAD SCI, V917, P387; Carlton SM, 1997, BRAIN RES, V763, P271, DOI 10.1016/S0006-8993(97)00489-7; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Chen WC, 2002, J INVEST DERMATOL, V119, P992, DOI 10.1046/j.1523-1747.2002.00613.x; COLDITZ IG, 1991, IMMUNOL CELL BIOL, V69, P215, DOI 10.1038/icb.1991.31; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 1996, GENOMICS, V34, P76, DOI 10.1006/geno.1996.0243; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; COS S, 1990, CANCER LETT, V50, P115, DOI 10.1016/0304-3835(90)90240-X; Cos S, 2000, FRONT NEUROENDOCRIN, V21, P133, DOI 10.1006/frne.1999.0194; Dicks P, 1996, J ENDOCRINOL, V151, P55, DOI 10.1677/joe.0.1510055; DONOHUE SJ, 1993, DNA CELL BIOL, V12, P715, DOI 10.1089/dna.1993.12.715; Dreher F, 1998, BRIT J DERMATOL, V139, P332, DOI 10.1046/j.1365-2133.1998.02447.x; Drobnik J, 1999, CYTOBIOS, V100, P49; Drobnik Jacek, 1996, Cytobios, V85, P51; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Dubocovich ML, 1999, ADV EXP MED BIOL, V460, P181; Eison Arlene S., 1993, Life Sciences, V53, P393; ENGLISH KB, 1992, ANAT REC, V232, P112, DOI 10.1002/ar.1092320112; Facciola G, 2001, EUR J CLIN PHARMACOL, V56, P881, DOI 10.1007/s002280000245; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; FILADELFI AMC, 1994, COMP BIOCHEM PHYS A, V109, P1027, DOI 10.1016/0300-9629(94)90252-6; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; FINOCCHIARO LME, 1988, J INTERFERON RES, V8, P705, DOI 10.1089/jir.1988.8.705; Finocchiaro LME, 1998, J PINEAL RES, V24, P22, DOI 10.1111/j.1600-079X.1998.tb00362.x; Fischer TW, 2004, BRIT J DERMATOL, V150, P341, DOI 10.1111/j.1365-2133.2004.05685.x; FITZPATRICK TB, 1997, DERMATOLOGY GEN MED; Frohlich PF, 2000, PHYSIOL BEHAV, V71, P383, DOI 10.1016/S0031-9384(00)00344-9; FUJII E, 1994, N-S ARCH PHARMACOL, V350, P361; Gambichler Thilo, 2002, BMC Dermatol, V2, P6, DOI 10.1186/1471-5945-2-6; GARCIACABALLERO T, 1989, ANAT REC, V225, P267, DOI 10.1002/ar.1092250402; GAUDET SJ, 1993, J INVEST DERMATOL, V101, P660, DOI 10.1111/1523-1747.ep12371672; Gillbro JM, 2004, J INVEST DERMATOL, V123, P346, DOI 10.1111/j.0022-202X.2004.23210.x; GOLDBERG JI, 1989, DEV BIOL, V131, P483, DOI 10.1016/S0012-1606(89)80019-3; Gordon J, 2003, TRENDS IMMUNOL, V24, P438, DOI 10.1016/S1471-4906(03)00176-5; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; GRANDO SA, 1997, CUR OPIN DERMATOL, V4, P462; GUPTA D, 1988, PINEAL GLAND CANC; Gurlek A, 2004, J PINEAL RES, V36, P58, DOI 10.1046/j.1600-079X.2003.00099.x; Hadley M.E., 1996, ENDOCRINOLOGY; HAGERMARK O, 1992, SKIN PHARMACOL, V5, P1; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Hu DN, 1998, MELANOMA RES, V8, P205, DOI 10.1097/00008390-199806000-00002; IBRAHEEM M, 1994, J ANAT, V185, P135; Iida Y, 2002, EUR J BIOCHEM, V269, P4780, DOI 10.1046/j.1432-1033.2002.03188.x; Itoh MT, 1999, MOL HUM REPROD, V5, P402, DOI 10.1093/molehr/5.5.402; Iyengar B, 2000, BIOL SIGNAL RECEPT, V9, P260; Johansson O, 1998, J INVEST DERMATOL, V111, P1010, DOI 10.1046/j.1523-1747.1998.00460.x; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; Kadekaro AL, 2004, J PINEAL RES, V36, P204, DOI 10.1111/j.1600-079X.2004.00119.x; Kam PCA, 1996, ANAESTHESIA, V51, P1133, DOI 10.1111/j.1365-2044.1996.tb15050.x; Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0; Kawakubo Y, 2000, J PHARMACOL EXP THER, V292, P150; Kawano H, 2001, BLOOD, V97, P1697, DOI 10.1182/blood.V97.6.1697; Kema IP, 2000, J CHROMATOGR B, V747, P33, DOI 10.1016/S0378-4347(00)00341-8; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; KHALIL Z, 1990, BRAIN RES, V527, P292, DOI 10.1016/0006-8993(90)91149-B; Kilanczyk E, 2003, CELL MOL BIOL LETT, V8, P333; Kim BC, 2001, J DERMATOL SCI, V26, P194; Kojima M, 2000, J BIOCHEM-TOKYO, V127, P121, DOI 10.1093/oxfordjournals.jbchem.a022572; KOPIN IJ, 1960, BIOCHIM BIOPHYS ACTA, V40, P377, DOI 10.1016/0006-3002(60)91374-3; KOPIN IJ, 1961, J BIOL CHEM, V236, P3072; Kroeze Wesley K., 2002, Current Topics in Medicinal Chemistry, V2, P507, DOI 10.2174/1568026023393796; Kumar C A, 2000, Med Sci Monit, V6, P471; Kvetnoy IM, 2002, NEUROENDOCRINOL LETT, V23, P121; Lee KS, 2003, EXP MOL MED, V35, P263, DOI 10.1038/emm.2003.35; Lefebvre H, 2001, J CLIN ENDOCR METAB, V86, P5001, DOI 10.1210/jc.86.10.5001; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; LERCHL A, 1993, NEUROENDOCRINOLOGY, V57, P359, DOI 10.1159/000126380; LOGAN A, 1980, J INVEST DERMATOL, V74, P47, DOI 10.1111/1523-1747.ep12514608; Lundeberg L, 2002, ARCH DERMATOL RES, V294, P393, DOI 10.1007/s00403-002-0350-y; MAIETTA G, 1991, ACTA DERM-VENEREOL, V71, P538; Martin M, 2000, FASEB J, V14, P1677; Matsuda M, 2004, DEV CELL, V6, P193, DOI 10.1016/S1534-5807(04)00022-X; Maurer M, 1997, J DERMATOL SCI, V16, P79, DOI 10.1016/S0923-1811(97)00043-1; Mayo JC, 2002, CELL MOL LIFE SCI, V59, P1706, DOI 10.1007/PL00012498; MCCLOGHRY E, 1992, J PINEAL RES, V13, P139, DOI 10.1111/j.1600-079X.1992.tb00068.x; MCELHINNEY DB, 1994, J INVEST DERMATOL, V102, P258, DOI 10.1111/1523-1747.ep12371773; MCEWAN M, 1987, J INVEST DERMATOL, V89, P82, DOI 10.1111/1523-1747.ep12580425; MENGEAUD V, 1994, MELANOMA RES, V4, P87, DOI 10.1097/00008390-199404000-00002; MEYSKENS FL, 1981, BRIT J CANCER, V43, P111, DOI 10.1038/bjc.1981.17; Mockus SM, 1998, J MOL NEUROSCI, V10, P163, DOI 10.1007/BF02761772; MOZZANICA N, 1988, ACTA DERM-VENEREOL, V68, P312; NASH MS, 1995, INVEST OPHTH VIS SCI, V36, P95; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2003, FASEB J, V17, P1373, DOI 10.1096/fj.02-1122fje; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Nelson CS, 2001, MOL ENDOCRINOL, V15, P1306, DOI 10.1210/me.15.8.1306; Nickel A, 2000, ARCH DERMATOL RES, V292, P366, DOI 10.1007/s004030000141; NIXON AJ, 1993, J EXP ZOOL, V267, P47, DOI 10.1002/jez.1402670108; NORDLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768, DOI 10.1210/jcem-45-4-768; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Nosjean O, 2001, BIOCHEM PHARMACOL, V61, P1369, DOI 10.1016/S0006-2952(01)00615-3; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; PAWELEK J, 1985, BIOL MOL CLIN ASPECT, P521; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Reiter RJ, 2002, ANN NY ACAD SCI, V957, P341, DOI 10.1111/j.1749-6632.2002.tb02938.x; Reiter RJ, 2002, NEUROENDOCRINOL LETT, V23, P9; Reiter RJ, 1996, EXP CLIN ENDOCR DIAB, V104, P10, DOI 10.1055/s-0029-1211415; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Richerson GB, 2004, NAT REV NEUROSCI, V5, P449, DOI 10.1038/nrn1409; Roberts JE, 2000, J PINEAL RES, V28, P165; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; RODRIGUEZ IR, 1994, J BIOL CHEM, V269, P31969; ROGAWSKI MA, 1979, J NEUROCHEM, V32, P1219, DOI 10.1111/j.1471-4159.1979.tb11049.x; ROSE J, 1987, GEN COMP ENDOCR, V65, P212, DOI 10.1016/0016-6480(87)90168-7; Roseboom PH, 1998, MOL BRAIN RES, V63, P189, DOI 10.1016/S0169-328X(98)00273-3; Ryoo YW, 2001, J DERMATOL SCI, V27, P162, DOI 10.1016/S0923-1811(01)00133-5; Sadrieh N, 1996, CANCER RES, V56, P2683; Schallreuter KU, 1997, J INVEST DERMATOL, V109, P31, DOI 10.1111/1523-1747.ep12276418; SCHALLREUTER KU, 1995, J INVEST DERMATOL, V104, P953, DOI 10.1111/1523-1747.ep12606218; Schallreuter KU, 1999, CELL MOL BIOL, V45, P943; SCHWARZ W, 1988, ACTA DERM-VENEREOL, V68, P224; Semak I, 2004, ARCH BIOCHEM BIOPHYS, V421, P61, DOI 10.1016/j.abb.2003.08.036; Serafeim A, 2002, BLOOD, V99, P2545, DOI 10.1182/blood.V99.7.2545; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SHUIWANG Y, 1993, EUR J PHARMACOL, V246, P89; Silva SO, 2000, BIOCHEM BIOPH RES CO, V279, P657, DOI 10.1006/bbrc.2000.3993; Siraki AG, 2002, TOXICOLOGY, V177, P81, DOI 10.1016/S0300-483X(02)00197-X; Skwarlo-Sonta K, 2002, NEUROENDOCRINOL LETT, V23, P61; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 2003, BBA-MOL BASIS DIS, V1639, P80, DOI 10.1016/S0925-4439(03)00124-8; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287; Slominski A, 2002, J INVEST DERMATOL, V119, P934, DOI 10.1046/j.1523-1747.2002.00156.x; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; SLOMINSKI A, 2004, IN PRESS PHYSL REV; Stehle JH, 2002, CELL TISSUE RES, V309, P173, DOI 10.1007/s00441-002-0583-2; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Sugden D, 1997, BIOL CELL, V89, P531, DOI 10.1016/S0248-4900(98)80009-9; Symoens J, 1990, Blood Coagul Fibrinolysis, V1, P219; TACHIBANA T, 1990, J INVEST DERMATOL, V94, P120, DOI 10.1111/1523-1747.ep12873982; Talley NJ, 2001, LANCET, V358, P2061, DOI 10.1016/S0140-6736(01)07103-3; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 1998, BIOCHEM BIOPH RES CO, V253, P614, DOI 10.1006/bbrc.1998.9826; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tesoriere L, 2001, FREE RADICAL RES, V35, P633, DOI 10.1080/10715760100301161; Theoharides TC, 1996, INT J TISSUE REACT, V18, P1; Tilden AR, 1997, J PINEAL RES, V22, P102, DOI 10.1111/j.1600-079X.1997.tb00310.x; Turner N, 2002, LIBR J, V127, P121; VAKKURI O, 1987, ENDOCRINOLOGY, V120, P2453, DOI 10.1210/endo-120-6-2453; VALVERDE P, 1995, EUR J BIOCHEM, V232, P257, DOI 10.1111/j.1432-1033.1995.tb20807.x; Vesela J, 2003, PHYSIOL RES, V52, P223; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Wang GA, 1998, J NEUROCHEM, V71, P1769; WEATHERHEAD B, 1981, J ENDOCRINOL, V90, P89, DOI 10.1677/joe.0.0900089; WEATHERHEAD B, 1982, PHYSL PATHOPHYSIOLOG, V7, P2165; Weisshaar E, 1997, INFLAMM RES, V46, P412, DOI 10.1007/s000110050213; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; Williams JA, 2000, CANCER RES, V60, P4667; Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5; XIAO Y, 1995, J REPROD FERTIL, V105, P9, DOI 10.1530/jrf.0.1050009; YAGA K, 1993, LIFE SCI, V52, P1231, DOI 10.1016/0024-3205(93)90106-D; YANG XJ, 1994, P NATL ACAD SCI USA, V91, P6659, DOI 10.1073/pnas.91.14.6659; YING SW, 1993, EUR J PHARM-MOLEC PH, V246, P89, DOI 10.1016/0922-4106(93)90084-M; Yu H. L., 2020, ARXIV PREPRINT ARXIV; Zhang XD, 2004, SCIENCE, V305, P217, DOI 10.1126/science.1097540; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008	194	274	286	2	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					176	194		10.1096/fj.04-2079rev	http://dx.doi.org/10.1096/fj.04-2079rev			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677341				2022-12-28	WOS:000227591900022
J	Bechmann, I; Goldmann, J; Kovac, AD; Kwidzinski, E; Simburger, E; Naftolin, F; Dirnagl, U; Nitsch, R; Priller, J				Bechmann, I; Goldmann, J; Kovac, AD; Kwidzinski, E; Simburger, E; Naftolin, F; Dirnagl, U; Nitsch, R; Priller, J			Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia	FASEB JOURNAL			English	Article						glial fibrillary acidic protein; caspase inhibitors	CENTRAL-NERVOUS-SYSTEM; GREEN FLUORESCENT PROTEIN; ENTORHINAL CORTEX LESION; MARROW-DERIVED CELLS; ADHESION MOLECULE EXPRESSION; BLOOD-BRAIN-BARRIER; RAT FASCIA-DENTATA; WALLERIAN DEGENERATION; HEMATOPOIETIC-CELLS; GLIAL-CELLS	In this study, we demonstrate the infiltration of blood-derived monocytic cells and their morphologic transformation into microglia in zones of acute, anterograde ( Wallerian) axonal degeneration induced by entorhinal cortex lesion (ECL). ECL was performed in mice which had received green fluorescent protein (GFP)-transduced bone marrow grafts allowing identification of blood-derived elements within the brain. While in the unlesioned hemisphere GFP(+) cells were restricted to perivascular and leptomeningeal sites, many round fluorescent cells appeared in hippocampal zones of axonal degeneration at 24 h post lesion (hpl). Within 72 hpl, these GFP(+) cells acquired ramified, microglia-like morphologies, which persisted for at least 7 days post ECL. Differentiation of GFP(+) cells into glial fibrillary acidic protein (GFAP)(+) astrocytes was never observed. To exclude that this recruitment is an artifact of irradiation or bone marrow transplantation, the fluorescent cell tracker 6-carboxylfluorescein diacetate (CFDA) was injected into spleens of normal mice 1 day before ECL. Again, fluorescent cells appeared at the lesion site and along the layers of axonal degeneration at 48 hpl and CFDA(+)/ MAC-1(+), cells exhibited amoeboid and ramified morphologies. Thus, blood-derived cells infiltrate not only the site of mechanical lesion, but also the layers of anterograde axonal degeneration, where they readily transform into microglia-like elements. A role for infiltrating leukocytes in facilitating or modulating postlesional plasticity, e.g., by phagocytosis of growth-inhibiting myelin should now be considered. Moreover, monocytic cells may serve as vehicles to transport therapeutic substances such as neurotrophic factors or caspase inhibitors to zones of axonal degeneration.	Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10098 Berlin, Germany; Carl Zeiss Jena GmbH Div, Adv Imaging Microscopy, Jena, Germany; Yale Univ, Dept Obstet & Gynecol, New Haven, CT USA; Charite, Dept Neurol, D-10098 Berlin, Germany; Charite, Dept Psychiat, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Carl Zeiss AG; Yale University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bechmann, I (corresponding author), Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10098 Berlin, Germany.	ingo.bechmann@charite.de	Priller, Josef/ABW-3835-2022; Nitsch, Robert/AAI-9129-2021	Glumm, Jana/0000-0001-5756-3718; Dirnagl, Ulrich/0000-0003-0755-6119; Priller, Josef/0000-0001-7596-0979				Babcock AA, 2003, J NEUROSCI, V23, P7922; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1997, HISTOCHEM CELL BIOL, V107, P391, DOI 10.1007/s004180050125; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Bechmann I, 2002, J NEUROIMMUNOL, V132, P60, DOI 10.1016/S0165-5728(02)00311-9; Bechmann I, 2001, EXP NEUROL, V168, P242, DOI 10.1006/exnr.2000.7618; Bechmann I, 2001, EUR J NEUROSCI, V14, P1651, DOI 10.1046/j.0953-816x.2001.01793.x; BECHMANN I, 2004, NEUROGLIA, P302; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; Dong JH, 2004, GLIA, V47, P102, DOI 10.1002/glia.10355; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; FAGAN AM, 1994, NEUROSCIENCE, V58, P705, DOI 10.1016/0306-4522(94)90449-9; Finsen B, 1999, ADV EXP MED BIOL, V468, P157; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GRIFFIN JW, 1992, J NEUROIMMUNOL, V40, P153, DOI 10.1016/0165-5728(92)90129-9; Haas CA, 1999, J NEUROSCI, V19, P9953; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hailer NP, 1998, BRAIN PATHOL, V8, P459; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; JENSEN MB, 1994, EXP BRAIN RES, V98, P245; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kovac AD, 2004, BRAIN PATHOL, V14, P249; KRALL WJ, 1994, BLOOD, V83, P2737; KREUTZBERG GW, 1978, J NEUROCYTOL, V7, P601, DOI 10.1007/BF01260892; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Li YQ, 2004, RADIAT RES, V161, P143, DOI 10.1667/RR3117; LYNCH G, 1972, BRAIN RES, V42, P311, DOI 10.1016/0006-8993(72)90533-1; McMahon EJ, 2002, J NEUROIMMUNOL, V130, P32, DOI 10.1016/S0165-5728(02)00205-9; NITSCH R, 1991, BRAIN RES, V554, P304, DOI 10.1016/0006-8993(91)90205-A; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; NITSCH R, 1993, HIPPOCAMPUS, V3, P481, DOI 10.1002/hipo.450030409; PAPALINO O, 1998, NAT MED, V4, P814; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Ramirez JJ, 2001, RESTOR NEUROL NEUROS, V19, P237; RENNO T, 1995, J IMMUNOL, V154, P944; Samms M, 2001, CELL IMMUNOL, V212, P16, DOI 10.1006/cimm.2001.1836; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; SCHMIDTMAYER J, 1994, GLIA, V12, P259, DOI 10.1002/glia.440120403; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; SIMARD AR, 2004, FASEB J         0414; Skutella T, 2001, TRENDS NEUROSCI, V24, P107, DOI 10.1016/S0166-2236(00)01717-3; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; THANOS S, 1991, NEUROSCI LETT, V127, P108, DOI 10.1016/0304-3940(91)90906-A; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Vallieres L, 2003, J NEUROSCI, V23, P5197; Wehner T, 2003, J NEUROSCI, V23, P5004; Yuan H, 2003, BRAIN RES, V969, P59, DOI 10.1016/S0006-8993(03)02278-9	65	92	96	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					647	+		10.1096/fj.04-2599fje	http://dx.doi.org/10.1096/fj.04-2599fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671154				2022-12-28	WOS:000226576600008
J	Gedik, CM; Collins, A; Dubois, J; Duez, P; Kouegnigan, L; Rees, JF; Loft, S; Moller, P; Jensen, A; Poulsen, H; Riss, B; Weimann, A; Cadet, J; Douki, T; Ravant, JL; Sauvaigo, S; Faure, H; Morel, I; Morin, B; Epe, B; Eckert, I; Hartwig, A; Schwerdtle, T; Dolara, P; Giovannelli, L; Lodovici, M; Guglielmi, F; Olinski, R; Bialkowski, K; Foksinski, M; Gackowski, D; Durackova, Z; Muchova, J; Korytar, P; Sivonova, M; Dusinska, M; Mislanova, C; Petrovska, H; Smolkova, B; Vina, J; Lloret, A; Saez, G; Moller, L; Hofer, T; Eriksson, H; Gremaud, E; Herbert, K; Wild, C; Kelly, F; Dunster, C; White, A; Wood, S; Vaughan, N				Gedik, CM; Collins, A; Dubois, J; Duez, P; Kouegnigan, L; Rees, JF; Loft, S; Moller, P; Jensen, A; Poulsen, H; Riss, B; Weimann, A; Cadet, J; Douki, T; Ravant, JL; Sauvaigo, S; Faure, H; Morel, I; Morin, B; Epe, B; Eckert, I; Hartwig, A; Schwerdtle, T; Dolara, P; Giovannelli, L; Lodovici, M; Guglielmi, F; Olinski, R; Bialkowski, K; Foksinski, M; Gackowski, D; Durackova, Z; Muchova, J; Korytar, P; Sivonova, M; Dusinska, M; Mislanova, C; Petrovska, H; Smolkova, B; Vina, J; Lloret, A; Saez, G; Moller, L; Hofer, T; Eriksson, H; Gremaud, E; Herbert, K; Wild, C; Kelly, F; Dunster, C; White, A; Wood, S; Vaughan, N		ESCODD	Establishing the background level of base oxidation in human lymphocyte DNA: results of an interlaboratory validation study	FASEB JOURNAL			English	Article						DNA oxidation; 8-oxodGuo; HPLC; comet assay; FPG	DIFFERENT LABORATORIES; MAMMALIAN-CELLS; DAMAGE; 8-OXO-7,8-DIHYDRO-2'-DEOXYGUANOSINE	Accurate measurement of low levels of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodGuo) in DNA is hampered by the ease with which guanine is oxidized during preparation of DNA for analysis. ESCODD, a consortium of mainly European laboratories, has attempted to minimize this artifact and to provide standard, reliable protocols for sample preparation and analysis. ESCODD has now analyzed 8-oxodGuo in the DNA of lymphocytes isolated from venous blood from healthy young male volunteers in several European countries. Two approaches were used. Analysis of 8-oxodGuo by HPLC with electrochemical detection was performed on lymphocytes from 10 groups of volunteers, in eight countries. The alternative enzymic approach was based on digestion of DNA with formamidopyrimidine DNA glycosylase (FPG) to convert 8-oxo-7,8-dihydroguanine (8-oxoGua) to apurinic sites, subsequently measured as DNA breaks using the comet assay (7 groups of volunteers, in six countries). The median concentration of 8-oxodGuo in lymphocyte DNA, calculated from the mean values of each group of subjects as determined by HPLC, was 4.24 per 10(6) guanines. The median concentration of FPG-sensitive sites, measured with the comet assay, was 0.34 per 10(6) guanines. Identical samples of HeLa cells were supplied to all participants as a reference standard. The median values for 8-oxodGuo in HeLa cells were 2.78 per 10(6) guanines (by HPLC) and 0.50 per 10(6) guanines (by enzymic methods). The discrepancy between chromatographic and FPG-based approaches may reflect overestimation by HPLC (if spurious oxidation is still not completely controlled) or underestimation by the enzymic method. Meanwhile, it is clear that the true background level of base oxidation in DNA is orders of magnitude lower than has often been claimed in the past.	Univ Oslo, Dept Nutr, N-0316 Oslo, Norway; Rowett Res Inst, Aberdeen AB21 9SB, Scotland; Free Univ Brussels, Inst Pharm, Brussels, Belgium; Catholic Univ Louvain, Louvain, Belgium; Univ Copenhagen, Copenhagen, Denmark; Copenhagen Univ Hosp, Rigshospitalet, Copenhagen, Denmark; DSM CEA Grenoble, Grenoble, France; Univ Hosp, Grenoble, France; Univ Rennes 1, Rennes, France; Univ Bordeaux 1, Talence, France; Johannes Gutenberg Univ Mainz, Mainz, Germany; Univ Karlsruhe, Karlsruhe, Germany; Univ Florence, Florence, Italy; Ludwik Rydygier Med Univ, Bydgoszcz, Poland; Comenius Univ, Fac Med, Bratislava, Slovakia; Inst Prevent & Clin Med, Bratislava, Slovakia; Univ Valencia, Valencia, Spain; Karolinska Inst, Stockholm, Sweden; Ctr Rech Nestle, Lausanne, Switzerland; Univ Leicester, Leicester LE1 7RH, Leics, England; Univ Leeds, Leeds LS2 9JT, W Yorkshire, England; Kings Coll London, London WC2R 2LS, England	University of Oslo; University of Aberdeen; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; University of Copenhagen; University of Copenhagen; CEA; CHU Grenoble Alpes; Universite de Rennes; UDICE-French Research Universities; Universite de Bordeaux; Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology; University of Florence; Nicolaus Copernicus University; Ludwik Rydygier Collegium Medicum; Comenius University Bratislava; University of Valencia; Karolinska Institutet; Nestle SA; University of Leicester; University of Leeds; University of London; King's College London	Collins, A (corresponding author), Univ Oslo, Dept Nutr, POB 1046 Blindern, N-0316 Oslo, Norway.	a.r.collins@medisin.uio.no	Hartwig, Andrea/H-1196-2017; Ďuračková, Zdenka/ABD-1310-2021; Foksinski, Marek/D-4942-2014; Lloret, Ana/AAB-1061-2019; Muchova, Jana/AAT-5661-2020; Gackowski, Daniel/G-5693-2012; Cadet, Jean/M-2971-2018; Smolkova, Bozena/AAW-4529-2020; Sivoňová, Monika MKS Kmeťová/X-7315-2018; MOREL, Isabelle/Y-8872-2019; Vina, Jose/AAB-3069-2021; Bialkowski, Karol/E-2328-2014; DOUKI, Thierry/H-2108-2018; Olinski, Ryszard/E-9607-2014	Hartwig, Andrea/0000-0003-3826-3319; Foksinski, Marek/0000-0002-1338-8230; Muchova, Jana/0000-0001-7419-6913; Gackowski, Daniel/0000-0002-7259-1511; Cadet, Jean/0000-0003-2594-9485; Smolkova, Bozena/0000-0002-4906-5652; Vina, Jose/0000-0001-9709-0089; Bialkowski, Karol/0000-0002-3836-8076; DOUKI, Thierry/0000-0002-5022-071X; Giovannelli, Lisa/0000-0002-4027-4693; Olinski, Ryszard/0000-0001-9927-8755; Saez, Guillermo/0000-0002-8164-4048; Herbert, Karl/0000-0002-6760-7929; Rees, jean Francois/0000-0002-8171-6689; Duez, Pierre/0000-0002-0484-1478; Lloret, Ana/0000-0003-0266-0304; Dusinska, Maria/0000-0003-1358-1652; MOREL, Isabelle/0000-0001-7160-968X; Collins, Andrew/0000-0001-5916-6871				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Collins A, 2003, FREE RADICAL BIO MED, V34, P1089, DOI 10.1016/s0891-5849(03)00041-8; Collins A, 2002, CARCINOGENESIS, V23, P2129, DOI 10.1093/carcin/23.12.2129; Collins A, 1997, CARCINOGENESIS, V18, P1833, DOI 10.1093/carcin/18.9.1833; Collins Andrew R, 2002, Methods Mol Biol, V186, P147; Collins AR, 2002, FREE RADICAL RES, V36, P239, DOI 10.1080/10715760290019246; EPE B, 1994, METHOD ENZYMOL, V234, P122; Gedik CM, 2002, CARCINOGENESIS, V23, P1441, DOI 10.1093/carcin/23.9.1441; Hartwig A, 1996, TOXICOL LETT, V88, P85, DOI 10.1016/0378-4274(96)03722-8; Merzenich H, 2001, CANCER EPIDEM BIOMAR, V10, P515; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; Ravanat JL, 2002, CARCINOGENESIS, V23, P1911, DOI 10.1093/carcin/23.11.1911; Riis B, 2002, FREE RADICAL RES, V36, P649, DOI 10.1080/10715760290029047; Singh R, 2003, RAPID COMMUN MASS SP, V17, P126, DOI 10.1002/rcm.883	14	357	365	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					82	84		10.1096/fj.04-1767fje	http://dx.doi.org/10.1096/fj.04-1767fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15533950	Green Submitted			2022-12-28	WOS:000226576600046
J	Wang, SN; Wilkes, MC; Leof, EB; Hirschberg, R				Wang, SN; Wilkes, MC; Leof, EB; Hirschberg, R			Imatinib mesylate blocks a non-smad TGF-beta pathway and reduces renal fibrogenesis in vivo	FASEB JOURNAL			English	Article						ECM; renal interstitial fibrosis; unilaterial ureteral obstruction; experimental renal fibrosis	TRANSFORMING-GROWTH-FACTOR; UNILATERAL URETERAL OBSTRUCTION; ABL TYROSINE KINASE; MESSENGER-RNA; DIABETIC-NEPHROPATHY; TARGETED DISRUPTION; TISSUE FIBROSIS; INHIBITOR; CELLS; FAILURE	Transforming growth factor-beta (TGF-beta) is the single most important cytokine promoting renal fibrogenesis. p21-activated kinase-2 (PAK2) and activation of abelson nonreceptor tyrosine kinase (c-abl) have been shown recently to be smad-independent, fibroblast-specific targets downstream of the activated TGF-beta receptor. In the current study we show that in cultured NRK49F-renal fibroblasts ( but not in tubular or mesangial cells) TGF-beta similarly activates PAK2 as well as c-abl and induces cell proliferation. Inhibition of the c-abl kinase with imatinib mesylate prevents increased proliferation after TGF-beta addition without affecting PAK2. These in vitro findings were extended to rats with unilateral obstructive nephropathy, a disease model of TGF-beta-driven renal fibrogenesis. In obstructed kidneys, PAK2 and c-abl activity were increased but only c-abl activation was blocked by imatinib. Treatment with imatinib did not prevent renal interstitial infiltration of macrophages or phosphorylation and nuclear translocation of smad2/3 in obstructed kidneys. In contrast, imatinib substantially inhibited an increase in the number of interstitial fibroblasts and myofibroblasts and reduced the expression and interstitial accumulation of collagen type III, collagen type IV and fibronectin. These findings indicate that TGF-beta-induced activation of the nonreceptor c-abl tyrosine kinase regulates fibroblast proliferation and, by this means, is a costimulatory signal in TGF-beta-dependent renal fibrogenesis. Inhibition of c-abl activity with imatinib mesylate ameliorates experimental renal fibrosis in rats.	Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA; Mayo Clin, Coll Med Biochem & Mol Biol, Rochester, MN USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Mayo Clinic	Hirschberg, R (corresponding author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St, Torrance, CA 90502 USA.	rhirschberg@labiomed.org		Wilkes, Mark/0000-0002-9600-6831	NIDDK NIH HHS [DK63360] Funding Source: Medline; NIGMS NIH HHS [GM55816, GM54200] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK063360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055816, R01GM054200, R37GM055816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BOHLE A, 1991, PATHOL RES PRACT, V187, P251; BOHLE A, 1994, EXP NEPHROL, V2, P205; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fujimoto M, 2003, BIOCHEM BIOPH RES CO, V305, P1002, DOI 10.1016/S0006-291X(03)00885-4; Fukuda K, 2001, AM J PHYSIOL-RENAL, V281, pF513, DOI 10.1152/ajprenal.2001.281.3.F513; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hu B, 2003, AM J RESP CELL MOL, V29, P397, DOI 10.1165/rcmb.2003-0063OC; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Johnson DW, 1998, KIDNEY INT, V54, P747, DOI 10.1046/j.1523-1755.1998.00048.x; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kitiyakara C, 2002, NEPHROL DIAL TRANSPL, V17, P685, DOI 10.1093/ndt/17.4.685; Klahr S, 2002, AM J PHYSIOL-RENAL, V283, pF861, DOI 10.1152/ajprenal.00362.2001; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Letterio JJ, 1998, MINER ELECTROL METAB, V24, P161, DOI 10.1159/000057365; MASSAGUE J, 1985, J BIOL CHEM, V260, P4551; Oda T, 2001, KIDNEY INT, V60, P587, DOI 10.1046/j.1523-1755.2001.030002587.x; Pou M, 2003, LEUKEMIA LYMPHOMA, V44, P1239, DOI 10.1080/1042819031000079140; Roberts AB, 2001, CHEST, V120, p43S, DOI 10.1378/chest.120.1_suppl.S43-a; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sommer M, 2000, NEPHRON, V84, P49, DOI 10.1159/000045538; Strutz F, 1996, EXP NEPHROL, V4, P267; TAFT JL, 1994, DIABETES, V43, P1046, DOI 10.2337/diabetes.43.8.1046; Taneda S, 2003, J AM SOC NEPHROL, V14, P2544, DOI 10.1097/01.ASN.0000089828.73014.C8; Wang SN, 2000, AM J PHYSIOL-RENAL, V278, pF554; Wang SN, 2003, AM J PHYSIOL-RENAL, V284, pF1006, DOI 10.1152/ajprenal.00382.2002; Wang SN, 2001, J AM SOC NEPHROL, V12, P2392, DOI 10.1681/ASN.V12112392; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122	39	227	241	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					1	11		10.1096/fj.04-2370com	http://dx.doi.org/10.1096/fj.04-2370com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629889				2022-12-28	WOS:000226576600036
J	Bucciantini, M; Rigacci, S; Berti, A; Pieri, L; Cecchi, C; Nosi, D; Formigli, L; Chiti, F; Stefani, M				Bucciantini, M; Rigacci, S; Berti, A; Pieri, L; Cecchi, C; Nosi, D; Formigli, L; Chiti, F; Stefani, M			Patterns of cell death triggered in two different cell lines by HypF-N prefibrillar aggregates	FASEB JOURNAL			English	Article						protein aggregation; aggregate toxicity; amyloid fibrils; cell apoptosis; cell necrosis	OXIDATIVE STRESS; COMMON MECHANISM; ENDOPLASMIC-RETICULUM; PROTEIN AGGREGATION; CD95 APO-1/FAS; PRION PROTEIN; APOPTOSIS; FAS; ACTIVATION; DAMAGE	The finding that aggregates of disease-unrelated proteins can induce cell death indicates that proteins may act as potential toxins. Cells experiencing toxic protein aggregates often display modifications of the redox status and ion balance, eventually leading to apoptosis; however, in some cases, tissue and cultured cell types die with features of necrosis. To elucidate the pathways leading to such different outcomes, we studied the biochemical features of death in H-END and NIH/3T3 cells exposed to prefibrillar aggregates of a disease-unrelated protein. The two types of cells died by apoptosis and necrosis, respectively. The pattern of caspase and proapoptotic factor activation was investigated together with the extent of mitochondria impairment and the energy load in either cell line. Our data depict a scenario where the events related to the extrinsic pathway of apoptosis are the same in the two cell lines, the difference in the final outcome being related to the extent of mitochondria derangement, possibly due to the different ability of the cells to counteract ion homeostasis impairment.	Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy; Univ Florence, Dept Anat Histol & Forens Med, I-50134 Florence, Italy; Univ Florence, Ctr Excellence Mol & Clin Studies Chron Inflammat, I-50134 Florence, Italy	University of Florence; University of Florence; University of Florence	Stefani, M (corresponding author), Univ Florence, Dept Biochem Sci, Viale Morgagni 50, I-50134 Florence, Italy.	stefani@scibio.unifi.it		Cecchi, Cristina/0000-0001-8387-7737; bucciantini, monica/0000-0002-5243-9301; STEFANI, MASSIMO/0000-0002-4490-1922; , Laura/0000-0003-0779-9014				Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Bhagat YA, 2002, MAGN RESON MATER PHY, V14, P223, DOI 10.1016/S1352-8661(02)00067-4; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; del Arroyo AG, 2000, ONCOGENE, V19, P3647, DOI 10.1038/sj.onc.1203662; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Ferrari D, 2002, CELL CALCIUM, V32, P413, DOI 10.1016/S0143416002002014; Ferreiro E, 2004, J NEUROSCI RES, V76, P872, DOI 10.1002/jnr.20135; Gebbink MFBG, 2004, BLOOD, V104, P1601, DOI 10.1182/blood-2004-02-0433; Giri K, 2003, FEBS LETT, V555, P380, DOI 10.1016/S0014-5793(03)01294-8; Gniadecki R, 2004, BIOCHEM BIOPH RES CO, V320, P165, DOI 10.1016/j.bbrc.2004.05.145; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly JW, 2003, J CELL BIOL, V161, P461, DOI 10.1083/jcb.200304074; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kourie JI, 2002, CLIN EXP PHARMACOL P, V29, P741, DOI 10.1046/j.1440-1681.2002.03737.x; Kranenburg O, 2003, FEBS LETT, V539, P149, DOI 10.1016/S0014-5793(03)00218-7; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mattson MP, 2002, NEUROMOL MED, V2, P215, DOI 10.1385/NMM:2:2:215; Mattson MP, 1999, METHOD ENZYMOL, V309, P733; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nicotera P, 2004, ONCOGENE, V23, P2757, DOI 10.1038/sj.onc.1207559; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Svanborg C, 2003, ADV CANCER RES, V88, P1; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Velez-Pardo C, 2001, J ALZHEIMERS DIS, V3, P409, DOI 10.3233/JAD-2001-3408; Walsh DM, 2004, PROTEIN PEPTIDE LETT, V11, P213, DOI 10.2174/0929866043407174; WATT JA, 1994, BRAIN RES, V661, P147, DOI 10.1016/0006-8993(94)91191-6; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	61	38	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					437	+		10.1096/fj.04-3086fje	http://dx.doi.org/10.1096/fj.04-3086fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15604358	Green Published			2022-12-28	WOS:000226091000012
J	Zhang, W; Qin, LY; Wang, TG; Wei, SJ; Gao, HM; Liu, J; Wilson, B; Liu, B; Zhang, WQ; Kim, HC; Hong, JS				Zhang, W; Qin, LY; Wang, TG; Wei, SJ; Gao, HM; Liu, J; Wilson, B; Liu, B; Zhang, WQ; Kim, HC; Hong, JS			3-Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity	FASEB JOURNAL			English	Article						Parkinson's disease; inflammation; neuroprotection; microglia; astroglia	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; PARKINSONS-DISEASE; RAT MODEL; MICROGLIAL ACTIVATION; INTRANIGRAL INJECTION; PROMOTES RECOVERY; MOUSE MODEL; L-DOPA; DEGENERATION	The purpose of this study was to develop a novel therapy for Parkinson's disease (PD). We recently reported that dextromethorphan (DM), an active ingredient in a variety of widely used anticough remedies, protected dopaminergic neurons in rat primary mesencephalic neuron-glia cultures against lipopolysaccharide (LPS)-mediated degeneration and provided potent protection for dopaminergic neurons in a MPTP mouse model. The underlying mechanism for the protective effect of DM was attributed to its anti-inflammatory activity through inhibition of microglia activation. In an effort to develop more potent compounds for the treatment of PD, we have screened a series of analogs of DM, and 3-hydroxymorphinan (3-HM) emerged as a promising candidate for this purpose. Our study using primary mesencephalic neuron-glia cultures showed that 3-HM provided more potent neuroprotection against LPS-induced dopaminergic neurotoxicity than its parent compound. The higher potency of 3-HM was attributed to its neurotrophic effect in addition to the anti-inflammatory effect shared by both DM and 3-HM. First, we showed that 3-HM exerted potent neuroprotective and neurotrophic effects on dopaminergic neurons in rat primary mesencephalic neuron-glia cultures treated with LPS. The neurotrophic effect of 3-HM was glia-dependent since 3-HM failed to show any protective effect in the neuron-enriched cultures. We subsequently demonstrated that it was the astroglia, not the microglia, that contributed to the neurotrophic effect of 3-HM. This conclusion was based on the reconstitution studies, in which we added different percentages of microglia ( 10 - 20%) or astroglia ( 40 - 50%) back to the neuron-enriched cultures and found that 3-HM was neurotrophic after the addition of astroglia, but not microglia. Furthermore, 3-HM-treated astroglia-derived conditioned media exerted a significant neurotrophic effect on dopaminergic neurons. It appeared likely that 3-HM caused the release of neurotrophic factor(s) from astroglia, which in turn was responsible for the neurotrophic effect. Second, the anti-inflammatory mechanism was also important for the neuroprotective activity of 3-HM because the more microglia were added back to the neuron-enriched cultures, the more significant neuroprotective effect was observed. The anti-inflammatory mechanism of 3-HM was attributed to its inhibition of LPS-induced production of an array of pro-inflammatory and neurotoxic factors, including nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), prostaglandin E-2 (PGE(2)) and reactive oxygen species (ROS). In conclusion, this study showed that 3-HM exerted potent neuroprotection by acting on two different targets: a neurotrophic effect mediated by astroglia and an anti-inflammatory effect mediated by the inhibition of microglial activation. 3-HM thus possesses these two important features necessary for an effective neuroprotective agent. In view of the well-documented very low toxicity of DM and its analogs, this report may provide an important new direction for the development of therapeutic interventions for inflammation-related diseases such as PD.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Natl Ctr Toxicogenet, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Inorgan Carcinogenesis Sect, Comparat Carcinogenesis Lab, NCI,NIH, Res Triangle Pk, NC 27709 USA; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China; Dalian Med Univ, Clin Hosp 1, Dept Neurol, Dalian, Peoples R China; Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA; Kangwon Natl Univ, Coll Pharm, Chunchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS); Dalian Medical University; Dalian Medical University; State University System of Florida; University of Florida; Kangwon National University	Zhang, W (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	zhang11@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019; liu, Bin/A-7695-2009; gao, huiming/C-8454-2012	Hong, Jau-shyong/0000-0002-3056-8401; Wei, Sung Jen/0000-0002-9810-9041	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090082, ZIAES090082] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; Aloisi F, 1999, ADV EXP MED BIOL, V468, P123; Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Asanuma M, 2001, J NEUROCHEM, V76, P1895, DOI 10.1046/j.1471-4159.2001.00205.x; Asanuma Masato, 2003, Nihon Shinkei Seishin Yakurigaku Zasshi, V23, P111; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen XW, 2003, PARKINSONISM RELAT D, V10, P1, DOI 10.1016/S1353-8020(03)00097-X; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Ciesielska A, 2003, ACTA NEUROBIOL EXP, V63, P117; Connor B, 2001, CLIN EXP PHARMACOL P, V28, P896, DOI 10.1046/j.1440-1681.2001.03544.x; Cunningham LA, 2002, EXP NEUROL, V174, P230, DOI 10.1006/exnr.2002.7877; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Depino AM, 2003, EUR J NEUROSCI, V18, P2731, DOI 10.1111/j.1460-9568.2003.03014.x; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hornykiewicz O, 2002, AMINO ACIDS, V23, P65, DOI 10.1007/s00726-001-0111-9; Hurelbrink CB, 2004, EXP NEUROL, V185, P1, DOI 10.1016/j.expneurol.2003.09.018; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jellinger KA, 2001, ADV NEUROL, V86, P55; Jeohn GH, 2000, BRAIN RES, V880, P173, DOI 10.1016/S0006-8993(00)02737-2; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Jollivet C, 2004, BIOMATERIALS, V25, P933, DOI 10.1016/S0142-9612(03)00601-X; Katzenschlager Regina, 2002, Journal of Neurology, V249, P19; Kim HC, 2001, BIOORG MED CHEM LETT, V11, P1651, DOI 10.1016/S0960-894X(01)00262-1; Kordower JH, 2003, ANN NEUROL, V53, pS120, DOI 10.1002/ana.10485; Kostrzewa RM, 2002, AMINO ACIDS, V23, P57, DOI 10.1007/s00726-001-0110-x; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEE SH, 1992, J BIOL CHEM, V267, P25934; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; McGeer PL, 2001, ADV NEUROL, V86, P83; McGrath J, 2002, CELL TRANSPLANT, V11, P215; McGuire SO, 2001, EXP NEUROL, V169, P219, DOI 10.1006/exnr.2001.7688; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miyasaki JM, 2002, NEUROLOGY, V58, P11, DOI 10.1212/WNL.58.1.11; Muller Thomas, 2002, Expert Opin Pharmacother, V3, P1393, DOI 10.1517/14656566.3.10.1393; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Pan TH, 2004, NEUROLOGY, V62, P343; Petrova PS, 2003, J MOL NEUROSCI, V20, P173, DOI 10.1385/JMN:20:2:173; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Reichmann H, 2003, J NEURAL TRANSM, V110, P1393, DOI 10.1007/s00702-003-0081-z; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; THI NAD, 2004, GENE THER, V11, P746; Wallace JL, 2003, FUND CLIN PHARMACOL, V17, P11, DOI 10.1046/j.1472-8206.2003.00125.x; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Xie Z, 2002, J NEUROSCI, V22, P3484; Zhang W, 2004, FASEB J, V18, P589, DOI 10.1096/fj.03-0983fje	63	35	48	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					395	+		10.1096/fj.04-1586fje	http://dx.doi.org/10.1096/fj.04-1586fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15596482				2022-12-28	WOS:000226091000019
J	Wilding, JR; Schneider, JE; Sang, AE; Davies, KE; Neubauer, S; Clarke, K				Wilding, JR; Schneider, JE; Sang, AE; Davies, KE; Neubauer, S; Clarke, K			Dystrophin- and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins	FASEB JOURNAL			English	Article						magnetic resonance imaging (MRI); cardiomyopathy; heart failure; contractile dysfunction	MUSCLE LIM PROTEIN; DUCHENNE MUSCULAR-DYSTROPHY; DILATED CARDIOMYOPATHY; SKELETAL-MUSCLE; IN-VIVO; CONTRACTILE DYSFUNCTION; INTERMEDIATE FILAMENTS; GLYCOPROTEIN COMPLEX; MYOCYTE HYPERTROPHY; GENE-EXPRESSION	In humans, cytoskeletal dystrophin and muscle LIM protein (MLP) gene mutations can cause dilated cardiomyopathy, yet these mutations may have different effects in mice, owing to increased accumulation of other, compensatory cytoskeletal proteins. Consequently, we characterized left-ventricular (LV) morphology and function in vivo using high-resolution cine-magnetic resonance imaging (MRI) in 2- to 3-month old dystrophin-deficient (mdx) and MLP-null mice, and their respective controls. LV passive stiffness was assessed in isolated, perfused hearts, and cytoskeletal protein levels were determined using Western blot analyses. In mdx mouse hearts, LV-to-body weight ratio, cavity volume, ejection fraction, stroke volume, and cardiac output were normal. However, MLP-null mouse hearts had 1.2-fold higher LV-to-body weight ratios (P < 0.01), 1.5-fold higher end-diastolic volumes (P < 0.01), and decreased ejection fraction compared with controls (25% vs. 66%, respectively, P < 0.01), indicating dilated cardiomyopathy and heart failure. In both models, isolated, perfused heart end-diastolic pressure-volume relationships and passive left-ventricular stiffness were normal. Hearts from both models accumulated desmin and beta-tubulin, mdx mouse hearts accumulated utrophin and MLP, and MLP-null mouse hearts accumulated dystrophin and syncoilin. Although the increase in MLP and utrophin in the mdx mouse heart was able to compensate for the loss of dystrophin, accumulation of desmin, syncoilin and dystrophin were unable to compensate for the loss of MLP, resulting in heart failure.	Univ Oxford, Dept Physiol, Oxford OX1 3PT, England; Univ Oxford, Dept Cardiovasc Med, Oxford OX1 3PT, England; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3PT, England	University of Oxford; University of Oxford; University of Oxford	Clarke, K (corresponding author), Univ Oxford, Dept Physiol, Parks Rd, Oxford OX1 3PT, England.	james.wilding@cep.u-psud.fr; kieran.clarke@physiol.ox.ac.uk	Neubauer, Stefan/B-8448-2011		British Heart Foundation [PS/02/002/14893] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Agretto A, 2002, J AM SOC ECHOCARDIOG, V15, P891, DOI 10.1067/mje.2002.121197; Anderson JE, 1998, MUSCLE NERVE, V21, P1153, DOI 10.1002/(SICI)1097-4598(199809)21:9<1153::AID-MUS6>3.0.CO;2-6; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Balogh J, 2002, CARDIOVASC RES, V53, P439, DOI 10.1016/S0008-6363(01)00500-4; Bia BL, 1999, J MOL CELL CARDIOL, V31, P1857, DOI 10.1006/jmcc.1999.1018; Blake DJ, 2002, TRENDS CARDIOVAS MED, V12, P224, DOI 10.1016/S1050-1738(02)00166-4; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BORTONE AS, 1989, J AM COLL CARDIOL, V14, P613, DOI 10.1016/0735-1097(89)90102-2; Campbell WG, 2001, AM J PHYSIOL-CELL PH, V280, pC763, DOI 10.1152/ajpcell.2001.280.4.C763; Chopard A, 2000, ELECTROPHORESIS, V21, P517, DOI 10.1002/(SICI)1522-2683(20000201)21:3<517::AID-ELPS517>3.0.CO;2-9; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; Di Somma S, 2000, HEART, V84, P659, DOI 10.1136/heart.84.6.659; Esposito G, 2000, AM J PHYSIOL-HEART C, V279, pH3101, DOI 10.1152/ajpheart.2000.279.6.H3101; Fanin M, 1999, J NEUROL SCI, V165, P170, DOI 10.1016/S0022-510X(99)00102-1; Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002; Finsterer J, 2003, CARDIOLOGY, V99, P1, DOI 10.1159/000068446; Geier C, 2003, CIRCULATION, V107, P1390, DOI 10.1161/01.CIR.0000056522.82563.5F; GLANTZ SA, 1978, CIRC RES, V42, P171, DOI 10.1161/01.RES.42.2.171; Grzeskowiak R, 2003, CARDIOVASC RES, V59, P400, DOI 10.1016/S0008-6363(03)00426-7; Hassink RJ, 2003, J AM COLL CARDIOL, V41, P711, DOI 10.1016/S0735-1097(02)02933-9; Heineke J, 2003, CIRCULATION, V107, P1424, DOI 10.1161/01.CIR.0000055319.94801.FC; Heling A, 2000, CIRC RES, V86, P846, DOI 10.1161/01.RES.86.8.846; Hongo M, 2000, BASIC RES CARDIOL, V95, P431, DOI 10.1007/s003950070018; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; LAW DJ, 1994, J CELL SCI, V107, P1477; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; MANNING WJ, 1994, AM J PHYSIOL, V266, pH1672, DOI 10.1152/ajpheart.1994.266.4.H1672; McNally E, 2003, J MOL CELL CARDIOL, V35, P231, DOI 10.1016/S0022-2828(03)00018-X; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2; Nakamura A, 2001, NEUROMUSCULAR DISORD, V11, P251, DOI 10.1016/S0960-8966(00)00201-7; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; Omens JH, 2002, AM J PHYSIOL-HEART C, V282, pH680, DOI 10.1152/ajpheart.00773.2001; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; PFEFFER JM, 1991, AM J PHYSIOL, V260, pH1406, DOI 10.1152/ajpheart.1991.260.5.H1406; Planitzer G, 2002, HISTOCHEM J, V34, P345, DOI 10.1023/A:1023390811358; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Ruff J, 1998, MAGN RESON MED, V40, P43, DOI 10.1002/mrm.1910400106; Schneider AG, 1999, AM J PHYSIOL-CELL PH, V276, pC900, DOI 10.1152/ajpcell.1999.276.4.C900; Schneider JE, 2003, J MAGN RESON IMAGING, V18, P691, DOI 10.1002/jmri.10411; Skrabek RQ, 2001, MUSCLE NERVE, V24, P192, DOI 10.1002/1097-4598(200102)24:2<192::AID-MUS40>3.0.CO;2-S; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tseng BS, 2002, J APPL PHYSIOL, V93, P537, DOI 10.1152/japplphysiol.00202.2002; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; Vatta M, 2002, LANCET, V359, P936, DOI 10.1016/S0140-6736(02)08026-1; Walsh RA, 1997, CIRC RES, V80, P295, DOI 10.1161/01.RES.80.2.295; WEBER KT, 1988, CIRC RES, V62, P757, DOI 10.1161/01.RES.62.4.757; Weir AP, 2002, J BIOL CHEM, V277, P45285, DOI 10.1074/jbc.M205177200; Willmann R, 2001, AM J PHYSIOL-CELL PH, V280, pC273, DOI 10.1152/ajpcell.2001.280.2.C273; Yue YP, 2003, CIRCULATION, V108, P1626, DOI 10.1161/01.CIR.0000089371.11664.27; Zile MR, 2002, CIRCULATION, V105, P1503, DOI 10.1161/hc1202.105290	58	43	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					79	+		10.1096/fj.04-1731fje	http://dx.doi.org/10.1096/fj.04-1731fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15494447				2022-12-28	WOS:000224849900016
J	Goetze, JP; Gore, A; Moller, CH; Steinbruchel, DA; Rehfeld, JF; Nielsen, LB				Goetze, JP; Gore, A; Moller, CH; Steinbruchel, DA; Rehfeld, JF; Nielsen, LB			Acute myocardial hypoxia increases BNP gene expression	FASEB JOURNAL			English	Article						ANP; B-type natriuretic peptide; heart failure; ischemic heart disease	BRAIN NATRIURETIC PEPTIDE; VENTRICULAR SYSTOLIC DYSFUNCTION; INCREASED PLASMA-LEVELS; RISK STRATIFICATION; CARDIAC MYOCYTES; SERINE-PROTEASE; MESSENGER-RNA; HEART-FAILURE; ATRIAL; HUMANS	It is well established that cardiac failure increases cardiac B-type natriuretic peptide (BNP) expression due to myocardial stretching. However, patients with ischemic heart disease also display increased plasma BNP and proBNP concentrations despite preserved cardiac function. In this study, we examined whether acute myocardial hypoxia increases cardiac BNP expression. Surgical reduction of the blood flow to an area of the anterior ventricular wall in pigs reduced the myocardial oxygen tension from 46 +/- 4 to 13 +/- 5 mmHg. The tissue contents of VEGF and BNP mRNA increased 1.8-fold and 3.5-fold, respectively (n=10, P<0.005) in hypoxic compared with normoxic ventricular myocardium after 2.2 +/- 0.2 h; the magnitude of the increase in BNP mRNA expression was positively correlated with that of VEGF in hypoxic myocardium (r=0.66, P<0.05). In support of a hypoxia-induced increase of BNP gene transcription, the content of a premature BNP mRNA was increased in hypoxic myocardium (4.8-fold, P<0.005) and in freshly harvested ventricular myocytes when kept in culture flasks and oxygen-deprived for 3 h (2.2-fold, P=0.002). ProBNP peptide accumulated in the medium of freshly harvested ventricular myocyte cultures but was undetectable in ventricular myocardium, indicating rapid release of the newly synthesized proBNP peptide. Accordingly, the plasma proBNP concentration increased after 2 h of myocardial hypoxia (P=0.028). Cumulatively, the data suggest that acute hypoxia stimulates cardiac BNP expression.	Univ Copenhagen, Rigshosp, KB 3011, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Thorac Surg, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Nielsen, LB (corresponding author), Univ Copenhagen, Rigshosp, KB 3011, Dept Clin Biochem, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	larsbo@rh.dk						Bibbins-Domingo K, 2003, CIRCULATION, V108, P2987, DOI 10.1161/01.CIR.0000103681.04726.9C; Christoffersen C, 2002, HYPERTENSION, V40, P54, DOI 10.1161/01.HYP.0000021780.21830.DD; CHU A, 1989, CIRCULATION, V80, P1627, DOI 10.1161/01.CIR.80.6.1627; Chun YS, 2003, BIOCHEM J, V370, P149, DOI 10.1042/BJ20021087; Davidson NC, 1996, AM J CARDIOL, V77, P828, DOI 10.1016/S0002-9149(97)89176-X; de Bold AJ, 2001, CAN J PHYSIOL PHARM, V79, P705, DOI 10.1139/cjpp-79-8-705; de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Deo Rajat, 2003, Curr Cardiol Rep, V5, P271, DOI 10.1007/s11886-003-0062-8; Durocher D, 1998, RECENT PROG HORM RES, V53, P7; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Goetze JP, 2003, FASEB J, V17, P1105, DOI 10.1096/fj.02-0796fje; HANFORD DS, 1994, J BIOL CHEM, V269, P26227; Jernberg T, 2002, J AM COLL CARDIOL, V40, P437, DOI 10.1016/S0735-1097(02)01986-1; Jiang CW, 2002, PHYSIOL GENOMICS, V8, P23, DOI 10.1152/physiolgenomics.00058.2001; Kikuta K, 1996, AM HEART J, V132, P101, DOI 10.1016/S0002-8703(96)90396-8; Kudoh S, 2003, PROG BIOPHYS MOL BIO, V82, P57, DOI 10.1016/S0079-6107(03)00005-1; Latini R, 2002, CIRCULATION, V106, P2454, DOI 10.1161/01.CIR.0000036747.68104.AC; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Luo YX, 2001, CIRCULATION, V104, P202; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORITA E, 1993, CIRCULATION, V88, P82, DOI 10.1161/01.CIR.88.1.82; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; OKUMURA K, 1995, J AM COLL CARDIOL, V25, P342, DOI 10.1016/0735-1097(94)00407-H; Perhonen M, 1997, AM J PHYSIOL-REG I, V273, pR344, DOI 10.1152/ajpregu.1997.273.1.R344; Perko MJ, 2002, CARDIOVASC SURG, V10, P590, DOI 10.1016/S0967-2109(02)00134-5; Qi W, 2000, ACTA PHYSIOL SCAND, V169, P95; Rehfeld JF, 1998, CLIN CHEM, V44, P991; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Richards AM, 2001, J AM COLL CARDIOL, V37, P1781, DOI 10.1016/S0735-1097(01)01269-4; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Stanek B, 2001, J AM COLL CARDIOL, V38, P436, DOI 10.1016/S0735-1097(01)01383-3; Supaporn T, 1996, CLIN SCI, V90, P357, DOI 10.1042/cs0900357; TOTH M, 1994, AM J PHYSIOL, V266, pH1572, DOI 10.1152/ajpheart.1994.266.4.H1572; Wiese S, 2000, CIRCULATION, V102, P3074; Yamamoto K, 2000, J CARD FAIL, V6, P194, DOI 10.1054/jcaf.2000.9676; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zellner C, 1999, AM J PHYSIOL-HEART C, V276, pH1049, DOI 10.1152/ajpheart.1999.276.3.H1049; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239	47	158	165	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1928	+		10.1096/fj.03-1336fje	http://dx.doi.org/10.1096/fj.03-1336fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15576492				2022-12-28	WOS:000224243200017
J	Liu, F; Shollenberger, LM; Huang, L				Liu, F; Shollenberger, LM; Huang, L			Non-immunostimulatory nonviral vectors	FASEB JOURNAL			English	Article						gene therapy; cytokines; CpG motif	NF-KAPPA-B; PLASMID DNA; BACTERIAL-DNA; GENE-TRANSFER; IN-VIVO; INFLAMMATORY RESPONSE; CATIONIC LIPOSOMES; CPG MOTIFS; LUNG; COMPLEXES	The vectors for gene delivery are usually classified as viral and nonviral vectors. While the viral vectors are very efficient in transducing cells, safety concerns regarding their use in humans make nonviral vectors an attractive alternative. Among the nonviral vectors, the lipoplexes ( complexes of cationic liposome/pDNA) are the most studied and represent the most promising approaches for human clinical trials. However, an inflammatory response is invariably associated with administration of the lipoplexes, which must be avoided in the clinical application. Here, we have successfully developed a nonimmunostimulatory vector for gene therapy. The vector possesses dual functions of: 1) efficiently delivering a gene to target cells and 2) codelivering DNA and inflammatory suppressors into the immune cells where the released suppressor can inhibit cytokine production. The inflammatory suppressors successfully delivered by the vector included glucocorticoids, a nonsteroidal anti-inflammatory drug ( NSAID), an NF-kappaB inhibitor, and a natural compound from an herbal medicine. Intravenous injection of the vector dramatically suppressed the cytokine production induced by CpG motif pDNA, including TNF-alpha, IL-12 and IFN-gamma. This new gene vector has a great potential in clinical gene therapy. Another potential use of the vector is codelivery of an enhancer candidate, acting at the transcriptional and translational levels to improve the efficiency of gene transfer by the nonviral vector. Moreover, the unique feature of this vector is that it can be used as an easy and powerful tool for in vivo screening of anti-inflammatory drugs.	Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, F (corresponding author), Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, 718 Salk Hall, Pittsburgh, PA 15261 USA.	fliu@pitt.edu; leafh+@pitt.edu	Shollenberger, Lisa/A-1826-2009; Shollenberger, Lisa/ABA-7393-2021	Shollenberger, Lisa/0000-0002-0943-0838; Shollenberger, Lisa/0000-0002-0943-0838				Alton EWFW, 1998, GENE THER, V5, P291, DOI 10.1038/sj.gt.3300655; Audouy SAL, 2002, PHARM RES-DORDR, V19, P1599, DOI 10.1023/A:1020989709019; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Chen F, 1997, BIOCHEM BIOPH RES CO, V231, P99, DOI 10.1006/bbrc.1997.6057; Davis HL, 1998, J IMMUNOL, V160, P870; Elouahabi A, 2003, MOL THER, V7, P81, DOI 10.1016/S1525-0016(02)00032-1; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Freimark BD, 1998, J IMMUNOL, V160, P4580; GILKESON GS, 1989, J IMMUNOL, V142, P1482; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hofman CR, 2001, GENE THER, V8, P71, DOI 10.1038/sj.gt.3301373; Kobayashi N, 2001, J PHARMACOL EXP THER, V297, P853; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Li DG, 2001, WORLD J GASTROENTERO, V7, P627; Li S, 1999, AM J PHYSIOL-LUNG C, V276, pL796, DOI 10.1152/ajplung.1999.276.5.L796; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923; Niven R, 1998, J PHARM SCI, V87, P1292, DOI 10.1021/js980087a; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Rao MR, 2002, ACTA PHARMACOL SIN, V23, P1075; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sakurai F, 2002, GENE THER, V9, P1120, DOI 10.1038/sj.gt.3301784; Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689; Tan YD, 1999, HUM GENE THER, V10, P2153, DOI 10.1089/10430349950017149; Tan YD, 2001, MOL THER, V3, P673, DOI 10.1006/mthe.2001.0311; Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984; Yew NS, 2000, MOL THER, V1, P255, DOI 10.1006/mthe.2000.0036; Yew NS, 1999, HUM GENE THER, V10, P223, DOI 10.1089/10430349950019011; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015; Zuhorn IS, 2002, BBA-BIOMEMBRANES, V1560, P25, DOI 10.1016/S0005-2736(01)00448-5	30	72	75	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1779	+		10.1096/fj.04-2187fje	http://dx.doi.org/10.1096/fj.04-2187fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364893				2022-12-28	WOS:000224243200030
J	Dschietzig, T; Bartsch, C; Stangl, V; Baumann, G; Stangl, K				Dschietzig, T; Bartsch, C; Stangl, V; Baumann, G; Stangl, K			Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist	FASEB JOURNAL			English	Article						signal transduction; macrophages; cytokines	BETA-ISOFORM; EXPRESSION; BINDING; ANTAGONIST; MECHANISMS; OXYTOCIN; PLAYER; CELLS	The insulin-like peptide relaxin is a central hormone of pregnancy, but it also produces antifibrotic, myocardial, renal, central-nervous, and vascular effects. Recently, two G protein-coupled receptors, LGR7 and LGR8, have been identified as relaxin receptors. Prompted by reports on immunoregulatory effects of relaxin, we investigated possible interactions with the human glucocorticoid receptor (GR). Relaxin blunted the endotoxin-induced production of inflammatory cytokines (IL-1, IL-6, TNF-alpha) by human macrophages - an effect that was suppressed by the GR antagonist RU-486. In three different cell lines, relaxin induced GR activation, nuclear translocation, and DNA binding as assessed in GRE-luciferase assays. Coimmunoprecipitation experiments revealed physical interaction of endogenous and exogenous relaxin with cytoplasmic and nuclear GR. Relaxin competed with GR agonists for GR binding, both in vivo, in whole-cell assays, and in vitro, in fluorescence polarization assays. Relaxin was shown to up-regulate GR protein expression as well as the number of functionally active GR sites. In LGR7/8-free cells, the relaxin-mediated activation of GR was preserved. In conclusion, relaxin acts as GR agonist - a pathway pivotal to its effects on cytokine secretion by human macrophages. These findings may deepen our understanding of relaxin's abundant physiological actions, as well as our insights into general principles of hormone signaling.	Charite, Med Klin S Kardiol Angiol Pulmol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Dschietzig, T (corresponding author), Charite, Med Klin S Kardiol Angiol Pulmol, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	thomas.dschietzig@t-online.de		Dschietzig, Thomas Bernd/0000-0003-1186-8713				Almawi WY, 2002, J LEUKOCYTE BIOL, V71, P9; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bani D, 1997, ENDOCRINOLOGY, V138, P1909, DOI 10.1210/en.138.5.1909; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bortz JLG., 1990, VERTEILUNGSFREIE MET, DOI 10.1007/978-3-662-22593-6; BOURGEOIS S, 1984, EMBO J, V3, P751, DOI 10.1002/j.1460-2075.1984.tb01879.x; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; CIDLOWSKI JA, 1981, ENDOCRINOLOGY, V109, P1975; DAYANITHI G, 1987, NATURE, V325, P813, DOI 10.1038/325813a0; Dschietzig T, 2003, CELL MOL LIFE SCI, V60, P688, DOI 10.1007/s00018-003-2169-x; Dschietzig T, 2001, FASEB J, V15, P2187, DOI 10.1096/fj.01-0070com; Dschietzig T, 2003, CIRC RES, V92, P32, DOI 10.1161/01.RES.0000051884.27117.7E; EVANS BA, 1994, ENDOCRINE, V2, P81; GOLDSMITH LT, 1995, ENDOCRIN METAB CLIN, V24, P171, DOI 10.1016/S0889-8529(18)30058-6; HABER PL, 1989, J RHEUMATOL, V16, P949; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLM S, 1979, SCAND J STAT, V6, P65; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Masini E, 2002, BRIT J PHARMACOL, V137, P337, DOI 10.1038/sj.bjp.0704879; Neumann ID, 2002, PROG BRAIN RES, V139, P147; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; Piccinni MP, 1999, EUR J IMMUNOL, V29, P2241, DOI 10.1002/(SICI)1521-4141(199907)29:07<2241::AID-IMMU2241>3.0.CO;2-E; Pujols L, 2002, AM J PHYSIOL-CELL PH, V283, pC1324, DOI 10.1152/ajpcell.00363.2001; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; SCHLECHTE JA, 1982, J STEROID BIOCHEM, V16, P69, DOI 10.1016/0022-4731(82)90145-5; SCHWABE C, 1994, FASEB J, V8, P1152, DOI 10.1096/fasebj.8.14.7958621; Seibold JR, 2000, ANN INTERN MED, V132, P871, DOI 10.7326/0003-4819-132-11-200006060-00004; SHERWOOD OD, 1982, ADV EXP MED BIOL, V143, P115; SHIMOJO M, 1995, ENDOCR J, V42, P629, DOI 10.1507/endocrj.42.629; Sunder S, 2000, BEST PRACT RES CL OB, V14, P789, DOI 10.1053/beog.2000.0119; Watters JJ, 1998, PROG BRAIN RES, V119, P247; WAY SA, 1992, J ENDOCRINOL, V132, P149, DOI 10.1677/joe.0.1320149	42	70	74	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1536	+		10.1096/fj.03-1120fje	http://dx.doi.org/10.1096/fj.03-1120fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289446				2022-12-28	WOS:000223554900030
J	Nakayama, S; Yamashita, T; Konishi, M; Kazama, H; Kokubun, S				Nakayama, S; Yamashita, T; Konishi, M; Kazama, H; Kokubun, S			P2Y-mediated Ca2+ response is spatiotemporally graded and synchronized in sensory neurons: a two-photon photolysis study	FASEB JOURNAL			English	Article						caged ATP; purinoceptors; intracellular Ca2+ stores; graded and synchronized [Ca2+](i) rise; dorsal root ganglion	CALCIUM-CHANNELS; CAPSAICIN RECEPTOR; RELEASE; GANGLION; ATP; PAIN; ACTIVATION; EXCITATION; CADMIUM; MUSCLE	ATP is thought to be an initiator and modulator of noxious pain sensation. We employed two-photon photolysis to apply ATP locally and transiently, thus mimicking ATP release upon cell damage or exocytosis. Using this technique, an increase in intracellular Ca2+ concentration ([Ca2+](i)) was induced via P2Y receptors in individual sensory neurons, or in a neurite region. The ATP-induced [Ca2+](i) rise was attenuated by applications of either a phospholipase C inhibitor, or inhibitors for IP3 or ryanodine receptors. These results indicate that intracellular Ca2+ stores play a major role in contributing to the increase in [Ca2+](i). Spatiotemporal analysis revealed that local and transient applications of ATP increased [Ca2+](i) by release from intracellular stores, but in a unique, graded, and synchronized manner. 1) As the duration of local ATP application was prolonged, the latency decreased and the magnitude of the [Ca2+] i rise increased; 2) The time course of the rising phase of the [Ca2+](i) response to ATP was essentially the same over the cell body, once [Ca2+](i) had started to rise. It is anticipated that sensory responses may be modulated variably, depending on the spatiotemporal characteristics of the ATP-related [Ca2+](i) profile.	Tokyo Med Univ, Dept Physiol, Tokyo 1608402, Japan; Nihon Univ, Sch Med, Adv Med Res Ctr, Tokyo 1738610, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Nagoya, Aichi 4668550, Japan	Tokyo Medical University; Nihon University; Nagoya University	Konishi, M (corresponding author), Tokyo Med Univ, Dept Physiol, Tokyo 1608402, Japan.	mkonishi@tokyo-med.ac.jp						Abdulla FA, 1999, J AUTONOM NERV SYST, V78, P24, DOI 10.1016/S0165-1838(99)00058-2; Amir R, 1996, J NEUROSCI, V16, P4733; Ayar A, 1999, NEUROSCI LETT, V271, P171, DOI 10.1016/S0304-3940(99)00538-8; Boehm S, 1999, J NEUROSCI, V19, P737; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Boyer JL, 1997, MOL PHARMACOL, V52, P928, DOI 10.1124/mol.52.6.928; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; Denk Winfried, 1995, P445; Evans AR, 1996, BRAIN RES, V712, P265, DOI 10.1016/0006-8993(95)01447-0; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; Ferguson DR, 1999, BJU INT, V84, P235; GAMMON CM, 1989, J NEUROCHEM, V53, P95, DOI 10.1111/j.1471-4159.1989.tb07299.x; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Honda T, 1999, NEUROSCI LETT, V275, P45, DOI 10.1016/S0304-3940(99)00729-6; HOURANI SMO, 1992, BRIT J PHARMACOL, V105, P453, DOI 10.1111/j.1476-5381.1992.tb14274.x; Huang LYM, 1996, NEURON, V17, P135, DOI 10.1016/S0896-6273(00)80287-1; Idestrup CP, 1998, NEUROSCIENCE, V86, P913, DOI 10.1016/S0306-4522(98)00128-6; Imtiaz MS, 2002, BIOPHYS J, V83, P1877, DOI 10.1016/S0006-3495(02)73952-0; ITOH T, 1992, J PHYSIOL-LONDON, V451, P307, DOI 10.1113/jphysiol.1992.sp019166; Konishi M, 2001, JPN J PHYSIOL, V51, P127, DOI 10.2170/jjphysiol.51.127; KUSHMERICK MJ, 1969, SCIENCE, V166, P1297, DOI 10.1126/science.166.3910.1297; LINDSAY RM, 1991, CELLULAR NEUROBIOLOG, P3; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Liu SW, 1996, GEOL J U, p[2, 75 ]; Mason MJ, 2001, J PHYSIOL-LONDON, V533, P175, DOI 10.1111/j.1469-7793.2001.0175b.x; Matsuka Y, 2001, BRAIN RES, V915, P248, DOI 10.1016/S0006-8993(01)02888-8; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; Nakayama S, 2002, JPN J PHYSIOL, V52, P217, DOI 10.2170/jjphysiol.52.217; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Petersen M, 1996, NEUROSCIENCE, V75, P495, DOI 10.1016/0306-4522(96)00259-X; Petruska JC, 2000, EXP BRAIN RES, V134, P126, DOI 10.1007/s002210000414; Ralevic V, 1998, PHARMACOL REV, V50, P413; Smith AB, 1999, NEUROSCIENCE, V94, P891, DOI 10.1016/S0306-4522(99)00286-9; Solovyova N, 2002, EMBO J, V21, P622, DOI 10.1093/emboj/21.4.622; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; SWANDULLA D, 1989, P NATL ACAD SCI USA, V86, P1736, DOI 10.1073/pnas.86.5.1736; SZALLASI A, 1994, GEN PHARMACOL-VASC S, V25, P223, DOI 10.1016/0306-3623(94)90049-3; TAYLOR WR, 1988, J PHYSIOL-LONDON, V407, P433, DOI 10.1113/jphysiol.1988.sp017424; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Ueno S, 1999, BRIT J PHARMACOL, V126, P429, DOI 10.1038/sj.bjp.0702319; Usachev YM, 1999, J PHYSIOL-LONDON, V519, P115, DOI 10.1111/j.1469-7793.1999.0115o.x; Ward SM, 2000, CELL CALCIUM, V28, P233, DOI 10.1054/ceca.2000.0151; Washburn, 1929, INT CRITICAL TABLES, V5; YAMAGISHI T, 1992, N-S ARCH PHARMACOL, V346, P691	49	13	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1562	+		10.1096/fj.04-1933fje	http://dx.doi.org/10.1096/fj.04-1933fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289444				2022-12-28	WOS:000223554900027
J	Lai, R; Takeuchi, H; Lomas, LO; Jonczy, J; Rigden, DJ; Rees, HH; Turner, PC				Lai, R; Takeuchi, H; Lomas, LO; Jonczy, J; Rigden, DJ; Rees, HH; Turner, PC			A new type of antimicrobial protein with multiple histidines from the hard tick, Amblyomma hebraeum	FASEB JOURNAL			English	Article						hebraein; innate immunity; pH-dependent; hemolymph; SELDI-TOF	TOAD BOMBINA-MAXIMA; SALIVARY HISTATIN-5; CANDIDA-ALBICANS; PEPTIDES; ANTIBACTERIAL	A novel 11 kDa antimicrobial protein, named as hebraein, and having a unique amino acid sequence, was purified from the hemolymph of fed female Amblyomma hebraeum ticks. A full-length cDNA clone encoding hebraein was isolated from a cDNA library made from tick synganglia. Hebraein consists of 102 amino acids, including 6 cysteine residues; has 9 histidines in its C-terminal domain that are mainly present as HX repeats; and has no significant similarity to any known protein. The secondary structure prediction is very clearly all alpha-helical ( 4 - 6 helices) except for a very short extension at the C terminus. Such high alpha-helical content is quite different from known antimicrobial proteins. Recombinant hebraein and a mutant lacking the histidine residues in the C-terminal domain were constructed and expressed. Assayed at the slightly acidic pH equivalent of fed female tick hemolymph, the wild-type and the histidine-rich recombinant hebraein had stronger antimicrobial activities than the histidine-deficient mutant. The pH-dependent properties of histidine-rich antimicrobial proteins may allow the design of agents that would function selectively in specific pH environments. The results from protein profiling of hemolymph, analyzed by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry combined with ProteinChip technology and RT-PCR analysis suggested that this antimicrobial protein was up-regulated by blood feeding. Our findings describe a new type of antimicrobial protein with multiple cysteine and histidine residues, and with unique secondary structure.	Univ Liverpool, Sch Biol Sci, Huw H Rees Cellular Regulat & Signaling Div, Liverpool L69 7ZB, Merseyside, England; Ciphergen Biosyst Inc, Fremont, CA USA; Novartis Anim Hlth Ctr Rech Sante Anim, Basel, Switzerland	University of Liverpool; Novartis	Rees, HH (corresponding author), Univ Liverpool, Sch Biol Sci, Huw H Rees Cellular Regulat & Signaling Div, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	reeshh@liv.ac.uk		Rigden, Daniel/0000-0002-7565-8937				Brogden KA, 1996, P NATL ACAD SCI USA, V93, P412, DOI 10.1073/pnas.93.1.412; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Edgerton M, 2000, ANTIMICROB AGENTS CH, V44, P3310, DOI 10.1128/AAC.44.12.3310-3316.2000; Fogaca AC, 2004, DEV COMP IMMUNOL, V28, P191, DOI 10.1016/j.dci.2003.08.001; Gusman H, 2001, INFECT IMMUN, V69, P1402, DOI 10.1128/IAI.69.3.1402-1408.2001; JOHNS R, 2001, INSECT BIOCHEM MOLEC, V31, P957; KAUFMAN WR, 1973, J EXP BIOL, V58, P523; Kobayashi S, 2001, BIOCHEMISTRY-US, V40, P14330, DOI 10.1021/bi015626w; Lai R, 2002, BIOCHEM BIOPH RES CO, V295, P796, DOI 10.1016/S0006-291X(02)00762-3; Lai R, 2002, PEPTIDES, V23, P427, DOI 10.1016/S0196-9781(01)00641-6; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; Lee IH, 2001, J PEPT RES, V58, P445; Lehane MJ, 1997, P NATL ACAD SCI USA, V94, P11502, DOI 10.1073/pnas.94.21.11502; Lomas LO, 1997, P ROY SOC B-BIOL SCI, V264, P589, DOI 10.1098/rspb.1997.0084; Nakajima Y, 2002, INSECT MOL BIOL, V11, P611, DOI 10.1046/j.1365-2583.2002.00372.x; RICHARD ME, 1999, BIOCHIM BIOPHYS ACTA, V1462, P11; Schibli DJ, 2002, BIOCHEM CELL BIOL, V80, P667, DOI 10.1139/O02-147; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; TASIEMSKI A, 2004, IN PRESS J BIOL CHEM; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001; Yuan J, 2000, INSECT BIOCHEM MOLEC, V30, P1099, DOI 10.1016/S0965-1748(00)00087-4	21	60	65	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1447	+		10.1096/fj.03-1154fje	http://dx.doi.org/10.1096/fj.03-1154fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247144				2022-12-28	WOS:000222979200008
J	El-Agnaf, OMA; Paleologou, KE; Greer, B; Abogrein, AM; King, JE; Salem, SA; Fullwood, NJ; Benson, FE; Hewitt, R; Ford, KJ; Martin, FL; Harriot, P; Cookson, MR; Allsop, D				El-Agnaf, OMA; Paleologou, KE; Greer, B; Abogrein, AM; King, JE; Salem, SA; Fullwood, NJ; Benson, FE; Hewitt, R; Ford, KJ; Martin, FL; Harriot, P; Cookson, MR; Allsop, D			A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders	FASEB JOURNAL			English	Article						amyloid fibrils; drug discovery; neurodegeneration; peptide delivery	MULTIPLE-SYSTEM ATROPHY; SHEET BREAKER PEPTIDES; APOPTOTIC CELL-DEATH; BETA-SHEET; NEURODEGENERATIVE DISEASES; LEWY BODIES; WILD-TYPE; NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; HYDROGEN-PEROXIDE	Convergent biochemical and genetic evidence suggests that the formation of alpha-synuclein (alpha-syn) protein deposits is an important and, probably, seminal step in the development of Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). It has been reported that transgenic animals overexpressing human alpha-syn develop lesions similar to those found in the brain in PD, together with a progressive loss of dopaminergic cells and associated abnormalities of motor function. Inhibiting and/or reversing alpha-syn self-aggregation could, therefore, provide a novel approach to treating the underlying cause of these diseases. We synthesized a library of overlapping 7-mer peptides spanning the entire alpha-syn sequence, and identified amino acid residues 64-100 of alpha-syn as the binding region responsible for its self-association. Modified short peptides containing alpha-syn amino acid sequences from part of this binding region (residues 69-72), named alpha-syn inhibitors (ASI), were found to interact with full-length alpha-syn and block its assembly into both early oligomers and mature amyloid-like fibrils. We also developed a cell-permeable inhibitor of alpha-syn aggregation (ASID), using the polyarginine peptide delivery system. This ASID peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with alpha-syn(A53T), a familial PD-associated mutation. ASI peptides without this delivery system did not reverse levels of Fe(II)-induced DNA damage. Furthermore, the ASID peptide increased (P<0.0005) the number of cells stained positive for Bcl-2, while significantly (P<0.05) decreasing the percentage of cells stained positive for BAX. These short peptides could serve as lead compounds for the design of peptidomimetic drugs to treat PD and related disorders.	Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England; Queens Univ Belfast, Sch Biol & Biochem, Belfast BT9 7BL, Antrim, North Ireland; NIA, Neurogenet Lab, Bethesda, MD 20892 USA	Lancaster University; Queens University Belfast; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	El-Agnaf, OMA (corresponding author), Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England.	o.el-agnaf@lancaster.ac.uk	Cookson, Mark/AAW-2516-2021; Allsop, David/B-9725-2008	Cookson, Mark/0000-0002-1058-3831; Allsop, David/0000-0002-0513-5575; Benson, Fiona Elizabeth/0000-0002-3918-7015; Fullwood, Nigel James/0000-0002-9405-8515; L Martin, Francis/0000-0001-8562-4944	NATIONAL INSTITUTE ON AGING [ZIAAG000953, Z01AG000953] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baba M, 1998, AM J PATHOL, V152, P879; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2003, LANCET NEUROL, V2, P461, DOI 10.1016/S1474-4422(03)00481-2; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Hildeman DA, 2003, P NATL ACAD SCI USA, V100, P15035, DOI 10.1073/pnas.1936213100; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Kalantzi OI, 2004, CARCINOGENESIS, V25, P613, DOI 10.1093/carcin/bgh048; Kapurniotu A, 2002, J MOL BIOL, V315, P339, DOI 10.1006/jmbi.2001.5244; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Martin FL, 2003, J NEUROCHEM, V87, P620, DOI 10.1046/j.1471-4159.2003.02013.x; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Nagai Y, 2003, HUM MOL GENET, V12, P1253, DOI 10.1093/hmg/ddg144; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Noguchi H, 2004, NAT MED, V10, P305, DOI 10.1038/nm994; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Permanne B, 2002, FASEB J, V16, P860, DOI 10.1096/fj.01-0841fje; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ren H, 2001, BIOCHEM BIOPH RES CO, V288, P703, DOI 10.1006/bbrc.2001.5783; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yared E, 2002, MUTAGENESIS, V17, P345, DOI 10.1093/mutage/17.4.345	57	139	153	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1315	+		10.1096/fj.03-1346fje	http://dx.doi.org/10.1096/fj.03-1346fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180968				2022-12-28	WOS:000222327500026
J	Tepper, OM; Callaghan, MJ; Chang, EI; Galiano, RD; Bhatt, KA; Baharestani, S; Gan, J; Simon, B; Hopper, RA; Levine, JP; Gurtner, GC				Tepper, OM; Callaghan, MJ; Chang, EI; Galiano, RD; Bhatt, KA; Baharestani, S; Gan, J; Simon, B; Hopper, RA; Levine, JP; Gurtner, GC			Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2	FASEB JOURNAL			English	Article						therapeutic angiogenesis; growth factors	DOUBLE-BLIND TRIAL; GROWTH-FACTOR; GENE-THERAPY; EXPRESSION; VASCULOGENESIS; PROLIFERATION; MIGRATION; NONUNION; REPAIR; CELLS	Pulsed electromagnetic fields (PEMF) have been shown to be clinically beneficial, but their mechanism of action remains unclear. The present study examined the impact of PEMF on angiogenesis, a process critical for successful healing of various tissues. PEMF increased the degree of endothelial cell tubulization (sevenfold) and proliferation (threefold) in vitro. Media from PEMF cultures had a similar stimulatory effect, but heat denaturation ablated this activity. In addition, conditioned media was able to induce proliferative and chemotactic changes in both human umbilical vein endothelial cells and fibroblasts, but had no effect on osteoblasts. Angiogenic protein screening demonstrated a fivefold increase in fibroblast growth factor beta-2 (FGF-2), as well as smaller increases in other angiogenic growth factors (angiopoietin-2, thrombopoietin, and epidermal growth factor). Northern blot analysis demonstrated an increase in FGF-2 transcription, and FGF-2 neutralizing antibody inhibited the effects of PEMF. In vivo, PEMF exposure increased angiogenesis more than twofold. We conclude that PEMF augments angiogenesis primarily by stimulating endothelial release of FGF-2, inducing paracrine and autocrine changes in the surrounding tissue. These findings suggest a potential role for PEMF in therapeutic angiogenesis.	NYU, Sch Med, Microvasc Res & Vasc Tissue Engn Lab, New York, NY 10016 USA	New York University	Gurtner, GC (corresponding author), NYU, Med Ctr, Inst Reconstruct Plast Surg, TH-169,550 1st Ave, New York, NY 10016 USA.	geoffrey.gurtner@med.nyu.edu						Aaron RK, 2002, J ORTHOP RES, V20, P233, DOI 10.1016/S0736-0266(01)00084-5; BASSETT CAL, 1974, SCIENCE, V184, P575; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243; BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309; Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623-200110000-00009; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; DONSKI PK, 1979, PLAST RECONSTR SURG, V64, P239, DOI 10.1097/00006534-197908000-00017; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; Freshney R.I, 2000, CULTURE ANIMAL CELLS, P149; Guerkov HH, 2001, CLIN ORTHOP RELAT R, P265; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jasti A C, 2001, Biomed Sci Instrum, V37, P209; Kanno S, 1999, CIRCULATION, V99, P2682, DOI 10.1161/01.CIR.99.20.2682; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; RYABY JT, 1998, CLIN ORTHOP S, V355, P205; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SAVITZ DA, 1987, J OCCUP ENVIRON MED, V29, P47; SCOTT G, 1994, J BONE JOINT SURG AM, V76A, P820, DOI 10.2106/00004623-199406000-00005; SHARRARD WJW, 1990, J BONE JOINT SURG BR, V72, P347, DOI 10.1302/0301-620X.72B3.2187877; Steinbrech DS, 2000, AM J PHYSIOL-CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853; Stix G, 1998, SCI AM, V278, P33, DOI 10.1038/scientificamerican0398-33; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; YENPATTON GPA, 1988, J CELL PHYSIOL, V134, P37, DOI 10.1002/jcp.1041340105	26	160	180	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1231	+		10.1096/fj.03-0847fje	http://dx.doi.org/10.1096/fj.03-0847fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208265				2022-12-28	WOS:000222327500023
J	Simard, AR; Rivest, S				Simard, AR; Rivest, S			Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia	FASEB JOURNAL			English	Article						chimeric mice; GFP mice; gliogenesis; inflammation; innate immunity; antigen-presenting cells; macrophages; CD11c	INNATE IMMUNE-RESPONSE; ADULT-MOUSE BRAIN; MICE; ENCEPHALOMYELITIS; PLAY	Pluripotent stem cells can differentiate into a variety of cell types during tissue development and regeneration. However, it is still unclear whether bone marrow-derived stem cells can migrate across the blood-brain barrier in many regions of the central nervous system (CNS) and if these cells can readily differentiate into functional parenchymal microglia. We thus studied the differentiation fate of bone marrow stem cells upon immigration into the CNS. To this end, we systemically transplanted stem cells that express green fluorescent protein (GFP) into lethally irradiated mice and found that these cells immigrated into the brain parenchyma of many regions of the CNS. Nearly all of the infiltrating cells had a highly ramified morphology and colocalized with the microglial marker iba1. Moreover, these cells expressed high levels of the protein CD11c, indicating that microglia of bone marrow origin may be potent antigen presenting cells. These data suggest that microglia of blood origin could activate cells of the adaptive immune system and cause harm to the CNS. Therefore, these results may have great clinical relevance for both immune-derived neuronal disorders and cancer patients undergoing allogeneic hematopoietic stem-cell transplantation.	CHUL Res Ctr, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Rivest, S (corresponding author), CHUL Res Ctr, Mol Endocrinol Lab, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	Serge.Rivest@crchul.ulaval.ca	Simard, Alain/E-1493-2013	Simard, Alain/0000-0002-3499-6235; Rivest, Serge/0000-0002-6082-770X				Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Nadeau S, 2003, J NEUROSCI, V23, P5536, DOI 10.1523/jneurosci.23-13-05536.2003; Soulet D, 2003, J CELL BIOL, V162, P257, DOI 10.1083/jcb.200301097; Tran EH, 1998, J IMMUNOL, V161, P3767; Vallieres L, 2003, J NEUROSCI, V23, P5197; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442	14	279	293	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					998	+		10.1096/fj.04-1517fje	http://dx.doi.org/10.1096/fj.04-1517fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084516				2022-12-28	WOS:000221108800005
J	Watanabe, N; Araki, W; Chui, DH; Makifuchi, T; Ihara, Y; Tabira, T				Watanabe, N; Araki, W; Chui, DH; Makifuchi, T; Ihara, Y; Tabira, T			Glypican-1 as an A beta binding HSPG in the human brain: Its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease	FASEB JOURNAL			English	Article						beta-amyloid protein; SH-SY5Y cells; heparan sulfate proteoglycans	HEPARAN-SULFATE PROTEOGLYCAN; GPI-ANCHORED PROTEINS; INSOLUBLE MEMBRANE COMPARTMENT; AMYLOID-BETA; CELL-SURFACE; A-BETA-42 ACCUMULATION; SENILE PLAQUES; LIPID RAFTS; PEPTIDE; INHIBITION	Previous studies have suggested that heparan sulfate proteoglycans (HSPGs) play a role in deposition of beta-amyloid protein (Abeta) in the Alzheimer's disease (AD) brain. In the present study, we demonstrated that glypican-1 can bind fibrillar Abeta, and the binding is mainly mediated by heparan sulfate (HS) chains. Further analysis revealed that glypican-1 is the major HSPG localized in detergent-insoluble glycosphingolipid-enriched (DIG) domains where all machineries for Abeta production exist and Abeta is accumulated as monomeric and oligomeric forms. Immunohistochemical studies demonstrated that glypican-1 is localized in primitive plaques as well as classic plaques. Moreover, overexpression of glypican-1 and amyloid precursor protein in SH-SY5Y cells resulted in reduced cell viability and made cells more susceptible to thapsigargin-induced stress and Abeta toxicity. The results raise the possibility that glypican-1 interacts with oligomerized or polymerized Abeta in such a specific compartment as DIG, resulting not only in amyloid deposition in senile plaques of AD brain, but also in accelerating neuronal cell death in response to stress and Abeta.	Natl Inst Longev Sci, Aichi 4748522, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; Natl Saigata Hosp, Dept Clin Res, Niigata 9493193, Japan; Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan	National Center for Neurology & Psychiatry - Japan; RIKEN; University of Tokyo	Watanabe, N (corresponding author), Natl Inst Longev Sci, 36-3 Gengo, Aichi 4748522, Japan.	watanabn@nils.go.jp	Araki, Wataru/G-7913-2014	Araki, Wataru/0000-0001-8467-6937				ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bame KJ, 1997, J BIOL CHEM, V272, P17005, DOI 10.1074/jbc.272.27.17005; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; Castillo GM, 1997, J NEUROCHEM, V69, P2452; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; Chui DH, 2001, J ALZHEIMERS DIS, V3, P231; Chui DH, 1998, J NEUROSCI RES, V53, P99; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Donahue JE, 1999, P NATL ACAD SCI USA, V96, P6468, DOI 10.1073/pnas.96.11.6468; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FILMUS J, 2000, PROTEOGLYCANS, P161; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Ginsberg SD, 1999, J NEUROPATH EXP NEUR, V58, P815, DOI 10.1097/00005072-199908000-00004; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GONZALEZ AD, 1998, J CELL BIOL, V141, P1407; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guo Q, 1997, J NEUROSCI, V17, P4212; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; KOIKE F, 1988, J NEUROL SCI, V85, P9, DOI 10.1016/0022-510X(88)90031-7; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LITWACK ED, 1994, J NEUROSCI, V14, P3713; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; OGURI K, 1995, GLYCOCONJUGATE J, V12, P520; Oshima N, 2001, AM J PATHOL, V158, P2209, DOI 10.1016/S0002-9440(10)64693-7; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SNOW AD, 1994, AM J PATHOL, V144, P337; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Tabira T, 2002, FRONT BIOSCI-LANDMRK, V7, pA44, DOI 10.2741/tabira; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; van Horssen J, 2001, ACTA NEUROPATHOL, V102, P604; VANGOOL D, 1993, DEMENTIA, V4, P308, DOI 10.1159/000107338; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Verbeek MM, 1999, AM J PATHOL, V155, P2115, DOI 10.1016/S0002-9440(10)65529-0; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yanagisawa K, 1998, NEUROBIOL AGING, V19, pS65, DOI 10.1016/S0197-4580(98)00032-3; YANAGISAWA LP, 1998, FEBS LETT, V19, pS65; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	59	52	58	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1013	+		10.1096/fj.03-1040fje	http://dx.doi.org/10.1096/fj.03-1040fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084524				2022-12-28	WOS:000221108800013
J	Benmoyal-Segal, L; Vander, T; Shifman, S; Bryk, B; Ebstein, R; Marcus, EL; Stessman, J; Darvasi, A; Herishanu, Y; Friedman, A; Soreq, H				Benmoyal-Segal, L; Vander, T; Shifman, S; Bryk, B; Ebstein, R; Marcus, EL; Stessman, J; Darvasi, A; Herishanu, Y; Friedman, A; Soreq, H			Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease.	FASEB JOURNAL			English	Article						association study; environmental exposure; gene-environment interactions; genotyping neuroprotection	LINKAGE DISEQUILIBRIUM; GENETIC-POLYMORPHISM; OXIDATIVE STRESS; PARAOXONASE; PON1; EXPRESSION; ISRAEL; CHOLINESTERASES; SENSITIVITY; EXPOSURE	Exposure to agricultural insecticides, together with yet incompletely understood predisposing genotype/ phenotype elements, notably increase the risk of Parkinson's disease. Here, we report findings attributing the increased risk in an insecticide-exposed rural area in Israel to interacting debilitating polymorphisms in the ACHE/PON1 locus and corresponding expression variations. Polymorphisms that debilitate PON1 activity and cause impaired AChE overproduction under anticholinesterase exposure were strongly overrepresented in patients from agriculturally exposed areas, indicating that they confer risk of Parkinson's disease. Supporting this notion, serum AChE and PON1 activities were both selectively and significantly lower in patients than in healthy individuals and in carriers of the risky polymorphisms as compared with other Parkinsonian patients. Our findings suggest that inherited interactive weakness of AChE and PON1 expression increases the insecticide-induced occurrence of Parkinson's disease.	Hebrew Univ Jerusalem, Inst Life Sci, IL-91904 Jerusalem, Israel; Ben Gurion Univ Negev, Zlotowsky Ctr Neurosci, Dept Neurol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowsky Ctr Neurosci, Dept Neurosurg, IL-84105 Beer Sheva, Israel; Soroka Med Ctr, IL-84101 Beer Sheva, Israel; Herzog Hosp, Jerusalem, Israel; Mt Scopus Hadassah Univ Hosp, Jerusalem, Israel	Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University; Ben Gurion University; Soroka Medical Center; Hebrew University of Jerusalem; Herzog Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il	Marcus, Esther-Lee/GXG-3270-2022; Shifman, Sagiv/D-8749-2017	Shifman, Sagiv/0000-0003-4071-5361; Soreq, Hermona/0000-0002-0955-526X; Ebstein, Richard/0000-0002-3626-541X				Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Akhmedova SN, 2001, J NEUROL SCI, V184, P179, DOI 10.1016/S0022-510X(01)00439-7; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BARBEAU A, 1962, CAN MED ASSOC J, V87, P802; BATTEKS CF, 1993, AM J HUM GENET, V52, P928; Brenner T, 2003, FASEB J, V17, P214, DOI 10.1096/fj.02-0609com; Brophy VH, 2001, AM J HUM GENET, V68, P1428, DOI 10.1086/320600; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; Costa LG, 2003, ANNU REV MED, V54, P371, DOI 10.1146/annurev.med.54.101601.152421; De Palma G, 1998, LANCET, V352, P1986; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Drozdzik M, 2003, PHARMACOGENETICS, V13, P259, DOI 10.1097/01.fpc.0000054087.48725.dg; EHRLICH G, 1994, GENOMICS, V22, P288, DOI 10.1006/geno.1994.1386; Emborg ME, 1998, J COMP NEUROL, V401, P253; Goldsmith JR, 1997, ENVIRON RES, V73, P156, DOI 10.1006/enrs.1997.3696; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Grisaru D, 2001, MOL MED, V7, P93, DOI 10.1007/BF03401943; Herishanu YO, 1998, CAN J NEUROL SCI, V25, P127, DOI 10.1017/S0317167100033734; HERISHANU YO, 1989, CAN J NEUROL SCI, V16, P402, DOI 10.1017/S0317167100029462; HUANG X, 1994, CHEM RES TOXICOL, V7, P451, DOI 10.1021/tx00039a025; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kondo I, 1998, BRAIN RES, V806, P271, DOI 10.1016/S0006-8993(98)00586-1; Kudchodkar BJ, 2000, J NUTR, V130, P2427, DOI 10.1093/jn/130.10.2427; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LOEWENSTEINLICHTENSTEIN Y, 1995, NAT MED, V1, P1082, DOI 10.1038/nm1095-1082; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Nassar BA, 2002, CLIN BIOCHEM, V35, P205, DOI 10.1016/S0009-9120(02)00296-5; PIAZZA A, 1995, P NATL ACAD SCI USA, V92, P5836, DOI 10.1073/pnas.92.13.5836; Sanghera DK, 1997, ARTERIOSCL THROM VAS, V17, P1067, DOI 10.1161/01.ATV.17.6.1067; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Sklan EH, 2004, P NATL ACAD SCI USA, V101, P5512, DOI 10.1073/pnas.0307659101; SORENSEN K, 1986, CLIN CHIM ACTA, V158, P1, DOI 10.1016/0009-8981(86)90109-9; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; WEINER L, 1994, BIOCHEM BIOPH RES CO, V198, P915, DOI 10.1006/bbrc.1994.1130; WESTON J, 1986, NEUROSCIENCE, V17, P1079, DOI 10.1016/0306-4522(86)90078-3; XIE X, 1993, AM J HUM GENET, V53, P1107; ZAKUT H, 1988, CANCER, V61, P727, DOI 10.1002/1097-0142(19880215)61:4<727::AID-CNCR2820610416>3.0.CO;2-L; Zhao JH, 2000, HUM HERED, V50, P133, DOI 10.1159/000022901; Zhou FM, 2003, NEUROSCIENTIST, V9, P23, DOI 10.1177/1073858402239588	42	68	69	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					452	+		10.1096/fj.04-2106fje	http://dx.doi.org/10.1096/fj.04-2106fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629887				2022-12-28	WOS:000226576600034
J	Bhatia, M; Wong, FL; Fu, D; Lau, HY; Moochhala, SM; Moore, PK				Bhatia, M; Wong, FL; Fu, D; Lau, HY; Moochhala, SM; Moore, PK			Role of hydrogen sulfide in acute pancreatitis and associated lung injury	FASEB JOURNAL			English	Article						inflammation cystathionine-gamma-lyase; DL-propargylglycine; myeloperoxidase; caerulein	SMOOTH-MUSCLE RELAXANT; NITRIC-OXIDE SYNTHASE; INFLAMMATORY MEDIATORS; GAMMA-LYASE; IN-VITRO; H2S; MICE; INACTIVATION; INHIBITION; METABOLISM	Hydrogen sulfide (H2S) is a naturally occurring gas with potent vasodilator activity. Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system. Whilst H2S has been reported to relax precontracted rat arteries in vitro and to lower blood pressure in the rat, its effect in an inflammatory condition such as acute pancreatitis has not previously been reported. In this paper, we report the presence of H2S synthesizing enzyme activity and CSE ( as determined by mRNA signal) in the pancreas. Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204 +/- 59); prophylactic treatment: placebo, 10635 +/- 305; PAG, 7904 +/- 495; therapeutic treatment: placebo, 10427 +/- 470; PAG, 7811 +/- 428; P< 0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) ( prophylactic treatment: placebo, 5.78 +/- 0.63; PAG, 2.97 +/- 0.39; therapeutic treatment: placebo, 5.48 +/- 0.52; PAG, 3.03 +/- 0.47; P< 0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/ necrosis; 4) lung MPO activity ( fold increase over control) [ prophylactic treatment: placebo, 1.99 +/- 0.16; PAG, 1.34 +/- 0.14; therapeutic treatment: placebo, 2.03 +/- 0.12; PAG, 1.41 +/- 0.97; P< 0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury. These effects of CSE blockade suggest an important proinflammatory role of H2S in regulating the severity of pancreatitis and associated lung injury and raise the possibility that H2S may exert similar activity in other forms of inflammation.	Natl Univ Singapore, Fac Med, Dept Pharmacol, Singapore 117597, Singapore; Def Sci Org, Def Med & Environm Res Inst, Ctr Biomed Sci, Singapore 0511, Singapore	National University of Singapore	Bhatia, M (corresponding author), Natl Univ Singapore, Fac Med, Dept Pharmacol, Bldg MD2,18 Med Dr, Singapore 117597, Singapore.	mbhatia@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192				Abe K, 1996, J NEUROSCI, V16, P1066; Bhatia M, 2000, J PATHOL, V190, P117; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Bhatia M., 2002, Current Drug Targets - Inflammation and Allergy, V1, P343; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Bhatia M, 2003, AM J PHYSIOL-GASTR L, V284, pG830, DOI 10.1152/ajpgi.00140.2002; Bhatia M, 2001, Curr Opin Investig Drugs, V2, P496; Bhatia M, 2000, GUT, V47, P838, DOI 10.1136/gut.47.6.838; BHATIA M, 2004, MED CHEM REV ONLINE, V1, P25, DOI DOI 10.2174/1567203043480395; Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6; Cheng YQ, 2004, AM J PHYSIOL-HEART C, V287, pH2316, DOI 10.1152/ajpheart.00331.2004; Cuzzocrea S, 2002, SHOCK, V17, P416, DOI 10.1097/00024382-200205000-00013; DiMagno MJ, 2004, AM J PHYSIOL-GASTR L, V287, pG80, DOI 10.1152/ajpgi.00525.2003; Geng B, 2004, BIOCHEM BIOPH RES CO, V313, P362, DOI 10.1016/j.bbrc.2003.11.130; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Hui Y, 2003, J INFECTION, V47, P155, DOI 10.1016/S0163-4453(03)00043-4; JOHNSTON M, 1979, BIOCHEMISTRY-US, V18, P4690, DOI 10.1021/bi00588a033; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lau HY, 2005, BIOCHEM BIOPH RES CO, V327, P509, DOI 10.1016/j.bbrc.2004.12.030; Moore PK, 2003, TRENDS PHARMACOL SCI, V24, P609, DOI 10.1016/j.tips.2003.10.007; Ogasawara Y, 1997, BBA-GEN SUBJECTS, V1334, P33, DOI 10.1016/S0304-4165(96)00072-4; Patacchini R, 2004, BRIT J PHARMACOL, V142, P31, DOI 10.1038/sj.bjp.0705764; PIERRE KJ, 1976, CLIN CHEM, V22, P1219; REED DJ, 1995, METHOD ENZYMOL, V252, P92; Sanchez-Bernal C, 2004, PANCREAS, V28, pE9, DOI 10.1097/00006676-200401000-00021; Steegborn C, 1999, J BIOL CHEM, V274, P12675, DOI 10.1074/jbc.274.18.12675; Teague B, 2002, BRIT J PHARMACOL, V137, P139, DOI 10.1038/sj.bjp.0704858; UREN JR, 1978, BIOCHEM PHARMACOL, V27, P2807, DOI 10.1016/0006-2952(78)90194-6; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhang QY, 2004, BIOCHEM BIOPH RES CO, V317, P30, DOI 10.1016/j.bbrc.2004.02.176; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008; Zhong GZ, 2003, J HYPERTENS, V21, P1879, DOI 10.1097/00004872-200310000-00015	34	251	280	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					623	+		10.1096/fj.04-3023fje	http://dx.doi.org/10.1096/fj.04-3023fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671155				2022-12-28	WOS:000226576600009
J	Kumar, A; Kingdon, E; Norman, J				Kumar, A; Kingdon, E; Norman, J			The isoprostane 8-iso-PGF(2 alpha) suppresses monocyte adhesion to human microvascular endothelial cells via two independent mechanisms	FASEB JOURNAL			English	Article						inflammation; monocyte adhesion; thromboxane receptor; signaling	LIPID-PEROXIDATION; EXPRESSION; RECEPTORS; F-2-ISOPROSTANES; PROLIFERATION; MIGRATION; CYTOKINE; BIOLOGY; MARKER; ALPHA	Isoprostanes, produced in vivo by non-enzymatic free-radical-induced lipid peroxidation, are markers of oxidative stress. Elevated serum and urine levels of 8-iso-PGF(2alpha) have been reported in a variety of diseases, many of which are characterized by early perivascular inflammatory infiltrates. It has been suggested that, in addition to being markers of oxidative stress, isoprostanes may have pathogenic functions. In this study, we investigated the potential role of 8-iso-PGF(2alpha) in inflammation, focusing on its effects on adhesion of monocytes to microvascular endothelial cells, an early event in the inflammatory response. In monocyte adhesion assays, 8-iso- PGF(2alpha) (> 10(-8)M) suppressed both basal and TNF-alpha-induced monocyte adhesion to quiescent or proliferating human dermal (HMEC) and rat renal microvascular endothelial cells. In contrast, 8-iso-PGF(2alpha) stimulated monocyte adhesion to human umbilical vein endothelial cells ( HUVEC) as also reported by others. 8-Iso-PGF(2alpha) had no effect on the viability (Trypan Blue exclusion) of U937 monocytes or HMEC. 8-Iso-PGF(2alpha) also had no effect on HMEC surface expression of ICAM-1 or VCAM-1. Exposure of HMEC to 8-iso-PGF(2alpha) for 1-2 h was sufficient to reduce monocyte adhesion to the cell surface, and this effect was independent of de novo protein synthesis by HMEC. The effect of 8-iso-PGF(2alpha) was mimicked by a thromboxane receptor (TP) agonist (U46619) and blocked by a TP antagonist (SQ29548), indicating a TP-mediated process. Signal transduction pathway inhibitors (SB203580, curcumin, and PD98059) implicated p38 and JNK, but not ERK, in 8-iso-PGF(2alpha)-induced suppression of monocyte adhesion. In addition to a direct effect, conditioned medium (CM) transfer experiments suggest that 8-iso-PGF(2alpha) induces a secondary mediator, which also suppresses monocyte adhesion but via an alternative mechanism initiated between 3 - 4 h, which is TP-independent, requires new protein synthesis, and is primarily dependent on activation of p38. The data show that 8-iso-PGF(2alpha) can suppress the attachment of monocytes to HMECs via two independent pathways, indicating a potential anti-inflammatory effect of 8-iso-PGF(2alpha) in the microvasculature.	UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, Div Med, Ctr Nephrol, London NW3 2PF, England; Brighton & Sussex Univ Hosp Trust, Sussex Kidney Unit, Brighton, E Sussex, England	University of London; University College London; UCL Medical School	Norman, J (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, Div Med, Ctr Nephrol, 2nd Floor,Hampstead Campus,Rowland Hill St, London NW3 2PF, England.	j.norman@rfc.ucl.ac.uk						Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Chana RS, 2003, KIDNEY INT, V63, P889, DOI 10.1046/j.1523-1755.2003.00828.x; Cracowski JL, 2001, J VASC RES, V38, P93, DOI 10.1159/000051036; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; FAN JL, 1993, BIOL CELL, V79, P17, DOI 10.1016/0248-4900(93)90258-G; Floris S, 2003, J NEUROPATH EXP NEUR, V62, P780, DOI 10.1093/jnen/62.7.780; Fukunaga M, 1997, AM J PHYSIOL-RENAL, V272, pF477, DOI 10.1152/ajprenal.1997.272.4.F477; GOPAUL NK, 1995, FEBS LETT, V368, P225, DOI 10.1016/0014-5793(95)00649-T; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hart CM, 1998, PROSTAG LEUKOTR ESS, V58, P9, DOI 10.1016/S0952-3278(98)90124-7; Hellewell PG, 1999, PULM PHARMACOL THER, V12, P137, DOI 10.1006/pupt.1999.0189; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067, DOI 10.1152/ajplung.2001.280.6.L1067; Janssen LJ, 2002, J PHARMACOL EXP THER, V301, P1060, DOI 10.1124/jpet.301.3.1060; Janssen LJ, 2001, BRIT J PHARMACOL, V132, P127, DOI 10.1038/sj.bjp.0703784; Kinsella BT, 2001, BIOCHEM SOC T, V29, P641, DOI 10.1042/BST0290641; Leitinger N, 2001, FASEB J, V15, P1254, DOI 10.1096/fj.00-0498fje; LONGMIRE AW, 1994, PROSTAGLANDINS, V48, P247, DOI 10.1016/0090-6980(94)90011-6; Mayer K, 2002, AM J PHYSIOL-HEART C, V283, pH811, DOI 10.1152/ajpheart.00235.2002; Mene P, 1996, KIDNEY INT, V50, P417, DOI 10.1038/ki.1996.331; Mohler ER, 1996, BIOCHEM BIOPH RES CO, V225, P915, DOI 10.1006/bbrc.1996.1272; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Nonaka-Sarukawa M, 2003, HEART, V89, P871, DOI 10.1136/heart.89.8.871; Pratico D, 1999, ATHEROSCLEROSIS, V147, P1, DOI 10.1016/S0021-9150(99)00257-9; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; ROBERTS LJ, 1994, ANN NY ACAD SCI, V744, P237, DOI 10.1111/j.1749-6632.1994.tb52741.x; Rodriguez E, 2002, LIFE SCI, V71, P2181, DOI 10.1016/S0024-3205(02)01999-9; Stein CM, 1996, ARTHRITIS RHEUM-US, V39, P1146, DOI 10.1002/art.1780390711; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; Teupser D, 2001, BIOCHEM BIOPH RES CO, V289, P838, DOI 10.1006/bbrc.2001.6066; Theriault A, 2002, ATHEROSCLEROSIS, V160, P21, DOI 10.1016/S0021-9150(01)00540-8; Witztum JL, 1998, CURR OPIN LIPIDOL, V9, P441, DOI 10.1097/00041433-199810000-00008; Yura T, 1999, KIDNEY INT, V56, P471, DOI 10.1046/j.1523-1755.1999.00596.x; Zahler S, 1999, PROSTAG OTH LIPID M, V57, P319, DOI 10.1016/S0090-6980(98)00079-3; Zhang H, 2002, AM J PATHOL, V160, P2219, DOI 10.1016/S0002-9440(10)61169-8	40	28	33	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					443	+		10.1096/fj.03-1364fje	http://dx.doi.org/10.1096/fj.03-1364fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15640282	Bronze			2022-12-28	WOS:000226576600026
J	Clement, K; Viguerie, N; Poitou, C; Carette, C; Pelloux, V; Curat, CA; Sicard, A; Rome, S; Benis, A; Zucker, JD; Vidal, H; Laville, M; Barsh, GS; Basdevant, A; Stich, V; Cancello, R; Langin, D				Clement, K; Viguerie, N; Poitou, C; Carette, C; Pelloux, V; Curat, CA; Sicard, A; Rome, S; Benis, A; Zucker, JD; Vidal, H; Laville, M; Barsh, GS; Basdevant, A; Stich, V; Cancello, R; Langin, D			Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects	FASEB JOURNAL			English	Article						obesity; gene profiling; calorie restriction; microarray	INTERLEUKIN-1 RECEPTOR ANTAGONIST; INSULIN-RESISTANCE SYNDROME; IN-VIVO; EXPRESSION; MICROARRAY; WOMEN; FAT; MACROPHAGE; MARKERS; ATHEROSCLEROSIS	Adipose tissue produces inflammation and immunity molecules suspected to be involved in obesity-related complications. The pattern of expression and the nutritional regulation of these molecules in humans are poorly understood. We analyzed the gene expression profiles of subcutaneous white adipose tissue from 29 obese subjects during very low calorie diet (VLCD) using cDNA microarray and reverse transcription quantitative PCR. The patterns of expression were compared with that of 17 non-obese subjects. We determined whether the regulated genes were expressed in adipocytes or stromavascular fraction cells. Gene expression profiling identified 100 inflammation-related transcripts that are regulated in obese individuals when eating a 28 day VLCD but not a 2 day VLCD. Cluster analysis showed that the pattern of gene expression in obese subjects after 28 day VLCD was closer to the profile of lean subjects than to the pattern of obese subjects before VLCD. Weight loss improves the inflammatory profile of obese subjects through a decrease of proinflammatory factors and an increase of anti-inflammatory molecules. The genes are expressed mostly in the stromavascular fraction of adipose tissue, which is shown to contain numerous macrophages. The beneficial effect of weight loss on obesity-related complications may be associated with the modification of the inflammatory profile in adipose tissue.	Hop Hotel Dieu, Dept Nutr, INSERM, Dept Nutr,AP HP, F-75181 Paris 04, France; Univ Toulouse 3, Unite Rech Obesites Inserm UPS U586, Inst Louis Bugnard, Ctr Hosp Univ Toulouse, F-31062 Toulouse, France; Charles Univ Prague, Franco Czech Lab Clin Res Obes, French Inst Hlth & Med Res, Inserm U586, Prague, Czech Republic; Charles Univ Prague, Fac Med 3, Prague, Czech Republic; Goethe Univ Frankfurt, Inst Kardiovasc Physiol, D-6000 Frankfurt, Germany; Fac Med R Laennec, INSERM, U449, Lyon, France; Fac Med R Laennec, Human Nutr Res Ctr Lyon, Lyon, France; Univ Paris 13, LIM & BIO, F-93430 Villetaneuse, France; Stanford Univ, Sch Med, Dept Pediat & Genet, Howard Hughes Med Inst,Beckman Ctr, Stanford, CA 94305 USA; Charles Univ Prague, Fac Med 3, Dept Sports Med, Prague, Czech Republic; Charles Univ Prague, Fac Med 3, Obesity Unit, Prague, Czech Republic	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Charles University Prague; Charles University Prague; Goethe University Frankfurt; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris 13; Howard Hughes Medical Institute; Stanford University; Charles University Prague; Charles University Prague	Clement, K (corresponding author), Hop Hotel Dieu, Dept Nutr, INSERM, Dept Nutr,AP HP, Ave Paris 6 Univ,EA 3502, F-75181 Paris 04, France.	karine.clement@htd.ap-hop-paris.fr; langin@inserm.toulouse.fr	Benis, Arriel/M-6262-2016; Vidal, Hubert/M-6674-2017; ZUCKER, Jean-Daniel/K-3008-2016; Clément, karine/R-1120-2017; Viguerie, Nathalie/M-2422-2017	Benis, Arriel/0000-0002-9125-8300; Vidal, Hubert/0000-0002-9467-0317; ZUCKER, Jean-Daniel/0000-0002-5597-7922; Viguerie, Nathalie/0000-0002-1730-9915; Langin, Dominique/0000-0002-2669-7825; ROME, SOPHIE/0000-0003-3986-5936				Albu JB, 2000, ANN NY ACAD SCI, V904, P491; Argiles J M, 1998, Curr Opin Clin Nutr Metab Care, V1, P245, DOI 10.1097/00075197-199805000-00002; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bastard JP, 1999, CIRCULATION, V99, P2221; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Braat H, 2003, EXPERT OPIN BIOL TH, V3, P725, DOI 10.1517/eobt.3.5.725.21237; Bruunsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5; Charriere G, 2003, J BIOL CHEM, V278, P9850, DOI 10.1074/jbc.M210811200; Chiellini C, 2002, J CELL PHYSIOL, V190, P251, DOI 10.1002/JCP.10061; Clement K, 2002, GENOME RES, V12, P281, DOI 10.1101/gr.207702; Colgan SP, 1999, P NATL ACAD SCI USA, V96, P13938, DOI 10.1073/pnas.96.24.13938; Curat CA, 2004, DIABETES, V53, P1285, DOI 10.2337/diabetes.53.5.1285; Dusserre E, 2000, BBA-MOL BASIS DIS, V1500, P88, DOI 10.1016/S0925-4439(99)00091-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eriksson P, 2000, THROMB HAEMOSTASIS, V83, P545; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Feldman AL, 2002, BIOTECHNIQUES, V33, P906, DOI 10.2144/02334mt04; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Friedland RP, 2002, ANN NY ACAD SCI, V977, P387, DOI 10.1111/j.1749-6632.2002.tb04842.x; FRIEDRICHS WE, 1995, BIOCHEM BIOPH RES CO, V209, P250, DOI 10.1006/bbrc.1995.1496; Gabrielsson BG, 2003, OBES RES, V11, P699, DOI 10.1038/oby.2003.100; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Gomez-Ambrosi J, 2004, FASEB J, V18, P215, DOI 10.1096/fj.03-0591fje; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hanusch-Enserer U, 2003, INT J OBESITY, V27, P355, DOI 10.1038/sj.ijo.0802240; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; Juge-Aubry CE, 2003, DIABETES, V52, P1104, DOI 10.2337/diabetes.52.5.1104; Kopp HP, 2003, ARTERIOSCL THROM VAS, V23, P1042, DOI 10.1161/01.ATV.0000073313.16135.21; Laimer M, 2002, INT J OBESITY, V26, P659, DOI 10.1038/sj.ijo.0801970; Linder K, 2004, J LIPID RES, V45, P148, DOI 10.1194/jlr.M300256-JLR200; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Marculescu R, 2002, DIABETES, V51, P3582, DOI 10.2337/diabetes.51.12.3582; Marette A, 2002, CURR OPIN CLIN NUTR, V5, P377, DOI 10.1097/00075197-200207000-00005; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Mohamed-Ali V, 2001, J CLIN ENDOCR METAB, V86, P5864, DOI 10.1210/jc.86.12.5864; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Moraes RC, 2003, ENDOCRINOLOGY, V144, P4773, DOI 10.1210/en.2003-0456; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rome S, 2003, J BIOL CHEM, V278, P18063, DOI 10.1074/jbc.M300293200; Rose D.W., 1992, COMPILER, V10, P18; Saillan-Barreau C, 2003, BIOCHEM BIOPH RES CO, V309, P502, DOI 10.1016/j.bbrc.2003.08.034; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shin WS, 2002, ATHEROSCLEROSIS, V160, P91, DOI 10.1016/S0021-9150(01)00571-8; Smith SR, 2001, METABOLISM, V50, P425, DOI 10.1053/meta.2001.21693; Soukas A, 2000, GENE DEV, V14, P963; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Viguerie N, 2004, J CLIN ENDOCR METAB, V89, P2000, DOI 10.1210/jc.2003-031733; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	54	461	495	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1657	1669		10.1096/fj.04-2204com	http://dx.doi.org/10.1096/fj.04-2204com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522911				2022-12-28	WOS:000225482100034
J	Mura, C; Le Gac, G; Jacolot, S; Ferec, C				Mura, C; Le Gac, G; Jacolot, S; Ferec, C			Transcriptional regulation of the human HFE gene indicates high liver expression and erythropoiesis coregulation	FASEB JOURNAL			English	Article						HFE promoter; iron homeostasis; hemochromatosis	TRANSFERRIN RECEPTOR; IRON OVERLOAD; HEREDITARY HEMOCHROMATOSIS; MESSENGER-RNA; HLA-H; MUTATIONS; PROTEIN; PHENOTYPE; MOUSE; ABSORPTION	The human HFE gene is clearly involved in hereditary hemochromatosis, a common autosomal recessive genetic disorder of iron homeostasis. However, the precise role of the HFE protein is still undefined. Here, to obtain new insight, we analyzed the transcriptional regulation of HFE gene and defined the functional organization of the HFE promoter. Both in vitro transcription and reporter gene assay in transient transfection evidenced a high liver expression of the HFE mRNA. The 5' end analysis of mRNA showed two major initiation sites localized at - 265 and 195 directed by TATA-like sequences and a window of initiation within the - 120 to - 10 GC-rich region upstream of the first coding nucleotide. Positive cis-regulating elements were characterized within the - 1057/ -8 region, and a negative one extending upstream ( -1485/ -1057) was identified. DNase I footprinting analysis and gel shift assay revealed several protein binding sites, and subsequent functional analysis evidenced transactivation of HFE by liver-enriched C/EBPalpha, erythropoietic-specific GATA-1, and ubiquitous Sp1 transcription factors. These data bring some evidence of a role of HFE in the liver and a coregulation with erythropoiesis as other genes involved in iron homeostasis.	INSERM, U613, F-29200 Brest, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale	Mura, C (corresponding author), INSERM, U613, UBO 46 Rue Felix Le Dantec, F-29200 Brest, France.	Catherine.Mura@univ-brest.fr	Ferec, Claude/ABG-9699-2020; Le Gac, Gérald/AFQ-1679-2022	Ferec, Claude/0000-0002-2325-0710; LE GAC, Gerald/0000-0003-3236-7280				AIRD WC, 1994, J BIOL CHEM, V269, P883; Ajioka RS, 2002, BLOOD, V100, P1465, DOI 10.1182/blood-2001-11-0037; AUGERON C, 1984, CANCER RES, V44, P3961; Barton JC, 1999, BLOOD CELL MOL DIS, V25, P146; Beutler E, 1997, AM J HUM GENET, V61, P762; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Carella M, 1997, AM J HUM GENET, V60, P828; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; de Villiers JNP, 1999, HUM MOL GENET, V8, P1517, DOI 10.1093/hmg/8.8.1517; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Grover J, 2000, J BIOL CHEM, V275, P40967, DOI 10.1074/jbc.M004134200; Holmstrom P, 2003, J HEPATOL, V39, P308, DOI 10.1016/S0168-8278(03)00293-9; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kawabata H, 2001, BLOOD, V98, P1949, DOI 10.1182/blood.V98.6.1949; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LANS MS, 1994, J BIOL CHEM, V269, P14170; Le Gac G, 2003, BLOOD CELL MOL DIS, V30, P231, DOI 10.1016/S1079-9796(03)00036-6; Levy JE, 2000, J CLIN INVEST, V105, P1209, DOI 10.1172/JCI9635; Mattman A, 2002, BLOOD, V100, P1075, DOI 10.1182/blood-2002-01-0133; MCLAREN GD, 1991, J LAB CLIN MED, V117, P390; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505; Mura C, 1997, HUM GENET, V101, P271, DOI 10.1007/s004390050628; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Piperno A, 2000, GASTROENTEROLOGY, V119, P441, DOI 10.1053/gast.2000.9369; Pointon JJ, 2000, GENET TEST, V4, P151, DOI 10.1089/10906570050114867; Ponka P, 1997, BLOOD, V89, P1; POWELL LW, 1970, GUT, V11, P727, DOI 10.1136/gut.11.9.727; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Risch N, 1997, NAT GENET, V17, P375, DOI 10.1038/ng1297-375; Roetto A, 2001, BLOOD, V97, P2555, DOI 10.1182/blood.V97.9.2555; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434; Sanchez M, 1998, GENE, V225, P77, DOI 10.1016/S0378-1119(98)00519-8; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; TUGORES A, 1994, J BIOL CHEM, V269, P30789; Wallace DF, 2002, J HEPATOL, V36, P474, DOI 10.1016/S0168-8278(01)00304-X; Wallace DF, 1999, GASTROENTEROLOGY, V116, P1409, DOI 10.1016/S0016-5085(99)70505-6; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	52	20	23	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1922	+		10.1096/fj.04-2520fje	http://dx.doi.org/10.1096/fj.04-2520fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15467009				2022-12-28	WOS:000224849900028
J	Vissing, K; Andersen, JL; Schjerling, P				Vissing, K; Andersen, JL; Schjerling, P			Are exercise-induced genes induced by exercise?	FASEB JOURNAL			English	Article						dietary status; repeated biopsy effect; transcription factors; metabolic genes	HUMAN SKELETAL-MUSCLE; ALPHA-B-CRYSTALLIN; METABOLIC GENES; TRANSCRIPTIONAL ACTIVATION; CONTRACTILE ACTIVITY; RESISTANCE EXERCISE; GLUT-4 GENE; EXPRESSION; INTENSITY; RAT	Numerous human in vivo studies on skeletal muscle gene expression have investigated the effects of given interventions. These have been founded on the assumption that presampling can be regarded as a representative control for postintervention sampling. However, many genes are responsive to the metabolic status, which varies during the day, so that observed differences in gene expression between the pre- and post-sample may therefore be a result of the daily variations rather than an intervention. Furthermore, the sampling itself can cause a local stress response, which may also influence the expression of some genes in later samples from the same localized area. To test this, we performed a short-term human endurance exercise study in which muscle biopsies were obtained from healthy untrained individuals (n = 14) before and in the hours after exercise to measure the expression of mRNA for previously reported exercise-related genes (e.g., PPARgamma coactivator-1alpha (PGC-1alpha), pyruvate dehydrogenase kinase 4 (PDK4), MyoD, p21, (heat shock protein 72 (HSP72), lipoprotein lipase (LPL), citrate synthase (CS), and glucose transporter 4 (GLUT4)). To test for changes unrelated to exercise, one half of the subjects did not exercise. As suspected, several presumed exercise-induced genes were induced even without the exercise. Our data demonstrate that presampling is not always a representative control for postintervention sampling, illustrating that use of presampling can cause erroneous interpretations of the underlying induction signals.	Rigshosp, Copenhagen Muscle Res Ctr, Dept Mol Muscle Biol, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Schjerling, P (corresponding author), Rigshosp, Copenhagen Muscle Res Ctr, Dept Mol Muscle Biol, DK-2100 Copenhagen, Denmark.	viridis@biobase.dk	Andersen, Jesper L/W-6813-2019; Vissing, Kristian/GOP-0449-2022; Schjerling, Peter/F-6194-2011	Schjerling, Peter/0000-0001-7138-3211; Vissing, Kristian/0000-0001-5810-5241				Adams GR, 1999, J APPL PHYSIOL, V87, P1705, DOI 10.1152/jappl.1999.87.5.1705; ANDERSEN P, 1985, J APPL PHYSIOL, V59, P1647, DOI 10.1152/jappl.1985.59.5.1647; Bennett CD, 2001, EUR J COMBIN, V22, P27, DOI 10.1006/eujc.2000.0436; Bickel CS, 2003, J APPL PHYSIOL, V94, P2255, DOI 10.1152/japplphysiol.00014.2003; Brau L, 1997, BIOCHEM J, V322, P303; CAREY JO, 1994, BIOCHEM J, V298, P613, DOI 10.1042/bj2980613; Feasson L, 2002, J PHYSIOL-LONDON, V543, P297, DOI 10.1113/jphysiol.2002.018689; Febbraio MA, 2002, J PHYSIOL-LONDON, V538, P911, DOI 10.1113/jphysiol.2001.013145; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; Hargreaves M, 2002, MED SCI SPORT EXER, V34, P1505, DOI 10.1097/00005768-200209000-00017; Hildebrandt AL, 2003, AM J PHYSIOL-ENDOC M, V285, pE1021, DOI 10.1152/ajpendo.00234.2003; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; Jonsdottir IH, 2000, J PHYSIOL-LONDON, V528, P157, DOI 10.1111/j.1469-7793.2000.00157.x; Launay T, 2001, J HISTOCHEM CYTOCHEM, V49, P887, DOI 10.1177/002215540104900709; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; Neufer PD, 1996, J BIOL CHEM, V271, P24089, DOI 10.1074/jbc.271.39.24089; NEUFER PD, 1993, AM J PHYSIOL, V265, pC1597; Neufer PD, 1998, AM J PHYSIOL-CELL PH, V274, pC341, DOI 10.1152/ajpcell.1998.274.2.C341; Nordsborg N, 2003, J APPL PHYSIOL, V95, P1201, DOI 10.1152/japplphysiol.00257.2003; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Pilegaard H, 2002, J PHYSIOL-LONDON, V541, P261, DOI 10.1113/jphysiol.2002.016832; Psilander N, 2003, J APPL PHYSIOL, V95, P1038, DOI 10.1152/japplphysiol.00903.2002; RANTANEN J, 1995, LAB INVEST, V72, P341; SCHJERLING P, 2001, J APPL PHYSIOL, V88, P794; Siu PM, 2003, J APPL PHYSIOL, V94, P555, DOI 10.1152/japplphysiol.00821.2002; Tunstall RJ, 2002, BIOCHEM BIOPH RES CO, V294, P301, DOI 10.1016/S0006-291X(02)00473-4	28	84	85	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					94	+		10.1096/fj.04-2084fje	http://dx.doi.org/10.1096/fj.04-2084fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15516373				2022-12-28	WOS:000224849900001
J	Balschun, D; Wetzel, W; del Rey, A; Pitossi, F; Schneider, H; Zuschratter, W; Besedovsky, HO				Balschun, D; Wetzel, W; del Rey, A; Pitossi, F; Schneider, H; Zuschratter, W; Besedovsky, HO			Interleukin-6: a cytokine to forget	FASEB JOURNAL			English	Article						IL-6; LTP; spatial learning; hippocampus; rat	LONG-TERM POTENTIATION; FREELY MOVING RATS; DENTATE GYRUS; TRANSGENIC MICE; WORKING-MEMORY; CEREBRAL OVEREXPRESSION; HIPPOCAMPAL-LESIONS; PROTEIN-SYNTHESIS; LATE-PHASE; IN-VITRO	It is known that proinflammatory cytokines such as interleukin-6 (IL-6) are expressed in the central nervous system (CNS) during disease conditions and affect several brain functions including memory and learning. In contrast to these effects observed during pathological conditions, here we describe a physiological function of IL-6 in the "healthy" brain in synaptic plasticity and memory consolidation. During long-term potentiation (LTP) in vitro and in freely moving rats, IL-6 gene expression in the hippocampus was substantially increased. This increase was long lasting, specific to potentiation, and was prevented by inhibition of N-methyl-D-spartate receptors with (+/-)-2-amino-5-phosphonopentanoic acid (AP-5). Blockade of endogenous IL-6 by application of a neutralizing anti-IL6 antibody 90 min after tetanus caused a remarkable prolongation of LTP. Consistently, blockade of endogenous IL-6, 90 min after hippocampus-dependent spatial alternation learning resulted in a significant improvement of long-term memory. In view of the suggested role of LTP in memory formation, these data implicate IL-6 in the mechanisms controlling the kinetics and amount of information storage.	Univ Marburg, Inst Physiol, Div Immunophysiol, D-35037 Marburg, Germany; Leibniz Inst Neurobiol, D-39008 Magdeburg, Germany; Fdn Campomar, Inst Biomed Res, RA-1405 Buenos Aires, DF, Argentina	Philipps University Marburg; Leibniz Institut fur Neurobiologie (LIN); Leloir Institute	Besedovsky, HO (corresponding author), Univ Marburg, Inst Physiol, Div Immunophysiol, Deutschhausstr 2, D-35037 Marburg, Germany.	besedovs@mailer.uni-marburg.de		Pitossi, Fernando/0000-0001-5104-9726				Abraham WC, 1996, BRAIN RES, V722, P217, DOI 10.1016/0006-8993(96)00130-8; AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2; AGRANOFF BERNARD W., 1966, BRAIN RES, V1, P303, DOI 10.1016/0006-8993(66)90095-3; AUBERT A, 1995, BRAIN BEHAV IMMUN, V9, P129, DOI 10.1006/brbi.1995.1013; Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; Balschun D, 1999, LEARN MEMORY, V6, P138; Barrientos RM, 2002, BEHAV BRAIN RES, V134, P291, DOI 10.1016/S0166-4328(02)00043-8; BELLINGER FP, 1995, NEUROSCI LETT, V198, P95, DOI 10.1016/0304-3940(95)11976-4; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; BESEDOVSKY HO, 1991, J STEROID BIOCHEM, V40, P613, DOI 10.1016/0960-0760(91)90284-C; Cahill L, 2000, PROG BRAIN RES, V126, P29; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; Coogan AN, 1999, NEUROSCIENCE, V93, P57, DOI 10.1016/S0306-4522(99)00100-1; D'Arcangelo G, 2000, EUR J NEUROSCI, V12, P1241, DOI 10.1046/j.1460-9568.2000.00011.x; Dantzer R, 2001, BRAIN BEHAV IMMUN, V15, P7, DOI 10.1006/brbi.2000.0613; De Laurentiis A, 2000, NEUROIMMUNOMODULAT, V7, P77, DOI 10.1159/000026423; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GADIENT RA, 1994, BRAIN RES, V637, P10, DOI 10.1016/0006-8993(94)91211-4; Gibertini M, 1998, NEUROIMMUNOMODULAT, V5, P160, DOI 10.1159/000026332; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Jankowsky JL, 2000, LEARN MEMORY, V7, P400, DOI 10.1101/lm.32600; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; Kulla A, 1999, EUR J NEUROSCI, V11, P3864, DOI 10.1046/j.1460-9568.1999.00807.x; Li AJ, 1997, BRAIN RES, V748, P30, DOI 10.1016/S0006-8993(96)01283-8; MAIER SF, 1995, BRAIN RES, V695, P279, DOI 10.1016/0006-8993(95)00930-O; Matsumoto Y, 2001, EUR J PHARMACOL, V430, P283, DOI 10.1016/S0014-2999(01)01374-7; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MIZUMORI SJY, 1985, BEHAV NEUROSCI, V99, P220, DOI 10.1037/0735-7044.99.2.220; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; Pitossi F, 1997, J NEUROSCI RES, V48, P287, DOI 10.1002/(SICI)1097-4547(19970515)48:4<287::AID-JNR1>3.0.CO;2-7; Pugh CR, 1999, BEHAV BRAIN RES, V106, P109, DOI 10.1016/S0166-4328(99)00098-4; Reyes TM, 1998, AM J PHYSIOL-REG I, V274, pR139, DOI 10.1152/ajpregu.1998.274.1.R139; Scharf MT, 2002, J NEUROPHYSIOL, V87, P2770, DOI 10.1152/jn.2002.87.6.2770; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Seidenbecher T, 1997, P NATL ACAD SCI USA, V94, P1494, DOI 10.1073/pnas.94.4.1494; Song C, 2002, BRAIN BEHAV IMMUN, V16, P557, DOI 10.1016/S0889-1591(02)00012-0; STANTON PK, 1984, J NEUROSCI, V4, P3080; STEVENS R, 1973, BRAIN RES, V52, P203, DOI 10.1016/0006-8993(73)90659-8; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang XiaoLan, 1999, Journal of Herbs, Spices & Medicinal Plants, V6, P1, DOI 10.1300/J044v06n03_01; Yirmiya R, 2002, NEUROBIOL LEARN MEM, V78, P379, DOI 10.1006/nlme.2002.4072	46	215	226	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1788	+		10.1096/fj.04-1625fje	http://dx.doi.org/10.1096/fj.04-1625fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345694	Green Published, Green Accepted			2022-12-28	WOS:000224243200047
J	Stuermer, CAO; Langhorst, MF; Wiechers, MF; Legler, DF; von Hanwehr, SH; Guse, AH; Plattner, H				Stuermer, CAO; Langhorst, MF; Wiechers, MF; Legler, DF; von Hanwehr, SH; Guse, AH; Plattner, H			PrPc capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction	FASEB JOURNAL			English	Article						noncaveolar microdomains; reggie/flotillin; PrPc cross-linking	CELLULAR PRION PROTEIN; ANCHORED PROTEINS; MEMBRANE; IDENTIFICATION; MICRODOMAINS; ACTIVATION; EXPRESSION; DOMAINS; RECRUITMENT; COMPONENTS	The cellular prion protein (PrPc) resides in lipid rafts, yet the type of raft and the physiological function of PrPc are unclear. We show here that cross-linking of PrPc with specific antibodies leads to 1) PrPc capping in Jurkat and human peripheral blood T cells; 2) to cocapping with the intracellular lipid raft proteins reggie-1 and reggie-2; 3) to signal transduction as seen by MAP kinase phosphorylation and an elevation of the intracellular Ca2+ concentration; 4) to the recruitment of Thy-1, TCR/CD3, fyn, lck and LAT into the cap along with local tyrosine phosphorylation and F-actin polymerization, and later, internalization of PrPc together with the reggies into limp-2 positive lysosomes. Thus, PrPc association with reggie rafts triggers distinct transmembrane signal transduction events in T cells that promote the focal concentration of PrPc itself by guiding activated PrPc into preformed reggie caps and then to the recruitment of important interacting signaling molecules.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Univ Hosp Hamburg Eppendorf, Inst Biochem & Mol Biol Cellular Signal Transduct, Ctr Med Expt, Hamburg, Germany	University of Konstanz; University of Hamburg; University Medical Center Hamburg-Eppendorf	Stuermer, CAO (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Claudia.Stuermer@uni-konstanz.de		Legler, Daniel F./0000-0001-8610-4764				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Deininger SO, 2003, MOL CELL NEUROSCI, V22, P544, DOI 10.1016/S1044-7431(03)00028-9; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Durig J, 2000, BRIT J HAEMATOL, V108, P488, DOI 10.1046/j.1365-2141.2000.01881.x; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Foger N, 2001, J CELL SCI, V114, P1169; FRA AM, 1994, J BIOL CHEM, V269, P30745; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li RL, 2001, CELL IMMUNOL, V207, P49, DOI 10.1006/cimm.2000.1751; Mabbott NA, 1997, IMMUNOLOGY, V92, P161, DOI 10.1046/j.1365-2567.1997.00331.x; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; PETERS PJ, 2003, P NATL ACAD SCI USA, V162, P703; PRESKY DH, 1990, J IMMUNOL, V144, P860; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; SCHROEDER WT, 1994, J BIOL CHEM, V269, P19983; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schulte T, 1997, DEVELOPMENT, V124, P577; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Spielhaupter C, 2001, J BIOL CHEM, V276, P44604, DOI 10.1074/jbc.M103289200; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; VEGA MA, 1991, J BIOL CHEM, V266, P16818; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3	63	120	130	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1731	+		10.1096/fj.04-2150fje	http://dx.doi.org/10.1096/fj.04-2150fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345693				2022-12-28	WOS:000224243200046
J	Yang, GD; Sun, XF; Wang, R				Yang, GD; Sun, XF; Wang, R			Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3	FASEB JOURNAL			English	Article						blood vessel; ERK; gasotransmitter; p38; remodeling	N-TERMINAL KINASE; CARBON-MONOXIDE; NITRIC-OXIDE; CYTOCHROME-C; P38 KINASE; PATHWAY; ERK; SURVIVAL; STRESS; H2S	The endogenous production of hydrogen sulfide (H2S) and its physiological functions, including membrane hyperpolarization and smooth muscle cell relaxation, position this gas well in the family of gasotransmitters together with nitric oxide ( NO) and carbon monoxide (CO). In this study, we demonstrate that H2S at physiologically relevant concentrations induced apoptosis of human aorta smooth muscle cells (HASMCs). Exposure of HASMCs to H2S did not induce necrosis as verified with Trypan blue exclusion and LDH release analysis. After inhibiting endogenous H2S production, exogenous H2S induced much more significant apoptosis, which was not altered by the presence of albumin or glutathione. H2S treatment increased the activities of ERK and p38 mitogen-activated protein kinase (MAPK), but not c-Jun N-terminal kinase activity. Suppression of extracellular signal-regulated kinase (ERK) activity, but not of p38 activity, inhibited the H2S-induced apoptosis of HASMCs. The activation of ERK by H2S in HASMCs was accompanied by increased caspase-3 activity. Inhibition of caspase-3 by AC-DEVD-CHO attenuated the H2S-induced cell apoptosis. Inhibition of ERK by U0126 decreased caspase-3 activity, whereas AC-DEVD-CHO did not alter ERK activity. In conclusion, exogenous H2S induces apoptosis of HASMCs, which is significantly affected by the endogenous H2S level. Of the three investigated MAPKs, only ERK played an active role in mediating H2S-induced apoptosis of HASMCs by activating caspase-3. These findings may help reveal novel mechanisms for many diseases linked to H2S-related abnormal cellular proliferation and apoptosis.	Univ Saskatchewan, Coll Med, Dept Physiol, Cardiovasc Res Grp, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Wang, R (corresponding author), Univ Saskatchewan, Coll Med, Dept Physiol, Cardiovasc Res Grp, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	wangrui@duke.usask.ca	Yang, Guangdong/G-4129-2011; Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620				Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chen YR, 2000, INT J ONCOL, V16, P651; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Choi YJ, 2003, BIOCHEM BIOPH RES CO, V305, P176, DOI 10.1016/S0006-291X(03)00719-8; Cunningham KA, 2003, VIRUS RES, V92, P179, DOI 10.1016/S0168-1702(03)00044-3; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Deplancke B, 2003, FASEB J, V17, P1310, DOI 10.1096/fj.02-0883fje; Enomoto A, 2003, BIOCHEM BIOPH RES CO, V306, P837, DOI 10.1016/S0006-291X(03)01050-7; Frese S, 2003, ONCOGENE, V22, P5427, DOI 10.1038/sj.onc.1206842; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hershenson MB, 1997, CAN J PHYSIOL PHARM, V75, P898, DOI 10.1139/cjpp-75-7-898; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; Levonen AL, 2000, BIOCHEM J, V347, P291, DOI 10.1042/0264-6021:3470291; Najib S, 2002, CELL IMMUNOL, V220, P143, DOI 10.1016/S0008-8749(03)00027-3; Negre-Aminou P, 2002, BIOCHEM PHARMACOL, V64, P1483, DOI 10.1016/S0006-2952(02)01388-6; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Peyot ML, 2000, CIRC RES, V86, P76, DOI 10.1161/01.RES.86.1.76; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmid FX, 2003, EUR J CARDIO-THORAC, V23, P537, DOI 10.1016/S1010-7940(02)00833-3; Shiota M, 2003, ZOOL SCI, V20, P193, DOI 10.2108/zsj.20.193; Tamagno E, 2000, NEUROREPORT, V11, P1865, DOI 10.1097/00001756-200006260-00013; VALITUTTI S, 1990, ANN ALLERGY, V65, P463; Varghese J, 2003, APOPTOSIS, V8, P363, DOI 10.1023/A:1024121017841; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhang QY, 2004, BIOCHEM BIOPH RES CO, V317, P30, DOI 10.1016/j.bbrc.2004.02.176; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhao WM, 2003, CAN J PHYSIOL PHARM, V81, P848, DOI 10.1139/Y03-077; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	45	250	284	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1782	+		10.1096/fj.04-2279fje	http://dx.doi.org/10.1096/fj.04-2279fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15371330				2022-12-28	WOS:000224243200026
J	Ilani, T; Strous, RD; Fuchs, S				Ilani, T; Strous, RD; Fuchs, S			Dopaminergic regulation of immune cells via D-3 dopamine receptor: a pathway mediated by activated T cells	FASEB JOURNAL			English	Article						blood brain barrier; CNS; cytokines; neurotransmitter; schizophrenia	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CD4+AND CD8+T CELLS; IN-VITRO; SCHIZOPHRENIC-PATIENTS; LYMPHOCYTE FUNCTION; PARKINSONS-DISEASE; CYTOKINE PROFILES; BLOOD-LYMPHOCYTES; MESSENGER-RNA	Neuro-immune interactions enable mutual regulation of the nervous and immune systems. To date, evidence exists for manipulations of immune cells by neurotransmitters in the periphery. In this study, we suggest the existence of a pathway by which the brain affects immune cells. The pathway we describe here is mediated by dopamine receptors expressed on activated T cells, termed blasts. Blasts can cross the blood brain barrier regardless of antigen specificity and can therefore encounter neurotransmitters in the brain. We show that blasts have a unique response to dopaminergic activation, which has no counterpart in resting T cells. Dopaminergic activation of blasts induces a Th1 bias in their cytokine profile and causes changes in surface marker expression. We further suggest that these changes can subsequently be transferred to peripheral T cells. We have tested this pathway in two in vivo systems: in rats exogenously administered with L-dopa, and in schizophrenia, which is characterized by a central nervous system-restricted increase in dopamine. In both models, peripheral T cells exhibit similar features to those of dopaminergically activated blasts. The existence of such a pathway by which the brain can regulate immune cells opens a conceptually new direction in neuro-immune interactions.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Fac Med, Beer Yaakov Mental Hlth Ctr, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il		Ilani, Tal/0000-0003-2806-4455				Aloisi F, 2001, ANN MED, V33, P510, DOI 10.3109/07853890108995960; Amenta F, 2002, CELL MOL BIOL, V48, P415; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165-5728(99)00176-9; BERGQUIST J, 1994, P NATL ACAD SCI USA, V91, P12912, DOI 10.1073/pnas.91.26.12912; Carlsson A, 1999, BIOL PSYCHIAT, V46, P1388, DOI 10.1016/S0006-3223(99)00117-1; Cazzullo CL, 2002, PROG NEURO-PSYCHOPH, V26, P33, DOI 10.1016/S0278-5846(01)00221-4; Cazzullo CL, 2001, SCHIZOPHR RES, V47, P293, DOI 10.1016/S0920-9964(00)00046-3; COOKMILLS JM, 1995, IMMUNOLOGY, V85, P544; CUCHE JL, 1990, J LAB CLIN MED, V116, P681; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Ghosh MC, 2003, INT IMMUNOPHARMACOL, V3, P1019, DOI 10.1016/S1567-5769(03)00100-0; Goldstein DS, 2003, J PHARMACOL EXP THER, V305, P800, DOI 10.1124/jpet.103.049270; GUY W, 1976, US DHEW PUBLICATION, V76, P338; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Ilani T, 2002, CELL MOL NEUROBIOL, V22, P47, DOI 10.1023/A:1015341712166; Kivisakk P, 2002, CLIN EXP IMMUNOL, V129, P510, DOI 10.1046/j.1365-2249.2002.01947.x; KOPIN IJ, 1985, PHARMACOL REV, V37, P333; Krakowski ML, 1997, EUR J IMMUNOL, V27, P2840, DOI 10.1002/eji.1830271115; Krakowski ML, 2000, EUR J IMMUNOL, V30, P1002, DOI 10.1002/(SICI)1521-4141(200004)30:4<1002::AID-IMMU1002>3.0.CO;2-2; Lehmann PV, 1998, AM J PATHOL, V153, P677, DOI 10.1016/S0002-9440(10)65609-X; Levine D, 2001, Top Magn Reson Imaging, V12, P25, DOI 10.1097/00002142-200102000-00004; Levite M, 2001, EUR J IMMUNOL, V31, P3504, DOI 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F; Levite M, 2000, ANN NY ACAD SCI, V917, P307; Mizruchin A, 1999, J NEUROIMMUNOL, V101, P201, DOI 10.1016/S0165-5728(99)00144-7; MORIKAWA K, 1994, CLIN EXP IMMUNOL, V95, P514; Nagai Y, 1996, NEUROLOGY, V46, P791, DOI 10.1212/WNL.46.3.791; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Owens T, 1998, RES IMMUNOL, V149, P781, DOI 10.1016/S0923-2494(99)80005-4; Picconi B, 2002, BRAIN, V125, P2635, DOI 10.1093/brain/awf269; Ricci A, 1998, J NEUROIMMUNOL, V92, P191, DOI 10.1016/S0165-5728(98)00207-0; Ricci A, 1999, J NEUROIMMUNOL, V96, P234, DOI 10.1016/S0165-5728(99)00042-9; Saha B, 2001, INT IMMUNOPHARMACOL, V1, P1363, DOI 10.1016/S1567-5769(01)00068-6; Saha B, 2001, NEUROIMMUNOMODULAT, V9, P23, DOI 10.1159/000049004; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHMIED M, 1993, AM J PATHOL, V143, P446; Steinman L, 1996, P NATL ACAD SCI USA, V93, P2253, DOI 10.1073/pnas.93.6.2253; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Theodoropoulou S, 2001, SCHIZOPHR RES, V47, P13, DOI 10.1016/S0920-9964(00)00007-4; Vajkoczy P, 2001, J CLIN INVEST, V108, P557; Wandinger KP, 1999, J NEUROIMMUNOL, V98, P214, DOI 10.1016/S0165-5728(99)00093-4; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; Zangen A, 2001, PSYCHOPHARMACOLOGY, V155, P434, DOI 10.1007/s002130100746	46	76	85	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11								10.1096/fj.04-1652fje	http://dx.doi.org/10.1096/fj.04-1652fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319371				2022-12-28	WOS:000223554900006
J	Townsend, PA; Scarabelli, TM; Pasini, E; Gitti, G; Menegazzi, M; Suzuki, H; Knight, RA; Latchman, DS; Stephanou, A				Townsend, PA; Scarabelli, TM; Pasini, E; Gitti, G; Menegazzi, M; Suzuki, H; Knight, RA; Latchman, DS; Stephanou, A			Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis	FASEB JOURNAL			English	Article						myocardial infarction; cardioprotection; transcription factor; heart	ENDOTHELIAL-CELLS; ISCHEMIA; TRANSCRIPTION; KINASE; EXPRESSION; INDUCTION	We have previously demonstrated that STAT-1 plays a critical role in promoting apoptotic cell death in cardiac myocytes following ischemia/reperfusion (I/R) injury. Epigallocatechin-3-gallate ( EGCG), the major constituent of green tea, has recently been reported to inhibit STAT-1 activity in noncardiac cells. In the present study, we have assessed the protective effects of EGCG and green tea extract (GTE) infusion on both cultures of cardiac myocytes and the isolated rat heart. EGCG reduced STAT-1 phosphorylation and protected cardiac myocytes against I/R-induced apoptotic cell death. Moreover, EGCG reduced the expression of a known STAT-1 pro-apoptotic target gene, Fas receptor. More interestingly, oral administration of GTE as well as EGCG infusion limited the extent of infarct size and attenuated the magnitude of myocyte apoptosis in the isolated rat heart exposed to I/R injury. This reduction cell death was associated with improved hemodynamic recovery and ventricular function in the ischemic/reperfused rat heart. This is the first report to show that consumption of green tea is able to mediate cardioprotection and enhance cardiac function during I/R injury. Because GTE-mediated cardioprotection is achieved, at least in part, through inhibition of STAT-1 activity, we may postulate that a similar action can be implemented in the clinical setting to minimize STAT-1 activation levels in patients with acute coronary artery disease (CAD).	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; St John Hosp & Med Ctr, Div Cardiol, Detroit, MI USA; Univ Verona, Dept Neurosci, Biochem Sect, I-37134 Verona, Italy	University of London; University College London; St. John Hospital & Medical Center; University of Verona	Townsend, PA (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	a.stephanou@ich.ucl.ac.uk	Pasini, Evasio/AAC-1798-2020; Menegazzi, Marta/AAE-7079-2019; Townsend, Paul/AAF-8234-2020	Pasini, Evasio/0000-0003-2836-4490; Menegazzi, Marta/0000-0003-1310-9227; Townsend, Paul/0000-0001-8956-9508				Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Jeremias I, 2000, CIRCULATION, V102, P915; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LEE S, 2002, NEUROSCI LETT, V287, P191; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Menegazzi M, 2001, FASEB J, V15, P1309, DOI 10.1096/fj.00-0519fje; Nagai K, 2002, BRAIN RES, V956, P319, DOI 10.1016/S0006-8993(02)03564-3; Roth E, 1998, Curr Opin Clin Nutr Metab Care, V1, P97; Saurin AT, 2000, FASEB J, V14, P2237, DOI 10.1096/fj.99-0671com; Scarabelli T, 2001, CIRCULATION, V104, P253, DOI 10.1161/01.CIR.104.3.253; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stephanou A, 2002, EUR CYTOKINE NETW, V13, P401; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2001, CELL DEATH DIFFER, V8, P434, DOI 10.1038/sj.cdd.4400846; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Takagi Y, 2002, J CEREBR BLOOD F MET, V22, P1311, DOI 10.1097/01.WCB.0000034148.72481.F4; Uchida S., 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS302, DOI 10.1111/j.1440-1681.1995.tb02928.x	22	147	160	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1612	+		10.1096/fj.04-1716fje	http://dx.doi.org/10.1096/fj.04-1716fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319365				2022-12-28	WOS:000223554900010
J	Botta, R; Gao, E; Stassi, G; Bonci, D; Pelosi, E; Zwas, D; Patti, M; Colonna, L; Baiocchi, M; Coppola, S; Ma, X; Condorelli, G; Peschle, C				Botta, R; Gao, E; Stassi, G; Bonci, D; Pelosi, E; Zwas, D; Patti, M; Colonna, L; Baiocchi, M; Coppola, S; Ma, X; Condorelli, G; Peschle, C			Heart infarct in NOD-SCID mice: Therapeutic vasculogenesis by transplantation of human CD34(+) cells and low dose CD34(+)KDR(+) cells	FASEB JOURNAL			English	Article						neoangiogenesis; endothelial precursors; hematopoietic stem cells	ENDOTHELIAL PROGENITOR CELLS; MYOCARDIAL-ISCHEMIA; CARDIAC-MUSCLE; STEM-CELLS; NEOVASCULARIZATION; CARDIOMYOCYTES; VIVO; ANGIOGENESIS; REGENERATION; ANGIOBLASTS	Hematopoietic ( Hem) and endothelial ( End) lineages derive from a common progenitor cell, the hemangioblast: specifically, the human cord blood (CB) CD34(+)KDR(+) cell fraction comprises primitive Hem and End cells, as well as hemangioblasts. In humans, the potential therapeutic role of Hem and End progenitors in ischemic heart disease is subject to intense investigation. Particularly, the contribution of these cells to angiogenesis and cardiomyogenesis in myocardial ischemia is not well established. In our studies, we induced myocardial infarct (MI) in the immunocompromised NOD-SCID mouse model, and monitored the effects of myocardial transplantation of human CB CD34(+) cells on cardiac function. Specifically, we compared the therapeutic effect of unseparated CD34(+) cells vs. PBS and mononuclear cells (MNCs); moreover, we compared the action of the CD34(+) KDR+ cell subfraction vs. the CD34(+) KDR- subset. CD34(+) cells significantly improve cardiac function after MI, as compared with PBS/MNCs. Similar beneficial actions were obtained using a 2-log lower number of CD34(+)KDR(+) cells, while the same number of CD34(+)KDR(-) cells did not have any effects. The beneficial effect of CD34(+)KDR(+) cells may mostly be ascribed to their notable resistance to apoptosis and to their angiogenic action, since cardiomyogenesis was limited. Altogether, our results indicate that, within the CD34(+) cell population, the CD34(+)KDR(+) fraction is responsible for the improvement in cardiac hemodynamics and hence represents the candidate active CD34(+) cell subset.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; Thomas Jefferson Univ, Dept Med, Ctr Translat Med, Philadelphia, PA 19107 USA; Univ Palermo, Dept Surg & Oncol Sci, I-90133 Palermo, Italy; Thomas Jefferson Univ, Dept Med, Div Cardiol, Philadelphia, PA 19107 USA; Mol Cardiol Lab, I-00128 Rome, Italy; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA	Jefferson University; Istituto Superiore di Sanita (ISS); Jefferson University; University of Palermo; Jefferson University; University of California System; University of California San Diego	Peschle, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Bluemle Life Sci Bldg,Room 609-233,S 10th St, Philadelphia, PA 19107 USA.	cesare.peschle@mail.jci.tju.edu	Bonci, Desiree/K-6488-2016; Condorelli, Gerolama/AAC-3472-2022; pelosi, elvira/J-7298-2016; Stassi, Giorgio/AAC-1175-2022; Coppola, Simona/A-6638-2015; Condorelli, Gianluigi/Q-6736-2017	Bonci, Desiree/0000-0002-2472-5140; Condorelli, Gerolama/0000-0003-0177-8829; pelosi, elvira/0000-0002-3043-6249; Coppola, Simona/0000-0001-7851-9409; Baiocchi, Marta/0000-0003-0976-0690; Condorelli, Gianluigi/0000-0003-0481-6843	NHLBI NIH HHS [1R01HL6368] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P9977, DOI 10.1073/pnas.161120198; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; ONDORELLI GL, 1999, CIRCULATION, V23, P3071; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pelosi E, 2002, BLOOD, V100, P3203, DOI 10.1182/blood-2002-05-1511; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tsuda T, 2003, CARDIOVASC RES, V59, P926, DOI 10.1016/S0008-6363(03)00519-4; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	26	83	89	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1392	+		10.1096/fj.03-0879fje	http://dx.doi.org/10.1096/fj.03-0879fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231728				2022-12-28	WOS:000222979200030
J	Rogers, MS; Rohan, RM; Birsner, AE; D'Amato, RJ				Rogers, MS; Rohan, RM; Birsner, AE; D'Amato, RJ			Genetic loci that control the angiogenic response to basic fibroblast growth factor	FASEB JOURNAL			English	Article						quantitative trait locus; QTL; corneal neovascularization; recombinant inbred; BXD	QUANTITATIVE TRAIT LOCI; CUTANEOUS MALIGNANT-MELANOMA; INDUCED MAMMARY-TUMOR; NF-KAPPA-B; ENDOTHELIAL-CELLS; ANTITUMOR-ACTIVITY; MICE; POLYMORPHISMS; MOUSE; VEGF	Angiogenesis is controlled by a balance between stimulatory growth factors and endogenous inhibitors. We propose that the balance of stimulators and inhibitors, as well as the general sensitivity of the endothelium to these factors, varies from individual to individual. Indeed, we have found that individual mouse strains have dramatically different responses to growth factor-induced neovascularization. Quantitative trait loci (QTLs), which influence the extent of angiogenesis induced by vascular endothelial growth factor ( VEGF), were previously identified by our laboratory. Since genetic susceptibility may vary according to the angiogenic stimulator, we have undertaken a similar mapping approach to identify QTLs that influence basic fibroblast growth factor (FGF2) induced neovascularization in the BXD series of recombinant inbred mouse strains. Composite and multiple interval mapping identified areas of chromosomes 4, 13, 15, and 18. These new angiogenesis QTLs, named AngFq1 through AngFq4 ( for angiogenesis due to FGF2), are different from previously identified VEGF QTLs. The mapped regions contain several genes involved in the angiogenic process including matrix metalloproteinase 16, eph receptor A7, angiopoetin 1, endothelial lipase, and autotaxin. Differences in these regions may influence individual susceptibility to angiogenesis related diseases such as cancer, macular degeneration, atherosclerosis, and arthritis.	Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	D'Amato, RJ (corresponding author), Childrens Hosp, Dept Surg, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA.	robert.damato@childrens.harvard.edu	Rogers, Michael S/A-9814-2009; Rogers, Michael/AAE-2217-2019	Rogers, Michael S/0000-0002-5250-8434; Rogers, Michael/0000-0002-5250-8434	NEI NIH HHS [R01-EY12726] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012726] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Balasubramanian SP, 2002, BRIT J CANCER, V87, P1057, DOI 10.1038/sj.bjc.6600625; Beamer WG, 1998, CANCER RES, V58, P3694; Blake JA, 2002, NUCLEIC ACIDS RES, V30, P113, DOI 10.1093/nar/30.1.113; Blankenhorn EP, 2003, MAMM GENOME, V14, P250, DOI 10.1007/s00335-002-2222-3; Bovenkamp DE, 2001, DNA CELL BIOL, V20, P203, DOI 10.1089/104454901750219080; Brockmann GA, 2000, GENOME RES, V10, P1941, DOI 10.1101/gr.GR1499R; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Cheverud JM, 2001, MAMM GENOME, V12, P3, DOI 10.1007/s003350010218; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Erb MH, 2002, CURR EYE RES, V24, P245, DOI 10.1076/ceyr.24.4.245.8412; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; Goodwin A. M., 2002, Angiogenesis, V5, P1, DOI 10.1023/A:1021563510866; Gupta AR, 2001, J GENE MED, V3, P252, DOI 10.1002/1521-2254(200105/06)3:3<252::AID-JGM185>3.0.CO;2-S; Hatano T, 2003, NEUROSURGERY, V53, P393, DOI 10.1227/01.NEU.0000073595.92557.36; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Horvat S, 2000, MAMM GENOME, V11, P2, DOI 10.1007/s003350010002; Howell WM, 2002, GENES IMMUN, V3, P229, DOI 10.1038/sj.gene.6363851; Howell WM, 2001, GENES IMMUN, V2, P25, DOI 10.1038/sj.gene.6363726; Iughetti P, 2001, CANCER RES, V61, P7375; Jansen RC, 1996, TRENDS PLANT SCI, V1, P89, DOI 10.1016/S1360-1385(96)80040-9; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Kao CH, 1999, GENETICS, V152, P1203; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kreuter M, 2002, ANN HEMATOL, V81, pS74; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; LANDER ES, 1989, GENETICS, V121, P185; Lane NE, 2003, OSTEOPOROSIS INT, V14, P374, DOI 10.1007/s00198-003-1374-7; Le Voyer T, 2000, MAMM GENOME, V11, P883, DOI 10.1007/s003350010163; Le Voyer T, 2001, GENOMICS, V74, P253, DOI 10.1006/geno.2001.6562; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Masinde GL, 2001, GENOME RES, V11, P2027, DOI 10.1101/gr.203701; Masinde Godfred L, 2002, Funct Integr Genomics, V2, P98, DOI 10.1007/s10142-002-0053-7; McCarron SL, 2002, CANCER RES, V62, P3369; McLaren J, 2000, HUM REPROD UPDATE, V6, P45, DOI 10.1093/humupd/6.1.45; Miura S, 2003, ARTERIOSCL THROM VAS, V23, P802, DOI 10.1161/01.ATV.0000066134.79956.58; Morohashi K, 2003, CHEST, V123, P1520, DOI 10.1378/chest.123.5.1520; Morris KH, 1999, MAMM GENOME, V10, P225, DOI 10.1007/s003359900977; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Nam SW, 2001, CANCER RES, V61, P6938; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; POTTER M, 1994, CANCER RES, V54, P969; Rogers MS, 2003, FASEB J, V17, P2112, DOI 10.1096/fj.03-0246fje; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Scatena MT, 2002, TRENDS CARDIOVAS MED, V12, P83, DOI 10.1016/S1050-1738(01)00151-7; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shofuda K, 1998, LAB INVEST, V78, P915; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Smith SK, 2001, BRIT J OBSTET GYNAEC, V108, P777, DOI 10.1111/j.1471-0528.2001.00211.x; Suto J, 1998, MAMM GENOME, V9, P506, DOI 10.1007/s003359900809; Symons RCA, 2002, P NATL ACAD SCI USA, V99, P11299, DOI 10.1073/pnas.162566999; Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; Vaughn TT, 1999, GENET RES, V74, P313, DOI 10.1017/S0016672399004103; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692; Wolf JB, 2002, HEREDITY, V89, P300, DOI 10.1038/sj.hdy.6800140; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; ZENG ZB, 1994, GENETICS, V136, P1457; ZENG ZB, 1993, P NATL ACAD SCI USA, V90, P10972, DOI 10.1073/pnas.90.23.10972; ZENG ZB, 1994, P 5 WORLD C GEN APPL, V22, P65; Zorick TS, 2001, EUR J HUM GENET, V9, P811, DOI 10.1038/sj.ejhg.5200721	67	38	39	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1050	1059		10.1096/fj.03-1241com	http://dx.doi.org/10.1096/fj.03-1241com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15226265				2022-12-28	WOS:000222979200032
J	Tou, JS; Smith, BC; Bojanowski, CM; Meleth, AD; Gery, I; Csaky, KG; Chew, EY; Chan, CC				Tou, JS; Smith, BC; Bojanowski, CM; Meleth, AD; Gery, I; Csaky, KG; Chew, EY; Chan, CC			The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration	FASEB JOURNAL			English	Article						chemoattractant; single nucleotide polymorphism; archived paraffin-embedded slide; gene expression; risk factor	APOLIPOPROTEIN-E; RECEPTOR CX3CR1; GENETIC RISK; FRACTALKINE; CX(3)CR1; DRUSEN; INFLAMMATION; POLYMORPHISM; ASSOCIATION; MACULOPATHY	This study examined the association between the sequence variation/expression of CX3CR1, a chemokine receptor, and age-related macular degeneration (AMD). Peripheral blood from 85 AMD patients and 105 subjects without AMD (controls), as well as ocular tissue from 40 pathological sections with AMD and two normal eye sections, were screened for V249I and T280M, two single nucleotide polymorphisms (SNPs) in CX3CR1. An increased prevalence, with the highest odds ratio of 3.57, of the I249 and M280 carriers was found among the AMD cases as compared with the controls. When comparing CX3CR1 expression in the archived eye sections, CX3CR1 transcripts were not detectable in the maculae of AMD eyes bearing T/M280; however, transcripts were detected in the maculae of normal eyes bearing T/T280 or T/M280 as well as in the AMD maculae bearing T/T280. Furthermore, lower CX3CR1 protein expression was observed in the maculae of AMD eyes bearing T/M280 compared with the controls bearing T/T280. The I249 and M280 alleles result in a lowered number of receptor binding sites and a decreased ligand affinity. Our data suggest that a decrease, caused by sequence variation and/or lower CX3CR1 expression, in CX3CR1-induced cellular activities could contribute to AMD development.	NEI, Immunol Lab, Bethesda, MD 20892 USA; NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA; NEI, HHMI, Bethesda, MD 20892 USA; NEI, Sect Gene Therapy, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Chan, CC (corresponding author), NEI, Immunol Lab, Bldg 10,10 Ctr Dr,Rm 10N103, Bethesda, MD 20892 USA.	chanc@nei.nih.gov			Intramural NIH HHS [Z01 EY000222-22, Z01 EY000418-04, Z99 EY999999] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000222, Z01EY000069, Z01EY000418] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4; Anand R, 2000, OPHTHALMOLOGY, V107, P2224; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5; Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613; DeVries ME, 2003, J BIOL CHEM, V278, P11985, DOI 10.1074/jbc.M211422200; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483; Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1; Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8; Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646; la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003; Lutty G, 1999, MOL VIS, V5; Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701; McDermott D H, 2000, Science, V290, P2031; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500; Schmidt S, 2000, MOL VIS, V6, P287; Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191; Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558; Sunnemark D, 2003, BRAIN PATHOL, V13, P617; Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001	40	157	165	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1297	+		10.1096/fj.04-1862fje	http://dx.doi.org/10.1096/fj.04-1862fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208270	Green Accepted			2022-12-28	WOS:000222327500016
J	Ma, DWL; Seo, JM; Davidson, LA; Callaway, ES; Fan, YY; Lupton, JR; Chapkin, RS				Ma, DWL; Seo, JM; Davidson, LA; Callaway, ES; Fan, YY; Lupton, JR; Chapkin, RS			n-3 PUFA Alter caveolae lipid composition and resident protein localization in mouse colon	FASEB JOURNAL			English	Article						caveolin-1; cholesterol; endothelial constitutive nitric oxide synthase; fatty acids; Ras Proteins	POLYUNSATURATED FATTY-ACIDS; ELECTRON MICROSCOPY; H-RAS; EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; SIGNAL-TRANSDUCTION; MEMBRANE RAFTS; FISH-OIL; CHOLESTEROL; CELLS	Caveolae, by virtue of their unique lipid environment, serve as signaling platforms that regulate cellular events. Perturbations in caveolae lipid composition have been shown in vitro to displace proteins from lipid microdomains, thereby altering their functionality and subsequent downstream signaling. Because membrane remodeling may not be accurately represented by using pharmacological treatments and in vitro models, we investigated the in vivo ability of dietary n-3 polyunsaturated fatty acids (PUFA) to alter caveolae lipid environment and the compartmentalization of resident proteins in mouse colonic mucosa. n-3 PUFA were examined for their chemoprotective, membrane lipid-modifying properties. Colonic caveolae in mice fed n-6 or n-3 PUFA enriched diets were characteristically enriched in cholesterol, sphingomyelin, and caveolin-1. n-3 PUFA feeding, compared with n-6 PUFA, significantly altered colonic caveolae microenvironment by increasing phospholipid n-3 fatty acyl content and reducing both cholesterol (by 46%) and caveolin-1 (by 53%), without altering total cellular levels. Concomitantly, localization of caveolae-resident signaling proteins H-Ras and eNOS in colonic caveolae was decreased by n-3 PUFA, by 45 and 56%, respectively. The distribution of noncaveolae proteins K-Ras and clathrin was unaffected. Moreover, EGF-stimulated H-Ras, but not K-Ras activation was significantly suppressed following n-3 PUFA feeding, in parallel with the selective alterations in their microlocalization. These findings reveal a novel modality by which n-3 PUFA remodel membrane microdomains in vivo and thereby alter caveolae protein localization and functionality.	Texas A&M Univ, Fac Nutr, Mol & Cell Biol sect, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Chapkin, RS (corresponding author), Texas A&M Univ, Fac Nutr, Mol & Cell Biol sect, 442 Kleberg Ctr,TAMU 2471, College Stn, TX 77843 USA.	r-chapkin@tamu.edu		Chapkin, Robert/0000-0002-6515-3898; Ma, David/0000-0002-1165-5972	NATIONAL CANCER INSTITUTE [R01CA082907, R01CA059034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA059034, CA-59034, CA-82907] Funding Source: Medline; NIEHS NIH HHS [P30-ES-09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brzustowicz MR, 2002, BIOCHEMISTRY-US, V41, P12509, DOI 10.1021/bi0262808; CHAPKIN RS, 1990, LIPIDS, V25, P827, DOI 10.1007/BF02535905; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Davidson LA, 1999, CARCINOGENESIS, V20, P785, DOI 10.1093/carcin/20.5.785; Field FJ, 1998, J LIPID RES, V39, P1938; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRITSCHE KL, 1988, J NUTR, V118, P425, DOI 10.1093/jn/118.4.425; Hailstones D, 1998, J LIPID RES, V39, P369; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hashimoto M, 1999, LIPIDS, V34, P1297, DOI 10.1007/s11745-999-0481-6; Hong MY, 2002, CARCINOGENESIS, V23, P1919, DOI 10.1093/carcin/23.11.1919; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; KALT MR, 1971, J ULTRA MOL STRUCT R, V36, P633, DOI 10.1016/S0022-5320(71)90020-7; Kim K, 1997, INT J CANCER, V71, P767, DOI 10.1002/(SICI)1097-0215(19970529)71:5<767::AID-IJC13>3.0.CO;2-5; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Mitchell DC, 1998, BIOPHYS J, V75, P896, DOI 10.1016/S0006-3495(98)77578-2; MOLLENHAUER HH, 1964, STAIN TECHNOL, V39, P111; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Schroeder F, 2001, EXP BIOL MED, V226, P873, DOI 10.1177/153537020122601002; Shaikh SR, 2002, BIOCHEMISTRY-US, V41, P10593, DOI 10.1021/bi025712b; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Thai TP, 2001, HUM MOL GENET, V10, P127, DOI 10.1093/hmg/10.2.127; White MA, 2001, NAT CELL BIOL, V3, pE172, DOI 10.1038/35087098; Zhu Y, 2000, ARTERIOSCL THROM VAS, V20, P2465, DOI 10.1161/01.ATV.20.11.2465	48	153	159	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1040	+		10.1096/fj.03-1430fje	http://dx.doi.org/10.1096/fj.03-1430fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084525				2022-12-28	WOS:000221108800014
J	Castino, R; Davies, J; Beaucourt, S; Isidoro, C; Murphy, D				Castino, R; Davies, J; Beaucourt, S; Isidoro, C; Murphy, D			Autophagy is a prosurvival mechanism in cells expressing an autosomal dominant familial neurohypophyseal diabetes insipidus mutant vasopressin transgene	FASEB JOURNAL			English	Article						apoptosis; transgenic; adFNDI; antidiuretic hormone; VP	HYPOTHALAMIC NEURONS; INHIBITION; HEREDITARY; INDUCTION; APOPTOSIS; MACROAUTOPHAGY; POLYGLUTAMINE; EXPANSIONS; DIVERSITY; BECLIN	Autosomal dominant familial neurohypophyseal diabetes insipidus (adFNDI) is a progressive, inherited neurodegenerative disorder that presents as polydipsia and polyuria as a consequence of a loss of secretion of the antidiuretic hormone vasopressin (VP) from posterior pituitary nerve terminals. VP gene mutations cause adFNDI. Rats expressing an adFNDI VP transgene (Cys67stop) show a neuronal pathology characterized by autophagic structures in the cell body. adFNDI has thus been added to the list of protein aggregation diseases, along with Alzheimer's, Parkinson's and Huntington's, which are associated with autophagy, a bulk process that delivers regions of cytosol to lysosomes for degradation. However, the role of autophagy in these diseases is unclear. To address the relationships between mutant protein accumulation, autophagy, cell survival, and cell death, we have developed a novel and tractable in vitro system. We have constructed adenoviral vectors (Ads) that express structural genes encoding either the Cys67stop mutant protein (Ad-VCAT-Cys67 stop) or an epitope-tagged wild-type VP precursor (Ad-VCAT). After infection of mouse neuroblastoma Neuro2a cells, Ad-VCAT encoded material enters neurite processes and accumulates in terminals, while the Cys67stop protein is confined to enlarged vesicles in the cell body. Similar to the intracellular derangements seen in the Cys67stop rats, these structures are of ER origin, and colocalize with markers of autophagy. Neither Ad-VCAT-Cys67 stop nor Ad-VCAT expression affected cell viability. However, inhibition of autophagy or lysosomal protein degradation, while having no effect on Ad-VCAT-expressing cells, significantly increased apoptotic cell death following Ad-VCAT-Cys67 stop expression. These data suggest that activation of autophagy by the stress of the expression of an adFNDI mutant protein is a prosurvival mechanism.	Univ Bristol, Mol Neuroendocrinol Res GRp, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol BS1 3NY, Avon, England; Amedeo Avogadro Univ, Dept Med Sci, Lab Mol Pathol, I-28100 Novara, Italy	University of Bristol; University of Eastern Piedmont Amedeo Avogadro	Murphy, D (corresponding author), Univ Bristol, Mol Neuroendocrinol Res GRp, Henry Wellcome Labs Integrat Neurosci & Endocrino, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	d.murphy@bristol.ac.uk	Isidoro, Ciro/J-6063-2016; Murphy, David/C-3967-2012	Isidoro, Ciro/0000-0002-5494-3034; Murphy, David/0000-0003-2946-0353; Beaucourt, Stephanie/0000-0001-9394-6425				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Castino R, 2002, INT J CANCER, V97, P775, DOI 10.1002/ijc.10139; Chen Quan, 2001, ScientificWorldJournal, V1, P142, DOI 10.1100/tsw.2001.233; Christensen JH, 2003, APMIS, V111, P92; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Davies J, 2002, J NEUROENDOCRINOL, V14, P629, DOI 10.1046/j.1365-2826.2002.00822.x; de Bree FM, 2000, FEBS LETT, V475, P175, DOI 10.1016/S0014-5793(00)01623-9; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klein JP, 2004, NEUROBIOL DIS, V15, P221, DOI 10.1016/j.nbd.2003.10.009; KNIGHT CG, 1976, BIOCHEM J, V155, P117, DOI 10.1042/bj1550117; Kurokawa H, 1998, RADIOLOGY, V207, P79, DOI 10.1148/radiology.207.1.9530302; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Mahoney CP, 2002, J CLIN ENDOCR METAB, V87, P870, DOI 10.1210/jc.87.2.870; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; NAGAI I, 1984, ACTA ENDOCRINOL-COP, V105, P318, DOI 10.1530/acta.0.1050318; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Petiot A, 2002, CELL STRUCT FUNCT, V27, P431, DOI 10.1247/csf.27.431; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; REEVES WB, 1992, WILLIAMS TXB ENDOCRI, P311; Russell TA, 2003, J CLIN INVEST, V112, P1697, DOI 10.1172/JCI200318616; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Si-Hoe SL, 2000, FASEB J, V14, P1680; Waller S, 1996, ENDOCRINOLOGY, V137, P5068, DOI 10.1210/en.137.11.5068; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	43	37	37	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1021	+		10.1096/fj.04-3162fje	http://dx.doi.org/10.1096/fj.04-3162fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15781609				2022-12-28	WOS:000227901300011
J	Iida, M; Heike, T; Yoshimoto, M; Baba, S; Doi, H; Nakahata, T				Iida, M; Heike, T; Yoshimoto, M; Baba, S; Doi, H; Nakahata, T			Identification of cardiac stem cells with FLK1, CD31, and VE-cadherin expression during embryonic stem cell differentiation	FASEB JOURNAL			English	Article						embryoid bodies; ES cells; cardiomyocyte differentiation; blastocysts	COMMON PRECURSOR; C-KIT; RECEPTOR; MOUSE; MODEL	We evaluated the expression of the FLK1, one of the lateral mesoderim early markers where cardiogenesis occurs, to characterize and isolate cardiac stem/progenitor cells from ES cells. Dissociated cells from embryoid bodies (EBs) on day 3, 4, or 5 were collected into two subpopulations with or without FLK1 expression and coculture on OP9 stromal cells was continued to examine whether contracting colonies came out or not. FLK1(+) cells from EBs at days 3 and 4 formed spontaneous contracting colonies more efficiently than FLK1(-) cells on the same days, but not at day 5. Most contracting cardiac colonies derived from FLK1 cells mainly on day 4 were detected on endothelial cells along with hematopoietic cells. Further characterization of cells with these capabilities into three lineages revealed the FLK1(+) CD31-VE-cadherin phenotype. Our findings indicate that FLK1(+) cells, especially FLK1(+) CD31(-)VE-cadherin(-) cells, could act as cardiohemangioblasts to form cardiac cells as well as endothelial cells and hematopoietic cells.	Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Heike, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto 6068507, Japan.	heike@kuhp.kyoto-u.ac.jp	Yoshimoto, Momoko/N-4238-2014; Yoshimoto, Momoko/AFP-3523-2022	Yoshimoto, Momoko/0000-0002-7272-6682; Yoshimoto, Momoko/0000-0002-7272-6682				BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Choi K, 1998, DEVELOPMENT, V125, P725; Choi K, 2002, J HEMATOTH STEM CELL, V11, P91, DOI 10.1089/152581602753448568; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; Etzion S, 2002, CIRCULATION, V106, pI125, DOI 10.1161/01.cir.0000032888.55215.b8; Etzion S, 2001, J MOL CELL CARDIOL, V33, P1321, DOI 10.1006/jmcc.2000.1391; Faloon P, 2000, DEVELOPMENT, V127, P1931; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Jamali M, 2001, J BIOL CHEM, V276, P42252, DOI 10.1074/jbc.M107814200; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; KODAMA H, 1994, EXP HEMATOL, V22, P979; LINTS TJ, 1993, DEVELOPMENT, V119, P969; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P251, DOI 10.1006/jmcc.2001.1494; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Sucov HM, 1998, ANNU REV PHYSIOL, V60, P287, DOI 10.1146/annurev.physiol.60.1.287; WILSON V, 1993, DEVELOPMENT, V117, P1321; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568	29	39	43	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					371	378		10.1096/fj.04-1998com	http://dx.doi.org/10.1096/fj.04-1998com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746180	Green Submitted			2022-12-28	WOS:000227901300037
J	Lee, KS; Park, SJ; Hwang, PH; Yi, HK; Song, CH; Chai, OH; Kim, JS; Lee, MK; Lee, YC				Lee, KS; Park, SJ; Hwang, PH; Yi, HK; Song, CH; Chai, OH; Kim, JS; Lee, MK; Lee, YC			PPAR-gamma modulates allergic inflammation through upregulation of PTEN	FASEB JOURNAL			English	Article						asthma; eosinophils; phosphatidylinositol 3-kinase; signal transduction	ACTIVATED-RECEPTOR-GAMMA; NF-KAPPA-B; AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTOR; HUMAN EOSINOPHILS; TUMOR-SUPPRESSOR; IN-VITRO; ASTHMA; MECHANISMS; APOPTOSIS	The ligand-activated nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma) has been shown to regulate cell activation, differentiation, proliferation, and/or apoptosis. PPAR gamma is also associated with anti-inflammatory responses. However, the signaling mechanism remains elusive. We have used a mouse model for asthma to determine the effect of PPAR gamma agonists, rosiglitazone or pioglitazone, and PPAR gamma on allergen-induced bronchial inflammation and airway hyperresponsiveness. Administration of PPAR gamma agonists or adenovirus carrying PPAR gamma cDNA (AdPPAR gamma) reduced bronchial inflammation and airway hyperresponsiveness. Expression of PPAR gamma was increased by ovalbumin (OVA) inhalation, and the increase was further enhanced by the administration of the PPAR gamma agonists or AdPPAR gamma. Levels of IL-4, IL-5, IL-13, and eosinophil cationic protein were increased after OVA inhalation, and the increased levels were significantly reduced by the administration of PPAR gamma agonists or AdPPAR gamma. The results also showed that the administration of PPAR gamma agonists or AdPPAR gamma up-regulated phosphatase and tensin homologue deleted on chromosome ten (PTEN) expression in allergen-induced asthmatic lungs. This up-regulation correlated with decreased phosphatidylinositol 3-kinase activity as measured by reduced phosphorylation of Akt. These findings demonstrate a protective role of PPAR gamma in the pathogenesis of the asthma phenotype through regulation of PTEN expression.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Pediat, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Anat, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561712, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr,Dept Med, Div Endocrinol & Metab, Seoul, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, 634-18 Keumamdong, Jeonju 561712, South Korea.	leeyc@chonbuk.ac.kr						Alves AC, 1996, EUR J PHARMACOL, V312, P89, DOI 10.1016/0014-2999(96)00357-3; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dunzendorfer S, 1998, J LEUKOCYTE BIOL, V64, P828, DOI 10.1002/jlb.64.6.828; Ezeamuzie CI, 2001, AM J RESP CRIT CARE, V164, P1633, DOI 10.1164/ajrccm.164.9.2101104; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Honda K, 2004, J ALLERGY CLIN IMMUN, V113, P882, DOI 10.1016/j.jaci.2004.02.036; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tigani B, 2001, EUR J PHARMACOL, V433, P217, DOI 10.1016/S0014-2999(01)01515-1; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Yamada KM, 2001, J CELL SCI, V114, P2375; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Zhu XD, 2000, J IMMUNOL METHODS, V240, P157, DOI 10.1016/S0022-1759(00)00192-7	37	113	120	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1033	+		10.1096/fj.04-3309fje	http://dx.doi.org/10.1096/fj.04-3309fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788448				2022-12-28	WOS:000227901300002
J	Ferrington, DA; Husom, AD; Thompson, LV				Ferrington, DA; Husom, AD; Thompson, LV			Altered proteasome structure, function, and oxidation in aged muscle	FASEB JOURNAL			English	Article						aging; immunoproteasome; skeletal muscle; calmodulin; 20S proteasome	NECROSIS-FACTOR-ALPHA; SKELETAL-MUSCLE; 20S PROTEASOME; MULTICATALYTIC PROTEINASE; OXIDIZED CALMODULIN; S PROTEASOMES; DEGRADATION; SUBUNITS; COMPLEX; HSP90	The proteasome is the main protease for degrading oxidized proteins. We asked whether altered proteasome function contributes to the accumulation of oxidized muscle proteins with aging. Proteasome structure, function, and oxidation state were compared in young and aged F344BN rat fast-twitch skeletal muscle. In proteasome-enriched homogenates from aged muscle, we observed a two- to threefold increase in content of the 20S proteasome that was due to a corresponding increase in immunoproteasome. Content of the regulatory proteins, PA700 and PA28, relative to the 20S were reduced 75% with aging. Upon addition of exogenous PA700, there was a twofold increase in peptide hydrolysis in aged muscle, suggesting the endogenous content of PA700 is inadequate for complete activation of the 20S. Measures of catalytic activity showed a 50% reduction in specific activity for proteasome-enriched homogenates with aging. With purification of the 20S, proteasome specific activity was equivalent between ages, indicating that endogenous regulators inhibit proteasome in aged muscle. Significantly less degradation of oxidized calmodulin by the 20S from aged muscle was observed. Partial rescue of activity for aged 20S by DTT implies oxidation of functionally significant cysteines. These results demonstrate significant age-related changes in proteasome structure, function, and oxidation state that could inhibit removal of oxidized proteins.	Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Phys Med & Rehabil, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Ferrington, DA (corresponding author), Univ Minnesota, Dept Ophthalmol, 380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.	ferri013@umn.edu		Ferrington, Deborah/0000-0003-2561-7464	NATIONAL EYE INSTITUTE [R01EY013623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K02AG021626, R01AG017768] Funding Source: NIH RePORTER; NEI NIH HHS [EY 013623] Funding Source: Medline; NIA NIH HHS [K02 AG021626, R01 AG017768, AG17768, AG21626] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andersson M, 1999, EXP EYE RES, V69, P129, DOI 10.1006/exer.1999.0688; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; Bardag-Gorce F, 1999, MOL BIOL REP, V26, P89, DOI 10.1023/A:1006968208077; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Carrard G, 2002, INT J BIOCHEM CELL B, V34, P1461, DOI 10.1016/S1357-2725(02)00085-7; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; Dahlmann B, 2001, BIOCHIMIE, V83, P295, DOI 10.1016/S0300-9084(01)01240-8; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; Eleuteri AM, 2002, PROTEINS, V48, P169, DOI 10.1002/prot.10101; Ferrington DA, 1998, J BIOL CHEM, V273, P5885, DOI 10.1074/jbc.273.10.5885; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; Gaczynska M, 2001, MECH AGEING DEV, V122, P235, DOI 10.1016/S0047-6374(00)00246-3; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Greiwe JS, 2001, FASEB J, V15, P475, DOI 10.1096/fj.00-0274com; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; Hallermalm K, 2001, BLOOD, V98, P1108, DOI 10.1182/blood.V98.4.1108; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Husom AD, 2004, ARCH BIOCHEM BIOPHYS, V421, P67, DOI 10.1016/j.abb.2003.10.010; Kanski J, 2003, FREE RADICAL BIO MED, V35, P1229, DOI 10.1016/S0891-5849(03)00500-8; Kloetzel PM, 1999, BIOL CHEM, V380, P293, DOI 10.1515/BC.1999.040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson L, 1998, ACTA PHYSIOL SCAND, V163, pS27, DOI 10.1046/j.1365-201x.1998.00375.x; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022; Lu XH, 2001, ARCH BIOCHEM BIOPHYS, V387, P163, DOI 10.1006/abbi.2001.2270; MA CP, 1994, J BIOL CHEM, V269, P3539; McNerlan SE, 2002, EXP GERONTOL, V37, P227, DOI 10.1016/S0531-5565(01)00188-7; Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1; Nelson JE, 2000, BIOCHEM CELL BIOL, V78, P115, DOI 10.1139/bcb-78-2-115; Piccinini M, 2003, J NEUROIMMUNOL, V135, P135, DOI 10.1016/S0165-5728(02)00439-3; Radak Z, 2002, EXP GERONTOL, V37, P1423, DOI 10.1016/S0531-5565(02)00116-X; Radak Z, 2002, PFLUG ARCH EUR J PHY, V445, P273, DOI 10.1007/s00424-002-0918-6; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; SCHLAGGER G, 1999, STAT BIOCH PRIMER; Short KR, 2004, AM J PHYSIOL-ENDOC M, V286, pE92, DOI 10.1152/ajpendo.00366.2003; Singh S, 2002, ARCH BIOCHEM BIOPHYS, V405, P147, DOI 10.1016/S0003-9861(02)00341-7; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; VINER RI, 1999, BIOCHEM J, V15, P657; Whittier JE, 2004, J BIOL CHEM, V279, P46135, DOI 10.1074/jbc.M406048200; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zainal TA, 2000, FASEB J, V14, P1825, DOI 10.1096/fj.99-0881com	50	187	191	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					664	+		10.1096/fj.04-2578fje	http://dx.doi.org/10.1096/fj.04-2578fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677694				2022-12-28	WOS:000226576600003
J	Esparza, J; Kruse, M; Lee, J; Michaud, M; Madri, JA				Esparza, J; Kruse, M; Lee, J; Michaud, M; Madri, JA			MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity	FASEB JOURNAL			English	Article						MMP-9; MT1-MMP; EAE; T lymphocyte	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GELATINASE-B; T-CELLS; ALPHA-4 INTEGRIN; DEFICIENT MICE; G-PROTEIN; IN-VIVO; MIGRATION; ANGIOGENESIS; ARTHRITIS	Matrix metalloproteinase-2 (MMP-2; gelatinase A) is known to degrade a broad range of extracellular matrix components and chemokines, and has important roles in the processes of cell migration, invasion, and involution during development, as well as during tumor growth and metastasis and in inflammation and repair. To better elucidate the roles of this matrix metalloproteinase in the development and progression of experimental autoimmune encephalomyelitis, we used MMP-2-deficient (KO) mice. Surprisingly, we found that MMP-2 KO mice exhibited an earlier onset and more severe disease than did their wild-type (WT) counterparts. WT mice engrafted with MMP-2 KO bone marrow exhibited a similar earlier onset and more severe clinical disease score than WT mice engrafted with WT bone marrow. Lymphocytes derived from MMP-2 KO mice exhibited increased transmigration through endothelial cell monolayers as well as through collagen type IV and laminin-coated BD BIOCOAT inserts(R), which correlated with a 3-fold increase in expression of MMP-9 and was abrogated by inhibition of MMP activity. We demonstrated a correlation between expression levels of MMP-9 and MT1-MMP expression and suggest a signaling pathway involving tethering of MMP-2 to MT1-MMP as a modulator of MMP-9 expression. Last, we discuss other possible MMP-2-mediated mechanisms which may contribute to the observed phenotype.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06520 USA.	joseph.Madri@yale.edu		Michaud, Michael/0000-0001-7332-4987; Lee, Janet/0000-0002-3563-8843	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028373, R01HL051018] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL28373, R01-HL51018] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alt C, 2002, EUR J IMMUNOL, V32, P2133, DOI 10.1002/1521-4141(200208)32:8<2133::AID-IMMU2133>3.0.CO;2-W; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CID MC, 1994, EUR J IMMUNOL, V24, P1377, DOI 10.1002/eji.1830240621; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Duffy MJ, 2003, THROMB HAEMOSTASIS, V89, P622; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gepstein A, 2002, ARTHRITIS RHEUM-US, V46, P3240, DOI 10.1002/art.10690; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Graesser D, 2000, J NEUROIMMUNOL, V109, P121, DOI 10.1016/S0165-5728(00)00275-7; Graesser D, 1998, LAB INVEST, V78, P1445; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643; JAMES SP, 1994, MEASUREMENT BASIC IM, V2; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; Madri J A, 2000, Dev Immunol, V7, P103, DOI 10.1155/2000/79045; Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rozanov DV, 2002, FEBS LETT, V527, P51, DOI 10.1016/S0014-5793(02)03153-8; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; SOUNNI NE, 2004, IN PRESS J BIOL CHEM; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; SWANBORG RH, 1996, EXPT AUTOIMMUNE ENCE, V3; Tani Kenji, 2001, Journal of Medical Investigation, V48, P133; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; UEKITA T, 2004, IN PRESS J BIOL CHEM; Vajkoczy P, 2001, J CLIN INVEST, V108, P557; Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432-1033.2003.03760.x; Vu TH, 2001, NAT GENET, V28, P202, DOI 10.1038/90023; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	41	88	92	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1682	1691		10.1096/fj.04-2445com	http://dx.doi.org/10.1096/fj.04-2445com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522913				2022-12-28	WOS:000225482100036
J	Gavins, FNE; Kamal, AM; D'Amico, M; Oliani, SM; Perretti, M				Gavins, FNE; Kamal, AM; D'Amico, M; Oliani, SM; Perretti, M			Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct	FASEB JOURNAL			English	Article						FPR; ischemia/reperfusion; PMN	ISCHEMIA-REPERFUSION INJURY; ENDOTHELIAL-CELL-ADHESION; ACUTE CORONARY SYNDROMES; LIPOXIN A(4) RECEPTOR; LIPOCORTIN 1; ACTIVATES NEUTROPHILS; T-LYMPHOCYTES; IN-VITRO; LEUKOCYTE; INFLAMMATION	Recent interest in the annexin 1 field has come from the notion that specific G-protein-coupled receptors, members of the formyl-peptide receptor (FPR) family, appear to mediate the anti-inflammatory actions of this endogenous mediator. Administration of the annexin 1 N-terminal derived peptide Ac2-26 to mice after 25 min ischemia significantly attenuated the extent of acute myocardial injury as assessed 60 min postreperfusion. Evident at the dose of 1 mg/kg (similar to9 nmol per animal), peptide Ac2-26 cardioprotection was intact in FPR null mice. Similarly, peptide Ac2-26 inhibition of specific markers of heart injury (specifically myeloperoxidase activity, CXC chemokine KC contents, and endogenous annexin 1 protein expression) was virtually identical in heart samples collected from wild-type and FPR null mice. Mouse myocardium expressed the mRNA for FPR and the structurally related lipoxin A(4) receptor, termed ALX; thus, comparable equimolar doses of two ALX agonists (W peptide and a stable lipoxin A4 analog) exerted cardioprotection in wild-type and FPR null mice to an equal extent. Curiously, marked (>95%) blood neutropenia produced by an anti-mouse neutrophil serum did not modify the extent of acute heart injury, whereas it prevented the protection afforded by peptide Ac2-26. Thus, this study sheds light on the receptor mechanism(s) mediating annexin 1-induced cardioprotection and shows a pivotal role for ALX and circulating neutrophil, whereas it excludes any functional involvement of mouse FPR. These mechanistic data can help in developing novel therapeutics for acute cardioprotection.	Barts & London, Queen Mary Sch Med & Dent, William Harvey Res Inst, Ctr Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples 2, Dept Expt Med, I-80138 Naples, Italy; UNESP, IBILCE, Dept Biol, Sao Paulo, Brazil	University of London; Queen Mary University London; Universita della Campania Vanvitelli; Universidade Estadual Paulista	Perretti, M (corresponding author), Barts & London, Queen Mary Sch Med & Dent, William Harvey Res Inst, Ctr Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	Gavins, Felicity N. E./AAU-6010-2020; Oliani, Sonia Maria/E-3476-2012	Gavins, Felicity N. E./0000-0001-7008-5423; Oliani, Sonia Maria/0000-0003-0918-2130; d'amico, michele/0000-0002-6899-0595				ABE Y, 1993, BRIT HEART J, V70, P132; Anguera I, 2002, AM HEART J, V144, P811, DOI 10.1067/mhj.2002.124831; Baxter GF, 2002, BASIC RES CARDIOL, V97, P268, DOI 10.1007/s00395-002-0366-7; Blum A, 1996, LANCET, V347, P56, DOI 10.1016/S0140-6736(96)91585-8; Bonder CS, 2004, J IMMUNOL, V172, P45, DOI 10.4049/jimmunol.172.1.45; Cerwinka WH, 2003, AM J PHYSIOL-HEART C, V284, pH535, DOI 10.1152/ajpheart.00311.2002; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Christophe T, 2001, J BIOL CHEM, V276, P21585, DOI 10.1074/jbc.M007769200; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; D'Amico M, 2000, FASEB J, V14, P1867; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; de Lemos JA, 2003, CIRCULATION, V107, P690, DOI 10.1161/01.CIR.0000049742.68848.99; Dewald O, 2003, P NATL ACAD SCI USA, V100, P2700, DOI 10.1073/pnas.0438035100; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; He R, 2000, J IMMUNOL, V165, P4598, DOI 10.4049/jimmunol.165.8.4598; JOHN C, 2001, J ENDOCRINOL, V169, pP150; John CD, 2004, TRENDS ENDOCRIN MET, V15, P103, DOI 10.1016/j.tem.2004.02.001; Jones SP, 2000, AM J PHYSIOL-HEART C, V279, pH2196; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; La M, 2001, EUR J PHARMACOL, V429, P263, DOI 10.1016/S0014-2999(01)01325-5; La M, 2001, FASEB J, V15, P2247, DOI 10.1096/fj.01-0196com; LATINI R, 1994, J CARDIOVASC PHARM, V23, P1, DOI 10.1097/00005344-199401000-00026; Le YY, 1999, J IMMUNOL, V163, P6777; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Lefer AM, 1998, CIRCULATION, V98, P1322, DOI 10.1161/01.CIR.98.13.1322; Lefer DJ, 2002, BASIC RES CARDIOL, V97, P263, DOI 10.1007/s00395-002-0363-x; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9; Mallat Z, 2002, HEART, V88, P467, DOI 10.1136/heart.88.5.467; MANCUSO F, 1995, J IMMUNOL, V155, P377; MAULIK N, 1993, CIRCULATION, V88, P387; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Pannitteri G, 1997, AM J CARDIOL, V80, P622, DOI 10.1016/S0002-9149(97)00434-7; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 2003, NEWS PHYSIOL SCI, V18, P60, DOI 10.1152/nips.01424.2002; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; RELTON JK, 1991, J EXP MED, V174, P305, DOI 10.1084/jem.174.2.305; Ritchie RH, 2003, EUR J PHARMACOL, V461, P171, DOI 10.1016/S0014-2999(03)01314-1; Scalia R, 2001, CIRCULATION, V103, P2598; Schottelius AJ, 2002, J IMMUNOL, V169, P7063, DOI 10.4049/jimmunol.169.12.7063; Solito E, 2003, FASEB J, V17, P1544, DOI 10.1096/fj.02-0941fje; Spagnoli LG, 2002, J AM COLL CARDIOL, V40, P1579, DOI 10.1016/S0735-1097(02)02376-8; Stokes KY, 2002, MICROCIRCULATION, V9, P407, DOI 10.1038/sj.mn.7800148; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Varda-Bloom N, 2000, J MOL CELL CARDIOL, V32, P2141, DOI 10.1006/jmcc.2000.1261; Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8	56	58	61	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					100	+		10.1096/fj.04-2178fje	http://dx.doi.org/10.1096/fj.04-2178fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15507472				2022-12-28	WOS:000224849900007
J	Kutcher, ME; Klagsbrun, M; Mamluk, R				Kutcher, ME; Klagsbrun, M; Mamluk, R			VEGF is required for the maintenance of dorsal root ganglia blood vessels but not neurons during development	FASEB JOURNAL			English	Article						endothelial cells; sensory neurons; kinase inhibitor	ENDOTHELIAL-GROWTH-FACTOR; IN-VIVO; NERVOUS-SYSTEM; RECEPTOR; EXPRESSION; ANGIOGENESIS; RAT; DIFFERENTIATION; NEUROPILIN; SURVIVAL	Vascular endothelial growth factor ( VEGF) is a potent regulator of vascular function through its control of multiple endothelial cell functions. In addition to its key role in vascularization, VEGF has recently been shown to have neurotrophic activity during hypoxic stress. In the central and peripheral motor nervous system, VEGF treatment increased neuronal vascularization and perfusion, as well as having direct trophic effects on neurons and Schwann cells. However, the role of VEGF in the sensory nervous system remains unclear. To characterize the differential effects of VEGF on endothelial cells and neurons in sensory ganglia, we used explanted mouse dorsal root ganglia (DRG), a culture system containing neurons and endothelial cells in close apposition. We show that VEGF is expressed by neurons and satellite cells, but not by endothelial cells or pericytes. On the other hand, the tyrosine kinase VEGF receptor VEGFR-2 was robustly expressed by endothelial cells throughout the extensive DRG capillary network, but not found at either the transcript or protein level in sensory neurons or other nonendothelial cells of the DRG. Both soluble receptor sequestration of VEGF and small molecule kinase inhibition of VEGFR-2 signaling rapidly disrupted the connectivity, branching, and structural integrity of the capillary network of embryonic DRG; this effect was no longer evident postnatally. However, VEGF inhibition showed no detectable effect on neuronal health at any stage analyzed. These data suggest that endogenous VEGF is a strict requirement for vascular, but not neuronal, maintenance in developing sensory ganglia.	Childrens Hosp, Vasc Biol Program, Karp Family Res Labs, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Klagsbrun, M (corresponding author), Childrens Hosp, Vasc Biol Program, Karp Family Res Labs, Room 12-210,300 Longwood Ave, Boston, MA 02115 USA.	michael.klagsbrun@childrens.harvard.edu		Kutcher, Matthew/0000-0003-4566-5359	NCI NIH HHS [CA45548, CA37392] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037392, R56CA037392, R37CA037392, P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; BAKER DM, 1989, J NEUROCYTOL, V18, P647, DOI 10.1007/BF01187084; Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHENG L, 2004, IN PRESS J BIOL CHEM; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Darland D. C., 2001, Angiogenesis, V4, P11, DOI 10.1023/A:1016611824696; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; Feng D, 2000, J HISTOCHEM CYTOCHEM, V48, P545, DOI 10.1177/002215540004800412; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012-1606(03)00356-7; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hogan KA, 2004, DEVELOPMENT, V131, P1503, DOI 10.1242/dev.01039; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; MATSUDA S, 1984, CELL TISSUE RES, V235, P13; Matsuda S, 1996, ANAT EMBRYOL, V193, P475; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pinter E, 2001, AM J PATHOL, V158, P1199, DOI 10.1016/S0002-9440(10)64069-2; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2001, NEUROREPORT, V12, P105, DOI 10.1097/00001756-200101220-00028; Stupack D.G., 2002, SCI STKE, P7; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tille JC, 2001, J PHARMACOL EXP THER, V299, P1073; Wood JM, 2000, CANCER RES, V60, P2178; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084	44	33	36	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1952	+		10.1096/fj.04-2320fje	http://dx.doi.org/10.1096/fj.04-2320fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15479766				2022-12-28	WOS:000224849900023
J	Mandolesi, G; Madeddu, F; Bozzi, Y; Maffei, L; Ratto, GM				Mandolesi, G; Madeddu, F; Bozzi, Y; Maffei, L; Ratto, GM			Acute physiological response of mammalian central neurons to axotomy: ionic regulation and electrical activity	FASEB JOURNAL			English	Article						calcium; imaging; membrane potential; patch clamp; regeneration; trauma	SPINAL-CORD-INJURY; WHITE-MATTER INJURY; SODIUM-CALCIUM EXCHANGE; TRAUMATIC AXONAL INJURY; RETINAL GANGLION-CELLS; IN-VITRO; HIPPOCAMPAL-NEURONS; NA+-CA2+ EXCHANGER; GENE-EXPRESSION; NEURITE TRANSECTION	The transection of the axon of central neurons has dramatic consequences on the damaged cells and nerves. Injury activates molecular programs leading to a complex repertoire of responses that, depending on the cellular context, include activation of sprouting, axonal degeneration, and cell death. Although the cellular mechanisms started at the time of lesion are likely to shape the changes affecting injured cells, the acute physiological reaction to trauma of mammalian central neurons is not completely understood yet. To characterize the physiology of the acute response to axonal transection, we have developed a model of in vitro axotomy of neurons cultured from the rodent cortex. Imaging showed that axotomy caused an increase of calcium in the soma and axon. Propagation of the response to the soma required the activation of voltage-dependent sodium channels, since it was blocked by tetrodotoxin. The electrophysiological response to axotomy was recorded in patched neurons kept in the current clamp configuration: injury was followed by vigorous spiking activity that caused a sodium load and the activation of transient calcium currents that were opened by each action potential. The decrease of the electrochemical gradient of sodium caused inversion of the Na-Ca exchanger that provided an additional mean of entry for calcium. Finally, we determined that inhibition of the physiological response to axotomy hindered the regeneration of a new neurite. These data provide elements of the framework required to link the axotomy itself to the downstream molecular machinery that contributes to the determination of the long-term fate of injured neurons and axons.	CNR, Inst Neurosci, I-56100 Pisa, Italy; Scuola Normale Super Pisa, I-56100 Pisa, Italy; IRCCS Santa Lucia Fdn, I-00179 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); Scuola Normale Superiore di Pisa; IRCCS Santa Lucia	Ratto, GM (corresponding author), CNR, Inst Neurosci, I-56100 Pisa, Italy.	gimmi@in.cnr.it	Ratto, Gian Michele/AAX-8514-2020; Mandolesi, Georgia/G-6595-2011; Ratto, Gian Michele/AAB-8719-2021	Ratto, Gian Michele/0000-0001-9632-7769; Mandolesi, Georgia/0000-0003-3612-6820				Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 2000, NEUROSCIENCE, V99, P179, DOI 10.1016/S0306-4522(00)00165-2; Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bradke F, 2000, CURR BIOL, V10, P1467, DOI 10.1016/S0960-9822(00)00807-1; Brown AM, 2001, J NEUROPHYSIOL, V85, P900, DOI 10.1152/jn.2001.85.2.900; Buki A, 2000, J NEUROSCI, V20, P2825; CACERES A, 1986, J NEUROSCI, V6, P714; Caroni P, 1997, BIOESSAYS, V19, P767, DOI 10.1002/bies.950190906; Caroni P, 1998, ESSAYS BIOCHEM, V33, P53, DOI 10.1042/bse0330053; Chu GKT, 2001, NEUROSCIENCE, V102, P945, DOI 10.1016/S0306-4522(00)00514-5; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; Eddleman CS, 1998, NEUROSCI LETT, V256, P123, DOI 10.1016/S0304-3940(98)00709-5; Eddleman CS, 2000, BIOPHYS J, V79, P1883, DOI 10.1016/S0006-3495(00)76438-1; FAWCETT JW, 1992, TRENDS NEUROSCI, V15, P5, DOI 10.1016/0166-2236(92)90338-9; Fishman HM, 2003, NEWS PHYSIOL SCI, V18, P115, DOI 10.1152/nips.01429.2002; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; GILL A, 1992, AM J CARDIOL, V69, pD11; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanz S, 2003, NEURON, V40, P1095, DOI 10.1016/S0896-6273(03)00770-0; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 1998, BIOMETALS, V11, P345, DOI 10.1023/A:1009257909785; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hayashi K, 2002, NEUROSCIENCE, V110, P7, DOI 10.1016/S0306-4522(01)00592-9; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Lehning EJ, 1996, J NEUROCHEM, V66, P493; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Lin H, 2003, J NEUROBIOL, V57, P204, DOI 10.1002/neu.10275; Liu XZ, 1997, J NEUROSCI, V17, P5395; LoPachin RM, 1999, J NEUROPHYSIOL, V82, P2143, DOI 10.1152/jn.1999.82.5.2143; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Perlson E, 2004, J NEUROBIOL, V58, P287, DOI 10.1002/neu.10316; Perlson E, 2004, MOL CELL PROTEOMICS, V3, P510, DOI 10.1074/mcp.M400004-MCP200; RABACCHI SA, 1994, J NEUROSCI, V14, P5292; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; REHDER V, 1992, NEUROSCIENCE, V51, P565, DOI 10.1016/0306-4522(92)90296-E; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Rosenberg LJ, 2001, J NEUROSCI RES, V66, P191, DOI 10.1002/jnr.1211; Rutherford LC, 1997, J NEUROSCI, V17, P4527; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sattler R, 1996, BRAIN RES, V719, P239, DOI 10.1016/0006-8993(96)00125-4; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Steffensen I, 1997, BRAIN RES, V776, P1, DOI 10.1016/S0006-8993(97)00868-8; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; STYS PK, 1992, J NEUROSCI, V12, P430; Teng YD, 1997, J NEUROSCI, V17, P4359; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Vanhoutte P, 2003, CURR OPIN NEUROBIOL, V13, P366, DOI 10.1016/S0959-4388(03)00073-4; Verbny Y, 2002, J NEUROPHYSIOL, V88, P802, DOI 10.1152/jn.2002.88.2.802; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; XIE XY, 1991, J NEUROSCI, V11, P3257; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SP, 1997, EUR J NEUROSCI, V9, P1273, DOI 10.1111/j.1460-9568.1997.tb01482.x; Zhang XP, 2000, J NEUROBIOL, V45, P84, DOI 10.1002/1097-4695(20001105)45:2<84::AID-NEU3>3.0.CO;2-4; Ziv NE, 1997, J NEUROSCI, V17, P3568	75	74	74	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1934	+		10.1096/fj.04-1805fje	http://dx.doi.org/10.1096/fj.04-1805fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15451889				2022-12-28	WOS:000224243200009
J	Maurice, P; Legrand, C; Fauvel-Lafeve, F				Maurice, P; Legrand, C; Fauvel-Lafeve, F			Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen	FASEB JOURNAL			English	Article						platelet aggregation; glycoprotein; platelet-collagen interaction	RECEPTOR-GAMMA-CHAIN; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN IB-ALPHA; C-TERMINAL PEPTIDE; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA(2)BETA(1); FLOW CONDITIONS; IMMUNOGLOBULIN SUPERFAMILY; INCLUDING PLC-GAMMA-2; VI	Platelet adhesion to vascular collagens is an essential step in the initiation of hemostasis and thrombosis. Several platelet receptors interact with type I and type III collagens, including GP Ia/IIa and GP VI. We recently described a new platelet receptor (TIIICBP) specific for a type III collagen-related primary binding sequence, the KOGEOGPK octapeptide. Here, we characterize platelet adhesion to the immobilized octapeptide and demonstrate that this adhesion 1) is Ca2+ and Mg2+ independent, suggesting a noninvolvement of GP Ia/IIa; 2) is not inhibited by an antibody against GP VI; and 3) triggers platelet protein tyrosine phosphorylation. Whereas TXA(2) has minimal effects, released ADP via only P2Y(12) potentiates platelet adhesion to the octapeptide. Octapeptide-induced platelet adhesion triggers platelet signaling through tyrosine phosphorylation of the 68 kDa subunit of TIIICBP, Syk, PLCgamma2, and FAK. Tyrosine phosphorylation of the FcR gamma-chain and LAT is also observed but to a lesser extent than with type III collagen, suggesting the requirement of GP VI for full tyrosine phosphorylation of FcR gamma-chain and LAT. The present study provides evidence for a critical role for the type III collagen-related KOGEOGPK octapeptide in mediating platelet adhesion and signaling, and consequently in platelet-collagen interactions.	Univ Paris 07, Hop St Louis, U553,INSERM, Inst Hematol,IFR St Louis, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fauvel-Lafeve, F (corresponding author), Hop St Louis, INSERM, U553, 1 Ave Calude Vellefaux, F-75475 Paris 10, France.	f.lafeve@chu-stlouis.fr	Maurice, Pascal/AAM-9126-2021	MAURICE, Pascal/0000-0003-2167-4808				Arderiu G, 2002, BIOCHEM J, V364, P65, DOI 10.1042/bj3640065; Atkinson BT, 2001, EUR J BIOCHEM, V268, P5242, DOI 10.1046/j.0014-2956.2001.02448.x; Barnes MJ, 1996, BIOPOLYMERS, V40, P383, DOI 10.1002/(SICI)1097-0282(1996)40:4<383::AID-BIP4>3.0.CO;2-S; BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; FAUVEL F, 1979, THROMB RES, V16, P269, DOI 10.1016/0049-3848(79)90289-5; FAUVELLAFEVE F, 1993, THROMB RES, V71, P193, DOI 10.1016/0049-3848(93)90094-5; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V354, P255, DOI 10.1006/abbi.1998.0637; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V353, P239, DOI 10.1006/abbi.1998.0598; FUJII T, 1975, H-S Z PHYSIOL CHEM, V356, P1793, DOI 10.1515/bchm2.1975.356.2.1793; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Guidetti GF, 2003, BBA-MOL CELL RES, V1640, P43, DOI 10.1016/S0167-4889(02)00401-9; Hers I, 2000, EUR J BIOCHEM, V267, P2088, DOI 10.1046/j.1432-1327.2000.01214.x; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jarvis GE, 2002, BRIT J PHARMACOL, V137, P107, DOI 10.1038/sj.bjp.0704834; Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583; Kamiguti AS, 2000, ARCH BIOCHEM BIOPHYS, V374, P356, DOI 10.1006/abbi.1999.1627; Kanaji S, 2003, J BIOL CHEM, V278, P39452, DOI 10.1074/jbc.M300199200; KARNIGUIAN A, 1983, THROMB RES, V32, P593, DOI 10.1016/0049-3848(83)90061-0; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Kunapuli SP, 2003, CURR OPIN PHARMACOL, V3, P175, DOI 10.1016/S1471-4892(03)00007-9; Lecut C, 2003, J THROMB HAEMOST, V1, P2653, DOI 10.1111/j.1538-7836.2003.00495.x; Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200; Marshall SJ, 2002, BIOCHEM J, V361, P297, DOI 10.1042/0264-6021:3610297; Miura Y, 2000, THROMB RES, V98, P301, DOI 10.1016/S0049-3848(00)00182-1; Monnet E, 2000, J BIOL CHEM, V275, P10912, DOI 10.1074/jbc.275.15.10912; Monnet E, 2001, THROMB HAEMOSTASIS, V86, P694, DOI 10.1055/s-0037-1616106; Monnet E, 2000, THROMB RES, V98, P423, DOI 10.1016/S0049-3848(00)00199-7; MOROI M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P1, DOI 10.1016/0167-4889(92)90092-P; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; Nakamura T, 1999, J BIOL CHEM, V274, P11897, DOI 10.1074/jbc.274.17.11897; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Rauterberg J, 1993, Curr Top Pathol, V87, P163; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Staatz WD, 1997, BIOCHEM MOL BIOL INT, V42, P577; SUGIYAMA T, 1987, BLOOD, V69, P1712; Trumel C, 2003, J THROMB HAEMOST, V1, P320, DOI 10.1046/j.1538-7836.2003.00068.x; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Tulasne D, 2001, BLOOD, V98, P3346, DOI 10.1182/blood.V98.12.3346; Verkleij MW, 1998, BLOOD, V91, P3808; Verkleij MW, 1999, THROMB HAEMOSTASIS, V82, P1137; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; Wu CC, 1996, BIOCHEM BIOPH RES CO, V220, P388, DOI 10.1006/bbrc.1996.0415	53	17	17	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1339	1347		10.1096/fj.03-1151com	http://dx.doi.org/10.1096/fj.03-1151com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333577				2022-12-28	WOS:000224243200053
J	Van Laethem, A; Van Kelst, S; Lippens, S; Declercq, W; Vandenabeele, P; Janssens, S; Vandenheede, JR; Garmyn, M; Agostinis, P				Van Laethem, A; Van Kelst, S; Lippens, S; Declercq, W; Vandenabeele, P; Janssens, S; Vandenheede, JR; Garmyn, M; Agostinis, P			Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes	FASEB JOURNAL			English	Article						skin equivalents; skin organ cultures; photocarcinogenesis; HaCaT cells	RADIATION-INDUCED APOPTOSIS; ULTRAVIOLET-B RADIATION; EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE; CELL-DEATH; INDEPENDENT PATHWAY; RECEPTOR ACTIVATION; PHOSPHORYLATION; BCL-2; PROMOTES	This study establishes that activation of p38 MAPK by UVB represents a crucial signal required for the conformational change and translocation of Bax to the mitochondria in human keratinocytes. UVB-induced Bax translocation and mitochondrial cytochrome c release, which precede caspase activation and other endpoints of the apoptotic program such as chromatin fragmentation and loss of mitochondrial transmembrane potential, are blocked by genetic or pharmacological inhibition of the p38alpha MAPK. Inhibition of p38 MAPK strongly reduces the UVB-induced formation of sunburn cells and blocks Bax conformational change both in cultured human keratinocytes and in human skin, providing clear evidence for the physiological role of the p38 MAPK-Bax pathway in the removal of precancerous, UVB-damaged keratinocytes. Furthermore, we show that Bcl-2 overexpression, but not the pan-caspase inhibitor zVAD-fmk, blocks Bax conformational change and its subsequent translocation downstream of p38 MAPK. These data indicate that the activation of p38 MAPK by UVB engages a caspase-independent death signal leading to mitochondrial membrane permeabilization and apoptosis in human keratinocytes and suggest that p38 MAPK might have a preventive role in the process of photocarcinogenesis.	Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dermatol Lab, B-3000 Louvain, Belgium; State Univ Ghent VIB, Dept Mol Biomed Res, Ghent, Belgium; Catholic Univ Louvain, Fac Med, Dept Cardiol, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB); Ghent University; Universite Catholique Louvain	Agostinis, P (corresponding author), Catholic Univ Louvain, Div Biochem, Herestr 49, B-3000 Louvain, Belgium.	patricia.agostinis@med.kuleuven.ac.be	Agostinis, Patrizia/AAO-2468-2020; Vandenabeele, Peter/AAD-5793-2022; Lippens, Saskia/C-1343-2009; Vandenabeele, Peter/C-8597-2009; Agostinis, Patrizia/ABI-1177-2020	Vandenabeele, Peter/0000-0002-6669-8822; Agostinis, Patrizia/0000-0003-1314-2115; Lippens, Saskia/0000-0002-8261-3462				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Assefa Z, 2003, FEBS LETT, V540, P125, DOI 10.1016/S0014-5793(03)00238-2; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; DECRAENE D, IN PRESS J INVEST DE; Delehedde M, 2001, J INVEST DERMATOL, V116, P366, DOI 10.1046/j.1523-1747.2001.01260.x; Desbiens KM, 2003, BIOCHEM J, V372, P631, DOI 10.1042/BJ20021565; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GILCHREST BA, 1983, J INVEST DERMATOL, V81, pS184, DOI 10.1111/1523-1747.ep12541084; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Hildesheim J, 2004, J INVEST DERMATOL, V122, P497, DOI 10.1111/j.1523-1747.2004.22229.x; Hildesheim J, 2002, CANCER RES, V62, P7305; Jost M, 2001, J INVEST DERMATOL, V116, P860, DOI 10.1046/j.1523-1747.2001.01356.x; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li SP, 2003, CANCER RES, V63, P3473; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Muller-Rover S, 2000, AM J PATHOL, V156, P1395, DOI 10.1016/S0002-9440(10)65008-0; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Paramio JM, 2000, MOL CARCINOGEN, V29, P251, DOI 10.1002/1098-2744(200012)29:4<251::AID-MC1007>3.0.CO;2-O; Pfundt R, 2001, J PATHOL, V193, P248; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Shou Y, 2003, TOXICOL SCI, V75, P99, DOI 10.1093/toxsci/kfg157; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang XD, 2001, GENE DEV, V15, P2922; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200	55	131	138	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1946	+		10.1096/fj.04-2285fje	http://dx.doi.org/10.1096/fj.04-2285fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15388671	Green Published			2022-12-28	WOS:000224243200013
J	Patchev, AV; Gotz, F; Rohde, W				Patchev, AV; Gotz, F; Rohde, W			Differential role of estrogen receptor isoforms in sex-specific brain organization	FASEB JOURNAL			English	Article						reproductive functions; defeminization; ER alpha; ER beta	CENTRAL-NERVOUS-SYSTEM; SEXUALLY DIMORPHIC NUCLEUS; PREOPTIC AREA; MESSENGER-RNA; SDN-POA; RAT; LESIONS; BEHAVIOR; HORMONES; ALPHA	Transient activation of estrogen receptors ( ER) in the developing brain during a limited perinatal "window of time" is recognized as a key mechanism of defeminization of neural control of reproductive function and sexual behavior. Two major ER isoforms, alpha and beta, are present in neural circuits that govern ovarian cycle and sexual behavior. Using highly selective ER agonists, this study provides the first evidence for distinct contribution of individual ER isoforms to the process of estrogen dependent defeminization. Neonatal activation of the ERalpha in female rats resulted in abrogation of cyclic ovarian activity and female sexual behavior in adulthood. These effects are associated with male-like alterations in the morphology of the anteroventral periventricular (AVPV) and sexually dimorphic nucleus of the preoptic area (SDN-POA), as well as refractoriness to estrogen-mediated induction of sexual receptivity. Exposure to an ERbeta-selective agonist induced persistent estrus and had a strong defeminizing effect on the hypothalamic gonadotropin "surge generator" AVPV. However, neonatal ER activation failed to alter female sexual behavior, responsiveness to estrogens and morphometric features of the behaviorally relevant SDN-POA. Thus, although co-present in several brain regions involved in the control of female reproductive function, ER isoforms convey different, and probably not synergistic, chemical signals in the course of neonatal sex-specific brain organization.	Humboldt Univ, Sch Med Charite, Inst Expt Endocrinol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Patchev, AV (corresponding author), Humboldt Univ, Sch Med Charite, Inst Expt Endocrinol, Schumannstr 20-21, D-10117 Berlin, Germany.	Alexandre.Patchev@charite.de	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X				ARNOLD AP, 1984, ANNU REV NEUROSCI, V7, P413, DOI 10.1146/annurev.ne.07.030184.002213; Beach FA, 1944, J CLIN ENDOCRINOL, V4, P126, DOI 10.1210/jcem-4-3-126; Beyer C, 1999, ANAT EMBRYOL, V199, P379, DOI 10.1007/s004290050236; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DEJONGE FH, 1989, BRAIN RES BULL, V23, P483, DOI 10.1016/0361-9230(89)90194-9; DOHLER KD, 1991, INT REV CYTOL, V131, P1, DOI 10.1016/S0074-7696(08)62016-1; DONCARLOS LL, 1995, DEV BRAIN RES, V84, P253, DOI 10.1016/0165-3806(94)00179-4; DORNER G, 1976, HOMRONES BRAIN DIFFE; FABER KA, 1993, REPROD TOXICOL, V7, P35, DOI 10.1016/0890-6238(93)90007-T; GORSKI RA, 1980, J COMP NEUROL, V193, P529, DOI 10.1002/cne.901930214; Hegele-Hartung C, 2004, P NATL ACAD SCI USA, V101, P5129, DOI 10.1073/pnas.0306720101; Laflamme N, 1998, J NEUROBIOL, V36, P357, DOI 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V; Lephart ED, 2002, NEUROTOXICOL TERATOL, V24, P5, DOI 10.1016/S0892-0362(01)00197-0; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; MADEIRA MD, 1995, PROG NEUROBIOL, V45, P275, DOI 10.1016/0301-0082(94)00052-J; McDonnell DP, 2002, RECENT PROG HORM RES, V57, P295, DOI 10.1210/rp.57.1.295; PFAFF DW, 1994, PHYSL REPRODUCTION, V2, P107; PHOENIX CH, 1959, ENDOCRINOLOGY, V65, P369, DOI 10.1210/endo-65-3-369; PILGRIM C, 1994, NEUROSCIENCE, V60, P843, DOI 10.1016/0306-4522(94)90267-4; Roberts N, 2000, BRIT J RADIOL, V73, P679, DOI 10.1259/bjr.73.871.11089458; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Swanson LW, 1999, BRAIN MAPS STRUCTURE; TORANALLERAND CD, 1984, ANN NY ACAD SCI, V435, P101, DOI 10.1111/j.1749-6632.1984.tb13743.x; WIEGAND SJ, 1978, ENDOCRINOLOGY, V102, P1645, DOI 10.1210/endo-102-5-1645; WIEGAND SJ, 1982, NEUROENDOCRINOLOGY, V34, P395, DOI 10.1159/000123335	25	66	66	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1568	+		10.1096/fj.04-1959fje	http://dx.doi.org/10.1096/fj.04-1959fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289439				2022-12-28	WOS:000223554900021
J	Jurgensen, JS; Rosenberger, C; Wiesener, MS; Warnecke, C; Horstrup, JH; Grafe, M; Philipp, S; Griethe, W; Maxwell, PH; Frei, U; Bachmann, S; Willenbrock, R; Eckardt, KU				Jurgensen, JS; Rosenberger, C; Wiesener, MS; Warnecke, C; Horstrup, JH; Grafe, M; Philipp, S; Griethe, W; Maxwell, PH; Frei, U; Bachmann, S; Willenbrock, R; Eckardt, KU			Persistent induction of HIF-1 alpha and -2 alpha in cardiomyocytes and stromal cells of ischemic myocardium	FASEB JOURNAL			English	Article						hypoxia; ischemia; infarction; endothelium; macrophages	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; HEME OXYGENASE-1 PROTECTS; NITRIC-OXIDE SYNTHASE; PAS DOMAIN PROTEIN-1; INFARCTION MODEL; EARLY EXPRESSION; FACTOR 1-ALPHA; HEART-FAILURE; FACTOR-ALPHA; HIF-ALPHA	Hypoxia-inducible factor (HIF)-1alpha and -2alpha are key regulators of the transcriptional response to hypoxia and pivotal in mediating the consequences of many disease states. In the present work, we define their temporo-spatial accumulation after myocardial infarction and systemic hypoxia. Rats were exposed to hypoxia or underwent coronary artery ligation. Immunohistochemistry was used for detection of HIF-1alpha and - 2alpha proteins and target genes, and mRNA levels were determined by RNase protection. Marked nuclear accumulation of HIF-1alpha and - 2alpha occurred after both systemic hypoxia and coronary ligation in cardiomyocytes as well as interstitial and endothelial cells (EC) without pronounced changes in HIF mRNA levels. While systemic hypoxia led to widespread induction of HIF, expression after coronary occlusion occurred primarily at the border of infarcted tissue. This expression persisted for 4 wk, included infiltrating macrophages, and colocalized with target gene expression. Subsets of cells simultaneously expressed both HIF-alpha subunits, but EC more frequently induced HIF-2alpha. A progressive increase of HIF-2alpha but not HIF-1alpha occurred in areas remote from the infarct, including the interventricular septum. Cardiomyocytes and cardiac stromal cells exhibit a marked potential for a prolonged transcriptional response to ischemia mediated by HIF. The induction of HIF-1alpha and - 2alpha appears to be complementary rather than solely redundant.	Humboldt Univ, Charite, Dept Nephrol & Med Intens Care, D-13353 Berlin, Germany; Humboldt Univ, Charite, Dept Cardiol, D-13353 Berlin, Germany; Humboldt Univ, Charite, Inst Anat, D-13353 Berlin, Germany; German Heart Ctr, Berlin, Germany; Univ London Imperial Coll Sci Technol & Med, Renal Sect, London, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; Imperial College London	Eckardt, KU (corresponding author), Humboldt Univ, Charite, Dept Nephrol & Med Intens Care, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	kai-uwe.eckardt@charite.de	Maxwell, Patrick H/C-5557-2008	Maxwell, Patrick H/0000-0002-0338-2679				Bing RJ, 2001, CARDIOVASC RES, V51, P13, DOI 10.1016/S0008-6363(01)00250-4; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Burke B, 2002, J PATHOL, V196, P204, DOI 10.1002/path.1029; Choi AMK, 2001, CIRC RES, V89, P105, DOI 10.1161/res.89.2.105; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GRAFE M, 1994, AM J PHYSIOL-HEART C, V267, pH2138, DOI 10.1152/ajpheart.1994.267.6.H2138; Heba G, 2001, J VASC RES, V38, P288, DOI 10.1159/000051057; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kakinuma Y, 2001, CIRCULATION, V103, P2387; Kim CH, 2002, CIRC RES, V90, pE25, DOI 10.1161/hh0202.104923; Ladoux A, 1997, BIOCHEM BIOPH RES CO, V240, P552, DOI 10.1006/bbrc.1997.7708; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee RJ, 2000, CIRCULATION, V102, P898; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Moldovan NI, 2000, CIRC RES, V87, P378; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sakai S, 1996, CIRCULATION, V93, P1214, DOI 10.1161/01.CIR.93.6.1214; Semenza GL, 2000, GENE DEV, V14, P1983; Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Takeuchi K, 1998, CIRCULATION, V98, pII234; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Vargas SO, 1999, MODERN PATHOL, V12, P635; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Willam C, 2000, CIRC RES, V87, P370; Williams RS, 2000, J CLIN INVEST, V106, P813, DOI 10.1172/JCI11205; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; Yue P, 1998, J MOL CELL CARDIOL, V30, P1615, DOI 10.1006/jmcc.1998.0727; Zhong H, 2000, CANCER RES, V60, P1541; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	48	99	102	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1415	+		10.1096/fj.04-1605fje	http://dx.doi.org/10.1096/fj.04-1605fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247145				2022-12-28	WOS:000222979200007
J	Chen, XD; Fisher, LW; Robey, PG; Young, MF				Chen, XD; Fisher, LW; Robey, PG; Young, MF			The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation	FASEB JOURNAL			English	Article						microenvironment; osteoblastic progenitors	BONE MORPHOGENETIC PROTEIN-4; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; TARGETED DISRUPTION; STROMAL CELLS; DECORIN; EXPRESSION; CBFA1; GENE; ABNORMALITIES	Biglycan (bgn) is a small leucine-rich proteoglycan enriched in extracellular matrices of skeletal tissues. Bgn-deficient mice develop age-related osteopenia with a phenotype that resembles osteoporosis and premature arthritis. In the present study, we have examined the differentiation of bgn-deficient osteoblasts from neonatal murine calvariae and found that the absence of bgn caused less BMP-4 binding, which reduced the sensitivity of osteoblasts to BMP-4 stimulation. The loss of sensitivity resulted in a reduction of Cbfa1 expression, which ultimately led to a defect in the differentiation of osteoblasts. However, the response of bgn-deficient osteoblasts to BMP-4 was completely rescued by reintroduction of biglycan by viral transfection. We propose that biglycan modulates BMP-4-induced signaling to control osteoblast differentiation.	Natl Inst Dent & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Chen, XD (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, Bldg 30,Room 225,9000 Rockville Pike,MSC 4320, Bethesda, MD 20892 USA.	xchen@dir.nidr.nih.gov	Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Young, Marian F/0000-0003-0929-8854; Chen, Xiao-Dong/0000-0003-1602-806X	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000074, ZIADE000380, ZIADE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379, Z01DE000074, Z01DE000380] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Andrades JA, 2001, PROTOPLASMA, V218, P95, DOI 10.1007/BF01288365; BAB I, 1988, BONE MINER, V4, P373; BANERJEE U, 1997, LOOP TR RESTRUCT COM, V3, P1; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331; Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362; Cohn D H, 2001, Novartis Found Symp, V232, P195; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HORTON WA, 1987, PEDIATR RES, V22, P324, DOI 10.1203/00006450-198709000-00017; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; James IE, 1996, J BONE MINER RES, V11, P1453; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KRESSE H, 1994, EUR J CLIN CHEM CLIN, V32, P259; Larrain J, 2000, DEVELOPMENT, V127, P821; LIU F, 1995, MOL CELL BIOL, V15, P3479; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; Natsume T, 1997, J BIOL CHEM, V272, P11535; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; Silver FH, 2001, CRIT REV BIOMED ENG, V29, P373, DOI 10.1615/CritRevBiomedEng.v29.i4.10; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; Stordeur P, 2002, J IMMUNOL METHODS, V259, P55, DOI 10.1016/S0022-1759(01)00489-6; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	39	170	185	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					948	958		10.1096/fj.03-0899com	http://dx.doi.org/10.1096/fj.03-0899com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15173106				2022-12-28	WOS:000222327500012
J	Zeini, M; Hortelano, S; Traves, PG; Gomez-Valdes, AG; Pujol, A; Perales, JC; Bartrons, R; Bosca, L				Zeini, M; Hortelano, S; Traves, PG; Gomez-Valdes, AG; Pujol, A; Perales, JC; Bartrons, R; Bosca, L			Assessment of a dual regulatory role for NO in liver regeneration after partial hepatectomy: protection against apoptosis and retardation of hepatocyte proliferation	FASEB JOURNAL			English	Article						nitric oxide synthase; transgenic; gene therapy	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; RAPID ACTIVATION; INJURY; MICE; INTERLEUKIN-6; CYTOKINE; ANIMALS; ENZYMES; GROWTH	The role of hepatic nitric oxide (NO) in liver regeneration after partial hepatectomy (PH) was studied in animals carrying a nitric oxide synthase-2 transgene under the control of the phospho(enol)pyruvate carboxykinase promoter. These mice expressed NOS-2 in liver cells under fasting conditions. Liver mass recovery and molecular parameters related to cell proliferation were determined after PH. Preexisting hepatic NO synthesis, as well as NO delivery by NO-donors, impaired early signaling (for example, attenuated NF-kappa B activation and TNF-alpha. and IL-6 release). The regenerative process was also impaired as a result of an insufficient proliferative response, but mouse survival after surgery was not compromised. However, NO exerted a protective role against apoptosis in transgenic hepatectomized mice. Local production of NO in liver cells, achieved by hydrodynamic-based transfection with a NOS-2-encoding plasmid, also resulted in delayed liver recovery after PH and also protected against Fas-mediated apoptosis. These data show that sustained presence of NO after PH exerts a dual role: attenuating liver regeneration while efficiently protecting against liver apoptosis.	Univ Complutense, Fac Farm, Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain; Univ Complutense, Fac Farm, Ctr Nacl Invest Cardiovasc, E-28040 Madrid, Spain; Univ Barcelona, Dept Ciencies Fisiol 2, Barcelona, Spain; Univ Autonoma Barcelona, Ctr Biotecnol Anim & Terapia Genica, Unidad Anim Transgen, E-08193 Barcelona, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid; University of Barcelona; Autonomous University of Barcelona	Bosca, L (corresponding author), Univ Complutense, Fac Farm, Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain.	lbosca@cnic.es	Hortelano, Sonsoles/A-7954-2010; PERALES, JOSE C. C/D-5586-2012; Pujol, Anna/J-7939-2017; PERALES, JOSE C./AAC-3156-2019; G. Traves, Paqui/L-5693-2014; PERALES, JOSE C/J-7457-2017; Bosca, Lisardo/A-2059-2008	Hortelano, Sonsoles/0000-0003-2528-0072; PERALES, JOSE C. C/0000-0001-7363-2226; Pujol, Anna/0000-0002-3484-598X; PERALES, JOSE C./0000-0001-7363-2226; G. Traves, Paqui/0000-0001-5749-8426; PERALES, JOSE C/0000-0001-7363-2226; Bosca, Lisardo/0000-0002-0253-5469; G. Gomez-Valades, Alicia/0000-0002-4088-1338; Bartrons, Ramon/0000-0001-9349-5847				Blindenbacher A, 2003, HEPATOLOGY, V38, P674, DOI 10.1053/jhep.2003.50378; Bohlinger I, 1995, HEPATOLOGY, V22, P1829, DOI 10.1016/0270-9139(95)90212-0; Clavien PA, 1997, HEPATOLOGY, V25, P1294, DOI 10.1002/hep.510250544; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DINARELLO CA, 1995, CURR BIOL, V5, P587, DOI 10.1016/S0960-9822(95)00116-3; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P2652, DOI 10.1073/pnas.041603898; Higgins GM, 1931, ARCH PATHOL, V12, P186; HORTELANO S, 1995, HEPATOLOGY, V21, P776; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Laszlo F, 1997, EUR J PHARMACOL, V334, P99, DOI 10.1016/S0014-2999(97)01163-1; Leu JI, 2003, MOL CELL BIOL, V23, P1251, DOI 10.1128/MCB.23.4.1251-1259.2003; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; LI J, 1999, AM J PHYSIOL, V276, P1069; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mojena M, 2001, FASEB J, V15, P583; Morio LA, 2001, TOXICOL APPL PHARM, V172, P44, DOI 10.1006/taap.2000.9133; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Navarro-Lerida I, 2004, J CELL SCI, V117, P1687, DOI 10.1242/jcs.01002; OBOLENSKAYA M, 1994, BIOCHEM BIOPH RES CO, V204, P1305, DOI 10.1006/bbrc.1994.2605; OBOLENSKAYA MY, 1994, BIOCHEM BIOPH RES CO, V202, P571, DOI 10.1006/bbrc.1994.1966; Pinkoski MJ, 2000, AM J PHYSIOL-GASTR L, V278, pG354, DOI 10.1152/ajpgi.2000.278.3.G354; Rai RM, 1996, AM J PHYSIOL-GASTR L, V270, pG909, DOI 10.1152/ajpgi.1996.270.6.G909; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Russo MW, 2004, GASTROENTEROLOGY, V126, P1448, DOI 10.1053/j.gastro.2004.01.025; Sakamoto T, 1999, HEPATOLOGY, V29, P403, DOI 10.1002/hep.510290244; Taub R, 2003, J CLIN INVEST, V112, P978, DOI 10.1172/JCI20031200319974; Togo S, 2004, J HEPATOL, V40, P464, DOI 10.1016/j.jhep.2003.11.005; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Wustefeld T, 2000, HEPATOLOGY, V32, P514, DOI 10.1053/jhep.2000.16604; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Zhu W, 2000, FREE RADICAL BIO MED, V29, P870, DOI 10.1016/S0891-5849(00)00396-8	37	24	30	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					995	+		10.1096/fj.04-3233fje	http://dx.doi.org/10.1096/fj.04-3233fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788446				2022-12-28	WOS:000227901300005
J	Perez, GI; Jurisicova, A; Matikainen, T; Moriyama, T; Kim, MR; Takai, Y; Pru, JK; Kolesnick, RN; Tilly, JL				Perez, GI; Jurisicova, A; Matikainen, T; Moriyama, T; Kim, MR; Takai, Y; Pru, JK; Kolesnick, RN; Tilly, JL			A central role for ceramide in the age-related acceleration of apoptosis in the female germline	FASEB JOURNAL			English	Article						aging; ovary; oocyte; Bax	CELL-DEATH; OXIDATIVE STRESS; DEFICIENT MICE; CUMULUS CELLS; BAX; GENE; ACTIVATION; EXPRESSION; MEMBRANE; OOCYTES	An age-dependent acceleration of apoptosis occurs in female germ cells (oocytes), and this requires communication between the oocyte and its surrounding somatic ( cumulus) cells. Here we show in aged mice that ceramide is translocated from cumulus cells into the adjacent oocyte and induces germ cell apoptosis that can be prevented by sphingosine-1-phosphate. Trafficking of ceramide requires gap junction-dependent communication between the cumulus cells and the oocyte as well as intact lipid rafts. Further, the occurrence of the elevated incidence of apoptosis in oocytes of aged females is concomitant with an enhanced sensitivity of the oocyte to a spike in cytosolic ceramide levels, as well as increased bax mRNA and Bax protein levels. Thus, the force driving the age-related increase in female germ cell death is multifactorial, but changes in the intercellular trafficking of ceramide, along with hypersensitivity of oocytes to ceramide, are key factors in this process.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv,Vincent Ctr Reprod, Boston, MA 02114 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Memorial Sloan Kettering Cancer Center	Perez, GI (corresponding author), Michigan State Univ, Dept Physiol, 4173 BPS, E Lansing, MI 48824 USA.	perezg@msu.edu	Jurisicova, Andrea/E-4580-2013; Perez, Gloria I/GMX-1286-2022	Kim, Mee-Ran/0000-0003-4492-0768	NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG12279] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anisimov VN, 2003, EXP GERONTOL, V38, P1041, DOI 10.1016/S0531-5565(03)00169-4; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; Braeckman BP, 2001, MECH AGEING DEV, V122, P673, DOI 10.1016/S0047-6374(01)00222-6; Brandwagt BF, 2000, P NATL ACAD SCI USA, V97, P4961, DOI 10.1073/pnas.97.9.4961; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chi FL, 2004, ARCH OTOLARYNGOL, V130, P307, DOI 10.1001/archotol.130.3.307; Contreras FX, 2003, J BIOL CHEM, V278, P37169, DOI 10.1074/jbc.M303206200; Cottrell D A, 2000, Curr Opin Clin Nutr Metab Care, V3, P473, DOI 10.1097/00075197-200011000-00009; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Cutler RG, 2001, MECH AGEING DEV, V122, P895, DOI 10.1016/S0047-6374(01)00246-9; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Diatlovitskaia E V, 1995, Biokhimiia, V60, P1302; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; DOWNS SM, 1995, DEV BIOL, V167, P502, DOI 10.1006/dbio.1995.1044; FADDY MJ, 1992, HUM REPROD, V7, P1342, DOI 10.1093/oxfordjournals.humrep.a137570; Fujino Y, 1996, HUM REPROD, V11, P1480; Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grazide S, 2004, J BIOL CHEM, V279, P18256, DOI 10.1074/jbc.M314105200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Gulbins Erich, 2002, Subcell Biochem, V36, P229; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Jazwinski SM, 2000, TRENDS GENET, V16, P506, DOI 10.1016/S0168-9525(00)02119-3; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; JIN K, 1994, ACTA DERM-VENEREOL, V74, P337; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; Knight JA, 2001, ADV CLIN CHEM, V35, P1, DOI 10.1016/S0065-2423(01)35014-X; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187; Lang KS, 2004, AM J PHYSIOL-RENAL, V286, pF1046, DOI 10.1152/ajprenal.00263.2003; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Muradian K, 2001, Z GERONTOL GERIATR, V34, P441, DOI 10.1007/s003910170015; Nagasawa H, 2002, CANCER RES, V62, P2531; Nicolas A S, 1999, J Nutr Health Aging, V3, P77; Obeid Lina M, 2003, Sci Aging Knowledge Environ, V2003, pPE27, DOI 10.1126/sageke.2003.39.pe27; Pan H, 2001, GENOMICS, V77, P58, DOI 10.1006/geno.2001.6614; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perez GI, 1997, HUM REPROD, V12, P2781, DOI 10.1093/humrep/12.12.2781; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; RAMBHATLA L, 1995, MOL REPROD DEV, V41, P314, DOI 10.1002/mrd.1080410306; RICHARDSON SJ, 1987, J CLIN ENDOCR METAB, V65, P1231, DOI 10.1210/jcem-65-6-1231; Rucker EB, 2000, MOL ENDOCRINOL, V14, P1038, DOI 10.1210/me.14.7.1038; Schondorf T, 2001, CLIN EXP MED, V1, P1, DOI 10.1007/PL00012236; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wilcke M, 2001, BBA-PROTEIN STRUCT M, V1544, P358, DOI 10.1016/S0167-4838(00)00250-8; Wu J, 2000, FERTIL STERIL, V74, P1137, DOI 10.1016/S0015-0282(00)01597-1	67	77	88	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					860	+		10.1096/fj.04-2903fje	http://dx.doi.org/10.1096/fj.04-2903fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728664				2022-12-28	WOS:000227591900011
J	Frantz, S; Calvillo, L; Tillmanns, J; Elbing, I; Dienesch, C; Bischoff, H; Ertl, G; Bauersachs, J				Frantz, S; Calvillo, L; Tillmanns, J; Elbing, I; Dienesch, C; Bischoff, H; Ertl, G; Bauersachs, J			Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose	FASEB JOURNAL			English	Article						diabetes mellitus; myocardial infarction; inflammation; oxidative stress	ISCHEMIA-REPERFUSION INJURY; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTOR; IN-VIVO; DIABETES-MELLITUS; OXIDATIVE STRESS; HEART; TOLERANCE; MORTALITY	Protective effects of the alpha-glucosidase inhibitor acarbose have been reported for various diabetic complications. In the STOP-NIDDM study, even patients without overt diabetes, but with impaired glucose tolerance, had a reduction in cardiovascular events when treated with acarbose. Therefore, we investigated the effect of repetitive postprandial hyperglycemia on the cardiac ischemia/reperfusion injury in vivo. Mice were treated daily by single applications of placebo, sucrose ( 4 g/kg body weight), or sucrose + acarbose ( 10 mg/kg body weight) by gavage for 7 days. Acarbose treatment significantly reduced the sucrose-induced increase in plasma glucose concentration. Subsequently, animals underwent 30 min of ischemia by coronary artery ligation and 24 h of reperfusion in vivo. In the sucrose group, ischemia/reperfusion damage was significantly increased (infarct/area at risk, placebo vs. sucrose, 38.8 +/- 7.5% vs. 62.2 +/- 4.8%, P< 0.05). This was prevented by acarbose treatment (infarct/area at risk 30.7 +/- 7.2%). While myocardial inflammation was similar in all groups, oxidative stress as indicated by a significant increase in lipid peroxides was enhanced in the sucrose, but not in the sucrose + acarbose group. In summary, repetitive postprandial hyperglycemia increases ischemia/reperfusion damage. This effect can be prevented by treatment with the alpha-glucosidase inhibitor acarbose.	Univ Wurzburg, Med Klin, D-97080 Wurzburg, Germany; Bayer AG, BHC PH R EU CV III, D-5600 Wuppertal, Germany	University of Wurzburg; Bayer AG	Bauersachs, J (corresponding author), Univ Wurzburg, Med Klin, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	bauersachs_j@medizin.uni-wuerzburg.de	Frantz, Stefan/G-1723-2012; calvillo, laura/K-1901-2019	calvillo, laura/0000-0002-5151-8243				Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; CARREA FP, 1991, CIRC RES, V68, P1652, DOI 10.1161/01.RES.68.6.1652; Ceriello A, 2001, DIABETOLOGIA, V44, P834; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Ebel D, 2003, PFLUG ARCH EUR J PHY, V446, P175, DOI 10.1007/s00424-003-1051-x; Feuvray D, 1997, CARDIOVASC RES, V34, P113, DOI 10.1016/S0008-6363(97)00037-0; Frantz S, 2004, BRIT J PHARMACOL, V141, P9, DOI 10.1038/sj.bjp.0705585; Frantz S, 2003, CARDIOVASC RES, V57, P749, DOI 10.1016/S0008-6363(02)00723-X; Frantz S, 2003, J MOL CELL CARDIOL, V35, P685, DOI 10.1016/S0022-2828(03)00113-5; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Jones SP, 2003, AM J PHYSIOL-HEART C, V284, pH277, DOI 10.1152/ajpheart.00236.2002; Jones SP, 1999, AM J PHYSIOL-HEART C, V277, pH763, DOI 10.1152/ajpheart.1999.277.2.H763; Kersten JR, 1998, AM J PHYSIOL-HEART C, V275, pH721, DOI 10.1152/ajpheart.1998.275.2.H721; King GL, 2004, HISTOCHEM CELL BIOL, V122, P333, DOI 10.1007/s00418-004-0678-9; Lefer DJ, 2001, FASEB J, V15, P1454, DOI 10.1096/fj.00-0819fje; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Paulson DJ, 1997, CARDIOVASC RES, V34, P104, DOI 10.1016/S0008-6363(97)00018-7; PULS W, 1977, NATURWISSENSCHAFTEN, V64, P536, DOI 10.1007/BF00483562; Rodriguez BL, 1996, DIABETES CARE, V19, P587, DOI 10.2337/diacare.19.6.587; Schafer A, 2004, THROMB HAEMOSTASIS, V92, P97, DOI 10.1160/th04-02-0118; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Vinten-Johansen J, 2004, CARDIOVASC RES, V61, P481, DOI 10.1016/j.cardiores.2003.10.011; Wolever TMS, 1998, DIABETES CARE, V21, P336, DOI 10.2337/diacare.21.3.336; WONG SHY, 1987, CLIN CHEM, V33, P214; Ye F, 2002, PHYTOMEDICINE, V9, P161, DOI 10.1078/0944-7113-00065; ZUANETTI G, 1993, J AM COLL CARDIOL, V22, P1788, DOI 10.1016/0735-1097(93)90758-S	30	52	55	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					591	+		10.1096/fj.04-2459fje	http://dx.doi.org/10.1096/fj.04-2459fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671153				2022-12-28	WOS:000226576600007
J	Judge, S; Jang, YM; Smith, A; Hagen, T; Leeuwenburgh, C				Judge, S; Jang, YM; Smith, A; Hagen, T; Leeuwenburgh, C			Age-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: implications for the mitochondrial theory of aging	FASEB JOURNAL			English	Article						longevity; postmitotic; calorie restriction; life extension	FREE-RADICAL GENERATION; RAT-HEART MITOCHONDRIA; CALORIC RESTRICTION; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; OXIDIZED PROTEINS; OXIDASE; DAMAGE; DNA; IDENTIFICATION	Mitochondrial dysfunction and the accumulation of oxidative damage to macromolecules are believed to play key roles in the aging process. Characterization of age-related changes to cardiac mitochondria has been complicated by the fact that two distinct populations of mitochondria exist in the myocardium: subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria (IFM). We investigated whether differences in hydrogen peroxide production (H2O2) and oxidative stress existed between cardiac SSM and IFM isolated from young ( 6 mo) and old ( 24 mo) male Fischer-344 rats. There was a significant increase in oxidative stress levels (4-hydroxy-2-nonenal-modified proteins, protein carbonyls, and malondialdehyde) in IFM with age. In contrast, only protein carbonyls were elevated in SSM with age. Significant age-related increases in MnSOD, GPX, and CAT activities were detected in IFM, while in SSM, MnSOD, and GPX activities increased with age and CAT activity declined. These increases in antioxidant enzyme activity likely occurred in response to increased mitochondrial production of superoxide and hydrogen peroxide. Indeed, SSM produced more H2O2 with age, while the increase in IFM was not significant, but this may be due to the higher antioxidant enzyme activity observed in IFM compared with SSM. Finally, reduced glutathione levels were significantly lower in IFM compared with SSM in both young and old rats, while glutathione reductase activity was not different with age or mitochondrial subpopulations, indicating increased consumption of glutathione. The accumulation of oxidant-induced damage in IFM may be a major contributing factor to the age-related alterations in myocardial function. Our results emphasize the importance of studying both mitochondrial populations when attempting to elucidate the contribution of mitochondrial dysfunction to myocardial aging.	Univ Florida, Biochem Aging Lab, Gainesville, FL 32611 USA; Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	State University System of Florida; University of Florida; Oregon State University; Oregon State University	Leeuwenburgh, C (corresponding author), Univ Florida, Biochem Aging Lab, POB 118206, Gainesville, FL 32611 USA.	cleeuwen@ufl.edu		Leeuwenburgh, Christiaan/0000-0003-0826-4257	NATIONAL INSTITUTE ON AGING [R01AG017994, R01AG021042] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; ANVERSA P, 1990, CIRC RES, V67, P871, DOI 10.1161/01.RES.67.4.871; Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958; BASS DA, 1983, J IMMUNOL, V130, P1910; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN JJ, 1994, FREE RADICAL BIO MED, V17, P411, DOI 10.1016/0891-5849(94)90167-8; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FROLKIS VV, 1988, GERONTOLOGY, V34, P64, DOI 10.1159/000212932; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; JI LL, 1991, AM J PHYSIOL, V261, pR386, DOI 10.1152/ajpregu.1991.261.2.R386; JI LL, 1993, MED SCI SPORT EXER, V25, P225; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; KATZ AM, 1991, HOSP PRACT, V26, P78; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Lakatta EG, 2002, COMP BIOCHEM PHYS A, V132, P699, DOI 10.1016/S1095-6433(02)00124-1; Leeuwenburgh C, 2001, CURR MED CHEM, V8, P829, DOI 10.2174/0929867013372896; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P37, DOI 10.1006/jmcc.2000.1273; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; Musatov A, 2002, BIOCHEMISTRY-US, V41, P8212, DOI 10.1021/bi025896u; MUSCARI C, 1990, BASIC RES CARDIOL, V85, P172, DOI 10.1007/BF01906970; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; OLIVETTI G, 1994, CARDIOVASC RES, V28, P1199, DOI 10.1093/cvr/28.8.1199; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; PALMER JW, 1977, J BIOL CHEM, V252, P8731; PALMER JW, 1985, ARCH BIOCHEM BIOPHYS, V236, P691, DOI 10.1016/0003-9861(85)90675-7; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; Phaneuf S, 2002, AM J PHYSIOL-REG I, V282, pR423, DOI 10.1152/ajpregu.00296.2001; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; SIRI FM, 1991, AM J PHYSIOL, V261, pH514, DOI 10.1152/ajpheart.1991.261.2.H514; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stowe DF, 2004, ANTIOXID REDOX SIGN, V6, P439, DOI 10.1089/152308604322899512; Suh JH, 2003, FREE RADICAL BIO MED, V35, P1064, DOI 10.1016/S0891-5849(03)00468-4	56	230	237	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					419	+		10.1096/fj.04-2622fje	http://dx.doi.org/10.1096/fj.04-2622fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15642720				2022-12-28	WOS:000226576600025
J	Desrumaux, C; Risold, PY; Schroeder, H; Deckert, V; Masson, D; Athias, A; Laplanche, H; Le Guern, N; Blache, D; Jiang, XC; Tall, A; Desor, D; Lagrost, L				Desrumaux, C; Risold, PY; Schroeder, H; Deckert, V; Masson, D; Athias, A; Laplanche, H; Le Guern, N; Blache, D; Jiang, XC; Tall, A; Desor, D; Lagrost, L			Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice.	FASEB JOURNAL			English	Article						tocopherol; neurodegenerative diseases; alpha-tocopherol; PLTP-deficient mice	TOCOPHEROL TRANSFER PROTEIN; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; MOUSE MODELS; NEURODEGENERATIVE DISEASES; PLASMA; ANTIOXIDANTS; ATHEROSCLEROSIS	Vitamin E supplementation constitutes a promising strategy in the prevention of neurodegenerative diseases. Here, we show that a phospholipid transfer protein (PLTP) is widely expressed in the brain where it appears to function as a transfer factor for alpha-tocopherol, the main isomer of vitamin E. PLTP deficiency results in significant depletion of brain alpha-tocopherol in both homozygous ( - 30.1%, P< 0.0002) and heterozygous ( - 18.0%, P< 0.05) PLTP knocked-out mice. alpha-tocopherol depletion in PLTP-deficient homozygotes is associated with the elevation of lipofuscin (+ 25% and + 450% increases in cortex and substantia nigra, respectively), cholesterol oxides (+54.5%, P< 0.05), and cellular peroxides (+ 32.3%, P< 0.01) in the brain. Complete PLTP deficiency in homozygotes is accompanied by increased anxiety as shown by fewer entries (8.3% vs. 44.4% in controls, P< 0.01) and less time spent (1.7% vs. 41.3% in controls, P< 0.05) in the open arms of an elevated plus-maze, in the absence of locomotor deterioration. Thus, the vitamin E transfer activity of PLTP appears to be a key process in preventing oxidative damage in the brain, and PLTP-deficient mice could be a new model of the contribution of oxidative brain injury in the etiology of neurodegenerative diseases.	Fac Med, INSERM, U498, IFR100,Lab Biochim Lipoprot, F-21079 Dijon, France; Fac Med & Pharm, Histol Lab, Besancon, France; Fac Sci, Lab Neurosci Comportementales, Vandoeuvre Les Nancy, France; SUNY Downstate Med Ctr, Brooklyn, NY 11203 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Lorraine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University	Lagrost, L (corresponding author), Fac Med, INSERM, U498, IFR100,Lab Biochim Lipoprot, 7 Bd Jeanne dArc,BP 87900, F-21079 Dijon, France.	Laurent.Lagrost@u-bourgogne.fr	Desrumaux, Catherine/O-1925-2018; Masson, David/R-6633-2019; MASSON, David/AAC-8896-2022; Tall, Alan/AAT-8528-2021; MASSON, David/R-4557-2017; Risold, Pierre-Yves/AAJ-9535-2021; Risold, Pierre-Yves/M-7730-2018	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; Risold, Pierre-Yves/0000-0001-6801-591X; DECKERT, Valerie/0000-0001-5728-1710				Albers JJ, 2004, CURR OPIN LIPIDOL, V15, P255, DOI 10.1097/00041433-200406000-00004; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Behl C, 2002, FREE RADICAL BIO MED, V33, P182, DOI 10.1016/S0891-5849(02)00883-3; Bertoli-Avella AM, 2004, HUM GENET, V114, P413, DOI 10.1007/s00439-004-1097-7; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Chowdhury PK, 2004, PHOTOCHEM PHOTOBIOL, V79, P21; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; Copp RP, 1999, BRAIN RES, V822, P80, DOI 10.1016/S0006-8993(99)01090-2; Di Matteo V, 2003, CNS NEUROL DISORD-DR, V2, P95, DOI 10.2174/1568007033482959; Esposito E, 2002, NEUROBIOL AGING, V23, P719, DOI 10.1016/S0197-4580(02)00078-7; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Gander R, 2002, J LIPID RES, V43, P636; GOHIL K, FREE RADIC BIOL MED, V35, P1343; Guyard-Dangremont V, 1998, COMP BIOCHEM PHYS B, V120, P517, DOI 10.1016/S0305-0491(98)10038-X; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Higgins GA, 2003, BEHAV PHARMACOL, V14, P419, DOI 10.1097/01.fbp.0000088420.18414.ff; Iuliano L, 2003, ANAL BIOCHEM, V312, P217, DOI 10.1016/S0003-2697(02)00467-0; Jiang XC, 2002, FRONT BIOSCI-LANDMRK, V7, pD1634, DOI 10.2741/jiang1; Jiang XC, 2002, J BIOL CHEM, V277, P31850, DOI 10.1074/jbc.M205077200; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Katsanidis E, 1999, FREE RADICAL BIO MED, V27, P1137, DOI 10.1016/S0891-5849(99)00205-1; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; Lie J, 2004, J LIPID RES, V45, P805, DOI 10.1194/jlr.M300487-JLR200; MONJI A, 1994, BRAIN RES, V634, P62, DOI 10.1016/0006-8993(94)90258-5; Moosmann B, 2002, EXPERT OPIN INV DRUG, V11, P1407, DOI 10.1517/13543784.11.10.1407; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Phinney AL, 2003, NEUROL RES, V25, P590, DOI 10.1179/016164103101202020; Pratico D, 2002, FASEB J, V16, P1138, DOI 10.1096/fj.02-0012fje; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972; Pratico Domenico, 2002, Sci Aging Knowledge Environ, V2002, pre5; Price DL, 1996, BRAIN PATHOL, V6, P467, DOI 10.1111/j.1750-3639.1996.tb00876.x; Rao AV, 2002, NUTR NEUROSCI, V5, P291, DOI 10.1080/1028415021000033767; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; Schlitt A, 2003, ARTERIOSCL THROM VAS, V23, P1857, DOI 10.1161/01.ATV.0000094433.98445.7F; Sun AY, 1998, J BIOMED SCI, V5, P401; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Treuting PM, 2002, EXP MOL PATHOL, V72, P49, DOI 10.1006/exmp.2001.2405; van Haperen R, 2002, J BIOL CHEM, V277, P48938, DOI 10.1074/jbc.M209128200; Vuletic S, 2003, J LIPID RES, V44, P1113, DOI 10.1194/jlr.M300046-JLR200; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Yang XP, 2003, ARTERIOSCL THROM VAS, V23, P1601, DOI 10.1161/01.ATV.0000085841.55248.13; Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098	48	101	104	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					296	+		10.1096/fj.04-2400fje	http://dx.doi.org/10.1096/fj.04-2400fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576481				2022-12-28	WOS:000226091000025
J	Montuschi, P; Barnes, PJ; Roberts, LJ				Montuschi, P; Barnes, PJ; Roberts, LJ			Isoprostanes: markers and mediators of oxidative stress	FASEB JOURNAL			English	Review						lipid peroxidation; F-2-isoprostanes; neuroprostanes; F-ring	8-EPI-PROSTAGLANDIN F-2 ALPHA; ENHANCED LIPID-PEROXIDATION; EXHALED BREATH CONDENSATE; IN-VIVO FORMATION; OXIDANT STRESS; PLATELET ACTIVATION; 8-ISO-PROSTAGLANDIN F2-ALPHA; ALZHEIMERS-DISEASE; VITAMIN-E; INCREASED 8,12-ISO-IPF(2-ALPHA)-VI	Some years ago it was discovered that prostaglandin F-2-like compounds are formed in vivo by nonenzymatic free radical-catalyzed peroxidation of arachidonic acid. Because these compounds are a series of isomers that contain the prostane ring of prostaglandins, they were termed F-2-isoprostanes. Intermediates in the isoprostane pathway are prostaglandin H-2-like compounds that become reduced to form F-2-isoprostanes but also undergo rearrangement in vivo to form E-2-, D-2-, A(2)-, J(2)-isoprostanes, isothromboxanes, and highly reactive gamma-ketoaldehydes, termed isoketals. Analogous compounds have also been shown to be formed from free radical mediated oxidation of docosoahexaenoic acid. Because docosahexaenoic acid is highly enriched in neurons, these compounds have been termed neuroprostanes and neuroketals. An important aspect of the discovery of isoprostanes is that measurement of F-2-isoprostanes has emerged as one of the most reliable approaches to assess oxidative stress status in vivo, providing an important tool to explore the role of oxidative stress in the pathogenesis of human disease. Measurement of F-4-neuroprostanes has also proved of value in exploring the role of oxidative stress in neurodegenerative diseases. Products of the isoprostane pathway have been found to exert potent biological actions and therefore may participate as physiological mediators of disease.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Univ Cattolica Sacro Cuore, Sch Med, Dept Pharmacol, I-00168 Rome, Italy; Natl Heart & Lung Inst, Fac Med, Imperial Coll, Dept Thorac Med, London, England	Vanderbilt University; Vanderbilt University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Imperial College London	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, 522 RRB,23rd & Pierce Ave, Nashville, TN 37232 USA.	jack.roberts@vanderbilt.edu		MONTUSCHI, Paolo/0000-0001-5589-1750; Barnes, Peter/0000-0002-5122-4018	NIGMS NIH HHS [GM42056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, R01GM042056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboutwerat A, 2003, BBA-MOL BASIS DIS, V1637, P142, DOI 10.1016/S0925-4439(02)00225-9; Audoly LP, 2000, CIRCULATION, V101, P2833, DOI 10.1161/01.CIR.101.24.2833; Bachi A, 1996, FREE RADICAL BIO MED, V20, P619, DOI 10.1016/0891-5849(95)02087-X; Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747; Beauchamp MH, 2001, J APPL PHYSIOL, V90, P2279, DOI 10.1152/jappl.2001.90.6.2279; Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Burke A, 2002, TRANSPLANTATION, V74, P217, DOI 10.1097/00007890-200207270-00012; CAILLEUX A, 1993, FREE RADICAL RES COM, V18, P323, DOI 10.3109/10715769309147499; Carpenter CT, 1998, CHEST, V114, P1653, DOI 10.1378/chest.114.6.1653; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Ciabattoni G, 2000, AM J RESP CRIT CARE, V162, P1195, DOI 10.1164/ajrccm.162.4.9911071; Cracowski JL, 2002, TRENDS PHARMACOL SCI, V23, P360, DOI 10.1016/S0165-6147(02)02053-9; Cracowski JL, 2002, AM J GASTROENTEROL, V97, P99; Cracowski JL, 2001, ARTHRITIS RHEUM-US, V44, P1143, DOI 10.1002/1529-0131(200105)44:5<1143::AID-ANR196>3.0.CO;2-#; Davi G, 2001, CIRCULATION, V104, P1124, DOI 10.1161/hc3501.095287; Davi G, 1999, CIRCULATION, V99, P224; Davi G, 1997, ARTERIOSCL THROM VAS, V17, P3230, DOI 10.1161/01.ATV.17.11.3230; Davies SS, 2002, FASEB J, V16, P715, DOI 10.1096/fj.01-0696fje; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; Dietz S, 2002, BRILLS TIBET STU LIB, V2, P13; Dworski R, 1999, AM J RESP CRIT CARE, V160, P1947, DOI 10.1164/ajrccm.160.6.9903064; Fam SS, 2002, J BIOL CHEM, V277, P36076, DOI 10.1074/jbc.M205638200; Fessel JP, 2002, P NATL ACAD SCI USA, V99, P16713, DOI 10.1073/pnas.252649099; Fontana L, 2002, CIRCULATION, V106, P2434, DOI 10.1161/01.CIR.0000037223.92135.38; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; Gay CA, 2003, ANAL BIOCHEM, V315, P29, DOI 10.1016/S0003-2697(02)00606-1; Gopaul NK, 2000, FREE RADICAL RES, V33, P115, DOI 10.1080/10715760000300671; Gopaul NK, 2000, FREE RADICAL BIO MED, V28, P806, DOI 10.1016/S0891-5849(00)00167-2; Greco A, 2000, NEUROCHEM RES, V25, P1357, DOI 10.1023/A:1007608615682; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HALLIWELL B, 1987, FEBS LETT, V213, P9, DOI 10.1016/0014-5793(87)81455-2; Halliwell B, 2000, CARDIOVASC RES, V47, P410, DOI 10.1016/S0008-6363(00)00097-3; Helmersson J, 1999, PROSTAG LEUKOTR ESS, V61, P203; Helmersson J, 2001, PROSTAG LEUKOTR ESS, V65, P99, DOI 10.1054/plef.2001.0295; Holt S, 1999, LANCET, V353, P1241, DOI 10.1016/S0140-6736(98)05768-7; Hou X, 2001, AM J PHYSIOL-REG I, V281, pR391, DOI 10.1152/ajpregu.2001.281.2.R391; Hou X, 2000, STROKE, V31, P516, DOI 10.1161/01.STR.31.2.516; Ide T, 2002, ARTERIOSCL THROM VAS, V22, P438, DOI 10.1161/hq0302.104515; Ikizler TA, 2002, CLIN NEPHROL, V58, P190; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067, DOI 10.1152/ajplung.2001.280.6.L1067; Janssen LJ, 2002, J PHARMACOL EXP THER, V301, P1060, DOI 10.1124/jpet.301.3.1060; Kawikova I, 1996, AM J RESP CRIT CARE, V153, P590, DOI 10.1164/ajrccm.153.2.8564103; Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11; Klein T, 1997, J PHARMACOL EXP THER, V282, P1658; Knutson MD, 1999, FREE RADICAL BIO MED, V27, P560, DOI 10.1016/S0891-5849(99)00095-7; Kritharides L, 2002, ATHEROSCLEROSIS, V164, P211, DOI 10.1016/S0021-9150(02)00011-4; Kromer BM, 1996, BRIT J PHARMACOL, V119, P1276, DOI 10.1111/j.1476-5381.1996.tb16033.x; Kunapuli P, 1997, J BIOL CHEM, V272, P27147, DOI 10.1074/jbc.272.43.27147; Kunapuli P, 1998, J BIOL CHEM, V273, P22442, DOI 10.1074/jbc.273.35.22442; Lahaie I, 1998, AM J PHYSIOL-REG I, V274, pR1406, DOI 10.1152/ajpregu.1998.274.5.R1406; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536; Marley R, 1997, GASTROENTEROLOGY, V112, P208, DOI 10.1016/S0016-5085(97)70237-3; McAdam BF, 2000, J CLIN INVEST, V105, P1473, DOI 10.1172/JCI9523; Meagher E, 2001, TRENDS CARDIOVAS MED, V11, P162, DOI 10.1016/S1050-1738(01)00105-0; Meagher EA, 1999, J CLIN INVEST, V104, P805, DOI 10.1172/JCI5584; Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178; Minuz P, 2002, CIRCULATION, V106, P2800, DOI 10.1161/01.CIR.0000039528.49161.E9; Monteverde F, 1999, J MATER PROCESS MANU, V8, P2, DOI 10.1106/2PCG-JEFH-5A1E-1J7H; Montine TJ, 1999, AM J PATHOL, V155, P863, DOI 10.1016/S0002-9440(10)65185-1; Montine TJ, 1999, NEUROLOGY, V52, P1104, DOI 10.1212/WNL.52.5.1104; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; Montuschi P, 2000, THORAX, V55, P205, DOI 10.1136/thorax.55.3.205; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Montuschi P, 2002, NAT REV DRUG DISCOV, V1, P238, DOI 10.1038/nrd751; Montuschi P, 1998, AM J RESP CRIT CARE, V158, P1524, DOI 10.1164/ajrccm.158.5.9803102; Montuschi P, 2002, TRENDS PHARMACOL SCI, V23, P232, DOI 10.1016/S0165-6147(02)02020-5; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Moore KP, 1998, J BIOL CHEM, V273, P31731, DOI 10.1074/jbc.273.48.31731; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; MORROW JD, 1993, J LIPID MEDIATOR, V6, P417; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; Nonaka-Sarukawa M, 2003, HEART, V89, P871, DOI 10.1136/heart.89.8.871; Okazawa A, 1997, AM J RESP CRIT CARE, V155, P436, DOI 10.1164/ajrccm.155.2.9032175; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; Pratico D, 2000, ANN NEUROL, V48, P795, DOI 10.1002/1531-8249(200011)48:5<795::AID-ANA15>3.0.CO;2-#; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Pratico D, 1998, AM J RESP CRIT CARE, V158, P1709, DOI 10.1164/ajrccm.158.6.9709066; Pratico D, 1998, J INVEST MED, V46, P51; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Proudfoot J, 1999, ANAL BIOCHEM, V272, P209, DOI 10.1006/abio.1999.4187; PRYOR WA, 1976, LIPIDS, V11, P370, DOI 10.1007/BF02532843; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; Reilly MP, 1998, CIRCULATION, V98, P2822, DOI 10.1161/01.CIR.98.25.2822; Reilly MP, 1997, CIRCULATION, V96, P3314; Richelle M, 1999, FEBS LETT, V459, P259, DOI 10.1016/S0014-5793(99)01259-4; Roberts LJ, 1996, J BIOL CHEM, V271, P20617, DOI 10.1074/jbc.271.34.20617; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Stein CM, 1996, ARTHRITIS RHEUM-US, V39, P1146, DOI 10.1002/art.1780390711; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; Vassalle C, 2003, CORONARY ARTERY DIS, V14, P213, DOI 10.1097/01.mca.0000063504.13456.c3; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; Yura T, 1999, KIDNEY INT, V56, P471, DOI 10.1046/j.1523-1755.1999.00596.x	109	560	596	1	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1791	1800		10.1096/fj.04-2330rev	http://dx.doi.org/10.1096/fj.04-2330rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576482				2022-12-28	WOS:000226091000029
J	Rong, LL; Yan, SF; Wendt, T; Hans, D; Pachydaki, S; Bucciarelli, LG; Adebayo, A; Qu, W; Lu, Y; Kostov, K; Lalla, E; Yan, SD; Gooch, C; Szabolcs, M; Trojaborg, W; Hays, AP; Schmidt, AM				Rong, LL; Yan, SF; Wendt, T; Hans, D; Pachydaki, S; Bucciarelli, LG; Adebayo, A; Qu, W; Lu, Y; Kostov, K; Lalla, E; Yan, SD; Gooch, C; Szabolcs, M; Trojaborg, W; Hays, AP; Schmidt, AM			RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways	FASEB JOURNAL			English	Article						transgenic mice; signal transduction; sciatic nerve	GLYCATION END-PRODUCTS; ADHESION MOLECULES L1; NEURITE OUTGROWTH; IN-VITRO; N-CAM; RECEPTOR; AMPHOTERIN; PROTEINS; BINDING; INJURY	Axotomy of peripheral nerve stimulates events in multiple cell types that initiate a limited inflammatory response to axonal degeneration and simultaneous outgrowth of neurites into the distal segments after injury. We found that pharmacological blockade of RAGE impaired peripheral nerve regeneration in mice subjected to RAGE blockade and acute crush of the sciatic nerve. As our studies revealed that RAGE was expressed in axons and in infiltrating mononuclear phagocytes upon injury, we tested the role of RAGE in these distinct cell types on nerve regeneration. Transgenic mice expressing signal transduction-deficient RAGE in mononuclear phagocytes or peripheral neurons were generated and subjected to unilateral crush injury to the sciatic nerve. Transgenic mice displayed decreased functional and morphological recovery compared with littermate controls, as assessed by motor and sensory conduction velocities; and myelinated fiber density. In double transgenic mice expressing signal transduction deficient RAGE in both mononuclear phagocytes and peripheral neurons, regeneration was even further impaired, suggesting the critical interplay between RAGE-modulated inflammation and neurite outgrowth in nerve repair. These findings suggest that RAGE signaling in inflammatory cells and peripheral neurons plays an important role in plasticity of the peripheral nervous system.	Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, 630 W 168th St,P&S 17-401, New York, NY 10032 USA.	ams11@columbia.edu	Gooch, Clifton L/M-1874-2016	Gooch, Clifton L/0000-0002-2210-2038				Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Azzouz M, 1996, EXP NEUROL, V138, P189, DOI 10.1006/exnr.1996.0057; BEUCHE W, 1986, BRAIN RES, V378, P97, DOI 10.1016/0006-8993(86)90289-1; BURNHAM PA, 1974, NEUROBIOLOGY, V4, P57; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Jaffee BD, 2000, BIOCHEM BIOPH RES CO, V268, P647, DOI 10.1006/bbrc.2000.2184; Kiefer R, 2001, PROG NEUROBIOL, V64, P109, DOI 10.1016/S0301-0082(00)00060-5; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Liu RY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-17-j0003.2001; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MIDRONI G, 1995, BIOPSY DIAGNOSIS PER, P40; NIEKE J, 1985, DIFFERENTIATION, V30, P141, DOI 10.1111/j.1432-0436.1985.tb00525.x; REICHERT F, 1994, J NEUROSCI, V14, P3231; RONG LL, 2004, FASEB J; Ropert C, 2001, J IMMUNOL, V166, P3423, DOI 10.4049/jimmunol.166.5.3423; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Schwaiger FW, 2000, EUR J NEUROSCI, V12, P1165, DOI 10.1046/j.1460-9568.2000.00005.x; Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009; Sheu JY, 2000, EXP NEUROL, V166, P392, DOI 10.1006/exnr.2000.7508; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; Srikrishna G, 2002, J NEUROCHEM, V80, P998, DOI 10.1046/j.0022-3042.2002.00796.x; SVENSSON B, 1995, NEUROSCI LETT, V200, P33, DOI 10.1016/0304-3940(95)12066-D; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; VARON S, 1973, BRAIN RES, V54, P51, DOI 10.1016/0006-8993(73)90033-4; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	31	108	110	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1818	1825		10.1096/fj.04-1900com	http://dx.doi.org/10.1096/fj.04-1900com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576485				2022-12-28	WOS:000226091000032
J	Vila, G; Papazoglou, M; Stalla, J; Theodoropoulou, M; Stalla, GK; Holsboer, F; Paez-Pereda, M				Vila, G; Papazoglou, M; Stalla, J; Theodoropoulou, M; Stalla, GK; Holsboer, F; Paez-Pereda, M			Sonic hedgehog regulates CRH signal transduction in the adult pituitary	FASEB JOURNAL			English	Article						corticotropin-releasing hormone; corticotropin; pro-opiomelanocortin	CORTICOTROPIN-RELEASING-FACTOR; PROOPIOMELANOCORTIN GENE-TRANSCRIPTION; EXPRESSION; RECEPTORS; PATHWAYS; HORMONE; GLI; INVOLVEMENT; ANXIETY; PROTEIN	Sonic hedgehog (Shh) is a signaling protein that binds to Patched and mediates its effects through Gli transcription factors. Shh is important in regulating survival and growth in both the embryo and the adult. It is known to be involved in pituitary development, but its role in the adult pituitary has not been investigated. Here, we show Shh and Gli1 immunoreactivity in adult human corticotroph cells. Administration of Shh (5 mug/ml) alone and in combination with corticotrophin-releasing hormone (CRH; 100 nM) in dispersed rat anterior pituitary and AtT-20 mouse corticotrophinoma cells increased corticotrophin (ACTH) secretion and proopiomelanocortin (POMC) promoter activity. Shh and CRH act additively in increasing CRH receptor 1 (CRH-R1). Unexpectedly, we found that CRH on its own increased Gli-dependent transcription, which in turn stimulated POMC transcription. Gli1 is necessary for CRH signaling, since knocking down Gli1 by RNA interference abolished the stimulatory effect of CRH on POMC. Taken together, our results demonstrate a new role for Shh and Gli1 in corticotroph function and provide a new link between Shh and CRH signaling pathways.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Paez-Pereda, M (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 10, D-80804 Munich, Germany.	marcelo@mpipsykl.mpg.de	Theodoropoulou, Marily/S-9546-2017; Vila, Greisa/P-1335-2018	Theodoropoulou, Marily/0000-0002-7378-4374; Paez-Pereda, Marcelo/0000-0001-6029-0706; Vila, Greisa/0000-0003-1918-1959				Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; ARZT E, 1992, J CLIN INVEST, V90, P1944, DOI 10.1172/JCI116072; Arzt E, 1999, FRONT NEUROENDOCRIN, V20, P71, DOI 10.1006/frne.1998.0176; Autelitano DJ, 1996, MOL CELL ENDOCRINOL, V119, P25, DOI 10.1016/0303-7207(96)03791-4; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Boutillier A L, 1998, Pituitary, V1, P33, DOI 10.1023/A:1009966808106; BOUTILLIER AL, 1995, MOL ENDOCRINOL, V9, P745, DOI 10.1210/me.9.6.745; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; Brar BK, 2004, ENDOCRINOLOGY, V145, P1718, DOI 10.1210/en.2003-1023; Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495; GAGNER JP, 1987, MOL ENDOCRINOL, V1, P677, DOI 10.1210/mend-1-10-677; Grammatopoulos DK, 2002, TRENDS ENDOCRIN MET, V13, P436, DOI 10.1016/S1043-2760(02)00670-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; LIU B, 1992, MOL CELL BIOL, V12, P3978, DOI 10.1128/MCB.12.9.3978; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Muller MB, 2003, NAT NEUROSCI, V6, P1100, DOI 10.1038/nn1123; Muller MB, 2001, ENDOCRINOLOGY, V142, P4150, DOI 10.1210/en.142.9.4150; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Nikodemova M., 2002, Archives of Physiology and Biochemistry, V110, P123, DOI 10.1076/apab.110.1.123.901; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; Paez-Pereda M, 2001, J CLIN INVEST, V108, P1123, DOI 10.1172/JCI11098; Pereda MP, 2000, J CLIN ENDOCR METAB, V85, P263, DOI 10.1210/jc.85.1.263; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Reul JMHM, 2002, CURR OPIN PHARMACOL, V2, P23, DOI 10.1016/S1471-4892(01)00117-5; Roessler E, 2003, P NATL ACAD SCI USA, V100, P13424, DOI 10.1073/pnas.2235734100; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Scully KM, 2002, SCIENCE, V295, P2231, DOI 10.1126/science.1062736; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; Treier M, 2001, DEVELOPMENT, V128, P377	35	35	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					281	+		10.1096/fj.04-2138fje	http://dx.doi.org/10.1096/fj.04-2138fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15572433				2022-12-28	WOS:000225482100002
J	Chan, MHS; McGee, SL; Watt, MJ; Hargreaves, M; Febbraio, MA				Chan, MHS; McGee, SL; Watt, MJ; Hargreaves, M; Febbraio, MA			Altering dietary nutrient intake that reduces glycogen content leads to phosphorylation of nuclear p38 MAP kinase in human skeletal muscle: association with IL-6 gene transcription during contraction	FASEB JOURNAL			English	Article						cytokines; JNK; nuclear transcription factors; myocellular	NF-KAPPA-B; JUN NH2-TERMINAL KINASE; C-JUN; SIGNALING PATHWAYS; INTERLEUKIN-6; EXPRESSION; EXERCISE; ACTIVATION; INCREASES; LIPOPOLYSACCHARIDE	To determine the effect of glycogen availability and contraction on intracellular signaling and IL-6 gene transcription, eight males performed 60 min of exercise on two occasions: either with prior ingestion of a normal (Con) or low carbohydrate (LCHO) diet that reduced pre-exercise muscle glycogen content. Muscle biopsies were obtained and analyzed for IL-6 mRNA. In addition, nuclear proteins were isolated from the samples and analyzed for the mitogen-activated protein kinases ( MAPK) c-jun amino-terminal kinase (JNK) 1 and 2 and p38 MAPK. Nuclear fractions were also analyzed for the phosphorylated forms of JNK (p-JNK) and p38 MAPK (p-p38 MAPK) and the abundance of the nuclear transcription factors nuclear factor of activated T cells (NFAT) and nuclear factor kappa-beta (NF-kappabeta). No differences were observed in the protein abundance of total JNK 1/2, p38 MAPK, NFAT, or NF-kappabeta before exercise, but the nuclear abundance of p-p38 MAPK was higher (P<0.05) in LCHO. Contraction resulted in an increase (P<0.05) in nuclear p-JNK 1/2, but there were no differences when comparing CON with LCHO. The fold increase in IL-6 mRNA with contraction was potentiated (P<0.05) in LCHO. A correlation between pre-exercise nuclear phosphorylated p38 MAPK and contraction-induced fold increase in IL-6 mRNA was performed, revealing a highly significant correlation (r=0.96; P<0.01). We next incubated L6 myotubes in ionomycin ( a compound known to induce IL-6 mRNA) with or without the pyridinylimidazole p38 MAPK inhibitor SB203580. Treatments did not affect total nuclear p38 MAPK, but ionomycin increased (P<0.05) both nuclear p-p38 MAPK and IL-6 mRNA. The addition of SB203580 to ionomycin decreased (P<0.05) nuclear p-p38 MAPK and totally abolished (P<0.05) the ionomycin-induced increase in IL-6 mRNA. These data suggest that reduced carbohydrate intake that results in low intramuscular glycogen leads to phosphorylation of p38 MAPK at the nucleus. Furthermore, phosphorylation of p38 MAPK in the nucleus appears to be an upstream target for IL-6, providing new insights into the regulation of IL-6 gene transcription.	Royal Melbourne Inst Technol, Sch Med Sci, Skeletal Muscle Res Lab, Bundoora, Vic 3083, Australia; Deakin Univ, Sch Exercise & Nutr Sci, Ctr Phys Act & Nutr, Burwood 3125, Australia	Royal Melbourne Institute of Technology (RMIT); Deakin University	Febbraio, MA (corresponding author), RMIT Univ, Sch Med Sci, Skeletal Muscle Res Lab, POB 71, Bundoora, Vic 3083, Australia.	mark.febbraio@rmit.edu.au	Febbraio, Mark/AAE-9632-2019; Watt, Matthew J/B-2089-2014	McGee, Sean/0000-0001-6953-106X; Chan, Stanley/0000-0002-4103-9441; Febbraio, Mark/0000-0002-9296-4418; Hargreaves, Mark/0000-0002-3694-5335				Aronson D, 1998, BIOCHEM BIOPH RES CO, V251, P106, DOI 10.1006/bbrc.1998.9435; Baldwin J, 2003, J APPL PHYSIOL, V94, P2181, DOI 10.1152/japplphysiol.00866.2002; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Carey AL, 2003, BIOCHEM BIOPH RES CO, V302, P837, DOI 10.1016/S0006-291X(03)00267-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; Frost RA, 2003, AM J PHYSIOL-REG I, V285, pR1153, DOI 10.1152/ajpregu.00164.2003; Frost RA, 2002, AM J PHYSIOL-REG I, V283, pR698, DOI 10.1152/ajpregu.00039.2002; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; Hiscock N, 2004, FASEB J, V18, P992, DOI 10.1096/fj.03-1259fje; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; KELLER C, 2002, J PHYSL, pP539; Keller ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Kosmidou I, 2002, AM J RESP CELL MOL, V26, P587, DOI 10.1165/ajrcmb.26.5.4598; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Li NX, 2000, METHOD ENZYMOL, V319, P273; Luo GJ, 2003, AM J PHYSIOL-REG I, V284, pR1249, DOI 10.1152/ajpregu.00490.2002; McGee SL, 2003, DIABETES, V52, P926, DOI 10.2337/diabetes.52.4.926; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Starkie RL, 2001, J PHYSIOL-LONDON, V533, P585, DOI 10.1111/j.1469-7793.2001.0585a.x; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; STRAUSS CC, 1992, J ANXIETY DISORD, V6, P89, DOI 10.1016/0887-6185(92)90029-7; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Ullum H, 1996, J ACQ IMMUN DEF SYND, V13, P93, DOI 10.1097/00042560-199609000-00013; Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673	33	91	94	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1785	+		10.1096/fj.03-1039fje	http://dx.doi.org/10.1096/fj.03-1039fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345683				2022-12-28	WOS:000224243200036
J	Maga, G; Blanca, G; Shevelev, I; Frouin, I; Ramadan, K; Spadari, S; Villani, G; Hubscher, U				Maga, G; Blanca, G; Shevelev, I; Frouin, I; Ramadan, K; Spadari, S; Villani, G; Hubscher, U			The human DNA polymerase lambda interacts with PCNA through a domain important for DNA primer binding and the interaction is inhibited by p21(/WAF1/CIP1)	FASEB JOURNAL			English	Article						DNA replication; cell cycle; abasic sites; protein-protein interactions	CELL NUCLEAR ANTIGEN; REPLICATION; REPAIR; PROTEINS; KINASE; ROLES; BETA; ETA; CDK	In this paper we show that DNA polymerase lambda (pol lambda) interacts with proliferating cell nuclear antigen ( PCNA) in vivo in human cells. Moreover, by using recombinant mutated PCNA, we could demonstrate that pol lambda interacts with both the interdomain-connecting loop and the nearby hydrophobic pocket on the anterior of PCNA and that critical residues within a helix-hairpin-helix domain of pol lambda, important for proper DNA primer binding, are also involved in the enzyme's interaction with PCNA. Finally, we show that the tumor suppressor protein p21(WAF1/CIP1) can efficiently compete in vitro with pol lambda for binding to PCNA. Given the high rate of frameshift mutations induced by pol lambda and its ability to bypass abasic sites, accurate regulation of pol lambda activity by PCNA and p21 concerted action might be important for preventing genetic instability.	CNR, IGM, I-27100 Pavia, Italy; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Consiglio Nazionale delle Ricerche (CNR); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Zurich	Maga, G (corresponding author), CNR, IGM, Via Abbiategrasso 207, I-27100 Pavia, Italy.	maga@igm.cnr.it	Maga, Giovanni/C-5409-2009	Maga, Giovanni/0000-0001-8092-1552				Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Blanca G, 2003, BIOCHEMISTRY-US, V42, P7467, DOI 10.1021/bi034198m; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Delarue M, 2002, EMBO J, V21, P427, DOI 10.1093/emboj/21.3.427; Frouin I, 2003, EMBO REP, V4, P666, DOI 10.1038/sj.embor.embor886; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Maga G, 2002, J BIOL CHEM, V277, P48434, DOI 10.1074/jbc.M206889200; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Ramadan K, 2003, J MOL BIOL, V328, P63, DOI 10.1016/S0022-2836(03)00265-1; Ramadan K, 2002, J BIOL CHEM, V277, P18454, DOI 10.1074/jbc.M200421200; Shevelev I, 2003, NUCLEIC ACIDS RES, V31, P6916, DOI 10.1093/nar/gkg896; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	32	24	26	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1743	+		10.1096/fj.04-2268fje	http://dx.doi.org/10.1096/fj.04-2268fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15358682	Green Accepted			2022-12-28	WOS:000224243200034
J	Moodie, FM; Marwick, JA; Anderson, CS; Szulakowski, P; Biswas, SK; Bauter, MR; Kilty, I; Rahman, I				Moodie, FM; Marwick, JA; Anderson, CS; Szulakowski, P; Biswas, SK; Bauter, MR; Kilty, I; Rahman, I			Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappa B activation and proinflammatory cytokine release in alveolar epithelial cells	FASEB JOURNAL			English	Article						oxidants; histone acetylation; deacetylation; A549 cells; COPD; HDAC2	HISTONE DEACETYLASE; GENE-TRANSCRIPTION; ACETYLATION; INHIBITION; GLUTATHIONE; ALPHA; EXPRESSION; KINASE; INFLAMMATION; DEGRADATION	Oxidative stress is implicated in lung inflammation due to its effect on proinflammatory gene transcription. Changes in gene transcription depend on chromatin remodeling and the relative activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Alterations in the nuclear histone acetylation: deacetylation balance may result in uncontrolled transcription of specific proinflammatory genes. We studied the effect of hydrogen peroxide (H2O2) and cigarette smoke condensate (CSC) on histone acetylation: deacetylation in human alveolar epithelial cells (A549). H2O2 and CSC significantly increased acetylation of histone H4 proteins and were associated with decreased HDAC activity and HDAC2 levels in A549 cells. Also, the decreased HDAC2 activity was due to protein modification by aldehydes and nitric oxide products. Pretreatment of A549 cells with N-acetyl-L-cysteine attenuated the oxidant-mediated reduction in HDAC activity. Treatment of A549 cells with CSC did not cause nuclear factor-kappaB (NF-kappaB) activation or expression and release of either interleukin (IL)-8 or IL-6. However, H2O2, tumor necrosis factor-alpha (TNF-alpha), and IL-1beta significantly increased NF-kappaB activation and expression of IL-8 compared with control cells. Interestingly, CSC dose dependently inhibited TNF-alpha- and IL-1beta-mediated NF-kappaB activation and IL-8 expression. Thus, H2O2 and CSC enhance acetylation of histone proteins and decrease histone deacetylase activity but differentially regulate proinflammatory cytokine release in alveolar epithelial cells.	Univ Edinburgh, Sch Med, MRC, Ctr Inflammat Res,ELEGI & Colt Res Labs, Edinburgh, Midlothian, Scotland; Pfizer Global Res & Dev, Sandwich, Kent, England; Univ Rochester, Med Ctr, Dept Environm Med, Div Lung Biol & Dis, Rochester, NY 14642 USA	University of Edinburgh; Pfizer; University of Rochester	Rahman, I (corresponding author), Univ Rochester, Med Ctr, Dept Environm Med, Div Lung Biol, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	irfan_rahman@urmc.rochester.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES01247] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fusunyan RD, 1999, MOL MED, V5, P631, DOI 10.1007/BF03402075; Gebel S, 2001, TOXICOL SCI, V59, P75, DOI 10.1093/toxsci/59.1.75; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Horton ND, 1999, J BIOL CHEM, V274, P9200, DOI 10.1074/jbc.274.14.9200; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2000, METH MOLEC MED, V44, P309, DOI 10.1385/1-59259-072-1:309; Ito K., 2001, FASEB Journal, V15, P1110; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; Ng KW, 1997, EMBO J, V16, P2072, DOI 10.1093/emboj/16.8.2072; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pender SLF, 2000, AM J PHYSIOL-GASTR L, V279, pG918, DOI 10.1152/ajpgi.2000.279.5.G918; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; RAGIONE FD, 2001, FEBS LETT, V499, P199; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; RAHMAN I, 1995, AM J PHYSIOL-LUNG C, V269, pL285, DOI 10.1152/ajplung.1995.269.3.L285; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tomita K, 2003, BIOCHEM BIOPH RES CO, V301, P572, DOI 10.1016/S0006-291X(02)03029-2; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vayssier M, 1998, BIOCHEM BIOPH RES CO, V252, P249, DOI 10.1006/bbrc.1998.9586; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Witherden IR, 2004, AM J RESP CELL MOL, V30, P500, DOI 10.1165/rcmb.4890; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	54	231	246	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1897	+		10.1096/fj.04-1506fje	http://dx.doi.org/10.1096/fj.04-1506fje			35	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456740				2022-12-28	WOS:000224243200004
J	Pozo, D; Delgado, M				Pozo, D; Delgado, M			The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?	FASEB JOURNAL			English	Article						immune response; autoimmunity; Th cells; vasoactive intestinal peptide	VASOACTIVE-INTESTINAL-PEPTIDE; ACTIVATING POLYPEPTIDE PACAP; IN-VIVO; TRANSGENIC MICE; CELL EXPRESSION; VPAC2 RECEPTOR; CUTTING EDGE; AUTOIMMUNE; ARTHRITIS; DISEASE	Neuroimmunomodulation has experienced an explosive growth not only in basic research, but expanding to the point that prospective clinical research could be now a reality. A crucial factor for the functioning of this intimate bidirectional network was the demonstration that the immune and neuroendocrine systems speak a mutual biochemical language. This implies 1) production of neuroendocrine hormones and neuropeptides by immune cells and of cytokines by neuroendocrine cells; 2) evidence for shared receptors on cells of the immune and neuroendocrine systems; 3) effect of neuroendocrine mediators on immune functions; and 4) effect of cytokines on the neuroendocrine system. This reduces traditional differences between neurotransmitters, hormones, and immune mediators and raises the following question: what can we now regard as immune or neuroendocrine? Vasoactive intestinal peptide (VIP) is one example of this paradigm. VIP has traditionally been classified as a neuropeptide/neurotransmitter based in its capacity to mediate and regulate neuronal functions. Recent work has demonstrated that VIP is produced by T cells, especially Th2 cells, and that through specific receptors it exerts immunological functions typically ascribed to Th2 cytokines in nervous and immune systems. Here, we postulate that instead of a neuropeptide, VIP could be fully considered a type 2 cytokine with a key role in neuroimmunology.	CSIC, Inst Parasitol & Biomed, Granada, Spain; Univ Seville, Dept Med Biochem & Mol Biol, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Sevilla	Delgado, M (corresponding author), CSIC, Inst Parasitol & Biomed, Granada, Spain.	mdelgado@ipb.csic.es	Delgado, Mario/P-1524-2016; Pozo, David/C-2149-2017	Delgado, Mario/0000-0003-1893-5982; Pozo, David/0000-0002-3732-4960				Abad C, 2003, GASTROENTEROLOGY, V124, P961, DOI 10.1053/gast.2003.50141; Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Colwell CS, 2003, AM J PHYSIOL-REG I, V285, pR939, DOI 10.1152/ajpregu.00200.2003; de Wied D, 1974, EXCERPTA MED INT C S, V359, P653; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 2004, J LEUKOCYTE BIOL, V75, P1122, DOI 10.1189/jlb.1203626; Delgado M, 2003, FASEB J, V17, P1922, DOI 10.1096/fj.02-1029fje; Delgado M, 2003, FASEB J, V17, P944, DOI 10.1096/fj.02-0799fje; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; Delgado M, 2001, J IMMUNOL, V166, P2907, DOI 10.4049/jimmunol.166.5.2907; Delgado M, 2003, TRENDS IMMUNOL, V24, P221, DOI 10.1016/S1471-4906(03)00069-3; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Delgado M, 1999, J IMMUNOL, V163, P3629; Delgado M, 2001, J IMMUNOL, V167, P966, DOI 10.4049/jimmunol.167.2.966; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gomariz R, 2000, ANN NY ACAD SCI, V921, P284; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Gozes I, 2003, CURR PHARM DESIGN, V9, P483, DOI 10.2174/1381612033391667; Grimm MC, 2003, J IMMUNOL, V171, P4990, DOI 10.4049/jimmunol.171.10.4990; GUERRERO JM, 1981, MOL CELL ENDOCRINOL, V21, P151, DOI 10.1016/0303-7207(81)90052-6; Henning RJ, 2001, CARDIOVASC RES, V49, P27, DOI 10.1016/S0008-6363(00)00229-7; Iversen L, 1999, TRENDS NEUROSCI, V22, P482, DOI DOI 10.1016/S0166-2236(99)01429-0; Kastin AJ, 2000, TRENDS NEUROSCI, V23, P113, DOI 10.1016/S0166-2236(99)01525-8; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; McCulloch DA, 2002, BIOCHEM SOC T, V30, P441, DOI 10.1042/bst0300441; Netea MG, 2003, TRENDS IMMUNOL, V24, P254, DOI 10.1016/S1471-4906(03)00079-6; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Petkov V, 2003, J CLIN INVEST, V111, P1339, DOI 10.1172/JCI200317500; PIPER PJ, 1970, NATURE, V225, P1144, DOI 10.1038/2251144a0; Pozo D, 1997, BBA-MOL CELL RES, V1359, P250, DOI 10.1016/S0167-4889(97)00104-3; Pozo D, 2003, TRENDS MOL MED, V9, P211, DOI 10.1016/S1471-4914(03)00049-2; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; Strand FL, 1999, NEUROPEPTIDES REGULA; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Tuncel N, 2000, PEPTIDES, V21, P81, DOI 10.1016/S0196-9781(99)00177-1; VANRAMPELBERGH J, 1997, BIOCHIM BIOPHYS ACTA, V135, P249; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; Williams RO, 2002, ARTHRITIS RHEUM, V46, P271, DOI 10.1002/1529-0131(200201)46:1<271::AID-ART10039>3.0.CO;2-C; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Yung SL, 2003, J BIOL CHEM, V278, P10273, DOI 10.1074/jbc.M211945200	45	72	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1325	1334		10.1096/fj.03-1440hyp	http://dx.doi.org/10.1096/fj.03-1440hyp			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333575	Green Submitted			2022-12-28	WOS:000224243200051
J	Wang, Y; Wimmer, U; Lichtlen, P; Inderbitzin, D; Stieger, B; Meier, PJ; Hunziker, L; Stallmach, T; Forrer, R; Rulicke, T; Georgiev, O; Schaffner, W				Wang, Y; Wimmer, U; Lichtlen, P; Inderbitzin, D; Stieger, B; Meier, PJ; Hunziker, L; Stallmach, T; Forrer, R; Rulicke, T; Georgiev, O; Schaffner, W			Metal-responsive transcription factor-1 (MTF-1) is essential for embryonic liver development and heavy metal detoxification in the adult liver	FASEB JOURNAL			English	Article						heavy metal stress; cadmium toxicity; hematopoiesis; conditional knockout	PLACENTA GROWTH-FACTOR; METALLOTHIONEIN GENE-EXPRESSION; NF-KAPPA-B; MICE LACKING; C-JUN; MOUSE; CELLS; ZINC; DIFFERENTIATION; DEFICIENT	Metal-responsive transcription factor-1 (MTF-1) activates the transcription of metallothionein genes and other target genes in response to heavy metal load and other stresses such as hypoxia and oxidative stress. It also has an essential function during embryogenesis: targeted disruption of Mtf1 in the mouse results in lethal liver degeneration on day 14 of gestation. Here we studied Mtf1 knockout mice at embryonic and adult stages, the latter by means of conditional knockout. Hepatocytes from Mtf1 null mutant and wild-type embryos were taken into culture on day 12.5 of gestation. Both initially appeared normal, but mutant cells were lost within a few days. Furthermore, Mtf1 null hepatocytes were poorly, if at all, rescued by cocultivation with wild-type rat embryo hepatocytes, indicating a cell-autonomous defect. When the Mtf1 gene was excised by Cre recombinase after birth in liver and bone marrow and to a lesser extent in other organs, mice were viable under non-stress conditions but highly susceptible to cadmium toxicity, in support of a role of MTF-1 in coping with heavy metal stress. An additional MTF-1 function was revealed upon analysis of the hematopoietic system in conditional knockout mice where leukocytes, especially lymphocytes, were found to be severely underrepresented. Together, these findings point to a critical role of MTF-1 in embryonic liver formation, heavy metal toxicity, and hematopoiesis.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Dept Internal Med, Div Clin Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Klin Pathol, CH-8091 Zurich, Switzerland; Univ Zurich, Vet Med Labor, CH-8091 Zurich, Switzerland; Univ Zurich, Biol Zent Labor, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich; University of Zurich; University of Zurich; University of Zurich	Schaffner, W (corresponding author), Univ Zurich, Inst Mol Biol, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	walter.schaffner@molbio.unizh.ch	Stieger, Bruno/U-6323-2017	Stieger, Bruno/0000-0002-7190-5785; Hunziker, Lukas/0000-0003-0081-8518				Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Birchmeier C, 1997, CIBA F SYMP, V212, P169; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Egli D, 2003, EMBO J, V22, P100, DOI 10.1093/emboj/cdg012; Erickson JC, 1997, J NEUROSCI, V17, P1271; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Giroux S, 1998, DEV BIOL, V195, P16, DOI 10.1006/dbio.1997.8823; Green CJ, 2001, CANCER RES, V61, P2696; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Kelly EJ, 1996, J NUTR, V126, P1782; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lacal PM, 2000, J INVEST DERMATOL, V115, P1000, DOI 10.1046/j.1523-1747.2000.00199.x; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lichtlen P, 1999, BIOL CHEM, V380, P711, DOI 10.1515/BC.1999.089; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nordberg M, 2000, CELL MOL BIOL, V46, P451; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Reimold AM, 2000, GENE DEV, V14, P152; Ren XY, 2003, WORLD J GASTROENTERO, V9, P1554, DOI 10.3748/wjg.v9.i7.1554; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schofield JP, 1999, HEPATOLOGY, V29, P181, DOI 10.1002/hep.510290112; SCHULZ WA, 1988, EXP CELL RES, V174, P433, DOI 10.1016/0014-4827(88)90313-8; Shiojiri N, 1997, TOHOKU J EXP MED, V181, P1, DOI 10.1620/tjem.181.1; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	42	78	79	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1071	1079		10.1096/fj.03-1282com	http://dx.doi.org/10.1096/fj.03-1282com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15226267				2022-12-28	WOS:000222979200034
J	Scholzen, TE; Steinhoff, M; Sindrilaru, A; Schwarz, A; Bunnett, NW; Luger, TA; Armstrong, CA; Ansel, JC				Scholzen, TE; Steinhoff, M; Sindrilaru, A; Schwarz, A; Bunnett, NW; Luger, TA; Armstrong, CA; Ansel, JC			Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage	FASEB JOURNAL			English	Article						neurogenic inflammation; tachykinins; tachykinin receptors; substance P; sensory neurons	GENE-RELATED PEPTIDE; TACHYKININ NK1 RECEPTOR; SUBSTANCE-P RECEPTORS; GUINEA-PIG ILEUM; DENDRITIC CELLS; HUMAN-MONOCYTES; NEUTRAL ENDOPEPTIDASE; HUMAN-SKIN; NEUTROPHIL ACCUMULATION; CIRCULAR MUSCLE	Sensory neuropeptides such as neurokinin A (NKA) or particularly substance P (SP) by neurokinin receptor (NK-R) activation modulate skin and immune cells functions during neurogenic inflammation. In this study, we examined the relative importance of SP/NK-1Rs or NKA/NK-2Rs in a murine model for allergic contact dermatitis (ACD) and tested if the functional absence of NK-Rs will impair inflammatory response in vivo. Mice lacking NK-1Rs (C57BL/6J-NK-1R(-/-)) displayed a significantly reduced ACD inflammatory ear swelling response to dinitrofluorobenzene (DNFB) with histological less edema and 50% fewer infiltrating leukocytes compared with the ACD response in wild-type (+/+) animals. In NK-1R(+/+) mice, transient NK-1R inhibition impaired ACD sensitization. In vitro haptenized bone marrow-derived dendritic cells from NK-1R(+/+) mice matured in the presence of an NK-1R antagonist displayed a reduced capability to induce T cell proliferation in vitro and ACD after adoptive transfer into naive wild-type mice in vivo. By contrast, NK-2R inhibition significantly enhanced the ACD response in NK-1R null or in wild-type mice, whereas epicutaneous application of NK-2R agonists diminished the ACD inflammation. Thus, NK-1R and SP are required for antigen sensitization and a full inflammatory response to cutaneous allergens and NKA and the NK-2R mediate a contrasting anti-inflammatory role in ACD. Thus, SP, NKA, NK-1R, and NK-2R have important but differential roles in the regulation of cutaneous inflammatory responses.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany; Univ Munster, Dept Dermatol, Inst Expt Dermatol, D-48149 Munster, Germany; Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA	University of Munster; University of Munster; Northwestern University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scholzen, TE (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Von Esmarch Str 58, D-48149 Munster, Germany.	thoscho@uni-muenster.de	Sindrilaru, Anca/G-1203-2014; Steinhoff, Martin/F-6312-2013	Steinhoff, Martin/0000-0002-7090-2187; Bunnett, Nigel W./0000-0003-3367-0644	NIAID NIH HHS [AI41493] Funding Source: Medline; NIAMS NIH HHS [R03AR44969] Funding Source: Medline; NICHD NIH HHS [HD33024] Funding Source: Medline; NIDDK NIH HHS [DK48207, DK39957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039957, R37DK039957] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahluwalia AA, 1998, BRIT J PHARMACOL, V124, P1013, DOI 10.1038/sj.bjp.0701978; ANSEL JC, 1993, J IMMUNOL, V150, P4478; Ansel JC, 1996, J INVEST DERMATOL, V106, P198, DOI 10.1111/1523-1747.ep12330326; ASAHINA A, 1995, J IMMUNOL, V154, P3056; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BRAIN SD, 1986, J INVEST DERMATOL, V87, P533, DOI 10.1111/1523-1747.ep12455620; Brunelleschi S, 1996, NEUROPEPTIDES, V30, P456, DOI 10.1016/S0143-4179(96)90010-4; Brunelleschi S, 2000, NEUROPEPTIDES, V34, P45, DOI 10.1054/npep.1999.0786; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 2002, BRIT J PHARMACOL, V136, P271, DOI 10.1038/sj.bjp.0704697; De Giorgio R, 1998, J NEUROIMMUNOL, V82, P175, DOI 10.1016/S0165-5728(97)00201-4; EK L, 1990, J INVEST DERMATOL, V94, P761; FONG TM, 1996, NEUROGENIC INFLAMMAT, P3; GILLARDON F, 1995, EUR J PHARM-ENVIRON, V293, P395, DOI 10.1016/S0014-2999(95)80098-0; GOEBELER M, 1994, ARCH DERMATOL RES, V286, P341, DOI 10.1007/BF00402226; Grabbe S, 1996, J IMMUNOL, V156, P473; Gunzer M, 2001, J IMMUNOL METHODS, V258, P55, DOI 10.1016/S0022-1759(01)00466-5; GUTWALD J, 1991, J INVEST DERMATOL, V96, P695, DOI 10.1111/1523-1747.ep12470630; Ho WZ, 1997, J IMMUNOL, V159, P5654; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; Holzer P, 1991, PHARMACOL REV, V43, P144; Ichinose M, 1996, PEPTIDES, V17, P1405, DOI 10.1016/S0196-9781(96)00198-2; Inoue A, 1999, J NEUROCHEM, V73, P2206; JEANJEAN AP, 1995, NEUROSCIENCE, V68, P151, DOI 10.1016/0306-4522(95)00106-S; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; Labeur MS, 1999, J IMMUNOL, V162, P168; Lai JP, 1998, J NEUROIMMUNOL, V86, P80, DOI 10.1016/S0165-5728(98)00025-3; Lambrecht BN, 1999, EUR J IMMUNOL, V29, P3815, DOI 10.1002/(SICI)1521-4141(199912)29:12<3815::AID-IMMU3815>3.0.CO;2-#; LEPRE M, 1994, EUR J PHARMACOL, V258, P23, DOI 10.1016/0014-2999(94)90053-1; Lieb K, 1996, J NEUROIMMUNOL, V67, P77; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; MAGGI CA, 1994, BRIT J PHARMACOL, V112, P150, DOI 10.1111/j.1476-5381.1994.tb13045.x; MAGGI CA, 1994, BRIT J PHARMACOL, V112, P161, DOI 10.1111/j.1476-5381.1994.tb13046.x; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; Marriott I, 2001, J NEUROIMMUNOL, V114, P131, DOI 10.1016/S0165-5728(00)00466-5; Marriott I, 2000, J NEUROIMMUNOL, V102, P163, DOI 10.1016/S0165-5728(99)00182-4; MCELROY AB, 1992, J MED CHEM, V35, P2582, DOI 10.1021/jm00092a008; MCGREGOR PE, 1994, J PHARMACOL TOXICOL, V32, P73, DOI 10.1016/1056-8719(94)90056-6; Niizeki H, 1997, J IMMUNOL, V159, P5183; OKAMOTO A, 1994, BIOCHEM J, V299, P683, DOI 10.1042/bj2990683; PAYAN DG, 1984, J IMMUNOL, V132, P1601; PERRETTI M, 1993, IMMUNOLOGY, V80, P73; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; Quinlan KL, 1998, AM J PHYSIOL-CELL PH, V275, pC1580, DOI 10.1152/ajpcell.1998.275.6.C1580; Rameshwar P, 1997, ACTA HAEMATOL-BASEL, V98, P59; RAMESHWAR P, 1993, J IMMUNOL, V151, P2484; REGOLI D, 1996, NEUROGENIC INFLAMMAT, P91; Reilly DM, 1997, BRIT J DERMATOL, V137, P163, DOI 10.1046/j.1365-2133.1997.18001893.x; Ricciardolo FLM, 2000, BRIT J PHARMACOL, V129, P915, DOI 10.1038/sj.bjp.0703135; Saban R, 2000, AM J PATHOL, V156, P775, DOI 10.1016/S0002-9440(10)64944-9; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Scholzen T, 1998, EXP DERMATOL, V7, P81, DOI 10.1111/j.1600-0625.1998.tb00307.x; Scholzen TE, 2003, J IMMUNOL, V170, P3866, DOI 10.4049/jimmunol.170.7.3866; Scholzen TE, 2002, J INVEST DERMATOL, V119, P308; Scholzen TE, 2001, J IMMUNOL, V166, P1285, DOI 10.4049/jimmunol.166.2.1285; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Song IS, 2000, EXP DERMATOL, V9, P42, DOI 10.1034/j.1600-0625.2000.009001042.x; Staniek V, 1999, PATHOBIOLOGY, V67, P51, DOI 10.1159/000028051; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Sunderkotter C, 2001, EXP DERMATOL, V10, P391, DOI 10.1034/j.1600-0625.2001.100602.x; SUNG CP, 1992, PEPTIDES, V13, P429, DOI 10.1016/0196-9781(92)90071-A; van der Kleij HPM, 2003, J IMMUNOL, V171, P2074, DOI 10.4049/jimmunol.171.4.2074; Zachariae H, 1970, Allerg Asthma (Leipz), V16, P9; ZENG XP, 1994, J PHARMACOL EXP THER, V270, P1295	64	39	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1007	+		10.1096/fj.03-0658fje	http://dx.doi.org/10.1096/fj.03-0658fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084523				2022-12-28	WOS:000221108800012
J	Song, L; Tuan, RS				Song, L; Tuan, RS			Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow	FASEB JOURNAL			English	Article						plasticity; osteogenesis; adipogenesis; chondrogenesis	PROGENITOR CELLS; DNA METHYLATION; TRABECULAR BONE; DIFFERENTIATION; HETEROGENEITY; PLURIPOTENCY; REGENERATION; EXPRESSION; PHENOTYPE; FUSION	Transdifferentiation is a process whereby one cell type committed to and progressing along a specific developmental lineage switches into another cell type of a different lineage through genetic reprogramming. Even though this process has been well studied and established in amphibian systems, it is unclear if mammalian cells possess the same potential. Recent in vivo transplantation studies showed that adult mesenchymal stem cells (MSCs) were able to differentiate into mesoderm-derived cell types as well as cells with neuroectodermal and endodermal characteristics, suggesting that transdifferentiation occurs in mammalian systems. However, there are concerns over these findings because of the possibility of progenitor cell contamination and cell fusion. In this study, we have developed an in vitro differentiation strategy to assess if human MSCs that have differentiated into a given mesenchyme cell lineage can transdifferentiate into other cell types in response to inductive extracellular cues. Our results showed that fully differentiated cells from hMSCs were capable of dedifferentiation and transdifferentiation into cells of another developmental lineage at single cell levels.	NIAMSD, Cartilage & Orthopaed Branch, NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Tuan, RS (corresponding author), NIAMSD, Cartilage & Orthopaed Branch, NIH, US Dept HHS, 50 South Dr,Room 1503, Bethesda, MD 20892 USA.	tuanr@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041131, Z01AR041131] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097-4644(20010401)81:1<23::AID-JCB1021>3.0.CO;2-H; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0; BERESFORD JN, 1992, J CELL SCI, V102, P341; Caterson E, 2002, MOL BIOTECHNOL, V20, P245, DOI 10.1385/MB:20:3:245; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; Eisenberg Leonard M., 2003, Birth Defects Research, V69, P209, DOI 10.1002/bdrc.10017; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Li LH, 1999, EXP CELL RES, V253, P541, DOI 10.1006/excr.1999.4666; Ma HL, 2003, J BIOMED MATER RES A, V64A, P273, DOI 10.1002/jbm.a.10370; MORRISON J, 1989, ANN CLIN PSYCHIATRY, V1, P25; Muraglia A, 2000, J CELL SCI, V113, P1161; Noth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736-0266(02)00018-9; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Nye HLD, 2003, DEV DYNAM, V226, P280, DOI 10.1002/dvdy.10236; Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006-291X(02)00661-7; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; OWEN ME, 1987, J CELL SCI, V87, P731; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tsonis PA, 2000, DEV BIOL, V221, P273, DOI 10.1006/dbio.2000.9667; Tuli R, 2003, MOL BIOTECHNOL, V23, P37, DOI 10.1385/MB:23:1:37; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Wang ML, 2002, J ORTHOP RES, V20, P1175, DOI 10.1016/S0736-0266(02)00076-1; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	31	291	310	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					980	+		10.1096/fj.03-1100fje	http://dx.doi.org/10.1096/fj.03-1100fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084518				2022-12-28	WOS:000221108800007
J	Bogdanovich, S; Perkins, KJ; Krag, TOB; Whittemore, SA; Khurana, TS				Bogdanovich, S; Perkins, KJ; Krag, TOB; Whittemore, SA; Khurana, TS			Myostatin propeptide-mediated amelioration of dystrophic pathophysiology	FASEB JOURNAL			English	Article						DAM; dystroglycan complex; neuromuscular disease; dystrophin; extracellular matrix	DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE MASS; MDX MOUSE; MICE; GENE; ACTIVATION; EXPRESSION; PROTEIN; ORGANIZATION; HYPERTROPHY	Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this transforming growth factor-beta (TGF-beta) superfamily member negatively regulates muscle growth. Myostatin blockade therefore offers a strategy for reversing muscle wasting in Duchenne's muscular dystrophy (DMD) without resorting to genetic manipulation. Here, we demonstrate that pharmacological blockade using a myostatin propeptide stabilized by fusion to IgG-Fc improved pathophysiology of the mdx mouse model of DMD. Functional benefits evidenced by specific force improvement, exceeded those reported previously using myostatin antibody-mediated blockade. More importantly, use of a propeptide blockade strategy obviates possibilities of anti-idiotypic responses that could potentially limit the effectiveness of antibody-mediated myostatin blockade strategies over time. This study provides a novel pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD and since it uses an endogenous inhibitor of myostatin should help circumvent technical hurdles and toxicity associated with conventional gene or cell based therapies.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penns Muscle Inst, Philadelphia, PA 19104 USA; Glostrup Cty Hosp, Dept Expt Med, Glostrup, Denmark; Wyeth Res, Cardiovasc & Metab Dis Dept, Cambridge, MA USA	University of Pennsylvania; University of Pennsylvania; University of Copenhagen; Pfizer	Khurana, TS (corresponding author), Univ Penn, Sch Med, Dept Physiol, A-601 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	tsk@mail.med.upenn.edu	Krag, Thomas/AAD-3307-2021	Krag, Thomas/0000-0001-9330-668X				Amthor H, 2002, DEV BIOL, V251, P241, DOI 10.1006/dbio.2002.0812; Bachrach E, 2004, P NATL ACAD SCI USA, V101, P3581, DOI 10.1073/pnas.0400373101; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bogdanovich S, 2004, J MOL MED, V82, P102, DOI 10.1007/s00109-003-0484-1; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; Kapsa R, 2003, LANCET NEUROL, V2, P299, DOI 10.1016/S1474-4422(03)00382-X; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Krag TOB, 2004, P NATL ACAD SCI USA, V101, P13856, DOI 10.1073/pnas.0405972101; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Lynch GS, 2001, NEUROMUSCULAR DISORD, V11, P260, DOI 10.1016/S0960-8966(00)00192-9; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MUNTONI F, 1993, J NEUROL SCI, V120, P71, DOI 10.1016/0022-510X(93)90027-V; Nishino I, 2002, CURR OPIN NEUROL, V15, P539, DOI 10.1097/00019052-200210000-00004; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Sohn RL, 2004, EXPERT OPIN BIOL TH, V4, P1, DOI 10.1517/14712598.4.1.1; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Szabo G, 1998, MAMM GENOME, V9, P671, DOI 10.1007/s003359900843; Thies RS, 2001, GROWTH FACTORS, V18, P251; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; van Deutekom JCT, 2003, NAT REV GENET, V4, P774, DOI 10.1038/nrg1180; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006-291X(02)02953-4; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; Zammit PS, 2002, NAT MED, V8, P1355, DOI 10.1038/nm1202-1355; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	45	189	210	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					543	549		10.1096/fj.04-2796com	http://dx.doi.org/10.1096/fj.04-2796com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791004				2022-12-28	WOS:000228865300038
J	Brabant, G; Muller, G; Horn, R; Roden, M; Nave, H				Brabant, G; Muller, G; Horn, R; Roden, M; Nave, H			Hepatic leptin signaling in obesity	FASEB JOURNAL			English	Article						leptin receptor; AMPK; PEPCK	DIET-INDUCED OBESITY; BOUND LEPTIN; FOOD-INTAKE; IN-VIVO; INSULIN; PROTEIN; RECEPTOR; GLUCOSE; RAT; METABOLISM	Obesity, a state of apparent "leptin resistance," is well known to be associated with insulin resistance. In diet-induced obesity (DIO), hepatic insulin signaling is impaired but the link between leptin and insulin signaling pathways is only incompletely defined. The aim of the present study was to evaluate the effects of DIO on leptin and insulin cross-signaling in the liver. Leptin receptor expression was measured by in situ hybridization with pan-leptin receptor probes and by immunoblotting. Furthermore, intracellular signaling was investigated in vivo under basal conditions and at 45 and 360 min after stimulation with a bolus of human recombinant leptin (hrec-leptin; 1 mg/kg body wt) or saline. At baseline, all forms of the leptin receptor were markedly to completely down-regulated in DIO rats. Hrec-leptin bolus injection stimulated leptin-dependent signaling with a fivefold increase in JAK-2pY in lean but not in DIO rats. Basal IRpY, IRS-1pY, IRS-1p85, IRS-2pY, IRSp85, and PKBpT308 levels were reduced (P<0.01) in DIO rats as compared with lean controls. Basal GSK-3 beta serine phosphorylation (S9) was higher (P<0.01) in lean animals along with lower basal PEPCK activity compared with DIO rats consistent with the insulin and leptin resistance of the latter. Only in lean animals phosphorylation of PKB (T308) and GSK-3 beta (S9) was acutely stimulated by leptin at 45 min followed by inhibition at 6 h after application. AMPK alpha. protein levels as well as basal and leptin-stimulated total and alpha-specific AMPK activity were comparable in both groups. These data show that in a model of dietary-induced obesity 1) leptin receptors and subsequent signaling events are down-regulated, 2) basal insulin signaling is impaired, and 3) the cross-talk between leptin and insulin signaling is differentially regulated by the nutritional status, which is sensed by AMPK in rat liver. Thus, the liver seems to play a major role in the modulation of the leptin signal and insulin resistance in obesity.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Aventis Pharma, Frankfurt, Germany; Hanusch Hosp, Dept Med, Vienna, Austria; Hannover Med Sch, Dept Funct & Appl Anat, D-3000 Hannover, Germany	Hannover Medical School; Sanofi-Aventis; WGKK - Hanusch Hospital; Hannover Medical School	Brabant, G (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neubergstr 1, D-30625 Hannover, Germany.	brabant.georg@mh-hannover.de	Roden, Michael/AAD-3843-2019; Kielstein, Heike/GNW-4839-2022; Anderwald, Christian Heinz/AAG-2271-2021	Anderwald, Christian Heinz/0000-0001-7485-0815; Muller, Gunter/0000-0001-6178-8215				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Anderwald C, 2002, MOL ENDOCRINOL, V16, P1612, DOI 10.1210/me.16.7.1612; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Brabant G, 2000, DIABETOLOGIA, V43, P438, DOI 10.1007/s001250051326; Brabant G, 2004, EUR J CLIN INVEST, V34, P831, DOI 10.1111/j.1365-2362.2004.01427.x; Bryson JM, 1999, AM J PHYSIOL-ENDOC M, V277, pE417, DOI 10.1152/ajpendo.1999.277.3.E417; Ceddia RB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0158rev; Ceddia RB, 1999, INT J OBESITY, V23, P1207, DOI 10.1038/sj.ijo.0801095; Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Gupta G, 2000, AM J PHYSIOL-ENDOC M, V278, pE985, DOI 10.1152/ajpendo.2000.278.6.E985; Hidaka S, 2002, FASEB J, V16, P509, DOI 10.1096/fj.01-0164com; Huang W, 2004, J BIOL CHEM, V279, P21695, DOI 10.1074/jbc.M401546200; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Lam NT, 2004, MOL ENDOCRINOL, V18, P1333, DOI 10.1210/me.2002-0193; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; Lin S, 2000, BRAIN RES, V875, P89, DOI 10.1016/S0006-8993(00)02580-4; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Nave H, 1998, J EXP ANIM SCI, V39, P67; Nemecz M, 1999, HEPATOLOGY, V29, P166, DOI 10.1002/hep.510290110; Roden M, 2000, HEPATOLOGY, V32, P1045, DOI 10.1053/jhep.2000.18712; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Surwit RS, 2000, DIABETES, V49, P1203, DOI 10.2337/diabetes.49.7.1203; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Wilsey J, 2004, J ENDOCRINOL, V181, P297, DOI 10.1677/joe.0.1810297; Yang GQ, 2004, MOL ENDOCRINOL, V18, P1354, DOI 10.1210/me.2004-0027; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348	33	81	89	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1048	+		10.1096/fj.04-2846fje	http://dx.doi.org/10.1096/fj.04-2846fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788447				2022-12-28	WOS:000227901300001
J	Hwang, YYC; Shaw, S; Kaneko, M; Redd, H; Marrero, MB; Ramasamy, R				Hwang, YYC; Shaw, S; Kaneko, M; Redd, H; Marrero, MB; Ramasamy, R			Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury	FASEB JOURNAL			English	Article						protein kinase C; niacin; sorbitol dehydrogenase	PROTEIN-KINASE-C; DIABETIC-RATS; REPERFUSION INJURY; INHIBITION; HEART; CARDIOMYOPATHY; DYSFUNCTION; ACTIVATION; PROTECTION; INCREASES	The aldose reductase pathway has been demonstrated to be a key component of myocardial ischemia reperfusion injury. Previously, we demonstrated that increased lactate/pyruvate ratio, a measure of cytosolic NADH/NAD+, is an important change that drives the metabolic cascade mediating ischemic injury. This study investigated signaling mechanisms by which the aldose reductase pathway mediates myocardial ischemic injury. Specifically, the influence of the aldose reductase pathway flux on JAK-STAT signaling was examined in perfused hearts. Induction of global ischemia in rats resulted in JAK2 activation followed by STAT5 activation. Pharmacological inhibition of aldose reductase or sorbitol dehydrogenase blocked JAK2 and STAT5 activation and was associated with lower lactate/pyruvate ratio and lower protein kinase C activity. Niacin, known to lower cytosolic NADH/NAD+ ratio independent of the aldose reductase pathway inhibition, also blocked JAK2 and STAT5 activation. Inhibition of protein kinase C also blocked JAK2 and STAT5 activation. Transgenic mice overexpressing human aldose reductase exhibited increased JAK2 and STAT5 activation. Pharmacological inhibition of JAK2 reduced ischemic injury and improved functional recovery similar to that observed in aldose reductase pathway inhibited mice hearts. These data, for the first time, demonstrate JAK-STAT signaling by the aldose reductase pathway in ischemic hearts and is, in part, due to changes in cytosolic redox state.	Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA	Columbia University; University System of Georgia; Augusta University	Ramasamy, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, P&17,401 Columbia Univ,630 W 168th St, New York, NY 10032 USA.	rr260@columbia.edu		Ramasamy, Ravichandran/0000-0002-3666-3346	NHLBI NIH HHS [HL-68954, HL-61783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061783, R01HL068954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Booz GW, 2002, J MOL CELL CARDIOL, V34, P1443, DOI 10.1006/jmcc.2002.2076; Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061; Hahn HS, 2002, CIRC RES, V91, P741, DOI 10.1161/01.RES.0000037091.64492.69; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; Hwang YYC, 2004, FASEB J, V18, P1192, DOI 10.1096/fj.03-1400com; Hwang YYC, 2003, FASEB J, V17, P2331, DOI 10.1096/fj.03-0128fje; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; KASHIWAGI A, 1992, METABOLISM, V41, P1041, DOI 10.1016/0026-0495(92)90283-G; Lundmark JL, 1999, AM J PHYSIOL-HEART C, V277, pH999, DOI 10.1152/ajpheart.1999.277.3.H999; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mascareno E, 2001, CIRCULATION, V104, P325, DOI 10.1161/01.CIR.104.3.325; Park JW, 1998, INT J CARDIOL, V65, P139, DOI 10.1016/S0167-5273(98)00117-X; Podewski EK, 2003, CIRCULATION, V107, P798, DOI 10.1161/01.CIR.0000057545.82749.FF; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Ramasamy R, 1999, CARDIOVASC RES, V42, P130, DOI 10.1016/S0008-6363(98)00303-4; Ramasamy R, 1998, AM J PHYSIOL-HEART C, V275, pH195, DOI 10.1152/ajpheart.1998.275.1.H195; Shaw S, 2003, J BIOL CHEM, V278, P30634, DOI 10.1074/jbc.M305008200; Strasser RH, 1999, CIRC RES, V85, P77; Tracey WR, 2000, AM J PHYSIOL-HEART C, V279, pH1447, DOI 10.1152/ajpheart.2000.279.4.H1447; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; Trueblood NA, 2000, AM J PHYSIOL-HEART C, V279, pH764, DOI 10.1152/ajpheart.2000.279.2.H764; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; XIA P, 1995, J CLIN INVEST, V96, P733, DOI 10.1172/JCI118117; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798	27	40	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					795	+		10.1096/fj.04-2780fje	http://dx.doi.org/10.1096/fj.04-2780fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746188				2022-12-28	WOS:000227901300029
J	Agrawal, AK; Shapiro, BH				Agrawal, AK; Shapiro, BH			Neonatal phenobarbital imprints overexpression of cytochromes P450 with associated increase in tumorigenesis and reduced life span	FASEB JOURNAL			English	Article						CYP; life expectancy; perinatal origins of adult disease	GROWTH-HORMONE; PHENYTOIN EXPOSURE; PRENATAL EXPOSURE; ENZYME-INDUCTION; DNA METHYLATION; HEPATIC CYP2B1; PLASMA PROFILE; SENESCENT MALE; FEMALE RATS; ADULT-RATS	Perinatal exposure to phenobarbital produces a range of permanent reproductive, growth, locomoter, and learning dysfunctions in animals as well as humans. In addition, the affected individuals exhibit latently expressed (i.e., postpubertal) above normal activity levels of hepatic multicytochrome P450-dependent drug metabolizing enzymes. We report that in spite of apparent normal health for the better part of their lives, daily administration of therapeutic-like doses of phenobarbital to male and female rat pups during the first postpartum week reduced life expectancy by similar to 20%. Necropsy at the time of natural death revealed an associated two- to threefold increase in the incidence of tumors in barbiturate-exposed rats of both sexes and a three-to fourfold increase in urinary tract pathologies in male rats. At 2 yr of age, in agreement with an overexpression of hepatic CYP2C6 and CYP2C7, both in vitro and in vivo drug metabolism was more rapid in the phenobarbital-imprinted male and female animals. Moreover, when the senescent rats were rechallenged with a nominal dose of the barbiturate, males and females neonatally exposed to phenobarbital exhibited a dramatic overinduction of multicytochrome P450-dependent drug metabolizing enzymes as well as an overexpression of individual isoforms of cytochrome P450 implicated in enhanced susceptibility to tumorigenesis. Our findings support the growing realization that many adult diseases have their origins in early life by emphasizing that unlike adults, the new born is "plastic," and even therapeutic drugs may produce "silent" programming defects that subtly, but irrevocably, jeopardize life-long well-being.	Univ Penn, Sch Vet Med, Labs Biochem, Philadelphia, PA 19104 USA	University of Pennsylvania	Shapiro, BH (corresponding author), Univ Penn, Sch Vet Med, Labs Biochem, 3800 Spruce St, Philadelphia, PA 19104 USA.	shapirob@vet.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016358] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16358] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGRAWAL AK, 1995, AM J PHYSIOL-ENDOC M, V268, pE439, DOI 10.1152/ajpendo.1995.268.3.E439; Agrawal AK, 1996, J PHARMACOL EXP THER, V279, P991; Agrawal AK, 2000, J PHARMACOL EXP THER, V293, P1027; Agrawal AK, 2003, DRUG METAB DISPOS, V31, P612, DOI 10.1124/dmd.31.5.612; AGRAWAL AK, 1995, ANAL BIOCHEM, V224, P455, DOI 10.1006/abio.1995.1071; Agrawal AK, 1996, MOL PHARMACOL, V49, P523; ALBRIGHT PS, 1980, EPILEPSIA, V21, P681, DOI 10.1111/j.1528-1157.1980.tb04321.x; BAGLEY DM, 1985, BIOCHEM PHARMACOL, V34, P1007, DOI 10.1016/0006-2952(85)90603-3; BANDIERA S, 1992, ARCH BIOCHEM BIOPHYS, V296, P286, DOI 10.1016/0003-9861(92)90574-G; Bathum L, 1998, EUR J CLIN PHARMACOL, V54, P427, DOI 10.1007/s002280050487; CARL GF, 1988, RES COMMUN CHEM PATH, V61, P365; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESTEIL T, 1986, J PHARMACOL EXP THER, V236, P269; Dessens AB, 2000, ACTA PAEDIATR, V89, P533, DOI 10.1080/080352500750027808; DESSENS AB, 1994, ACTA PAEDIATR, V83, P54, DOI 10.1111/j.1651-2227.1994.tb13385.x; Dessens AB, 2001, TERATOLOGY, V64, P181, DOI 10.1002/tera.1063; Dessens AB, 1999, ARCH SEX BEHAV, V28, P31, DOI 10.1023/A:1018789521375; Dhir RN, 2003, P NATL ACAD SCI USA, V100, P15224, DOI 10.1073/pnas.2434273100; DIWAN BA, 1988, CANCER RES, V48, P2492; DIWAN BA, 1995, TOXICOL APPL PHARM, V132, P115, DOI 10.1006/taap.1995.1092; FARIS RA, 1983, CANCER RES, V43, P2576; GOLD E, 1978, J NATL CANCER I, V61, P1031; HENDERSON CJ, 1992, BIOCHIM BIOPHYS ACTA, V1118, P99, DOI 10.1016/0167-4838(92)90135-Z; JANZ D, 1982, EPILEPSIA, V23, pS53, DOI 10.1111/j.1528-1157.1982.tb06091.x; KALTER H, 1983, NEW ENGL J MED, V308, P491, DOI 10.1056/NEJM198303033080904; KELLY TE, 1984, AM J MED GENET, V19, P435, DOI 10.1002/ajmg.1320190303; Koch S, 1999, EPILEPSIA, V40, P1237, DOI 10.1111/j.1528-1157.1999.tb00852.x; LUBET RA, 1989, J AM COLL TOXICOL, V8, P259, DOI 10.3109/10915818909019550; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; NAU H, 1982, CLIN PHARMACOKINET, V7, P508, DOI 10.2165/00003088-198207060-00003; NOBLE RL, 1959, CANCER RES, V19, P1125; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OMIECINSKI CJ, 1990, MOL PHARMACOL, V38, P462; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; Pampori NA, 1996, MOL PHARMACOL, V50, P1148; PAMPORI NA, 1995, BIOTECHNIQUES, V18, P588; RAM PA, 1991, MOL ENDOCRINOL, V5, P13, DOI 10.1210/mend-5-1-13; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; REINISCH JM, 1982, NEUROSCI BIOBEHAV R, V6, P311, DOI 10.1016/0149-7634(82)90043-4; REINISCH JM, 1995, JAMA-J AM MED ASSOC, V274, P1518, DOI 10.1001/jama.274.19.1518; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; RYAN DE, 1990, PHARMACOL THERAPEUT, V45, P153, DOI 10.1016/0163-7258(90)90029-2; SCHUETZ EG, 1990, J BIOL CHEM, V265, P1188; SHAPIRO BH, 1989, ENDOCRINOLOGY, V125, P2935, DOI 10.1210/endo-125-6-2935; SONTANIEMI EA, 1978, BR J CLIN PHARM, V5, P71; TAVOLONI N, 1983, P SOC EXP BIOL MED, V174, P20; VORHEES CV, 1983, J PHARMACOL EXP THER, V227, P274; VORHEES CV, 1985, NEUROBEH TOXICOL TER, V7, P471; Watson RE, 2002, TOXICOL SCI, V67, P11, DOI 10.1093/toxsci/67.1.11; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1991, METHODS ENZYMOL, V206, P249; YAFFE SJ, 1990, DEV PHARMACOL THERAP, V15, P215, DOI 10.1159/000457649; YANAI J, 1979, BIOCHEM PHARMACOL, V28, P1429, DOI 10.1016/0006-2952(79)90448-9	54	21	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					470	+		10.1096/fj.04-2550fje	http://dx.doi.org/10.1096/fj.04-2550fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15634872				2022-12-28	WOS:000226576600032
J	Descamps, FJ; Martens, E; Proost, P; Starckx, S; Van den Steen, PE; Van Damme, J; Opdenakker, G				Descamps, FJ; Martens, E; Proost, P; Starckx, S; Van den Steen, PE; Van Damme, J; Opdenakker, G			Gelatinase B/matrixmetalloproteinase-9 provokes cataract by cleaving lens beta B1 crystallin	FASEB JOURNAL			English	Article						neutrophil; crystallins; granulocyte-chemotactic protein-2	GRANULOCYTE CHEMOTACTIC PROTEIN-2; HUMAN CORNEAL CELLS; B-DEFICIENT MICE; UVEITIS; CHILDHOOD; IDENTIFICATION; INDUCTION; RADIATION; CALPAIN; MMP-9	Cataract is a common cause of blindness and results from destruction of the microarchitecture of the lens. It is observed in many genetic syndromes, infections, inflammatory diseases and during aging. Fluctuations in lens density and light scattering by altered refraction index form the physical basis for this process, but the pathogenesis is poorly understood. Increased levels of gelatinase B/matrix metalloproteinase-9 have been reported for cataract-associated disorders such as eye inflammation and diabetes. We demonstrate that incubation of lenses with gelatinase B leads immediately to cataract. In complete eye extracts, betaB1 crystallin was identified as the major gelatinase B substrate by combination of proteomics, mass spectrometry, and Edman degradation analysis. The cleavage of betaB1 crystallin was also observed in vivo after endogenous gelatinase B-induction by the chemokine granulocyte chemotactic protein-2 in wild-type mice but not in gelatinase B-/- mice.	Katholieke Univ Leuven, Rega Inst Med Res, Immunobiol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Opdenakker, G (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Immunobiol Lab, Minderbroedersstr 10, B-3000 Louvain, Belgium.	ghislain.opdenakker@rega.kuleuven.ac.be	Opdenakker, Ghislain/Q-3130-2017; Van den Steen, Philippe E/K-5132-2012; Martens, Erik/F-9214-2015; Opdenakker, Ghislain/V-8562-2019; Proost, Paul/V-3052-2017	Opdenakker, Ghislain/0000-0003-1714-2294; Van den Steen, Philippe E/0000-0002-7334-9145; Martens, Erik/0000-0002-7947-6567; Opdenakker, Ghislain/0000-0003-1714-2294; Proost, Paul/0000-0002-0133-5545; Van Damme, Jo/0000-0002-6707-1167				Abu El-Asrar AM, 1998, AM J OPHTHALMOL, V125, P844, DOI 10.1016/S0002-9394(98)00041-5; Cuello C, 2002, BRIT J OPHTHALMOL, V86, P290, DOI 10.1136/bjo.86.3.290; DAVID LL, 1993, J BIOL CHEM, V268, P1937; de Boer J, 2003, BRIT J OPHTHALMOL, V87, P879, DOI 10.1136/bjo.87.7.879; Deane JS, 1997, ACTA OPHTHALMOL SCAN, V75, P82; Descamps FJ, 2002, LAB INVEST, V82, P1607, DOI 10.1097/01.LAB.0000038556.54069.73; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; GREENWOOD J, 1994, LAB INVEST, V70, P39; Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159; JOSE JG, 1986, EXP EYE RES, V42, P11, DOI 10.1016/0014-4835(86)90013-8; Kennedy M, 1997, INVEST OPHTH VIS SCI, V38, P2483; Kosano H, 1999, LIFE SCI, V64, P2307, DOI 10.1016/S0024-3205(99)00184-8; Kotaniemi K, 2003, CLIN EXP RHEUMATOL, V21, P395; Kozak I, 2003, PHYSIOL RES, V52, P229; Kut C, 1997, CELL BIOL INT, V21, P347, DOI 10.1006/cbir.1997.0150; Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; McCarty CA, 2002, DEV OPHTHALMOL, V35, P21; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; PROOST P, 1993, J IMMUNOL, V150, P1000; Shestopalov VI, 2003, J CELL SCI, V116, P4191, DOI 10.1242/jcs.00738; Shih M, 2001, CURR EYE RES, V22, P458, DOI 10.1076/ceyr.22.6.458.5483; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Starckx S, 2002, J INTERF CYTOK RES, V22, P965, DOI 10.1089/10799900260286678; Stempel D, 2003, INVEST OPHTH VIS SCI, V44, P203, DOI 10.1167/iovs.01-1261; Tamiya S, 2000, EXP EYE RES, V71, P591, DOI 10.1006/exer.2000.0916; TugalTutkun I, 1996, OPHTHALMOLOGY, V103, P375; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; VanDamme J, 1997, J LEUKOCYTE BIOL, V62, P563, DOI 10.1002/jlb.62.5.563; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1	34	22	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					29	35		10.1096/fj.04-1837com	http://dx.doi.org/10.1096/fj.04-1837com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629892				2022-12-28	WOS:000226576600039
J	Guscetti, F; Nath, N; Denko, N				Guscetti, F; Nath, N; Denko, N			Functional characterization of human proapoptotic molecules in yeast S-cerevisiae	FASEB JOURNAL			English	Article						Bcl-2; Bax; Bid; Bad; BNip3; BNip3L; Noxa; Puma; metacaspase	BCL-2 FAMILY-MEMBERS; HYPOXIC CELL-DEATH; MITOCHONDRIAL-MEMBRANE; BH3-ONLY PROTEINS; INDUCE APOPTOSIS; MAMMALIAN-CELLS; BAX; PHOSPHORYLATION; EXPRESSION; PLAYS	The presence of a complete (BH1-3) proapoptotic molecule is necessary for the induction of the intrinsic apoptotic cascade in mammalian cells. It is unclear, however, what distinct roles the members of the large family of BH3-only proapoptotic molecules play in apoptosis. Although biochemical analysis of these molecules can characterize binding efficiencies of BH3 family members, the biologic consequences of these interactions are difficult to predict. We have, therefore, established three functional categories of BH3-only human proapoptotic proteins based on their toxicity after expression in budding yeast: directly killing (tBid), sensitizing in Bax/Bcl-2 expressing cells ( Bad or Puma), and non-toxic (BNip3, BNip3L, and Noxa). The mechanism of killing by the proapoptotic molecules in yeast, however, is not due to activation of the recently described yeast metacaspase MCA1.	Stanford Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, Stanford, CA 94305 USA	Stanford University	Denko, N (corresponding author), Stanford Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, Room 1245 CCSR S,269 Campus Dr, Stanford, CA 94305 USA.	ndenko@stanford.edu	denko, nicholas/F-8444-2010; Guscetti, Franco/C-2672-2018	Guscetti, Franco/0000-0002-3173-4811	NCI NIH HHS [CA7166] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouillet P, 2002, J CELL SCI, V115, P1567; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Camougrand N, 2003, MOL MICROBIOL, V47, P495, DOI 10.1046/j.1365-2958.2003.03311.x; CHEN JC, 1997, SOFT COMPUT, V1, P19; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; Polcic P, 2003, BIOCHEM J, V374, P393, DOI 10.1042/BJ20030690; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	30	25	25	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					464	+		10.1096/fj.04-2316fje	http://dx.doi.org/10.1096/fj.04-2316fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15632273				2022-12-28	WOS:000226576600033
J	Li, J; Culman, J; Hortnagl, H; Zhao, Y; Gerova, N; Timm, M; Blume, A; Zimmermann, M; Seidel, K; Dirnagl, U; Unger, T				Li, J; Culman, J; Hortnagl, H; Zhao, Y; Gerova, N; Timm, M; Blume, A; Zimmermann, M; Seidel, K; Dirnagl, U; Unger, T			Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury	FASEB JOURNAL			English	Article						medial cerebral artery occlusion; AT1 receptor	II RECEPTOR SUBTYPES; AT(2) RECEPTOR; CARDIOVASCULAR MORBIDITY; CANDESARTAN CILEXETIL; CHRONIC PRETREATMENT; TRANSCRIPTION FACTOR; NEURITE OUTGROWTH; CONVERTING-ENZYME; ARTERY OCCLUSION; MORTALITY-RATE	Several lines of clinical and experimental evidence suggest an important role of the renin-angiotensin system in ischemic brain injury although the cellular regulation of the angiotensin AT1 and AT2 receptors and their potential relevance in this condition have not yet been clearly defined. We first assessed the regulation of brain AT1 and AT2 receptors in response to transient unilateral medial cerebral artery occlusion in rats by real-time RT-PCR, Western blot, and immunofluorescence labeling. AT2 receptors in the peri-infarct zone were significantly upregulated 2 days after transient focal cerebral ischemia. Increased AT2 receptors, which were abundantly distributed in a large number of brain regions adjacent to the infarct area including cerebral frontal cortex, piriform cortex, striatum, and hippocampus, were exclusively expressed in neurons. By contrast, AT1 receptors, which remained unaltered, were mainly expressed in astrocytes. In neurons of ischemic striatum, increased AT2 receptors were associated with intense neurite outgrowth. Blockade of central AT2 receptors with PD123177 abolished the neuroprotective effects of central AT1 receptor blockade with irbesartan on infarct size and neurological outcome. In primary cortical neurons, stimulation of AT2 receptors supported neuronal survival and neurite outgrowth. Our data indicate that cerebral AT2 receptors exert neuroprotective actions in response to ischemia-induced neuronal injury, possibly by supporting neuronal survival and neurite outgrowth in peri-ischemic brain areas.	Charite Univ Med Berlin, Inst Pharmacol & Toxicol, Cardiovasc Res Ctr, D-10115 Berlin, Germany; Charite Univ Med Berlin, Dept Expt Neurol, D-10115 Berlin, Germany; Univ Kiel, Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24098 Kiel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Schleswig Holstein University Hospital	Unger, T (corresponding author), Charite Univ Med Berlin, Inst Pharmacol & Toxicol, Cardiovasc Res Ctr, Hess Str 3-4, D-10115 Berlin, Germany.	thomas.unger@charite.de	Li, Jun/C-4390-2011; Zhao, Yi/A-8806-2010	Dirnagl, Ulrich/0000-0003-0755-6119; SEIDEL, KERSTIN/0000-0002-9166-7032				ARENDT T, 1986, NEUROSCIENCE, V19, P1265, DOI 10.1016/0306-4522(86)90141-7; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Cote F, 1999, J BIOL CHEM, V274, P31686, DOI 10.1074/jbc.274.44.31686; Culman J, 2001, J RENIN-ANGIO-ALDO S, V2, P96, DOI 10.3317/jraas.2001.019; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Diep QN, 1999, HYPERTENSION, V34, P617, DOI 10.1161/01.HYP.34.4.617; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FERNANDEZ LA, 1986, STROKE, V17, P82, DOI 10.1161/01.STR.17.1.82; Fournier A, 2004, J AM COLL CARDIOL, V43, P1343, DOI 10.1016/j.jacc.2003.10.060; Gallinat S, 1998, MOL BRAIN RES, V57, P111, DOI 10.1016/S0169-328X(98)00079-5; GEHLERT DR, 1991, NEUROSCIENCE, V44, P501, DOI 10.1016/0306-4522(91)90073-W; Gohlke P, 2002, J HYPERTENS, V20, P909, DOI 10.1097/00004872-200205000-00026; Groth W, 2003, J HYPERTENS, V21, P2175, DOI 10.1097/00004872-200311000-00028; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Harms C, 2000, FASEB J, V14, P1814, DOI 10.1096/fj.99-0899com; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HOHLE S, 1995, EUR J PHARMACOL, V275, P277, DOI 10.1016/0014-2999(95)00005-6; Inada Y, 1997, CLIN EXP HYPERTENS, V19, P1079, DOI 10.3109/10641969709083206; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Iwai M, 2004, CIRCULATION, V110, P843, DOI 10.1161/01.CIR.0000138848.58269.80; Kagiyama T, 2003, REGUL PEPTIDES, V110, P241, DOI 10.1016/S0167-0115(02)00223-9; KALISZEWSKI C, 1988, J CEREBR BLOOD F MET, V8, P149, DOI 10.1038/jcbfm.1988.43; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Lenkei Z, 1997, FRONT NEUROENDOCRIN, V18, P383, DOI 10.1006/frne.1997.0155; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Li DY, 1999, CARDIOVASC RES, V41, P109, DOI 10.1016/S0008-6363(98)00196-5; Lucius R, 1998, J EXP MED, V188, P661, DOI 10.1084/jem.188.4.661; Makino I, 1996, NEUROPEPTIDES, V30, P596, DOI 10.1016/S0143-4179(96)90043-8; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Reinecke K, 2003, FASEB J, V17, P2094, DOI 10.1096/fj.02-1193fje; STIER CT, 1993, J HYPERTENS, V11, pS37; Stroth U, 1998, MOL BRAIN RES, V53, P187, DOI 10.1016/S0169-328X(97)00298-2; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; Walther T, 2002, FASEB J, V16, P169, DOI 10.1096/fj.01-0601com; Zhao Y, 2003, J NEUROCHEM, V85, P759, DOI 10.1046/j.1471-4159.2003.01719.x	43	218	228	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					617	+		10.1096/fj.04-2960fje	http://dx.doi.org/10.1096/fj.04-2960fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665034				2022-12-28	WOS:000226576600013
J	Donati, C; Meacci, E; Nuti, F; Becciolini, L; Farnararo, M; Bruni, P				Donati, C; Meacci, E; Nuti, F; Becciolini, L; Farnararo, M; Bruni, P			Sphingosine 1-phosphate regulates myogenic differentiation: a major role for S1P(2) receptor	FASEB JOURNAL			English	Article						antisense oligodeoxyribonucleotides; pertussis toxin; sphingolipid; MAP kinase	PROTEIN-COUPLED RECEPTOR; KINASE ACTIVATION; C2C12 MYOBLASTS; DOWN-REGULATION; PHOSPHOLIPASE-D; KAPPA-B; SPHINGOSINE-1-PHOSPHATE; GROWTH; P38; INDUCTION	In this study a novel biological activity of sphingosine 1-phosphate (S1P) in C2C12 myoblasts was identified. In these cells the bioactive lipid profoundly regulated myogenesis exerting an antimitogenic activity, by reducing serum-induced cell proliferation, and acting as powerful prodifferentiating agent by enhancing the expression of myogenic differentiation markers such as myogenin, myosin heavy chain, and caveolin-3. The S1P-dependent diminution of serum-induced labeled thymidine incorporation was abrogated by antisense oligodeoxyribonucleotides (ODN) to S1P(2), but not to S1P(1) or S1P(3) receptor, also expressed in C2C12 cells, implicating S1P(2) in the biological response. Using antisense ODN and short interfering RNA treatment, we highlighted the key role played by S1P(2) in the S1P-dependent induction of muscle-specific gene products. Notably, S1P(2) overexpression increased the content of myogenic markers and hastened the onset of differentiated muscle phenotype in comparison with control cells. Cell treatment with pertussis toxin did not affect the biological responses to S1P, ruling out the involvement of Gi-mediated events in the signaling promoted by the sphingolipid. Among the various signaling pathways activated by S1P, the activation of ERK1/ERK2 and p38 MAPK, both identified as downstream effectors of S1P(2), was required for the inhibition of cell proliferation and the stimulation of myogenic differentiation, respectively.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Ist Interuniv Miol, I-50134 Florence, Italy	University of Florence; University of Florence	Bruni, P (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale GB Morgagni 50, I-50134 Florence, Italy.	paola.bruni@unifi.it	donati, chiara/AAN-2682-2021; Bruni, Paola/A-1151-2008	donati, chiara/0000-0003-2224-4199; Bruni, Paola/0000-0002-1151-3413				Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Formigli L, 2002, AM J PHYSIOL-CELL PH, V282, pC1361, DOI 10.1152/ajpcell.00378.2001; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Grounds MD, 1998, ANN NY ACAD SCI, V854, P78, DOI 10.1111/j.1749-6632.1998.tb09894.x; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Ikeda H, 2003, GASTROENTEROLOGY, V124, P459, DOI 10.1053/gast.2003.50049; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Meacci E, 2000, FEBS LETT, V482, P97, DOI 10.1016/S0014-5793(00)02039-1; Meacci E, 1999, FEBS LETT, V457, P184, DOI 10.1016/S0014-5793(99)01033-9; Meacci E, 2004, BIOCHEM J, V381, P655, DOI 10.1042/BJ20031636; Meacci E, 2003, BBA-MOL CELL BIOL L, V1633, P133, DOI 10.1016/S1388-1981(03)00106-9; Meacci E, 2002, BIOCHEM J, V362, P349, DOI 10.1042/0264-6021:3620349; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raucci A, 2004, J BIOL CHEM, V279, P1747, DOI 10.1074/jbc.M310384200; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000	40	97	101	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					449	+		10.1096/fj.04-1780fje	http://dx.doi.org/10.1096/fj.04-1780fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15625079				2022-12-28	WOS:000226091000004
J	Li, YW; Kelly, WG; Logsdon, JM; Schurko, AM; Harfe, BD; Hill-Harfe, KL; Kahn, RA				Li, YW; Kelly, WG; Logsdon, JM; Schurko, AM; Harfe, BD; Hill-Harfe, KL; Kahn, RA			Functional genomic analysis of the ADP-ribosylation factor family of GTPases: phylogeny among diverse eukaryotes and function in C-elegans	FASEB JOURNAL			English	Article						Arf family; protein sequence; eukaryotic evolution; RAS superfamily; regulatory protein	GTP-BINDING PROTEIN; HEAT-LABILE ENTEROTOXINS; PHOSPHOLIPASE-D; FACTORS ARFS; SACCHAROMYCES-CEREVISIAE; SELECTIVE AMPLIFICATION; ENDOPLASMIC-RETICULUM; MEMBRANE TRAFFICKING; DOWNSTREAM EFFECTOR; RNA INTERFERENCE	ADP-ribosylation factor (Arf) and Arf-like (Arl) proteins are a family of highly conserved 21 kDa GTPases that emerged early in the evolution of eukaryotes. These proteins serve regulatory roles in vesicular traffic, lipid metabolism, microtubule dynamics, development, and likely other cellular processes. We found evidence for the presence of 6 Arf family members in the protist Giardia lamblia and 22 members in mammals. A phylogenetic analysis was performed to delineate the evolutionary relationships among Arf family members and to attempt to organize them by both their evolutionary origins and functions in cells and/or organisms. The similar to 100 protein sequences analyzed from animals, fungi, plants, and protists clustered into 11 groups, including Arfs, nine Arls, and Sar proteins. To begin functional analyses of the family in a metazoan model organism, we examined roles for all three C. elegans Arfs (Arf-1, Arf-3, and Arf-6) and three Arls (Arl-1, Arl-2, and Arl-3) by use of RNA-mediated interference (RNAi). Injection of double-stranded RNA ( dsRNA) encoding Arf-1 or Arf-3 into N2 hermaphrodites produced embryonic lethality in their offspring and, later, sterility in the injected animals themselves. Injection of Arl-2 dsRNA resulted in a disorganized germline and sterility in early offspring, with later offspring exhibiting an early embryonic arrest. Thus, of the six Arf family members examined in C. elegans, at least three are required for embryogenesis. These data represent the first analysis of the role(s) of multiple members of this family in the development of a multicellular organism.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biol, Atlanta, GA USA	Emory University; Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Logsdon, John M/B-7812-2009; Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [R01 GM068029, R01 GM067226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], PHYLIP PHYLOGENY INF; Antoshechkin I, 2002, DEV CELL, V2, P579, DOI 10.1016/S1534-5807(02)00146-6; Bargmann CI, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews1005; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BRENNER S, 1974, GENETICS, V77, P71; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Casanova JE, 2003, PROTEINS CELL REG, V1, P283; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hillig RC, 2000, STRUCTURE, V8, P1239, DOI 10.1016/S0969-2126(00)00531-1; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Hoyt MA, 1997, GENETICS, V146, P849; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Jackson CL, 2003, CURR BIOL, V13, pR174, DOI 10.1016/S0960-9822(03)00116-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 2004, ARF FAMILY GTPASES, V1; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LEE FJS, 1994, J BIOL CHEM, V269, P21555; Logsdon Jr J. M., 2004, ARF FAMILY GTPASES; Lu L, 2003, MOL BIOL CELL, V14, P3767, DOI 10.1091/mbc.E03-01-0864; Lu L, 2001, J CELL SCI, V114, P4543; MADDISON WP, 2003, MACCLADE; McElver J, 2000, PLANT CELL, V12, P1379, DOI 10.1105/tpc.12.8.1379; Mello C, 1995, METHOD CELL BIOL, V48, P451; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1991, MOL MICROBIOL, V5, P2621, DOI 10.1111/j.1365-2958.1991.tb01971.x; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mueller AG, 2002, MOL CELL BIOL, V22, P1488, DOI 10.1128/MCB.22.5.1488-1494.2002; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; Ota R, 2000, MOL BIOL EVOL, V17, P798, DOI 10.1093/oxfordjournals.molbev.a026358; Panic B, 2003, MOL CELL, V12, P863, DOI 10.1016/S1097-2765(03)00356-3; Panic B, 2003, CURR BIOL, V13, P405, DOI 10.1016/S0960-9822(03)00091-5; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Praitis V, 2001, GENETICS, V157, P1217; Price SR, 1996, MOL CELL BIOCHEM, V159, P15; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Radcliffe PA, 2000, FEBS LETT, V468, P84, DOI 10.1016/S0014-5793(00)01202-3; Radhakrishna H, 1999, J CELL SCI, V112, P855; Schafer DA, 2000, TRAFFIC, V1, P892; Schurmann A, 2002, MOL CELL BIOL, V22, P2761, DOI 10.1128/MCB.22.8.2761-2768.2002; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Setty SRG, 2003, CURR BIOL, V13, P401, DOI 10.1016/S0960-9822(03)00089-7; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shern JF, 2003, J BIOL CHEM, V278, P40829, DOI 10.1074/jbc.M308678200; Song J, 1998, J CELL SCI, V111, P2257; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	84	88	94	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1834	1850		10.1096/fj.04-2273com	http://dx.doi.org/10.1096/fj.04-2273com			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576487				2022-12-28	WOS:000226091000034
J	Hamada, K; Vannier, E; Sacheck, JM; Witsell, AL; Roubenoff, R				Hamada, K; Vannier, E; Sacheck, JM; Witsell, AL; Roubenoff, R			Senescence of human skeletal muscle impairs the local inflammatory cytokine response to acute eccentric exercise	FASEB JOURNAL			English	Article						aging; real-time PCR; sarcopenia	TRANSFORMING-GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; TNF-ALPHA; GENE-EXPRESSION; PROTEIN-SYNTHESIS; FACTOR-BETA; TGF-BETA; INTERLEUKIN-6; YOUNG; DIFFERENTIATION	The impact of aging on the cytokine response of human skeletal muscle to exercise-induced injury remains poorly understood. We enrolled physically active, young (23-35 years old, n = 15) and old (66-78 years old, n = 15) men to perform 45 min of downhill running (16% descent) at 75% VO2max. Biopsies of vastus lateralis were obtained 24 h before and 72 h after acute eccentric exercise. Transcripts for inflammatory (TNF-alpha, IL-1beta) and anti-inflammatory cytokines (IL-6, TGF-beta(1)) were quantified by real-time PCR. Before exercise, cytokine transcripts did not differ with age. At old age, exercise induced a blunted accumulation of transcripts encoding the panleukocyte surface marker CD18 (young: 10.1-fold increase, P < 0.005; old: 4.7-fold increase, P = 0.02; young vs. old: P < 0.05). In both age groups, CD18 transcript accumulation strongly correlated with TNF-alpha (young, r = 0.87, P < 0.001; old, r = 0.72, P = 0.002) and TGF-beta(1) transcript accumulation (young, r = 0.80, P < 0.001; old, r = 0.64, P = 0.008). At old age, there was no correlation between IL-1beta and CD18 transcript accumulation. Furthermore, exercise induced IL-6 transcript accumulation in young (3.6-fold, P = 0.057) but not in old men. Our results suggest that aging impairs the adaptive response of human skeletal muscle to eccentric exercise by differential modulation of a discrete set of inflammatory and anti-inflammatory cytokine genes.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Otsuka Pharmaceut Co Ltd, Saga Nutraceut Res Inst, Saga 8420195, Japan; Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Otsuka Pharmaceutical; Tufts Medical Center	Vannier, E (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	evannier@tufts-nemc.org		Roubenoff, Ronenn/0000-0002-3959-3179	NIA NIH HHS [AG15797] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R21AG015797] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSTIN L, 1991, J NEUROL SCI, V101, P193, DOI 10.1016/0022-510X(91)90045-9; BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; BRANDES ME, 1991, J IMMUNOL, V147, P1600; CANNON JG, 1989, AM J PHYSIOL, V257, pR451, DOI 10.1152/ajpregu.1989.257.2.R451; CANNON JG, 1990, AM J PHYSIOL, V259, pR1214, DOI 10.1152/ajpregu.1990.259.6.R1214; Chen WJ, 1999, MICROBES INFECT, V1, P1367, DOI 10.1016/S1286-4579(99)00249-X; Cooney RN, 1999, SHOCK, V11, P235, DOI 10.1097/00024382-199904000-00002; Darcissac ECA, 1996, CELL IMMUNOL, V169, P294, DOI 10.1006/cimm.1996.0121; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; DOHM GL, 1985, AM J PHYSIOL, V248, pE588, DOI 10.1152/ajpendo.1985.248.5.E588; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Fiatarone Singh Maria A., 1999, American Journal of Physiology, V277, pE135; FIELDING RA, 1993, AM J PHYSIOL, V265, pR166, DOI 10.1152/ajpregu.1993.265.1.R166; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; Greiwe JS, 2001, FASEB J, V15, P475, DOI 10.1096/fj.00-0274com; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Ivey FM, 2000, J GERONTOL A-BIOL, V55, pM641, DOI 10.1093/gerona/55.11.M641; Jozsi AC, 2000, MECH AGEING DEV, V120, P45, DOI 10.1016/S0047-6374(00)00178-0; Koziol JA, 1997, AM STAT, V51, P301, DOI 10.2307/2685895; Lang CH, 2002, AM J PHYSIOL-ENDOC M, V282, pE336, DOI 10.1152/ajpendo.00366.2001; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; LYNN WA, 1991, J IMMUNOL, V147, P3072; Malm C, 2000, J PHYSIOL-LONDON, V529, P243, DOI 10.1111/j.1469-7793.2000.00243.x; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Moldoveanu AI, 2000, J APPL PHYSIOL, V89, P1499, DOI 10.1152/jappl.2000.89.4.1499; Nagaraju K, 1998, CLIN EXP IMMUNOL, V113, P407; Okazaki S, 1996, CELL PROLIFERAT, V29, P173; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; Sacheck JM, 2003, FREE RADICAL BIO MED, V34, P1575, DOI 10.1016/S0891-5849(03)00187-4; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; Starkie RL, 2001, AM J PHYSIOL-CELL PH, V280, pC769, DOI 10.1152/ajpcell.2001.280.4.C769; Stupka N, 2001, J APPL PHYSIOL, V91, P1669, DOI 10.1152/jappl.2001.91.4.1669; Toft AD, 2002, AM J PHYSIOL-CELL PH, V283, pC289, DOI 10.1152/ajpcell.00583.2001; Tsujinaka T, 1996, J CLIN INVEST, V97, P244, DOI 10.1172/JCI118398; Vaday GG, 2001, J LEUKOCYTE BIOL, V69, P613; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1989, J CELL BIOCHEM, V40, P193, DOI 10.1002/jcb.240400208; WAHL SM, 1990, ANN NY ACAD SCI, V593, P188, DOI 10.1111/j.1749-6632.1990.tb16111.x; WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, pE422, DOI 10.1152/ajpendo.1995.268.3.E422; Welle S, 2001, PHYSIOL GENOMICS, V5, P67, DOI 10.1152/physiolgenomics.2001.5.2.67	44	104	107	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					264	+		10.1096/fj.03-1286fje	http://dx.doi.org/10.1096/fj.03-1286fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15556970				2022-12-28	WOS:000225482100007
J	Ishikawa, F; Yasukawa, M; Yoshida, S; Nakamura, K; Nagatoshi, Y; Kanemaru, T; Shimoda, K; Shimoda, S; Miyamoto, T; Okamura, J; Shultz, LD; Harada, M				Ishikawa, F; Yasukawa, M; Yoshida, S; Nakamura, K; Nagatoshi, Y; Kanemaru, T; Shimoda, K; Shimoda, S; Miyamoto, T; Okamura, J; Shultz, LD; Harada, M			Human cord blood- and bone marrow-derived CD34(+) cells regenerate gastrointestinal epithelial cells	FASEB JOURNAL			English	Article						stem cell; plasticity; fusion; epithelium	STEM-CELLS; HEPATOCYTES	In the present study, we aimed to clarify the capacity of human cord blood- and bone marrow-derived progenitor cells to generate gastrointestinal epithelial cells in clinical and experimental transplantation settings. First, in a clinical transplantation setting, gastrointestinal tissues derived from female pediatric or juvenile recipients of allogeneic sex-mismatched bone marrow and cord blood transplantation were examined for the presence of donor-derived epithelial cells. Gastrointestinal specimens of allogeneic recipients included Y chromosome(+) cytokeratin(+) epithelial cells at a frequency of 0.4 - 1.9%. To further determine the capacity of purified human progenitor cells, human cord blood- or bone marrow-derived CD34(+) cells were transplanted into newborn NOD/SCID/beta2-microglobulin(null) mice as an experimental transplantation assay. When gastrointestinal tissues derived from recipient mice were subjected to FISH and immunofluorescence analyses, human epithelial cells were identified at a frequency of 0.24 - 0.58% at 3 months posttransplantation. Finally, double FISH analyses using species-specific probes revealed that human chromosome+ epithelial cells did not possess any murine chromosomes, indicating that donor-derived epithelial cells were not generated only by cell fusion. On the basis of these findings, it is concluded that purified human cord blood and bone marrow CD34(+) progenitor cells can generate gastrointestinal epithelial cells across allogeneic and xenogeneic histocompatibility barriers.	Kyushu Univ, Grad Sch Med, Dept Med & Biosystem Sci, Higashi Ku, Fukuoka 8128582, Japan; Ehime Univ, Sch Med, Dept Internal Med 1, Shigenobu, Ehime 79102, Japan; Kurume Univ, Dept Anat 2, Kurume, Fukuoka 830, Japan; Kyushu Natl Canc Ctr, Sect Pediat, Fukuoka, Japan; Kyushu Univ, Fukuoka 812, Japan; Jackson Lab, Bar Harbor, ME 04609 USA	Kyushu University; Ehime University; Kurume University; Kyushu University; Jackson Laboratory	Ishikawa, F (corresponding author), Kyushu Univ, Grad Sch Med, Dept Med & Biosystem Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	f_ishika@intmed1.med.kyushu-u.ac.jp	石川, 文彦/L-4488-2014					Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Bianchi DW, 2002, NEW ENGL J MED, V346, P1410; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Ishikawa F, 2002, EXP HEMATOL, V30, P488, DOI 10.1016/S0301-472X(02)00784-1; Ishikawa F, 2003, LEUKEMIA, V17, P960, DOI 10.1038/sj.leu.2402878; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KAUR P, 1986, CELL TISSUE KINET, V19, P601, DOI 10.1111/j.1365-2184.1986.tb00761.x; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Meignin V, 2004, BLOOD, V103, P360, DOI 10.1182/blood-2003-06-1843; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Okamoto R, 2002, NAT MED, V8, P1011, DOI 10.1038/nm755; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Podolsky DK, 2003, J GASTROENTEROL, V38, P63; Sandborn WJ, 2002, GASTROENTEROLOGY, V122, P1592, DOI 10.1053/gast.2002.33426; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Suzuki A, 2002, J CELL BIOL, V156, P173, DOI 10.1083/jcb.200108066; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Van den Brande JMH, 2002, ANN NY ACAD SCI, V973, P166; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wirtz S, 2003, GENE THER, V10, P854, DOI 10.1038/sj.gt.3302013; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	29	24	28	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1958	+		10.1096/fj.04-2396fje	http://dx.doi.org/10.1096/fj.04-2396fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15467008				2022-12-28	WOS:000224849900027
J	Kumar, A; Murphy, R; Robinson, P; Wei, L; Boriek, AM				Kumar, A; Murphy, R; Robinson, P; Wei, L; Boriek, AM			Cyclic mechanical strain inhibits skeletal myogenesis through activation of focal adhesion kinase, Rac-1 GTPase, and NF-kappa B transcription factor	FASEB JOURNAL			English	Article						skeletal myogenesis; C2C12 cells; cyclic stretch; FAK; Rac-1; NF-kappa B	FIBROBLAST-GROWTH-FACTOR; MUSCLE SATELLITE CELLS; RHO-FAMILY GTPASES; PROTEIN-KINASE; SIGNALING PATHWAYS; BINDING PROTEIN; TERMINAL KINASE; GENE-EXPRESSION; DIFFERENTIATION; STRETCH	Myogenesis is a multistep developmental program that generates and regenerates skeletal muscles. Several extracellular factors have been identified that participate in the regulation of myogenesis. Although skeletal muscles are always subjected to mechanical stress in vivo, the role of mechanical forces in the regulation of myogenesis remains unknown. We have investigated the molecular mechanisms by which cyclic mechanical strain modulates myogenesis. Application of cyclic mechanical strain using the computer-controlled Flexcell Strain Unit increased the proliferation of C2C12 cells and inhibited their differentiation into myotubes. Cyclic strain increased the activity of cyclin-dependent kinase 2 (cdk2) and the cellular level of cyclin A, and inhibited the expression of myosin heavy chain and formation of myotubes in C2C12 cultures. The activity of nuclear factor-kappa B (NF-kappaB) transcription factor and the expression of NF-kappaB-regulated genes, cyclin D1 and IL-6, were augmented in response to mechanical strain. Cyclic strain also increased the activity of Rho GTPases, especially Rac-1. The inhibition of Rho GTPases activity, by overexpression of Rho GDP dissociation inhibitor (Rho-GDI), inhibited the strain-induced activation of NF-kappaB in C2C12 cells. Overexpression of either NF-kappaB inhibitory protein IkappaBalphaDeltaN (a degradation resistant mutant IkappaBalpha) or Rho-GDI blocked the strain-induced proliferation of C2C12 cells. Furthermore, overexpression of FRNK, a dominant negative mutant of focal adhesion kinase (FAK), inhibited the strain-induced proliferation of C2C12 cells. Our study demonstrates that cyclic mechanical strain inhibits myogenesis through the activation of FAK, Rac-1, and NF-kappaB.	Baylor Coll Med, Dept Med, Pulm & Crit Care Sect, Houston, TX 77030 USA	Baylor College of Medicine	Kumar, A (corresponding author), Baylor Coll Med, Dept Med, Pulm & Crit Care Sect, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	axkumar@bcm.tmc.edu		Kumar, Ashok/0000-0002-2444-9529; Robinson, Prema/0000-0002-6798-4839; Kumar, Ashok/0000-0001-8571-2848	NHLBI NIH HHS [R01 HL63134] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063134] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto T, 2001, MAT SCI ENG C-BIO S, V17, P75, DOI 10.1016/S0928-4931(01)00340-X; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bassel-Duby R, 2003, BIOCHEM BIOPH RES CO, V311, P1133, DOI 10.1016/j.bbrc.2003.09.020; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; Bruce-Staskal PJ, 2002, J CELL SCI, V115, P2689; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carson JA, 2000, J APPL PHYSIOL, V88, P337, DOI 10.1152/jappl.2000.88.1.337; CARY LA, 1999, FRONT BIOSCI, V4, P102; Chen Jennifer C J, 2003, Reprod Biol Endocrinol, V1, P101, DOI 10.1186/1477-7827-1-101; Clark CB, 2004, EXP CELL RES, V292, P265, DOI 10.1016/j.yexcr.2003.09.017; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DELGADO I, 2003, INT J BIOCHEM CELL B, V35, P1151; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Granet C, 2001, BIOCHEM BIOPH RES CO, V284, P622, DOI 10.1006/bbrc.2001.5023; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hughes SM, 2001, CURR BIOL, V11, pR237, DOI 10.1016/S0960-9822(01)00114-2; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ilic D, 1997, J CELL SCI, V110, P401; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; JAMES RS, 1995, J EXP BIOL, V198, P491; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2003, J BIOL CHEM, V278, P18868, DOI 10.1074/jbc.M212777200; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, J IMMUNOL, V161, P776; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morgan JE, 2003, INT J BIOCHEM CELL B, V35, P1151, DOI 10.1016/S1357-2725(03)00042-6; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nikolovski J, 2003, FASEB J, V17, P455, DOI 10.1096/fj.02-0459fje; Nobe K, 2001, CIRC RES, V88, P1283, DOI 10.1161/hh1201.092035; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Proske U, 2001, J PHYSIOL-LONDON, V537, P333, DOI 10.1111/j.1469-7793.2001.00333.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Robinson P, 2003, J INFECT DIS, V188, P290, DOI 10.1086/376836; Roy R R, 1991, Exerc Sport Sci Rev, V19, P269; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sakamoto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1081, DOI 10.1152/ajpendo.00228.2003; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; Sorci G, 2004, MOL CELL BIOL, V24, P4880, DOI 10.1128/MCB.24.11.4880-4894.2004; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; Tidball JG, 1999, J BIOL CHEM, V274, P33155, DOI 10.1074/jbc.274.46.33155; VAN AL, 1997, GENE DEV, V11, P2295; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wei L, 2002, DEVELOPMENT, V129, P1705; Wretman C, 2000, ACTA PHYSIOL SCAND, V170, P45; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	95	94	102	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1524	1535		10.1096/fj.04-2414com	http://dx.doi.org/10.1096/fj.04-2414com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466361				2022-12-28	WOS:000224849900036
J	Foltz, M; Boll, M; Raschka, L; Kottra, G; Daniel, H				Foltz, M; Boll, M; Raschka, L; Kottra, G; Daniel, H			A novel bifunctionality: PAT1 and PAT2 mediate electrogenic proton/amino acid and electroneutral proton/fatty acid symport	FASEB JOURNAL			English	Article						Xenopus laevis oocytes; SCFA; proton symporter; ph-recording	CHAIN FATTY-ACIDS; GRADIENT-DEPENDENT TRANSPORT; LUMINAL MEMBRANE-VESICLES; CACO-2 CELLS; MOLECULAR-BIOLOGY; PLASMA-MEMBRANE; BUTYRATE UPTAKE; AMINO-ACIDS; ABSORPTION; FAMILY	Recently, the PAT family of proton-dependent amino acid transporters has been identified as a novel class of mammalian amino acid symporters. PAT1 and PAT2 members mediate electrogenic uptake of small, neutral amino acids and derivatives by cotransport of protons. Analysis of the structural requirements for substrate recognition by PAT1 identified that a free amino group in a substrate is not essential for recognition. We therefore hypothesized that PAT1 and its ortholog PAT2 may also be able to recognize and transport the homologous short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. We examined in Xenopus laevis oocytes whether the SCFAs interact with the transporter by employing flux studies, electrophysiology and intracellular pH recordings. SCFAs did not induce positive inward currents but inhibited glycine-induced transport currents. PAT-mediated uptake of radiolabeled proline was also dose-dependently reduced by SCFA and could be described by first order competition kinetics with apparent K-i-values for butyrate of 6.0 +/- 0.7 and 7.6 +/- 1.3 mM for PAT1 and PAT2, respectively. Acetate as well as propionate uptake was significantly enhanced in oocytes expressing PAT1 or PAT2. An electroneutral H+/SCFA symport mode was demonstrated by recording intracellular pH changes under voltage clamp conditions with rate constants for the initial intracellular acidification in the presence of SCFAs significantly increased in PAT-expressing oocytes. In conclusion, our data demonstrate that the PAT1 and PAT2 proteins are capable to transport selected SCFAs in an electroneutral and the homologous amino acids in an electrogenic mode and are therefore a paradigm for bifunctional solute carriers.	Tech Univ Munich, Ctr Life & Food Sci, Inst Nutr Sci, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Daniel, H (corresponding author), Tech Univ Munich, Ctr Life & Food Sci, Inst Nutr Sci, Mol Nutr Unit, Hochfeldweg 2, D-85350 Freising Weihenstephan, Germany.	daniel@wzw.tum.de	Daniel, Hannelore/B-8982-2009					Agulhon C, 2003, J COMP NEUROL, V462, P71, DOI 10.1002/cne.10712; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Boll M, 2003, MOL MEMBR BIOL, V20, P261, DOI 10.1080/0968768031000100759; Boll M, 2003, GENOMICS, V82, P47, DOI 10.1016/S0888-7543(03)00099-5; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; Cavaglieri CR, 2003, LIFE SCI, V73, P1683, DOI 10.1016/S0024-3205(03)00490-9; Charney AN, 1998, AM J PHYSIOL, V274, P518; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Chen Z, 2003, BIOCHEM BIOPH RES CO, V304, P747, DOI 10.1016/S0006-291X(03)00648-X; CLAUSEN MR, 1994, GASTROENTEROLOGY, V106, P423, DOI 10.1016/0016-5085(94)90601-7; Cook SI, 1998, ALIMENT PHARM THER, V12, P499, DOI 10.1046/j.1365-2036.1998.00337.x; DESOIGNIE R, 1994, GASTROENTEROLOGY, V107, P347, DOI 10.1016/0016-5085(94)90158-9; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Gasnier B, 2004, PFLUG ARCH EUR J PHY, V447, P756, DOI 10.1007/s00424-003-1091-2; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; HEDIGER MA, 1995, J PHYSIOL-LONDON, V482P, pS7; JESSEN H, 1988, BIOCHIM BIOPHYS ACTA, V942, P262; JESSEN H, 1991, J PHYSIOL-LONDON, V436, P149, DOI 10.1113/jphysiol.1991.sp018544; Kottra G, 2002, J BIOL CHEM, V277, P32683, DOI 10.1074/jbc.M204192200; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MASCOLO N, 1991, GASTROENTEROLOGY, V101, P331, DOI 10.1016/0016-5085(91)90008-9; Massillon D, 2003, J BIOL CHEM, V278, P40694, DOI 10.1074/jbc.M303182200; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; MORTENSEN FV, 1991, BRIT J SURG, V78, P1208, DOI 10.1002/bjs.1800781019; Ogawa H, 2003, BIOCHEM BIOPH RES CO, V309, P512, DOI 10.1016/j.bbrc.2003.08.026; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; POMARE EW, 1985, J CLIN INVEST, V75, P1448, DOI 10.1172/JCI111847; RAJENDRAN VM, 1987, J BIOL CHEM, V262, P14974; REMESY C, 1980, REPROD NUTR DEV, V20, P1339, DOI 10.1051/rnd:19800725; REYNOLDS DA, 1993, GASTROENTEROLOGY, V105, P725, DOI 10.1016/0016-5085(93)90889-K; Ritzhaupt A, 1998, J PHYSIOL-LONDON, V507, P819, DOI 10.1111/j.1469-7793.1998.819bs.x; ROIGAARDPETERSEN H, 1987, AM J PHYSIOL, V253, pF15, DOI 10.1152/ajprenal.1987.253.1.F15; Rubio-Aliaga I, 2004, J BIOL CHEM, V279, P2754, DOI 10.1074/jbc.M305556200; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Stein J, 2000, EUR J NUTR, V39, P121, DOI 10.1007/s003940070028; THWAITES DT, 1994, J MEMBRANE BIOL, V140, P143; THWAITES DT, 1993, FEBS LETT, V333, P78, DOI 10.1016/0014-5793(93)80378-8; THWAITES DT, 1995, BRIT J PHARMACOL, V115, P761, DOI 10.1111/j.1476-5381.1995.tb14998.x; Thwaites DT, 2000, BRIT J PHARMACOL, V129, P457, DOI 10.1038/sj.bjp.0703069; THWAITES DT, 1995, J MEMBRANE BIOL, V145, P245; Tyagi S, 2002, AM J PHYSIOL-GASTR L, V282, pG676, DOI 10.1152/ajpgi.00173.2000; VONENGELHARDT W, 1994, J PHYSIOL-LONDON, V477, P365, DOI 10.1113/jphysiol.1994.sp020198; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003; WUNZ TM, 1993, AM J PHYSIOL, V264, pF948, DOI 10.1152/ajprenal.1993.264.6.F948	47	41	41	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1758	+		10.1096/fj.03-1387fje	http://dx.doi.org/10.1096/fj.03-1387fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345686				2022-12-28	WOS:000224243200039
J	Huang, STJ; Vo, KCT; Lyell, DJ; Faessen, GH; Tulac, S; Tibshirani, R; Giaccia, AJ; Giudice, LC				Huang, STJ; Vo, KCT; Lyell, DJ; Faessen, GH; Tulac, S; Tibshirani, R; Giaccia, AJ; Giudice, LC			Developmental response to hypoxia	FASEB JOURNAL			English	Article						intrauterine growth restriction; fetal growth; hypoxic response	FACTOR-BINDING PROTEIN-1; GROWTH-FACTOR-I; EXCITATORY AMINO-ACIDS; FETAL-GROWTH; INTRAUTERINE GROWTH; GENE-EXPRESSION; BIRTH-WEIGHT; CARDIOVASCULAR-RESPONSES; BRAIN-INJURY; CORD SERUM	Molecular mechanisms underlying fetal growth restriction due to placental insufficiency and in utero hypoxia are not well understood. In the current study, time- dependent (3 h-11 days) changes in fetal tissue gene expression in a rat model of in utero hypoxia compared with normoxic controls were investigated as an initial approach to understand molecular events underlying fetal development in response to hypoxia. Under hypoxic conditions, litter size was reduced and IGFBP-1 was up-regulated in maternal serum and in fetal liver and heart. Tissue-specific, distinct regulatory patterns of gene expression were observed under acute vs. chronic hypoxic conditions. Induction of glycolytic enzymes was an early event in response to hypoxia during organ development; consistently, tissue-specific induction of calcium homeostasis-related genes and suppression of growth-related genes were observed, suggesting mechanisms underlying hypoxia-related fetal growth restriction. Furthermore, induction of inflammation-related genes in placentas exposed to long-term hypoxia (11 days) suggests a mechanism for placental dysfunction and impaired pregnancy outcome accompanying in utero hypoxia.	Stanford Univ, Dept Obstet & Gynecol, Med Ctr, Stanford, CA 94305 USA	Stanford University	Giudice, LC (corresponding author), Stanford Univ, Dept Obstet & Gynecol, Med Ctr, 300 Pasteur Dr,Room HH 333, Stanford, CA 94305 USA.	giudice@stanford.edu	Huang, Se-Te/F-6881-2013		NICHD NIH HHS [5 R01 HD36732] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036732] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTHABE O, 1985, PLACENTA, V6, P265, DOI 10.1016/S0143-4004(85)80056-4; BABAJKO S, 1993, ENDOCRINOLOGY, V132, P2586, DOI 10.1210/en.132.6.2586; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Belkacemi L, 2002, ENDOCRINE, V19, P57, DOI 10.1385/ENDO:19:1:57; BODDY K, 1974, J PHYSIOL-LONDON, V243, P599, DOI 10.1113/jphysiol.1974.sp010768; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; CLARK GD, 1989, CLIN PERINATOL, V16, P459, DOI 10.1016/S0095-5108(18)30641-9; COHN HE, 1974, AM J OBSTET GYNECOL, V120, P817, DOI 10.1016/0002-9378(74)90587-0; DEGRAUW TJ, 1986, BIOL NEONATE, V49, P85, DOI 10.1159/000242515; FANT M, 1993, REGUL PEPTIDES, V48, P29, DOI 10.1016/0167-0115(93)90333-4; Gibson JM, 2001, MOL HUM REPROD, V7, P79, DOI 10.1093/molehr/7.1.79; GIUDICE LC, 1995, J CLIN ENDOCR METAB, V80, P1548, DOI 10.1210/jc.80.5.1548; Gluckman PD, 1997, ACTA PAEDIATR, V86, P153; GOPDA N, 2003, ANTIOXID REDOX SIGN, V5, P467; Hochachka PW, 1999, BRAZ J MED BIOL RES, V32, P661, DOI 10.1590/S0100-879X1999000600001; Holemans K, 2003, J SOC GYNECOL INVEST, V10, P392, DOI 10.1016/S1071-5576(03)00134-5; Ibanez L, 2000, ANN ENDOCRINOL-PARIS, V61, P141; IWAMOTO HS, 1992, AM J PHYSIOL, V263, pE1151; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; Kelley KM, 2002, J ENDOCRINOL, V175, P3, DOI 10.1677/joe.0.1750003; Kovacs CS, 2002, AM J PHYSIOL-ENDOC M, V282, pE721, DOI 10.1152/ajpendo.00369.2001; Langford K, 1998, HUM REPROD, V13, P1389, DOI 10.1093/humrep/13.5.1389; LANGFORD KS, 1993, EUR J CLIN INVEST, V23, P503, DOI 10.1111/j.1365-2362.1993.tb00958.x; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Maulik D, 1999, BRAIN RES, V817, P117, DOI 10.1016/S0006-8993(98)01235-9; MCLELLAN KC, 1992, ENDOCRINOLOGY, V131, P1619, DOI 10.1210/en.131.4.1619; MORI A, 1993, MED BIOL ENG COMPU S, V31, pS49; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Odegard RA, 2000, OBSTET GYNECOL, V96, P950, DOI 10.1016/S0029-7844(00)01040-1; Ostlund E, 1997, HUM REPROD, V12, P840, DOI 10.1093/humrep/12.4.840; PukaSundvall M, 1997, BRAIN RES, V750, P325, DOI 10.1016/S0006-8993(97)00024-3; Redman C W, 2001, Gynecol Obstet Fertil, V29, P518, DOI 10.1016/S1297-9589(01)00180-1; Schulze A, 2001, NAT CELL BIOL, V3, pE190, DOI 10.1038/35087138; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SHEPPARD BL, 1976, BRIT J OBSTET GYNAEC, V83, P948, DOI 10.1111/j.1471-0528.1976.tb00781.x; SOOTHILL PW, 1994, ACTA PAEDIATR, V83, P55, DOI 10.1111/j.1651-2227.1994.tb13289.x; Tapanainen PJ, 1997, HORM RES, V48, P227, DOI 10.1159/000185520; TAPANAINEN PJ, 1994, PEDIATR RES, V36, P152, DOI 10.1203/00006450-199408000-00004; TIERNEY EP, 2003, PHYSL GENOMICS; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; UNGER C, 1988, JAMA-J AM MED ASSOC, V259, P3427, DOI 10.1001/jama.259.23.3427; VERHAEGHE J, 1993, AM J OBSTET GYNECOL, V169, P89, DOI 10.1016/0002-9378(93)90137-8; Verhaeghe J, 2001, J ENDOCRINOL, V170, P585, DOI 10.1677/joe.0.1700585; WALSH SW, 1985, AM J OBSTET GYNECOL, V152, P335, DOI 10.1016/S0002-9378(85)80223-4; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WOODWORTH SH, 1994, J CLIN ENDOCR METAB, V78, P1225, DOI 10.1210/jc.78.5.1225; Yiu V, 1999, AM J KIDNEY DIS, V33, P253, DOI 10.1016/S0272-6386(99)70297-0; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388	51	56	61	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1348	1365		10.1096/fj.03-1377com	http://dx.doi.org/10.1096/fj.03-1377com			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333578				2022-12-28	WOS:000224243200054
J	Khatib, L; Golan, DE; Cho, M				Khatib, L; Golan, DE; Cho, M			Physiologic electrical stimulation provokes intracellular calcium increase mediated by phospholipase C activation in human osteoblasts	FASEB JOURNAL			English	Article						calcium homeostasis; stretch-activated cation receptors	FIELD INDUCED REDISTRIBUTION; NONSELECTIVE CATION CHANNEL; GROWTH-FACTOR; CELLS; RECEPTORS; EPITHELIALIZATION; RELAXATION; EXPRESSION; WOUNDS; ALPHA	Strong exogenous electrical stimulation (ES) can induce changes in intracellular calcium ion concentration ([Ca2+](i)). It remains to be elucidated, however, whether physiologically relevant ES (e.g., 1-2 V/cm) could alter [Ca2+](i). We have used fluorescence microscopy to quantify [Ca2+](i) changes in response to direct current (dc) ES in human fetal osteoblasts. Increases in [Ca2+](i) in response to 2 V/cm ES show a noticeable (20-min) time delay, followed by a 45-fold rise from the baseline of 40 nM to 1.8 muM. Treatment of cells with verapamil does not affect ES-induced [Ca2+](i) increases, but inhibition of phospholipase C ( PLC) does prevent such increases, which suggests that receptor-regulated release of Ca2+ from intracellular stores is likely to be involved. Treatment of cells with the stretch-activated cation channel (SACC) blocker Gd3+ partially inhibits ES-induced [Ca2+](i) increases, as does chelation of intracellular Ca2+. These results are consistent with a model in which physiologically relevant ES does not activate voltage-gated Ca2+ channels (VGCCs) directly, but rather stimulates PLC-coupled cell surface receptors that induce [Ca2+](i) increases by activating IP3-dependent intracellular processes. The Ca2+ influx that follows PLC activation is likely mediated by activation of mechanically operated SACCs.	Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Cho, M (corresponding author), Univ Illinois, Dept Bioengn, 851 S Morgan St M-C 063, Chicago, IL 60607 USA.	mcho@uic.edu		Cho, Myoung Rae/0000-0002-8191-8045	NHLBI NIH HHS [HL-70819, HL-32854] Funding Source: Medline; NIGMS NIH HHS [GM-60741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL070819, R01HL032854, R37HL032854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BECKER RO, 1977, CLIN ORTHOP RELAT R, V124, P75; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACK J, 1988, TISSUE ENG, P195; Black J., 1987, ELECT STIMULATION IT; BRIGHTON CT, 1981, J BONE JOINT SURG AM, V63, P847, DOI 10.2106/00004623-198163050-00030; BRIGHTON CT, 1995, CLIN ORTHOP RELAT R, V321, P223; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; CHEN N, AM J PHYSL, V278, pC989; CHIANG M, 1991, DEV BIOL, V146, P377, DOI 10.1016/0012-1606(91)90239-Y; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; Cho M, 2002, J INEQUAL APPL, V7, P1, DOI 10.1080/10755830290013362; Cho MR, 2002, IEEE T PLASMA SCI, V30, P1504, DOI 10.1109/TPS.2002.804200; Cho MR, 1999, FASEB J, V13, P677, DOI 10.1096/fasebj.13.6.677; CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677; Cukjati D, 2001, MED BIOL ENG COMPUT, V39, P542, DOI 10.1007/BF02345144; Di Sario A, 2002, J HEPATOL, V36, P179, DOI 10.1016/S0168-8278(01)00242-2; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; GIUGNI TD, 1987, J CELL BIOL, V104, P1291, DOI 10.1083/jcb.104.5.1291; Iglesia DDS, 1996, J EXP ZOOL, V274, P56, DOI 10.1002/(SICI)1097-010X(19960101)274:1<56::AID-JEZ6>3.0.CO;2-E; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; LAUFFENBURGER DA, 1993, RECEPTORY MODELS BIN; Lee MJ, 2002, EXP MOL MED, V34, P265, DOI 10.1038/emm.2002.37; Malhi GS, 2002, J PSYCHOSOM RES, V53, P709, DOI 10.1016/S0022-3999(02)00423-3; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; McGinnis M E, 1986, Prog Clin Biol Res, V210, P231; MCLAUGHLIN S, 1981, BIOPHYS J, V34, P85, DOI 10.1016/S0006-3495(81)84838-2; ONUMA EK, 1988, J CELL BIOL, V106, P2067, DOI 10.1083/jcb.106.6.2067; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; Potts RO, 2002, DIABETES-METAB RES, V18, pS49, DOI 10.1002/dmrr.210; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; Ryder KD, 2001, J BONE MINER RES, V16, P240, DOI 10.1359/jbmr.2001.16.2.240; Shen MR, 2002, J BIOL CHEM, V277, P45776, DOI 10.1074/jbc.M207993200; Sperelakis N., 2001, CELL PHYSL SOURCEBOO, Vthird; TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148; TITUSHKIN I, 2004, IN PRESS MODE CELL T; Trollinger DR, 2002, J CELL PHYSIOL, V193, P1, DOI 10.1002/jcp.10144; TSONG TY, 1988, METHOD ENZYMOL, V157, P240; TSONG TY, 1988, ANNU REV PHYSIOL, V50, P273; WESTKAMP M, 2000, J MEMBRANE BIOL, V178, P11	42	61	62	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1903	+		10.1096/fj.04-1814fje	http://dx.doi.org/10.1096/fj.04-1814fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385433				2022-12-28	WOS:000224243200016
J	McNamara, N; Gallup, M; Khong, A; Sucher, A; Maltseva, I; Fahy, JV; Basbaum, C				McNamara, N; Gallup, M; Khong, A; Sucher, A; Maltseva, I; Fahy, JV; Basbaum, C			Adenosine up-regulation of the mucin gene, MU2, in asthma	FASEB JOURNAL			English	Article						CLCA1; EGFR	PROTEIN-COUPLED RECEPTORS; BRONCHOALVEOLAR LAVAGE FLUID; ACTIVATED CHLORIDE CHANNEL; BETA-GAMMA-SUBUNITS; EPITHELIAL-CELLS; EGF RECEPTOR; AIRWAY HYPERREACTIVITY; MUCUS OVERPRODUCTION; 5'-FLANKING REGION; BRONCHIAL-ASTHMA	Mucus hypersecretion is a hallmark of asthma that contributes to airway obstruction. While the etiology is not well understood, hypersecretion has been linked to the presence of cytokines such as IL-4, IL-5, IL-9, and IL-13 in the inflamed airway. The presence of adenosine has also been noted in asthmatic airways, and adenosine-mediated signaling in mast cells has been implicated in the severe bronchoconstriction and inflammation prevalent in these patients ( 1, 2). Here we examine the possibility that adenosine also contributes to mucus hypersecretion by airway epithelial cells. Results in cultured airway epithelial cells showed that MUC2 mucin expression increased in response to adenosine. This appeared to be mediated by a pathway initiated at the adenosine A1 receptor that transduced signals through a Ca2+-activated Cl- channel and EGFR. That this signaling cascade is relevant to asthmatic hypersecretion was indicated by results showing that mucin induction by asthmatic tracheal aspirates was reduced by A1, CLCA1, and EGFR inhibitors. These results suggest that adenosine cooperates with inflammatory cytokines to stimulate mucin production in the asthmatic airway and supports the use of A1, CLCA1, and EGFR inhibitors in the treatment of asthma.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pulm, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Dept Anat, Box 0452,513 Parnassus,HSW 1330, San Francisco, CA 94143 USA.	cbas@itsa.ucsf.edu			NEI NIH HHS [K23 EY00371] Funding Source: Medline; NHLBI NIH HHS [HLP0124136, HLR0143762] Funding Source: Medline; NATIONAL EYE INSTITUTE [K23EY000371] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, R01HL043762] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Carlstedt I, 1995, BIOCHEM SOC T, V23, P845, DOI 10.1042/bst0230845; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Cohn L, 1999, J IMMUNOL, V162, P6178; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; Fozard JR, 2000, CLIN EXP ALLERGY, V30, P1213; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; Hakonarson H, 1998, AM J RESP CRIT CARE, V158, pS115, DOI 10.1164/ajrccm.158.supplement_2.13tac700; HALEEN SJ, 1987, LIFE SCI, V40, P555, DOI 10.1016/0024-3205(87)90369-9; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; Jacobson KA, 1997, NEUROPHARMACOLOGY, V36, P1157, DOI 10.1016/S0028-3908(97)00104-4; JACOBSON KA, 1987, BIOCHEM PHARMACOL, V36, P1697, DOI 10.1016/0006-2952(87)90056-6; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; Jiang JL, 1996, J MED CHEM, V39, P4667, DOI 10.1021/jm960457c; KIM KC, 1991, BRIT J PHARMACOL, V103, P1053, DOI 10.1111/j.1476-5381.1991.tb12299.x; KUAN SF, 1987, CANCER RES, V47, P5715; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee FS, 2002, CYTOKINE GROWTH F R, V13, P11, DOI 10.1016/S1359-6101(01)00024-7; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; LEE KS, 1986, BRAIN RES, V368, P394, DOI 10.1016/0006-8993(86)90589-5; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEALE TW, 1988, LIFE SCI, V43, P1671, DOI 10.1016/0024-3205(88)90478-X; SHEEHAN JK, 1995, AM J RESP CELL MOL, V13, P748, DOI 10.1165/ajrcmb.13.6.7576713; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; TANIZAKI Y, 1993, J ASTHMA, V30, P257, DOI 10.3109/02770909309054525; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; UKENA D, 1986, LIFE SCI, V39, P743, DOI 10.1016/0024-3205(86)90023-8; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; VANBELLE H, 1987, AM J PHYSIOL, V252, pH886, DOI 10.1152/ajpheart.1987.252.5.H886; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	61	51	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1770	+		10.1096/fj.04-1964fje	http://dx.doi.org/10.1096/fj.04-1964fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345696				2022-12-28	WOS:000224243200049
J	Lee, HJ; Cho, CH; Hwang, SJ; Choi, HH; Kim, KT; Ahn, SY; Kim, JH; Oh, JL; Lee, GM; Koh, GY				Lee, HJ; Cho, CH; Hwang, SJ; Choi, HH; Kim, KT; Ahn, SY; Kim, JH; Oh, JL; Lee, GM; Koh, GY			Biological characterization of angiopoietin-3 and angiopoietin-4	FASEB JOURNAL			English	Article						Ang3; Ang4; Ang1; Tie2	ENDOTHELIAL-CELL SURVIVAL; TIE2 RECEPTOR; GROWTH-FACTOR; EXPRESSION; MICE; ANGIOGENESIS; ACTIVATION; HYPOXIA; GENE; BINDING	The angiopoietin (Ang) family of growth factors includes Ang1, Ang2, Ang3, and Ang4, all of which bind to the endothelial receptor tyrosine kinase Tie2. Ang3 ( mouse) and Ang4 ( human) are interspecies orthologs. In experiments with human endothelial cell lines, Ang3 was identified as an antagonist of Tie2 and Ang4 was identified as an agonist of Tie2. However, the biological roles of Ang3 and Ang4 are unknown. We examined the biological effect of recombinant Ang3 and Ang4 proteins in primary cultured endothelial cells and in vivo in mice. Recombinant Ang3 and Ang4 formed disulfide-linked dimers. Ang4 ( 400 ng/mL) markedly increased Tie2 and Akt phosphorylation in primary cultured HUVECs whereas Ang3 ( 400 ng/mL) did not produce significant changes. Accordingly, Ang4, but not Ang3, induced survival and migration in primary cultured HUVECs. Unexpectedly, intravenously administered Ang3 ( 30 mug) was more potent than Ang4 ( 30 mug) in phosphorylating the Tie2 receptor in lung tissue from mice in vivo. Accordingly, Ang3 was more potent than Ang4 in phosphorylating Akt in primary cultured mouse lung microvascular endothelial cells. Ang3 and Ang4 both produced potent corneal angiogenesis extending from the limbus across the mouse cornea in vivo. Thus, Ang3 and Ang4 are agonists of Tie2, but mouse Ang3 has strong activity only on endothelial cells of its own species.	Korea Adv Inst Sci & Technol, Biomed Res Ctr, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Koh, GY (corresponding author), Korea Adv Inst Sci & Technol, Biomed Res Ctr, 373-1 Guseong Dong, Taejon 305701, South Korea.	gykoh@kaist.ac.kr	Lee, Gyun Min/C-2020-2011; Kim, Juhyun/AAD-6817-2019; Cho, Chung-Hyun/H-7286-2012; Koh, Gou Young/C-1615-2011	Kim, Juhyun/0000-0002-3098-5010; 				Abdulmalek K, 2001, AM J PHYSIOL-LUNG C, V281, pL582, DOI 10.1152/ajplung.2001.281.3.L582; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Brown LF, 2000, AM J PATHOL, V156, P2179, DOI 10.1016/S0002-9440(10)65088-2; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Currie MJ, 2002, J PATHOL, V198, P502, DOI 10.1002/path.1228; Currie MJ, 2001, CLIN CANCER RES, V7, P918; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2002, FASEB J, V16, P1126, DOI 10.1096/fj.01-0805fje; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Kim I, 2001, CARDIOVASC RES, V49, P872, DOI 10.1016/S0008-6363(00)00295-9; Koh GY, 2002, EXP MOL MED, V34, P1; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lee S, 2003, FASEB J, V17, pA326, DOI 10.1096/fj.02-0570fje; Lund EL, 2004, INT J CANCER, V108, P833, DOI 10.1002/ijc.11662; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MUTHUKKARUPPAN V, 1979, SCIENCE, V205, P1416, DOI 10.1126/science.472760; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Yamakawa M, 2003, CIRC RES, V93, P664, DOI 10.1161/01.RES.0000093984.48643.D7; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	37	116	135	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1200	1208		10.1096/fj.03-1466com	http://dx.doi.org/10.1096/fj.03-1466com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15284220				2022-12-28	WOS:000223554900035
J	Li, WJ; Hou, LF; Hua, ZW; Wang, X				Li, WJ; Hou, LF; Hua, ZW; Wang, X			Interleukin-1 induces beta-calcitonin gene-related peptide secretion in human type II alveolar epithelial cells	FASEB JOURNAL			English	Article						neuroimmunology; neuropeptide; inflammation; chemokine	PROTEIN-KINASE-C; AIRWAY HYPERRESPONSIVENESS; NEUROEPITHELIAL BODIES; RESPIRATORY-TRACT; SENSORY NEURONS; EXPRESSION; CGRP; RELEASE; LYMPHOCYTES; NEUROPEPTIDES	Calcitonin gene-related peptide ( CGRP) is a 37-amino acid neuropeptide mainly present in sensory nerve fibers, which is present in almost all organs, but it is also found in cultured rat type II alveolar epithelial cells (AEII). Our data have previously shown that CGRP may play an important role in inflammation as an immunomodulator. Proinflammatory factor IL-1 induces CGRP release from neuron-derived sources. However, whether IL-1 can induce CGRP secretion from a nonneural source, AEII cells, is not known. In the present study, we demonstrated that human AEII A549 cells expressed beta-CGRP, and IL-1beta (0.001- 50 ng/ml) directly increased CGRP secretion from these cells in a time- and concentration-dependent manner. The mRNA level of beta-CGRP was also elevated by IL-1beta ( 1 ng/ml). In addition, we found that IL-1beta-induced CGRP production was mediated through the PKC-p38 mitogen-activated protein (MAP) kinase-NF-kappaB signaling pathway. Furthermore, IL-1beta-induced chemokines MCP-1 and IL-8 were partially inhibited by exogenous hCGRP (0.1- 10 nM) and potentiated by hCGRP(8-37) ( 0.1- 10 nM), a CGRP(1)-receptor antagonist. In addition, the CGRP-inhibited chemokine effect was partially reduced by Rp-cAMP, a cAMP-PK inhibitor. These results suggest that AEII-derived CGRP may act in an autocrine/paracrine mode and play an important inhibitory role in the local area in lung inflammatory diseases.	Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100083, Peoples R China; Peking Univ, Dept Physiol, Beijing 100083, Peoples R China	Peking University; Peking University; Peking University	Wang, X (corresponding author), Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100083, Peoples R China.	xwang@bjmu.edu.cn						ADRIAENSEN D, 1991, HISTOCHEMISTRY, V95, P567, DOI 10.1007/BF00266743; Bellibas SE, 1996, PEPTIDES, V17, P563, DOI 10.1016/0196-9781(96)00027-7; Bracci-Laudiero L, 2002, J NEUROIMMUNOL, V123, P58, DOI 10.1016/S0165-5728(01)00475-1; Brouns I, 2003, AM J RESP CELL MOL, V28, P275, DOI 10.1165/rcmb.2002-0117OC; BUCKLEY TL, 1991, J IMMUNOL, V146, P3424; CADIEUX A, 1986, NEUROSCIENCE, V19, P605, DOI 10.1016/0306-4522(86)90285-X; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chung KF, 2001, EUR RESPIR J, V18, p50S, DOI 10.1183/09031936.01.00229701; CLEMENTI G, 1994, LIFE SCI, V54, pPL119, DOI 10.1016/0024-3205(94)90011-6; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Dakhama A, 2002, AM J RESP CRIT CARE, V165, P1137, DOI 10.1164/ajrccm.165.8.2109058; DAVIES D, 1992, ANN NY ACAD SCI, V657, P405, DOI 10.1111/j.1749-6632.1992.tb22786.x; Evans BN, 2000, J BIOL CHEM, V275, P31438, DOI 10.1074/jbc.M005604200; Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36; HASTINGS RH, 1995, AM J RESP CELL MOL, V13, P563, DOI 10.1165/ajrcmb.13.5.7576692; He Yanling, 2002, Zhonghua Yi Xue Za Zhi, V82, P131; Hou LF, 2003, J NEUROSCI RES, V73, P188, DOI 10.1002/jnr.10651; Hou LF, 2001, J NEUROSCI RES, V66, P592, DOI 10.1002/jnr.1249; Ichinose M, 1996, PEPTIDES, V17, P1405, DOI 10.1016/S0196-9781(96)00198-2; Kawase T, 2003, EUR J PHARMACOL, V470, P125, DOI 10.1016/S0014-2999(03)01763-1; Keith IM, 2000, PHYSIOL RES, V49, P519; KEITH IM, 1991, HISTOCHEMISTRY, V96, P311, DOI 10.1007/BF00271351; Levite M, 1998, J IMMUNOL, V160, P993; Lin CH, 2000, MOL PHARMACOL, V57, P36; LUNDBERG JM, 1985, EUR J PHARMACOL, V108, P315, DOI 10.1016/0014-2999(85)90456-X; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Monton C, 1998, Monaldi Arch Chest Dis, V53, P56; Neri LM, 2002, HISTOL HISTOPATHOL, V17, P1311, DOI 10.14670/HH-17.1311; Nystedt JM, 2002, J NEUROCHEM, V82, P1330, DOI 10.1046/j.1471-4159.2002.01035.x; Opree A, 2000, J NEUROSCI, V20, P6289, DOI 10.1523/JNEUROSCI.20-16-06289.2000; REINSHAGEN M, 1994, GASTROENTEROLOGY, V106, P1208, DOI 10.1016/0016-5085(94)90011-6; Reinshagen M, 1998, J PHARMACOL EXP THER, V286, P657; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; SINGARAM C, 1991, GASTROENTEROLOGY, V100, P560, DOI 10.1016/0016-5085(91)90231-9; Springer J, 2003, PULM PHARMACOL THER, V16, P121, DOI 10.1016/S1094-5539(03)00049-X; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Stankiewicz W, 2002, MEDIAT INFLAMM, V11, P307, DOI 10.1080/09629350210000015719; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; Strieter RM, 2003, CURR OPIN INFECT DIS, V16, P193, DOI 10.1097/00001432-200306000-00002; Sun W, 2003, EUR J IMMUNOL, V33, P233, DOI 10.1002/immu.200390026; Tonnel AB, 2001, INT ARCH ALLERGY IMM, V124, P267, DOI 10.1159/000053729; Townley RG, 2003, CLIN REV ALLERG IMMU, V24, P85, DOI 10.1385/CRIAI:24:1:85; Tran MT, 2000, J IMMUNOL, V164, P4307, DOI 10.4049/jimmunol.164.8.4307; VASKO MR, 1994, J NEUROSCI, V14, P4987; Wang HC, 2002, J NEUROIMMUNOL, V130, P155, DOI 10.1016/S0165-5728(02)00221-7; Wang Shengxian, 2001, Zhonghua Jiehe He Huxi Zazhi, V24, P725; Wang X, 1999, J NEUROIMMUNOL, V94, P95, DOI 10.1016/S0165-5728(98)00230-6; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xing LY, 2002, BRAIN BEHAV IMMUN, V16, P17, DOI 10.1006/brbi.2000.0601; Xing LY, 2000, J IMMUNOL, V165, P4359, DOI 10.4049/jimmunol.165.8.4359; XU H, 1999, NATL MED J CHINA, V79, P385; Xu Hui, 1999, Zhonghua Jiehe He Huxi Zazhi, V22, P558	55	35	40	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1603	+		10.1096/fj.04-1737fje	http://dx.doi.org/10.1096/fj.04-1737fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319367				2022-12-28	WOS:000223554900012
J	Stenovec, M; Kreft, M; Poberaj, I; Betz, WJ; Zorec, R				Stenovec, M; Kreft, M; Poberaj, I; Betz, WJ; Zorec, R			Slow spontaneous secretion from single large dense-core vesicles monitored in neuroendocrine cells	FASEB JOURNAL			English	Article						lactotrophs; fusion pore; membrane capacitance; atrial natriuretic peptide; FM 4-64	MEMBRANE-FUSION; EXOCYTOSIS; RELEASE; GRANULES; PORES; ENDOCYTOSIS; DYNAMICS	Hormones are released from cells by passing through an exocytotic pore that forms after vesicle and plasma membrane fusion. In stimulated exocytosis vesicle content is discharged swiftly. Although rapid vesicle discharge has also been proposed to mediate basal secretion, this has not been studied directly. We investigated basal hormone release by preloading fluorescent peptides into single vesicles. The hormone discharge, monitored with confocal microscopy, was compared with the simultaneous loading of vesicle by FM styryl dye. In stimulated vesicles FM 4-64 (4 muM), loading and hormone discharge occurs within seconds. In contrast, in approximate to 50% of spontaneously releasing vesicles, the vesicle content discharge and the FM 4-64 loading were slow (approximate to 3 min). These results show that in peptide secreting neuroendocrine cells the elementary vesicle content discharge differs in basal and in stimulated exocytosis. It is proposed that the view dating back for some decades, which is that, at rest, the vesicle discharge of hormones and neurotransmitters is similar to that occurring after stimulation, needs to be extended. In addition to the classical paradigm that secretory capacity of a cell is determined by controlling the probability of occurrence of elementary exocytotic events, one will have to consider activity modulation of elementary exocytotic events as well.	Celica Biomed Sci Ctr, Ljubljana 1000, Slovenia; Univ Ljubljana, Sch Med, Neuroendocrinol Mol Cell Physiol Lab, Ljubljana 1000, Slovenia; Fac Math & Phys Ljubljana, Dept Phys, Ljubljana, Slovenia; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO USA	University of Ljubljana; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Zorec, R (corresponding author), Celica Biomed Sci Ctr, Stegne 21, Ljubljana 1000, Slovenia.	robert.zorec@mf.uni.lj.si	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Zorec, Robert/0000-0002-7478-3875	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036665] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS36665-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; BENTABOU S, 1994, J PHYSIOL-LONDON, V476, P29; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Burgoyne RD, 2001, BIOCHEM SOC T, V29, P467, DOI 10.1042/BST0290467; Cochilla AJ, 2000, J CELL BIOL, V150, P839, DOI 10.1083/jcb.150.4.839; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dietl P, 2000, CELL BIOL INT, V24, P803, DOI 10.1006/cbir.2000.0630; DOUGLAS WW, 1985, ELECTROPHYSIOL SECRE; Duncan RR, 2003, NATURE, V422, P176, DOI 10.1038/nature01389; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; Henkel AW, 2000, EMBO J, V19, P84, DOI 10.1093/emboj/19.1.84; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Katz B., 1966, NERVE MUSCLE SYNAPSE; Kreft M, 2004, COMPUT METH PROG BIO, V74, P63, DOI 10.1016/S0169-2607(03)00071-3; Kreft M, 1997, PFLUG ARCH EUR J PHY, V434, P212, DOI 10.1007/s004240050387; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; Lollike K, 1998, BIOPHYS J, V75, P53, DOI 10.1016/S0006-3495(98)77494-6; LONGSWORTH LG, 1953, J AM CHEM SOC, V75, P5705, DOI 10.1021/ja01118a065; LONGSWORTH LG, 1952, J AM CHEM SOC, V74, P4155, DOI 10.1021/ja01136a059; Marty A., 1983, SINGLE CHANNEL RECOR; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OZAWA S, 1986, PHYSIOL REV, V66, P887, DOI 10.1152/physrev.1986.66.4.887; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Tani T, 2002, CELL BIOL INT, V26, P853, DOI 10.1006/cbir.2002.0937; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; WALKER AM, 1980, ENDOCRINOLOGY, V107, P1095, DOI 10.1210/endo-107-4-1095; Weise R, 2000, J MEMBRANE BIOL, V174, P15, DOI 10.1007/s002320001027; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473; ZUPANCIC G, 1994, J PHYSIOL-LONDON, V480, P539, DOI 10.1113/jphysiol.1994.sp020382	41	58	58	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1270	+		10.1096/fj.03-1397fje	http://dx.doi.org/10.1096/fj.03-1397fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180959				2022-12-28	WOS:000222327500031
J	Ziel, KA; Campbell, CC; Wilson, GL; Gillespie, MN				Ziel, KA; Campbell, CC; Wilson, GL; Gillespie, MN			Ref-1/Ape is critical for formation of the hypoxia-inducible transcriptional complex on the hypoxic response element of the rat pulmonary artery endothelial cell VEGF gene	FASEB JOURNAL			English	Article						vascular endothelial growth factor; PAEC; HIF-1	SMOOTH-MUSCLE-CELLS; FACTOR-I; HUMAN AP-ENDONUCLEASE-1; BINDING-PROTEIN; DNA-DAMAGE; MITOCHONDRIAL; REPRESSION; MECHANISM; CALCIUM; 1-ALPHA	The co-transcription factor and DNA repair enzyme, Redox effector factor1/apurinic/apyrimidinic endonuclease (Ref-1/Ape), facilitates DNA binding and transcriptional activity of a number of transactivating factors, including those governing hypoxia-induced gene expression HIF-1. It is not known, however, whether Ref-1/Ape is a component of the hypoxic transcriptional complex. Electrophoretic mobility shift assays failed to detect direct DNA binding of Ref-1/Ape to either the HIF-1 or AP1 DNA recognition sequences present in the hypoxic response element of the VEGF gene. However, immunodepletion of Ref-1/Ape from nuclear extract prevented DNA binding of ATF/CREB and HIF-1 to the HIF-1 DNA recognition sequence. DNA affinity-precipitation analyses showed that Ref-1/Ape was part of the multiprotein transcriptional complex forming on a 64-mer sequence encompassing a minimal hypoxic response element. Immunodepletion of Ref-1/Ape prevented probe association with HIF-1, p300, ATF, and CREB. Co-immunoprecipitation experiments indicated that Ref-1/Ape present in nuclear extract interacted with HIF-1 and p300 but not ATF/CREB. However, when Ref-1/Ape was immunoprecipitated from the oligonucleotide probe, both HIF-1 and p300 remained probe-associated while ATF/CREB co-immunoprecipitated. These findings suggest that Ref-1/Ape is a critical component of the hypoxia-inducible transcriptional complex forming on the VEGF gene's hypoxic response element and that the presence of Ref-1/Ape in the complex is required for the apparent high affinity association between HIF-1 and its DNA recognition sequence.	Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama	Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, MSB 3344, Mobile, AL 36688 USA.	mgillesp@jaguar1.usouthal.edu						Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Babal P, 2002, AM J PHYSIOL-LUNG C, V282, pL840, DOI 10.1152/ajplung.00347.2001; Bhakat KK, 2003, METHOD ENZYMOL, V371, P292; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Englander EW, 1999, J NEUROSCI RES, V58, P262, DOI 10.1002/(SICI)1097-4547(19991015)58:2<262::AID-JNR6>3.0.CO;2-W; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Grishko V, 2001, FASEB J, V15, P1267, DOI 10.1096/fj.00-0755fje; He TR, 2003, AM J PHYSIOL-HEART C, V285, pH804, DOI 10.1152/ajpheart.01080.2002; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Moller P, 2001, FASEB J, V15, P1181, DOI 10.1096/fj.00-0703com; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; WANG GL, 1993, J BIOL CHEM, V268, P21513; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	22	59	64	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					986	+		10.1096/fj.03-1160fje	http://dx.doi.org/10.1096/fj.03-1160fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084519				2022-12-28	WOS:000221108800008
J	Zhao, L; Tong, TJ; Zhang, ZY				Zhao, L; Tong, TJ; Zhang, ZY			Expression of the Leo1-like domain of replicative senescence down-regulated Leo1-like (RDL) protein promotes senescence of 2BS fibroblasts	FASEB JOURNAL			English	Article						replicative senescence; subtractive hybridization; RDL; Leo1-like domain	GENE-EXPRESSION; CAENORHABDITIS-ELEGANS; REPLICATIVE SENESCENCE; MICROARRAY ANALYSIS; ELONGATION-FACTORS; GROWTH-FACTOR; IN-VITRO; CELLS; IDENTIFICATION; FIBROBLASTS	Replicative senescence is thought to relate to aging in vivo and tumor suppression. In this report, we isolated a gene and designated it as RDL (replicative senescence down-regulated Leol-like gene). RDEs expression decreased upon replicative senescence of human diploid 2BS fibroblasts. Overexpression of RDL slightly delayed 2BS fibroblast senescence, whereas suppression of RDL expression imposed no obvious effects on senescence. However, introduction of cDNA fragment encoding the Leol-like domain of RDLp (Leo) alone shortened the replicative life span of 2BS fibroblasts and promoted several senescent features; the introduction of truncated RDL cDNA fragment resulting from deletion of Leo (RDILeo(-)) significantly prolonged 2BS life span and caused a noticeable delay of these senescent features. We demonstrated that introduction of Leo obviously increased the expression of p16(INK4a), p21(WAF1), and PTEN, whereas introduction of RDL-Leo(-) distinctly decreased p16(INK4a) expression. Taken together, our results suggest that the Leol-like domain of RDLp is a senescence-associated domain that accelerates the senescence of 2BS fibroblasts and that there should be another counteractive domain in the remaining part of RDLp.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Peking Univ Res Ctr Aging, Beijing 100083, Peoples R China	Peking University; Peking University	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	tj@bjmu.edu.cn	Zhao, Liang/K-1484-2014	Zhao, Liang/0000-0002-3489-7421				BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; BELL GI, 1983, NATURE, V304, P368, DOI 10.1038/304368a0; Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Bucher MH, 2002, ACTA CRYSTALLOGR D, V58, P392, DOI 10.1107/S0907444901021187; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Coates PJ, 2002, J PATHOL, V196, P371, DOI 10.1002/path.1073; Derventzi A, 1996, ANTICANCER RES, V16, P2901; Dierick JF, 2002, FEBS LETT, V531, P499, DOI 10.1016/S0014-5793(02)03604-9; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIPAOLO BR, 1995, EXP CELL RES, V220, P178, DOI 10.1006/excr.1995.1304; DOLE MG, 1995, CANCER RES, V55, P2576; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; Endege WO, 1999, BIOTECHNIQUES, V26, P542, DOI 10.2144/99263cr04; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Garbarino JE, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-18; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; LeckaCzernik B, 1996, EXP GERONTOL, V31, P159, DOI 10.1016/0531-5565(95)02014-4; LI JH, 1995, MECH AGEING DEV, V80, P25, DOI 10.1016/0047-6374(94)01557-3; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MAGDOLEN V, 1994, BBA-GENE STRUCT EXPR, V1218, P205, DOI 10.1016/0167-4781(94)90013-2; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nauck MA, 1999, DIABETOLOGIA, V42, P373, DOI 10.1007/s001250051165; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Semov A, 2002, ANAL BIOCHEM, V302, P38, DOI 10.1006/abio.2001.5515; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Spector D. L., 1998, CELLS LAB MANUAL; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Walhout AJM, 2002, CURR BIOL, V12, P1952, DOI 10.1016/S0960-9822(02)01279-4; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682	45	5	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					521	532		10.1096/fj.04-2689com	http://dx.doi.org/10.1096/fj.04-2689com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791002				2022-12-28	WOS:000228865300036
J	Krick, S; Hanze, J; Eul, B; Savai, R; Seay, U; Grimminger, F; Lohmeyer, J; Klepetko, W; Seeger, W; Rose, F				Krick, S; Hanze, J; Eul, B; Savai, R; Seay, U; Grimminger, F; Lohmeyer, J; Klepetko, W; Seeger, W; Rose, F			Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1 alpha and an autocrine angiotensin system	FASEB JOURNAL			English	Article						pulmonary hypertension; vascular remodeling	INDUCIBLE FACTOR-I; CONVERTING ENZYME; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; CELLULAR PROLIFERATION; RECEPTOR EXPRESSION; INDUCED APOPTOSIS; RNA INTERFERENCE; EPITHELIAL-CELLS; HYPERTROPHY	Pulmonary artery adventitial fibroblasts (FBPA) may play a central role in lung vascular remodeling under conditions of hypoxia and inflammation, the result being pulmonary hypertension and cor pulmonale. In cultured human FBPA, both angiotensin II (Ang II) and hypoxia promoted cell cycle progression and cell proliferation and suppressed apoptosis. These effects were further enhanced when both stimuli were applied simultaneously. Hypoxia elevated the expression of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and increased the expression of genes regulated by the hypoxia-responsive element (HRE). Up-regulation of both angiotensin-converting enzyme (ACE) and Ang II receptor type 1 (AT1) was also observed. Exogenous Ang II further increased HIF/HRE-dependent signaling in FBPA, whereas suppression of the autocrine ACE-Ang II-AT1 loop with inhibitors of ACE, AT1, and phosphatidylinositol 3-kinase (PI3K) reduced the proliferative response to both hypoxia and exogenous Ang II. Overexpression of HIF-1 alpha by transient transfection caused the same proliferative effect and up-regulation of AT1 expression that were observed under hypoxic conditions. In contrast, small interfering RNA targeting HIF-1 alpha inhibited hypoxia-induced ACE and AT1 expression. Our studies indicate that the ACE-Ang II-AT1 system serves as a positive feedback loop and fosters FBPA proliferation under hypoxic conditions, with the PI3K-HIF-HRE axis as the central effector pathway. This pathway may thus facilitate vascular remodeling under hypoxic conditions.	Univ Giessen, Dept Internal Med 2, D-35392 Giessen, Germany; Vienna Univ Hosp, Dept Cardiothorac Surg, Vienna, Austria	Justus Liebig University Giessen; University Hospital Vienna	Krick, S (corresponding author), Univ Giessen, Dept Internal Med 2, Klinikstr 36, D-35392 Giessen, Germany.	Stefanie.Krick@innere.med.uni-giessen.de		Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276; Savai, Rajkumar/0000-0003-1538-2091				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Adamy C, 2002, AM J PHYSIOL-HEART C, V283, pH733, DOI 10.1152/ajpheart.01088.2001; Belknap JK, 1997, AM J RESP CELL MOL, V16, P366, DOI 10.1165/ajrcmb.16.4.9115746; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chassagne C, 2000, AM J RESP CELL MOL, V22, P323, DOI 10.1165/ajrcmb.22.3.3701; Chen EY, 2001, CANCER RES, V61, P2429; Durmowicz A G, 1999, Pediatr Rev, V20, pe91; DZAU VJ, 1984, J CARDIOVASC PHARM, V6, pS377, DOI 10.1097/00005344-198406002-00012; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GIBBONS GH, 1990, CARDIOVASC DRUG THER, V4, P237, DOI 10.1007/BF01857638; Hanze J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI 10.1016/j.bbrc.2003.10.153; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lijnen PJ, 2003, METHOD FIND EXP CLIN, V25, P541, DOI 10.1358/mf.2003.25.7.778094; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Marshall RP, 2003, CURR PHARM DESIGN, V9, P715, DOI 10.2174/1381612033455431; Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004; Matsubara H, 1998, ENDOCR J, V45, P137, DOI 10.1507/endocrj.45.137; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Morrell NW, 1997, CARDIOVASC RES, V34, P393, DOI 10.1016/S0008-6363(97)00049-7; MORRELL NW, 1995, J CLIN INVEST, V96, P1823, DOI 10.1172/JCI118228; MURPHY JD, 1981, J PEDIATR-US, V98, P962, DOI 10.1016/S0022-3476(81)80605-1; Ohuchi N, 2004, COMP BIOCHEM PHYS C, V137, P281, DOI 10.1016/j.cca.2004.02.003; Orte C, 2000, J PATHOL, V192, P379, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Rose F, 2002, FASEB J, V16, P1660, DOI 10.1096/fj.02-0420fje; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; Schuttert JB, 2003, PFLUG ARCH EUR J PHY, V446, P387, DOI 10.1007/s00424-003-1026-y; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Stenmark KR, 2000, PHYSIOL RES, V49, P503; Stenmark KR, 2002, CHEST, V122, p326S, DOI 10.1378/chest.122.6_suppl.326S; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; Stenmark KR, 1999, ADV EXP MED BIOL, V474, P231; Strauss BH, 2000, AM J RESP CELL MOL, V22, P1; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V277, pL1245, DOI 10.1152/ajplung.1999.277.6.L1245; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V276, pL885, DOI 10.1152/ajplung.1999.276.5.L885; Wang RQ, 2000, J CELL PHYSIOL, V185, P253; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; Welsh DJ, 2001, AM J RESP CRIT CARE, V164, P282, DOI 10.1164/ajrccm.164.2.2008054; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wolf G, 2004, AM J NEPHROL, V24, P415, DOI 10.1159/000080086; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	54	69	74	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					857	+		10.1096/fj.04-2890fje	http://dx.doi.org/10.1096/fj.04-2890fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15718424				2022-12-28	WOS:000227591900028
J	Vincent, AM; McLean, LL; Backus, C; Feldman, EL				Vincent, AM; McLean, LL; Backus, C; Feldman, EL			Short-term and hyperglycemia produces oxidative damage and apoptosis in neurons	FASEB JOURNAL			English	Article						reactive oxygen species; dorsal root ganglion; diabetic neuropathy	ALPHA-LIPOIC ACID; ANTIOXIDANT ENZYME-ACTIVITIES; DORSAL-ROOT GANGLION; LIPID-PEROXIDATION; ACTIVATED CASPASE-3; GENE-EXPRESSION; CELL-CULTURE; STRESS; SUPEROXIDE; NEUROPATHY	Dorsal root ganglia neurons in culture die through programmed cell death when exposed to elevated glucose, providing an in vitro model system for the investigation of the mechanisms leading to diabetic neuropathy. This study examines the time course of programmed cell death induction, regulation of cellular antioxidant capacity, and the protective effects of antioxidants in neurons exposed to hyperglycemia. We demonstrate that the first 2 h of hyperglycemia are sufficient to induce oxidative stress and programmed cell death. Using fluorimetric analysis of reactive oxygen species (ROS) production, in vitro assays of antioxidant enzymes, and immunocytochemical assays of cell death, we demonstrate superoxide formation, inhibition of aconitase, and lipid peroxidation within 1 h of hyperglycemia. These are followed by caspase-3 activation and DNA fragmentation. Antioxidant potential increases by 3-6 h but is insufficient to protect these neurons. Application of the antioxidant a-lipoic acid potently prevents glucose-induced oxidative stress and cell death. This study identifies cellular therapeutic targets to prevent diabetic neuropathy. Since oxidative stress is a common feature of the micro- and macrovascular complications of diabetes, the present findings have broad application to the treatment of diabetic patients.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vincent, AM (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	andreav@umich.edu		Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [R01 NS38849)] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alho H, 1998, RESTOR NEUROL NEUROS, V12, P159; Ametov AS, 2003, DIABETES CARE, V26, P770, DOI 10.2337/diacare.26.3.770; Apfel SC, 1999, DIABETES OBES METAB, V1, P3, DOI 10.1046/j.1463-1326.1999.00006.x; Bassi AM, 2002, TOXICOL IN VITRO, V16, P339, DOI 10.1016/S0887-2333(02)00016-4; Bhor VM, 2004, INT J BIOCHEM CELL B, V36, P89, DOI 10.1016/S1357-2725(03)00142-0; Bitar MS, 2004, HORM METAB RES, V36, P542, DOI 10.1055/s-2004-825760; BOQUIST L, 1985, FEBS LETT, V183, P173, DOI 10.1016/0014-5793(85)80979-0; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cheng C, 2003, DIABETES, V52, P2363, DOI 10.2337/diabetes.52.9.2363; Cotter MA, 2003, LIFE SCI, V73, P1813, DOI 10.1016/S0024-3205(03)00508-3; Dincer Y, 2002, CLIN EXP PHARMACOL P, V29, P281, DOI 10.1046/j.1440-1681.2002.03642.x; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Feldman EL, 2003, J CLIN INVEST, V111, P431, DOI 10.1172/JCI200317863; Feldman EL, 2002, Ellenberg and Rifkin's diabetes mellitus, P771; Grillo CA, 2003, NEUROSCIENCE, V121, P133, DOI 10.1016/S0306-4522(03)00343-9; Guegan C, 1999, NEUROBIOL DIS, V6, P180, DOI 10.1006/nbdi.1999.0240; Haak E, 2000, EXP CLIN ENDOCR DIAB, V108, P168, DOI 10.1055/s-2000-7739; Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Jones SC, 1999, DIABETOLOGIA, V42, P1113, DOI 10.1007/s001250051279; Kishi M, 2002, DIABETES, V51, P819, DOI 10.2337/diabetes.51.3.819; KISHI M, 2001, J PERIPHER NERV SYST, V6, P152; Kowluru RA, 2002, FREE RADICAL RES, V36, P993, DOI 10.1080/1071576021000006572; Kucukatay V, 2003, ARCH ENVIRON HEALTH, V58, P14, DOI 10.3200/AEOH.58.1.14-22; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Limaye PV, 2003, MOL CELL BIOCHEM, V243, P147, DOI 10.1023/A:1021620414979; Maritim AC, 2003, J NUTR BIOCHEM, V14, P288, DOI 10.1016/S0955-2863(03)00036-6; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nickander KK, 1996, FREE RADICAL BIO MED, V21, P631, DOI 10.1016/0891-5849(96)00172-4; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Obrosova IG, 1999, INVEST OPHTH VIS SCI, V40, P680; Obrosova IG, 2003, DIABETES, V52, P864, DOI 10.2337/diabetes.52.3.864; Obrosova IG, 2000, FASEB J, V14, P1548, DOI 10.1096/fj.14.11.1548; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Polydefkis M, 2003, JAMA-J AM MED ASSOC, V290, P1371, DOI 10.1001/jama.290.10.1371; Pratico D, 2001, LIPIDS, V36, pS45, DOI 10.1007/s11745-001-0681-0; Quagliaro L, 2003, DIABETES, V52, P2795, DOI 10.2337/diabetes.52.11.2795; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; Saengsirisuwan V, 2004, AM J PHYSIOL-ENDOC M, V287, pE529, DOI 10.1152/ajpendo.00013.2004; Schmeichel AM, 2003, DIABETES, V52, P165, DOI 10.2337/diabetes.52.1.165; Singleton JR, 2003, DIABETES, V52, P2867, DOI 10.2337/diabetes.52.12.2867; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Srinivasan P, 2002, INT J ONCOL, V20, P983; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Sumner CJ, 2003, NEUROLOGY, V60, P108, DOI 10.1212/WNL.60.1.108; TAKEUCHI A, 1995, AM J PHYSIOL-RENAL, V268, pF13, DOI 10.1152/ajprenal.1995.268.1.F13; Turk HM, 2002, ACTA DIABETOL, V39, P117, DOI 10.1007/s005920200029; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Vincent AM, 2004, DIABETES, V53, P726, DOI 10.2337/diabetes.53.3.726; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Yildirim O, 2002, BIOL TRACE ELEM RES, V90, P143, DOI 10.1385/BTER:90:1-3:143; Zochodne DW, 1999, BRAIN PATHOL, V9, P369; Zochodne DW, 2001, BRAIN, V124, P2319, DOI 10.1093/brain/124.11.2319	54	212	236	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					638	+		10.1096/fj.04-2513fje	http://dx.doi.org/10.1096/fj.04-2513fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677696	Green Published			2022-12-28	WOS:000226576600045
J	Landgraf, P; Sieg, F; Wahle, P; Meyer, G; Kreutz, MR; Pape, HC				Landgraf, P; Sieg, F; Wahle, P; Meyer, G; Kreutz, MR; Pape, HC			A maternal blood-borne factor promotes survival of the developing thalamus	FASEB JOURNAL			English	Article						Y-P30; survival-promoting peptide; sprouting; optic nerve crush; inflammation	NEUROTROPHIC FACTORS; SUBPLATE ZONE; AXONAL INJURY; IN-VITRO; NEURONS; EXPRESSION; PEPTIDE; CORTEX; IDENTIFICATION; ISOFORMS	In this report, we describe the identification of a polypeptide survival-promoting factor that is produced by maternal and early postnatal peripheral blood mononuclear cells (PBMCs) of the immune system in Long-Evans rats and humans. The factor, termed Y-P30, most likely arises from proteolytic processing of a larger precursor protein and accumulates mainly in pyramidal neurons of the developing cortex and hippocampus but not in astrocytes. It was released from neurons grown in culture and substantially promotes survival of cells in explant monocultures of perinatal thalamus from the offspring. Y-P30 mRNA was not detectable in infant or adult brain and was present only in blood cells of pregnant rats and humans but not in nonpregnant controls. However, Y-P30 transcription could be induced in PBMCs of adult animals by a central nervous system lesion (i.e., optic nerve crush), which points to a potential role of the factor not only in neuronal development but also in neuroinflammation after white matter injury.	Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, AG Mol Mech Plast, D-39118 Magdeburg, Germany; Otto Von Guericke Univ, Inst Physiol, Magdeburg, Germany; Ruhr Univ Bochum, Fac Biol, AG Dev Biol, D-4630 Bochum, Germany; Univ La Laguna, Fac Med, Dept Anat, Tenerife, Spain	Leibniz Institut fur Neurobiologie (LIN); Otto von Guericke University; Ruhr University Bochum; Universidad de la Laguna	Kreutz, MR (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, AG Mol Mech Plast, Brenneckestr 6, D-39118 Magdeburg, Germany.	kreutz@ifn-magdeburg.de		Meyer, Gundela/0000-0002-5730-828X; Sieg, Frank/0000-0001-9637-3239				Cunningham TJ, 1998, J NEUROSCI, V18, P7047; Cunningham TJ, 2002, EXP NEUROL, V177, P32, DOI 10.1006/exnr.2002.7979; Cunningham TJ, 2000, EXP NEUROL, V163, P457, DOI 10.1006/exnr.2000.7390; Engelmann R, 2001, BRAIN RES, V889, P251, DOI 10.1016/S0006-8993(00)03145-0; Flad T, 2002, J IMMUNOL METHODS, V270, P53, DOI 10.1016/S0022-1759(02)00229-6; Garnica AD, 1996, J AM COLL NUTR, V15, P206; HENSCHEL R, 1994, EUR J NEUROSCI, V6, P1239, DOI 10.1111/j.1460-9568.1994.tb00313.x; KOSTOVIC I, 1990, J COMP NEUROL, V297, P441, DOI 10.1002/cne.902970309; Kreutz MR, 1998, J NEUROSCI, V18, P8278; Kreutz MR, 2004, EUR J NEUROSCI, V19, P247, DOI 10.1111/j.1460-9568.2004.03087.x; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Lotto RB, 1997, EUR J NEUROSCI, V9, P1940, DOI 10.1111/j.1460-9568.1997.tb00761.x; Lotto RB, 2001, J NEUROSCI, V21, P3904, DOI 10.1523/JNEUROSCI.21-11-03904.2001; MOLLIVER ME, 1973, BRAIN RES, V50, P403, DOI 10.1016/0006-8993(73)90741-5; Molnar Z, 1999, EXP NEUROL, V156, P363, DOI 10.1006/exnr.1999.7032; NAEGELE JR, 1991, P NATL ACAD SCI USA, V88, P330, DOI 10.1073/pnas.88.2.330; Obst K, 1997, EUR J NEUROSCI, V9, P2571, DOI 10.1111/j.1460-9568.1997.tb01686.x; OBST K, 1995, EUR J NEUROSCI, V7, P2139, DOI 10.1111/j.1460-9568.1995.tb00636.x; RENNIE S, 1994, NEUROSCIENCE, V61, P547, DOI 10.1016/0306-4522(94)90433-2; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Seldenbecher CI, 2004, J MOL BIOL, V336, P957, DOI 10.1016/j.jmb.2003.12.054; Sieg F, 1998, DEV BRAIN RES, V110, P83, DOI 10.1016/S0165-3806(98)00097-2; Sieg F, 1999, J NEUROTRAUM, V16, P1197, DOI 10.1089/neu.1999.16.1197; Wahle P, 2003, DEVELOPMENT, V130, P611, DOI 10.1242/dev.00224	24	22	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					225	+		10.1096/fj.04-1789fje	http://dx.doi.org/10.1096/fj.04-1789fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15583035				2022-12-28	WOS:000226091000022
J	Gerdin, MJ; Masana, MI; Rivera-Bermudez, MA; Hudson, RL; Earnest, DJ; Gillette, MU; Dubocovich, ML				Gerdin, MJ; Masana, MI; Rivera-Bermudez, MA; Hudson, RL; Earnest, DJ; Gillette, MU; Dubocovich, ML			Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin	FASEB JOURNAL			English	Article						desensitization; internalization; protein kinase C; SCN2.2 cells; circadian rhythms	PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; PHASE ADVANCES; C3H/HEN MOUSE; CELL-LINES; KINASE-C; EXPRESSION; RHYTHMS; TRAFFICKING; ENDOCYTOSIS	The hormone melatonin phase shifts circadian rhythms generated by the mammalian biological clock, the suprachiasmatic nucleus (SCN) of the hypothalamus, through activation of G protein-coupled MT2 melatonin receptors. This study demonstrated that pretreatment with physiological concentrations of melatonin (30-300 pM or 7-70 pg/mL) decreased the number of hMT(2) melatonin receptors heterologously expressed in mammalian cells in a time and concentration-dependent manner. Furthermore, hMT(2)-GFP melatonin receptors heterologously expressed in immortalized SCN2.2 cells or in non-neuronal mammalian cells were internalized upon pretreatment with both physiological (300 pM or 70 pg/mL) and supraphysiological (10 nM or 2.3 ng/mL) concentrations of melatonin. The decrease in MT2 melatonin receptor number induced by melatonin (300 pM for 1 h) was reversible and reached almost full recovery after 8 h; however, after treatment with 10 nM melatonin full recovery was not attained even after 24 h. This recovery process was partially protein synthesis dependent. Furthermore, exposure to physiological concentrations of melatonin (300 pM) for a time mimicking the nocturnal surge (8 h) desensitized functional responses mediated through melatonin activation of endogenous MT2 receptors, i.e., stimulation of protein kinase C (PKC) in immortalized SCN2.2 cells and phase shifts of circadian rhythms of neuronal firing in the rat SCN brain slice. We conclude that in vivo the nightly secretion of melatonin desensitizes endogenous MT2 melatonin receptors in the mammalian SCN thereby providing a temporally integrated profile of sensitivity of the mammalian biological clock to a melatonin signal.	Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60680 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Human Anat & Med Neurobiol, College Stn, TX USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Illinois System; University of Illinois Urbana-Champaign	Dubocovich, ML (corresponding author), Northwestern Univ, Dept Mol Pharmacol & Biol Chem S215, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	mdubo@northwestern.edu		Earnest, David/0000-0003-4433-6481	NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH067320, R01MH052685, R01MH042922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155, P01NS039546] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42922, F31 MH 67320-01, R01 MH052685-06, R01 MH042922-18, MH 52685, R01 MH042922, R01 MH052685] Funding Source: Medline; NINDS NIH HHS [P01 NS39546, NS22155, R01 NS022155] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi A, 2002, GLIA, V39, P268, DOI 10.1002/glia.10109; Al-Ghoul WM, 1998, NEUROREPORT, V9, P4063, DOI 10.1097/00001756-199812210-00011; Allen G, 2001, J NEUROSCI, V21, P7937, DOI 10.1523/JNEUROSCI.21-20-07937.2001; ARMSTRONG SM, 1991, ADV PINEAL, V5, P259; Benloucif S, 1996, J BIOL RHYTHM, V11, P113, DOI 10.1177/074873049601100204; Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Dubocovich ML, 2003, FRONT BIOSCI-LANDMRK, V8, pD1093, DOI 10.2741/1089; Dubocovich ML, 1998, FASEB J, V12, P1211, DOI 10.1096/fasebj.12.12.1211; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Earnest DJ, 1999, J NEUROBIOL, V39, P1, DOI 10.1002/(SICI)1097-4695(199904)39:1<1::AID-NEU1>3.0.CO;2-F; GAUER F, 1993, BRAIN RES, V602, P153, DOI 10.1016/0006-8993(93)90256-M; Gerdin MJ, 2004, BIOCHEM PHARMACOL, V67, P2023, DOI 10.1016/j.bcp.2004.01.027; Gerdin MJ, 2003, J PHARMACOL EXP THER, V304, P931, DOI 10.1124/jpet.102.044990; Hunt AE, 2001, AM J PHYSIOL-CELL PH, V280, pC110, DOI 10.1152/ajpcell.2001.280.1.C110; Hurst WJ, 2002, BIOCHEM BIOPH RES CO, V292, P20, DOI 10.1006/bbrc.2002.6589; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lewy AJ, 1998, PSYCHIAT RES, V77, P57, DOI 10.1016/S0165-1781(97)00128-5; Lewy AJ, 2002, CHRONOBIOL INT, V19, P649, DOI 10.1081/CBI-120004546; Lewy AJ, 1998, CHRONOBIOL INT, V15, P71, DOI 10.3109/07420529808998671; Liang FQ, 1998, NEUROSCI LETT, V242, P89, DOI 10.1016/S0304-3940(98)00062-7; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; MacKenzie RS, 2002, BIOCHEM PHARMACOL, V63, P587, DOI 10.1016/S0006-2952(01)00881-4; Masana MI, 2003, BIOCHEM PHARMACOL, V65, P731, DOI 10.1016/S0006-2952(02)01627-1; Masana MI, 2000, J PINEAL RES, V28, P185, DOI 10.1034/j.1600-079X.2001.280309.x; MCARTHUR AJ, 1991, BRAIN RES, V565, P158, DOI 10.1016/0006-8993(91)91748-P; McArthur AJ, 1997, ENDOCRINOLOGY, V138, P627, DOI 10.1210/en.138.2.627; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Poirel VJ, 2002, BRAIN RES, V946, P64, DOI 10.1016/S0006-8993(02)02824-X; River-Bermudez MA, 2004, BRAIN RES, V1002, P21, DOI 10.1016/j.brainres.2003.12.008; Rivera-Bermudez MA, 2003, NEUROSCI LETT, V346, P37, DOI 10.1016/S0304-3940(03)00590-1; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Roy D, 2001, ENDOCRINOLOGY, V142, P4711, DOI 10.1210/en.142.11.4711; TENN C, 1993, MOL CELL ENDOCRINOL, V98, P43, DOI 10.1016/0303-7207(93)90234-B; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Weaver DR, 1996, NEUROREPORT, V8, P109, DOI 10.1097/00001756-199612200-00022; Wirz-Justice A, 2002, J PINEAL RES, V32, P1, DOI 10.1034/j.1600-079x.2002.10808.x; WittEnderby PA, 1996, MOL PHARMACOL, V50, P166; Zeitzer JM, 1999, AM J MED, V107, P432, DOI 10.1016/S0002-9343(99)00266-1	41	114	118	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1646	1656		10.1096/fj.03-1339com	http://dx.doi.org/10.1096/fj.03-1339com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522910				2022-12-28	WOS:000225482100033
J	Meininger, CJ; Cai, SJ; Parker, JL; Channon, KM; Kelly, KA; Becker, EJ; Wood, MK; Wade, LA; Wu, GY				Meininger, CJ; Cai, SJ; Parker, JL; Channon, KM; Kelly, KA; Becker, EJ; Wood, MK; Wade, LA; Wu, GY			GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats	FASEB JOURNAL			English	Article						endothelial dysfunction; nitric oxide synthase; diabetes; vascular complications	DEPENDENT VASODILATION; BB RAT; SYNTHASE; DYSFUNCTION; METABOLISM; MELLITUS; ANALOGS	Nitric oxide ( NO) synthesis in endothelial cells is impaired in diabetes. We previously showed that impaired NO synthesis in the spontaneously diabetic BB (BBd) rat is due to decreased levels of tetrahydrobiopterin (BH4), secondary to decreased expression of GTP cyclohydrolase I (GTPCH). The aim of this study was to utilize adenoviral GTPCH gene transfer to reverse BH4 deficiency and repair the ability of endothelial cells to produce NO. GTPCH gene transfer increased BH4 levels in BBd endothelial cells from 0.17 +/- 0.02 ( mean +/- SE) to 73.37 +/- 14.42 pmol/million cells and NO production from 0.77 +/- 0.07 to 18.74 +/- 5.52 nmol/24 h/million cells. To demonstrate a functional effect of increasing BH4 concentrations in tissues, we transferred GTPCH into aortic rings from BBd and Zucker diabetic fatty (ZDF) rats, models of human type I and type II diabetes, respectively. GTPCH gene transfer led to a dose-dependent increase in acetylcholine-induced vasorelaxation, preventable by inhibiting NO synthase. Maximal relaxation of virus-treated rings (10(10) virus particles/ml) to acetylcholine was significantly higher than sham-treated rings (BBd 64% vs. 37%, P< 0.005; ZDF 80% vs. 44%, P< 0.05). This study demonstrates that GTPCH gene transfer can reverse BH4 deficiency in both type I and type II diabetes and provides an experimental basis for using gene therapy to treat cardiovascular complications in diabetic patients.	Texas A&M Univ Syst HSC, Inst Cardiovasc Res, Dept Med Physiol, Temple, TX 76504 USA; Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Univ Mary Hardin Baylor, Dept Biol, Belton, TX 76513 USA; Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Oxford; Texas A&M University System; Texas A&M University College Station	Meininger, CJ (corresponding author), Texas A&M Univ Syst HSC, Inst Cardiovasc Res, Dept Med Physiol, 702 SW HK Dodgen Loop,MRB 110G, Temple, TX 76504 USA.	cjm@tamu.edu		channon, keith/0000-0002-1043-4342				Alp NJ, 2003, J CLIN INVEST, V112, P725, DOI 10.1172/JCI200317786; Cai S, 2002, CARDIOVASC RES, V55, P838, DOI 10.1016/S0008-6363(02)00460-1; Chan NN, 2000, DIABETOLOGIA, V43, P137, DOI 10.1007/s001250050022; De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393; Etgen GJ, 2000, METABOLISM, V49, P684, DOI 10.1016/S0026-0495(00)80049-9; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P175; Griffin KL, 1999, J APPL PHYSIOL, V87, P1948, DOI 10.1152/jappl.1999.87.5.1948; Harding CO, 2004, MOL GENET METAB, V81, P52, DOI 10.1016/j.ymgme.2003.10.002; Heitzer T, 2000, DIABETOLOGIA, V43, P1435, DOI 10.1007/s001250051551; Hynes SO, 2004, AM J PHYSIOL-HEART C, V286, pH570, DOI 10.1152/ajpheart.00669.2003; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Kohli R, 2004, J NUTR, V134, P600, DOI 10.1093/jn/134.3.600; Li H, 2000, J CHROMATOGR B, V746, P199, DOI 10.1016/S0378-4347(00)00328-5; Marinos RS, 2001, AM J PHYSIOL-HEART C, V281, pH482, DOI 10.1152/ajpheart.2001.281.2.H482; Meininger CJ, 2000, BIOCHEM J, V349, P353, DOI 10.1042/0264-6021:3490353; Mitchell BM, 2003, AM J PHYSIOL-HEART C, V285, pH2165, DOI 10.1152/ajpheart.00253.2003; Pannirselvam M, 2002, BRIT J PHARMACOL, V136, P255, DOI 10.1038/sj.bjp.0704683; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; PIEPER GM, 1996, LIFE SCI, V58, P147; Tiefenbacher CP, 2003, PFLUG ARCH EUR J PHY, V447, P1, DOI 10.1007/s00424-003-1131-y; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 2002, BIOCHEM J, V362, P733, DOI 10.1042/0264-6021:3620733; Vasquez-Vivar J, 2002, ARTERIOSCL THROM VAS, V22, P1655, DOI 10.1161/01.ATV.0000029122.79665.D9; WU GY, 1995, AM J PHYSIOL-HEART C, V269, pH1312, DOI 10.1152/ajpheart.1995.269.4.H1312; Zheng JS, 2003, CIRCULATION, V108, P1238, DOI 10.1161/01.CIR.0000089082.40285.C3	25	69	74	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1900	+		10.1096/fj.04-1702fje	http://dx.doi.org/10.1096/fj.04-1702fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15467010				2022-12-28	WOS:000224849900029
J	Nilsson, I; Rolny, C; Wu, Y; Pytowski, B; Hicklin, D; Alitalo, K; Claesson-Welsh, L; Wennstrom, S				Nilsson, I; Rolny, C; Wu, Y; Pytowski, B; Hicklin, D; Alitalo, K; Claesson-Welsh, L; Wennstrom, S			Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development	FASEB JOURNAL			English	Article						embryoid body; endothelial cell; hypoxia; VEGFR-3	EMBRYONIC STEM-CELLS; IN-VITRO; TYROSINE KINASE; VEGF-C; FLT-1; ANGIOGENESIS; EXPRESSION; MOUSE; GENE; VASCULOGENESIS	Reduced tissue oxygen tension ( hypoxia) is appreciated as an efficient stimulus for neovascularization. The effect of hypoxia on the very first stages of vascular development is, however, less well characterized. Here we show that hypoxic conditions (1% O-2) potently stimulated formation of an extensive vascular network during a discrete stage of mouse embryonal stem cell differentiation. The morphological changes correlated with an expanding pool of endothelial cells and with activation of the vascular endothelial growth factor-d (Vegf-d) and Vegf receptor-3 genes. VEGF receptor-3 expression was confined to vascular endothelial cells and analysis of the lymphatic marker Prox-1 revealed no expansion of lymphatic endothelial cells. Administration of neutralizing antibodies against either VEGF receptor-3 or VEGF receptor-2 impaired vascular network formation, whereas neutralizing antibodies against VEGF receptor-1 potentiated development of immature vascular structures. In addition, sequestering of VEGF receptor-3 ligands reduced vascularization in a manner similar to neutralization of VEGF receptor-3. We conclude that hypoxia-driven vascular development requires the activity of VEGF receptor-3.	Uppsala Univ, Dept Genet & Pathol, Vasc Biol Unit, Rudbeck Lab, S-75185 Uppsala, Sweden; ImClone Syst Inc, Dept Immunol, New York, NY USA; Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, Helsinki, Finland	Uppsala University; Eli Lilly; University of Helsinki	Wennstrom, S (corresponding author), Uppsala Univ, Dept Genet & Pathol, Vasc Biol Unit, Rudbeck Lab, S-75185 Uppsala, Sweden.	Stefan.Wennstrom@genpat.uu.se	Rolny, Charlotte/AET-0493-2022; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Rolny, Charlotte/0000-0003-4979-9266				Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Baldwin ME, 2002, BIOESSAYS, V24, P1030, DOI 10.1002/bies.10173; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; BURRI PH, 1990, ANAT REC, V228, P35, DOI 10.1002/ar.1092280107; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; HIRASHIMA M, 2002, BLOOD; Hiratsuka S, 2001, CANCER RES, V61, P1207; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397; Keller G, 1999, NAT MED, V5, P151, DOI 10.1038/5512; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kubo H, 2000, BLOOD, V96, P546; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MAGNUSSON P, 2004, IN PRESS J CELL SCI; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Maltepe E, 1998, J MOL MED-JMM, V76, P391, DOI 10.1007/s001090050231; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; PARK JE, 1994, J BIOL CHEM, V269, P25646; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROSSANT J, 1993, PHILOS T R SOC B, V339, P207, DOI 10.1098/rstb.1993.0018; Saaristo A, 2000, AM J PATHOL, V157, P7, DOI 10.1016/S0002-9440(10)64510-5; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Teng XW, 2002, CHEST, V121, p82S, DOI 10.1378/chest.121.3_suppl.82S-a; Torii MA, 1999, DEVELOPMENT, V126, P443; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; WANG R, 1992, DEVELOPMENT, V114, P303; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Wartenberg M, 1998, LAB INVEST, V78, P1301; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	57	35	36	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1507	1515		10.1096/fj.03-1276com	http://dx.doi.org/10.1096/fj.03-1276com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466359				2022-12-28	WOS:000224849900034
J	Iacobini, C; Menini, S; Oddi, G; Ricci, C; Amadio, L; Pricci, F; Olivieri, A; Sorcini, M; Di Mario, U; Pesce, C; Pugliese, G				Iacobini, C; Menini, S; Oddi, G; Ricci, C; Amadio, L; Pricci, F; Olivieri, A; Sorcini, M; Di Mario, U; Pesce, C; Pugliese, G			Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor	FASEB JOURNAL			English	Article						RAGE; extracellular matrix; kidney disease	GLYCATION END-PRODUCTS; GENE-EXPRESSION; DIABETIC-NEPHROPATHY; MATRIX METALLOPROTEINASES; MESANGIAL EXPANSION; OXIDATIVE STRESS; BINDING-PROTEIN; RAGE; ACTIVATION; INHIBITOR	We previously showed that mice lacking galectin-3/AGE-receptor 3 develop accelerated diabetic glomerulopathy. To further investigate the role of galectin-3/AGE-receptor function in the pathogenesis of diabetic renal disease, galectin-3 knockout ( KO) and coeval wild-type (WT) mice were injected for 3 months with 30 mug/day of N-epsilon-carboxymethyllysine (CML)-modified or unmodified mouse serum albumin (MSA). Despite receiving equal doses of CML, KO had higher circulating and renal AGE levels and showed more marked renal functional and structural changes than WT mice, with significantly higher proteinuria, albuminuria, glomerular, and mesangial area and glomerular sclerosis index. Renal 4-hydroxy-2-nonenal content and NFkappaB activation were also more pronounced in KO-CML vs. WT-CML. Kidney mRNA levels of fibronectin, laminin, collagen IV, and TGF-beta were up-regulated, whereas those of matrix metalloproteinase-2 and -14 were down-regulated, again more markedly in KO-CML than WT-CML mice. Basal and CML-induced RAGE and 80K-H mRNA levels were higher in KO vs. WT mice. MSA injection did not produce any significant effect in both genotypes. The association of galectin-3 ablation with enhanced susceptibility to AGE-induced renal disease, increased AGE levels and signaling, and altered AGE-receptor pattern indicates that galectin-3 is operating in vivo as an AGE receptor to afford protection toward AGE-dependent tissue injury.	Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; Univ Genoa, Sch Med, DISTBIMO, I-16132 Genoa, Italy; Univ Roma La Sapienza, Dept Clin Sci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); University of Genoa; Sapienza University Rome	Pugliese, G (corresponding author), Dipartimento Sci Clin Endocrinol, Viale Policlin 155, I-00161 Rome, Italy.	giuseppe.pugliese@uniroma1.it	Menini, Stefano/G-1130-2010; Pricci, Flavia/K-7739-2016; Pugliese, Giuseppe/G-8776-2012; Olivieri, Antonella/AAC-1644-2019	Menini, Stefano/0000-0001-7328-2385; Pricci, Flavia/0000-0002-1877-4376; Olivieri, Antonella/0000-0002-7565-4370; Pugliese, Giuseppe/0000-0003-1574-0397				ABEL M, 1995, NEPHROL DIAL TRANSPL, V10, P1662; Arar C, 1998, FEBS LETT, V430, P307, DOI 10.1016/S0014-5793(98)00683-8; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Benotmane AM, 1997, ANAL BIOCHEM, V250, P181, DOI 10.1006/abio.1997.2231; Bierhaus A, 1997, DIABETES, V46, P1481, DOI 10.2337/diabetes.46.9.1481; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Degenhardt TP, 2002, KIDNEY INT, V61, P939, DOI 10.1046/j.1523-1755.2002.00207.x; DelPrete D, 1997, DIABETOLOGIA, V40, P1449, DOI 10.1007/s001250050848; Di Mario U, 2001, DIABETOLOGIA, V44, P674, DOI 10.1007/s001250051676; EDELSTEIN D, 1992, DIABETES, V41, P26, DOI 10.2337/diabetes.41.1.26; Figarola JL, 2003, DIABETOLOGIA, V46, P1140, DOI 10.1007/s00125-003-1162-0; Forbes JM, 2003, FASEB J, V17, P1762, DOI 10.1096/fj.02-1102fje; FUKUI M, 1992, DIABETES, V41, P1520, DOI 10.2337/diabetes.41.12.1520; Gaedeke J, 2001, CONTRIB NEPHROL, V135, P153; He CJ, 2000, KIDNEY INT, V58, P1931, DOI 10.1046/j.1523-1755.2000.00365.x; Hofmann SM, 2002, DIABETES, V51, P2082, DOI 10.2337/diabetes.51.7.2082; Horiuchi S, 1996, DIABETES, V45, pS73, DOI 10.2337/diab.45.3.S73; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; HSU DK, 1992, J BIOL CHEM, V267, P14167; Iacobini C, 2003, J AM SOC NEPHROL, V14, pS264, DOI 10.1097/01.ASN.0000077402.95720.B4; Iwashima Y, 2000, BIOCHEM BIOPH RES CO, V277, P368, DOI 10.1006/bbrc.2000.3685; Karachalias N, 2003, BIOCHEM SOC T, V31, P1423; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lenz O, 2000, J AM SOC NEPHROL, V11, P574, DOI 10.1681/ASN.V113574; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; McLennan SV, 2000, DIABETOLOGIA, V43, P642, DOI 10.1007/s001250051353; Mitsuhashi T, 1997, J IMMUNOL METHODS, V207, P79, DOI 10.1016/S0022-1759(97)00110-5; Nachtigal M, 1998, AM J PATHOL, V152, P1199; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Nakamura S, 2003, AM J KIDNEY DIS, V41, pS68, DOI 10.1053/ajkd.2003.50088; NAKAMURA T, 1994, RENAL PHYSIOL BIOCH, V17, P316; Ochieng J, 1998, BIOCHEM BIOPH RES CO, V246, P788, DOI 10.1006/bbrc.1998.8708; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pesce C, 1998, ANAT REC, V251, P66, DOI 10.1002/(SICI)1097-0185(199805)251:1<66::AID-AR11>3.0.CO;2-9; Pesce C, 2002, NEPHRON, V90, P484, DOI 10.1159/000054738; Pricci F, 2000, KIDNEY INT, V58, pS31, DOI 10.1046/j.1523-1755.2000.07706.x; Pugliese G, 2001, FASEB J, V15, P2471, DOI 10.1096/fj.01-0006com; Pugliese G, 1997, DIABETES, V46, P1198, DOI 10.2337/diabetes.46.7.1198; Pugliese G, 2000, DIABETES, V49, P1249, DOI 10.2337/diabetes.49.7.1249; RAIJ L, 1984, KIDNEY INT, V26, P137, DOI 10.1038/ki.1984.147; RECKELHOFF JF, 1993, DIABETES, V42, P1425, DOI 10.2337/diabetes.42.10.1425; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; Sano H, 1999, MECH AGEING DEV, V107, P333, DOI 10.1016/S0047-6374(99)00011-1; Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Stitt AW, 1999, BIOCHEM BIOPH RES CO, V256, P549, DOI 10.1006/bbrc.1999.0291; Suzuki D, 1999, J AM SOC NEPHROL, V10, P822; Tanji N, 2000, J AM SOC NEPHROL, V11, P1656, DOI 10.1681/ASN.V1191656; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Wautier MP, 2003, DIABETES METAB, V29, P44, DOI 10.1016/S1262-3636(07)70006-X; Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0; Wilkinson-Berka JL, 2002, DIABETES, V51, P3283, DOI 10.2337/diabetes.51.11.3283; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Zhu WQ, 2001, BIOCHEM BIOPH RES CO, V280, P1183, DOI 10.1006/bbrc.2001.4256	65	87	88	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1773	+		10.1096/fj.04-2031fje	http://dx.doi.org/10.1096/fj.04-2031fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15361471	Green Submitted			2022-12-28	WOS:000224243200032
J	Cooper, TM; Mockett, RJ; Sohal, BH; Sohal, RS; Orr, WC				Cooper, TM; Mockett, RJ; Sohal, BH; Sohal, RS; Orr, WC			Effect of caloric restriction on life span of the housefly, Musca domestica	FASEB JOURNAL			English	Article						aging; metabolic rate; insect nutrition; oxygen; fertility	DIETARY RESTRICTION; EXTENSION; LONGEVITY; GROWTH	Caloric restriction (CR) has been found to extend the life spans of a wide variety of species, transcending phylogenetic boundaries. The objective of this study was to test the generality of this phenomenon, using the male housefly as an insect model in which food intake can be quantified precisely. Sucrose was found to promote a longer life span than diets additionally containing proteins and lipids. Flies were fed sucrose or a more complex diet ad libitum (AL), or in amounts ranging from 50% to 100% of the average amount consumed by young flies. CR shortened rather than prolonged the life span of houseflies, particularly flies fed sucrose only. The rate of oxygen consumption was not affected by caloric restriction or by the exclusion of proteins and lipids from the diet, and the reproductive activity of male flies remained unchanged by sucrose feeding. Thus, it is unlikely that the life-shortening effects of CR can be explained either in terms of an adaptive response in metabolic rate or use of a suboptimal food source. Results of this study contradict the widely held view that CR has a life-extending effect in all species.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	Southern Methodist University; University of Southern California	Orr, WC (corresponding author), So Methodist Univ, Dept Biol Sci, Dedman Life Sci Bldg,6501 Airline Rd, Dallas, TX 75275 USA.	borr@mail.smu.edu			NATIONAL INSTITUTE ON AGING [R01AG007657] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG7657] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSTAD SN, 1989, EXP GERONTOL, V24, P83, DOI 10.1016/0531-5565(89)90037-5; BOURG L, 1991, AGE NUTR, V2, P90; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; COMFORT A, 1963, GERONTOLOGY, V8, P150, DOI 10.1159/000211216; FANESTIL DD, 1965, J GERONTOL, V20, P462; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; Jiang JC, 2000, FASEB J, V14, P2135; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; MASORO E, 2002, CALORIE RESTRICTION; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; RAGLAND SS, 1973, EXP GERONTOL, V8, P135, DOI 10.1016/0531-5565(73)90003-X; RAGLAND SS, 1984, THESIS SO METHODIST; RUDZINSKA MA, 1952, J GERONTOL, V7, P544; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; WEST L, 1951, HOUSEFLY ITS NATURAL	22	80	83	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1591	+		10.1096/fj.03-1464fje	http://dx.doi.org/10.1096/fj.03-1464fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319362				2022-12-28	WOS:000223554900003
J	Tomassini, B; Malisan, F; Franchi, L; Nicolo, C; Brea-Calvo, G; Saito, T; Testi, R				Tomassini, B; Malisan, F; Franchi, L; Nicolo, C; Brea-Calvo, G; Saito, T; Testi, R			Calnexin suppresses GD3 synthase-induced apoptosis	FASEB JOURNAL			English	Article						ceramide-mediated stress response; sialyltransferase; mitochondrial damage	MITOCHONDRIAL PERMEABILITY TRANSITION; CHO-K1 CELLS; MOLECULAR CHAPERONE; GANGLIOSIDE GD3; N-GLYCOSYLATION; EXPRESSION; GLYCOSYLTRANSFERASES; DEFICIENT; ALPHA; MICE	An accelerated activity of the GD3 synthase (ST8), with consequent GD3 accumulation, is part of the response to environmental stressors in different cell types. Depending on specific, yet largely undefined, cellular settings, this can be followed by adaptation or apoptosis, the latter mostly due to GD3-induced mitochondrial damage. Here we show that subcellular localization of ST8 could significantly affect the biological outcome of GD3 accumulation. Binding to the molecular chaperone calnexin causes the retention of ST8 within the endoplasmic reticulum ( ER) and prevents its relocalization to the Golgi. Calnexin-dependent ER retention does not affect the activity of ST8; yet the de novo synthesized GD3 largely fails to reach the mitochondria. Accordingly, overexpression of calnexin suppresses the pro-apoptotic activity of ST8, while the loss of calnexin sensitizes the cells to ST8-induced apoptosis. Reconstitution of calnexin confers protection to deficient cells. Thus, calnexin controls the biological outcome of GD3 accumulation and reveals a novel role in the stress response.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Immunol & Signal Transduct, I-00133 Rome, Italy; Chiba Univ, Grad Sch Med, Dept Mol Genet, Chiba, Japan; RIKEN Ctr Allergy & Immunol, Lab Cell Signaling, Yokohama, Kanagawa, Japan	University of Rome Tor Vergata; Chiba University; RIKEN	Testi, R (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Immunol & Signal Transduct, Via Montpellier 1, I-00133 Rome, Italy.	roberto.testi@flashnet.it	Saito, Takashi/C-9684-2009; Brea-Calvo, Gloria/N-4728-2014	Saito, Takashi/0000-0001-9495-3547; Brea-Calvo, Gloria/0000-0001-5536-6868; MALISAN, FLORENCE/0000-0002-0213-9407				Bieberich E, 2000, J NEUROCHEM, V74, P2359, DOI 10.1046/j.1471-4159.2000.0742359.x; Bieberich E, 2002, BIOCHEMISTRY-US, V41, P11479, DOI 10.1021/bi0259958; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; Daniotti JL, 2002, NEUROCHEM RES, V27, P1421, DOI 10.1023/A:1021684018665; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Denzel A, 2002, MOL CELL BIOL, V22, P7398, DOI 10.1128/MCB.22.21.7398-7404.2002; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; Giraudo CG, 2003, J BIOL CHEM, V278, P40262, DOI 10.1074/jbc.M305455200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Li F, 2001, BIOCHEM BIOPH RES CO, V289, P725, DOI 10.1006/bbrc.2001.6001; Malisan F, 2002, BBA-MOL CELL BIOL L, V1585, P179, DOI 10.1016/S1388-1981(02)00339-6; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rippo MR, 2000, EUR CYTOKINE NETW, V11, P487; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SCOTT JE, 1995, J IMMUNOL, V155, P143	25	29	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1553	+		10.1096/fj.04-1675fje	http://dx.doi.org/10.1096/fj.04-1675fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319364				2022-12-28	WOS:000223554900005
J	Leite, RS; Brown, AG; Strauss, JF				Leite, RS; Brown, AG; Strauss, JF			Tumor necrosis factor-alpha suppresses the expression of steroid receptor coactivator-1 and-2: A possible mechanism contributing to changes in steroid hormone responsiveness	FASEB JOURNAL			English	Article						progesterone receptor; uterine smooth muscle cells; parturition; cofactors; inflammation	HUMAN PROGESTERONE-RECEPTOR; FACTOR-KAPPA-B; FETAL MEMBRANES; HUMAN LABOR; BINDING; PARTURITION; TERM; COREPRESSORS; CYTOKINES; PRETERM	Inflammation is associated in some tissues with diminished responsiveness to steroid hormone action. We hypothesized that proinflammatory cytokines alter steroid hormone sensitivity, in part, by reducing levels of key nuclear receptor coactivators. Treatment of cultured human uterine smooth muscle cells (UtSMC) with TNF-alpha significantly reduced mRNA for the coactivators, SRC-1 (42%, P< 0.01) and 2 (47%, P< 0.03), and diminished the respective protein levels, but did not significantly alter the mRNAs encoding SRC-3, CBP and the corepressors, NCoR and SMRT; or progesterone receptor protein levels. To assess TNF-alpha effects on steroid hormone-mediated transcriptional activity, UtSMC were transfected with progesterone receptor B (PR-B) and a model PRE(2)-luciferase reporter construct. Transfected UtSMC were treated with progesterone alone or in the presence of TNF-alpha, and assayed for luciferase activity. TNF-alpha (10 ng/ml) diminished progesterone-stimulated PR-B-mediated transactivation by similar to60% (P< 0.02). The TNF-alpha-dependent decrease in PRE-luciferase activity was fully prevented by cotransfection with SRC-2, and partially prevented with exogenous SRC-1. In conclusion, TNF-alpha impairs progesterone-stimulated PR-B-mediated transactivation, and these effects appear to be due, in part, to reduced expression of SRC-1 and -2, which is a novel mechanism by which inflammation can functionally block steroid hormone action.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Strauss, JF (corresponding author), 1354 Biomed Res Bldg,II-III 421 Curie Blvd, Philadelphia, PA 19104 USA.	jfs3@mail.med.upenn.edu			FIC NIH HHS [D43-TW00671] Funding Source: Medline; NICHD NIH HHS [T32-HD07305, R01 HD34612] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034612, T32HD007305] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000671] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; ANDERSON ABM, 1975, J ENDOCRINOL, V66, P61, DOI 10.1677/joe.0.0660061; Arechavaleta-Velasco F, 2002, BIOL REPROD, V67, P1952, DOI 10.1095/biolreprod.102.004721; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; CSAPO AI, 1965, P NATL ACAD SCI USA, V54, P1069, DOI 10.1073/pnas.54.4.1069; Fukuda H, 2002, INT J GYNECOL OBSTET, V77, P123, DOI 10.1016/S0020-7292(02)00016-4; Garland SM, 2002, J REPROD IMMUNOL, V57, P169, DOI 10.1016/S0165-0378(02)00018-9; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Henderson D, 2001, AM J OBSTET GYNECOL, V185, P579, DOI 10.1067/mob.2001.116753; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Keelan JA, 2003, PLACENTA, V24, pS33, DOI 10.1053/plac.2002.0948; Keelan JA, 1997, CLIN OBSTET GYNECOL, V40, P460, DOI 10.1097/00003081-199709000-00004; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MCDONNELL DP, 1995, TRENDS ENDOCRIN MET, V6, P133, DOI 10.1016/1043-2760(95)00065-P; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; ONATE SA, 1995, SCIENCE, V270, P1354; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; Peltier M, 2003, REPROD BIOL ENDOCRIN, V1, P122, DOI [10.1186/1477-7827-1-122, DOI 10.1186/1477-7827-1-122]; Rowan BG, 2000, STEROIDS, V65, P545, DOI 10.1016/S0039-128X(00)00112-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIITERI PK, 1982, BIOL REPROD, V26, P1, DOI 10.1095/biolreprod26.1.1; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Steinborn A, 1995, PROSTAGLANDINS, V50, P237, DOI 10.1016/0090-6980(95)00138-7; Steinborn A, 1996, J PERINAT MED, V24, P381, DOI 10.1515/jpme.1996.24.4.381; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Xu JJ, 1998, ELECTROCHEM SOLID ST, V1, P1, DOI 10.1149/1.1390615; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Young A, 2002, BIOL REPROD, V66, P445, DOI 10.1095/biolreprod66.2.445	38	29	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1418	+		10.1096/fj.04-1684fje	http://dx.doi.org/10.1096/fj.04-1684fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231721				2022-12-28	WOS:000222979200016
J	Maupas-Schwalm, F; Auge, N; Robinet, C; Cambus, JP; Parsons, SJ; Salvayre, R; Negre-Salvayre, A				Maupas-Schwalm, F; Auge, N; Robinet, C; Cambus, JP; Parsons, SJ; Salvayre, R; Negre-Salvayre, A			The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator	FASEB JOURNAL			English	Article						tPA; sphingosine kinase; Src	SMOOTH-MUSCLE-CELLS; SPHINGOSINE KINASE TYPE-2; LOW-DENSITY-LIPOPROTEIN; UROKINASE RECEPTOR; SIGNALING PATHWAY; CYTOSKELETON REORGANIZATION; EPITHELIAL-CELLS; PROTEIN-KINASE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE	Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV-304 carcinoma cells, tPA and ATF (the N-terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine-1-phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D-erythro-2-(N-myristoylamino)-1-phenyl-propanol (D-MAPP) and N-N'-dimethyl sphingosine (DMS), two classical inhibitors of sphingosine-1-phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase-1 that was mediated by a common pertussis toxin (PTX)-sensitive mechanism. The tPA-induced sphingosine kinase-1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK-cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 ( early phase peaking at 15 min). Sphingosine kinase-1 activation was followed by a second phase of ERK1/2 phosphorylation ( peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D-MAPP and DMS, by anti-EGD-1 antibodies and in SrcK-cells ( in which the mitogenic signaling was rescued by sphingosine-1-phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA-induced mitogenic signaling.	CHU Rangueil, INSERM, U466, F-31043 Toulouse 4, France; CHU Rangueil, Hematol Lab, F-31054 Toulouse, France; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; University of Virginia; University of Virginia	Salvayre, R (corresponding author), CHU Rangueil, INSERM, U466, IFR 31,1 Ave Jean Poulhes,TSA 50032, F-31059 Toulouse 9, France.	salvayre@rangueil.inserm.fr; anesalv@rangueil.inserm.fr		Maupas-Schwalm, Francoise/0000-0002-7355-7091; Negre-Salvayre, Anne/0000-0003-2136-5706; Auge, Nathalie/0000-0003-2088-7211				Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Binder BR, 2002, NEWS PHYSIOL SCI, V17, P56, DOI 10.1152/nips.01369.2001; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Irigoyen JP, 1999, BIOCHEM BIOPH RES CO, V262, P666, DOI 10.1006/bbrc.1999.1202; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; Levade T, 2001, CIRC RES, V89, P957, DOI 10.1161/hh2301.100350; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu GL, 2002, J BIOL CHEM, V277, P48427, DOI 10.1074/jbc.M202130200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; Montuori N, 2001, FEBS LETT, V508, P379, DOI 10.1016/S0014-5793(01)03104-0; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Shetty S, 2001, J BIOL CHEM, V276, P24549, DOI 10.1074/jbc.M101605200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Wang Y, 2001, MED RES REV, V21, P146, DOI 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4	53	35	37	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1398	+		10.1096/fj.03-1123fje	http://dx.doi.org/10.1096/fj.03-1123fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231724				2022-12-28	WOS:000222979200026
J	Spitkovsky, D; Sasse, P; Kolossov, E; Bottinger, C; Fleischmann, BK; Hescheler, J; Wiesner, RJ				Spitkovsky, D; Sasse, P; Kolossov, E; Bottinger, C; Fleischmann, BK; Hescheler, J; Wiesner, RJ			Activity of complex III of the mitochondrial electron transport chain is essential for early heart muscle cell differentiation	FASEB JOURNAL			English	Article						cardiomyocyte; development; embryonic stem cells; embryoid bodies; respiratory chain	EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; RAT-TISSUES; DNA; CARDIOMYOCYTES; DEPOLARIZATION; CARDIOMYOPATHY; MAINTENANCE; SURVIVAL	During development of the heart, mitochondria proliferate within cardiomyocytes. It is unclear whether this is a response to the increasing energy demand or whether it is part of the developmental program. To investigate the role of the electron transport chain (ETC) in this process, we used transgenic murine embryonic stem (ES) cells in which the green fluorescent protein gene is under control of the alpha-myosin heavy chain promoter (alpha-MHC), allowing easy monitoring of cardiomyocyte differentiation. Spontaneous contraction of these cells within embryoid bodies (EBs) was not affected by inhibition of the ETC, suggesting that early heart cell function is sufficiently supported by anaerobic ATP production. However, heart cell development was completely blocked when adding antimycin A, an inhibitor of ETC complex III, before initiation of differentiation, whereas KCN did not block differentiation, strongly suggesting that specifically complex III function rather than mitochondrial ATP production is necessary for early heart cell development. When the underlying mechanism was examined, we noticed that antimycin A but not KCN lead to inhibition of spontaneous intracellular Ca++ oscillations, whereas both substances decreased mitochondrial membrane potential, as expected. We postulate that mitochondrial complex III activity is necessary for these Ca++ oscillations, which in turn are a prerequisite for cardiomyocyte differentiation.	Univ Cologne, Inst Vegetat Physiol, D-50931 Cologne, Germany; Univ Cologne, Inst Neurophysiol, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany; Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany; Axiogenesis AG, D-50931 Cologne, Germany	University of Cologne; University of Cologne; University of Bonn	Wiesner, RJ (corresponding author), Univ Cologne, Inst Vegetat Physiol, Robert Koch Str 39, D-50931 Cologne, Germany.	Rudolf.Wiesner@uni-koeln.de	Spitkovsky, Dimitry/ABA-1605-2020; Sasse, Philipp/G-9866-2013	Sasse, Philipp/0000-0002-8502-9472				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Collins TJ, 2000, BIOCHEM J, V347, P593, DOI 10.1042/0264-6021:3470593; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Finck BN, 2002, COLD SPRING HARB SYM, V67, P371, DOI 10.1101/sqb.2002.67.371; GAGNON J, 1991, MOL CELL BIOCHEM, V107, P21, DOI 10.1007/BF02424572; Garstka HL, 2003, NUCLEIC ACIDS RES, V31, P5039, DOI 10.1093/nar/gkg717; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; HERZBERG NH, 1993, EUR J CELL BIOL, V61, P400; Hoffmann S, 2004, FREE RADICAL BIO MED, V36, P765, DOI 10.1016/j.freeradbiomed.2003.12.019; HOHL C, 1987, ARCH BIOCHEM BIOPHYS, V259, P527, DOI 10.1016/0003-9861(87)90519-4; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467; Li JA, 2002, J CELL BIOL, V158, P103, DOI 10.1083/jcb.200204092; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; Marin-Garcia J, 2000, MOL CELL BIOCHEM, V210, P47, DOI 10.1023/A:1007031919298; MARINGARCIA J, 1994, J MOL CELL CARDIOL, V26, P1029, DOI 10.1006/jmcc.1994.1123; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; WIESNER RJ, 1992, BIOCHEM BIOPH RES CO, V183, P553, DOI 10.1016/0006-291X(92)90517-O; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x	31	59	61	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1300	+		10.1096/fj.03-0520fje	http://dx.doi.org/10.1096/fj.03-0520fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180963				2022-12-28	WOS:000222327500029
J	Massoud, TF; Paulmurugan, R; Gambhir, SS				Massoud, TF; Paulmurugan, R; Gambhir, SS			Molecular imaging of homodimeric protein-protein interactions in living subjects	FASEB JOURNAL			English	Article						bioluminescence; luciferase; Renilla; complementation; dimerization; thymidine kinase	SIMPLEX-VIRUS TYPE-1; RESONANCE ENERGY-TRANSFER; GREEN FLUORESCENT PROTEIN; REPORTER GENE-EXPRESSION; THYMIDINE KINASE; RECEPTOR DIMERIZATION; FRET MICROSCOPY; CELL-SURFACE; COMPLEMENTATION; COMPLEX	Homodimeric protein interactions are potent regulators of cellular functions, but are particularly challenging to study in vivo. We used a split synthetic renilla luciferase (hRLUC) complementation-based bioluminescence assay to study homodimerization of herpes simplex virus type 1 thymidine kinase (TK) in mammalian cells and in living mice. We quantified and imaged homodimerization of TK chimeras containing N-terminal (N-hRLUC) or C-terminal (C-hRLUC) fragments of hRLUC in the upstream and downstream positions, respectively (tail-to-head homodimer). This was monitored using luminometry (68-fold increase, and was significantly [P< 0.01] above background light emission) and by CCD camera imaging of living mice implanted with ex vivo transfected 293T cells (2.7-fold increase, and is significantly [P< 0.01] above background light emission). We also made a mutant-TK to generate N-hRLUC mutant TK and mutant TK-C-hRLUC by changing a single amino acid at position 318 from arginine to cysteine, a key site that has previously been reported to be essential for TK homodimerization, to support the specificity of the hRLUC complementation signal from TK homodimerization. Ex vivo substrate (8-H-3 Penciclovir) accumulation assays in 293T cells expressing the TK protein chimeras showed active TK enzyme. We also devised an experimental strategy by constructing variant TK chimeras ( possessing extra N-hRLUC or C-hRLUC 'spacers') to monitor incremental lack of association of the tail-to-head TK homodimer. Application of this potentially generalizable assay to screen for molecules that promote or disrupt ubiquitous homodimeric protein - protein interactions could serve not only as an invaluable tool to understand biological networks but could also be applied to drug discovery and validation in living subjects.	Stanford Univ, Sch Med, James H Clark Ctr, Dept Radiol, Stanford, CA 94305 USA; Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Cambridge, Sch Clin Med, Dept Radiol, Cambridge CB2 2QQ, England; Univ Cambridge, Sch Clin Med, Dept Oncol, Cambridge CB2 2QQ, England; Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; Stanford Univ, Sch Med, James H Clark Ctr, Bio X Program, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Cambridge; University of Cambridge; Medical College of Wisconsin; Stanford University	Gambhir, SS (corresponding author), Stanford Univ, Sch Med, James H Clark Ctr, Dept Radiol, 318 Campus Dr,East Wing,1st Floor, Stanford, CA 94305 USA.	sgambhir@stanford.edu		Paulmurugan, Ramasamy/0000-0001-7155-4738	NATIONAL CANCER INSTITUTE [R01CA082214, U54CA119367, P50CA114747] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA119367, R01 CA082214, P50 CA114747, 2R01 CA82214-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bardsley B, 1998, CHIRALITY, V10, P14; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; Bollag D M, 1994, Methods Mol Biol, V36, P1; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Doyle ML, 1997, CURR OPIN BIOTECH, V8, P31, DOI 10.1016/S0958-1669(97)80154-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Gautier I, 2001, BIOPHYS J, V80, P3000, DOI 10.1016/S0006-3495(01)76265-0; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Lakey JH, 1998, CURR OPIN STRUC BIOL, V8, P119, DOI 10.1016/S0959-440X(98)80019-5; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Lu L, 2002, PROTEINS, V49, P350, DOI 10.1002/prot.10222; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Paulmurugan R, 2003, ANAL CHEM, V75, P1584, DOI 10.1021/ac020731c; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; Ponstingl H, 2000, PROTEINS, V41, P47; Ray P, 2002, P NATL ACAD SCI USA, V99, P3105, DOI 10.1073/pnas.052710999; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Saijo M, 2002, J MED VIROL, V66, P388, DOI 10.1002/jmv.2157; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Tavare JM, 2001, J ENDOCRINOL, V170, P297, DOI 10.1677/joe.0.1700297; Valdar WSJ, 2001, PROTEINS, V42, P108; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Veselovsky AV, 2002, J MOL RECOGNIT, V15, P405, DOI 10.1002/jmr.597; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wild K, 1997, PROTEIN SCI, V6, P2097; Williams NE, 2000, METHOD CELL BIOL, V62, P449; Wurth C, 2001, J MOL BIOL, V313, P657, DOI 10.1006/jmbi.2001.5060; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	34	45	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1105	+		10.1096/fj.03-1128fje	http://dx.doi.org/10.1096/fj.03-1128fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132989	Green Accepted			2022-12-28	WOS:000221883200025
J	Clayton, A; Turkes, A; Dewitt, S; Steadman, R; Mason, MD; Hallett, MB				Clayton, A; Turkes, A; Dewitt, S; Steadman, R; Mason, MD; Hallett, MB			Adhesion and signaling by B cell-derived exosomes: the role of integrins	FASEB JOURNAL			English	Article						calcium signaling; inflammation; ICAM-1; fibroblasts	ACTIVATION; MATURATION; MICROVESICLES; LYMPHOCYTES; LIGATION; PROTEINS; VESICLES; RELEASE	Exosomes are nanometer-sized vesicles secreted by various cells, with potentially diverse roles in physiology. Although emphasis has been placed on their involvement in immune modulation, their potential for more wide-ranging biological effects has not been appreciated. A common exosome feature is the expression of adhesion molecules, which include the integrin family. We have for the first time addressed the possible function of B cell-derived exosome-integrins by examining adhesive interactions of exosomes ( immobilized onto beads) with extracellular matrix (ECM) components and cytokine-treated fibroblasts. Integrin (beta1 and beta2) expression was demonstrated by Western blotting and flow cytometry. Binding studies ( with blocking antibodies) demonstrated their function in adhesion to collagen-I, fibronectin, and tumor necrosis factor (TNF)-alpha-activated fibroblasts. Exosome adhesion to TNF-alpha-activated fibroblasts also triggered integrin-dependent changes in cytosolic calcium, measured by single cell imaging. Thus, B cell-derived exosomes express functional integrins, which are capable of mediating anchorage to ECM and cell-surface adhesion molecules, and may be a novel mode of delivering adhesion signals at distances beyond that of direct cell-cell contact during inflammation.	Cardiff Univ, Velindre Hosp, Dept Med, Sect Clin Oncol, Cardiff CF14 2TL, S Glam, Wales; Cardiff Univ, Dept Surg, Neutrophil Signaling Grp, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Velindre Hospital; Cardiff University; Cardiff University	Clayton, A (corresponding author), Cardiff Univ, Velindre Hosp, Dept Med, Sect Clin Oncol, Whitchurch, Cardiff CF14 2TL, S Glam, Wales.	aled.clayton@velindre-tr.wales.nhs.uk	Hallett, Maurice/I-6866-2012; Mason, Malcolm D/H-6979-2013; Steadman, Robert/O-1614-2016	Hallett, Maurice/0000-0001-8197-834X; Steadman, Robert/0000-0002-1303-2496; Dewitt, Sharon/0000-0001-8169-8241				Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Blaber R, 2003, J AM SOC NEPHROL, V14, P116, DOI 10.1097/01.ASN.0000040595.35207.62; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Clayton A, 1998, J CELL SCI, V111, P443; Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5; Clayton A, 2003, EUR J IMMUNOL, V33, P522, DOI 10.1002/immu.200310028; Denzer K, 2000, J IMMUNOL, V165, P1259, DOI 10.4049/jimmunol.165.3.1259; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; DOYLE A, 1994, CELL TISSUE CULTURE, V2; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; HALLETT MB, 1990, CELL CALCIUM, V11, P655, DOI 10.1016/0143-4160(90)90020-U; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HURLEY EA, 1991, J VIROL, V65, P3958, DOI 10.1128/JVI.65.7.3958-3963.1991; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Karlsson M, 2001, EUR J IMMUNOL, V31, P2892, DOI 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I; Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7; LANGE TS, 1994, EXP CELL RES, V214, P381, DOI 10.1006/excr.1994.1271; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Leitinger B, 2002, J CELL SCI, V115, P963; Nimako M, 1997, CANCER RES, V57, P4855; Rabesandratana H, 1998, BLOOD, V91, P2573, DOI 10.1182/blood.V91.7.2573.2573_2573_2580; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	32	233	252	2	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					977	+		10.1096/fj.03-1094fje	http://dx.doi.org/10.1096/fj.03-1094fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059973				2022-12-28	WOS:000221108800024
J	Moghimi, SM; Hunter, AC; Murray, JC				Moghimi, SM; Hunter, AC; Murray, JC			Nanomedicine: current status and future prospects	FASEB JOURNAL			English	Review						nanotechnology; nanosized drug delivery systems; nanoparticles; medical imaging; gene therapy; nanofibers; macrophage; endothelium; intracellular delivery; extravasation; toxicity	ULTRASMALL SUPERPARAMAGNETIC PARTICLES; PEGYLATED LIPOSOMAL DOXORUBICIN; TARGETED DRUG-DELIVERY; IN-VIVO; QUANTUM DOTS; ENDOTHELIAL-CELLS; GENE-THERAPY; IRON-OXIDE; COMPLEMENT ACTIVATION; PHOSPHOLIPASE-A2 ACTIVATION	Applications of nanotechnology for treatment, diagnosis, monitoring, and control of biological systems has recently been referred to as "nanomedicine" by the National Institutes of Health. Research into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumor cells, as well as tumor neovasculature) are key targets. Today, nanotechnology and nanoscience approaches to particle design and formulation are beginning to expand the market for many drugs and are forming the basis for a highly profitable niche within the industry, but some predicted benefits are hyped. This article will highlight rational approaches in design and surface engineering of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parenteral administration. Potential pitfalls or side effects associated with nanoparticles are also discussed.	Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England; Univ Hosp, Wolfson Digest Dis Ctr, Canc Res UK, Tumour Cytokine Biol Grp, Nottingham, England	University of Brighton; Cancer Research UK; Nottingham University Hospital NHS Trust; University of Nottingham	Moghimi, SM (corresponding author), Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England.	s.m.moghimi@brighton.ac.uk	; Hunter, Alan/D-4573-2016	Moghimi, Seyed Moein/0000-0003-0836-926X; Hunter, Alan/0000-0003-1100-7761				Adams ML, 2003, J PHARM SCI-US, V92, P1343, DOI 10.1002/jps.10397; Agrawal AK, 2000, ADV DRUG DELIVER REV, V41, P135, DOI 10.1016/S0169-409X(99)00061-7; Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Alves-Rosa F, 2000, BLOOD, V96, P2834, DOI 10.1182/blood.V96.8.2834.h8002834_2834_2840; Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244; Anderson DG, 2004, NAT BIOTECHNOL, V22, P863, DOI 10.1038/nbt981; Andresen TL, 2004, J MED CHEM, V47, P1694, DOI 10.1021/jm031029r; Apostolopoulos V, 2000, EUR J IMMUNOL, V30, P1714, DOI 10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Assa-Munt N, 2001, BIOCHEMISTRY-US, V40, P2373, DOI 10.1021/bi002101f; Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y; Bandak S, 1999, ANTI-CANCER DRUG, V10, P911, DOI 10.1097/00001813-199911000-00007; Barenholz Y, 2001, CURR OPIN COLLOID IN, V6, P66, DOI 10.1016/S1359-0294(00)00090-X; Barrera P, 2000, ARTHRITIS RHEUM-US, V43, P1951, DOI 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K; Batrakova EV, 2003, J PHARMACOL EXP THER, V304, P845, DOI 10.1124/jpet.102.043307; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; BRAET F, 1995, HEPATOLOGY, V21, P180, DOI 10.1016/0270-9139(95)90427-1; Cavazzana-Calvo M, 2004, NATURE, V427, P779, DOI 10.1038/427779a; Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3; Chanan-Khan A, 2003, ANN ONCOL, V14, P1430, DOI 10.1093/annonc/mdg374; Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100; Christofidou-Solomidou M, 2000, AM J PHYSIOL-LUNG C, V278, pL794, DOI 10.1152/ajplung.2000.278.4.L794; Clark HA, 1999, ANAL CHEM, V71, P4831, DOI 10.1021/ac990629o; Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875; Cui ZR, 2003, CRIT REV THER DRUG, V20, P103, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10; Curnis F, 2002, J CLIN INVEST, V110, P475, DOI 10.1172/JCI200215223; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; Danenberg HD, 2003, J CARDIOVASC PHARM, V42, P671, DOI 10.1097/00005344-200311000-00014; Dardzinski BJ, 2001, MAGN RESON IMAGING, V19, P1209, DOI 10.1016/S0730-725X(01)00448-9; Davidsen J, 2003, BBA-BIOMEMBRANES, V1609, P95, DOI 10.1016/S0005-2736(02)00659-4; Davidsen J, 2002, BBA-BIOMEMBRANES, V1564, P256, DOI 10.1016/S0005-2736(02)00461-3; Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334; Dileo J, 2003, MOL THER, V7, P640, DOI 10.1016/S1525-0016(03)00064-9; Dousset V, 1999, AM J NEURORADIOL, V20, P223; Drummond DC, 1999, PHARMACOL REV, V51, P691; Drummond DC, 2000, PROG LIPID RES, V39, P409, DOI 10.1016/S0163-7827(00)00011-4; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Fenske DB, 2001, CURR OPIN MOL THER, V3, P153; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Gao ZG, 2002, NANO LETT, V2, P979, DOI 10.1021/nl025604a; Gbadamosi JK, 2002, FEBS LETT, V532, P338, DOI 10.1016/S0014-5793(02)03710-9; Gogolak P, 2003, J MOL RECOGNIT, V16, P299, DOI 10.1002/jmr.650; Goren D, 2000, CLIN CANCER RES, V6, P1949; Haag R, 2004, ANGEW CHEM INT EDIT, V43, P278, DOI 10.1002/anie.200301694; Haining WN, 2004, J IMMUNOL, V173, P2578, DOI 10.4049/jimmunol.173.4.2578; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Haviv YS, 2002, CANCER RES, V62, P4273; Hirko A, 2003, CURR MED CHEM, V10, P1185, DOI 10.2174/0929867033457412; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Hunter AC, 2002, DRUG DISCOV TODAY, V7, P998, DOI 10.1016/S1359-6446(02)02444-3; Jaffer FA, 2004, CIRC RES, V94, P433, DOI 10.1161/01.RES.0000119321.18573.5A; Jain RK, 2001, J CONTROL RELEASE, V74, P7, DOI 10.1016/S0168-3659(01)00306-6; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; Jones RA, 2004, J CONTROL RELEASE, V96, P379, DOI 10.1016/j.jconrel.2004.02.011; Jorgensen K, 2002, FEBS LETT, V531, P23, DOI 10.1016/S0014-5793(02)03408-7; Kabanov AV, 2003, J CONTROL RELEASE, V91, P75, DOI 10.1016/S0168-3659(03)00211-6; Kichler A, 2004, J GENE MED, V6, pS3, DOI 10.1002/jgm.507; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Kooi ME, 2003, CIRCULATION, V107, P2453, DOI 10.1161/01.CIR.0000068315.98705.CC; Kossovsky N, 1996, J CONTROL RELEASE, V39, P383, DOI 10.1016/0168-3659(95)00169-7; Kramer M, 2004, CHEMBIOCHEM, V5, P1081, DOI 10.1002/cbic.200300905; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; LAM KH, 1993, J BIOMED MATER RES, V27, P1569, DOI 10.1002/jbm.820271214; Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; LaVan DA, 2002, NAT REV DRUG DISCOV, V1, P77, DOI 10.1038/nrd707; Lavasanifar A, 2002, PHARMACEUT RES, V19, P418, DOI 10.1023/A:1015127225021; Liu T, 2000, PAIN, V86, P25, DOI 10.1016/S0304-3959(99)00306-1; LIVERSIDGE GG, 1995, INT J PHARM, V125, P91, DOI 10.1016/0378-5173(95)00122-Y; Lukyanov AN, 2003, J CONTROL RELEASE, V91, P97, DOI 10.1016/S0168-3659(03)00217-7; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p; Mandal M, 2004, MOL PHARMACEUT, V1, P2, DOI 10.1021/mp034021m; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; McIntyre JO, 2004, BIOCHEM J, V377, P617, DOI 10.1042/BJ20030582; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; Metselaar JM, 2004, ANN RHEUM DIS, V63, P348, DOI 10.1136/ard.2003.009944; Miller CB, 2004, BONE MARROW TRANSPL, V33, P543, DOI 10.1038/sj.bmt.1704408; Mischler R, 2002, VACCINE, V20, pB17, DOI 10.1016/S0264-410X(02)00512-1; Moghimi SM, 2004, BBA-MOL BASIS DIS, V1689, P103, DOI 10.1016/j.bbadis.2004.02.005; Moghimi SM, 2004, SCIENCE, V303, P626, DOI 10.1126/science.303.5658.626; Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Moghimi SM, 2003, FEBS LETT, V540, P241, DOI 10.1016/S0014-5793(03)00273-4; Moghimi SM, 2002, BBA-MOL CELL RES, V1590, P131, DOI 10.1016/S0167-4889(02)00204-5; Moghimi SM, 2001, PHARM RES-DORDR, V18, P1, DOI 10.1023/A:1011054123304; Moghimi SM, 1999, ADV DRUG DELIVER REV, V37, P295, DOI 10.1016/S0169-409X(98)00099-4; Morgan MT, 2003, J AM CHEM SOC, V125, P15485, DOI 10.1021/ja0347383; Munn LL, 2003, DRUG DISCOV TODAY, V8, P396, DOI 10.1016/S1359-6446(03)02686-2; Muro S, 2003, AM J PHYSIOL-CELL PH, V285, pC1339, DOI 10.1152/ajpcell.00099.2003; Murray JC, 2004, BRIT J CANCER, V91, pS75; Murray JC, 2003, CRIT REV THER DRUG, V20, P139, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.20; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Nishiyama N, 2003, BIOCONJUGATE CHEM, V14, P449, DOI 10.1021/bc025555t; Oh KT, 2004, J CONTROL RELEASE, V94, P411, DOI 10.1016/j.jconrel.2003.10.018; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Omidi Y, 2003, J DRUG TARGET, V11, P311, DOI 10.1080/10611860310001636908; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com; Panyam J, 2004, MOL PHARMACEUT, V1, P77, DOI 10.1021/mp034002c; Pasqualini R, 2002, TRENDS MOL MED, V8, P563, DOI 10.1016/S1471-4914(02)02429-2; Pastorino F, 2003, CANCER RES, V63, P7400; Perez JM, 2004, CHEMBIOCHEM, V5, P261, DOI 10.1002/cbic.200300730; Phillips WT, 2000, J PHARMACOL EXP THER, V295, P309; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; Poole C., 2003, INTRO NANOTECHNOLOGY; PORTER CJH, 1992, FEBS LETT, V305, P62, DOI 10.1016/0014-5793(92)80655-Z; Quintana A, 2002, PHARM RES-DORDR, V19, P1310, DOI 10.1023/A:1020398624602; Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494; Raja KS, 2003, BIOMACROMOLECULES, V4, P472, DOI 10.1021/bm025740+; Ran S, 1998, CANCER RES, V58, P4646; Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Ruehm SG, 2001, CIRCULATION, V103, P415; Ruoslahti E, 2002, DRUG DISCOV TODAY, V7, P1138, DOI 10.1016/S1359-6446(02)02501-1; Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9; Saleh A, 2004, BRAIN, V127, P1670, DOI 10.1093/brain/awh191; Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974; Sapra P, 2002, CANCER RES, V62, P7190; Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192; Scherpereel A, 2001, FASEB J, V15, P416, DOI 10.1096/fj.00-0022com; Schmidt-Wolf GD, 2003, TRENDS MOL MED, V9, P67, DOI 10.1016/S1471-4914(03)00005-4; Shadkchan Y, 2004, MED MYCOL, V42, P123, DOI 10.1080/13693780310001624583; Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/713853956; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058; Somia N, 2000, NAT REV GENET, V1, P91, DOI 10.1038/35038533; St Croix B, 2000, SCIENCE, V289, P1197; Steiniger SCJ, 2004, INT J CANCER, V109, P759, DOI 10.1002/ijc.20048; Sudimack J, 2000, ADV DRUG DELIVER REV, V41, P147, DOI 10.1016/S0169-409X(99)00062-9; Szebeni J, 2001, CRIT REV THER DRUG, V18, P567; Szebeni J, 2001, INT IMMUNOPHARMACOL, V1, P721, DOI 10.1016/S1567-5769(01)00006-6; Taton TA, 2001, J AM CHEM SOC, V123, P5164, DOI 10.1021/ja0102639; Taylor PR, 2004, P NATL ACAD SCI USA, V101, P1963, DOI 10.1073/pnas.0308490100; Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100; Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100; Turunen MP, 2002, MOL THER, V6, P306, DOI 10.1006/mthe.2002.0668; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Uwatoku T, 2003, CIRC RES, V92, pE62, DOI 10.1161/01.RES.0000069021.56380.E2; Veerareddy PR, 2004, DRUG TODAY, V40, P133, DOI 10.1358/dot.2004.40.2.799425; Verderone G, 2000, J MED CHEM, V43, P1367, DOI 10.1021/jm9911579; Voura EB, 2004, NAT MED, V10, P993, DOI 10.1038/nm1096; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Watson A, 2003, BIOTECHNIQUES, V34, P296, DOI 10.2144/03342bi01; Wickham TJ, 2000, GENE THER, V7, P110, DOI 10.1038/sj.gt.3301115; Winter PM, 2003, CANCER RES, V63, P5838; Wolff G, 1997, J VIROL, V71, P624, DOI 10.1128/JVI.71.1.624-629.1997; Wu GS, 2000, XENOTRANSPLANTATION, V7, P214, DOI 10.1034/j.1399-3089.2000.00071.x; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; Zitzmann S, 2002, CANCER RES, V62, P5139	161	1422	1517	7	993	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					311	330		10.1096/fj.04-2747rev	http://dx.doi.org/10.1096/fj.04-2747rev			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746175				2022-12-28	WOS:000227901300032
J	Ziel, KA; Grishko, V; Campbell, CC; Breit, JF; Wilson, GL; Gillespie, MN				Ziel, KA; Grishko, V; Campbell, CC; Breit, JF; Wilson, GL; Gillespie, MN			Oxidants in signal transduction: impact on DNA integrity and gene expression	FASEB JOURNAL			English	Article						VEGF; mitochondrial DNA damage; reactive oxygen species; nuclear genomic integrity	SMOOTH-MUSCLE-CELLS; OXIDATIVE BASE MODIFICATIONS; HYPOXIA-INDUCIBLE FACTOR-1; ARTERY ENDOTHELIAL-CELLS; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; BENDING PROPENSITY; PULMONARY-ARTERIES; MAMMALIAN-CELLS; NUCLEAR-DNA	Physiological stimuli using reactive oxygen species (ROS) as second messengers caused nucleotide-specific base modifications in the hypoxic response element of the VEGF gene in lung vascular cells, with the 3' guanine of the HIF-1 DNA recognition sequence uniformly targeted. Modeling this effect by replacing the targeted guanine with an abasic site increased incorporation of HIF-1 and the bi-functional DNA repair enzyme and transcriptional coactivator, Ref-1/Ape1, into the transcriptional complex and engendered more robust reporter gene expression. Oxidants generated in the context of physiological signaling thus affect nuclear DNA integrity and may facilitate gene expression by optimizing DNA-protein interactions.	Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Ctr Lung Biol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama; University of South Alabama	Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA.	mgillesp@jaguar1.usouthal.edu						Ayadi L, 2000, J BIOMOL STRUCT DYN, V17, P645, DOI 10.1080/07391102.2000.10506555; Babal P, 2000, AM J PHYSIOL-LUNG C, V278, pL610, DOI 10.1152/ajplung.2000.278.3.L610; Babal P, 2002, AM J PHYSIOL-LUNG C, V282, pL840, DOI 10.1152/ajplung.00347.2001; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BRUKNER I, 1995, J BIOMOL STRUCT DYN, V13, P309, DOI 10.1080/07391102.1995.10508842; CHAN WCW, 2000, P SOC PHOTO-OPT INS, V1, P2; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Epe B, 2002, BIOL CHEM, V383, P467, DOI 10.1515/BC.2002.049; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Gabrielian A, 1996, FEBS LETT, V393, P124, DOI 10.1016/0014-5793(96)00837-X; Giese B, 2002, ANNU REV BIOCHEM, V71, P51, DOI 10.1146/annurev.biochem.71.083101.134037; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Grishko V, 2001, FASEB J, V15, P1267, DOI 10.1096/fj.00-0755fje; Grishko V, 2001, AM J PHYSIOL-LUNG C, V280, pL1300, DOI 10.1152/ajplung.2001.280.6.L1300; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Henle ES, 1999, J BIOL CHEM, V274, P962, DOI 10.1074/jbc.274.2.962; Hoffmann S, 2004, FREE RADICAL BIO MED, V36, P765, DOI 10.1016/j.freeradbiomed.2003.12.019; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; Lhomme J, 1999, BIOPOLYMERS, V52, P65, DOI 10.1002/1097-0282(1999)52:2<65::AID-BIP1>3.0.CO;2-U; Liu JQ, 2003, AM J PHYSIOL-LUNG C, V285, pL322, DOI 10.1152/ajplung.00337.2002; LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Malins DC, 2000, P NATL ACAD SCI USA, V97, P12442, DOI 10.1073/pnas.230438797; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; Odom DT, 2001, NUCLEIC ACIDS RES, V29, P2026, DOI 10.1093/nar/29.10.2026; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; Rachofsky EL, 2001, COMB CHEM HIGH T SCR, V4, P675; Rai P, 2001, J MOL BIOL, V312, P1089, DOI 10.1006/jmbi.2001.5010; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rodriguez H, 1997, ARCH BIOCHEM BIOPHYS, V338, P207, DOI 10.1006/abbi.1996.9820; Salazar JJ, 1997, MUTAT RES-DNA REPAIR, V385, P139, DOI 10.1016/S0921-8777(97)00047-5; Shukla A, 2003, AM J PHYSIOL-LUNG C, V285, pL1018, DOI 10.1152/ajplung.00038.2003; Spinella F, 2002, J BIOL CHEM, V277, P27850, DOI 10.1074/jbc.M202421200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	48	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					387	394		10.1096/fj.04-2805com	http://dx.doi.org/10.1096/fj.04-2805com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746182				2022-12-28	WOS:000227901300039
J	Lemkine, GF; Raji, A; Alfama, G; Turque, N; Hassani, Z; Alegria-Prevot, O; Samarut, J; Levi, G; Demeneix, BA				Lemkine, GF; Raji, A; Alfama, G; Turque, N; Hassani, Z; Alegria-Prevot, O; Samarut, J; Levi, G; Demeneix, BA			Adult neural stem cell cycling in vivo requires thyroid hormone and its alpha receptor	FASEB JOURNAL			English	Article						subventricular zone; NSC; TH	CENTRAL-NERVOUS-SYSTEM; HISTONE H3; OLIGODENDROCYTE DIFFERENTIATION; XENOPUS-LAEVIS; GENE-TRANSFER; MOUSE-BRAIN; PHOSPHORYLATION; EXPRESSION; PROLIFERATION; MICE	Thyroid hormones (TH) are essential for brain development. However, information on if and how this key endocrine factor affects adult neurogenesis is fragmentary. We thus investigated the effects of TH on proliferation and apoptosis of stem cells in the subventricular zone(SVZ), as well as on migration of transgene-tagged neuroblasts out of the stem cell niche. Hypothyroidism significantly reduced all three of these processes, inhibiting generation of new cells. To determine the mechanisms relaying TH action in the SVZ, we analyzed which receptor was implicated and whether the effects were played out directly at the level of the stem cell population. The alpha TH receptor( TR alpha), but not TR beta, was found to be expressed in nestin positive progenitor cells of the SVZ. Further,use of TR alpha mutant mice showed TR alpha to be required to maintain full proliferative activity. Finally, a direct TH transcriptional effect, not mediated through other cell populations, was revealed by targeted gene transfer to stem cells in vivo. Indeed, TH directly modulated transcription from the c-myc promoter reporter construct containing a functional TH response element containing TRE but not from a mutated TRE sequence. We conclude that liganded-TR alpha is critical for neurogenesis in the adult mammalian brain.	Museum Natl Hist Nat, CNRS, UMR 5166, F-75231 Paris, France; Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, F-69364 Lyon, France	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Demeneix, BA (corresponding author), Museum Natl Hist Nat, CNRS, UMR 5166, F-75231 Paris, France.	demeneix@mnhn.fr	Levi, Giovanni/B-4416-2013; Samarut, Jacques/AAD-2587-2019	Levi, Giovanni/0000-0002-7041-6787				Abdallah B, 1996, INT J DEV BIOL, V40, P507; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; BAAS D, 1994, NEUROSCI LETT, V176, P47, DOI 10.1016/0304-3940(94)90868-0; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; BEARD MD, 1987, DEV BRAIN RES, V36, P181, DOI 10.1016/0165-3806(87)90022-8; Billon N, 2001, DEV BIOL, V235, P110, DOI 10.1006/dbio.2001.0293; BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Davis Jennifer Duncan, 2003, Curr Psychiatry Rep, V5, P384, DOI 10.1007/s11920-003-0073-6; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; FORREST D, 1990, ONCOGENE, V5, P309; Forrest D, 2002, ENDOCRINOLOGY, V143, P2466, DOI 10.1210/en.143.7.2466; Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Harpavat S, 2003, THYROID, V13, P1013, DOI 10.1089/105072503770867183; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; JACOBSON M, 2004, DEV NEUROBIOLOGY; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; LabatMoleur F, 1996, GENE THER, V3, P1010; Lemkine GF, 1999, J DRUG TARGET, V7, P305, DOI 10.3109/10611869909085513; Lemkine GF, 2002, MOL CELL NEUROSCI, V19, P165, DOI 10.1006/mcne.2001.1084; LEZOUALCH F, 1995, J BIOL CHEM, V270, P12100, DOI 10.1074/jbc.270.20.12100; Macchia PE, 2001, P NATL ACAD SCI USA, V98, P349, DOI 10.1073/pnas.011306998; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marsh-Armstrong N, 1999, NEURON, V24, P871, DOI 10.1016/S0896-6273(00)81034-X; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Morte B, 2004, ENDOCRINOLOGY, V145, P1386, DOI 10.1210/en.2003-1123; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; Saghatelyan A, 2004, NAT NEUROSCI, V7, P347, DOI 10.1038/nn1211; Samuels MH, 1998, THYROID, V8, P803, DOI 10.1089/thy.1998.8.803; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; Tokumoto YM, 2001, EMBO J, V20, P5261, DOI 10.1093/emboj/20.18.5261	45	134	145	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					863	+		10.1096/fj.04-2916fje	http://dx.doi.org/10.1096/fj.04-2916fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728663	Green Published			2022-12-28	WOS:000227591900010
J	Mutch, DM; Grigorov, M; Berger, A; Fay, LB; Roberts, MA; Watkins, SM; Williamson, G; German, JB				Mutch, DM; Grigorov, M; Berger, A; Fay, LB; Roberts, MA; Watkins, SM; Williamson, G; German, JB			An integrative metabolism approach identifies stearoyl-CoA desaturase as a target for an arachidonate-enriched diet	FASEB JOURNAL			English	Article						arachidonic acid; global error assessment (GEA) model; lipid metabolism; liver; metabolomics; microarray; mouse; nutrigenomics; singular value decomposition	POLYUNSATURATED FATTY-ACIDS; SINGULAR-VALUE DECOMPOSITION; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; GENE; N-3; EXPRESSION; PATHWAY; LIVER; MICE	Epidemiological studies have correlated diets containing higher intakes of PUFA with lower rates of chronic metabolic diseases. The molecular mechanisms regulated by the consumption of PUFA were examined by using an integrative metabolism approach assaying the liver transcriptome and lipid-metabolome of mice fed a control diet, an arachidonate (AA)-enriched fungal oil, an eicosapentaenoic ( EPA)/docosahexaenoic (DHA)-enriched fish oil, or a combination of the two oils. Hepatic gene transcription and fatty acid ( FA) metabolism were significantly altered by diets enriched with AA, as revealed by global error assessment and singular value decomposition (SVD) analysis, respectively. SVD analysis of the lipid data, reinforced with transcriptomics, suggests that the chronic feeding of AA modulates molecular endpoints similar to those previously reported in the obesity-resistant SCD1-/- mouse, namely, genes involved in lipid oxidation/synthesis and the significant changes in FA metabolism stemming from a repressed SCD1 activity. Specifically, the total levels and FA composition of several phospholipid (PL) species were significantly changed, with phosphatidylcholine ( PC) demonstrating the greatest alterations. Reduced PC levels were linked to decreased expression of enzymes in PC biosynthesis ( choline kinase, - 2.2-fold; glycerol-3-phosphate acyltransferase, 2.0- fold). Alterations in PL-FA composition were related to decreased expression of FA biosynthetic genes [ fatty acid synthetase, - 3.7-fold; stearoyl-CoA desaturase-1 (SCD1), - 1.8-fold]. Lower hepatic SCD1 gene expression levels were reflected in various aspects of FA metabolism through increased concentrations of palmitic ( fungal oil, + 45%; combination, + 106%) and stearic acids ( fungal oil, + 60%; combination, + 63%) in PC. Importantly, an integrated approach showed that these effects were not attenuated by the addition of an EPA/DHA-enriched fish oil, thereby identifying a previously unrecognized and distinct role for AA in the regulation of hepatic lipid metabolism.	Nestle Res Ctr, CH-1000 Lausanne, Switzerland; Univ Lausanne, Ctr integrat Genom, Lausanne, Switzerland; Lipom Technol Inc, Sacramento, CA USA; Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA	Nestle SA; University of Lausanne; University of California System; University of California Davis	Roberts, MA (corresponding author), Nestle Purina Pet Care Mail Zone 11T,1 Checkerboa, St Louis, MO 63164 USA.	mrsci68@yahoo.com	Williamson, Gary/AAE-9665-2019	Williamson, Gary/0000-0002-5624-6267; Mutch, David/0000-0002-0908-7259				Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Alter O, 2003, P NATL ACAD SCI USA, V100, P3351, DOI 10.1073/pnas.0530258100; Anderle P, 2004, NUTRITION, V20, P103, DOI 10.1016/j.nut.2003.09.018; Bellenger J, 2004, FASEB J, V18, P773, DOI 10.1096/fj.03-0950fje; Berger Alvin, 2002, Lipids Health Dis, V1, P2, DOI 10.1186/1476-511X-1-2; Bougnoux P, 1999, Curr Opin Clin Nutr Metab Care, V2, P121, DOI 10.1097/00075197-199903000-00005; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Cadroy Y, 1998, J IMMUNOL, V160, P6145; Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y; Clarke SD, 2001, J NUTR, V131, P1129, DOI 10.1093/jn/131.4.1129; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; Crawford MA, 2000, AM J CLIN NUTR, V71, p275S, DOI 10.1093/ajcn/71.1.275S; Das UN, 2000, PROSTAG LEUKOTR ESS, V63, P351, DOI 10.1054/plef.2000.0226; Duplus E, 2002, BIOCHEM PHARMACOL, V64, P893, DOI 10.1016/S0006-2952(02)01157-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; German JB, 2002, J NUTR, V132, P2486, DOI 10.1093/jn/132.9.2486; Gerster H, 1998, INT J VITAM NUTR RES, V68, P159; Gonzalez B, 2000, PROSTAG LEUKOTR ESS, V62, P299, DOI 10.1054/plef.2000.0158; Green P, 1998, J NEUROSCI RES, V52, P129, DOI 10.1002/(SICI)1097-4547(19980415)52:2<129::AID-JNR1>3.0.CO;2-C; Griffin JL, 2004, PHYSIOL GENOMICS, V17, P140, DOI 10.1152/physiolgenomics.00158.2003; Ikeda I, 1996, J NUTR SCI VITAMINOL, V42, P541, DOI 10.3177/jnsv.42.541; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; Kramer JA, 2003, J NUTR, V133, P57, DOI 10.1093/jn/133.1.57; Lee DP, 2001, J LIPID RES, V42, P1979; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Legrand P, 1997, J NUTR, V127, P249, DOI 10.1093/jn/127.2.249; MANSOURIAN R, 2004, IN PRESS BIOINFORMAT; Marmillot P, 2000, METABOLISM, V49, P508, DOI 10.1016/S0026-0495(00)80017-7; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Moriguchi T, 2001, J LIPID RES, V42, P419; Murthy M, 2002, J LIPID RES, V43, P611; Mutch DM, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-17; Nordoy A, 2001, LIPIDS, V36, pS127, DOI 10.1007/s11745-001-0695-7; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; Petrik MBH, 2000, J NUTR, V130, P1153, DOI 10.1093/jn/130.5.1153; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Pischon T, 2003, CIRCULATION, V108, P155, DOI 10.1161/01.CIR.0000079224.46084.C2; Rapoport SI, 2001, J LIPID RES, V42, P678; Ridgway ND, 2003, BIOCHEM J, V372, P811, DOI 10.1042/BJ20030252; Roche HM, 2000, AM J CLIN NUTR, V71, p232S, DOI 10.1093/ajcn/71.1.232s; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Uauy R, 2000, AM J CLIN NUTR, V71, p245S, DOI 10.1093/ajcn/71.1.245S; Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Watanabe S, 2001, PROSTAG OTH LIPID M, V66, P109, DOI 10.1016/S0090-6980(01)00152-6; Watkins SM, 2001, LIPIDS, V36, P247, DOI 10.1007/s11745-001-0714-8; Zeisel SH, 2001, J NUTR, V131, P1319, DOI 10.1093/jn/131.4.1319; Zhou L, 2001, J LIPID RES, V42, P1521	54	21	24	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1								10.1096/fj.04-2674fje	http://dx.doi.org/10.1096/fj.04-2674fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15670975				2022-12-28	WOS:000226576600012
J	Fewlass, DC; Noboa, K; Pi-Sunyer, FX; Johnston, JM; Yan, SD; Tezapsidis, N				Fewlass, DC; Noboa, K; Pi-Sunyer, FX; Johnston, JM; Yan, SD; Tezapsidis, N			Obesity-related leptin regulates Alzheimer's A beta	FASEB JOURNAL			English	Article						leptin signaling; AD; A beta production	AMYLOID-PRECURSOR-PROTEIN; APOLIPOPROTEIN-E; PRION PROTEIN; FOOD-INTAKE; METABOLISM; PRESENILIN; EXPRESSION; RECEPTOR; PEPTIDE; NEURONS	Abeta peptide is the major proteinateous component of the amyloid plaques found in the brains of Alzheimer's disease ( AD) patients and is regarded by many as the culprit of the disorder. It is well documented that brain lipids are intricately involved in Abeta-related pathogenic pathways. An important modulator of lipid homeostasis is the pluripotent peptide leptin. Here we demonstrate leptin's ability to modify Abeta levels in vitro and in vivo. Similar to methyl-beta-cyclodextrin, leptin reduces beta-secretase activity in neuronal cells possibly by altering the lipid composition of membrane lipid rafts. This phenotype contrasts treatments with cholesterol and etomoxir, an inhibitor of carnitine-palmitoyl transferase-1. Conversely, inhibitors of acetyl CoA carboxylase and fatty acid synthase mimicked leptin's action. Leptin was also able to increase apoE-dependent Abeta uptake in vitro. Thus, leptin can modulate bidirectional Abeta kinesis, reducing its levels extracellularly. Most strikingly, chronic administration of leptin to AD-transgenic animals reduced the brain Abeta load, underlying its therapeutic potential.	Columbia Univ Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; St Lukes Roosevelt Hosp, New York Obes Res Ctr, New York, NY USA; Neurotez, W Orange, NJ USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Tezapsidis, N (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, 630 W 168th St, New York, NY 10032 USA.	nik.tezapsidis@verizon.net						BarrettConnor E, 1996, J AM GERIATR SOC, V44, P1147, DOI 10.1111/j.1532-5415.1996.tb01362.x; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BISSOLI L, 2002, J NUTR HEALTH AGING, V6, P247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chung WK, 1998, AM J PHYSIOL-REG I, V274, pR985, DOI 10.1152/ajpregu.1998.274.4.R985; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Couce ME, 1997, NEUROENDOCRINOLOGY, V66, P145, DOI 10.1159/000127232; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Isidori AM, 2000, J CLIN ENDOCR METAB, V85, P1954, DOI 10.1210/jc.85.5.1954; Johnsingh AA, 2000, FEBS LETT, V465, P53, DOI 10.1016/S0014-5793(99)01664-6; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; KEMPEN HJ, 1995, J LIPID RES, V36, P1796; LaDu MJ, 2001, NEUROCHEM INT, V39, P427, DOI 10.1016/S0197-0186(01)00050-X; Lemaire-Vieille C, 2000, P NATL ACAD SCI USA, V97, P5422, DOI 10.1073/pnas.080081197; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mobbs CV, 2002, NAT MED, V8, P335, DOI 10.1038/nm0402-335; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; PUBLIELLI L, 2001, NAT CELL BIOL, V3, P905; Qiu WQ, 1997, J BIOL CHEM, V272, P6641, DOI 10.1074/jbc.272.10.6641; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shanley LJ, 2002, NAT NEUROSCI, V5, P299, DOI 10.1038/nn824; SHIMODA K, 1992, BRAIN RES, V586, P319, DOI 10.1016/0006-8993(92)91642-R; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; TAKESHIMA T, 1994, J NEUROSCI, V14, P4769; Takeshima T, 1996, J NEUROSCI METH, V67, P27, DOI 10.1016/S0165-0270(96)00002-7; Tezapsidis N, 2003, FASEB J, V17, P1322, DOI 10.1096/fj.02-0980fje; Ur E, 2002, NEUROENDOCRINOLOGY, V75, P264, DOI 10.1159/000054718; Watson GS, 2003, CNS DRUGS, V17, P27, DOI 10.2165/00023210-200317010-00003; Wood WG, 2002, NEUROBIOL AGING, V23, P685, DOI 10.1016/S0197-4580(02)00018-0; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yu YH, 2002, J BIOL CHEM, V277, P50876, DOI 10.1074/jbc.M207353200; Yu YH, 2004, AM J PHYSIOL-ENDOC M, V286, pE402, DOI 10.1152/ajpendo.00247.2003	49	230	239	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1870	1878		10.1096/fj.04-2572com	http://dx.doi.org/10.1096/fj.04-2572com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576490				2022-12-28	WOS:000226091000037
J	Rong, LL; Trojaborg, W; Qu, W; Kostov, K; Du Yan, S; Gooch, C; Szabolcs, M; Hays, AP; Schmidt, AM				Rong, LL; Trojaborg, W; Qu, W; Kostov, K; Du Yan, S; Gooch, C; Szabolcs, M; Hays, AP; Schmidt, AM			Antagonism of RAGE suppresses peripheral nerve regeneration	FASEB JOURNAL			English	Article						inflammation; axonal regeneration; peripheral nervous system	GLYCATION END-PRODUCTS; MOUSE SCIATIC-NERVE; NEURITE OUTGROWTH; BINDING-PROTEINS; CELL-SURFACE; RECEPTOR; S100; AMPHOTERIN; BLOCKADE; MICE	Axotomy of peripheral nerve triggers events that coordinate a limited inflammatory response to axonal degeneration and initiation of neurite outgrowth. Inflammatory and neurite outgrowth-promoting roles for the receptor for advanced glycation end products (RAGE) have been suggested, so we tested its role in peripheral nerve regeneration. Analysis of immunohistochemical localization of RAGE by confocal microscopy revealed that RAGE was expressed in axons and infiltrating mononuclear phagocytes upon unilateral sciatic nerve crush in mice. Administration of soluble RAGE, the extracellular ligand binding domain of RAGE, or blocking F(ab')(2) fragments of antibodies raised to either RAGE or its ligands, S100/calgranulins or amphoterin, reduced functional recovery as assessed by motor and sensory nerve conduction velocities and sciatic functional index and reduced regeneration, as assessed by myelinated fiber density after acute crush of the sciatic nerve. In parallel, in mice subjected to RAGE blockade, decreased numbers of mononuclear phagocytes infiltrated the distal nerve segments after crush. These findings provide the first evidence of an innate function of the ligand/RAGE axis and suggest that RAGE plays an important role in regeneration of the peripheral nervous system.	Columbia Univ, Med Ctr, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA; Columbia Univ, Med Ctr, Dept Pathol, New York, NY USA; Columbia Univ, Med Ctr, Dept Physiol & Cellular Biophys, New York, NY USA	Columbia University; Columbia University; Columbia University; Columbia University	Schmidt, AM (corresponding author), Columbia Univ, Med Ctr, Dept Surg, Div Surg Sci, 530 W 168th St,P&S 17-401, New York, NY 10032 USA.	ams11@columbia.edu	Gooch, Clifton L/M-1874-2016	Gooch, Clifton L/0000-0002-2210-2038				Azzouz M, 1996, EXP NEUROL, V138, P189, DOI 10.1006/exnr.1996.0057; BEUCHE W, 1986, BRAIN RES, V378, P97, DOI 10.1016/0006-8993(86)90289-1; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Haglid KG, 1997, BRAIN RES, V753, P196, DOI 10.1016/S0006-8993(96)01463-1; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kennedy JM, 2000, BRAIN, V123, P2118, DOI 10.1093/brain/123.10.2118; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Kury P, 2001, CURR OPIN NEUROL, V14, P635, DOI 10.1097/00019052-200110000-00013; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Rammes A, 1997, J BIOL CHEM, V272, P9496; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; REICHERT F, 1994, J NEUROSCI, V14, P3231; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831; Yang Z, 2001, J LEUKOCYTE BIOL, V69, P986; Yao M, 1998, LARYNGOSCOPE, V108, P1141, DOI 10.1097/00005537-199808000-00007	27	81	82	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1812	1817		10.1096/fj.04-1899com	http://dx.doi.org/10.1096/fj.04-1899com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576484				2022-12-28	WOS:000226091000031
J	Salinas, D; Haggie, PM; Thiagarajah, JR; Song, YL; Rosbe, K; Finkbeiner, WE; Nielson, DW; Verkman, AS				Salinas, D; Haggie, PM; Thiagarajah, JR; Song, YL; Rosbe, K; Finkbeiner, WE; Nielson, DW; Verkman, AS			Submucosal gland dysfunction as a primary defect in cystic fibrosis	FASEB JOURNAL			English	Article						CFTR; airway; mucus; fluorescence microscopy; photobleaching	BRONCHIAL MUCOUS GLANDS; AIRWAY SURFACE LIQUID; LUNG-DISEASE; TRACHEAL GLANDS; ION COMPOSITION; SECRETION; PATHOGENESIS; TRANSPORT; CHLORIDE; INFANTS	It has been proposed that defective submucosal gland function in CF airways is a major determinant of CF airway disease. We tested the hypothesis that submucosal gland function is defective early in CF subjects with minimal clinical disease. Functional assays of gland fluid secretion rate and viscosity were performed on freshly obtained nasal biopsies from 6 CF subjects and 5 non-CF controls (age range 2 - 22 years). Secretions from individual submucosal glands were visualized by light/fluorescence microscopy after orienting and immobilizing biopsy specimens in a custom chamber. The viscosity of freshly secreted gland fluid after pilocarpine, measured by fluorescence recovery after photobleaching of microinjected FITC-dextran, was 4.9 +/- 0.2- vs. 2.2 +/- 0.2-fold greater than water viscosity in CF vs. non-CF specimens, respectively (SE, P< 10(-4)). Gland fluid secretion rate in CF specimens, measured by video imaging (4.5 +/- 0.5 nL/min/gland, n=6), was 2.7 - fold reduced compared to non-CF specimens ( n=3, P< 0.05). Quantitative histology revealed similar size and morphology of submucosal glands in CF and non-CF specimens. Our results suggest that defective airway submucosal gland function is an early, primary defect in CF. Therapies directed at normalizing gland fluid secretion early in CF may thus reduce lung disease.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL73854] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R01DK043840, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballard ST, 1999, AM J PHYSIOL-LUNG C, V277, pL694, DOI 10.1152/ajplung.1999.277.4.L694; CHOW CW, 1982, EUR J PEDIATR, V139, P240, DOI 10.1007/BF00442171; Donaldson SH, 2003, CURR OPIN PULM MED, V9, P486, DOI 10.1097/00063198-200311000-00007; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ESTERLY JR, 1968, JOHNS HOPKINS MED J, V122, P94; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; FINKBEINER WE, 1994, AM J PHYSIOL, V267, pL206, DOI 10.1152/ajplung.1994.267.2.L206; GERMAN VF, 1980, AM REV RESPIR DIS, V122, P413; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; JACQUOT J, 1993, EUR RESPIR J, V6, P169; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; King M, 1987, Eur J Respir Dis Suppl, V153, P165; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Konstan MW, 2002, ADV DRUG DELIVER REV, V54, P1409, DOI 10.1016/S0169-409X(02)00146-1; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; OPPENHEIMER EH, 1981, HUM PATHOL, V12, P36, DOI 10.1016/S0046-8177(81)80240-7; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; STURGESS J, 1982, AM J PATHOL, V106, P303; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Trout L, 1998, AM J PHYSIOL-LUNG C, V274, pL258, DOI 10.1152/ajplung.1998.274.2.L258; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; YAMAYA M, 1991, AM J PHYSIOL, V261, pL491, DOI 10.1152/ajplung.1991.261.6.L491	27	63	70	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					431	+		10.1096/fj.04-2879fje	http://dx.doi.org/10.1096/fj.04-2879fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15596485				2022-12-28	WOS:000226091000017
J	Murashov, AK; Pak, ES; Hendricks, WA; Owensby, JP; Sierpinski, PL; Tatko, LM; Fletcher, PL				Murashov, AK; Pak, ES; Hendricks, WA; Owensby, JP; Sierpinski, PL; Tatko, LM; Fletcher, PL			Directed differentiation of embryonic stem cells into dorsal interneurons	FASEB JOURNAL			English	Article						Wnt; spinal cord	SPINAL-CORD; MOTOR-NEURONS; SONIC HEDGEHOG; AXON GROWTH; TRANSPLANTATION; SPECIFICATION; IDENTITY; CULTURE; OLIGODENDROCYTES; EXPRESSION	During neural development caudalization and dorsoventral patterning of the neural tube is directed by several inductive factors including retinoic acid, sonic hedgehog (Shh), bone morphogenetic proteins (BMPs), and Wnt signaling. The purpose of the current study was to investigate whether dorsal interneurons specific for the spinal cord can be generated from mouse embryonic stem (ES) cells using known inductive signals. Here we show that specific combination of developmental signaling molecules including all trans-retinoic acid, Shh, bone morphogenetic protein 2 (BMP2), and Wnt3A can direct differentiation of ES cells into dorsal interneurons possessing appropriate neuronal markers, synaptic proteins and functional neurotransmitter machineries. We introduce a concept that Wnt3A morphogenic action relies on crosstalk with both Shh and BMP2 signaling pathways.	E Carolina Univ, Sch Med, Dept Physiol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Murashov, AK (corresponding author), E Carolina Univ, Sch Med, Dept Physiol, Brody Bldg 6N-98,600 Moye Blvd, Greenville, NC 27858 USA.	murashoval@mail.ecu.edu	Murashov, Alexander K/F-2241-2011	Murashov, Alexander K/0000-0002-8912-5891; Fletcher, Paul/0000-0002-3200-4693				Appel B, 2003, NEURON, V40, P461, DOI 10.1016/S0896-6273(03)00688-3; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Butler SJ, 2003, NEURON, V38, P389, DOI 10.1016/S0896-6273(03)00254-X; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gulacsi A, 2003, J NEUROSCI, V23, P9862; Gunhaga L, 2003, NAT NEUROSCI, V6, P701, DOI 10.1038/nn1068; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Lee SK, 2001, NAT NEUROSCI, V4, P1183, DOI 10.1038/nn750; Liu RY, 2002, MOL CELL NEUROSCI, V20, P2, DOI 10.1006/mcne.2002.1107; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lovell-Badge R, 2001, NATURE, V414, P88, DOI 10.1038/35102150; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Megason SG, 2002, DEVELOPMENT, V129, P2087; Muller T, 2002, NEURON, V34, P551, DOI 10.1016/S0896-6273(02)00689-X; Muroyama Y, 2004, BIOCHEM BIOPH RES CO, V313, P915, DOI 10.1016/j.bbrc.2003.12.023; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Panchision DM, 2002, CURR OPIN GENET DEV, V12, P478, DOI 10.1016/S0959-437X(02)00329-5; Price SR, 2002, CELL, V109, P205, DOI 10.1016/S0092-8674(02)00695-5; Schnorrer F, 2004, CURR BIOL, V14, pR19, DOI 10.1016/j.cub.2003.12.016; Sockanathan S, 2003, NEURON, V40, P97, DOI 10.1016/S0896-6273(03)00532-4; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; Trousse F, 2001, DEVELOPMENT, V128, P3927; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Yabe T, 2002, J NEUROSCI RES, V68, P161, DOI 10.1002/jnr.10210; Yu X, 2003, NAT NEUROSCI, V6, P1169, DOI 10.1038/nn1132; Yung SY, 2002, P NATL ACAD SCI USA, V99, P16273, DOI 10.1073/pnas.232586699	32	41	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					252	+		10.1096/fj.04-2251fje	http://dx.doi.org/10.1096/fj.04-2251fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545303				2022-12-28	WOS:000225482100017
J	Sutherland, BA; Shaw, OM; Clarkson, AN; Jackson, DM; Sammut, IA; Appleton, I				Sutherland, BA; Shaw, OM; Clarkson, AN; Jackson, DM; Sammut, IA; Appleton, I			Neuroprotective effects of (-)-epigallocatechin gallate after hypoxia-ischemia-induced brain damage: novel mechanisms of action	FASEB JOURNAL			English	Article						EGCG; NOS; ROS	NITRIC-OXIDE SYNTHASE; GREEN TEA EXTRACT; EPIGALLOCATECHIN GALLATE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; 6-HYDROXYDOPAMINE-INDUCED APOPTOSIS; MITOCHONDRIAL HYPEROXIDATION; ELECTRICAL RECOVERY; HIPPOCAMPAL SLICES; NADH FLUORESCENCE	(-)-Epigallocatechin gallate (EGCG) is a potent antioxidant that is neuroprotective against ischemia-induced brain damage. However, the neuroprotective effects and possible mechanisms of action of EGCG after hypoxia-ischemia (HI) have not been investigated. Therefore, we used a modified "Levine" model of HI to determine the effects of EGCG. Wistar rats were treated with either 0.9% saline or 50 mg/kg EGCG daily for 1 day and 1 h before HI induction and for a further 2 days post-HI. At 26-days-old, both groups underwent permanent left common carotid artery occlusion and exposure to 8% oxygen/92% nitrogen atmosphere for 1 h. Histological assessment showed that EGCG significantly reduced infarct volume (38.0 +/- 16.4 mm(3)) in comparison to HI + saline (99.6 +/- 15.6 mm(3)). In addition, EGCG significantly reduced total (622.6 +/- 85.8 pmol L-[H-3]citrulline/30 min/mg protein) and inducible nitric oxide synthase (iNOS) activity (143.2 +/- 77.3 pmol L-[H-3]citrulline/30 min/mg protein) in comparison to HI+ saline controls (996.6 +/- 113.6 and 329.7 +/- 59.6 pmol L-[H-3]citrulline/30 min/mg protein for total NOS and iNOS activity, respectively). Western blot analysis demonstrated that iNOS protein expression was also reduced. In contrast, EGCG significantly increased endothelial and neuronal NOS protein expression compared with HI controls. EGCG also significantly preserved mitochondrial energetics (complex I-V) and citrate synthase activity. This study demonstrates that the neuroprotective effects of EGCG are, in part, due to modulation of NOS isoforms and preservation of mitochondrial complex activity and integrity. We therefore conclude that the in vivo neuroprotective effects of EGCG are not exclusively due to its antioxidant effects but involve more complex signal transduction mechanisms.	Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand	University of Otago	Appleton, I (corresponding author), Univ Otago, Dept Pharmacol & Toxicol, POB 913, Dunedin, New Zealand.	ian.appleton@stonebow.otago.ac.nz	Sutherland, Brad/J-3920-2014; Sutherland, Brad/AAX-2725-2020	Sutherland, Brad/0000-0002-0791-0950; Clarkson, Andrew/0000-0003-3804-3834; Sammut, Ivan/0000-0002-9217-9452; Shaw, Odette/0000-0001-7158-1074				ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Aucamp J, 1997, ANTICANCER RES, V17, P4381; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Chan MMY, 1997, BIOCHEM PHARMACOL, V54, P1281, DOI 10.1016/S0006-2952(97)00504-2; CHAN MMY, 1995, CANCER LETT, V96, P23, DOI 10.1016/0304-3835(95)03913-H; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Clarkson AN, 2004, FASEB J, V18, P1114, DOI 10.1096/fj.03-1203fje; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Endres M, 2004, TRENDS NEUROSCI, V27, P283, DOI 10.1016/j.tins.2004.03.009; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Frei B, 2003, J NUTR, V133, p3275S, DOI 10.1093/jn/133.10.3275S; GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F; Guo QN, 1996, BBA-LIPID LIPID MET, V1304, P210, DOI 10.1016/S0005-2760(96)00122-1; GUTTERIDGE JMC, 1990, ARCH BIOCHEM BIOPHYS, V283, P223, DOI 10.1016/0003-9861(90)90635-C; Hong JT, 2001, BRAIN RES, V888, P11, DOI 10.1016/S0006-8993(00)02935-8; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; HUANG Z, 1996, J CEREB BLOOD FLOW M, V15, P378; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Ikeda K, 2003, TOXICOLOGY, V189, P55, DOI 10.1016/S0300-483X(03)00152-5; Inanami O, 1998, FREE RADICAL RES, V29, P359, DOI 10.1080/10715769800300401; Jin CF, 2001, J AGR FOOD CHEM, V49, P6033, DOI 10.1021/jf010903r; Jude EB, 1999, DIABETOLOGIA, V42, P748, DOI 10.1007/s001250051224; Kakuda T, 2002, BIOL PHARM BULL, V25, P1513, DOI 10.1248/bpb.25.1513; Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Kelly MR, 2001, J CELL BIOCHEM, V81, P647, DOI 10.1002/jcb.1097; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; LEE JA, 1992, CIRC RES, V71, P58, DOI 10.1161/01.RES.71.1.58; Lee SR, 2003, PHYTOTHER RES, V17, P206, DOI 10.1002/ptr.1090; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; LEVINE S, 1960, AM J PATHOL, V36, P1; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Nagai K, 2002, BRAIN RES, V956, P319, DOI 10.1016/S0006-8993(02)03564-3; Nie GJ, 2002, ARCH BIOCHEM BIOPHYS, V397, P84, DOI 10.1006/abbi.2001.2636; Paquay JBG, 2000, J AGR FOOD CHEM, V48, P5768, DOI 10.1021/jf981316h; Perez-Pinzon MA, 1998, BRAIN RES, V786, P165, DOI 10.1016/S0006-8993(97)01438-8; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SATO Y, 1989, TOHOKU J EXP MED, V157, P337, DOI 10.1620/tjem.157.337; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; SOUSSI B, 1990, ACTA PHYSIOL SCAND, V138, P107, DOI 10.1111/j.1748-1716.1990.tb08822.x; Suzuki M, 2004, MED SCI MONITOR, V10, pBR166; Tedeschi E, 2004, MOL PHARMACOL, V65, P111, DOI 10.1124/mol.65.1.111; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Vannucci RC, 1999, J NEUROSCI RES, V55, P158, DOI 10.1002/(SICI)1097-4547(19990115)55:2<158::AID-JNR3>3.0.CO;2-1; WATANABE H, 1990, FREE RADICAL BIO MED, V8, P507, DOI 10.1016/0891-5849(90)90150-H; Wei IH, 2004, BRAIN RES, V999, P73, DOI 10.1016/j.brainres.2003.11.056; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22	61	105	112	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					258	+		10.1096/fj.04-2806fje	http://dx.doi.org/10.1096/fj.04-2806fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15569775				2022-12-28	WOS:000225482100003
J	Volonte, D; Liu, YH; Galbiati, F				Volonte, D; Liu, YH; Galbiati, F			The modulation of caveolin-1 expression controls satellite cell activation during muscle repair	FASEB JOURNAL			English	Article						caveolae; hepatocyte growth factor; muscle regeneration	HEPATOCYTE GROWTH-FACTOR; P42/44 MAP KINASE; ADULT SKELETAL-MUSCLE; ONCOGENICALLY TRANSFORMED-CELLS; GENE-EXPRESSION; TRANSGENIC MICE; MUSCULAR-DYSTROPHY; SIGNALING PATHWAYS; NITRIC-OXIDE; IN-VITRO	We have previously shown that caveolin-1, the principal structural protein component of caveolar membrane domains, inhibits cellular proliferation and induces cell cycle arrest. We demonstrate here for the first time that caveolin-1 is expressed in satellite cells but not in mature muscle fibers. Satellite cells are quiescent myogenic precursors that, after muscle injury, become mitotically active, proliferate, and fuse together or, to existing myofibers, to form new muscle fibers. We show that down-regulation of caveolin-1 expression occurs in satellite cells/myogenic precursor cells (MPCs) during muscle regeneration and that hepatocyte growth factor, which is produced after muscle injury, down-regulates caveolin-1. We also demonstrate that down-regulation of endogenous caveolin-1 expression activates ERK and that activation of the p42/44 MAP kinase pathway is necessary to promote muscle regeneration. Finally, we show that overexpression of caveolin-1 inhibits muscle repair mechanisms both in vitro and in vivo. Taken together, these results propose caveolin-1 as a novel regulator of satellite cell functions and suggest that the following signaling pathway modulates satellite cell activation during muscle repair: injured fibers release HGF --> HGF down-regulates caveolin-1 protein expression --> down-regulation of caveolin-1 activates ERK --> activation of ERK promotes muscle repair by stimulating the proliferation and migration of MPCs toward the wounded area.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Galbiati, F (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.	feg5@pitt.edu	Wilson, Matthew H/K-3193-2013; Galbiati, Ferruccio/AAF-3527-2020	Liu, Youhua/0000-0002-4740-805X				ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Andree B, 2002, MOL CELL BIOL, V22, P1504, DOI 10.1128/MCB.22.5.1504-1512.2002; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; BISCHOFF R, 1989, MED SCI SPORTS EXERC, V21, P164; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cooper RN, 1999, J CELL SCI, V112, P2895; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; COUTEAUX R, 1988, BIOL CELL, V62, P171, DOI 10.1016/0248-4900(88)90034-2; Dai CS, 2002, J AM SOC NEPHROL, V13, P411, DOI 10.1681/ASN.V132411; DALBIS A, 1989, DEV BIOL, V135, P320, DOI 10.1016/0012-1606(89)90182-6; EHLER E, 1995, CIRCULATION, V92, P3289, DOI 10.1161/01.CIR.92.11.3289; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Galbiati F, 2000, P NATL ACAD SCI USA, V97, P9689, DOI 10.1073/pnas.160249097; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Garry DJ, 2000, P NATL ACAD SCI USA, V97, P5416, DOI 10.1073/pnas.100501197; Garry DJ, 1997, DEV BIOL, V188, P280, DOI 10.1006/dbio.1997.8657; Haxhinasto K, 2004, AM J PHYSIOL-CELL PH, V287, pC1125, DOI 10.1152/ajpcell.00530.2003; IRINTCHEV A, 1994, DEV DYNAM, V199, P326, DOI 10.1002/aja.1001990407; Ishii A, 2001, BIOCHEM J, V356, P737, DOI 10.1042/0264-6021:3560737; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KANDA S, 1996, CELL GROWTH DIFFER, V92, P3289; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Launay T, 2001, J HISTOCHEM CYTOCHEM, V49, P887, DOI 10.1177/002215540104900709; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; MOSS FP, 1971, ANAT REC, V170, P421, DOI 10.1002/ar.1091700405; NOBLE M, 1995, TRANSGENIC RES, V4, P215, DOI 10.1007/BF01969114; Pirskanen A, 2000, DEV BIOL, V224, P189, DOI 10.1006/dbio.2000.9784; SCHULTZ E, 1978, J EXP ZOOL, V206, P451, DOI 10.1002/jez.1402060314; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; SMITH TH, 1993, DEVELOPMENT, V117, P1125; SNOW MH, 1990, ANAT REC, V227, P437, DOI 10.1002/ar.1092270407; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Volonte D, 2003, MOL BIOL CELL, V14, P4075, DOI 10.1091/mbc.E03-03-0161; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; WINCHESTER PK, 1991, AM J PHYSIOL, V260, pC206, DOI 10.1152/ajpcell.1991.260.2.C206; YABLONKAREUVENI Z, 1995, MICROSC RES TECHNIQ, V30, P366, DOI 10.1002/jemt.1070300504; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199	53	86	91	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					237	+		10.1096/fj.04-2215fje	http://dx.doi.org/10.1096/fj.04-2215fje			36	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545301				2022-12-28	WOS:000225482100021
J	Giordanengo, V; Ollier, L; Lanteri, M; Lesimple, J; March, D; Thyss, S; Lefebvre, JC				Giordanengo, V; Ollier, L; Lanteri, M; Lesimple, J; March, D; Thyss, S; Lefebvre, JC			Epigenetic reprogramming of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) in HIV-1-infected CEM T cells	FASEB JOURNAL			English	Article						sialic acid; promoter; methylation; bisulfite	ALTERED GLYCOSYLATION; IMMUNE RESTORATION; SIALIC ACIDS; METHYLATION; EXPRESSION; INFECTION; GENE; LYMPHOCYTES; PROMOTER; CD43	Sialylated glycoconjugates mediate several key lymphocyte functions. We previously reported that hyposialylation occurred in latently HIV-1-infected CEM T cells, despite the fully preserved catalytic activity of several sialyltransferases. We show now that these cells are affected by a down-regulation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), which leads to a dramatic decrease in the synthesis of CMP-sialic acid, the donor substrate of all sialyltransferases. The GNE gene promoter was found to be located in a CpG island with several regulatory motifs CREB, SP1, and AP-2. De novo hypermethylation of this promoter was observed in HIV-1-infected CEM cells. This phenomenon might explain some immunological disorders that persist in infected individuals despite long-term therapeutically controlled viral replication. Indeed, an overall decrease in sialic acid engraftment can affect glycoproteins, notably those in which the sialylation status is crucial to ensure homing, recirculation, and survival of lymphocytes.	Fac Med, INSERM, U50, Virol Lab, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Lefebvre, JC (corresponding author), Fac Med, INSERM, U50, Virol Lab, IFR 50,Ave Valombrose, F-06107 Nice 2, France.	lefebvre@unice.fr		giordanengo, valerie/0000-0002-5114-1124				ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Carcelain G, 2001, CURR OPIN IMMUNOL, V13, P483, DOI 10.1016/S0952-7915(00)00245-4; CHELUCCI C, 1995, BLOOD, V85, P1181, DOI 10.1182/blood.V85.5.1181.bloodjournal8551181; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; Fang JY, 2001, J VIROL, V75, P9753, DOI 10.1128/JVI.75.20.9753-9761.2001; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; Giordanengo V, 1999, AIDS, V13, P1141, DOI 10.1097/00002030-199906180-00020; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; GIORDANENGO V, 1995, BLOOD, V86, P2302, DOI 10.1182/blood.V86.6.2302.bloodjournal8662302; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; JAHNER D, 1985, NATURE, V315, P594, DOI 10.1038/315594a0; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lanteri M, 2003, GLYCOBIOLOGY, V13, P909, DOI 10.1093/glycob/cwg110; Lederman MM, 2001, AIDS, V15, pS11, DOI 10.1097/00002030-200102002-00003; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; LEFEBVRE JC, 1994, VIROLOGY, V199, P265, DOI 10.1006/viro.1994.1124; Li XD, 1996, VIROLOGY, V225, P196, DOI 10.1006/viro.1996.0588; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; OBRIEN MC, 1995, BIOCHEM BIOPH RES CO, V207, P903, DOI 10.1006/bbrc.1995.1271; Oetke C, 2003, BIOCHEM BIOPH RES CO, V308, P892, DOI 10.1016/S0006-291X(03)01471-2; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; REMOLDODONNELL E, 1987, BLOOD, V70, P104; Rossi D, 2003, BRIT J HAEMATOL, V123, P475, DOI 10.1046/j.1365-2141.2003.04644.x; Ruiz ME, 1998, J IMMUNOL, V161, P4169; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SMITH DF, 1990, J BIOL CHEM, V265, P6225; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka J, 2003, AIDS, V17, P167, DOI 10.1097/00002030-200301240-00005; Valdez H, 2002, AIDS, V16, P1859, DOI 10.1097/00002030-200209270-00002; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Zhao SF, 1998, J INFECT DIS, V178, P1623, DOI 10.1086/314506	39	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1961	+		10.1096/fj.04-2467fje	http://dx.doi.org/10.1096/fj.04-2467fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15469965				2022-12-28	WOS:000224849900025
J	Scragg, JL; Fearon, IM; Boyle, JP; Ball, SG; Varadi, G; Peers, C				Scragg, JL; Fearon, IM; Boyle, JP; Ball, SG; Varadi, G; Peers, C			Alzheimer's amyloid peptides mediate hypoxic up-regulation of L-type Ca2+ channels	FASEB JOURNAL			English	Article						chronic hypoxia; Alzheimer's disease; ion channel	PRESYNAPTIC CALCIUM CHANNELS; EATON MYASTHENIC SYNDROME; PRECURSOR PROTEIN; BETA-PEPTIDES; CAROTID-BODY; CELLULAR MECHANISMS; CELLS; CHEMORECEPTORS; INVOLVEMENT; SECRETASE	We examined the effects of chronic hypoxia on recombinant human L-type Ca2+ channel alpha(1C) subunits stably expressed in HEK 293 cells, using whole-cell patch-clamp recordings. Current density was dramatically increased following 24 h exposure to chronic hypoxia (CH), and membrane channel protein levels were enhanced. CH also increased the levels of Alzheimer's amyloid beta peptides (AbetaPs), determined immunocytochemically. Pharmacological prevention of AbetaP production (via exposure to inhibitors of secretase enzymes that are required to cleave AbetaP from its precursor protein) prevented hypoxic augmentation of currents, as did inhibition of vesicular trafficking with bafilomycin A1. The enhancing effect of AbetaPs or CH were abolished following incubation with the monoclonal 3D6 antibody, raised against the extracellular N' terminus of AbetaP. Immunolocalization and immunoprecipitation studies provided compelling evidence that AbetaPs physically associated with the a1C subunit, and this association was promoted by hypoxia. These data suggest an important role for AbetaPs in mediating the increase in Ca2+ channel activity following CH and show that AbetaPs act post-transcriptionally to promote a1C subunit insertion into (and/or retention within) the plasma membrane. Such an action will likely contribute to the Ca2+ dyshomeostasis of Alzheimer's disease and may contribute to the mechanisms underlying the known increased incidence of this neurodegenerative disease following hypoxic	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Leeds; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; McMaster University	Peers, C (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.	c.s.peers@leeds.ac.uk		Peers, Chris/0000-0002-8354-346X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL 22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; DAVIDSON RM, 1994, BRAIN RES, V643, P324, DOI 10.1016/0006-8993(94)90041-8; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Fearon IM, 2000, CIRC RES, V87, P537, DOI 10.1161/01.RES.87.7.537; Fearon IM, 1997, J PHYSIOL-LONDON, V500, P551, DOI 10.1113/jphysiol.1997.sp022041; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; Green KN, 2002, J NEUROCHEM, V81, P1043, DOI 10.1046/j.1471-4159.2002.00907.x; Green KN, 2001, J NEUROCHEM, V77, P953, DOI 10.1046/j.1471-4159.2001.00338.x; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Johnson D, 1997, EDN, V42, P94; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Kokmen E, 1996, NEUROLOGY, V46, P154, DOI 10.1212/WNL.46.1.154; LANG B, 1987, J PHYSIOL-LONDON, V390, P257, DOI 10.1113/jphysiol.1987.sp016698; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; MacManus A, 2000, J BIOL CHEM, V275, P4713, DOI 10.1074/jbc.275.7.4713; Masters CL, 1998, BRIT MED J, V316, P446, DOI 10.1136/bmj.316.7129.446; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Moroney J T, 1997, Ann N Y Acad Sci, V826, P433, DOI 10.1111/j.1749-6632.1997.tb48498.x; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; PEERS C, 1993, NEUROSCI LETT, V153, P45, DOI 10.1016/0304-3940(93)90073-T; Peers C, 2001, RESP RES, V2, P145, DOI 10.1186/rr51; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; STEA A, 1995, J NEUROSCI, V15, P2192, DOI 10.1523/JNEUROSCI.15-03-02192.1995; Taylor SC, 1999, J BIOL CHEM, V274, P31217, DOI 10.1074/jbc.274.44.31217; Ueda K, 1997, J NEUROCHEM, V68, P265; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; WEIR EK, 1995, FASEB J, V9, P183, DOI 10.1096/fasebj.9.2.7781921; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295; Yokota M, 1996, J CEREBR BLOOD F MET, V16, P1219, DOI 10.1097/00004647-199611000-00016	42	45	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					150	+		10.1096/fj.04-2659fje	http://dx.doi.org/10.1096/fj.04-2659fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15494446				2022-12-28	WOS:000224849900015
J	Szeto, HH; Schiller, PW; Zhao, KS; Luo, GX				Szeto, HH; Schiller, PW; Zhao, KS; Luo, GX			Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides	FASEB JOURNAL			English	Article						membrane transduction; mitochondria; permeability transition; cytoplasm; confocal microscopy	BASIC DOMAIN; PLASMA-MEMBRANE; CYTOCHROME-C; PEPTIDES; TAT; HIV-1; INTERNALIZATION; MECHANISM; DELIVERY; ANALOGS	Fluorescent labels are commonly used to investigate the mechanisms of cellular uptake and intracellular distribution of cell-penetrating peptides. However, labels such as fluorescein and rhodamine are relatively large and very lipophilic and may significantly alter physicochemical properties of small peptides. To minimize the impact of the fluorescent probe on a tetrapeptide, we substituted one of the amino acids (Lys(4)) in a tetrapeptide ([Dmt(1)]DALDA, Dmt- D-Arg-Phe-Lys-NH2 where Dmt = 2', 6'-dimethyltyrosine) with two different fluorescent amino acids (beta-dansyl-L-alpha,beta-diaminopropionic acid (dnsDap(4)) or beta-anthraniloyl-L-alpha,beta-diaminopropionic acid (atnDap(4))). Initial studies with confocal laser scanning microscopy (CLSM) showed very different localization patterns for the two fluorescent analogs, with [Dmt(1), atnDap(4)] DALDA showing mitochondrial localization and [Dmt(1), dnsDap(4)] DALDA showing diffuse cytoplasmic localization. Studies with isolated mouse liver mitochondria suggested that [Dmt(1), dnsDap(4)] DALDA targeted the mitochondrial matrix resulting in mitochondrial depolarization, opening of the permeability transition pore, mitochondrial swelling, and rapid release of the peptide into the cytoplasm. In contrast, [Dmt(1), atnDap(4)] DALDA was retained in the inner mitochondrial membrane and did not induce mitochondrial swelling. Furthermore, [Dmt(1), atnDap(4)] DALDA protected mitochondria against Ca2+-induced swelling. Importantly, the unlabeled parent peptide [Dmt(1)] DALDA behaved like [Dmt(1), atnDap(4)] DALDA and was mitoprotective. These findings suggest that experimental results obtained with fluorescent labels must be interpreted with caution, and the use of multiple fluorophores, together with confirmation using the original or radiolabeled molecule, is recommended.	Cornell Univ, Joan & Sanford I Weill Med coll, Dept Pharmacol, New York, NY 10021 USA; Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ H2W 1R7, Canada	Cornell University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Szeto, HH (corresponding author), Cornell Univ, Joan & Sanford I Weill Med coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	hhszeto@med.cornell.edu			NIDA NIH HHS [DA08924] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008924] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENJOUAD A, 1993, FEBS LETT, V319, P119, DOI 10.1016/0014-5793(93)80049-Z; Berezowska I, 2003, PEPTIDES, V24, P1195, DOI 10.1016/j.peptides.2003.07.004; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P469, DOI 10.1006/bbrc.2001.4790; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Schiller PW, 2000, EUR J MED CHEM, V35, P895, DOI 10.1016/S0223-5234(00)01171-5; VARDANIS A, 1977, J BIOL CHEM, V252, P807; Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Zhao GM, 2003, J PHARMACOL EXP THER, V307, P947, DOI 10.1124/jpet.103.054775; Zhao KS, 2003, J PHARMACOL EXP THER, V304, P425, DOI 10.1124/jpet.102.040147	22	70	72	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					118	+		10.1096/fj.04-1982fje	http://dx.doi.org/10.1096/fj.04-1982fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15489247				2022-12-28	WOS:000224849900017
J	Zucker, S; Crabbe, JC; Cooper, G; Finkelman, F; Largman, C; McCarley, RW; Rice, L; Rubin, J; Richardson, B; Seil, F; Snider, GL; Vandenbark, AA				Zucker, S; Crabbe, JC; Cooper, G; Finkelman, F; Largman, C; McCarley, RW; Rice, L; Rubin, J; Richardson, B; Seil, F; Snider, GL; Vandenbark, AA			Veterans Administration support for medical research: opinions of the endangered species of physician-scientists	FASEB JOURNAL			English	Article						VA training; basic research; patient care	HEALTH-CARE SYSTEM; BIOMEDICAL-RESEARCH; VA RESEARCH; FUTURE; CHALLENGES; GRANTS; CHIEF	Over the past three decades the Veterans Affairs (VA) Research program has evolved into a powerful, peer-reviewed funding mechanism for basic and translational research that has resulted in numerous important contributions to medical science and improvements in patient care. Continuity in VA Merit Review funding has fostered and nurtured the scientific careers of a large number of physician-scientists who have remained devoted to the mission of performing creative and innovative research that affects the patient care mission of the VA. VA medical research policies have undergone a major overhaul in the past year. Although many of these changes (de-emphasizing bench research and revamping the peer review process) have recently been reversed, the future direction of VA research remains in flux. The goal of this manuscript is to demonstrate the importance of the Merit Review medical research funding mechanism not just to the VA, but to the entire nation's health care system. To achieve this goal, the opinions of 65 established VA medical investigators were obtained regarding the past success and future direction of VA research. The conclusions reached include the following. 1) Merit Review research funding has been essential to the training, recruitment, and retention of productive VA physician-scientists. 2) The VA research program has contributed both basic and clinical innovations that have led to improvements in medical care. Contributions of VA researchers to excellence in many aspects of patient care at VA hospitals have been extraordinary. 3) Development of initiatives that entice outstanding Ph. D.' s to develop their careers in the VA has been crucial to the success of the program. 4) The VA research program has fostered a mutually beneficial relationship with affiliated medical schools. 5) Better methods to quantify VA research contributions and outcomes are essential for future program development.	Vet Adm Med Ctr, Northport, NY 11768 USA; Vet Adm Med Ctr, Charleston, SC 29403 USA; Vet Adm Med Ctr, Cincinnati, OH 45220 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Vet Adm Med Ctr, Brockton, MA 02401 USA; Vet Adm Med Ctr, Cleveland, OH 44106 USA; Vet Adm Med Ctr, Atlanta, GA 30033 USA; Vet Adm Med Ctr, Ann Arbor, MI 48105 USA; Vet Adm Med Ctr, Portland, OR USA; Vet Adm Med Ctr, Boston, MA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Zucker, S (corresponding author), Mail Code 151,79 Middleville Rd, Northport, NY 11768 USA.	stanley.zucker@med.va.gov	McCarley, Robert W/N-5562-2014; Seil, Fredrick/W-1618-2019; Shenton, Martha/V-8780-2019	McCarley, Robert W/0000-0001-5705-7495; 	NIAAA NIH HHS [P60 AA010760] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Barnett PG, 1996, ACAD MED, V71, P1074, DOI 10.1097/00001888-199610000-00014; *BLUE RIBB COMM LA, 2003, REP OFF RES DEV VET; Couzin J, 2003, SCIENCE, V302, P1306, DOI 10.1126/science.302.5649.1306; Couzin J, 2003, SCIENCE, V301, P24, DOI 10.1126/science.301.5629.24; Couzin J, 2003, SCIENCE, V300, P574, DOI 10.1126/science.300.5619.574; CROOK E, 2003, J INVEST MED, V51, P191; DETRE T, 1991, ACAD MED, V66, P90, DOI 10.1097/00001888-199102000-00007; FISHER ES, 1995, JAMA-J AM MED ASSOC, V273, P651, DOI 10.1001/jama.273.8.651; FUESSNER JR, 2002, MED CARE, V40, pV4; GRONVALL JA, 1989, ACAD MED, V64, P61, DOI 10.1097/00001888-198902000-00002; Kizer KW, 1997, HOSP HEALTH SERV ADM, V42, P283; *NAT RES COUNC, 1968, EV BIOM RES ED VET; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Rutherford GW, 1999, ACAD MED, V74, P773, DOI 10.1097/00001888-199907000-00010; Smith CB, 1997, WESTERN J MED, V167, P420; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; *VET ADM COMM BIOM, 1977, BIOM RES VET ASS; *VET HLTH ADM RES, 1996, FIN REP; Zemlo TR, 2000, FASEB J, V14, P221, DOI 10.1096/fasebj.14.2.221	19	7	7	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1481	1486		10.1096/fj.04-1573lfe	http://dx.doi.org/10.1096/fj.04-1573lfe			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466355				2022-12-28	WOS:000224849900030
J	He, QJ; Peng, H; Collins, SJ; Triche, TJ; Wu, LT				He, QJ; Peng, H; Collins, SJ; Triche, TJ; Wu, LT			Retinoid-modulated MAT1 ubiquitination and CAK activity	FASEB JOURNAL			English	Article						MAT1-dependent CAK activity; decreased CAK phosphorylation of RAR alpha; proliferation/differentiation transition	CDK-ACTIVATING KINASE; ACID RECEPTOR-ALPHA; TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; CELL-CYCLE CONTROL; PROTEASOME PATHWAY; RETINOBLASTOMA PROTEIN; ASSEMBLY FACTOR; RAR-ALPHA; S-PHASE	Human cyclin-dependent kinase (CDK)-activating kinase (CAK) has a dual function in cross-regulation of cell cycle and differentiation, whereas menage a trois 1 (MAT1) assembles CAK and determines CAK's substrate specificity. Although the dynamic state of MAT1 protein levels is found to modulate CAK activity, how intracellular regulation of MAT1 controls CAK activity is unknown. Recent studies demonstrate that retinoic acid (RA)-induced human HL60 cell proliferation/differentiation (P/D) transition is accompanied by MAT1 degradation and decreased CAK phosphorylation of retinoic acid receptor alpha (RARa). Thus, we investigated the biochemical pathway of MAT1 degradation and its relationship with CAK phosphorylation of RARa. We find that RA induces ubiquitination-proteolysis of MAT1 and that ubiquitin-proteasome targets CAK-free MAT1 only. RA-induced MAT1 ubiquitination reduces CAK abundance and decreases CAK phosphorylation of RARa, whereas inhibition of MAT1 ubiquitination resists this RA-effect. These findings reveal that RA induces MAT1 ubiquitination to decrease CAK phosphorylation of RARa, suggesting a novel mechanism of RA-mediated P/D transition in which MAT1 ubiquitination may act as an integral part of RA-effect to decrease CAK activity in the switch from proliferation to differentiation.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA; Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98104 USA	University of Southern California; Children's Hospital Los Angeles; Fred Hutchinson Cancer Center	Wu, LT (corresponding author), Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pathol, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu	he, qiaojun/F-3198-2010					Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POON RYC, 1994, J CELL SCI, V107, P2789; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shah SA, 2001, SURG ONCOL, V10, P43, DOI 10.1016/S0960-7404(01)00018-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; WU LT, 1994, ONCOGENE, V9, P2089; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; YEE A, 1995, CANCER RES, V55, P6058; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	53	14	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1734	+		10.1096/fj.04-2182fje	http://dx.doi.org/10.1096/fj.04-2182fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345685				2022-12-28	WOS:000224243200038
J	Mallat, Z; Heymes, C; Corbaz, A; Logeart, D; Alouani, S; Cohen-Solal, A; Seidler, T; Hasenfuss, G; Chvatchko, Y; Shah, AM; Tedgui, A				Mallat, Z; Heymes, C; Corbaz, A; Logeart, D; Alouani, S; Cohen-Solal, A; Seidler, T; Hasenfuss, G; Chvatchko, Y; Shah, AM; Tedgui, A			Evidence for altered interleukin (IL)-18 pathway in human heart failure	FASEB JOURNAL			English	Article						congestive heart failure; inflammation; cytokines; ischemia	TUMOR-NECROSIS-FACTOR; GAMMA-INDUCING FACTOR; OXIDE SYNTHASE INHIBITION; BLOOD MONONUCLEAR-CELLS; CIRCULATING LEVELS; INTERFERON-GAMMA; IFN-GAMMA; CARDIAC MYOCYTES; TNF-ALPHA; IL-18	Interleukin (IL)-18 is the interferon-gamma- inducing factor and has potent proinflammatory activities. IL-18 has been recently implicated in atherosclerotic plaque instability and myocardial ischemia-reperfusion injury. However, it is unknown whether IL-18 expression is increased in human myocardium or if it has any role in heart failure. We analyzed the expression of IL-18, its receptor IL-18Ralpha, and its endogenous inhibitor, IL-18 binding protein (IL-18BP) in myocardial tissue from patients with end-stage heart failure ( ischemic or dilated cardiomyopathy) and controls by use of quantitative real-time reverse transcriptase polymerase chain reaction, Western blot or immunohistochemical techniques. Plasma levels of IL-18 were also determined in 48 patients with heart failure. IL-18 mRNA and protein levels were up-regulated in the myocardium of patients with ischemic cardiomyopathy. Both ischemic and dilated myocardium showed increased IL-18Ralpha levels, suggesting potential biological effects. In addition, mRNA levels of IL-18 BP were down-regulated in the failing myocardium. Finally, plasma IL-18 levels were significantly elevated in patients with heart failure and were higher in those who died at follow-up than in survivors. The results suggest a potential role for the immunoinflammatory IL-18 signaling pathway in the pathophysiology of heart failure and identify novel therapeutic targets for future testing.	Hop Lariboisiere, INSERM, U541, Inst Federat Rech Paris 7, F-75475 Paris 10, France; Kings Coll London, GKT Sch Med, Dept Cardiol, London, England; Univ Gottingen, Dept Cardiol, D-3400 Gottingen, Germany; Serono Pharmaceut Res Inst, Geneva, Switzerland; Hop Beaujon, Serv Cardiol, Clichy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; King's College London; University of Gottingen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Mallat, Z (corresponding author), Hop Lariboisiere, INSERM, U541, Inst Federat Rech Paris 7, 41 Bd Chapelle, F-75475 Paris 10, France.	ziad.mallat@larib.inserm.fr	Seidler, Tim/ABH-8333-2020; Heymes, Christophe/Y-9368-2019; Mallat, Ziad/D-4041-2012; Seidler, Tim/B-3929-2014	Seidler, Tim/0000-0002-6158-5087; Heymes, Christophe/0000-0002-6666-6193; Mallat, Ziad/0000-0003-0443-7878; Shah, Ajay/0000-0002-6547-0631				Aukrust P, 2001, CIRCULATION, V104, P1494, DOI 10.1161/hc3801.096353; Baumgarten G, 2000, TRENDS CARDIOVAS MED, V10, P216, DOI 10.1016/S1050-1738(00)00063-3; Blankenberg S, 2002, CIRCULATION, V106, P24, DOI 10.1161/01.CIR.0000020546.30940.92; Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044; Cao RH, 1999, FASEB J, V13, P2195, DOI 10.1096/fasebj.13.15.2195; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cotton JM, 2001, CIRCULATION, V104, P2318, DOI 10.1161/hc4401.098515; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; Dinarello CA, 2000, EUR CYTOKINE NETW, V11, P483; Fantuzzi G, 1999, J CLIN INVEST, V104, P761, DOI 10.1172/JCI7501; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; Francis GS, 1999, CIRCULATION, V99, P3213, DOI 10.1161/01.CIR.99.25.3213; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Guttenplan N, 2001, Heart Dis, V3, P313; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Hashimoto W, 1999, J IMMUNOL, V163, P583; Hjalmarson A, 1999, LANCET, V353, P2001; Jeremias I, 2000, CIRCULATION, V102, P915; Kelly RA, 1997, CIRCULATION, V95, P778; Koglin J, 1999, CIRCULATION, V99, P836, DOI 10.1161/01.CIR.99.6.836; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Mallat Z, 2001, CIRC RES, V89, pE41, DOI 10.1161/hh1901.098735; Mallat Z, 2001, CIRCULATION, V104, P1598, DOI 10.1161/hc3901.096721; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Naito Y, 2002, HEART, V88, P296, DOI 10.1136/heart.88.3.296; Narula Jagat, 2001, Cardiology Clinics, V19, P113, DOI 10.1016/S0733-8651(05)70198-3; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pomerantz BJ, 2001, P NATL ACAD SCI USA, V98, P2871, DOI 10.1073/pnas.041611398; Puren AJ, 1998, J CLIN INVEST, V101, P711, DOI 10.1172/JCI1379; Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256; Raeburn CD, 2002, AM J PHYSIOL-HEART C, V283, pH650, DOI 10.1152/ajpheart.00043.2002; Testa M, 1996, J AM COLL CARDIOL, V28, P964, DOI 10.1016/S0735-1097(96)00268-9; Tsutsui H, 1999, IMMUNITY, V11, P359, DOI 10.1016/S1074-7613(00)80111-9; Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; Woldbaek PR, 2003, CARDIOVASC RES, V59, P122, DOI 10.1016/S0008-6363(03)00339-0; Yamaoka-Tojo M, 2002, J CARD FAIL, V8, P21, DOI 10.1054/jcaf.2002.31628; Yndestad A, 2003, CARDIOVASC RES, V60, P141, DOI 10.1016/S0008-6363(03)00362-6; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	45	117	126	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1752	+		10.1096/fj.04-2426fje	http://dx.doi.org/10.1096/fj.04-2426fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15371332				2022-12-28	WOS:000224243200024
J	Philip-Couderc, P; Pathak, A; Smih, F; Dambrin, C; Harmancey, R; Buys, S; Galinier, M; Massabuau, P; Roncalli, J; Senard, JM; Rouet, P				Philip-Couderc, P; Pathak, A; Smih, F; Dambrin, C; Harmancey, R; Buys, S; Galinier, M; Massabuau, P; Roncalli, J; Senard, JM; Rouet, P			Uncomplicated human obesity is associated with a specific cardiac transcriptome: involvement of the Wnt pathway	FASEB JOURNAL			English	Article						heart; arterial hypertension; functional genomics	HEART-RATE-VARIABILITY; BETA-CATENIN; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; BLOOD-PRESSURE; RISK-FACTORS; HYPERTENSION; FAILURE; MICROARRAYS; HYPERTROPHY	A dramatic increase in obesity prevalence and cardiovascular morbidity is expected for the coming years. However, with relevance to the heart, little is known about the specific contribution of obesity on associated morbidity. Consequently, global analysis of gene regulations in human heart was undertaken to monitor molecular regulations related to obesity or to obesity-related hypertension. Transcriptome analysis using cDNA arrays was performed in right appendage biopsies from obese patients ( n = 5), from patients with arterial hypertension with ( n = 5) or without obesity ( n = 5), and from 5 leans. All biopsies came from patients that had cardiac surgery and coronary bypass. Statistical analysis of the data revealed 2686 differentially expressed genes out of 11,500 when compared with lean tissues. Differential expression was verified by real-time PCR in 84% of 50 randomly chosen genes. Among genes encountered, 397 were specifically regulated in obese, 1,299 in non-obese hypertensive, and 355 in obese hypertensive patients, respectively, whereas an additional set of 153 genes was differentially expressed in all these situations. Ontology analysis, hierarchical clustering, and molecular pathway analysis indicated that the heart molecular picture of obesity differs clearly from that observed for obesity-related hypertension or arterial hypertension. Clearly, the Wnt pathway known to be involved in cardiac hypertrophy mechanisms, showed opposite regulation in obese heart compared with hypertensive heart and potentially prevented the development of cardiac remodeling in obese patients. All over, this work shows that uncomplicated obesity has a strong impact on cardiac gene expression, which could be considered as precursor signs for future cardiac disease and also demonstrates that obesity-related hypertension generates a heart-molecular-distinct phenotype that cannot be predicted by a simple sum of the impact of obesity and arterial hypertension on gene expression.	Univ Toulouse 3, Ctr Hosp Univ Toulouse, Inst Louis Bugnard,Fac Med,Unite Rech Obes, Lab Pharmacol Med & Clin,INSERM,U586, F-31073 Toulouse, France; Toulouse Univ Hosp, Dept Cardiovasc Surg, Toulouse, France; Toulouse Univ Hosp, Dept Cardiol, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; CHU de Toulouse	Rouet, P (corresponding author), Univ Toulouse 3, Ctr Hosp Univ Toulouse, Inst Louis Bugnard,Fac Med,Unite Rech Obes, Lab Pharmacol Med & Clin,INSERM,U586, 37 Allees Jules Guesde, F-31073 Toulouse, France.	Philippe.rouet@toulouse.inserm.fr	Pathak, Atul/ABC-5223-2020; Pathak, Atul/E-7532-2010	Pathak, Atul/0000-0001-6151-0096; GALINIER, Michel/0000-0003-1735-3390; Senard, Jean-Michel/0000-0001-7679-1281; Rouet, Philippe/0000-0001-6204-2079				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Barrans JD, 2001, BIOCHEM BIOPH RES CO, V280, P964, DOI 10.1006/bbrc.2000.4137; Boheler KR, 2003, P NATL ACAD SCI USA, V100, P2754, DOI 10.1073/pnas.0436564100; BURT DW, 1992, BIOCHEM BIOPH RES CO, V187, P1298, DOI 10.1016/0006-291X(92)90444-P; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; Galinier M, 2000, EUR HEART J, V21, P475, DOI 10.1053/euhj.1999.1875; Gerhold D, 2001, PHYSIOL GENOMICS, V5, P161, DOI 10.1152/physiolgenomics.2001.5.4.161; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Henriksen PA, 2002, CARDIOVASC RES, V54, P16, DOI 10.1016/S0008-6363(01)00516-8; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Itoh M, 2002, HEART VESSELS, V17, P36, DOI 10.1007/s003800200040; Karason K, 1999, AM J CARDIOL, V83, P1242, DOI 10.1016/S0002-9149(99)00066-1; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Kikuya M, 2000, HYPERTENSION, V36, P901, DOI 10.1161/01.HYP.36.5.901; La Rovere MT, 1998, LANCET, V351, P478; Lukas A, 2003, EUR J CLIN INVEST, V33, P223, DOI 10.1046/j.1365-2362.2003.01139.x; MacKenna D, 2000, CARDIOVASC RES, V46, P257, DOI 10.1016/S0008-6363(00)00030-4; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100; O'Brien PE, 2002, AM J SURG, V184, p4S, DOI 10.1016/S0002-9610(02)01172-8; Paoni NF, 2001, TRENDS CARDIOVAS MED, V11, P218, DOI 10.1016/S1050-1738(01)00110-4; Pelat M, 1999, HYPERTENSION, V34, P1066, DOI 10.1161/01.HYP.34.5.1066; Philip-Couderc P, 2003, HYPERTENSION, V41, P414, DOI 10.1161/01.HYP.0000057573.32425.95; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Ross RS, 2002, J CARD FAIL, V8, pS326, DOI 10.1054/jcaf.2002.129263; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; SAYE JA, 1989, AM J PHYSIOL, V256, pC448, DOI 10.1152/ajpcell.1989.256.2.C448; Shen BJ, 2003, AM J EPIDEMIOL, V157, P701, DOI 10.1093/aje/kwg045; Tan FL, 2002, P NATL ACAD SCI USA, V99, P11387, DOI 10.1073/pnas.162370099; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Verwaerde P, 1999, J HYPERTENS, V17, P1135, DOI 10.1097/00004872-199917080-00013	39	18	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1539	+		10.1096/fj.03-1242fje	http://dx.doi.org/10.1096/fj.03-1242fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289443				2022-12-28	WOS:000223554900025
J	Donnes, P; Hoglund, A; Sturm, M; Comtesse, N; Backes, C; Meese, E; Kohlbacher, O; Lenhof, HP				Donnes, P; Hoglund, A; Sturm, M; Comtesse, N; Backes, C; Meese, E; Kohlbacher, O; Lenhof, HP			Integrative analysis of cancer-related data using CAP	FASEB JOURNAL			English	Article						cancer-associated protein database; overexpression	HUMAN PROTEIN FUNCTION; HIGH EXPRESSION; TUMOR-ANTIGENS; GENE; PREDICTION; MENINGIOMA; RESPONSES	The development of human cancer is a highly complex process and can be considered the result of several combined events, such as genetic alterations, disturbance of signal transduction, or failure of immunological surveillance. Cancer-related databases usually focus on specific fields of research, e. g., cancer genetics or cancer immunology, whereas the complexity of cancer genesis requires an integrated analysis of heterogeneous data from several sources. Here we present the cancer-associated protein database (CAP), a novel analysis system for cancer-related data. CAP integrates data from multiple external databases, augments these data with functional annotations, and offers tools for statistical analysis of these data. We have employed CAP to analyze genes that have been found to cause an autoimmune response in cancer. In particular, we explored the connection between the autoimmune response, mutations, and overexpression of these genes. Our preliminary results suggest that mutations are not significant contributors to raising an antibody response against tumor antigens, whereas overexpression seems to play a more important role. We hereby demonstrate how different types of data can be integrated and analyzed successfully, providing interesting results. As the amount of available data is growing rapidly, a combined analysis will play an important role in exploring the genetic and immunological basis of cancer. CAP is freely available at the following web site: http://www.bioinf.uni-sb.de/CAP/.	Univ Tubingen, Dept Simulat Biol Syst, D-72076 Tubingen, Germany; Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany; Univ Saarland, Inst Human Genet, D-66421 Homburg, Germany; Univ Tubingen, Dept Simulat Biol Syst, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Saarland University; Saarland University; Eberhard Karls University of Tubingen	Kohlbacher, O (corresponding author), Univ Tubingen, Dept Simulat Biol Syst, Sand 14, D-72076 Tubingen, Germany.	oliver.kohlbacher@uni-tuebingen.de	Kohlbacher, Oliver/B-7310-2008; Meese, Eckart Ulrich/ABD-1983-2021; Kohlbacher, Oliver/AAF-3297-2021	Kohlbacher, Oliver/0000-0003-1739-4598; Kohlbacher, Oliver/0000-0003-1739-4598; Sturm, Marc/0000-0002-6552-8362; Donnes, Pierre/0000-0002-4613-2952				Angelopoulou K, 2000, CLIN BIOCHEM, V33, P53, DOI 10.1016/S0009-9120(99)00084-3; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Bayani J, 2002, CANCER RES, V62, P3466; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brass N, 1999, BLOOD, V93, P2158, DOI 10.1182/blood.V93.7.2158.407a34_2158_2166; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; Buckingham S, 2004, NATURE, V428, P774, DOI 10.1038/428774a; Cheng L, 1999, INT J CANCER, V84, P220, DOI 10.1002/(SICI)1097-0215(19990621)84:3<220::AID-IJC4>3.0.CO;2-S; Cheung KH, 1998, BIOINFORMATICS, V14, P486, DOI 10.1093/bioinformatics/14.6.486; Comtesse N, 2002, ONCOGENE, V21, P239, DOI 10.1038/sj/onc/1205005; Comtesse N, 1999, CLIN CANCER RES, V5, P3560; Diesinger I, 2002, INT J CANCER, V102, P372, DOI 10.1002/ijc.10714; Donnes P, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-25; Fischer U, 2001, CLIN EXP IMMUNOL, V126, P206, DOI 10.1046/j.1365-2249.2001.01635.x; Hazan C, 2002, CANCER, V95, P634, DOI 10.1002/cncr.10685; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Henrique R, 2000, J AM ACAD DERMATOL, V43, P991, DOI 10.1067/mjd.2000.109282; Hua SJ, 2001, BIOINFORMATICS, V17, P721, DOI 10.1093/bioinformatics/17.8.721; Jensen LJ, 2003, BIOINFORMATICS, V19, P635, DOI 10.1093/bioinformatics/btg036; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; Meese E, 2002, GENE CHROMOSOME CANC, V33, P107, DOI 10.1002/gcc.1224; Mitrunen K, 2003, MUTAT RES-REV MUTAT, V544, P9, DOI 10.1016/S1383-5742(03)00016-4; Monz D, 2001, CLIN CANCER RES, V7, P113; Nair R, 2002, PROTEIN SCI, V11, P2836, DOI 10.1110/ps.0207402; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nishie A, 2001, CLIN CANCER RES, V7, P2145; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rumbaugh J, 1999, UNIFIED MODELLING LA; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Soussi T, 2000, CANCER RES, V60, P1777; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; Zhou Y, 2003, CANCER RES, V63, P5781	35	7	7	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1465	+		10.1096/fj.04-1797fje	http://dx.doi.org/10.1096/fj.04-1797fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231723				2022-12-28	WOS:000222979200015
J	Baron, RM; Carvajal, IM; Fredenburgh, LE; Liu, XL; Porrata, Y; Cullivan, ML; Haley, KJ; Sonna, LA; De Sanctis, GT; Ingenito, EP; Perrella, MA				Baron, RM; Carvajal, IM; Fredenburgh, LE; Liu, XL; Porrata, Y; Cullivan, ML; Haley, KJ; Sonna, LA; De Sanctis, GT; Ingenito, EP; Perrella, MA			Nitric oxide synthase-2 down-regulates surfactant protein-B expression and enhances endotoxin-induced lung injury in mice	FASEB JOURNAL			English	Article						acute respiratory distress syndrome; inflammation; cytokines; gene transcription; LPS	RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR MACROPHAGES; EPITHELIAL-CELLS; GENE-EXPRESSION; MOUSE; DYSFUNCTION; SEPSIS; ARDS	Acute respiratory distress syndrome ( ARDS) is a life-threatening ailment characterized by severe lung injury involving inflammatory cell recruitment to the lung, cytokine production, surfactant dysfunction, and up-regulation of nitric oxide synthase 2 (NOS2) resulting in nitric oxide ( NO) production. We hypothesized that NO production from NOS2 expressed in lung parenchymal cells in a murine model of ARDS would correlate with abnormal surfactant function and reduced surfactant protein-B (SP-B) expression. Pulmonary responses to nebulized endotoxin (lipopolysaccharide, LPS) were evaluated in wild-type (WT) mice, NOS2 null (-/-) mice, and NOS2-chimeric animals derived from bone marrow transplantation. NOS2(-/-) animals exhibited significantly less physiologic lung dysfunction and loss of SP-B expression than did WT animals. However, lung neutrophil recruitment and bronchoalveolar lavage cytokine levels did not significantly differ between NOS2(-/-) and WT animals. Chimeric animals for NOS2 exhibited the phenotype of the recipient and therefore demonstrated that parenchymal production of NOS2 is critical for the development of LPS-induced lung injury. Furthermore, administration of NO donors, independent of cytokine stimulation, decreased SP-B promoter activity and mRNA expression in mouse lung epithelial cells. This study demonstrates that expression of NOS2 in lung epithelial cells is critical for the development of lung injury and mediates surfactant dysfunction independent of NOS2 inflammatory cell expression and cytokine production.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; USA, Environm Med Res Inst, Thermal & Mt Med Div, Natick, MA 01760 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu		Liu, Xiaoli/0000-0003-2904-4413	NHLBI NIH HHS [HL60788] Funding Source: Medline; NIAID NIH HHS [AI054465] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI054465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIRKHANIAN JD, 1993, BIOCHIM BIOPHYS ACTA, V1168, P315, DOI 10.1016/0005-2760(93)90188-F; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bhandari V, 2003, FRONT BIOSCI-LANDMRK, V8, pE361, DOI 10.2741/1086; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; CIFUENTES J, 1995, J APPL PHYSIOL, V78, P1800, DOI 10.1152/jappl.1995.78.5.1800; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Frank JA, 2003, CRIT CARE, V7, P233, DOI 10.1186/cc1829; GODLESKI JJ, 1972, J EXP MED, V136, P630, DOI 10.1084/jem.136.3.630; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; Hallman M, 1996, SEMIN PERINATOL, V20, P173, DOI 10.1016/S0146-0005(96)80046-2; Hallman M, 1996, J APPL PHYSIOL, V80, P2035, DOI 10.1152/jappl.1996.80.6.2035; HEFFNER JE, 1989, AM REV RESPIR DIS, V140, P531, DOI 10.1164/ajrccm/140.2.531; Hickey MJ, 2002, FASEB J, V16, P1141, DOI 10.1096/fj.01-0764fje; Ingenito EP, 1999, J APPL PHYSIOL, V86, P1702, DOI 10.1152/jappl.1999.86.5.1702; Ingenito EP, 2001, AM J RESP CELL MOL, V25, P35, DOI 10.1165/ajrcmb.25.1.4021; Kobayashi A, 1998, CHEST, V113, P1632, DOI 10.1378/chest.113.6.1632; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Kristof AS, 1998, AM J RESP CRIT CARE, V158, P1883, DOI 10.1164/ajrccm.158.6.9802100; Layne MD, 2001, FASEB J, V15, P2733, DOI 10.1096/fj.01-0374fje; LUTCHEN KR, 1993, J APPL PHYSIOL, V75, P478, DOI 10.1152/jappl.1993.75.1.478; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mark L, 1999, AM J PHYSIOL-LUNG C, V276, pL491, DOI 10.1152/ajplung.1999.276.3.L491; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; POSSMAYER F, 1990, AM REV RESPIR DIS, V142, P749, DOI 10.1164/ajrccm/142.4.749; Pryhuber GS, 1996, AM J PHYSIOL-LUNG C, V270, pL714, DOI 10.1152/ajplung.1996.270.5.L714; Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B; Salinas D, 2003, AM J PHYSIOL-LUNG C, V285, pL1153, DOI 10.1152/ajplung.00084.2003; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; Shanley TP, 2002, CRIT CARE MED, V30, P1960, DOI 10.1097/00003246-200209000-00003; Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187; VASANTHI VR, 2002, AM J PHYSIOL-LUNG C, V282, pL872; Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017; Wang LF, 2001, BIOCHEM BIOPH RES CO, V283, P694, DOI 10.1006/bbrc.2001.4842; Wang ZD, 1998, AM J RESP CRIT CARE, V158, P28, DOI 10.1164/ajrccm.158.1.9709041; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029	40	25	29	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1276	+		10.1096/fj.04-1518fje	http://dx.doi.org/10.1096/fj.04-1518fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208261				2022-12-28	WOS:000222327500003
J	Zhu, SY; Tytgat, J				Zhu, SY; Tytgat, J			Evolutionary epitopes of Hsp90 and p23: implications for their interaction	FASEB JOURNAL			English	Article						molecular chaperone; evolutionary tracing; protein-protein interaction; conformational pathway	TERMINAL DOMAIN; ATP HYDROLYSIS; TRACE ANALYSIS; PROTEIN; CHAPERONE; BINDING; COCHAPERONE; SITE; DIMERIZATION; PREDICTION	The amino-terminal domain (N-domain) of Hsp90 represents the ATP binding site and is important for interaction with its cochaperone, p23. Whereas some evidence suggests that p23 may bind to this domain in an ATP-dependent manner and that this process requires the dimerization of two N-domains, the interaction sites between them and the molecular mechanism of coupling these two events to p23 binding remain unsolved. As a first step toward establishing the interaction mechanism, we used the evolutionary tracing (ET) method [Lichtarge, O., Bourne, H. R., and Cohen, F. E. (1996) J. Mol. Biol. 257, 342-358] to identify the putative functional surfaces of Hsp90 and p23, and combined with protein-protein docking techniques, to predict their binding interface. Both evolutionarily privileged surfaces of Hsp90 and p23 identified by ET appear on this putative interface. An analysis of the complex model produced using the ET results combined with available experimental data highlights a putative conformational pathway in the ATP binding domain of Hsp90, where a series of conformational changes transfer the ATP-induced N-domain dimerization signal for the binding of p23. In this pathway, the closure of "lid" may result in reorientation of the helix alpha1 and the following loop (residues 10-27 in yeast Hsp90), which will expose more hydrophobic surface, and thus triggers the dimerization of N-domain.	Catholic Univ Louvain, Toxicol Lab, B-3000 Louvain, Belgium	Universite Catholique Louvain	Tytgat, J (corresponding author), Catholic Univ Louvain, Toxicol Lab, E Van Evenstr 4, B-3000 Louvain, Belgium.	tytgat@pharm.kuleuven.ac.be	Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Courilleau D, 2000, J BIOL CHEM, V275, P17344, DOI 10.1074/jbc.M000887200; Duret L, 1998, GENOME RES, V8, P348, DOI 10.1101/gr.8.4.348; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; Filipek S, 2003, ANNU REV BIOPH BIOM, V32, P375, DOI 10.1146/annurev.biophys.32.110601.142520; Goh CS, 2000, J MOL BIOL, V299, P283, DOI 10.1006/jmbi.2000.3732; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Grotzinger J, 2002, BBA-MOL CELL RES, V1592, P215, DOI 10.1016/S0167-4889(02)00316-6; Innis CA, 2000, PROTEIN ENG, V13, P839, DOI 10.1093/protein/13.12.839; Krebs WG, 2002, PROTEINS, V48, P682, DOI 10.1002/prot.10168; KUMAR S, 2001, MEGA2 MOL EVOLUTIONA; Lichtarge O, 2002, CURR OPIN STRUC BIOL, V12, P21, DOI 10.1016/S0959-440X(02)00284-1; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Morelli X, 2000, J BIOL CHEM, V275, P23204, DOI 10.1074/jbc.M909835199; Nollen EAA, 2002, J CELL SCI, V115, P2809; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Oxelmark E, 2003, J BIOL CHEM, V278, P36547, DOI 10.1074/jbc.M305960200; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Smith GR, 2002, CURR OPIN STRUC BIOL, V12, P28, DOI 10.1016/S0959-440X(02)00285-3; Soldano KL, 2003, J BIOL CHEM, V278, P48330, DOI 10.1074/jbc.M308661200; Sowa ME, 2000, P NATL ACAD SCI USA, V97, P1483, DOI 10.1073/pnas.030409597; Sowa ME, 2001, NAT STRUCT BIOL, V8, P234, DOI 10.1038/84974; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhu SY, 2004, PROTEINS, V54, P361, DOI 10.1002/prot.10588	41	22	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					940	947		10.1096/fj.04-1570hyp	http://dx.doi.org/10.1096/fj.04-1570hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15173105				2022-12-28	WOS:000222327500011
J	Flogel, U; Godecke, A; Klotz, LO; Schrader, J				Flogel, U; Godecke, A; Klotz, LO; Schrader, J			Role of myoglobin in the antioxidant defense of the heart	FASEB JOURNAL			English	Article						reactive oxygen species; reperfusion; ischemia; cardiac function and energetics	ISCHEMIA-REPERFUSION INJURY; SPERM-WHALE MYOGLOBIN; NITRIC-OXIDE; HYDROGEN-PEROXIDE; CREATINE-KINASE; FREE-RADICALS; MYOCARDIAL-ISCHEMIA; ENZYMATIC FUNCTION; MICE; SUPEROXIDE	Although the primary function of myoglobin (Mb) has been considered to be cellular O-2 storage and supply, recent studies have shown that Mb in addition can act as NO oxidase. Here we report that Mb also significantly contributes to the attenuation of oxidative stress in cardiac muscle. In support of this hypothesis, we found that in isolated perfused hearts of Mb-deficient (myo(-/-)) mice oxidative challenge by intracoronary infused H2O2 ( 1- 300 muM) or superoxide formed by 2,3-dimethoxy-1,4-naphtoquinone (0.1-30 muM), respectively, depressed cardiac contractility to a greater extent than in wild-type (WT) hearts, e.g., up to [H2O2] = 10 muM there was a significant left ventricular developed pressure ( LVDP) decrease in myo(-/-) hearts only (90.4 +/- 4.2 vs. 98.1 +/- 0.7% of control, n=6, P< 0.05). Likewise in an ischemia/reperfusion protocol, myo-/- hearts showed a delayed recovery of postischemic function as compared with WT controls (e.g., LVDP was 35.6 +/- 7.5 vs. 22.4 +/- 5.3 mmHg, respectively, after 10 min of reperfusion, P< 0.05, n=8), which correlated well with an enhanced release of reactive oxygen species in myo-/- hearts as measured by online lucigenin-enhanced chemiluminescence [e.g. 465 +/- 87 relative light units (RLU) in myo(-/-) vs. 287 +/- 73 RLU in WT after 2.5 min of reperfusion, P< 0.05, n=8]. P-31 NMR spectroscopy revealed concomitantly a more pronounced phosphocreatine overshoot during reperfusion in the knockout but only minute alterations in ATP and pH(i). Our data show that lack of Mb leads to increased vulnerability of cardiac function to oxidative challenge either pharmacologically induced or endogenously generated. We propose that Mb is a key element influencing redox pathways in cardiac muscle to functionally and metabolically protect the heart from oxidative damage.	Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Flogel, U (corresponding author), Univ Dusseldorf, Inst Herz & Kreislaufphysiol, Univ Str 1, D-40225 Dusseldorf, Germany.	floegel@uni-duesseldorf.de	Klotz, Lars Oliver/AAC-5051-2019	Klotz, Lars Oliver/0000-0002-1261-8911				Alayash AI, 1999, J BIOL CHEM, V274, P2029, DOI 10.1074/jbc.274.4.2029; Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; ALLENTOFF AJ, 1992, J AM CHEM SOC, V114, P9744, DOI 10.1021/ja00051a003; ARDUINI A, 1990, FREE RADICAL BIO MED, V9, P511, DOI 10.1016/0891-5849(90)90130-B; ARDUINI A, 1991, OXIDATIVE DAMAGE REP, P406; BANERJEE A, 1991, AM J PHYSIOL, V261, pH590, DOI 10.1152/ajpheart.1991.261.2.H590; BROWN JM, 1989, SURGERY, V105, P496; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; FERRARI R, 1991, AM J CLIN NUTR, V53, pS215, DOI 10.1093/ajcn/53.1.215S; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; Flogel U, 1999, J MOL CELL CARDIOL, V31, P827, DOI 10.1006/jmcc.1998.0921; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; Garry DJ, 2003, TRENDS CARDIOVAS MED, V13, P111, DOI 10.1016/S1050-1738(02)00256-6; Garry DJ, 1998, NATURE, V395, P905, DOI 10.1038/27681; GEORGE P, 1951, NATURE, V168, P164, DOI 10.1038/168164b0; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200; Gunther MR, 1999, FREE RADICAL BIO MED, V26, P1388, DOI 10.1016/S0891-5849(98)00338-4; GUYTON GP, 1995, J APPL PHYSIOL, V79, P1148, DOI 10.1152/jappl.1995.79.4.1148; HAGLER L, 1979, J BIOL CHEM, V254, P6505; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; ICHIHARA K, 1984, AM HEART J, V108, P1594, DOI 10.1016/0002-8703(84)90735-X; KAPLAN LJ, 1993, J SURG RES, V54, P311, DOI 10.1006/jsre.1993.1049; Kaplan LJ, 1996, J SURG RES, V62, P103, DOI 10.1006/jsre.1996.0181; Kobert R, 1900, ARCH GESAMTE PHYSIOL, V82, P603, DOI 10.1007/BF01795645; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LIVINGSTON DJ, 1985, J BIOL CHEM, V260, P5699; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Meeson AP, 2001, CIRC RES, V88, P713, DOI 10.1161/hh0701.089753; Merx Marc W., 2001, FASEB Journal, V15, P1077; Moller JKS, 2002, CHEM REV, V102, P1167, DOI 10.1021/cr000078y; Moore KP, 1998, J BIOL CHEM, V273, P31731, DOI 10.1074/jbc.273.48.31731; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916; Schenkman KA, 1997, J APPL PHYSIOL, V82, P86, DOI 10.1152/jappl.1997.82.1.86; Schlieper G, 2004, AM J PHYSIOL-REG I, V286, pR786, DOI 10.1152/ajpregu.00043.2003; SHI MM, 1994, J BIOL CHEM, V269, P26512; SIMPSON PJ, 1987, J LAB CLIN MED, V110, P13; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; Wan LL, 1998, P NATL ACAD SCI USA, V95, P12825, DOI 10.1073/pnas.95.22.12825; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WHITBURN KD, 1987, ARCH BIOCHEM BIOPHYS, V253, P419, DOI 10.1016/0003-9861(87)90195-0; WHITBURN KD, 1985, J INORG BIOCHEM, V24, P35, DOI 10.1016/0162-0134(85)85012-1; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Witting PK, 2002, BIOCHEMISTRY-US, V41, P11495, DOI 10.1021/bi025835w; WU H, 1923, J BIOCHEM-TOKYO, V2, P189; Wunderlich C, 2003, CIRC RES, V92, P1352, DOI 10.1161/01.RES.0000079026.70629.E5; Yasmin W, 1997, CARDIOVASC RES, V33, P422, DOI 10.1016/S0008-6363(96)00254-4; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018	62	125	126	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1156	+		10.1096/fj.03-1382fje	http://dx.doi.org/10.1096/fj.03-1382fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132981				2022-12-28	WOS:000221883200016
J	Li, GR; Cui, G; Tzeng, NS; Wei, SJ; Wang, TG; Block, ML; Hong, JS				Li, GR; Cui, G; Tzeng, NS; Wei, SJ; Wang, TG; Block, ML; Hong, JS			Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage	FASEB JOURNAL			English	Article						DM; femtomolar; inflammation; microglia; neuroprotection; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; INJURY FOLLOWING TRANSIENT; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; OPIOID PEPTIDE; FOCAL ISCHEMIA; NADPH OXIDASE; RAT	Inflammation in the brain has increasingly been recognized to play an important role in the pathogenesis of several neuro degenerative disorders, including Parkinson's disease (PD). Progress in the search for effective therapeutic strategies that can halt this degenerative process remains limited. We previously showed that micromolar concentrations of dextromethorphan (DM), a major ingredient of widely used antitussive remedies, reduced the inflammation-mediated degeneration of dopaminergic neurons through the inhibition of microglial activation. In this study, we report that femto- and micromolar concentrations of DM (both pre- and post-treatment) showed equal efficacy in protecting lipopolysaccharide (LPS)-induced dopaminergic neuron death in midbrain neuron-glia cultures. Both concentrations of DM decreased LPS-induced release of nitric oxide, tumor necrosis factor-alpha, prostaglandin E-2 and superoxide from microglia in comparable degrees. The important role of superoxide was demonstrated by DM's failure to show a neuroprotective effect in neuron-glia cultures from NADPH oxidase-deficient mice. These results suggest that the neuroprotective effect elicited by femtomolar concentrations of DM is mediated through the inhibition of LPS-induced proinflammatory factors, especially superoxide. These findings suggest a novel therapeutic concept of using "ultra-low" drug concentrations for the intervention of inflammation-related neurodegenerative diseases.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Natl Ctr Toxicogenom, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Chapel Hill, NC USA; Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Psychiat, Taipei, Taiwan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; National Defense Medical Center; Tri-Service General Hospital	Li, GR (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233,MD-F1-01 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	guorongl@med.unc.edu; hong3@niehs.nih.gov	Tzeng, Nian-Sheng/AAU-4945-2021; Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Wei, Sung Jen/0000-0002-9810-9041; Block, Michelle/0000-0001-8303-7914	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101411] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BASKIN DS, 1984, NATURE, V312, P551, DOI 10.1038/312551a0; Britton P, 1997, LIFE SCI, V60, P1729, DOI 10.1016/S0024-3205(97)00132-X; Christensen ST, 1996, CELL BIOL INT, V20, P437, DOI 10.1006/cbir.1996.0055; Crain SM, 2001, BRAIN RES, V888, P75, DOI 10.1016/S0006-8993(00)03010-9; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; EFANOV AM, 1994, FEBS LETT, V355, P114, DOI 10.1016/0014-5793(94)01109-5; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GATLEY SJ, 1976, BIOCHEM J, V158, P307, DOI 10.1042/bj1580307; GEORGE CP, 1988, BRAIN RES, V440, P375, DOI 10.1016/0006-8993(88)91011-6; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Hayashi T, 2002, SYNAPSE, V43, P86, DOI 10.1002/syn.10019; Jenner P, 1996, PATHOL BIOL, V44, P57; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; KUTTAN SC, 1991, J CARDIOVASC PHARM, V17, P929, DOI 10.1097/00005344-199106000-00011; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2001, J PHARMACOL EXP THER, V298, P1133; Liu J, 2001, LIFE SCI, V69, P1833, DOI 10.1016/S0024-3205(01)01267-X; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MONYER H, 1988, BRAIN RES, V446, P144, DOI 10.1016/0006-8993(88)91304-2; PRINCE DA, 1988, NEUROSCI LETT, V85, P291, DOI 10.1016/0304-3940(88)90581-2; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; RAMESHWAR P, 1993, J IMMUNOL, V151, P2484; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Sharp BM, 1998, BIOCHEM PHARMACOL, V56, P289, DOI 10.1016/S0006-2952(98)00155-5; Souza HP, 2001, AM J PHYSIOL-HEART C, V280, pH658, DOI 10.1152/ajpheart.2001.280.2.H658; STEINBERG GK, 1988, STROKE, V19, P1112, DOI 10.1161/01.STR.19.9.1112; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; Yoshida LS, 1998, J BIOL CHEM, V273, P27879, DOI 10.1074/jbc.273.43.27879	37	65	72	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					489	496		10.1096/fj.04-2555com	http://dx.doi.org/10.1096/fj.04-2555com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15790998				2022-12-28	WOS:000228865300032
J	Zhang, W; Wang, TG; Pei, Z; Miller, DS; Wu, XF; Block, ML; Wilson, B; Zhang, WQ; Zhou, Y; Hong, JS; Zhang, J				Zhang, W; Wang, TG; Pei, Z; Miller, DS; Wu, XF; Block, ML; Wilson, B; Zhang, WQ; Zhou, Y; Hong, JS; Zhang, J			Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease	FASEB JOURNAL			English	Article						microglia; phagocytosis; innate immunity; aging; oxidative stress; protein aggregation; inflammation	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; ROTENONE-INDUCED DEGENERATION; NIGRAL DOPAMINERGIC-NEURONS; NADPH OXIDASE; NEURODEGENERATIVE DISEASES; MESENCEPHALIC NEURONS; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; MOUSE MODEL; MUTATION	A growing body of evidence indicates that an inflammatory process in the substantia nigra, characterized by activation of resident microglia, likely either initiates or aggravates nigral neurodegeneration in Parkinson's disease (PD). To study the mechanisms by which nigral microglia are activated in PD, the potential role of alpha-synuclein (a major component of Lewy bodies that can cause neurodegeneration when aggregated) in microglial activation was investigated. The results demonstrated that in a primary mesencephalic neuron-glia culture system, extracellular aggregated human alpha-synuclein indeed activated microglia; microglial activation enhanced dopaminergic neurodegeneration induced by aggregated alpha-synuclein. Furthermore, microglial enhancement of alpha-synuclein-mediated neurotoxicity depended on phagocytosis of alpha-synuclein and activation of NADPH oxidase with production of reactive oxygen species. These results suggest that nigral neuronal damage, regardless of etiology, may release aggregated alpha-synuclein into substantia nigra, which activates microglia with production of proinflammatory mediators, thereby leading to persistent and progressive nigral neuro degeneration in PD. Finally, NADPH oxidase could be an ideal target for potential pharmaceutical intervention, given that it plays a critical role in alpha-synuclein-mediated microglial activation and associated neurotoxicity.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China; Dalian Med Univ, Clin Hosp 1, Dept Neurol, Dalian, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Dalian Medical University; Dalian Medical University	Zhang, J (corresponding author), Univ Washington, Sch Med, Harborview Med Ctr, Div Neuropathol, 703C Res & Training Bldg,Campus Box 359635,325 9t, Seattle, WA 98104 USA.	zhangj@u.washington.edu	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090082, Z01ES080048, ZIAES080048, ZIAES090082] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Aimi Y, 1996, Parkinsonism Relat Disord, V2, P69, DOI 10.1016/1353-8020(96)00004-1; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BLOCK ML, 2004, IN PRESS FASEB J; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cunningham LA, 2002, EXP NEUROL, V174, P230, DOI 10.1006/exnr.2002.7877; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Eikelenboom P, 2004, J NEURAL TRANSM, V111, P281, DOI 10.1007/s00702-003-0055-1; Elkon H, 2002, J MOL NEUROSCI, V18, P229, DOI 10.1385/JMN:18:3:229; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kordower JH, 2003, ANN NEUROL, V53, pS120, DOI 10.1002/ana.10485; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; LOWE JS, 2002, GREENFIELDS NEUROPAT, V2, P325; McGeer PL, 2002, NEUROSCI LETT, V326, P67, DOI 10.1016/S0304-3940(02)00300-2; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; Mirza B, 2000, NEUROSCIENCE, V95, P425; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Sulzer D, 2001, NAT MED, V7, P1280, DOI 10.1038/nm1201-1280; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; YAMADA T, 1992, ACTA NEUROPATHOL, V84, P100, DOI 10.1007/BF00427222; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	49	876	911	2	68	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					533	542		10.1096/fj.04-2751com	http://dx.doi.org/10.1096/fj.04-2751com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791003				2022-12-28	WOS:000228865300037
J	Baczko, I; Jones, L; McGuigan, CF; Fox, JEM; Gandhi, M; Giles, WR; Clanachan, AS; Light, PE				Baczko, I; Jones, L; McGuigan, CF; Fox, JEM; Gandhi, M; Giles, WR; Clanachan, AS; Light, PE			Plasma-membrane K-ATP channel-mediated cardioprotection involves posthypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia	FASEB JOURNAL			English	Article						ischemia/reperfusion; plasma membrane ATP-sensitive potassium channel; Na+/Ca2+ exchanger; diastolic [Ca2+](i); potassium channel opener	SENSITIVE POTASSIUM CHANNELS; NA+/CA2+ EXCHANGER; RAT HEARTS; VENTRICULAR MYOCYTES; METABOLIC INHIBITION; CARDIAC MYOCYTES; BETA-OXIDATION; CA2+ OVERLOAD; DIAZOXIDE; ACTIVATION	Our recent data demonstrate that activation of pmK(ATP) channels polarizes the membrane of cardiornyocytes and reduces Na+/Ca2+ exchange-mediated Ca2+ overload. However, it is important that these findings be extended into contractile models of hypoxia/reoxygenation injury to further test the notion that pmK(ATP) channel activation affords protection against contractile dysfunction and calcium overload. Single rat heart right ventricular myocytes were enzymatically isolated, and cell contractility and Ca2+ transients in field-stimulated myocytes were measured in a cellular model of metabolic inhibition and reoxygenation. Activation of pmK(ATP) with P-1075 (5 mu M) or inhibition of the Na+/Ca2+ exchanger with KB-R7943 (5 mu M) reduced reoxygenation-induced diastolic Ca2+ overload and improved the rate and magnitude of posthypoxic contractile recovery during the first few minutes of reoxygenation. Moreover, diastolic Ca2+ overload and posthypoxic contractile dysfunction were aggravated in ventricular myocytes either subjected to specific blockade of pmK(ATP) with HMR1098 (20 mu M) or expressing the dominant-negative pmK(ATP) construct Kir6.2(AAA) in the presence of P-1075. Our results suggest that a common mechanism, involving resting membrane potential-modulated increases in diastolic [Ca2+](i), is responsible for the development of contractile dysfunction during reoxygenation following metabolic inhibition. This novel and highly plausible cellular mechanism for pmK(ATP)-mediated cardioprotection may have direct clinical relevance as evidenced by the following findings: a hypokalemic polarizing cardioplegia solution supplemented with the pmK(ATP) opener P-1075 improved Ca2+ homeostasis and recovery of function compared with hyperkalemic depolarizing St. Thomas' cardioplegia following contractile arrest in single ventricular myocytes and working rat hearts. We therefore propose that activation of pmK(ATP) channels improves posthypoxic cardiac function via reductions in abnormal diastolic Ca2+ homeostasis mediated by reverse-mode Na+/Ca2+ exchange.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada; UCSD, Dept Bioengn, La Jolla, CA USA	University of Alberta; University of Calgary; University of California System; University of California San Diego	Light, PE (corresponding author), Univ Alberta, Dept Pharmacol, 9-58 Med Sci, Edmonton, AB T6G 2H7, Canada.	peter.light@ualberta.ca	Baczko, István/I-7752-2019	Baczko, István/0000-0002-9588-0797				Baczko I, 2004, BRIT J PHARMACOL, V141, P1059, DOI 10.1038/sj.bjp.0705702; Baczko I, 2003, J PHYSIOL-LONDON, V550, P889, DOI 10.1113/jphysiol.2003.043372; Baumann P, 2002, AM J PHYSIOL-HEART C, V283, pH2296, DOI 10.1152/ajpheart.00393.2002; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; BOUCHARD RA, 1993, J PHYSIOL-LONDON, V472, P391, DOI 10.1113/jphysiol.1993.sp019953; Chambers DJ, 1999, ANN THORAC SURG, V68, P1960, DOI 10.1016/S0003-4975(99)01020-6; Cohen MV, 1996, ANNU REV MED, V47, P21, DOI 10.1146/annurev.med.47.1.21; COHEN NM, 1995, ANN THORAC SURG, V60, P858, DOI 10.1016/0003-4975(95)00210-C; COLE WC, 1991, CIRC RES, V69, P571, DOI 10.1161/01.RES.69.3.571; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Dobson GP, 2004, J THORAC CARDIOV SUR, V127, P794, DOI 10.1016/S0022-5223(03)01192-9; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Eigel BN, 2001, AM J PHYSIOL-HEART C, V281, pH2184, DOI 10.1152/ajpheart.2001.281.5.H2184; Finegan BA, 2003, ANESTHESIOLOGY, V98, P379, DOI 10.1097/00000542-200302000-00018; Fox JEM, 2005, J CARDIOVASC PHARM, V45, P30, DOI 10.1097/00005344-200501000-00006; Fox JEM, 2002, BRIT J PHARMACOL, V135, P480, DOI 10.1038/sj.bjp.0704455; GALINANES M, 1992, CARDIOVASC RES, V26, P1063, DOI 10.1093/cvr/26.11.1063; Gao WD, 1996, CIRC RES, V78, P455; Gogelein H, 2000, CARDIOVASC DRUG REV, V18, P157; Grimmsmann T, 1998, BRIT J PHARMACOL, V123, P781, DOI 10.1038/sj.bjp.0701663; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Grover GJ, 1995, CARDIOVASC RES, V30, P731; Hanley PJ, 2005, J PHYSIOL-LONDON, V562, P307, DOI 10.1113/jphysiol.2004.073932; Hanley PJ, 2003, J PHYSIOL-LONDON, V547, P387, DOI 10.1113/jphysiol.2002.037044; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; HEARSE DJ, 1995, CARDIOVASC RES, V30, P1; HOSODA H, 1994, ANN THORAC SURG, V58, P1631, DOI 10.1016/0003-4975(94)91649-7; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; Kim SJ, 2001, CIRC RES, V89, P831, DOI 10.1161/hh2101.098547; Kobayashi S, 2004, AM J PHYSIOL-HEART C, V287, pH1072, DOI 10.1152/ajpheart.00133.2004; Lalli MJ, 1998, PFLUG ARCH EUR J PHY, V436, P957, DOI 10.1007/s004240050729; Lawrence CL, 2001, BRIT J PHARMACOL, V134, P535, DOI 10.1038/sj.bjp.0704289; LEUNG JM, 1993, J CARDIAC SURG, V8, P220; Light PE, 2001, FASEB J, V15, P2586, DOI 10.1096/fj.01-0188com; Lin R, 2004, ANN THORAC SURG, V78, P970, DOI 10.1016/j.athoracsur.2004.03.084; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Liu YG, 2001, MOL PHARMACOL, V59, P225, DOI 10.1124/mol.59.2.225; Magee WP, 2003, AM J PHYSIOL-HEART C, V284, pH903, DOI 10.1152/ajpheart.00784.2002; MARBAN E, 1989, CIRCULATION, V80, P17; MCPHERSON CD, 1993, AM J PHYSIOL, V265, pH1809, DOI 10.1152/ajpheart.1993.265.5.H1809; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; Schafer C, 2001, CARDIOVASC RES, V51, P241, DOI 10.1016/S0008-6363(01)00282-6; Shimoni Y, 1998, AM J PHYSIOL-ENDOC M, V275, pE568, DOI 10.1152/ajpendo.1998.275.4.E568; SMALLWOOD JK, 1988, J CARDIOVASC PHARM, V12, P102, DOI 10.1097/00005344-198807000-00014; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Suzuki M, 2003, CIRCULATION, V107, P682, DOI 10.1161/01.CIR.0000055187.67365.81; XU XP, 1993, J PHARMACOL EXP THER, V266, P978; YAO Z, 1994, CIRCULATION, V89, P1768; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	55	29	33	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					980	+		10.1096/fj.04-3008fje	http://dx.doi.org/10.1096/fj.04-3008fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15774423	Green Accepted			2022-12-28	WOS:000227901300015
J	Matarrese, P; Straface, E; Pietraforte, D; Gambardella, L; Vona, R; Maccaglia, A; Minetti, M; Malorni, W				Matarrese, P; Straface, E; Pietraforte, D; Gambardella, L; Vona, R; Maccaglia, A; Minetti, M; Malorni, W			Peroxynitrite induces senescence and apoptosis of red blood cells through the activation of aspartyl and cysteinyl proteases	FASEB JOURNAL			English	Article						erythrocyte; nitric oxide; cell death; aging; oxidative stress	OBSTRUCTIVE PULMONARY-DISEASE; HUMAN-ERYTHROCYTE-MEMBRANE; OXIDATIVE STRESS; NITRIC-OXIDE; PHOSPHATIDYLSERINE EXPOSURE; PHOSPHOLIPID ASYMMETRY; GLYCOPHORIN-A; CYTOPLASMIC DOMAIN; N-ACETYLCYSTEINE; BAND-3	Changes in the oxidative status of erythrocytes can reduce cell lifetime, oxygen transport, and delivery capacity to peripheral tissues and have been associated with a plethora of human diseases. Among reactive oxygen and nitrogen species of importance in red blood cell (RBC) homeostasis, superoxide and nitric oxide radicals play a key role. In the present work, we evaluated subcellular effects induced by peroxynitrite, the product of the fast reaction between superoxide and nitric oxide. Peroxynitrite induced 1) oxidation of oxyhemoglobin to methemoglobin, 2) cytoskeleton rearrangement, 3) ultrastructural alterations, and 4) altered expression of band-3 and decreased expression of glycophorin A. With respect to control cells, this occurred in a significantly higher percentage of human RBC (similar to 40%). The presence of antioxidants inhibited these modifications. Furthermore, besides these senescence-associated changes, other important modifications, absent in control RBC and usually associated with apoptotic cell death, were detected in a small but significant subset of peroxynitrite-exposed RBC (similar to 7%). Active protease cathepsin E and mu-calpain increased; activation of caspase 2 and caspase 3 was detected; and phosphatidylserine externalization, an early marker of apoptosis, was observed. Conversely, inhibition of cathepsin E, mu-calpain, as well as caspase 2 and 3 by specific inhibitors resulted in a significant impairment of erythrocyte "apoptosis." Altogether, these results indicate that peroxynitrite, a milestone of redox-mediated damage in human pathology, can hijack human RBC toward senescence and apoptosis by a mechanism involving both cysteinyl and aspartyl proteases.	Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, I-00161 Rome, Italy; Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Malorni, W (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, Viale Regina Elena 299, I-00161 Rome, Italy.	Malorni@iss.it	Matarrese, Paola/A-4369-2014; Malorni, Walter/G-5874-2016; Pietraforte, Donatella/G-1816-2011; Vona, Rosa/AAL-4747-2021	Vona, Rosa/0000-0003-4501-8661; Pietraforte, Donatella/0000-0001-6370-912X; malorni, walter/0000-0002-1223-7000				Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Bilto YY, 1998, CLIN HEMORHEOL MICRO, V18, P165; Boas FE, 1998, P NATL ACAD SCI USA, V95, P3077, DOI 10.1073/pnas.95.6.3077; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; Bratosin D, 2002, VOX SANG, V83, P307, DOI 10.1111/j.1423-0410.2002.tb05324.x; CAPRARI P, 1995, CHEM-BIOL INTERACT, V94, P243, DOI 10.1016/0009-2797(94)03339-A; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Comporti M, 2002, FREE RADICAL BIO MED, V32, P568, DOI 10.1016/S0891-5849(02)00759-1; CONNOR J, 1994, J BIOL CHEM, V269, P2399; Daugas E, 2001, CELL DEATH DIFFER, V8, P1131, DOI 10.1038/sj.cdd.4400953; de Jong K, 2001, BLOOD, V98, P1577, DOI 10.1182/blood.V98.5.1577; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fiorani M, 2002, FREE RADICAL BIO MED, V32, P64, DOI 10.1016/S0891-5849(01)00762-6; Galli F, 2002, NITRIC OXIDE-BIOL CH, V6, P186, DOI 10.1006/niox.2001.0397; GLASER T, 1994, P NATL ACAD SCI USA, V91, P7879, DOI 10.1073/pnas.91.17.7879; Grant SG, 1997, GENET TEST, V1, P261, DOI 10.1089/gte.1997.1.261; Groves JD, 1999, BIOCHEM SOC T, V27, P917, DOI 10.1042/bst0270917; Grzelak A, 2001, CELL BIOL INT, V25, P1163, DOI 10.1006/cbir.2001.0778; HUGHES HM, 1989, BIOCHEM J, V259, P537, DOI 10.1042/bj2590537; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P451; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kean LS, 2002, EXP HEMATOL, V30, P394, DOI 10.1016/S0301-472X(02)00780-4; Kiefer CR, 2000, CURR OPIN HEMATOL, V7, P113, DOI 10.1097/00062752-200003000-00007; Koppenol S, 1998, BBA-BIOMEMBRANES, V1369, P221, DOI 10.1016/S0005-2736(97)00224-1; Kuypers F A, 1998, Curr Opin Hematol, V5, P122; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; Kyoizumi S, 1998, HUM GENET, V103, P405, DOI 10.1007/s004390050841; Lang F, 2003, PFLUG ARCH EUR J PHY, V447, P121, DOI 10.1007/s00424-003-1150-8; Lang KS, 2002, CELL PHYSIOL BIOCHEM, V12, P365, DOI 10.1159/000067907; Mallozzi C, 1997, FASEB J, V11, P1281, DOI 10.1096/fasebj.11.14.9409547; Malorni W, 2000, FEBS LETT, V468, P125, DOI 10.1016/S0014-5793(00)01187-X; Mandal D, 2003, J BIOL CHEM, V278, P52551, DOI 10.1074/jbc.M306914200; Mandal D, 2002, FEBS LETT, V513, P184, DOI 10.1016/S0014-5793(02)02294-9; Manno S, 2002, P NATL ACAD SCI USA, V99, P1943, DOI 10.1073/pnas.042688399; Manodori AB, 2002, J LAB CLIN MED, V140, P161, DOI 10.1067/mlc.2002.126504; Matarrese P, 2002, AM J PATHOL, V160, P1507, DOI 10.1016/S0002-9440(10)62577-1; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; Mesquita R, 2002, CLIN HEMORHEOL MICRO, V27, P137; MORROT G, 1986, P NATL ACAD SCI USA, V83, P6863, DOI 10.1073/pnas.83.18.6863; Neri M, 2000, ANAL CELL PATHOL, V21, P35, DOI 10.1155/2000/512786; Ohnishi S. T., 1994, MEMBRANE ABNORMALITI, P1; Pagano G, 1998, MED HYPOTHESES, V51, P253, DOI 10.1016/S0306-9877(98)90084-6; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Patel S, 1999, NAT CELL BIOL, V1, P467, DOI 10.1038/70249; Phumala N, 2003, FREE RADICAL RES, V37, P129, DOI 10.1080/1071576031000060607; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Piagnerelli M, 2003, CRIT CARE MED, V31, P2156, DOI 10.1097/01.CCM.0000079608.00875.14; PICCININI G, 1995, MECH AGEING DEV, V78, P15, DOI 10.1016/0047-6374(94)01511-J; Poole J, 2000, BLOOD REV, V14, P31, DOI 10.1054/blre.1999.0124; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; RADI R, 1991, J BIOL CHEM, V266, P4244; Reliene R, 2002, BLOOD, V100, P2208, DOI 10.1182/blood.V100.6.2208.h81802002208_2208_2215; Ristoff E, 2002, J INHERIT METAB DIS, V25, P223, DOI 10.1023/A:1015634032042; Romero N, 1999, ARCH BIOCHEM BIOPHYS, V368, P23, DOI 10.1006/abbi.1999.1272; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Schrier SL, 2002, CURR OPIN HEMATOL, V9, P123, DOI 10.1097/00062752-200203000-00007; Steinberg MH, 2003, ANNU REV MED, V54, P89, DOI 10.1146/annurev.med.54.101601.152439; Straface E, 2002, BIOCHEM BIOPH RES CO, V290, P1393, DOI 10.1006/bbrc.2002.6340; Straface E, 2000, BIOCHEM BIOPH RES CO, V279, P552, DOI 10.1006/bbrc.2000.3981; TANAKA KI, 1976, BIOCHIM BIOPHYS ACTA, V426, P218, DOI 10.1016/0005-2736(76)90333-3; vonRuckmann B, 1997, BBA-BIOMEMBRANES, V1325, P226, DOI 10.1016/S0005-2736(96)00261-1; WALDER JA, 1984, J BIOL CHEM, V259, P238; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Wood BL, 1996, BLOOD, V88, P1873; YAMAMOTO K, 1989, J BIOCHEM-TOKYO, V105, P114, DOI 10.1093/oxfordjournals.jbchem.a122604; Yasin Z, 2003, BLOOD, V102, P365, DOI 10.1182/blood-2002-11-3416	72	91	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					416	+		10.1096/fj.04-2450fje	http://dx.doi.org/10.1096/fj.04-2450fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15650007				2022-12-28	WOS:000226576600022
J	Yam, GHF; Zuber, C; Roth, J				Yam, GHF; Zuber, C; Roth, J			A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder	FASEB JOURNAL			English	Article						chemical chaperone; protein misfolding disease; Fabry disease; alpha-galactosidase A; lysosomes	ALPHA-GALACTOSIDASE; FABRY-DISEASE; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MOLECULAR CHAPERONES; SECRETORY PATHWAY; RESIDUAL ACTIVITY; CRYOULTRAMICROTOMY; MANIFESTATIONS; GLYCOSYLATION	Mutations in proteins that induce misfolding and proteasomal degradation are common causes of inherited diseases. Fabry disease is a lysosomal storage disorder caused by a deficiency of alpha-galactosidase A activity in lysosomes resulting in an accumulation of glycosphingolipid globotriosylceramide (Gb3). Some classical Fabry hemizygotes and all cardiac variants have residual alpha-galactosidase A activity, but the mutant enzymes are unstable. Such mutant enzymes appear to be misfolded, recognized by the ER protein quality control, and degraded before sorting into lysosomes. Hence, correction of the trafficking defect of mutant but catalytically active enzyme into lysosomes would be beneficial for treatment of the disease. Here we show that a nontoxic competitive inhibitor (1-deoxygalactonojirimycin) of alpha-galactosidase A functions as a chemical chaperone by releasing ER-retained mutant enzyme from BiP. The treatment with subinhibitory doses resulted in efficient, long-term lysosomal trafficking of the ER-retained mutant alpha-galactosidase A. Successful clearance of lysosomal Gb3 storage and a near-normal lysosomal phenotype was achieved in human Fabry fibroblasts harboring different types of mutations. Small molecule chemical chaperones will be therapeutically useful for various lysosomal storage disorders as well as for other genetic metabolic disorders caused by mutant but nonetheless catalytically active enzymes.	Univ Zurich, Dept Pathol, Div Cell & Mol Pathol, CH-8091 Zurich, Switzerland	University of Zurich	Roth, J (corresponding author), Univ Zurich, Dept Pathol, Div Cell & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	juergen.roth@usz.ch	Yam, Gary Hin-Fai/ABE-1710-2020					[Anonymous], 2014, METABOLIC MOL BASES; BISHOP DF, 1981, AM J HUM GENET, V33, pA71; Branton MH, 2002, MEDICINE, V81, P122, DOI 10.1097/00005792-200203000-00003; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; ISHII S, 1993, BIOCHEM BIOPH RES CO, V197, P1585, DOI 10.1006/bbrc.1993.2659; Ishii S, 1998, GLYCOCONJUGATE J, V15, P591, DOI 10.1023/A:1006915926732; Kase R, 2000, BBA-MOL BASIS DIS, V1501, P227, DOI 10.1016/S0925-4439(00)00024-7; Kimura K, 2002, BRIT J DERMATOL, V147, P545, DOI 10.1046/j.1365-2133.2002.04902.x; KORNREICH R, 1989, T ASSOC AM PHYSICIAN, V102, P30; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; MacDermot KD, 2001, J MED GENET, V38, P750, DOI 10.1136/jmg.38.11.750; Matsuda J, 2003, P NATL ACAD SCI USA, V100, P15912, DOI 10.1073/pnas.2536657100; MAYES JS, 1981, CLIN CHIM ACTA, V112, P247, DOI 10.1016/0009-8981(81)90384-3; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; ROMEO G, 1975, BIOCHEM GENET, V13, P615, DOI 10.1007/BF00484919; ROTH J, 1989, METHOD CELL BIOL, V31, P513; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; Roth J, 2002, CHEM REV, V102, P285, DOI 10.1021/cr000423j; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; Zuber C, 2000, MOL BIOL CELL, V11, P4227, DOI 10.1091/mbc.11.12.4227	32	124	134	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					12	18		10.1096/fj.04-2375com	http://dx.doi.org/10.1096/fj.04-2375com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629890				2022-12-28	WOS:000226576600037
J	Glaser, T; Perez-Bouza, A; Klein, K; Brustle, O				Glaser, T; Perez-Bouza, A; Klein, K; Brustle, O			Generation of purified oligodendrocyte progenitors from embryonic stem cells	FASEB JOURNAL			English	Article						lineage selection; myelination; neural repair	CENTRAL-NERVOUS-SYSTEM; IN-VITRO DIFFERENTIATION; MYELIN-DEFICIENT RAT; HUMAN SCHWANN-CELLS; NEURAL PRECURSORS; SPINAL-CORD; NUCLEOTIDE 3'-PHOSPHODIESTERASE; MULTIPLE-SCLEROSIS; ADHESION MOLECULE; LINEAGE CELLS	Demyelination is a key component in the pathogenesis of many neurological disorders. Transplantation of myelinating cells may offer a therapeutic approach to restore neurological function in these diseases. Recent findings suggest that pluripotent embryonic stem (ES) cells can serve as an unlimited donor source for neural transplantation. The clinical application of ES cells for myelin repair will depend critically on the ability to enrich oligodendroglial progenitors in high purity. Combining controlled differentiation in the presence of growth factors and genetic lineage selection, we devised a cell culture protocol yielding highly purified oligodendrocyte progenitors. Murine ES cell clones stably transfected with a construct encoding the beta-galactosidase-neomycine phosphotransferase fusion protein (betageo) under control of the 2'3'-cyclic nucleotide 3'-phosphodiesterase (CNP) promoter were differentiated into bipotential glial precursors. Subsequent induction of a CNP-positive stage and selection in neomycine resulted in a homogenous cell population with a pre-oligodendrocyte phenotype. The selected cells continued to proliferate in the presence of FGF-2 and PDGF and, upon growth factor withdrawal, differentiated into mature galactocerebroside (GalC)-positive oligodendrocytes. Transplantation studies in myelin-deficient (md) rats indicate that ES cell-derived oligodendrocyte progenitors generated with this method may serve as an attractive donor source for myelin repair.	Univ Bonn, Med Ctr, Inst Resconstruct Neurobiol, D-53105 Bonn, Germany; Hertie Fdn, D-53105 Bonn, Germany	University of Bonn	Brustle, O (corresponding author), Univ Bonn, Med Ctr, Inst Resconstruct Neurobiol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	brustle@uni-bonn.de						ABNEY ER, 1983, DEV BIOL, V100, P166, DOI 10.1016/0012-1606(83)90207-5; Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; Almazan G, 2001, MICROSC RES TECHNIQ, V52, P753, DOI 10.1002/jemt.1060; Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; BARONVANEVERCOOREN A, 1992, DEV NEUROSCI-BASEL, V14, P73, DOI 10.1159/000111650; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Ben-Hur T, 1998, J NEUROSCI, V18, P5777, DOI 10.1523/jneurosci.18-15-05777.1998; Billon N, 2002, J CELL SCI, V115, P3657, DOI 10.1242/jcs.00049; Blakemore WF, 2000, CELL TRANSPLANT, V9, P289, DOI 10.1177/096368970000900214; BLAKEMORE WF, 1985, J NEUROL SCI, V70, P207, DOI 10.1016/0022-510X(85)90088-7; BLAKEMORE WF, 1977, NATURE, V266, P68, DOI 10.1038/266068a0; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Chandross KJ, 1999, J NEUROSCI, V19, P759, DOI 10.1523/jneurosci.19-02-00759.1999; DAMJANOV I, 1993, INT J DEV BIOL, V37, P39; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; DUBOISDALCQ M, 1987, EMBO J, V6, P2587, DOI 10.1002/j.1460-2075.1987.tb02549.x; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Finley MFA, 1999, J NEUROBIOL, V40, P271, DOI 10.1002/(SICI)1097-4695(19990905)40:3<271::AID-NEU1>3.0.CO;2-C; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Franklin RJM, 1996, EXP NEUROL, V137, P263, DOI 10.1006/exnr.1996.0025; Franklin RJM, 2002, BRAIN RES BULL, V57, P827, DOI 10.1016/S0361-9230(01)00765-1; GALLO V, 1995, J NEUROSCI, V15, P394; Gravel M, 1998, J NEUROSCI RES, V53, P393; Grinspan J, 2002, J NEUROPATH EXP NEUR, V61, P297, DOI 10.1093/jnen/61.4.297; GRINSPAN JB, 1995, J NEUROSCI RES, V41, P540, DOI 10.1002/jnr.490410414; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HARDY R, 1991, DEVELOPMENT, V111, P1061; Honmou O, 1996, J NEUROSCI, V16, P3199; JESSEN KR, 1990, DEVELOPMENT, V109, P91; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KOEPPEN AH, 1988, J NEUROL SCI, V84, P315, DOI 10.1016/0022-510X(88)90135-9; KURIYAMA T, 1990, 6TH P INT CRYOC C, V2, P3; Learish RD, 1999, ANN NEUROL, V46, P716, DOI 10.1002/1531-8249(199911)46:5<716::AID-ANA6>3.0.CO;2-M; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Mujtaba T, 1999, DEV BIOL, V214, P113, DOI 10.1006/dbio.1999.9418; Nagasawa K, 2001, CURR DRUG METAB, V2, P355, DOI 10.2174/1389200013338243; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; REYNOLDS R, 1988, DEVELOPMENT, V102, P409; Rodriguez-Pena A, 1999, J NEUROBIOL, V40, P497, DOI 10.1002/(SICI)1097-4695(19990915)40:4<497::AID-NEU7>3.0.CO;2-#; RUTKOWSKI JL, 1995, NAT MED, V1, P80, DOI 10.1038/nm0195-80; SCHERER SS, 1994, NEURON, V12, P1363, DOI 10.1016/0896-6273(94)90451-0; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Shields SA, 2000, J NEUROSCI RES, V60, P571, DOI 10.1002/(SICI)1097-4547(20000601)60:5<571::AID-JNR1>3.0.CO;2-Q; Stangel M, 2002, PROG NEUROBIOL, V68, P361, DOI 10.1016/S0301-0082(02)00105-3; Svendsen CN, 1999, TRENDS NEUROSCI, V22, P357, DOI 10.1016/S0166-2236(99)01428-9; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; Tucker KL, 1997, NUCLEIC ACIDS RES, V25, P3745, DOI 10.1093/nar/25.18.3745; VANDENBERG LH, 1995, ANN NEUROL, V38, P674, DOI 10.1002/ana.410380419; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; WARRINGTON AE, 1992, J NEUROSCI RES, V33, P338, DOI 10.1002/jnr.490330218; Zhang SC, 1998, J NEUROCYTOL, V27, P475, DOI 10.1023/A:1006953023845; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zorick TS, 1999, DEVELOPMENT, V126, P1397; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	75	62	66	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					112	+		10.1096/fj.04-1931fje	http://dx.doi.org/10.1096/fj.04-1931fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15486057				2022-12-28	WOS:000224849900021
J	Mitra, R; Dharajiya, N; Kumari, L; Varalakshmi, C; Khar, A				Mitra, R; Dharajiya, N; Kumari, L; Varalakshmi, C; Khar, A			Migration of antigen presenting cells from periphery to the peritoneum during an inflammatory response: role of chemokines and cytokines	FASEB JOURNAL			English	Article						APCs; antigen presentation; cellular influx; antitumor activity	DENDRITIC CELLS; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; FUNCTIONAL LIGAND; ORGAN DEVELOPMENT; RAT HISTIOCYTOMA; LYMPH-NODES; TUMOR SITE; LYMPHOTOXIN; EXPRESSION	We demonstrate the migration of antigen presenting cells (APCs), macrophages, and dendritic cells from the subcutaneous site to the peritoneum after they have picked up the antigen, using cell tracking dye. The migration of the APCs is more universal as it was also observed after injection of MethA tumor, DH-5alpha cells, and leishmania parasites, in addition to AK-5 tumor cells. Cellular migration is mediated by several chemokines and cytokines that also induce heavy influx of immune cells into the peritoneum. MIP-3beta secreted by the mesothelial cells is involved in the cellular influx into the peritoneum, whereas IL-12 and IFN-gamma produced by the APCs induced activation of immune cells in the peritoneum. Our results suggest an antigen presentation function for the APCs in the peritoneum as studied by lymphoproliferation assays. These studies indicate antigen presentation function of the activated migratory APCs from the distant subcutaneous site to the peritoneum, suggesting it acts as an important lymphoid organ involved in the enhancement of effector cell function.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Khar, A (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	khar@ccmb.res.in						ABBAS AK, 1998, CELLULAR MOL IMMUNOL, P278; AUSTYN JM, 1988, J EXP MED, V167, P646, DOI 10.1084/jem.167.2.646; BANKS TA, 1995, J IMMUNOL, V155, P1685; Bhaumik S, 2001, EXP CELL RES, V266, P44, DOI 10.1006/excr.2001.5201; Brenan M, 2000, EUR J IMMUNOL, V30, P1527, DOI 10.1002/1521-4141(200006)30:6<1527::AID-IMMU1527>3.0.CO;2-4; CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Gretz JE, 1997, IMMUNOL REV, V156, P11, DOI 10.1111/j.1600-065X.1997.tb00955.x; HENDRIKS HR, 1983, EUR J IMMUNOL, V13, P663, DOI 10.1002/eji.1830130811; Hirao M, 2000, CANCER RES, V60, P2209; IJSSELMUIDEN OE, 1989, J IMMUNOL METHODS, V119, P35, DOI 10.1016/0022-1759(89)90378-5; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717; KHAR A, 1993, INT J ONCOL, V2, P393; KHAR A, 1986, JNCI-J NATL CANCER I, V76, P871; Khar A, 2001, IMMUNOL REV, V184, P244, DOI 10.1034/j.1600-065x.2001.1840122.x; KHAR A, 1990, IN VITRO CELL DEV B, V26, P1024; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; KRIST LFG, 1995, ANAT REC, V241, P163, DOI 10.1002/ar.1092410204; Kubicka U, 1996, SCAND J IMMUNOL, V44, P157, DOI 10.1046/j.1365-3083.1996.d01-297.x; MARIATHASAN S, 1995, J INFLAMM, V45, P72; Matsumoto M, 1997, IMMUNOL REV, V156, P137, DOI 10.1111/j.1600-065X.1997.tb00965.x; Muralikrishna T, 1998, DNA CELL BIOL, V17, P603, DOI 10.1089/dna.1998.17.603; NARUMI S, 1990, J BIOL CHEM, V265, P7036; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; OTOVA B, 1987, FOLIA BIOL-PRAGUE, V33, P363; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROMANI N, 1989, J EXP MED, V169, P1169, DOI 10.1084/jem.169.3.1169; Sharma S, 2003, HUM GENE THER, V14, P1511, DOI 10.1089/104303403322495025; VALLE MT, 1995, CLIN EXP IMMUNOL, V101, P172; Wu Q, 1999, J EXP MED, V190, P629, DOI 10.1084/jem.190.5.629; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Young AJ, 1999, SEMIN IMMUNOL, V11, P73, DOI 10.1006/smim.1999.0163	35	12	14	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1764	+		10.1096/fj.04-1855fje	http://dx.doi.org/10.1096/fj.04-1855fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15358681				2022-12-28	WOS:000224243200035
J	Alexaki, VI; Charalampopoulos, I; Kampa, M; Vassalou, H; Theodoropoulos, P; Stathopoulos, EN; Hatzoglou, A; Gravanis, A; Castanas, E				Alexaki, VI; Charalampopoulos, I; Kampa, M; Vassalou, H; Theodoropoulos, P; Stathopoulos, EN; Hatzoglou, A; Gravanis, A; Castanas, E			Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation	FASEB JOURNAL			English	Article						estrogen steroid receptor; membrane steroid receptor; rat pheochromocytoma cells	NONGENOMIC ACTIONS; BREAST-CANCER; PC12 CELLS; GENDER DIFFERENCES; APOPTOSIS; PROTEIN; BINDING; MODULATION; MECHANISMS; ALPHA	The neuroprotective role of estrogen (E-2) is supported by a multitude of experimental and epidemiological data, although its mode of action is not fully understood. The present work was conducted to study the underlying mechanisms of its neuroprotective action, using the rat cell line PC12, an established model for neuronal cell apoptosis and survival. Our results show that E2 ( but not androgens or progestins) prevent growth inhibition and apoptosis of PC12 cells, induced by serum deprivation. Several mechanisms of action were investigated: 1) intracellular estrogen receptors (ERs) have been identified but do not appear to mediate the protective effect of E2. 2) The antioxidant properties of E2 cannot explain their protective actions at the concentrations used (10(-12)- 10(-6) M). 3) Finally, membrane sites for E-2 have been identified, and the underlying initial signaling cascade (2-30 min after E-2) has been tested, showing Ca2+ mobilization --> PI3K activation --> Akt phosporylation. NOS activation. Inhibition of PI3K or NOS completely reversed the anti-apoptotic effect of E-2. These results suggest a new mechanism of neuroprotective action of estrogen.	Univ Crete, Sch Med, Lab Expt Endocrinol, GR-71003 Iraklion, Greece; Univ Crete, Sch Med, Pharmacol Lab, GR-71003 Iraklion, Greece; Univ Crete, Sch Med, Biochem Lab, GR-71003 Iraklion, Greece; Univ Crete, Sch Med, Pathol Lab, GR-71003 Iraklion, Greece	University of Crete; University of Crete; University of Crete; University of Crete	Castanas, E (corresponding author), Univ Crete, Sch Med, Lab Expt Endocrinol, POB 2208, GR-71003 Iraklion, Greece.	castanas@med.uoc.gr	Castanas, Elias/E-7007-2010; Charalampopoulos, Ioannis/I-6319-2012; Alexaki, Vasileia Ismini/K-5527-2019	Castanas, Elias/0000-0002-8370-1835; Charalampopoulos, Ioannis/0000-0003-3415-7332; Alexaki, Vasileia Ismini/0000-0003-3935-8985				Behl C, 1999, TRENDS PHARMACOL SCI, V20, P441, DOI 10.1016/S0165-6147(99)01392-9; Behl C, 2000, J NEUROCYTOL, V29, P351, DOI 10.1023/A:1007109222673; Beyer C, 2003, J NEUROCHEM, V87, P545, DOI 10.1046/j.1471-4159.2003.02042.x; BRANN DW, 1995, J STEROID BIOCHEM, V52, P113, DOI 10.1016/0960-0760(94)00160-N; BURKE MD, 1994, BIOCHEM PHARMACOL, V48, P923, DOI 10.1016/0006-2952(94)90363-8; Cardona-Gomez GP, 2002, J STEROID BIOCHEM, V83, P211, DOI 10.1016/S0960-0760(02)00261-3; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Chambliss KL, 2002, STEROIDS, V67, P413, DOI 10.1016/S0039-128X(01)00177-5; Chatzaki E, 2003, MOL HUM REPROD, V9, P91, DOI 10.1093/molehr/gag011; Chen HB, 1998, CURR EYE RES, V17, P642, DOI 10.1076/ceyr.17.6.642.5174; Dermitzaki E, 2002, J BIOL CHEM, V277, P12280, DOI 10.1074/jbc.M111236200; Evans SJ, 2000, ENDOCRINOLOGY, V141, P2294, DOI 10.1210/en.141.7.2294; Falkenstein E, 1999, ENDOCRINOLOGY, V140, P5999, DOI 10.1210/en.140.12.5999; Falkenstein E, 1996, BIOCHEM BIOPH RES CO, V229, P86, DOI 10.1006/bbrc.1996.1761; Falkenstein E, 2000, J CLIN ENDOCR METAB, V85, P2072, DOI 10.1210/jc.85.5.2072; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gollapudi L, 1999, J NEUROSCI RES, V56, P471, DOI 10.1002/(SICI)1097-4547(19990601)56:5<471::AID-JNR3>3.3.CO;2-T; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; HATZOGLOU A, 1994, CLIN CHIM ACTA, V227, P97, DOI 10.1016/0009-8981(94)90139-2; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Johnston SRD, 2003, CLIN CANCER RES, V9, p524S; Kampa M, 2002, FASEB J, V16, P1429, DOI 10.1096/fj.02-0131fje; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kelly MJ, 2002, J STEROID BIOCHEM, V83, P187, DOI 10.1016/S0960-0760(02)00249-2; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; KENNEDY SW, 1993, ANAL BIOCHEM, V211, P102, DOI 10.1006/abio.1993.1239; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kurokawa H, 2003, CLIN CANCER RES, V9, p511S; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Maclusky NJ, 2003, NEUROSCIENCE, V118, P741, DOI 10.1016/S0306-4522(02)00940-5; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785; MIRANDA RC, 1994, HORM BEHAV, V28, P367, DOI 10.1006/hbeh.1994.1033; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Picazo O, 2003, BRAIN RES, V990, P20, DOI 10.1016/S0006-8993(03)03380-8; Roth A, 1999, J NEUROSCI RES, V57, P399; ROTHE G, 1994, METHOD ENZYMOL, V233, P539; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Simoncini T, 2002, STEROIDS, V67, P935, DOI 10.1016/S0039-128X(02)00040-5; Simoncini T, 2003, EUR J ENDOCRINOL, V148, P281, DOI 10.1530/eje.0.1480281; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Stathopoulos Efstathios N, 2003, BMC Clin Pathol, V3, P1, DOI 10.1186/1472-6890-3-1; Svensson AL, 1999, NEUROREPORT, V10, P3485, DOI 10.1097/00001756-199911260-00004; Venihaki M, 1997, ENDOCRINOLOGY, V138, P698, DOI 10.1210/en.138.2.698; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	57	71	73	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1594	+		10.1096/fj.04-1495fje	http://dx.doi.org/10.1096/fj.04-1495fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289442				2022-12-28	WOS:000223554900024
J	Gnidehou, S; Caillou, B; Talbot, M; Ohayon, R; Kaniewski, J; Noel-Hudson, MS; Morand, S; Agnangji, D; Sezan, A; Courtin, F; Virion, A; Dupuy, C				Gnidehou, S; Caillou, B; Talbot, M; Ohayon, R; Kaniewski, J; Noel-Hudson, MS; Morand, S; Agnangji, D; Sezan, A; Courtin, F; Virion, A; Dupuy, C			Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide close to the thyroglobulin iodination site	FASEB JOURNAL			English	Article						thyroid gland; nitroreductase; NADPH; NADH	THYROID EPITHELIAL-CELLS; CATHEPSIN-B; BIOCHEMICAL-CHARACTERIZATION; CONGENITAL HYPOTHYROIDISM; SIMPLE GOITER; DEIODINATION; EXPRESSION; DIIODOTYROSINE; FLAVOPROTEIN; PURIFICATION	In the thyroid, iodotyrosine dehalogenase acts on the mono and diiodotyrosines released during the hydrolysis of thyroglobulin to liberate iodide, which can then reenter the hormone-producing pathways. It has been reported that the deiodination of iodotyrosines occurs predominantly in the microsomes and is mediated by NADPH. Recently, two cDNAs, 7401- and 7513-base pairs long that encode proteins with a conserved nitroreductase domain were published in GenBank as iodotyrosine dehalogenase 1 ( DEHAL1) and iodotyrosine dehalogenase 1B (DEHAL1B), respectively. We report here our investigation of the localization and activity of one of these isoforms, DEHAL1. DEHAL1 mRNA is highly expressed in the thyroid, is up-regulated by cAMP, and encodes a transmembrane protein that efficiently catalyzes the NADPH-dependent deiodination of mono (L-MIT) and diiodotyrosine (L-DIT), with greater activity vs. L-MIT. Iodotyrosine deiodinase was active in HEK293 cells transfected by DEHAL1 cDNA, but not in CHO cells. A fraction of DEHAL1 protein is exposed to the cell surface, as indicated by biotinylation experiments. Immunohistochemistry studies showed that DEHAL1 proteins accumulate at the apical pole of thyrocytes. Taken together, these findings indicate that the deiodination reaction occurs at the apical pole of the thyrocyte and is involved in a rapid iodide recycling process at and/or close to the organification site.	Univ Paris 11, Fac Pharm, INSERM, U486, F-92296 Chatenay Malabry, France; Inst Gustave Roussy, CEA LRC 29V, UMR CNRS 8125, F-94805 Villejuif, France; Lab Biomembrane FAST, Cotonou, Benin; Gregory Pincus, INSERM, U488, F-94276 Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)	Dupuy, C (corresponding author), Univ Paris 11, Fac Pharm, INSERM, U486, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	corinne.dupuy@cep.u-psud.fr						Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Brix K, 1996, ENDOCRINOLOGY, V137, P1963, DOI 10.1210/en.137.5.1963; BRYANT C, 1991, CHEM BIOCH FLAVOENZY, V2; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUFOER J C, 1964, Expos Annu Biochim Med, V25, P213; CHOUFOER JC, 1960, J CLIN ENDOCR METAB, V20, P983, DOI 10.1210/jcem-20-7-983; DUNN AD, 1991, J BIOL CHEM, V266, P20198; Dunn AD, 1996, ENDOCRINOLOGY, V137, P3279, DOI 10.1210/en.137.8.3279; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; FETZNER S, 1994, MICROBIOL REV, V58, P641, DOI 10.1128/MMBR.58.4.641-685.1994; Friedrichs B, 2003, J CLIN INVEST, V111, P1733, DOI 10.1172/JCI200315990; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GOSWAMI A, 1976, ENDOCRINOLOGY, V101, P331; GREEN WL, 1968, ENDOCRINOLOGY, V83, P336, DOI 10.1210/endo-83-2-336; GREER MA, 1968, ENDOCRINOLOGY, V83, P405, DOI 10.1210/endo-83-3-405; HAYE B, 1985, MOL CELL ENDOCRINOL, V43, P41, DOI 10.1016/0303-7207(85)90040-1; ISMAILBEIGI F, 1977, J CLIN ENDOCR METAB, V44, P499, DOI 10.1210/jcem-44-3-499; KUSAKABE T, 1963, J CLIN ENDOCR METAB, V23, P132, DOI 10.1210/jcem-23-2-132; KUSAKABE T, 1964, J CLIN ENDOCR METAB, V24, P456, DOI 10.1210/jcem-24-5-456; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonard JL, 1986, THYROID HORMONE META, P189; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; Linke M, 2002, J CELL SCI, V115, P4877, DOI 10.1242/jcs.00184; MATSUDA K, 1965, ENDOCRINOLOGY, V76, P1012, DOI 10.1210/endo-76-6-1012; Moreno JC, 2003, HORM RES, V60, P96, DOI 10.1159/000074509; Moreno JC, 2002, J ENDOCRINOL INVE S7, V25, P23; PITTRIVERS R, 1959, THYROID HORMONES, P163; ROCHE J, 1952, BIOCHIM BIOPHYS ACTA, V9, P161, DOI 10.1016/0006-3002(52)90143-1; ROSENBERG IN, 1984, METHOD ENZYMOL, V107, P488; ROSENBERG IN, 1979, J BIOL CHEM, V254, P2318; Saito T, 1997, J CLIN ENDOCR METAB, V82, P3331, DOI 10.1210/jc.82.10.3331; SOLIS SJC, 2004, IN PRESS J ENDOCRINO; STANBURY JB, 1957, J BIOL CHEM, V228, P801; STANBURY JB, 1958, J BIOL CHEM, V233, P106; STANBURY JB, 1955, J CLIN ENDOCR METAB, V15, P1216, DOI 10.1210/jcem-15-10-1216; TAUROG A, 1956, ENDOCRINOLOGY, V58, P121, DOI 10.1210/endo-58-1-121; Tepel C, 2000, J CELL SCI, V113, P4487; TONG W, 1954, J BIOL CHEM, V207, P59; Valverde-R C, 2004, INT REV CYTOL, V234, P143, DOI 10.1016/S0074-7696(04)34004-0; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996	41	80	85	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1574	+		10.1096/fj.04-2023fje	http://dx.doi.org/10.1096/fj.04-2023fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289438				2022-12-28	WOS:000223554900029
J	Qing, H; Zhou, WH; Christensen, MA; Sun, XL; Tong, YG; Song, WH				Qing, H; Zhou, WH; Christensen, MA; Sun, XL; Tong, YG; Song, WH			Degradation of BACE by the ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article						Alzheimer's disease; APP; A beta	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; CLEAVING ENZYME; DISEASE; CLEAVAGE; SITE; EXPRESSION; IDENTIFICATION; PURIFICATION; INHIBITION	The amyloid beta protein (Abeta) is derived from beta-amyloid precursor protein (APP). Cleavage of APP by beta-secretase generates a C-terminal fragment (APPCTFbeta or C99), which is subsequently cleaved by gamma-secretase to produce Abeta. BACE (or BACE1), the major beta-secretase involved in cleaving APP, has been identified as a Type 1 membrane-associated aspartyl protease. In this study, we found that treatment with proteasome inhibitors resulted in an increase in APP C99 levels, suggesting that APP processing at the beta-secretase site may be affected by the ubiquitin-proteasome pathway. To investigate whether the degradation of BACE is mediated by the proteasome pathway, cells stably transfected with BACE were treated with lactacystin. We found that BACE protein degradation was inhibited by lactacystin in a time- and dose-dependent manner. Non-proteasome protease inhibitors had no effect on BACE degradation. BACE protein is ubiquitinated. Furthermore, lactacystin increased APP C99 production and Abeta generation. Our data demonstrate that the degradation of BACE proteins and APP processing are regulated by the ubiquitin-proteasome pathway.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; Tong, Yigang/0000-0002-8503-8045				Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Christie G, 1999, J NEUROCHEM, V73, P195, DOI 10.1046/j.1471-4159.1999.0730195.x; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; De Vrij FMS, 2001, FASEB J, V15, P2680, DOI 10.1096/fj.01-0438com; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Tanaka K, 1998, GENES CELLS, V3, P499, DOI 10.1046/j.1365-2443.1998.00207.x; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	47	133	136	3	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1571	+		10.1096/fj.04-1994fje	http://dx.doi.org/10.1096/fj.04-1994fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289451	Bronze			2022-12-28	WOS:000223554900019
J	Weaver, JGR; Rouse, MS; Steckelberg, JM; Badley, AD				Weaver, JGR; Rouse, MS; Steckelberg, JM; Badley, AD			Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis	FASEB JOURNAL			English	Article						SIRS; cytokine; lymphocyte; CLP; protease inhibitor	TUMOR-NECROSIS-FACTOR; CELL-DEATH; LYMPHOCYTE APOPTOSIS; CECAL LIGATION; MONOCYTE DEACTIVATION; ANTIGEN PRESENTATION; UNITED-STATES; TGF-BETA; MACROPHAGES; ENDOTOXIN	The pathophysiology of sepsis involves excessive lymphocyte apoptosis, which correlates with adverse outcomes, and disordered cytokine production, which may promote host injury. As the protease inhibitor (PI) class of antiretroviral agents is known to prevent apoptosis in vitro, we evaluated their effect on survival, lymphocyte apoptosis, and consequent cytokine production in mice with sepsis induced by cecal ligation and perforation. Mice pretreated with PIs have improved survival (67%; P< 0.0005) compared with controls (17%) and a significant ( P< 0.05) reduction in lymphocyte apoptosis. Even mice receiving therapy beginning 4 h after perforation demonstrated improved survival (50%; P< 0.05) compared with controls. PI therapy is also associated with an increase in the Th1 cytokine TNF-alpha ( P< 0.05) early in sepsis and a reduction in the Th2 cytokines IL-6 and IL-10 ( P< 0.05) late in sepsis; despite no intrinsic antibacterial effects, PI also reduced quantitative bacterial blood cultures. The beneficial effects of PI appear to be specific to lymphocyte apoptosis, as lymphocyte-deficient Rag1-/- mice did not experience benefit from treatment with PI. Thus, inhibition of lymphocyte apoptosis by PI is a candidate approach for the treatment of sepsis.	Mayo Clin & Mayo Fdn, Div Infect Dis, Translat Program Immunvirol & Biodef, Rochester, MN 55905 USA; Univ Ottawa, Div Gen Surg, Ottawa, ON, Canada; Mayo Clin & Mayo Fdn, Translat Immunovirol & Biodef Res Program, Rochester, MN 55905 USA	Mayo Clinic; University of Ottawa; Mayo Clinic	Badley, AD (corresponding author), Mayo Clin & Mayo Fdn, Div Infect Dis, Translat Program Immunvirol & Biodef, 200 1st St NW, Rochester, MN 55905 USA.	badley.andrew@mayo.edu	badley, andrew d/O-9022-2014	Badley, Andrew/0000-0001-7796-7680	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054187, R01AI040384] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI40384-06, R21 AI54187-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Ayala A, 1996, BLOOD, V87, P4261, DOI 10.1182/blood.V87.10.4261.bloodjournal87104261; Ayala A, 1998, BLOOD, V91, P1362, DOI 10.1182/blood.V91.4.1362; Ayala A, 1996, SHOCK, V5, P79, DOI 10.1097/00024382-199602000-00001; Badley AD, 1998, J CLIN INVEST, V102, P79, DOI 10.1172/JCI2691; BAKER CC, 1983, SURGERY, V94, P331; Barker RN, 1999, PATHOBIOLOGY, V67, P302, DOI 10.1159/000028085; CHAUDRY IH, 1979, SURGERY, V85, P205; Chen WJ, 2001, IMMUNITY, V14, P715, DOI 10.1016/S1074-7613(01)00147-9; Chung CS, 2003, J LEUKOCYTE BIOL, V74, P344, DOI 10.1189/jlb.0102006; CHUNG CS, 2001, AM J PHYSIOL, V280, pC812; Cinel I, 2002, PHARMACOL RES, V46, P119, DOI 10.1016/S1043-6618(02)00075-0; Coopersmith CM, 2003, CRIT CARE MED, V31, P1630, DOI 10.1097/01.CCM.0000055385.29232.11; Coopersmith CM, 2002, CRIT CARE MED, V30, P195, DOI 10.1097/00003246-200201000-00028; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Coutinho HB, 1997, J CLIN PATHOL, V50, P294, DOI 10.1136/jcp.50.4.294; DEBETS JMH, 1989, CRIT CARE MED, V17, P489, DOI 10.1097/00003246-198906000-00001; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Echtenacher B, 2001, INFECT IMMUN, V69, P3550, DOI 10.1128/IAI.69.6.3550-3555.2001; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FINK MP, 1990, J SURG RES, V49, P186, DOI 10.1016/0022-4804(90)90260-9; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; Fowler DE, 2002, INT J MOL MED, V9, P443; Freeman BD, 2000, CRIT CARE MED, V28, P1701, DOI 10.1097/00003246-200006000-00001; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; GORONZY J, 1989, J IMMUNOL, V142, P1134; Gray HW, 2002, SEMIN NUCL MED, V32, P159, DOI 10.1053/snuc.2002.124176; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Heidecke CD, 1999, AM J SURG, V178, P288, DOI 10.1016/S0002-9610(99)00183-X; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss R S, 2001, Science, V294, P1783; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Hotchkiss RS, 2003, P NATL ACAD SCI USA, V100, P6724, DOI 10.1073/pnas.1031788100; Hotchkiss RS, 2000, J IMMUNOL, V164, P3675, DOI 10.4049/jimmunol.164.7.3675; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hotchkiss RS, 2002, J IMMUNOL, V168, P2493, DOI 10.4049/jimmunol.168.5.2493; Husain Kareem D, 2003, Curr Opin Crit Care, V9, P159, DOI 10.1097/00075198-200304000-00013; Lederer JA, 1999, SHOCK, V11, P153, DOI 10.1097/00024382-199903000-00001; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; McDonald PP, 1999, J IMMUNOL, V163, P6164; MEAKINS JL, 1977, ANN SURG, V186, P241, DOI 10.1097/00000658-197709000-00002; *NAT STAND C L, 2003, M7A6 ND CL NAT STAND; O'Reilly M, 1999, SHOCK, V12, P411, DOI 10.1097/00024382-199912000-00001; Oberholzer A, 2001, SHOCK, V16, P83, DOI 10.1097/00024382-200116020-00001; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; Oberholzer C, 2001, FASEB J, V15, P879, DOI 10.1096/fj.00-058rev; Ortiz A, 2003, BIOCHEM PHARMACOL, V66, P1589, DOI 10.1016/S0006-2952(03)00515-X; Pellegrin I, 2002, AIDS, V16, P1331, DOI 10.1097/00002030-200207050-00004; Pellegrini JD, 2000, J SURG RES, V88, P200, DOI 10.1006/jsre.1999.5797; Phenix BN, 2000, AIDS RES HUM RETROV, V16, P559, DOI 10.1089/088922200308972; Phenix BN, 2001, BLOOD, V98, P1078, DOI 10.1182/blood.V98.4.1078; Power C, 2002, SHOCK, V18, P197, DOI 10.1097/00024382-200209000-00001; Pruitt JH, 1996, BLOOD, V87, P3282; Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; ROGY MA, 1994, J AM COLL SURGEONS, V178, P132; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Sayeed MM, 2003, CRIT CARE MED, V31, P1864, DOI 10.1097/01.CCM.0000056692.52111.F1; Sileri P, 2002, DIGEST DIS SCI, V47, P929, DOI 10.1023/A:1014733226337; Tinsley KW, 2000, SHOCK, V13, P1, DOI 10.1097/00024382-200013010-00001; Volk HD, 1996, INTENS CARE MED, V22, pS474, DOI 10.1007/BF01743727; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WANG SD, 1994, J IMMUNOL, V152, P5014; Wilson JX, 2003, CAN J NEUROL SCI, V30, P98, DOI 10.1017/S031716710005335X; Zeerleder S, 2003, CRIT CARE MED, V31, P1947, DOI 10.1097/01.CCM.0000074719.40109.95	74	59	64	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1185	1191		10.1096/fj.03-1230com	http://dx.doi.org/10.1096/fj.03-1230com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15284218				2022-12-28	WOS:000223554900033
J	Darash-Yahana, M; Pikarsky, E; Abramovitch, R; Zeira, E; Pal, B; Karplus, R; Beider, K; Avniel, S; Kasem, S; Galun, E; Peled, A				Darash-Yahana, M; Pikarsky, E; Abramovitch, R; Zeira, E; Pal, B; Karplus, R; Beider, K; Avniel, S; Kasem, S; Galun, E; Peled, A			Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis	FASEB JOURNAL			English	Article						chemokine receptor; prostate tumors	CHEMOKINE RECEPTOR CXCR4; CELL-DERIVED FACTOR-1-ALPHA; PROSTATE-CANCER METASTASIS; NOD/SCID MICE; BONE-MARROW; FACTOR-I; ENDOTHELIAL-CELLS; MOLECULAR-BASIS; OVARIAN-CANCER; T-CELLS	Hormone refractory metastatic prostate cancer remains an incurable disease. We found that high expression levels of the chemokine receptor CXCR4 correlated with the presence of metastatic disease in prostate cancer patients. Positive staining for CXCL12, the ligand for CXCR4, was mainly present in the tumor-associated blood vessels and basal cell hyperplasia. Subcutaneous xenografts of PC3 and 22Rv1 prostate tumors that overexpressed CXCR4 in NOD/SCID mice were two- to threefold larger in volume and weight vs. controls. Moreover, blood vessel density, functionality, invasiveness of tumors into the surrounding tissues, and metastasis to the lymph node and lung were significantly increased in these tumors. Neutralizing the interactions of CXCL12/CXCR4 in vivo with CXCR4 specific antibodies inhibited the CXCR4-dependent tumor growth and vascularization. In vitro, CXCL12 induced the proliferation and VEGF secretion but not migration of PC3 and 22Rv1 cells overexpressing CXCR4. Similar effects of CXCR4 overexpression on tumor growth in vivo were also noted in two breast cancer lines, suggesting that the observed effect of CXCR4 is not unique to prostate tumor cells. Thus high levels of the chemokine receptor CXCR4 induce a more aggressive phenotype in prostate cancer cells and identify CXCR4 as a potential therapeutic target in advanced cases of metastatic prostate cancer.	Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, MRI Lab, HBRC, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Peled, A (corresponding author), Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, POB 12000, IL-91120 Jerusalem, Israel.	peled@hadassah.org.il	Galun, Eithan/AAD-9117-2022; pikarsky, eli/GXV-7099-2022	Galun, Eithan/0000-0002-6243-6702; pikarsky, eli/0000-0003-4186-7105				Abramovitch R, 1998, MAGN RESON MED, V39, P813, DOI 10.1002/mrm.1910390519; Abramovitch R, 1999, CANCER RES, V59, P5012; Bachelder RE, 2002, CANCER RES, V62, P7203; Barbero S, 2003, CANCER RES, V63, P1969; Beider K, 2003, BLOOD, V102, P1951, DOI 10.1182/blood-2002-10-3293; Bernards R, 2003, NATURE, V425, P247, DOI 10.1038/425247a; Cashman J, 2002, BLOOD, V99, P792, DOI 10.1182/blood.V99.3.792; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Foster CS, 1999, BJU INT, V83, P171; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; Juarez J, 2004, HISTOL HISTOPATHOL, V19, P299, DOI 10.14670/HH-19.299; Kanda S, 2003, J BIOL CHEM, V278, P257, DOI 10.1074/jbc.M204771200; Kijowski J, 2001, STEM CELLS, V19, P453, DOI 10.1634/stemcells.19-5-453; Koshiba T, 2000, CLIN CANCER RES, V6, P3530; Lapidot T, 2001, ANN NY ACAD SCI, V938, P83, DOI 10.1111/j.1749-6632.2001.tb03577.x; Milliken D, 2002, CLIN CANCER RES, V8, P1108; Minamiguchi H, 2001, BRIT J HAEMATOL, V115, P175, DOI 10.1046/j.1365-2141.2001.03068.x; Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nemeth JA, 1999, CANCER RES, V59, P1987; Neuhaus T, 2003, CELL PROLIFERAT, V36, P75, DOI 10.1046/j.1365-2184.2003.00262.x; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Peled A, 2002, STEM CELLS, V20, P259, DOI 10.1634/stemcells.20-3-259; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Sehgal A, 1998, J SURG ONCOL, V69, P99, DOI 10.1002/(SICI)1096-9098(199810)69:2<99::AID-JSO10>3.0.CO;2-M; Shen W, 2001, EXP HEMATOL, V29, P1439, DOI 10.1016/S0301-472X(01)00741-X; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Taichman RS, 2002, CANCER RES, V62, P1832; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	43	318	355	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1240	+		10.1096/fj.03-0935fje	http://dx.doi.org/10.1096/fj.03-0935fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180966				2022-12-28	WOS:000222327500037
J	Sugano, M; Tsuchida, K; Hata, T; Makino, N				Sugano, M; Tsuchida, K; Hata, T; Makino, N			In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats	FASEB JOURNAL			English	Article						soluble TNF-alpha receptor 1; gene therapy; sTNFR1; plasmid	TUMOR-NECROSIS-FACTOR; CHRONIC HEART-FAILURE; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; EXPRESSION; ISCHEMIA; CARDIOMYOPATHY; HYPERTROPHY; REPERFUSION; APOPTOSIS	Increased circulating and cardiac TNF-alpha levels during myocardial ischemia have been found in both experimental animals and patients with ischemic heart disease and advanced heart failure. Soluble TNF-alpha receptor 1 (sTNFR1) is an antagonist to TNF-alpha. In the present study, we examined whether sTNFR1 improves cardiac function in rats after myocardial infarction. Male Wistar rats were subjected to left coronary artery (LCA) ligation. Immediately after the ligation, a total of 200 mug of either the sTNFR1 or LacZ plasmid was injected into three different sites in the left ventricular wall. From 1 to 21 days after LCA ligation, TNF-alpha bioactivity in the heart was higher in rats receiving LacZ plasmid than in sham-operated rats, whereas sTNFR1 plasmid significantly suppressed the increase. The LV diastolic dimension was significantly lower, and the fractional shortening was significantly higher in rats treated with the sTNFR1 plasmid than in those treated with the LacZ plasmid. At 21 days after LCA ligation, the LV end-diastolic pressure was also significantly lower in the rats treated with the sTNFR1 plasmid. In addition, the sTNFR1 expression plasmid had significantly reduced the infarct size. In conclusion, TNF-alpha bioactivity in the heart increased during the early stage of infarction and remained elevated. This elevation seemed partially responsible for the impairment of LV function and the increased infarct size. Suppression of TNF-alpha bioactivity from the early stage of infarction with the sTNFR1 plasmid improved cardiac function and reduced infarct size.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Clin Gerontol, Dept Mol & Cellular Biol, Beppu, Oita 8740838, Japan	Kyushu University	Sugano, M (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Clin Gerontol, Dept Mol & Cellular Biol, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.	massy@tsurumi.beppu.kyushu-u.ac.jp						Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Chung ES, 2003, CIRCULATION, V107, P3133, DOI 10.1161/01.CIR.0000077913.60364.D2; Gurevitch J, 1997, J AM COLL CARDIOL, V30, P1554, DOI 10.1016/S0735-1097(97)00328-8; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Iversen PO, 2001, AM J PHYSIOL-HEART C, V281, pH2211, DOI 10.1152/ajpheart.2001.281.5.H2211; Kajstura J, 1996, LAB INVEST, V74, P86; KAPADIA S, 1995, AM J PHYSIOL-HEART C, V268, pH517, DOI 10.1152/ajpheart.1995.268.2.H517; Kubota T, 2000, CIRCULATION, V101, P2518, DOI 10.1161/01.CIR.101.21.2518; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; Kurrelmeyer KM, 2000, P NATL ACAD SCI USA, V97, P5456, DOI 10.1073/pnas.070036297; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Li DY, 1999, AM HEART J, V137, P1145, DOI 10.1016/S0002-8703(99)70375-3; Makino N, 1996, J MOL CELL CARDIOL, V28, P507, DOI 10.1006/jmcc.1996.0047; MCMURRAY J, 1991, BRIT HEART J, V66, P356; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Ridker PM, 2000, CIRCULATION, V101, P2149, DOI 10.1161/01.CIR.101.18.2149; Selinsky CL, 1998, IMMUNOLOGY, V94, P88; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Su X, 1998, ARTHRITIS RHEUM-US, V41, P139, DOI 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.3.CO;2-K; Sugano M, 2002, FASEB J, V16, P1421, DOI 10.1096/fj.01-0894fje; Takeshita S, 1996, LAB INVEST, V74, P1061; Tsurumi Y, 1997, CIRCULATION, V96, P382; VADDI K, 1994, CIRCULATION, V90, P694, DOI 10.1161/01.CIR.90.2.694; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250	28	42	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					911	+		10.1096/fj.03-1148fje	http://dx.doi.org/10.1096/fj.03-1148fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15117889				2022-12-28	WOS:000220522800001
J	Johns, TG; Mellman, I; Cartwright, GA; Ritter, G; Old, LJ; Burgess, AW; Scott, AM				Johns, TG; Mellman, I; Cartwright, GA; Ritter, G; Old, LJ; Burgess, AW; Scott, AM			The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor	FASEB JOURNAL			English	Article						epidermal growth factor receptor; glycosylation; endoplasmic reticulum; antibody therapy	GROWTH-FACTOR RECEPTOR; GLYCOSYLATION-DEPENDENT ACQUISITION; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; MONOCLONAL-ANTIBODY; LIGAND-BINDING; CARCINOMA-CELLS; LUNG CARCINOMAS; CANCER-THERAPY; MUTANT	Overexpression of the EGFR is commonly caused by EGFR gene amplification and is sometimes associated with expression of a variant EGFR (de2-7 EGFR or EGFRvIII) bearing an internal deletion in its extracellular domain. mAb 806 is a novel EGFR antibody with significant antitumor activity that recognizes both the de2-7 EGFR and a subset of the wild-type (wt) EGFR when overexpressed, but does not bind the EGFR expressed in normal tissues. Recently, we demonstrated that the mAb 806 epitope is restricted to a short cysteine loop of the EGFR (amino acids 287-302) that is only available for antibody binding in a transitional form of the receptor, which occurs as the receptor changes from its inactive tethered conformation to a dimeric untethered form. The truncation associated with the de2-7 EGFR mutation renders this receptor constitutively untethered, leading to increased binding of mAb 806. We now show that mAb 806 preferentially binds the immature high-mannose wt and de2-7 EGFR precursors normally located in the endoplasmic reticulum, indicating that this form of the wt EGFR is also constitutively untethered. Using the unique specificity of mAb 806, we clearly demonstrated the presence of these high-mannose EGFR precursors on the cell surface. Given that the high-mannose forms of the wt EGFR must be untethered they may contribute to the spontaneous EGFR signaling reported in cells overexpressing the receptor. These precursor forms of the EGFR thus represent novel tumor targets and contribute to the exceptional selectivity of mAb 806 for EGFR when overexpressed in cancer cells. As our observations are likely to apply to other receptors overexpressed in cancer, they suggest a strategy for developing antitumor antibodies even when the target receptor is expressed in normal tissue.	Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program, Heidelberg, Vic 3084, Australia; Royal Melbourne Hosp, Epithelial Biochem Lab, Parkville, Vic 3050, Australia; Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT USA; Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York Branch, New York, NY 10021 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Ludwig Institute for Cancer Research; Yale University; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Johns, TG (corresponding author), Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program, Level 6,Studley Rd, Heidelberg, Vic 3084, Australia.	Terry.Johns@ludwig.edu.au	Johns, Terrance/C-2441-2008; Mellman, Ira/ABG-5896-2020	Johns, Terrance/0000-0002-8874-4543; Scott, Andrew/0000-0002-6656-295X				Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Baselga J, 2002, ONCOLOGIST, V7, P2; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; GAMOU S, 1988, J BIOCHEM-TOKYO, V104, P388, DOI 10.1093/oxfordjournals.jbchem.a122478; Ge H, 2002, INT J CANCER, V98, P357, DOI 10.1002/ijc.10224; Hakomori S, 1996, CANCER RES, V56, P5309; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; JOHNS TG, 2005, IN PRESS J BIOL CHEM; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; Luwor RB, 2001, CANCER RES, V61, P5355; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mishima K, 2001, CANCER RES, V61, P5349; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nagane M, 1996, CANCER RES, V56, P5079; Narita Y, 2002, CANCER RES, V62, P6764; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Orntoft TF, 1999, ELECTROPHORESIS, V20, P362, DOI 10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.3.CO;2-M; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Ryu JS, 1999, ENDOCRINOLOGY, V140, P3904, DOI 10.1210/en.140.9.3904; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Zhen YJ, 2003, BIOCHEMISTRY-US, V42, P5478, DOI 10.1021/bi027101p	38	63	74	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					780	+		10.1096/fj.04-1766fje	http://dx.doi.org/10.1096/fj.04-1766fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15774576				2022-12-28	WOS:000227901300013
J	Sakhalkar, HS; Hanes, J; Fu, J; Benavides, U; Malgor, R; Borruso, CL; Kohn, LD; Kujiaka, DT; Goetz, DJ				Sakhalkar, HS; Hanes, J; Fu, J; Benavides, U; Malgor, R; Borruso, CL; Kohn, LD; Kujiaka, DT; Goetz, DJ			Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules	FASEB JOURNAL			English	Article						colitis; inflammation; endothelial cell adhesion molecules; biodegradable polymer; targeted drug delivery; microspheres	ACTIVATED ENDOTHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; E-SELECTIN IMMUNOCONJUGATE; TARGETED DRUG-DELIVERY; ULCERATIVE-COLITIS; CROHNS-DISEASE; P-SELECTIN; DEXAMETHASONE; NANOPARTICLES; EXPRESSION	The expression of certain endothelial cell adhesion molecules (ECAMs) is increased in the vasculature of the inflamed bowel (e.g., colitis), thereby providing an opportunity for targeted drug delivery. We recently demonstrated that biodegradable particles conjugated with ligands to ECAMs exhibit significant selective adhesion to ECAM expressing endothelium. In the present study, we used a murine model of colitis to determine whether poly(lactic acid)-poly(ethylene glycol) particles conjugated with a VCAM-I ligand (alpha-V) exhibit enhanced adhesion to colitic vasculature. In post-capillary venules of the colon, significantly more alpha-V particles accumulate in colitic mice relative to (i) control mice (i.e., selectivity) and (ii) particles bearing a control ligand (i.e., ligand efficiency). The selectivity and ligand efficiency of alpha-V particles were a function of the total number of particles infused. The highest selectivity observed within our test regime was 3, while ligand efficiency increased linearly with the number of particles injected to a value of 24. This work represents a significant step towards achieving a targeted drug delivery scheme for the treatment of inflammatory bowel disease and indicates that the efficiency of targeting is dependent on the dose regime.	Ohio Univ, Dept Chem Engn, Stocker Ctr 172, Athens, OH 45701 USA; Ohio Univ, Dept Biol Sci, Athens, OH 45701 USA; Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA; Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA; Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA	Ohio University; Ohio University; Ohio University; Ohio University; Johns Hopkins University	Goetz, DJ (corresponding author), Ohio Univ, Dept Chem Engn, Stocker Ctr 172, Athens, OH 45701 USA.	goetzd@ohio.edu			NIGMS NIH HHS [GM57640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asgeirsdottir SA, 2003, BIOCHEM PHARMACOL, V65, P1729, DOI 10.1016/S0006-2952(03)00122-9; Caprilli R, 2002, ALIMENT PHARM THER, V16, P1579, DOI 10.1046/j.1365-2036.2002.01319.x; Chapman PT, 1996, ARTHRITIS RHEUM, V39, P1371, DOI 10.1002/art.1780390815; Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dickerson JB, 2001, BIOTECHNOL BIOENG, V73, P500, DOI 10.1002/bit.1085; Eniola AO, 2002, BIOMATERIALS, V23, P2167, DOI 10.1016/S0142-9612(01)00349-0; Everts M, 2002, J IMMUNOL, V168, P883, DOI 10.4049/jimmunol.168.2.883; Everts M., 2001, DRUG TARGETING ORGAN, P171; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769, DOI 10.1152/ajpgi.1997.273.4.G769; Fu J, 2004, MACROMOLECULES, V37, P7174, DOI 10.1021/ma049853s; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; GRISHAM MB, 1999, INFLAMM BOWEL DIS, P55; Kirsner JB, 1999, ITAL J GASTROENTEROL, V31, P651; Kok RJ, 2002, PHARM RES-DORDR, V19, P1730, DOI 10.1023/A:1020769716288; Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775; Langer R, 1998, NATURE, V392, P5; MURTHY SNS, 1993, DIGEST DIS SCI, V38, P1722, DOI 10.1007/BF01303184; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Panes J, 1998, GASTROENTEROLOGY, V114, P1066, DOI 10.1016/S0016-5085(98)70328-2; Sakhalkar HS, 2003, P NATL ACAD SCI USA, V100, P15895, DOI 10.1073/pnas.2631433100; Salem AK, 2001, BIOMACROMOLECULES, V2, P575, DOI 10.1021/bm010030+; SCHURMANN GM, 1995, GUT, V36, P411, DOI 10.1136/gut.36.3.411; Shigematsu T, 2001, AM J PHYSIOL-GASTR L, V281, pG1309, DOI 10.1152/ajpgi.2001.281.5.G1309; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4; Soriano A, 2000, LAB INVEST, V80, P1541, DOI 10.1038/labinvest.3780164; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Wiewrodt R, 2002, BLOOD, V99, P912, DOI 10.1182/blood.V99.3.912; Xu CT, 2004, WORLD J GASTROENTERO, V10, P2311	31	38	39	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					792	+		10.1096/fj.04-2668fje	http://dx.doi.org/10.1096/fj.04-2668fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764649				2022-12-28	WOS:000227901300016
J	Carlin, SM; Resink, TJ; Tamm, M; Roth, M				Carlin, SM; Resink, TJ; Tamm, M; Roth, M			Urokinase signal transduction and its role in cell migration	FASEB JOURNAL			English	Article						uPAR; signaling; FAK; SHP2; cell migration	FOCAL-ADHESION-KINASE; RENAL EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; PLASMINOGEN-ACTIVATOR; INTEGRIN FUNCTION; RECEPTOR; APOPTOSIS; SRC; PHOSPHATASE; CASPASES	Urokinase and its receptor uPAR play a role in cell migration that is being actively characterized. We previously reported that urokinase potentiates cell migration in human airway smooth muscle cells only where there is some primary migratory stimulus such as PDGF or recent exposure to growth medium. In this study, we examined the signaling of urokinase through its receptor, which lacks an intracellular domain and is presumed to act through associations with other membrane proteins. Whereas PDGF ( 30 min) and PDGF with urokinase increased the amount of the tyrosine dephosphorylase SHP2 in the membrane fraction, urokinase alone ( 30 min) decreased membrane SHP2. Analysis of the time course of urokinase stimulation showed that SHP2 was brought into association with the urokinase receptor uPAR between 2.5 and 20 min of urokinase, and later dissociated from it. Focal adhesion kinase was steadily lost from association with uPAR during urokinase stimulation, but its phosphorylation state increased and it became cleaved to smaller molecules. Association of uPAR with caveolin also decreased during urokinase stimulation. In contrast, the tyrosine kinase Src increased in the membrane fraction in response to urokinase stimulation. Disruption of raft structures by cyclodextrin treatment led to potentiation of PDGF chemotaxis, similar to urokinase action. Blocking of dephosphorylase activity with vanadate reduced basal cell migration and blocked the action of urokinase on PDGF chemotaxis. These observations support a role for urokinase in altering the phosphorylation state of focal adhesions, leading to breakdown of their structure and facilitation of cell motility.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Woolcock Inst Med Res, Camperdown, NSW, Australia	University of Basel; University of Sydney; Woolcock Institute of Medical Research	Roth, M (corresponding author), Univ Basel Hosp, Dept Res, Hebelstr 20, CH-4031 Basel, Switzerland.	michelr@med.usyd.edu.au	Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821				AGUIRREGHISO JA, 2002, ONCOGENE, V21, P2513; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Carlin SM, 2003, AM J PHYSIOL-LUNG C, V284, pL1020, DOI 10.1152/ajplung.00092.2002; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EL L, 1980, J BIOCHEM BIOPH METH, V3, P207; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514, DOI 10.1152/ajplung.1995.269.4.L514; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Kohyama T, 2001, AM J PHYSIOL-LUNG C, V281, pL1257, DOI 10.1152/ajplung.2001.281.5.L1257; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Ossowski L, 1999, MEDICINA-BUENOS AIRE, V59, P547; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285	33	33	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					195	202		10.1096/fj.04-1644com	http://dx.doi.org/10.1096/fj.04-1644com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677342				2022-12-28	WOS:000227591900023
J	Nash, JE; Johnston, TH; Collingridge, GL; Garner, CC; Brotchie, JM				Nash, JE; Johnston, TH; Collingridge, GL; Garner, CC; Brotchie, JM			Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia	FASEB JOURNAL			English	Article						synaptic plasticity; trafficking	LEVODOPA-INDUCED DYSKINESIAS; TUMOR-SUPPRESSOR PROTEIN; KINASE ANCHORING PROTEIN; NMDA RECEPTOR SUBUNITS; D-ASPARTATE RECEPTORS; RAT MODEL; 6-HYDROXYDOPAMINE-LESIONED RAT; GLUTAMATE RECEPTORS; STRIATAL NMDA; NIGROSTRIATAL FUNCTION	Abnormalities in subcellular localization and interaction between receptors and their signaling molecules occur within the striatum in Parkinson's disease (PD) and L-DOPA-induced dyskinesia ( LID). Synapse-associated proteins (SAPs), for example, PSD-95 and SAP97 organize the molecular architecture of synapses and regulate interactions between receptors and downstream-signaling molecules. Here, we show that expression and subcellular distribution of PSD-95 and SAP97 are altered in the striatum of unilateral 6-OHDA-lesioned rats following repeated vehicle ( a model of PD) or L-DOPA administration ( a model of L-DOPA-induced dyskinesia). Furthermore, following dopamine-depletion and development of behavioral deficits in Rotorod performance, indicative of parkinsonism, we observed a dramatic decrease in total striatal levels of PSD-95 and SAP97 ( to 25.6 +/- 9.9% and 19.0 +/- 5.0% of control, respectively). The remaining proteins were redistributed from the synapse into vesicular compartments. L-DOPA ( 6.5mg/ kg twice a day, 21 days) induced a rotational response, which became markedly enhanced with repeated treatment ( day 1: - 15.8 +/- 7.3 rotations cf day 21: 758.2 +/- 114.0 rotations). Post L-DOPA treatment, PSD-95 and SAP97 levels increased (367.4 +/- 43.2% and 159.9 +/- 9.5% from control values, respectively), with both being redistributed toward synaptic membranes from vesicular compartments. In situ hybridization showed that changes in total levels of PSD-95, but not SAP97, were accompanied by qualitatively similar changes in mRNA. These data highlight the potential role of abnormalities in the subcellular distribution of SAPs in the pathophysiology of a neurological disease.	Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; Univ Bristol, Sch Med Sci, Dept Anat, MRC,Ctr Synapt Plast, Bristol BS8 1TD, Avon, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Stanford University; University of Bristol	Nash, JE (corresponding author), 399 Bathurst St,MCL 11-419, Toronto, ON M5T 2Y4, Canada.	jnash@uhnres.utoronto.ca	Johnston, Tom H/D-2531-2018; Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	Johnston, Tom H/0000-0002-1537-8175; Collingridge, Graham L/0000-0002-9572-5359; Brotchie, Jonathan/0000-0003-2337-0816; Garner, Craig/0000-0003-1970-5417				ALTAR CA, 1987, J NEUROCHEM, V48, P390, DOI 10.1111/j.1471-4159.1987.tb04106.x; Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTCHIE JM, 2004, IN PRESS J NEURAL T; Calabresi P, 2000, ANN NEUROL, V47, pS60; Calon F, 2000, TRENDS NEUROSCI, V23, pS92, DOI 10.1016/S1471-1931(00)00026-4; Centonze D, 1999, J NEUROPHYSIOL, V82, P3575, DOI 10.1152/jn.1999.82.6.3575; Chase TN, 2001, ADV NEUROL, V86, P355; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dunah AW, 2000, MOL PHARMACOL, V57, P342; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Duty S, 1998, EXP NEUROL, V150, P223, DOI 10.1006/exnr.1997.6771; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gomez LL, 2002, J NEUROSCI, V22, P7027; Graybiel AM, 2000, TRENDS NEUROSCI, V23, pS71, DOI 10.1016/S1471-1931(00)00027-6; Henry B, 1998, EXP NEUROL, V151, P334, DOI 10.1006/exnr.1998.6819; Henry B, 2003, EXP NEUROL, V183, P458, DOI 10.1016/S0014-4886(03)00064-5; Henry B, 1998, Adv Neurol, V78, P53; Henry B, 1999, EXP NEUROL, V155, P204, DOI 10.1006/exnr.1998.6996; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; INGHAM CA, 1993, EXP BRAIN RES, V93, P17, DOI 10.1007/BF00227776; Ingham CA, 1998, J NEUROSCI, V18, P4732; INGHAM CA, 1989, BRAIN RES, V503, P334, DOI 10.1016/0006-8993(89)91686-7; JOHNSTON TH, IN PRESS EXP NEUROL; Konradi C, 2004, NEUROBIOL DIS, V17, P219, DOI 10.1016/j.nbd.2004.07.005; Kreienkamp HJ, 2002, BIOCHEM SOC T, V30, P464, DOI 10.1042/bst0300464; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Losi G, 2003, J PHYSIOL-LONDON, V548, P21, DOI 10.1113/jphysiol.2002.034918; Lundblad M, 2004, NEUROBIOL DIS, V16, P110, DOI 10.1016/j.nbd.2004.01.007; Lundblad M, 2002, EUR J NEUROSCI, V15, P120, DOI 10.1046/j.0953-816x.2001.01843.x; MARSDEN CA, 1989, HPLC MACROMOLECULES; Mok H, 2002, J NEUROSCI, V22, P5253; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muriel MP, 2002, MOVEMENT DISORD, V17, P1174, DOI 10.1002/mds.10256; Nash JE, 2000, J NEUROSCI, V20, P7782; Oh JD, 1999, BRAIN RES, V821, P433, DOI 10.1016/S0006-8993(99)01121-X; Okabe S, 2001, J NEUROSCI, V21, P6105, DOI 10.1523/JNEUROSCI.21-16-06105.2001; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; PAPA SM, 1995, BRAIN RES, V701, P13, DOI 10.1016/0006-8993(95)00924-3; PAPA SM, 1994, BRAIN RES, V662, P69, DOI 10.1016/0006-8993(94)90796-X; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Picconi B, 2004, J NEUROSCI, V24, P5283, DOI 10.1523/JNEUROSCI.1224-04.2004; Picconi B, 2003, NAT NEUROSCI, V6, P501, DOI 10.1038/nn1040; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Rascol O, 2000, ANN NEUROL, V47, pS179; Ravenscroft P, 2004, EXP NEUROL, V185, P36, DOI 10.1016/j.expneurol.2003.09.001; Reuver SM, 1998, J CELL SCI, V111, P1071; Segovia G, 2003, MOVEMENT DISORD, V18, P138, DOI 10.1002/mds.10312; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Silverdale MA, 2003, ADV NEUROL, V91, P273; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tahar AH, 2003, ADV NEUROL, V91, P51; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; UNGERSTEDT U, 1970, Brain Research, V24, P485, DOI 10.1016/0006-8993(70)90187-3; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Whishaw IQ, 2003, J NEUROSCI METH, V126, P13, DOI 10.1016/S0165-0270(03)00049-9; Winkler C, 2002, NEUROBIOL DIS, V10, P165, DOI 10.1006/nbdi.2002.0499; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; ZIGMOND MJ, 1990, TRENDS NEUROSCI, V13, P290, DOI 10.1016/0166-2236(90)90112-N	65	61	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					583	+		10.1096/fj.04-1854fje	http://dx.doi.org/10.1096/fj.04-1854fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703272				2022-12-28	WOS:000227591900019
J	Kolossov, E; Lu, ZJ; Drobinskaya, I; Gassanov, N; Duan, YQ; Sauer, H; Manzke, O; Bloch, W; Bohlen, H; Hescheler, J; Fleischmann, BK				Kolossov, E; Lu, ZJ; Drobinskaya, I; Gassanov, N; Duan, YQ; Sauer, H; Manzke, O; Bloch, W; Bohlen, H; Hescheler, J; Fleischmann, BK			Identification and characterization of embryonic stem cell-derived pacemaker and atrial cardiomyocytes	FASEB JOURNAL			English	Article						ES cells; cardiac differentiation; alpha-myosin heavy chain promoter; atrial-like cells; pacemaker-like cells	GREEN FLUORESCENT PROTEIN; MYOSIN GENE-EXPRESSION; HEAVY-CHAIN GENE; CARDIAC-MUSCLE; CA2+ CHANNEL; IN-VITRO; HEART; TISSUE; CARDIOMYOGENESIS; MORPHOGENESIS	The aim of this study was to identify and functionally characterize cardiac subtypes during early stages of development. For this purpose, transgenic embryonic stem cells were generated using the alpha-myosin heavy chain promoter driving the expression of the enhanced green fluorescent protein (EGFP). EGFP-positive clusters of cells were first observed as early as 7 days of development, thus, even before the initiation of the contractile activity. Flow cytometry and single-cell fluorescence measurements evidenced large diversities of EGFP intensity. Patch-clamp experiments showed EGFP expression exclusively in pacemaker and atrial but not ventricular cells. The highest fluorescence intensities were detected in pacemaker-like cardiomyocytes. In accordance, multielectrode-array recordings of whole embryoid bodies confirmed that the pacemaker center coincided with strongly EGFP-positive areas. The cardiac subtypes displayed already at this early stage differential characteristics of electrical activity and ion channel expression. Thus, quantitation of the alpha-myosin heavy chain driven reporter gene expression allows identification and functional characterization of early cardiac subtypes.	Axiogenesis AG, Cologne, Germany; Univ Cologne, Inst Nuerophysiol, Cologne, Germany; Univ Cologne, Inst Internal Med 1, Cologne, Germany; German Sports Univ, Dept Mol & Cellular Sport Med, Cologne, Germany; Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany	University of Cologne; University of Cologne; German Sport University Cologne; University of Bonn	Kolossov, E (corresponding author), Univ Bonn, Inst Physiol 1, Argelanderstr 2A, D-53115 Bonn, Germany.	eugen.kolossov@axiogenesis.com; bernd.fleischmann@uni-bonn.de						Abi-Gerges N, 2000, J PHYSIOL-LONDON, V523, P377, DOI 10.1111/j.1469-7793.2000.t01-2-00377.x; Accili EA, 2002, NEWS PHYSIOL SCI, V17, P32, DOI 10.1152/physiologyonline.2002.17.1.32; ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; DEGROOT IJM, 1989, ANAT REC, V224, P365, DOI 10.1002/ar.1092240305; DIFRANCESCO D, 1995, CARDIOVASC RES, V29, P449, DOI 10.1016/S0008-6363(96)88518-X; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Fijnvandraat AC, 2003, CARDIOVASC RES, V58, P399, DOI 10.1016/S0008-6363(03)00282-7; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; GORZA L, 1986, J CELL BIOL, V102, P1758, DOI 10.1083/jcb.102.5.1758; Gryshchenko O, 2000, PFLUG ARCH EUR J PHY, V439, P798, DOI 10.1007/s004240051007; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Igelmund P, 1999, PFLUG ARCH EUR J PHY, V437, P669, DOI 10.1007/s004240050831; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KAMINO K, 1991, PHYSIOL REV, V71, P53, DOI 10.1152/physrev.1991.71.1.53; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; KUROO M, 1986, J CLIN INVEST, V77, P340, DOI 10.1172/JCI112310; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; NANOT J, 1977, J EMBRYOL EXP MORPH, V37, P133; RINDT H, 1993, J BIOL CHEM, V268, P5332; Robbins J, 1997, TRENDS CARDIOVAS MED, V7, P185, DOI 10.1016/S1050-1738(97)00048-0; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; TAYLOR JJ, 1978, AM J PHYSIOL, V235, pH407, DOI 10.1152/ajpheart.1978.235.4.H407; VANMIEROP LH, 1967, AM J PHYSIOL, V212, P407, DOI 10.1152/ajplegacy.1967.212.2.407; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; WESSELS A, 1991, ANAT REC, V229, P355, DOI 10.1002/ar.1092290309; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Xie LH, 1997, AM J PHYSIOL-HEART C, V272, pH1741, DOI 10.1152/ajpheart.1997.272.4.H1741; YUTZEY KE, 1995, DEV BIOL, V170, P531, DOI 10.1006/dbio.1995.1234; Zammit PS, 2000, DEV DYNAM, V217, P75, DOI 10.1002/(SICI)1097-0177(200001)217:1<75::AID-DVDY7>3.0.CO;2-L	34	85	101	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					577	+		10.1096/fj.03-1451fje	http://dx.doi.org/10.1096/fj.03-1451fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15659535				2022-12-28	WOS:000226576600021
J	McDaid, J; Yamashita, K; Chora, A; Ollinger, R; Strom, TB; Li, XC; Bach, FH; Soares, MP				McDaid, J; Yamashita, K; Chora, A; Ollinger, R; Strom, TB; Li, XC; Bach, FH; Soares, MP			Heme oxygenase-1 modulates the allo-immune response by promoting activation-induced cell death of T cells	FASEB JOURNAL			English	Article						T lymphocytes; apoptosis; cellular activation	ISCHEMIA/REPERFUSION INJURY; OVEREXPRESSION; INDUCTION; APOPTOSIS; ALLOGRAFT; GENE; INHIBITION; SUPPRESSES; PROTECTS; STRESS	Heme oxygenase-1 (HO-1), which degrades heme into three products (carbon monoxide, free iron, and biliverdin), plays a protective role in many models of disease via its anti-inflammatory, anti-apoptotic, and anti-proliferative actions. Overexpression of HO-1 has been shown to suppress immune responses and prolong the survival of allografts; however, the underlying mechanism is not clear. We demonstrate two "new" properties of HO-1 that mediate activation induced cell death (AICD) of allo-antigen-responsive murine CD4(+) T cells, resulting in immunomodulation. First, it functions in vivo and in vitro to "boost" the proliferative response of CD4(+) T cells to allo-antigens in the early phase of allo-antigen-driven immune responses. This "boosting" effect is accompanied with a significant increase of activation markers and IL-2 production. Second, it exerts a pro-apoptotic effect in those activated T cells after the initial burst of proliferation. We further show that the AICD effect is mediated through the Fas/CD95- FasL signal transduction pathway. Correlating with the above-mentioned findings is the observed prolongation of mouse heart graft survival when HO-1 is expressed in vivo in both donor and recipient. In conclusion, induction of HO-1 expression accelerates clonal deletion of peripheral alloreactive CD4(+) T cells by promoting AICD, which is presumably a key mechanism for its immunomodulatory effects such as in prolonging the survival of transplanted organs.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Immunobiol Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Immunol, Boston, MA 02215 USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Instituto Gulbenkian de Ciencia	Soares, MP (corresponding author), Gulbenkian Inst Sci, Inflammat Lab, Rua Quinta Grande 6, P-2780 Oeiras, Portugal.	mpsoares@igc.gulbenkian.pt	Ferreira Chora, Angelo/AAZ-6503-2021; Soares, Miguel P/G-4188-2011; Strom, Terry B./E-9268-2010; Öllinger, Robert/D-1538-2009	Ferreira Chora, Angelo/0000-0002-7941-7196; Strom, Terry B./0000-0002-7570-0736; Ollinger, Robert/0000-0002-4499-1673; Soares, Miguel/0000-0002-9314-4833; Li, Xian Chang/0000-0002-5981-2762	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058688, R01HL067040] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-58688, R01 HL-67040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; Araujo JA, 2003, J IMMUNOL, V171, P1572, DOI 10.4049/jimmunol.171.3.1572; Berberat PO, 2003, FASEB J, V17, P1724, DOI 10.1096/fj.03-0229fje; Bouchet D, 2002, TRANSPL IMMUNOL, V9, P235, DOI 10.1016/S0966-3274(02)00037-0; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chauveau C, 2002, AM J TRANSPLANT, V2, P581, DOI 10.1034/j.1600-6143.2002.20702.x; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Ducoroy P, 2003, BLOOD, V101, P194, DOI 10.1182/blood-2002-02-0603; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Genestier L, 1998, J CLIN INVEST, V102, P322, DOI 10.1172/JCI2676; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Leung DTM, 2000, J IMMUNOL, V164, P3527, DOI 10.4049/jimmunol.164.7.3527; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RASHID A, 1992, J IMMUNOL, V148, P1382; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; Tsui TY, 2003, CIRCULATION, V107, P2623, DOI 10.1161/01.CIR.0000066911.03770.8D; Tullius SG, 2002, TRANSPLANTATION, V74, P591, DOI 10.1097/00007890-200209150-00001; Van Parijs L, 1998, J IMMUNOL, V160, P2065; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Visner GA, 2003, CIRCULATION, V107, P911, DOI 10.1161/01.CIR.0000048191.75585.60; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; WATERFIELD JD, 1987, IMMUNOLOGY, V61, P173; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 1998, TRANSPL IMMUNOL, V6, P84, DOI 10.1016/S0966-3274(98)80022-1	41	85	92	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					458	+		10.1096/fj.04-2217fje	http://dx.doi.org/10.1096/fj.04-2217fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15640283				2022-12-28	WOS:000226576600027
J	Roato, I; Grano, M; Brunetti, G; Colucci, S; Mussa, A; Bertetto, O; Ferracini, R				Roato, I; Grano, M; Brunetti, G; Colucci, S; Mussa, A; Bertetto, O; Ferracini, R			Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement	FASEB JOURNAL			English	Article						bone metastases; osteoclast; osteolysis; T lymphocytes	KAPPA-B LIGAND; REGULATORY T-CELLS; BLOOD MONONUCLEAR-CELLS; RECEPTOR ACTIVATOR; PERIPHERAL-BLOOD; MULTIPLE-MYELOMA; DIFFERENTIATION FACTOR; LUNG-CANCER; RESORPTION; DISEASE	Bone metastases represents a common cause of morbidity in patients suffering many types of cancer: breast, lung, kidney, prostate, and multiple myeloma. Osteolytic metastases often cause severe pain, pathologic fractures, hypercalcemia, spinal cord compression, and other nerve-compression syndromes. Osteoclasts (OCs), cells deriving from granulocitic-macrophagic lineage, are responsible for osteolysis, which may be reduced by inhibiting both OCs formation and activity. By studying bone osteolytic metastases mechanism in solid tumors, we report here our findings that cancer patients with bone involvement display an increase in osteoclasts precursors, compared with both healthy controls and cancer patients without bone metastases. Peripheral blood mononuclear cells (PBMCs) from patients with osteolytic lesions show osteoclastogenesis without adding M-CSF, RANKL, or TNF-alpha. However, these factors are necessary to generate OCs from healthy donors, non-osteolytic patient PBMCs and T-cell depleted PBMCs. OCs derived from cancer patients show more resorption pits than OCs from healthy donors and express genes involved in osteoclastogenesis. Our data show that a spontaneous osteoclastogenesis occurs in patients affected by osteolytic lesions and may be supported by factors released by T lymphocytes. These factors could give a priming to osteoclast precursors and promote osteoclastogenesis. In fact, T-cell depleted PBMCs do not differentiate into OCs without adding M-CSF and RANKL. Moreover, we do not obtain a higher number of OCs by increasing RANKL doses in cultures, and OCs and T lymphocytes mRNA level are detected for TNF-alpha but not for RANKL. The addition of OPG to PBMCs cultures do not modify spontaneous osteoclastogenesis. A neutralizing anti-TNF-alpha antibody in unstimulated PBMC cultures of osteolytic cancer patients induces an inhibition of osteoclastogenesis.	Univ & ASO San Giovanni Battista, CeRMS, I-10126 Turin, Italy; Univ Bari, Dept Human Anat & Histol, I-70121 Bari, Italy; Univ & ASO San Giovanni Battista, Dept Med Oncol, I-10126 Turin, Italy; ASO San Giovanni Battista, Dept Orthopaed, Turin, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Universita degli Studi di Bari Aldo Moro; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Roato, I (corresponding author), Univ & ASO San Giovanni Battista, CeRMS, I-10126 Turin, Italy.	roato78@libero.it	Ferracini, Riccardo/AAL-4622-2020; Giacomina, Brunetti/J-7692-2016	Giacomina, Brunetti/0000-0002-0681-1432; bertetto, oscar/0000-0001-5133-2724; Roato, Ilaria/0000-0003-3029-4743; Colucci, Silvia/0000-0001-9970-3539; Grano, Maria/0000-0002-7121-5899				Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Assuma R, 1998, J IMMUNOL, V160, P403; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Berenson JR, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34071; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688; Capanna R, 2001, J BONE JOINT SURG BR, V83B, P471, DOI 10.1302/0301-620X.83B4.12202; COLUCCI S, 2004, BLOOD; DEMULDER A, 1993, ENDOCRINOLOGY, V133, P1978, DOI 10.1210/en.133.5.1978; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood-2002-04-1121; GREGORETTI MG, 1995, LEUKEMIA, V9, P1392; Hofbauer LC, 2001, CANCER-AM CANCER SOC, V92, P460, DOI 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D; HORTON MA, 1985, CANCER RES, V45, P5663; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Massey HM, 1999, BRIT J HAEMATOL, V106, P167; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Onizuka S, 1999, CANCER RES, V59, P3128; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736-0266(02)00106-7; Shimizu J, 1999, J IMMUNOL, V163, P5211; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sprent J, 2001, CURR OPIN IMMUNOL, V13, P248, DOI 10.1016/S0952-7915(00)00211-9; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Wolf AM, 2003, CLIN CANCER RES, V9, P606; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272; Woo EY, 2001, CANCER RES, V61, P4766; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yee C, 2002, NAT REV CANCER, V2, P409, DOI 10.1038/nrc820	44	79	82	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					228	+		10.1096/fj.04-1823fje	http://dx.doi.org/10.1096/fj.04-1823fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15550550				2022-12-28	WOS:000225482100008
J	Unnikrishnan, M; Burleigh, BA				Unnikrishnan, M; Burleigh, BA			Inhibition of host connective tissue growth factor expression: a novel Trypanosoma cruzi-mediated response	FASEB JOURNAL			English	Article						parasite; extracellular matrix; infection; mitogen-activated kinases	INTESTINAL EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; TGF-BETA; GENE-EXPRESSION; MAMMALIAN-CELLS; BACTERIAL PROTEINASES; EXTRACELLULAR-MATRIX; CTGF EXPRESSION; INVASION; FIBROBLASTS	Connective tissue growth factor ( CTGF) is a secreted cytokine that plays a fundamental role in the development of tissue fibrosis by mediating many of the profibrotic effects of TGF-beta. We present the novel finding that the intracellular pathogen Trypanosoma cruzi elicits immediate and sustained repression of basal CTGF expression in dermal fibroblasts, followed by down-regulation of the extracellular matrix proteins, fibronectin, and collagen I alpha1. To address mechanisms underlying this response, the major CTGF-regulating pathways were investigated. We report that both T. cruzi trypomastigotes and secreted parasite factor(s) antagonize TGF-beta-dependent induction of CTGF in fibroblasts. Of the TGF-beta-dependent signaling pathways required for CTGF expression, we demonstrate that T. cruzi interferes with cellular Erk1/2 phosphorylation but not Smad3 signaling. While increased stimulation of Erk phosphorylation alone was insufficient to override the parasite-mediated repression of CTGF, stimulation of fibroblasts with increased concentrations of TGF-beta, which activates both Smad3 and Erk1/2, completely abrogated this inhibition. Together with the finding that T. cruzi-mediated down-regulation of CTGF expression requires de novo host cell protein synthesis, our data indicate that the unique ability of T. cruzi to interfere with the host fibrogenic response is a complex process requiring input from multiple host cell signaling pathways.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Burleigh, BA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bburleig@hsph.harvard.edu		Unnikrishnan, Meera/0000-0001-5417-9331	NHLBI NIH HHS [HL073227] Funding Source: Medline; NIAID NIH HHS [AI47960] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047960] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Baldwin DN, 2003, GENOME BIOL, V4; Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burleigh BA, 2002, CELL MICROBIOL, V4, P701, DOI 10.1046/j.1462-5822.2002.00226.x; BURLEIGH BA, 1995, J BIOL CHEM, V270, P5172, DOI 10.1074/jbc.270.10.5172; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; Caler EV, 2000, INFECT IMMUN, V68, P6602, DOI 10.1128/IAI.68.12.6602-6610.2000; Chen MM, 2000, J MOL CELL CARDIOL, V32, P1805, DOI 10.1006/jmcc.2000.1215; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Chuenkova MV, 2001, P NATL ACAD SCI USA, V98, P9936, DOI 10.1073/pnas.161298398; de Avalos SV, 2002, J BIOL CHEM, V277, P639, DOI 10.1074/jbc.M109037200; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Eckmann L, 2000, J BIOL CHEM, V275, P14084, DOI 10.1074/jbc.275.19.14084; Fan WH, 2000, BIOCHEM BIOPH RES CO, V275, P312, DOI 10.1006/bbrc.2000.3314; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gebbia JA, 2001, INFECT IMMUN, V69, P456, DOI 10.1128/IAI.69.1.456-462.2001; Grellier P, 2001, J BIOL CHEM, V276, P47078, DOI 10.1074/jbc.M106017200; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Gull K, 2001, INT J PARASITOL, V31, P443, DOI 10.1016/S0020-7519(01)00154-0; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; Hishikawa K, 2000, EUR J PHARMACOL, V392, P19, DOI 10.1016/S0014-2999(00)00115-1; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Igarashi A, 1998, J CUTAN PATHOL, V25, P143, DOI 10.1111/j.1600-0560.1998.tb01706.x; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; Kirchhoff LV, 1996, GASTROENTEROL CLIN N, V25, P517, DOI 10.1016/S0889-8553(05)70261-2; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nowinski D, 2002, J INVEST DERMATOL, V119, P449, DOI 10.1046/j.1523-1747.2002.01841.x; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rishikof DC, 2002, J CELL BIOCHEM, V85, P496, DOI 10.1002/jcb.10144; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; Rodriguez A, 1999, J BIOL CHEM, V274, P16754, DOI 10.1074/jbc.274.24.16754; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; Santana JM, 1997, BIOCHEM J, V325, P129, DOI 10.1042/bj3250129; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; Tabibzadeh S, 2002, FRONT BIOSCI-LANDMRK, V7, pD1231; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Williams EJ, 2000, J HEPATOL, V32, P754, DOI 10.1016/S0168-8278(00)80244-5; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	53	15	16	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					1625	1635		10.1096/fj.04-1554com	http://dx.doi.org/10.1096/fj.04-1554com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522908				2022-12-28	WOS:000225482100031
J	Naaz, A; Holsberger, DR; Iwamoto, GA; Nelson, A; Kiyokawa, H; Cooke, PS				Naaz, A; Holsberger, DR; Iwamoto, GA; Nelson, A; Kiyokawa, H; Cooke, PS			Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity	FASEB JOURNAL			English	Article						p27; p21; adipogenesis; insulin resistance; transgenic; cell cycle	ADIPOSE-TISSUE CELLULARITY; INSULIN-RECEPTOR; GLUCOSE-INTOLERANCE; KNOCKOUT MICE; ADIPOGENESIS; CHILDHOOD; MUSCLE; DIFFERENTIATION; DEGRADATION; OVERWEIGHT	Adipocyte hyperplasia is characteristic of some forms of human obesity, but the role of adipocyte number in obesity and how normal adipocyte number is established are unclear. Preadipocytes proliferate and then differentiate to become mitotically quiescent adipocytes. This involves exit from the cell cycle, a process regulated by cell cycle inhibitors such as the cyclin-dependent kinase inhibitors (CDKIs) p27 and p21. 3T3-L1 preadipocytes show marked changes in p27 and p21 during differentiation, suggesting CDKIs may regulate establishment of adipocyte number in vivo. To study the role of these CDKIs in adipogenesis, we analyzed adult p27 knockout (p27KO), p21 knockout (p21KO), p27/p21 double knockout (DBKO), and wildtype (WT) mice. Adult DBKO mice weighed 100% more and had fourfold increases in body fat percentage compared with WT. Fat pad weights were increased 80, 90, and 500% in p27KO, p21KO, and DBKO mice, respectively, compared with WT. Adipocyte numbers of p27KO, p21KO, and DBKO mice were 1.9-, 1.7-, and 6.1-fold, respectively, that of WT; adipocyte size was not increased. DBKO mice showed glucose intolerance, insulin insensitivity, hepatic steatosis and dyslipidemia; gradations of these effects occurred in p27KO and p21KO mice. In conclusion, p27KO and p21KO mice are obese because of adipocyte hyperplasia, and DBKO mice have further increases in obesity and adipocyte hyperplasia, indicating that their functions in establishing adipocyte number are not redundant. p27 and p21 are major regulators of adipocyte number in vivo, and knockouts lacking one or both of these proteins provide models for producing adipocyte hyperplasia and understanding its metabolic consequences.	Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA; Univ Illinois, Dept Kinesiol, Urbana, IL 61802 USA; Univ Illinois, Div Nutr Sci, Urbana, IL 61802 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cooke, PS (corresponding author), Univ Illinois, Dept Vet Biosci, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	p-cooke@uiuc.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NIA NIH HHS [AG024387] Funding Source: Medline; NICHD NIH HHS [HD38085] Funding Source: Medline; NIEHS NIH HHS [ES11590] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG024387] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cariou B, 2004, ENDOCRINOLOGY, V145, P1926, DOI 10.1210/en.2003-0882; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; HAGER A, 1977, METABOLISM, V26, P607, DOI 10.1016/0026-0495(77)90082-8; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; HIRSCH J, 1976, CLIN ENDOCRINOL META, V5, P299, DOI 10.1016/S0300-595X(76)80023-0; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; JOHNSON PR, 1972, J LIPID RES, V13, P2; KIRKLAND JL, 1990, AM J PHYSIOL, V258, pC206, DOI 10.1152/ajpcell.1990.258.2.C206; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Lin J, 2003, BIOCHEM BIOPH RES CO, V300, P938, DOI 10.1016/S0006-291X(02)02949-2; Marques BG, 1998, AM J PHYSIOL-REG I, V275, pR1898, DOI 10.1152/ajpregu.1998.275.6.R1898; Martorell R, 2001, J NUTR, V131, p874S, DOI 10.1093/jn/131.3.874S; MERSMANN HJ, 1986, J ANIM SCI, V62, P980, DOI 10.2527/jas1986.624980x; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; MOSSBERG HO, 1989, LANCET, V2, P491; Ortenblad A, 2002, INT J MANAG REV, V4, P87, DOI 10.1111/1468-2370.00078; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHNEIDER BS, 1981, AM J PHYSIOL, V240, pE358, DOI 10.1152/ajpendo.1981.240.4.E358; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Turnbull A, 2004, J PAEDIATR CHILD H, V40, P33, DOI 10.1111/j.1440-1754.2004.00286.x; Vanhala M, 1998, BRIT MED J, V317, P319, DOI 10.1136/bmj.317.7154.319; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	34	110	111	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1925	+		10.1096/fj.04-2631fje	http://dx.doi.org/10.1096/fj.04-2631fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15469964				2022-12-28	WOS:000224849900024
J	Broedl, UC; Jin, WJ; Fuki, IV; Glick, JM; Rader, DJ				Broedl, UC; Jin, WJ; Fuki, IV; Glick, JM; Rader, DJ			Structural basis of endothelial lipase tropism for HDL	FASEB JOURNAL			English	Article						lipoprotein lipase; lipoprotein hydrolysis; lipoprotein binding	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; HEPATIC LIPASE; TRIGLYCERIDE LIPASE; PANCREATIC LIPASE; ENHANCES BINDING; CHIMERIC LIPASE; CATALYTIC SITE; GENE FAMILY	Lipoprotein lipase (LPL) and endothelial lipase (EL), the most closely related enzymes among the members of the triglyceride lipase gene family with regard to primary sequence, have distinct lipolytic properties ( triglyceride lipase vs. phospholipase) as well as different preferences for specific types of lipoproteins [triglyceride-rich lipoproteins vs. high density lipoprotein (HDL)] Lipid substrate specificity is believed to be conferred by the lid region located in the amino-terminal domain of the enzymes, whereas surprisingly little work has been done to identify the region mediating lipoprotein substrate specificity. To determine the domain responsible for lipoprotein preference within each enzyme, we generated the domain chimeric enzyme LPL-EL. The heterologous carboxy-terminal ( C terminal) domain did not change lipid substrate preference ( triglyceride vs. phospholipase) as determined by using artificial substrates. The EL C-terminal domain, however, enabled LPL-EL to bridge HDL particles like wild-type EL, whereas LPL only mediated binding of very low density lipoprotein. Unlike wild-type LPL, LPL-EL had substantial ability to hydrolyze HDL lipids similar to that of wild-type EL. Overexpression of LPL-EL in wild-type mice resulted in significantly reduced levels of HDL cholesterol and phospholipids by 93 and 85%, respectively, similar to the extent seen in EL-expressing mice, whereas no reduction of these parameters was observed in LPL-expressing mice. We conclude that the C-terminal domain of EL is crucial for the ability of EL to bind and to hydrolyze HDL and converts LPL to an enzyme fully capable of hydrolyzing HDL, highlighting the importance of the C-terminal lipase domain in lipoprotein substrate preference.	Univ Penn, Med Ctr, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rader, DJ (corresponding author), Univ Penn, Med Ctr, Sch Med, Dept Med, 654 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	rader@mail.med.upenn.edu			NHLBI NIH HHS [HL55323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055323, R37HL055323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Broedl UC, 2004, CIRC RES, V94, P1554, DOI 10.1161/01.RES.0000130657.00222.39; Broedl UC, 2003, J BIOL CHEM, V278, P40688, DOI 10.1074/jbc.M304367200; Chahinian H, 2000, CURR PROTEIN PEPT SC, V1, P91, DOI 10.2174/1389203003381487; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jin WJ, 2002, GENOMICS, V80, P268, DOI 10.1006/geno.2002.6837; Kobayashi J, 1996, J BIOL CHEM, V271, P26296, DOI 10.1074/jbc.271.42.26296; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; Maugeais C, 2003, CIRCULATION, V108, P2121, DOI 10.1161/01.CIR.0000092889.24713.DC; McCoy MG, 2002, J LIPID RES, V43, P921; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; Rader DJ, 2000, CURR OPIN LIPIDOL, V11, P141, DOI 10.1097/00041433-200004000-00006; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; Sato T, 1997, J BIOL CHEM, V272, P2192; Sonoda H, 2002, J BIOL CHEM, V277, P34254, DOI 10.1074/jbc.M201659200; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R., 1984, LIPASES, P84; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG H, 1994, J BIOL CHEM, V269, P10319; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	36	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1891	+		10.1096/fj.03-1307fje	http://dx.doi.org/10.1096/fj.03-1307fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456739				2022-12-28	WOS:000224243200006
J	Huang, SS; Leal, SM; Chen, CL; Liu, IH; Huang, JS				Huang, SS; Leal, SM; Chen, CL; Liu, IH; Huang, JS			Identification of insulin receptor substrate proteins as key molecules for the T beta R-V/LRP-1-mediated growth inhibitory signaling cascade in epithelial and myeloid cells	FASEB JOURNAL			English	Article						IGFBP-3; (Q(3)A(4)Y(15)L(16)) IGF-I; serine-specific dephosphorylation; IRS-1; IRS-2	FACTOR-BETA RECEPTOR; FACTOR-BINDING PROTEIN-3; TGF-BETA; TYROSINE PHOSPHORYLATION; IRS PROTEINS; KINASE-ACTIVITY; DNA-SYNTHESIS; V RECEPTOR; FACTOR-I; TRANSDUCTION	The type V TGF-beta receptor (TbetaR-V) mediates IGF-independent growth inhibition by IGFBP-3 and mediates growth inhibition by TGF-beta (1) in concert with the other TGF-beta receptor types. TbetaR-V was recently found to be identical to LRP-1. Here we find that insulin and (Q(3)A(4)Y(15)L(16)) IGF-I (an IGF-I analog that has a low affinity for IGFBP-3) antagonize growth inhibition by IGFBP-3 in mink lung epithelial cells (Mv1Lu cells) stimulated by serum. In these cells, IGFBP-3 induces serine-specific dephosphorylation of IRS-1 and IRS-2. The IGFBP-3-induced dephosphorylation of IRS-2 is prevented by cotreatment of cells with insulin, (Q(3)A(4)Y(15)L(16)) IGF-I, or TbetaR-V/LRP-1 antagonists. The magnitude of the IRS-2 dephosphorylation induced by IGFBP-3 positively correlates with the degree of growth inhibition by IGFBP-3 in Mv1Lu cells and mutant cells derived from Mv1Lu cells. Stable transfection of murine 32D myeloid cells ( which lack endogenous IRS proteins and are insensitive to growth inhibition by IGFBP-3) with IRS-1 or IRS-2 cDNA confers sensitivity to growth inhibition by IGFBP-3; this IRS-mediated growth inhibition can be completely reversed by insulin in 32D cells stably expressing IRS-2 and the insulin receptor. These results suggest that IRS-1 and IRS-2 are key molecules for the TbetaRV/LRP-1-mediated growth inhibitory signaling cascade.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangss@slu.edu			NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Bu GJ, 2001, INT REV CYTOL, V209, P79; Buckley J. S., 1995, SPE ADV TECH SER, V3, P53; CASCIERI MA, 1989, J CELL PHYSIOL, V139, P181, DOI 10.1002/jcp.1041390125; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CONOVER A, 1989, HORM METAB RES, V21, P59, DOI 10.1055/s-2007-1009151; Devi GR, 2001, GROWTH HORM IGF RES, V11, P231, DOI 10.1054/ghir.2001.0231; Dong F, 2002, J CELL PHYSIOL, V190, P63, DOI 10.1002/jcp.10034; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gagnon AM, 1998, J CELL PHYSIOL, V175, P370, DOI 10.1002/(SICI)1097-4652(199806)175:3<370::AID-JCP15>3.0.CO;2-9; Gucev ZS, 1996, CANCER RES, V56, P1545; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Huang JS, 2002, FASEB J, V16, P1269, DOI 10.1096/fj.02-0103fje; Huang SS, 2004, FEBS LETT, V565, P117, DOI 10.1016/j.febslet.2004.03.082; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; LEAL SM, 1999, THESIS ST LOUIS U ST; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Liu QJ, 1999, J BIOL CHEM, V274, P20002, DOI 10.1074/jbc.274.28.20002; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCluskey A, 2002, J MED CHEM, V45, P1151, DOI 10.1021/jm010066k; Monzavi R, 2002, BEST PRACT RES CL EN, V16, P433, DOI 10.1053/beem.2002.0212; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Oh Youngman, 1995, Progress in Growth Factor Research, V6, P503, DOI 10.1016/0955-2235(95)00025-9; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PERALDI P, 1996, J BIOL CHEM, V271, P13081; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Roehrich ME, 2003, J BIOL CHEM, V278, P18368, DOI 10.1074/jbc.M300102200; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; Saudan P, 2000, EMBO J, V19, P4351, DOI 10.1093/emboj/19.16.4351; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Taipale J, 1996, J BIOL CHEM, V271, P4342; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J	61	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1719	+		10.1096/fj.04-1872fje	http://dx.doi.org/10.1096/fj.04-1872fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15371331				2022-12-28	WOS:000224243200025
J	Fricke, I; Mitchell, D; Petersen, F; Bohle, A; Bulfone-Paus, S; Brandau, S				Fricke, I; Mitchell, D; Petersen, F; Bohle, A; Bulfone-Paus, S; Brandau, S			Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigen-presenting cells	FASEB JOURNAL			English	Article						platelets; dendritic cells; NK cells; inflammation; BCG	CXC-CHEMOKINE PLATELET-FACTOR-4; DENDRITIC CELLS; IN-VITRO; DISTINCT SUBSETS; RELEASE; ALPHA; NEUTROPHILS; ACTIVATION; EXPRESSION; RESPONSES	Recent evidence suggests that platelets are not only involved in haemostatic processes but also modulate immune responses. As antigen-presenting cells (APC) are of crucial importance for the regulation of immunity, in this study we wanted to define the role of platelet factor 4 (PF-4) as one of the major platelet-derived chemokines on the transition of monocytes into APCs. Our experiments show that within 3 days PF-4 in conjunction with IL-4 induces a rapid differentiation of monocytes into APC. These PFAPC (PF-4/IL-4 differentiated APC) display unique phenotypical and functional characteristics setting them apart from macrophages and conventional dendritic cells. Functional studies revealed that PFAPC preferentially stimulated proliferation of lymphocytes and lytic NK activity while they induced only moderate cytokine responses. Beyond day 3 of differentiation, PFAPC became less immunostimulatory and maintained their capacity to phagocytose particulate material even after LPS-induced maturation. These experiments uncover a previously unknown role for the platelet-derived CXC-chemokine PF-4 in differentiation of human APC. Our data further support the newly discovered function of platelets in immunomodulation and provide new evidence for a rapid transition of monocytes into APC under the influence of inflammatory stimuli.	Res Ctr Borstel, Div Immunotherapy, D-23845 Borstel, Germany; Res Ctr Borstel, Div Immunobiol, D-23845 Borstel, Germany; Res Ctr Borstel, Div Biochem Immunol, D-23845 Borstel, Germany; Helios Agnes KArll Hosp, Bad Schwartau, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel	Brandau, S (corresponding author), Res Ctr Borstel, Div Immunotherapy, PArkallee 1-40, D-23845 Borstel, Germany.	sbrandau@fz-borstel.de		Fricke, Ingo/0000-0001-7638-3181; Brandau, Sven/0000-0002-2702-4163				Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Brandt E, 2000, IMMUNOL REV, V177, P204, DOI 10.1034/j.1600-065X.2000.17705.x; BRINDLEY LL, 1983, J CLIN INVEST, V72, P1218, DOI 10.1172/JCI111077; Chang CCJ, 2000, J IMMUNOL, V165, P3584, DOI 10.4049/jimmunol.165.7.3584; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Dauer M, 2003, J IMMUNOL, V170, P4069, DOI 10.4049/jimmunol.170.8.4069; DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; Di Pucchio T, 2003, EUR J IMMUNOL, V33, P358; Duperrier K, 2000, J IMMUNOL METHODS, V238, P119, DOI 10.1016/S0022-1759(00)00147-2; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Ebner S, 2002, J IMMUNOL, V168, P6199, DOI 10.4049/jimmunol.168.12.6199; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Fleischer J, 2002, J IMMUNOL, V169, P770, DOI 10.4049/jimmunol.169.2.770; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GRAGEGRIEBENOW E, 1993, EUR J IMMUNOL, V23, P3126, DOI 10.1002/eji.1830231213; Hart PH, 1996, IMMUNOLOGY, V89, P599, DOI 10.1046/j.1365-2567.1996.d01-779.x; Ho CSK, 2002, BLOOD, V99, P2897, DOI 10.1182/blood.V99.8.2897; Kalia R, 1999, COMPUT SCI ENG, V1, P2; Kim KD, 1999, IMMUNOLOGY, V97, P626; Klinger MHF, 2002, J INTERF CYTOK RES, V22, P913, DOI 10.1089/10799900260286623; Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897; Loskog A, 2002, CANCER GENE THER, V9, P846, DOI 10.1038/sj.cgt.7700507; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Marti F, 2002, J LEUKOCYTE BIOL, V72, P590; Narendran P, 2002, ANN NY ACAD SCI, V958, P170; PERVUSHINA O, IN PRESS J IMMUNOL; Petersen F, 1996, J IMMUNOL, V156, P1954; Pickl WF, 1996, J IMMUNOL, V157, P3850; Pietschmann P, 2000, SCAND J IMMUNOL, V51, P377; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; Randolph GJ, 2002, J EXP MED, V196, P517, DOI 10.1084/jem.20011608; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Scheuerer B, 2000, BLOOD, V95, P1158, DOI 10.1182/blood.V95.4.1158.004k31_1158_1166; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Thurnher M, 1997, INT J CANCER, V70, P128; Turpin J, 1986, J Clin Apher, V3, P111, DOI 10.1002/jca.2920030207; Xia CQ, 2003, INT IMMUNOL, V15, P1007, DOI 10.1093/intimm/dxg100; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040	44	43	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1588	+		10.1096/fj.03-1435fje	http://dx.doi.org/10.1096/fj.03-1435fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319366				2022-12-28	WOS:000223554900011
J	Tang, W; Ingalls, CP; Durham, WJ; Snider, J; Reid, MB; Wu, GY; Matzuk, MM; Hamilton, SL				Tang, W; Ingalls, CP; Durham, WJ; Snider, J; Reid, MB; Wu, GY; Matzuk, MM; Hamilton, SL			Altered excitation-contraction coupling with skeletal muscle specific FKBP12 deficiency	FASEB JOURNAL			English	Article						ryanodine receptor; cre/loxP mouse models	RYANODINE RECEPTOR FUNCTION; CENTRAL CORE DISEASE; RELEASE CHANNEL; CALCINEURIN; DIAPHRAGM; MYOTUBES; FIBERS; CELLS; MICE; FAILURE	The immunophilin FKBP12 binds the skeletal muscle Ca2+ release channel or ryanodine receptor (RyR1), but the functional consequences of this interaction are not known. In this study, we have generated skeletal muscle specific FKBP12-deficient mice to investigate the role of FKBP12 in skeletal muscle. Primary myotubes from these mice show no obvious change in either Ca2+ stores or resting Ca2+ levels but display decreased voltage-gated intracellular Ca2+ release and increased L-type Ca2+ currents. Consistent with the decreased voltage-gated Ca2+ release, maximal tetanic force production is decreased and the force frequency curves are shifted to the right in extensor digitorum longus (EDL) muscles of the mutant mice. In contrast, there is no decrease in maximal tetanic force production in the mutant diaphragm or soleus muscle. The force frequency curve is shifted to the left in the FKBP12-deficient diaphragm muscle compared with controls. No changes in myosin heavy chain (MHC) phenotype are observed in EDL or soleus muscle of the FKBP12-deficient mice, but diaphragm muscle displays an increased ratio of slow to fast MHC isoforms. Also, calcineurin levels are increased in the diaphragm of the mutant mice but not in the soleus or EDL. In summary, FKBP12 deficiency alters both orthograde and retrograde coupling between the L-type Ca2+ channel and RyR1 and the consequences of these changes depend on muscle type and activity. In highly used muscles such as the diaphragm, adaptation to the loss of FKBP12 occurs, possibly due to the increased Ca2+ influx.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Georgia State Univ, Dept Kinesiol & Hlth, Atlanta, GA 30303 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University System of Georgia; Georgia State University	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.	susanh@bcm.tmc.edu		Hamilton, Susan/0000-0003-0241-9369	NHLBI NIH HHS [HL-45721] Funding Source: Medline; NIAMS NIH HHS [AR-44864, AR-41802] Funding Source: Medline; NICHD NIH HHS [HD32067] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD032067] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044864, R01AR041802] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; Avila G, 2003, J BIOL CHEM, V278, P22600, DOI 10.1074/jbc.M205866200; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; Clancy JS, 1999, AM J PHYSIOL-REG I, V277, pR1205; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; Geiger PC, 1999, J APPL PHYSIOL, V87, P1894, DOI 10.1152/jappl.1999.87.5.1894; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Ingalls CP, 1998, J APPL PHYSIOL, V85, P58, DOI 10.1152/jappl.1998.85.1.58; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; LARACH MG, 1989, ANESTH ANALG, V69, P511; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; Schuhmeier RP, 2003, BIOPHYS J, V84, P1065, DOI 10.1016/S0006-3495(03)74923-6; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Sewry CA, 2002, NEUROMUSCULAR DISORD, V12, P930, DOI 10.1016/S0960-8966(02)00135-9; Shin DW, 2002, BIOPHYS J, V83, P2539, DOI 10.1016/S0006-3495(02)75265-X; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Staib JL, 2002, AM J PHYSIOL-REG I, V283, pR583, DOI 10.1152/ajpregu.00080.2002; THOMASON DB, 1986, J APPL PHYSIOL, V60, P1923, DOI 10.1152/jappl.1986.60.6.1923; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976	35	38	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1597	+		10.1096/fj.04-1587fje	http://dx.doi.org/10.1096/fj.04-1587fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289441				2022-12-28	WOS:000223554900023
J	Guenther, E; Schmid, S; Wheeler-Schilling, T; Albach, G; Grunder, T; Fauser, S; Kohler, K				Guenther, E; Schmid, S; Wheeler-Schilling, T; Albach, G; Grunder, T; Fauser, S; Kohler, K			Developmental plasticity of NMDA receptor function in the retina and the influence of light	FASEB JOURNAL			English	Article						retinal ganglion cells; light modulation; neurotransmitter receptor; development; glutamate receptor	OCULAR DOMINANCE PLASTICITY; NR2A SUBUNIT EXPRESSION; GANGLION-CELLS; NEUROTRANSMITTER REGULATION; SYNAPTIC CURRENTS; VISUAL EXPERIENCE; GLUTAMATE; RAT; BRAIN; STRATIFICATION	Despite the early expression of NMDA receptors (NMDARs) in the retina, not much is known about their regulation and involvement in plasticity processes during retinal development and synapse formation. Here we report that NMDAR function in the inner retina is developmentally regulated and controlled by ambient light condition. A prominent down-regulation after eye opening of NMDAR function was observed in rat retinal ganglion cells (RGCs), which was prevented by dark rearing the animals for 1 month but was again induced by subsequent light exposure. As shown by molecular analysis of single RGCs, alterations in the subunit composition of NMDAR did not account for the light-dependent regulation of NMDAR function. Immunocytochemistry showed no differences in the NMDAR protein expression pattern between normal and dark-reared animals. In conclusion, our data clearly demonstrate that NMDAR function is modulated during periods of retinal plasticity independent of structural alterations in its subunit composition and thus different from mechanisms observed in higher visual centers.	Univ Tubingen, Hosp Eye, Dept Pathophysiol Vis & Neuroophthalmol, Div Expt Ophthalmol,Lab Cell Physiol & Mol Biol, D-72076 Tubingen, Germany; Univ Tubingen, Nat Med Sci Inst NMI, D-72770 Reutlingen, Germany; Univ Tubingen, Inst Zool, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Guenther, E (corresponding author), NMI Reutlingen, Markwiesenstr 55, D-72770 Reutlingen, Germany.	guenther@nmi.de	Schmid, Susanne/J-3201-2012	Schmid, Susanne/0000-0001-5366-8061; Dr. Guenther, Elke/0000-0002-8758-1607; Wheeler-Schilling, Thomas H./0000-0003-3754-0193				Barnstable C J, 1993, Curr Opin Neurobiol, V3, P520, DOI 10.1016/0959-4388(93)90050-9; Bear MF, 1996, PROG BRAIN RES, V108, P205, DOI 10.1016/S0079-6123(08)62541-8; Bisti S, 1998, J NEUROSCI, V18, P5019; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; BODNARENKO SR, 1995, J NEUROSCI, V15, P7037; Brandstatter JH, 1998, VISION RES, V38, P1385, DOI 10.1016/S0042-6989(97)00176-4; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; COHEN ED, 1994, VISUAL NEUROSCI, V11, P317, DOI 10.1017/S0952523800001668; Constantine-Paton M, 1998, CURR OPIN NEUROBIOL, V8, P139, DOI 10.1016/S0959-4388(98)80017-2; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DUVOISIN RM, 1995, NEUROSCI LETT, V183, P83, DOI 10.1016/0304-3940(94)11120-8; Flint AC, 1997, J NEUROSCI, V17, P2469; Fox K, 1999, NAT NEUROSCI, V2, P297, DOI 10.1038/7203; Fox Kevin, 1994, Current Opinion in Neurobiology, V4, P112, DOI 10.1016/0959-4388(94)90040-X; Grunder T, 2000, INVEST OPHTH VIS SCI, V41, P3600; Grunder T, 2000, J NEUROBIOL, V44, P333; Grzywacz NM, 1998, VISUAL NEUROSCI, V15, P1119, DOI 10.1017/S0952523898156109; GUENTHER E, 1994, J NEUROSCI METH, V51, P177, DOI 10.1016/0165-0270(94)90008-6; Herkert M, 1998, EUR J NEUROSCI, V10, P1553, DOI 10.1046/j.1460-9568.1998.00164.x; HERMES B, 1992, INT J DEV NEUROSCI, V10, P215, DOI 10.1016/0736-5748(92)90061-4; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; Izumi Y, 1995, NEUROBIOL DIS, V2, P139, DOI 10.1006/nbdi.1995.0015; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; Kroger RHH, 1996, VISION RES, V36, P3879, DOI 10.1016/S0042-6989(96)00132-0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Liets LC, 2001, PROG BRAIN RES, V134, P1; MASSEY SC, 1990, J NEUROPHYSIOL, V63, P16, DOI 10.1152/jn.1990.63.1.16; MULLER F, 1992, NEUROSCI LETT, V138, P179, DOI 10.1016/0304-3940(92)90500-7; PENG YW, 1995, NEUROSCIENCE, V66, P483, DOI 10.1016/0306-4522(94)00569-Q; Philpot BD, 2001, NEURON, V29, P157, DOI 10.1016/S0896-6273(01)00187-8; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; Roberts EB, 1999, J NEUROPHYSIOL, V81, P2587, DOI 10.1152/jn.1999.81.5.2587; Roberts EB, 1998, J NEUROPHYSIOL, V80, P1021, DOI 10.1152/jn.1998.80.3.1021; Schmid S, 1998, NEUROSCIENCE, V85, P249, DOI 10.1016/S0306-4522(97)00644-1; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Taylor WR, 1996, VISUAL NEUROSCI, V13, P979, DOI 10.1017/S0952523800009202; Tehrani A, 2000, INVEST OPHTH VIS SCI, V41, P314; Tian N, 2003, NEURON, V39, P85, DOI 10.1016/S0896-6273(03)00389-1; Tian N, 2001, NEURON, V32, P439, DOI 10.1016/S0896-6273(01)00470-6; Velte TJ, 1996, J NEUROPHYSIOL, V75, P2129, DOI 10.1152/jn.1996.75.5.2129; WEIDMAN TA, 1969, INVEST OPHTH VISUAL, V8, P60; WINGATE RJT, 1994, J NEUROSCI, V14, P6621; Wong WT, 2001, NAT NEUROSCI, V4, P351, DOI 10.1038/85987; Wong WT, 2000, J NEUROSCI, V20, P351, DOI 10.1523/JNEUROSCI.20-01-00351.2000; Wu SM, 1998, VISION RES, V38, P1371, DOI 10.1016/S0042-6989(97)00296-4; Xue J, 2002, DEV BRAIN RES, V138, P61, DOI 10.1016/S0165-3806(02)00460-1; Xue J, 2001, MOL BRAIN RES, V91, P196, DOI 10.1016/S0169-328X(01)00141-3	47	24	24	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1433	+		10.1096/fj.03-0618fje	http://dx.doi.org/10.1096/fj.03-0618fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247153				2022-12-28	WOS:000222979200011
J	Sun, XC; Zemel, MB				Sun, XC; Zemel, MB			Role of uncoupling protein 2 (UCP2) expression and 1 alpha,25-dihydroxyvitamin D-3 in modulating adipocyte apoptosis	FASEB JOURNAL			English	Article						calcitriol; calcium; mitochondrial potential; obesity	CELL-DEATH; ENDOPLASMIC-RETICULUM; BCL-2 FAMILY; INTRACELLULAR CALCIUM; ENERGY RESTRICTION; DIETARY CALCIUM; CA2+; MITOCHONDRIA; INHIBITION; INDUCTION	We previously found that 1alpha, 25-dihydroxyvitamin D-3 [1alpha, 25-(OH)(2)-D-3] modulates adipocyte lipid metabolism via a Ca2+-dependent mechanism and inhibits adipocyte UCP2 expression, indicating that the anti-obesity effects of dietary calcium are mediated by suppression of 1a, 25-(OH)(2)-D-3 levels. However, because UCP2 reduces mitochondrial potential, we have evaluated the roles of UCP2, mitochondrial uncoupling, and 1alpha, 25-(OH)(2)-D-3 in adipocyte apoptosis. Overexpressing UCP2 in 3T3-L1 cells induced marked reductions in mitochondrial potential (Deltapsi) and ATP production (P< 0.01), increases in the expression of caspases (P< 0.05), and a decrease in Bcl-2/Bax expression ratio (P< 0.01). Physiological doses of 1 alpha, 25-(OH)(2)-D-3 (0.1 - 10 nM) restored mitochondrial Delta psi in LI-UCP2 cells and protected against UCP2 overexpression-induced apoptosis ( P< 0.01), whereas a high dose ( 100 nM) stimulated apoptosis in 3T3-L1 and L1-UCP2 cells (P< 0.05). 1 alpha, 25-(OH)(2)-D-3 stimulated cytosolic Ca2+ dose-dependently in both 3T3-L1 and L1-UCP2 cells. However, physiological doses suppressed mitochondrial Ca2+ levels by similar to 50% whereas the high dose increased mitochondrial Ca2+ by 25% (P< 0.05); this explains stimulation of apoptosis by the high dose of 1alpha, 25-(OH)(2)-D-3. Using high-calcium diets to suppress 1alpha, 25-(OH)(2)-D-3 stimulated adipose tissue apoptosis in aP2 transgenic mice ( P< 0.01), suggesting that increasing dietary calcium stimulates adipose apoptosis and thereby further contributes to an anti-obesity effect of dietary calcium.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.	mzemel@utk.edu		sun, xiaocun/0000-0003-3053-1518; Zemel, Michael/0000-0003-4104-5750				Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Elias J, 2003, RECENT RESULTS CANC, V164, P319; Ferrara C, 2002, PEDIATR RADIOL, V32, P413, DOI 10.1007/s00247-001-0617-z; Festjens N, 2003, ACTA HAEMATOL-BASEL, V111, P7, DOI 10.1159/000074483; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kato T, 2002, LIFE SCI, V71, P581, DOI 10.1016/S0024-3205(02)01725-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Ma TS, 1998, ANN NY ACAD SCI, V853, P325, DOI 10.1111/j.1749-6632.1998.tb08291.x; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; McCarty MF, 2000, MED HYPOTHESES, V55, P187, DOI 10.1054/mehy.1999.1010; McConkey David J., 1996, Scanning Microscopy, V10, P777; Narvaez CJ, 2003, J STEROID BIOCHEM, V84, P199, DOI 10.1016/S0960-0760(03)00029-3; Niesler CU, 1998, DIABETES, V47, P1365, DOI 10.2337/diabetes.47.8.1365; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sergeev IN, 2003, ENDOCRINE, V22, P169, DOI 10.1385/ENDO:22:2:169; Shi H, 2002, FASEB J, V16, P1808, DOI 10.1096/fj.02-0255fje; Shi H, 2001, FASEB J, V15, P2751, DOI 10.1096/fj.01-0584fje; Shi H, 2001, FASEB J, V15, P291; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Sun XC, 2003, FASEB J, V17, pA746; Swamy N, 2003, J CELL BIOCHEM, V89, P909, DOI 10.1002/jcb.10585; Takadera T, 1998, BBA-MOL CELL RES, V1401, P63, DOI 10.1016/S0167-4889(97)00116-X; Tang YZ, 2004, GASTROENTEROLOGY, V126, P220, DOI 10.1053/j.gastro.2003.10.077; Tantral L, 2004, CELL BIOCHEM FUNCT, V22, P35, DOI 10.1002/cbf.1050; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wagner N, 2003, EXP EYE RES, V77, P1, DOI 10.1016/s0014-4835(03)00108-8; Weedon D, 1979, Am J Dermatopathol, V1, P133; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; Xue BZ, 2001, FASEB J, V15, P2527, DOI 10.1096/fj.01-0278fje; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yang NC, 2002, ANAL BIOCHEM, V306, P323, DOI 10.1006/abio.2002.5698; Zemel MB, 2003, LIPIDS, V38, P139, DOI 10.1007/s11745-003-1044-6; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132; Zemel MB, 2004, OBES RES, V12, P582, DOI 10.1038/oby.2004.67	51	74	97	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1430	+		10.1096/fj.04-1971fje	http://dx.doi.org/10.1096/fj.04-1971fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231722				2022-12-28	WOS:000222979200012
J	Whiteman, M; Armstrong, JS; Cheung, NS; Siau, JL; Rose, P; Schantz, JT; Jones, DP; Halliwell, B				Whiteman, M; Armstrong, JS; Cheung, NS; Siau, JL; Rose, P; Schantz, JT; Jones, DP; Halliwell, B			Peroxynitrite mediates calcium-dependent mitochondrial dysfunction and cell death via activation of calpains	FASEB JOURNAL			English	Article						mitochondria; nitrosative stress; apoptosis; SIN-1; reactive nitrogen species	PERMEABILITY TRANSITION PORE; NITRIC-OXIDE; REACTIVE OXYGEN; TYROSINE-NITRATION; HYPOCHLOROUS ACID; OXIDATIVE DAMAGE; CYTOCHROME-C; APOPTOSIS; CARTILAGE; NECROSIS	Chondrocyte cell death is a hallmark of inflammatory and degenerative joint diseases such as rheumatoid arthritis ( RA) and osteoarthritis (OA), but the molecular and cellular mechanisms involved have yet to be elucidated. Because 3-nitrotyrosine, a marker for reactive nitrogen species such as peroxynitrite, has been observed in OA and RA cartilage and has been associated with chondrocyte cell death, we investigated the mechanisms by which peroxynitrite induces cell death in human articular chondrocytes. The earliest biochemical event observed, subsequent to treatment with either peroxynitrite or the peroxynitrite generator SIN-1, was a rapid rise in intracellular calcium that lead to mitochondrial dysfunction and cell death. Although, chondrocyte death exhibited several classical hallmarks of apoptosis, including annexin V labeling, increased fraction of cells with subG1 DNA content and DNA condensation, we did not find evidence for caspase involvement either by Western blotting, fluorimetric assays, or caspase inhibition. Additionally, peroxynitrite did not inhibit cellular caspase activity. Furthermore, using other established assays of cell viability, including the MTT assay and release of lactate dehydrogenase, we found that the predominant mode of cell death involved calcium-dependent cysteine proteases, otherwise known as calpains. Our data show, for the first time, that peroxynitrite induces mitochondrial dysfunction in cells via a calcium-dependent process that leads to caspase-independent apoptosis mediated by calpains.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Plast Surg, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Bioengn, Singapore 117597, Singapore; Emory Univ, Sch Med, Ctr Clin & Mol Nutr, Clin Biomarkers Lab, Atlanta, GA USA	National University of Singapore; National University of Singapore; National University of Singapore; Emory University	Whiteman, M (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, 8 Med Dr, Singapore 117597, Singapore.	bchwml@nus.edu.sg		Halliwell, Barry/0000-0002-3560-7123				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Bauerova K, 1999, GEN PHYSIOL BIOPHYS, V18, P15; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Blattner JR, 2001, ANAL BIOCHEM, V295, P220, DOI 10.1006/abio.2001.5219; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Brookes PS, 2004, AM J PHYSIOL-HEART C, V286, pH39, DOI 10.1152/ajpheart.00742.2003; Cassina P, 2002, J NEUROSCI RES, V67, P21, DOI 10.1002/jnr.10107; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Cuzzocrea S, 2002, CRIT CARE MED, V30, P2284, DOI 10.1097/00003246-200210000-00017; Cuzzocrea S, 2000, AM J PATHOL, V157, P2065, DOI 10.1016/S0002-9440(10)64845-6; Darzynkiewicz Z, 2000, METHOD ENZYMOL, V322, P18; Del Carlo M, 2002, ARTHRITIS RHEUM, V46, P394, DOI 10.1002/art.10056; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; Georget M, 2002, FASEB J, V16, P1636, DOI 10.1096/fj.02-0292fje; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GREENACRE SAB, 2001, FREE RADICAL RES, V34, P514; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; Hadjigogos K, 2003, PANMINERVA MED, V45, P7; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; HALLIWELL B, 1995, ANN RHEUM DIS, V54, P505, DOI 10.1136/ard.54.6.505; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; He LH, 2003, J BIOL CHEM, V278, P16755, DOI 10.1074/jbc.M300153200; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Holm P, 1998, EUR J PHARMACOL, V346, P97, DOI 10.1016/S0014-2999(98)00009-0; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ishii M, 1999, J CARDIOVASC PHARM, V33, P295, DOI 10.1097/00005344-199902000-00018; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Jang D, 1998, FREE RADICAL BIO MED, V24, P1511, DOI 10.1016/S0891-5849(97)00459-0; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kim HA, 2000, J RHEUMATOL, V27, P455; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471-4892(03)00037-7; Loeser RF, 2002, ARTHRITIS RHEUM, V46, P2349, DOI 10.1002/art.10496; Mapp PI, 2001, ARTHRITIS RHEUM, V44, P1534, DOI 10.1002/1529-0131(200107)44:7<1534::AID-ART276>3.0.CO;2-#; Matsuo M, 2001, ACTA MED OKAYAMA, V55, P333; Murphy MP, 1998, GEN PHARMACOL, V31, P179, DOI 10.1016/S0306-3623(97)00418-7; Mykles DL, 2001, METHOD CELL BIOL, V66, P247; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Rose P, 2003, BIOCHEM BIOPH RES CO, V302, P397, DOI 10.1016/S0006-291X(03)00193-1; Sandhu JK, 2003, J RHEUMATOL, V30, P1173; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; Simpson PB, 1998, J PHYSIOL-LONDON, V508, P413, DOI 10.1111/j.1469-7793.1998.413bq.x; Spencer JPE, 1996, CHEM RES TOXICOL, V9, P1152, DOI 10.1021/tx960084i; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Studer R, 1999, OSTEOARTHR CARTILAGE, V7, P377, DOI 10.1053/joca.1998.0216; SUZUKI K, 1990, ARTHRITIS RHEUM, V33, P728, DOI 10.1002/art.1780330516; SZOMOR Z, 1995, ANN RHEUM DIS, V54, P477, DOI 10.1136/ard.54.6.477; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Trakranrungsie N, 2001, LIFE SCI, V69, P2349, DOI 10.1016/S0024-3205(01)01320-0; Ueta E, 2003, INT J CANCER, V103, P717, DOI 10.1002/ijc.10832; VANDERVLIET A, 1994, BIOCHEM J, V303, P295, DOI 10.1042/bj3030295; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Whiteman M, 2003, ARTHRITIS RHEUM-US, V48, P3140, DOI 10.1002/art.11284; Whiteman M, 2003, J BIOL CHEM, V278, P8380, DOI 10.1074/jbc.M211086200; YAMAMOTO S, 1992, ARTHRITIS RHEUM-US, V35, P1309, DOI 10.1002/art.1780351111; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yatsugi N, 2000, J Orthop Sci, V5, P150, DOI 10.1007/s007760050142; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	77	84	94	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1395	+		10.1096/fj.03-1096fje	http://dx.doi.org/10.1096/fj.03-1096fje			35	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240564				2022-12-28	WOS:000222979200027
J	Austenaa, LMI; Carlsen, H; Ertesvag, A; Alexander, G; Blomhoff, HK; Blomhoff, R				Austenaa, LMI; Carlsen, H; Ertesvag, A; Alexander, G; Blomhoff, HK; Blomhoff, R			Vitamin A status significantly alters nuclear factor-kappa B activity assessed by in vivo imaging	FASEB JOURNAL			English	Article						retinoic acid; AGN 194310; vitamin A deficiency; molecular imaging	TRANS-RETINOIC ACID; CYTOKINE PRODUCTION; X-RECEPTOR; ACTIVATION; TRANSCRIPTION; DEFICIENCY; INHIBITION; EXPRESSION; MICE; INFLAMMATION	Our study aimed to investigate, in vivo, the relationship between vitamin A status and NF-kappaB activity, a transcription factor central in regulating inflammatory and immune responses. We used a novel transgenic murine NF-kappaB-luciferase reporter model that enabled molecular imaging of NF-kappaB activity in live mice via an intensified image-capture apparatus. Whole-body luminescence, which reflects overall NF-kappaB activity, was elevated 2.2-fold in vitamin A-deficient (VAD) mice compared with control mice. Specifically, NF-kappaB activity in VAD mice was increased 1.8-fold in the lymph nodes and 1.4-fold in the thymus and, NF-kappaB induction in UVB radiation-exposed skin was also enhanced in VAD mice compared with control mice. The administration of all-trans retinoic acid to VAD mice resulted in a transient reduction in NF-kappaB activity and, conversely, a single dose of the RAR-pan-antagonist, AGN 194310, administered to control mice, led to a marked, transient induction of whole-body luminescence. Our results suggest that vitamin A status, and vitamin A itself, affects NF-kappaB activity in vivo and that the elevated NF-kappaB activity in VAD may be a mechanism underlying some of the features of VAD syndrome.	Univ Oslo, Fac Med, Dept Nutr, Oslo, Norway; Univ Oslo, Fac Med, Dept Biochem, Oslo, Norway	University of Oslo; University of Oslo	Blomhoff, R (corresponding author), Univ Oslo, Fac Med, Dept Nutr, Oslo, Norway.	rune.blomhoff@medisin.uio.no		Carlsen, Harald/0000-0001-5123-5756				Aronica MA, 1999, J IMMUNOL, V163, P5116; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Bellamy C., 1998, STATE WORLDS CHILDRE; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CANTORNA MT, 1995, EUR J IMMUNOL, V25, P1673, DOI 10.1002/eji.1830250629; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Chadwick CC, 1998, EXP CELL RES, V239, P423, DOI 10.1006/excr.1997.3913; Chen QY, 2002, IMMUNOLOGY, V107, P199, DOI 10.1046/j.1365-2567.2002.01485.x; Corn RA, 2003, J IMMUNOL, V171, P1816, DOI 10.4049/jimmunol.171.4.1816; Cui DM, 2000, J NUTR, V130, P1132, DOI 10.1093/jn/130.5.1132; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Ferreira V, 1999, J IMMUNOL, V162, P6442; Feuillard J, 2000, INT IMMUNOL, V12, P613, DOI 10.1093/intimm/12.5.613; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Hisada T, 1999, EUR J PHARMACOL, V377, P63, DOI 10.1016/S0014-2999(99)00405-7; Horton JW, 2001, J TRAUMA, V50, P397, DOI 10.1097/00005373-200103000-00002; Jolly CA, 2001, CELL IMMUNOL, V213, P122, DOI 10.1006/cimm.2001.1866; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lin L, 2004, SCIENCE, V303, P1017, DOI 10.1126/science.1093889; Livrea M. A., 1994, Retinoids: from basic science to clinical applications., P293; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Reifen R, 2002, J NUTR, V132, P2743, DOI 10.1093/jn/132.9.2743; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Stephensen CB, 2002, J IMMUNOL, V168, P4495, DOI 10.4049/jimmunol.168.9.4495; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Swamidas GP, 1999, J NUTR, V129, P1285, DOI 10.1093/jn/129.7.1285; *WHO, 2003, VIT A DEF; Wiedermann U, 1996, SCAND J IMMUNOL, V44, P578, DOI 10.1046/j.1365-3083.1996.d01-351.x	38	47	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1255	+		10.1096/fj.03-1098fje	http://dx.doi.org/10.1096/fj.03-1098fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180954				2022-12-28	WOS:000222327500033
J	Meyer, M; Belke, DD; Trost, SU; Swanson, E; Dieterle, T; Scott, B; Cary, SP; Ho, P; Bluhm, WF; McDonough, PM; Silverman, GJ; Dillmann, WH				Meyer, M; Belke, DD; Trost, SU; Swanson, E; Dieterle, T; Scott, B; Cary, SP; Ho, P; Bluhm, WF; McDonough, PM; Silverman, GJ; Dillmann, WH			A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation	FASEB JOURNAL			English	Article						FRET; SERCA; PLN-Ab	SARCOPLASMIC-RETICULUM CA2+-ATPASE; HEART-FAILURE; DILATED CARDIOMYOPATHY; MYOCARDIAL-CONTRACTILITY; VENTRICULAR MYOCYTES; MONOCLONAL-ANTIBODY; PROTEIN EXPRESSION; GENE-TRANSFER; MOUSE HEARTS; STIMULATION	Many cardiovascular disease states end in progressive heart failure. Changes in intracellular calcium handling, including a reduced activity of the sarcoplasmic reticulum calcium pump (SERCA), contribute to this contractile dysfunction. As the regulatory protein phospholamban can inhibit the calcium pump, we evaluated it as a potential target to improve cardiac function. In this study, we describe a recombinant antibody-based protein (PLN-Ab) that binds to the cytoplasmic domain of phospholamban. Fluorescence resonance energy transfer (FRET) studies suggest that PLN-Ab mimics the effects of phospholamban phosphorylation. PLN-Ab accelerated the decay of the calcium transient when expressed in neonatal rat and adult mouse ventricular cardiac myocytes. In addition, direct injection of adenovirus encoding PLN-Ab into the diabetic mouse heart enhanced contractility when measured in vivo by echo cardiography and in ex vivo Langendorff perfused hearts. The PLN-Ab provides a novel therapeutic approach to improving contractility through in vivo expression of an antibody inside cardiac myocytes.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dillmann, WH (corresponding author), Univ Calif San Diego, Dept Med, 5063 Basic Sci Bldg, La Jolla, CA 92192 USA.	wdillmann@ucsd.edu	Dieterle, Thomas/CAA-2532-2022; Dieterle, Thomas/AAG-3619-2019	Dieterle, Thomas/0000-0002-3740-1903; Meyer, Markus/0000-0002-4398-5642; Scott, Brian/0000-0002-1321-7204; Silverman, Gregg/0000-0001-9480-9457	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052946, R01HL054030, R01HL066917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI046637, R01AI040305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770, P30AR047360] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54030, HL-66917, HL-52946] Funding Source: Medline; NIAID NIH HHS [AI-40305, AI-46637] Funding Source: Medline; NIAMS NIH HHS [AR-40770, P30 AR-47360] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Cary SP, 2000, J IMMUNOL, V164, P4730, DOI 10.4049/jimmunol.164.9.4730; del Monte F, 2001, CIRCULATION, V104, P1424, DOI 10.1161/hc3601.095574; Drago GA, 1998, ANN NY ACAD SCI, V853, P273, DOI 10.1111/j.1749-6632.1998.tb08278.x; Eizema K, 2000, CIRCULATION, V101, P2193, DOI 10.1161/01.CIR.101.18.2193; Haghighi K, 2003, J CLIN INVEST, V111, P869, DOI 10.1172/JCI200317892; Haghighi K, 2001, J BIOL CHEM, V276, P24145, DOI 10.1074/jbc.M102403200; He HP, 1999, CIRCULATION, V100, P974, DOI 10.1161/01.CIR.100.9.974; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Kim HW, 2001, LIFE SCI, V70, P367, DOI 10.1016/S0024-3205(01)01483-7; Kiss E, 1998, CIRC RES, V83, P608, DOI 10.1161/01.RES.83.6.608; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MAHLER F, 1975, AM J CARDIOL, V35, P626, DOI 10.1016/0002-9149(75)90048-X; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOVSESIAN MA, 1990, J CLIN INVEST, V85, P1698, DOI 10.1172/JCI114623; Netticadan T, 2001, DIABETES, V50, P2133, DOI 10.2337/diabetes.50.9.2133; PACKER M, 1993, J AM COLL CARDIOL, V22, pA119, DOI 10.1016/0735-1097(93)90474-F; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1974, J BIOL CHEM, V249, P6174; Trost SU, 2002, DIABETES, V51, P1166, DOI 10.2337/diabetes.51.4.1166; Zhong Y, 2001, AM J PHYSIOL-HEART C, V281, pH1137, DOI 10.1152/ajpheart.2001.281.3.H1137	34	29	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1312	+		10.1096/fj.03-1231fje	http://dx.doi.org/10.1096/fj.03-1231fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180962				2022-12-28	WOS:000222327500027
J	Bonen, A; Parolin, ML; Steinberg, GR; Calles-Escandon, J; Tandon, NN; Glatz, JFC; Luiken, JJFP; Heigenhauser, GJF; Dyck, DJ				Bonen, A; Parolin, ML; Steinberg, GR; Calles-Escandon, J; Tandon, NN; Glatz, JFC; Luiken, JJFP; Heigenhauser, GJF; Dyck, DJ			Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36	FASEB JOURNAL			English	Article						FABPpm; esterification; oxidation; muscle	MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; LIPID-METABOLISM; CELLULAR REDISTRIBUTION; MEMBRANE-TRANSPORT; CARDIAC MYOCYTES; PALMITATE UPTAKE; BINDING PROTEIN; MORBIDLY OBESE	We examined whether, in human obesity and type 2 diabetes, long chain fatty acid (LCFA) transport into skeletal muscle is upregulated and contributes to an excess intramuscular triacylglycerol accumulation. In giant sarcolemmal vesicles prepared from human skeletal muscle, LCFA transport rates were upregulated similar to4-fold and were associated with an increased intramuscular triacylglycerol content in obese individuals and in type 2 diabetics. In these individuals, the increased sarcolemmal LCFA transport rate was not associated with an altered expression of FAT/CD36 or FABPpm. Instead, the increase in the LCFA transport rate was associated with an increase in sarcolemmal FAT/CD36 but not sarcolemmal FABPpm. Rates of fatty acid esterification were increased threefold in isolated human muscle strips obtained from obese subjects, while concomitantly rates of fatty acid oxidation were not altered. Thus, the increased rate of fatty acid transport may contribute to the increased rates of triacylglycerol accumulation in human skeletal muscle. The altered FAT/CD36 trafficking in muscle from obese subjects and type 2 diabetics juxtaposes the known alterations in GLUT4 trafficking, i.e., GLUT4 is known to be retained in its intracellular depots while FAT/CD36 is retained at the sarcolemma. This redistribution of FAT/CD36 to the sarcolemma may contribute to the etiology of insulin resistance in human muscle, and hence, FAT/CD36 provides another potential therapeutic target for the prevention and/or treatment of insulin resistance.	Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada; Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; Wake Forest Univ, Bowman Gray Sch Med, Sect Endocrinol & Metab, Winston Salem, NC 27157 USA; Baptist Med Ctr, Winston Salem, NC 27157 USA; Otsuka Amer Pharmaceut Inc, Thrombosis & Vasc Biol Lab, Rockville, MD 20850 USA; Maastricht Univ, Dept Mol Genet, NL-6200 MD Maastricht, Netherlands; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	University of Guelph; University of Waterloo; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Maastricht University; McMaster University	Bonen, A (corresponding author), Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada.	abonen@uoguelph.ca	Heigenhauser, George/AAH-5043-2019	Steinberg, Gregory/0000-0001-5425-8275				Abumrad N, 1998, J LIPID RES, V39, P2309; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Anderwald C, 2002, DIABETES, V51, P3025, DOI 10.2337/diabetes.51.10.3025; Bergmeyer H. U., 1983, METHODS ENZYMATIC AN; Berk PD, 1999, J BIOL CHEM, V274, P28626, DOI 10.1074/jbc.274.40.28626; Berk PD, 1996, SEMIN LIVER DIS, V16, P107, DOI 10.1055/s-2007-1007224; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Binnert C, 2000, AM J PHYSIOL-ENDOC M, V279, pE1072, DOI 10.1152/ajpendo.2000.279.5.E1072; Blaak EE, 2002, DIABETES, V51, P784, DOI 10.2337/diabetes.51.3.784; Boden G, 1999, DIABETES, V48, P577, DOI 10.2337/diabetes.48.3.577; BODEN G, 1996, DIABETES, V45, P3; Bonen A, 2000, J BIOL CHEM, V275, P14501, DOI 10.1074/jbc.275.19.14501; Bonen A, 1999, CAN J APPL PHYSIOL, V24, P515, DOI 10.1139/h99-033; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; Bradbury MW, 2000, BIOCHEM J, V345, P423, DOI 10.1042/0264-6021:3450423; CALLESESCANDON J, 1995, LIFE SCI, V58, P19, DOI 10.1016/0024-3205(95)02251-1; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; Dyck DJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE888, DOI 10.1152/ajpendo.1998.275.5.E888; Dyck DJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE600, DOI 10.1152/ajpendo.2001.281.3.E600; Dyck DJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE340, DOI 10.1152/ajpendo.1997.272.3.E340; Ellis BA, 2000, AM J PHYSIOL-ENDOC M, V279, pE554, DOI 10.1152/ajpendo.2000.279.3.E554; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; Glatz JFC, 2001, J MOL NEUROSCI, V16, P123, DOI 10.1385/JMN:16:2-3:123; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Hajri T, 2001, J BIOL CHEM, V276, P23661, DOI 10.1074/jbc.M100942200; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Hulver MW, 2003, AM J PHYSIOL-ENDOC M, V284, pE741, DOI 10.1152/ajpendo.00514.2002; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kiens B, 1997, BIOCHEM BIOPH RES CO, V231, P463, DOI 10.1006/bbrc.1997.6118; Luiken JJFP, 2003, DIABETES, V52, P1627, DOI 10.2337/diabetes.52.7.1627; Luiken JJFP, 2002, AM J PHYSIOL-ENDOC M, V283, pE612, DOI 10.1152/ajpendo.00011.2002; Luiken JJFP, 2002, DIABETES, V51, P3113, DOI 10.2337/diabetes.51.10.3113; Luiken JJFP, 2002, AM J PHYSIOL-ENDOC M, V282, pE491, DOI 10.1152/ajpendo.00419.2001; Luiken JJFP, 2001, J BIOL CHEM, V276, P40567, DOI 10.1074/jbc.M100052200; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; Miyaoka K, 2001, LANCET, V357, P686, DOI 10.1016/S0140-6736(00)04138-6; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; Schaffer JE, 2002, AM J PHYSIOL-ENDOC M, V282, pE239, DOI 10.1152/ajpendo.00462.2001; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Steinberg GR, 2002, J BIOL CHEM, V277, P8854, DOI 10.1074/jbc.M107683200; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V283, pE187, DOI 10.1152/ajpendo.00542.2001; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; Turcotte LP, 2001, DIABETES, V50, P1389, DOI 10.2337/diabetes.50.6.1389; Turcotte LP, 2000, MOL CELL BIOCHEM, V210, P53, DOI 10.1023/A:1007046929776; VANNIEUWENHOVEN FA, 1995, CIRCULATION, V92, P2848, DOI 10.1161/01.CIR.92.10.2848; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Wilmsen HM, 2003, AM J PHYSIOL-ENDOC M, V285, pE354, DOI 10.1152/ajpendo.00491.2001; Yanai H, 2001, THROMB HAEMOSTASIS, V86, P995; YASKELPIS BB, 1999, METABOLISM, V48, P671	60	301	315	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1144	+		10.1096/fj.03-1065fje	http://dx.doi.org/10.1096/fj.03-1065fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132977				2022-12-28	WOS:000221883200012
J	Kimura, Y; Kimura, H				Kimura, Y; Kimura, H			Hydrogen sulfide protects neurons from oxidative stress	FASEB JOURNAL			English	Article						glutamate toxicity; oxytosis; cystine transport; glutathione; neuroprotection	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; GLUTAMATE TOXICITY; CELL-LINE; BRAIN-TISSUE; RAT-KIDNEY; GLUTATHIONE; CYSTINE; METABOLISM; NEUROTOXICITY	Hydrogen sulfide (H2S), which is a well-known toxic gas, is found in relatively high concentrations in the brain. Although a neuromodulatory role of H2S has been demonstrated, little is known of its other biological functions. Here we show that H2S protects primary cultures of neurons from death in a well-studied model of oxidative stress caused by glutamate, a process called oxidative glutamate toxicity - or oxytosis. We found that H2S increases the glutathione levels, which normally decrease during the cell death cascade, by enhancing the activity of gamma-glutamylcysteine synthetase and up-regulating cystine transport. Cystine ( cysteine) is the rate-limiting substrate of glutathione synthesis. These observations reveal that H2S protects neurons from oxytosis by increasing the production of the antioxidant glutathione.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Kimura, H (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Kimura, Hideo/J-6811-2016	Kimura, Hideo/0000-0002-6069-0475; 				ABE K, 1990, JPN J PHARMACOL, V53, P221, DOI 10.1254/jjp.53.221; Abe K, 1996, J NEUROSCI, V16, P1066; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bannai S., 1989, GLUTATHIONE CENTENNI, P407; CHO Y, 1990, J NEUROCHEM, V55, P2091, DOI 10.1111/j.1471-4159.1990.tb05800.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; Devai I, 2002, ENVIRON TECHNOL, V23, P319, DOI 10.1080/09593332508618412; EKLOW L, 1981, FEBS LETT, V127, P125, DOI 10.1016/0014-5793(81)80357-2; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; Herschbach C, 2000, PLANT PHYSIOL, V124, P461, DOI 10.1104/pp.124.1.461; Kwak WJ, 2003, FEMS MICROBIOL LETT, V219, P99, DOI 10.1016/S0378-1097(02)01198-9; Maher P, 1996, J NEUROSCI, V16, P6394; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03-1052fje; Noctor G, 1996, PLANT PHYSIOL, V112, P1071, DOI 10.1104/pp.112.3.1071; OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184; Perry George, 2002, Journal of Biomedicine & Biotechnology, V2, P120, DOI 10.1155/S1110724302203010; REIFFENSTEIN RJ, 1992, ANNU REV PHARMACOL, V32, P109, DOI 10.1146/annurev.pa.32.040192.000545; Sagara Y, 1998, J NEUROSCI, V18, P6662; SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Sunda W, 2002, NATURE, V418, P317, DOI 10.1038/nature00851; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; VORNOV JJ, 1991, J NEUROCHEM, V56, P996, DOI 10.1111/j.1471-4159.1991.tb02020.x; WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8; YAN N, 1990, J BIOL CHEM, V265, P1588; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	38	672	766	3	76	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1165	+		10.1096/fj.04-1815fje	http://dx.doi.org/10.1096/fj.04-1815fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155563				2022-12-28	WOS:000221883200006
J	Malan, D; Ji, GJ; Schmidt, A; Addicks, K; Hescheler, J; Levi, RC; Bloch, W; Fleischmann, BK				Malan, D; Ji, GJ; Schmidt, A; Addicks, K; Hescheler, J; Levi, RC; Bloch, W; Fleischmann, BK			Nitric oxide, a key signaling molecule in the murine early embryonic heart	FASEB JOURNAL			English	Article						muscarinic signaling; regulation of I-Ca; embryonic development; ventricular cardiomyocytes	DEPENDENT PROTEIN-KINASE; BETA-ADRENERGIC MODULATION; PIG VENTRICULAR MYOCYTES; CALCIUM CURRENT; CA2+ CURRENT; MICE LACKING; CARDIAC MYOCYTES; CHOLINERGIC MODULATION; GUANYLATE-CYCLASE; CYCLIC-AMP	Nitric oxide ( NO) is thought to play an important role as a signaling molecule in embryonic and adult cardiomyocytes; however, its involvement in muscarinic signaling is still unclear. The aim of the present work was to analyze the muscarinic modulation of the L-type Ca2+ current (I-Ca) in early- and late-stage embryonic ventricular cardiomyocytes. Muscarinic stimulation depressed basal I-Ca by 30.1 +/- 3.2% (n = 27) in early-stage cardiomyocytes. Pharmacological evidence suggested that the muscarinic modulation was mediated through generation of NO, activation of cGMP-dependent phosphodiesterase (PDE) 2, and ensuing lowering of cyclic AMP/protein kinase A (cAMP/PKA) levels. Conversely, in late-stage cardiomyocytes, muscarinic regulation of I-Ca occurred in a NO-independent manner via inhibition of prestimulated adenylyl cyclase (AC). To unequivocally prove the involvement of NO and to identify the nitric oxide synthase (NOS) isoform(s), we analyzed muscarinic signaling in embryonic ventricular cardiomyocytes of NOS2 (-/-) and NOS3 (-/-) mice. The early- stage NOS3 (-/-) cardiomyocytes lacked muscarinic modulation, whereas it was preserved in NOS2 (-/-) cells. Moreover, at the late embryonic stage, muscarinic modulation of ICa was intact in both strains. Thus, NO is the key regulator of muscarinic signaling in the early embryonic ventricle, whereas at later stages, signaling occurs through a NO-independent pathway.	Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany; Univ Turin, INFM, Dept Anim & Human Biol, I-10124 Turin, Italy; Univ Cologne, Inst Neurophysiol, D-5000 Cologne, Germany; Univ Cologne, Inst Anat, D-5000 Cologne 41, Germany; German Sport Univ Cologne, Dept Mol & Cellular Sport Med, Cologne, Germany	University of Bonn; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Turin; University of Cologne; University of Cologne; German Sport University Cologne	Fleischmann, BK (corresponding author), Univ Bonn, Inst Physiol 1, Argelanderstr 2A, D-53115 Bonn, Germany.	bernd.fleischmann@uni-bonn.de						Abi-Gerges N, 2001, J PHYSIOL-LONDON, V531, P117, DOI 10.1111/j.1469-7793.2001.0117j.x; An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Bett GCL, 2002, J PHYSIOL-LONDON, V542, P107, DOI 10.1113/jphysiol.2002.017335; Bloch W, 2001, J CELL BIOL, V154, P753, DOI 10.1083/jcb.200103011; Bloch W, 1999, CARDIOVASC RES, V43, P675, DOI 10.1016/S0008-6363(99)00160-1; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; FISCHMEISTER R, 1991, LIFE SCI, V48, P2365, DOI 10.1016/0024-3205(91)90369-M; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; Godecke A, 2001, J PHYSIOL-LONDON, V532, P195, DOI 10.1111/j.1469-7793.2001.0195g.x; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; Han XQ, 1998, P NATL ACAD SCI USA, V95, P6510, DOI 10.1073/pnas.95.11.6510; Hare JM, 1999, NAT MED, V5, P273, DOI 10.1038/6486; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hu H, 1997, CIRC RES, V81, P742; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; Kojda G, 1999, CARDIOVASC RES, V42, P206, DOI 10.1016/S0008-6363(98)00315-0; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lacampagne A, 1995, CARDIOVASC RES, V30, P799, DOI 10.1016/0008-6363(95)00128-X; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Malan D, 2003, J CELL PHYSIOL, V197, P284, DOI 10.1002/jcp.10368; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Mery PF, 1997, LIFE SCI, V60, P1113, DOI 10.1016/S0024-3205(97)00055-6; Nagashima M, 2001, J MOL CELL CARDIOL, V33, P533, DOI 10.1006/jmcc.2000.1327; Poteser M, 2001, J BIOL CHEM, V276, P14797, DOI 10.1074/jbc.M008244200; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Rosemblit N, 1999, DEV BIOL, V206, P163, DOI 10.1006/dbio.1998.9120; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Vandecasteele G, 1999, NAT MED, V5, P331, DOI 10.1038/6553; Vandecasteele G, 2001, J PHYSIOL-LONDON, V533, P329, DOI 10.1111/j.1469-7793.2001.0329a.x; Wang YG, 2000, CARDIOVASC RES, V48, P310, DOI 10.1016/S0008-6363(00)00178-4; Zakharov SI, 1996, CIRC RES, V78, P925, DOI 10.1161/01.RES.78.5.925	41	20	20	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1108	+		10.1096/fj.03-1158fje	http://dx.doi.org/10.1096/fj.03-1158fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132985				2022-12-28	WOS:000221883200020
J	Waltregny, D; Glenisson, W; Tran, SL; North, BJ; Verdin, E; Colige, A; Castronovo, V				Waltregny, D; Glenisson, W; Tran, SL; North, BJ; Verdin, E; Colige, A; Castronovo, V			Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility	FASEB JOURNAL			English	Article						siRNA; cytoskeleton; collagen lattice contraction	HUMAN SIR2; CLASS-I; PROTEIN SIR2; P53; CLONING; EXPRESSION; NAD; MICROTUBULE; FIBROBLASTS; TUBULIN	Although originally characterized as nuclear enzymes controlling the stability of nucleosomes, histone deacetylases (HDACs) may also exert their activity within the cytosol. Recently, we have demonstrated that HDAC8, a class I HDAC, is a novel, prominently cytosolic marker of smooth muscle differentiation. As HDAC8 displays a striking stress fiber-like pattern of distribution and is coexpressed in vivo with smooth muscle alpha-actin (alpha-SMA) and smooth muscle myosin heavy chain, we have explored the possible participation of this HDAC in smooth muscle cytoskeleton regulation. Cell fractionation assays performed with primary human smooth muscle cells (HSMCs) showed that HDAC8, in contrast to HDAC1 and HDAC3, was enriched in cytoskeleton-bound protein fractions and insoluble cell pellets, suggesting an association of HDAC8 with the cystoskeleton. Coimmunoprecipitation experiments using HSMCs, NIH-3T3 cells, and human prostate tissue lysates further demonstrated that HDAC8 associates with alpha-SMA but not with P-actin. HDAC8 silencing through RNA interference strongly reduced the capacity of HSMCs to contract collagen lattices. Mock transfections had no effect on HSMC contractily, and transfections with small interfering RNAs (siRNAs) specific for HDAC6, a cytosolic HDAC that functions as an alpha-tubulin deacetylase, resulted in a weak contraction inhibition. Although mock- and HDAC6 siRNA-transfected HSMCs showed no noticeable morphological changes, HDAC8 siRNA-transfected HSMCs displayed a size reduction with diminished cell spreading after replating. Altogether, our findings indicate that HDAC8 associates with the smooth muscle actin cytoskeleton and may regulate the contractile capacity of smooth muscle cells.	Univ Liege, Metastasis Res Lab, Liege, Belgium; Univ Liege, Dept Urol, Liege, Belgium; Univ Liege, Lab Connect Tissues Biol, Liege, Belgium; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA	University of Liege; University of Liege; University of Liege; University of California System; University of California San Francisco; The J David Gladstone Institutes	Waltregny, D (corresponding author), CHU Sart Tilman, Metastasis Res Lab, Pathol Bldg,Bat B23,Level 1, B-4000 Liege, Belgium.	David.Waltregny@ulg.ac.be	Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Carraway CAC, 2000, PRACT APPROACH SER, P51; CHAPONNIER C, 1995, J CELL BIOL, V130, P887, DOI 10.1083/jcb.130.4.887; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DELVOYE P, 1983, J INVEST DERMATOL, V81, P267, DOI 10.1111/1523-1747.ep12518288; DELVOYE P, 1991, J INVEST DERMATOL, V97, P898, DOI 10.1111/1523-1747.ep12491651; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Forte JG, 1998, AM J PHYSIOL-CELL PH, V274, pC97, DOI 10.1152/ajpcell.1998.274.1.C97; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; LAMBERT CA, 1992, LAB INVEST, V66, P444; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEGEE PC, 1990, SCIENCE, V247, P841; Niessen P, 2004, EXP CELL RES, V292, P170, DOI 10.1016/j.yexcr.2003.09.005; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Ruzanov PV, 1999, J CELL SCI, V112, P3487; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; SNABES MC, 1981, J BIOL CHEM, V256, P6291; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Waltregny D, 2004, EUR J HISTOCHEM, V48, P273; Waltregny D, 2004, AM J PATHOL, V165, P553, DOI 10.1016/S0002-9440(10)63320-2; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; WHEELER TM, 1994, PROSTATE, V25, P274, DOI 10.1002/pros.2990250507; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zeng LF, 2003, J BIOL CHEM, V278, P24594, DOI 10.1074/jbc.M301955200; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	64	158	164	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					966	+		10.1096/fj.04-2303fje	http://dx.doi.org/10.1096/fj.04-2303fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15772115				2022-12-28	WOS:000227901300014
J	Krasnova, IN; Ladenheim, B; Cadet, JL				Krasnova, IN; Ladenheim, B; Cadet, JL			Amphetamine induces apoptosis of medium spiny striatal projection neurons via the mitochondria-dependent pathway	FASEB JOURNAL			English	Article						striatum; caspase-3; Bax; striatal dopaminergic terminals	INNERVATED BRAIN-REGIONS; SUBSTITUTED AMPHETAMINES; DOPAMINE; DEATH; BAX; NEUROTOXICITY; ACTIVATION; CASPASE-3; MICE; P53	Amphetamine ( AMPH) is a psychostimulant whose chronic abuse may cause impairments in attention and memory in humans. These cognitive deficits might be related to neurotoxic effects of the drug. One such toxic effect is the well-described destruction of striatal dopaminergic terminals in mammals. In the present study, we investigated the possibility that AMPH might also cause neuronal apoptosis in the rodent striatum. Administration of a dose of the drug ( 10 mg/kg, 4 times, every 2 h) that is toxic to dopaminergic terminals resulted in the appearance of striatal cells that were positive for cleaved caspase-3 and for terminal deoxynucleotidyl transferase- mediated biotin- dUTP nick-end labeling ( TUNEL), observations that are indicative of an ongoing apoptotic process. Dual immunofluorescence staining revealed that cleaved caspase-3-positive cells express calbindin and DARPP-32, but not somatostatin, parvalbumin, or cholinergic markers. In addition, AMPH also caused increased expression of p53 and Bax at both transcript and protein levels; in contrast, Bcl-2 levels were decreased after the AMPH injections. Moreover, Bax knockout mice showed resistance to AMPH-induced apoptotic cell death but not to AMPH-induced destruction of dopaminergic terminals. When taken together, these observations indicate that injections of doses of AMPH that are known to destroy striatal dopamine terminals can also cause apoptotic death of postsynaptic medium spiny projection neurons via mitochondria-dependent mechanisms.	NIDA, Mol Neuropsychiat Branch, Intramural Res Program, DHHS,NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Branch, Intramural Res Program, DHHS,NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	JCADET@intra.nida.nih.gov			NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000174, Z01DA000153, ZIADA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALLDREDGE BK, 1989, NEUROLOGY, V39, P1037, DOI 10.1212/WNL.39.8.1037; ANDERSSON M, 1991, J SMALL ANIM PRACT, V32, P1, DOI 10.1111/j.1748-5827.1991.tb00844.x; Bowyer JF, 1998, J PHARMACOL EXP THER, V286, P1074; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cregan SP, 1999, J NEUROSCI, V19, P7860; Cyr M, 2003, P NATL ACAD SCI USA, V100, P11035, DOI 10.1073/pnas.1831768100; Deng XL, 1999, J NEUROSCI, V19, P10107; Deng XL, 2001, MOL BRAIN RES, V93, P64, DOI 10.1016/S0169-328X(01)00184-X; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ekshyyan O, 2004, FRONT BIOSCI-LANDMRK, V9, P1567, DOI 10.2741/1357; ELLISON G, 1978, SCIENCE, V201, P276, DOI 10.1126/science.26975; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fukumura M, 1998, BRAIN RES, V806, P1, DOI 10.1016/S0006-8993(98)00656-8; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; Huang NK, 1997, LIFE SCI, V61, P2219, DOI 10.1016/S0024-3205(97)00924-7; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jakab RL, 2002, BRAIN RES, V958, P52, DOI 10.1016/S0006-8993(02)03439-X; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANOWSKY DS, 1979, PSYCHOPHARMACOLOGY, V65, P73, DOI 10.1007/BF00491982; Jayanthi S, 2001, FASEB J, V15, P1745, DOI 10.1096/fj.01-0025com; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; KALANT H, 1975, CAN MED ASSOC J, V112, P299; Kawaguchi Y, 1997, NEUROSCI RES, V27, P1, DOI 10.1016/S0168-0102(96)01134-0; KAWAGUCHI Y, 1995, TRENDS NEUROSCI, V18, P527, DOI 10.1016/0166-2236(95)98374-8; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Krasnova IN, 2002, FASEB J, V16, P1379, DOI 10.1096/fj.01-0796com; Krasnova IN, 2001, NEUROSCIENCE, V107, P265, DOI 10.1016/S0306-4522(01)00351-7; Lotharius J, 2001, ANN NEUROL, V49, P79, DOI 10.1002/1531-8249(200101)49:1<79::AID-ANA11>3.0.CO;2-D; Marin O, 2000, J NEUROSCI, V20, P6063; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; McKetin R, 1997, DRUG ALCOHOL DEPEN, V48, P235, DOI 10.1016/S0376-8716(97)00132-4; Melega WP, 1996, SYNAPSE, V22, P63, DOI 10.1002/(SICI)1098-2396(199601)22:1<63::AID-SYN7>3.0.CO;2-G; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILLER DB, 1994, J PHARMACOL EXP THER, V270, P752; Mitchell I, 2003, IUBMB LIFE, V55, P293, DOI 10.1080/1521654031000153012; Mitchell IJ, 1999, PROG NEUROBIOL, V59, P691, DOI 10.1016/S0301-0082(99)00019-2; Mitchell IJ, 1998, NEUROSCIENCE, V84, P489, DOI 10.1016/S0306-4522(97)00534-4; Mitchell IJ, 2002, NEUROSCIENCE, V109, P89, DOI 10.1016/S0306-4522(01)00455-9; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morrill J, 2003, HIST TODAY, V53, P28; Murray JB, 1998, J PSYCHOL, V132, P227, DOI 10.1080/00223989809599162; Namura S, 1998, J NEUROSCI, V18, P3659; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ornstein TJ, 2000, NEUROPSYCHOPHARMACOL, V23, P113, DOI 10.1016/S0893-133X(00)00097-X; OUIMET CC, 1984, J NEUROSCI, V4, P111; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Qiu JH, 2002, J NEUROSCI, V22, P3504; RICAURTE GA, 1984, BRAIN RES, V303, P359, DOI 10.1016/0006-8993(84)91221-6; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Roth KA, 2001, MENT RETARD DEV D R, V7, P261, DOI 10.1002/mrdd.1036; RYAN LJ, 1990, BRAIN RES, V518, P67, DOI 10.1016/0006-8993(90)90955-B; Scheffel U, 1996, SYNAPSE, V23, P61; SCHOUSBOE A, 1992, PROG BRAIN RES, V94, P199; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; SULZER D, 1995, J NEUROSCI, V15, P4102; Svenningsson P, 2003, SCIENCE, V302, P1412, DOI 10.1126/science.1089681; Thiriet N, 2002, FASEB J, V16, P1887, DOI 10.1096/fj.02-0502com; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; WAGNER GC, 1980, NEUROLOGY, V30, P547; WALAAS SI, 1984, J NEUROSCI, V4, P84; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	71	54	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					851	+		10.1096/fj.04-2881fje	http://dx.doi.org/10.1096/fj.04-2881fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15731293				2022-12-28	WOS:000227591900006
J	Brouet, A; DeWever, J; Martinive, P; Havaux, X; Bouzin, C; Sonveaux, P; Feron, O				Brouet, A; DeWever, J; Martinive, P; Havaux, X; Bouzin, C; Sonveaux, P; Feron, O			Antitumor effects of in vivo caveolin gene delivery are associated with the inhibition of the proangiogenic and vasodilatory effects of nitric oxide	FASEB JOURNAL			English	Article						tumor vasculature; NO; endothelial; cationic liposomes	ENDOTHELIAL GROWTH-FACTOR; FACTOR-INDUCED ANGIOGENESIS; PROSTATE-CANCER; SURVIVAL/CLONAL GROWTH; KNOCKOUT MICE; UP-REGULATION; TUMOR; SYNTHASE; CELLS; EXPRESSION	In tumors, caveolin-1, the structural protein of caveolae, constitutes a key switch through its function as a tumor suppressor and a promoter of metastases. In endothelial cells (EC), caveolin is also known to directly interact with the endothelial nitric oxide synthase ( eNOS) and thereby to modulate nitric oxide (NO)-mediated processes including vasodilation and angiogenesis. In this study, we examined whether the modulation of the stoichiometry of the caveolin/eNOS complex in EC lining tumor blood vessels could affect the tumor vasculature and consecutively tumor growth. For this purpose, we used cationic lipids, which are delivery systems effective at targeting tumor vs. normal vascular networks. We first documented that in vitro caveolin transfection led to the inhibition of both VEGF-induced EC migration and tube formation on Matrigel. The DNA-lipocomplex was then administered through the tail vein of tumor-bearing mice. The direct interaction between recombinant caveolin and native eNOS was validated in coimmunoprecipitation experiments from tumor extracts. A dramatic tumor growth delay was observed in mice transfected with caveolin- vs. sham-transfected animals. Using laser Doppler imaging and microprobes, we found that in the early time after lipofection (e.g., when macroscopic effects on the integrity of the tumor vasculature were not detectable), caveolin expression impaired NO-dependent tumor blood flow. At later stages post-transfection, a decrease in tumor microvessel density in the central core of caveolin- transfected tumors was also documented. In conclusion, our study reveals that by exploiting the exquisite regulatory interaction between eNOS and caveolin and the propensity of cationic lipids to target EC lining tumor blood vessels, caveolin plasmid delivery appears to be a safe and efficient way to block neoangiogenesis and vascular function in solid tumors, independently of any direct effects on tumor cells.	UCL Med Sch, Unit Pharmacol & Therapeut, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Div Cardiol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Feron, O (corresponding author), UCL Med Sch, Unit Pharmacol & Therapeut, FATH 5349,53 Ave E Mounier, B-1200 Brussels, Belgium.	feron@mint.ucl.ac.be	FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286; Sonveaux, Pierre/0000-0001-6484-8834				Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Dini L, 1998, LIVER, V18, P229; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 2001, CIRC RES, V88, P129; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Gratton JP, 2003, CANCER CELL, V4, P31, DOI 10.1016/S1535-6108(03)00168-5; Griffoni C, 2000, BIOCHEM BIOPH RES CO, V276, P756, DOI 10.1006/bbrc.2000.3484; Hayashi K, 2001, CANCER RES, V61, P2361; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Ignarro LJ, 2002, J PHYSIOL PHARMACOL, V53, P503; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; Lavie Y, 2001, ADV DRUG DELIVER REV, V49, P317, DOI 10.1016/S0169-409X(01)00144-2; Li LK, 2001, CANCER RES, V61, P4386; Michael Emily, 1997, EARLY SCI MED, V2, P272, DOI DOI 10.1163/157338297X00159; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Sonveaux P, 2003, CANCER RES, V63, P1012; Sonveaux P, 2004, CIRC RES, V95, P154, DOI 10.1161/01.RES.0000136344.27825.72; Tahir SA, 2001, CANCER RES, V61, P3882; TAPER HS, 1966, CANCER RES, V26, P143; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; VOLPE JP, 1985, CLIN EXP METASTAS, V3, P281, DOI 10.1007/BF01585082; Woodman SE, 2003, AM J PATHOL, V162, P2059, DOI 10.1016/S0002-9440(10)64337-4; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	38	39	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					602	+		10.1096/fj.04-2682fje	http://dx.doi.org/10.1096/fj.04-2682fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15623570				2022-12-28	WOS:000226091000007
J	Waetzig, GH; Rosenstiel, P; Arlt, A; Till, A; Brautigam, K; Schafer, H; Rose-John, S; Seegert, D; Schreiber, S				Waetzig, GH; Rosenstiel, P; Arlt, A; Till, A; Brautigam, K; Schafer, H; Rose-John, S; Seegert, D; Schreiber, S			Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta 1	FASEB JOURNAL			English	Article						anti-inflammatory agents; autoimmune diseases; inflammation; mitogen-activated protein kinases; signal transduction	INFLAMMATORY-BOWEL-DISEASE; ACTIVATED PROTEIN-KINASE; PROPRIA T-LYMPHOCYTES; GROWTH-FACTOR-BETA; FACTOR-ALPHA; CROHNS-DISEASE; TGF-BETA; IN-VITRO; MONOCYTIC CELLS; FAS LIGAND	The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in inflammatory disorders. Transmembrane TNF-alpha and its two receptors are cleaved by the proteinase TNF-alpha converting enzyme (TACE), resulting in appreciable serum levels of soluble TNF-alpha and soluble TNF-alpha receptors (sTNFR1 and -2). The only known functions of sTNFR1 are to antagonize and buffer circulating TNF-alpha. Here, we present evidence that sTNFR1 exerts immunoregulatory functions by induction of apoptosis in monocytes through reverse signaling via transmembrane TNF-alpha. sTNFR1-induced apoptosis is independent of death receptor pathways but depends on autocrine transforming growth factor (TGF)-beta1 signaling through the mitogen-activated protein kinase p38alpha. This novel mechanism has implications for understanding the physiological role of sTNFR1 and for TNF-alpha-blocking therapies of autoimmune diseases.	Schleswig Holstein Univ Med Ctr, Inst Clin Mol Biol, D-24105 Kiel, Germany; Schleswig Holstein Univ Med Ctr, Lab Mol Gastroenterol & Hepatol, Dept Med 1, D-24105 Kiel, Germany; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Conaris Res Inst AG, D-24118 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel	Schreiber, S (corresponding author), Schleswig Holstein Univ Med Ctr, Inst Clin Mol Biol, Schittenhelmstr 12, D-24105 Kiel, Germany.	s.schreiber@mucosa.de	Rosenstiel, Philip/A-5137-2009; Arlt, Alexander/G-7308-2019; Rose-John, Stefan/A-7998-2010; Waetzig, Georg/AAV-7486-2021; Seegert, Dirk/B-8826-2011; Till, Andreas/AAO-6375-2021; Braeutigam, Karen/F-3518-2014; Schäfer, Heiner/C-1055-2011; Till, Andreas/E-9661-2013	Rosenstiel, Philip/0000-0002-9692-8828; Arlt, Alexander/0000-0002-6160-1059; Rose-John, Stefan/0000-0002-7519-3279; Till, Andreas/0000-0002-0139-9143				ALLANLA, 2003, NAT CELL BIOL, V5, P647; ANDUS T, 1992, HEPATOLOGY, V16, P749, DOI 10.1002/hep.1840160322; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; Baier A, 2003, CURR OPIN RHEUMATOL, V15, P274, DOI 10.1097/00002281-200305000-00015; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Boirivant M, 1999, GASTROENTEROLOGY, V116, P557, DOI 10.1016/S0016-5085(99)70177-0; BOMBARA C, 1992, J CELL PHYSIOL, V153, P30, DOI 10.1002/jcp.1041530106; CORTI A, 1995, J INTERF CYTOK RES, V15, P143, DOI 10.1089/jir.1995.15.143; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Duan RS, 2002, J AUTOIMMUN, V19, P169, DOI 10.1006/jaut.2002.0618; Eissner G, 2000, J IMMUNOL, V164, P6193, DOI 10.4049/jimmunol.164.12.6193; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fernandez-Real JM, 2003, J CLIN ENDOCR METAB, V88, P2714, DOI 10.1210/jc.2002-021583; GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897; HADZISELIMOVIC F, 1995, GUT, V37, P260, DOI 10.1136/gut.37.2.260; Haeffner A, 1997, J IMMUNOL, V158, P1310; Harashima S, 2001, J IMMUNOL, V166, P130, DOI 10.4049/jimmunol.166.1.130; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUMBERT M, 1994, AM J RESP CRIT CARE, V149, P1681, DOI 10.1164/ajrccm.149.6.8004330; Ina K, 1999, J IMMUNOL, V163, P1081; KELLEY JL, 1987, EXP MOL PATHOL, V46, P266, DOI 10.1016/0014-4800(87)90049-9; Kirchner S, 2004, J LEUKOCYTE BIOL, V75, P324, DOI 10.1189/jlb.0703343; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; Krause Stefan W., 1996, Immunobiology, V196, P522; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lugering A, 2001, GASTROENTEROLOGY, V121, P1145, DOI 10.1053/gast.2001.28702; Mitoma H, 2004, GASTROENTEROLOGY, V126, P934, DOI 10.1053/j.gastro.2004.01.036; Moon YS, 2004, METABOLISM, V53, P863, DOI 10.1016/j.metabol.2004.02.007; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 2000, J IMMUNOL, V164, P4672, DOI 10.4049/jimmunol.164.9.4672; Noguchi M, 1998, GUT, V43, P203, DOI 10.1136/gut.43.2.203; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Pelaia G, 2003, AM J RESP CELL MOL, V29, P12, DOI 10.1165/rcmb.2002-0074OC; POCSIK E, 1995, J INFLAMM, V45, P152; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Randow F, 1997, J IMMUNOL, V158, P2911; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Spengler U, 1996, CYTOKINE, V8, P864, DOI 10.1006/cyto.1996.0115; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; STEINSHAMN S, 1995, BRIT J HAEMATOL, V89, P719; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Suzuki I, 2000, J IMMUNOL, V165, P5537, DOI 10.4049/jimmunol.165.10.5537; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; ten Hove T, 2002, GUT, V50, P206, DOI 10.1136/gut.50.2.206; Trinchard-Lugan I, 2001, EUR CYTOKINE NETW, V12, P391; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Waetzig GH, 2003, GASTROENTEROLOGY, V125, P633, DOI 10.1016/S0016-5085(03)00979-X; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Wiley SR, 1996, J IMMUNOL, V157, P3635	62	81	82	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					91	+		10.1096/fj.04-2073fje	http://dx.doi.org/10.1096/fj.04-2073fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15514103				2022-12-28	WOS:000224849900004
J	Albani, D; Peverelli, E; Rametta, R; Batelli, S; Veschini, L; Negro, A; Forloni, G				Albani, D; Peverelli, E; Rametta, R; Batelli, S; Veschini, L; Negro, A; Forloni, G			Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70	FASEB JOURNAL			English	Article						Parkinson's disease; Lewy bodies; neurodegeneration; dopaminergic cells; oxidative stress	FAMILIAL PARKINSONS-DISEASE; CHAPERONE-LIKE ACTIVITY; OXIDATIVE STRESS; NEURONAL CELLS; BINDING DOMAIN; HEAT-SHOCK; IN-VITRO; MUTATION; DEGENERATION; AGGREGATION	alpha-Synuclein (alpha-syn) is a 140-amino acid presinaptic protein whose mutations A30P and A53T have been linked to familiar Parkinson's disease (PD). Many data suggest that alpha-syn aggregation is the key event that triggers alpha-syn-mediated neurotoxicity. Nevertheless, other lines of evidence proposed a protective role of alpha-syn against oxidative stress (a major feature of PD), even if the exact mechanism of this protective action and the role of the pathogenetic mutations to this respect have not been elucidated yet. To address these points, we developed an in vitro model of oxidative stress by exposing PC12 cells to hydrogen peroxide (H2O2) (150 muM) for 72 h, and we evaluated alpha-syn-mediated protection delivering increasing amounts of alpha-syn (wild type [WT] or mutated) inside cells using the fusion proteins TAT-alpha-syn (WT, A30P, and A53T). We found that nanomolar amounts of TAT-alpha-syn-mediated protected against oxidative stress and other cellular injuries (6-hydroxydopamine and serum deprivation), whereas micromolar amounts of the fusion proteins were intrinsically toxic to cells. The protective effect was independent from the presence of the mutations A30P and A53T, but no protection occurred when cells were challenged with the proteasome inhibitors lactacystin and MG132. We verified that the protection mechanism required the presence of the C-terminal domain of alpha-syn, as nanomolar amounts of the C-terminal truncated fusion protein TAT-alpha-syn (WT[1-97]) failed in preventing H2O2 toxicity. To further characterize the molecular mechanisms at the basis of alpha-syn protection, we investigated the possible involvement of the chaperone protein HSP70 that is widely implicated in neuroprotection. We found that, at nanomolar concentrations, TAT-alpha-syn was able to increase HSP70 protein level, whereas at the micromolar scale, TAT-alpha-syn decreased HSP70 at the protein level. These effects on HSP70 were independent from the presence of alpha-syn pathogenetic mutations but required the alpha-syn C-terminal domain. The implications for a-synmediated neurotoxicity and for PD pathogenesis and progression are discussed.	Ist Ric Farmacol Mario Negri, Dept Neurosci, I-20157 Milan, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Padua	Forloni, G (corresponding author), Ist Ric Farmacol Mario Negri, Dept Neurosci, Via Eritrea 62, I-20157 Milan, Italy.	forloni@marionegri.it	Forloni, Gianluigi/AAB-2115-2020; ALBANI, DIEGO/I-5183-2018	Forloni, Gianluigi/0000-0001-5374-3914; ALBANI, DIEGO/0000-0002-7050-6723; Veschini, Lorenzo/0000-0003-3820-7472; rametta, raffaela/0000-0003-0091-9394; Peverelli, Erika/0000-0002-4424-7895; NEGRO, ALESSANDRO/0000-0003-3142-7632				Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cookson MR, 2003, NEUROMOL MED, V3, P1, DOI 10.1385/NMM:3:1:1; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Forloni G, 2000, ANN NEUROL, V47, P632, DOI 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.3.CO;2-E; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Hashimoto M, 2003, ANN NY ACAD SCI, V991, P171; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hattori N, 2003, J NEUROL, V250, P2, DOI 10.1007/s00415-003-1302-y; Helfand SL, 2002, SCIENCE, V295, P809, DOI 10.1126/science.1069544; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PJ, 2003, J NEUROCHEM, V86, P196, DOI 10.1046/j.1471-4159.2003.01835.x; Kemp TJ, 2003, BIOCHEM BIOPH RES CO, V307, P416, DOI 10.1016/S0006-291X(03)01215-4; Kim TD, 2002, BIOCHEMISTRY-US, V41, P13782, DOI 10.1021/bi026284c; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lykkebo S, 2002, NEUROMOL MED, V2, P115, DOI 10.1385/NMM:2:2:115; Ma QL, 2003, J ALZHEIMERS DIS, V5, P139, DOI 10.3233/JAD-2003-5208; Manning-Bog AB, 2003, J NEUROSCI, V23, P3095; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Park SM, 2002, BLOOD, V100, P2506, DOI 10.1182/blood.V100.7.2506; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sato K, 1996, BRAIN RES, V740, P117, DOI 10.1016/S0006-8993(96)00846-3; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Warner TT, 2003, ANN NEUROL, V53, pS16, DOI 10.1002/ana.10487; Wersinger C, 2003, MOL CELL NEUROSCI, V24, P91, DOI 10.1016/S1044-7431(03)00124-6; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Yenari MA, 2002, ADV EXP MED BIOL, V513, P281; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	47	67	71	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1713	+		10.1096/fj.04-1621fje	http://dx.doi.org/10.1096/fj.04-1621fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345691				2022-12-28	WOS:000224243200044
J	Serafino, A; Vallebona, PS; Lazzarino, G; Tavazzi, B; Rasi, G; Pierimarchi, P; Andreola, F; Moroni, G; Galvano, G; Galvano, F; Garaci, E				Serafino, A; Vallebona, PS; Lazzarino, G; Tavazzi, B; Rasi, G; Pierimarchi, P; Andreola, F; Moroni, G; Galvano, G; Galvano, F; Garaci, E			Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside	FASEB JOURNAL			English	Article						anthocyanin; melanoma differentiation; electron microscopy; confocal microscopy	MALIGNANT-MELANOMA; RETINOIC ACID; VITAMIN-C; IN-VITRO; INHIBITION; ANTHOCYANINS; EXPRESSION; CYANIDIN; PROLIFERATION; MELANOCYTES	Great attention has been recently given to a flavonoid of the anthocyanin class, cyanidin-3-O-beta-glucopyranoside (C-3-G), which is widely spread throughout the plant kingdom, and is present in both fruits and vegetables of human diets. In this study, we investigated the effect of C-3-G on proliferation and differentiation of human melanoma cells. Both morphological and functional parameters were evaluated, using electron and confocal microscopy, cytofluorometric analysis, HPLC assay, Western blot analysis, and enzymatic assay, as appropriate. A treatment with a single dose of C-3-G decreased cell proliferation without affecting cell viability and without inducing apoptosis or necrosis. The mitotic index and cell percentage in S phase were significantly lower in C-3-G treated cells compared with untreated control. C-3-G treatment induced, in a dose- and time-dependent manner, melanoma cell differentiation characterized by a strong increase in dendrite outgrowth accompanied with a remodeling of the microtubular network, a dramatic increase of focal adhesion and an increased expression of "brain specific" cytoskeletal components such as NF-160 and NF-200 neurofilament proteins. C-3-G treatment also induced increase of cAMP levels and up-regulation of tyrosinase expression and activity resulting in an enhanced melanin synthesis and melanosome maturation. Up-regulation of the melanoma differentiation antigen Melan-A/MART-1 in treated cells respect to the untreated control was also recorded. Data obtained provide evidence that a single treatment with C-3-G is able to revert the human melanoma cells from the proliferating to the differentiated state. We conclude that C-3-G is a very promising molecule to include in the strategies for treatment of melanoma; also because of its nutritional relevance.	CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy; Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Univ Catania, Dept Agron Agrochem & Anim Prod Sci, Catania, Italy; Univ Reggio Calabria, Dept Agroforestry & Environm Sci, I-89100 Reggio Di Calabria, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; University of Catania; Catholic University of the Sacred Heart; University of Catania; Universita Mediterranea di Reggio Calabria	Serafino, A (corresponding author), CNR, Inst Neurobiol & Mol Med, Via Fosso del Cavaliere 100, I-00133 Rome, Italy.	annalucia.serafino@ims.rm.cnr.it	TAVAZZI, BARBARA/AAB-9830-2019; Rasi, Guido/AAC-8172-2021; Pierimarchi, Pasquale/AAX-2833-2020; Serafino, Annalucia/AAC-1719-2019; Galvano, Fabio/F-8122-2010; GARACI, ENRICO/AAB-3349-2021; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Rasi, Guido/0000-0002-2191-1386; Serafino, Annalucia/0000-0002-1142-4752; Galvano, Fabio/0000-0003-0644-0755; Moroni, Gabriella/0000-0002-1215-423X; lazzarino, giuseppe/0000-0002-5917-7279				Amorini AM, 2001, FREE RADICAL RES, V35, P953, DOI 10.1080/10715760100301451; Bialy TL, 2002, DERMATOL SURG, V28, P1143, DOI 10.1046/j.1524-4725.2002.02114.x; Bishop JAN, 1997, CANCER METAST REV, V16, P141, DOI 10.1023/A:1005752510012; Briviba K, 2001, NUTR CANCER, V41, P172, DOI 10.1207/S15327914NC41-1&amp;2_24; Burton RC, 2000, CA-CANCER J CLIN, V50, P209, DOI 10.3322/canjclin.50.4.209; Busam KJ, 1998, AM J SURG PATHOL, V22, P976, DOI 10.1097/00000478-199808000-00007; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cal C., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P77, DOI 10.2174/1568011033353443; Chen YT, 1996, P NATL ACAD SCI USA, V93, P5915, DOI 10.1073/pnas.93.12.5915; Demary K, 2001, CANCER LETT, V163, P103, DOI 10.1016/S0304-3835(00)00676-5; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; Fang D, 2001, AM J PATHOL, V158, P2107, DOI 10.1016/S0002-9440(10)64682-2; Fitzpatrick TB, 1979, DERMATOLOGY GENERAL, P131; Hagiwara A, 2001, CANCER LETT, V171, P17, DOI 10.1016/S0304-3835(01)00510-9; HOLZMANN B, 1987, INT J CANCER, V39, P466, DOI 10.1002/ijc.2910390410; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; Ichikawa Haruyo, 2001, J Med Food, V4, P211, DOI 10.1089/10966200152744481; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kahkonen MP, 2003, J AGR FOOD CHEM, V51, P628, DOI 10.1021/jf025551i; Kirkin AF, 1998, APMIS, V106, P665, DOI 10.1111/j.1699-0463.1998.tb00210.x; Koide T, 1997, CANCER BIOTHER RADIO, V12, P277, DOI 10.1089/cbr.1997.12.277; Kosala Raymond, 2000, SIGKDD EXPLORATIONS, V2, P1, DOI DOI 10.1145/360402.360406; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Le Douarin N.M., 1982, NEURAL CREST; Lee HS, 2002, J AGR FOOD CHEM, V50, P1243, DOI 10.1021/jf011205+; Lee KW, 2002, LANCET, V359, P172, DOI 10.1016/S0140-6736(02)07358-0; Lopez-Lazaro M, 2002, Curr Med Chem Anticancer Agents, V2, P691; Martinez-Esparza M, 2001, INT J BIOCHEM CELL B, V33, P971, DOI 10.1016/S1357-2725(01)00068-1; Melino G, 1993, CLIN CHEM ENZYM COMM, V6, P105; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nagao N, 2000, J CANCER RES CLIN, V126, P511, DOI 10.1007/s004320000120; Niles RM, 2003, J NUTR, V133, p282S, DOI 10.1093/jn/133.1.282S; Oberley TD, 2002, AM J PATHOL, V160, P403, DOI 10.1016/S0002-9440(10)64857-2; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; Pereda MP, 1999, BRIT J CANCER, V81, P381, DOI 10.1038/sj.bjc.6690705; Reed JA, 1999, AM J PATHOL, V155, P549, DOI 10.1016/S0002-9440(10)65150-4; Savouret JF, 2002, BIOMED PHARMACOTHER, V56, P84, DOI 10.1016/S0753-3322(01)00158-5; Seeram NP, 2003, J AGR FOOD CHEM, V51, P1948, DOI 10.1021/jf025993u; Sovak Milos, 2001, J Med Food, V4, P93, DOI 10.1089/109662001300341752; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; Tsuda T, 1999, FEBS LETT, V449, P179, DOI 10.1016/S0014-5793(99)00407-X; Wang HB, 2003, J AGR FOOD CHEM, V51, P1839, DOI 10.1021/jf0260747; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714	48	49	59	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1940	+		10.1096/fj.04-1925fje	http://dx.doi.org/10.1096/fj.04-1925fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15451888				2022-12-28	WOS:000224243200008
J	Izzotti, A; Cartiglia, C; Longobardi, M; Balansky, RM; D'Agostini, F; Lubet, RA; De Flora, S				Izzotti, A; Cartiglia, C; Longobardi, M; Balansky, RM; D'Agostini, F; Lubet, RA; De Flora, S			Alterations of gene expression in skin and lung of mice exposed to light and cigarette smoke	FASEB JOURNAL			English	Article						environmental cigarette smoke; UV-containing light; multigene expression; cDNA array; hairless mice	S-TRANSFERASE-P; HAIRLESS MICE; SULINDAC; CARCINOGENESIS; APOPTOSIS; MECHANISM; CELLS; KERATINOCYTES; MODULATION; ACTIVATION	We previously showed that sunlight-mimicking light induces genotoxic damage not only in skin but also even in lung, bone marrow, and peripheral blood of hairless mice. Moreover, light and smoke acted synergically in the respiratory tract. To clarify the mechanisms involved, we investigated by cDNA-arrays the expression of 746 toxicologically relevant genes in skin and lungs of mice exposed for 28 days to light and/or environmental cigarette smoke. Glutathione-S- transferase-Pi and catalase were overexpressed in the lungs of mice exposed to light only. Moreover, the light induced in skin the expression of genes involved in carcinogenesis, photoaging, and production of genotoxic and oxidizing derivatives traveling at a distance. Smoke induced the expression of multiple genes in both skin and lung, which reflect adaptive responses and mechanisms related to cancer and, possibly, to emphysema and stroke. As shown in mice exposed to both light and smoke, the light tended to increase smoke-induced gene expression in lungs, while smoke tended to attenuate light-induced gene expression in skin. The oral administration of the nonsteroidal anti-inflammatory drug sulindac inhibited the light-induced overexpression of cyclooxygenase-2 and oxidative stress-related genes in skin, and down-regulated smoke-induced genes involved in oxidative stress, removal of damaged proteins, inflammation, and immune response in lung. These results provide a mechanistic insight explaining the systemic alterations induced by both light and smoke in mouse skin and lungs.	Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; NCI, Rockville, MD USA; Natl Oncol Ctr, Sofia 1756, Bulgaria	University of Genoa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Oncology Center - Bulgaria	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it		izzotti, alberto/0000-0002-8588-0347	NCI NIH HHS [N01-CN-752008] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Mohanna MA, 2001, CARCINOGENESIS, V22, P573, DOI 10.1093/carcin/22.4.573; Balansky RM, 2003, CARCINOGENESIS, V24, P1525, DOI 10.1093/carcin/bgg108; Bentham G, 1999, MUTAGENESIS, V14, P527, DOI 10.1093/mutage/14.6.527; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; DAGOSTINI F, 1994, CANCER RES, V54, P5081; DAVIS WB, 1991, LUNG SCI F, P1821; De Flora S, 2003, MUTAT RES-FUND MOL M, V523, P237, DOI 10.1016/S0027-5107(02)00340-8; DEFLORA S, 1992, NATURE, V356, P569, DOI 10.1038/356569a0; DeFlora S, 1997, MUTAGENESIS, V12, P431, DOI 10.1093/mutage/12.6.431; Fukuda A, 1997, BIOCHEM BIOPH RES CO, V236, P505, DOI 10.1006/bbrc.1997.6585; Gebel S, 2004, CARCINOGENESIS, V25, P169, DOI 10.1093/carcin/bgg193; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HAYES JA, 1977, LAB ANIM SCI, V27, P762; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; HIGGINSON J, 1979, JNCI-J NATL CANCER I, V63, P1291; IDELL S, 1983, CLIN CHEST MED, V4, P359; INCHIOSA MA, 1990, RES COMMUN CHEM PATH, V67, P63; *INT AG RES CANC, 2003, IARC MON EV CARC RIS, V83; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; Isoherranen K, 1999, BRIT J DERMATOL, V140, P1017; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Jiang WD, 2001, P NATL ACAD SCI USA, V98, P9790, DOI 10.1073/pnas.171066498; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Ossola JO, 1998, INT J BIOCHEM CELL B, V30, P285, DOI 10.1016/S1357-2725(97)00109-X; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; RAO CV, 1995, CANCER RES, V55, P1464; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shimada T, 1996, CANCER RES, V56, P2979; Soh JW, 2000, CLIN CANCER RES, V6, P4136; STEVENS JB, 1980, FED PROC, V39, P3138; Thilly WG, 2003, NAT GENET, V34, P255, DOI 10.1038/ng1205; TILL GO, 1983, J TRAUMA, V23, P269, DOI 10.1097/00005373-198304000-00001; Vogel U, 2002, CARCINOGENESIS, V23, P1505, DOI 10.1093/carcin/23.9.1505; WADDELL WR, 1995, J SURG ONCOL, V58, P252, DOI 10.1002/jso.2930580411; Waddell WR, 1998, CLIN SCI, V95, P385, DOI 10.1042/CS19970251; Wei HC, 2002, CANCER LETT, V185, P21, DOI 10.1016/S0304-3835(02)00240-9; Wilson MR, 2000, EXP CELL RES, V254, P257, DOI 10.1006/excr.1999.4771; Yin ZM, 2000, CANCER RES, V60, P4053; Zidovetzki R, 1999, STROKE, V30, P651, DOI 10.1161/01.STR.30.3.651	39	52	55	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1559	+		10.1096/fj.04-1877fje	http://dx.doi.org/10.1096/fj.04-1877fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289447				2022-12-28	WOS:000223554900028
J	Tompa, P; Csermely, P				Tompa, P; Csermely, P			The role of structural disorder in the function of RNA and protein chaperones	FASEB JOURNAL			English	Review						chaperone evolution; chaperone function; entropy transfer; intrinsically unstructured protein	HIV-1 NUCLEOCAPSID PROTEIN; C-TERMINAL EXTENSION; HEAT-SHOCK-PROTEIN; ALPHA-A-CRYSTALLIN; INTRINSICALLY UNSTRUCTURED PROTEINS; INTRON IN-VIVO; MOLECULAR CHAPERONE; INDUCED FIT; COMPLEMENTARY SEQUENCE; UNFOLDED PROTEIN	Chaperones are highly sophisticated protein machines that assist the folding of RNA molecules or other proteins. Their function is generally thought to require a fine-tuned and highly conserved structure: despite the recent recognition of the widespread occurrence of structural disorder in the proteome, this structural trait has never been generally considered in molecular chaperones. In this review we give evidence for the prevalence of functional regions without a well-defined 3-D structure in RNA and protein chaperones. By considering a variety of individual examples, we suggest that the structurally disordered chaperone regions either function as molecular recognition elements that act as solubilizers or locally loosen the structure of the kinetically trapped folding intermediate via transient binding to facilitate its conformational search. The importance of structural disorder is underlined by a predictor of natural disordered regions, which shows an extremely high proportion of such regions, unparalleled in any other protein class, within RNA chaperones: 54.2% of their residues fall into disordered regions and 40% fall within disordered regions longer than 30 consecutive residues. Structural disorder also prevails in protein chaperones, for which frequency values are 36.7% and 15%, respectively. In keeping with these and other details, a novel "entropy transfer" model is presented to account for the mechanistirole of structural disorder in chaperone function.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Semmelweis Univ, Dept Med Chem, H-1085 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Semmelweis University	Tompa, P (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	tompa@enzim.hu	Csermely, Peter/J-2067-2017	Csermely, Peter/0000-0001-9234-0659				Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Azoulay J, 2003, J MOL BIOL, V326, P691, DOI 10.1016/S0022-2836(02)01430-4; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Bhattacharyya J, 1999, J BIOL CHEM, V274, P15505, DOI 10.1074/jbc.274.22.15505; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brown HG, 1997, BIOCHEMISTRY-US, V36, P15035, DOI 10.1021/bi9721748; Clodi E, 1999, EMBO J, V18, P3776, DOI 10.1093/emboj/18.13.3776; Cristofari G, 1999, J BIOL CHEM, V274, P36643, DOI 10.1074/jbc.274.51.36643; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Csermely P, 1999, BIOESSAYS, V21, P959, DOI 10.1002/(SICI)1521-1878(199911)21:11<959::AID-BIES8>3.0.CO;2-1; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Csermely P, 1997, TRENDS BIOCHEM SCI, V22, P147, DOI 10.1016/S0968-0004(97)01026-8; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Demchenko AP, 2001, J MOL RECOGNIT, V14, P42, DOI 10.1002/1099-1352(200101/02)14:1<42::AID-JMR518>3.0.CO;2-8; DiNitto JP, 2003, J MOL BIOL, V330, P979, DOI 10.1016/S0022-2836(03)00685-5; Doi N, 1998, FEBS LETT, V430, P150, DOI 10.1016/S0014-5793(98)00674-7; Dunker A K, 2000, Genome Inform Ser Workshop Genome Inform, V11, P161; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Fu XM, 2003, BIOCHEM BIOPH RES CO, V308, P627, DOI 10.1016/S0006-291X(03)01450-5; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P13057, DOI 10.1074/jbc.270.22.13057; Hardesty B, 2001, PROG NUCLEIC ACID RE, V66, P41; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Jacks A, 2003, STRUCTURE, V11, P833, DOI 10.1016/S0969-2126(03)00121-7; Kim TD, 2002, BIOCHEMISTRY-US, V41, P13782, DOI 10.1021/bi026284c; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; Lorsch JR, 2002, CELL, V109, P797, DOI 10.1016/S0092-8674(02)00804-8; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; Mohr S, 2002, CELL, V109, P769, DOI 10.1016/S0092-8674(02)00771-7; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; Mukhopadhyay R, 2001, FEBS LETT, V505, P374, DOI 10.1016/S0014-5793(01)02844-7; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Pasta SY, 2002, J BIOL CHEM, V277, P45821, DOI 10.1074/jbc.M206499200; Persson M, 1999, BIOCHEMISTRY-US, V38, P432, DOI 10.1021/bi981442e; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; PONTIUS BW, 1993, TRENDS BIOCHEM SCI, V18, P181, DOI 10.1016/0968-0004(93)90111-Y; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; Poole AM, 1998, J MOL EVOL, V46, P1, DOI 10.1007/PL00006275; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Semrad K, 1998, GENE DEV, V12, P1327, DOI 10.1101/gad.12.9.1327; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; Sulijoadikusumo I, 2001, BIOCHEMISTRY-US, V40, P11559, DOI 10.1021/bi015526q; Tisne C, 2001, J MOL BIOL, V306, P443, DOI 10.1006/jmbi.2000.4391; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Treiber DK, 2001, CURR OPIN STRUC BIOL, V11, P309, DOI 10.1016/S0959-440X(00)00206-2; Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Waldsich C, 2002, GENE DEV, V16, P2300, DOI 10.1101/gad.231302; Weeks KM, 1997, CURR OPIN STRUC BIOL, V7, P336, DOI 10.1016/S0959-440X(97)80048-6; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	65	431	438	2	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1169	1175		10.1096/fj.04-1584rev	http://dx.doi.org/10.1096/fj.04-1584rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15284216				2022-12-28	WOS:000223554900031
J	Weinreb, O; Bar-Am, O; Amit, T; Chillag-Talmor, O; Youdim, MBH				Weinreb, O; Bar-Am, O; Amit, T; Chillag-Talmor, O; Youdim, MBH			Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members	FASEB JOURNAL			English	Article						survival genes and proteins; neurotrophic factors; rasagiline; propargylamine; Parkinson's disease	ANTI-PARKINSON DRUG; NEUROTROPHIC FACTOR; CELL-DEATH; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; GENE-EXPRESSION; MAP KINASE; RASAGILINE; APOPTOSIS; INHIBITOR	This study provides new insights into neuroprotection involving interaction of protein kinase C (PKC) pathway with Bcl-2 family proteins. Using a model of serum deprivation, we investigated the mechanism by which the anti-Parkinson/monoamine oxidase (MAO)-B inhibitor drug, rasagiline, exerts its neuroprotective effect in rat pheochromocytoma PC12 cells. Here, we report that rasagiline (0.1 - 10 muM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKCepsilon mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs. Moreover, rasagiline inhibited the cleavage and activation of procaspase-3 and poly (ADP-ribose) polymerase (PARP), whereas the PKC inhibitor, GF109203X, reversed these actions. Similarly, rasagiline decreased serum-free-induced levels of the important regulator of cell death, Bad, which was also blocked by GF109203X, indicating the involvement of PKC in rasagiline-induced cell survival. Furthermore, these studies have established that PKC- and Bcl-2-dependent neuroprotective activity of rasagiline is dependent on its propargyl moiety, because propargylamine had similar effects with the same potency.	Technion Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Fac Med, Rappaport Family Res Inst, IL-31096 Haifa, Israel; Technion Fac Med, Eve Topf & USA Natl PArkinson Fdn Ctr Excellence, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akao Y, 2002, NEUROSCI LETT, V326, P105, DOI 10.1016/S0304-3940(02)00332-4; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Durkin JP, 1997, J NEUROCHEM, V68, P1400; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finberg JPM, 1998, NEUROREPORT, V9, P703; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Han YS, 2004, BRIT J PHARMACOL, V141, P997, DOI 10.1038/sj.bjp.0705688; Hsieh YC, 2003, SHOCK, V19, P582, DOI 10.1097/01.shk.0000065705.84144.ed; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Katsura K, 2003, NEUROL RES, V25, P522, DOI 10.1179/016164103101201760; Kochman A, 2003, POL J PHARMACOL, V55, P389; KRIBBEN A, 1993, AM J PHYSIOL, V265, pC939, DOI 10.1152/ajpcell.1993.265.4.C939; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Maroto R, 1997, J NEUROCHEM, V69, P514; Maruyama W, 2004, NEUROCHEM INT, V44, P393, DOI 10.1016/j.neuint.2003.08.005; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; Middleton G, 2001, DEVELOPMENT, V128, P447; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parain K, 1999, NEUROREPORT, V10, P557, DOI 10.1097/00001756-199902250-00021; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sagi Y., 2003, Neural Plasticity, V10, P227; SAGI Y, 2001, NEURAL PLAST, V8, P197; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Selvatici R, 2003, J NEUROSCI RES, V71, P64, DOI 10.1002/jnr.10464; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Weinreb O, 2003, FASEB J, V17, P935, DOI 10.1096/fj.02-0712fje; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Yogev-Falach M, 2003, FASEB J, V17, P2325, DOI 10.1096/fj.03-0078fje; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim M B, 1991, J Neural Transm Suppl, V34, P61; Youdim MBH, 2003, BIOCHEM PHARMACOL, V66, P1635, DOI 10.1016/S0006-2952(03)00535-5; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; Youdim Moussa Bh, 2003, Expert Rev Neurother, V3, P737, DOI 10.1586/14737175.3.6.737; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	51	157	168	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1471	+		10.1096/fj.04-1916fje	http://dx.doi.org/10.1096/fj.04-1916fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247150				2022-12-28	WOS:000222979200002
J	Bounou, S; Giguere, JF; Cantin, R; Gilbert, C; Imbeault, M; Martin, G; Tremblay, MJ				Bounou, S; Giguere, JF; Cantin, R; Gilbert, C; Imbeault, M; Martin, G; Tremblay, MJ			The importance of virus-associated host ICAM-1 in human immunodeficiency virus type 1 dissemination depends on the cellular context	FASEB JOURNAL			English	Article						HIV; AIDS; monocytes; macrophages; T lymphocytes; dendritic cells; lymphoid tissue	FUNCTION-ASSOCIATED ANTIGEN-1; DC-SIGN INTERACTIONS; MONOCYTE-DERIVED MACROPHAGES; CD4(+) T-CELLS; DENDRITIC CELLS; ANTIRETROVIRAL THERAPY; MONOCLONAL-ANTIBODIES; PRIMATE LENTIVIRUSES; ADHESION MOLECULES; VIRAL INFECTIVITY	The primary objective of this study was to define whether the nature of virion-bound host cell membrane proteins influenced the process of human immunodeficiency virus 1 (HIV-1) capture and transmission. We pulsed cells of monocytoid lineage (established and primary) and CD4-negative epithelial cells transiently expressing DC-SIGN or LFA-1 with isogenic HIV-1 particles either devoid or bearing host-derived ICAM-1 or ICAM-3 before incubation with an indicator cell line. To our surprise, the ICAM-1/LFA-1 association was a more efficient transmission factor than the combined gp120/DC-SIGN and ICAM-3/DC-SIGN interactions. The involvement of the association between virus-bound ICAM-1 and its natural ligand LFA-1 in virus binding and carriage was confirmed when using more physiological cellular targets, i.e., human lymphoid tissues cultured ex vivo. However, the contribution of virus-anchored host ICAM-1 to the process of retention and transmission of HIV-1 could not be confirmed when using primary human cells of macrophage/dendritic lineage as transmitter cells and autologous CD4(+) T lymphocytes as targets. Altogether these data underscore the complexity of factors participating in virus-cell contact and efficient dissemination of HIV-1 to target cells.	CHU Laval, Res Ctr, Ctr Infect Dis, Lab Human Immunoretrovirol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Tremblay, MJ (corresponding author), CHU Laval, Res Ctr, Ctr Infect Dis, Lab Human Immunoretrovirol, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	michel.j.tremblay@crchul.ulaval.ca		Giguere, Jean-Francois/0000-0001-8234-2917; bounou, salim/0000-0001-8312-5420; Imbeault, Michael/0000-0002-0073-0922; Gilbert, Caroline/0000-0003-2722-1180				Baribaud F, 2002, J VIROL, V76, P9135, DOI 10.1128/JVI.76.18.9135-9142.2002; Baribaud F, 2001, VIROLOGY, V286, P1, DOI 10.1006/viro.2001.0975; Bastiani L, 1997, J VIROL, V71, P3444, DOI 10.1128/JVI.71.5.3444-3450.1997; BASTIANI L, 1999, AIDS RES HUM RETROV, V15, P895; BAZIL V, 1990, FOLIA BIOL-PRAGUE, V36, P41; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; Cantin R, 1997, J VIROL, V71, P1922, DOI 10.1128/JVI.71.3.1922-1930.1997; Cantin R, 1997, BLOOD, V90, P1091, DOI 10.1182/blood.V90.3.1091.1091_1091_1100; Cantin R, 1996, VIROLOGY, V218, P372, DOI 10.1006/viro.1996.0206; Carr JM, 1999, VIROLOGY, V265, P319, DOI 10.1006/viro.1999.0047; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; Cosma A, 1999, AIDS, V13, P2033, DOI 10.1097/00002030-199910220-00005; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fujiwara M, 1999, J VIROL, V73, P3603, DOI 10.1128/JVI.73.5.3603-3607.1999; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Giguere JF, 2002, J IMMUNOL, V169, P2762, DOI 10.4049/jimmunol.169.5.2762; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; Gummuluru S, 2002, J VIROL, V76, P10692, DOI 10.1128/JVI.76.21.10692-10701.2002; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; Hioe CE, 1998, AIDS RES HUM RETROV, V14, pS247; Hioe CE, 2001, J VIROL, V75, P1077, DOI 10.1128/JVI.75.2.1077-1082.2001; Kacani L, 1998, J VIROL, V72, P6671, DOI 10.1128/JVI.72.8.6671-6677.1998; Kilby JM, 2001, CLIN INFECT DIS, V33, P873, DOI 10.1086/322647; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003; Lee B, 2001, J VIROL, V75, P12028, DOI 10.1128/JVI.75.24.12028-12038.2001; Levy JA, 2002, LANCET, V359, P2212, DOI 10.1016/S0140-6736(02)09314-5; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024; Olinger GG, 2000, J VIROL, V74, P8550, DOI 10.1128/JVI.74.18.8550-8557.2000; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8932; Pohlmann S, 2001, J VIROL, V75, P10523, DOI 10.1128/JVI.75.21.10523-10526.2001; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Rizzuto CD, 1997, J VIROL, V71, P4847, DOI 10.1128/JVI.71.6.4847-4851.1997; Roos JW, 2000, VIROLOGY, V273, P307, DOI 10.1006/viro.2000.0431; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; Sanders RW, 2002, J VIROL, V76, P7812, DOI 10.1128/JVI.76.15.7812-7821.2002; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Tardif MR, 2003, J VIROL, V77, P12299, DOI 10.1128/JVI.77.22.12299-12309.2003; Tominaga Y, 1998, J IMMUNOL, V161, P4016; Tremblay MJ, 1998, IMMUNOL TODAY, V19, P346, DOI 10.1016/S0167-5699(98)01286-9; Trumpfheller C, 2003, INT IMMUNOL, V15, P289, DOI 10.1093/intimm/dxg030; Tsunetsugu-Yokota Y, 1997, VIROLOGY, V239, P259, DOI 10.1006/viro.1997.8895; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Woska JR, 1998, J BIOL CHEM, V273, P4725, DOI 10.1074/jbc.273.8.4725; Wu L, 2002, P NATL ACAD SCI USA, V99, P1568, DOI 10.1073/pnas.032654399; Wu L, 2002, J VIROL, V76, P5905, DOI 10.1128/JVI.76.12.5905-5914.2002; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	65	34	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1294	+		10.1096/fj.04-1755fje	http://dx.doi.org/10.1096/fj.04-1755fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208262				2022-12-28	WOS:000222327500007
J	Chai, JY; Jones, MK; Tarnawski, AS				Chai, JY; Jones, MK; Tarnawski, AS			Serum response factor is a critical requirment for VEGF signaling in endothelial cells and VEGF-induced angiogenesis	FASEB JOURNAL			English	Article						SRF; vascular endothelial growth factor; actin dynamics	GROWTH-FACTOR; GASTRIC-ULCERS; GENE; PROLIFERATION; TRANSCRIPTION; ACTIVATION; MECHANISMS; MIGRATION; INHIBITION; PROMOTER	Angiogenesis, new capillary blood vessel formation, is essential for embryonic development, wound healing, and cancer growth. Vascular endothelial growth factor (VEGF) induces angiogenesis by activating endothelial cell migration and proliferation. Serum response factor (SRF) is a transcription factor important for embryonic development and activation of immediate early gene expression. The roles of SRF in endothelial cell biology and angiogenesis have not been explored. Here we demonstrate that SRF is a downstream mediator of VEGF signaling in endothelial cells and a critical requirement for VEGF-induced angiogenesis. Knockdown of SRF protein levels in human and rat endothelial cells abolished VEGF-induced in vitro angiogenesis, impaired endothelial cell migration and proliferation, and inhibited VEGF-induced actin polymerization and immediate early gene expression. Injection of SRF antisense expression plasmid into gastric ulcers in rats significantly inhibited in vivo angiogenesis in granulation tissue. Mechanistically, this study also revealed that VEGF promotes SRF expression and nuclear translocation and increases SRF binding activity to DNA in endothelial cells through both Rho-actin and MEK-ERK dependent signaling pathways. These findings have potential therapeutic implications, e.g., local anti-SRF treatment may inhibit angiogenesis crucial for tumor growth.	Vet Affairs Med Ctr, Dept Med Gastroenterol, Gastroenterol Sect 111G, Long Beach, CA 90822 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Tarnawski, AS (corresponding author), Vet Affairs Med Ctr, Dept Med Gastroenterol, Gastroenterol Sect 111G, 5901 E 7th St, Long Beach, CA 90822 USA.	atarnawski@yahoo.com	Chai, Jianyuan/A-8300-2009; Chai, Jianyuan/AAJ-5892-2020	Chai, Jianyuan/0000-0001-6975-6867				Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Breslin JW, 2003, AM J PHYSIOL-HEART C, V284, pH92, DOI 10.1152/ajpheart.00330.2002; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; Ehring GR, 2000, J PHYSIOL PHARMACOL, V51, P799; Fahmy RG, 2002, J CELL BIOCHEM, V84, P575, DOI 10.1002/jcb.10057.abs; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Jones MK, 2000, J PHYSIOL PHARMACOL, V51, P813; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Pai Rama, 2000, Molecular Cell Biology Research Communications, V4, P111, DOI 10.1006/mcbr.2000.0260; Ponce ML, 2001, METH MOLEC MED, V46, P205, DOI 10.1385/1-59259-143-4:205; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schor AM, 2001, METH MOLEC MED, V46, P145, DOI 10.1385/1-59259-143-4:145; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Settleman J, 2003, MOL CELL, V11, P1121, DOI 10.1016/S1097-2765(03)00189-8; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Strowski MZ, 2004, FASEB J, V18, P218, DOI 10.1096/fj.03-0055fje; Suhardja A, 2003, MICROSC RES TECHNIQ, V60, P70, DOI 10.1002/jemt.10245; TARNAWSKI A, 1990, J CLIN GASTROENTEROL, V12, pS148, DOI 10.1097/00004836-199001001-00025; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835	38	74	76	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1264	+		10.1096/fj.03-1232fje	http://dx.doi.org/10.1096/fj.03-1232fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180964				2022-12-28	WOS:000222327500032
J	Ioannidis, JPA				Ioannidis, JPA			Global estimates of high-level brain drain and deficit	FASEB JOURNAL			English	Article						citations; scientific impact; migration; research; development	ACADEMIC MEDICINE; WOMEN PHYSICIANS; SCIENCE	Brain drain, the international migration of scientists in search of better opportunities, has been a long-standing concern, but quantitative measurements are uncommon and limited to specific countries or disciplines. We need to understand brain drain at a global level and estimate the extent to which scientists born in countries with low opportunities never realize their potential. Data on 1523 of the most highly cited scientists for 1981-1999 are analyzed. Overall, 31.9% of these scientists did not reside in the country where they were born (range 18.1-54.6% across 21 different scientific fields). There was great variability across developed countries in the proportions of foreign-born resident scientists and emigrating scientists. Countries without a critical mass of native scientists lost most scientists to migration. This loss occurred in both developed and developing countries. Adjusting for population and using the U. S. as reference, the number of highly cited native-born scientists was at least 75% of the expected number in only 8 countries other than the U. S. It is estimated that similar to94% of the expected top scientists worldwide have not been able to materialize themselves due to various adverse conditions. Scientific deficit is only likely to help perpetuate these adverse conditions.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; Fdn Res & Technol Hellas, Inst Biomed Res, Ioannina, Greece; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Tufts University	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011					Breithaupt H, 2000, EMBO REP, V1, P104, DOI 10.1093/embo-reports/kvd041; Brumfiel G, 2004, NATURE, V427, P190, DOI 10.1038/427190a; Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5; Garfield E, 1996, BRIT MED J, V313, P411, DOI 10.1136/bmj.313.7054.411; GIBBS WW, 1995, SCI AM, V273, P92, DOI 10.1038/scientificamerican0895-92; *I SCI INF, HIGHL CIT RES; Ioannidis JP, 2004, J TRANSL MED, V2, P5, DOI DOI 10.1186/1479-5876-2-5; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; Levin SG, 1999, SCIENCE, V285, P1213, DOI 10.1126/science.285.5431.1213; Levy LF, 2003, BRIT MED J, V327, P170, DOI 10.1136/bmj.327.7407.170; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Nonnemaker L, 2000, NEW ENGL J MED, V342, P399, DOI 10.1056/NEJM200002103420606; Palepu A, 1998, JAMA-J AM MED ASSOC, V280, P767, DOI 10.1001/jama.280.9.767; PEARSON R, 1986, NATURE, V319, P84, DOI 10.1038/319084a0; Pierson AS, 2000, NATURE, V407, P13, DOI 10.1038/35024218; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; *UN, 1981, ANN DEM REP; Wojcik C, 2004, NATURE, V427, P196, DOI 10.1038/427196b; 2001, NATURE LONDON, V410, P1	19	40	40	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					936	939		10.1096/fj.03-1394lfe	http://dx.doi.org/10.1096/fj.03-1394lfe			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15173104				2022-12-28	WOS:000222327500010
J	Leask, A; Abraham, DJ				Leask, A; Abraham, DJ			TGF-beta signaling and the fibrotic response	FASEB JOURNAL			English	Review						Smad; MAP kinase; CTGF; prostacyclin; TNF-alpha; scleroderma; ED-A fibronectin	GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; IDIOPATHIC PULMONARY-FIBROSIS; COLLAGEN GENE-EXPRESSION; HEPATIC STELLATE CELLS; HUMAN MESANGIAL CELLS; MICE LACKING SMAD3; EXTRACELLULAR-MATRIX; FACTOR CTGF; TRANSFORMING GROWTH-FACTOR-BETA-1	The cause of fibrotic diseases, pathologies characterized by excessive production, deposition, and contraction of extracellular matrix, is unknown. To understand the molecular basis of fibrotic disease, it is essential to appreciate how matrix deposition is normally controlled and how this process is dysregulated in fibrogenesis. This review discusses the current state of knowledge concerning interactions among the profibrotic proteins transforming growth factor-beta (TGF-beta), connective tissue growth factor (CTGF, CCN2), and ED-A fibronectin (ED- A FN) and the antifibrotic proteins tumor necrosis factor-alpha (TNF-alpha) and gamma-interferon (IFN-gamma).	UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Rheumatol, London NW3 2PF, England	University of London; University College London; UCL Medical School	Leask, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Rheumatol, Rowland Hill St, London NW3 2PF, England.	a.leask@rfc.ucl.ac.uk	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015					Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; ALLEN JT, 1909, AM J RESP CELL MOL B, V21, P693; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; ASSAD L, 1993, VIRCHOWS ARCH B, V63, P307, DOI 10.1007/BF02899277; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BALINT GA, 1994, EXP TOXICOL PATHOL, V46, P37, DOI 10.1016/S0940-2993(11)80011-4; Ball DK, 2003, REPRODUCTION, V125, P271, DOI 10.1530/rep.0.1250271; Ball DK, 2003, J ENDOCRINOL, V176, pR1, DOI 10.1677/joe.0.176R001; Bedossa P, 2003, J PATHOL, V200, P504, DOI 10.1002/path.1397; Bettoni L, 2002, CLIN RHEUMATOL, V21, P244, DOI 10.1007/PL00011223; Bitzer M, 2000, GENE DEV, V14, P187; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BREUSS JM, 1995, J CELL SCI, V108, P2241; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Chin GS, 2001, PLAST RECONSTR SURG, V108, P423, DOI 10.1097/00006534-200108000-00022; Coker RK, 1997, AM J PATHOL, V150, P981; Cordeiro MF, 2003, GENE THER, V10, P59, DOI 10.1038/sj.gt.3301865; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; di Mola FF, 2002, ANN SURG, V235, P60, DOI 10.1097/00000658-200201000-00008; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Dugina V, 2001, J CELL SCI, V114, P3285; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Eckes B, 2000, MATRIX BIOL, V19, P325, DOI 10.1016/S0945-053X(00)00077-9; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; Fogo AB, 1999, EXP NEPHROL, V7, P147; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GILLERY P, 1992, EUR J CELL BIOL, V57, P244; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; GULLER S, 1994, ANN NY ACAD SCI, V734, P132, DOI 10.1111/j.1749-6632.1994.tb21741.x; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HATAMOCHI A, 1994, ARCH DERMATOL RES, V287, P115, DOI 10.1007/BF00370729; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Hill AG, 2000, WORLD J SURG, V24, P624, DOI 10.1007/s002689910103; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holmes A, 2003, J BIOL CHEM, V278, P41728, DOI 10.1074/jbc.M305019200; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; Kasuga H, 2001, KIDNEY INT, V60, P1745, DOI 10.1046/j.1523-1755.2001.00990.x; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; KULKARNI AB, 1993, AM J PATHOL, V143, P3; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LAWRENCE DA, 1984, J CELL PHYSIOL, V121, P184, DOI 10.1002/jcp.1041210123; Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2002, ARTHRITIS RHEUM-US, V46, P1857, DOI 10.1002/art.10333; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Lee JL, 2003, TOXICOL APPL PHARM, V192, P294, DOI 10.1016/S0041-008X(03)00301-6; LeRoy E C, 1990, Eur Cytokine Netw, V1, P215; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; LIN RY, 1995, ANN SURG, V222, P146, DOI 10.1097/00000658-199508000-00006; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Maeda T, 2002, BIOCHEM BIOPH RES CO, V294, P791, DOI 10.1016/S0006-291X(02)00556-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsui S, 1997, J HEPATOL, V27, P843, DOI 10.1016/S0168-8278(97)80322-4; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; Mead AL, 2003, INVEST OPHTH VIS SCI, V44, P3394, DOI 10.1167/iovs.02-0978; Miller LA, 2001, J HISTOCHEM CYTOCHEM, V49, P41, DOI 10.1177/002215540104900105; Mori R, 2002, FASEB J, V16, P963, DOI 10.1096/fj.01-0776com; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Mori Y, 2003, ARTHRITIS RHEUM-US, V48, P1964, DOI 10.1002/art.11157; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishida T, 2003, J CELL PHYSIOL, V196, P265, DOI 10.1002/jcp.10277; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Nunes I, 1998, J Am Optom Assoc, V69, P643; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OYAMA F, 1989, BIOCHEMISTRY-US, V28, P1428, DOI 10.1021/bi00429a072; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; Petkova DK, 2003, HISTOPATHOLOGY, V43, P381, DOI 10.1046/j.1365-2559.2003.01718.x; Querfeld C, 1999, J DERMATOL SCI, V21, P13, DOI 10.1016/S0923-1811(99)00008-0; Riquet FB, 2000, MOL MED, V6, P705, DOI 10.1007/BF03402050; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Rodriguez-Pena A, 2001, NEPHROL DIAL TRANSPL, V16, P34, DOI 10.1093/ndt/16.suppl_1.34; Roelen BAJ, 2003, AM J PHYSIOL-CELL PH, V285, pC823, DOI 10.1152/ajpcell.00053.2003; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SALTZMAN LE, 1982, BIOCHEM J, V204, P25, DOI 10.1042/bj2040025; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Schmid P, 1998, AM J PATHOL, V152, P485; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Scorza R, 2001, CLIN EXP RHEUMATOL, V19, P503; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; SHAH M, 1994, J CELL SCI, V107, P1137; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; Takagawa S, 2003, J INVEST DERMATOL, V121, P41, DOI 10.1046/j.1523-1747.2003.12308.x; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Van Vliet AI, 2001, J PATHOL, V193, P256; VARGA J, 1986, BIOCHEM BIOPH RES CO, V138, P974, DOI 10.1016/S0006-291X(86)80591-5; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wang SN, 2001, KIDNEY INT, V60, P96, DOI 10.1046/j.1523-1755.2001.00776.x; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yu Q, 2000, GENE DEV, V14, P163; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	149	1860	2000	8	245	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					816	827		10.1096/fj.03-1273rev	http://dx.doi.org/10.1096/fj.03-1273rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15117886				2022-12-28	WOS:000221883200030
J	Tchaicheeyan, O				Tchaicheeyan, O			Is peptide bond cis/trans isomerization a key stage in the chemo-mechanical cycle of motor proteins?	FASEB JOURNAL			English	Article						energy transduction; kinesin; mechano-chemical coupling; molecular mechanism; myosin	SINGLE MYOSIN MOLECULE; CONFORMATION; HYDROLYSIS; MECHANICS; KINESINS; ATPASE	Motor proteins such as myosin and kinesin are responsible for actively directed movement in vivo. The physicochemical mechanism underlying their function is still obscure. A novel and unifying model concerning the motors driving mechanism is suggested here. This model resides within the framework of the well-studied "swinging lever-arm" hypothesis, stating that cis/trans peptide bond isomerization (CTI) is a key stage in the chemo-mechanical coupling within actomyosin-the complex of the motor ( myosin) and its specific track ( actin). CTI is suggested to propel myosin's lever-arm swing. The model addresses on the submolecular level a broad spectrum of actomyosin's functional characteristics, such as kinetics, energetics, force exertion, stepping, and directionality. The model may be tested first with relative ease in kinesin-a smaller motor that could be specifically modified with unnatural amino acids using bacterial expression. Suggested modifications may be used for labeling and functional decoupling.	Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Tchaicheeyan, O (corresponding author), Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel.	toren@tx.technion.ac.il						An SSA, 1999, J AM CHEM SOC, V121, P11558, DOI 10.1021/ja9930317; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; CHUNG HH, 1993, P NATL ACAD SCI USA, V90, P10145, DOI 10.1073/pnas.90.21.10145; COREY RB, 1953, PROC R SOC SER B-BIO, V141, P10, DOI 10.1098/rspb.1953.0011; Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375; Endow SA, 1999, NAT CELL BIOL, V1, pE163, DOI 10.1038/14113; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fischer G, 2000, CHEM SOC REV, V29, P119, DOI 10.1039/a803742f; Flint DG, 2002, CHEM BIOL, V9, P391, DOI 10.1016/S1074-5521(02)00109-6; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14495, DOI 10.1021/bi990508i; Higuchi H, 2002, CURR OPIN CELL BIOL, V14, P50, DOI 10.1016/S0955-0674(01)00293-9; Houdusse A, 2001, CURR OPIN STRUC BIOL, V11, P182, DOI 10.1016/S0959-440X(00)00188-3; Howard J., 2001, MECH MOTOR PROTEINS; Hugel T, 2002, SCIENCE, V296, P1103, DOI 10.1126/science.1069856; Huxley AF, 2000, PHILOS T ROY SOC B, V355, P433, DOI 10.1098/rstb.2000.0584; Huxley HE, 2000, PHILOS T R SOC B, V355, P539, DOI 10.1098/rstb.2000.0595; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Murphy CT, 2001, NAT CELL BIOL, V3, P311, DOI 10.1038/35060110; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reimer U, 2002, BIOPHYS CHEM, V96, P203, DOI 10.1016/S0301-4622(02)00013-3; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; Sasaki N, 2003, BIOCHEMISTRY-US, V42, P90, DOI 10.1021/bi026051l; Scherer G, 1998, J AM CHEM SOC, V120, P5568, DOI 10.1021/ja980181t; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; Schiene-Fischer C, 2001, J AM CHEM SOC, V123, P6227, DOI 10.1021/ja0042480; Schmid FX, 2002, ADV PROTEIN CHEM, V59, P243; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Vale RD, 2000, PHILOS T ROY SOC B, V355, P449, DOI 10.1098/rstb.2000.0586; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; WIBERG KB, 1995, J AM CHEM SOC, V117, P2201, DOI 10.1021/ja00113a009; WOLEDGE R, 1985, ENERGETIC ASPECTS MU, V41	39	26	26	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					783	789		10.1096/fj.03-1027hyp	http://dx.doi.org/10.1096/fj.03-1027hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15117883				2022-12-28	WOS:000221883200027
J	Li, J; Zhu, M; Manning-Bog, AB; Di Monte, DA; Fink, AL				Li, J; Zhu, M; Manning-Bog, AB; Di Monte, DA; Fink, AL			Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease	FASEB JOURNAL			English	Article						alpha-synuclein; A beta peptide; catecholamines; oxidation	ALPHA-SYNUCLEIN AGGREGATION; IN-VITRO; QUINONE FORMATION; OXYGEN RADICALS; PROTEIN DAMAGE; BETA-SYNUCLEIN; A-BETA; INHIBITION; NEUROTOXICITY; PROTOFIBRILS	Protein deposition diseases involve the aggregation of normally soluble proteins, leading to both fibrillar and amorphous deposits. The aggregation of alpha-synuclein is associated with Parkinson's disease, and the aggregation of the Abeta peptide is associated with Alzheimer's disease. Here we show that L-dopa, dopamine, and other catecholamines dissolve fibrils of alpha-synuclein and Abeta peptide generated in vitro. The catecholamines also inhibited the fibrillation of these proteins. In addition, intraneuronal alpha-synuclein deposits formed in a mouse model were dissolved by incubation of tissue slices with L-dopa. These catecholamines are susceptible to oxidative breakdown, and we show that oxidation products are more effective than the parent compounds in inhibition. The ability to dissolve fibrils provides a new approach for studying mechanisms and consequences (e.g., the relationship between fibril formation and neurodegeneration) of protein aggregation. It is also likely to help in the development of strategies for the prevention and treatment of protein deposition diseases.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Parkinsons Inst, Sunnyvale, CA USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu		Di Monte, Donato/0000-0002-8296-836X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES10806] Funding Source: Medline; NINDS NIH HHS [R01 NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; Baba M, 1998, AM J PATHOL, V152, P879; BIRKMAYER W, 1985, J NEURAL TRANSM, V64, P113, DOI 10.1007/BF01245973; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cullen KM, 1996, NEURODEGENERATION, V5, P177, DOI 10.1006/neur.1996.0025; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FREDRIKSSON A, 1994, PHARMACOL TOXICOL, V75, P36, DOI 10.1111/j.1600-0773.1994.tb00321.x; Goedert M, 2001, CLIN CHEM LAB MED, V39, P308, DOI 10.1515/CCLM.2001.047; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; LANGE KW, 1994, J NEURAL TRANSM-SUPP, P183; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Lemos-Amado F, 2001, RAPID COMMUN MASS SP, V15, P2466, DOI 10.1002/rcm.498; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Muralikrishnan D, 1998, FASEB J, V12, P905, DOI 10.1096/fasebj.12.10.905; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Rajagopalan S, 2001, MECH AGEING DEV, V122, P1499, DOI 10.1016/S0047-6374(01)00283-4; Remiao F, 2003, BIOMED CHROMATOGR, V17, P6, DOI 10.1002/bmc.203; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; SCHMIDT ML, 1995, AM J PATHOL, V147, P503; Sebastiao MP, 2000, BIOCHEM J, V351, P273, DOI 10.1042/0264-6021:3510273; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Spencer JPE, 1996, FREE RADICAL RES, V24, P95, DOI 10.3109/10715769609088005; Stenstad T, 1996, J RHEUMATOL, V23, P93; Tatsuno Y, 1990, Nihon Hoigaku Zasshi, V44, P174; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3	46	196	205	1	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					962	+		10.1096/fj.03-0770fje	http://dx.doi.org/10.1096/fj.03-0770fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059976				2022-12-28	WOS:000221108800027
J	Cuzzocrea, S; Di Paola, R; Mazzon, E; Cortes, U; Genovese, T; Muia, C; Li, WX; Xu, WZ; Li, JH; Zhang, J; Wang, ZQ				Cuzzocrea, S; Di Paola, R; Mazzon, E; Cortes, U; Genovese, T; Muia, C; Li, WX; Xu, WZ; Li, JH; Zhang, J; Wang, ZQ			PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion	FASEB JOURNAL			English	Article						SAO shock; ischemia and reperfusion; PARG inhibitor; neutrophil infiltration; organ injury	ADP-RIBOSE SYNTHETASE; POLY(ADP-RIBOSE) GLYCOHYDROLASE; RAT MODEL; INHIBITOR; POLYMERASE; ISCHEMIA; INFLAMMATION; SHOCK	Poly (ADP-ribosyl)ation, an early post-translational modification in response to DNA damage, is catalyzed by poly (ADP-ribose) polymerase (PARP-1) and catabolized by poly(ADP-ribose) glycohydrolase (PARG). The aim of this study was to investigate the role of PARG on the modulation of the inflammatory response caused by splanchnic ischemia and reperfusion. SAO shock in rats and wild-type (WT) mice was associated with a significant neutrophil infiltration in the ileum and production of tumor necrosis factor-alpha (TNF-alpha). Reperfused ileum tissue sections from SAO-shocked WT mice and rats showed positive staining for P-selectin and ICAM-1 localized mainly in the vascular endothelial cells. Genetic disruption of the PARG gene in mice or pharmacological inhibition of PARG by PARG inhibitors significantly improved the histological status of the reperfused tissues associated with reduced expression of P-selectin and ICAM-1, neutrophil infiltration into the reperfused intestine, and TNF-alpha production. These results suggest that PARG activity modulates the inflammatory response in ischemia/reperfusion and participates in end (target) organ damage under these conditions.	Torre Biol Policlin Univ, Dept Clin & Expt Med & Pharmacol, Messina, Italy; Int Agcy Res Canc, F-69372 Lyon, France; Guilford Pharmaceut Inc, Baltimore, MD USA; Lilium Pharmaceut, Cockeysville, MD USA	World Health Organization; International Agency for Research on Cancer (IARC)	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Torre Biol Policlin Univ, Via C Valeria Gazzi, I-98100 Messina, Italy.	salvator@unime.it	di paola, rosanna/U-4356-2019; Mazzon, Emanuela/AAL-4334-2020	di paola, rosanna/0000-0001-6725-8581; GENOVESE, Tiziana/0000-0002-3335-7327; mazzon, emanuela/0000-0002-5073-717X				ALVAREZGONZALEZ R, 1995, BIOCHIMIE, V77, P403, DOI 10.1016/0300-9084(96)88153-3; AOKI K, 1995, BIOCHEM BIOPH RES CO, V210, P329, DOI 10.1006/bbrc.1995.1665; Bernardi R, 1997, BBA-PROTEIN STRUCT M, V1338, P60, DOI 10.1016/S0167-4838(96)00188-4; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CAPUTI AP, 1980, J PHARMACOL EXP THER, V215, P309; Cortes U, 2004, MOL CELL BIOL, V24, P7163, DOI 10.1128/MCB.24.16.7163-7178.2004; Cuzzocrea S, 1999, J LEUKOCYTE BIOL, V66, P471, DOI 10.1002/jlb.66.3.471; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Di Paola R, 2004, EUR J PHARMACOL, V492, P203, DOI 10.1016/j.ejphar.2004.03.033; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Errando C L, 1994, Rev Esp Anestesiol Reanim, V41, P237; Genovese T, 2004, CRIT CARE MED, V32, P1365, DOI 10.1097/01.CCM.0000127775.70867.0C; Granger DN, 1997, AM J PHYSIOL-GASTR L, V273, pG982, DOI 10.1152/ajpgi.1997.273.5.G982; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LI J, 2000, Patent No. 00025787; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; Lu XCM, 2003, BRAIN RES, V978, P99, DOI 10.1016/S0006-8993(03)02774-4; Maruta H, 1997, BIOCHEM BIOPH RES CO, V236, P265, DOI 10.1006/bbrc.1997.6910; Mazzon E, 2002, SHOCK, V17, P222, DOI 10.1097/00024382-200203000-00011; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Quesada P, 1996, EXP CELL RES, V226, P183, DOI 10.1006/excr.1996.0217; SLAMA JT, 1995, J MED CHEM, V38, P389, DOI 10.1021/jm00002a021; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TANUMA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P227, DOI 10.1016/0003-9861(91)90289-U; TANUMA S, 1989, BIOCHEM INT, V19, P1395; TAVASSOLI M, 1985, BIOCHIM BIOPHYS ACTA, V827, P228, DOI 10.1016/0167-4838(85)90207-9; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WETHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Zhang J, 2002, DRUG FUTURE, V27, P371, DOI 10.1358/dof.2002.027.04.669101; ZIMMERMANN BJ, 1993, PATHOPHYSIOLOGY SHOC, P322	35	46	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					558	566		10.1096/fj.04-3117com	http://dx.doi.org/10.1096/fj.04-3117com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791006				2022-12-28	WOS:000228865300040
J	Mayerhofer, M; Aichberger, KJ; Florian, S; Krauth, MT; Hauswirth, AW; Derdak, S; Sperr, WR; Esterbauer, H; Wagner, O; Marosi, C; Pickl, WF; Deininger, M; Weisberg, E; Druker, BJ; Griffin, JD; Sillaber, C; Valent, P				Mayerhofer, M; Aichberger, KJ; Florian, S; Krauth, MT; Hauswirth, AW; Derdak, S; Sperr, WR; Esterbauer, H; Wagner, O; Marosi, C; Pickl, WF; Deininger, M; Weisberg, E; Druker, BJ; Griffin, JD; Sillaber, C; Valent, P			Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells	FASEB JOURNAL			English	Article						CML; Bcr-Abl; imatinib; vascular endothelial growth factor	CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; INDUCED G(1) ARREST; BCR-ABL; IMATINIB MESYLATE; CYTOGENETIC RESPONSES; MAMMALIAN PROTEIN; RESIDUAL DISEASE; INTERFERON-ALPHA; CANCER-THERAPY	The mammalian target of rapamycin (mTOR) has recently been described to be constitutively activated in B cr-Abl-transformed cells and to mediate rapamycin-induced inhibition of growth in respective cell lines. We have recently shown that rapamycin down-regulates expression of vascular endothelial growth factor (VEGF), a mediator of leukemia-associated angiogenesis, in primary CML cells. In the present study, we analyzed growth-inhibitory in vitro and in vivo effects of rapamycin on primary CML cells and asked whether rapamycin-induced suppression of VEGF in leukemic cells is related to growth inhibition. Rapamycin dose dependently inhibited growth of primary CML cells obtained from patients with imatinib-responsive or imatinib-resistant disease as well as growth of B cr-Abl-transformed imatinib-resistant cell lines. Moreover, we observed potent cytoreductive effects of rapamycin in a patient with imatinib-resistant Bcr-Abl+ leukemia. The growth-inhibitory effects of rapamycin on CML cells were found to be associated with G1 cell cycle arrest and with induction of apoptosis. In all cell types tested, rapamycin was found to down-regulate expression of VEGF. However, exogenously added VEGF did not counteract the rapamycin-induced decrease in proliferation. In conclusion, rapamycin inhibits growth of CML cells in vitro and in vivo and, in addition, down-regulates expression of VEGF. Both effects may contribute to the antileukernic activity of the drug in CML.	Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1097 Vienna, Austria; Med Univ Vienna, Inst Immunol, A-1097 Vienna, Austria; Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost, A-1097 Vienna, Austria; Med Univ Vienna, Dept Internal Med 1, Div Oncol, A-1097 Vienna, Austria; Oregon Hlth Sci Univ, Inst Canc, Ctr hematol Malignancies, Portland, OR 97201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Howard Hughes Med Inst, Portland, OR USA	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Oregon Health & Science University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Mayerhofer, M (corresponding author), Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1097 Vienna, Austria.	matthias.mayerhofer@univie.ac.at	Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Pickl, Winfried F/E-5682-2011; Sperr, Mast/V-4767-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Druker, Brian/0000-0001-8331-8206; Pickl, Winfried F./0000-0003-0430-4952; Sperr, Wolfgang/0000-0003-3288-8027; Esterbauer, Harald/0000-0001-7343-7455				Avramis IA, 2003, CANCER CHEMOTH PHARM, V52, P307, DOI 10.1007/s00280-003-0668-y; Bellamy WT, 1999, CANCER RES, V59, P728; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Ebos JML, 2002, MOL CANCER RES, V1, P89; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; GAMBACORTIPASSERIN, 2003, LANCET ONCOL, V4, P75; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Goldman J, 2005, CURR OPIN HEMATOL, V12, P33, DOI 10.1097/01.moh.0000148551.93303.9e; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hochhaus A, 2001, SCIENCE, V293, P2163; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Hosoi H, 1999, CANCER RES, V59, P886; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Huang SL, 2001, CANCER RES, V61, P3373; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; JANOWSKAWIECZOREK, 2002, LEUKEMIA, V16, P1160; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kohmura K, 2004, J CELL PHYSIOL, V198, P370, DOI 10.1002/jcp.10426; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Krystal GW, 2001, DRUG RESIST UPDATE, V4, P16, DOI 10.1054/drup.2000.0176; Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood-2003-01-0305; Legros L, 2004, BLOOD, V104, P495, DOI 10.1182/blood-2003-08-2695; LIVAK KJ, 1995, PCR METH APPL, V4, P357; LUKE H, 2003, BLOOD, V102, pA72; Ly C, 2003, CANCER RES, V63, P5716; Marley SB, 2002, BRIT J HAEMATOL, V116, P162, DOI 10.1046/j.1365-2141.2002.03237.x; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Metcalfe SM, 1997, ONCOGENE, V15, P1635, DOI 10.1038/sj.onc.1201341; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nimmanapalli R, 2002, CURR OPIN ONCOL, V14, P616, DOI 10.1097/00001622-200211000-00005; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Brien S, 2003, CANCER, V98, P888, DOI 10.1002/cncr.11620; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Seufferlein T, 1996, CANCER RES, V56, P3895; SHI YF, 1995, CANCER RES, V55, P1982; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Verstovsek S, 2003, LEUKEMIA RES, V27, P661, DOI 10.1016/S0145-2126(02)00275-8; von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Yu CR, 2003, CANCER RES, V63, P2118	63	53	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					960	+		10.1096/fj.04-1973fje	http://dx.doi.org/10.1096/fj.04-1973fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15784722				2022-12-28	WOS:000227901300007
J	Lucas, R; Warner, TD; Vojnovic, I; Mitchell, JA				Lucas, R; Warner, TD; Vojnovic, I; Mitchell, JA			Cellular mechanisms of acetaminophen: role of cyclooxygenase	FASEB JOURNAL			English	Article						cyclooxygenase-2; nonsteroidal anti-inflammatory drugs; rofecoxib; lipid peroxide	PROSTAGLANDIN H-2 SYNTHASES; H SYNTHASE; INHIBITION; CYCLO-OXYGENASE-2; SPECIFICITY; PARACETAMOL; PEROXIDASE; SYNTHETASE; ACTIVATION; SALICYLATE	Acetaminophen is one of the most commonly used drugs for the safe and effective treatment of pain and fever. Acetaminophen works by lowering cyclo-oxygenase products preferentially in the central nervous system, where oxidant stress is strictly limited. However, the precise mechanism of action for acetaminophen on cyclo-oxygenase activity is debated. Two theories prevail. First, it is suggested that acetaminophen selectively inhibits a distinct form of cyclooxygenase, cyclo-oxygenase-3. Second, it is suggested that acetaminophen has no affinity for the active site of cyclo-oxygenase but instead blocks activity by reducing the active oxidized form of cyclo-oxygenase to an inactive form. Here, we have used an in vitro model of cyclo-oxygenase-2 activity (A549 cells stimulated with IL-1 beta) to show that acetaminophen is an effective inhibitor of cyclo-oxygenase activity in intact cells. However, acetaminophen, unlike nonsteroidal antiinflammatory drugs ( NSAIDs), cannot inhibit activity in broken cell preparations. The inhibitory effects of acetaminophen were abolished by increasing intracellular oxidation conditions with the cell-permeable hydroperoxide t-butylOOH. Similarly the inhibitory effects of the cyclooxygenase-2 selective inhibitor rofecoxib or the mixed cyclo-oxygenase-1/cyclo-oxygenase-2 inhibitors ibuprofen and naproxen were significant reduced by t-butylOOH. By contrast, the inhibitory effects of indomethacin or diclofenac, which also inhibit both cyclo- oxygenase-1 and cyclo- oxygenase-2, were unaffected by t-butylOOH. These observations dispel the notion that cyclo- oxygenase-3 is involved in the actions of acetaminophen and provide evidence that supports the theory that acetaminophen interferes with the oxidation state of cyclo- oxygease. Moreover, they suggest for the first time that the inhibitory effects of some NSAIDs, including the newly introduced cyclo- oxygenase-2 selective inhibitor rofecoxib, owe part of their inhibitory actions to effects on oxidation state of cyclo- oxygenase. Our data with t-butylOOH and NSAIDs illustrates an, as yet, undeveloped therapeutic window for the "cyclo-oxygenase inhibitor". Specifically, combining active site selectively with actions on enzyme oxidation state would allow for a broader range of tissue selective drugs.	Univ London Imperial Coll Sci Technol & Med, NHLI, Royal Brompton Hosp, UCCM, London SW3 6LY, England; Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England	Imperial College London; Royal Brompton Hospital; University of London; Queen Mary University London	Mitchell, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, NHLI, Royal Brompton Hosp, UCCM, Dovehouse St, London SW3 6LY, England.	j.a.mitchell@imperial.ac.uk	Lucas, Rut/H-6050-2015; Warner, Timothy D/A-1980-2009; Mitchell, Jane A/A-1991-2009	Lucas, Rut/0000-0002-4697-7832; Warner, Timothy D/0000-0003-3988-4408; 				Aronoff DM, 2003, J PHARMACOL EXP THER, V304, P589, DOI 10.1124/jpet.102.042853; Bambai B, 2000, J BIOL CHEM, V275, P27608; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Dinchuk JE, 2003, IMMUNOL LETT, V86, P121, DOI 10.1016/S0165-2478(02)00268-7; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; HANEL AM, 1982, BIOCHEM PHARMACOL, V31, P3307, DOI 10.1016/0006-2952(82)90565-2; Kis B, 2003, J CEREBR BLOOD F MET, V23, P1287, DOI 10.1097/01.WCB.0000090681.07515.81; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MOLDEUS P, 1982, BIOCHEM PHARMACOL, V31, P1363, DOI 10.1016/0006-2952(82)90029-6; Ouellet M, 2001, ARCH BIOCHEM BIOPHYS, V387, P273, DOI 10.1006/abbi.2000.2232; Perini RF, 2003, CURR PHARM DESIGN, V9, P2207, DOI 10.2174/1381612033454027; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; WARNER TD, 2004, IN PRESS J PHARM EXP	18	90	96	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					635	+		10.1096/fj.04-2437fje	http://dx.doi.org/10.1096/fj.04-2437fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15705740				2022-12-28	WOS:000227591900013
J	Xu, KY; Takimoto, E; Juang, GJ; Zhang, Q; Rohde, H; Myers, AC				Xu, KY; Takimoto, E; Juang, GJ; Zhang, Q; Rohde, H; Myers, AC			Evidence that the H1-H2 domain of alpha 1 subunit of (Na++K+)-ATPase participates in the regulation of cardiac contraction	FASEB JOURNAL			English	Article						structure and function; antibody; positive inotropic effect; molecular regulation	NA+-K+-ATPASE; ADENOSINE-TRIPHOSPHATASE; RYANODINE RECEPTORS; MOLECULAR-CLONING; SODIUM-PUMP; NA,K-ATPASE; SITE; POLYPEPTIDE; ANTIBODY; AFFINITY	(Na++K+)-ATPase (NKA) plays an important role in ion homeostasis and regulates cardiac contraction. To understand the molecular basis of its cardiac regulatory functions, we investigated whether the primary structure of the H1-H2 domain in alpha-1 (alpha1) subunit of the enzyme plays a role in myocardial contractile regulation. Here we show that site-specific binding to this alpha1 H1-H2 domain with a targeted antibody (SSA78) markedly augments intracellular Ca2+ transients and contraction of rat ventricular cardiomyocytes without inactivating NKA. In vivo SSA78 infusion in mice results in a positive inotropic effect with enhanced contractile function yet no change in relaxation, indicating a direct cardiac effect linked to the H1-H2 domain. Competitive immunofluorescent staining and flow cytometry reveal that SSA78 binding is antagonized by ouabain, supporting the interaction of SSA78 at one of the glycoside-effecter sites. These new findings suggest that the H1-H2 domain of alpha1 subunit of NKA is a critical determinant of enzyme biologic activity, which couples to enhanced myocyte calcium transient and inotropic action.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Clin Immunol, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University	Xu, KY (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St,Room 308, Baltimore, MD 21201 USA.	kxu002@umaryland.edu	Takimoto, Eiki/AAC-5100-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052175, R29HL048198, R01HL048198] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52175, HL48198] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1982, NATURE, V296, P167, DOI 10.1038/296167a0; ALLEN DG, 1985, NATURE, V316, P674, DOI 10.1038/316674a0; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BERS DM, 2002, NATURE, V415, P197; CHU A, 1988, METHOD ENZYMOL, V157, P36; Eisner D. A., 1992, HEART CARDIOVASCULAR, P863; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FORBUSH B, 1979, BIOCHEMISTRY-US, V18, P2308, DOI 10.1021/bi00578a027; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; Georgakopoulos D, 2001, J PHYSIOL-LONDON, V534, P535, DOI 10.1111/j.1469-7793.2001.00535.x; Hauptman PJ, 1999, CIRCULATION, V99, P1265, DOI 10.1161/01.CIR.99.9.1265; Jo SH, 2002, CIRC RES, V91, P46, DOI 10.1161/01.RES.0000024115.67561.54; JONES LR, 1988, METHOD ENZYMOL, V157, P85; KANO I, 1989, FEBS LETT, V250, P91, DOI 10.1016/0014-5793(89)80691-X; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490; KYTE J, 1971, J BIOL CHEM, V246, P4157; KYTE J, 1987, BIOCHEMISTRY-US, V26, P8350, DOI 10.1021/bi00399a049; KYTE J, 1981, NATURE, V292, P201, DOI 10.1038/292201a0; Liu J, 2000, J BIOL CHEM, V275, P27838; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; McDonough AA, 1996, AM J PHYSIOL-CELL PH, V270, pC1221, DOI 10.1152/ajpcell.1996.270.4.C1221; McDonough AA, 2002, BASIC RES CARDIOL S1, V97, P1, DOI [10.1007/s003950200024, DOI 10.1007/S003950200024]; Nishio M, 2002, AM J PHYSIOL-HEART C, V283, pH2045, DOI 10.1152/ajpheart.00203.2002; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; REPKE KRH, 1995, FEBS LETT, V359, P107, DOI 10.1016/0014-5793(95)00020-A; SCHNEIDER JW, 1985, P NATL ACAD SCI USA, V82, P6357, DOI 10.1073/pnas.82.18.6357; Sham JSK, 1998, P NATL ACAD SCI USA, V95, P15096, DOI 10.1073/pnas.95.25.15096; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHULL MM, 1987, P NATL ACAD SCI USA, V84, P4039, DOI 10.1073/pnas.84.12.4039; Skou JC, 1998, BIOSCIENCE REP, V18, P155, DOI 10.1023/A:1020196612909; SMITH T W, 1988, New England Journal of Medicine, V318, P358; Tian J, 2001, AM J PHYSIOL-HEART C, V281, pH1899, DOI 10.1152/ajpheart.2001.281.5.H1899; Wang JN, 2001, AM J PHYSIOL-CELL PH, V281, pC1336, DOI 10.1152/ajpcell.2001.281.4.C1336; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; XIE Z, 1994, NA PUMP, P49; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x; Xu KY, 2001, BIOCHEM BIOPH RES CO, V289, P167, DOI 10.1006/bbrc.2001.5974	40	6	8	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					53	61		10.1096/fj.04-2329com	http://dx.doi.org/10.1096/fj.04-2329com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629895				2022-12-28	WOS:000226576600042
J	Legler, DF; Doucey, MA; Schneider, P; Chapatte, L; Bender, FC; Bron, C				Legler, DF; Doucey, MA; Schneider, P; Chapatte, L; Bender, FC; Bron, C			Differential insertion of GPI-anchored GFPs into lipid rafts of live cells	FASEB JOURNAL			English	Article						glycosylphosphatidyl-inositol; green fluorescent protein	TARGETING PROTEINS; MEMBRANE-PROTEINS; DOMAINS; SURFACE; PHOSPHATIDYLINOSITOL; THY-1; PURIFICATION; MICRODOMAINS; RECRUITMENT; ENDOCYTOSIS	Partitioning of proteins in cholesterol and sphingolipid enriched plasma membrane microdomains, called lipid rafts, is critical for many signal transduction and protein sorting events. Although raft partitioning of many signaling molecules remains to be determined, glycosylphosphatidyl-inositol (GPI)-anchored proteins possess high affinity for lipid rafts and are currently exploited as markers to investigate fundamental mechanisms in protein sorting and signal transduction events. In this study, we demonstrate that two recombinant GPI-anchored green fluorescent proteins (GFP-GPIs) that differ in their GPI signal sequence confer distinct localization in plasma membrane microdomains. GFP fused to the GPI signal of the decay accelerating factor GFP-GPI(DAF) partitioned exclusively in lipid rafts, whereas GFP fused to the GPI signal of TRAIL-R3, GFP-GPI(TRAIL-R3), associated only minimally with microdomains. In addition, we investigated the unique ability of purified GFP-GPIs to insert into membrane microdomains of primary lymphocytes. This cell surface painting allows rapid, stable, and functional association of the GPI-anchored proteins with the target cell plasma membrane. The distinct membrane localization of the two GFP-GPIs was observed irrespective of whether the GPI-anchored molecules were painted or transfected. Furthermore, we show that painted GFP-GPI(DAF) was totally dependent on the GPI anchor and that the membrane insertion was increased by the addition of raft-associated lipids such as cholesterol, sphingomyelin, and dipalmitoyl-phosphatidylethanolamine. Thus, this study provides evidence that different GPI signal sequences lead to distinct membrane microdomain localization and that painted GFP-GPI(DAF) serves as an excellent fluorescent marker for lipid rafts in live cells.	Univ Konstanz, Dept Biol, Div Immunol, D-78457 Constance, Germany; Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland	University of Konstanz; University of Lausanne	Legler, DF (corresponding author), Univ Konstanz, Dept Biol, Div Immunol, Univ Str 10,Room P1105, D-78457 Constance, Germany.	Daniel.Legler@uni-konstanz.de		Schneider, Pascal/0000-0003-0677-9409; Legler, Daniel F./0000-0001-8610-4764				Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cebecauer M, 1998, BIOCHEM BIOPH RES CO, V243, P706, DOI 10.1006/bbrc.1998.8149; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chen R, 2002, J CELL BIOCHEM, V84, P68, DOI 10.1002/jcb.1267; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Horejsi V, 2002, TRENDS IMMUNOL, V23, P562, DOI 10.1016/S1471-4906(02)02330-X; HUANG JH, 1994, IMMUNITY, V1, P607, DOI 10.1016/1074-7613(94)90050-7; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Legler DF, 2004, EUR J IMMUNOL, V34, P1608, DOI 10.1002/eji.200424938; Legler DF, 2001, FASEB J, V15, P1601, DOI 10.1096/fj.00-0841fje; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; LUESCHER B, 1985, J IMMUNOL, V134, P1084; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Magalhaes AC, 2002, J BIOL CHEM, V277, P33311, DOI 10.1074/jbc.M203661200; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; McHugh RS, 1999, CANCER RES, V59, P2433; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Milhiet PE, 2002, EMBO REP, V3, P485, DOI 10.1093/embo-reports/kvf096; MOLLBY R, 1973, BIOCHIM BIOPHYS ACTA, V321, P569, DOI 10.1016/0005-2744(73)90200-3; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; NAGARAJAN S, 1995, J IMMUNOL METHODS, V184, P241, DOI 10.1016/0022-1759(95)00095-R; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Premkumar DRD, 2001, J CELL BIOCHEM, V82, P234, DOI 10.1002/jcb.1154; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sedwick CA, 2002, SCI STKE, V122, P2; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WALTER EI, 1992, J BIOL CHEM, V267, P1245; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231	51	96	99	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					73	+		10.1096/fj.03-1338fje	http://dx.doi.org/10.1096/fj.03-1338fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15516372	Green Published			2022-12-28	WOS:000224849900002
J	Granata, R; Trovato, L; Garbarino, G; Taliano, M; Ponti, R; Sala, G; Ghidoni, R; Ghigo, E				Granata, R; Trovato, L; Garbarino, G; Taliano, M; Ponti, R; Sala, G; Ghidoni, R; Ghigo, E			Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: Involvement of the sphingolipid signaling pathways	FASEB JOURNAL			English	Article						doxorubicin; ceramide; sphingosine kinase	FACTOR-BINDING PROTEIN-3; GROWTH-FACTOR-I; CERAMIDE SYNTHASE; EPITHELIAL-CELLS; GENE-EXPRESSION; CANCER CELLS; MECHANISM; DEATH; ANGIOGENESIS; ACTIVATION	Insulin-like growth factor binding protein (IGFBP)-3 has both growth-inhibiting and growth-promoting effects at the cellular level. The cytotoxic action of several anticancer drugs is linked to increased ceramide generation through sphingomyelin hydrolysis or de novo biosynthesis. Herein, we investigated the role of IGFBP-3 on apoptosis of human umbilical vein endothelial cells ( HUVEC) and its relationship with ceramide levels. We report that IGFBP-3 exerts dual effects on HUVEC, potentiating doxorubicin-induced apoptosis but enhancing survival in serum-starved conditions. Ceramide was increased by IGFBP-3 in the presence of doxorubicin and decreased when IGFBP-3 was added alone to cells cultured in serum-free medium. The protection exerted by the ceramide synthase inhibitor fumonisin B1 over doxorubicin-induced apoptosis was enhanced by IGFBP-3 with concomitant reduction of ceramide levels. IGFBP-3 alone activated sphingosine kinase (SK) and increased SK1 mRNA; the SK inhibitor N,N-dimethylsphingosine (DMS) blocked IGFBP-3 antiapoptotic effect. Moreover, IGFBP-3 increased IGF-I mRNA and dramatically enhanced IGF-I release. IGF-I receptor (IGF-IR) and its downstream signaling pathways Akt and ERK were phosphorylated by IGFBP-3, whereas inhibition of IGF-IR phosphorylation with tyrphostin AG1024 suppressed the antiapopoptic effect of IGFBP-3. Finally, IGFBP-3 increased endothelial cell motility in all experimental conditions. These findings provide evidence that IGFBP-3 differentially regulates endothelial cell apoptosis by involvement of the sphingolipid signaling pathways. Moreover, the survival effect of IGFBP-3 seems to be mediated by the IGF-IR.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab, I-10126 Turin, Italy; Univ Turin, Sect Clin & Oncol Dermatol, I-10126 Turin, Italy; Univ Milan, Milan, Italy; San Paolo Univ Hosp, Biochem & Mol Biol Lab, Milan, Italy	University of Turin; University of Turin; University of Milan	Ghigo, E (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Corso Dogliotti 14, I-10126 Turin, Italy.	ezio.ghigo@unito.it	Granata, Riccarda/K-7775-2016	Granata, Riccarda/0000-0003-4164-7313; Trovato, Letizia/0000-0001-6004-795X; GHIDONI, RICCARDO/0000-0002-6300-5867				Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Bjarnason R, 1998, J CLIN ENDOCR METAB, V83, P1566, DOI 10.1210/jc.83.5.1566; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Buckley J. S., 1995, SPE ADV TECH SER, V3, P53; Cohen P, 2000, AM J PHYSIOL-LUNG C, V278, pL545, DOI 10.1152/ajplung.2000.278.3.L545; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Desai K, 2002, BBA-MOL CELL BIOL L, V1585, P188, DOI 10.1016/S1388-1981(02)00340-2; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Granata R, 2003, J ENDOCRINOL INVEST, V26, P1231, DOI 10.1007/BF03349163; HAN DKM, 1995, AM J PATHOL, V147, P267; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Lee DY, 2002, BIOCHEM BIOPH RES CO, V294, P480, DOI 10.1016/S0006-291X(02)00491-6; Liu LQ, 2003, ONCOL RES, V13, P359; LIU YY, 2004, IN PRESS J LIPID RES; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Martin JL, 2003, J BIOL CHEM, V278, P2969, DOI 10.1074/jbc.M210739200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; McCaig C, 2002, BRIT J CANCER, V86, P1963, DOI 10.1038/sj.bjc.6600355; Michiels C, 2003, J CELL PHYSIOL, V196, P430, DOI 10.1002/jcp.10333; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Perry DK, 2000, ANN NY ACAD SCI, V905, P91; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Schmid MC, 2003, INT J CANCER, V103, P577, DOI 10.1002/ijc.10874; Shigematsu S, 1999, ENDOCR J, V46, pS59; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; TANIMOTO T, 2004, IN PRESS CIRC RES; Tedgui A, 2001, CIRC RES, V88, P877, DOI 10.1161/hh0901.090440; Turner HE, 2003, ENDOCR REV, V24, P600, DOI 10.1210/er.2002-0008; Veldman RJ, 2004, BRIT J CANCER, V90, P917, DOI 10.1038/sj.bjc.6601581; Yamada M, 1999, CATAL SURV JPN, V3, P3, DOI 10.1023/A:1019063416425	52	99	101	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1456	+		10.1096/fj.04-1618fje	http://dx.doi.org/10.1096/fj.04-1618fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247143				2022-12-28	WOS:000222979200006
J	Joussen, AM; Poulaki, V; Le, ML; Koizumi, K; Esser, C; Janicki, H; Schraermeyer, U; Kociok, N; Fauser, S; Kirchhof, B; Kern, TS; Adamis, AP				Joussen, AM; Poulaki, V; Le, ML; Koizumi, K; Esser, C; Janicki, H; Schraermeyer, U; Kociok, N; Fauser, S; Kirchhof, B; Kern, TS; Adamis, AP			A central role for inflammation in the pathogenesis of diabetic retinopathy	FASEB JOURNAL			English	Article						adhesion molecules; retina; vascular lesions	INTERCELLULAR-ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; SELECTIN; RETINA; MODEL; ANGIOPOIETIN-1; LEUKOSTASIS; MOUSE; DEATH; RATS	Diabetic retinopathy is a leading cause of adult vision loss and blindness. Much of the retinal damage that characterizes the disease results from retinal vascular leakage and nonperfusion. Diabetic retinal vascular leakage, capillary nonperfusion, and endothelial cell damage are temporary and spatially associated with retinal leukocyte stasis in early experimental diabetes. Retinal leukostasis increases within days of developing diabetes and correlates with the increased expression of retinal intercellular adhesion molecule-1 (ICAM-1) and CD18. Mice deficient in the genes encoding for the leukocyte adhesion molecules CD18 and ICAM-1 were studied in two models of diabetic retinopathy with respect to the long-term development of retinal vascular lesions. CD18(-/-) and ICAM-1(-/-) mice demonstrate significantly fewer adherent leukocytes in the retinal vasculature at 11 and 15 months after induction of diabetes with STZ. This condition is associated with fewer damaged endothelial cells and lesser vascular leakage. Galactosemia of up to 24 months causes pericyte and endothelial cell loss and formation of acellular capillaries. These changes are significantly reduced in CD18(-/-) and ICAM(-/-) deficient mice. Basement membrane thickening of the retinal vessels is increased in long-term galactosemic animals independent of the genetic strain. Here we show that chronic, low-grade subclinical inflammation is responsible for many of the signature vascular lesions of diabetic retinopathy. These data highlight the central and causal role of adherent leukocytes in the pathogenesis of diabetic retinopathy. They also underscore the potential utility of anti-inflammatory treatment in diabetic retinopathy.	Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany; Univ Cologne, Ctr Ophthalmol, Angiogenesis Lab, D-50924 Cologne, Germany; Univ Cologne, Ctr Mol Med ZMMK, Cologne, Germany; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, Boston, MA USA; Harvard Univ, Sch Med, Childrens Hosp, Surg Res Lab, Boston, MA USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Diabet Res, Cleveland, OH 44106 USA; Eyetech Res Ctr, Woburn, MA USA	University of Cologne; University of Cologne; University of Cologne; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Boston Children's Hospital; Harvard Medical School; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Joussen, AM (corresponding author), Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	JoussenA@aol.com; tony.adamis@eyetk.com	Joussen, Antonia/AAA-6901-2022		NEI NIH HHS [EY12611, EY11627] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011627, R01EY012611] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; BULLARD SR, 1994, EXP EYE RES, V58, P641, DOI 10.1006/exer.1994.1061; CHIECO P, 1993, TOXICOL PATHOL, V21, P402, DOI 10.1177/019262339302100409; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; CUTLER LS, 1979, VIRCHOWS ARCH A, V382, P301, DOI 10.1007/BF00430406; FREEDMAN SF, 1992, EXP EYE RES, V55, P767, DOI 10.1016/0014-4835(92)90181-Q; Joussen AM, 2002, FASEB J, V16, P76, DOI 10.1096/fj.02-0157fje; Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; Karadayi K, 2003, OCUL IMMUNOL INFLAMM, V11, P123, DOI 10.1076/ocii.11.2.123.15920; Kern TS, 1996, ARCH OPHTHALMOL-CHIC, V114, P986, DOI 10.1001/archopht.1996.01100140194013; KERN TS, 1995, EXP EYE RES, V60, P545, DOI 10.1016/S0014-4835(05)80069-7; KERN TS, 1995, INVEST OPHTH VIS SCI, V36, P490; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Knudsen ST, 2003, AM J PHYSIOL-ENDOC M, V284, pE1, DOI 10.1152/ajpendo.00198.2002; KOHNER EM, 1970, AM J OPHTHALMOL, V69, P778, DOI 10.1016/0002-9394(70)93420-3; Limb GA, 1999, INVEST OPHTH VIS SCI, V40, P2453; MCLEOD DS, 1995, AM J PATHOL, V147, P642; MILLER JW, 1994, AM J PATHOL, V145, P574; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; SCHRODER S, 1991, AM J PATHOL, V139, P81; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; WILSON RW, 1993, J IMMUNOL, V151, P1571; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789	26	880	955	1	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1450	+		10.1096/fj.03-1476fje	http://dx.doi.org/10.1096/fj.03-1476fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231732				2022-12-28	WOS:000222979200022
J	Lavitrano, M; Smolenski, RT; Musumeci, A; Maccherini, M; Slominska, E; di Florio, E; Bracco, A; Mancini, A; Stassi, G; Patti, M; Giovannoni, R; Froio, A; Simeone, F; Forni, M; Bacci, ML; D'Alise, G; Cozzi, E; Otterbein, LE; Yacoub, MH; Bach, FH; Calise, F				Lavitrano, M; Smolenski, RT; Musumeci, A; Maccherini, M; Slominska, E; di Florio, E; Bracco, A; Mancini, A; Stassi, G; Patti, M; Giovannoni, R; Froio, A; Simeone, F; Forni, M; Bacci, ML; D'Alise, G; Cozzi, E; Otterbein, LE; Yacoub, MH; Bach, FH; Calise, F			Carbon monoxide improves cardiac energetics and safeguards the heart during reperfusion after cardiopulmonary bypass in pigs	FASEB JOURNAL			English	Article						ischemia reperfusion; heart arrest; apoptosis; hypoxia	HEME OXYGENASE-1 PROTECTS; LUNG INJURY; MYOCARDIAL PROTECTION; CLINICAL IMPLICATIONS; PROVIDES PROTECTION; BRIEF ISCHEMIA; CONSEQUENCES; SUPPRESSES; EXPRESSION; REJECTION	Ischemia-reperfusion injury, a clinical problem during cardiac surgery, involves worsened adenosine trisphosphate (ATP) generation and damage to the heart. We studied carbon monoxide ( CO) pretreatment, proven valuable in rodents but not previously tested in large animals, for its effects on pig hearts subjected to cardiopulmonary bypass with cardioplegic arrest. Hearts of CO-treated pigs showed significantly higher ATP and phosphocreatine levels, less interstitial edema, and apoptosis of cardiomyocytes and required fewer defibrillations after bypass. We conclude that treatment with CO improves the energy status, prevents edema formation and apoptosis, and facilitates recovery in a clinically relevant model of cardiopulmonary bypass surgery.	Univ Milano Bicocca, Dept Med Sperimentale Ambientale & Biotecnol Med, Mol Med Lab, I-20052 Milan, Italy; Harefield Hosp, Imperial Coll, Heart Sci Ctr, Harefield, Middx, England; Univ Naples Federico II, Dept Cardiac Surg, Naples, Italy; Univ Siena, Dept Cardiothorac Surg, I-53100 Siena, Italy; Med Univ Gdansk, Dept Biochem, Gdansk, Poland; AORN Cardarelli Hosp, Naples, Italy; Univ Palermo, Sch Med, Dept Surg & Oncol Sci, I-90133 Palermo, Italy; Univ Bologna, Dept Morfofisiol Vet & Prod Anim, Bologna, Italy; Azienda Osped Padova, CORIT, Padua, Italy; Univ Pittsburgh, Sch Med, Dept Pulm & Crit Care Med, Pittsburgh, PA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA	University of Milano-Bicocca; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of Naples Federico II; University of Siena; Fahrenheit Universities; Medical University Gdansk; Antonio Cardarelli Hospital; University of Palermo; University of Bologna; University of Padua; Azienda Ospedaliera - Universita di Padova; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lavitrano, M (corresponding author), Univ Milano Bicocca, Dept Med Sperimentale Ambientale & Biotecnol Med, Mol Med Lab, Via Cadore 48, I-20052 Milan, Italy.	marialuisa.lavitrano@unimib.it	Froio, Alberto/A-6727-2009; Smolenski, Ryszard T/B-9713-2013; Giovannoni, Roberto/A-1413-2009; Bacci, Maria Laura/B-8494-2013; Stassi, Giorgio/AAC-1175-2022; Lavitrano, Marialuisa/H-3417-2012	Giovannoni, Roberto/0000-0002-7706-0672; Smolenski, Ryszard/0000-0002-0190-9414; Cozzi, Emanuele/0000-0001-7855-5055; Forni, Monica/0000-0003-1310-6202; Slominska, Ewa/0000-0002-3037-1844; Bacci, Maria Laura/0000-0001-6702-5868				Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Caputo M, 1998, EUR J CARDIO-THORAC, V14, P467, DOI 10.1016/S1010-7940(98)00233-4; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; GALINANES M, 1990, CARDIOSCIENCE, V1, P127; Kloner RA, 2001, CIRCULATION, V104, P2981, DOI 10.1161/hc4801.100038; Kloner RA, 2001, CIRCULATION, V104, P3158, DOI 10.1161/hc5001.100039; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Miro O, 1998, PHARMACOL TOXICOL, V82, P199, DOI 10.1111/j.1600-0773.1998.tb01425.x; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; SMOLENSKI RT, 1990, J CHROMATOGR-BIOMED, V527, P414, DOI 10.1016/S0378-4347(00)82125-8; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Vinten-Johansen J, 2003, ANN THORAC SURG, V75, pS691, DOI 10.1016/S0003-4975(02)04694-5; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314	21	98	102	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1093	+		10.1096/fj.03-0996fje	http://dx.doi.org/10.1096/fj.03-0996fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132974				2022-12-28	WOS:000221883200009
J	Ge, YW; Maloney, B; Sambamurti, K; Lahiri, DK				Ge, YW; Maloney, B; Sambamurti, K; Lahiri, DK			Functional characterization of the 5 ' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression	FASEB JOURNAL			English	Article						aging; beta-protein; dementia; transcription; secretase	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; DISEASE; BRAIN; MICE; APP; CYTOKINES; CLONING	Pathological characteristics of Alzheimer's disease (AD) include amyloid-beta (Abeta) plaques. Abeta is derived from the Abeta peptide precursor protein (APP) by gamma- and beta-secretases, the latter known as beta-site APP-cleaving enzyme 1 (BACE1, or herein BACE). We have also described potentially important regions in the promoter of BACE, which may regulate its activity ( 1). Herein, we have functionally dissected the regulatory regions within the BACE promoter into areas containing positive and negative regulatory elements. The 4.1 kb promoter region (- 3765/+ 364, + 1 being the transcription start site [TSS]) includes positive regulatory element in the - 2975 to - 2062 region flanked on either side by negative regulatory elements at - 3764/-2975 and - 2062/-1056. This is separated from the minimal promoter and 5' UTR by a neutral region of roughly 700 base pairs (bp). A 91 bp fragment (224/314) is the shortest region with a significant reporter gene activity and constitutes the minimal promoter element for BACE. Neuronal preference of the promoter was apparent in the 141 bp fragment (224/364) that contained the 91 bp fragment. Gel shift results also suggest the strongest signal of DNA-protein interaction with the 91 bp fragment in neuronal nuclear extracts. This interaction was strongly blocked by an activator protein (AP) 2 binding oligomer. Super gel shift assays suggest that both the AP2-binding oligomer and the 91 bp fragment interfered with each other's binding capacity. An AP2 sequence is predicted to occur within the 91 bp fragment. We also found stimulating protein (SP) 1-binding sites in this region of the promoter. Thus, functional and gel shift analysis indicate that the 91 bp fragment containing the AP2 and SP1 binding sites constitutes the core promoter region of BACE. Changes in the activity of this region could play an important role in regulating BACE activity in neurons.	Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Med Univ S Carolina, Charleston, SC 29425 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Medical University of South Carolina	Lahiri, DK (corresponding author), 791 N Union Dr, Indianapolis, IN 46206 USA.	dlahiri@iupui.edu	Lahiri, Debomoy/AAZ-3322-2020; Sambamurti, Kumar/A-1620-2012; Maloney, Bryan J/C-4924-2011	Sambamurti, Kumar/0000-0001-9507-9214; Maloney, Bryan J/0000-0003-2364-9649	NIA NIH HHS [AG18379, AG18884] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bigl M, 2000, NEUROSCI LETT, V292, P107, DOI 10.1016/S0304-3940(00)01452-X; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Ge YW, 2002, ANN NY ACAD SCI, V973, P463, DOI 10.1111/j.1749-6632.2002.tb04684.x; Ghosh C, 2000, MOL BIOL REP, V27, P113, DOI 10.1023/A:1007173906990; Ghosh C, 1999, J MOL NEUROSCI, V13, P77, DOI 10.1385/JMN:13:1-2:77; Hartlage-Rubsamen M, 2003, GLIA, V41, P169, DOI 10.1002/glia.10178; Hook VYH, 2003, J NEUROSCI RES, V74, P393, DOI 10.1002/jnr.10784; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Lange-Dohna C, 2003, J NEUROSCI RES, V73, P73, DOI 10.1002/jnr.10639; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rossner S, 2001, J NEUROSCI RES, V64, P437; SAMBAMURTI K, 2004, FASEB J         0401, DOI DOI 10.1096/FJ.03-1738FJE; SCHUG J, TESS TRANSCRIPTION E; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vattemi G, 2003, EXP NEUROL, V179, P150, DOI 10.1016/S0014-4886(02)00025-0; Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	30	53	54	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1037	+		10.1096/fj.03-1379fje	http://dx.doi.org/10.1096/fj.03-1379fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059977				2022-12-28	WOS:000221108800028
J	Liu, RY; Loll, PJ; Eckenhoff, RG				Liu, RY; Loll, PJ; Eckenhoff, RG			Structural basis for high-affinity volatile anesthetic binding in a natural 4-helix bundle protein	FASEB JOURNAL			English	Article						anesthesia; halothane; isofurane; X-ray ctystallography; calorimetry; ferritin	POSTOPERATIVE COGNITIVE DYSFUNCTION; RESOLUTION CRYSTAL-STRUCTURES; HUMAN SERUM-ALBUMIN; GENERAL-ANESTHETICS; 4-ALPHA-HELIX BUNDLE; FIREFLY LUCIFERASE; HALOTHANE; MECHANISMS; RECEPTORS; FERRITIN	Physiologic sites for inhaled anesthetics are presumed to be cavities within transmembrane 4-alpha-helix bundles of neurotransmitter receptors, but confirmation of binding and structural detail of such sites remains elusive. To provide such detail, we screened soluble proteins containing this structural motif, and found only one that exhibited evidence of strong anesthetic binding. Ferritin is a 24-mer of 4-alpha-helix bundles; both halothane and isoflurane bind with K-A values of similar to 10(5) M-1, higher than any previously reported inhaled anesthetic-protein interaction. The crystal structures of the halothane/apoferritin and isoflurane/apoferritin complexes were determined at 1.75 angstrom resolution, revealing a common anesthetic binding pocket within an interhelical dimerization interface. The high affinity is explained by several weak polar contacts and an optimal host/guest packing relationship. Neither the acidic protons nor ether oxygen of the anesthetics contribute to the binding interaction. Compared with unliganded apoferritin, the anesthetic produced no detectable alteration of structure or B factors. The remarkably high affinity of the anesthetic/apoferritin complex implies greater selectivity of protein sites than previously thought, and suggests that direct protein actions may underlie effects at lower than surgical levels of anesthetic, including loss of awareness.	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19104 USA	University of Pennsylvania; Drexel University	Eckenhoff, RG (corresponding author), Univ Penn, Dept Anesthesia, 305 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	roderiic.eckenhoff@uphs.upenn.edu		Eckenhoff, Roderic/0000-0002-5581-746X	PHS HHS [P-01 55876] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Chiara DC, 2003, BIOCHEMISTRY-US, V42, P13457, DOI 10.1021/bi0351561; DICKINSON R, 1993, BIOPHYS J, V64, P1264, DOI 10.1016/S0006-3495(93)81491-7; DIPAULO T, 1974, NATURE, V252, P171; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; Eckenhoff R G, 2001, Mol Interv, V1, P258; Evans G, 2002, ACTA CRYSTALLOGR D, V58, P976, DOI 10.1107/S0907444902005486; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Johansson JS, 2000, BIOPHYS J, V78, P982, DOI 10.1016/S0006-3495(00)76656-2; Johansson JS, 2005, FEBS J, V272, P573, DOI 10.1111/j.1742-4658.2004.04500.x; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Ke Y, 2003, LANCET NEUROL, V2, P246, DOI 10.1016/S1474-4422(03)00353-3; KENDIG JJ, 1994, EUR J PHARMACOL, V264, P427, DOI 10.1016/0014-2999(94)00499-4; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Liu R, 2002, J BIOL CHEM, V277, P36373, DOI 10.1074/jbc.M205479200; Liu ZW, 2004, J PHYS CHEM A, V108, P781, DOI 10.1021/jp0368482; Manderson GA, 2002, BIOCHEMISTRY-US, V41, P4080, DOI 10.1021/bi0160718; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mecozzi S, 1998, CHEM-EUR J, V4, P1016, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1016::AID-CHEM1016>3.0.CO;2-B; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moller JT, 1998, LANCET, V351, P1742; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olsen JA, 2004, CHEMBIOCHEM, V5, P666, DOI 10.1002/cbic.200300907; PRECIGOUX G, 1994, ACTA CRYSTALLOGR D, V50, P739, DOI 10.1107/S0907444994003227; Raines DE, 1996, ANESTHESIOLOGY, V84, P663, DOI 10.1097/00000542-199603000-00022; Scharf D, 1996, CHEM PHYS LETT, V258, P276, DOI 10.1016/0009-2614(96)00652-5; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SEDENSKY MM, 1987, SCIENCE, V236, P952, DOI 10.1126/science.3576211; Tang P, 2002, P NATL ACAD SCI USA, V99, P16035, DOI 10.1073/pnas.252522299; Tang P, 2001, J COMPUT CHEM, V22, P436, DOI 10.1002/1096-987X(200103)22:4<436::AID-JCC1014>3.0.CO;2-U; Theil E. C., 2001, HDB METALLOPROTEINS, P771; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; Trudell JR, 2002, BBA-BIOMEMBRANES, V1565, P91, DOI 10.1016/S0005-2736(02)00512-6; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xi J, 2004, J BIOL CHEM, V279, P19628, DOI 10.1074/jbc.M313864200	46	102	105	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					567	576		10.1096/fj.04-3171com	http://dx.doi.org/10.1096/fj.04-3171com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791007				2022-12-28	WOS:000228865300041
J	Fang, J; Xia, C; Cao, ZX; Zheng, JZ; Reed, E; Jiang, BH				Fang, J; Xia, C; Cao, ZX; Zheng, JZ; Reed, E; Jiang, BH			Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways	FASEB JOURNAL			English	Article						vascular endothelial growth factor; ovarian cancer; hypoxia inducible factor 1; tumor growth; HUVEC	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; OVARIAN-CANCER; TUMOR ANGIOGENESIS; DEPENDENT PHOSPHORYLATION; GENE-TRANSCRIPTION; KINASE ACTIVATION; PROTEIN-KINASE; MAP KINASE	Apigenin is a nontoxic dietary flavonoid that has been shown to possess anti-tumor properties and therefore poses special interest for the development of a novel chemopreventive and/or chemotherapeutic agent for cancer. Ovarian cancer is one of the most common causes of cancer death among women. Here we demonstrate that apigenin inhibits expression of vascular endothelial growth factor (VEGF) in human ovarian cancer cells. VEGF plays an important role in tumor angiogenesis and growth. We found that apigenin inhibited VEGF expression at the transcriptional level through expression of hypoxia-inducible factor 1 alpha (HIF-1 alpha). Apigenin inhibited expression of HIF-1 alpha and VEGF via the PI3K/AK-T/p70S6K1 and HDM2/ p53 pathways. Apigenin inhibited tube formation in vitro by endothelial cells. These findings reveal a novel role of apigenin in inhibiting HIF-1 and VEGF expression that is important for tumor angiogenesis and growth, identifying new signaling molecules that mediate this regulation.	W Virginia Univ, Dept Microbiol Immunol & Cell Biol, MBR Canc Ctr, Morgantown, WV 26506 USA	West Virginia University	Jiang, BH (corresponding author), W Virginia Univ, Dept Microbiol Immunol & Cell Biol, MBR Canc Ctr, Morgantown, WV 26506 USA.	bhjiang@hsc.wvu.edu		Jiang, Bing-Hua/0000-0003-4526-2031	NCRR NIH HHS [RR16440] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Angelov L, 1999, CANCER RES, V59, P5536; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blancher C, 2001, CANCER RES, V61, P7349; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; BOONE CW, 1990, CANCER RES, V50, P2; Borgstrom P, 1996, CANCER RES, V56, P4032; Brekken RA, 2000, CANCER RES, V60, P5117; Byrne AT, 2003, CLIN CANCER RES, V9, P5721; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Duthie G, 2000, CURR OPIN LIPIDOL, V11, P43, DOI 10.1097/00041433-200002000-00007; Fang J, 2004, MOL PHARMACOL, V66, P178, DOI 10.1124/mol.66.1.178; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fotsis T, 1997, CANCER RES, V57, P2916; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Knowles HJ, 2003, CANCER RES, V63, P1764; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang LW, 2000, ADV ENG MATER, V2, P110, DOI 10.1002/(SICI)1527-2648(200003)2:3<110::AID-ADEM110>3.0.CO;2-4; Wong C, 2003, GYNECOL ONCOL, V91, P513, DOI 10.1016/j.ygyno.2003.08.022; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yin F, 2001, ANTICANCER RES, V21, P413; Zhang L, 2003, CANCER RES, V63, P4225; Zhang L, 2002, AM J PATHOL, V161, P2295, DOI 10.1016/S0002-9440(10)64505-1; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	62	242	257	3	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					342	353		10.1096/fj.04-2175com	http://dx.doi.org/10.1096/fj.04-2175com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746177				2022-12-28	WOS:000227901300034
J	Kim, NH; Choi, JK; Jeong, BH; Kim, JI; Kwon, MS; Carp, RI; Kim, YS				Kim, NH; Choi, JK; Jeong, BH; Kim, JI; Kwon, MS; Carp, RI; Kim, YS			Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres	FASEB JOURNAL			English	Article						protein misfolding cyclic amplification; manganese; metal-catalyzed oxidation	CELLULAR PRION PROTEIN; SCRAPIE-INFECTED MICE; METHIONINE RESIDUES; OXIDATIVE STRESS; COPPER; AGGREGATION; RECOMBINANT; DISEASE; ACCUMULATION; CONFORMATION	The PMCA (protein misfolding cyclic amplification) technique has been shown to drive the amplification of misfolded prion protein by PrPSc seeds during several cycles of incubation-sonication. Here, we report that cyclic amplification of normal hamster brain homogenates treated with a number of transition metals (manganese [Mn], copper [Cu], and iron [Fe]) leads to conversion of PrPc into protease-resistant PrPres. The efficiency of PrPres formation and the glycoforms induced by Mn were different from those obtained by Cu and Fe. Previous results have shown higher Mn and lower Cu levels in the affinity-purified PrPSc from the brain of prion diseases compared with normal hamster brain homogenates. We focused on Mn because we observed higher levels of Mn in whole brain, mitochondria, and scrapie-associated fibril-enriched fractions from the brains of animals with prion disease. In C the presence of minute quantities of Mn-induced PrPres template with a large amount of PrPC, PrPres amplification is observed. A metal chelater, EDTA reverses the effect of Mn on PrPres amplification, suggesting that Mn may play a role in the formation of PrPres. It has been proposed that metal-catalyzed oxidation of PrP leads to the oxidation of amino acids and extensive aggregation of oxidized PrP. Carboxyl acids such as deoxycholic acid (DA) are oxidized molecules produced by 3' oxidation pathway. In in vitro studies, the potent effect of Mn on PrPres amplification is augmented by DA in a dose-dependent manner. On the basis of the evidence of the elevated Mn levels in scrapie-associated fibril (SAF)-enriched preparations from the brains of animals with prion disease, Mn-loaded PrP and oxidized molecules such as carboxyl acids may contribute to the formation of the scrapie isoform of PrP in prion diseases.	Hallym Univ, Coll Med, Ilsong Inst Life Sci, Anyang 431060, Kyounggi Do, South Korea; Kangwon Natl Univ, Dept Vet Med, Chunchon, Kangwon Do, South Korea; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA	Hallym University; Kangwon National University; Institute for Basic Research in Developmental Disabilities	Kim, YS (corresponding author), Hallym Univ, Coll Med, Ilsong Inst Life Sci, Ilsong Bldg,1605-4 Gwanyang Dong, Anyang 431060, Kyounggi Do, South Korea.	yskim@hallym.ac.kr	Jeong, Byung-Hoon/AAA-3425-2020	Jeong, Byung-Hoon/0000-0002-4525-9994				Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Cardinale A, 2005, J BIOL CHEM, V280, P685, DOI 10.1074/jbc.M407360200; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; DOI S, 1988, J GEN VIROL, V69, P955, DOI 10.1099/0022-1317-69-4-955; Giese A, 2004, BIOCHEM BIOPH RES CO, V320, P1240, DOI 10.1016/j.bbrc.2004.06.075; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Kim BH, 2004, MOL BRAIN RES, V124, P40, DOI 10.1016/j.molbrainres.2004.02.005; Kim JI, 2001, ANN NY ACAD SCI, V928, P182, DOI 10.1111/j.1749-6632.2001.tb05648.x; Kim NH, 2000, BRAIN RES, V884, P98, DOI 10.1016/S0006-8993(00)02907-3; Kourie JI, 2001, CROAT MED J, V42, P359; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maji SK, 2002, TETRAHEDRON, V58, P8695, DOI 10.1016/S0040-4020(02)01093-1; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; Milatovic D, 2002, BRAIN RES, V957, P330, DOI 10.1016/S0006-8993(02)03669-7; MORITA A, 1994, BIOL TRACE ELEM RES, V42, P165, DOI 10.1007/BF02785387; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Requena JR, 2004, ARCH BIOCHEM BIOPHYS, V432, P188, DOI 10.1016/j.abb.2004.09.012; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Satheeshkumar KS, 2002, CHEM COMMUN, P2244, DOI 10.1039/b206886a; Shaked GM, 2002, ANN NEUROL, V52, P416, DOI 10.1002/ana.10298; Shiraishi N, 2002, FEBS LETT, V511, P118, DOI 10.1016/S0014-5793(01)03324-5; Soto C, 2001, TRENDS MOL MED, V7, P109, DOI 10.1016/S1471-4914(01)01931-1; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Washo-Stultz D, 2002, CANCER LETT, V177, P129, DOI 10.1016/S0304-3835(01)00786-8; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; Wong BS, 2000, BIOCHEM BIOPH RES CO, V276, P1217, DOI 10.1006/bbrc.2000.3604; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; Wong BS, 1999, BIOCHEM BIOPH RES CO, V259, P352, DOI 10.1006/bbrc.1999.0802; Wong BS, 2000, BIOCHEM BIOPH RES CO, V269, P726, DOI 10.1006/bbrc.2000.2355; Wong BS, 2001, J NEUROCHEM, V79, P689, DOI 10.1046/j.1471-4159.2001.00625.x; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x	43	61	65	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					783	+		10.1096/fj.04-2117fje	http://dx.doi.org/10.1096/fj.04-2117fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15758042				2022-12-28	WOS:000227901300022
J	Thangam, EB; Venkatesha, RT; Zaidi, AK; Jordan-Sciutto, KL; Goncharov, DA; Kryrnskaya, VP; Amrani, Y; Panettieri, RA; Ali, H				Thangam, EB; Venkatesha, RT; Zaidi, AK; Jordan-Sciutto, KL; Goncharov, DA; Kryrnskaya, VP; Amrani, Y; Panettieri, RA; Ali, H			Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact	FASEB JOURNAL			English	Article						complement; asthma; chemokine; cytokine	FC-EPSILON-RI; SIGNAL-REGULATED KINASE; AFFINITY IGE RECEPTOR; CHEMOKINE PRODUCTION; C3A ANAPHYLATOXIN; HUMAN-LEUKOCYTES; UP-REGULATION; C5A RECEPTOR; CUTTING EDGE; ACTIVATION	Growing evidence suggests that anaphylatoxins, C3a and C5a, play important roles in innate immunity and may also participate in the pathogenesis of asthma. Previous studies with animal models and immunohistochemistry analysis of lung tissue indicated that anaphylatoxins may regulate airway hyperresponsiveness (AHR) in asthma via the activation of their cell surface G protein-coupled receptors (C3aR and C5aR) in airway smooth muscle (ASM) cells. Using RTPCR, flow cytometry, and confocal microscopy, we made the surprising observation that while C3aR and C5aR were expressed in human mast cells, they were not present in cultured primary human or murine ASM cells. Furthermore, we could not detect C3aR in smooth muscle-positive cells of human trachea or bronchus. Interestingly, incubation of human mast cells with ASM cells, but not its culture supernatant, caused a significant enhancement of C3a-induced mast cell degranulation. Although stem cell factor (SCF) and its receptor c-kit are constitutively expressed on ASM cells and mast cells, respectively, neutralizing antibodies to SCF and c-kit failed to inhibit ASM cell-mediated enhancement of mast cell degranulation. However, dexamethasone-treated ASM cells were normal for cell surface SCF expression but were significantly less effective in enhancing C3a-induced mast cell degranulation when compared with untreated cells. These findings suggest that cell-cell interaction between ASM cells and mast cells, via a SCF-c-kit-independent but dexamethasone-sensitive mechanism, enhances C3a-induced mast cell degranulation, which likely regulates ASM function, thus contributing to the pathogenesis of asthma.	Univ Penn, Sch Dent Med, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ali, H (corresponding author), Univ Penn, Sch Dent Med, Dept Pathol, 240 S 40th St, Philadelphia, PA 19104 USA.	ali@path.dental.upenn.edu	Amrani, Yassine/Q-6323-2019; Amrani, Yassine/A-1826-2013; panettieri, reynold/AAG-9485-2019; Jordan-Sciutto, Kelly L/A-1046-2007	Amrani, Yassine/0000-0002-7042-6926; 	NHLBI NIH HHS [HL67663, R01 HL063372, P50 HL067663, R01 HL055301, P01 HL067663, 2R01-HL64063, 1R01-HL63372, 2R01-HL-55301, R01 HL064063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064063, P01HL067663, P50HL067663, R01HL055301, R01HL063372] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2001, J IMMUNOL, V167, P3559, DOI 10.4049/jimmunol.167.7.3559; Ali H, 2000, J IMMUNOL, V165, P7215, DOI 10.4049/jimmunol.165.12.7215; ALI H, 1994, J BIOL CHEM, V269, P24557; Amrani Y, 2003, INT J BIOCHEM CELL B, V35, P272, DOI 10.1016/S1357-2725(02)00259-5; Amrani Y, 1999, J IMMUNOL, V163, P2128; Amrani Y, 2000, MOL PHARMACOL, V58, P237, DOI 10.1124/mol.58.1.237; Andrade MVM, 2004, J IMMUNOL, V172, P7254, DOI 10.4049/jimmunol.172.12.7254; Bachar O, 2004, EUR J IMMUNOL, V34, P1196, DOI 10.1002/eji.200324569; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; BISCHOFF SC, 1990, P NATL ACAD SCI USA, V87, P6813, DOI 10.1073/pnas.87.17.6813; Boels K, 2003, BRIT J PHARMACOL, V140, P932, DOI 10.1038/sj.bjp.0705521; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P1711, DOI 10.1111/j.1365-2222.2003.01827.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Choi WS, 2002, J IMMUNOL, V168, P5682, DOI 10.4049/jimmunol.168.11.5682; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589; Fayyazi A, 1999, AM J PATHOL, V154, P495, DOI 10.1016/S0002-9440(10)65295-9; Fayyazi A, 2000, IMMUNOLOGY, V99, P38, DOI 10.1046/j.1365-2567.2000.00911.x; Freund V, 2002, EUR RESPIR J, V20, P458, DOI 10.1183/09031936.02.00269202; GALLI SJ, 1993, AM J PATHOL, V142, P965; Gerard NP, 2002, CURR OPIN IMMUNOL, V14, P705, DOI 10.1016/S0952-7915(02)00410-7; GLOVSKY MM, 1979, J CLIN INVEST, V64, P804, DOI 10.1172/JCI109527; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Henson P, 2000, NAT IMMUNOL, V1, P190, DOI 10.1038/79723; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Huang CD, 2003, AM J RESP CELL MOL, V28, P330, DOI 10.1165/rcmb.2002-0040OC; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Hundley TR, 2001, J IMMUNOL, V167, P1629, DOI 10.4049/jimmunol.167.3.1629; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Kacani L, 2001, J IMMUNOL, V166, P3410, DOI 10.4049/jimmunol.166.5.3410; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kassel O, 1998, MOL PHARMACOL, V54, P1073, DOI 10.1124/mol.54.6.1073; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Maruoka S, 2000, AM J RESP CRIT CARE, V161, P922, DOI 10.1164/ajrccm.161.3.9906059; Nilsson G, 1996, J IMMUNOL, V157, P1693; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Panettieri RA, 2003, RESP PHYSIOL NEUROBI, V137, P277, DOI 10.1016/S1569-9048(03)00153-8; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Sayama Koichi, 2002, BMC Immunol, V3, P5, DOI 10.1186/1471-2172-3-5; Song RP, 2003, AM J PHYSIOL-LUNG C, V284, pL50, DOI 10.1152/ajplung.00212.2002; STIMLER NP, 1980, AM J PATHOL, V100, P327; Takabayashi T, 1998, J INFECT DIS, V177, P1622, DOI 10.1086/515316; TAKAMINE J, 1901, J PHYSL, V27, P29; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Tkaczyk C, 2003, J BIOL CHEM, V278, P48474, DOI 10.1074/jbc.M301350200; Tliba O, 2003, BRIT J PHARMACOL, V140, P1159, DOI 10.1038/sj.bjp.0705558; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Venkatesha RT, 2005, MOL IMMUNOL, V42, P581, DOI 10.1016/j.molimm.2004.09.009; Woolhiser MR, 2004, CLIN IMMUNOL, V110, P172, DOI 10.1016/j.clim.2003.11.007; Yamamoto T, 2000, IMMUNOLOGY, V99, P435, DOI 10.1046/j.1365-2567.2000.00973.x; Zhu YM, 2003, J BIOL CHEM, V278, P29366, DOI 10.1074/jbc.M301785200; Zwirner J, 1997, EUR J IMMUNOL, V27, P2317, DOI 10.1002/eji.1830270928; Zwirner J, 1999, IMMUNOLOGY, V97, P166	67	42	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					798	+		10.1096/fj.04-2797fje	http://dx.doi.org/10.1096/fj.04-2797fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15758041				2022-12-28	WOS:000227901300024
J	Lahiri, DK; Ge, YW; Maloney, B				Lahiri, DK; Ge, YW; Maloney, B			Characterization of the APP proximal promoter and 5 '-untranslated regions: identification of cell-type specific domains and implications in APP gene expression and Alzheimer's disease	FASEB JOURNAL			English	Article						amyloid; beta protein; cytokine; interleukin; TGF beta-1	AMYLOID PRECURSOR PROTEIN; MESSENGER-RNA; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; REGULATORY ELEMENTS; RESPONSIVE ELEMENT; TGF-BETA; INTERLEUKIN-1; LINES; TRANSLATION	Alzheimer's disease is characterized by brain deposition of toxic amyloid beta-peptide (A beta), generated from the A beta precursor protein (APP). APP gene expression is regulated via the proximal promoter region (PPR; - 46/- 1 in the human sequence; + 1 transcription start) and the 5'- untranslated region (5'-UTR; + 1/+ 147). We have recently identified a unique CAGA sequence, "amyloid," (+83/+86) present only in the APP gene from amyloid plaque-forming species, absent in all APP-like-proteins' (APLP1 and APLP2) genes. To assay functional activity of PPR + UTR and 5'- UTR regions that either contain or lack the " amyloid" box, we tested nine constructs in transient transfection studies. We observed significantly high reporter gene activity with - 46/144, - 46/100, - 46/54, and 54/144 constructs. The 54/100 fragment, which contains a transforming growth factor-beta/"amyloid"/interleukin-1 acute box cassette, showed different activity depending on cell type. Electrophoretic mobility shift assay ( EMSA) showed distinct DNA-nuclear protein interaction in all fragments, differing among both cell types and specific fragment. Reporter gene expression corroborates with the DNA-protein binding pattern. To directly examine the " amyloid" box, we generated oligomers for CAGA mutants or mutated adjacent nucleotides. EMSA results showed that altering " amyloid" or adjacent sequence alters specific DNA-nuclear protein interaction in both mutation- and cell-type-specific manners. Reporter gene assay reveals mutant-specific expression effects. Therefore, the - 46/54 region appears to be essential for basal expression of the APP gene, the 54/100 and 100/144 regions may have tissue-specific activity, and the " amyloid" CAGA box plays a role in APP gene regulation.	Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Lahiri, DK (corresponding author), Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, 791 Union Dr, Indianapolis, IN 46202 USA.	dlahiri@iupui.edu	Maloney, Bryan J/C-4924-2011; Lahiri, Debomoy/AAZ-3322-2020	Maloney, Bryan J/0000-0003-2364-9649; 	NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER; NIA NIH HHS [AG18884, AG18379] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arango D, 2001, AM J MED GENET, V103, P138, DOI 10.1002/1096-8628(20011001)103:2<138::AID-AJMG1529>3.0.CO;2-8; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ge YW, 2004, J NEUROCHEM, V90, P1432, DOI 10.1111/j.1471-4159.2004.02608.x; Ghosh C, 2000, MOL BIOL REP, V27, P113, DOI 10.1023/A:1007173906990; Ghosh C, 1999, J MOL NEUROSCI, V13, P77, DOI 10.1385/JMN:13:1-2:77; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; Kongsvik TL, 2002, J BIOL CHEM, V277, P16484, DOI 10.1074/jbc.M201583200; Kumar VB, 2000, PEPTIDES, V21, P1769, DOI 10.1016/S0196-9781(00)00339-9; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; Lahiri DK, 2004, ANN NY ACAD SCI, V1030, P282, DOI 10.1196/annals.1329.035; LAHIRI DK, 1995, MOL BRAIN RES, V32, P233, DOI 10.1016/0169-328X(95)00078-7; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maloney B, 2004, FASEB J, V18, P1288, DOI 10.1096/fj.03-1703fje; Perez RG, 1997, J NEUROSCI, V17, P9407; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Schug JaOGC, 1998, TECHNICAL REPORTS CO, P1; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; SHAPIRO BA, 1988, COMPUT APPL BIOSCI, V4, P387; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Song WH, 1998, GENE, V217, P151, DOI 10.1016/S0378-1119(98)00337-0; SPARKS DL, 2003, P NATL ACAD SCI USA, V100, P11193; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	41	38	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					653	+		10.1096/fj.04-2900fje	http://dx.doi.org/10.1096/fj.04-2900fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703276				2022-12-28	WOS:000227591900018
J	Paajarvi, G; Roudier, E; Crisby, M; Hogberg, J; Stenius, U				Paajarvi, G; Roudier, E; Crisby, M; Hogberg, J; Stenius, U			HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage	FASEB JOURNAL			English	Article						pravastatin; 3-hydroxy-3-methyl-glutaryl-CoA	INDUCED APOPTOSIS; LOVASTATIN; CANCER; AKT; RISK; UBIQUITINATION; TRANSLOCATION; PRAVASTATIN; CISPLATIN; EPITOPES	3-Hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors, statins, are widely used cholesterol-lowering drugs and have been shown to have anticancer effects in many models. We have investigated the effect of statins on Mdm2, a p53-specific ubiquitin ligase. It was found that pravastatin induced Mdm2 phosphorylation at Ser166 and at 2A10 antibody-specific epitopes in HepG2 cells, while mRNA levels were unchanged. Furthermore, pravastatin was found to induce phosphorylation of mTOR at Ser2448. Ser166 phosphorylation of Mdm2 was abrogated by an inhibitor of mTOR, rapamycin, but not by the PI3-kinase inhibitors LY294002 and wortmannin. Ser166 phosphorylation of Mdm2 has been associated to active Mdm2 and has been shown to increase its ubiquitin ligase activity and lead to increased p53 degradation. Our data show that statins attenuated the p53 response to DNA damage. Thus, in HepG2 cells pravastatin and simvastatin pretreatment attenuated the p53 response to DNA damage induced by 5-fluorouracil and benzo( a) pyrene. Similar attenuation was induced when p53 stabilization was induced by the inhibitor of nuclear export, leptomycin B. Furthermore, in the DNA-damaged cells, half-lives of Mdm2 and p53 were decreased by statins, indicating a more rapid formation of p53/Mdm2 complexes and facilitated p53 degradation. The induction of p53 responsive genes and apoptosis was attenuated. Mdm2 and p53 were also studied in vivo in rat liver employing immunohistochemistry, and it was found that constitutive Mdm2 expression was changed in livers of pravastatin-treated rats. We also show that the p53 response to a challenging dose of diethylnitrosamine was attenuated in hepatocytes in situ and in primary cultures of hepatocytes by pravastatin pretreatment. Taken together, these data indicate that statins induce an mTOR-dependent Ser166 phosphorylation of Mdm2, and this effect may attenuate the duration and intensity of the p53 response to DNA damage in hepatocytes.	Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Neurotec Dept, Div Geriatr Med, Stockholm, Sweden; Karolinska Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Stenius, U (corresponding author), Karolinska Inst, Inst Environm Med, Box 210, S-17177 Stockholm, Sweden.	ulla.stenius@imm.ki.se						Agarwal B, 1999, CLIN CANCER RES, V5, P2223; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Balass M, 2002, PEPTIDES, V23, P1719, DOI 10.1016/S0196-9781(02)00147-X; Bellosta S, 2004, CIRCULATION, V109, P50, DOI 10.1161/01.CIR.0000131519.15067.1f; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Chan KKW, 2003, CLIN CANCER RES, V9, P10; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Feleszko W, 1998, EUR J CANCER, V34, P406, DOI 10.1016/S0959-8049(97)10034-X; Finnberg N, 2004, CARCINOGENESIS, V25, P113, DOI 10.1093/carcin/bgg185; Fritz G, 2003, INT J RADIAT BIOL, V79, P601, DOI 10.1080/09553000310001609233; Gnad R, 2000, MOL PHARMACOL, V58, P1389, DOI 10.1124/mol.58.6.1389; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2000.1716; Kaye JA, 2004, BRIT J CANCER, V90, P635, DOI 10.1038/sj.bjc.6601566; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maya R, 2000, ONCOGENE, V19, P3213, DOI 10.1038/sj.onc.1203658; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2001, GENE, V264, P139, DOI 10.1016/S0378-1119(00)00589-8; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; OREN M, 2003, CELL DEATH DIFFER, V10, P413; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Silins I, 2001, CARCINOGENESIS, V22, P2023, DOI 10.1093/carcin/22.12.2023; Skaletz-Rorowski A, 2003, CARDIOVASC RES, V57, P253, DOI 10.1016/S0008-6363(02)00618-1; Tanaka T, 2000, J NEUROSCI, V20, P2852; UBRICH C, 2002, CIRC RES, V90, P737; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	43	45	49	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					476	+		10.1096/fj.04-2745fje	http://dx.doi.org/10.1096/fj.04-2745fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15625077				2022-12-28	WOS:000226091000003
J	Oshio, K; Watanabe, H; Song, Y; Verkman, AS; Manley, GT				Oshio, K; Watanabe, H; Song, Y; Verkman, AS; Manley, GT			Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1	FASEB JOURNAL			English	Article						water transport; brain injury	BRAIN EDEMA; SECRETION; PERMEABILITY; TRANSPORT; EPITHELIA; DELETION	Aquaporin-1 (AQP1) is a water channel expressed strongly at the ventricular-facing surface of choroid plexus epithelium. We developed novel methods to compare water permeability in isolated choroid plexus of wild-type vs. AQP1 null mice, as well as intracranial pressure (ICP) and cerebrospinal fluid (CSF) production and absorption. Osmotically induced water transport was rapid in choroid plexus from wild-type mice and reduced by fivefold by AQP1 deletion. AQP1 deletion did not affect choroid plexus size or structure. By stereotaxic puncture of the lateral ventricle with a microneedle, ICP was 9.5 +/- 1.4 cm H2O in wild-type mice and 4.2 +/- 0.4 cm H2O in AQP1 null mice. CSF production, an isosmolar fluid secretion process, was measured by a dye dilution method involving fluid collections using a second microneedle introduced into the cisterna magna. CSF production in wild-type mice was (in mul min(-1)) 0.37 +/- 0.04 (control), 0.16 +/- 0.03 (acetazolamide-treated), and 1.14 +/- 0.15 (forskolin-treated), and reduced by similar to25% in AQP1 null mice. Pressure-dependent CSF outflow, measured from steady-state ICP at different ventricular infusion rates, was not affected by AQP1 deletion. In a model of focal brain injury, AQP1 null mice had remarkably reduced ICP and improved survival compared with wild-type mice. The reduced ICP and CSF production in AQP1 null mice provides direct functional evidence for the involvement of AQP1 in CSF dynamics, suggesting AQP1 inhibition as a novel option for therapy of elevated ICP.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu			NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; BERING EA, 1963, J NEUROSURG, V20, P1050, DOI 10.3171/jns.1963.20.12.1050; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665; DENG QS, 1992, NEUROSCI LETT, V143, P146, DOI 10.1016/0304-3940(92)90253-4; Farinas J, 1997, J GEN PHYSIOL, V110, P283, DOI 10.1085/jgp.110.3.283; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MCCOMB JG, 1983, J NEUROSURG, V59, P369, DOI 10.3171/jns.1983.59.3.0369; MILHORAT TH, 1971, SCIENCE, V173, P330, DOI 10.1126/science.173.3994.330; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Oshio K, 2003, ACT NEUR S, V86, P525; Pallone TL, 2000, J CLIN INVEST, V105, P215, DOI 10.1172/JCI8214; PAPPENHEIMER JR, 1962, AM J PHYSIOL, V203, P763, DOI 10.1152/ajplegacy.1962.203.5.763; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RUBIN RC, 1966, J NEUROSURG, V25, P430, DOI 10.3171/jns.1966.25.4.0430; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SEGAL MB, 1977, EXP EYE RES, V25, P127, DOI 10.1016/S0014-4835(77)80012-2; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Speake T, 2001, MICROSC RES TECHNIQ, V52, P49, DOI 10.1002/1097-0029(20010101)52:1<49::AID-JEMT7>3.0.CO;2-C; URSINO M, 1988, ANN BIOMED ENG, V16, P379, DOI 10.1007/BF02364625; Verkman AS, 2002, ANN MED, V34, P192, DOI 10.1080/713782138; WELCH K, 1963, AM J PHYSIOL, V205, P617, DOI 10.1152/ajplegacy.1963.205.3.617; WRIGHT EM, 1977, EXP EYE RES, V25, P149, DOI 10.1016/S0014-4835(77)80013-4; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; [No title captured]	37	313	323	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					76	+		10.1096/fj.04-1711fje	http://dx.doi.org/10.1096/fj.04-1711fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15533949				2022-12-28	WOS:000225482100025
J	Ott, MC; Scott, JR; Bihari, A; Badhwar, A; Otterbein, LE; Gray, DK; Harris, KA; Potter, RF				Ott, MC; Scott, JR; Bihari, A; Badhwar, A; Otterbein, LE; Gray, DK; Harris, KA; Potter, RF			Inhalation of carbon monoxide prevents liver injury and inflammation following hind limb ischemia/reperfusion	FASEB JOURNAL			English	Article						heme oxygenase; microcirculation; leukocyte adhesion	REMOTE HEPATIC-INJURY; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; HEME OXYGENASE-1; LEUKOCYTE RECRUITMENT; ISCHEMIA-REPERFUSION; PARENCHYMAL INJURY; SINUSOIDAL TONE; ORGAN FAILURE; SMOOTH-MUSCLE	The induction of heme oxygenase (HO), the rate limiting enzyme in the conversion of heme into carbon monoxide (CO) and biliverdin, limits liver injury following remote trauma such as hind limb ischemia/reperfusion (I/R). Using intravital video microscopy, we tested the hypothesis that inhaled CO (250 ppm) would mimic HO-derived liver protection. Hind limb I/R significantly decreased sinusoidal diameter and volumetric flow, increased leukocyte accumulation within sinusoids, increased leukocyte rolling and adhesion within postsinusoidal venules, and significantly increased hepatocyte injury compared with naive animals. Inhalation of CO alone did not alter any microcirculatory or inflammatory parameters. Inhalation of CO following I/R restored volumetric flow, decreased stationary leukocytes within sinusoids, decreased leukocyte rolling and adhesion within postsinusoidal venules, and significantly reduced hepatocellular injury following hind limb I/R. HO inhibition did not alter microcirculatory parameters in naive mice, but did increase inflammation, as well as increase hepatocyte injury following hind limb I/R. Inhalation of CO during HO inhibition significantly reduced such microcirculatory deficits, hepatic inflammation, and injury in response to hind limb I/R. In conclusion, these results suggest that HO-derived hepatic protection is mediated by CO, and inhalation of low concentrations of CO may represent a novel therapeutic approach to prevent remote organ injury during systemic inflammatory response syndrome, or SIRS.	Victoria Res Labs, Ctr Crit Illness Res, Lawson Hlth Res Inst, London, ON N6A 4G5, Canada; Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; London Hlth Sci Ctr, Dept Gen Surg, London, ON, Canada	Western University (University of Western Ontario); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; London Health Sciences Centre	Potter, RF (corresponding author), Victoria Res Labs, Ctr Crit Illness Res, Lawson Hlth Res Inst, 6th Floor,800 Commissioners Rd E, London, ON N6A 4G5, Canada.	rpotter@uwo.ca		Ott, Michael/0000-0002-0816-7089				Alberti C, 2003, AM J RESP CRIT CARE, V168, P77, DOI 10.1164/rccm.200208-785OC; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brock RW, 1999, AM J PHYSIOL-GASTR L, V277, pG55, DOI 10.1152/ajpgi.1999.277.1.G55; Brock RW, 2001, AM J PHYSIOL-GASTR L, V280, pG279, DOI 10.1152/ajpgi.2001.280.2.G279; Brock RW, 1999, HEPATOLOGY, V30, P137, DOI 10.1002/hep.510300132; Brun-Buisson C, 2000, INTENS CARE MED, V26, pS64, DOI 10.1007/s001340051121; Fondevila C, 2003, TRANSPLANT P, V35, P1798, DOI 10.1016/S0041-1345(03)00720-6; Fox-Robichaud A, 2000, HEPATOLOGY, V31, P1123, DOI 10.1053/he.2000.6961; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Harbrecht BG, 2002, J TRAUMA, V53, P517, DOI 10.1097/00005373-200209000-00020; Harbrecht BG, 2001, AM SURGEON, V67, P122; Iwasashi H, 2003, SURG TODAY, V33, P30, DOI 10.1007/s005950300005; JAESCHKE H, 2003, SHOCK, V18, P152; Kato Y, 2003, HEPATOLOGY, V38, P364, DOI 10.1053/jhep.2003.50300; Katori M, 2002, TRANSPL IMMUNOL, V9, P227, DOI 10.1016/S0966-3274(02)00043-6; Lalor PF, 2002, J IMMUNOL, V169, P983, DOI 10.4049/jimmunol.169.2.983; Lawlor DK, 1999, J VASC SURG, V30, P533, DOI 10.1016/S0741-5214(99)70081-9; McCarter SD, 2003, GENE THER, V10, P1629, DOI 10.1038/sj.gt.3302063; Menezes J, 1999, AM J PHYSIOL-GASTR L, V277, pG144, DOI 10.1152/ajpgi.1999.277.1.G144; Moore BA, 2003, GASTROENTEROLOGY, V124, P377, DOI 10.1053/gast.2003.50060; Morisaki H, 2002, ANESTHESIOLOGY, V97, P701, DOI 10.1097/00000542-200209000-00025; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Nie RG, 2002, J HEPATOL, V36, P624, DOI 10.1016/S0168-8278(02)00025-9; Ohlmann A, 2003, EXP BIOL MED, V228, P584, DOI 10.1177/15353702-0322805-51; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 1999, CHEST, V116, p61S, DOI 10.1378/chest.116.suppl_1.61S-a; Pannen BHJ, 1998, J CLIN INVEST, V102, P1220, DOI 10.1172/JCI3428; RAMOS KS, 1989, BIOCHEM PHARMACOL, V38, P1368, DOI 10.1016/0006-2952(89)90347-X; Rensing H, 2002, HEPATOLOGY, V36, P1453, DOI 10.1053/jhep.2002.36934; Rensing H, 1999, CRIT CARE MED, V27, P2766, DOI 10.1097/00003246-199912000-00027; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; Sarady JK, 2004, FASEB J, V18, P854, DOI 10.1096/fj.03-0643fje; Sass G, 2003, HEPATOLOGY, V38, P909, DOI 10.1053/jhep.2003.50386; Sass G, 2001, J CLIN INVEST, V107, P439, DOI 10.1172/JCI10613; Scott JR, 2002, AM J PHYSIOL-GASTR L, V283, pG561, DOI 10.1152/ajpgi.00462.2001; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; Tanaka Jin, 2003, Leg Med (Tokyo), V5, P146, DOI 10.1016/S1344-6223(03)00076-2; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; UTZ J, 1991, BIOCHEM PHARMACOL, V41, P1195, DOI 10.1016/0006-2952(91)90658-R; Vachharajani TJ, 2000, AM J PHYSIOL-HEART C, V278, pH1613, DOI 10.1152/ajpheart.2000.278.5.H1613; Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416; Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456; Wunder C, 2002, J PHYSIOL-LONDON, V540, P1013, DOI 10.1113/physiol.2001.015446; Xiang L, 2003, INFLAMM RES, V52, P353, DOI 10.1007/s00011-003-1184-6; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003; Zuckerbraun BS, 2003, HEPATOLOGY, V37, P742, DOI 10.1053/jhep.2003.50139	50	48	56	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					106	+		10.1096/fj.04-2514fje	http://dx.doi.org/10.1096/fj.04-2514fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15514102				2022-12-28	WOS:000224849900003
J	Chu, GX; Kerr, JP; Mitton, B; Egnaczyk, GF; Vazquez, JA; Shen, ML; Kilby, GW; Stevenson, TI; Maggio, JE; Vockley, J; Rapundalo, ST; Kranias, EG				Chu, GX; Kerr, JP; Mitton, B; Egnaczyk, GF; Vazquez, JA; Shen, ML; Kilby, GW; Stevenson, TI; Maggio, JE; Vockley, J; Rapundalo, ST; Kranias, EG			Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling	FASEB JOURNAL			English	Article						phospholamban; phosphorylation; contractility; energetics; heart failure	CARDIAC TROPONIN-T; PHOSPHOLAMBAN ABLATION; HYPERTROPHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; CONTRACTILE PROTEINS; TROPOMYOSIN-1; PHOSPHORYLATION; IDENTIFICATION; GROWTH; MICE	Depressed sarcoplasmic reticulum (SR) Ca-cycling is a hallmark of human and experimental heart failure. Strategies to improve this impairment by either increasing SERCA2a levels or decreasing phospholamban (PLN) activity have been suggested as promising therapeutic targets. Indeed, ablation of PLN gene in mice was associated with greatly enhanced cardiac Ca-cycling and performance. Intriguingly, this hyperdynamic cardiac function was maintained throughout the lifetime of the mouse without observable pathological consequences. To determine the cellular alterations in the expression or modification of myocardial proteins, which are associated with the enhanced cardiac contractility, we performed a proteomics-based analysis of PLN knockout (PLN-KO) hearts in comparison to isogenic wild-types. By use of 2-dimensional gel electrophoresis (2-DE), similar to3300 distinct protein spots were detected in either wild-type or PLN-KO ventricles. Protein spots observed to be altered between PLN-KO and wild-type hearts were subjected to tryptic peptide mass fingerprinting for identification by MALDI-TOF mass spectrometry in combination with LC/MS/MS analysis. In addition, two-dimensional P-32-autoradiography was performed to analyze the phosphorylation profiles of PLN-KO cardiomyocytes. We identified alterations in the expression level of more than 100 ventricular proteins, along with changes in phosphorylation status of important regulatory proteins in the PLN-KO. These protein changes were observed mainly in two subcellular compartments: the cardiac contractile apparatus, and metabolism/energetics. Our findings suggest that numerous alterations in protein expression and phosphorylation state occurred upon ablation of PLN and that a complex functional relationship among proteins involved in calcium handling, myofibrils, and energy production may exist to coordinately maintain the hyperdynamic cardiac contractile performance of the PLN-KO mouse in the long term.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Pfizer Global Res & Dev, Ann Arbor, MI USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	University System of Ohio; University of Cincinnati; Pfizer; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert B Sabin Way, Cincinnati, OH 45267 USA.	litsa.kranias@uc.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457; Kerr, Jaclyn/0000-0002-1416-276X	NHLBI NIH HHS [HL-64018, HL-26057, HL-56370, HL-52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064018, R37HL026057, P50HL052318, R01HL056370, R01HL026057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Chien KR, 2000, NAT MED, V6, P942, DOI 10.1038/79595; Chu GX, 2004, CIRC RES, V94, P184, DOI 10.1161/01.RES.0000107198.90218.21; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Javadpour MM, 2003, J CLIN INVEST, V112, P768, DOI 10.1172/JC1200315967; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; Lu QW, 2003, J MOL CELL CARDIOL, V35, P1421, DOI 10.1016/j.yjmcc.2003.09.003; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; Pan Y, 2004, P NATL ACAD SCI USA, V101, P2241, DOI 10.1073/pnas.0308174101; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Sakamoto K, 2000, BIOCHEM BIOPH RES CO, V269, P137, DOI 10.1006/bbrc.2000.2233; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Schwinger RHG, 2000, BASIC RES CARDIOL, V95, P12, DOI 10.1007/s003950050003; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Slack JP, 2001, J MOL CELL CARDIOL, V33, P1031, DOI 10.1006/jmcc.2001.1370; Song QJ, 2003, J CLIN INVEST, V111, P859, DOI 10.1172/JCI200316738; Stangl K, 2002, BIOCHEM BIOPH RES CO, V291, P542, DOI 10.1006/bbrc.2002.6476; Torricelli F, 2003, AM J CARDIOL, V92, P1358, DOI 10.1016/j.amjcard.2003.08.031; van der Velden J, 2003, CARDIOVASC RES, V57, P37, DOI 10.1016/S0008-6363(02)00606-5; Wolska BM, 2003, PFLUG ARCH EUR J PHY, V446, P1, DOI 10.1007/s00424-002-0900-3; Zhao W, 2003, CARDIOVASC RES, V57, P71, DOI 10.1016/S0008-6363(02)00609-0; Zheng MZ, 2004, AM J PHYSIOL-HEART C, V286, pH424, DOI 10.1152/ajpheart.00110.2003	34	21	24	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1725	+		10.1096/fj.04-2025fje	http://dx.doi.org/10.1096/fj.04-2025fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15358683				2022-12-28	WOS:000224243200033
J	Larcher, JC; Gasmi, L; Viranaicken, W; Edde, B; Bernard, R; Ginzburg, I; Denoulet, P				Larcher, JC; Gasmi, L; Viranaicken, W; Edde, B; Bernard, R; Ginzburg, I; Denoulet, P			Ilf3 and NF90 associate with the axonal targeting element of Tau mRNA	FASEB JOURNAL			English	Article						microtubule; protein-RNA interactions; Northwestern blotting; mRNA trafficking; 2-D PAGE	INTRACELLULAR-LOCALIZATION; PROTEIN; BINDING; IDENTIFICATION; EXPRESSION; ARGININE; CELLS; PHOSPHOPROTEINS; METHYLATION; TRANSPORT	In neurons, the selective translocation of Tau mRNA toward axons is due to the presence of a nucleotide sequence located in its 3' untranslated region and serving as axonal targeting element. Using this RNA sequence as a probe by a Northwestern approach, we have detected several proteins that interact with the targeting RNA element and could potentially be involved in Tau mRNA translocation, translation halting, and/or stabilization. Among them, two proteins were identified as the interleukin enhancer binding factor 3 (Ilf3) and NF90, two isoforms derived from a single gene product through alternative splicing. Each protein comprises two double-stranded RNA binding motifs that can interact with the predicted stem-loop secondary structure of the axonal targeting element. Specific antibodies raised against common or specific peptide sequences showed that both Ilf3 and NF90 are polymorphic proteins that are detected in neuronal nuclei and cell bodies, as well as in the proximal neuritic segments. This observation favors the idea that Ilf3 and NF90 are part of a protein complex that escorts Tau mRNA toward the axon.	Univ Paris 06, Biochim Cellulaire Lab, CNRS, UMR 7098, F-75252 Paris 05, France; CRBM, CNRS, UPR 1086, F-34293 Montpellier, France; Univ Paris 06, CNRS, UMR 7101, F-75252 Paris 05, France; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Weizmann Institute of Science	Larcher, JC (corresponding author), Univ Paris 06, Biochim Cellulaire Lab, CNRS, UMR 7098, 9 Quai St Bernard,Batiment C,Case 265, F-75252 Paris 05, France.	jclarche@snv.jussieu.fr						Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; Aronov S, 2002, J CELL SCI, V115, P3817, DOI 10.1242/jcs.00058; Aronov S, 2001, J NEUROSCI, V21, P6577, DOI 10.1523/JNEUROSCI.21-17-06577.2001; Aronov S, 1999, J MOL NEUROSCI, V12, P131, DOI 10.1007/BF02736927; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; BEHAR L, 1995, INT J DEV NEUROSCI, V13, P113, DOI 10.1016/0736-5748(95)00001-W; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Goedert M, 1996, J CELL SCI, V109, P2661; Gwizdek C, 2004, J BIOL CHEM, V279, P884, DOI 10.1074/jbc.M306808200; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kim S, 1998, AMINO ACIDS, V15, P291, DOI 10.1007/BF01320895; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARCHER JC, 1992, DEV BIOL, V154, P195, DOI 10.1016/0012-1606(92)90059-P; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; LITMAN P, 1994, NEURON, V13, P1463, DOI 10.1016/0896-6273(94)90432-4; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Moldrich RX, 2000, J NEUROSCI RES, V59, P788, DOI 10.1002/(SICI)1097-4547(20000315)59:6<788::AID-JNR11>3.0.CO;2-K; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Palacios IM, 2001, ANNU REV CELL DEV BI, V17, P569, DOI 10.1146/annurev.cellbio.17.1.569; SADOT E, 1994, J MOL BIOL, V241, P325, DOI 10.1006/jmbi.1994.1508; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; Wild K, 2002, CURR OPIN STRUC BIOL, V12, P72, DOI 10.1016/S0959-440X(02)00292-0; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; Zuker M., 1999, V70, P11	42	46	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1761	+		10.1096/fj.04-1763fje	http://dx.doi.org/10.1096/fj.04-1763fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364895				2022-12-28	WOS:000224243200028
J	Lee, YC; Lee, KS; Park, SJ; Park, HS; Lim, JS; Park, KH; Im, MJ; Choi, IW; Lee, HK; Kim, UH				Lee, YC; Lee, KS; Park, SJ; Park, HS; Lim, JS; Park, KH; Im, MJ; Choi, IW; Lee, HK; Kim, UH			Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid	FASEB JOURNAL			English	Article						eosinophilia; NF-kappa B; oxidative stress; signal transduction	NF-KAPPA-B; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; LUNG-DISEASES; GROWTH-FACTOR; T-CELLS; GLUTATHIONE; ACTIVATION; RESPONSES	Oxidative stress plays an important role in the pathogenesis of bronchial asthma. An excess production of reactive oxygen species (ROS) and defective endogenous antioxidant defense mechanisms may be present in asthma. Reduced glutathione (GSH) is one of the most important reducing agents against oxidant free radicals. A reducing agent, L-2-oxothiazolidine-4-carboxylic acid (OTC), a prodrug of cysteine, increases intracellular GSH. We have used a mouse model for asthma to determine effects of OTC on allergen-induced bronchial inflammation and airway hyper-responsiveness. The administration of OTC reduced bronchial inflammation and airway hyper-responsiveness. ROS generation in bronchoalveolar lavage fluids was increased by ovalbumin ( OVA) inhalation, but this increase was diminished by administration of OTC. The increased IL-4, IL-5, IL-13, and eosinophil cationic protein levels in lungs after OVA inhalation were significantly reduced by the administration of OTC. In addition, the increased expression of ICAM-1, VCAM-1, RANTES, and eotaxin in lungs after OVA inhalation was significantly reduced by the administration of OTC. We also showed that the increased NF-kappaB levels in nuclear protein extracts of lung tissues at 72 h after OVA inhalation were decreased by the administration of OTC. These findings suggest that OTC may reduce airway inflammation and hyper-responsiveness through regulation of NF-kappaB activity.	Chonbuk Natl Univ Med Sch, Dept Internal Med, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Dept Biochem, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Dept Immunol, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Inst Cardiovasc Res, Jeonju 561712, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ Med Sch, Dept Internal Med, 634-18 Keumamdong, Jeonju 561712, South Korea.	leeyc@chonbuk.ac.kr						Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337; ASTI C, 1995, PHARMACOL RES, V31, P387, DOI 10.1016/1043-6618(95)80094-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Blesa S, 2002, PHARMACOL RES, V45, P135, DOI 10.1006/phrs.2001.0917; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cheng JJ, 1996, BIOCHEM BIOPH RES CO, V225, P100, DOI 10.1006/bbrc.1996.1136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cortijo J, 1999, FREE RADICAL BIO MED, V27, P392, DOI 10.1016/S0891-5849(99)00070-2; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Han MK, 2002, J BIOL CHEM, V277, P5315, DOI 10.1074/jbc.M106439200; Han SJ, 2002, J BIOL CHEM, V277, P44715, DOI 10.1074/jbc.M202524200; Harper R, 2001, AM J RESP CELL MOL, V25, P178, DOI 10.1165/ajrcmb.25.2.4471; HAZELTON GA, 1986, J PHARMACOL EXP THER, V237, P341; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519, DOI 10.1164/ajrccm.149.2.8306055; JUN DY, 1997, J BIOL CHEM, V272, P30952; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee M, 2002, BIOCHEM J, V366, P937, DOI 10.1042/BJ20020453; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Mori A, 1999, J ALLERGY CLIN IMMUN, V103, pS429, DOI 10.1016/S0091-6749(99)70158-2; MOSLEN MT, 1989, J PHARMACOL EXP THER, V248, P157; Nishida S, 2002, FREE RADICAL RES, V36, P601, DOI 10.1080/10715760210872; Oiry J, 1999, J MED CHEM, V42, P4733, DOI 10.1021/jm980289j; OWEN S, 1991, NEW ENGL J MED, V325, P586; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Rahman I, 1997, THORAX, V52, P565, DOI 10.1136/thx.52.6.565; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; SANG F, 1997, J BIOL CHEM, V272, P23086; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stutz AM, 1999, J IMMUNOL, V163, P4383; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Verhasselt V, 1999, J IMMUNOL, V162, P2569; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936; WILLIAMSON JM, 1982, P NATL ACAD SCI-BIOL, V79, P6246, DOI 10.1073/pnas.79.20.6246; Zhang MJ, 2002, FREE RADICAL BIO MED, V32, P454, DOI 10.1016/S0891-5849(01)00825-5	49	62	63	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1917	+		10.1096/fj.04-2212fje	http://dx.doi.org/10.1096/fj.04-2212fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385436				2022-12-28	WOS:000224243200018
J	Walduck, A; Schmitt, A; Lucas, B; Aebischer, T; Meyer, TF				Walduck, A; Schmitt, A; Lucas, B; Aebischer, T; Meyer, TF			Transcription profiling analysis of the mechanisms of vaccine-induced protection against H-pylori	FASEB JOURNAL			English	Article						microarray; immunization; mouse; recombinant Salmonella; helicobacter	GASTRIC EPITHELIAL-CELLS; CD4(+) T-CELLS; SMALL-INTESTINE; MICE; EXPRESSION; RESPONSES; IMMUNITY; LEPTIN; HOST; PROLIFERATION	Development of a vaccine against H. pylori is regarded as desirable alternative to the current antibiotic therapy regimens. Mice immunized with an attenuated recombinant Salmonella typhimurium expressing H. pylori urease subunits A& B have dramatically reduced bacterial loads after a single dose. The mechanism(s) of protection against this largely extra-cellular pathogen are not fully understood. The aim of this study was to identify genes that were regulated specifically in response to immunization, in order to gain a broader picture of the immune response in the immunized gastric epithelium. Gene expression in RNA isolated from the gastric mucosa of immunized and infected Balb/c mice was compared with that in infected only mice at 1, 3, and 14 days after challenge with a mouse-adapted strain of H. pylori. We show that infection with H. pylori causes an immediate reaction in vivo, which was clearly divided into acute and chronic phases, and further that the transcriptional response in the H. pylori infected and immunized gastric mucosa is unique. Analysis of gene expression patterns at day 14 post-infection suggested not only the beginning of a lymphocytic infiltrate, but of an integrated epithelial response characterized by increased expression of genes controlling cell cycle and turnover. This observation was confirmed in independent experiments. The global approach has brought new insights to the effect of immunization on the gastric epithelium and has led us to propose a new multi-factorial model for the mechanisms underlying vaccine-induced protection.	Max Planck Inst Infect Biol, Dept Mol Biol, Berlin, Germany	Max Planck Society	Meyer, TF (corresponding author), Max Planck Inst Infect Biol, Dept Mol Biol, Schumanstr 21-22, Berlin, Germany.	meyer@mpiib-berlin.mpg.de	Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679; Aebischer, Toni/0000-0002-4875-8457; Walduck, Anna/0000-0002-9624-4370				Aebischer T, 2001, INFECT IMMUN, V69, P556, DOI 10.1128/IAI.69.1.556-558.2001; Aebischer T, 2000, J BIOTECHNOL, V83, P77, DOI 10.1016/S0168-1656(00)00301-1; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Blanchard AP, 1996, NAT BIOTECHNOL, V14, P1649, DOI 10.1038/nbt1296-1649; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; Braissant O, 1998, BIOCHEMICA, V1, P10; Court M, 2003, J PATHOL, V201, P303, DOI 10.1002/path.1422; Cox JM, 2001, INFECT IMMUN, V69, P6970, DOI 10.1128/IAI.69.11.6970-6980.2001; De Lisle RC, 1998, AM J PHYSIOL-GASTR L, V275, pG219, DOI 10.1152/ajpgi.1998.275.2.G219; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277; Gomez-Duarte OG, 1998, VACCINE, V16, P460, DOI 10.1016/S0264-410X(97)00247-8; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; Kamal M, 2001, CLIN EXP IMMUNOL, V126, P117, DOI 10.1046/j.1365-2249.2001.01589.x; Koesling J, 2001, VACCINE, V20, P413, DOI 10.1016/S0264-410X(01)00355-3; Lucas B, 2001, INFECT IMMUN, V69, P1714, DOI 10.1128/IAI.69.3.1714-1721.2001; Madsen J, 2003, EUR J IMMUNOL, V33, P2327, DOI 10.1002/eji.200323972; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Mills JC, 2001, P NATL ACAD SCI USA, V98, P13687, DOI 10.1073/pnas.231332398; Mohammadi M, 1997, GASTROENTEROLOGY, V113, P1848, DOI 10.1016/S0016-5085(97)70004-0; Mueller A, 2003, P NATL ACAD SCI USA, V100, P12289, DOI 10.1073/pnas.1635231100; Murray E, 2002, INFECT IMMUN, V70, P1481, DOI 10.1128/IAI.70.3.1481-1487.2002; Pappo J, 1999, INFECT IMMUN, V67, P337, DOI 10.1128/IAI.67.1.337-341.1999; Parvin MN, 2002, BBA-MOL CELL RES, V1542, P116, DOI 10.1016/S0167-4889(01)00172-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raso GM, 2002, BRIT J PHARMACOL, V137, P799, DOI 10.1038/sj.bjp.0704903; Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999; Sepulveda AR, 2002, ALIMENT PHARM THERAP, V16, P145, DOI 10.1046/j.1365-2036.16.s2.4.x; Siegmund B, 2002, GASTROENTEROLOGY, V122, P2011, DOI 10.1053/gast.2002.33631; Sommi P, 2002, EXP CELL RES, V281, P128, DOI 10.1006/excr.2002.5629; Song Hong, 2002, Di Yi Jun Yi Da Xue Xue Bao, V22, P59; Sutton P, 2001, IMMUNOL CELL BIOL, V79, P67, DOI 10.1046/j.1440-1711.2001.00977.x; Thim L, 2000, REGUL PEPTIDES, V90, P61, DOI 10.1016/S0167-0115(00)00110-5; van Doorn NEM, 1999, INFECT IMMUN, V67, P3040, DOI 10.1128/IAI.67.6.3040-3046.1999; Walduck A, 2004, CURR OPIN MICROBIOL, V7, P33, DOI 10.1016/j.mib.2003.12.010; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	37	21	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1955	+		10.1096/fj.04-2321fje	http://dx.doi.org/10.1096/fj.04-2321fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456742				2022-12-28	WOS:000224243200005
J	Kerkis, A; Kerkis, I; Radis-Baptista, G; Oliveira, EB; Vianna-Morgante, AM; Pereira, LV; Yamane, T				Kerkis, A; Kerkis, I; Radis-Baptista, G; Oliveira, EB; Vianna-Morgante, AM; Pereira, LV; Yamane, T			Crotamine is a novel cell-penetrating protein from the venom of rattlesnake Crotalus durissus terrificus	FASEB JOURNAL			English	Article						chromosomes; centrosomes; cell penetrating peptide	EMBRYONIC STEM-CELLS; IN-VITRO DIFFERENTIATION; ARGININE-RICH PEPTIDES; TAT-MEDIATED DELIVERY; AMINO-ACID SEQUENCE; INTRACELLULAR DELIVERY; INTERCELLULAR TRAFFICKING; ANTIMICROBIAL PEPTIDES; TRANSDUCTION; DOMAINS	Herein we report that crotamine, a small lysine- and cysteine-rich protein from the venom of the South American rattlesnake, can rapidly penetrate into different cell types and mouse blastocysts in vitro. In vivo, crotamine strongly labels cells from mouse bone marrow and spleen and from peritoneal liquid, as shown by fluorescent confocal laser-scanning microscopy. Nuclear localization of crotamine was observed in both fixed and unfixed cells. In the cytoplasm, crotamine specifically associates with centrosomes and thus allows us to follow the process of centriole duplication and separation. In the nucleus, it binds to the chromosomes at S/G2 phase, when centrioles start dividing. Moreover, crotamine appears as a marker of actively proliferating cells, as shown by 5-BrdU cell-proliferation assay. Crotamine in the micromolar range proved nontoxic to any of the cell cultures tested and did not affect the pluripotency of ES cells or the development of mouse embryos.	Univ Sao Paulo, Inst Biociencias, Dept Biol, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Mol Toxicol Lab, Sao Paulo, Brazil; Univ Sao Paulo, Dept Bioquim & Imunol, BR-14049 Ribeirao Preto, Brazil	Universidade de Sao Paulo; Instituto Butantan; Universidade de Sao Paulo	Kerkis, A (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Biol, Rua Matao 277, BR-05508900 Sao Paulo, Brazil.	akerkis@usp.br	RADIS-BAPTISTA, GANDHI/H-9574-2016; RADIS-BAPTISTA, GANDHI/J-4991-2019; Pereira, Lygia V/C-1049-2012; Kerkis, Irina/AAD-1006-2019	RADIS-BAPTISTA, GANDHI/0000-0001-9210-092X; RADIS-BAPTISTA, GANDHI/0000-0001-9210-092X; Pereira, Lygia V/0000-0002-0002-725X; 				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bautch VL, 1996, DEV DYNAM, V205, P1; Bieber AL, 1997, J TOXICOL-TOXIN REV, V16, P33, DOI 10.3109/15569549709064092; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Cashman SM, 2002, MOL THER, V6, P813, DOI 10.1006/mthe.2002.0806; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dilber MS, 1999, GENE THER, V6, P12, DOI 10.1038/sj.gt.3300838; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DRIN G, 2003, J BIOL CHEM; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Ford KG, 2000, MECH AGEING DEV, V121, P113; FOX JW, 1979, BIOCHEMISTRY-US, V18, P678, DOI 10.1021/bi00571a020; FRAICHARD A, 1995, J CELL SCI, V108, P3181; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LAURE CJ, 1975, H-S Z PHYSIOL CHEM, V356, P213; Leahy A, 1999, J EXP ZOOL, V284, P67, DOI 10.1002/(SICI)1097-010X(19990615)284:1&lt;67::AID-JEZ10&gt;3.0.CO;2-O; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; Martin A, 2002, J VIROL, V76, P4961, DOI 10.1128/JVI.76.10.4961-4970.2002; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Olsnes S, 2003, PHYSIOL REV, V83, P163, DOI 10.1152/physrev.00021.2002; OWNBY CL, 1976, AM J PATHOL, V85, P149; Peitz M, 2002, P NATL ACAD SCI USA, V99, P4489, DOI 10.1073/pnas.032068699; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Radis-Baptista G, 1999, TOXICON, V37, P973, DOI 10.1016/S0041-0101(98)00226-8; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Scholz G, 1999, CELLS TISSUES ORGANS, V165, P203, DOI 10.1159/000016700; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sukoyan MA, 2002, BRAZ J MED BIOL RES, V35, P535, DOI 10.1590/S0100-879X2002000500004; TALBOT NC, 1993, MOL REPROD DEV, V36, P139, DOI 10.1002/mrd.1080360204; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WILSON AP, 1986, ANIMAL CELL CULTURE, P182; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Yoon HY, 2002, NEUROCHEM INT, V41, P37, DOI 10.1016/S0197-0186(01)00138-3; Yuan JP, 2002, CANCER RES, V62, P4186	54	91	96	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1407	+		10.1096/fj.03-1459fje	http://dx.doi.org/10.1096/fj.03-1459fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231729				2022-12-28	WOS:000222979200023
J	Droetto, S; Viale, A; Primo, L; Jordaney, N; Bruno, S; Pagano, M; Piacibello, W; Bussolino, F; Aglietta, M				Droetto, S; Viale, A; Primo, L; Jordaney, N; Bruno, S; Pagano, M; Piacibello, W; Bussolino, F; Aglietta, M			Vasculogenic potential of long term repopulating cord blood progenitors	FASEB JOURNAL			English	Article						endothelial progenitor cell (EPC); hematopoietic stem cell (HSC)	HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; EX-VIVO EXPANSION; BONE-MARROW; GENE-TRANSFER; TUMOR ANGIOGENESIS; LENTIVIRAL VECTORS; PERIPHERAL-BLOOD; IN-VIVO; NEOVASCULARIZATION	In the adult, involvement of bone marrow-derived circulating endothelial progenitor cells (EPCs) in tissue revascularization (vasculogenesis) and the cooperation of hematopoietic cell subsets in supporting this process have been described in different experimental animal models. However, the effective contribution of such cells in restoring organ vascularization in a clinical setting needs to be clarified. In this study, a mouse transplantation model was engrafted by human cord blood hematopoietic stem and progenitor cells to follow the behavior of donor-derived endothelial and hematopoietic cells in the presence of a localized source of an angiogenic inducer. Human endothelial markers (CD31(+)/CD45(-), VE-cadherin(+)) were always detectable in the bone marrow of transplanted mice, while they were only randomly detectable in peripheral neovascularization sites. To investigate the ability of human transplanted hematopoietic stem cells to support new vessel formation in response to altered homeostatic conditions, chimeric mice were further treated by systemic injection of human mononuclear cells (MNCs). Our data indicate that MNC administration in transplanted mice enhances vasculogenesis in the newly formed vessels. Taken together these results suggest that human-derived EPCs, long-term engrafting a xenotransplantation model, have hematopoietic and endothelial developmental potential, which can be modulated by altering the physiological conditions of host microenvironment.	Univ Turin, Sch Med, IRCC, Div Clin Oncol, I-10060 Candiolo, TO, Italy; Univ Turin, Sch Med, IRCC, Div Mol & Angiogensis, I-10060 Candiolo, TO, Italy; Univ Turin, Dept Oncol Sci, I-10060 Candiolo, TO, Italy; Univ Turin, Dept Biomed Sci & Oncol, I-10060 Candiolo, TO, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Turin	Droetto, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Clin Oncol, I-10060 Candiolo, TO, Italy.	sara.droetto@ircc.it	; Bussolino, Federico/K-2500-2016	AGLIETTA, Massimo/0000-0002-2255-7972; Bussolino, Federico/0000-0002-5348-1341; PRIMO, Luca/0000-0002-1294-0441; BRUNO, Stefania/0000-0002-8879-9536				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Cairo MS, 1997, BLOOD, V90, P4665, DOI 10.1182/blood.V90.12.4665.4665_4665_4678; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crisa L, 1999, BLOOD, V94, P3928, DOI 10.1182/blood.V94.11.3928.423k02_3928_3940; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; DIPIETRO LA, 1993, AM J PATHOL, V143, P678; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hillebrands JL, 2003, ARTERIOSCL THROM VAS, V23, P380, DOI 10.1161/01.ATV.0000059337.60393.64; Huang YQ, 2000, BLOOD, V95, P1993, DOI 10.1182/blood.V95.6.1993; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lane WJ, 2000, BLOOD, V96, P4152; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Luttun A, 2002, TRENDS CARDIOVAS MED, V12, P88, DOI 10.1016/S1050-1738(01)00152-9; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744; PASSANITI A, 1992, LAB INVEST, V67, P519; Piacibello W, 1999, BLOOD, V93, P3736, DOI 10.1182/blood.V93.11.3736.411k01_3736_3749; Piacibello W, 2002, BLOOD, V100, P4391, DOI 10.1182/blood.V100.13.4391; POLVERINI PJ, 1984, LAB INVEST, V51, P635; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233; Tordjman R, 2001, BLOOD, V97, P1968, DOI 10.1182/blood.V97.7.1968; Vigna E, 2000, J GENE MED, V2, P308; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Wartiovaara U, 1998, THROMB HAEMOSTASIS, V80, P171, DOI 10.1055/s-0037-1615158	50	17	23	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1273	+		10.1096/fj.03-1444fje	http://dx.doi.org/10.1096/fj.03-1444fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208264				2022-12-28	WOS:000222327500017
J	Johnson, GB; Riggs, BL; Platt, JL				Johnson, GB; Riggs, BL; Platt, JL			A genetic basis for the "Adonis" phenotype of low adiposity and strong bones	FASEB JOURNAL			English	Article						Toll-like receptor 4; osteoporosis; obesity; fat; CD14	TOLL-LIKE RECEPTOR-4; POSTMENOPAUSAL WOMEN; MURINE MACROPHAGES; CUTTING EDGE; LIPOPOLYSACCHARIDE; CD14; MICE; LPS; DIFFERENTIATION; MOUSE	Toll receptors in Drosophila contribute to host defense and establish the body plan. Mammalian homologues of Toll, the Toll-like receptors (TLRs), are thought to function only in host defense. Here, we report that mice harboring mutations in TLR4 or in CD14, a co-receptor for TLR4, have an "ideal" body plan consisting of increased bone mineral content, density, and size as well as decreased body fat. These mutant mice live long lives, have normal activity and fertility, and show no evidence of infection. Unlike many strains of caged wild-type mice, they do not become obese. Although all mice continue to gain body fat, bone content, and overall weight, the difference in bone content and body fat between mutant and wild- type mice increases with age. Thus, defects in TLR4/CD14 complex generate an "Adonis" phenotype, characterized by this ideal body type, and this function could potentially be exploited for the treatment of osteoporosis and obesity.	Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Pediat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Platt, JL (corresponding author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW,Med Sci Bldg 2-66, Rochester, MN 55905 USA.	platt.jeffrey@mayo.edu	Johnson, Geoffrey B/AAG-2729-2021; Platt, Jeffrey/AHB-0480-2022	Johnson, Geoffrey B/0000-0002-4866-1401; Platt, Jeffrey/0000-0002-4915-0419; Johnson, Geoffrey/0000-0002-9781-4072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053733] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46810] Funding Source: Medline; NIAID NIH HHS [AI53733] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akhter MP, 2000, CALCIFIED TISSUE INT, V67, P337, DOI 10.1007/s002230001144; Amano S, 1997, J CELL PHYSIOL, V173, P301, DOI 10.1002/(SICI)1097-4652(199712)173:3<301::AID-JCP1>3.0.CO;2-R; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; Brot C, 1997, J INTERN MED, V242, P505, DOI 10.1111/j.1365-2796.1997.tb00024.x; Chiang CY, 2003, J PERIODONTAL RES, V38, P36, DOI 10.1034/j.1600-0765.2003.01617.x; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Hou L, 2000, INFECT IMMUN, V68, P4681, DOI 10.1128/IAI.68.8.4681-4687.2000; Itoh K, 2003, J IMMUNOL, V170, P3688, DOI 10.4049/jimmunol.170.7.3688; Jensen L, 2003, J BONE MINER RES, V18, P333, DOI 10.1359/jbmr.2003.18.2.333; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnson GB, 2003, TRENDS IMMUNOL, V24, P19, DOI 10.1016/S1471-4906(02)00014-5; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; Khosla S, 2002, ENDOCRINOLOGY, V143, P4161, DOI 10.1210/en.2002-220843; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406; McCauley LK, 2002, J PERIODONTOL, V73, P1377, DOI 10.1902/jop.2002.73.11.1377; Means TK, 1999, J IMMUNOL, V163, P6748; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Perera PY, 1997, J IMMUNOL, V158, P4422; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Premer DM, 2002, INFLAMMATION, V26, P97, DOI 10.1023/A:1014840412552; Siris ES, 2001, JAMA-J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; TRAYHURN P, 2003, SCI STKE, pPE7; VOGEL SN, 1994, INFECT IMMUN, V62, P4454, DOI 10.1128/IAI.62.10.4454-4459.1994; Wang W, 2002, VLSI DES, V14, P183, DOI 10.1080/10655140290010097; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	34	49	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1282	+		10.1096/fj.04-1572fje	http://dx.doi.org/10.1096/fj.04-1572fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208271				2022-12-28	WOS:000222327500005
J	Maloney, B; Ge, YW; Greig, N; Lahiri, DK				Maloney, B; Ge, YW; Greig, N; Lahiri, DK			Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease	FASEB JOURNAL			English	Article						phylogenetic analysis; aging; dementia; rational drug design	PRECURSOR PROTEIN GENE; MESSENGER-RNA; 5'-UNTRANSLATED REGION; TGF-BETA; TRANSGENIC MICE; CELL-LINES; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATION; REGULATES EXPRESSION; SIGNALING CROSSTALK	Potentially toxic amyloid beta-peptide (Abeta) in Alzheimer's disease ( AD) is generated from a family of Abeta-containing precursor proteins (APP), which is regulated via the 5'-untranslated region (5'-UTR) of its mRNA. We analyzed 5'-UTRs of the APP superfamily, including amyloid plaque-forming and non-amyloid plaque-forming species, and of prions (27 different DNA sequences). A "CAGA" sequence proximal to the "ATG" start codon was present in a location unique to APP genes of amyloid plaque-forming species and absent in all other genes surveyed. This CAGA box is immediately upstream of an interleukin-1-responsive element (acute box). In addition, the proximal CAGA box is predicted to appear on a stem-loop structure in both human and guinea pig APP mRNA. This stem-loop is part of a predicted bulge-loop that encompasses a known iron regulatory element (IRE). Electrophoretic mobility shift with segments of the APP 5'-UTR showed that a region with the proximal CAGA sequence binds nuclear proteins, and this UTR fragment is active in a reporter gene functional assay. Thus, the 5'-UTR in the human APP but not those of APP-like proteins contains a specific region that may participate in APP regulation and may determine a more general model for amyloid generation as seen in AD. The 5'-UTR of human APP contains several interesting control elements, such as an acute box element, a CAGA box, an IRE, and a transforming growth factor-beta-responsive element, that could control APP expression and provide suitable and specific drug targets for AD.	Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; NIA, Neurosci Lab, NIH, Baltimore, MD 21224 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Lahiri, DK (corresponding author), Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, 791 Union Dr, Indianapolis, IN 46202 USA.	dlahiri@iupui.edu	Lahiri, Debomoy/AAZ-3322-2020; Maloney, Bryan J/C-4924-2011	Maloney, Bryan J/0000-0003-2364-9649	NIA NIH HHS [AG 18379, AG 18884] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018379, Z01AG000311, R01AG018884] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Apelt J, 1997, INT J DEV NEUROSCI, V15, P95, DOI 10.1016/S0736-5748(96)00073-1; Bales KR, 2000, NEUROBIOL AGING, V21, P427, DOI 10.1016/S0197-4580(00)00143-3; Beck M, 2003, NEUROCHEM RES, V28, P637, DOI 10.1023/A:1022850113083; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burton T, 2002, BIOCHEM BIOPH RES CO, V295, P713, DOI 10.1016/S0006-291X(02)00725-8; Burton T, 2002, BIOCHEM BIOPH RES CO, V295, P702, DOI 10.1016/S0006-291X(02)00724-6; Cappai R, 1999, FEBS LETT, V442, P95, DOI 10.1016/S0014-5793(98)01635-4; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; De Schutter J., 1998, Control Problems in Robotics and Automation, P1, DOI 10.1007/BFb0015073; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Flanders KC, 2003, AM J PATHOL, V163, P2247, DOI 10.1016/S0002-9440(10)63582-1; Ge YW, 2002, ANN NY ACAD SCI, V973, P463, DOI 10.1111/j.1749-6632.2002.tb04684.x; Ghosh C, 2000, MOL BIOL REP, V27, P113, DOI 10.1023/A:1007173906990; Ghosh C, 1999, J MOL NEUROSCI, V13, P77, DOI 10.1385/JMN:13:1-2:77; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heber S, 2000, J NEUROSCI, V20, P7951; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kumar VB, 2000, PEPTIDES, V21, P1769, DOI 10.1016/S0196-9781(00)00339-9; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; LAHIRI DK, UNPUB APP GENE EXPRE; Law AKT, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-1; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; Lund LH, 2003, J GEN VIROL, V84, P603, DOI 10.1099/vir.0.18645-0; Mahal SP, 2001, GENE, V268, P105, DOI 10.1016/S0378-1119(01)00424-3; Maldonado TA, 2002, J NEUROBIOL, V53, P11, DOI 10.1002/neu.10086; Masliah E, 2001, NEUROCHEM INT, V39, P393, DOI 10.1016/S0197-0186(01)00046-8; Payton S, 2003, J MOL NEUROSCI, V20, P267, DOI 10.1385/JMN:20:3:267; Reese MG, 2001, COMPUT CHEM, V26, P51, DOI 10.1016/S0097-8485(01)00099-7; Reyes A, 2000, MOL BIOL EVOL, V17, P979, DOI 10.1093/oxfordjournals.molbev.a026379; Reyes A, 2000, GENE, V259, P177, DOI 10.1016/S0378-1119(00)00438-8; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Roberts AB, 2001, CHEST, V120, p43S, DOI 10.1378/chest.120.1_suppl.S43-a; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rogers JT, 2002, J MOL NEUROSCI, V19, P77, DOI 10.1007/s12031-002-0014-6; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; SCHOLLEN E, 1995, BIOCHEM BIOPH RES CO, V211, P115, DOI 10.1006/bbrc.1995.1785; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Song WH, 1998, GENE, V217, P151, DOI 10.1016/S0378-1119(98)00337-0; Tanaka M, 2001, MOL BRAIN RES, V91, P81, DOI 10.1016/S0169-328X(01)00125-5; Tashiro H, 1998, NEUROPATH APPL NEURO, V24, P284, DOI 10.1046/j.1365-2990.1998.00117.x; Tian F, 2003, CANCER RES, V63, P8284; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; Watanabe H, 2004, NATURE, V429, P382, DOI 10.1038/nature02564; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Yanagisawa M, 2001, FEBS LETT, V489, P139, DOI 10.1016/S0014-5793(01)02095-6; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	66	41	42	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1288	+		10.1096/fj.03-1703fje	http://dx.doi.org/10.1096/fj.03-1703fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208260				2022-12-28	WOS:000222327500002
J	Chen, G; Bower, KA; Ma, CL; Fang, SY; Thiele, CJ; Luo, J				Chen, G; Bower, KA; Ma, CL; Fang, SY; Thiele, CJ; Luo, J			Glycogen synthase kinase 3 beta (GSK3 beta) mediates 6-hydroxydopamine-induced neuronal death	FASEB JOURNAL			English	Article						apoptosis; caspases; endoplasmic reticulum stress; neurodegeneration; neurotrophins	ENDOPLASMIC-RETICULUM STRESS; CEREBELLAR GRANULE NEURONS; UNFOLDED PROTEIN RESPONSE; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; INDUCED APOPTOSIS; CELL-DEATH; PARKINSONIAN-PATIENTS; NEUROBLASTOMA-CELLS; TAU PHOSPHORYLATION	The causes of sporadic Parkinson's disease (PD) are poorly understood. 6-Hydroxydopamine (6-OHDA), a PD mimetic, is widely used to model this neurodegenerative disorder in vitro and in vivo; however, the underlying mechanisms remain incompletely elucidated. We demonstrate here that 6-OHDA evoked endoplasmic reticulum ( ER) stress, which was characterized by an up-regulation in the expression of GRP78 and GADD153 (Chop), cleavage of procaspase-12, and phosphorylation of eukaryotic initiation factor-2 alpha in a human dopaminergic neuronal cell line (SH-SY5Y) and cultured rat cerebellar granule neurons (CGNs). Glycogen synthase kinase-3 beta (GSK3beta) responds to ER stress, and its activity is regulated by phosphorylation. 6-OHDA significantly inhibited phosphorylation of GSK3beta at Ser9, whereas it induced hyperphosphorylation of Tyr216 with little effect on GSK3beta expression in SH-SY5Y cells and PC12 cells (a rat dopamine cell line), as well as CGNs. Furthermore, 6-OHDA decreased the expression of cyclin D1, a substrate of GSK3beta, and dephosphorylated Akt, the upstream signaling component of GSK3beta. Protein phosphatase 2A (PP2A), an ER stress-responsive phosphatase, was involved in 6-OHDA-induced GSK3beta dephosphorylation (Ser9). Blocking GSK3beta activity by selective inhibitors ( lithium, TDZD-8, and L803-mts) prevented 6-OHDA-induced cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP), DNA fragmentations and cell death. With a tetracycline (Tet)-controlled TrkB inducible system, we demonstrated that activation of TrkB in SH-SY5Y cells alleviated 6-OHDA-induced GSK3beta dephosphorylation (Ser9) and ameliorated 6-OHDA neurotoxicity. TrkB activation also protected CGNs against 6-OHDA-induced damage. Although antioxidants also offered neuroprotection, they had little effect on 6-OHDA-induced GSK3beta activation. These results suggest that GSK3beta is a critical intermediate in pro-apoptotic signaling cascades that are associated with neurodegenerative diseases, thus providing a potential target site amenable to pharmacological intervention.	W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; Chinese Acad Sci, SIBS, Inst Nutr Sci, Shanghai, Peoples R China	West Virginia University; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.	jluo@hsc.wvu.edu	Fang, Shengyun/H-3802-2011; Luo, Jia/E-4674-2012	Luo, Jia/0000-0002-6968-3618; Fang, Shengyun/0000-0001-7280-5463	NCI NIH HHS [CA90385] Funding Source: Medline; NIAAA NIH HHS [AA12968] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA012968] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ANDREW R, 1993, NEUROCHEM RES, V18, P1175, DOI 10.1007/BF00978370; Benisty S, 1998, NEUROSCIENCE, V86, P813, DOI 10.1016/S0306-4522(98)00126-2; Betarbet R, 2002, BRAIN PATHOL, V12, P499; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; COHEN G, 1974, J BIOL CHEM, V249, P2447; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Dechant G, 2001, CELL TISSUE RES, V305, P229, DOI 10.1007/s004410100378; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIMATTEO Y, 2003, CURR DRUG TARGET CNS, V2, P95; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Elkon H, 2001, CELL MOL NEUROBIOL, V21, P771, DOI 10.1023/A:1015160323009; Foulstone EJ, 1999, NEUROSCI LETT, V264, P125, DOI 10.1016/S0304-3940(99)00166-4; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; FREI B, 1986, FEBS LETT, V198, P99, DOI 10.1016/0014-5793(86)81192-9; Glazner GW, 1998, J COMP NEUROL, V391, P42, DOI 10.1002/(SICI)1096-9861(19980202)391:1<42::AID-CNE4>3.0.CO;2-R; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hara H, 2003, MOL BRAIN RES, V119, P125, DOI 10.1016/j.molbrainres.2003.08.021; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Hetman M, 2000, J NEUROSCI, V20, P2567; Ho R, 2002, CANCER RES, V62, P6462; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Hou ST, 2001, J NEUROCHEM, V78, P287, DOI 10.1046/j.1471-4159.2001.00402.x; HYNES MA, 1994, J NEUROSCI RES, V37, P144, DOI 10.1002/jnr.490370118; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jaboin J, 2002, CANCER RES, V62, P6756; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Kim CJ, 1999, AM J PATHOL, V155, P1661, DOI 10.1016/S0002-9440(10)65481-8; Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Li Z, 2001, DEV BRAIN RES, V132, P47, DOI 10.1016/S0165-3806(01)00294-2; Lin SZ, 2003, LIFE SCI, V72, P1635, DOI 10.1016/S0024-3205(02)02442-6; Linert W, 1996, BBA-MOL BASIS DIS, V1316, P160, DOI 10.1016/0925-4439(96)00020-8; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Luo J, 2003, J BIOL CHEM, V278, P4542, DOI 10.1074/jbc.M208295200; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1108; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neff F, 2002, ANN NY ACAD SCI, V973, P70, DOI 10.1111/j.1749-6632.2002.tb04608.x; Nishio T, 1998, NEUROREPORT, V9, P2847, DOI 10.1097/00001756-199808240-00030; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sarabi A, 2000, EXP NEUROL, V170, P283, DOI 10.1006/exnr.2001.7714; Shastry BS, 2002, DRUG TODAY, V38, P445, DOI 10.1358/dot.2002.38.6.678351; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Storch A, 2000, J NEUROCHEM, V75, P2259, DOI 10.1046/j.1471-4159.2000.0752259.x; Sun YB, 2002, J CELL PHYSIOL, V192, P225, DOI 10.1002/jcp.10132; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; Tsuboi K, 2000, BRAIN RES, V866, P55, DOI 10.1016/S0006-8993(00)02219-8; Ugarte SD, 2003, J NEUROSCI RES, V73, P105, DOI 10.1002/jnr.10632; Volpe BT, 1998, NEUROSCIENCE, V83, P741, DOI 10.1016/S0306-4522(97)00424-7; von Coelln R, 2001, J NEUROCHEM, V77, P263, DOI 10.1046/j.1471-4159.2001.t01-1-00236.x; Warner TT, 2003, ANN NEUROL, V53, pS16, DOI 10.1002/ana.10487; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; YOUDIM MBH, 1993, J NEURAL TRANSM-GEN, P57	85	257	274	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1162	+		10.1096/fj.04-1551fje	http://dx.doi.org/10.1096/fj.04-1551fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132987				2022-12-28	WOS:000221883200022
J	Corry, DB; Kiss, A; Song, LZ; Song, L; Xu, J; Lee, SH; Werb, Z; Kheradmand, F				Corry, DB; Kiss, A; Song, LZ; Song, L; Xu, J; Lee, SH; Werb, Z; Kheradmand, F			Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines	FASEB JOURNAL			English	Article						chemotaxis; cytokines; gelatinase B; matrix metalloproteinase-9	BRONCHIAL EPITHELIAL-CELLS; MATRIX METALLOPROTEINASES; AIRWAY HYPERREACTIVITY; ADAPTIVE IMMUNITY; GELATINASE B; MURINE MODEL; IN-VIVO; ASTHMA; MICE; EOSINOPHILS	The mechanisms that initiate allergic lung inflammation are relevant to expression of diseases such as asthma, but the factors underlying resolution of inflammation are equally important. Previously, we demonstrated the importance of matrix metalloproteinase 2 (MMP2) for airway egression of lung eosinophils, a critical anti-inflammatory mechanism without which mice are rendered highly susceptible to lethal asphyxiation. Here we show that leukocyte MMP9 is the dominant airway MMP controlling inflammatory cell egression. The allergic lung phenotype of MMP9(-/-) mice was similar to WT and was not altered by concomitant deletion of the MMP2 gene ( double knockout; dko). However, inflammatory cells accumulated aberrantly in the lungs of allergen-challenged MMP9(-/-) and dko mice and fewer eosinophils and neutrophils were present in bronchoalveolar lavage. These aberrant cellular trafficking patterns were explained by disruption of transepithelial chemokine gradients, in MMP2(-/-) mice affecting only eotaxin (CCL11), but in MMP9(-/-) and dko mice involving eotaxin, MARC (CCL7), and TARC (CCL17). Thus, by establishing multiple transepithelial chemokine gradients, MMP9 is broadly implicated in the resolution of allergic inflammation, an essential protective mechanism that overlaps with a more limited role played by MMP2.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Pulm & Crit Care Med Sect, Houston, TX 77030 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Francisco	Kheradmand, F (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza Suite 520B, Houston, TX 77030 USA.	farrahk@bcm.tmc.edu	Lee, Seung-Hyo/B-9922-2015	Lee, Seung-Hyo/0000-0003-0010-4072	NHLBI NIH HHS [R01 HL069585, HL 69585, K02 HL072062, HL 72419, K02 HL 72062, R01 HL072419] Funding Source: Medline; NIAID NIH HHS [AI 53194, P01 AI053194-050004, P01 AI053194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL072062, R01HL072419, R01HL069585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Betsuyaku T, 1999, AM J RESP CELL MOL, V20, P1303, DOI 10.1165/ajrcmb.20.6.3558; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Cataldo D, 2000, INT ARCH ALLERGY IMM, V123, P259, DOI 10.1159/000024452; Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1999, CURR OPIN IMMUNOL, V11, P610, DOI 10.1016/S0952-7915(99)00025-4; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; DUBOIS GR, 1994, ANN NY ACAD SCI, V725, P268, DOI 10.1111/j.1749-6632.1994.tb39809.x; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; Geske FJ, 2002, INT J HEMATOL, V76, P16, DOI 10.1007/BF02982714; GLEICH GJ, 1993, AGENT ACTION SUPPL, V43, P223; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hozumi A, 2001, AM J PHYSIOL-LUNG C, V281, pL1444, DOI 10.1152/ajplung.2001.281.6.L1444; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kheradmand F, 2002, J CELL SCI, V115, P839; KORENAGA M, 1994, INT J PARASITOL, V24, P951, DOI 10.1016/0020-7519(94)90159-7; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lee KS, 2003, J ALLERGY CLIN IMMUN, V111, P1278, DOI 10.1067/mai.2003.1501; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9; Luster AD, 2001, GASTROENTEROLOGY, V120, P291, DOI 10.1053/gast.2001.21403; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; McGuire JK, 2003, AM J PATHOL, V162, P1831, DOI 10.1016/S0002-9440(10)64318-0; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SMITH H, 1992, CLIN EXP ALLERGY, V22, P187, DOI 10.1111/j.1365-2222.1992.tb03072.x; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sweet David G, 2002, Paediatr Respir Rev, V3, P140, DOI 10.1016/S1526-0550(02)00010-0; Vermaelen KY, 2003, J IMMUNOL, V171, P1016, DOI 10.4049/jimmunol.171.2.1016; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang M, 1999, P NATL ACAD SCI USA, V96, P6885, DOI 10.1073/pnas.96.12.6885; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yao PM, 1998, AM J RESP CELL MOL, V18, P813, DOI 10.1165/ajrcmb.18.6.2984	56	160	166	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					995	+		10.1096/fj.03-1412fje	http://dx.doi.org/10.1096/fj.03-1412fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059974	Green Accepted			2022-12-28	WOS:000221108800025
J	D'Alessandris, C; Andreozzi, F; Federici, M; Cardellini, M; Brunetti, A; Ranalli, M; Del Guerra, S; Lauro, D; Del Prato, S; Marchetti, P; Lauro, R; Sesti, G				D'Alessandris, C; Andreozzi, F; Federici, M; Cardellini, M; Brunetti, A; Ranalli, M; Del Guerra, S; Lauro, D; Del Prato, S; Marchetti, P; Lauro, R; Sesti, G			Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells	FASEB JOURNAL			English	Article						glucose toxicity; hexosamine pathway; diabetes mellitus	HEXOSAMINE PATHWAY; INDUCE APOPTOSIS; SECRETION; RECEPTOR; GLUCOSE; POLYMORPHISM; SURVIVAL; ISLETS; RAT; DYSFUNCTION	Because adverse effects of glucose were attributed to its increased routing through the hexosamine pathway (HBP), we inquired whether HBP activation affects pancreatic beta-cell survival. Exposure of human islets to high glucose resulted in increased apoptosis of beta-cells upon serum deprivation that was reversed by azaserine. Also, glucosamine, a direct precursor of the downstream product of the HBP, increased human beta-cells apoptosis upon serum deprivation, which was reversed by benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside (BADGP), an inhibitor of protein O-glycosylation. These results were reproduced in RIN rat beta-cells. Glucosamine treatment resulted in inhibition of tyrosine-phosphorylation of the insulin receptor (IR), IRS-1, and IRS-2, which was associated with increased O-glycosylation. These changes caused impaired activation of the PI 3-kinase/Akt survival signaling that resulted in reduced GSK-3 and FOXO1a inactivation. BADGP reversed the glucosamine-induced reduction in insulin-stimulated phosphorylation of IR, IRS-1, IRS-2, Akt, GSK-3, and FOXO1a. Impaired FOXO1a inactivation sustained expression of the pro-apoptotic protein Bim, without affecting Bad, Bcl-XL, or Bcl-2 expression. These results indicate that hyperglycemia may increase susceptibility to apoptosis of human and rat beta-cell through activation of the HBP. Increased routing of glucose through this metabolic pathway results in impaired activation of the IR/IRSs/PI3-kinase/ Akt survival pathway by induction of O-glycosylation of signaling molecules.	Univ Magna Graecia di Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, Biochem Lab, IDI,IRCCS, Rome, Italy; Univ Pisa, Dept Endocrinol & Metab, Metab Unit, Pisa, Italy	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Pisa	Sesti, G (corresponding author), Univ Magna Graecia di Catanzaro, Dipartimento Med Sperimentale & Clin, Via Tommaso Campanella 115, I-88100 Catanzaro, Italy.	sesti@unicz.it	Sesti, Giorgio/B-1509-2012; Cardellini, Marina/AAC-1096-2019; Lauro, Davide/K-4683-2018; Marchetti, Piero/J-7439-2013; Federici, Massimo/G-9940-2012; Brunetti, Antonio/K-7756-2016; Del Prato, Stefano/K-3405-2016; Del+Prato, Stefano/AAC-9197-2021; Andreozzi, Francesco/J-4073-2018	Marchetti, Piero/0000-0003-4907-0635; Federici, Massimo/0000-0003-4989-5194; Del Prato, Stefano/0000-0002-5388-0270; Sesti, Giorgio/0000-0002-1618-7688; Lauro, Davide/0000-0002-8597-4415; Brunetti, Antonio/0000-0003-1533-8779; Andreozzi, Francesco/0000-0001-9375-1513	Telethon [E.1309] Funding Source: Medline	Telethon(Fondazione Telethon)		Aikawa R, 2000, CIRCULATION, V102, P2873; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Borboni P, 1999, ENDOCRINOLOGY, V140, P5530, DOI 10.1210/en.140.12.5530; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; Federici M, 2001, FASEB J, V15, P22; Federici M, 1999, DIABETES, V48, P2277, DOI 10.2337/diabetes.48.12.2277; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUPTA R, IDENTIFYING INTRACEL; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; Hennige AM, 2002, BIOCHEM BIOPH RES CO, V290, P85, DOI 10.1006/bbrc.2001.6144; Hribal ML, 2003, FASEB J, V17, P1340, DOI 10.1096/fj.02-0685fje; James LR, 2002, DIABETES, V51, P1146, DOI 10.2337/diabetes.51.4.1146; KAHN CR, 1995, NATURE, V373, P384; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Konrad RJ, 2002, INT J MOL MED, V10, P535; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Sesti G, 2002, ANN MED, V34, P444, DOI 10.1080/078538902321012397; Sesti G, 2003, DIABETES, V52, P1280, DOI 10.2337/diabetes.52.5.1280; Shankar RR, 1998, METABOLISM, V47, P573, DOI 10.1016/S0026-0495(98)90242-6; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	47	71	73	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					959	+		10.1096/fj.03-0725fje	http://dx.doi.org/10.1096/fj.03-0725fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059979				2022-12-28	WOS:000221108800030
J	Smith, J; Kontermann, RE; Embleton, J; Kumar, S				Smith, J; Kontermann, RE; Embleton, J; Kumar, S			Antibody phage display technologies with special reference to angiogenesis	FASEB JOURNAL			English	Review						vasculogenesis; angiogenic therapy; vascular targeting; VEGF; CD105	SINGLE-CHAIN FV; HUMANIZED MONOCLONAL-ANTIBODY; ENDOTHELIAL GROWTH-FACTOR; ED-B DOMAIN; TARGETED DELIVERY; TISSUE FACTOR; THERAPEUTIC ANGIOGENESIS; TUMOR NEOVASCULATURE; RHEUMATOID-ARTHRITIS; CELL-PROLIFERATION	The presence of blood vessels is a prerequisite for normal development, tissue growth, and tissue repair. However, its abnormal occurrence or absence can also potentiate disease processes. Angiogenic therapies have been used to stimulate blood vessel growth in ischemic conditions such as severe end-stage peripheral vascular disease, ischemic heart disease and stroke and for inhibition of angiogenesis in tumors. The targeting and identification of novel endothelial cell (EC) markers that can ultimately be used in angiogenic strategies is an expanding field but is limited by the availability of reagents. For instance repeated injection of mouse monoclonal antibodies (Mabs) against angiogenic EC, can result in the production of autoantibodies. Therefore, these mouse Mabs cannot be used for therapeutic purposes. Phage display technology was employed in this context to select antibodies, proteins, and peptides against known or novel EC antigens. Furthermore, technologies have been developed that enable the specific targeting of epitopes on cells including the endothelium with high-affinity/ avidity antibodies. The focus for these antibody targeting strategies are markers that are unique or up-regulated on angiogenic EC including the vascular endothelial growth factor receptor (VEGFR) KDR, endoglin (CD105), and the extracellular domain B (ED-B) domain of fibronectin (IN). These markers are reviewed herein.	Univ Manchester, Manchester M13 9PT, Lancs, England; Vectron Therapeut AG, Marburg, Germany; Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital	Smith, J (corresponding author), Univ Manchester, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Jusmith@fs1.scg.man.ac.uk	Kontermann, Roland E./F-9263-2014					Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; Adams GP, 1998, IN VIVO, V12, P11; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Atwell JL, 1999, PROTEIN ENG, V12, P597, DOI 10.1093/protein/12.7.597; Azzazy HME, 2002, CLIN BIOCHEM, V35, P425, DOI 10.1016/S0009-9120(02)00343-0; Ballara SC, 1999, INT J EXP PATHOL, V80, P235, DOI 10.1046/j.1365-2613.1999.00129.x; Balza E, 2001, INT J CANCER, V94, P579, DOI 10.1002/ijc.1505; Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679; Borsi L, 2003, BLOOD, V102, P4384, DOI 10.1182/blood-2003-04-1039; Bredow S, 2000, EUR J CANCER, V36, P675, DOI 10.1016/S0959-8049(99)00335-4; Brekke OH, 2003, CURR OPIN PHARMACOL, V3, P544, DOI 10.1016/j.coph.2003.05.002; Brekken RA, 2002, INT J CANCER, V100, P123, DOI 10.1002/ijc.10462; Brocks B, 2001, MOL MED, V7, P461, DOI 10.1007/BF03401851; Brown KC, 2000, CURR OPIN CHEM BIOL, V4, P16, DOI 10.1016/S1367-5931(99)00045-9; Cai MQ, 2003, BIOCHEM BIOPH RES CO, V309, P946, DOI 10.1016/j.bbrc.2003.08.086; Cai XH, 1997, P NATL ACAD SCI USA, V94, P9261, DOI 10.1073/pnas.94.17.9261; CAI XH, 1995, P NATL ACAD SCI USA, V92, P6537, DOI 10.1073/pnas.92.14.6537; Cao YH, 2004, SEMIN CANCER BIOL, V14, P139, DOI 10.1016/j.semcancer.2003.09.018; Carlsson R, 2001, Expert Rev Mol Diagn, V1, P102, DOI 10.1586/14737159.1.1.102; Carnemolla B, 2002, BLOOD, V99, P1659, DOI 10.1182/blood.V99.5.1659; Carnemolla B, 1999, AM J PATHOL, V154, P1345, DOI 10.1016/S0002-9440(10)65388-6; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Cooke SP, 2001, CANCER RES, V61, P3653; Costello B, 2004, INT J CANCER, V109, P436, DOI 10.1002/ijc.11699; de Haard H, 1998, ADV DRUG DELIVER REV, V31, P5, DOI 10.1016/S0169-409X(97)00091-4; Demartis S, 2001, EUR J NUCL MED, V28, P534, DOI 10.1007/s002590100480; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Garrard Lisa J., 1992, Current Opinion in Biotechnology, V3, P474, DOI 10.1016/0958-1669(92)90074-S; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Halin C, 2002, NAT BIOTECHNOL, V20, P264, DOI 10.1038/nbt0302-264; Hall BL, 1998, IMMUNOTECHNOLOGY, V4, P127, DOI 10.1016/S1380-2933(98)00016-5; Hannum RS, 2001, MICROVASC RES, V61, P287, DOI 10.1006/mvre.2001.2302; Henry TD, 1999, BMJ-BRIT MED J, V318, P1536, DOI 10.1136/bmj.318.7197.1536; Holt L J, 2000, Nucleic Acids Res, V28, pE72, DOI 10.1093/nar/28.15.e72; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; HOOGENBOOM HR, 1992, IMMUNOL REV, V130, P41, DOI 10.1111/j.1600-065X.1992.tb01520.x; Hoogenboom HR, 1997, TRENDS BIOTECHNOL, V15, P62, DOI 10.1016/S0167-7799(97)84205-9; Hu JL, 2004, BIOCHEM PHARMACOL, V67, P1001, DOI 10.1016/j.bcp.2003.10.030; Huang SC, 1996, OBSTET GYNECOL, V87, P1019; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Hughes GC, 2004, ANN THORAC SURG, V77, P812, DOI 10.1016/j.athoracsur.2003.09.060; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Jung S, 1999, J MOL BIOL, V294, P163, DOI 10.1006/jmbi.1999.3196; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Kobayashi T, 2000, J SURG RES, V89, P189, DOI 10.1006/jsre.2000.5828; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Korn T, 2004, J IMMUNOTHER, V27, P99, DOI 10.1097/00002371-200403000-00003; Kupsch JM, 1999, CLIN CANCER RES, V5, P925; Lee LS, 1999, BIOCONJUGATE CHEM, V10, P973, DOI 10.1021/bc990076o; Lei Y, 2004, BASIC RES CARDIOL, V99, P121, DOI 10.1007/s00395-004-0447-x; Lekkerkerker A, 1999, J IMMUNOL METHODS, V231, P53, DOI 10.1016/S0022-1759(99)00140-4; Li LY, 2004, INT J RADIAT ONCOL, V58, P1215, DOI 10.1016/j.ijrobp.2003.10.057; Lode HN, 1999, P NATL ACAD SCI USA, V96, P1591, DOI 10.1073/pnas.96.4.1591; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Lu D, 2003, J BIOL CHEM, V278, P43496, DOI 10.1074/jbc.M307742200; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; Marty C, 2002, BRIT J CANCER, V87, P106, DOI 10.1038/sj.bjc.6600423; Maruta F, 2003, J DRUG TARGET, V11, P53, DOI 10.1080/1061186031000086063; MATTESON EL, 1995, ARTHRITIS RHEUM, V38, P1187, DOI 10.1002/art.1780380903; McDonald DM, 2002, CANCER RES, V62, P5381; Molema G, 1998, IMMUNOL TODAY, V19, P392, DOI 10.1016/S0167-5699(98)01314-0; Mutuberria R, 1999, J IMMUNOL METHODS, V231, P65, DOI 10.1016/S0022-1759(99)00141-6; Nettelbeck DM, 2001, MOL THER, V3, P882, DOI 10.1006/mthe.2001.0342; Nilsson F, 2001, CANCER RES, V61, P711; Persaud K, 2004, J CELL SCI, V117, P2745, DOI 10.1242/jcs.01138; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Ran S, 1998, CANCER RES, V58, P4646; Rippmann JF, 2000, BIOCHEM J, V349, P805, DOI 10.1042/bj3490805; Romanov VI, 2003, CURR CANCER DRUG TAR, V3, P119, DOI 10.2174/1568009033482010; Ruan B, 1998, PROTEIN SCI, V7, P2345, DOI 10.1002/pro.5560071111; Sanz L, 2002, GENE THER, V9, P1049, DOI 10.1038/sj.gt.3301725; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; Sieber V, 1998, NAT BIOTECHNOL, V16, P955, DOI 10.1038/nbt1098-955; Siegel DL, 2002, TRANSFUS CLIN BIOL, V9, P15, DOI 10.1016/S1246-7820(01)00210-5; Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73; SODERLIND E, 1995, GENE, V160, P269, DOI 10.1016/0378-1119(95)00200-P; Soderlind E, 1999, IMMUNOTECHNOLOGY, V4, P279; STEED DL, 1995, J VASC SURG, V21, P71, DOI 10.1016/S0741-5214(95)70245-8; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Thompson WD, 1999, J PATHOL, V187, P503, DOI 10.1002/(SICI)1096-9896(199904)187:5<503::AID-PATH279>3.0.CO;2-2; Trail PA, 1999, CURR OPIN IMMUNOL, V11, P584, DOI 10.1016/S0952-7915(99)00012-6; Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Vitaliti A, 2000, CANCER RES, V60, P4311; Viti F, 1999, CANCER RES, V59, P347; Viti F, 2002, CURR OPIN DRUG DISC, V5, P204; Volkel T, 2004, BBA-BIOMEMBRANES, V1663, P158, DOI 10.1016/S0005-2736(04)00085-9; Volkel T, 2004, BIOCHEM BIOPH RES CO, V317, P515, DOI 10.1016/j.bbrc.2004.03.074; Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506; Wilder RL, 2002, ANN RHEUM DIS, V61, P96, DOI 10.1136/ard.61.suppl_2.ii96; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Wuest T, 2001, J BIOTECHNOL, V92, P159, DOI 10.1016/S0168-1656(01)00355-8; Yau TM, 2004, J THORAC CARDIOV SUR, V127, P1180, DOI 10.1016/j.jtcvs.2003.09.052; Zwaginga JJ, 2003, CLIN EXP PHARMACOL P, V30, P900, DOI 10.1046/j.1440-1681.2003.03931.x; Zwick MB, 1998, CURR OPIN BIOTECH, V9, P427, DOI 10.1016/S0958-1669(98)80017-7	107	24	31	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					331	341		10.1096/fj.04-2863rev	http://dx.doi.org/10.1096/fj.04-2863rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746176				2022-12-28	WOS:000227901300033
J	Atherton, PJ; Babraj, JA; Smith, K; Singh, J; Rennie, MJ; Wackerhage, H				Atherton, PJ; Babraj, JA; Smith, K; Singh, J; Rennie, MJ; Wackerhage, H			Selective activation of AMPK-PGC-1 alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation	FASEB JOURNAL			English	Article						PKB(Akt); signal transduction; skeletal muscle	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; SKELETAL-MUSCLE; MAMMALIAN TARGET; MITOCHONDRIAL BIOGENESIS; ELONGATION-FACTOR-2 KINASE; EXERCISE; PHOSPHORYLATION; RAPAMYCIN; TRANSCRIPTION	Endurance training induces a partial fast-to-slow muscle phenotype transformation and mitochondrial biogenesis but no growth. In contrast, resistance training mainly stimulates muscle protein synthesis resulting in hypertrophy. The aim of this study was to identify signaling events that may mediate the specific adaptations to these types of exercise. Isolated rat muscles were electrically stimulated with either high frequency (HFS; 6x10 repetitions of 3 s-bursts at 100 Hz to mimic resistance training) or low frequency (LFS; 3 h at 10 Hz to mimic endurance training). HFS significantly increased myofibrillar and sarcoplasmic protein synthesis 3 h after stimulation 5.3- and 2.7-fold, respectively. LFS had no significant effect on protein synthesis 3 h after stimulation but increased UCP3 mRNA 11.7-fold, whereas HFS had no significant effect on UCP3 mRNA. Only LFS increased AMPK phosphorylation significantly at Thr172 by approximate to 2-fold and increased PGC-1 alpha protein to 1.3 times of control. LFS had no effect on PKB phosphorylation but reduced TSC2 phosphorylation at Thr1462 and deactivated translational regulators. In contrast, HFS acutely increased phosphorylation of PKB at Ser473 5.3-fold and the phosphorylation of TSC2, mTOR, GSK-3 beta at PKB-sensitive sites. HFS also caused a prolonged activation of the translational regulators p70 S6k, 4E-BP1, eIF-2B, and eEF2. These data suggest that a specific signaling response to LFS is a specific activation of the AMPK-PGC-1 alpha signaling pathway which may explain some endurance training adaptations. HFS selectively activates the PKB-TSC2-mTOR cascade causing a prolonged activation of translational regulators, which is consistent with increased protein synthesis and muscle growth. We term this behavior the "AMPK-PKB switch." We hypothesize that the AMPK-PKB switch is a mechanism that partially mediates specific adaptations to endurance and resistance training, respectively.	Univ Cent Lancashire, Dept Biol Sci, Preston PR1 2HE, Lancs, England; Univ Dundee, Sch Life Sci, Dundee, Scotland; Univ Nottingham, Clin Physiol Lab, Nottingham, England	University of Central Lancashire; University of Dundee; University of Nottingham	Singh, J (corresponding author), Univ Cent Lancashire, Dept Biol Sci, Preston PR1 2HE, Lancs, England.	jsingh3@uclan.ac.uk	Rennie, Michael J/B-1762-2008	Babraj, John/0000-0002-7427-7841; Smith, Ken/0000-0001-8971-6635	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049869] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 49869] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Baar Keith, 2000, Molecular Cell Biology Research Communications, V4, P76, DOI 10.1006/mcbr.2000.0257; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Bolster DR, 2003, J PHYSIOL-LONDON, V553, P213, DOI 10.1113/jphysiol.2003.047019; BONEN A, 1994, AM J PHYSIOL, V266, pE1, DOI 10.1152/ajpendo.1994.266.1.E1; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; CHENG SW, 2004, IN PRESS J BOIL CHEM; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Garlick PJ, 1997, BAILLIERE CLIN ENDOC, V11, P629, DOI 10.1016/S0950-351X(97)80910-X; Gautsch TA, 1998, AM J PHYSIOL-CELL PH, V274, pC406, DOI 10.1152/ajpcell.1998.274.2.C406; Hernandez JM, 2000, J APPL PHYSIOL, V88, P1142, DOI 10.1152/jappl.2000.88.3.1142; Higginson J, 2002, PFLUG ARCH EUR J PHY, V445, P437, DOI 10.1007/s00424-002-0939-1; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kubukeli ZN, 2002, SPORTS MED, V32, P489, DOI 10.2165/00007256-200232080-00002; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; MILLER RG, 1987, MUSCLE NERVE, V10, P810, DOI 10.1002/mus.880100906; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Nader GA, 2001, J APPL PHYSIOL, V90, P1936, DOI 10.1152/jappl.2001.90.5.1936; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Rennie MJ, 2004, ANNU REV PHYSIOL, V66, P799, DOI 10.1146/annurev.physiol.66.052102.134444; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Sakamoto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1081, DOI 10.1152/ajpendo.00228.2003; SAKAMOTO K, 2004, IN PRESS AM J PHYSIO; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SCHWENK WF, 1984, ANAL BIOCHEM, V141, P101; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Taylor PM, 1996, J EXP BIOL, V199, P923; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Tipton KD, 2001, INT J SPORT NUTR EXE, V11, P109, DOI 10.1123/ijsnem.11.1.109; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williamson DL, 2001, J APPL PHYSIOL, V91, P1955, DOI 10.1152/jappl.2001.91.5.1955; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Wretman C, 2001, J PHYSIOL-LONDON, V535, P155, DOI 10.1111/j.1469-7793.2001.00155.x; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang SY, 1996, J MUSCLE RES CELL M, V17, P487, DOI 10.1007/BF00123364; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	60	336	361	0	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					786	+		10.1096/fj.04-2179fje	http://dx.doi.org/10.1096/fj.04-2179fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15716393				2022-12-28	WOS:000227591900026
J	Wang, Q; Downey, GP; Abreu, M; Bajenova, E; Kapus, A; McCulloch, CA				Wang, Q; Downey, GP; Abreu, M; Bajenova, E; Kapus, A; McCulloch, CA			Mitochondrial function is a critical determinant of IL-1-induced ERK activation	FASEB JOURNAL			English	Article						Ca2+ signals; gingival fibroblasts; mitochondria	OPERATED CA2+ ENTRY; NF-KAPPA-B; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; CALCIUM; STORE; RECEPTOR; KINASE; INTERLEUKIN-1-BETA; FIBROBLASTS	Interleukin-1 (IL-1) is a potent, proinflammatory cytokine, but local environmental factors in inflamed sites or in sepsis may affect cell metabolism and energetics, including the amplitude and duration of IL-1-induced signals, thereby leading to loss of tissue homeostasis. Currently, the mechanisms by which disruption of cell energetics affects inflammatory signaling are incompletely understood. Here, we examined the impact of cell energetics and mitochondrial function on the regulation of IL-1-induced Ca2+ signals and ERK activation in human gingival fibroblasts, cells that are important targets for IL-1-induced destruction of extracellular matrix in inflamed connective tissues. In untreated cells, IL-1 induced a prolonged increase of free intracellular calcium, which was required for ERK activation. Inhibition of cellular energetics by selective depolarization of mitochondria blocked Ca2+ uptake and almost completely abolished IL-1-induced cytosolic Ca2+ signals and ERK activation. IL-1 caused rapid Ca2+ release from the endoplasmic reticulum ( ER), concomitant with mitochondrial Ca2+ uptake from ER and non-ER stores. Disruption of mitochondrial energetics abrogated IL-1 induced Ca2+ release from the ER but left other vital cellular functions intact. The negative effect of mitochondrial depolarization on ER release was bypassed by BAPTA/AM, indicating that mitochondrial Ca2+ buffering is the key mechanism in regulating ER release. Thus, in gingival fibroblasts, mitochondrial Ca2+ uptake is essential not only for shaping the kinetics and duration, but also the generation of, IL-1-induced Ca2+ signals. Consequently, mitochondria regulate key downstream effectors of IL-1, including MAP kinases.	Univ Toronto, CIHR Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Med, Div Respirol, Toronto, ON, Canada; Univ Hlth Network Res Inst, Toronto Gen Div, Res Inst, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Toronto Gen Hosp, Div Surg, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	McCulloch, CA (corresponding author), Univ Toronto, CIHR Grp Matrix Dynam, Room 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca		Downey, Gregory P/0000-0003-3253-5862				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Arora PD, 2001, J BIOL CHEM, V276, P14100, DOI 10.1074/jbc.M010298200; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Boyle DL, 1997, ARTHRITIS RHEUM, V40, P1772, DOI 10.1002/art.1780401008; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brealey David, 2003, Curr Infect Dis Rep, V5, P365, DOI 10.1007/s11908-003-0015-9; Camello C, 2002, CELL CALCIUM, V32, P355, DOI 10.1016/S0143416002001926; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; HONIG J, 1989, J PERIODONTAL RES, V24, P362, DOI 10.1111/j.1600-0765.1989.tb00883.x; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mogensen TH, 2003, J IMMUNOL, V170, P6224, DOI 10.4049/jimmunol.170.12.6224; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 2001, J CELL SCI, V114, P2223; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; RICHARDS D, 1988, ARCH ORAL BIOL, V33, P237, DOI 10.1016/0003-9969(88)90184-7; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Trollinger DR, 2000, BIOPHYS J, V79, P39, DOI 10.1016/S0006-3495(00)76272-2; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; Wang Q, 2003, FASEB J, V17, pA1072	40	12	12	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					837	+		10.1096/fj.04-2657fje	http://dx.doi.org/10.1096/fj.04-2657fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728661				2022-12-28	WOS:000227591900008
J	Parson, W; Kirchebner, R; Muhlmann, R; Renner, K; Kofler, A; Schmidt, S; Kofler, R				Parson, W; Kirchebner, R; Muhlmann, R; Renner, K; Kofler, A; Schmidt, S; Kofler, R			Cancer cell line identification by short tandem repeat profiling: power and limitations	FASEB JOURNAL			English	Article						DNA fingerprinting; leukemia cell line; glucocorticoid-induced apoptosis; genetic instability		Cancer cell lines are used worldwide in biological research, and data interpretation depends on unambiguous attribution of the respective cell line to its original source. Short-tandem-repeat (STR) profiling ( DNA fingerprinting) is the method of choice for this purpose; however, the genetic stability of cell lines under various experimental conditions is not well defined. We tested the effect of long-term culture, subcloning, and generation of drug-resistant subclones on fingerprinting profiles in four widely used leukemia cell lines. The DNA fingerprinting profile remained unaltered in two of them ( U937 and K562) throughout 12 months in culture, and the vast majority of subclones derived therefrom by limiting dilution after long-term culture revealed the same profile, indicating a high degree of stability and clonotypic homogeneity. In contrast, two other cell lines (CCRF-CEM and Jurkat) showed marked alterations in DNA fingerprinting profiles during long-term culture. Limiting dilution subcloning revealed extensive clonotypic heterogeneity with subclones differing in up to eight STR loci from the parental culture. Similar heterogeneity was observed in subclones generated by selection culture for drug resistance where DNA fingerprinting proved useful in identifying possible resistance mechanisms. Thus, common tissue culture procedures may dramatically affect the fingerprinting profile of certain cell lines and thus render definition of their origin difficult.	Med Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Med Univ Innsbruck, Inst Legal Med, A-6020 Innsbruck, Austria; Med Univ Innsbruck, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Kofler, R (corresponding author), Med Univ Innsbruck, Tyrolean Canc Res Inst, Innrain 66, A-6020 Innsbruck, Austria.	reinhard.kofler@uibk.ac.at	Renner, Kathrin/H-3211-2013; Parson, Walther/AAD-6845-2020	Parson, Walther/0000-0002-5692-2392; Renner, Kathrin/0000-0002-7116-1368				Geley S, 1996, CANCER RES, V56, P5033; Hillmann AG, 2000, CANCER RES, V60, P2056; Lee JY, 2002, CANCER GENET CYTOGEN, V137, P124, DOI 10.1016/S0165-4608(02)00565-4; Muller S, 2004, GENE CHROMOSOME CANC, V39, P59, DOI 10.1002/gcc.10301; STONE JF, 1995, MUTAT RES-DNAGING G, V338, P107, DOI 10.1016/0921-8734(95)00016-Y	5	97	100	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					434	+		10.1096/fj.04-3062fje	http://dx.doi.org/10.1096/fj.04-3062fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15637111				2022-12-28	WOS:000226576600031
J	Aavik, E; Mahapatra, A; Boldrick, J; Chen, X; Barry, C; DuToit, D; Sarwal, M; Hayry, P				Aavik, E; Mahapatra, A; Boldrick, J; Chen, X; Barry, C; DuToit, D; Sarwal, M; Hayry, P			Correlation between gene expression and morphological alterations in baboon carotid after balloon dilatation injury	FASEB JOURNAL			English	Article						balloon angioplasty; carotid arteries; genes	SMOOTH-MUSCLE-CELLS; CDNA ARRAY ANALYSIS; ABDOMINAL AORTIC-ANEURYSMS; RENAL-ALLOGRAFT REJECTION; DNA MICROARRAY; UP-REGULATION; ATHEROSCLEROSIS; PROLIFERATION; ANGIOPLASTY; APOPTOSIS	Treatment for fibroproliferative restenosis after angioplasty and endovascular surgery is an unmet medical need. Rational therapy and drug design still lack the very basic knowledge about the underlying biological processes leading to pathological changes in the vessel wall. We have developed a primate model for vascular response to denudation-overstretch injury of baboon carotid artery. With this model, we have investigated the time course of vascular expression of 41,000 human cDNA clones and correlated these changes with carotid histology and function. Analysis revealed 20,788 differentially regulated cDNA clones. After high stringency data selection, the most prominently regulated 1629 cDNA clones representing 1510 genes of known function were clustered. Genes corresponding to functional and anatomical alterations in the injured carotid wall were further aligned into functional groups according to Gene Ontology classification. The observed expression patterns faithfully reflected the functional and anatomical alterations observed in the vascular wall in response to injury. The analysis presents a tentative model for genomic response to balloon catheter injury and a road map to identify time-related genomic alterations in human vascular specimens.	Univ Helsinki, Transplantat Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum, Rat Drug Design Program, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat Transplantat, Stanford, CA 94305 USA; Univ Stellenbosch, Dept Surg, Cape Town, South Africa	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Stanford University; Stanford University; Stellenbosch University	Hayry, P (corresponding author), Univ Helsinki, Transplantat Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	pekka.hayry@helsinki.fi						Aavik E, 2002, FASEB J, V16, P724, DOI 10.1096/fj.01-0272fje; Absi TS, 2003, J THORAC CARDIOV SUR, V126, P344, DOI 10.1016/S0022-5223(02)73576-9; Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Archacki SR, 2003, PHYSIOL GENOMICS, V15, P65, DOI 10.1152/physiolgenomics.00181.2002; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Chua MS, 2003, PEDIATR NEPHROL, V18, P319, DOI 10.1007/s00467-003-1083-7; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Du Toit D, 2001, ANN MED, V33, P63, DOI 10.3109/07853890109002061; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Faber BCG, 2001, CIRC RES, V89, P547, DOI 10.1161/hh1801.096340; Geary RL, 2002, ARTERIOSCL THROM VAS, V22, P2010, DOI 10.1161/01.ATV.0000038147.93527.35; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grimm PC, 2001, NEW ENGL J MED, V345, P93, DOI 10.1056/NEJM200107123450203; Higgins JPT, 2004, MOL BIOL CELL, V15, P649, DOI 10.1091/mbc.E03-06-0432; Hilker M, 2003, EUR J CARDIO-THORAC, V23, P620, DOI 10.1016/S1010-7940(03)00017-4; Hiltunen MO, 2002, ATHEROSCLEROSIS, V165, P23, DOI 10.1016/S0021-9150(02)00187-9; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Malik N, 1998, CIRCULATION, V98, P1657, DOI 10.1161/01.CIR.98.16.1657; Martinet W, 2002, ARTERIOSCL THROM VAS, V22, P2023, DOI 10.1161/01.ATV.0000041843.44312.12; Muller BT, 2002, EUR J VASC ENDOVASC, V24, P356, DOI 10.1053/ejvs.2002.1731; Murray JI, 2004, MOL BIOL CELL, V15, P2361, DOI 10.1091/mbc.E03-11-0799; Myllarniemi M, 1997, FASEB J, V11, P1119, DOI 10.1096/fasebj.11.13.9367346; Napoli C, 2003, HEART, V89, P597, DOI 10.1136/heart.89.6.597; Neuville P, 2000, ARTERIOSCL THROM VAS, V20, P1882, DOI 10.1161/01.ATV.20.8.1882; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; Perlman H, 1997, CIRCULATION, V95, P981; Sarwal M, 2003, NEW ENGL J MED, V349, P125, DOI 10.1056/NEJMoa035588; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Thyberg J, 1997, J HISTOCHEM CYTOCHEM, V45, P837, DOI 10.1177/002215549704500608; Tung WS, 2001, J VASC SURG, V34, P143, DOI 10.1067/mva.2001.113310; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Wilcox JN, 2001, ANN NY ACAD SCI, V947, P68; Zohlnhofer D, 2001, CIRCULATION, V103, P1396, DOI 10.1161/01.CIR.103.10.1396	35	12	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					130	+		10.1096/fj.04-2225fje	http://dx.doi.org/10.1096/fj.04-2225fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15496494				2022-12-28	WOS:000224849900013
J	Puri, N; Eller, MS; Byers, HR; Dykstra, S; Kubera, J; Gilchrest, BA				Puri, N; Eller, MS; Byers, HR; Dykstra, S; Kubera, J; Gilchrest, BA			Telomere-based DNA damage responses: a new approach to melanoma	FASEB JOURNAL			English	Article						melanocyte; apoptosis; differentiation; p73; livin/ML-IAP	HUMAN OVARIAN-CANCER; TUMOR-INFILTRATING LYMPHOCYTES; THYMIDINE DINUCLEOTIDES; METASTATIC MELANOMA; CUTANEOUS MELANOMA; HUMAN MELANOCYTES; CELL-CYCLE; APOPTOSIS; MELANOGENESIS; EXPRESSION	Melanoma is the most fatal skin cancer, often highly resistant to chemotherapy. Here we show that treatment with an 11-base DNA oligonucleotide homologous to the telomere 3' overhang sequence (T-oligo) induces apoptosis of several established human melanoma cell lines, including the aggressive MM-AN line, whereas normal human melanocytes exposed to the same or higher T-oligo concentrations show only transient cell cycle arrest, implying that malignant cells are more sensitive to T-oligo effects. When MM-AN cells were briefly exposed to T-oligo in culture and injected into the flank or tail vein of SCID mice, eventual tumor volume and number of metastases were reduced 85-95% compared with control mice. Similarly, T-oligos administered intralesionally or systemically selectively inhibited the growth of previously established MM-AN tumor nodules in the flank and peritoneal cavity by 85 to 90% without detectable toxicity. We previously showed that T-oligos act through ATM, p95/Nbs1, E2F1, p16(INK4A), p53, and the p53 homologue p73 to modulate downstream effectors and now additionally demonstrate striking down-regulation of the inhibitor of apoptosis protein livin/ML-IAP. We suggest that T-oligo mimics a physiologic DNA damage signal that is frequently masked in malignant cells and thereby activates innate cancer prevention responses. T-oligos may provide a novel therapeutic approach to melanoma.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St,J Bldg, Boston, MA 02118 USA.	bgilchre@bu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR050110] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR050110-02] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agami R, 1999, NATURE, V399, P809; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; BYERS HR, 1993, MELANOMA RES, V3, P247; BYERS HR, 1991, AM J PATHOL, V139, P423; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; CHEN C, 1995, CANCER RES, V55, P4230; Couzin J, 2002, SCIENCE, V298, P522, DOI 10.1126/science.298.5593.522; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GILCHREST BA, 1984, J INVEST DERMATOL, V83, P370, DOI 10.1111/1523-1747.ep12264638; Glaessl A, 1999, ARCH DERMATOL RES, V291, P81, DOI 10.1007/s004030050387; Goukassian DA, 2002, FASEB J, V16, P754, DOI 10.1096/fj.01-0829fje; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Maeda T, 1999, MUTAT RES-DNA REPAIR, V433, P137, DOI 10.1016/S0921-8777(98)00071-8; Miracco C, 2000, INT J CANCER, V88, P411, DOI 10.1002/1097-0215(20001101)88:3<411::AID-IJC13>3.3.CO;2-G; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nonoyama S, 1996, Int Rev Immunol, V13, P289, DOI 10.3109/08830189609061753; PaineMurrieta GD, 1997, CANCER CHEMOTH PHARM, V40, P209, DOI 10.1007/s002800050648; Parris CN, 1999, BRIT J CANCER, V79, P47, DOI 10.1038/sj.bjc.6690010; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ramirez Ruben D., 1999, Neoplasia (New York), V1, P42, DOI 10.1038/sj.neo.7900004; RIVOLTINI L, 1995, J IMMUNOL, V154, P2257; Sasaki H, 2000, CANCER RES, V60, P5659; Slingluff CL, 2000, CANCER IMMUNOL IMMUN, V48, P661, DOI 10.1007/s002620050015; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Villa R, 2000, INT J ONCOL, V16, P995; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Yang P, 2000, INT J ONCOL, V17, P913; Zhang H, 2002, INT J ONCOL, V21, P43; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	56	69	74	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1373	1381		10.1096/fj.04-1774com	http://dx.doi.org/10.1096/fj.04-1774com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333580				2022-12-28	WOS:000224243200056
J	Sweeney, C; Morrow, D; Birney, YA; Coyle, S; Hennessy, C; Scheller, A; Cummins, PM; Walls, D; Redmond, EM; Cahill, PA				Sweeney, C; Morrow, D; Birney, YA; Coyle, S; Hennessy, C; Scheller, A; Cummins, PM; Walls, D; Redmond, EM; Cahill, PA			Notch 1 and 3 receptors modulate vascular smooth muscle cell growth, apoptosis and migration via a CBF-1/RBP-Jk dependent pathway	FASEB JOURNAL			English	Article						vascular disease; cell fate; developmental; phenotype; signaling	3 INTRACELLULAR DOMAIN; ENDOTHELIAL-CELLS; PULSE PRESSURE; RBP-J; NOTCH; DIFFERENTIATION; EXPRESSION; PROLIFERATION; ACTIVATION; RECEPTOR	Vascular smooth muscle cell (SMC) fate decisions ( cell growth, migration, and apoptosis) are fundamental features in the pathogenesis of vascular disease. We investigated the role of Notch 1 and 3 receptor signaling in controlling adult SMC fate in vitro by establishing that hairy enhancer of split (hes-1 and -5) and related hrt's (hrt-1, -2, and -3) are direct downstream target genes of Notch 1 and 3 receptors in SMC and identified an essential role for nuclear protein CBF-1/RBP-Jk in their regulation. Constitutive expression of active Notch 1 and 3 receptors (Notch IC) resulted in a significant up-regulation of CBF-1/RBP-Jk-dependent promoter activity and Notch target gene expression concomitant with significant increases in SMC growth while concurrently inhibiting SMC apoptosis and migration. Moreover, inhibition of endogenous Notch mediated CBF-1/RBP-Jk regulated gene expression with a non-DNA binding mutant of CBF-1, a Notch IC deleted of its delta RAM domain and the Epstein-Barr virus encoded RPMS-1, in conjunction with pharmacological inhibitors of Notch IC receptor trafficking ( brefeldin A and monensin), resulted in a significant decrease in cell growth while concomitantly increasing SMC apoptosis and migration. These findings suggest that endogenous Notch receptors and downstream target genes control vascular cell fate in vitro. Notch signaling, therefore, represents a novel therapeutic target for disease states in which changes in vascular cell fate occur in vivo.	Dublin City Univ, Fac Sci & Hlth, Vasc Hlth Res Ctr, Dublin 9, Ireland; Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; Dublin City Univ, Natl Ctr Sensor Res, Dublin 9, Ireland; Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA	Dublin City University; Dublin City University; Dublin City University; University of Rochester	Cahill, PA (corresponding author), Dublin City Univ, Fac Sci & Hlth, Vasc Hlth Res Ctr, Dublin 9, Ireland.	paul.cahill@dcu.ie	Cahill, Paul A/E-8061-2011	Cahill, Paul A/0000-0002-5385-6502; Redmond, Eileen M/0000-0001-8642-4418; Walls, Dermot/0000-0002-2244-2294	NHLBI NIH HHS [HL59696] Funding Source: Medline; NIAAA NIH HHS [AA-12610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059696, R29HL059696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABEDI H, 1995, CARDIOVASC RES, V30, P544, DOI 10.1016/0008-6363(95)00092-5; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bongarzone ER, 2000, J NEUROSCI RES, V62, P319, DOI 10.1002/1097-4547(20001101)62:3<319::AID-JNR1>3.0.CO;2-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHILL PA, 1991, BIOCHEM BIOPH RES CO, V179, P1606, DOI 10.1016/0006-291X(91)91758-5; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; Cappadona C, 1999, EXP CELL RES, V250, P174, DOI 10.1006/excr.1999.4502; D'Amore PA, 2002, CELL, V110, P289, DOI 10.1016/S0092-8674(02)00869-3; DELALUNA S, 1988, GENE, V62, P121; DICORLETO PE, 1993, AM J HYPERTENS, V6, pS314; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Favre CJ, 2003, AM J PHYSIOL-HEART C, V285, pH1917, DOI 10.1152/ajpheart.00983.2002; Ferguson JE, 2003, CELL CYCLE, V2, P211, DOI 10.4161/cc.2.3.366; Iso T, 2003, ARTERIOSCL THROM VAS, V23, P543, DOI 10.1161/01.ATV.0000060892.81529.8F; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kalaria RN, 2002, J NEURAL TRANSM-SUPP, P75; Kato H, 1997, DEVELOPMENT, V124, P4133; Kleinstreuer C, 2001, CRIT REV BIOMED ENG, V29, P1, DOI 10.1615/CritRevBiomedEng.v29.i1.10; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Majesky Mark W, 2003, Curr Atheroscler Rep, V5, P208, DOI 10.1007/s11883-003-0026-x; Manabe Ichiro, 2003, Curr Atheroscler Rep, V5, P214, DOI 10.1007/s11883-003-0027-9; Marchenko GN, 2003, BIOCHEM J, V372, P503, DOI 10.1042/BJ20030174; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Redmond EM, 2001, CIRCULATION, V103, P597, DOI 10.1161/01.CIR.103.4.597; Redmond EM, 1999, THROMB HAEMOSTASIS, V81, P293; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Sakai T, 1998, J VIROL, V72, P6034, DOI 10.1128/JVI.72.7.6034-6039.1998; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwartz Robert S, 2002, Rev Cardiovasc Med, V3 Suppl 5, pS4; Shawber C, 1996, DEVELOPMENT, V122, P3765; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Smith P, 2001, SEMIN CANCER BIOL, V11, P469, DOI 10.1006/scbi.2001.0414; Smith PR, 2000, J VIROL, V74, P3082, DOI 10.1128/JVI.74.7.3082-3092.2000; Sullivan DD, 2003, BRIT J CANCER, V89, P228, DOI 10.1038/sj.bjc.6601107; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Wang WL, 2003, BIOCHEM BIOPH RES CO, V308, P596, DOI 10.1016/S0006-291X(03)01453-0; Wang WL, 2002, J BIOL CHEM, V277, P23165, DOI 10.1074/jbc.M201409200; Weinstein BM, 2002, COLD SPRING HARB SYM, V67, P155, DOI 10.1101/sqb.2002.67.155; Zhang JX, 2001, J VIROL, V75, P2946, DOI 10.1128/JVI.75.6.2946-2956.2001; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	57	116	123	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1421	+		10.1096/fj.04-1700fje	http://dx.doi.org/10.1096/fj.04-1700fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247148				2022-12-28	WOS:000222979200005
J	Watt, MJ; Steinberg, GR; Chan, S; Garnham, A; Kemp, BE; Febbraio, MA				Watt, MJ; Steinberg, GR; Chan, S; Garnham, A; Kemp, BE; Febbraio, MA			beta-adrenergic stimulation of skeletal muscle HSL can be overridden by AMPK signaling	FASEB JOURNAL			English	Article						intramuscular triacylglycerol; exercise; lipolysis	HORMONE-SENSITIVE LIPASE; ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; FATTY-ACID OXIDATION; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; EXERCISE INTENSITY; RAT; TRIACYLGLYCEROL; ADRENALINE; GLYCOGEN	Hormone-sensitive lipase (HSL), an important regulatory enzyme for triacylglycerol hydrolysis within skeletal muscle, is controlled by beta-adrenergic signaling as well as intrinsic factors related to contraction and energy turnover. In the current study, we tested the capacity of 5' AMP-activated protein kinase ( AMPK) to suppress beta-adrenergic stimulation of HSL activity. Eight male subjects completed 60 min of cycle exercise at 70% VO2 peak on two occasions: either with normal ( CON) or low (LG) pre-exercise muscle glycogen content, which is known to enhance exercise-induced AMPK activity. Muscle samples were obtained before and immediately after exercise. Pre-exercise glycogen averaged 375 +/- 35 and 163 +/- 27 mmol.kg(-1) dm for CON and LG, respectively. AMPK alpha-2 was not different between trials at rest and was increased (3.7-fold, P<0.05) by exercise during LG only. HSL activity did not differ between trials at rest and increased (0 min: 1.67 +/- 0.13; 60 min: 2.60 +/- 0.26 mmol.min(-1).kg(-1) dm) in CON. The exercise-induced increase in HSL activity was attenuated by AMPK a-2 activation in LG. The attenuated HSL activity during LG occurred despite higher plasma epinephrine levels (60 min: CON, 1.96 +/- 0.29 vs LG, 4.25 +/- 0.60 nM, P<0.05) compared with CON. Despite the attenuated HSL activity in LG, IMTG was decreased by exercise (0 min: 27.1 +/- 2.0; 60 min: 22.5 +/- 2.0 mmol.kg(-1) dm, P<0.05), whereas no net reduction occurred in CON. To confirm the apparent effect of AMPK on HSL activity, we performed experiments in muscle cell culture. The epineprine-induced increase in HSL activity was totally attenuated (P<0.05) by AICAR administration in L6 myotubes. These data provide new evidence indicating that AMPK is a major regulator of skeletal muscle HSL activity that can override alpha-adrenergic stimulation. However, the increased IMTG degradation in LG suggests factors other than HSL activity are important for IMTG degradation.	RMIT Univ, Sch Med Sci, Skeletal Muscle Res Lab, Bundoora, Vic, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Deakin Univ, Sch Hlth Sci, Burwood, Australia	Royal Melbourne Institute of Technology (RMIT); St. Vincent's Institute of Medical Research; Deakin University	Watt, MJ (corresponding author), RMIT Univ, Sch Med Sci, Skeletal Muscle Res Lab, POB 71, Bundoora, Vic 3083, Australia.	matthew.watt@rmit.edu.au	Kemp, Bruce E/L-2633-2014; Watt, Matthew J/B-2089-2014; Kemp, Bruce/G-9602-2019; Febbraio, Mark/AAE-9632-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Febbraio, Mark/0000-0002-9296-4418; Steinberg, Gregory/0000-0001-5425-8275; Chan, Stanley/0000-0002-4103-9441				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; Dean D, 2000, DIABETES, V49, P1295, DOI 10.2337/diabetes.49.8.1295; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; Donsmark M, 2003, J PHYSIOL-LONDON, V550, P845, DOI 10.1113/jphysiol.2003.042333; FRAYN KN, 1980, J LIPID RES, V21, P139; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Guo ZK, 2000, J APPL PHYSIOL, V89, P2057, DOI 10.1152/jappl.2000.89.5.2057; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HARRIS RC, 1974, SCAND J CLIN LAB INV, V33, P109; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Kawanaka K, 2000, AM J PHYSIOL-ENDOC M, V279, pE1311, DOI 10.1152/ajpendo.2000.279.6.E1311; Kelley DE, 2002, ANNU REV NUTR, V22, P325, DOI 10.1146/annurev.nutr.22.010402.102912; Kjaer M, 2000, J PHYSIOL-LONDON, V528, P371, DOI 10.1111/j.1469-7793.2000.00371.x; Langfort J, 2000, BIOCHEM J, V351, P207, DOI 10.1042/0264-6021:3510207; Langfort J, 2003, ACTA PHYSIOL SCAND, V178, P51, DOI 10.1046/j.1365-201X.2003.01111.x; Langfort J, 1999, BIOCHEM J, V340, P459, DOI 10.1042/0264-6021:3400459; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; PERONNET F, 1991, CAN J SPORT SCI, V16, P23; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Watt MJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE412, DOI 10.1152/ajpendo.00023.2003; Watt MJ, 2003, J PHYSIOL-LONDON, V547, P301, DOI 10.1113/jphysiol.2002.034595; Watt MJ, 2003, J APPL PHYSIOL, V95, P314, DOI 10.1152/japplphysiol.01181.2002; Watt MJ, 2002, J APPL PHYSIOL, V93, P1185, DOI 10.1152/japplphysiol.00197.2002; Watt MJ, 2003, J PHYSIOL-LONDON, V550, P325, DOI 10.1113/jphysiol.2003.043133; WOJTASZEWSKI JF, BIOCH BIOPHYS RES CO, V298, P309; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Wojtaszewski JFP, 2000, J PHYSIOL-LONDON, V528, P221, DOI 10.1111/j.1469-7793.2000.t01-1-00221.x	38	65	69	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1445	+		10.1096/fj.03-1067fje	http://dx.doi.org/10.1096/fj.03-1067fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231718				2022-12-28	WOS:000222979200028
J	Clarkson, AN; Liu, HZ; Pearson, L; Kapoor, M; Harrison, JC; Sammut, IA; Jackson, DM; Appleton, I				Clarkson, AN; Liu, HZ; Pearson, L; Kapoor, M; Harrison, JC; Sammut, IA; Jackson, DM; Appleton, I			Neuroprotective effects of spermine following hypoxia-ischemia-induced brain damage: A mechanistic study	FASEB JOURNAL			English	Article						polyamines; arginase activity; nitric oxide synthase	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; ORNITHINE-DECARBOXYLASE ACTIVITY; MITOCHONDRIAL RESPIRATORY-CHAIN; RAT-BRAIN; HIPPOCAMPAL SLICES; CELL-DEATH; ELECTRICAL RECOVERY; NADH FLUORESCENCE	The polyamines (spermine, putrescine, and spermidine) can have neurotoxic or neuroprotective properties in models of neurodegeneration. However, assessment in a model of hypoxia ischemia (HI) has not been defined. Furthermore, the putative mechanisms of neuroprotection have not been elucidated. Therefore, the present study examined the effects of the polyamines in a rat pup model of HI and determined effects on key enzymes involved in inflammation, namely, nitric oxide synthase (NOS) and arginase. In addition, effects on mitochondrial function were investigated. The polyamines or saline were administered i.p. at 10mg/kg/day for 6 days post-HI. Histological assessment 7 days post-HI revealed that only spermine significantly ( P<0.01) reduced infarct size from 46.14 +/- 10.4mm(3) ( HI + saline) to 4.9 +/- 2.7 mm(3). NOS activity was significantly increased following spermine treatment in the left (ligated) hemisphere compared with nonintervention controls (P< 0.01) and HI + saline (P< 0.05). In contrast, spermine decreased arginase activity compared with HI + saline but was still significantly elevated in comparison to nonintervention controls ( P< 0.01). Assessment of mitochondrial function in the HI + saline group, revealed significant and extensive damage to complex-I ( P< 0.01) and IV (P< 0.001) and loss of citrate synthase activity (P< 0.05). No effect on complex II-III was observed. Spermine treatment significantly prevented all these effects. This study has therefore confirmed the neuroprotective effects of spermine in vivo. However, for the first time, we have shown that this effect may, in part, be due to increased NOS activity and preservation of mitochondrial function.	Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand	University of Otago	Appleton, I (corresponding author), Univ Otago, Dept Pharmacol & Toxicol, POB 913, Dunedin, New Zealand.	ian.appleton@stonebow.otago.ac.nz		Clarkson, Andrew/0000-0003-3804-3834; Sammut, Ivan/0000-0002-9217-9452; Harrison, Joanne/0000-0002-2431-4480				ABE K, 1993, BRAIN RES, V605, P322, DOI 10.1016/0006-8993(93)91759-L; ALMEIDA A, 1995, J NEUROCHEM, V65, P1698; Baskaya MK, 1997, BRAIN RES, V744, P302; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Brown GC, 2002, FREE RADICAL BIO MED, V33, P1440, DOI 10.1016/S0891-5849(02)01112-7; Coert BA, 2000, NEUROSCI LETT, V282, P5, DOI 10.1016/S0304-3940(00)00856-9; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; FARBISZEWSKI R, 1995, ACTA NEUROBIOL EXP, V55, P254; Ferchmin PA, 2000, BRAIN RES, V859, P273, DOI 10.1016/S0006-8993(00)01973-9; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; GUTTERIDGE JMC, 1990, ARCH BIOCHEM BIOPHYS, V283, P223, DOI 10.1016/0003-9861(90)90635-C; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Henley CM, 1997, J NEUROCHEM, V69, P259; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; HUANG Z, 1996, J CEREB BLOOD FLOW M, V15, P378; Iadecola C, 1997, J NEUROSCI, V17, P9157; JENSEN JR, 1987, J NEUROCHEM, V48, P765, DOI 10.1111/j.1471-4159.1987.tb05583.x; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KOENIG H, 1990, STROKE, V21, P98; LAPIDUS RG, 1992, FEBS LETT, V313, P314, DOI 10.1016/0014-5793(92)81217-A; LEE JA, 1992, CIRC RES, V71, P58, DOI 10.1161/01.RES.71.1.58; LENZEN S, 1992, BIOCHEM J, V286, P597, DOI 10.1042/bj2860597; Maccarrone M, 2001, FEBS LETT, V507, P30, DOI 10.1016/S0014-5793(01)02949-0; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; MUNIR M, 1993, BRAIN RES, V616, P163, DOI 10.1016/0006-8993(93)90205-2; NEGARDT C, 2003, CELL BIOL INT, V27, P115; OHMORI S, 1988, RES COMMUN CHEM PATH, V62, P235; PASCHEN W, 1991, BRAIN RES, V566, P354, DOI 10.1016/0006-8993(91)91726-H; PASCHEN W, 1992, NEUROSCI LETT, V135, P121, DOI 10.1016/0304-3940(92)90150-6; PASCHEN W, 1991, J CEREB BLOOD FLO S2, V11, P59; PEGG AE, 1982, AM J PHYSIOL, V243, P212; Perez-Pinzon MA, 1998, BRAIN RES, V786, P165, DOI 10.1016/S0006-8993(97)01438-8; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; PHILLIPS JE, 1982, BIOCHEM BIOPH RES CO, V108, P174, DOI 10.1016/0006-291X(82)91847-2; RADI R, 1991, J BIOL CHEM, V266, P4244; Rao AM, 2000, J NEUROCHEM, V74, P1106; RAO AM, 1995, J NEUROCHEM, V65, P2639; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Rossignol F, 2003, J CELL BIOCHEM, V89, P67, DOI 10.1002/jcb.10484; Sammut IA, 2001, AM J PATHOL, V158, P1821, DOI 10.1016/S0002-9440(10)64138-7; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SILVERSTEIN FS, 1986, J NEUROCHEM, V47, P1614, DOI 10.1111/j.1471-4159.1986.tb00803.x; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SOUSSI B, 1990, ACTA PHYSIOL SCAND, V138, P107, DOI 10.1111/j.1748-1716.1990.tb08822.x; Stefanelli C, 1999, FEBS LETT, V451, P95, DOI 10.1016/S0014-5793(99)00549-9; Stefanelli C, 1998, FEBS LETT, V437, P233, DOI 10.1016/S0014-5793(98)01239-3; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TADOLINI B, 1988, BIOCHEM J, V249, P33, DOI 10.1042/bj2490033; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22	61	58	61	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1114	+		10.1096/fj.03-1203fje	http://dx.doi.org/10.1096/fj.03-1203fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132986				2022-12-28	WOS:000221883200021
J	Garnier, A; Fortin, D; Zoll, J; N'Guessan, B; Mettauer, B; Lampert, E; Veksler, V; Ventura-Clapier, R				Garnier, A; Fortin, D; Zoll, J; N'Guessan, B; Mettauer, B; Lampert, E; Veksler, V; Ventura-Clapier, R			Coordinated changes in mitochondrial function and biogenesis in healthy and diseased human skeletal muscle	FASEB JOURNAL			English	Article						endurance training; heart failure; mitochondrial function; mitochondrial biogenesis	CHRONIC HEART-FAILURE; GAMMA COACTIVATOR-1-ALPHA EXPRESSION; TRANSCRIPTION FACTOR-A; OXIDATIVE CAPACITY; CONTRACTILE ACTIVITY; MAMMALIAN-CELLS; EXERCISE TOLERANCE; FIBER-TYPE; PGC-1-ALPHA; PROTEIN	We examined the transcriptional signaling cascade involved in the changes of mitochondrial biogenesis and mitochondrial function of skeletal muscle and of the exercise capacity of humans in response to long-term physical activity and chronic heart failure (CHF). Biopsy samples of vastus lateralis muscle were obtained from 18 healthy subjects with different fitness levels ( assessed by maximal oxygen uptake, VO2 peak). We compared 9 sedentary subjects with 10 CHF patients undergoing transplantation. Muscle oxidative capacity was measured in permeabilized fibers (Vmax). Transcript levels of target genes were quantified by RT-PCR. In healthy subjects, VO2 peak was linearly related to Vmax (P< 0.01) and to the gene expression of mitochondrial proteins and of the coactivator PGC-1 alpha and its downstream transcription factors. A coordinate increase in PGC-1 alpha and mRNA levels of proteins nvolved in degradation, fusion, and fission of mitochondria was observed associated with calcineurin activation. Despite decreased VO2 peak, in CHF patients skeletal muscles showed preserved Vmax in accordance with preserved markers and transcription factors of mitochondrial biogenesis and dynamics, with no calcineurin activation. The results provide strong support for a central role for PGC-1 alpha and calcineurin activation in mitochondrial biogenesis in healthy and diseased human skeletal muscles.	Fac Pharm Chatenay Malabry, INSERM, U446, F-92296 Chatenay Malabry, France; ULP, Fac Med, Dept Physiol, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Garnier, A (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U446, F-92296 Chatenay Malabry, France.	anne.garnier@psud.fr	N'guessan, Benoit Banga/AAH-6421-2020	N'guessan, Benoit Banga/0000-0002-0749-2218; Ventura-Clapier, Renee/0000-0002-7488-4123; Garnier, Anne/0000-0002-6241-4554; Veksler, Vladimir/0000-0002-8869-9594				Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Bengtsson J, 2001, PFLUG ARCH EUR J PHY, V443, P61, DOI 10.1007/s004240100628; Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; De Sousa E, 2000, CIRCULATION, V102, P1847; DREXLER H, 1992, CIRCULATION, V85, P1751, DOI 10.1161/01.CIR.85.5.1751; DREXLER H, 1989, CIRCULATION, V79, P491, DOI 10.1161/01.CIR.79.3.491; Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104; Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Hoppeler H, 2003, MED SCI SPORT EXER, V35, P95, DOI 10.1097/00005768-200301000-00016; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Luciakova K, 1999, FEBS LETT, V444, P186, DOI 10.1016/S0014-5793(99)00058-7; Meirhaeghe A, 2003, BIOCHEM J, V373, P155, DOI 10.1042/BJ20030200; Mettaure B, 2001, J AM COLL CARDIOL, V38, P947, DOI 10.1016/S0735-1097(01)01460-7; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; PooleWilson PA, 1996, J MOL CELL CARDIOL, V28, P2275, DOI 10.1006/jmcc.1996.0220; Rojo M, 2002, J CELL SCI, V115, P1663; Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB; Santel A, 2003, J CELL SCI, V116, P2763, DOI 10.1242/jcs.00479; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Short KR, 2003, DIABETES, V52, P1888, DOI 10.2337/diabetes.52.8.1888; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Tonkonogi M, 1998, J PHYSIOL-LONDON, V510, P279, DOI 10.1111/j.1469-7793.1998.279bz.x; Tunstall RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE66, DOI 10.1152/ajpendo.00475.2001; Ventura-Clapier R, 2004, J PHYSIOL-LONDON, V555, P1, DOI 10.1113/jphysiol.2003.055095; Vescovo G, 1998, CIRCULATION, V98, P1742, DOI 10.1161/01.CIR.98.17.1742; Williams AD, 2004, J CARD FAIL, V10, P141, DOI 10.1016/j.cardfail.2003.09.004; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yamaguchi F, 1999, BRIT J PHARMACOL, V126, P1585, DOI 10.1038/sj.bjp.0702471; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zoll J, 2002, J PHYSIOL-LONDON, V543, P191, DOI 10.1113/jphysiol.2002.019661	48	151	160	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					43	52		10.1096/fj.04-2173com	http://dx.doi.org/10.1096/fj.04-2173com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629894				2022-12-28	WOS:000226576600041
J	Murphy, JF; Lennon, F; Steele, C; Kelleher, D; Fitzgerald, D; Long, A				Murphy, JF; Lennon, F; Steele, C; Kelleher, D; Fitzgerald, D; Long, A			Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and cell proliferation in human vascular endothelial cells	FASEB JOURNAL			English	Article						vascular endothelial growth factor; prostacyclin; COX	GROWTH-FACTOR; HYALURONIC-ACID; ADHESION MOLECULES; TUMOR ANGIOGENESIS; NITRIC-OXIDE; TNF-ALPHA; KAPPA-B; ACTIVATION; EXPRESSION; FRAGMENTS	CD44 is a receptor for hyaluronic acid and is found on the surface of hematopoetic cells and in mesenchymal tissue. It is also expressed on endothelial cells (EC). Cyclooxygenase ( COX) is the rate-limiting enzyme in the production of prostaglandins in EC. Here we show that engagement of CD44 with signaling monoclonal antibodies (mAbs) or its natural ligand hyaluronic acid induces COX-2 and prostacyclin (PGI(2)) formation in human EC. This induction was blocked by mAbs that have been shown to inhibit CD44-mediated intracellular signaling. COX-1 induction was not observed after CD44 ligation. CD44-stimulated COX-2 activation/PGI(2) production was accompanied by the production of the potent endothelial mitogen, vascular endothelial growth factor ( VEGF) and was inhibited by a neutralizing VEGF antibody. Moreover, this COX-2 induction was also associated with an increase in EC proliferation that was inhibited by the blocking anti-CD44 mAbs and a COX-2- specific inhibitor. This is the first study to show that engagement of CD44 with mAbs or its natural ligand induces COX-2, generates VEGF, and thus leads to an increase in EC proliferation. Results from this study may have important and widespread implications for the development of novel therapeutic agents for modulating blood vessel growth during ischemic heart disease, during inflammation, or around solid tumors.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland; Royal Coll Surgeons Ireland, Dept Biochem, Dublin 2, Ireland; Univ Ireland Trinity Coll, Dept Clin Med, Dublin 8, Ireland; St James Hosp, Dublin Mol Med Ctr, Dublin 8, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; Trinity College Dublin; Trinity College Dublin; University College Dublin	Murphy, JF (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, St Stephens Green, Dublin 2, Ireland.	joseph.murphy@emmerex.com						ANSTEE DJ, 1991, IMMUNOLOGY, V74, P197; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; Dohadwala M, 2001, J BIOL CHEM, V276, P20809, DOI 10.1074/jbc.C100140200; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Foger N, 2000, EUR J IMMUNOL, V30, P2888; Friedl P, 2000, Dev Immunol, V7, P249, DOI 10.1155/2000/56473; Gee K, 2002, J IMMUNOL, V169, P5660, DOI 10.4049/jimmunol.169.10.5660; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; Gunthert U, 1999, CURR TOP MICROBIOL, V246, P307; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horton MR, 1999, J IMMUNOL, V162, P4171; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JONES DA, 1993, J BIOL CHEM, V272, P31742; Katoh S, 2003, J CLIN INVEST, V111, P1563, DOI 10.1172/JCI200316583; KELLEHER D, 1994, EUR J IMMUNOL, V24, P1013, DOI 10.1002/eji.1830240437; Keller JB., 1995, SURV APPL MATH, V1, P1; Kim HS, 2003, LUNG CANCER-J IASLC, V42, P163, DOI 10.1016/S0169-5002(03)00290-3; LESLEY J, 1998, FRONT BIOSCI, V3, P616; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lokeshwar VB, 2000, J UROLOGY, V163, P348, DOI 10.1016/S0022-5347(05)68050-0; Masferrer JL, 2000, CANCER RES, V60, P1306; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Murphy JF, 2003, BRIT J HAEMATOL, V121, P157, DOI 10.1046/j.1365-2141.2003.04247.x; Murphy JF, 2001, FASEB J, V15, P1667, DOI 10.1096/fj.00-0757fje; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Ohizumi I, 2000, BBA-MOL CELL RES, V1497, P197, DOI 10.1016/S0167-4889(00)00063-X; Oshima M, 2001, CANCER RES, V61, P1733; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Ponta H., 1998, FRONT BIOSCI, V3, P650; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Rahmanian M, 2002, INT J CANCER, V97, P601, DOI 10.1002/ijc.10087; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; SIROIS J, 1992, J BIOL CHEM, V267, P11586; Smith T, 1893, B BUREAU ANIM IND, P1; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Tarnawski AS, 2003, J MOL MED, V81, P627, DOI 10.1007/s00109-003-0479-y; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Trejdosiewicz LK, 1998, CYTOKINE, V10, P756, DOI 10.1006/cyto.1998.0361; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Uracz W, 2002, J PHYSIOL PHARMACOL, V53, P643; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Yamada Y, 2003, ONCOL REP, V10, P1919	54	55	58	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					446	+		10.1096/fj.03-1376fje	http://dx.doi.org/10.1096/fj.03-1376fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15640281	Green Published			2022-12-28	WOS:000226576600029
J	Phillips, T; Leeuwenburgh, C				Phillips, T; Leeuwenburgh, C			Muscle fiber-specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction	FASEB JOURNAL			English	Article						aging; muscle fiber type; life-extension; exercise	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; MITOCHONDRIAL ABNORMALITIES; IKK-GAMMA; AGE; COMPLEX; MEN; ACTIVATION	Increased tumor necrosis factor-alpha (TNF-alpha) levels have been found with age and are connected to muscle atrophy and cell loss, yet the signaling events that occur in vivo are unknown. Calorie restriction (CR), a robust intervention shown to repeatedly evade the physiological declines associated with aging, has been reported to reduce TNF-alpha and may assist in understanding the mechanisms of muscle sarcopenia. The effects of age and CR on muscle mass, myocyte area, fiber number, myocyte TNF-alpha expression, plasma TNF-alpha levels, and specific elements linked with the TNF-alpha signaling cascade (TNF-R1, IKKgamma, IkappaBalpha, p65, NF-kappaB binding activity, FADD, caspase-8, and DNA fragmentation) were investigated in soleus ( predominately Type I fiber), and superficial vastus lateralis (SVL, predominately Type II fiber), of 6-month-old ad libitum fed (6AL), 26-month-old ad libitum fed (26AL), and 26-month-old calorie-restricted (26CR) male Fischer 344 rats ( CR = 40% restriction compared with ad libitum). Plasma TNF-alpha was increased with age, and the age-associated rise was attenuated with life-long CR. In soleus muscle, we reported a greater capacity to cultivate inflammatory signaling through the transcription factor NF-kappaB compared with that detected in SVL with age. In contrast, in the SVL TNF-alpha stimulated apoptotic signaling with age to a much higher extent than was observed in the soleus. Moreover, a reduction in muscle mass, cross-sectional area, and fiber number in the SVL coincided with this age-linked elevation in apoptosis. In agreement with CR's ability, TNF-alpha stimulation of both inflammatory and apoptotic pathways were abrogated. Our results suggest that TNF-alpha signals transmitted to specific fiber types determine the decision of selecting life or death signaling pathways and are linked to the extent of fiber loss experienced in the aging muscle. Such a specific potential may constitute a major proponent in the pathogenesis of sarcopenia.	Univ Florida, Biochem Aging Lab, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Leeuwenburgh, C (corresponding author), Univ Florida, Biochem Aging Lab, 25 FLG,POB 118206, Gainesville, FL 32611 USA.	cleeuwen@ufl.edu		Leeuwenburgh, Christiaan/0000-0003-0826-4257	NIA NIH HHS [R01-AG17994, AG21042] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG017994, R01AG021042] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALNAQEEB MA, 1987, J ANAT, V153, P31; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bartke A, 2001, J GERONTOL A-BIOL, V56, pB340, DOI 10.1093/gerona/56.8.B340; Baumgartner RN, 1999, MECH AGEING DEV, V107, P123, DOI 10.1016/S0047-6374(98)00130-4; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; BUA EA, 2004, FASEB J; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203; Dalla Libera L, 1999, AM J PHYSIOL-CELL PH, V277, pC982, DOI 10.1152/ajpcell.1999.277.5.C982; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; DOHERTY TJ, 1993, J APPL PHYSIOL, V74, P868, DOI 10.1152/jappl.1993.74.2.868; Dutta C, 1997, J NUTR, V127, pS992, DOI 10.1093/jn/127.5.992S; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greiwe JS, 2001, FASEB J, V15, P475, DOI 10.1096/fj.00-0274com; Gupta S, 2002, J CLIN IMMUNOL, V22, P185, DOI 10.1023/A:1016089607548; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; Kim HJ, 2002, FREE RADICAL BIO MED, V32, P991, DOI 10.1016/S0891-5849(02)00798-0; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; LARSSON L, 1995, PROG NEUROBIOL, V45, P397, DOI 10.1016/0301-0082(95)98601-Z; LARSSON L, 1978, ACTA PHYSIOL SCAND, V103, P31, DOI 10.1111/j.1748-1716.1978.tb06187.x; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luff AR, 1998, ANN NY ACAD SCI, V854, P92, DOI 10.1111/j.1749-6632.1998.tb09895.x; MCKIERNAN S, 2004, FASEB J; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morin CL, 1997, J GERONTOL A-BIOL, V52, pB190, DOI 10.1093/gerona/52A.4.B190; Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504; Nair K S, 2000, Mayo Clin Proc, V75 Suppl, pS14; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paolisso G, 1998, AM J PHYSIOL-ENDOC M, V275, pE294, DOI 10.1152/ajpendo.1998.275.2.E294; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Roubenoff R, 2003, AM J MED, V115, P429, DOI 10.1016/j.amjmed.2003.05.001; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Spaulding CC, 1997, MECH AGEING DEV, V93, P87, DOI 10.1016/S0047-6374(96)01824-6; SPOONER CE, 1992, CLIN IMMUNOL IMMUNOP, V62, pS11, DOI 10.1016/0090-1229(92)90036-N; Suh Y, 2002, MECH AGEING DEV, V123, P881, DOI 10.1016/S0047-6374(02)00025-8; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Vescovo G, 1998, J MOL CELL CARDIOL, V30, P2449, DOI 10.1006/jmcc.1998.0807; World Medical Association, 2002, AM J PHYSIOL-REG I, V283, pR281, DOI DOI 10.1152/AJPREGU.00279.2002; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	60	213	224	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					668	+		10.1096/fj.04-2870fje	http://dx.doi.org/10.1096/fj.04-2870fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665035				2022-12-28	WOS:000226576600014
J	Birukova, AA; Birukov, KG; Smurova, K; Adyshev, D; Kaibuchi, K; Alieva, I; Garcia, JGN; Verin, AD				Birukova, AA; Birukov, KG; Smurova, K; Adyshev, D; Kaibuchi, K; Alieva, I; Garcia, JGN; Verin, AD			Novel role of microtubules in thrombin-induced endothelial barrier dysfunction	FASEB JOURNAL			English	Article						thrombin; G-proteins; Rho-kinase; tau; pulmonary endothelium	NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TAU; RHO-KINASE; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; NEURITE RETRACTION; ADENYLYL-CYCLASE; TYROSINE KINASES; MAMMALIAN-CELLS	Disturbances in endothelial cell (EC) barrier regulation are critically dependent upon rearrangements of EC actin cytoskeleton. However, the role of microtubule (MT) network in the regulation of EC permeability is not well understood. We examined involvement of MT remodeling in thrombin-induced EC permeability and explored MT regulation by heterotrimeric G12/13 proteins and by small GTPase Rho. Thrombin induced phosphorylation of MT regulatory protein tau at Ser(409) and Ser(262) and peripheral MT disassembly, which was linked to increased EC permeability. MT stabilization by taxol attenuated thrombin-induced permeability, actin remodeling, and paracellular gap formation and diminished thrombin-induced activation of Rho and Rho-kinase. Expression of activated Galpha12/13 subunits involved in thrombin-mediated signaling or their effector p115RhoGEF involved in Rho activation caused MT disassembly, whereas p115RhoGEF-specific negative regulator RGS preserved MT from thrombin-induced disassembly. Consistent with these results, expression of activated RhoA and Rho-kinase induced MT disassembly. Conversely, thrombin-induced disassembly of peripheral MT network was attenuated by expression of dominant negative RhoA and Rho-kinase mutants or by pharmacological inhibition of Rho-kinase. Collectively, our data demonstrate for the first time a critical involvement of MT disassembly in thrombin-induced EC barrier dysfunction and indicate G-protein-dependent mechanisms of thrombin-induced MT alteration.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 117234, Russia; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi, Japan	Johns Hopkins University; Lomonosov Moscow State University; Nagoya University	Birukova, AA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 5200 Eastern Ave,MFL Ctr Tower 660, Baltimore, MD 21224 USA.	abirukov@jhmi.edu	Birukov, Konstantin/FJB-5755-2022; Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [HL58064, HL67307, HL68062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107920, P01HL058064, R01HL068062, R01HL067307] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007; Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055; Birukova AA, 2004, AM J PHYSIOL-LUNG C, V287, pL86, DOI 10.1152/ajplung.00441.2003; Borbiev T, 2000, ANAL BIOCHEM, V285, P260, DOI 10.1006/abio.2000.4763; Cross D, 1996, EXP CELL RES, V229, P378, DOI 10.1006/excr.1996.0383; da Costa SR, 2000, CELL MOTIL CYTOSKEL, V47, P253, DOI 10.1002/1097-0169(200012)47:4<253::AID-CM1>3.0.CO;2-S; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Fitzpatrick FA, 2003, INT IMMUNOPHARMACOL, V3, P1699, DOI 10.1016/j.intimp.2003.08.007; Fritsche J, 1999, MOL CELL NEUROSCI, V14, P398, DOI 10.1006/mcne.1999.0777; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Groeneveld ABJ, 2002, VASC PHARMACOL, V39, P247, DOI 10.1016/S1537-1891(03)00013-2; Gupta RP, 1999, ARCH BIOCHEM BIOPHYS, V365, P268, DOI 10.1006/abbi.1999.1165; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Ingelson M, 1996, NEUROSCI LETT, V220, P9, DOI 10.1016/S0304-3940(96)13218-3; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Lee TYJ, 2003, MICROSC RES TECHNIQ, V60, P115, DOI 10.1002/jemt.10250; Leung T, 1996, MOL CELL BIOL, V16, P5313; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Manolopoulos VG, 1997, BBA-MOL CELL RES, V1356, P321, DOI 10.1016/S0167-4889(97)00002-5; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; OLESEN OF, 1994, BIOCHEM BIOPH RES CO, V201, P716, DOI 10.1006/bbrc.1994.1759; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schwer HD, 2001, CURR BIOL, V11, P579, DOI 10.1016/S0960-9822(01)00153-1; SINGH TJ, 1994, MOL CELL BIOCHEM, V131, P181; Song YH, 2000, J CELL BIOCHEM, V80, P229; Storck J, 1996, THROMB RES, V81, P121, DOI 10.1016/0049-3848(95)00220-0; Suo ZM, 2003, J BIOL CHEM, V278, P37681, DOI 10.1074/jbc.M301406200; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	55	158	165	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1879	1890		10.1096/fj.04-2328com	http://dx.doi.org/10.1096/fj.04-2328com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576491				2022-12-28	WOS:000226091000038
J	Kury, P; Zickler, P; Stoll, G; Hartung, HP; Jander, S				Kury, P; Zickler, P; Stoll, G; Hartung, HP; Jander, S			Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowth	FASEB JOURNAL			English	Article						regeneration; inflammation; axotomy; dorsal root ganglion; extracellular matrix	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RAT OPTIC-NERVE; WALLERIAN DEGENERATION; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; LIGAND INTERACTION; SPINAL-CORD; IN-VITRO; REGENERATION	Transected axons can regenerate beyond the site of injury in the peripheral but not in the central nervous system (CNS). Increasing evidence implicates inflammatory processes as modulators of axon regeneration after injury. In this study, we addressed a possible role of the matricellular glycoprotein osteopontin (OPN) using crush lesions of the optic and sciatic nerve as models of central and peripheral axotomy, respectively. OPN was strongly expressed by macrophages at the crush site in the optic but not sciatic nerve, indicating fundamental differences in the molecular programming of macrophages in both systems. Functionally, OPN exerted potent growth-inhibitory effects in an in vitro assay of axon outgrowth. Therefore, OPN expression by lesion-associated macrophages may contribute to the nonpermissive nature of the adult CNS preventing axonal regeneration following injury.	Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany	Heinrich Heine University Dusseldorf; University of Wurzburg	Jander, S (corresponding author), Univ Dusseldorf, Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany.	jander@uni-duesseldorf.de		Zickler, Philipp/0000-0002-2852-7360				Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Fitch MT, 1999, J NEUROSCI, V19, P8182; Frank M, 1996, GLIA, V16, P227, DOI 10.1002/(SICI)1098-1136(199603)16:3<227::AID-GLIA5>3.0.CO;2-Z; Giachelli CM, 1998, AM J PATHOL, V152, P353; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Jander S, 2002, J NEUROSCI RES, V67, P156, DOI 10.1002/jnr.10099; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; Jander S, 2001, BRAIN PATHOL, V11, P27; Jansson M, 2002, J IMMUNOL, V168, P2096, DOI 10.4049/jimmunol.168.5.2096; Lazarov-Spiegler O, 1998, GLIA, V24, P329, DOI 10.1002/(SICI)1098-1136(199811)24:3<329::AID-GLIA7>3.0.CO;2-X; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Liaw L, 1998, J CLIN INVEST, V101, P1468; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Murphy P, 1996, DEVELOPMENT, V122, P2847; MURRY CE, 1994, AM J PATHOL, V145, P1450; Ophascharoensuk V, 1999, KIDNEY INT, V56, P571, DOI 10.1046/j.1523-1755.1999.00580.x; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Schroeter M, 2003, AM J PATHOL, V163, P1517, DOI 10.1016/S0002-9440(10)63508-0; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; STOLL G, 1989, J NEUROSCI, V9, P2327; Stoll G, 1999, BRAIN PATHOL, V9, P313; Takahashi F, 2001, AM J RESP CELL MOL, V24, P264, DOI 10.1165/ajrcmb.24.3.4293; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Wang XK, 1998, J NEUROSCI, V18, P2075; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509	40	24	25	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					398	+		10.1096/fj.04-1777fje	http://dx.doi.org/10.1096/fj.04-1777fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15625076				2022-12-28	WOS:000226091000001
J	Cazorla, O; Szilagyi, S; Le Guennec, JY; Vassort, G; Lacampagne, A				Cazorla, O; Szilagyi, S; Le Guennec, JY; Vassort, G; Lacampagne, A			Transmural stretch-dependent regulation of contractile properties in rat heart and its alteration after myocardial infarction	FASEB JOURNAL			English	Article						Ca2+ sensitization; Frank-Starling law; ventricular myocytes; myosin light chain 2; heart failure	LIGHT-CHAIN PHOSPHORYLATION; FRANK-STARLING MECHANISM; MYOFILAMENT CA2+ SENSITIVITY; SKINNED CARDIAC-MUSCLE; FAILING HUMAN HEART; PROTEIN-KINASE-C; VENTRICULAR MYOCYTES; CALCIUM SENSITIVITY; LENGTH DEPENDENCE; MYOSIN-FILAMENTS	The "stretch-sensitization" response is essential to the regulation of heart contractility. An increase in diastolic volume improves systolic contraction. The cellular mechanisms of this modulation, the Frank-Starling law, are still uncertain. Moreover, their alterations in heart failure remains controversial. Here, using left ventricular skinned rat myocytes, we show a nonuniform stretch-sensitization of myofilament activation across the ventricular wall. Stretch-dependent Ca2+ sensitization of myofilaments increases from sub-epicardium to sub-endocardium and is correlated with an increase in passive tension. This passive tension-dependent component of myofibrillar activation is not associated with expression of titin isoforms, changes in troponin I level, and phosphorylation status. Instead, we observe that stretch induces phosphorylation of ventricular myosin light chain 2 isoform (VLC2b) in sub-endocardium specifically. Thus, VLC2b phosphorylation could act as a stretch-dependent modulator of activation tuned within normal heart. Moreover, in postmyocardial infarcted rat, the gradient of stretch-dependent Ca2+ sensitization disappears associated with a lack of VLC2b phosphorylation in sub-endocardium. In conclusion, nonuniformity is a major characteristic of the normal adult left ventricle (LV). The heterogeneous myocardial deformation pattern might be caused not only by the morphological heterogeneity of the tissue in the LV wall, but also by the nonuniform contractile properties of the myocytes across the wall. The loss of a contractile transmural gradient after myocardial infarction should contribute to the impaired LV function.	CHU Arnaud de Villeneuve, INSERM, U637, F-34295 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Vassort, G (corresponding author), CHU Arnaud de Villeneuve, INSERM, U637, F-34295 Montpellier, France.	vassort@montp.inserm.fr	cazorla, olivier/D-8376-2016; LE GUENNEC, Jean-Yves/P-1067-2016; Lacampagne, Alain/S-3719-2016	cazorla, olivier/0000-0003-0775-203X; Lacampagne, Alain/0000-0003-0264-1787				Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; Anand IS, 1997, CIRCULATION, V96, P3974, DOI 10.1161/01.cir.96.11.3974; Bogaert J, 2001, AM J PHYSIOL-HEART C, V280, pH610; Cazorla O, 1999, J MOL CELL CARDIOL, V31, P1215, DOI 10.1006/jmcc.1999.0954; Cazorla O, 2003, BRIT J PHARMACOL, V139, P99, DOI 10.1038/sj.bjp.0705221; Cazorla O, 1997, J MOL CELL CARDIOL, V29, P1629, DOI 10.1006/jmcc.1997.0402; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Cazorla O, 2001, CIRC RES, V88, P1028, DOI 10.1161/hh1001.090876; Cazorla O, 2000, J MOL CELL CARDIOL, V32, P735, DOI 10.1006/jmcc.2000.1115; CLEMENT O, 1992, BIOCHEM J, V285, P311, DOI 10.1042/bj2850311; CRAIG R, 1987, J CELL BIOL, V105, P1319, DOI 10.1083/jcb.105.3.1319; Davis JS, 2001, CELL, V107, P631, DOI 10.1016/S0092-8674(01)00586-4; de Tombe PP, 1998, CARDIOVASC RES, V37, P367, DOI 10.1016/S0008-6363(97)00275-7; Fuchs F, 1996, J MOL CELL CARDIOL, V28, P1375, DOI 10.1006/jmcc.1996.0129; Fukuda N, 2003, J PHYSIOL-LONDON, V553, P147, DOI 10.1113/jphysiol.2003.049759; Fukuda N, 2001, CIRCULATION, V104, P1639, DOI 10.1161/hc3901.095898; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Granzier HL, 2004, CIRC RES, V94, P284, DOI 10.1161/01.RES.0000117769.88862.F8; HATHAWAY DR, 1985, AM J PHYSIOL, V249, pC345; Helmes M, 1996, CIRC RES, V79, P619, DOI 10.1161/01.RES.79.3.619; Holubarsch C, 1996, CIRCULATION, V94, P683, DOI 10.1161/01.CIR.94.4.683; Konhilas JP, 2003, J PHYSIOL-LONDON, V547, P951, DOI 10.1113/jphysiol.2002.038117; Konhilas JP, 2002, CIRC RES, V90, P59, DOI 10.1161/hh0102.102269; KONHILAS JP, 2003, J PHYSL         0124; KOPP SJ, 1979, J BIOL CHEM, V254, P2007; Lakatta E. G, 1992, HEART CARDIOVASCULAR, P1325; LIU XL, 1995, J MOL CELL CARDIOL, V27, P2613, DOI 10.1006/jmcc.1995.0048; MARGOSSIAN SS, 1992, CIRCULATION, V85, P1720, DOI 10.1161/01.CIR.85.5.1720; Metzger JM, 1999, CIRC RES, V84, P1310, DOI 10.1161/01.RES.84.11.1310; MORANO I, 1988, J MOL CELL CARDIOL, V20, P875, DOI 10.1016/S0022-2828(88)80142-1; Moss RL, 2002, CIRC RES, V90, P11, DOI 10.1161/res.90.1.11; Neagoe C, 2002, CIRCULATION, V106, P1333, DOI 10.1161/01.CIR.0000029803.93022.93; Pi YQ, 2003, J PHYSIOL-LONDON, V552, P845, DOI 10.1113/jphysiol.2003.045260; RODRIGUEZ EK, 1993, AM J PHYSIOL, V264, pH1048, DOI 10.1152/ajpheart.1993.264.4.H1048; SCHWINGER RHG, 1994, CIRC RES, V74, P959, DOI 10.1161/01.RES.74.5.959; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Toursel T, 2002, J APPL PHYSIOL, V92, P1465, DOI 10.1152/japplphysiol.00621.2001; van der Velden J, 2003, CARDIOVASC RES, V57, P505, DOI 10.1016/S0008-6363(02)00662-4; van der Velden J, 2003, CARDIOVASC RES, V57, P37, DOI 10.1016/S0008-6363(02)00606-5; van der Velden J, 2002, BASIC RES CARDIOL S1, V97, P1118, DOI DOI 10.1007/S003950200040; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; Wannenburg T, 1997, AM J PHYSIOL-HEART C, V273, pH2428, DOI 10.1152/ajpheart.1997.273.5.H2428	43	66	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					88	+		10.1096/fj.04-2066fje	http://dx.doi.org/10.1096/fj.04-2066fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15498894	Green Submitted			2022-12-28	WOS:000224849900012
J	Ziesche, R; Petkov, V; Lambers, C; Erne, P; Block, LH				Ziesche, R; Petkov, V; Lambers, C; Erne, P; Block, LH			The calcium channel blocker amlodipine exerts its anti-proliferative action via p21((Waf1/Cip1)) gene activation	FASEB JOURNAL			English	Article						VSMC; glucocorticoid receptor; intracellular calcium; CCB	SMOOTH-MUSCLE-CELLS; LOW-DENSITY-LIPOPROTEIN; NF-KAPPA-B; TRANSCRIPTION FACTORS; C/EBP FAMILY; INTERLEUKIN-6 GENE; NUCLEAR-FACTOR; PROLIFERATION; GROWTH; BINDING	Proliferation of vascular smooth muscle cells (VSMC) contributes to the progression of atherosclerotic plaques. Calcium channel blockers have been shown to reduce VSMC proliferation, but the underlying molecular mechanism remains unclear. p21((Waf1/Cip1)) is a potent inhibitor of cell cycle progression. Here, we demonstrate that amlodipine (10(-6) to 10(-8) M) activates de novo synthesis of p21((Waf1/Cip1)) in vitro. We show that amlodipine-dependent activation of p21((Waf1/Cip1)) involves the action of the glucocorticoid receptor (GR) and C/EBP-alpha. The underlying pathway apparently involves the action of mitogen-activated protein kinase or protein kinase C, but not of extracellular signal-related kinase or changes of intracellular calcium. Amlodipine-induced p21((Waf1/Cip1)) promoter activity and expression were abrogated by C/EBP-alpha antisense oligonucleotide or by the GR antagonist RU486. Amlodipine-dependent inhibition of cell proliferation was partially reversed by RU486 at 10(-8) M (58% +/- 29%), antisense oligonucleotides targeting C/EBP-alpha (91% +/- 26%), or antisense mRNAs targeting p21((Waf1/Cip1)) (96% +/- 32%, n = 6); scrambled antisense oligonucleotides or those directed against C/EBP-alpha were ineffective. The data suggest that the anti-proliferative action of amlodipine is achieved by induction of the p21((Waf1/Cip1)) gene, which may explain beneficial covert effects of this widely used cardiovascular therapeutic drug beyond a more limited role as a vascular relaxant.	Univ Vienna, Dept Internal Med 4, A-1010 Vienna, Austria; Kantonsspital Luzern, Dept Cardiol, Luzern, Switzerland	University of Vienna; Lucerne Cantonal Hospital	Block, LH (corresponding author), Univ Hosp Vienna, Dept Internal Med 4, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	lutz-henning.block@akh-wien.ac.at						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Cattaruzza M, 2001, J BIOL CHEM, V276, P36999, DOI 10.1074/jbc.M105158200; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; Condorelli G, 2001, FASEB J, V15, P2162, DOI 10.1096/fj.01-0032com; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Eickelberg O, 1999, CIRCULATION, V99, P2276, DOI 10.1161/01.CIR.99.17.2276; Faggioli L, 1996, EUR J BIOCHEM, V239, P624, DOI 10.1111/j.1432-1033.1996.0624u.x; George SJ, 2001, GENE THER, V8, P668, DOI 10.1038/sj.gt.3301431; Hamilton CA, 2002, ATHEROSCLEROSIS, V160, P345, DOI 10.1016/S0021-9150(01)00605-0; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; Koshiyama H, 1999, J CARDIOVASC PHARM, V33, P894, DOI 10.1097/00005344-199906000-00009; Lag M, 2000, EXP LUNG RES, V26, P383, DOI 10.1080/019021400408326; Lai YM, 2002, HYPERTENS RES, V25, P109, DOI 10.1291/hypres.25.109; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; Mason RP, 2001, PHARMACOTHERAPY, V21, p209S, DOI 10.1592/phco.21.14.209S.34600; Nathe TJ, 2002, ARTERIOSCL THROM VAS, V22, P1293, DOI 10.1161/01.ATV.0000023428.69244.49; Papakonstantinou E, 1998, GLYCOBIOLOGY, V8, P821, DOI 10.1093/glycob/8.8.821; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Rudiger JJ, 2002, FASEB J, V16, P177, DOI 10.1096/fj.01-0226com; Ruiz-Torres A, 2003, INT J CLIN PHARM TH, V41, P386; Sanz-Gonzalez SM, 2000, FRONT BIOSCI, V5, pD619, DOI 10.2741/sanz; Stepien O, 1998, J CARDIOVASC PHARM, V31, P786, DOI 10.1097/00005344-199805000-00019; Tsuda Y, 2002, EUR J PHARMACOL, V446, P15, DOI 10.1016/S0014-2999(02)01811-3; Velarde V, 2001, J APPL PHYSIOL, V91, P1412, DOI 10.1152/jappl.2001.91.3.1412; Vijayagopal P, 2001, ATHEROSCLEROSIS, V157, P353, DOI 10.1016/S0021-9150(00)00742-5; Yang CM, 2001, BRIT J PHARMACOL, V132, P1531, DOI 10.1038/sj.bjp.0703976; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhao M, 2002, ARCH BIOCHEM BIOPHYS, V400, P199, DOI 10.1016/S0003-9861(02)00028-0	31	6	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1516	1523		10.1096/fj.04-1662com	http://dx.doi.org/10.1096/fj.04-1662com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466360				2022-12-28	WOS:000224849900035
J	Steiner, AA; Dogan, MD; Ivanov, AI; Patel, S; Rudaya, AY; Jennings, DH; Orchinik, M; Pace, TWW; O'Connor, KA; Watkins, LR; Romanovsky, AA				Steiner, AA; Dogan, MD; Ivanov, AI; Patel, S; Rudaya, AY; Jennings, DH; Orchinik, M; Pace, TWW; O'Connor, KA; Watkins, LR; Romanovsky, AA			A new function of the leptin receptor: mediation of the recovery from lipopolysaccharide-induced hypothermia	FASEB JOURNAL			English	Article						fever; body temperature; systemic inflammation; cytokines; tumor necrosis factor; corticosterone; Koletsky rats	TUMOR-NECROSIS-FACTOR; BROWN ADIPOSE-TISSUE; PITUITARY-ADRENAL AXIS; OBESE ZUCKER RATS; NF-KAPPA-B; OB/OB MICE; ACUTE-INFLAMMATION; PLASMA LEPTIN; GENE-PRODUCT; FACTOR-ALPHA	Obese (f/f) Koletsky rats lack the leptin receptor (LR), whereas their lean (F/?) counterparts bear a fully functional LR. By using f/f and F/? rats, we studied whether the LR is involved in lipopolysaccharide (LPS)-induced fever and hypothermia. The body temperature responses to LPS (10 or 100 mug/kg iv) were measured in Koletsky rats exposed to a thermoneutral (28degreesC) or cool (22degreesC) environment. Rats of both genotypes responded to LPS with fever at 28degreesC and with dose-dependent hypothermia at 22degreesC. The fever responses of the f/f and F/? rats were identical. The hypothermic response of the f/f rats was markedly prolonged compared with that of the F/? rats. The prolonged hypothermic response to LPS in the f/f rats was accompanied by enhanced NF-kappaB signaling in the hypothalamus and an exaggerated rise in the plasma concentration of tumor necrosis factor (TNF)-alpha. The f/f rats did not respond to LPS with an increase in the plasma concentration of corticosterone or adrenocorticotropic hormone, whereas their F/? counterparts did. The hypothermic response to TNF-alpha (80 mug/kg iv) was markedly prolonged in the f/f rats. These data show that the LR is essential for the recovery from LPS hypothermia. LR-dependent mechanisms of the recovery from LPS hypothermia include activation of the anti-inflammatory hypothalamo-pituitary-adrenal axis, inhibition of both the production and hypothermic action of TNF-alpha, and suppression of inflammatory (via NF-kappaB) signaling in the hypothalamus.	St Josephs Hosp, Systemic Inflammat Lab, Phoenix, AZ 85013 USA; Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Univ Colorado, Dept Psychol, Boulder, CO 80309 USA	St. Joseph's Hospital and Medical Center; Emory University; Arizona State University; Arizona State University-Tempe; University of Colorado System; University of Colorado Boulder	Steiner, AA (corresponding author), St Josephs Hosp, Systemic Inflammat Lab, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	aromano@chw.edu	Ivanov, Andrei/V-1672-2019; Steiner, Alexandre A/G-1288-2012; Güner, Müberra Devrim/U-9518-2019; Güner, Müberra Devrim/Q-1305-2015	Steiner, Alexandre A/0000-0002-0802-4619; Güner, Müberra Devrim/0000-0001-6982-9026; Güner, Müberra Devrim/0000-0001-6982-9026; Romanovsky, Andrej/0000-0003-3772-8575	NINDS NIH HHS [NS-41233] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041233] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE S, 1988, JPN J CANCER RES, V79, P305, DOI 10.1111/j.1349-7006.1988.tb01591.x; Agnello D, 1998, AM J PHYSIOL-REG I, V275, pR913, DOI 10.1152/ajpregu.1998.275.3.R913; Arnalich F, 1999, J INFECT DIS, V180, P908, DOI 10.1086/314963; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BIBBY DC, 1989, J PHYSIOL-LONDON, V410, P367, DOI 10.1113/jphysiol.1989.sp017538; Bik W, 2001, NEUROENDOCRINOL LETT, V22, P208; Bornstein SR, 1998, J CLIN ENDOCR METAB, V83, P280, DOI 10.1210/jc.83.1.280; BUTLER LD, 1989, J NEUROIMMUNOL, V24, P143, DOI 10.1016/0165-5728(89)90108-2; Cabot C, 1998, BRAIN RES BULL, V46, P529, DOI 10.1016/S0361-9230(98)00050-1; CLEMMER TP, 1992, CRIT CARE MED, V20, P1395, DOI 10.1097/00003246-199210000-00006; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Costa A, 2001, FUNCT NEUROL, V16, P205; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; DASCOMBE MJ, 1989, INT J OBESITY, V13, P367; El-Solh A, 2001, CHEST, V120, P1989, DOI 10.1378/chest.120.6.1989; Faggioni R, 2000, AM J PATHOL, V156, P1781, DOI 10.1016/S0002-9440(10)65049-3; Faggioni R, 1999, AM J PHYSIOL-REG I, V276, pR136, DOI 10.1152/ajpregu.1999.276.1.R136; FERRAN C, 1990, TRANSPLANTATION, V50, P642, DOI 10.1097/00007890-199010000-00023; Fox AS, 2000, HORM BEHAV, V37, P377, DOI 10.1006/hbeh.2000.1580; GIRARDIER L, 1995, J PHYSIOL-LONDON, V488, P779, DOI 10.1113/jphysiol.1995.sp021009; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Han SJ, 2002, J BIOL CHEM, V277, P44715, DOI 10.1074/jbc.M202524200; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; HOLT S, 1983, BIOCHEM J, V214, P215, DOI 10.1042/bj2140215; Huang QL, 1998, ENDOCRINOLOGY, V139, P1524, DOI 10.1210/en.139.4.1524; Ivanov AI, 2002, AM J PHYSIOL-REG I, V282, pR311, DOI 10.1152/ajpregu.00376.2001; Kelly JF, 2004, DIABETES, V53, P911, DOI 10.2337/diabetes.53.4.911; KOZAK W, 1995, AM J PHYSIOL-REG I, V269, pR23, DOI 10.1152/ajpregu.1995.269.1.R23; Laflamme N, 1999, J NEUROCHEM, V73, P309, DOI 10.1046/j.1471-4159.1999.0730309.x; Leon LR, 1998, AM J PHYSIOL-REG I, V275, pR269, DOI 10.1152/ajpregu.1998.275.1.R269; Liu YJ, 2003, DIABETES, V52, P1409, DOI 10.2337/diabetes.52.6.1409; Livingstone DEW, 2000, ENDOCRINOLOGY, V141, P560, DOI 10.1210/en.141.2.560; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; Maskrey M, 2001, AM J PHYSIOL-REG I, V281, pR1675, DOI 10.1152/ajpregu.2001.281.5.R1675; Nadeau S, 2002, J IMMUNOL, V169, P3370, DOI 10.4049/jimmunol.169.6.3370; NICHOLSON WE, 1984, CLIN CHEM, V30, P259; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PLOTSKY PM, 1992, ENDOCRINOLOGY, V130, P1931, DOI 10.1210/en.130.4.1931; Romanovsky AA, 1997, AM J PHYSIOL-REG I, V273, pR407, DOI 10.1152/ajpregu.1997.273.1.R407; Romanovsky AA, 1996, AM J PHYSIOL-REG I, V270, pR693, DOI 10.1152/ajpregu.1996.270.4.R693; Romanovsky AA, 1998, AM J PHYSIOL-REG I, V275, pR323, DOI 10.1152/ajpregu.1998.275.1.R323; Romanovsky AA, 1998, AM J PHYSIOL-REG I, V275, pR332, DOI 10.1152/ajpregu.1998.275.1.R332; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; SEYDOUX J, 1990, AM J PHYSIOL, V259, pR61, DOI 10.1152/ajpregu.1990.259.1.R61; Takahashi N, 1999, J EXP MED, V189, P207, DOI 10.1084/jem.189.1.207; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tollner B, 2000, PFLUG ARCH EUR J PHY, V440, P925, DOI 10.1007/s004240000386; TRIANDAFILLOU J, 1983, AM J PHYSIOL, V244, pE145, DOI 10.1152/ajpendo.1983.244.2.E145; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; WuPeng XS, 1997, DIABETES, V46, P513, DOI 10.2337/diabetes.46.3.513; YORK D, 1984, AM J PHYSIOL, V246, pE391, DOI 10.1152/ajpendo.1984.246.5.E391; Zarkesh-Esfahani H, 2001, J IMMUNOL, V167, P4593, DOI 10.4049/jimmunol.167.8.4593; ZUCKERMAN SH, 1989, EUR J IMMUNOL, V19, P301, DOI 10.1002/eji.1830190213	57	37	37	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1949	+		10.1096/fj.04-2295fje	http://dx.doi.org/10.1096/fj.04-2295fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15388670				2022-12-28	WOS:000224243200014
J	del Monte, F; Dalal, R; Tabchy, A; Couget, J; Bloch, KD; Peterson, R; Hajjar, RJ				del Monte, F; Dalal, R; Tabchy, A; Couget, J; Bloch, KD; Peterson, R; Hajjar, RJ			Transcriptional changes following restoration of SERCA2a levels in failing rat hearts	FASEB JOURNAL			English	Article						heart failure; calcium ATPase; transcript profile	SARCOPLASMIC-RETICULUM CA2+-ATPASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; ADENOVIRAL GENE-TRANSFER; IN-VIVO; VENTRICULAR-FUNCTION; SIGNAL-TRANSDUCTION; AKT ACTIVATION; FAILURE; TENSIN; EXPRESSION	Heart failure is characterized at the cellular level by impaired contractility and abnormal Ca2+ homeostasis. We have previously shown that restoration of a key enzyme that controls intracellular Ca2+ handling, the sarcoplasmic reticulum Ca2+ ATPase (SERCA2a), induces functional improvement in heart failure. We used high-density oligonucleotide arrays to explore the effects of gene transfer of SERCA2a on genetic reprogramming in a model of heart failure. A total of 1,300 transcripts were identified to be unmodified by the effect of virus alone. Of those, 251 transcripts were found to be up- or down-regulated upon failure. A total of 51 transcripts which were either up- ( 27) or down- ( 24) regulated in heart failure were normalized to the nonfailing levels by the restoration of SERCA2a by gene transfer. The microarray analysis identified new genes following SERCA2a restoration in heart failure, which will give us insights into their role in the normalization of multiple pathways within the failing cell.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Harvard Univ, Bauer Ctr Genom Res, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University	del Monte, F (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, E 149 13th St, Charlestown, MA 02129 USA.	fdelmonte@partners.org	del Monte, Federica/AAB-3982-2019; del Monte, Federica/AAF-3961-2020	del Monte, Federica/0000-0001-9506-9665				Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4; Blaxall BC, 2003, PHYSIOL GENOMICS, V15, P105, DOI 10.1152/physiolgenomics.00087.2003; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; Bristow MR, 2003, J AM COLL CARDIOL, V41, P1107, DOI 10.1016/S0735-1097(03)00051-2; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Cook SA, 2002, CIRC RES, V91, P559, DOI 10.1161/01.RES.0000036019.55901.62; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; Del Monte F, 2002, PHYSIOL GENOMICS, V9, P49, DOI 10.1152/physiolgenomics.00035.2001; del Monte F, 2004, P NATL ACAD SCI USA, V101, P5622, DOI 10.1073/pnas.0305778101; del Monte F, 2001, CIRCULATION, V104, P1424, DOI 10.1161/hc3601.095574; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Hajjar RJ, 1997, CIRCULATION, V95, P423; Hajjar RJ, 1998, P NATL ACAD SCI USA, V95, P5251, DOI 10.1073/pnas.95.9.5251; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Haq S, 2001, CIRCULATION, V103, P670; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JANKOWSKI SA, 1995, MAMM GENOME, V6, P744, DOI 10.1007/BF00354299; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Matsui T, 2001, CIRCULATION, V104, P330; Michael A, 2004, J BIOL CHEM, V279, P21383, DOI 10.1074/jbc.M401413200; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Nielsen TH, 2000, J APPL MICROBIOL, V89, P992, DOI 10.1046/j.1365-2672.2000.01201.x; PATCH LA, 1995, J CELL SCI, V108, P1371; Ueno S, 2003, BIOCHEM BIOPH RES CO, V307, P771, DOI 10.1016/S0006-291X(03)01252-X; WEIGT C, 1992, J MOL BIOL, V227, P593, DOI 10.1016/0022-2836(92)90915-7; Yang JC, 2000, CIRCULATION, V102, P3046	28	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1474	+		10.1096/fj.04-1714fje	http://dx.doi.org/10.1096/fj.04-1714fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247151				2022-12-28	WOS:000222979200004
J	Fuentealba, J; Olivares, R; Ales, E; Tapia, L; Rojo, J; Arroyo, G; Aldea, M; Criado, M; Gandia, L; Garcia, AG				Fuentealba, J; Olivares, R; Ales, E; Tapia, L; Rojo, J; Arroyo, G; Aldea, M; Criado, M; Gandia, L; Garcia, AG			A choline-evoked [Ca2+](C) signal causes catecholamine release and hyperpolarization of chromaffin cells	FASEB JOURNAL			English	Article						choline; alpha7 nicotinic receptor; calcium signal; neurotransmitter release	NICOTINIC ACETYLCHOLINE-RECEPTOR; HIGH-CALCIUM PERMEABILITY; ALPHA-BUNGAROTOXIN; ADRENAL-MEDULLA; MOLECULAR-CLONING; CHANNELS; SUBUNIT; NEURONS; AGONIST; ACTIVATION	In bovine chromaffin cells fast-superfused with Krebs-HEPES solution containing 1 - 2 mM Ca2+, 5 s pulses of choline ( 1 - 10 mM), elicited catecholamine secretory responses that were only similar to10% of those evoked by ACh (0.01 - 0.1 mM). However, in high-Ca2+ solutions (10 - 20 mM) the size of the choline secretory responses approached those of ACh. The choline responses ( 10 mM choline in 20 mM Ca2+, 10Cho/20Ca(2+)) tended to decline upon repetitive pulsing, whereas those of ACh were well maintained. The confocal [Ca2+](c) increases evoked by 10Cho/20Ca(2+) were similar to those of ACh. Whereas 10Cho/20Ca(2+) caused mostly hyperpolarization of chromaffin cells, 0.1 ACh/20 Ca2+ caused first depolarization and then hyperpolarization; in regular solutions (2 mM Ca2+), the hyperpolarizing responses did not show up. In Xenopus oocytes injected with mRNA for bovine alpha7 nicotinic receptors (nAChRs), 10Cho/20 Ca2+ fully activated an inward current; in oocytes expressing alpha3beta4, however, the inward current elicited by choline amounted to only 4% of the size of alpha7 current. Our results suggest that choline activates the entry of Ca2+ through a7 nAChRs; this leads to a cytosolic concentration of calcium ([Ca2+](c)) rise that causes the activation of nearby Ca2+-dependent K+ channels and the hyperpolarization of the chromaffin cell. This response, which could be unmasked provided that cells were stimulated with high-Ca2+ solutions, may be the underlying mechanism through which choline exerts a modulatory effect on the electrical activity of the chromaffin cell and on neurotransmitter release at cholinergic synapses.	Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Inst Teofilo Hernando, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Hosp Princesa, Inst Invest Gerontol & Metab, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Serv Farmacol Clin, E-28029 Madrid, Spain; Univ Miguel Hernandez, CSIC, Inst Neurociencias, Alicante, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Garcia, AG (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Inst Teofilo Hernando, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.	agg@uam.es	Criado, Manuel/K-5109-2014; Rojo, Jonathan/K-5942-2014; Ales, Eva/E-6315-2010; GANDIA, LUIS/L-2889-2013; Del Moral, Gonzalo/H-3996-2015; Aldea, Marcos/H-8154-2015; GARCIA, ANTONIO G/E-9961-2018	Criado, Manuel/0000-0002-3953-0346; Rojo, Jonathan/0000-0003-1155-2858; Ales, Eva/0000-0002-5536-4616; GANDIA, LUIS/0000-0001-9597-8519; Del Moral, Gonzalo/0000-0001-5581-0471; Aldea, Marcos/0000-0003-2146-2733; GARCIA, ANTONIO G/0000-0002-6517-3565				Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; ARTALEJO AR, 1993, PFLUG ARCH EUR J PHY, V423, P97, DOI 10.1007/BF00374966; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BORGES R, 1986, J NEUROSCI METH, V16, P289, DOI 10.1016/0165-0270(86)90054-3; CamposCaro A, 1997, J NEUROCHEM, V68, P488; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; Cuchillo-Ibanez I, 2002, PFLUG ARCH EUR J PHY, V444, P133, DOI 10.1007/s00424-002-0810-4; Cuevas J, 1998, J NEUROSCI, V18, P10335; Dani JA, 2001, BIOL PSYCHIAT, V49, P166, DOI 10.1016/S0006-3223(00)01011-8; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; DOUGLAS WW, 1965, NATURE, V208, P1102, DOI 10.1038/2081102a0; Fabian-Fine R, 2001, J NEUROSCI, V21, P7993, DOI 10.1523/JNEUROSCI.21-20-07993.2001; FELDBERG W, 1934, J PHYSL, V137, P218; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GARCIA AG, 2000, SEAFOOD FRESHWATER T, P91; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; HERRERO CJ, 1999, BRIT J PHARMACOL, V6, P1375; HOLZ RW, 1981, SCIENCE, V214, P466, DOI 10.1126/science.7291988; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KAGEYAMA H, 1984, J NEUROSCI METH, V10, P9, DOI 10.1016/0165-0270(84)90074-8; KILPATRICK DL, 1981, J NEUROCHEM, V37, P125, DOI 10.1111/j.1471-4159.1981.tb05299.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRNJEVIC K, 1979, SCIENCE, V206, P1321, DOI 10.1126/science.515735; KUMAKURA K, 1980, NATURE, V283, P489, DOI 10.1038/283489a0; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; Lopez MG, 1998, P NATL ACAD SCI USA, V95, P14184, DOI 10.1073/pnas.95.24.14184; MANDELZYS A, 1995, J NEUROPHYSIOL, V74, P1212, DOI 10.1152/jn.1995.74.3.1212; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MILEDI R, 1989, J PHYSIOL-LONDON, V415, P189, DOI 10.1113/jphysiol.1989.sp017718; MOLLARD P, 1995, P NATL ACAD SCI USA, V92, P3065, DOI 10.1073/pnas.92.7.3065; MONTIEL C, 1995, J PHYSIOL-LONDON, V486, P427, DOI 10.1113/jphysiol.1995.sp020823; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; MULLE C, 1992, NEURON, V8, P937, DOI 10.1016/0896-6273(92)90208-U; PAPKE RL, 1991, J PHYSIOL-LONDON, V440, P95, DOI 10.1113/jphysiol.1991.sp018698; Papke RL, 1996, NEUROSCI LETT, V213, P201; Seddik R, 2003, EUR J PHARMACOL, V471, P165, DOI 10.1016/S0014-2999(03)01860-0; SEGUELA P, 1993, J NEUROSCI, V13, P596; STAUDERMAN KA, 1991, J BIOL CHEM, V266, P19150; Taylor Palmer, 1999, P213; TRIFARO JM, 1980, NEUROSCIENCE, V5, P1533, DOI 10.1016/0306-4522(80)90018-4; TROUSLARD J, 1993, J PHYSIOL-LONDON, V468, P53, DOI 10.1113/jphysiol.1993.sp019759; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; WARD JM, 1990, FEBS LETT, V270, P45, DOI 10.1016/0014-5793(90)81231-C; WILSON SP, 1977, J NEUROCHEM, V28, P687, DOI 10.1111/j.1471-4159.1977.tb10615.x; Yu CR, 1998, J PHYSIOL-LONDON, V509, P651, DOI 10.1111/j.1469-7793.1998.651bm.x; ZHOU Z, 1993, PFLUG ARCH EUR J PHY, V425, P511, DOI 10.1007/BF00374879	49	21	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1468	+		10.1096/fj.04-1828fje	http://dx.doi.org/10.1096/fj.04-1828fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231719				2022-12-28	WOS:000222979200014
J	Brizzi, MF; Dentelli, P; Rosso, A; Calvi, C; Gambino, R; Cassader, M; Salvidio, G; Deferrari, G; Camussi, G; Pegoraro, L; Pagano, G; Cavallo-Perin, P				Brizzi, MF; Dentelli, P; Rosso, A; Calvi, C; Gambino, R; Cassader, M; Salvidio, G; Deferrari, G; Camussi, G; Pegoraro, L; Pagano, G; Cavallo-Perin, P			RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and P21(waf) to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy	FASEB JOURNAL			English	Article						MC; signal transduction and activators of transcription; AGE	GROWTH-FACTOR-BETA; GLYCATION END-PRODUCTS; MATRIX GENE-EXPRESSION; PROTEIN-KINASE-C; HIGH GLUCOSE; RETINOBLASTOMA PROTEIN; EXTRACELLULAR-MATRIX; ACTIVATION; ALBUMIN; HYPERTROPHY	The molecular events associated with acute and chronic exposure of mesangial cells (MC) to hyperglycemia were evaluated. We found that, unlike high glucose (HG) and Amadori adducts, advanced glycation end products (AGE) and transforming growth factor-beta (TGF-beta) induced p21(waf) expression and accumulation of MC in G(0)/G(1). TGF-beta1 blockade inhibited AGE-mediated collagen production but only partially affected AGE-induced p21(waf) expression and cell-cycle events, indicating that AGE by binding to AGE receptor (RAGE) per se could control MC growth. Moreover, AGE and TGF-beta treatment led to the activation of the signal transduction and activators of transcription (STAT)5 and the formation of a STAT5/p21SIE2 complex. The role of STAT5 in AGE- and TGF-beta-mediated p21(Waf) expression and growth arrest, but not collagen production, was confirmed by the expression of the dominant negative STAT5 (DeltaSTAT5) or the constitutively activated STAT5 (1*6-STAT5) constructs. Finally, in p21(waf)-/- fibroblasts both AGE and TGF-beta failed to inhibit cell-cycle progression. A potential in vivo role of these mechanisms was sustained by the increasing immunoreactivity for the activated STAT5 and p21(waf) in kidney biopsies from early to advanced stage of diabetic nephropathy. Our data indicate that AGE- and TGF-beta-mediated signals, by converging on STAT5 activation and p21(waf) expression, may regulate MC growth.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Univ Genoa, Dept Internal Med, Genoa, Italy	University of Turin; University of Genoa	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	GAMBINO, Roberto/AAC-7517-2022; Camussi, Giovanni/J-7624-2016; Brizzi, Maria Felice/J-7882-2016	GAMBINO, Roberto/0000-0003-1902-3627; Camussi, Giovanni/0000-0003-2795-232X; DEFERRARI, GIACOMO/0000-0001-8703-2416				Al-Douahji M, 1999, KIDNEY INT, V56, P1691, DOI 10.1046/j.1523-1755.1999.00728.x; Amiri F, 2002, KIDNEY INT, V61, P1605, DOI 10.1046/j.1523-1755.2002.00311.x; Border WA, 1998, KIDNEY INT, V54, P1390, DOI 10.1046/j.1523-1755.1998.00127.x; Brizzi MF, 2002, DIABETES, V51, P3311, DOI 10.2337/diabetes.51.11.3311; Brizzi MF, 2002, J CLIN INVEST, V109, P111, DOI 10.1172/JCI13617; Brizzi MF, 1999, MOL BIOL CELL, V10, P3463, DOI 10.1091/mbc.10.10.3463; Bussolati B, 1999, AM J PATHOL, V154, P623, DOI 10.1016/S0002-9440(10)65307-2; Chen S, 2000, KIDNEY INT, V58, pS40, DOI 10.1046/j.1523-1755.2000.07707.x; CHRISTIANSEN JS, 1981, DIABETOLOGIA, V20, P451; COHEN MP, 1995, MOL CELL BIOCHEM, V151, P61, DOI 10.1007/BF01076897; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; Cohen MP, 1999, AM J PHYSIOL-RENAL, V276, pF684, DOI 10.1152/ajprenal.1999.276.5.F684; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Feliers D, 2002, DIABETES, V51, P3290, DOI 10.2337/diabetes.51.11.3290; Forbes JM, 2003, J AM SOC NEPHROL, V14, pS254, DOI 10.1097/01.ASN.0000077413.41276.17; Franch HA, 1996, AM J PHYSIOL-CELL PH, V270, pC932, DOI 10.1152/ajpcell.1996.270.3.C932; Griffin SV, 2003, SEMIN NEPHROL, V23, P569, DOI 10.1053/S0270-9295(03)00133-5; Guh JY, 2001, AM J KIDNEY DIS, V38, P1096, DOI 10.1053/ajkd.2001.28616; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Jerums G, 2003, ARCH BIOCHEM BIOPHYS, V419, P55, DOI 10.1016/j.abb.2003.08.017; Kim YS, 2001, J LAB CLIN MED, V138, P59, DOI 10.1067/mlc.2001.115494; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Lam S, 2003, DIABETES, V52, P2975, DOI 10.2337/diabetes.52.12.2975; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; Miele C, 2003, J BIOL CHEM, V278, P47376, DOI 10.1074/jbc.M301088200; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Preisig P, 1999, KIDNEY INT, V56, P1193, DOI 10.1046/j.1523-1755.1999.00708.x; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Schmidt AM, 2000, TRENDS ENDOCRIN MET, V11, P368, DOI 10.1016/S1043-2760(00)00311-8; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; Takeuchi M, 2001, MOL MED, V7, P783, DOI 10.1007/BF03401969; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; Wang XD, 2002, DIABETES, V51, P3505, DOI 10.2337/diabetes.51.12.3505; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097; ZIYADEH FN, 1993, MOL CELL BIOCHEM, V125, P19, DOI 10.1007/BF00926830; ZIYADEH FN, 1997, KIDNEY INT S, V60, P7	50	45	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1249	+		10.1096/fj.03-1053fje	http://dx.doi.org/10.1096/fj.03-1053fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180953				2022-12-28	WOS:000222327500034
J	Jones, DP; Go, YM; Anderson, CL; Ziegler, TR; Kinkade, JM; Kirlin, WG				Jones, DP; Go, YM; Anderson, CL; Ziegler, TR; Kinkade, JM; Kirlin, WG			Cysteine/cystine couple is a newly recognized node in the circuitry for biologic redox signaling and control	FASEB JOURNAL			English	Article						proliferation; differentiation; apoptosis; phase 2 enzymes; oxidative stress	DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; CACO-2 CELLS; HUMAN PLASMA; GLUTATHIONE; THIOREDOXIN; APOPTOSIS; THIOL; STATE	Redox mechanisms function in control of gene expression, cell proliferation, and apoptosis, but the circuitry for redox signaling remains unclear. Cysteine and methionine are the only amino acids in proteins that undergo reversible oxidation/reduction under biologic conditions and, as such, provide a means for control of protein activity, protein-protein interaction, protein trafficking, and protein-DNA interaction. Hydrogen peroxide and other reactive oxygen species (ROS) provide a mechanism to oxidize signaling proteins. However, oxidation of sulfur-containing side chains of cysteine and methionine by ROS can result in oxidation states of sulfur (e.g., sulfinate, sulfonate, sulfone) that are not reducible under biologic conditions. Thus, mechanisms for oxidation that protect against over-oxidation of these susceptible residues and prevent irreversible loss of activity would be advantageous. The present study shows that the steady-state redox potential of the cysteine/cystine couple (E-h = -145 mV) in cells is sufficiently oxidized (>90 mV) relative to the GSH/GSSG (-250 mV) and thioredoxin (Trx1, -280 mV) redox couples for the cysteine/cystine couple to function as an oxidant in redox switching. Consequently, the cysteine/cystine couple provides a means to oxidize proteins without direct involvement of more potent oxidants. A circuitry model incorporating cysteine as a redox node, along with Trx1 and GSH, reveals how selective interactions between the different thiol/disulfide couples and reactive protein thiols could differentially regulate metabolic functions. Moreover, inclusion of cysteine/cystine as a signaling node distinct from GSH and Trx1 significantly expands the redox range over which protein thiol/disulfide couples may operate to control physiologically relevant processes.	Emory Univ, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA; Emory Univ, Ctr Clin & Mol Nutr, Atlanta, GA 30322 USA; Emory Univ, Grad Program Nutr Hlth Sci, Atlanta, GA 30322 USA; Morehouse Sch Med, Dept Pharmacol & Toxicol, Atlanta, GA 30310 USA	Emory University; Emory University; Emory University; Emory University; Emory University; Morehouse School of Medicine	Jones, DP (corresponding author), Emory Univ, Dept Med, 4131 Rollins Res Ctr, Atlanta, GA 30322 USA.	jpjones@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009047, R03ES009313, R01ES011195] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55850] Funding Source: Medline; NIEHS NIH HHS [ES09047, ES09313, ES011195] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Fayos BE, 1997, ENDOTHELIUM-J ENDOTH, V5, P339, DOI 10.3109/10623329709052598; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Kwon YH, 2001, AM J PHYSIOL-ENDOC M, V280, pE804, DOI 10.1152/ajpendo.2001.280.5.E804; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; LASH LH, 1986, ARCH BIOCHEM BIOPHYS, V247, P120, DOI 10.1016/0003-9861(86)90540-0; Lawrence CL, 2002, FASEB J, V16, pA996; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MANNERVIK B, 1983, BIOCHEM J, V213, P519, DOI 10.1042/bj2130519; Miller LT, 2002, J NUTR, V132, P2303, DOI 10.1093/jn/132.8.2303; MILLER LT, 2001, THESIS EMORY U ATLAN; Nkabyo YS, 2002, AM J PHYSIOL-GASTR L, V283, pG1352, DOI 10.1152/ajpgi.00183.2002; Noda T, 2002, CELL PROLIFERAT, V35, P117, DOI 10.1046/j.1365-2184.2002.00229.x; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; REED DJ, 1978, FUNCTIONS GLUTATHION, P13; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Sies H., 1982, METABOLIC COMPARTMEN, P205; Stadtman ER, 2002, MOL CELL BIOCHEM, V234, P3, DOI 10.1023/A:1015916831583; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Watson WH, 2003, FEBS LETT, V543, P144, DOI 10.1016/S0014-5793(03)00430-7; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	38	227	246	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1246	+		10.1096/fj.03-0971fje	http://dx.doi.org/10.1096/fj.03-0971fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180957				2022-12-28	WOS:000222327500035
J	Danesh, FR; Kanwar, YS				Danesh, FR; Kanwar, YS			Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy	FASEB JOURNAL			English	Review						diabetes; endothelium; nitric oxide	ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN; NITRIC-OXIDE SYNTHASE; COENZYME-A-REDUCTASE; SMOOTH-MUSCLE-CELLS; CORONARY-HEART-DISEASE; AKT/PROTEIN KINASE-B; ANGIOTENSIN-II; PLASMA-CONCENTRATION; MESSENGER-RNA	3-Hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase inhibitors or statins are competitive inhibitors of the rate-limiting enzyme in cholesterol biosynthesis. Several large landmark clinical studies have shown a marked reduction of cardiovascular mortality and morbidity in patients treated with statins. Because of the strong association between serum cholesterol levels and coronary artery disease, investigators initially assumed that the predominant beneficial effects of statins result from their lipid-lowering properties. However, more recent observations have suggested that the clinical benefits of statins may be in part independent of their cholesterol-lowering effects. The pleiotropic or cholesterol-independent effects of statins might result from preventing the production of isoprenoids. Isoprenoids serve as important lipid attachments for the post-translational modification of a variety of proteins such as small GTP binding proteins implicated in intracellular signaling. The list of different pleiotropic effects of statins is still growing and, among others, includes the modulatory effects of statins on endothelial function, oxidative stress, coagulation, plaque stability, and inflammation. The pleiotropic effects of statins represent an area of great interest in prevention and therapy of cardiovascular and other chronic diseases. An area of particular interest is the potential beneficial effects of statins in diabetes and its micro/macrovascular complications. This review summarizes our current understanding of the pleiotropic effects of statins in diabetes and the modulatory effects of statins in various pathobiological pathways involved in diabetes and its complications.	Northwestern Univ, Feinberg Sch Med, Div Nephrol Hypertens, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Pathol & Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Danesh, FR (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Nephrol, 303 E Chicago Ave, Chicago, IL 60611 USA.	f-rahimi@northwestern.edu		Danesh, Farhad/0000-0001-6849-5239	NIDDK NIH HHS [DK28492, DK064106, DK60635] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064106, R37DK028492, R01DK028492, R01DK060635] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; American Diabetes Association, 2001, DIABETES CARE S1, V24, pS69; Amos A.F., 1997, DIABET MED S5, V14, P1; Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; ARNOLD GW, 1977, APPL ANIM ETHOL, V3, P263, DOI 10.1016/0304-3762(77)90007-4; Aviram M, 1998, ATHEROSCLEROSIS, V138, P271, DOI 10.1016/S0021-9150(98)00032-X; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bates DO, 1999, MICROCIRCULATION, V6, P83, DOI 10.1038/sj.mn.7300054; BERGE KG, 1991, EUR J CLIN PHARMACOL, V40, pS49, DOI 10.1007/BF01409409; Blaha V, 1998, Acta Medica (Hradec Kralove), V41, P87; Blanco-Colio LM, 2002, ATHEROSCLEROSIS, V161, P17, DOI 10.1016/S0021-9150(01)00613-X; Borghi Claudio, 2002, J Clin Hypertens (Greenwich), V4, P277, DOI 10.1111/j.1524-6175.2002.00499.x; Brenchley PE, 1996, J NEPHROL, V9, P10; BROWN WV, 1990, EUR HEART J, V11, P15, DOI 10.1093/eurheartj/11.suppl_H.15; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; BUCHWALD H, 1995, J AM COLL CARDIOL, V26, P351, DOI 10.1016/0735-1097(95)80006-3; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Ceriello A, 2000, DIABETES, V49, P2170, DOI 10.2337/diabetes.49.12.2170; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; Cha DR, 2000, KIDNEY INT, V58, pS104, DOI 10.1046/j.1523-1755.2000.07717.x; Chiarelli F, 2000, DIABETIC MED, V17, P650, DOI 10.1046/j.1464-5491.2000.00350.x; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Chowdhury T, 2002, EYE, V16, P689, DOI 10.1038/sj.eye.6700205; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Clarkson P, 1996, J AM COLL CARDIOL, V28, P573, DOI 10.1016/0735-1097(96)82380-1; Cohen MP, 2003, ARCH BIOCHEM BIOPHYS, V419, P25, DOI 10.1016/j.abb.2003.08.012; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229; Corsini A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163-7258(99)00045-5; CURCIO F, 1992, IN VITRO CELL DEV-AN, V28A, P787; CURCIO F, 1995, THROMB HAEMOSTASIS, V74, P969; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; Davignon J, 2001, ANN ENDOCRINOL-PARIS, V62, P101; Davis ME, 2001, CIRCULATION, V103, P2; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Duriez P, 2001, Expert Opin Pharmacother, V2, P1777, DOI 10.1517/14656566.2.11.1777; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; Evans M, 2002, DRUG SAFETY, V25, P649, DOI 10.2165/00002018-200225090-00004; Faggiotto A, 1999, HYPERTENSION, V34, P987, DOI 10.1161/01.HYP.34.4.987; Ford ES, 1999, DIABETES CARE, V22, P1971, DOI 10.2337/diacare.22.12.1971; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Gaw A, 2002, ATHEROSCLEROSIS SUPP, V2, P5, DOI 10.1016/S1567-5688(01)00018-6; Gimbrone MA, 1997, J CLIN INVEST, V100, pS61; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gudehithlu KF, 1999, INT J ARTIF ORGANS, V22, P297, DOI 10.1177/039139889902200501; Guerci B, 2001, DIABETES METAB, V27, P425; Guyton JR, 1998, AM J CARDIOL, V82, p18U, DOI 10.1016/S0002-9149(98)00767-X; HARRIS KPG, 1990, AM J KIDNEY DIS, V15, P16, DOI 10.1016/S0272-6386(12)80587-7; Hatanaka T, 2000, CLIN PHARMACOKINET, V39, P397, DOI 10.2165/00003088-200039060-00002; Hess D C, 2001, Expert Opin Pharmacother, V2, P153, DOI 10.1517/14656566.2.1.153; Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200; HOMMEL E, 1992, DIABETOLOGIA, V35, P447, DOI 10.1007/BF02342442; Hoshi S, 2002, BIOCHEM BIOPH RES CO, V290, P177, DOI 10.1006/bbrc.2001.6138; Igel M, 2001, EUR J CLIN PHARMACOL, V57, P357, DOI 10.1007/s002280100329; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; Ikeda U, 2001, J CARDIOVASC PHARM, V38, P69, DOI 10.1097/00005344-200107000-00008; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Izumo N, 2001, METHOD FIND EXP CLIN, V23, P389, DOI 10.1358/mf.2001.23.7.662123; JAMES GL, 1994, J BIOL CHEM, V269, P14182; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47, DOI 10.1055/s-0037-1612902; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kashiwagi A, 1996, DIABETES, V45, pS84, DOI 10.2337/diab.45.3.S84; KASISKE BL, 1988, CIRC RES, V62, P367, DOI 10.1161/01.RES.62.2.367; Kearney D, 1999, J AM COLL CARDIOL, V33, P1305; Kiener PA, 2001, INT IMMUNOPHARMACOL, V1, P105, DOI 10.1016/S0162-3109(00)00272-1; Kim SI, 2000, KIDNEY INT, V58, pS88, DOI 10.1046/j.1523-1755.2000.07714.x; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Knapp AC, 2000, ATHEROSCLEROSIS, V152, P217, DOI 10.1016/S0021-9150(99)00462-1; Korlipara K, 2002, INT J CLIN PRACT, V56, P379; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Kushner I, 2001, CLEV CLIN J MED, V68, P535, DOI 10.3949/ccjm.68.6.535; LAM KSL, 1995, DIABETOLOGIA, V38, P604, DOI 10.1007/s001250050326; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; LEE SK, 1993, NEPHROL DIAL TRANSPL, V8, P1338; LEONARD S, 1990, J BIOL CHEM, V265, P5157; Liang KH, 2003, KIDNEY INT, V64, P192, DOI 10.1046/j.1523-1755.2003.00041.x; Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MASATO E, 2002, CIRCULATION, V105, P1756; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Mattingly RR, 2002, J PHARMACOL EXP THER, V303, P74, DOI 10.1124/jpet.102.036061; McFarlane SI, 2001, J CLIN ENDOCR METAB, V86, P713, DOI 10.1210/jc.86.2.713; McFarlane SI, 2002, J CLIN ENDOCR METAB, V87, P1451, DOI 10.1210/jc.87.4.1451; McLaren M, 1999, CLIN APPL THROMB-HEM, V5, P21, DOI 10.1177/107602969900500105; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Muniyappa R, 2000, AM J PHYSIOL-HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; Nishio E, 1996, EUR J PHARMACOL, V301, P203, DOI 10.1016/0014-2999(96)00063-5; ODONNELL MP, 1992, HYPERTENSION, V20, P651, DOI 10.1161/01.HYP.20.5.651; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274, DOI 10.1152/ajpheart.1995.268.6.H2274; Paniagua JA, 2002, DIABETES, V51, P2596, DOI 10.2337/diabetes.51.8.2596; Park SH, 2001, KIDNEY INT, V59, P1695, DOI 10.1046/j.1523-1755.2001.0590051695.x; Pasceri V, 2001, CIRCULATION, V103, P2531; PEDERSEN TR, 1994, LANCET, V344, P1383; Pietsch A, 1996, BIOCHEM PHARMACOL, V52, P433, DOI 10.1016/0006-2952(96)00245-6; RELEUNG WH, 1993, LANCET, V341, P1496; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Robert B, 2000, AM J PHYSIOL-RENAL, V279, pF275, DOI 10.1152/ajprenal.2000.279.2.F275; Rodriguez-Moran M, 1999, J DIABETES COMPLICAT, V13, P211, DOI 10.1016/S1056-8727(99)00047-1; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sadeghi NM, 2000, J IMMUNOL, V165, P2712, DOI 10.4049/jimmunol.165.5.2712; Samii A, 1999, NEUROSCI LETT, V262, P159, DOI 10.1016/S0304-3940(99)00064-6; Schalkwijk CG, 1999, DIABETOLOGIA, V42, P351, DOI 10.1007/s001250051162; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Senthil D, 2003, KIDNEY INT, V64, P468, DOI 10.1046/j.1523-1755.2003.00135.x; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115; Speidl WS, 2002, AM HEART J, V144, P449, DOI 10.1067/mhj.2002.124353; Stehouwer CDA, 1997, CARDIOVASC RES, V34, P55, DOI 10.1016/S0008-6363(96)00272-6; Stein E, 2002, ATHEROSCLEROSIS SUPP, V2, P19, DOI 10.1016/S1567-5688(01)00020-4; Suzumura K, 2000, CLIN EXP PHARMACOL P, V27, P709, DOI 10.1046/j.1440-1681.2000.03315.x; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tan KCB, 2002, J CLIN ENDOCR METAB, V87, P563, DOI 10.1210/jc.87.2.563; Tan KCB, 1999, J CLIN ENDOCR METAB, V84, P3212, DOI 10.1210/jc.84.9.3212; Teo KK, 2002, DRUGS, V62, P1707, DOI 10.2165/00003495-200262120-00001; TESFAMARIAM B, 1991, J CLIN INVEST, V87, P1643, DOI 10.1172/JCI115179; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tonolo G, 1997, DIABETES CARE, V20, P1891, DOI 10.2337/diacare.20.12.1891; Tsuchida K, 1999, DIABETOLOGIA, V42, P579, DOI 10.1007/s001250051198; Umetani N, 1996, BBA-LIPID LIPID MET, V1303, P199, DOI 10.1016/0005-2760(96)00098-7; *US REN DAT SYST, 2001, USRDS ANN DAT REP AT; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Usui H, 2003, NEPHROL DIAL TRANSPL, V18, P265, DOI 10.1093/ndt/18.2.265; VAN AL, 1997, GENE DEV, V11, P2295; van de Ree MA, 2003, ATHEROSCLEROSIS, V166, P129, DOI 10.1016/S0021-9150(02)00316-7; Veselka J, 2002, CORONARY ARTERY DIS, V13, P151, DOI 10.1097/00019501-200205000-00003; Vincent L, 2002, ARTERIOSCL THROM VAS, V22, P623, DOI 10.1161/01.ATV.0000012283.15789.67; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wagner AH, 2000, ARTERIOSCL THROM VAS, V20, P61, DOI 10.1161/01.ATV.20.1.61; Wasada T, 1998, METABOLISM, V47, P27, DOI 10.1016/S0026-0495(98)90188-3; Wassmann S, 2001, HYPERTENSION, V37, P1450, DOI 10.1161/01.HYP.37.6.1450; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wierzbicki A S, 2001, Expert Opin Pharmacother, V2, P819, DOI 10.1517/14656566.2.5.819; Williams B, 1998, MINER ELECTROL METAB, V24, P400, DOI 10.1159/000057401; Williams B, 1997, DIABETOLOGIA, V40, pS118, DOI 10.1007/s001250051423; Xu CB, 2002, BIOCHEM PHARMACOL, V64, P497, DOI 10.1016/S0006-2952(02)01189-9; Yoshizumi Masanori, 2001, Journal of Medical Investigation, V48, P11; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	163	76	80	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					805	815		10.1096/fj.03-0839rev	http://dx.doi.org/10.1096/fj.03-0839rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15117885				2022-12-28	WOS:000221883200029
J	Ingram, JL; Rice, AB; Geisenhoffer, K; Madtes, DK; Bonner, JC				Ingram, JL; Rice, AB; Geisenhoffer, K; Madtes, DK; Bonner, JC			IL-13 and IL-1 beta promote lung fibroblast growth through coordinated up-regulation of PDGF-AA and PDGF-R alpha	FASEB JOURNAL			English	Article						stromal cells; cytokines; cytokine receptors; cellular proliferation; lung	SMOOTH-MUSCLE-CELLS; RECEPTOR-ALPHA; TRANSFORMING GROWTH-FACTOR-BETA-1; AIRWAYS HYPERREACTIVITY; PULMONARY-FIBROSIS; IN-VITRO; INTERLEUKIN-13; PROLIFERATION; MYOFIBROBLASTS; EXPRESSION	Peribronchiolar fibrosis is a prominent feature of airway remodeling in asthma and involves fibroblast growth and collagen deposition. Interleukin-13 (IL-13), a T-helper 2 cytokine, is a key mediator of airway remodeling in asthma, yet the mechanism through which IL-13 promotes fibroblast growth has not been investigated. In this study, we show that IL-13 stimulates the mitogenesis of mouse, rat, and human lung fibroblasts through release of a soluble mitogen that we identified as PDGF-AA. The IL-13-induced growth of human lung fibroblasts was attenuated by an anti-PDGF-AA neutralizing antibody, and IL-13 stimulated human lung fibroblasts to secrete PDGF-AA. Fibroblasts derived from mouse embryos possessing the lethal Patch mutation, which lack the PDGF-Ralpha, showed no mitogenic response to IL-13. However, Patch cells did exhibit IL-13-induced STAT-6 phosphorylation. Stable transfection of the PDGF-Ralpha into Patch cells restored the growth response to PDGF-AA and IL-13. Through the use of lung fibroblasts from STAT-6-deficient mice, we showed that IL-13-induced PDGF-AA release is STAT-6 dependent, but PDGF-AA-induced growth is STAT-6 independent. Finally, we showed that IL-1beta enhanced IL-13-induced mitogenesis of rat lung fibroblasts through up-regulation of the PDGF-Ralpha. Our findings indicate that IL-13 acts in synergy with IL-1beta to stimulate growth by coordinately up-regulating PDGF-AA and the PDGF-Ralpha, respectively.	NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Fred Hutchinson Cancer Center	Bonner, JC (corresponding author), CIIT Ctr Hlth Res, POB 12137, Res Triangle Pk, NC 27709 USA.	jbonner@ciit.org						Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; BATTEGAY EJ, 1995, J IMMUNOL, V154, P6040; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; BONNER JC, 1991, AM J RESP CELL MOL, V5, P539, DOI 10.1165/ajrcmb/5.6.539; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72, DOI 10.1152/ajplung.1998.274.1.L72; BONNER JC, 1995, AM J RESP CELL MOL, V13, P496, DOI 10.1165/ajrcmb.13.4.7546780; Booth BW, 2001, AM J RESP CELL MOL, V25, P739, DOI 10.1165/ajrcmb.25.6.4659; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Coin PG, 1996, J IMMUNOL, V156, P4797; Doucet C, 2000, ONCOGENE, V19, P5898, DOI 10.1038/sj.onc.1203933; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Gabay C, 1999, BLOOD, V93, P1299, DOI 10.1182/blood.V93.4.1299.404k26_1299_1307; Greenfeder S, 2001, RESP RES, V2, P71, DOI 10.1186/rr41; Hancock A, 1998, AM J RESP CELL MOL, V18, P60, DOI 10.1165/ajrcmb.18.1.2627; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Kraft M, 2001, J ALLERGY CLIN IMMUN, V107, P602, DOI 10.1067/mai.2001.113760; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LASKY JA, 1995, AM J RESP CELL MOL, V12, P162, DOI 10.1165/ajrcmb.12.2.7865215; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; Lindroos PM, 1998, J IMMUNOL, V161, P3464; LINDROOS PM, 1995, AM J RESP CELL MOL, V13, P455, DOI 10.1165/ajrcmb.13.4.7546776; Madtes DK, 1999, AM J RESP CELL MOL, V20, P924, DOI 10.1165/ajrcmb.20.5.3526; Mattes J, 2001, J IMMUNOL, V167, P1683, DOI 10.4049/jimmunol.167.3.1683; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; SEIFERT RA, 1994, J BIOL CHEM, V269, P13951; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; Wang YZ, 2000, J BIOL CHEM, V275, P22550, DOI 10.1074/jbc.M909785199; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499, DOI 10.1152/ajplung.1998.274.4.L499; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	39	66	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1132	+		10.1096/fj.03-1492fje	http://dx.doi.org/10.1096/fj.03-1492fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155567				2022-12-28	WOS:000221883200002
J	Song, QJ; Young, KB; Chu, GX; Gulick, J; Gerst, M; Grupp, IL; Robbins, J; Kranias, EG				Song, QJ; Young, KB; Chu, GX; Gulick, J; Gerst, M; Grupp, IL; Robbins, J; Kranias, EG			Overexpression of phospholamban in slow-twitch skeletal muscle is associated with depressed contractile function and muscle remodeling	FASEB JOURNAL			English	Article						transgenesis; Ca2+-cycling protein; fiber type	HEAVY-CHAIN GENE; CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; PROTEIN-KINASE; IN-VIVO; DILATED CARDIOMYOPATHY; FKBP12 BINDING; FIBER-TYPE; PHOSPHORYLATION	The relative amount of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) and its crucial inhibitor phospholamban (PLN) are closely regulated and play a pivotal role in maintaining muscle function. The functional importance of PLN has been intensively investigated in cardiac muscle. However, little is known about the role of PLN in the slow-twitch skeletal muscle, which expresses a significantly lower level of PLN but a similar level of SERCA2a compared with cardiac muscle. Thus, to define the physiological significance of PLN in slow-twitch skeletal muscle, we generated transgenic mice with PLN-specific overexpression in soleus, which is largely composed of slow-muscle fibers. The PLN protein levels and the PLN/SERCA2a ratio in transgenic soleus were comparable with those in cardiac muscle. Assessment of isometric-twitch contractions indicated that PLN overexpression was associated with depressed rates of contraction and relaxation, which were not linked to reduced SERCA2a abundance, although the levels of other key Ca2+-handling proteins, including ryanodine receptor, FKBP12, and L-type Ca2+ channel, were significantly decreased. However, isoproterenol stimulation reversed the inhibitory effects of PLN on the transgenic soleus twitch kinetics. Furthermore, the PLN-overexpressing soleus had smaller muscle size, mass, and cross-sectional area compared with wild-types. Interestingly, the percentage of slow fibers was increased in PLN-overexpressing soleus. Taken together, these findings indicate that increased PLN expression in slow-twitch skeletal muscle is associated with impaired contractile function and muscle remodeling.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert B Sabin Way,POB 670575, Cincinnati, OH 45267 USA.	Litsa.Kranias@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064018, R01HL026057, R37HL026057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26057, HL64018] Funding Source: Medline; PHS HHS [P4012358] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Avila G, 2003, J BIOL CHEM, V278, P22600, DOI 10.1074/jbc.M205866200; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; Brittsan AG, 2000, J BIOL CHEM, V275, P12129, DOI 10.1074/jbc.275.16.12129; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; CARL SL, 1995, MUSCLE NERVE, V18, P1232, DOI 10.1002/mus.880181104; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHIN ER, 1996, PHYSIOLOGIST, V39, pA75; Dash R, 2001, CIRCULATION, V103, P889, DOI 10.1161/01.CIR.103.6.889; Dulhunty AF, 2002, PROG BIOPHYS MOL BIO, V79, P45, DOI 10.1016/S0079-6107(02)00013-5; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KARCZEWSKI P, 1987, BIOMED BIOCHIM ACTA, V46, P433; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; Knotts S, 1996, DEV DYNAM, V206, P182, DOI 10.1002/(SICI)1097-0177(199606)206:2<182::AID-AJA7>3.0.CO;2-E; KRANIAS EG, 1985, BIOCHEM J, V226, P113, DOI 10.1042/bj2260113; Kubis HP, 2003, AM J PHYSIOL-CELL PH, V285, pC56, DOI 10.1152/ajpcell.00377.2002; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; MENDEZ J, 1960, METABOLISM, V9, P184; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Movsesian Matthew A., 1992, Second Messengers and Phosphoproteins, V14, P151; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; RINDT H, 1993, J BIOL CHEM, V268, P5332; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Slack JP, 1997, AM J PHYSIOL-CELL PH, V273, pC1, DOI 10.1152/ajpcell.1997.273.1.C1; SRETER FA, 1987, AM J PHYSIOL, V253, pC296, DOI 10.1152/ajpcell.1987.253.2.C296; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; Ward CW, 2003, FASEB J, V17, P1517, DOI 10.1096/fj.02-1083fje; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615	46	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					974	+		10.1096/fj.03-1058fje	http://dx.doi.org/10.1096/fj.03-1058fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059971				2022-12-28	WOS:000221108800022
J	Rosenblatt-Velin, N; Lerch, R; Papageorgiou, I; Montessuit, C				Rosenblatt-Velin, N; Lerch, R; Papageorgiou, I; Montessuit, C			Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation	FASEB JOURNAL			English	Article						hypertrophy; myocytes; metabolism; signal transduction	GLUCOSE TRANSPORTER GLUT4; HEART-MUSCLE-CELLS; SKELETAL-MUSCLE; RAT-HEART; 3T3-L1 ADIPOCYTES; IN-VIVO; CARDIAC-HYPERTROPHY; VENTRICULAR CELLS; GENE-EXPRESSION; ISCHEMIA	Myocardium undergoing remodeling in vivo exhibits insulin resistance that has been attributed to a shift from the insulin-sensitive glucose transporter GLUT4 to the fetal, less insulin-sensitive, isoform GLUT1. To elucidate the role of altered GLUT4 expression in myocardial insulin resistance, glucose uptake and the expression of the glucose transporter isoforms GLUT4 and GLUT1 were measured in adult rat cardiomyocytes (ARC). ARC in culture spontaneously undergo dedifferentiation, hypertrophy-like spreading, and return to a fetal-like gene expression pattern. Insulin stimulation of 2-deoxy-D-glucose uptake was completely abolished on day 2 and 3 of culture and recovered thereafter. Although GLUT4 protein level was reduced, the time-course of unresponsiveness to insulin did not correlate with altered expression of GLUT1 and GLUT4. However, translocation of GLUT4 to the sarcolemma in response to insulin was completely abolished during transient insulin resistance. Insulin-mediated phosphorylation of Akt was not reduced, indicating that activation of phosphatidylinositol 3-kinase (PI3K) was preserved. On the other hand, total and phosphorylated Cbl was reduced during insulin resistance, suggesting that activation of Cbl/CAP is essential for insulin-mediated GLUT4 translocation, in addition to activation of PI3K. Pharmacological inhibition of contraction in insulin-sensitive ARC reduced insulin sensitivity and lowered phosphorylated Cbl. The results suggest that transient insulin resistance in ARC is related to impairment of GLUT4 translocation. A defect in the PI3K-independent insulin signaling pathway involving Cbl seems to contribute to reduced insulin responsiveness and may be related to contractile arrest.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland	University of Geneva	Montessuit, C (corresponding author), Univ Hosp Geneva, Div Cardiol, 24 Micheli Crest, CH-1211 Geneva 14, Switzerland.	christophe.montessuit@hcuge.ch		Montessuit, Christophe/0000-0002-2580-7711; Rosenblatt, Nathalie/0000-0003-2011-2862				BARNARD RJ, 1992, FASEB J, V6, P3238, DOI 10.1096/fasebj.6.14.1426762; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Doenst T, 2001, METABOLISM, V50, P1083, DOI 10.1053/meta.2001.25605; Egert S, 1999, CIRC RES, V84, P1407; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; Fares N, 1998, J PHYSIOL-LONDON, V506, P73, DOI 10.1111/j.1469-7793.1998.073bx.x; FISCHER Y, 1991, LIFE SCI, V49, P1679, DOI 10.1016/0024-3205(91)90310-8; FISCHER Y, 1995, ENDOCRINOLOGY, V136, P412, DOI 10.1210/en.136.2.412; Garvey WT, 1998, J CLIN INVEST, V101, P2377, DOI 10.1172/JCI1557; GWATHMEY JK, 1991, CIRC RES, V69, P1280, DOI 10.1161/01.RES.69.5.1280; HARIHARAN R, 1995, CIRCULATION, V91, P2435, DOI 10.1161/01.CIR.91.9.2435; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; LORELL BH, 1984, J AM COLL CARDIOL, V3, P341, DOI 10.1016/S0735-1097(84)80018-2; MESSERLI JM, 1995, MICROSC RES TECHNIQ, V30, P521, DOI 10.1002/jemt.1070300609; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Paternostro G, 1999, CARDIOVASC RES, V42, P246, DOI 10.1016/S0008-6363(98)00233-8; Paternostro G, 1996, J CLIN INVEST, V98, P2094, DOI 10.1172/JCI119015; PATERNOSTRO G, 1995, CARDIOVASC RES, V30, P205, DOI 10.1016/0008-6363(95)00019-4; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SALTIS J, 1991, J BIOL CHEM, V266, P261; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SIVITZ WI, 1991, ENDOCRINOLOGY, V128, P2387, DOI 10.1210/endo-128-5-2387; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; Tardy-Cantalupi I, 1999, J MOL CELL CARDIOL, V31, P1143, DOI 10.1006/jmcc.1999.0952; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WEINBERG EO, 1995, CIRCULATION, V92, P385; Young LH, 1997, CIRCULATION, V95, P415	32	30	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					872	+		10.1096/fj.03-1095fje	http://dx.doi.org/10.1096/fj.03-1095fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15117888				2022-12-28	WOS:000220522800002
J	Philippova, M; Ivanov, D; Allenspach, R; Takuwa, Y; Erne, P; Resink, T				Philippova, M; Ivanov, D; Allenspach, R; Takuwa, Y; Erne, P; Resink, T			RhoA and Rac mediate endothelial cell polarization and detachment induced by T-cadherin	FASEB JOURNAL			English	Article						adhesion molecules; cytoskeleton; cell phenotype; small GTPases; signaling	SMOOTH-MUSCLE-CELLS; N-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; VASCULAR CELLS; FAMILY GTPASES; GROWTH-FACTOR; UP-REGULATION; BETA-CATENIN; IN-VITRO; ADHESION	T-cadherin (T-cad) is an atypical GPI- anchored member of the cadherin superfamily. Ligation of T-cad receptors on endothelial cells prevents cell spreading, promotes elongation and polarization, decreases adhesion to the matrix, and facilitates migration. This study investigates involvement of Rho GTPases in T-cad signaling. Human umbilical vein endothelial cells were infected with adenoviral vectors expressing dominant-negative and/or constitutively active mutants of RhoA (N19RhoA/RhoA63), ROCK (RB/PH(TT)/CAT), and Rac1 (N17RAC). Mutant-infected and empty vector-infected cells were compared with respect to their ability to detach and polarize when plated on substratum containing recombinant T-cad protein used as a ligand mimicking homophilic T-cad interactions. ROCK involvement was also studied using specific inhibitor Y-27632. Adhesion assays, analysis of cell phenotype, and actin cytoskeleton organization using TRITC-labeled phalloidin demonstrated that T-cad-induced cell polarization includes two complementary components: RhoA/ROCK pathway is necessary for cell contraction, stress fiber assembly, and inhibition of spreading, whereas Rac is required for formation of actin-rich lamellipodia at the leading edges of polarized cells. Individual repression of either pathway only partially prevented cell polarization and detachment, while simultaneous repression of RhoA and Rac pathways fully eliminated responses to homophilic T-cad ligation. In conclusion, these data suggest that T-cad induces cell deadhesion and polarization via RhoA-ROCK and Rac-dependent mechanisms.	Univ Basel Hosp, Dept Res, Cardiovasc Labs, CH-4031 Basel, Switzerland; Kanazawa Univ, Sch Med, Div Physiol, Kanazawa, Ishikawa 9208640, Japan; Luzern Kantonsspital, Div Cardiol, CH-6000 Luzern, Switzerland	University of Basel; Kanazawa University; Lucerne Cantonal Hospital	Resink, T (corresponding author), Univ Basel Hosp, Dept Res, Cardiovasc Labs, Hebelstr 20, CH-4031 Basel, Switzerland.	Therese-J.Resink@unibas.ch	Filippova, Maria/GXH-7313-2022	Filippova, Maria/0000-0003-3124-3155				Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Angst BD, 2001, J CELL SCI, V114, P629; Blindt R, 2004, CARDIOVASC RES, V62, P212, DOI 10.1016/j.cardiores.2004.01.004; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Eto Y, 2000, AM J PHYSIOL-HEART C, V278, pH1744, DOI 10.1152/ajpheart.2000.278.6.H1744; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Fujiwara H, 2004, EXP CELL RES, V292, P67, DOI 10.1016/j.yexcr.2003.08.010; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gerhardt H, 1999, EUR J NEUROSCI, V11, P1191, DOI 10.1046/j.1460-9568.1999.00526.x; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Guan JL, 2004, SCIENCE, V303, P773, DOI 10.1126/science.1094376; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; Iso T, 2003, ARTERIOSCL THROM VAS, V23, P543, DOI 10.1161/01.ATV.0000060892.81529.8F; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Jones M, 2002, ARTERIOSCL THROM VAS, V22, P1972, DOI 10.1161/01.ATV.0000036416.14084.5A; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Koller E, 1996, J BIOL CHEM, V271, P30061, DOI 10.1074/jbc.271.47.30061; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Liao F, 2000, CANCER RES, V60, P6805; Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Pearce JD, 2004, J VASC SURG, V39, P223, DOI 10.1016/S0741-5214(03)01037-1; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Philippova M, 2003, HISTOCHEM CELL BIOL, V120, P353, DOI 10.1007/s00418-003-0584-6; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shima DT, 2000, CURR OPIN GENET DEV, V10, P536, DOI 10.1016/S0959-437X(00)00124-6; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Wojciak-Stothard B, 2003, J CELL BIOL, V161, P429, DOI 10.1083/jcb.200210135; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Wyder L, 2000, CANCER RES, V60, P4682; Xue W, 1997, CANCER RES, V57, P1682; Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748	59	44	47	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					588	+		10.1096/fj.04-2430fje	http://dx.doi.org/10.1096/fj.04-2430fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703273				2022-12-28	WOS:000227591900015
J	Quick, AM; Cipolla, MJ				Quick, AM; Cipolla, MJ			Pregnancy-induced up-regulation of aquaporin-4 protein in brain and its role in eclampsia	FASEB JOURNAL			English	Article						aquaporins; blood-brain barrier; AQP4 protein expression	WATER CHANNEL; VASOGENIC EDEMA; BLOOD; EXPRESSION; ASTROCYTES; TRANSPORT; INJURY; AQP4; FLOW	Neurologic complications of eclampsia are thought to be similar to hypertensive encephalopathy in which an acute, excessive elevation in blood pressure causes blood-brain barrier (BBB) disruption and edema formation. Because women who develop eclampsia are in general normotensive and asymptomatic prior to pregnancy, we hypothesized that pregnancy alone predisposes the brain to edema formation by up-regulation of aquaporin 4 (AQP4), a water channel in the brain that has been shown to positively correlate with edema formation. To test this hypothesis, we compared localization ( immunohistochemistry), mRNA (RT-PCR), and protein levels ( Western analysis) of AQP4 in brains from Sprague Dawley rats that were nonpregnant (NP, proestrous), mid-pregnant ( MP, days 9 - 10), late-pregnant ( LP, days 19 - 20), and postpartum ( PP, days 3 - 4). AQP4 mRNA was detected in the brains of all the animals and was localized primarily around the brain parenchymal blood vessels, strongly implicating its role in BBB function. Western analysis revealed that the major AQP4 band at similar to 32 kDa was significantly elevated in MP, LP, and PP animals compared with NP by 9-, 22-, and 17-fold, respectively. These results suggest that pregnancy and the postpartum state upregulate AQP4 protein located around the intraparenchymal blood vessels, a consequence that could promote edema formation when blood pressure is acutely and excessively elevated, as during eclampsia. - Quick, A. M., Cipolla, M. J. Pregnancy-induced up-regulation of aquaporin-4 protein in brain and its role in eclampsia.	Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Obstet & Gynecol, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont	Cipolla, MJ (corresponding author), Univ Vermont, Coll Med, Dept Neurol, 89 Beaumont Ave,Given C454, Burlington, VT 05405 USA.	Marilyn.Cipolla@uvm.edu	Quick, Allison/AAH-8533-2020; Quick, Allison/E-3902-2011; Cipolla, Marilyn J./B-7098-2009; Quick, Allison/AAH-7715-2020	Quick, Allison/0000-0002-2260-6586; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045940] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR16435] Funding Source: Medline; NINDS NIH HHS [R01 NS045940, NS045940] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Belfort MA, 2002, AM J OBSTET GYNECOL, V187, P626, DOI 10.1067/mob.2002.125241; Brightman M, 1989, IMPLICATIONS BLOOD B, P53; CIPOLLA MJ, 2004, M J PHYSL, V86, pH2127; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DINSDALE HB, 1998, STROKE PATHOPHYSIOLO, P869; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Engelter ST, 2000, NEURORADIOLOGY, V42, P818, DOI 10.1007/s002340000439; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Ishibashi K, 2000, REV PHYSIOL BIOCH P, V141, P1, DOI 10.1007/BFb0119576; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Lu MQ, 1996, P NATL ACAD SCI USA, V93, P10908, DOI 10.1073/pnas.93.20.10908; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mas J.-L., 1998, CEREBROVASC DIS, P1684; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Nico B, 2001, J CELL SCI, V114, P1297; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; Ohara M, 1998, J CLIN INVEST, V101, P1076, DOI 10.1172/JCI649; Richard C, 2003, ENDOCRINOLOGY, V144, P1533, DOI 10.1210/en.2002-0033; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Schaefer PW, 1997, STROKE, V28, P1082, DOI 10.1161/01.STR.28.5.1082; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Verkman AS, 2002, J ANAT, V200, P617, DOI 10.1046/j.1469-7580.2002.00058.x; Verkman AS, 2002, ANN MED, V34, P192, DOI 10.1080/713782138; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Williams KP, 1999, AM J OBSTET GYNECOL, V181, P1162, DOI 10.1016/S0002-9378(99)70101-8	34	50	54	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					170	175		10.1096/fj.04-1901hyp	http://dx.doi.org/10.1096/fj.04-1901hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677340				2022-12-28	WOS:000227591900021
J	Kerkhoff, C; Nacken, W; Benedyk, M; Dagher, MC; Sopalla, C; Doussiere, J				Kerkhoff, C; Nacken, W; Benedyk, M; Dagher, MC; Sopalla, C; Doussiere, J			The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67(phox) and Rac-2	FASEB JOURNAL			English	Article						neutrophils; cytosolic phox proteins; MRP8/14; superoxide O2(.-); gene silencing	CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; HUMAN NEUTROPHIL ACTIVATION; PHENYLARSINE OXIDE; PLASMA-MEMBRANE; INTERMEDIATE-FILAMENTS; FLAVOCYTOCHROME-B; CYTOCHROME B(558); CYTOSOLIC FACTORS; REACTIVE OXYGEN	The Ca2+- and arachidonic acid-binding S100A8/A9 protein complex was recently identified by in vitro studies as a novel partner of the phagocyte NADPH oxidase. The present study demonstrated its functional relevance by the impaired oxidase activity in neutrophil-like NB4 cells, after specific blockage of S100A9 expression, and bone marrow polymorphonuclear neutrophils from S100A9(-/-) mice. The impaired oxidase activation could also be mimicked in a cell-free system by pretreatment of neutrophil cytosol with an S100A9-specific antibody. Further analyses gave insights into the molecular mechanisms by which S100A8/A9 promoted NADPH oxidase activation. In vitro analysis of oxidase activation as well as protein-protein interaction studies revealed that S100A8 is the privileged interaction partner for the NADPH oxidase complex since it bound to p67(phox) and Rac, whereas S100A9 did interact with neither p67phox nor p47(phox). Moreover, S100A8/A9 transferred the cofactor arachidonic acid to NADPH oxidase as shown by the impotence of a mutant S100A8/A9 complex unable to bind arachidonic acid to enhance NADPH oxidase activity. It is concluded that S100A8/A9 plays an important role in phagocyte NADPH oxidase activation.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; UJF, Dept Reponse & Dynam Cellulaires, Lab Biochim & Biophys Syst Integres, UMR CEA CNRS 5092, Grenoble, France; IZKF, Munster, Germany	University of Munster; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Kerkhoff, C (corresponding author), Univ Munster, Inst Expt Dermatol, Rontgenstr 21, D-48149 Munster, Germany.	kerkhoc@uni-muenster.de		DAGHER, Marie-Claire/0000-0001-6878-3169				ABO A, 1992, J BIOL CHEM, V267, P16767; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURKHARDT K, 1995, TRANSPLANT P, V27, P890; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; Doussiere J, 2001, BIOCHEM BIOPH RES CO, V285, P1317, DOI 10.1006/bbrc.2001.5324; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P16394, DOI 10.1021/bi991502w; Doussiere J, 1998, EUR J BIOCHEM, V251, P649, DOI 10.1046/j.1432-1327.1998.2510649.x; Doussiere J, 2002, EUR J BIOCHEM, V269, P3246, DOI 10.1046/j.1432-1033.2002.03002.x; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Faure J, 2001, BIOCHIMIE, V83, P409, DOI 10.1016/S0300-9084(01)01263-9; Foubert TR, 2002, BBA-BIOMEMBRANES, V1567, P221, DOI 10.1016/S0005-2736(02)00619-3; Frosch M, 2004, J LEUKOCYTE BIOL, V75, P198, DOI 10.1189/jlb.0203076; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Geiszt M, 2001, J LEUKOCYTE BIOL, V69, P191; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; GREEN TR, 1990, J BIOL CHEM, V265, P19324; Grogan A, 1997, J CELL SCI, V110, P3071; Guignard F, 1996, EUR J BIOCHEM, V241, P265, DOI 10.1111/j.1432-1033.1996.0265t.x; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; HOWARD TH, 1987, J CLIN INVEST, V79, P1359, DOI 10.1172/JCI112962; JOUAN A, 1993, ANAL BIOCHEM, V214, P252, DOI 10.1006/abio.1993.1485; Kato M, 2002, J IMMUNOL, V169, P5252, DOI 10.4049/jimmunol.169.9.5252; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Kerkhoff C, 1999, FEBS LETT, V460, P134, DOI 10.1016/S0014-5793(99)01322-8; Kerkhoff C, 2002, J BIOL CHEM, V277, P41879, DOI 10.1074/jbc.M207990200; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LEMARCHAND P, 1992, J BIOL CHEM, V267, P19379; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; Liu L, 1996, J IMMUNOL METHODS, V192, P173, DOI 10.1016/0022-1759(96)00049-X; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MULLER G, 1993, ARTERIOSCLER THROMB, V13, P1317, DOI 10.1161/01.ATV.13.9.1317; N'Diaye EN, 1997, LEUKEMIA, V11, P2131, DOI 10.1038/sj.leu.2400855; Nacken W, 2004, FEBS LETT, V572, P289, DOI 10.1016/j.febslet.2004.07.024; Nacken W, 2003, MICROSC RES TECHNIQ, V60, P569, DOI 10.1002/jemt.10299; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTH J, 1993, BLOOD, V82, P1875; Roulin K, 1999, EXP CELL RES, V247, P410, DOI 10.1006/excr.1998.4382; SAKATA A, 1987, J IMMUNOL, V138, P4353; SAWAI T, 1993, BIOCHEM BIOPH RES CO, V195, P264, DOI 10.1006/bbrc.1993.2039; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Sopalla C, 2002, BIOL CHEM, V383, P1895, DOI 10.1515/BC.2002.213; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Vaissiere C, 1999, J LEUKOCYTE BIOL, V65, P629, DOI 10.1002/jlb.65.5.629; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; van den Bos C, 1998, PROTEIN EXPRES PURIF, V13, P313, DOI 10.1006/prep.1998.0917; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	68	120	135	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					467	+		10.1096/fj.04-2377fje	http://dx.doi.org/10.1096/fj.04-2377fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15642721				2022-12-28	WOS:000226576600024
J	De Pablos, RM; Herrera, AJ; Villaran, RF; Cano, J; Machado, A				De Pablos, RM; Herrera, AJ; Villaran, RF; Cano, J; Machado, A			Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra	FASEB JOURNAL			English	Article						LPS; neurodegeneration; tyrosine hydroxylase inhibition; Parkinson's disease	PARKINSONS-DISEASE; ENVIRONMENTAL-TEMPERATURE; INTRANIGRAL INJECTION; BRAIN DOPAMINE; CELL-DEATH; METHAMPHETAMINE; MICROGLIA; TYROSINE; RELEASE; NEURODEGENERATION	Intranigral injection of lipopolysaccharide (LPS), a potent inductor of inflammation, induces degeneration of dopaminergic neurons, along with an inflammatory process that features activation of microglial cells and loss of astrocytes. To test the involvement of dopamine (DA) in this degeneration induced by LPS, we treated albino Wistar rats with different concentrations of alpha-methyl-p-tyrosine (alpha-MPT), an inhibitor of tyrosine hydroxylase (TH) activity. Results showed that alpha-MPT prevented LPS-induced loss of TH immunostaining and expression of mRNA for TH and DA transporter; it also prevented substantial activation of microglial cells. Loss of the astroglial population, a marker of damage in our model, was also prevented. This protective effect resulted from inhibition of TH and the consequent decrease in DA concentration, because treatment with L-DOPA/benserazide, which bypasses TH inhibition induced by alpha-MPT, reversed the protective effect produced by this drug. These results point out the important contribution of DA to the vulnerability and degeneration of dopaminergic neurons of the substantia nigra. Knowledge about the involvement of DA in this process may lead to the possibility of new protection strategies against this important degenerative process.	Univ Seville, Fac Farm, Dept Bioquim Bromatol Toxicol & Med Legal, E-41012 Seville, Spain	University of Sevilla	Machado, A (corresponding author), Univ Seville, Fac Farm, Dept Bioquim Bromatol Toxicol & Med Legal, C Prof Garcia Gonzalez 2, E-41012 Seville, Spain.	machado@us.es	IBIS, ENVEJECIMIENTO/O-9381-2015; de Pablos, Rocio M./L-1889-2014; Herrera, Antonio J/L-1894-2014	de Pablos, Rocio M./0000-0002-8683-9805; Herrera, Antonio J/0000-0002-3379-9598				Albers DS, 1995, J PHARMACOL EXP THER, V275, P1104; Ali SF, 1996, ANN NY ACAD SCI, V801, P187, DOI 10.1111/j.1749-6632.1996.tb17441.x; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; BOWYER JF, 1993, PHARMACOL BIOCHEM BE, V44, P87, DOI 10.1016/0091-3057(93)90284-Z; BOWYER JF, 1994, J PHARMACOL EXP THER, V268, P1571; BOWYER JF, 1992, J PHARMACOL EXP THER, V260, P817; Castano A, 1998, J NEUROCHEM, V70, P1584; Chesselet MF, 2003, MOL PSYCHIATR, V8, P369, DOI 10.1038/sj.mp.4001289; Choi HJ, 2003, J NEUROCHEM, V86, P143, DOI 10.1046/j.1471-4159.2003.01808.x; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; DIAZ J, 1995, NEUROSCIENCE, V65, P731, DOI 10.1016/0306-4522(94)00527-C; Dong ZZ, 2003, P NATL ACAD SCI USA, V100, P12438, DOI 10.1073/pnas.2132992100; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Herrera AJ, 2000, NEUROBIOL DIS, V7, P429, DOI 10.1006/nbdi.2000.0289; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hunot S, 2003, ANN NEUROL, V53, pS49, DOI 10.1002/ana.10481; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Jonkers N, 2000, EUR J PHARMACOL, V407, P281, DOI 10.1016/S0014-2999(00)00753-6; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MILLER DB, 1994, J PHARMACOL EXP THER, V270, P752; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; PASINETTI GM, 1989, MOL BRAIN RES, V5, P203, DOI 10.1016/0169-328X(89)90036-3; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Possel H, 2000, GLIA, V32, P51, DOI 10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4; Sakka N, 2003, NEUROREPORT, V14, P2425, DOI 10.1097/00001756-200312190-00027; Santiago M, 2000, BRAIN RES, V858, P26, DOI 10.1016/S0006-8993(99)02485-3; Sian J, 1999, J NEURAL TRANSM, V106, P443, DOI 10.1007/s007020050171; SPECTOR S, 1965, J PHARMACOL EXP THER, V147, P86; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; WEISSMAN A, 1966, J PHARMACOL EXP THER, V151, P339; WHITE FJ, 1988, PHARMACOL BIOCHEM BE, V30, P189, DOI 10.1016/0091-3057(88)90442-X; Xu GL, 2002, ALZ DIS ASSOC DIS, V16, P191, DOI 10.1097/00002093-200207000-00010; Yuan J, 2001, J NEUROCHEM, V77, P1338, DOI 10.1046/j.1471-4159.2001.00339.x	41	37	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					407	+		10.1096/fj.04-2153fje	http://dx.doi.org/10.1096/fj.04-2153fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15625078				2022-12-28	WOS:000226091000002
J	Kotelevets, L; van Hengel, J; Bruyneel, E; Mareel, M; van Roy, F; Chastre, E				Kotelevets, L; van Hengel, J; Bruyneel, E; Mareel, M; van Roy, F; Chastre, E			Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness	FASEB JOURNAL			English	Article						junctional complexes; beta-catenin; AKT protein kinase; Src; E-cadherin	PTEN TUMOR-SUPPRESSOR; E-CADHERIN EXPRESSION; LIPID PHOSPHATASE-ACTIVITY; INTEGRIN-LINKED KINASE; CELL-CELL ADHESION; PDZ DOMAIN; BETA-CATENIN; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOLIPASE C-GAMMA-1; BINDING-PROTEINS	We recently established the critical role of the lipid phosphatase activity of the PTEN tumor suppressor in stabilizing cell-cell contacts and suppressing invasiveness. To delineate the effector systems involved, we investigated the interaction of PTEN with E-cadherin junctional complexes in kidney and colonic epithelial cell lines. PTEN and the p85 regulatory subunit of phosphatidylinositol 3-OH kinase (PI3K) co-immunoprecipitated with E-cadherin and catenins. By using a yeast two-hybrid assay, we demonstrated that PTEN interacted indirectly with beta-catenin by binding the scaffolding protein MAGI-1b. This model was corroborated in various ways in mammalian cells. Ectopic expression of MAGI-1b potentiated the interaction of PTEN with junctional complexes, promoted E-cadherin-dependent cell-cell aggregation, and reverted the Src-induced invasiveness of kidney MDCKts-src cells. In this model, MAGI-1b slightly decreased the activity of AKT, a downstream effector of PI3K. By using dominant-negative and constitutively active AKT expression vectors, we demonstrated that this kinase was included in the pathways involved in Src-induced destabilization of junctional complexes and was necessary and sufficient to trigger invasiveness. We propose that the recruitment of PTEN at adherens junctions by MAGI-1b and the local down-regulation of phosphatidylinositol-3,4,5-trisphosphate pools and downstream effector systems at the site of cell-cell contacts are focal points for restraining both disruption of junctional complexes and induction of tumor cell invasion.	INSERM, Fac Med Xavier Bichat, U410, F-75018 Paris, France; VIB Ghent Univ, Dept Mol Biomed Res, B-9052 Ghent, Belgium; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University Hospital	Chastre, E (corresponding author), INSERM, Fac Med Xavier Bichat, U410, 16 Rue Huchard, F-75018 Paris, France.	chastre@bichat.inserm.fr	van Roy, Frans M/C-6123-2009; CHASTRE, Eric/L-8446-2018	van Roy, Frans M/0000-0003-4358-1039; CHASTRE, Eric/0000-0002-8993-1228				Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Georgescu MM, 2000, CANCER RES, V60, P7033; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Grille SJ, 2003, CANCER RES, V63, P2172; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1997, CANCER RES, V57, P2124; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wells A, 2003, CLIN EXP METASTAS, V20, P285, DOI 10.1023/A:1024088922957; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	45	127	128	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					115	+		10.1096/fj.04-1942fje	http://dx.doi.org/10.1096/fj.04-1942fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15629897				2022-12-28	WOS:000225482100030
J	Hinault, C; Mothe-Satney, I; Gautier, N; Lawrence, JC; Van Obberghen, E				Hinault, C; Mothe-Satney, I; Gautier, N; Lawrence, JC; Van Obberghen, E			Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice	FASEB JOURNAL			English	Article						glucose metabolism; phosphorylation; signaling; insulin-resistance	PROTEIN-KINASE B; P70 S6 KINASE; MESSENGER-RNA TRANSLATION; MAMMALIAN TARGET; SKELETAL-MUSCLE; PHAS-I; GROWTH-FACTOR; RAPAMYCIN; PHOSPHORYLATION; CELLS	Amino acids are nutrients responsible for mammalian target of rapamycin ( mTOR) regulation in mammalian cells. The mTOR protein is mainly known for its role in regulating cell growth, notably via protein synthesis. In addition to amino acids, mTOR is regulated by insulin via a phosphatidylinositol 3-kinase ( PI 3-kinase)-dependent pathway. mTOR mediates crosstalk between amino acids and insulin signaling. We show that in freshly isolated rat adipocytes, insulin stimulates the phosphorylation of mTOR on serine 2448, a protein kinase B (PKB) consensus phosphorylation site. This site is also phosphorylated by amino acids, which in contrast to insulin do not activate PKB. Moreover, insulin and amino acids have an additive effect on mTOR phosphorylation, indicating that they act via two independent pathways. Importantly, amino acids, notably leucine, permit insulin to stimulate PKB when PI 3-kinase is inhibited. They also rescue glucose transport and the mTOR pathway. Further, leucine alone can improve insulin activation of PKB in db/db mice. Our results define the importance of amino acids in insulin signaling and reveal leucine as a key amino acid in disease situations associated with insulin-resistance in adipocytes.	Fac Med, Inst Federatif Rech, INSERM, U145, F-06107 Nice 02, France; Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA USA; Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Virginia; University of Virginia	Mothe-Satney, I (corresponding author), Fac Med, Inst Federatif Rech, INSERM, U145, Ave Valombrose, F-06107 Nice 02, France.	satney@unice.fr	MOTHE-SATNEY, ISABELLE/Q-6377-2016; hinault, charlotte/P-6003-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385; hinault, charlotte/0000-0002-3588-039X				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anthony JC, 2000, J NUTR, V130, P2413; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; KODAMA H, 1994, DIABETOLOGIA, V37, P739, DOI 10.1007/s001250050173; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Lynch CJ, 2001, J NUTR, V131, p861S, DOI 10.1093/jn/131.3.861S; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; RODBELL M, 1964, J BIOL CHEM, V239, P375; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	42	70	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1894	+		10.1096/fj.03-1409fje	http://dx.doi.org/10.1096/fj.03-1409fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15479767				2022-12-28	WOS:000224849900022
J	Carretero, M; del Rio, M; Garcia, M; Escamez, MJ; Mirones, I; Rivas, L; Balague, C; Jorcano, JL; Larcher, F				Carretero, M; del Rio, M; Garcia, M; Escamez, MJ; Mirones, I; Rivas, L; Balague, C; Jorcano, JL; Larcher, F			A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides	FASEB JOURNAL			English	Article						AMP; burn wounds; mulitdrug resistance	HUMAN BETA-DEFENSIN; ANTIBIOTIC LL-37/HCAP-18; HUMAN LUNG; SKIN; LL-37; SURFACE; DIFFERENTIATION; EPITHELIUM; WOUNDS; MODEL	Infection represents a major associated problem in severely burned patients, as it causes skin graft failure and increases the risk of mortality. Topical and systemic antibiotic treatment is limited by the appearance of resistant bacterial strains. Antimicrobial peptides (AMPs) are gene-encoded "natural antibiotics" that form part of the innate mechanism of defense and may be active against such antibiotic-resistant microorganisms. Several microbicidal peptides are expressed in human skin under inflammatory conditions, and their function is not only limited to microbial killing but also influences tissue repair and adaptive immunity. Protein delivery through cutaneous gene therapy is a promising therapeutic tool for both skin and nonskin diseases. Here we present a gene transfer approach aimed at delivering antimicrobial peptides from keratinocytes. Adenoviral vectors encoding antimicrobial peptide genes were used to infect human keratinocytes growing either on plastic or as part of cultured skin equivalents. Inhibition of bacterial growth occurred both in conditioned media and in direct contact with AMPs gene-transduced keratinocytes. In addition, we showed cooperative effects after transfer of combinations of genes encoding for AMPs with structural differences. Combined cutaneous tissue engineering in conjunction with ( microbicidal) gene therapy emerges as a tailored therapeutic approach that is useful for wound coverage and, in this case, concomitantly combating infection.	Fdn Marcelino Botin, CIEMAT, Madrid 28040, Spain; CSIC, Ctr Invest Biol, Madrid, Spain; Almirall Prodesfarma SA, Barcelona, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Almirall	Larcher, F (corresponding author), Fdn Marcelino Botin, CIEMAT, Ave Complutense 22,Edificio 7, Madrid 28040, Spain.	fernando.larcher@ciemat.es	Toledano, Maria José Escámez/F-5297-2016; Carretero, Marta/C-3842-2017; DEL RIO, MARCELA/H-2796-2015; Larcher, Fernando/J-1527-2016; Rivas, Luis/O-8657-2017; Escamez, Maria-José/AAF-6038-2020; Carretero, Marta/AAF-3380-2021	Toledano, Maria José Escámez/0000-0002-5434-1885; Carretero, Marta/0000-0001-6152-3102; DEL RIO, MARCELA/0000-0003-2910-7189; Larcher, Fernando/0000-0002-6771-3561; Rivas, Luis/0000-0002-2958-3233; Escamez, Maria-José/0000-0002-5434-1885; Mirones, Isabel/0000-0001-6921-4590				Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; DELRIO M, 2002, EUROPEAN REV, V10, P369; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Gallo RL, 2002, J ALLERGY CLIN IMMUN, V110, P823, DOI 10.1067/mai.2002.129801; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Huang GTJ, 2002, HUM GENE THER, V13, P2017, DOI 10.1089/10430340260395875; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Liu AY, 2002, J INVEST DERMATOL, V118, P275, DOI 10.1046/j.0022-202x.2001.01651.x; Llames SG, 2004, TRANSPLANTATION, V77, P350, DOI 10.1097/01.TP.0000112381.80964.85; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Marshall SH, 2003, ELECTRON J BIOTECHN, V6, P271, DOI 10.4067/S0717-34582003000300011; Meana A, 1998, BURNS, V24, P621, DOI 10.1016/S0305-4179(98)00107-7; Nagaoka I, 2000, INFLAMM RES, V49, P73, DOI 10.1007/s000110050561; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ortega MR, 2000, BURNS, V26, P724, DOI 10.1016/S0305-4179(00)00052-8; Schmid P, 2001, J INVEST DERMATOL, V116, P471, DOI 10.1046/j.1523-1747.2001.01279.x; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Spirito F, 2001, J GENE MED, V3, P21, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM156>3.0.CO;2-I; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Valerie EJ, 2003, BURNS, V29, P15, DOI 10.1016/S0305-4179(02)00203-6; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001	28	48	49	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1931	+		10.1096/fj.04-1515fje	http://dx.doi.org/10.1096/fj.04-1515fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456737				2022-12-28	WOS:000224243200003
J	Stoyanova, V; Rossetti, S; van Unen, L; Oostra, BA; Hoogeveen, AT				Stoyanova, V; Rossetti, S; van Unen, L; Oostra, BA; Hoogeveen, AT			Loss of FMR1 hypermethylation in somatic cell heterokaryons	FASEB JOURNAL			English	Article						fragile X syndrome; FMR1 promoter; active demethylation	DNA DEMETHYLATION; METHYLATION ANALYSIS; GENE; 5-METHYLCYTOSINE; TRANSCRIPTION; REACTIVATION; IDENTIFICATION; HETEROGENEITY; EXPRESSION	Fragile X syndrome is associated with a trinucleotide (CGG) repeat expansion in the 5'-untranslated region of the FMR1 gene and hypermethylation of the FMR1 promoter. Rare cases of clinically normal males (HFM) have been identified with an expanded CGG repeat; however, here, the FMR1 promoter is not methylated. Using classical complementation ( cell fusion) studies, we analyzed if possible differences in the genetic background between HFM and cells from individuals with fragile X syndrome (FX cells) could have an influence on the methylation status of the FMR1 promoter. We observed that demethylation of the hypermethylated FMR1 promoter can occur when FX cells are complemented ( by cell fusion) with cells from HFM as well as with cells from control individuals. The observed demethylation is specific and can happen without DNA replication. In contrast, demethylation was not observed when cells from unrelated individuals with fragile X syndrome were fused, indicating that FX cells have lost the necessary factor(s) to demethylate the aberrantly methylated FMR1 promoter.	Erasmus MC, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Hoogeveen, AT (corresponding author), Erasmus MC, Dept Clin Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	a.hoogeveen@erasmusmc.nl						Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Cedar H, 1999, NATURE, V397, P568, DOI 10.1038/17492; Chiurazzi P, 1998, HUM MOL GENET, V7, P109, DOI 10.1093/hmg/7.1.109; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270; Hagerman RJ, 2002, FRAGILE X SYNDROME D, P3; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HOOGEVEEN AT, 1980, NATURE, V285, P500, DOI 10.1038/285500a0; JONGKIND JF, 1979, EXP CELL RES, V120, P444, DOI 10.1016/0014-4827(79)90410-5; Kress C, 2001, FEBS LETT, V494, P135, DOI 10.1016/S0014-5793(01)02328-6; Kubota T, 1997, NAT GENET, V16, P16, DOI 10.1038/ng0597-16; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Pietrobono R, 2002, NUCLEIC ACIDS RES, V30, P3278, DOI 10.1093/nar/gkf434; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; SMEETS HJM, 1995, HUM MOL GENET, V4, P2103, DOI 10.1093/hmg/4.11.2103; SMITH KT, 2004, HUM MOL GENET; Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Weiss A, 1997, GENES CELLS, V2, P481, DOI 10.1046/j.1365-2443.1997.1390337.x; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; Wohrle D, 2001, AM J HUM GENET, V69, P504, DOI 10.1086/322739; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157	35	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1964	+		10.1096/fj.04-2499fje	http://dx.doi.org/10.1096/fj.04-2499fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15377638				2022-12-28	WOS:000224243200020
J	Takeda, K; Araki, W; Akiyama, H; Tabira, T				Takeda, K; Araki, W; Akiyama, H; Tabira, T			Amino-truncated amyloid beta-peptide (A beta 5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain	FASEB JOURNAL			English	Article						BACE; alpha-secretase; apoptosis	CEREBRAL-CORTEX; NEURONS; SECRETASE; ACTIVATION; A-BETA-42; APOPTOSIS; PATHWAY; CELLS; TAU; PRESENILIN-2	Caspase activation and apoptosis are implicated in Alzheimer's disease ( AD). In view of the finding that the amyloid precursor protein (APP) undergoes caspase-mediated cleavage in the cytoplasmic region, we analyzed amyloid beta-peptide (Abeta) production in human neuronal and nonneuronal cells expressing wild-type APP and the caspase-cleaved form of APP (APPDeltaC). Biochemical analyses, including immunoprecipitation/mass spectrometry, revealed that APPDeltaC-expressing cells secrete increased levels of amino-terminally truncated Abeta5-40/42 and reduced levels of Abeta1-40/42, compared with wild-type APP-expressing cells. We propose that Abeta5-40/42 is derived from alternative beta-cleavage of APP by alpha-secretase-like protease(s), based on data from treatment of cells with inhibitors of BACE and alpha-secretase. Apoptosis induction resulted in this alternative cleavage of APP in wild-type APP-expressing cells. Moreover, immunohistochemical staining of the AD brain with an end-specific antibody to Abeta5-40/42 revealed peptide deposits in vascular lesions with amyloid angiopathy. The data collectively suggest that caspase cleavage of APP leads to increased production and deposition of Abeta5-40/42 in the AD brain, and highlight the significance of amino-truncated Abeta in the pathogenesis of AD.	NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; NCGG, Natl Inst Longev Sci, Dept Vasc Dementia Res, Aichi 4748522, Japan; Tokyo Inst Psychiat, Setagaya Ku, Tokyo 1568585, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo Institute of Psychiatry	Araki, W (corresponding author), NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan.	araki@ncnp.go.jp; tabira@nils.go.jp	Araki, Wataru/G-7913-2014	Araki, Wataru/0000-0001-8467-6937				Akiyama H, 1999, GLIA, V25, P324, DOI 10.1002/(SICI)1098-1136(19990215)25:4<324::AID-GLIA2>3.0.CO;2-5; Akiyama H, 1997, NEUROCHEM RES, V22, P1499, DOI 10.1023/A:1021910729963; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Ayala-Grosso C, 2002, BRAIN PATHOL, V12, P430; Chui DH, 2001, J ALZHEIMERS DIS, V3, P231; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; KOO EH, 1994, J BIOL CHEM, V269, P17386; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Russo C, 1997, FEBS LETT, V409, P411, DOI 10.1016/S0014-5793(97)00564-4; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Sergeant N, 2003, J NEUROCHEM, V85, P1581, DOI 10.1046/j.1471-4159.2003.01818.x; Shinkai Y, 1997, ANN NEUROL, V42, P899, DOI 10.1002/ana.410420612; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takeda K, 2004, EUR J NEUROSCI, V19, P258, DOI 10.1111/j.0953-816X.2003.03135.x; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Zheng WH, 2002, NEUROSCIENCE, V115, P201, DOI 10.1016/S0306-4522(02)00404-9	42	42	44	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1755	+		10.1096/fj.03-1070fje	http://dx.doi.org/10.1096/fj.03-1070fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364896				2022-12-28	WOS:000224243200027
J	Bifulco, M; Laezza, C; Valenti, M; Ligresti, A; Portella, G; Di Marzo, V				Bifulco, M; Laezza, C; Valenti, M; Ligresti, A; Portella, G; Di Marzo, V			A new strategy to block tumor growth by inhibiting endocannabinoid inactivation	FASEB JOURNAL			English	Article						AA-5-HT; VDM-11; KiMol	CANNABINOID RECEPTOR; VANILLOID RECEPTORS; ANANDAMIDE; SYSTEM; CELLS; MODULATION; EXPRESS; LIGAND; AMIDES; BINDS	Endocannabinoid signaling has been shown to be enhanced in several cancer tissues and malignant cells, and studies in cell lines have shown that this up-regulation might serve the purpose of providing transformed cells with a further means to inhibit their proliferation. Here we investigated the effect of inhibitors of endocannabinoid degradation on the growth of rat thyroid tumor xenografts induced in athymic mice. VDM-11, a selective inhibitor of endocannabinoid cellular re-uptake, and arachidonoyl- serotonin (AA-5-HT), a selective blocker of endocannabinoid enzymatic hydrolysis, both inhibited the growth in vivo of tumor xenografts induced by the subcutaneous injection of rat thyroid transformed (KiMol) cells. This effect was accompanied by significantly enhanced endocannabinoid concentrations in the tumors excised at the end of the in vivo experiments. Endocannabinoids, as well as VDM-11 and AA-5-HT, inhibited the growth in vitro of the transformed rat thyroid cells used to induce the tumors in vivo, and their effect was reversed at least in part by the cannabinoid CB1 receptor antagonist SR141716A. This compound, however, when administered alone, did not enhance, but instead slightly inhibited, the growth of rat thyroid transformed cells both in vitro and in tumor xenografts induced in vivo. These findings indicate that endocannabinoids tonically control tumor growth in vivo by both CB1-mediated and non-CB1-mediated mechanisms and that, irrespective of the molecular mechanism of their anti-proliferative action, inhibitors of their inactivation might be used for the development of novel anti-cancer drugs.	CNR, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; Univ Naples Federico II, CNR, Endocannabinoid Res Grp, Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, SA, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Salerno	Di Marzo, V (corresponding author), CNR, Ist Chim Biomol, Via Campi Flegrei 34, I-80078 Pozzuoli, NA, Italy.	maubiful@unina.it; vdimarzo@icmib.na.cnr.it	Portella, Giuseppe/AFU-6826-2022; laez, chi/AAW-4437-2020; Di Marzo, Vincenzo/AAD-7742-2019; Ligresti, Alessia/B-7564-2015	Di Marzo, Vincenzo/0000-0002-1490-3070; Ligresti, Alessia/0000-0003-1787-3900; Bifulco, Maurizio/0000-0002-1771-4531; PORTELLA, Giuseppe/0000-0001-8276-9769				Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Bisogno T, 1998, BIOCHEM BIOPH RES CO, V248, P515, DOI 10.1006/bbrc.1998.8874; Bisogno T, 2001, EUR J BIOCHEM, V268, P1982, DOI 10.1046/j.1432-1327.2001.02072.x; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; de Lago E, 2004, EUR J PHARMACOL, V484, P249, DOI 10.1016/j.ejphar.2003.11.027; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; Deutsch DG, 2002, PROSTAG LEUKOTR ESS, V66, P201, DOI 10.1054/plef.2001.0358; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2000, EUR J PHARMACOL, V406, P363, DOI 10.1016/S0014-2999(00)00687-7; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; FONTANA A, 1995, PROSTAG LEUKOTR ESS, V53, P301, DOI 10.1016/0952-3278(95)90130-2; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Izzo AA, 2003, GASTROENTEROLOGY, V125, P765, DOI 10.1016/S0016-5085(03)00892-8; Jacobsson SOP, 2001, J PHARMACOL EXP THER, V299, P951; Jarai Z, 2000, HYPERTENSION, V35, P679, DOI 10.1161/01.HYP.35.2.679; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2003, J NEUROCHEM, V85, P1018, DOI 10.1046/j.1471-4159.2003.01759.x; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; Pagotto U, 2001, J CLIN ENDOCR METAB, V86, P2687, DOI 10.1210/jc.86.6.2687; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; Schmid PC, 2002, LIPIDS, V37, P907, DOI 10.1007/s11745-002-0978-z; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	31	136	145	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1606	+		10.1096/fj.04-1754fje	http://dx.doi.org/10.1096/fj.04-1754fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289448				2022-12-28	WOS:000223554900016
J	Bando, Y; Tsukamoto, Y; Katayama, T; Ozawa, K; Kitao, Y; Hori, O; Stern, DM; Yamauchi, A; Ogawa, S				Bando, Y; Tsukamoto, Y; Katayama, T; Ozawa, K; Kitao, Y; Hori, O; Stern, DM; Yamauchi, A; Ogawa, S			ORP150/HSP12A protects renal tubular epithelium from ischemia-induced cell death	FASEB JOURNAL			English	Article						stress protein; acute renal failure; apoptosis; ischemic injury	OXYGEN-REGULATED PROTEIN; MOLECULAR CHAPERONE; EXPRESSION; ORP150; HYPOXIA; INDUCTION; APOPTOSIS; TRANSPORT; NEURONS; STRESS	The 150 kDa oxygen-regulated protein (ORP150) is an inducible endoplasmic reticulum ( ER) chaperone with cytoprotective properties in settings of cell stress, such as ischemia/reperfusion (I/R). Renal tissue from patients with acute renal failure displayed strong induction of ORP150 in tubular epithelium. In a rodent model of renal I/R injury, ORP150 was expressed in both the ischemic and contralateral kidney, principally in the thick ascending loop of Henle ( TAL) and distal tubules. Cultured renal epithelial cells exposed to hypoxic or hyperosmotic conditions displayed induction of ORP150. Renal tubular epithelial cells stably transfected with ORP150 sense or antisense cDNA displayed a strong correlation between ORP150 expression and vulnerability to hypoxic/osmotic stress; higher levels of ORP150 were protective, whereas lower levels increased susceptibility to cell death. Compared with nontransgenic controls, transgenic mice overexpressing ORP150 subjected to renal I/R displayed a blunted rise of serum creatinine and blood urea nitrogen, and enhanced survival of TAL, consistent with cytoprotection. In contrast, heterozygous ORP150(+/-) mice, with lower levels of ORP150, showed enhanced renal injury. These data are consistent with the possibility that ORP150 exerts cytoprotective effects in renal tubular epithelia subjected to I/R injury and suggest a key role for ER stress in the renal tubular response to acute renal failure.	Asahikawa Med Coll, Dept Anat 1, Asahikawa, Hokkaido 0788510, Japan; Osaka Med Ctr Canc, Dept Pathol, Higashinari Ku, Osaka 5378511, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka 5650871, Japan; Osaka Rosai Hosp, Dept Med, Div Nephrol, Sakai, Osaka 5918025, Japan; Kanazawa Univ, Sch Med, Dept Neurosci, Kanazawa, Ishikawa 9208640, Japan; Med Coll Georgia, Deans Off, Augusta, GA 30912 USA	Asahikawa Medical College; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University; Osaka Rosai Hospital; Kanazawa University; University System of Georgia; Augusta University	Bando, Y (corresponding author), Asahikawa Med Coll, Dept Anat 1, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.	ybando@asahikawa-med.ac.jp						Akcetin Z, 1999, UROL RES, V27, P306, DOI 10.1007/s002400050155; Aufricht C, 1998, AM J PHYSIOL-RENAL, V274, pF215, DOI 10.1152/ajprenal.1998.274.1.F215; Bando Y, 2000, AM J PHYSIOL-CELL PH, V278, pC1172, DOI 10.1152/ajpcell.2000.278.6.C1172; Bidmon B, 2000, KIDNEY INT, V58, P2400, DOI 10.1046/j.1523-1755.2000.00423.x; Brady H.R., 1996, KIDNEY, P1200; BREZIS M, 1994, AM J PHYSIOL-RENAL, V267, pF1059, DOI 10.1152/ajprenal.1994.267.6.F1059; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; Cuttle L, 2001, KIDNEY INT, V59, P1779, DOI 10.1046/j.1523-1755.2001.0590051779.x; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; Kelly KJ, 2000, SEMIN NEPHROL, V20, P4; Kelly KJ, 2001, J CLIN INVEST, V108, P1291, DOI 10.1172/JCI13018; Kitao Y, 2001, J CLIN INVEST, V108, P1439, DOI 10.1172/JCI200112978; Kobayashi T, 2003, TRANSGENIC RES, V12, P13, DOI 10.1023/A:1022176004928; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P229, DOI 10.1038/jcbfm.1993.28; Miyazaki M, 2002, J CEREBR BLOOD F MET, V22, P979, DOI 10.1097/00004647-200208000-00009; Neuhofer W, 2001, J AM SOC NEPHROL, V12, P2565, DOI 10.1681/ASN.V12122565; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Ozawa K, 2001, CANCER RES, V61, P4206; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI11772; SCHUMER M, 1992, AM J PATHOL, V140, P831; Shimizu H, 2000, CRIT CARE MED, V28, P809, DOI 10.1097/00003246-200003000-00033; Tamatani M, 2001, NAT MED, V7, P317, DOI 10.1038/85463; Tsukamoto Y, 1996, J CLIN INVEST, V98, P1930, DOI 10.1172/JCI118994; Yamauchi A, 1997, KIDNEY INT, V51, P1847, DOI 10.1038/ki.1997.252; Yamauchi A, 1996, J CLIN INVEST, V97, P263, DOI 10.1172/JCI118401; Yamauchi A, 1998, KIDNEY INT, V54, pS183, DOI 10.1046/j.1523-1755.1998.06741.x	32	68	80	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1401	+		10.1096/fj.03-1161fje	http://dx.doi.org/10.1096/fj.03-1161fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240565				2022-12-28	WOS:000222979200025
J	Roman, J; Ritzenthaler, JD; Acosta, AG; Rivera, HN; Roser-Page, S				Roman, J; Ritzenthaler, JD; Acosta, AG; Rivera, HN; Roser-Page, S			Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling	FASEB JOURNAL			English	Article						nicotinic receptors; CREB; protein kinases; signal transduction; gene transcription	BLOOD MONONUCLEAR-CELLS; PROTEIN-KINASE-C; ACETYLCHOLINE-RECEPTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL REGULATION; CHEMOTACTIC ACTIVITY; GROWTH-FACTOR; INTEGRINS; BINDING	Tobacco-related lung diseases are associated with alterations in tissue remodeling and are characterized by increased matrix deposition. Among the matrix molecules found to be highly expressed in tobacco-related lung diseases is fibronectin, a cell adhesive glycoprotein implicated in tissue injury and repair. We hypothesize that nicotine, a component of tobacco, stimulates the expression of fibronectin in lung fibroblasts via the activation of intracellular signals that lead to increased fibronectin gene transcription. In support of this, we found that nicotine stimulated the expression of fibronectin in lung fibroblasts and that its stimulatory effect was associated with activation of protein kinase C and mitogen-activated protein kinases, increased levels of intracellular cAMP, and phosphorylation and DNA binding of the transcription factor CREB. Increased transcription of the gene was dependent on cAMP-response elements (CREs) present on the 5' end of its gene promoter. The stimulatory effect of nicotine on fibronectin expression was abolished by alpha-bungarotoxin, an inhibitor of alpha7 nicotinic acetylcholine receptors (alpha7 AChRs). Of note, nicotine increased the expression of alpha7 nAChRs on fibroblasts. Our data suggest that nicotine induces lung fibroblasts to produce fibronectin by stimulating alpha7 nAChR-dependent signals that regulate the transcription of the fibronectin gene.	Emory Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Dept Med, Atlanta, GA USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Roman, J (corresponding author), Emory Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Whitehead Biomed Res Bldg,615 Michael St,Suite 20, Atlanta, GA 30322 USA.	jroman@emory.edu						Aztiria EM, 2000, NEUROCHEM RES, V25, P171, DOI 10.1023/A:1007512121082; BITTERMAN PB, 1983, J CELL BIOL, V97, P1925, DOI 10.1083/jcb.97.6.1925; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BOWERSOX JC, 1982, CANCER RES, V42, P2547; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breese CR, 1997, J COMP NEUROL, V387, P385, DOI 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X; Cattaneo MG, 1997, BIOCHEM J, V328, P499; CHANG ZL, 1993, J LEUKOCYTE BIOL, V53, P79, DOI 10.1002/jlb.53.1.79; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DENHOLM EM, 1989, AM J PATHOL, V135, P571; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; END P, 1991, RECEPTORS EXTRACELLU, P79; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graves KL, 1996, AM J PHYSIOL-LUNG C, V271, pL61, DOI 10.1152/ajplung.1996.271.1.L61; GUDEWICZ PW, 1994, J LEUKOCYTE BIOL, V55, P423, DOI 10.1002/jlb.55.4.423; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hiemke C, 1996, NEUROSCI LETT, V214, P171, DOI 10.1016/0304-3940(96)12908-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kirkpatrick CJ, 2001, JPN J PHARMACOL, V85, P24, DOI 10.1254/jjp.85.24; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; Lee BH, 1996, BIOCHEM MOL BIOL INT, V39, P895; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; LUCEY EC, 1985, AM REV RESPIR DIS, V132, P362; MACKENZIE TD, 1994, NEW ENGL J MED, V330, P975, DOI 10.1056/NEJM199404073301406; MCDONAGH J, 1985, PLASMA FIBRONECTIN S, P121; Michaelson JE, 2002, AM J PHYSIOL-LUNG C, V282, pL291, DOI 10.1152/ajplung.00445.2000; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; PACIFICI R, 1992, J CLIN INVEST, V89, P61, DOI 10.1172/JCI115586; Perez RL, 2000, J INTERF CYTOK RES, V20, P795, DOI 10.1089/10799900050151067; PEREZ RL, 1995, J IMMUNOL, V154, P1879; Perez RL, 1999, AM J RESP CELL MOL, V20, P1059, DOI 10.1165/ajrcmb.20.5.3281; Petty TL, 2002, CHEST, V121, p116S, DOI 10.1378/chest.121.5_suppl.116S; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; Rivera-Marrero CA, 2000, MICROB PATHOGENESIS, V29, P231, DOI 10.1006/mpat.2000.0383; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; ROMAN J, 1992, AM J RESP CELL MOL, V6, P472, DOI 10.1165/ajrcmb/6.5.472; Roman J, 1996, IMMUNOL RES, V15, P163, DOI 10.1007/BF02918505; ROMAN J, 1991, DEVELOPMENT, V112, P551; Roman J, 1999, IMMUNOLOGY, V98, P228; Roman J, 2000, CYTOKINE, V12, P1581, DOI 10.1006/cyto.2000.0759; ROMAN J, 1997, LUNG SCI FDN; ROMAN J, 1998, INTERSTITIAL LUNG DI, P207; ROWELL PP, 1983, J PHARMACOL METHOD, V9, P249, DOI 10.1016/0160-5402(83)90064-5; ROY F, 1993, J BIOMED MATER RES, V27, P389, DOI 10.1002/jbm.820270312; Ryder MI, 1998, J PERIODONTAL RES, V33, P359, DOI 10.1111/j.1600-0765.1998.tb02211.x; Sekhon HS, 1999, J CLIN INVEST, V103, P637, DOI 10.1172/JCI5232; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Shiomi T, 2003, EXP LUNG RES, V29, P1, DOI 10.1080/01902140303761; SONG WD, 1995, RESPIRATION, V62, P125; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; THURLBECK WM, 1990, CLIN CHEST MED, V11, P389; Tipton DA, 1995, J PERIODONTOL, V66, P1056, DOI 10.1902/jop.1995.66.12.1056; URAKAWA N, 1994, INT J LEGAL MED, V106, P232, DOI 10.1007/BF01225411; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; VILLIGER B, 1981, AM REV RESPIR DIS, V124, P652; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZHOU X, 1992, AM J PHYSIOL, V262, pL600, DOI 10.1152/ajplung.1992.262.5.L600; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	67	79	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1436	+		10.1096/fj.03-0826fje	http://dx.doi.org/10.1096/fj.03-0826fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247149				2022-12-28	WOS:000222979200010
J	Kunkel, EJ; Dea, M; Ebens, A; Hytopoulos, E; Melrose, J; Nguyen, D; Ota, KS; Plavec, I; Wang, Y; Watson, SR; Butcher, EC; Berg, EL				Kunkel, EJ; Dea, M; Ebens, A; Hytopoulos, E; Melrose, J; Nguyen, D; Ota, KS; Plavec, I; Wang, Y; Watson, SR; Butcher, EC; Berg, EL			An integrative biology approach for analysis of drug action in models of human vascular inflammation	FASEB JOURNAL			English	Article						endothelium; leukocyte; chemokine; adhesion; systems biology	ENDOTHELIAL-CELLS; ROSUVASTATIN; ACTIVATION; SIMVASTATIN; EXPRESSION; INHIBITOR; ARTHRITIS; STATINS; SYSTEMS	Unexpected drug activities discovered during clinical testing establish the need for better characterization of compounds in human disease-relevant conditions early in the discovery process. Here, we describe an approach to characterize drug function based on statistical analysis of protein expression datasets from multiple primary human cell-based models of inflammatory disease. This approach, termed Biologically Multiplexed Activity Profiling (BioMAP), provides rapid characterization of drug function, including mechanism of action, secondary or off-target activities, and insights into clinical phenomena. Using three model systems containing primary human endothelial cells and peripheral blood mononuclear cells in different environments relevant to vascular inflammation and immune activation, we show that BioMAP profiles detect and discriminate multiple functional drug classes, including glucocorticoids; TNF-alpha antagonists; and inhibitors of HMG-CoA reductase, calcineurin, IMPDH, PDE4, PI-3 kinase, hsp90, and p38 MAPK, among others. The ability of cholesterol lowering HMG-CoA reductase inhibitors (statins) to improve outcomes in rheumatic disease patients correlates with the activities of these compounds in our BioMAP assays. In addition, the activity profiles identified for the immunosuppressants mycophenolic acid, cyclosporin A, and FK-506 provide a potential explanation for a reduced incidence of posttransplant cardiovascular disease in patients receiving mycophenolic acid. BioMAP profiling can allow integration of meaningful human biology into drug development programs.	Bioseek Inc, Burlingame, CA 94010 USA; Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA	Stanford University	Berg, EL (corresponding author), Bioseek Inc, 863-C Mitten Rd, Burlingame, CA 94010 USA.	eberg@bioseekinc.com	Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI048255, R43AI049048] Funding Source: NIH RePORTER; NIAID NIH HHS [R43 AI049048, R43 AI048255] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abud-Mendoza C, 2003, LUPUS, V12, P607, DOI 10.1191/0961203303lu429oa; Aukrust P, 1998, CIRCULATION, V97, P1136, DOI 10.1161/01.CIR.97.12.1136; Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006-2952(97)00535-2; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Davidov EJ, 2003, DRUG DISCOV TODAY, V8, P175, DOI 10.1016/S1359-6446(03)02600-X; Davidson M, 2002, AM J CARDIOL, V89, P268, DOI 10.1016/S0002-9149(01)02226-3; Davidson MH, 2002, EXPERT OPIN INV DRUG, V11, P125, DOI 10.1517/13543784.11.1.125; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; GERRITSEN ME, 1995, AM J PATHOL, V147, P278; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Kanda H, 2002, J RHEUMATOL, V29, P2024; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524; Liu WL, 2002, ACTA PHARMACOL SIN, V23, P213; McTaggart F, 2001, AM J CARDIOL, V87, p28B; Melrose J, 1998, J IMMUNOL, V161, P2457; MIKSICEK RJ, 1994, J STEROID BIOCHEM, V49, P153, DOI 10.1016/0960-0760(94)90005-1; Miller LW, 2002, AM J TRANSPLANT, V2, P807, DOI 10.1034/j.1600-6143.2002.20902.x; Muller WA, 1999, J LEUKOCYTE BIOL, V66, P698, DOI 10.1002/jlb.66.5.698; Plavec I, 2004, P NATL ACAD SCI USA, V101, P1223, DOI 10.1073/pnas.0308221100; Pober JS, 2001, ANN NY ACAD SCI, V941, P12; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959	29	56	61	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1279	+		10.1096/fj.04-1538fje	http://dx.doi.org/10.1096/fj.04-1538fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208272				2022-12-28	WOS:000222327500004
J	Dunzendorfer, S; Lee, HK; Soldau, K; Tobias, PS				Dunzendorfer, S; Lee, HK; Soldau, K; Tobias, PS			Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS-responses	FASEB JOURNAL			English	Article						innate immunity; endothelium; endotoxin	LIPOPOLYSACCHARIDE-BINDING PROTEIN; BACTERIAL LIPOPOLYSACCHARIDE; SCAVENGER RECEPTOR; GOLGI-APPARATUS; ACTIVATION; RECOGNITION; ENDOTOXIN; CD14; INTERNALIZATION; NEUTROPHILS	Endothelial cells are activated by microbial agonists through Toll-like receptors (TLRs) to express inflammatory mediators; this is of significance in acute as well as chronic inflammatory states such as septic shock and atherosclerosis, respectively. We investigated mechanisms of lipopolysaccharide (LPS)-induced cell activation in human coronary artery endothelial cells (HCAEC) using a combination of FACS, confocal microscopy, RT-PCR, and functional assays. We found that TLR4, in contrast to TLR2, is not only located intracellularly but also functions intracellularly. That being the case, internalization of LPS is required for activation. We further characterized the HCAEC LPS uptake system and found that HCAEC exhibit an effective LPS uptake only in the presence of LPS binding protein (LBP). In addition to its function as a catalyst for LPS-CD14 complex formation, LBP enables HCAEC activation at low LPS concentrations by facilitating the uptake, and therefore delivery, of LPS-CD14 complexes to intracellular TLR4-MD-2. LBP-dependent uptake involves a scavenger receptor pathway. Our findings may be of pathophysiological relevance in the initial response of the organism to infection. Results further suggest that LBP levels, which vary as LBP is an acute phase reactant, could be relevant to initiating inflammatory responses in the vasculature in response to chronic or recurring low LPS.	Scripps Res Inst, Dept Immunol IMM12, La Jolla, CA 92037 USA	Scripps Research Institute	Tobias, PS (corresponding author), Scripps Res Inst, Dept Immunol IMM12, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tobias@scripps.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-23584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Cao JJ, 2003, CIRCULATION, V108, P166, DOI 10.1161/01.CIR.0000079160.07364.6A; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Detmers PA, 1996, J IMMUNOL, V157, P5589; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Hailman E, 1996, J IMMUNOL, V156, P4384; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Hijiya N, 2002, PATHOBIOLOGY, V70, P18, DOI 10.1159/000066000; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Kitchens RL, 1998, J IMMUNOL, V160, P1920; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lehr HA, 2001, CIRCULATION, V104, P914, DOI 10.1161/hc3401.093153; Leturcq DJ, 1996, J CLIN INVEST, V98, P1533, DOI 10.1172/JCI118945; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1995, J INFLAMM, V45, P49; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SHINJI H, 1993, J LEUKOCYTE BIOL, V54, P336, DOI 10.1002/jlb.54.4.336; SHNYRA A, 1995, INFECT IMMUN, V63, P865, DOI 10.1128/IAI.63.3.865-873.1995; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; WEINGARTEN R, 1993, J LEUKOCYTE BIOL, V53, P518, DOI 10.1002/jlb.53.5.518; Wiedermann CJ, 1999, J AM COLL CARDIOL, V34, P1975, DOI 10.1016/S0735-1097(99)00448-9; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051; Zeuke S, 2002, CARDIOVASC RES, V56, P126, DOI 10.1016/S0008-6363(02)00512-6	48	119	126	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1117	+		10.1096/fj.03-1263fje	http://dx.doi.org/10.1096/fj.03-1263fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132988				2022-12-28	WOS:000221883200024
J	Birrell, MA; McCluskie, K; Wong, SS; Donnelly, LE; Barnes, PJ; Belvisi, MG				Birrell, MA; McCluskie, K; Wong, SS; Donnelly, LE; Barnes, PJ; Belvisi, MG			Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappa B-independent mechanism	FASEB JOURNAL			English	Article						rodent; lung; neutrophils; airway inflammation; rat	NITRIC-OXIDE SYNTHASE; NATURAL POLYPHENOLIC COMPOUND; LYMPHOCYTE-PROLIFERATION; PERITONEAL-MACROPHAGES; TRANS-RESVERATROL; MONOCYTE ADHESION; GENE-EXPRESSION; IN-VITRO; ACTIVATION; APOPTOSIS	Consumption of a naturally occurring polyphenol, resveratrol, in particular through drinking moderate amounts of red wine, has been suggested to be beneficial to health. A plethora of in vitro studies published demonstrate various anti-inflammatory actions of resveratrol. The aim of this research was to determine whether any of these anti-inflammatory effects translate in vivo in a rodent model of LPS induced airway inflammation. Resveratrol reduced lung tissue neutrophilia to a similar magnitude as that achieved by treatment with budesonide. This was associated with a reduction in pro-inflammatory cytokines and prostanoid levels. Interestingly, the reduction did not appear to be due to an impact on NF-kappa B activation or the expression of the respective genes as suggested by various in vitro publications. These results suggest that resveratrol may possess anti-inflammatory properties via a novel mechanism. Elucidation of this mechanism may lead to potential new therapies for the treatment of chronic inflammation.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Resp Pharmacol Grp, London SW3 6LY, England	Imperial College London	Belvisi, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Resp Pharmacol Grp, Dovehouse St, London SW3 6LY, England.	m.belvisi@imperial.ac.uk	Belvisi, Maria G/A-3055-2009	Donnelly, Louise/0000-0002-0753-5425; Barnes, Peter/0000-0002-5122-4018				Adams AE, 1999, J CELL BIOCHEM, V74, P587, DOI 10.1002/(SICI)1097-4644(19990915)74:4<587::AID-JCB8>3.0.CO;2-G; Alonso A, 1996, EUR J IMMUNOL, V26, P2165, DOI 10.1002/eji.1830260931; Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Banerjee S, 2002, CANCER RES, V62, P4945; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Boscolo P, 2003, ANN CLIN LAB SCI, V33, P226; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Brzozowski T, 2000, J PHYSIOL-PARIS, V94, P83, DOI 10.1016/S0928-4257(00)00145-5; BURRELL R, 1988, AM REV RESPIR DIS, V137, P100, DOI 10.1164/ajrccm/137.1.100; Cho DI, 2002, LIFE SCI, V71, P2071, DOI 10.1016/S0024-3205(02)01971-9; Clement MV, 1998, BLOOD, V92, P996; Culpitt SV, 2003, THORAX, V58, P942, DOI 10.1136/thorax.58.11.942; Dallal O, 2003, BIOL NEONATE, V83, P201, DOI 10.1159/000068921; deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792; DONNELLY LE, 2002, AM J CRIT CARE MED, V165, pA614; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Feng YH, 2002, ACTA PHARMACOL SIN, V23, P1002; Ferrero ME, 1998, AM J CLIN NUTR, V68, P1208, DOI 10.1093/ajcn/68.6.1208; Ferrero ME, 1998, TRANSPLANT P, V30, P4191, DOI 10.1016/S0041-1345(98)01388-8; Flohe S, 1999, CYTOKINE, V11, P796, DOI 10.1006/cyto.1998.0490; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Gao XH, 2001, BIOCHEM PHARMACOL, V62, P1299, DOI 10.1016/S0006-2952(01)00775-4; German JB, 2000, ANNU REV NUTR, V20, P561, DOI 10.1146/annurev.nutr.20.1.561; Haddad E, 2001, BRIT J PHARMACOL, V132, P1715, DOI 10.1038/sj.bjp.0704022; Haddad EB, 2002, J IMMUNOL, V169, P974, DOI 10.4049/jimmunol.169.2.974; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hsieh TC, 1999, CANCER RES, V59, P2596; Hsieh TC, 2002, BIOCHEM BIOPH RES CO, V297, P1311, DOI 10.1016/S0006-291X(02)02384-7; Jang DS, 1999, BIOCHEM PHARMACOL, V57, P705, DOI 10.1016/S0006-2952(98)00350-5; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kuo PL, 2002, LIFE SCI, V72, P23, DOI 10.1016/S0024-3205(02)02177-X; LIU X, 1996, MULT SCLER, V1, P2; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Martin AR, 2004, BIOCHEM PHARMACOL, V67, P1399, DOI 10.1016/j.bcp.2003.12.024; Martinez J, 2000, BIOCHEM PHARMACOL, V59, P865, DOI 10.1016/S0006-2952(99)00380-9; MASFERRER JL, 1994, J PHARMACOL EXP THER, V270, P1340; McCluskie K, 2004, J PHARMACOL EXP THER, V311, P625, DOI 10.1124/jpet.104.068890; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; OLeary EC, 1997, AM J RESP CELL MOL, V16, P267, DOI 10.1165/ajrcmb.16.3.9070611; OLeary EC, 1996, AM J RESP CELL MOL, V15, P97, DOI 10.1165/ajrcmb.15.1.8679228; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; Pendurthi UR, 2002, THROMB RES, V106, P243, DOI 10.1016/S0049-3848(02)00141-X; Ramos CDL, 2003, CYTOKINE, V21, P214, DOI 10.1016/S1043-4666(03)00050-4; REMICK DG, 1990, AM J PATHOL, V136, P49; Rodgers HC, 2002, AM J PHYSIOL-LUNG C, V283, pL612, DOI 10.1152/ajplung.00483.2001; Rotondo S, 1998, BRIT J PHARMACOL, V123, P1691, DOI 10.1038/sj.bjp.0701784; Rovai LE, 1998, J LEUKOCYTE BIOL, V64, P494, DOI 10.1002/jlb.64.4.494; Rupnow HL, 2002, BIOL REPROD, V66, P468, DOI 10.1095/biolreprod66.2.468; Sanz MJ, 2002, BRIT J PHARMACOL, V135, P1872, DOI 10.1038/sj.bjp.0704644; Stanford SJ, 2000, BRIT J PHARMACOL, V129, P835, DOI 10.1038/sj.bjp.0703151; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; ULICH TR, 1995, AM J PHYSIOL-LUNG C, V268, pL245, DOI 10.1152/ajplung.1995.268.2.L245; Underwood SL, 1997, BRIT J PHARMACOL, V122, P439, DOI 10.1038/sj.bjp.0701398; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zeldin DC, 2001, AM J RESP CELL MOL, V25, P457, DOI 10.1165/ajrcmb.25.4.4505; Zhong M, 1999, PHYTOMEDICINE, V6, P79, DOI 10.1016/S0944-7113(99)80039-7	65	139	152	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					840	+		10.1096/fj.04-2691fje	http://dx.doi.org/10.1096/fj.04-2691fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15734790				2022-12-28	WOS:000227591900003
J	Zcharia, E; Zilka, R; Yaar, A; Yacoby-Zeevi, O; Zetser, A; Metzger, S; Sarid, R; Naggi, A; Casu, B; Ilan, N; Vlodavsky, I; Abramovitch, R				Zcharia, E; Zilka, R; Yaar, A; Yacoby-Zeevi, O; Zetser, A; Metzger, S; Sarid, R; Naggi, A; Casu, B; Ilan, N; Vlodavsky, I; Abramovitch, R			Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models	FASEB JOURNAL			English	Article						heparan sulfate; keratinocytes; blood vessel maturation; extracellular matrix; MRI; tissue repair; wound fluid	GROWTH-FACTORS; EXTRACELLULAR-MATRIX; LAMINARIN SULFATE; TUMOR-METASTASIS; MAMMALIAN HEPARANASE; ENZYMATIC-ACTIVITY; NITRIC-OXIDE; KEY ENZYME; EXPRESSION; INHIBITION	Orchestration of the rapid formation and reorganization of new tissue observed in wound healing involves not only cells and polypeptides but also the extracellular matrix (ECM) microenvironment. The ability of heparan sulfate (HS) to interact with major components of the ECM suggests a key role for HS in maintaining the structural integrity of the ECM. Heparanase, an endoglycosidase- degrading HS in the ECM and cell surface, is involved in the enzymatic machinery that enables cellular invasion and release of HS-bound polypeptides residing in the ECM. Bioavailabilty and activation of multitude mediators capable of promoting cell migration, proliferation, and neovascularization are of particular importance in the complex setting of wound healing. We provide evidence that heparanase is normally expressed in skin and in the wound granulation tissue. Heparanase stimulated keratinocyte cell migration and wound closure in vitro. Topical application of recombinant heparanase significantly accelerated wound healing in a flap/punch model and markedly improved flap survival. These heparanase effects were associated with enhanced wound epithelialization and blood vessel maturation. Similarly, a marked elevation in wound angiogenesis, evaluated by MRI analysis and histological analyses, was observed in heparanase-overexpressing transgenic mice. This effect was blocked by a novel, newly developed, heparanase-inhibiting glycol-split fragment of heparin. These results clearly indicate that elevation of heparanase levels in healing wounds markedly accelerates tissue repair and skin survival that are mediated primarily by an enhanced angiogenic response.	Hadassah Hebrew Univ Med Ctr, Dept Oncol, Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Med, Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Gene Therapy, Jerusalem, Israel; InSight Biopharmaceut, Rehovot, Israel; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; G Ronzoni Inst Chem & Biochem Res, Milan, Italy	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Bar Ilan University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Ilan, N (corresponding author), Technion Israel Inst Technol, Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	netailan@tx.technion.ac.il; vlodavsk@cc.huji.ac.il			NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER; NCI NIH HHS [CA106456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramovitch R, 1998, BRIT J CANCER, V77, P440, DOI 10.1038/bjc.1998.70; Abramovitch R, 1999, CANCER RES, V59, P5012; Andriessen MP, 1997, J PATHOL, V183, P264; Bennett SP, 2003, BRIT J SURG, V90, P133, DOI 10.1002/bjs.4019; Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Casu B, 2004, J MED CHEM, V47, P838, DOI 10.1021/jm030893g; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CUNNINGHAM LD, 1992, J CLIN INVEST, V89, P878, DOI 10.1172/JCI115667; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2004, J PATHOL, V203, P594, DOI 10.1002/path.1554; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Gong F, 2003, J BIOL CHEM, V278, P35152, DOI 10.1074/jbc.M300925200; HOFFMAN R, 1995, J CELL SCI, V108, P3591; Hoffman R, 1996, BRIT J CANCER, V73, P1183, DOI 10.1038/bjc.1996.228; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; MAGRATH JA, 1997, J PATHOL, V183, P251; Marchetti D, 2003, INT J CANCER, V104, P167, DOI 10.1002/ijc.10930; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Mustoe Thomas A., 1994, Wound Repair and Regeneration, V2, P277, DOI 10.1046/j.1524-475X.1994.20408.x; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Norfleet AM, 2000, WOUND REPAIR REGEN, V8, P517, DOI 10.1046/j.1524-475x.2000.00517.x; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rolny C, 2002, J BIOL CHEM, V277, P19315, DOI 10.1074/jbc.M111805200; Saijo M, 2003, HISTOCHEM CELL BIOL, V120, P493, DOI 10.1007/s00418-003-0589-1; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; Schubert SY, 2004, LAB INVEST, V84, P535, DOI 10.1038/labinvest.3700084; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Takase H, 1999, J CARDIOVASC PHARM, V33, P223, DOI 10.1097/00005344-199902000-00007; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Varki NM, 2002, SEMIN THROMB HEMOST, V28, P53, DOI 10.1055/s-2002-20564; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 2003, PATHOPHYSIOL HAEMO T, V33, P59, DOI 10.1159/000073296; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WU LC, 1995, GROWTH FACTORS, V12, P29, DOI 10.3109/08977199509003211; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200; Yamawaki H, 2000, BRIT J PHARMACOL, V131, P1546, DOI 10.1038/sj.bjp.0703771; Zetser A, 2003, CANCER RES, V63, P7733; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	60	130	140	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					211	221		10.1096/fj.04-1970com	http://dx.doi.org/10.1096/fj.04-1970com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677344				2022-12-28	WOS:000227591900025
J	Dreiza, CM; Brophy, CM; Komalavilas, P; Furnish, EJ; Joshi, L; Pallero, MA; Murphy-Ullrich, JE; von Rechenberg, M; Ho, YSJ; Richardson, B; Xu, NF; Zhen, YJ; Peltier, JM; Panitch, A				Dreiza, CM; Brophy, CM; Komalavilas, P; Furnish, EJ; Joshi, L; Pallero, MA; Murphy-Ullrich, JE; von Rechenberg, M; Ho, YSJ; Richardson, B; Xu, NF; Zhen, YJ; Peltier, JM; Panitch, A			Transducible heat shock protein 20 (HSP20) phosphopeptide alters cytoskeletal dynamics	FASEB JOURNAL			English	Article						14-3-3 proteins; cofilin; actin; proteomics	SHOCK-RELATED PROTEIN; SERINE 16; ACTIN; PHOSPHORYLATION; COFILIN; IDENTIFICATION; KINASE	Activation of cyclic nucleotide dependent signaling pathways leads to relaxation of smooth muscle, alterations in the cytoskeleton of cultured cells, and increases in the phosphorylation of HSP20. To determine the effects of phosphorylated HSP20 on the actin cytoskeleton, phosphopeptide analogs of HSP20 were synthesized. These peptides contained 1) the amino acid sequence surrounding the phosphorylation site of HSP20, 2) a phosphoserine, and 3) a protein transduction domain. Treatment of Swiss 3T3 cells with phosphopeptide analogs of HSP20 led to loss of actin stress fibers and focal adhesion complexes as demonstrated by immunocytochemistry, interference reflection microscopy, and biochemical quantitation of globular-actin. Treatment with phosphopeptide analogs of HSP20 also led to dephosphorylation of the actin depolymerizing protein cofilin. Pull-down assays demonstrated that 14-3-3 proteins associated with phosphopeptide analogs of HSP20 ( but not peptide analogs in which the serine was not phosphorylated). The binding of 14-3-3 protein to phosphopeptide analogs of HSP20 prevented the association of cofilin with 14-3-3. These data suggest that HSP20 may modulate actin cytoskeletal dynamics by competing with the actin depolymerizing protein cofilin for binding to the scaffolding protein 14-3-3. Interestingly, the entire protein was not needed for this effect, suggesting that the association is modulated by phosphopeptide motifs of HSP20. These data also suggest the possibility that cyclic nucleotide dependent relaxation of smooth muscle may be mediated by a thin filament ( actin) regulatory process. Finally, these data suggest that protein transduction can be used as a tool to elucidate the specific function of peptide motifs of proteins.	Arizona State Univ, Harrington Dept Bioengn, Tempe, AZ 85287 USA; Carl T Hayden VAMC, Phoenix, AZ USA; Arizona State Univ, Biodesign Inst, Tempe, AZ USA; Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Prolexys Pharmaceut Inc, Salt Lake City, UT USA; Arizona State Univ, Sch Life Sci, Tempe, AZ USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; University of Alabama System; University of Alabama Birmingham; Arizona State University; Arizona State University-Tempe	Brophy, CM (corresponding author), Arizona State Univ, Harrington Dept Bioengn, ECG 334,POB 879709, Tempe, AZ 85287 USA.	colleen.brophy@asu.edu	Panitch, Alyssa/F-4413-2012	Zhen, Eugene/0000-0002-0162-5665; Joshi, Lokesh/0000-0002-3612-0747	NHLBI NIH HHS [R01 HL58027] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058027] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Beall AC, 1997, J BIOL CHEM, V272, P11283; Birkenfeld J, 2003, BIOCHEM J, V369, P45, DOI 10.1042/BJ20021152; Brophy CM, 1999, J VASC SURG, V29, P326, DOI 10.1016/S0741-5214(99)70385-X; Brophy CM, 1999, J BIOL CHEM, V274, P6324, DOI 10.1074/jbc.274.10.6324; Flynn CR, 2003, FASEB J, V17, P1358, DOI 10.1096/fj.02-1028fje; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; Gunst SJ, 2003, RESP PHYSIOL NEUROBI, V137, P151, DOI 10.1016/S1569-9048(03)00144-7; HEACOCK CS, 1983, ANAL BIOCHEM, V135, P22, DOI 10.1016/0003-2697(83)90725-X; Macomson SD, 2002, NEUROSURGERY, V51, P204, DOI 10.1097/00006123-200207000-00029; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Rembold C M, 2001, BMC Physiol, V1, P10, DOI 10.1186/1472-6793-1-10; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Takuma T, 1996, J BIOCHEM, V120, P35; Tessier DJ, 2003, J SURG RES, V111, P152, DOI 10.1016/S0022-4804(03)00113-6; Wang Y, 1999, FEBS LETT, V462, P25, DOI 10.1016/S0014-5793(99)01496-9; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Woodrum D, 2003, J VASC SURG, V37, P874, DOI 10.1067/mva.2003.153; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	26	81	89	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					261	+		10.1096/fj.04-2911fje	http://dx.doi.org/10.1096/fj.04-2911fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15598710				2022-12-28	WOS:000226091000016
J	Navarro, A; Anand-Apte, B; Parat, MO				Navarro, A; Anand-Apte, B; Parat, MO			A role for caveolae in cell migration	FASEB JOURNAL			English	Review						angiogenesis; caveolin-1; endothelial cell; motility	NITRIC-OXIDE SYNTHASE; INTEGRIN-MEDIATED ADHESION; MEMBRANE RAFT MICRODOMAINS; ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; LIPID RAFTS; PLASMA-MEMBRANE; DOWN-REGULATION; MATRIX-METALLOPROTEINASE; ENDOPLASMIC-RETICULUM	Caveolae are specialized plasma membrane subdomains capable of transport and sophisticated compartmentalization of cell signaling. Numerous cell functions, including cell type-specific functions, involve caveolae and require caveolin-1, the major protein component of these organelles. Caveolae are particularly abundant in endothelial cells and participate in endothelial transcytosis, vascular permeability, vasomotor tone control, and vascular reactivity. Caveolin-1 drives the formation of plasma membrane caveolae and anchors them to the actin cytoskeleton, modulates cell interaction with the extracellular matrix, pulls together and regulates signaling molecules, and transports cholesterol. Via these functions, caveolin-1 might play an important role in cell movement through control of cell membrane composition and membrane surface expansion, polarization of signaling molecules and matrix proteolysis, and/or cytoskeleton remodeling. Caveolae and caveolin-1 are polarized in migrating endothelial cells, indicating they may play a role in cell motility. Several studies have shown that manipulation of caveolin-1 expression affects cell migration in a complex way. We are reviewing the current data and hypotheses in favor of an essential role for caveolae in cell migration.	Cleveland Clin Fdn, Dept Anesthesiol Res, Cleveland, OH 44122 USA; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Parat, MO (corresponding author), Cleveland Clin Fdn, Dept Anesthesiol Res, 9500 Euclid Ave, Cleveland, OH 44122 USA.	paratm@ccf.org	Parat, Marie-Odile/G-4410-2010	Parat, Marie-Odile/0000-0003-4895-7381	NEI NIH HHS [R01 EY016490, R29 EY012109, R29EY012109] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY016490, R29EY012109] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Axel DI, 2000, J CARDIOVASC PHARM, V35, P619, DOI 10.1097/00005344-200004000-00016; Boyd NL, 2003, AM J PHYSIOL-HEART C, V285, pH1113, DOI 10.1152/ajpheart.00302.2003; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; Bretscher MS, 1998, CURR OPIN CELL BIOL, V10, P537, DOI 10.1016/S0955-0674(98)80070-7; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Cavallo-Medved D, 2003, NEOPLASIA, V5, P507, DOI 10.1016/S1476-5586(03)80035-0; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Dedkova EN, 2002, J PHYSIOL-LONDON, V539, P77, DOI 10.1113/jphysiol.2001.013258; Del Pozo MA, 2004, CELL CYCLE, V3, P725; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Fernandez I, 2002, P NATL ACAD SCI USA, V99, P11193, DOI 10.1073/pnas.172196599; Frank PG, 2003, ARTERIOSCL THROM VAS, V23, P1161, DOI 10.1161/01.ATV.0000070546.16946.3A; FUJIMOTO T, 1995, J CELL SCI, V108, P7; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Gratton JP, 2003, CANCER CELL, V4, P31, DOI 10.1016/S1535-6108(03)00168-5; Griffoni C, 2000, BIOCHEM BIOPH RES CO, V276, P756, DOI 10.1006/bbrc.2000.3484; Guan JL, 2004, SCIENCE, V303, P773, DOI 10.1126/science.1094376; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hocking DC, 2002, J CELL BIOL, V158, P175, DOI 10.1083/jcb.200112031; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kolega J, 1998, J CELL SCI, V111, P2085; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; Lee PC, 1999, AM J PHYSIOL-HEART C, V277, pH1600, DOI 10.1152/ajpheart.1999.277.4.H1600; Li H, 1998, ENDOCRINOLOGY, V139, P4991, DOI 10.1210/en.139.12.4991; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Manes S, 2001, SEMIN IMMUNOL, V13, P147, DOI 10.1006/smim.2000.0306; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Michel T, 1999, BRAZ J MED BIOL RES, V32, P1361, DOI 10.1590/S0100-879X1999001100006; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nabeshima K, 2000, CANCER RES, V60, P3364; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Park DS, 2003, BIOCHEMISTRY-US, V42, P15124, DOI 10.1021/bi0356348; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; Pierini LM, 2000, BLOOD, V95, P2471; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; Regina A, 2004, J NEUROSCI RES, V75, P291, DOI 10.1002/jnr.10865; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; ROHLICH P, 1976, J ULTRA MOL STRUCT R, V57, P94, DOI 10.1016/S0022-5320(76)80059-7; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Schmoranzer J, 2003, J CELL SCI, V116, P4513, DOI 10.1242/jcs.00748; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; Senda T, 1997, EXP CELL RES, V230, P163, DOI 10.1006/excr.1996.3414; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Seveau S, 2001, MOL BIOL CELL, V12, P3550, DOI 10.1091/mbc.12.11.3550; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simantov R, 2003, FRONT BIOSCI-LANDMRK, V8, pS874, DOI 10.2741/1168; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 2002, METHOD ENZYMOL, V353, P131; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Sonveaux P, 2004, CIRC RES, V95, P154, DOI 10.1161/01.RES.0000136344.27825.72; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stan RV, 2002, MICROSC RES TECHNIQ, V57, P350, DOI 10.1002/jemt.10089; Sun RJ, 2002, EUR BIOPHYS J BIOPHY, V30, P605, DOI 10.1007/s00249-001-0195-x; Tang W, 2004, J BIOL CHEM, V279, P11112, DOI 10.1074/jbc.M312947200; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Vasanji A, 2004, DEV CELL, V6, P29, DOI 10.1016/S1534-5807(03)00397-6; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wedlich-Soldner R, 2003, NAT CELL BIOL, V5, P267, DOI 10.1038/ncb0403-267; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; Wickstrom SA, 2002, CANCER RES, V62, P5580; Woodman SE, 2003, AM J PATHOL, V162, P2059, DOI 10.1016/S0002-9440(10)64337-4; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	129	134	138	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1801	1811		10.1096/fj.04-2516rev	http://dx.doi.org/10.1096/fj.04-2516rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576483				2022-12-28	WOS:000226091000030
J	Soares-Da-Silva, P; Serrao, MP; Pinho, MJ; Bonifacio, MJ				Soares-Da-Silva, P; Serrao, MP; Pinho, MJ; Bonifacio, MJ			Cloning and gene silencing of LAT2, the L-3,4-dihydroxyphenylalanine (L-DOPA) transporter, in pig renal LLC-PK1 epithelial cells	FASEB JOURNAL			English	Article						LAT2; siRNA; LLC-PK1 cells; amino acid exchanger	AMINO-ACID TRANSPORTERS; CEREBRAL ENDOTHELIAL-CELLS; BLOOD-BRAIN-BARRIER; MOLECULAR-BIOLOGY; P-GLYCOPROTEIN; HEAVY-CHAIN; SALT INTAKE; KIDNEY; HYPERTENSION; SODIUM	Organ-specific overexpression of type 2 L-amino acid transporter (LAT2) in the kidney of the spontaneous hypertensive rat ( SHR), accompanied by an enhanced ability to take up L-DOPA, may constitute the basis for the enhanced renal production of dopamine in the SHR in an attempt overcome the deficient dopamine-mediated natriuresis. To understand the physiological role of LAT2-mediated L-DOPA handling, we used 21-nucleotide small interfering RNA duplexes ( siRNA) to specifically suppress LAT2 expression in LLC-PK1 cells, a cell line that retains several properties of proximal tubular epithelial cells and takes up L-DOPA largely through Na+-independent transporters. After cloning the LLC-PK1 LAT2 gene, one target region of LAT2 mRNA ( nt 97-117) was selected by scanning the length of the LAT2 gene for AA-dinucleotide sequences and downstream 19 nucleotides. Levels of LAT2 cDNA, determined by real-time quantitative RT-PCR, were markedly (P< 0.05) reduced by LAT2 siRNA but not by the mismatch LAT2 siRNA. The LAT2 siRNA but not the mismatch LAT2 siRNA, reduced by 85% [C-14]-L-DOPA accumulation, a time- and concentration-dependent effect. The efflux of intracellular [C-14]-L-DOPA was markedly increased ( P< 0.05) by L-DOPA and L-leucine. The [C-14]-L-DOPA outward transport was decreased 90% by LAT2 siRNA, but not by the mismatch LAT2 siRNA. However, treatment with the siRNA LAT2 did not affect the L-DOPA-induced fractional outflow of [C-14]-L-DOPA. The Na+-independent and pH-sensitive L-DOPA transporter may include the hetero amino acid exchanger LAT2, whose activation results in trans-stimulation of L-DOPA outward transfer.	Fac Med, Inst Pharmacol & Therapeut, P-4200 Oporto, Portugal	Universidade do Porto	Soares-Da-Silva, P (corresponding author), Fac Med, Inst Pharmacol & Therapeut, P-4200 Oporto, Portugal.	psoaresdasilva@netcabo.pt	Soares-da-Silva, Patricio/A-6704-2015	Soares-da-Silva, Patricio/0000-0002-2446-5078; Pinho, Maria Joao/0000-0001-8173-0379; Serrao, Paula/0000-0002-3663-7500				AUDUS KL, 1986, J NEUROCHEM, V47, P484; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fraga S, 2002, J NUTR, V132, P733, DOI 10.1093/jn/132.4.733; Gomes P, 1999, BRAIN RES, V829, P143, DOI 10.1016/S0006-8993(99)01387-6; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; Hussain T, 2003, EXP BIOL MED, V228, P134, DOI 10.1177/153537020322800202; Jose PA, 2002, CURR HYPERTENS REP, V4, P237, DOI 10.1007/s11906-002-0013-6; Jose PA, 2002, CURR OPIN NEPHROL HY, V11, P87, DOI 10.1097/00041552-200201000-00013; Kageyama T, 2000, BRAIN RES, V879, P115, DOI 10.1016/S0006-8993(00)02758-X; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; Lucas-Teixeira VA, 2000, CLIN EXP HYPERTENS, V22, P455, DOI 10.1081/CEH-100100084; Motulsky H., 1999, ANAL DATA GRAPHPAD P; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Pinho MJ, 2003, HYPERTENSION, V42, P613, DOI 10.1161/01.HYP.0000091822.00166.B1; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; RACZ K, 1985, CIRC RES, V57, P889, DOI 10.1161/01.RES.57.6.889; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Sampaio-Maia B, 2001, AM J PHYSIOL-CELL PH, V280, pC333, DOI 10.1152/ajpcell.2001.280.2.C333; Sanada H, 1995, Hypertens Res, V18 Suppl 1, pS179, DOI 10.1291/hypres.18.SupplementI_S179; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Soares-Da-Silva P, 2000, AM J PHYSIOL-RENAL, V279, pF736, DOI 10.1152/ajprenal.2000.279.4.F736; Soares-da-Silva P, 1998, BRIT J PHARMACOL, V123, P13, DOI 10.1038/sj.bjp.0701572; Soares-da-Silva P, 2000, J PHARMACOL EXP THER, V293, P697; Soares-da-Silva P, 1998, AM J PHYSIOL-RENAL, V274, pF243, DOI 10.1152/ajprenal.1998.274.2.F243; SOARESDASILVA P, 1993, J AM SOC NEPHROL, V3, P1591; SOARESDASILVA P, 1992, BRIT J PHARMACOL, V105, P811, DOI 10.1111/j.1476-5381.1992.tb09062.x; SOARESDASILVA P, 1993, J PHARMACOL EXP THER, V264, P406; Vieira-Coelho MA, 1999, HYPERTENSION, V34, P666, DOI 10.1161/01.HYP.34.4.666; WADE LA, 1975, J NEUROCHEM, V25, P837, DOI 10.1111/j.1471-4159.1975.tb04415.x; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; YOSHIMURA M, 1990, J AUTON PHARMACOL, V10, pS67, DOI 10.1111/j.1474-8673.1990.tb00230.x	36	19	20	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1489	1498		10.1096/fj.04-1787com	http://dx.doi.org/10.1096/fj.04-1787com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466357				2022-12-28	WOS:000224849900032
J	Guillet, C; Prod'homme, M; Balage, M; Gachon, P; Giraudet, C; Morin, L; Grizard, J; Boirie, Y				Guillet, C; Prod'homme, M; Balage, M; Gachon, P; Giraudet, C; Morin, L; Grizard, J; Boirie, Y			Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans	FASEB JOURNAL			English	Article						sarcopenia; post-prandial anabolism; insulin; signaling pathways	HUMAN SKELETAL-MUSCLE; AMINO-ACIDS; TRANSLATION INITIATION; INSULIN-RESISTANCE; SYNTHESIS RATES; BODY-FAT; HYPERINSULINEMIA; STIMULATION; LEUCINE; MITOCHONDRIAL	Age-related loss of muscle protein may involve a decreased response to anabolic factors of muscle protein synthesis through dysregulation of translation factors. To verify this hypothesis, we simultaneously investigated muscle protein synthesis and expression of some factors implicated in insulin signal transduction during hyperinsulinemia and hyperaminoacidemia in 6 young (25 +/- 1 year; mean +/- SEM) and 8 elderly subjects (72 +/- 2 year). Incorporation of L-[1-C-13] leucine in muscle proteins ( fractional synthesis rate, FSR) was measured in vastus lateralis, before and during a euglycemic hyperinsulinemic hyperaminoacidemic clamp, together with Western blot analysis of protein kinase B (PKB), mTOR, 4E-BP1, and S6K1 phosphorylation. In basal state, muscle protein FSR was reduced in elderly in comparison with young subjects ( 0.061 +/- 0.004% per hour) vs 0.082 +/- 0.010% per hour, elderly vs. young, P< 0.05). During clamp, muscle protein FSR was stimulated in young (0.119 +/- 0.006% per hour; P< 0.05), but this response was significantly lower in elderly subjects ( 0.084 +/- 0.005% per hour, P< 0.05 vs young subjects). Phosphorylation of PKB, mTOR, and 4E-BP1 were similarly increased by insulin and amino acid in both groups, except for S6K1 phosphorylation, which was not stimulated in elderly subjects. In conclusion, 1) response of muscle protein synthesis to insulin and amino acid is impaired in elderly humans; 2) a defect in S6K1 pathway activation may be responsible for this alteration. This modification is a mechanistic basis of sarcopenia development during aging.	UMR Univ Auvergne, INRA, CRNH,CHU, Unite Metab Prot Energet, Clermont Ferrand, France; INRA, CRNH, Unite Nutr & Metab Prot, Clermont Ferrand, France	CHU Clermont Ferrand; INRAE; INRAE	Boirie, Y (corresponding author), Lab Nutr Humaine, Unite Metab Prot Energet, BP 321,58 Rue Montalembert, F-63009 Clermont Ferrand 1, France.	boirie@clermont.inra.fr						Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; BAILLIE AGS, 1992, AM J PHYSIOL, V262, pE1, DOI 10.1152/ajpendo.1992.262.1.E1; Balage M, 2001, AM J PHYSIOL-ENDOC M, V281, pE565, DOI 10.1152/ajpendo.2001.281.3.E565; BENNET WM, 1990, AM J PHYSIOL, V259, pE185, DOI 10.1152/ajpendo.1990.259.2.E185; BODEN G, 1993, DIABETES CARE, V16, P728, DOI 10.2337/diacare.16.5.728; Boirie Y, 2001, DIABETES, V50, P2652, DOI 10.2337/diabetes.50.12.2652; Bryhni B, 2003, METABOLISM, V52, P850, DOI 10.1016/S0026-0495(03)00100-8; COON PJ, 1992, J CLIN ENDOCR METAB, V75, P1125, DOI 10.1210/jc.75.4.1125; DARDEVET D, 1994, ENDOCRINOLOGY, V134, P1475, DOI 10.1210/en.134.3.1475; Dardevet D, 2002, J NUTR, V132, P95, DOI 10.1093/jn/132.1.95; Dardevet D, 2000, J NUTR, V130, P2630, DOI 10.1093/jn/130.11.2630; Davis TA, 2002, AM J PHYSIOL-ENDOC M, V282, pE880, DOI 10.1152/ajpendo.00517.2001; Greiwe JS, 2001, AM J PHYSIOL-ENDOC M, V281, pE466, DOI 10.1152/ajpendo.2001.281.3.E466; Guillet C, 2004, EXP GERONTOL, V39, P745, DOI 10.1016/j.exger.2004.02.011; Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, pE620, DOI 10.1152/ajpendo.2000.278.4.E620; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P214, DOI 10.1093/ajcn/52.2.214; Hillier T, 2000, J CLIN ENDOCR METAB, V85, P4900, DOI 10.1210/jc.85.12.4900; Hillier TA, 1998, AM J PHYSIOL-ENDOC M, V274, pE1067, DOI 10.1152/ajpendo.1998.274.6.E1067; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Liu ZQ, 2002, J CLIN ENDOCR METAB, V87, P5553, DOI 10.1210/jc.2002-020424; Ljungqvist OH, 1997, AM J PHYSIOL-ENDOC M, V273, pE564, DOI 10.1152/ajpendo.1997.273.3.E564; Long W, 2000, AM J PHYSIOL-ENDOC M, V279, pE301, DOI 10.1152/ajpendo.2000.279.2.E301; MOSONI L, 1995, AM J PHYSIOL-ENDOC M, V268, pE328, DOI 10.1152/ajpendo.1995.268.2.E328; NAIR KS, 1995, J GERONTOL A-BIOL, V50, P107; NEWMAN E, 1994, METABOLISM, V43, P70, DOI 10.1016/0026-0495(94)90159-7; O'Connor PMJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE40, DOI 10.1152/ajpendo.00563.2002; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Rimbert V, 2004, FASEB J, V18, P737, DOI 10.1096/fj.03-1104fje; Roubenoff R, 2000, J Nutr Health Aging, V4, P140; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100; Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896; Vary TC, 1999, AM J PHYSIOL-ENDOC M, V277, pE1077, DOI 10.1152/ajpendo.1999.277.6.E1077; Volpi E, 2003, AM J CLIN NUTR, V78, P250, DOI 10.1093/ajcn/78.2.250; Volpi E, 1998, J CLIN INVEST, V101, P2000, DOI 10.1172/JCI939; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Volpi E, 2000, J CLIN ENDOCR METAB, V85, P4481, DOI 10.1210/jc.85.12.4481; Volpi E, 1999, AM J PHYSIOL-ENDOC M, V277, pE513, DOI 10.1152/ajpendo.1999.277.3.E513; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; WELLE S, 1993, AM J PHYSIOL, V264, pE693, DOI 10.1152/ajpendo.1993.264.5.E693; Wolfe RR, 2002, J NUTR, V132, p3219S, DOI 10.1093/jn/131.10.3219S; WOLFSON L, 1995, J GERONTOL A-BIOL, V50, P64	43	307	317	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1586	+		10.1096/fj.03-1341fje	http://dx.doi.org/10.1096/fj.03-1341fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319361	Bronze			2022-12-28	WOS:000223554900002
J	Haroon, ZA; Amin, K; Lichtlen, P; Sato, B; Huynh, NT; Wang, ZH; Schaffner, W; Murphy, BJ				Haroon, ZA; Amin, K; Lichtlen, P; Sato, B; Huynh, NT; Wang, ZH; Schaffner, W; Murphy, BJ			Loss of metal transcription factor-1 suppresses tumor growth through enhanced matrix deposition	FASEB JOURNAL			English	Article						MTF-1; fibrosis; tumorigenesis	FACTOR-BETA; CROSS-LINKING; TISSUE TRANSGLUTAMINASE; GENE-EXPRESSION; TGF-BETA; METALLOTHIONEIN EXPRESSION; FACTOR MTF-1; MESSENGER-RNA; CELL-PROLIFERATION; RESPONSE ELEMENTS	Metal transcription factor-1 (MTF-1) is a ubiquitous transcriptional regulator and chromatin insulator with roles in cellular stress responses and embryonic development. The studies described herein establish for the first time the involvement of MTF-1 in tumor development. Genetically manipulated ras- transformed mouse embryonic fibroblasts (MEFs), wild-type (MTF-1(+/+)), or nullizygous for MTF-1 (MTF-1(-/-)) were used to develop fibrosarcoma tumors. Loss of MTF-1 resulted in delayed tumor growth associated with increased matrix collagen deposition and reductions in vasculature density. Molecular consequences of MTF-1 loss include increased expression and activation of the transforming growth factor-beta1 (TGF-beta1) and tissue transglutaminase (tTG), two proteins with documented roles in the production and stabilization of extracellular matrix (ECM). Our findings support the hypothesis that MTF-1 enhances the ability of the developing tumor mass to evade fibrosis and scarring of the tumor, a critical step in tumor cell proliferation.	SRI Int, Biosci Div, Menlo Pk, CA 94025 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Zurich, Inst Mol Biol, Zurich, Switzerland	SRI International; Duke University; University of Zurich	Murphy, BJ (corresponding author), SRI Int, Biosci Div, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA.	brian.murphy@sri.com		Amin, Khalid/0000-0001-8992-8419	NCI NIH HHS [CA57692-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057692, R29CA057692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achary MP, 2000, CYTOGENET CELL GENET, V91, P39, DOI 10.1159/000056815; Adilakshmi T, 2002, J BIOL CHEM, V277, P4147, DOI 10.1074/jbc.M109785200; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Daniels PJ, 2003, NUCLEIC ACIDS RES, V31, P6710, DOI 10.1093/nar/gkg913; der Maur Adrian Auf, 1999, Biological Chemistry, V380, P175; Donnini S, 1999, J PATHOL, V189, P66, DOI 10.1002/(SICI)1096-9896(199909)189:1<66::AID-PATH390>3.0.CO;2-X; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Egli D, 2003, EMBO J, V22, P100, DOI 10.1093/emboj/cdg012; Elias JM, 1997, BIOTECH HISTOCHEM, V72, P78, DOI 10.3109/10520299709082216; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; Green CJ, 2001, CANCER RES, V61, P2696; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Haroon ZA, 2000, ANN SURG, V231, P137, DOI 10.1097/00000658-200001000-00020; Haroon ZA, 2002, CANCER BIOL THER, V1, P121, DOI 10.4161/cbt.55; Haroon ZA, 2001, LAB INVEST, V81, P83, DOI 10.1038/labinvest.3780214; Haroon ZA, 1999, LAB INVEST, V79, P1679; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Ioachim E, 1999, PATHOL RES PRACT, V195, P809, DOI 10.1016/S0344-0338(99)80102-2; Ioachim EE, 2001, ANTICANCER RES, V21, P1757; Izawa JI, 1998, UROLOGY, V52, P767, DOI 10.1016/S0090-4295(98)00323-9; Jasani B, 1997, HISTOPATHOLOGY, V31, P211, DOI 10.1046/j.1365-2559.1997.2140848.x; Jin RX, 2002, CARCINOGENESIS, V23, P81, DOI 10.1093/carcin/23.1.81; Kodama J, 1997, EUR J GYNAECOL ONCOL, V18, P508; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Le DM, 2003, J NEUROSCI, V23, P4034; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Maier H, 1997, ACTA NEUROPATHOL, V94, P599, DOI 10.1007/s004010050755; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; McCluggage WG, 1999, HISTOPATHOLOGY, V34, P51; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; Moussa M, 1997, CLIN INVEST MED, V20, P371; Murphy BJ, 1999, CANCER RES, V59, P1315; Nomura M, 1998, J NEURO-ONCOL, V40, P123, DOI 10.1023/A:1006198422718; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Paterson IC, 2002, ONCOGENE, V21, P1616, DOI 10.1038/sj.onc.1205217; Perelman N, 2003, BLOOD, V102, P1506, DOI 10.1182/blood-2002-11-3422; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050; Rosenthal AK, 2000, ARTHRITIS RHEUM, V43, P1729, DOI 10.1002/1529-0131(200008)43:8<1729::AID-ANR8>3.0.CO;2-0; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Somji S, 2001, CANCER DETECT PREV, V25, P62; Sugita K, 2001, AM J DERMATOPATH, V23, P29, DOI 10.1097/00000372-200102000-00005; Sutter NB, 2003, P NATL ACAD SCI USA, V100, P1105, DOI 10.1073/pnas.242732999; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	68	29	33	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1176	1184		10.1096/fj.03-1205com	http://dx.doi.org/10.1096/fj.03-1205com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15284217				2022-12-28	WOS:000223554900032
J	Hollenbach, E; Neumann, M; Vieth, M; Roessner, A; Malfertheiner, P; Naumann, M				Hollenbach, E; Neumann, M; Vieth, M; Roessner, A; Malfertheiner, P; Naumann, M			Inhibition of p38 MAP kinase- and RICK/NF-kappa B-signaling suppresses inflammatory bowel disease	FASEB JOURNAL			English	Article						IBD; I kappa B; Rip-like interacting caspase-like apoptosis-regulatory protein kinase	ACTIVATED PROTEIN-KINASE; DEXTRAN SULFATE SODIUM; CROHNS-DISEASE; EXPERIMENTAL COLITIS; ULCERATIVE-COLITIS; NOD2; STRESS; MICE; TNF; EXPRESSION	Ulcerative colitis and Crohn's disease are the two entities of chronic inflammatory bowel diseases (IBD). One of the main pathogenic mechanisms is probably a dysregulated immune response triggered by products of the enteric bacterial flora. The goal of this study was to evaluate the effects of the p38 mitogen-activated protein kinase ( MAPK) inhibitor SB203580 on inflammatory responses using the DSS-induced experimental colitis model in mice reflecting human IBD. We found that SB203580 improved the clinical score, ameliorates the histological alterations, and reduces the mRNA levels of proinflammatory cytokines. In addition to p38 kinase activity, the "classical" and the "alternative" NF-kappaB pathways were also strongly activated during colitis induction. All three pathways were drastically down-regulated by SB203580 treatment. An analysis of the molecular basis of NF-kappaB activation revealed that Rip-like interacting caspase-like apoptosis-regulatory protein kinase ( RICK), a key component of a pathway leading to NF-kappaB induction, is also strongly inhibited by SB203580. Since RICK is an effector kinase of NOD2, an intracellular receptor of bacterial peptidoglycan, these results support the notion that NOD signaling could play a pivotal role in the IBD pathogenesis. Thus, RICK could represent a novel target for future therapies in human IBD.	Otto von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Otto von Guericke Univ, Dept Gastroenterol Hepatol & Infectiol, D-39120 Magdeburg, Germany; Otto von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Neumann, M (corresponding author), Otto von Guericke Univ, Inst Expt Internal Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	naumann@medizin.uni-magdeburg.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Andruilli A, 2004, GASTROENTEROLOGY, V126, P625, DOI 10.1053/j.gastro.2003.12.027; Axelsson LG, 1998, ALIMENT PHARM THER, V12, P925, DOI 10.1046/j.1365-2036.1998.00357.x; Axelsson LG, 1996, INFLAMM RES, V45, P181, DOI 10.1007/BF02285159; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BEAGLEY KW, 1991, GASTROENTEROLOGY, V100, P560; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; Brant SR, 2003, INFLAMM BOWEL DIS, V9, P281, DOI 10.1097/00054725-200309000-00001; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; D'Haens GR, 1998, GASTROENTEROLOGY, V114, P262, DOI 10.1016/S0016-5085(98)70476-7; Daperno M, 2002, ALIMENT PHARM THER, V16, P7, DOI 10.1046/j.1365-2036.16.s4.2.x; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Gionchetti P, 2002, ALIMENT PHARM THER, V16, P13, DOI 10.1046/j.1365-2036.16.s4.3.x; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Giraux P, 2001, NAT NEUROSCI, V4, P691, DOI 10.1038/89472; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Hampe J, 2002, LANCET, V359, P1661, DOI 10.1016/S0140-6736(02)08590-2; Hampe J, 1999, AM J HUM GENET, V65, P1647, DOI 10.1086/302677; Hartmann G, 2000, J PHARMACOL EXP THER, V292, P22; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kojouharoff G, 1997, CLIN EXP IMMUNOL, V107, P353, DOI 10.1111/j.1365-2249.1997.291-ce1184.x; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LU HAT, 1998, EMBO J, V17, P2817; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MURTHY SNS, 1993, DIGEST DIS SCI, V38, P1722, DOI 10.1007/BF01303184; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Neurath MF, 1998, ANN NY ACAD SCI, V859, P149, DOI 10.1111/j.1749-6632.1998.tb11119.x; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Parhar K, 2003, IMMUNOLOGY, V108, P502, DOI 10.1046/j.1365-2567.2003.01603.x; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; ten Hove T, 2002, GUT, V50, P507, DOI 10.1136/gut.50.4.507; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Waetzig GH, 2003, ALIMENT PHARM THER, V18, P17, DOI 10.1046/j.1365-2036.2003.01642.x; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Weih F, 1997, J IMMUNOL, V158, P5211; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wex T, 2003, CLIN CHEM LAB MED, V41, P1033, DOI 10.1515/CCLM.2003.159; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhao M, 1999, MOL CELL BIOL, V19, P21	60	174	190	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1550	+		10.1096/fj.04-1642fje	http://dx.doi.org/10.1096/fj.04-1642fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289440				2022-12-28	WOS:000223554900022
J	Fiedler, M; Muller-Holzner, E; Viertler, HP; Widschwendter, A; Laich, A; Pfister, G; Spoden, GA; Jansen-Durr, P; Zwerschke, W				Fiedler, M; Muller-Holzner, E; Viertler, HP; Widschwendter, A; Laich, A; Pfister, G; Spoden, GA; Jansen-Durr, P; Zwerschke, W			High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies	FASEB JOURNAL			English	Article						cervical cancer; retinoblastoma protein; SIL; anti-HPV 16 E7 antibodies	HUMAN-PAPILLOMAVIRUS TYPE-16; RISK HUMAN-PAPILLOMAVIRUS; RETINOBLASTOMA GENE-PRODUCT; MONKEY COS-1 CELLS; CARCINOMA CELLS; TRANSFORMING ACTIVITY; PEPTIDE APTAMERS; BINDING-PROTEIN; GROWTH ARREST; CANCER-CELLS	High-risk human papillomaviruses (HPVs) are major etiological agents of cervical cancer. Despite excellent epidemiological evidence for a direct role of HPV-16 in cervical carcinogenesis, molecular pathways underlying carcinogenesis in vivo remain obscure. The E7 gene is required for immortalization and maintenance of the transformed phenotype in vitro; however, little is known about its role for tumorigenesis in vivo. The E7 gene codes for an unstable protein the abundance of which in cervical biopsies is unknown. We show here that E7 protein levels strongly increase during cervical carcinogenesis, underlining its fundamental role in cervical cancer. The E7 protein was found predominantly in the nucleus and to a minor extent in the cytoplasm in the cervical cancer cell line Ca Ski in vitro and in invasive cervical carcinoma in situ, suggesting that nuclear resident E7 plays a major role in cervical carcinogenesis in humans. The retinoblastoma protein (pRb) is a major E7-target in vitro. We show here that pRb expression is initially upregulated in LSIL and disappears in later stages concomitant with increased E7 levels, suggesting that E7-driven degradation of pRb is involved in cervical tumorigenesis in humans.	Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria	University of Innsbruck; Austrian Academy of Sciences; University of Innsbruck	Zwerschke, W (corresponding author), Univ Innsbruck, Tyrolean Canc Res Inst, Innrain 66, A-6020 Innsbruck, Austria.	werner.zwerschke@uklibk.ac.at	Fiedler, Marc/ABD-5356-2021; Jansen-Dürr, Pidder/ABG-2466-2020	Fiedler, Marc/0000-0003-4269-7873; Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953; Pfister, Gerald/0000-0003-4928-6612				Angeline M, 2003, VIROLOGY, V317, P13, DOI 10.1016/j.virol.2003.08.024; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Boyer SN, 1996, CANCER RES, V56, P4620; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DOEBERITZ MV, 1992, INT J CANCER, V51, P831; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FUJIKAWA K, 1994, VIROLOGY, V204, P789, DOI 10.1006/viro.1994.1594; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harlow E., 1999, USING ANTIBODIES LAB; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HOWLEY PM, 2001, FIELDS VIROLOGY, V2; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KANDA T, 1991, VIROLOGY, V182, P723, DOI 10.1016/0042-6822(91)90613-G; Kanduc D, 2002, J VIROL, V76, P7040, DOI 10.1128/JVI.76.14.7040-7048.2002; Kehmeier E, 2002, VIROLOGY, V299, P72, DOI 10.1006/viro.2002.1502; KOSS LG, 1987, CANCER-AM CANCER SOC, V60, P1942, DOI 10.1002/1097-0142(19901015)60:8+<1942::AID-CNCR2820601504>3.0.CO;2-V; Kristensen GB, 1999, GYNECOL ONCOL, V74, P245, DOI 10.1006/gyno.1999.5420; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Munoz N, 2000, J CLIN VIROL, V19, P1, DOI 10.1016/S1386-6532(00)00125-6; Nauenburg S, 2001, FASEB J, V15, P592; Nobbenhuis MAE, 2001, LANCET, V358, P1782, DOI 10.1016/S0140-6736(01)06809-X; OLTERSDORF T, 1987, J GEN VIROL, V68, P2933, DOI 10.1099/0022-1317-68-11-2933; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rey O, 2000, VIROLOGY, V268, P372, DOI 10.1006/viro.1999.0175; Salcedo M, 2002, INT J EXP PATHOL, V83, P275, DOI 10.1046/j.1365-2613.2002.00198.x; Sano T, 1998, PATHOL INT, V48, P580, DOI 10.1111/j.1440-1827.1998.tb03954.x; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Stanley MA, 2001, J REPROD IMMUNOL, V52, P45, DOI 10.1016/S0165-0378(01)00113-9; STEGNER HE, 1986, INT J GYNECOL PATHOL, V5, P23, DOI 10.1097/00004347-198603000-00003; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Wheatley SP, 1998, METHOD CELL BIOL, V57, P313; WILCZYNSKI SP, 1988, HUM PATHOL, V19, P697, DOI 10.1016/S0046-8177(88)80176-X; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 2000, ADV CANCER RES, V78, P1; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	64	46	60	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1120	+		10.1096/fj.03-1332fje	http://dx.doi.org/10.1096/fj.03-1332fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155561				2022-12-28	WOS:000221883200008
J	De Wever, O; Nguyen, QD; Van Hoorde, L; Bracke, M; Bruyneel, E; Gespach, C; Mareel, M				De Wever, O; Nguyen, QD; Van Hoorde, L; Bracke, M; Bruyneel, E; Gespach, C; Mareel, M			Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac	FASEB JOURNAL			English	Article						fibroblast; transdifferentiation; collagen	HEPATOCYTE GROWTH-FACTOR; SMOOTH MUSCLE ACTIN; EPITHELIAL-CELLS; INVASIVE GROWTH; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; COLORECTAL-CARCINOMA; MET PROTOONCOGENE; CELLULAR INVASION	Myofibroblasts are present at the invasion front in colon cancer. In an attempt to understand their putative proinvasive activity, we have developed an in vitro model. Myofibroblasts isolated from colon cancer tissue or obtained through transdifferentiation of colon fibroblasts by transforming growth factor (TGF)-beta stimulate invasion of colon cancer cells into collagen type I and Matrigel. We identified two convergent proinvasive agents secreted by myofibroblasts: namely scatter factor/hepatocyte growth factor (SF/HGF) and the TGF-beta-upregulated extracellular matrix glycoprotein tenascin-C (TNC), each of which is necessary though not sufficient for invasion. Myofibroblast-stimulated invasion into collagen type I is characterized by a change from a round, nonmigratory morphotype with high RhoA and low Rac activity to an elongated, migratory morphotype with low RhoA and high Rac activity. RhoA inactivation is determined by the epidermal growth factor (EGF)-like repeats of TNC through EGF-receptor signaling that confers a permissive and priming signal for the proinvasive activity of SF/HGF that activates Rac via c-Met. We confirmed the validity of this mechanism by using pharmacological modulators and dominant negative or constitutive active mutants that interfere with RhoA-Rho kinase and Rac signaling. Our in vitro results point to a new putative proinvasive signal for colon cancer cells provided by myofibroblasts in the tumor stroma.	State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Ghent University; Ghent University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mareel, M (corresponding author), State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	marc.mareel@UGent.be	de wever, olivier/J-3094-2013	de wever, olivier/0000-0002-5453-760X				Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; Bracke M E, 2001, Methods Mol Med, V58, P81, DOI 10.1385/1-59259-137-X:081; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; Dueck M, 1999, INT J CANCER, V82, P477, DOI 10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fukuura T, 1998, BRIT J CANCER, V78, P454, DOI 10.1038/bjc.1998.514; HAZAN RB, 1997, CELL ADHES COMMUN, V4, P399; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; LIU C, 1992, ONCOGENE, V7, P181; M D, 2001, Methods Mol Med, V58, P61, DOI 10.1385/1-59259-137-X:061; Matsuda A, 1999, INVEST OPHTH VIS SCI, V40, P1071; MIURA S, 1993, J SURG ONCOL, V53, P36, DOI 10.1002/jso.2930530111; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nakayama H, 1998, JPN J CLIN ONCOL, V28, P615, DOI 10.1093/jjco/28.10.615; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; Parr C, 2000, INT J CANCER, V85, P563, DOI 10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Qian LW, 2003, CANCER LETT, V190, P105, DOI 10.1016/S0304-3835(02)00517-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIEDL SE, 1992, GASTROENTEROLOGY, V103, P400, DOI 10.1016/0016-5085(92)90827-L; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Van Hoorde L, 1999, CELL ADHES COMMUN, V7, P139, DOI 10.3109/15419069909034397; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376	54	299	306	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1016	+		10.1096/fj.03-1110fje	http://dx.doi.org/10.1096/fj.03-1110fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059978				2022-12-28	WOS:000221108800029
J	Passeron, T; Bahadoran, P; Bertolotto, C; Chiaverini, C; Busca, R; Valony, G; Bille, K; Ortonne, JP; Ballotti, R				Passeron, T; Bahadoran, P; Bertolotto, C; Chiaverini, C; Busca, R; Valony, G; Bille, K; Ortonne, JP; Ballotti, R			Cyclic AMP promotes a peripheral distribution of melanosomes and stimulates melanophilin/Slac2-a and actin association	FASEB JOURNAL			English	Article						melanocytes; alpha-melanocyte stimulating hormone	MELANOMA-CELL DIFFERENTIATION; MYOSIN-VA; GRISCELLI-SYNDROME; HUMAN MELANOCYTES; CRITICAL DETERMINANT; ORGANELLE TRANSPORT; MOLECULAR MOTORS; BINDING DOMAIN; LINKS RAB27A; WILD-TYPE	Melanosomes are melanin-containing organelles that belong to a recently individualized group of lysosome-related organelles. Recently, numerous reports have dissected the molecular mechanisms that control melanosome transport, but nothing was known about the possible regulation of melanosome distribution by exogenous physiological stimulus. In the present report, we demonstrate that a physiological melanocyte-differentiating agent such as alpha-melanocyte-stimulating hormone, through the stimulation of the cAMP pathway, induces a rapid centrifugal transport of melanosomes, leading to their accumulation at the dendrite tips of melanocytes. Interestingly, the small GTP binding proteins of the p21Rho family and one of their effectors, p160 Rho-associated kinase, but not PKA, play a key role in redistribution of melanosomes at the extremities of the dendrites. Further, we have investigated, at the molecular level, the effect of cAMP on the different proteins involved in the control of melanosome transport. We demonstrate that cAMP stimulates the expression of Rab27a and rapidly increases the interaction of the melanophilin/Slac2-a with actin. Thus, we propose that the stimulation of the interaction between melanophilin/Slac2-a and actin would allow the rapid accumulation of melanosomes in the actin-rich region of the dendrite extremities.	Fac Med Nice, INSERM, U597, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med Nice, INSERM, U597, Ave Valombrose, F-06107 Nice 2, France.	ballotti@unice.fr	Bertolotto-Ballotti, Corine/O-2155-2016; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013	Bertolotto, Corine/0000-0001-6971-7753; Bahadoran, Philippe/0000-0002-2481-0556; Passeron, Thierry/0000-0002-0797-6570; BALLOTTI, Robert/0000-0002-7322-4908				Al-Haddad AH, 2001, MOL BIOL CELL, V12, P2742, DOI 10.1091/mbc.12.9.2742; Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Baron CL, 2001, J CELL SCI, V114, P999; Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Byers HR, 2000, J INVEST DERMATOL, V114, P990, DOI 10.1046/j.1523-1747.2000.00957.x; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Griffiths G M, 1995, Curr Top Microbiol Immunol, V198, P39; Gross SP, 2002, J CELL BIOL, V156, P855, DOI 10.1083/jcb.200105055; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JIMBOW K, 1975, J CELL BIOL, V65, P481, DOI 10.1083/jcb.65.2.481; JIMENEZCERVANTES C, 1994, PIGM CELL RES, V7, P291, DOI 10.1111/j.1600-0749.1994.tb00630.x; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Kuwahara K, 1999, FEBS LETT, V452, P314, DOI 10.1016/S0014-5793(99)00680-8; Lambert J, 1999, CELL MOL BIOL, V45, P905; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; Miyashita Y, 1996, J EXP ZOOL, V276, P125, DOI 10.1002/(SICI)1097-010X(19961001)276:2<125::AID-JEZ5>3.0.CO;2-Q; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Nascimento AAC, 1997, MOL BIOL CELL, V8, P1971, DOI 10.1091/mbc.8.10.1971; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SAMMAK PJ, 1992, J CELL BIOL, V117, P57, DOI 10.1083/jcb.117.1.57; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Shukla A, 2000, RESP MED, V94, P10, DOI 10.1053/rmed.1999.0700; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; WIKSWO MA, 1973, YALE J BIOL MED, V46, P592; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	54	39	42	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					989	+		10.1096/fj.03-1240fje	http://dx.doi.org/10.1096/fj.03-1240fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059972				2022-12-28	WOS:000221108800023
J	Mendias, CL; Baar, K; Faulkner, JA				Mendias, CL; Baar, K; Faulkner, JA			Myostatin increases procollagen content in tendon-derived fibroblast cells	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences	MAR 31-APR 06, 2005	San Diego, CA	Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Invest Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut, Int Union Physiol Sci					Univ Michigan, Ann Arbor, MI 48109 USA; Univ Dundee, Dundee DD1 5EH, Scotland	University of Michigan System; University of Michigan; University of Dundee			Mendias, Christopher/C-5557-2018; Arruda, Ellen M/C-3579-2009	Mendias, Christopher/0000-0002-2384-0171; Borschel, Gregory/0000-0001-7691-5264; Baar, Keith/0000-0001-9337-6186					0	57	61	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 7	2005	19	5	2	S			A1118	A1118		10.1096/fj.04-2034fje	http://dx.doi.org/10.1096/fj.04-2034fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905ZS	15574489	Green Published			2022-12-28	WOS:000227610901007
J	Crimi, M; Bordoni, A; Menozzi, G; Riva, L; Fortunato, F; Galbiati, S; Del Bo, R; Pozzoli, U; Bresolin, N; Comi, GP				Crimi, M; Bordoni, A; Menozzi, G; Riva, L; Fortunato, F; Galbiati, S; Del Bo, R; Pozzoli, U; Bresolin, N; Comi, GP			Skeletal muscle gene expression profiling in mitochondrial disorders	FASEB JOURNAL			English	Article						mt DNA; MELAS; PEO; real-time PCR; microarray	CLUSTER-ANALYSIS; DNA MUTATIONS; TRANSCRIPTION; NUCLEAR; VARIABILITY; BIOGENESIS; METABOLISM; ACTIVATION; MECHANISMS; APOPTOSIS	Extremely variable clinic and genetic features characterize mitochondrial encephalomyopathy (ME M). Pathogenic mitochondrial DNA(mtDNA) defects can be divided into large-scale rearrangements and single point mutations. Clinical manifestations become evident when a threshold percentage of the total mtDNA is mutated. In some MEM, the "mutant load" in an affected tissue is directly related to the severity of the phenotype. However, the clinical phenotype is not simply a direct consequence of the relative abundance of mutated mtDNA. Other factors, such as nuclear background, can contribute to the disease process, resulting in a wide range of phenotypes caused by the same mutation. Using Affymetrix oligonucleotide cDNA microarrays(HG-U133A), we studied the gene expression profile of muscle tissue biopsies obtained from 12 MEM patients[4 common 4977 bp deleted mtDNA and 8 A3243G:4 progressive external ophthalmoplegia (PEO) and 4 mitochondrial myopathy,encephalopathy, lactic cidosis, and stroke-like episodes syndrome (MELAS) phenotypes] compared with age matched healthy individuals. We found several differentially expressed genes: 35 were markedly up-regulated in the mtDNA macro-deletion group(vs. the control group) and 4 decreased; 56 genes were dysregulated in A3243G-related disorders(53 down-regulated in PEO and 3 upregulated in MELAS). Finally, 12 genes were similarly regulated in the majority of the MEM patients under study. Amongst these, we identified an increased expression of genes related to the metabolism of the amino groups, as well as of several genes involved in genetic information processing. Moreover, few genes were similarly decreased in MEM patients vs. the control group. Real-time PCR demonstrated excellent reproducibility of the microarray-based findings. The observed expression changes are likely to represent a molecular signature for mitochondrial disorders. Furthermore,the differential expression profile of MELAS(A3243G) vs. PEOA3243G may support a role of nuclear background in contributing to these different clinical phenotypes. MEM microarray data are available from GEO database (http://www.ncbi.nlm.nih.gov/geo/) wit h the access ion number: GSE1462.	Univ Milan, Dept Neurol Sci, I-20122 Milan, Italy; IRCCS, Osped Maggiore Policlin, Dino Ferrari Ctr, I-20122 Milan, Italy; CEND, I-20122 Milan, Italy; IRCCS E Medea La Nostra Famiglia, I-23842 Bosisio Parini, LC, Italy; Polytech Univ, Dept Biomed Engn, I-20133 Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Eugenio Medea; Polytechnic University of Milan	Crimi, M (corresponding author), Univ Milan, Dept Neurol Sci, Pad Ne Ponti,Via F Sforza 35, I-20122 Milan, Italy.	marcreamy@tiscali.it	Galbiati, Sara/AAA-7115-2020; Pozzoli, Uberto/AAH-5492-2019; Riva, Laura/R-2562-2016	Galbiati, Sara/0000-0001-6810-359X; Pozzoli, Uberto/0000-0003-0670-7106; Bresolin, Nereo/0000-0001-6694-3595; Crimi, Marco/0000-0001-6903-9163; Comi, Giacomo/0000-0002-1383-5248; Riva, Laura/0000-0001-5688-4915				ALESSI DR, 1993, ONCOGENE, V8, P2015; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Augenlicht LH, 1999, ANN NY ACAD SCI, V889, P20, DOI 10.1111/j.1749-6632.1999.tb08720.x; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Camasamudram V, 2003, EUR J BIOCHEM, V270, P1128, DOI 10.1046/j.1432-1033.2003.03461.x; Colleluori DM, 2001, ARCH BIOCHEM BIOPHYS, V389, P135, DOI 10.1006/abbi.2001.2324; DELSITE R, 2002, MOL CANCER, V12, P6; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104; Gommans IMP, 2002, J MUSCLE RES CELL M, V23, P59, DOI 10.1023/A:1019984714528; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721; Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463; Jiang DW, 2003, J BIOL CHEM, V278, P4763, DOI 10.1074/jbc.M210410200; Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208; KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097; Koga Y, 2002, NEUROLOGY, V58, P827, DOI 10.1212/WNL.58.5.827; Li RH, 2003, BBA-GENE STRUCT EXPR, V1629, P53, DOI 10.1016/S0167-4781(03)00160-X; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q; Morris SM, 1997, GENE, V193, P157, DOI 10.1016/S0378-1119(97)00099-1; NAKASE H, 1990, AM J HUM GENET, V46, P418; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; RAO VLR, 1994, NEUROSCI LETT, V170, P27, DOI 10.1016/0304-3940(94)90230-5; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Rowland LP, 1983, MITOCHONDRIAL PATHOL, P141; Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2; Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070; SCRIVER CR, 1995, METABOLIC BASIS INHE; SEIDEL U, 1988, GENE, V66, P135, DOI 10.1016/0378-1119(88)90231-4; Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482; Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277; Silvestri G, 1997, MUSCLE NERVE, V20, P221; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48	55	48	50	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					866	+		10.1096/fj.04-3045fje	http://dx.doi.org/10.1096/fj.04-3045fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728662				2022-12-28	WOS:000227591900009
J	Schaaf, GJ; Ruijter, JM; van Ruissen, F; Zwijnenburg, DA; Waaijer, R; Valentijn, LJ; Benit-Deekman, J; van Kampen, AHC; Baas, F; Kool, M				Schaaf, GJ; Ruijter, JM; van Ruissen, F; Zwijnenburg, DA; Waaijer, R; Valentijn, LJ; Benit-Deekman, J; van Kampen, AHC; Baas, F; Kool, M			Full transcriptome analysis of rhabdomyosarcoma, normal and fetal skeletal muscle: statistical comparison of multiple SAGE libraries	FASEB JOURNAL			English	Article						G-test; gene ontology; literature-mining; myogenesis	GENE-EXPRESSION; SERIAL ANALYSIS; PEDIATRIC RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; CDNA MICROARRAYS; DIFFERENTIATION; IDENTIFICATION; PAX3-FKHR; OVEREXPRESSION; CARCINOMAS	Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children. Improved treatment strategies have increased overall survival, but the response of approximately one-third of the patients is still poor. To increase the knowledge of RMS pathogenesis, we performed the first full transcriptome analysis of RMS using serial analysis of gene expression ( SAGE). With a G-test for the simultaneous comparison of subsets of SAGE libraries of normal skeletal muscle, embryonal (ERMS) and alveolar ( ARMS) RMS, we identified 251 differentially expressed genes. A literature-mining procedure demonstrated that 158 of these genes have not previously been associated with RMS or normal muscle. Gene Ontology ( GO) analysis assigned 198 of the 251 genes to muscle-specific classes, including those involved in normal myogenic development, as well as tumor-related classes. Prominent GO classes were those associated with proliferation and actin reorganization, which are processes that play roles during early muscle development, muscle function, and tumor progression. Using custom microarrays, we confirmed the (up- or down-) regulation of 80% of 98 differentially expressed genes. Another SAGE library of 19- to 22-week- old fetal skeletal muscle was compared with the RMS and normal muscle transcriptomes. Cluster analysis showed that the RMS and fetal muscle SAGE libraries formed one cluster distinct from normal muscle samples. Moreover, the expression profile of 86% of the differentially expressed genes between normal muscle and RMS was highly similar in fetal muscle and RMS. In conclusion, the G-test is a robust tool for analyzing groups of SAGE libraries and correctly identifies genes marking the difference between fully differentiated skeletal muscle and RMS. This study not only substantiates the close association between embryonic myogenesis and RMS development but also provides a rich source of candidate genes to further elucidate the etiology of RMS or to identify diagnostic and/or prognostic markers.	Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurogenet, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Anat & Embryol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Schaaf, GJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	g.j.schaaf@amc.uva.nl	van Kampen, Antoine HC/C-1925-2008; Baas, Frank/F-9574-2010; Kool, Marcel/H-2541-2013; Schaaf, Gerben/AAK-5278-2020	Baas, Frank/0000-0003-3912-5428; Schaaf, Gerben/0000-0003-0189-9073; Zwijnenburg, Danny/0000-0002-9353-8904; van Ruissen, Fred/0000-0002-9458-7505				Astolfi A, 2001, GENE, V274, P139, DOI 10.1016/S0378-1119(01)00619-9; Baer C, 2004, INT J CANCER, V110, P687, DOI 10.1002/ijc.20171; Baggerly KA, 2003, BIOINFORMATICS, V19, P1477, DOI 10.1093/bioinformatics/btg173; Barber TD, 2002, GENOMICS, V79, P278, DOI 10.1006/geno.2002.6703; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Chen JJ, 2000, P NATL ACAD SCI USA, V97, P349, DOI 10.1073/pnas.97.1.349; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4; de Jonge RR, 2004, HUM MOL GENET, V13, P295, DOI 10.1093/hmg/ddh029; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Kappler R, 2003, J PATHOL, V200, P348, DOI 10.1002/path.1361; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Khan J, 1998, CANCER RES, V58, P5009; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; Man MZ, 2000, BIOINFORMATICS, V16, P953, DOI 10.1093/bioinformatics/16.11.953; Marics I, 2002, DEVELOPMENT, V129, P4559; Michiels EMC, 1999, PHYSIOL GENOMICS, V1, P83, DOI 10.1152/physiolgenomics.1999.1.2.83; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Pandita Ajay, 1999, Neoplasia (New York), V1, P262, DOI 10.1038/sj.neo.7900036; Ruijter JM, 2002, PHYSIOL GENOMICS, V11, P37, DOI 10.1152/physiolgenomics.00042.2002; Sokal R.R., 1995, BIOMETRY, P685; Stekel DJ, 2000, GENOME RES, V10, P2055, DOI 10.1101/gr.GR-1325RR; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Swierczynski SL, 2004, HUM PATHOL, V35, P357, DOI 10.1016/j.humpath.2003.10.012; TONIN PN, 1991, CANCER RES, V51, P5100; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Welle S, 1999, GENOME RES, V9, P506; WHANGPENG J, 1992, GENE CHROMOSOME CANC, V5, P299, DOI 10.1002/gcc.2870050405; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	39	42	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					404	+		10.1096/fj.04-2104fje	http://dx.doi.org/10.1096/fj.04-2104fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629888				2022-12-28	WOS:000226576600035
J	Jozsef, L; Khreiss, T; Filep, JG				Jozsef, L; Khreiss, T; Filep, JG			CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes	FASEB JOURNAL			English	Article						neutrophil survival; toll-like receptor-9; mitochondrial dysfunction; caspase-3; inflammation	PROGRAMMED CELL-DEATH; TOLL-LIKE RECEPTORS; ACTIVATED PROTEIN-KINASE; C-REACTIVE PROTEIN; NITRIC-OXIDE; ENDOTHELIAL-CELLS; AGING NEUTROPHILS; ACIDIFICATION; OLIGODEOXYNUCLEOTIDES; INFLAMMATION	Human neutrophil granulocytes die rapidly, and their survival is contingent upon rescue from programmed cell death by signals from the environment. We now show that a novel signal for delaying neutrophil apoptosis is unmethylated CpG motifs prevalent in bacterial DNA ( CpG-DNA). Human neutrophils express toll-like receptor 9 that recognizes these motifs. CpG-DNA, but not mammalian DNA or methylated bacterial DNA, markedly enhanced neutrophil viability by delaying spontaneous apoptosis. Endosomal maturation of CpG-DNA is prerequisite for these actions and was coupled to concurrent activation of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase/Akt signaling pathways, leading to phosphorylation of BAD at Ser(112) and Ser(136), respectively, and to prevention of decreases in mitochondrial transmembrane potential, cytochrome c release and caspase-3 activation. Consistently, pharmacological inhibition of either ERK or phosphatidylinositol 3-kinase partially reversed these actions of CpG-DNA; however, they did not produce additive inhibition. Furthermore, intravenous injection of CpG-DNA (200 mug/kg) into rats evoked slight decreases in blood pressure and induced a modest leukocytosis, whereas it effectively suppressed neutrophil apoptosis as assayed ex vivo. Our results indicate that unmethylated CpG motifs in bacterial DNA promote neutrophil survival by suppressing the apoptotic machinery and may therefore contribute to prolongation and amplification of inflammation.	Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Filep, JG (corresponding author), Maisonneuve Rosemont Hosp, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	janos.g.filep@umontreal.ca						Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Alvarado-Kristensson M, 2001, FASEB J, V15, P129, DOI 10.1096/fj.01-0817fje; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; COLOTTA F, 1992, BLOOD, V80, P2012; Cowdery J, 1996, J IMMUNOL, V156, P4570; COX G, 1995, AM J RESP CELL MOL, V12, P232, DOI 10.1165/ajrcmb.12.2.7865221; Filep JG, 1997, CIRC RES, V81, P840; Filep JG, 1996, BLOOD, V87, P5136, DOI 10.1182/blood.V87.12.5136.bloodjournal87125136; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gao JJ, 1999, J IMMUNOL, V163, P4095; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; Hacker G, 2002, IMMUNOLOGY, V105, P245; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356; Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LILES WC, 1995, BLOOD, V86, P3181; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sanghavi DM, 1998, FEBS LETT, V422, P179, DOI 10.1016/S0014-5793(98)00004-0; SAVILL J, 1994, EUR J CLIN INVEST, V24, P715, DOI 10.1111/j.1365-2362.1994.tb01067.x; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Stacey KJ, 2003, J IMMUNOL, V170, P3614, DOI 10.4049/jimmunol.170.7.3614; TONKINSON JL, 1994, NUCLEIC ACIDS RES, V22, P4268, DOI 10.1093/nar/22.20.4268; Trevani AS, 2003, EUR J IMMUNOL, V33, P3164, DOI 10.1002/eji.200324334; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Weighardt H, 2000, J IMMUNOL, V165, P4537, DOI 10.4049/jimmunol.165.8.4537; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Yamada H, 2002, J IMMUNOL, V169, P5590, DOI 10.4049/jimmunol.169.10.5590; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yi AK, 1998, J IMMUNOL, V160, P4755; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561; Zouki C, 2001, FASEB J, V15, P25	57	78	79	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1776	+		10.1096/fj.04-2048fje	http://dx.doi.org/10.1096/fj.04-2048fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345690				2022-12-28	WOS:000224243200043
J	von Kobbe, C; May, A; Grandori, C; Bohr, VA				von Kobbe, C; May, A; Grandori, C; Bohr, VA			Werner syndrome cells escape hydrogen peroxide-induced cell proliferation arrest	FASEB JOURNAL			English	Article						DNA damage; premature senescence	NORMAL HUMAN FIBROBLASTS; DNA-DAMAGE; SYNDROME PROTEIN; MAMMALIAN-CELLS; EXONUCLEASE ACTIVITY; GENOMIC INSTABILITY; GROWTH ARREST; P53; SENESCENCE; REPAIR	Werner syndrome (WS) is a rare disease caused by the lack of a functional nuclear WS protein (WRN). WS is characterized by the early onset of premature aging signs and a high incidence of sarcomas. WS diploid fibroblasts have a short life span and extensive genomic instability. Mammalian cells are continuously exposed to reactive oxygen species (ROS), which represent human mutagens and are thought to be a major contributor to the aging process. Hydrogen peroxide (H2O2) is a common ROS intermediate generated by various forms of oxidative stress. In response to H2O2-induced DNA damage, normal human diploid fibroblasts follow a pathway leading to irreversible proliferation arrest and premature senescence. Here we show that in contrast to normal human fibroblasts, WS diploid fibroblasts continue proliferating after extensive H2O2-induced DNA damage and accumulate oxidative DNA lesions. A direct role of WRN in this abnormal cellular response to H2O2 is demonstrated by interfering with WRN expression in normal human fibroblasts. We propose a role for WRN in the detection and/or processing of oxidative DNA lesions and in cellular responses to H2O2 as they relate to some of the phenotypical aspects of WS cells.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Fred Hutchinson Cancer Center	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	von Kobbe, Cayetano/0000-0003-3895-3790	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000727, Z01AG000727, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Benitez-Bribiesca L, 1999, ANN NY ACAD SCI, V887, P133, DOI 10.1111/j.1749-6632.1999.tb07928.x; Blander G, 2000, FASEB J, V14, P2138; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen LS, 2003, AGING CELL, V2, P191, DOI 10.1046/j.1474-9728.2003.00052.x; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; CHENG WH, 2003, TOPICS CURRENT GENET, P239; Cobb JA, 2002, FEBS LETT, V529, P43, DOI 10.1016/S0014-5793(02)03269-6; Cooper MP, 2000, GENE DEV, V14, P907; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DUVIC M, 1995, DERMATOL CLIN, V13, P163, DOI 10.1016/S0733-8635(18)30119-0; Franchitto A, 2003, CANCER RES, V63, P3289; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hartwig A, 2003, INT J CANCER, V104, P1, DOI 10.1002/ijc.10911; Hattori H, 2004, PATHOL INT, V54, P26, DOI 10.1111/j.1440-1827.2004.01585.x; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lebel M, 2001, CANCER RES, V61, P1816; Li BM, 2000, J BIOL CHEM, V275, P39800; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Oshima J, 2002, CANCER RES, V62, P547; Poot M, 2002, FASEB J, V16, P757, DOI 10.1096/fj.01-0906fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Prince PR, 1999, HUM GENET, V105, P132, DOI 10.1007/s004390051075; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schulz VP, 1996, HUM GENET, V97, P750; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; te Poele RH, 2002, CANCER RES, V62, P1876; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	57	59	60	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1970	+		10.1096/fj.04-1895fje	http://dx.doi.org/10.1096/fj.04-1895fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15459124				2022-12-28	WOS:000224243200001
J	Marques, C; Pereira, P; Taylor, A; Liang, JN; Reddy, VN; Szweda, LI; Shang, F				Marques, C; Pereira, P; Taylor, A; Liang, JN; Reddy, VN; Szweda, LI; Shang, F			Ubiquitin-dependent lysosomal degradation of the HNE-modified proteins in lens epithelial cells	FASEB JOURNAL			English	Article						lipid peroxidation; hydroxynonenal; proteasome; protein quality control	LIPID-PEROXIDATION; OXIDATIVE STRESS; PROTEOLYTIC SYSTEM; ALDEHYDIC PRODUCT; OXIDIZED PROTEINS; PROTEASOME; CONJUGATION; RECEPTOR; PATHWAY; IDENTIFICATION	4-Hydroxynonenal (HNE), a highly reactive lipid peroxidation product, may adversely modify proteins. Accumulation of HNE-modified proteins may be responsible for pathological lesions associated with oxidative stress. The objective of this work was to determine how HNE-modified proteins are removed from cells. The data showed that alphaB-crystallin modified by HNE was ubiquitinated at a faster rate than that of native alphaB-crystallin in a cell-free system. However, its susceptibility to proteasome-dependent degradation in the cell-free system did not increase. When delivered into cultured lens epithelial cells, HNE-modified alphaB-crystallin was degraded at a faster rate than that of unmodified alphaB-crystallin. Inhibition of the lysosomal activity stabilized HNE-modified alphaB-crystallin, but inhibition of the proteasome activity alone had little effect. To determine if other HNE-modified proteins are also degraded in a ubiquitin-dependent lysosomal pathway, lens epithelial cells were treated with HNE and the removal of HNE-modified proteins in the cells was monitored. The levels of HNE-modified proteins in the cell decreased rapidly upon removal of HNE from the medium. Depletion of ATP or the presence of MG132, a proteasome/lysosome inhibitor, resulted in stabilization of HNE-modified proteins. However, proteasome-specific inhibitors, lactacystin-beta-lactone and epoxomicin, could not stabilize HNE-modified proteins in the cells. In contrast, chloroquine, a lysosome inhibitor, stabilized HNE-modified proteins. The enrichment of HNE-modified proteins in the fraction of ubiquitin conjugates suggests that HNE-modified proteins are preferentially ubiquitinated. Taken together, these findings show that HNE-modified proteins are degraded via a novel ubiquitin and lysosomal-dependent but proteasome-independent pathway.	Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Univ Coimbra, IBILI, Ctr Ophatmol, Coimbra, Portugal; Harvard Univ, Brigham & Womens Hosp, Ophthalm Res Ctr, Boston, MA 02115 USA; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Tufts University; United States Department of Agriculture (USDA); Universidade de Coimbra; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; Case Western Reserve University	Shang, F (corresponding author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	fu.shang@tufts.edu	Pereira, Paulo/AAD-8375-2022; Marques, Carla/AAC-9838-2019	Pereira, Paulo/0000-0002-9908-2290; Marques, Carla/0000-0002-1817-4813	NATIONAL EYE INSTITUTE [R01EY011717, R29EY011717, R01EY013250] Funding Source: NIH RePORTER; NEI NIH HHS [R29 EY011717-04, R01 EY011717, R29 EY011717-03, R01 EY011717-06A1, R01 EY013250, R29 EY011717, R29 EY011717-05, EY11717, EY 13250] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; Blanc EM, 1997, J NEUROCHEM, V69, P570; BLONDIN J, 1987, MECH AGEING DEV, V41, P39, DOI 10.1016/0047-6374(87)90052-2; CADENAS E, 1983, BIOCHEM J, V214, P479, DOI 10.1042/bj2140479; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; de Melker AA, 2001, J CELL SCI, V114, P2167; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; Grune T, 2002, FASEB J, V16, P1602, DOI 10.1096/fj.02-0015com; Grune Tilman, 2003, Molecular Aspects of Medicine, V24, P195, DOI 10.1016/S0098-2997(03)00014-1; Haas AL, 1997, FASEB J, V11, P1257; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOLMSEN H, 1974, BIOCHEM J, V144, P385, DOI 10.1042/bj1440385; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Mark RJ, 1997, J NEUROCHEM, V68, P255; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; PAROLA M, 1990, CHEM-BIOL INTERACT, V73, P103, DOI 10.1016/0009-2797(90)90111-Y; REDDAN JR, 1993, EXP EYE RES, V56, P543, DOI 10.1006/exer.1993.1068; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; SCHWARTZ AL, 1988, EMBO J, V7, P2962; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Sun TX, 1999, J BIOL CHEM, V274, P34067, DOI 10.1074/jbc.274.48.34067; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; WINDSOR DP, 1993, J REPROD FERTIL, V99, P359, DOI 10.1530/jrf.0.0990359; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; Xiao B, 1999, BIOCHEMISTRY-US, V38, P11887, DOI 10.1021/bi990468i; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	48	91	96	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1424	+		10.1096/fj.04-1743fje	http://dx.doi.org/10.1096/fj.04-1743fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247152	Green Submitted, Green Accepted			2022-12-28	WOS:000222979200003
J	Hudry-Clergeon, H; Stengel, D; Ninio, E; Vilgrain, I				Hudry-Clergeon, H; Stengel, D; Ninio, E; Vilgrain, I			Platelet-activating factor increases VIE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3 '-kinase	FASEB JOURNAL			English	Article						adherens junction; VE cadherin; Akt; angiogenesis	FOCAL ADHESION KINASE; FACTOR RECEPTOR; VE-CADHERIN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; MAP-KINASE; FACTOR PAF; EXPRESSION; PERMEABILITY; PATHWAYS	Platelet-activating factor (PAF), a potent inflammatory mediator, is involved in endothelial permeability. This study was designed to characterize PAF receptor (PAF-R) expression and its specific contribution to the modifications of adherens junctions in mouse endothelial cells. We demonstrated that PAF-R was expressed in mouse endothelial cells and was functionally active in stimulating p42/p44 MAPK and phosphatidylinositol 3-kinase (PtdIns3'-kinase)/Akt activities. Treatment of cells with PAF induced a rapid time- and dose-dependent (10(-7) to 10(-10) M) increase in tyrosine phosphorylation of a subset of proteins ranging from 90 to 220 kDa, including the VE-cadherin, the latter effect being prevented by the tyrosine kinase inhibitors herbimycin A and bis-tyrphostin. We demonstrated that PAF promoted formation of multimeric aggregates of VE-cadherin with PtdIns3'-kinase, which was also inhibited by herbimycin and bis-tyrphostin. Finally, we show by immunostaining of endothelial cells VE-cadherin that PAF dissociated adherens junctions. The present data provide the first evidence that treatment of endothelial cells with PAF promoted activation of tyrosine kinases and the VE-cadherin tyrosine phosphorylation and PtdIns3'-kinase association, which ultimately lead to the dissociation of adherens junctions. Physical association between PtdIns3'-kinase, serving as a docking protein, and VE-cadherin may thus provide an efficient mechanism for amplification and perpetuation of PAF-induced cellular activation.	CEA Grenoble, INSERM,EMI 0219, Dept Response & Dynam Cellulaire, Lab Dev & Vieillissement Endothelium, F-38054 Grenoble, France; Univ Paris 06, Fac Med Pitie Salpetriere, INSERM,U525, Paris 13, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Vilgrain, I (corresponding author), CEA Grenoble, INSERM,EMI 0219, Dept Response & Dynam Cellulaire, Lab Dev & Vieillissement Endothelium, 17 Rue Martyrs, F-38054 Grenoble, France.	ivilgrain@cea.fr		VILGRAIN, Isabelle/0000-0002-5511-5871				Alexander JS, 2000, INFLAMMATION, V24, P99, DOI 10.1023/A:1007025325451; Axelrad TW, 2004, FASEB J, V18, P568, DOI 10.1096/fj.03-0479fje; Bazan HEP, 1997, CURR EYE RES, V16, P372, DOI 10.1076/ceyr.16.4.372.10699; Biancone L, 1999, AM J PATHOL, V155, P1731, DOI 10.1016/S0002-9440(10)65488-0; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Brocheriou I, 2000, CIRCULATION, V102, P2569; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; Calcerrada MC, 1999, BRAIN RES, V835, P275, DOI 10.1016/S0006-8993(99)01612-1; Calcerrada MC, 2002, NEUROCHEM RES, V27, P313, DOI 10.1023/A:1014911329489; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cascone I, 2003, J BIOL CHEM, V278, P50702, DOI 10.1074/jbc.M307234200; CHABRE O, 1995, ENDOCRINOLOGY, V136, P956, DOI 10.1210/en.136.3.956; CHAO W, 1992, J BIOL CHEM, V267, P6725; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; DHAR A, 1994, J BIOL CHEM, V269, P9123; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2002, PROSTAG OTH LIPID M, V68-9, P599, DOI 10.1016/S0090-6980(02)00058-8; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LIU B, 1995, BIOCHEM BIOPH RES CO, V214, P418, DOI 10.1006/bbrc.1995.2303; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; McManus LM, 2000, CRIT REV ORAL BIOL M, V11, P240, DOI 10.1177/10454411000110020701; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; PITTON C, 1989, J NATL CANCER I, V81, P1298, DOI 10.1093/jnci/81.17.1298; Pouyssegur J, 2000, SCIENCE, V290, P1515, DOI 10.1126/science.290.5496.1515; Prescott SM, 2002, ARTERIOSCL THROM VAS, V22, P727, DOI 10.1161/01.ATV.0000016153.47693.B2; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Rezaul K, 1997, BIOCHEM BIOPH RES CO, V239, P23, DOI 10.1006/bbrc.1997.7419; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Soldi R, 1996, ONCOGENE, V13, P515; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7; Zhang YP, 2003, J SOC GYNECOL INVEST, V10, P5, DOI 10.1016/S1071-5576(02)00185-5	45	51	55	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					512	520		10.1096/fj.04-2202com	http://dx.doi.org/10.1096/fj.04-2202com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791001	Green Accepted, Green Published			2022-12-28	WOS:000228865300035
J	Gao, HW; Neff, TA; Guo, RF; Speyer, CL; Sarma, JV; Tomlins, S; Man, YF; Riedemann, NC; Hoesel, LM; Younkin, E; Zetoune, FS; Ward, PA				Gao, HW; Neff, TA; Guo, RF; Speyer, CL; Sarma, JV; Tomlins, S; Man, YF; Riedemann, NC; Hoesel, LM; Younkin, E; Zetoune, FS; Ward, PA			Evidence for a functional role of the second C5a receptor C5L2	FASEB JOURNAL			English	Article						cecal ligation and puncture; IL-6	CHEMOATTRACTANT RECEPTOR; ANAPHYLATOXIN; EXPRESSION; CELLS; ANTIBODIES; PEPTIDE; PHOSPHORYLATION; STRATEGIES; MODEL; CD88	During experimental sepsis in rodents after cecal ligation and puncture (CLP), excessive C5a is generated, leading to interactions with C5aR, loss of innate immune functions of neutrophils, and lethality. In the current study, we have analyzed the expression of the second C5a receptor C5L2, the putative "default" or nonsignaling receptor for C5a. Rat C5L2 was cloned, and antibody was developed to C5L2 protein. After CLP, blood neutrophils showed a reduction in C5aR followed by its restoration, while C5L2 levels gradually increased, accompanied by the appearance of mRNA for C5L2. mRNA for C5L2 increased in lung and liver during CLP. Substantially increased C5L2 protein (defined by binding of I-125-anti-C5L2 IgG) occurred in lung, liver, heart, and kidney after CLP. With the use of serum IL-6 as a marker for sepsis, infusion of anti-C5aR dramatically reduced serum IL-6 levels, while anti-C5L2 caused a nearly fourfold increase in IL-6 when compared with CLP controls treated with normal IgG. When normal blood neutrophils were stimulated in vitro with LPS and C5a, the antibodies had similar effects on release of IL-6. These data provide the first evidence for a role for C5L2 in balancing the biological responses to C5a.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Leibniz Univ Hannover, Sch Med, Dept Trauma Surg, D-30625 Hannover, Germany	University of Michigan System; University of Michigan; Leibniz University Hannover	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Riedemann, Niels C/C-1633-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029507, R01GM029507] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29507] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; COCHRANE CG, 1968, J EXP MED, V127, P371, DOI 10.1084/jem.127.2.371; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Floreani AA, 1998, J IMMUNOL, V160, P5073; Gasque P, 1997, AM J PATHOL, V150, P31; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GIANNINI E, 1995, J IMMUNOL, V154, P4055; GOLDSTEI.IM, 1974, J IMMUNOL, V113, P1583; Guo RF, 2003, FASEB J, V17, P1889, DOI 10.1096/fj.03-0009fje; HANGEN DH, 1989, J SURG RES, V46, P195, DOI 10.1016/0022-4804(89)90055-3; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Huber-Lang MS, 2001, FASEB J, V15, P568; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; MORGAN EL, 1993, J IMMUNOL, V151, P377; Naik N, 1997, J CELL SCI, V110, P2381; Nataf S, 1999, J IMMUNOL, V162, P4018; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Riedemann NC, 2003, FASEB J, V17, P370, DOI 10.1096/fj.03-0708fje; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; Schieferdecker HL, 2000, J IMMUNOL, V164, P5453, DOI 10.4049/jimmunol.164.10.5453; SCHUMACHER WA, 1991, AGENTS ACTIONS, V34, P345, DOI 10.1007/BF01988727; SHIN HS, 1968, SCIENCE, V162, P361, DOI 10.1126/science.162.3851.361; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; Ward PA, 2003, SCAND J INFECT DIS, V35, P601, DOI 10.1080/00365540310015674; WETSEL RA, 1995, IMMUNOL LETT, V44, P183, DOI 10.1016/0165-2478(94)00212-A; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	36	105	112	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1003	+		10.1096/fj.04-3424fje	http://dx.doi.org/10.1096/fj.04-3424fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15784721	Green Published			2022-12-28	WOS:000227901300006
J	Bonev, BB; Breukink, E; Swiezewska, E; De Kruijff, B; Watts, A				Bonev, BB; Breukink, E; Swiezewska, E; De Kruijff, B; Watts, A			Targeting extracellular pyrophosphates underpins the high selectivity of nisin	FASEB JOURNAL			English	Article						lantibiotic; staphylococcal resistance; penicillin binding protein; vancomycin	PRECURSOR LIPID II; STAPHYLOCOCCUS-AUREUS; LANTIBIOTIC NISIN; PORE FORMATION; PEPTIDE; PEPTIDOGLYCAN; BIOSYNTHESIS; MEMBRANE; NMR; ANTIBIOTICS	The spread of infectious diseases and the increase in antibiotic resistance represent a life-threatening global development that calls for new approaches to control microorganisms. Of all potential targets, the essential and unique pathway of bacterial cell wall synthesis, targeted by the first known antibiotic penicillin, remains a perfect candidate for the development of new antibiotics. Here we show that the lantibiotic nisin exercises its antibacterial action by targeting peptidoglycan intermediates' extracellular pyrophosphate, unique to bacterial cell wall precursors. We show that nisin sequesters cell wall precursors found in the outer leaflet of bacterial plasma membranes, Lipid II and undecaprenyl pyrophosphate, into stable complexes. We propose a model of antibacterial action for nisin in which the terminal amino group of Ile1 targets the pyrophosphate groups of the bacterial cell wall precursors, where it docks via a hydrogen bond. The pyrophosphate moiety, a highly conserved chemical group different from the L-Lys-D-Ala-D-Ala docking motif for vancomycin, has no biochemical analogs with comparable properties and is unlikely to be susceptible to bacterial adaptations akin to those responsible for resistance to penicillins and vancomycin.	Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Oxford, Dept Biochem, Biomembrane Struct Unit, Oxford OX1 3QU, England; Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Utrecht, Netherlands; Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland; Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2RD, England	University of Nottingham; University of Oxford; Utrecht University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; University of Nottingham	Bonev, BB (corresponding author), Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England.	Boyan.Bonev@nottingham.ac.uk	Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660; Swiezewska, Ewa/0000-0002-3439-8948; Bonev, Boyan/0000-0001-7156-2412				BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Bonev B, 2001, PHYS CHEM CHEM PHYS, V3, P2904, DOI 10.1039/b103352m; Bonev BB, 2000, BIOCHEMISTRY-US, V39, P11425, DOI 10.1021/bi0001170; Breukink E, 2000, BIOCHEMISTRY-US, V39, P10247, DOI 10.1021/bi000915q; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; Chan WC, 1996, FEBS LETT, V390, P129, DOI 10.1016/0014-5793(96)00638-2; DelvesBroughton J, 1996, ANTON LEEUW INT J G, V69, P193, DOI 10.1007/BF00399424; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; Garau J, 2002, LANCET INFECT DIS, V2, P404, DOI 10.1016/S1473-3099(02)00316-X; Guillion T., 1989, J MAGN RESON, V81, P196; HAEBERLEN U, 1969, PHYS REV, V185, P420, DOI 10.1103/PhysRev.185.420; HARTMANN SR, 1962, PHYS REV, V128, P2042, DOI 10.1103/PhysRev.128.2042; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; Michel M, 1997, LANCET, V349, P1901, DOI 10.1016/S0140-6736(96)11192-2; Rogers LA, 1928, J BACTERIOL, V16, P211, DOI 10.1128/JB.16.4.211-229.1928; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; Swiezewska Ewa, 1994, Acta Biochimica Polonica, V41, P221; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; van Heusden HE, 2002, BIOCHEMISTRY-US, V41, P12171, DOI 10.1021/bi026090x; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Wright GD, 2003, CURR OPIN CHEM BIOL, V7, P563, DOI 10.1016/j.cbpa.2003.08.004	30	69	73	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1862	1869		10.1096/fj.04-2358com	http://dx.doi.org/10.1096/fj.04-2358com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576489	Green Submitted			2022-12-28	WOS:000226091000036
J	Martins-Green, M; Li, QJ; Yao, M				Martins-Green, M; Li, QJ; Yao, M			A new generation organ culture arising from cross-talk between multiple primary human cell types	FASEB JOURNAL			English	Article						stem cells; cell differentiation; 3-D culture; cocultures; bioengineering	RAT CARDIAC FIBROBLASTS; ENDOTHELIAL-CELLS; MATRIX METALLOPROTEINASES; SKIN SUBSTITUTES; ANGIOGENESIS; EXPRESSION; GROWTH; HYALURONAN; EPIDERMIS; TENASCIN	The inability to experiment directly on humans strongly constrains biomedical research, creating a great need to develop cultures that mimic human tissues and organs as experimental systems that can be used to directly understand and manipulate biological processes. The advent of availability of primary human cells now makes possible engineering of such organ cultures. Here we report the generation of a human "skin," arguably the simplest human tissue. Beginning with three primary cell types taken from adult tissues, this organ culture develops into a mature tissue containing a stratified epithelium and an interconnected network of mature microvessels, with appropriate matrix molecules and cytokines. Surprisingly, pericytes and monocytes appear adjacent to and within " blood" vessels, respectively. These cultures respond appropriately to stimulators of specific biological processes, providing a vehicle to investigate basic biological processes, such as 1) cell-cell and cell-microenvironment interaction; 2) transdifferentiation of one cell type to another and/or differentiation from stem cells present in adult tissues; and 3) opportunities for genetic manipulation of human tissues to understand function. Moreover, this "skin" can potentially be developed into a tailored "living bandage" for patients with impaired healing and can serve as prototype for the development of other human organ cultures.	Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA	University of California System; University of California Riverside	Martins-Green, M (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, Spieth Hall,900 Univ Av, Riverside, CA 92521 USA.	manuela.martins@ucr.edu						Allt G, 2001, CELLS TISSUES ORGANS, V169, P1, DOI 10.1159/000047855; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Balasubramani M, 2001, BURNS, V27, P534, DOI 10.1016/S0305-4179(01)00018-3; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; CLARK RAF, 1993, J DERMATOL SURG ONC, V19, P693, DOI 10.1111/j.1524-4725.1993.tb00413.x; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; DESAI M H, 1991, Journal of Burn Care and Rehabilitation, V12, P540, DOI 10.1097/00004630-199111000-00009; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; Fuchs E, 1998, Harvey Lect, V94, P47; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Hangai M, 2002, AM J PATHOL, V161, P1429, DOI 10.1016/S0002-9440(10)64418-5; Ilan N, 1998, J CELL SCI, V111, P3621; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Latijnhouwers MA, 1996, J PATHOL, V178, P30, DOI 10.1002/(SICI)1096-9896(199601)178:1<30::AID-PATH442>3.0.CO;2-7; Lee KH, 2000, YONSEI MED J, V41, P774, DOI 10.3349/ymj.2000.41.6.774; Lee S, 2002, J CLIN INVEST, V110, P1105, DOI 10.1172/JCI200215755; Li YL, 1999, CELL STRUCT FUNCT, V24, P255, DOI 10.1247/csf.24.255; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; Mazzalupo S, 2003, DEV DYNAM, V226, P356, DOI 10.1002/dvdy.10245; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549; PAECH C, 1993, ANAL BIOCHEM, V213, P440, DOI 10.1006/abio.1993.1446; Palmer-Kazen U, 2004, J VASC SURG, V39, P621, DOI 10.1016/j.jvs.2003.07.006; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Salamonsen LA, 2001, CELL TISSUE RES, V306, P335, DOI 10.1007/s004410100452; Sonoda M, 2000, AM J SPORT MED, V28, P90, DOI 10.1177/03635465000280012801; Viac J, 1997, ARCH DERMATOL RES, V289, P158, DOI 10.1007/s004030050172; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang KW, 2003, AI COMMUN, V16, P1; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yue H, 2004, J CARDIOVASC PHARM, V44, P223, DOI 10.1097/00005344-200408000-00012; Yue H, 2004, BASIC RES CARDIOL, V99, P257, DOI 10.1007/s00395-004-0472-9	38	9	9	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					222	+		10.1099/fj.04-1725fje	http://dx.doi.org/10.1099/fj.04-1725fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15591154				2022-12-28	WOS:000226091000021
J	Mordelet, E; Kissa, K; Cressant, A; Gray, F; Ozden, S; Vidal, C; Charneau, P; Granon, S				Mordelet, E; Kissa, K; Cressant, A; Gray, F; Ozden, S; Vidal, C; Charneau, P; Granon, S			Histopathological and cognitive defects induced by Nef in the brain	FASEB JOURNAL			English	Article						neuropathology; behavior; bone marrow-derived macrophages	HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; RESTRICTED HIV-1 INFECTION; MEDIAL PREFRONTAL LESIONS; POLYMERASE CHAIN-REACTION; AIDS DEMENTIA COMPLEX; CENTRAL DNA FLAP; NEURONAL APOPTOSIS; QUINOLINIC ACID	Complex mechanisms of human immunodeficiency virus type-1 (HIV-1) brain pathogenesis suggest the contribution of individual HIV-1 gene products. Among them, the Nef protein has been reported to harbor a major determinant of pathogenicity in AIDS-like disease. The goal of the present study was to determine whether Nef protein expressed in vivo by primary macrophages could induce a brain toxicity also affecting the behavior of the rat. To achieve this goal we grafted Nef-transduced macrophages into the rat hippocampus. Two months post-transplantation, we observed that Nef induces monocyte/macrophage recruitment, expression of TNF-alpha, and astrogliosis. No apoptotic event was detected. We further demonstrated that Nef neurotoxicity is associated with cognitive deficits.	Inst Pasteur, Unite Postulante Mycol Mol, F-75015 Paris, France; Inst Pasteur, Unite Postulante Macrophages & Dev Immun, Paris, France; Inst Pasteur, Unite Retrovirus & Transfert Genet, Paris, France; Hop Lariboisiere, Serv Anat & Cytol Pathol, F-75475 Paris, France; Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, Paris, France; EPHE, CRSSA, Serv Neurol, CEA, Fontenay Aux Roses, France; Inst Pasteur, Grp Virol Mol & Vectorol, Paris, France; Inst Pasteur, Unite Recepteurs & Cognit, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mordelet, E (corresponding author), Inst Pasteur, Unite Postulante Mycol Mol, 25 Rue Dr Roux, F-75015 Paris, France.	mordelet@pasteur.fr; granon@pasteur.fr	CHARNEAU, Pierre/M-1565-2017; Kissa, Karima/N-6801-2018	CHARNEAU, Pierre/0000-0003-1184-5773; Kissa, Karima/0000-0002-7683-3661; Granon, sylvie/0000-0001-9384-3119				ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Ambrosini E, 1999, GLIA, V27, P143; Bachis A, 2003, J NEUROSCI, V23, P5715; Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002; Balasingam V, 1996, J NEUROSCI, V16, P2945; Banda NK, 1997, APOPTOSIS, V2, P61, DOI 10.1023/A:1026439726053; BARCLAY AN, 1981, IMMUNOLOGY, V44, P727; BECKER JT, 1981, NEUROPSYCHOLOGIA, V19, P733, DOI 10.1016/0028-3932(81)90085-3; Berger JR, 2000, J PSYCHOPHARMACOL, V14, P214, DOI 10.1177/026988110001400304; Berthoz A, 1997, PHILOS T R SOC B, V352, P1437, DOI 10.1098/rstb.1997.0130; BUHOT MC, 1995, EUR J PHARMACOL, V285, P221, DOI 10.1016/0014-2999(95)00407-C; Compton DM, 1997, NEUROBIOL LEARN MEM, V68, P117, DOI 10.1006/nlme.1997.3793; Corasaniti MT, 2001, FUNCT NEUROL, V16, P31; Cressant A, 2003, BRAIN RES PROTOC, V12, P116, DOI 10.1016/j.brainresprot.2003.08.002; Cressant A, 1997, J NEUROSCI, V17, P2531; DEGANS J, 1989, CLIN NEUROL NEUROSUR, V91, P199, DOI 10.1016/0303-8467(89)90114-5; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Duzel E, 2003, J NEUROSCI, V23, P9439; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; Gendelman HE, 1997, AIDS, V11, pS35; Glass JD, 1996, ANNU REV NEUROSCI, V19, P1; Glass JD, 2001, MICROSC RES TECHNIQ, V54, P95, DOI 10.1002/jemt.1124; Granon S, 1996, BEHAV BRAIN RES, V78, P147, DOI 10.1016/0166-4328(95)00242-1; GRANON S, 1994, BEHAV NEUROSCI, V108, P883, DOI 10.1037/0735-7044.108.5.883; Gray F, 1998, REV NEUROL, V154, pS91; Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Haughey NJ, 2002, JAIDS-J ACQ IMM DEF, V31, pS55, DOI 10.1097/00126334-200210012-00005; Hodges H, 1996, COGNITIVE BRAIN RES, V3, P167, DOI 10.1016/0926-6410(96)00004-3; Kapasi AA, 2002, MOL MED, V8, P676, DOI 10.1007/BF03402031; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kedzierska Katherine, 2001, Antiviral Chemistry and Chemotherapy, V12, P133; Kelder W, 1998, ANN NEUROL, V44, P831, DOI 10.1002/ana.410440521; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Koedel U, 1999, J IMMUNOL, V163, P1237; Kohleisen B, 1999, AIDS, V13, P2331, DOI 10.1097/00002030-199912030-00004; Kramer-Hammerle S, 2001, AIDS RES HUM RETROV, V17, P597, DOI 10.1089/088922201300119699; KURE K, 1990, AM J PATHOL, V136, P1085; Liu XX, 2001, J BIOL CHEM, V276, P32763, DOI 10.1074/jbc.M101025200; Messam CA, 2000, J NEUROVIROL, V6, pS90; Mordelet E, 2002, GENE THER, V9, P46, DOI 10.1038/sj.gt.3301591; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nath A, 2000, ANN NEUROL, V47, P186, DOI 10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.3.CO;2-V; Nath Avindra, 2004, Curr Treat Options Neurol, V6, P139, DOI 10.1007/s11940-004-0023-6; Navia BA, 1997, NEUROIMAG CLIN N AM, V7, P581; Nottet HSLM, 1996, J NEUROVIROL, V2, P111, DOI 10.3109/13550289609146544; Percario Z, 2003, J LEUKOCYTE BIOL, V74, P821, DOI 10.1189/jlb.0403161; Persidsky Y, 1997, J NEUROVIROL, V3, P401, DOI 10.3109/13550289709031186; Poucet B, 1997, CRIT REV NEUROBIOL, V11, P101, DOI 10.1615/CritRevNeurobiol.v11.i2-3.10; RANKI A, 1994, ARCH VIROL, V139, P365, DOI 10.1007/BF01310798; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; Rasola A, 2001, J IMMUNOL, V166, P81, DOI 10.4049/jimmunol.166.1.81; Robichaud GA, 2000, AIDS RES HUM RETROV, V16, P1959, DOI 10.1089/088922200750054684; Rostasy K, 1999, ANN NEUROL, V46, P207, DOI 10.1002/1531-8249(199908)46:2<207::AID-ANA10>3.0.CO;2-4; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sasseville VG, 1996, AM J PATHOL, V149, P1459; SAVE E, 1992, BEHAV NEUROSCI, V106, P447, DOI 10.1037/0735-7044.106.3.447; SCHENK F, 1995, BEHAV BRAIN RES NATU, P277; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Sirven A, 2000, BLOOD, V96, P4103; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Smith DG, 2001, J NEUROVIROL, V7, P56; SPATAFORA M, 1988, Respiration, V54, P73; Sporer B, 2000, J NEUROIMMUNOL, V102, P125, DOI 10.1016/S0165-5728(99)00170-8; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; Suarez S, 2001, AIDS, V15, P195, DOI 10.1097/00002030-200101260-00008; SUAREZ S, 2000, FLAMMARION MED SCI F, P40; SUTHERLAND RJ, 1982, NEUROSCI LETT, V32, P125, DOI 10.1016/0304-3940(82)90261-0; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; Tardieu M, 1999, CURR OPIN NEUROL, V12, P377, DOI 10.1097/00019052-199908000-00002; Thinus-Blanc C., 1996, ANIMAL SPATIAL COGNI; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; Torres-Munoz J, 2001, J NEUROPATH EXP NEUR, V60, P885, DOI 10.1093/jnen/60.9.885; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yang YD, 2003, J VIROL, V77, P6700, DOI 10.1128/JVI.77.12.6700-6708.2003; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	86	30	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1851	1861		10.1096/fj.04-2308com	http://dx.doi.org/10.1096/fj.04-2308com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576488				2022-12-28	WOS:000226091000035
J	Elimova, E; Kisilevsky, R; Szarek, WA; Ancsin, JB				Elimova, E; Kisilevsky, R; Szarek, WA; Ancsin, JB			Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy	FASEB JOURNAL			English	Article						anti-amyloid; AA-amyloid; J774A.1 cells; thioflavin T; amyloid enhancing factor	SERUM AMYLOID-A; CREUTZFELDT-JAKOB-DISEASE; GERSTMANN-STRAUSSLER SYNDROME; FIBROBLAST-GROWTH-FACTOR; HUMAN APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; PRION PROTEIN; FIBRIL FORMATION; BINDING-SITES; BETA-PEPTIDE	To date 22 different polypeptides, including Abeta in Alzheimer's disease and PrPSc in prion disorders, are known to re-fold and assemble into highly organized fibrils, which associate with heparan sulfate (HS) proteoglycans to form tissue deposits called amyloid. Mononuclear phagocytes have long been thought to be involved in this process, and we describe a monocytic cell culture system that can transform the acute-phase protein serum amyloid A (SAA1.1) into AA-amyloid and appears to recapitulate all the main features of amyloidogenesis observed in vivo. These features in common include nucleation-dependent kinetics, identical proteolytic processing of SAA1.1, and co-deposition of HS with the fibrils. Heparin and polyvinylsulfonate previously reported to block AA-amyloidogenesis in mice are also effective inhibitors in this cell culture model. Furthermore, a synthetic peptide (27-mer) corresponding to a HS binding site of SAA, blocks amyloid deposition at a concentration that is several-orders-of-magnitude lower than any other peptide-based inhibitor previously reported. The 27-mer's inhibitory activity may target the amyloidogenic pathway specifically as it does not interfere with the binding of SAA to monocytes. These data provide direct evidence that SAA1.1: HS interactions are a critical step in AA-amyloidogenesis and suggest a novel treatment strategy for other amyloidoses.	Queens Univ, Kingston Gen Hosp, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Kingston Gen Hosp, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada	Ancsin, JB (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	3jba1@post.queensu.ca						Ahmad A, 2003, BIOCHEMISTRY-US, V42, P11404, DOI 10.1021/bi034868o; Ancsin JB, 1999, J BIOL CHEM, V274, P7172, DOI 10.1074/jbc.274.11.7172; Ancsin JB, 2003, AMYLOID, V10, P67, DOI 10.3109/13506120309041728; ARAI K, 1994, J PATHOL, V173, P127, DOI 10.1002/path.1711730209; ARGILES A, 1994, NEPHROL DIAL TRANSPL, V9, P662, DOI 10.1093/ndt/9.6.662; AXELRAD MA, 1982, LAB INVEST, V47, P139; BENDITT EP, 1971, FEBS LETT, V19, P169, DOI 10.1016/0014-5793(71)80506-9; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; Castillo GM, 1997, J NEUROCHEM, V69, P2452; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CHRONOPOULOS S, 1994, J PATHOL, V173, P361, DOI 10.1002/path.1711730412; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; ERICSSON LH, 1987, FEBS LETT, V218, P11, DOI 10.1016/0014-5793(87)81008-6; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOLDSMITH MR, 1979, ANAL BIOCHEM, V99, P33, DOI 10.1016/0003-2697(79)90041-1; GUIROY DC, 1994, ACTA NEUROPATHOL, V87, P526; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heegaard NHH, 2002, J BIOL CHEM, V277, P11184, DOI 10.1074/jbc.M108837200; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jiang XL, 1997, BIOCHEMISTRY-US, V36, P13187, DOI 10.1021/bi970408h; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KISILEVSKY R, 1992, LAB INVEST, V66, P778; KISILEVSKY R, 1994, INT J EXP CLIN INVES, V1, P174; Kluve-Beckerman B, 1999, AM J PATHOL, V155, P123, DOI 10.1016/S0002-9440(10)65107-3; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAGNUS JH, 1991, SCAND J IMMUNOL, V34, P63, DOI 10.1111/j.1365-3083.1991.tb01521.x; MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; McLaurin J, 2002, ANN NY ACAD SCI, V977, P376, DOI 10.1111/j.1749-6632.2002.tb04840.x; MEEK RL, 1986, J EXP MED, V163, P499, DOI 10.1084/jem.163.3.499; MIURA K, 1990, J IMMUNOL, V144, P610; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Muhleisen H, 1995, NEUROPATH APPL NEURO, V21, P505, DOI 10.1111/j.1365-2990.1995.tb01097.x; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Ohashi K, 2002, NEPHRON, V90, P158, DOI 10.1159/000049037; Park K, 2001, J BIOL CHEM, V276, P16611, DOI 10.1074/jbc.M008423200; PERLMUTTER LS, 1990, BRAIN RES, V508, P13, DOI 10.1016/0006-8993(90)91111-S; Rocken C, 1998, VIRCHOWS ARCH, V432, P547, DOI 10.1007/s004280050204; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Scrocchi LA, 2003, J STRUCT BIOL, V141, P218, DOI 10.1016/S1047-8477(02)00630-5; Scrocchi LA, 2002, J MOL BIOL, V318, P697, DOI 10.1016/S0022-2836(02)00164-X; Sengupta P, 2003, BIOCHEMISTRY-US, V42, P10506, DOI 10.1021/bi0341410; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIROO M, 1987, SCAND J IMMUNOL, V26, P709, DOI 10.1111/j.1365-3083.1987.tb02307.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SNOW AD, 1987, LAB INVEST, V56, P665; SNOW AD, 1988, AM J PATHOL, V133, P456; SNOW AD, 1991, J HISTOCHEM CYTOCHEM, V39, P1321, DOI 10.1177/39.10.1940305; SNOW AD, 1990, LAB INVEST, V63, P601; SNOW AD, 1985, LAB INVEST, V53, P37; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; TAKAHASHI M, 1989, VIRCHOWS ARCH A, V415, P411, DOI 10.1007/BF00747742; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; VANDUINEN SG, 1995, LAB INVEST, V73, P183; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com; YOUNG ID, 1992, ARCH PATHOL LAB MED, V116, P951; YOUNG ID, 1989, ACTA NEUROPATHOL, V78, P202, DOI 10.1007/BF00688210; Zhu H, 2001, MOL MED, V7, P517, DOI 10.1007/BF03401857	85	56	58	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1749	+		10.1096/fj.03-1436fje	http://dx.doi.org/10.1096/fj.03-1436fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345688				2022-12-28	WOS:000224243200041
J	Gassanov, N; Er, F; Zagidullin, N; Hoppe, UC				Gassanov, N; Er, F; Zagidullin, N; Hoppe, UC			Endothelin induces differentiation of ANP-EGFP expressing embryonic stem cells towards a pacemaker phenotype	FASEB JOURNAL			English	Article						conduction system; cardiogenesis; electrophysiology	PURKINJE-FIBER DIFFERENTIATION; ACTIVATED INWARD CURRENT; CARDIAC PRECURSOR CELLS; IN-VITRO; FUNCTIONAL-PROPERTIES; GENE-EXPRESSION; RETINOIC ACID; MUSCLE CELLS; MOUSE HEART; CARDIOMYOCYTES	Currently, only limited insight into mechanisms promoting the differentiation and specification of the mammalian cardiac conduction system is available. Therefore, we established a murine embryonic stem (ES) cell line stably expressing the enhanced green fluorescent protein (EGFP) under the transcriptional control of the human atrial natriuretic peptide (ANP) promoter to further characterize the development of very early stages of the mammalian cardiac conduction tissue. The cardiac nature of ANP-EGFP positive cells was confirmed by immunostaining. In ANP-EGFP expressing ES cell-derived cardiomyocytes, a distinct sublineage of pacemaker cells could be identified. Pacemaker cells displayed a spindle shape and exhibited a higher spontaneous beating rate, faster I-f current activation and larger I-f current densities compared with triangular atrial-like cardiocytes. Exposure to endothelin-1 significantly increased the percentage of pacemaker-like cells without affecting their electrophysiological properties. These findings were corroborated by immunostaining with antibodies against connexin 40 and connexin 45, known markers for cardiac conduction tissue. Conversely, treatment of ANP-EGFP expressing ES cells with neuregulin-1 exhibited no effect on differentiation. These results indicate that ANP-EGFP expression enables the identification of ES cell-derived pacemaker cells by their fluorescence and morphology and that endothelin-1 promotes the development of ANP-EGFP positive cardiomyocytes to a pacemaker-like phenotype.	Univ Cologne, Dept Internal Med 3, D-50924 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50924 Cologne, Germany	University of Cologne; University of Cologne	Hoppe, UC (corresponding author), Univ Cologne, Dept Internal Med 3, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	uta.hoppe@uni-koeln.de	Zagidullin, Naufal/O-8304-2016	Zagidullin, Naufal/0000-0003-2386-6707				Abi-Gerges N, 2000, J PHYSIOL-LONDON, V523, P377, DOI 10.1111/j.1469-7793.2000.t01-2-00377.x; Alcolea S, 2004, CIRC RES, V94, P100, DOI 10.1161/01.RES.0000108261.67979.2A; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Coppen SR, 1999, DEV GENET, V24, P82, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<82::AID-DVG9>3.0.CO;2-1; Coppen SR, 2003, MOL CELL BIOCHEM, V242, P121, DOI 10.1023/A:1021150014764; DELORME B, 1995, DEV DYNAM, V204, P358, DOI 10.1002/aja.1002040403; Delorme B, 1997, CIRC RES, V81, P423, DOI 10.1161/01.RES.81.3.423; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; Gepstein L, 2002, CIRC RES, V91, P866, DOI 10.1161/01.RES.0000041435.95082.84; Gourdie RG, 1998, P NATL ACAD SCI USA, V95, P6815, DOI 10.1073/pnas.95.12.6815; GOURDIE RG, 1995, DEVELOPMENT, V121, P1423; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hoppe UC, 1998, CIRCULATION, V97, P55, DOI 10.1161/01.CIR.97.1.55; Hoppe UC, 1998, CARDIOVASC RES, V38, P788, DOI 10.1016/S0008-6363(98)00047-9; Hoppe UC, 2001, P NATL ACAD SCI USA, V98, P5335, DOI 10.1073/pnas.091239098; Kanzawa N, 2002, DEVELOPMENT, V129, P3185; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; LAPOINTE MC, 1988, J BIOL CHEM, V263, P9075; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Pourrier M, 2003, J MEMBRANE BIOL, V194, P141, DOI 10.1007/s00232-003-2034-8; Rentschler S, 2002, P NATL ACAD SCI USA, V99, P10464, DOI 10.1073/pnas.162301699; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; Schiaffino S, 1997, CIRC RES, V80, P749, DOI 10.1161/01.RES.80.5.749; Takebayashi-Suzuki K, 2000, DEVELOPMENT, V127, P3523; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zhang YM, 2002, CIRCULATION, V106, P1294, DOI 10.1161/01.CIR.0000027585.05868.67	42	66	69	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1710	+		10.1096/fj.04-1619fje	http://dx.doi.org/10.1096/fj.04-1619fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345687				2022-12-28	WOS:000224243200040
J	Saaristo, A; Tammela, T; Timonen, J; Yla-Herttuala, S; Tukiainen, E; Asko-Seljavaara, S; Alitalo, K				Saaristo, A; Tammela, T; Timonen, J; Yla-Herttuala, S; Tukiainen, E; Asko-Seljavaara, S; Alitalo, K			Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds	FASEB JOURNAL			English	Article						skin flaps; edema; perfusion; lymphangiogenesis	LYMPHANGIOGENESIS; MUSCLE	Edema and insufficient blood perfusion are common problems in reconstructive surgery. The blood vasculature is reconstructed in microvascular flaps, whereas lymphatic vessel function is lost after surgical incision. Here, we demonstrate that vascular endothelial growth factor C (VEGF-C) gene transfer can be used to reconstruct a lymphatic vessel network severed by incision of skin flaps. We used adenoviral VEGF-C gene transfer at the edges of epigastric skin flaps in mice. Our results show that VEGF-C gene expression results in the formation of anastomoses between the lymphatic vessels of the skin flap and the surrounding lymphatic vasculature. Some spontaneous lymphangiogenesis also took place in the control mice, but the lymphatic vessels generated remained nonfunctional even 2 months postoperatively. In contrast, the VEGF-C treated mice demonstrated persistent lymphatic vessel function during the 2 month follow-up despite the transient nature of the adenoviral VEGF-C gene expression. The restoration of lymphatic function by VEGF-C in skin flaps provides new tools to promote vascular perfusion and to reduce tissue edema in skin and muscle flaps. These results have important implications for the prevention and treatment of surgically induced secondary lymphedema.	Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Plast Surg, FIN-00014 Helsinki, Finland; Paijat Hame Cent Hosp, Dept Surg, Lahti, Finland; Univ Kuopio, AI Virtanen Inst, Dept Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Gene Therapy Unit, FIN-70211 Kuopio, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Paijat Hame Central Hospital; University of Eastern Finland; University of Eastern Finland	Saaristo, A (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.FI	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; /0000-0003-3675-6961; Yla-Herttuala, Seppo/0000-0001-7593-2708				BELLMAN S, 1959, Acta Chir Scand, V116, P99; Diaz-Sandoval LJ, 2003, EXPERT OPIN BIOL TH, V3, P599, DOI 10.1517/14712598.3.4.599; Gurunluoglu R, 2002, ANN PLAS SURG, V49, P161, DOI 10.1097/00000637-200208000-00009; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Jung H, 2003, MICROSURG, V23, P374, DOI 10.1002/micr.10140; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; KERRIGAN CL, 1983, PLAST RECONSTR SURG, V72, P766, DOI 10.1097/00006534-198312000-00003; Lohela M, 2003, THROMB HAEMOSTASIS, V90, P167, DOI 10.1160/TH03-04-0200; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rockson SG, 2002, ANN NY ACAD SCI, V979, P64, DOI 10.1111/j.1749-6632.2002.tb04868.x; ROCKSON SG, 2002, ANN NY ACAD SCI, V979, P76; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Salmi A, 1996, PLAST RECONSTR SURG, V97, P1443, DOI 10.1097/00006534-199606000-00021; Shimoda H, 2004, CELL TISSUE RES, V316, P325, DOI 10.1007/s00441-004-0889-3; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yang Y, 1996, GENE THER, V3, P137; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Yla-Herttuala S, 2001, J INTERN MED, V250, P367; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830	24	73	80	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1707	+		10.1096/fj.04-1592fje	http://dx.doi.org/10.1096/fj.04-1592fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15361472				2022-12-28	WOS:000224243200031
J	Chen, SY; Dehart, DB; Sulik, KK				Chen, SY; Dehart, DB; Sulik, KK			Protection from ethanol-induced limb malformations by the superoxide dismutase/catalase mimetic EUK-134	FASEB JOURNAL			English	Article						ethanol; antitoxidant; apoptosis	FETAL ALCOHOL SYNDROME; NEURAL CREST CELLS; APICAL ECTODERMAL RIDGE; OXIDATIVE STRESS; FREE-RADICALS; HYDROGEN-PEROXIDE; IN-VITRO; VITAMIN-A; TOXICITY; OXYGEN	Based on previous in vitro studies that have illustrated prevention of ethanol-induced cell death by antioxidants, using an in vivo model, we have tested the anti-teratogenic potential of a potent synthetic superoxide dismutase plus catalase mimetic, EUK-134. The developing limb of C57BL/6J mice, which is sensitive to ethanol-induced reduction defects, served as the model system. On their ninth day of pregnancy, C57BL/6J mice were administered ethanol (two intraperitoneal doses of 2.9 g/kg given 4 h apart) alone or in combination with EUK-134 (two doses of 10 mg/kg). Pregnant control mice were similarly treated with either vehicle or EUK-134, alone. Within 15 h of the initial ethanol exposure, excessive apoptotic cell death was observed in the apical ectodermal ridge (AER) of the newly forming forelimb buds. Forelimb defects, including postaxial ectrodactyly, metacarpal, and ulnar deficiencies, occurred in 67.3% of the ethanol-exposed fetuses that were examined at 18 days of gestation. The right forelimbs were preferentially affected. No limb malformations were observed in control fetuses. Cell death in the AER of embryos concurrently exposed to ethanol and EUK-134 was notably reduced compared with that in embryos from ethanol-treated dams. Additionally, the antioxidant treatment reduced the incidence of forelimb malformations to 35.9%. This work illustrates that antioxidants can significantly improve the adverse developmental outcome that results from ethanol exposure in utero, diminishing the incidence and severity of major malformations that result from exposure to this important human teratogen.	Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Chen, SY (corresponding author), Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA.	syc@med.unc.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011605, P60AA011605, K01AA013908] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA013908, AA11605, K01 AA013908] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ahlgren SC, 2002, P NATL ACAD SCI USA, V99, P10476, DOI 10.1073/pnas.162356199; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Anaya-Prado R, 2002, TRANSPLANT P, V34, P2518, DOI 10.1016/S0041-1345(02)03471-1; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; Chen SY, 2000, J PHARMACOL EXP THER, V294, P134; Chen SY, 2001, FASEB J, V15, P1649, DOI 10.1096/fj.00-0862fje; Chen SY, 1996, ALCOHOL CLIN EXP RES, V20, P1071, DOI 10.1111/j.1530-0277.1996.tb01948.x; Chen SY, 1996, ALCOHOL, V13, P589; Chen SY, 2000, ALCOHOL, V20, P75, DOI 10.1016/S0741-8329(99)00058-0; CREMIN BJ, 1981, PEDIATR RADIOL, V11, P151, DOI 10.1007/BF00971818; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIS WL, 1990, J CRAN GENET DEV BIO, V10, P277; DEJONGE MH, 1995, PEDIATR RES, V37, P418, DOI 10.1203/00006450-199504000-00006; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Doctrow SR, 2002, J MED CHEM, V45, P4549, DOI 10.1021/jm020207y; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Dunty WC, 2001, ALCOHOL CLIN EXP RES, V25, P1523, DOI 10.1111/j.1530-0277.2001.tb02156.x; FREEMAN BA, 1982, LAB INVEST, V47, P412; FRIDOVICH I, 1984, CURR EYE RES, V3, P1, DOI 10.3109/02713688408997181; Gilbert SF, 2003, DEV BIOL, P523; GRUMMER MA, 1993, ALCOHOL CLIN EXP RES, V17, P592, DOI 10.1111/j.1530-0277.1993.tb00805.x; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HERRMANN J, 1980, EUR J PEDIATR, V133, P221, DOI 10.1007/BF00496080; INOUYE M, 1976, Congenital Anomalies, V16, P171; Johnson CS, 2003, DEV BIOL, V259, P583; KOTCH LE, 1992, TERATOLOGY, V46, P323, DOI 10.1002/tera.1420460403; KOTCH LE, 1995, TERATOLOGY, V52, P128, DOI 10.1002/tera.1420520304; Kurose I, 1996, ALCOHOL CLIN EXP RES, V20, pA77, DOI 10.1111/j.1530-0277.1996.tb01736.x; Kyselova Z, 2003, ARCH GERONTOL GERIAT, V36, P221, DOI 10.1016/S0167-4943(02)00167-X; Liu CQ, 2003, DEVELOPMENT, V130, P1327, DOI 10.1242/dev.00354; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Maier SE, 1999, ALCOHOL CLIN EXP RES, V23, P726, DOI 10.1111/j.1530-0277.1999.tb04176.x; Makarenkova H, 1997, J CELL BIOL, V138, P1125, DOI 10.1083/jcb.138.5.1125; MAO GD, 1993, J BIOL CHEM, V268, P416; MILAIRE J, 1985, TERATOLOGY, V32, P433, DOI 10.1002/tera.1420320313; MUKHERJEE AB, 1982, SCIENCE, V218, P700, DOI 10.1126/science.6890235; Mylonas C, 1999, IN VIVO, V13, P295; PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43, DOI 10.3109/10428199509059662; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; PUPPO A, 1988, BIOCHEM J, V249, P185, DOI 10.1042/bj2490185; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Reinke LA, 2002, FREE RADICAL BIO MED, V32, P953, DOI 10.1016/S0891-5849(02)00795-5; REINKE LA, 1997, J NUTR, V127, pS889; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; SAUNDERS JW, 1976, DEV BIOL, V50, P16, DOI 10.1016/0012-1606(76)90063-4; Schilling TF, 1999, DEV BIOL, V210, P277, DOI 10.1006/dbio.1999.9214; SPIEGEL PG, 1979, CLIN ORTHOP RELAT R, P58; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; STADTMAN ER, 1995, METHOD ENZYMOL, V258, P379; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TAYLOR JR, 1986, MED J AUSTRALIA, V144, P533, DOI 10.5694/j.1326-5377.1986.tb112281.x; Turpaev KT, 2002, BIOCHEMISTRY-MOSCOW+, V67, P281, DOI 10.1023/A:1014819832003; VANRENSBURG LJ, 1981, S AFR MED J, V59, P687; WEBSTER WS, 1983, TERATOLOGY, V27, P231, DOI 10.1002/tera.1420270211; West JR, 2001, ALCOHOL CLIN EXP RES, V25, P1051, DOI 10.1111/j.1530-0277.2001.tb02316.x; Wilkemeyer MF, 2003, P NATL ACAD SCI USA, V100, P8543, DOI 10.1073/pnas.1331636100; ZIMMERMAN EF, 1990, TERATOLOGY, V41, P453, DOI 10.1002/tera.1420410410	61	64	65	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1234	+		10.1096/fj.03-0850fje	http://dx.doi.org/10.1096/fj.03-0850fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208273				2022-12-28	WOS:000222327500022
J	Jung, CG; Hida, H; Nakahira, K; Ikenaka, K; Kim, HJ; Nishino, H				Jung, CG; Hida, H; Nakahira, K; Ikenaka, K; Kim, HJ; Nishino, H			Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells	FASEB JOURNAL			English	Article						dopamine; transplantation; neural differention; trophic factor; sonic hedgehog	CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE; IN-VITRO; TYROSINE-HYDROXYLASE; DEPLETED STRIATUM; TRANSPLANTATION; GENERATION; SURVIVAL; DIFFERENTIATION; ASTROCYTES	Neural stem cells are promising candidates for donor cells in neural transplantation. However, the mechanism by which neural stem cells differentiate into neurons is not well understood. In the present study, a serial analysis of gene expression (SAGE) was carried out to generate a gene file of neural stem (progenitor) cells from the mouse ventral mesencephalon. Among the 15,815 tags investigated, the mRNA of the housekeeping genes (elongation factor 1-alpha, ATPase subunit 6, GAPDH, actin), laminin receptor 1, HSP 70, pleiotrophin, and nestin were highly expressed. Because pleiotrophin (PTN) exhibits mitogenic and trophic effects on neural development and exhibits trophic effects on survival of dopaminergic (DAergic) neurons, we investigated the role of PTN in neurogenesis, especially to DAergic neurons. Here, we show that PTN increased the production of tyrosine hydroxylase (TH)-positive neurons from embryonic stem (ES) cell-derived nestin-positive cells. The expression of Nurr1 mRNA was enhanced by PTN. L-dopa in the culture medium was increased by PTN. This effect was as strong as with sonic hedgehog. Data suggest that PTN mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon, and PTN promotes the production of DAergic neurons from ES cell-derived nestin-positive cells.	Nagoya City Univ, Grad Sch Med Sci, Dept Neurophysiol & Brain Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Saitama Med Sch, Dept Physiol, Moroyama, Saitama 3500495, Japan; Okazaki Natl Res Inst, Natl Inst Physiol Sci, Div Learning & Memory Res, Okazaki, Aichi 4448585, Japan; Okazaki Natl Res Inst, Natl Inst Physiol Sci, Lab Neural Informat, Okazaki, Aichi 4448585, Japan	Nagoya City University; Saitama Medical University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB)	Jung, CG (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Neurophysiol & Brain Sci, Mizuho Ku, 1 Kawasui, Nagoya, Aichi 4678601, Japan.	jung@med.nagoya-cu.ac.jp		Jung, Cha-Gyun/0000-0002-0225-0658				ALEXANDRA R, 2001, MECH DEVELOP, V105, P93; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Fukamauchi F, 1997, BIOCHEM BIOPH RES CO, V231, P356, DOI 10.1006/bbrc.1997.6101; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Gammill LS, 2002, DEVELOPMENT, V129, P5731, DOI 10.1242/dev.00175; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Hida H, 2003, EUR J NEUROSCI, V17, P2127, DOI 10.1046/j.1460-9568.2003.02661.x; Hida H, 1999, NEUROSCI RES, V35, P101, DOI 10.1016/S0168-0102(99)00073-5; HIDA H, 2002, SOC NEUROSCI 2002 AB; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; Hynes M, 1999, CURR OPIN NEUROBIOL, V9, P26, DOI 10.1016/S0959-4388(99)80004-X; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KAWANO H, 1995, DEV BRAIN RES, V86, P101, DOI 10.1016/0165-3806(95)00018-9; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MATSUMOTO K, 1994, DEV BRAIN RES, V79, P229, DOI 10.1016/0165-3806(94)90127-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nakajima K, 2001, BRAIN RES, V916, P76, DOI 10.1016/S0006-8993(01)02866-9; Nishino H, 2000, EXP NEUROL, V164, P209, DOI 10.1006/exnr.2000.7426; Ohyama K, 1998, DEV BRAIN RES, V107, P219, DOI 10.1016/S0165-3806(97)00220-4; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516	37	70	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1237	+		10.1096/fj.03-0927fje	http://dx.doi.org/10.1096/fj.03-0927fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180956				2022-12-28	WOS:000222327500038
J	Kenchappa, RS; Diwakar, L; Annepu, J; Ravindranath, V				Kenchappa, RS; Diwakar, L; Annepu, J; Ravindranath, V			Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration	FASEB JOURNAL			English	Article						mitochondria; complex I; protein thiol; gender difference; brain	ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; RECEPTOR-ALPHA; PARKINSONS-DISEASE; BRAIN MITOCHONDRIA; GENE-EXPRESSION; MESSENGER-RNA; RAT-BRAIN; THIOLTRANSFERASE GLUTAREDOXIN; S-THIOLATION	Incidence of Parkinson's disease is lower in women as compared with men. Although neuroprotective effect of estrogen is recognized, the underlying molecular mechanisms are unclear. MPTP (1-methyl-4-phenyl-1, 2, 3, 6, tetrahydro-pyridine), a neurotoxin that causes Parkinson's disease-like symptoms acts through inhibition of mitochondrial complex I. Administration of MPTP to male mice results in loss of dopaminergic neurons in substantia nigra, whereas female mice are unaffected. Oxidation of critical thiol groups by MPTP disrupts mitochondrial complex I, and up-regulation of glutaredoxin ( a thiol disulfide oxidoreductase) is essential for recovery of complex I. Early events following MPTP exposure, such as increased AP1 transcription, loss of glutathione, and up-regulation of glutaredoxin mRNA is seen only in male mice, indicating that early response to neurotoxic insult does not occur in females. Pretreatment of female mice with ICI 182,780, estrogen receptor ( ER) antagonist sensitizes them to MPTP-mediated complex I dysfunction. Constitutive expression of glutaredoxin is significantly higher in female mice as compared with males. ICI 182,780 down-regulates glutaredoxin activity in female mouse brain regions ( midbrain and striatum), indicating that glutaredoxin expression is regulated through estrogen receptor signaling. Higher constitutive expression of glutaredoxin could potentially contribute to the neuroprotection seen in female mouse following exposure to neurotoxins, such as MPTP.	Natl Brain Res Ctr, Div Mol & Cellular Neurosci, Manesar 122050, Haryana, India; Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Bangalore 560029, Karnataka, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); National Institute of Mental Health & Neurosciences - India	Ravindranath, V (corresponding author), Natl Brain Res Ctr, Div Mol & Cellular Neurosci, Nainwal Mode, Manesar 122050, Haryana, India.	vijir@nbrc.ac.in		Jayshree, Nellore/0000-0002-2024-1093				Annepu J, 2000, NEUROSCI LETT, V289, P209, DOI 10.1016/S0304-3940(00)01300-8; Baldereschi M, 2000, NEUROLOGY, V55, P1358, DOI 10.1212/WNL.55.9.1358; Balijepalli S, 1999, J NEUROCHEM, V72, P1170, DOI 10.1046/j.1471-4159.1999.0721170.x; Behari M, 2001, J NEUROL SCI, V190, P49, DOI 10.1016/S0022-510X(01)00578-0; Behl C, 1999, TRENDS PHARMACOL SCI, V20, P441, DOI 10.1016/S0165-6147(99)01392-9; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Bi RF, 2001, P NATL ACAD SCI USA, V98, P13391, DOI 10.1073/pnas.241507698; Blurton-Jones MM, 1999, J COMP NEUROL, V405, P529, DOI 10.1002/(SICI)1096-9861(19990322)405:4<529::AID-CNE6>3.0.CO;2-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brueggemeier RW, 2001, J STEROID BIOCHEM, V78, P145, DOI 10.1016/S0960-0760(01)00090-5; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Ciana P, 2003, NAT MED, V9, P82, DOI 10.1038/nm809; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Dluzen DE, 2000, J NEUROCYTOL, V29, P387, DOI 10.1023/A:1007117424491; DUPUIS A, 1991, BIOCHEM J, V277, P11, DOI 10.1042/bj2770011; Ehrhart J, 2002, PARKINSONISM RELAT D, V8, P395, DOI 10.1016/S1353-8020(02)00020-2; Fabre E, 1999, J PHYSIOL BIOCHEM, V55, P325; FERREIRA A, 1991, J NEUROSCI, V11, P392; Freyaldenhoven TE, 1996, BRAIN RES, V735, P232, DOI 10.1016/0006-8993(96)00598-7; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; HURN PD, 2000, J CEREB BLOOD FLOW M, V20, P79; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Kenchappa RS, 2003, NEUROSCI LETT, V350, P51, DOI 10.1016/S0304-3940(03)00779-1; Kenchappa RS, 2002, J NEUROSCI, V22, P8402; KENCHAPPA RS, 2003, FASEB J         0119, DOI DOI 10.1096/FJ02-0771FJE; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; LIU GT, 1992, BIOCHEM PHARMACOL, V43, P147, DOI 10.1016/0006-2952(92)90271-J; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MASAHIKO S, 2000, J CEREB BLOOD FLOW M, V20, P112; McIlwain H, 1975, PRACTICAL NEUROCHEMI, P105; Miller DB, 1998, ANN NY ACAD SCI, V844, P153, DOI 10.1111/j.1749-6632.1998.tb08230.x; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; MUTHANE U, 1994, EXP NEUROL, V126, P195, DOI 10.1006/exnr.1994.1058; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; PAI KS, 1991, J NEUROSCI METH, V37, P209, DOI 10.1016/0165-0270(91)90026-V; Park JB, 1997, GENE, V197, P189, DOI 10.1016/S0378-1119(97)00262-X; Pelletier G, 2000, HISTOL HISTOPATHOL, V15, P1261, DOI 10.14670/HH-15.1261; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Ramirez AD, 2003, NEUROENDOCRINOLOGY, V77, P223, DOI 10.1159/000070277; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Salvatori L, 2003, ONCOGENE, V22, P4875, DOI 10.1038/sj.onc.1206784; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; Scoville SA, 1997, EXP NEUROL, V146, P596, DOI 10.1006/exnr.1997.6565; SENIUK NA, 1990, BRAIN RES, V527, P7, DOI 10.1016/0006-8993(90)91055-L; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SHIVAKUMAR BR, 1992, BRAIN RES, V595, P256, DOI 10.1016/0006-8993(92)91058-M; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; SHUGHRUE PJ, 1993, NEUROENDOCRINOLOGY, V57, P439, DOI 10.1159/000126390; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singh M, 1999, J NEUROSCI, V19, P1179; SIRINATHSINGHJI DJS, 1992, MOL BRAIN RES, V12, P267, DOI 10.1016/0169-328X(92)90093-Q; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; Stephans SE, 2002, NEUROTOXICOLOGY, V23, P569, DOI 10.1016/S0161-813X(02)00060-8; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; SUBBAIAH MTR, 1993, J CLIN ENDOCR METAB, V77, P95; SUGIOKA K, 1987, FEBS LETT, V210, P37, DOI 10.1016/0014-5793(87)81293-0; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; VARASTET M, 1994, NEUROSCIENCE, V63, P47, DOI 10.1016/0306-4522(94)90006-X; VAZQUEZ EJ, 2001, J INVEST MED, V49, pA285; Watters JJ, 1998, J NEUROSCI, V18, P6672; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Zhang L, 2001, NEUROREPORT, V12, P1919, DOI 10.1097/00001756-200107030-00030; Zhou Y, 2001, BIOCHEM BIOPH RES CO, V286, P1059, DOI 10.1006/bbrc.2001.5479	81	55	59	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1102	+		10.1096/fj.03-1075fje	http://dx.doi.org/10.1096/fj.03-1075fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132975				2022-12-28	WOS:000221883200010
J	Auger, JM; Kuijpers, MJE; Senis, YA; Watson, SP; Heemskerk, JWM				Auger, JM; Kuijpers, MJE; Senis, YA; Watson, SP; Heemskerk, JWM			Adhesion of human and mouse platelets to collagen under shear: a unifying model	FASEB JOURNAL			English	Article						Src kinase; thrombus; GPVI-mediated platelet activation	RECEPTOR-GAMMA-CHAIN; GLYCOPROTEIN IB-ALPHA; INTEGRIN ALPHA(2)BETA(1); THROMBUS FORMATION; TYROSINE PHOSPHORYLATION; ALPHA-2-BETA-1 INTEGRIN; MURINE PLATELETS; SRC KINASES; VI; ACTIVATION	There is presently confusion as to the roles of alpha 2 beta 1 and GPVI in supporting platelet adhesion and aggregate formation on collagen at intermediate/high shear. Recent studies have reported essential, partial, or dispensable roles for either receptor in supporting these events, and the possibility that there may be fundamental differences between their roles in human and mouse platelets has been proposed. Further, the recent recognition that Src family tyrosine kinases contribute to signaling by alpha 2 beta 1 and other adhesive receptors, in addition to GPVI, has added to this debate. The present study compares the roles of alpha 2 beta 1, GPVI, and Src-dependent kinases in supporting adhesion and aggregation in human and mouse platelets in whole blood using blocking antibodies, mutant mice, and a novel inhibitor of Src kinases, PD0173952, which is effective in plasma. The results demonstrate that the fundamental processes of adhesion and aggregate formation are conserved in mice and human platelets and that two mechanisms of stable adhesion and activation on collagen exist. These can be distinguished by the contributions of GPVI and alpha 2 beta 1, with GPVI-mediated platelet activation either preceding or following integrin-mediated adhesion. The relative contribution of each pathway depends on environmental conditions and may also reflect platelet heterogeneity. These observations form the basis of a unifying two-state model of platelet adhesion and aggregate formation on collagen that is conserved between human and mouse platelets.	Univ Birmingham, Sch Med, Inst Biomed Res, Div Med Sci,Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Biochem, Maastricht, Netherlands	University of Birmingham; Maastricht University	Auger, JM (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, Div Med Sci,Ctr Cardiovasc Sci, Wolfson Dr, Birmingham B15 2TT, W Midlands, England.	jma299@bham.ac.uk; JWM.Heemskerk@BIOCH.unimaas.nl	Heemskerk, Johan/AAM-8323-2021; Kuijpers, Marijke/AAN-9876-2021; Senis, Yotis/AAD-7183-2021; Watson, Stephen P/Q-6292-2016	Heemskerk, Johan/0000-0002-2848-5121; Watson, Stephen P/0000-0002-7846-7423; Senis, Yotis/0000-0002-0947-9957				Auger JM, 2003, J THROMB HAEMOST, V1, P2419, DOI 10.1046/j.1538-7836.2003.00464.x; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Heemskerk JWM, 2001, J PHYSIOL-LONDON, V535, P625, DOI 10.1111/j.1469-7793.2001.00625.x; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Jarvis GE, 2004, BIOCHEM J, V383, P581, DOI 10.1042/BJ20040654; Jarvis GE, 2004, PLATELETS, V15, P303, DOI 10.1080/09537100410001710254; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Lecut C, 2003, J THROMB HAEMOST, V1, P2653, DOI 10.1111/j.1538-7836.2003.00495.x; Mangin P, 2003, J BIOL CHEM, V278, P32880, DOI 10.1074/jbc.M302333200; Marshall SJ, 2002, BIOCHEM J, V361, P297, DOI 10.1042/0264-6021:3610297; Marshall SJ, 2004, BLOOD, V103, P2601, DOI 10.1182/blood-2003-09-3319; Moroi M, 2000, THROMB HAEMOSTASIS, V83, P769; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; POLANOWSKAGRABOWSK, 2003, ARTERIOSCL THROM VAS, V23, P1934; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Quek LS, 2000, BLOOD, V96, P4246; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; SIXMA JJ, 1995, THROMB HAEMOSTASIS, V74, P454; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Wonerow P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128	36	101	102	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					825	+		10.1096/fj.04-1940fje	http://dx.doi.org/10.1096/fj.04-1940fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15758040				2022-12-28	WOS:000227901300023
J	Serviddio, G; Di Venosa, N; Federici, A; D'Agostino, D; Rollo, T; Prigigallo, F; Altomare, E; Fiore, T; Vendemiale, G				Serviddio, G; Di Venosa, N; Federici, A; D'Agostino, D; Rollo, T; Prigigallo, F; Altomare, E; Fiore, T; Vendemiale, G			Brief hypoxia before normoxic reperfusion (postconditioning) protects the heart against ischemia-reperfusion injury by preventing mitochondria peroxyde production and glutathione depletion	FASEB JOURNAL			English	Article						hypoxic reperfusion; ischemia-reperfusion; mitochondria; oxidative stress	COMPLEX-I ACTIVITY; MYOCARDIAL-ISCHEMIA; NITRIC-OXIDE; RAT-HEART; CARDIOPULMONARY BYPASS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; DAMAGE; CARDIOLIPIN; GENERATION	Several recent works have shown that a brief ischemia applied during the onset of reperfusion (postconditioning) is cardioprotective in different animal models and that the early minutes of reperfusion are critical to its cardioprotection. This effect has been related to prevention of oxidative stress, but mechanisms have not been clearly demonstrated. The present study tested the hypothesis that mitochondria play a central role in peroxide production and oxidative stress during reperfusion and are responsible for the protective effect of postconditioning. Isolated perfused rat hearts were subjected to complete global ischemia for 45 min and reperfused for 40 min. Normoxic group was reperfused with a Krebs-Henseleit solution with the preischemic pO(2) level (600 mmHg); in the "hypoxic group,"normoxic reperfusion was preceded by 3 min with 150 mmHg pO(2). Reperfusion was stopped at 3 and 40 min. The rate of hydroperoxide production, GSH, GSSG, and carbonyl protein levels were measured in mitochondria at 3 min and at the end of reperfusion. GSH and GSSG were also measured in tissue. Hemodinamic function was monitored during the experiment. LVEDp increased and LVDp decreased in the normoxic group but not in the hypoxic group. The rate of mitochondrial peroxide production was higher in normoxic than in the hypoxic group 3 min after reperfusion and at its conclusion. Accordingly, GSH was oxidized in normoxic but not in hypoxic hearts. Mitochondria carbonyl proteins were significantly higher in normoxic than in the hypoxic group at the end of reperfusion. In this model, 1) hypoxic reperfusion at the onset of reperfusion reduces myocardial injury; 2) the major rate of mitochondrial peroxide production is 3 min after the onset of reperfusion; 3) cardioprotection of postconditioning correlates with reduced mitochondria peroxide production and prevention of GSH oxidation.	Univ Foggia, Dept Med & Occupat Sci, Mol Biol Lab, I-71100 Foggia, Italy; Univ Bari, Dept Emergency & Transplantat, I-70121 Bari, Italy; Univ Bari, Dept Pharmacol & Human Physiol, I-70121 Bari, Italy	University of Foggia; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Vendemiale, G (corresponding author), Univ Foggia, Dept Med & Occupat Sci, Mol Biol Lab, Viale Pinto, I-71100 Foggia, Italy.	g.vendemiale@unifg.it	D'AGOSTINO, DONATO/B-1679-2012; serviddio, gaetano/C-7629-2011	serviddio, gaetano/0000-0002-6424-7841; federici, antonio/0000-0001-5102-9995; D'AGOSTINO, DONATO/0000-0001-5887-7655				AMBROSIO G, 1991, J MOL CELL CARDIOL, V23, P1359, DOI 10.1016/0022-2828(91)90183-M; BABBS CF, 1991, AM J PATHOL, V139, P1069; BROWN JM, 1988, J CLIN INVEST, V81, P1297, DOI 10.1172/JCI113448; Buja LM, 1998, LAB INVEST, V78, P1345; COHEN MV, 1994, CIRC RES, V74, P998, DOI 10.1161/01.RES.74.5.998; Diaz RJ, 2004, CARDIOVASC RES, V62, P4, DOI 10.1016/j.cardiores.2004.01.036; FERRARI R, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90291-5; FULLER EO, 1985, J MOL CELL CARDIOL, V17, P71, DOI 10.1016/S0022-2828(85)80093-6; Ihnken K, 1998, J THORAC CARDIOV SUR, V116, P327, DOI 10.1016/S0022-5223(98)70134-5; IHNKEN K, 1995, J THORAC CARDIOV SUR, V110, P1255, DOI 10.1016/S0022-5223(95)70012-9; JEROUDI MO, 1994, AM J CARDIOL, V73, pB2, DOI 10.1016/0002-9149(94)90257-7; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kajstura J, 1996, LAB INVEST, V74, P86; Kin H, 2004, CARDIOVASC RES, V62, P74, DOI 10.1016/j.cardiores.2004.01.006; KUSUOKA H, 1992, ANNU REV PHYSIOL, V54, P243, DOI 10.1146/annurev.ph.54.030192.001331; LEFER DJ, 1993, CIRCULATION, V88, P2337, DOI 10.1161/01.CIR.88.5.2337; Leichtweis S, 2001, ACTA PHYSIOL SCAND, V172, P1, DOI 10.1046/j.1365-201X.2001.00820.x; Levine RL, 2000, METH MOL B, V99, P15; LIU YG, 1992, AM J PHYSIOL, V263, pH1107, DOI 10.1152/ajpheart.1992.263.4.H1107; MORITA K, 1994, J CLIN INVEST, V93, P2658, DOI 10.1172/JCI117279; OKAMOTO F, 1986, J THORAC CARDIOV SUR, V92, P613; Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; PENG CF, 1989, AM HEART J, V117, P515, DOI 10.1016/0002-8703(89)90723-0; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Serviddio G, 2004, HEPATOLOGY, V39, P711, DOI 10.1002/hep.20101; Sun K, 2004, WORLD J GASTROENTERO, V10, P1934; VANDEPLASSCHE G, 1989, J MOL CELL CARDIOL, V21, P383, DOI 10.1016/0022-2828(89)90649-4; Vendemiale G, 2001, TOXICOL LETT, V123, P209, DOI 10.1016/S0378-4274(01)00401-5; YELLON DM, 1990, CARDIOSCIENCE, V1, P89; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002	31	87	102	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					354	361		10.1096/fj.04-2338com	http://dx.doi.org/10.1096/fj.04-2338com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746178				2022-12-28	WOS:000227901300035
J	Bianchi, P; Pimentel, DR; Murphy, MP; Colucci, WS; Parini, A				Bianchi, P; Pimentel, DR; Murphy, MP; Colucci, WS; Parini, A			A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation	FASEB JOURNAL			English	Article						monoamine oxidases; hypertrophy; oxidative stress; heart; MAPK	RAT VENTRICULAR MYOCYTES; MONOAMINE-OXIDASE-A; ACTIVATED PROTEIN-KINASE; RENAL EPITHELIAL-CELLS; HEART-FAILURE; OXIDATIVE STRESS; STIMULATED HYPERTROPHY; ANGIOTENSIN-II; NADPH OXIDASE; INCREASES	Reactive oxygen species (ROS) play a critical role in cardiac hypertrophy. We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO A) is an important source of hydrogen peroxide in rat heart. In the present study, we investigated the potential role of hydrogen peroxide generated by MAO A in cardiomyocyte hypertrophy by serotonin. Serotonin (5 mu M, 48 h) induced hypertrophy in cultured adult rat ventricular myocytes, as reflected by increased (3)H-leucine incorporation (+ 43%, P< 0.001) and total protein content (+ 22%, P< 0.001). Serotonin also increased intracellular hydrogen peroxide and oxidative stress production, measured respectively by DCF fluorescence intensity and GSH/GSSG ratio, and promoted ERK1/2 phosphorylation ( P< 0.001). Serotonin effects were only partially inhibited by the 5-HT(2B) receptor antagonist SB 206553. In contrast, they were extensively (> 80%) prevented by the amine uptake inhibitor imipramine, the MAO inhibitor pargyline and the MEK inhibitor PD 98059. Cardiomyocyte hypertrophy and ERK activation were also inhibited by decreasing intracellular ROS by adenoviral overexpression of catalase or cardiomyocytes treatment with the iron chelator deferoxamine. These data suggest that part of cardiac hypertrophic effect of serotonin requires hydrogen peroxide production by MAO A and ERK1/2 activation. This newly recognized, receptor-independent mechanism of serotonin may contribute to myocardial remodeling and failure.	CHU Rangueil, Inst Louis Bugnard, INSERM, U388, F-31059 Toulouse, France; Boston Univ, Med Ctr, Cardiovasc Med Sect, Boston, MA USA; MRC, Dunn Human Nutr Unit, Cambridge, England	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Boston University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Parini, A (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U388, Bat L3,TSA 50032, F-31059 Toulouse, France.	parini@toulouse.inserm.fr	Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Colucci, Wilson/0000-0002-0576-9420; Parini, Angelo/0000-0002-9848-8838; Pimentel, David/0000-0002-0537-7195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20612, HL61639] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amin JK, 2001, J MOL CELL CARDIOL, V33, P131, DOI 10.1006/jmcc.2000.1285; Bianchi P, 2003, J AM SOC NEPHROL, V14, P855, DOI 10.1097/01.ASN.0000058909.00567.5C; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Cohen G, 1999, J NEUROCHEM, V73, P2310, DOI 10.1046/j.1471-4159.1999.0732310.x; Dhalla AK, 1996, J AM COLL CARDIOL, V28, P506, DOI 10.1016/0735-1097(96)00140-4; Ekelund UEG, 1999, CIRC RES, V85, P437, DOI 10.1161/01.RES.85.5.437; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; Fu LW, 2002, J PHYSIOL-LONDON, V544, P897, DOI 10.1113/jphysiol.2002.023374; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUFFROY C, 1984, LIFE SCI, V34, P535, DOI 10.1016/0024-3205(84)90486-7; He XS, 1996, GENE, V175, P121, DOI 10.1016/0378-1119(96)00136-9; Hill MF, 1996, AM J PATHOL, V148, P291; Holschneider DP, 2002, AM J PHYSIOL-HEART C, V282, pH1751, DOI 10.1152/ajpheart.00600.2001; Ide T, 1999, CIRC RES, V85, P357, DOI 10.1161/01.RES.85.4.357; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Li JM, 2002, HYPERTENSION, V40, P477, DOI 10.1161/01.HYP.0000032031.30374.32; Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536; Marcos E, 2003, AM J RESP CRIT CARE, V168, P487, DOI 10.1164/rccm.200210-1212OC; Maurel A, 2003, AM J PHYSIOL-HEART C, V284, pH1460, DOI 10.1152/ajpheart.00700.2002; Metais C, 1999, CIRCULATION, V100, P328; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2003, CIRCULATION, V107, P3223, DOI 10.1161/01.CIR.0000074224.57016.01; Nebigil CG, 2003, FASEB J, V17, P1373, DOI 10.1096/fj.02-1122fje; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Raasch W, 2002, J PHARMACOL EXP THER, V300, P428, DOI 10.1124/jpet.300.2.428; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Vindis C, 2001, KIDNEY INT, V59, P76, DOI 10.1046/j.1523-1755.2001.00468.x; Xiao L, 2001, J MOL CELL CARDIOL, V33, P779, DOI 10.1006/jmcc.2001.1348; YOUDIM MBH, 1991, BIOCHEM PHARMACOL, V41, P155, DOI 10.1016/0006-2952(91)90471-G	34	81	87	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					641	+		10.1096/fj.04-2518fje	http://dx.doi.org/10.1096/fj.04-2518fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703274				2022-12-28	WOS:000227591900016
J	Finn, J; MacLachlan, I; Cullis, P				Finn, J; MacLachlan, I; Cullis, P			Factors limiting autogene-based cytoplasmic expression systems	FASEB JOURNAL			English	Article						gene therapy; autogene; T7 RNAP; mRNA production; IRES	ENCEPHALOMYOCARDITIS VIRUS-RNA; RIBOSOME ENTRY SITE; CAP-INDEPENDENT TRANSLATION; INTERNAL INITIATION; MESSENGER-RNA; POLYMERASE; T7; SEQUENCE; GENE; PROMOTERS	The relatively low levels of transfection that can be achieved by current gene delivery systems have limited the therapeutic utility of gene transfer. This is especially true for non-viral gene delivery systems, where the levels of gene expression achieved are usually well below the levels achieved by viral gene transfer systems. Previous work from our laboratory describes an enhanced dual promoter autogene-based cytoplasmic expression system that gives rise to levels of gene expression 20-fold higher than that of a CMV nuclear expression plasmid control. Here various strategies are described to increase the levels of autogene-based gene expression by changing variables such as the type of nuclear promoter, phage RNAP gene, and IRES element. Although insights into the function of various IRES elements were gained, none of these changes demonstrated a significant increase in gene expression. However, determination of the mRNA levels achieved using quantitative RNase protection assays and immunofluorescence experiments revealed that transgene mRNA levels were saturated at up to 10 times higher than all other mRNA in the transfected cell combined. It follows that mRNA production, as well as translation, are important factors limiting autogene-based cytoplasmic expression.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Protiva Biotherapeut Inc, Burnaby, BC, Canada; Inex Pharmaceut Corp, Burnaby, BC, Canada	University of British Columbia	Finn, J (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	jdfinn@interchange.ubc.ca						AGOL VI, 1991, ADV VIRUS RES, V40, P103; Attal J, 1999, GENET ANAL-BIOMOL E, V15, P161, DOI 10.1016/S1050-3862(99)00021-2; Brisson M, 1999, GENE THER, V6, P263, DOI 10.1038/sj.gt.3300827; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chen CY, 1998, METH MOL B, V77, P355; DUBENDORFF JW, 1991, J MOL BIOL, V219, P61, DOI 10.1016/0022-2836(91)90857-3; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; Finn J, 2004, GENE THER, V11, P276, DOI 10.1038/sj.gt.3302172; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jackson RJ, 1995, RNA, V1, P985; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; LEARY SL, 1991, GENE, V106, P93, DOI 10.1016/0378-1119(91)90570-2; MEADOR JW, 1995, BIOTECHNIQUES, V18, P152; Pollard H, 2001, J GENE MED, V3, P153, DOI 10.1002/jgm.160; *PROM CORP, 2002, PROM TNT COUPL RET L; Wong ET, 2002, GENE THER, V9, P337, DOI 10.1038/sj.gt.3301667; Zarrin AA, 1999, BBA-GENE STRUCT EXPR, V1446, P135, DOI 10.1016/S0167-4781(99)00067-6	24	5	7	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					605	+		10.1096/fj.04-2769fje	http://dx.doi.org/10.1096/fj.04-2769fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677338				2022-12-28	WOS:000226576600004
J	Vallejo, J; Hardin, CD				Vallejo, J; Hardin, CD			Expression of caveolin-1 in lymphocytes induces caveolae formation and recruitment of phosphofructokinase to the plasma membrane	FASEB JOURNAL			English	Article						glycolytic enzymes; carbohydrate metabolism; PFK	VASCULAR SMOOTH-MUSCLE; GLYCOLYTIC-ENZYMES; GLUCOSE 1,6-BISPHOSPHATE; MELANOMA-CELLS; F-ACTIN; ASSOCIATION; COMPLEX; BINDING; PROTEIN; ATP	Compartmentation of carbohydrate metabolism has been shown in a wide range of tissues including reports of one compartment of glycolysis associated with the plasma membrane of cells. However, only in the erythrocyte has the physical basis for plasma membrane-associated glycolytic pathway been established. We have previously found that phosphofructokinase (PFK) appeared to colocalize with the fairly ubiquitous plasma membrane protein caveolin-1 (CAV-1), consistent with a role for CAV-1 as an anchor for glycolysis to the plasma membrane. To test the hypothesis that CAV-1 functions as a scaffolding protein for PFK, we transfected human lymphocytes ( a cell without CAV-1 expression) with human CAV-1 cDNA. We demonstrate that expression of CAV-1 in lymphocytes results in the formation of caveolae at the plasma membrane and affects the subcellular localization of PFK by recruiting PFK to the plasma membrane. Targeting of PFK by CAV-1 also was validated by the significant colocalization between the proteins after transfection, which resulted in a correlation of 0.97 +/- 0.004 between the two fluorophores. This finding is significant in as much as it illustrates the CAV-1 feasibility of generating binding sites for glycolytic enzymes on the plasma membrane. We therefore conclude that CAV-1 functions as a scaffolding protein for PFK and that this may contribute to the elucidation of the basis for carbohydrate compartmentation to the plasma membrane in a wide variety of cell types.	Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Hardin, CD (corresponding author), Univ Missouri, Dept Med Pharmacol & Physiol, MA 415 Med Sci Bldg, Columbia, MO 65212 USA.	HardinC@missouri.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060668] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL F32-07094] Funding Source: Medline; NIDDK NIH HHS [DK60668] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Ashkenazy-Shahar M, 1999, MOL GENET METAB, V67, P334, DOI 10.1006/mgme.1999.2877; BENTAL M, 1993, MAGN RESON MED, V29, P317, DOI 10.1002/mrm.1910290307; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; Cameron PL, 1997, J NEUROSCI, V17, P9520; CHENZION M, 1992, INT J BIOCHEM, V24, P1661, DOI 10.1016/0020-711X(92)90185-4; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Damico LA, 1996, J MOL CELL CARDIOL, V28, P989, DOI 10.1006/jmcc.1996.0092; DAUM G, 1988, BIOCHIM BIOPHYS ACTA, V939, P277, DOI 10.1016/0005-2736(88)90071-5; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; Glass-Marmor L, 1999, EUR J PHARMACOL, V370, P195, DOI 10.1016/S0014-2999(99)00155-7; GREEN DE, 1965, ARCH BIOCHEM BIOPHYS, V112, P635, DOI 10.1016/0003-9861(65)90107-4; HARDIN CD, 1992, J GEN PHYSIOL, V99, P21, DOI 10.1085/jgp.99.1.21; HARRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P306, DOI 10.1016/0167-4838(90)90242-8; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; Hoffman J F, 1997, Curr Opin Hematol, V4, P112; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; JENKINS JD, 1985, J BIOL CHEM, V260, P426; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; KARKHOFFSCHWEIZER R, 1987, BIOCHEM BIOPH RES CO, V146, P827, DOI 10.1016/0006-291X(87)90605-X; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Karniel M, 2000, MOL GENET METAB, V69, P40, DOI 10.1006/mgme.1999.2954; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Kimura A, 2002, J BIOL CHEM, V277, P40167; KNULL HR, 1980, J NEUROCHEM, V34, P222, DOI 10.1111/j.1471-4159.1980.tb04646.x; Lahtinen U, 2003, FEBS LETT, V538, P85, DOI 10.1016/S0014-5793(03)00135-2; LEHOTZKY A, 1994, BIOCHEM BIOPH RES CO, V204, P585, DOI 10.1006/bbrc.1994.2499; LEHOTZKY A, 1993, J BIOL CHEM, V268, P10888; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Lloyd PG, 2001, J CELL BIOCHEM, V82, P399, DOI 10.1002/jcb.1170; LOW PS, 1993, J BIOL CHEM, V268, P14627; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; PROVERBIO F, 1977, J GEN PHYSIOL, V69, P605, DOI 10.1085/jgp.69.5.605; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Samstag Y, 2003, J LEUKOCYTE BIOL, V73, P30, DOI 10.1189/jlb.0602272; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2001, J CELL PHYSIOL, V186, P329, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1045>3.0.CO;2-0; Schwartz D, 2000, MOL GENET METAB, V69, P159, DOI 10.1006/mgme.2000.2960; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sotgia F, 2003, AM J PATHOL, V163, P2619, DOI 10.1016/S0002-9440(10)63616-4; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; Taggart MJ, 2001, NEWS PHYSIOL SCI, V16, P61; Thyberg J, 2000, LAB INVEST, V80, P915, DOI 10.1038/labinvest.3780095; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Vallejo J, 2004, AM J PHYSIOL-CELL PH, V286, pC43, DOI 10.1152/ajpcell.00483.2002; Vertessy BG, 1997, J BIOL CHEM, V272, P25542, DOI 10.1074/jbc.272.41.25542; Vertessy BG, 1997, BIOCHEMISTRY-US, V36, P2051, DOI 10.1021/bi9623441; Vertessy BG, 1996, FEBS LETT, V379, P191, DOI 10.1016/0014-5793(95)01510-8; von Ruckmann B, 2002, BBA-BIOMEMBRANES, V1559, P43, DOI 10.1016/S0005-2736(01)00435-7; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Zwingmann C, 2001, GLIA, V34, P200, DOI 10.1002/glia.1054	63	20	20	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					586	+		10.1096/fj.04-2380fje	http://dx.doi.org/10.1096/fj.04-2380fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665033				2022-12-28	WOS:000226576600017
J	Wang, J; Ho, L; Qin, WP; Rocher, AB; Seror, I; Humala, N; Maniar, K; Dolios, G; Wang, R; Hof, PR; Pasinetti, GM				Wang, J; Ho, L; Qin, WP; Rocher, AB; Seror, I; Humala, N; Maniar, K; Dolios, G; Wang, R; Hof, PR; Pasinetti, GM			Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						AD; A beta neuropathology; neuritic plaque deposition	ALPHA-SECRETASE CLEAVAGE; LOW-FAT DIET; PRECURSOR PROTEIN; LOW-CARBOHYDRATE; TRANSGENIC MICE; IN-VIVO; CONVERTING-ENZYME; RISK-FACTORS; WEIGHT-LOSS; FOLLOW-UP	This study was designed to explore the possibility that caloric restriction (CR) may benefit Alzheimer's disease (AD) by preventing beta-amyloid (Abeta) neuropathology pivotal to the initiation and progression of the disease. We report that a CR dietary regimen prevents Abeta peptides generation and neuritic plaque deposition in the brain of a mouse model of AD neuropathology through mechanisms associated with promotion of anti-amyloidogenic alpha-secretase activity. Study findings support existing epidemiological evidence indicating that caloric intake may influence risk for AD and raises the possibility that CR may be used in preventative measures aimed at delaying the onset of AD amyloid neuropathology.	CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Adv Imaging Program, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu	Wang, Rong/A-8721-2009	Pasinetti, Giulio/0000-0002-1524-5196	NATIONAL INSTITUTE ON AGING [P01AG002219] Funding Source: NIH RePORTER; NIA NIH HHS [AG02219] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allinson TMJ, 2004, EUR J BIOCHEM, V271, P2539, DOI 10.1111/j.1432-1033.2004.04184.x; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Burns M, 2003, J NEUROSCI, V23, P5645; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Gustafson D, 2003, ARCH INTERN MED, V163, P1524, DOI 10.1001/archinte.163.13.1524; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Ledesma MD, 2003, EMBO REP, V4, P1190, DOI 10.1038/sj.embor.7400021; Lichtenthaler SF, 2004, J CLIN INVEST, V113, P1384, DOI 10.1172/JCI200421746; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; MAKIMURA H, 2003, BMC PHYSL, V3; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Meckling KA, 2004, J CLIN ENDOCR METAB, V89, P2717, DOI 10.1210/jc.2003-031606; Meyer JS, 2000, ANN NY ACAD SCI, V903, P411, DOI 10.1111/j.1749-6632.2000.tb06393.x; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mohajeri MH, 2004, FEBS LETT, V562, P16, DOI 10.1016/S0014-5793(04)00169-3; Nimchinsky EA, 2000, J COMP NEUROL, V416, P112, DOI 10.1002/(SICI)1096-9861(20000103)416:1<112::AID-CNE9>3.0.CO;2-K; Pedersen WA, 2004, NEUROBIOL DIS, V17, P500, DOI 10.1016/j.nbd.2004.08.003; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Ristow M, 2004, J MOL MED, V82, P510, DOI 10.1007/s00109-004-0552-1; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Takeda K, 2003, J ENDOCRINOL, V176, P237, DOI 10.1677/joe.0.1760237; VALLET PG, 1992, ACTA NEUROPATHOL, V83, P170, DOI 10.1007/BF00308476; Vanhanen M, 1998, CURR OPIN NEUROL, V11, P673, DOI 10.1097/00019052-199812000-00011; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WANG R, 1991, J BIOL CHEM, V266, P16960; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	38	206	224	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					659	+		10.1096/fj.04-3182fje	http://dx.doi.org/10.1096/fj.04-3182fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15650008				2022-12-28	WOS:000226576600023
J	McGarry, JG; Klein-Nulend, J; Mullender, MG; Prendergast, PJ				McGarry, JG; Klein-Nulend, J; Mullender, MG; Prendergast, PJ			A comparison of strain and fluid shear stress in stimulating bone cell responses - a computational and experimental study	FASEB JOURNAL			English	Article						cell deformation; cell biomechanics; bone remodeling	NITRIC-OXIDE SYNTHASE; HUMAN OSTEOBLAST PROLIFERATION; MECHANICAL STRAIN; ELASTIC PROPERTIES; PROSTAGLANDIN E-2; ACTIN-FILAMENTS; IN-VITRO; MECHANOTRANSDUCTION; CYTOSKELETON; OSTEOCYTES	Bone undergoes continuous remodeling in response to mechanical loading. However, the underlying mechanisms by which bone cells respond to their changing mechanical environment, that is, strain in the load-bearing matrix or fluid flow through the canalicular network, are not well understood. It has been established in vitro that bone cells respond differently to substrate strain and fluid shear stress treatments. Uncovering the mechanical basis of these differences represents a significant challenge to our understanding of cellular mechanotransduction and bone remodeling. To investigate this problem, we developed a biomechanical model of an adherent cell, to test the hypothesis that bone cells respond differently to 0.6 Pa fluid shear stress and 1,000 muepsilon substrate strain stimulation because of qualitative and quantitative differences in the cellular deformation caused. Fluid shear stress loading conditions resulted in maximum displacements at the apical surface of the cell similar to8 times higher than those due to strain at the cell-substrate interface and also caused higher stressing of all parts of the cell. Significantly, this shows that the deforming effects of fluid shear stress and strain on a cellular level are qualitatively different, which may provide a basis for explaining differences in bone cell responses to both stimuli as reported in several studies. Although our approach to modeling the morphology and complex physical environment of an adherent cell is certainly simplified, our results do show independent roles for fluid flow and strain as mechanical stimuli and highlight the importance of deformation on a cellular level in bone physiology.	Univ Dublin Trinity Coll, Ctr Bioengn, Dept Mech Engn, Dublin 2, Ireland; Univ Amsterdam, ACTA, Dept Oral Cell Biol, Amsterdam, Netherlands; Vrije Univ Amsterdam, Amsterdam, Netherlands	Trinity College Dublin; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Prendergast, PJ (corresponding author), Univ Dublin Trinity Coll, Ctr Bioengn, Dept Mech Engn, Dublin 2, Ireland.	pprender@tcd.ie	Mullender, Margriet/H-7756-2012	/0000-0002-6577-909X				Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138; Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021-9290(00)00231-1; BENAVRAHAM D, 1995, BIOPHYS J, V68, P1231, DOI 10.1016/S0006-3495(95)80299-7; Brown TD, 2000, J BIOMECH, V33, P3, DOI 10.1016/S0021-9290(99)00177-3; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Chambers TJ, 1997, ADV EXP MED BIOL, V433, P295; Charras GT, 2002, BIOPHYS J, V82, P2970, DOI 10.1016/S0006-3495(02)75638-5; CHOW JWM, 1993, AM J PHYSIOL, V265, pE340, DOI 10.1152/ajpendo.1993.265.2.E340; Dong C, 2000, J BIOMECH, V33, P35, DOI 10.1016/S0021-9290(99)00174-8; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; EVANS E, 1989, BIOPHYS J, V56, P151, DOI 10.1016/S0006-3495(89)82660-8; Fermor B, 1998, BONE, V22, P637, DOI 10.1016/S8756-3282(98)00047-7; FORWOOD MR, 1995, BONE, V17, pS197, DOI 10.1016/8756-3282(95)00292-L; Forwood MR, 1996, J BONE MINER RES, V11, P1688; Fox SW, 1996, AM J PHYSIOL-ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955; Frisch T, 2002, J BIOMECH, V35, P1137, DOI 10.1016/S0021-9290(02)00075-1; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Guilak F, 2000, BIOCHEM BIOPH RES CO, V269, P781, DOI 10.1006/bbrc.2000.2360; Guilak F, 2000, J BIOMECH, V33, P1663, DOI 10.1016/S0021-9290(00)00105-6; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108; HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706; Hung CT, 1996, J BIOMECH, V29, P1403, DOI 10.1016/0021-9290(96)84535-0; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; JANMEY PA, 1991, PHYSIOL REV, V78, P763; Johnson DL, 1996, AM J PHYSIOL-ENDOC M, V271, pE205, DOI 10.1152/ajpendo.1996.271.1.E205; JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142-9612(91)90186-E; Kamm RD, 2000, ASME INT C MECH BIOL, V242, P1; Karcher H, 2003, BIOPHYS J, V85, P3336, DOI 10.1016/S0006-3495(03)74753-5; Kaspar D, 2000, J BIOMECH, V33, P45, DOI 10.1016/S0021-9290(99)00171-2; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; Mathur AB, 2001, J BIOMECH, V34, P1545, DOI 10.1016/S0021-9290(01)00149-X; McCreadie BARBARA RIEMER, 1997, Comput Methods Biomech Biomed Engin, V1, P61, DOI 10.1080/01495739708936695; McGarry J G, 2004, Eur Cell Mater, V7, P27; MCGARRY JG, 2003, P INT C COMP BIOENG, V2, P552; Mosley JR, 1998, BONE, V23, P313, DOI 10.1016/S8756-3282(98)00113-6; Owan I, 1997, AM J PHYSIOL-CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658; Peake MA, 2000, J APPL PHYSIOL, V89, P2498, DOI 10.1152/jappl.2000.89.6.2498; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Prendergast PJ, 1997, CLIN BIOMECH, V12, P343, DOI 10.1016/S0268-0033(97)00018-1; RUBIN CT, 1987, J ORTHOPAED RES, V5, P300, DOI 10.1002/jor.1100050217; Shafrir Y, 2002, AM J PHYSIOL-CELL PH, V282, pC479, DOI 10.1152/ajpcell.00394.2001; Shin D, 1999, J ORTHOP RES, V17, P880, DOI 10.1002/jor.1100170613; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Stamenovic D, 1996, J THEOR BIOL, V181, P125, DOI 10.1006/jtbi.1996.0120; Tsuda Y, 1996, P NATL ACAD SCI USA, V93, P12937, DOI 10.1073/pnas.93.23.12937; Turner CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634; TURNER CH, 1995, AM J PHYSIOL-ENDOC M, V269, pE438, DOI 10.1152/ajpendo.1995.269.3.E438; Walker LM, 2000, J CELL BIOCHEM, V79, P648, DOI 10.1002/1097-4644(20001215)79:4<648::AID-JCB130>3.0.CO;2-Q; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang N, 2000, AM J PHYSIOL-CELL PH, V279, pC188, DOI 10.1152/ajpcell.2000.279.1.C188; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; You J, 2000, J BIOMECH ENG-T ASME, V122, P387, DOI 10.1115/1.1287161; Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123	59	131	136	0	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					482	+		10.1096/fj.04-2210fje	http://dx.doi.org/10.1096/fj.04-2210fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15625080	Green Published			2022-12-28	WOS:000226091000005
J	Di Giovanni, S; Faden, AI; Yakovlev, A; Duke-Cohan, JS; Finn, T; Thouin, M; Knoblach, S; De Biase, A; Bregman, BS; Hoffman, EP				Di Giovanni, S; Faden, AI; Yakovlev, A; Duke-Cohan, JS; Finn, T; Thouin, M; Knoblach, S; De Biase, A; Bregman, BS; Hoffman, EP			Neuronal plasticity after spinal cord injury: identification of a gene cluster driving neurite outgrowth	FASEB JOURNAL			English	Article						SCI; microtubule-associated proteins; GAP-43	PROTEIN 1A; FUNCTIONAL RECOVERY; AXONAL PLASTICITY; GLYCOPROTEIN MOG; NERVOUS-SYSTEM; ADULT-RAT; GROWTH; REGENERATION; EXPRESSION; CPG15	Functional recovery after spinal cord injury (SCI) may result in part from axon outgrowth and related plasticity through coordinated changes at the molecular level. We employed microarray analysis to identify a subset of genes the expression patterns of which were temporally coregulated and correlated to functional recovery after SCI. Steady-state mRNA levels of this synchronously regulated gene cluster were depressed in both ventral and dorsal horn neurons within 24 h after injury, followed by strong re-induction during the following 2 wk, which paralleled functional recovery. The identified cluster includes neuritin, attractin, microtubule-associated protein 1a, and myelin oligodendrocyte protein genes. Transcriptional and protein regulation of this novel gene cluster was also evaluated in spinal cord tissue and in single neurons and was shown to play a role in axonal plasticity. Finally, in vitro transfection experiments in primary dorsal root ganglion cells showed that cluster members act synergistically to drive neurite outgrowth.	Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC 20057 USA; Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA; Dana Farber Canc Inst D1526, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Georgetown University; Children's National Health System; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Faden, AI (corresponding author), Georgetown Univ, Sch Med, Dept Neurosci, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	fadena@georgetown.edu	Duke-Cohan, Jonathan/A-5812-2010	Duke-Cohan, Jonathan/0000-0002-9478-9609; Hoffman, Eric/0000-0001-6470-5139	NHLBI NIH HHS [U01 HL66614] Funding Source: Medline; NINDS NIH HHS [NS-1-2339] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONSO G, 1995, EXP NEUROL, V134, P35, DOI 10.1006/exnr.1995.1034; AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; Azmitia EC, 2002, PROG BRAIN RES, V136, P87; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Bulsara KR, 2002, SPINE, V27, P1946, DOI 10.1097/00007632-200209010-00030; Cantallops I, 2000, NAT NEUROSCI, V3, P1004, DOI 10.1038/79823; Coffey JC, 1997, J NEUROCYTOL, V26, P149, DOI 10.1023/A:1018579912831; Condic ML, 2002, NEUROREPORT, V13, pA37, DOI 10.1097/00001756-200203040-00002; Cornea-Hebert V, 2002, NEUROSCIENCE, V113, P23, DOI 10.1016/S0306-4522(02)00146-X; Corriveau RA, 1999, J NEUROSCI, V19, P7999, DOI 10.1523/jneurosci.19-18-07999.1999; Dewar D, 1997, ACTA NEUROPATHOL, V93, P71, DOI 10.1007/s004010050584; DEWAR J, 1997, BIOCHIM BIOPHYS ACTA, V9, P71; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; FEDOROFF S, 2001, PROTOCOLS NEURAL CEL, P95; Gavazzi I, 2001, CELL TISSUE RES, V305, P275, DOI 10.1007/s004410100365; Gregersen R, 2001, EXP BRAIN RES, V138, P384, DOI 10.1007/s002210100715; Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734; Kalb RG, 2000, CONT NEUROS, pV; KALB RK, 2000, NEUROBIOLOGY SPINAL, P113; Karim F, 2001, BRAIN RES REV, V36, P204, DOI 10.1016/S0165-0173(01)00096-0; Kawasaki T, 2001, NEUROSCI RES, V39, P347, DOI 10.1016/S0168-0102(00)00234-0; Kikukawa S, 1998, NEUROSCI LETT, V249, P135, DOI 10.1016/S0304-3940(98)00406-6; Kuramoto T, 2001, P NATL ACAD SCI USA, V98, P559, DOI 10.1073/pnas.98.2.559; Kuwamura M, 2002, LAB INVEST, V82, P1279, DOI 10.1097/01.LAB.0000032375.70196.26; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lee WCA, 2002, J NEUROSCI, V22, P1807, DOI 10.1523/JNEUROSCI.22-05-01807.2002; Li GL, 2002, BRAIN PATHOL, V12, P463; Lu XY, 1999, FEBS LETT, V462, P101, DOI 10.1016/S0014-5793(99)01494-5; MARCUS J, 2002, BIOCHIM BIOPHYS ACTA, V19, P406; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; Nedivi E, 1998, SCIENCE, V281, P1863, DOI 10.1126/science.281.5384.1863; Nedivi E, 2001, J COMP NEUROL, V435, P464, DOI 10.1002/cne.1044; Nicholls J, 1996, TRENDS NEUROSCI, V19, P229, DOI 10.1016/0166-2236(96)10021-7; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; Nunez J, 1997, J MOL NEUROSCI, V8, P207, DOI 10.1007/BF02736834; Oudega M, 1998, NEUROSCI LETT, V246, P81, DOI 10.1016/S0304-3940(98)00232-8; Pellier-Monnin V, 2001, J COMP NEUROL, V433, P239, DOI 10.1002/cne.1138; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; SEO J, 2003, IEEE ICME, V3, P461; Solly SK, 1996, GLIA, V18, P39, DOI 10.1002/(SICI)1098-1136(199609)18:1<39::AID-GLIA4>3.3.CO;2-T; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Tang W, 2000, P NATL ACAD SCI USA, V97, P6025, DOI 10.1073/pnas.110139897; Tang W, 2002, J NEUROPATH EXP NEUR, V61, P767, DOI 10.1093/jnen/61.9.767; Turnley AM, 1998, NEUROREPORT, V9, P1987, DOI 10.1097/00001756-199806220-00013; Uchida K, 2002, SPINE, V27, P480, DOI 10.1097/00007632-200203010-00008; Vaillant AR, 1998, J BIOL CHEM, V273, P13973, DOI 10.1074/jbc.273.22.13973; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	56	65	66	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					153	+		10.1096/fj.04-2694fje	http://dx.doi.org/10.1096/fj.04-2694fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522907				2022-12-28	WOS:000225482100026
J	Gustafsson, AJ; Ingelman-Sundberg, H; Dzabic, M; Awasum, J; Hoa, NK; Ostenson, CG; Pierro, C; Tedeschi, P; Woolcott, O; Chiounan, S; Lund, PE; Larsson, O; Islam, MS				Gustafsson, AJ; Ingelman-Sundberg, H; Dzabic, M; Awasum, J; Hoa, NK; Ostenson, CG; Pierro, C; Tedeschi, P; Woolcott, O; Chiounan, S; Lund, PE; Larsson, O; Islam, MS			Ryanodine receptor-operated activation of TRP-like channels can trigger critical Ca2+ signaling events in pancreatic beta-cells	FASEB JOURNAL			English	Article						islets of Langerhans; Ca2+-induced Ca2+ release; transient receptor potential channels	CAPACITATIVE CALCIUM-ENTRY; SMOOTH-MUSCLE CELLS; ENDOPLASMIC-RETICULUM; K+ CHANNELS; RELEASE; STORE; CAFFEINE; INFLUX; FLUORESCENCE; MECHANISMS	There is little information available concerning the link between the ryanodine (RY) receptors and the downstream Ca2+ signaling events in beta-cells. In fura-2 loaded INS-1E cells, activation of RY receptors by 9-methyl 5,7-dibromoeudistomin D (MBED) caused a rapid rise of [Ca2+](i) followed by a plateau and repetitive [Ca2+](i) spikes on the plateau. The [Ca2+](i) plateau was abolished by omission of extracellular Ca2+ and by SKF 96365. In the presence of SKF 96365, MBED produced a transient increase of [Ca2+](i), which was abolished by thapsigargin. Activation of RY receptors caused Ca2+ entry even when the ER Ca2+ pool was depleted by thapsigargin. The [Ca2+](i) plateau was not inhibited by nimodipine or ruthenium red, but was inhibited by membrane depolarization, La3+, Gd3+, niflumic acid, and 2-aminoethoxydiphenyl borate, agents that inhibit the transient receptor potential channels. The [Ca2+](i) spikes were inhibited by nimodipine and ryanodine, indicating that they were due to Ca2+ influx through the voltage-gated Ca2+ channels and Ca2+-induced Ca2+ release (CICR). Activation of RY receptors depolarized membrane potential as measured by patch clamp. Thus, activation of RY receptors leads to coherent changes in Ca2+ signaling, which includes activation of TRP-like channels, membrane depolarization, activation of the voltage-gated Ca2+ channels and CICR.	Stockholm Soder Hosp, Dept Med, Karolinska Inst, Res Ctr, S-11883 Stockholm, Sweden; Astra Res Ctr AB, R&D, S-15185 Sodertalje, Sweden; Karolinska Univ Hosp, Dept Mol Med, S-15185 Sodertalje, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Gustafsson, AJ (corresponding author), Stockholm Soder Hosp, Dept Med, Karolinska Inst, Res Ctr, S-11883 Stockholm, Sweden.	amajab@ki.se	Woolcott, Orison O./AAQ-3440-2020; Islam, Shahidul/K-3295-2019	Woolcott, Orison O./0000-0003-2905-972X; Islam, Shahidul/0000-0002-9016-1881				Akiba Y, 2004, BIOCHEM BIOPH RES CO, V321, P219, DOI 10.1016/j.bbrc.2004.06.149; Bennett DL, 1998, BIOCHEM J, V329, P349; Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje; Dyachok O, 2001, J CELL SCI, V114, P2179; Graves TK, 2003, ENDOCRINOLOGY, V144, P3565, DOI 10.1210/en.2002-0104; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERRERO A, 1994, J GEN PHYSIOL, V104, P395, DOI 10.1085/jgp.104.2.395; Guler AD, 2002, J NEUROSCI, V22, P6408; Harper JL, 2003, BIOCHEM PHARMACOL, V65, P329, DOI 10.1016/S0006-2952(02)01488-0; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; ISLAM MS, 2000, CALCIUM MOL BASIS CA, P402; Janssen SWJ, 2002, J HISTOCHEM CYTOCHEM, V50, P789, DOI 10.1177/002215540205000605; Kang GX, 2003, J PHYSIOL-LONDON, V546, P175, DOI 10.1113/jphysiol.2002.029959; Kermode H, 1998, FEBS LETT, V431, P59, DOI 10.1016/S0014-5793(98)00725-X; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Leech CA, 1997, J BIOL CHEM, V272, P17987, DOI 10.1074/jbc.272.29.17987; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maechler P, 2000, IUBMB LIFE, V50, P27, DOI 10.1080/15216540050176557; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; Miura Y, 1997, J PHYSIOL-LONDON, V503, P387, DOI 10.1111/j.1469-7793.1997.387bh.x; Ohi Y, 2001, JPN J PHARMACOL, V85, P382, DOI 10.1254/jjp.85.382; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; Putney JW, 2003, CELL CALCIUM, V34, P339, DOI 10.1016/S0143-4160(03)00143-X; Putney JW, 2001, J CELL SCI, V114, P2223; Qian F, 2002, DIABETES, V51, pS183, DOI 10.2337/diabetes.51.2007.S183; ROE MW, 1993, J BIOL CHEM, V268, P9953; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Sakura H, 1997, DIABETOLOGIA, V40, P528, DOI 10.1007/s001250050711; Seino-Umeda A, 1998, EUR J PHARMACOL, V357, P261, DOI 10.1016/S0014-2999(98)00589-5; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Walker RL, 2002, AM J PHYSIOL-CELL PH, V283, pC1637, DOI 10.1152/ajpcell.00266.2002; WORLEY JF, 1994, J BIOL CHEM, V269, P32055; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	43	26	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					301	+		10.1096/fj.04-2621fje	http://dx.doi.org/10.1096/fj.04-2621fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15572434				2022-12-28	WOS:000225482100001
J	Herzog, A; Siler, U; Spitzer, V; Seifert, N; Denelavas, A; Hunziker, PB; Hunziker, W; Goralczyk, R; Wertz, K				Herzog, A; Siler, U; Spitzer, V; Seifert, N; Denelavas, A; Hunziker, PB; Hunziker, W; Goralczyk, R; Wertz, K			Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate	FASEB JOURNAL			English	Article						DHT; 3 beta-adiol; IGF-I	ESTROGEN RECEPTOR-BETA; EPITHELIAL-CELLS; TISSUE DISTRIBUTION; TRANS-LYCOPENE; GROWTH-FACTORS; CANCER CELLS; HUMAN SERUM; VITAMIN-E; ER-BETA; INTERLEUKIN-6	Epidemiological evidence links consumption of lycopene, the red carotenoid of tomato, to reduced prostate cancer risk. We investigated the effect of lycopene in normal prostate tissue to gain insight into the mechanisms, by which lycopene can contribute to primary prostate cancer prevention. We supplemented young rats with 200 ppm lycopene for up to 8 wk, measured the uptake into individual prostate lobes, and analyzed lycopene-induced gene regulations in dorsal and lateral lobes after 8 wk of supplementation. Lycopene accumulated in all four prostate lobes over time, with all-trans lycopene being the predominant isoform. The lateral lobe showed a significantly higher total lycopene content than the other prostate lobes. Transcriptomics analysis revealed that lycopene treatment mildly but significantly reduced gene expression of androgen-metabolizing enzymes and androgen targets. Moreover, local expression of IGF-I was decreased in the lateral lobe. Lycopene also consistently reduced transcript levels of proinflammatory cytokines, immunoglobulins, and immunoglobulin receptors in the lateral lobe. This indicates that lycopene reduced inflammatory signals in the lateral prostate lobe. In summary, we show for the first time that lycopene reduced local prostatic androgen signaling, IGF-I expression, and basal inflammatory signals in normal prostate tissue. All of these mechanisms can contribute to the epidemiologically observed prostate cancer risk reduction by lycopene.	DSM Nutr Prod, Carotenoid Sect, CH-4002 Basel, Switzerland	DSM NV	Wertz, K (corresponding author), DSM Nutr Prod, Carotenoid Sect, POB 3255, CH-4002 Basel, Switzerland.	karin.wertz@dsm.com		Siler, Ulrich/0000-0002-2458-2629				Albrecht M, 2004, PROSTATE, V58, P82, DOI 10.1002/pros.10288; Aumuller G, 1996, ACTA ANAT, V156, P241; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Belanger A, 2003, TRENDS ENDOCRIN MET, V14, P473, DOI 10.1016/j.tem.2003.10.005; Boileau TWM, 2000, J NUTR, V130, P1613, DOI 10.1093/jn/130.6.1613; Bollito E, 2001, ANN ONCOL, V12, pS159, DOI 10.1093/annonc/12.suppl_2.S159; Boue SM, 2003, J AGR FOOD CHEM, V51, P2193, DOI 10.1021/jf021114s; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chang WY, 1999, PROSTATE, V40, P115; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Etminan M, 2004, CANCER EPIDEM BIOMAR, V13, P340; FENWICK, 2003, PHYTOCHEMICALS HLTH, P285; Ford ES, 2002, AM J CLIN NUTR, V76, P818, DOI 10.1093/ajcn/76.4.818; FREVERT CW, 1995, INFLAMMATION, V19, P133, DOI 10.1007/BF01534386; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Gann PH, 1999, CANCER RES, V59, P1225; GEMZIK B, 1992, ARCH BIOCHEM BIOPHYS, V296, P355, DOI 10.1016/0003-9861(92)90585-K; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Haddad JJ, 2002, EUR CYTOKINE NETW, V13, P250; Hansson J, 2001, ANN ONCOL, V12, pS145, DOI 10.1093/annonc/12.suppl_2.S145; Harris J, 2000, VET IMMUNOL IMMUNOP, V77, P163, DOI 10.1016/S0165-2427(00)00235-X; HAYASHI N, 1991, BIOL REPROD, V45, P308, DOI 10.1095/biolreprod45.2.308; Hobisch A, 1998, CANCER RES, V58, P4640; Hoosein Naseema M., 1998, Frontiers in Bioscience, V3, pD1274; IMPERATOMCGINLEY J, 1992, ENDOCRINOLOGY, V131, P1149, DOI 10.1210/en.131.3.1149; ISAACS JT, 1980, STEROIDS, V35, P139, DOI 10.1016/0039-128X(80)90099-9; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Keith IM, 2001, J UROLOGY, V166, P323, DOI 10.1016/S0022-5347(05)66153-8; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383; Kim IY, 2002, CANCER RES, V62, P5365; Klein T, 2001, BRIT J PHARMACOL, V133, P643, DOI 10.1038/sj.bjp.0704111; Konig JE, 2004, PROSTATE, V58, P121, DOI 10.1002/pros.10317; Korytko PJ, 2003, J NUTR, V133, P2788, DOI 10.1093/jn/133.9.2788; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lau KM, 2000, CANCER RES, V60, P3175; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Maliner-Stratton MS, 2001, NEOPLASIA, V3, P509, DOI 10.1038/sj.neo.7900178; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; NASLUND MJ, 1988, J UROLOGY, V140, P1049, DOI 10.1016/S0022-5347(17)41924-0; Obermuller-Jevic UC, 2003, J NUTR, V133, P3356, DOI 10.1093/jn/133.11.3356; Okamoto M, 1998, PROSTATE, V35, P255, DOI 10.1002/(SICI)1097-0045(19980601)35:4<255::AID-PROS4>3.0.CO;2-F; Pelletier G, 1998, J UROLOGY, V160, P577, DOI 10.1016/S0022-5347(01)62961-6; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; PRICE DOROTHY, 1963, NATL CANCER INST MONOGR, V12, P1; Prins GS, 1998, ENDOCRINOLOGY, V139, P874, DOI 10.1210/en.139.3.874; ROBINETTE CL, 1988, PROSTATE, V12, P271; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIES H, 1995, AM J CLIN NUTR, V62, P1315; Siler U, 2004, FASEB J, V18, P1019, DOI 10.1096/fj.03-1116fje; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; Stoker TE, 1999, BIOL REPROD, V61, P1636, DOI 10.1095/biolreprod61.6.1636; SUNDIN M, 1987, J BIOL CHEM, V262, P12293; THIEULANT ML, 1981, ENDOCRINOLOGY, V108, P1552, DOI 10.1210/endo-108-4-1552; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118, DOI 10.1152/ajplung.2000.278.6.L1118; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; van Breemen RB, 2002, J AGR FOOD CHEM, V50, P2214, DOI 10.1021/jf0110351; van Ommen B, 2002, CURR OPIN BIOTECH, V13, P517, DOI 10.1016/S0958-1669(02)00349-X; VANZUPTEN L, 1993, PRINCIPLES LAB SCI; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walfisch Y, 2003, BRIT J NUTR, V90, P759, DOI 10.1079/BJN2003955; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898	67	97	102	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					272	+		10.1096/fj.04-1905fje	http://dx.doi.org/10.1096/fj.04-1905fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545302				2022-12-28	WOS:000225482100022
J	Masri, B; Morin, N; Cornu, M; Knibiehler, B; Audigier, Y				Masri, B; Morin, N; Cornu, M; Knibiehler, B; Audigier, Y			Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells	FASEB JOURNAL			English	Article						G protein-coupled receptor; transduction; mouse	PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSLATIONAL CONTROL; SIGNALING PATHWAYS; HUMAN APJ; IN-VITRO; X-MSR	We report here that apelin (65-77) activates p70 S6 kinase (p70S6K), not only in CHO cells that have been stably transfected with the apelin receptor, but also in umbilical endothelial cells ( HUVEC), which express it endogenously. Apelin (65-77) induces a time-dependent phosphorylation of p70S6K at residues T421/S424 and T389. This dual phosphorylation is associated with two transduction cascades, involving a PI3K pathway and an ERK pathway, respectively. The PI3K pathway, which can be blocked by wortmannin, leads to phosphorylation of Akt at residues T308 or S473, which then promotes the phosphorylation of p70S6K at T421/S424 and T389. The ERK pathway is blocked by PD 098059, a MEK inhibitor, and results in the phosphorylation of p70S6K at T421/S424. Phosphorylation both of Akt and p70S6K is abrogated by pretreatment with pertussis toxin (PTX) and an inhibitor of atypical PKCs. In addition, we demonstrate that apelin (65-77) also increases the enzymatic activity of p70S6K and that the effects of the previously mentioned inhibitors on the level of T389 phosphorylation correlate with their action on enzyme activity. Interestingly, the main findings were reproduced in umbilical endothelial cells and apelin (65-77) promoted thymidine incorporation into DNA of these cells, revealing that apelin is a new mitogenic peptide for the endothelial cell.	CHU Rangueil, TSA 50032, INSERM, U589, F-31059 Toulouse 9, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Audigier, Y (corresponding author), CHU Rangueil, TSA 50032, INSERM, U589, 1 Ave Jean Poulhes, F-31059 Toulouse 9, France.	yaudig@toulouse.inserm.fr	Masri, Bernard/N-9856-2018	Masri, Bernard/0000-0002-4027-2604				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Devic E, 1999, MECH DEVELOP, V84, P199, DOI 10.1016/S0925-4773(99)00081-7; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Masri B, 2002, BIOCHEM BIOPH RES CO, V290, P539, DOI 10.1006/bbrc.2001.6230; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sahni A, 1999, J BIOL CHEM, V274, P14936, DOI 10.1074/jbc.274.21.14936; Saint-Geniez M, 2002, MECH DEVELOP, V110, P183, DOI 10.1016/S0925-4773(01)00558-5; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Seibenhener M L, 1999, Mol Cell Biol Res Commun, V2, P28, DOI 10.1006/mcbr.1999.0140; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wang GY, 2004, ENDOCRINOLOGY, V145, P1342, DOI 10.1210/en.2003-1116; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	54	174	191	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1909	+		10.1096/fj.04-1930fje	http://dx.doi.org/10.1096/fj.04-1930fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385434				2022-12-28	WOS:000224243200015
J	Weinmann, M; Jendrossek, V; Guner, D; Goecke, B; Belka, C				Weinmann, M; Jendrossek, V; Guner, D; Goecke, B; Belka, C			Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways	FASEB JOURNAL			English	Article						apoptosis; selection; radiotherapy; chemotherapy	CYTOCHROME-C; DEATH; BCL-2; OXYGENATION; ACTIVATION; RADIATION; CASPASE-8; PROTEASE; CANCER; FADD	The negative influence of hypoxia on the outcome of malignant tumors may be caused by direct oxygen effects, and potentially, the selection of resistant tumor cells under repetitive hypoxia. To evaluate whether cyclic hypoxia selects for resistant cells and to analyze the underlying mechanisms, the influence of cyclic hypoxia on intracellular death pathways was determined in tumor cells. It could be demonstrated that cyclic hypoxia selects for cells with increased resistance against hypoxia-induced apoptosis. These cells exhibited a cross-resistance against paradigmatic triggers of mitochondrial apoptotic pathways (ionizing radiation/etoposide). In contrast, TRAIL-receptor mediated apoptosis remained unaffected. Thus, cyclic hypoxia selects for cells with defects of the mitochondrial rather than receptor-mediated pathways. Selection of p53-defective cells has been described as a consequence of cyclic hypoxia; therefore, we evaluated the impact of hypoxic selection on activation of p21 and downstream mediators of p53-dependent apoptosis. p53 function and protein levels of key mediators of mitochondrial apoptosis remained unaffected by hypoxic selection. However, radiation-induced conformational changes of Bax were reduced after cyclic hypoxia. In summary, it could be demonstrated that hypoxic stress confers a selection pressure on mitochondrial apoptotic pathways and, consecutively, to an increased resistance toward mitochondrial death triggers.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Charite, Dept Radiat Oncol, Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seylerstr 3, D-72076 Tubingen, Germany.	claus.belka@uni-uebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Brizel DM, 1996, CANCER RES, V56, P941; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 1996, CANCER RES, V56, P4509; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Kim CY, 1997, CANCER RES, V57, P4200; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KISCHKEL FC, 2001, J BIOL CHEM, V2, P2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maecker HL, 2000, CANCER RES, V60, P4638; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Vaupel P, 1998, STRAHLENTHER ONKOL, V174, P6; VAUPEL P, 1987, CANCER RES, V47, P3496; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walenta S, 2000, CANCER RES, V60, P916; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Weinmann M, 2002, BRIT J CANCER, V86, P1355, DOI 10.1038/sj.bjc.6600237; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	45	52	52	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1906	+		10.1096/fj.04-1918fje	http://dx.doi.org/10.1096/fj.04-1918fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456741				2022-12-28	WOS:000224243200007
J	Teshima-Kondo, S; Kondo, K; Prado-Lourenco, L; Gonzalez-Herrera, IG; Rokutan, K; Bayard, F; Arnal, JF; Prats, AC				Teshima-Kondo, S; Kondo, K; Prado-Lourenco, L; Gonzalez-Herrera, IG; Rokutan, K; Bayard, F; Arnal, JF; Prats, AC			Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site	FASEB JOURNAL			English	Article						FGF-2; IRES; STZ; SMC	FIBROBLAST-GROWTH-FACTOR; TISSUE-SPECIFIC REGULATION; SMOOTH-MUSCLE-CELLS; ALTERNATIVE TRANSLATION; TRANSGENIC MICE; DIABETIC RATS; EXPRESSION; GLUCOSE; PROTEIN; GROWTH-FACTOR-2	Fibroblast growth factor 2 (FGF-2) is normally synthesized at low levels but is elevated in various pathophysiological conditions including diabetes-associated vascular diseases. FGF-2 expression is regulated translationally through an internal ribosome entry site (IRES) located in its mRNA, which allows a nonclassical cap-independent translation. We addressed the pathophysiological regulation of the IRES in vivo by using a streptozotocin-induced hyperglycemic model known to suppress markedly overall translation. Evaluation of FGF-2 IRES-dependent translation was performed with transgenic mice expressing dual luciferase bicistronic mRNA containing the FGF-2 IRES. FGF-2 IRES-dependent reporter activity increased 240% of control in the diabetic aorta although the reporter mRNA levels significantly decreased. Expression of endogenous FGF-2 protein in the aorta closely correlated with the IRES activity but not with FGF-2 mRNA levels. Moreover, the biosynthesis of endogenous FGF-2 protein was stimulated in an IRES-dependent manner by high glucose that significantly suppressed global protein synthesis in aortic smooth muscle cells from the transgenic mice. These results suggest that IRES-dependent translational regulation could play a pathological role in FGF-2 expression in vivo, especially in the cardiovascular consequences of diabetes.	CHU Rangueil, IFR31, Inst Louis Bugnard, INSERM,U589, F-31059 Toulouse 09, France; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Stress Sci, Tokushima 7708503, Japan; Prologue Biotech, MilleGen, F-31319 Labege, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Tokushima University	Prats, AC (corresponding author), CHU Rangueil, IFR31, Inst Louis Bugnard, INSERM,U589, F-31059 Toulouse 09, France.	Anne-Catherine.Prats@toulouse.inserm.fr	Kondo, Kazuya/J-9163-2012; Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; ARNAL, Jean Francois/0000-0003-2229-6300				Arnaud E, 1999, MOL CELL BIOL, V19, P505; ARNQVIST HJ, 1979, HORM METAB RES, V11, P384, DOI 10.1055/s-0028-1092744; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Galy B, 1999, CANCER RES, V59, P165; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HAMET P, 1985, METABOLISM, V34, P25, DOI 10.1016/S0026-0495(85)80006-8; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; KARPEN CW, 1992, DIABETES, V41, P222, DOI 10.2337/diabetes.41.2.222; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOWE WL, 1995, METABOLISM, V44, P1038, DOI 10.1016/0026-0495(95)90102-7; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; PAIN VM, 1983, AM J PHYSIOL, V245, pE604, DOI 10.1152/ajpendo.1983.245.6.E604; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Rokutan K, 1997, DIGEST DIS SCI, V42, P1880, DOI 10.1023/A:1018859026105; SIVALINGAM A, 1990, ARCH OPHTHALMOL-CHIC, V108, P869, DOI 10.1001/archopht.1990.01070080113046; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stephan CC, 1998, DIABETES, V47, P1771, DOI 10.2337/diabetes.47.11.1771; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; WILLIAMSON JR, 1988, DIABETES METAB REV, V4, P339, DOI 10.1002/dmr.5610040404; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	35	25	25	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1583	+		10.1096/fj.03-1118fje	http://dx.doi.org/10.1096/fj.03-1118fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289445	Green Submitted			2022-12-28	WOS:000223554900026
J	Romanova, EV; Fosser, KA; Rubakhin, SS; Nuzzo, RG; Sweedler, JV				Romanova, EV; Fosser, KA; Rubakhin, SS; Nuzzo, RG; Sweedler, JV			Engineering the morphology and electrophysiological parameters of cultured neurons by microfluidic surface patterning	FASEB JOURNAL			English	Article						controlled growth; action potential broadening; MALDI-MS; soft lithography; aplysia	GROWTH CONE MORPHOLOGY; BAG CELLS; ABDOMINAL-GANGLION; NEURITE OUTGROWTH; APLYSIA; MODULATION; SUBSTRATE; NETWORKS; MULTIPLE; NEUROPEPTIDES	The ability to control the orientation, morphology, and electrophysiological characteristics of neurons in culture allows the construction of neural circuits with defined physiological properties. Using microfluidic protein deposition onto chemically modified glass, we achieve the controlled growth of Aplysia neurons on geometrical patterns of poly-L-lysine and collagen IV, surrounded by nonadhesive regions of bovine albumin. We investigate the parameters essential for forming functional neuronal networks, the morphology, biochemistry, and electrophysiology under engineered cell culture conditions. We demonstrate that not only the orientation of neurite extension but also the number of primary neurites originating from the cell soma, their length, and branching pattern depend on the spatial constraints presented by the size and shape of the adhesion region on the patterned substrate. In addition, the physicochemical properties of the support layer influence the electrical activity of the cultured neurons. Substrate-dependent changes in the amplitude and in the dynamic parameters of the action potential cause decreased spike broadening in patterned neurons, which reflects changes in the number or functioning of active membrane ion channels. In contrast to morphology and electrophysiology, the neuropeptide content, as determined by mass spectrometry of individual patterned neurons, is not affected by the growth on patterned surfaces. Our results suggest that the morphological and electrophysiological parameters of neurons can be predictably altered/engineered by modulation of the chemical, physical, and topographical features of culture substrates. We also demonstrate that a full suite of techniques is required for functional characterization of neurons on engineered substrates	Univ Illinois, Beckman Inst, Dept Chem, Roger Adams Lab 71, Urbana, IL 61801 USA; Univ Illinois, Federick Seitz Mat Res Lab, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sweedler, JV (corresponding author), Univ Illinois, Beckman Inst, Dept Chem, Roger Adams Lab 71, 600 S Mathews Av, Urbana, IL 61801 USA.	jsweedle@uiuc.edu	Rubakhin, Stanislav S/E-6685-2017; Sweedler, Jonathan V/A-9405-2009	Rubakhin, Stanislav S/0000-0003-0437-1493; Sweedler, Jonathan V/0000-0003-3107-9922; Romanova, Elena/0000-0002-2040-3312				Chang JC, 2001, BIOSENS BIOELECTRON, V16, P527, DOI 10.1016/S0956-5663(01)00166-X; CLARK P, 1993, J CELL SCI, V105, P203; Corey JM, 2003, EXP NEUROL, V184, pS89, DOI 10.1016/S0014-4886(03)00392-3; Delamarche E, 1998, J AM CHEM SOC, V120, P500, DOI 10.1021/ja973071f; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; Folch A, 2000, ANNU REV BIOMED ENG, V2, P227, DOI 10.1146/annurev.bioeng.2.1.227; Fosser KA, 2003, ANAL CHEM, V75, P5775, DOI 10.1021/ac034634a; Garden RW, 1998, P NATL ACAD SCI USA, V95, P3972, DOI 10.1073/pnas.95.7.3972; GLASER EM, 1984, J NEUROSCI METH, V12, P37, DOI 10.1016/0165-0270(84)90045-1; Gruenbaum LM, 1999, LEARN MEMORY, V6, P292; Jung DR, 2001, CRIT REV BIOTECHNOL, V21, P111, DOI 10.1080/20013891081700; KACZMAREK LK, 1984, J NEUROPHYSIOL, V52, P340, DOI 10.1152/jn.1984.52.2.340; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; Kowtha VC, 1998, NEUROSCI LETT, V246, P9, DOI 10.1016/S0304-3940(98)00193-1; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P865, DOI 10.1152/jn.1970.33.6.865; Lauer L, 2002, BIOMATERIALS, V23, P3123, DOI 10.1016/S0142-9612(02)00056-X; MA MH, 1995, J NEUROSCI, V15, P6720; MATTSON MP, 1988, J NEUROSCI RES, V20, P331, DOI 10.1002/jnr.490200307; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; McDonald JC, 2000, ELECTROPHORESIS, V21, P27, DOI 10.1002/(SICI)1522-2683(20000101)21:1<27::AID-ELPS27>3.0.CO;2-C; MCMULLEN NT, 1984, J COMP NEUROL, V222, P383, DOI 10.1002/cne.902220306; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Monahan J, 2001, ANAL CHEM, V73, P3193, DOI 10.1021/ac001426z; NEWCOMB RW, 1990, BRAIN RES, V521, P229, DOI 10.1016/0006-8993(90)91547-T; PAYNE HR, 1992, CELL MOTIL CYTOSKEL, V21, P65, DOI 10.1002/cm.970210108; Prinz AA, 2000, BIOL CYBERN, V82, pL1, DOI 10.1007/PL00007969; ROBINSON PJ, 1971, BIOCHIM BIOPHYS ACTA, V242, P659, DOI 10.1016/0005-2744(71)90160-4; Rubakhin SS, 2003, ANAL CHEM, V75, P5374, DOI 10.1021/ac034498+; Rubakhin SS, 1999, J NEUROPHYSIOL, V81, P1251, DOI 10.1152/jn.1999.81.3.1251; SCHACHER S, 1983, J NEUROSCI, V3, P2403; Scholl M, 2000, J NEUROSCI METH, V104, P65, DOI 10.1016/S0165-0270(00)00325-3; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.0.CO;2-U; Tai HC, 1998, BIOTECHNOL PROGR, V14, P364, DOI 10.1021/bp980035r; Vogt AK, 2003, BIOTECHNOL PROGR, V19, P1562, DOI 10.1021/bp034016f; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wyart C, 2002, J NEUROSCI METH, V117, P123, DOI 10.1016/S0165-0270(02)00077-8; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	38	30	34	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1267	+		10.1096/fj.03-1368fje	http://dx.doi.org/10.1096/fj.03-1368fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208266				2022-12-28	WOS:000222327500018
J	de Roos, B; Duivenvoorden, I; Rucklidge, G; Reid, M; Ross, K; Lamers, RJAN; Voshol, PJ; Havekes, LM; Teusink, B				de Roos, B; Duivenvoorden, I; Rucklidge, G; Reid, M; Ross, K; Lamers, RJAN; Voshol, PJ; Havekes, LM; Teusink, B			Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data	FASEB JOURNAL			English	Article						fish oil; CLA; elaidic acid; lipoprotein metabolism; glucose metabolism	CONJUGATED LINOLEIC-ACID; CHOLESTEROL LEVELS; LIPID-COMPOSITION; BODY-COMPOSITION; GENE-EXPRESSION; DOWN-REGULATION; SERUM-LIPIDS; ATHEROSCLEROSIS; LIPOPROTEINS; METABOLISM	Dietary fatty acids have a profound impact on atherosclerosis, but mechanisms are not fully understood. We studied the effects of a saturated fat diet supplemented with fish oil, trans10,cis12 conjugated linoleic acid (CLA), or elaidic acid on lipid and glucose metabolism and liver protein levels of APOE*3 Leiden transgenic mice, a model for lipid metabolism and atherosclerosis. Fish oil lowered plasma and liver cholesterol and triglycerides, plasma free fatty acids, and glucose but increased plasma insulin. CLA lowered plasma cholesterol but increased plasma and liver triglycerides, plasma beta-hydroxybutyrate, and insulin. Elaidic acid lowered plasma and liver cholesterol. Proteomics identified significant regulation of 65 cytosolic and 8-membrane proteins. Many of these proteins were related to lipid and glucose metabolism, and to oxidative stress. Principal component analysis revealed that fish oil had a major impact on cytosolic proteins, and elaidic acid on membrane proteins. Correlation analysis between physiological and protein data revealed novel clusters of correlated variables, among which a metabolic syndrome cluster. The combination of proteomics and physiology gave new insights in mechanisms by which these dietary fatty acids regulate lipid metabolism and related pathways, for example, by altering protein levels of long-chain acyl-CoA thioester hydrolase and adipophilin in the liver.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland; TNO Prevent & Hlth, Gaubius Lab, Leiden, Netherlands; TNO Nutr & Food Res, Zeist, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Internal Med, Leiden, Netherlands; Wageningen Ctr Food Sci, NIZO Food Res, Ede, Netherlands	University of Aberdeen; Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; NIZO Food Research	de Roos, B (corresponding author), Rowett Res Inst, Greenburn Rd, Aberdeen AB21 9SB, Scotland.	b.deroos@rowett.ac.uk		Teusink, Bas/0000-0003-3929-0423				Aro A, 1997, AM J CLIN NUTR, V65, P1419, DOI 10.1093/ajcn/65.5.1419; Belury MA, 1997, LIPIDS, V32, P199, DOI 10.1007/s11745-997-0025-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; Clark PI, 2000, BRIT J CANCER, V83, P1; Clarke SD, 1999, AM J CLIN NUTR, V70, P566; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; Degrace P, 2003, FEBS LETT, V546, P335, DOI 10.1016/S0014-5793(03)00610-0; Delany JP, 1999, AM J PHYSIOL-REG I, V276, pR1172, DOI 10.1152/ajpregu.1999.276.4.R1172; den Boer M, 2004, ARTERIOSCL THROM VAS, V24, P644, DOI 10.1161/01.ATV.0000116217.57583.6e; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAVEKES LM, 1987, BIOCHEM J, V247, P739, DOI 10.1042/bj2470739; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HILL EG, 1982, P NATL ACAD SCI-BIOL, V79, P953, DOI 10.1073/pnas.79.4.953; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI [10.1146/annurev.nu.15.070195.002353, 10.1146/annurev.nutr.15.1.473]; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; LEE KN, 1994, ATHEROSCLEROSIS, V108, P19, DOI 10.1016/0021-9150(94)90034-5; Lee KN, 1998, BIOCHEM BIOPH RES CO, V248, P817, DOI 10.1006/bbrc.1998.8994; Lovejoy J C, 1999, Curr Atheroscler Rep, V1, P215, DOI 10.1007/s11883-999-0035-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Mori TA, 2001, CURR OPIN LIPIDOL, V12, P11, DOI 10.1097/00041433-200102000-00003; Moya-Camarena SY, 1999, J LIPID RES, V40, P1426; Munday JS, 1999, BRIT J NUTR, V81, P251, DOI 10.1017/S0007114599000458; Nicolosi RJ, 1997, ARTERY, V22, P266; Ohnuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P2200, DOI 10.1271/bbb.65.2200; Park Y, 2000, BBA-MOL CELL BIOL L, V1486, P285, DOI 10.1016/S1388-1981(00)00074-3; Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x; Peters JM, 2001, BBA-MOL CELL BIOL L, V1533, P233, DOI 10.1016/S1388-1981(01)00155-X; Post SM, 1997, ARTERIOSCL THROM VAS, V17, P3064, DOI 10.1161/01.ATV.17.11.3064; Post SM, 2000, ARTERIOSCL THROM VAS, V20, P1551, DOI 10.1161/01.ATV.20.6.1551; Roche HM, 2002, DIABETES, V51, P2037, DOI 10.2337/diabetes.51.7.2037; Roche HM, 2001, NUTR RES REV, V14, P173, DOI [10.1079/095442201108729187, 10.1079/NRR200122]; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Sessler AM, 1998, J NUTR, V128, P923, DOI 10.1093/jn/128.6.923; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Takahashi Y, 2003, BBA-MOL CELL BIOL L, V1631, P265, DOI 10.1016/S1388-1981(03)00038-6; Toomey S, 2003, BIOCHEM SOC T, V31, P1075, DOI 10.1042/BST0311075; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; van Oostrom AJHHM, 2002, J ROY SOC MED, V95, P54; van Vlijmen BJM, 1998, J LIPID RES, V39, P1181; vanVlijmen BJM, 1996, J CLIN INVEST, V97, P1184, DOI 10.1172/JCI118532; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; Volger OL, 2001, ATHEROSCLEROSIS, V157, P375, DOI 10.1016/S0021-9150(00)00750-4; Volger OL, 2001, ARTERIOSCL THROM VAS, V21, P1046, DOI 10.1161/01.ATV.21.6.1046; West DB, 1998, AM J PHYSIOL-REG I, V275, pR667; Wever RMF, 1998, CIRCULATION, V97, P108, DOI 10.1161/01.CIR.97.1.108; Yotsumoto H, 1998, FOOD RES INT, V31, P403, DOI 10.1016/S0963-9969(98)00103-3; ZAMBON A, 1993, J LIPID RES, V34, P1021	63	55	55	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					813	+		10.1096/fj.04-2974fje	http://dx.doi.org/10.1096/fj.04-2974fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15755870				2022-12-28	WOS:000227901300025
J	Fisher, I; Abraham, D; Bouri, K; Hoffman, EP; Muntoni, F; Morgan, J				Fisher, I; Abraham, D; Bouri, K; Hoffman, EP; Muntoni, F; Morgan, J			Prednisolone-induced changes in dystrophic skeletal muscle	FASEB JOURNAL			English	Article						muscular dystrophy; dystrophin; corticosteroids; microarrays; fiber type	DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT MDX MICE; LONG-TERM BENEFIT; GENE-EXPRESSION; IMMUNOPHILIN FKBP51; HINDLIMB MUSCLES; FIBER TYPES; MOUSE; CELLS; DIAPHRAGM	Although glucocorticoids delay the progression of Duchenne muscular dystrophy (DMD) their mechanism of action is unknown. Skeletal muscle gene expression profiles of mdx mice, an animal model of DMD, treated with prednisolone were compared with control mice at 1 and 6 wk. Of the 89 early differentially regulated genes and ESTs, delta-sarcoglycan, myosin Va, FK506-binding protein 51 (FKBP51), the potassium channel regulator potassium inwardly-rectifying channel Isk-like (IRK2) and ADAM 10 were overexpressed, whereas growth hormone-releasing hormone receptor (GHRHR) and Homer-2 were underexpressed. The 58 late differentially overexpressed genes included kallikreins ( 13, 16, and 26), FKBP51, PI3K alpha regulatory subunit, and IGFBP6, while underexpressed genes included NeuroD and nicotinic cholinergic receptor gamma. At both time points, overexpression of a cohort of genes relating to metabolism and proteolysis was apparent, alongside the differential expression of genes relating to calcium metabolism. Treatment did not increase muscle regeneration, reduce the number of infiltrating macrophages, or alter utrophin expression or localization. However, in the treated mdx soleus muscle, the percentage of slow fibers was significantly lower compared with untreated controls after 6 wk of treatment. These results show that glucocorticoids confer their benefit to dystrophic muscle in a complex fashion, culminating in a switch to a more normal muscle fiber type.	Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Muscle Cell Biol Grp, London W12 0NN, England; UCL, Royal Free Hosp, Sch Med, Ctr Rheumatol, London NW3 2QG, England; Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Paediat, Dubowitz Neuromuscular Ctr, London W12 0NN, England	Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Children's National Health System; Imperial College London; University of London; University College London	Morgan, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Muscle Cell Biol Grp, London W12 0NN, England.	jmorgan@csc.mrc.ac.uk	Morgan, Jennifer/C-6475-2008	Hoffman, Eric/0000-0001-6470-5139				AGARWAL DP, 1992, PHARMACOGENETICS, V2, P48, DOI 10.1097/00008571-199204000-00002; Anderson JE, 1996, MUSCLE NERVE, V19, P1576, DOI 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7; BORRIONE AC, 1989, EUR J BIOCHEM, V183, P413, DOI 10.1111/j.1432-1033.1989.tb14943.x; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Collins CA, 2003, INT J EXP PATHOL, V84, P165, DOI 10.1046/j.1365-2613.2003.00354.x; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Connolly AM, 2002, J NEUROIMMUNOL, V127, P80, DOI 10.1016/S0165-5728(02)00104-2; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Courdier-Fruh I, 2002, NEUROMUSCULAR DISORD, V12, pS95, DOI 10.1016/S0960-8966(02)00089-5; CURTIS A. S. G., 1960, MED AND BIOL, V10, P261; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; De Luca A, 2003, J PHARMACOL EXP THER, V304, P453, DOI 10.1124/jpet.102.041343; DESILVA S, 1987, ARCH NEUROL-CHICAGO, V44, P818, DOI 10.1001/archneur.1987.00520200022012; Dubowitz V, 2002, Eur J Paediatr Neurol, V6, P153, DOI 10.1053/ejpn.2002.0583; Fang J, 2000, J CELL BIOCHEM, V79, P164, DOI 10.1002/1097-4644(2000)79:1<164::AID-JCB10>3.0.CO;2-D; Fenichel G, 1997, NEUROLOGY, V48, P1225, DOI 10.1212/WNL.48.5.1225; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; FINK RHA, 1990, J PHYSIOL-LONDON, V420, P337, DOI 10.1113/jphysiol.1990.sp017916; Gaud A, 2004, NEUROMUSCULAR DISORD, V14, P365, DOI 10.1016/j.nmd.2004.02.011; Goldspink G, 1999, J ANAT, V194, P323, DOI 10.1046/j.1469-7580.1999.19430323.x; Granchelli JA, 2000, NEUROMUSCULAR DISORD, V10, P235, DOI 10.1016/S0960-8966(99)00126-1; Gross JG, 1999, MUSCLE NERVE, V22, P174, DOI 10.1002/(SICI)1097-4598(199902)22:2<174::AID-MUS5>3.0.CO;2-S; GUERRIERO V, 1980, ENDOCRINOLOGY, V106, P1198, DOI 10.1210/endo-106-4-1198; Hartel JV, 2001, MUSCLE NERVE, V24, P428, DOI 10.1002/1097-4598(200103)24:3<428::AID-MUS1018>3.3.CO;2-5; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; HUDECKI MS, 1993, RES COMMUN CHEM PATH, V79, P45; Jacobs SCJM, 1996, J NEUROL, V243, P410, DOI 10.1007/BF00869001; Jennische E, 2000, APMIS, V108, P747, DOI 10.1034/j.1600-0463.2000.d01-24.x; Jobling Andrew I, 2002, Clin Exp Optom, V85, P61; KISSEL JT, 1991, NEUROLOGY, V41, P667, DOI 10.1212/WNL.41.5.667; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; Li TK, 2002, J CELL BIOCHEM, V84, P460, DOI 10.1002/jcb.10026.abs; Lim JH, 2004, MUSCLE NERVE, V30, P456, DOI 10.1002/mus.20139; LOCASCIO V, 1995, CALCIFIED TISSUE INT, V56, P109, DOI 10.1007/BF00296340; Mayfield RK, 1996, DIABETES, V45, pS20, DOI 10.2337/diab.45.1.S20; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; McKay LI, 1997, MUSCLE NERVE, V20, P1318, DOI 10.1002/(SICI)1097-4598(199710)20:10<1318::AID-MUS17>3.0.CO;2-Z; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Pagel CN, 1999, J NEUROL SCI, V164, P103, DOI 10.1016/S0022-510X(99)00061-1; PARSONS SA, 2004, J BIOL CHEM; PASQUINI F, 1995, NEUROMUSCULAR DISORD, V5, P105, DOI 10.1016/0960-8966(94)00042-8; PASSAQUIN AC, 1993, J NEUROSCI RES, V35, P363, DOI 10.1002/jnr.490350403; PASTORET C, 1993, NEUROMUSCULAR DISORD, V3, P471, DOI 10.1016/0960-8966(93)90099-6; Perkins KJ, 2002, NEUROMUSCULAR DISORD, V12, pS78, DOI 10.1016/S0960-8966(02)00087-1; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7; Porter JD, 2003, NEUROMUSCULAR DISORD, V13, P223, DOI 10.1016/S0960-8966(02)00242-0; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; RIFAI Z, 1995, AM J PHYSIOL-ENDOC M, V268, pE67, DOI 10.1152/ajpendo.1995.268.1.E67; Roberts RG, 1995, ADV GENET, V33, P177, DOI 10.1016/S0065-2660(08)60334-X; Roig M, 2004, ACTA NEUROPATHOL, V107, P27, DOI 10.1007/s00401-003-0773-3; Rouger K, 2002, AM J PHYSIOL-CELL PH, V283, pC773, DOI 10.1152/ajpcell.00112.2002; SALMONS S, 1994, INT J SPORTS MED, V15, P136, DOI 10.1055/s-2007-1021035; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; SHERRATT TG, 1992, BIOCHEM J, V287, P755, DOI 10.1042/bj2870755; St-Pierre SJG, 2004, FASEB J, V18, P1937, DOI 10.1096/fj.04-1859fje; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; Takagi A, 1998, Rinsho Shinkeigaku, V38, P724; Tkatchenko AV, 2000, BBA-MOL BASIS DIS, V1500, P17, DOI 10.1016/S0925-4439(99)00084-8; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Vandebrouck C, 1999, NEUROSCI LETT, V269, P110, DOI 10.1016/S0304-3940(99)00418-8; Ward CW, 2004, J BIOL CHEM, V279, P5781, DOI 10.1074/jbc.M311422200; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; Wehling-Henricks M, 2004, NEUROMUSCULAR DISORD, V14, P483, DOI 10.1016/j.nmd.2004.04.008; WELLER B, 1991, MUSCLE NERVE, V14, P771, DOI 10.1002/mus.880140812; Yang LY, 1998, MUSCLE NERVE, V21, P394, DOI 10.1002/(SICI)1097-4598(199803)21:3<394::AID-MUS14>3.0.CO;2-#; Yang YH, 2004, ARTHRITIS RHEUM-US, V50, P976, DOI 10.1002/art.20201; Zhao P, 2002, J BIOL CHEM, V277, P30091, DOI 10.1074/jbc.M202668200	75	55	59	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					834	+		10.1096/fj.04-2511fje	http://dx.doi.org/10.1096/fj.04-2511fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15734791				2022-12-28	WOS:000227591900004
J	Hayashi, K; Kaufman, L; Ross, MD; Klotman, PE				Hayashi, K; Kaufman, L; Ross, MD; Klotman, PE			Definition of the critical domains required for homophilic targeting of mouse sidekick molecules	FASEB JOURNAL			English	Article						adhesion molecule; immunoglobulin domain; podocyte; HIV-associated nephropathy	HIV-ASSOCIATED NEPHROPATHY; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; COLLAPSING GLOMERULOPATHIES; IMMUNOGLOBULIN SUPERFAMILY; PODOCYTE PHENOTYPE; IGA NEPHROPATHY; PROLIFERATION; DISEASE; EXPRESSION; EPITHELIUM	Sidekick-1, a cell adhesion molecule of the immunoglobulin superfamily, is up-regulated in glomerular podocytes in the collapsing glomerulopathy of HIV-associated nephropathy (HIVAN). Sidekick-1 and its ortholog sidekick-2 have also been shown to function as neuronal targeting molecules, guiding developing neurons to specific synapses. In the current work, we overexpress mouse sidekick-1 and - 2 in HEK 293 T cells in order to characterize their binding specificities. Cells transiently transfected with either sidekick-1 or - 2 cDNA formed separate aggregates when mixed together, demonstrating that sidekicks are homophilic adhesion molecules. The transfection of the short splice variant ( lacking the first two Ig domains) or a construct encoding sidekick-1 with the second Ig domain deleted both resulted in nearly abolished adhesion. A beta-sheet strand peptide containing the sequence QLVILA corresponding to an amino acid sequence in the second Ig domain of sidekick-1 showed specific interaction with the recombinant first Ig domain-His protein of sidekick-1. Cells expressing a mutant sidekick-1 where the binding sequence QLVILA is deleted failed to mediate significant adhesion. Furthermore, cells transfected with a chimeric sidekick, where the first two Ig domains of sidekick-2 are replaced with the corresponding two Ig domains of sidekick-1, form aggregates with sidekick-1-transfected cells. The reverse chimera, where the first two Ig domains of sidekick-2 are substituted onto sidekick-1, was similarly able to form aggregates with sidekick-2-transfected cells. These results establish that the first and second Ig domains of sidekick-1 and - 2 are necessary and sufficient to mediate and target homophilic adhesion, and the QLVILA sequence is critical to the interaction. Understanding these functional domains has widespread implications in normal development and HIVAN pathogenesis.	CUNY Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA; Juntendo Univ, Sch Med, Dept Internal Med, Div Nephrol, Tokyo 113, Japan	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Juntendo University	Hayashi, K (corresponding author), CUNY Mt Sinai Sch Med, Div Nephrol, Annenberg Bldg,Room 23-38,1 Gustave L Levy Pl, New York, NY 10029 USA.	kayo.hayashi@mssm.edu			NIDDK NIH HHS [1 PO1 DK56492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056492] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA Y, 1998, P 9 GEN INF WORKSH G, P131; Barclay AN, 2003, SEMIN IMMUNOL, V15, P215, DOI 10.1016/S1044-5323(03)00047-2; Barisoni L, 2002, MICROSC RES TECHNIQ, V57, P254, DOI 10.1002/jemt.10084; Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; FRIES JWU, 1989, LAB INVEST, V60, P205; Hara M, 1998, AM J NEPHROL, V18, P35, DOI 10.1159/000013302; Hishiki T, 2001, KIDNEY BLOOD PRESS R, V24, P99, DOI 10.1159/000054214; Husain M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019642.55998.69; Kaufman L, 2004, J AM SOC NEPHROL, V15, P1721, DOI 10.1097/01.ASN.0000128975.28958.C2; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Lemley KV, 2002, KIDNEY INT, V61, P1475, DOI 10.1046/j.1523-1755.2002.00269.x; Lin YF, 2001, DEVELOPMENT, V128, P1573; Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522; Nakamura T, 2000, AM J NEPHROL, V20, P175, DOI 10.1159/000013580; Nguyen DNT, 1997, DEVELOPMENT, V124, P3303; SALZER JL, 1989, DEV NEUROSCI-BASEL, V11, P377, DOI 10.1159/000111914; Schwartz EJ, 2001, J AM SOC NEPHROL, V12, P1677, DOI 10.1681/ASN.V1281677; Shankland SJ, 2000, KIDNEY INT, V58, P674, DOI 10.1046/j.1523-1755.2000.00213.x; Shirato I, 1996, VIRCHOWS ARCH, V429, P255; White KE, 2002, DIABETES, V51, P3083, DOI 10.2337/diabetes.51.10.3083; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yu J, 2002, DEVELOPMENT, V129, P5301	27	19	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					614	+		10.1096/fj.04-2947fje	http://dx.doi.org/10.1096/fj.04-2947fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15703275				2022-12-28	WOS:000227591900017
J	Melchionna, R; Porcelli, D; Mangoni, A; Carlini, D; Liuzzo, G; Spinetti, G; Antonini, A; Capogrossi, MC; Napolitano, M				Melchionna, R; Porcelli, D; Mangoni, A; Carlini, D; Liuzzo, G; Spinetti, G; Antonini, A; Capogrossi, MC; Napolitano, M			Laminar shear stress inhibits CXCR4 expression on endothelial cells: functional consequences for atherogenesis	FASEB JOURNAL			English	Article						chemokine; atherosclerosis; apoptosis	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; CHEMOKINE RECEPTOR CXCR4; SIGNAL-REGULATED KINASE; VASCULAR SMOOTH-MUSCLE; FACTOR-I; ATHEROSCLEROTIC PLAQUES; HEMODYNAMIC FORCES; FLOW CONDITIONS; GROWTH-FACTOR	Laminar shear stress (LSS) represents a major athero-protective stimulus. However, the mechanisms for this effect are poorly characterized. As chemokine receptors modulate endothelial cell functions, we hypothesized that at least some LSS effects on endothelial cells (ECs) may be due to LSS-dependent changes in chemokine receptor expression and function. Exposure of Human umbilical vein endothelial cells (HUVECs) to 15 dynes/cm(2)/sec(-1) LSS strongly inhibited CXC chemokine receptor 4 (CXCR4) expression at the transcriptional level and impaired stromal-derived factor (SDF)-1/CXCL12-driven chemotaxis. On the contrary, low shear stress (SS; 4 dynes/cm(2)/sec(-1)) only marginally affected CXCR4 expression when compared with static control cells. Differently from CXCR4, the expression of SDF-1 mRNA was not affected by LSS treatment. CXCR4 overexpression induced a dose-dependent endothelial cell apoptosis that was enhanced by SDF-1 treatment and was caspase- dependent. CXCR4 overexpression inhibited the LSS-mediated antiapoptotic effect on ECs and was associated to impairment of LSS-induced ERK1/2 phosphorylation. These findings suggest that LSS-induced CXCR4 down-regulation may contribute to endothelial cell survival. Interestingly, the expression of the proatherogenic chemokines MCP-1 and IL-8 was induced by SDF-1 treatment and by CXCR4 overexpression in HUVECs. Further, the known LSS-induced inhibition of MCP-1 expression was impaired in CXCR4 overexpressing ECs. Finally, CXCR4 was abundantly expressed by human atherosclerotic plaque endothelium that is exposed to low/absent shear stress, while it was poorly expressed by minimally diseased carotid artery endothelium. In conclusion, LSS-dependent CXCR4 down-regulation may contribute to atheroprotection by favoring the integrity of the endothelial barrier and by inhibiting MCP-1 and IL-8 expression.	IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, I-00167 Rome, Italy; IRCCS, Ctr Cardiol Fdn I Monzino, Lab Biol Vasc & Terapia Genica, Rome, Italy; Univ Sacred Heart, Osped Gemelli, Inst Cardiol, I-00168 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Napolitano, M (corresponding author), IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, Via Monti di Creta 104, I-00167 Rome, Italy.	m.napolitano@idi.it	melchionna, Roberta/G-2479-2011; Antonini, Angelo/H-9726-2019; Napolitano, Monica/AAB-3982-2021; Spinetti, Gaia/T-8245-2018; Melchionna, Roberta/AAZ-4111-2021; LIUZZO, GIOVANNA/J-8090-2018	Antonini, Angelo/0000-0003-1040-2807; Spinetti, Gaia/0000-0001-7996-6809; Melchionna, Roberta/0000-0002-8410-9681; LIUZZO, GIOVANNA/0000-0002-5714-0907				Abi-Younes S, 2000, CIRC RES, V86, P131, DOI 10.1161/01.RES.86.2.131; Akimoto S, 2000, CIRC RES, V86, P185, DOI 10.1161/01.RES.86.2.185; Aurrand-Lions M, 2002, NAT IMMUNOL, V3, P116, DOI 10.1038/ni0202-116; Berk BC, 2001, ANN NY ACAD SCI, V947, P93; Bernardini G, 2000, BLOOD, V96, P4039, DOI 10.1182/blood.V96.13.4039.h8004039_4039_4045; Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556; Boisvert WA, 2000, IMMUNOL RES, V21, P129, DOI 10.1385/IR:21:2-3:129; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Damas JK, 2002, CIRCULATION, V106, P36, DOI 10.1161/01.CIR.0000020001.09990.90; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fernandis AZ, 2002, J BIOL CHEM, V277, P18111, DOI 10.1074/jbc.M200750200; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gimbrone MA, 1999, THROMB HAEMOSTASIS, V82, P722; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39; Hayes IM, 1998, ARTERIOSCL THROM VAS, V18, P397, DOI 10.1161/01.ATV.18.3.397; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Kaiser D, 1997, BIOCHEM BIOPH RES CO, V231, P586, DOI 10.1006/bbrc.1997.6146; Kanda S, 2003, J BIOL CHEM, V278, P257, DOI 10.1074/jbc.M204771200; Lataillade JJ, 2000, BLOOD, V95, P756, DOI 10.1182/blood.V95.3.756; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Malek AM, 1996, J CELL SCI, V109, P713; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moriuchi M, 1997, J IMMUNOL, V159, P4322; Murdoch C, 2000, J VASC RES, V37, P1, DOI 10.1159/000025707; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Odemis V, 2002, J BIOL CHEM, V277, P39801, DOI 10.1074/jbc.M200472200; Palumbo R, 2000, CIRCULATION, V102, P225, DOI 10.1161/01.CIR.102.2.225; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Salcedo R, 2003, BLOOD, V102, P1966, DOI 10.1182/blood-2002-11-3400; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Schecter AD, 2003, MICROCIRCULATION, V10, P265, DOI 10.1038/sj.mn.7800192; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Ullrich CK, 2000, BLOOD, V96, P1438, DOI 10.1182/blood.V96.4.1438.h8001438_1438_1442; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	69	40	44	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					629	+		10.1096/fj.04-2219fje	http://dx.doi.org/10.1096/fj.04-2219fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15705741				2022-12-28	WOS:000227591900014
J	Liu, LH; Bosmans, F; Maeterns, C; Zhu, RH; Wang, DC; Tytgat, J				Liu, LH; Bosmans, F; Maeterns, C; Zhu, RH; Wang, DC; Tytgat, J			Molecular basis of the mammalian potency of the scorpion alpha-like toxin, BmK M1	FASEB JOURNAL			English	Article						voltage-gated Na+ channels	SODIUM-CHANNEL; FUNCTIONAL EXPRESSION; MEMBRANE-PROTEIN; NEUROTOXIN; SITE; SELECTIVITY; SUBUNIT; BINDING; LQH-2; TIPE	In-depth structure-function studies of voltage-gated Na+ channels and peptide toxins are continuously increasing our understanding of their interaction. In this study, an effective yeast expression system was used to study the role of 14 N- and C-terminal residues from the a-like toxin BmK M1 from the Chinese scorpion Buthus martensii Karsch. With the use of site-directed mutagenesis, all of these residues were individually substituted by one or more amino acids, resulting in a total of 19 mutants. These were then subjected to a bioassay on mice, an elaborate electrophysiological characterization on three cloned voltage-gated Na+ channels (Na(v)1.2, Na(v)1.5, and para), and a circular dichroism analysis. Our results reveal large mutant-dependent differences that emphasize important and specific roles for the studied residues. By mutating single amino acids, we were able to redirect the a-like characteristics of BmK M1 (active on both mammals and insects) to either much higher mammal specificity or, in a few cases, total insect specificity. This study therefore represents a thorough mapping and elucidation of three epitopes that underlie the molecular basis of the mammalian and insecticidal potency of the scorpion a-like toxin, BmK M1 on voltage-gated Na+ channels.	Chinese Acad Sci, Inst Biophys, Ctr Molec Biol, Beijing 100101, Peoples R China; Univ Leuven, Lab Toxicol, B-3000 Leuven, Belgium	Chinese Academy of Sciences; Institute of Biophysics, CAS; KU Leuven	Wang, DC (corresponding author), Chinese Acad Sci, Inst Biophys, Ctr Molec Biol, 15 Datun Rd, Beijing 100101, Peoples R China.	dcwang@ibp.ac.cn; Jan.Tytgat@pharm.kuleuven.ac.be	Bosmans, Frank/T-5589-2017; Bosmans, Frank/A-9660-2013; Tytgat, Jan/F-1560-2010	Bosmans, Frank/0000-0002-6476-235X; Bosmans, Frank/0000-0002-6476-235X; Tytgat, Jan/0000-0003-1778-6022; Bosmans, Frank/0000-0002-0451-6050				Bosmans F, 2002, FEBS LETT, V532, P131, DOI 10.1016/S0014-5793(02)03653-0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen HJ, 2002, EUR J NEUROSCI, V16, P767, DOI 10.1046/j.1460-9568.2002.02142.x; Denac H, 2000, N-S ARCH PHARMACOL, V362, P453, DOI 10.1007/s002100000319; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Gordon D, 2003, TOXICON, V41, P125, DOI 10.1016/S0041-0101(02)00294-5; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Grolleau F, 2001, J EXP BIOL, V204, P711; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; He XL, 1999, J MOL BIOL, V292, P125, DOI 10.1006/jmbi.1999.3036; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Karbat I, 2004, J BIOL CHEM, V279, P31679, DOI 10.1074/jbc.M402048200; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Leipold E, 2004, MOL PHARMACOL, V65, P685, DOI 10.1124/mol.65.3.685; Li HM, 1996, J MOL BIOL, V261, P415, DOI 10.1006/jmbi.1996.0473; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MEIER J, 1986, TOXICON, V24, P395, DOI 10.1016/0041-0101(86)90199-6; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Seibert AL, 2004, BIOCHEMISTRY-US, V43, P7082, DOI 10.1021/bi0496135; Shao F, 1999, PROTEIN EXPRES PURIF, V17, P358, DOI 10.1006/prep.1999.1127; Sun YM, 2003, J BIOL CHEM, V278, P24125, DOI 10.1074/jbc.M211931200; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; Wang CG, 2003, BIOCHEMISTRY-US, V42, P4699, DOI 10.1021/bi0270438; Wang SY, 2003, CELL SIGNAL, V15, P151, DOI 10.1016/S0898-6568(02)00085-2; Warmke JW, 1997, J GEN PHYSIOL, V110, P119, DOI 10.1085/jgp.110.2.119; Xiong YM, 1997, TOXICON, V35, P1025, DOI 10.1016/S0041-0101(96)00224-3; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhu SY, 2004, J MOL EVOL, V58, P145, DOI 10.1007/s00239-003-2534-2; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zlotkin E, 1999, ANNU REV ENTOMOL, V44, P429, DOI 10.1146/annurev.ento.44.1.429	37	38	39	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					594	+		10.1096/fj.04-2485fje	http://dx.doi.org/10.1096/fj.04-2485fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677695				2022-12-28	WOS:000226576600044
J	Untersmayr, E; Bakos, N; Scholl, I; Kundi, M; Roth-Walter, F; Szalai, K; Riemer, AB; Ankersmit, HJ; Scheiner, O; Boltz-Nitulescu, G; Jensen-Jarolim, E				Untersmayr, E; Bakos, N; Scholl, I; Kundi, M; Roth-Walter, F; Szalai, K; Riemer, AB; Ankersmit, HJ; Scheiner, O; Boltz-Nitulescu, G; Jensen-Jarolim, E			Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients	FASEB JOURNAL			English	Article						food allergy; digestion; epidemiology; skin prick test; oral sensitization; ST2; simulated gastric fluid	FOOD ALLERGENS; ST2 PROTEIN; DIGESTIBILITY; PREVALENCE; EXPRESSION; OMEPRAZOLE; DYSPEPSIA; DIGESTION; BIOLOGY; ULCER	Recently, we have demonstrated that anti-ulcer drugs, such as H2-receptor blockers and proton pump inhibitors, promote the development of immediate type food allergy toward digestion-labile proteins in mice. The aim of this study was to examine the allergological relevance of these findings in humans. In an observational cohort study, we screened 152 adult patients from a gastroenterological outpatient clinic with negative case histories for atopy or allergy, who were medicated with H2-receptor blockers or proton pump inhibitors for 3 months. IgE reactivities to food allergens before and after 3 months of anti-acid treatment were compared serologically. Ten percent of the patients showed a boost of preexisting IgE antibodies and 15% de novo IgE formation toward numerous digestion-labile dietary compounds, like milk, potato, celery, carrots, apple, orange, wheat, and rye flour. Thus, the relative risk to develop food-specific IgE after anti-acid therapy was 10.5 (95% confidence interval: 1.44 - 76.48). The long-term effect was evaluated 5 months after therapy. Food-specific IgE could still be measured in 6% of the patients, as well as significantly elevated serum concentrations of ST2, a Th2-specific marker. An unspecific boost during the pollen season could be excluded, as 50 untreated control patients revealed no changes in their IgE pattern. In line with our previous animal experiments, our data strongly suggest that anti-ulcer treatment primes the development of IgE toward dietary compounds in long-term acid-suppressed patients.	Med Univ Vienna, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Hetenyi Geza Hosp, Dept Dermatol, H-5000 Szolnok, Hungary; Med Univ Vienna, Dept Occupat & Social Hlth, A-1090 Vienna, Austria; Med Univ Vienna, Dept CT Surg, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at	Jensen-Jarolim, Erika/C-5120-2018; Untersmayr, Eva/GRY-4470-2022; Roth-Walter, Franziska/V-4651-2017	Jensen-Jarolim, Erika/0000-0003-4019-5765; Roth-Walter, Franziska/0000-0001-5005-9228; Riemer, Angelika/0000-0002-5865-0714; Ankersmit, Hendrik Jan/0000-0002-8761-3517; Untersmayr, Eva/0000-0002-1963-499X				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Bjornsson E, 1996, ANN ALLERG ASTHMA IM, V77, P327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGET DW, 1990, GASTROENTEROLOGY, V99, P345, DOI 10.1016/0016-5085(90)91015-X; CHIVERTON SG, 1989, GUT, V30, P594, DOI 10.1136/gut.30.5.594; COOK GC, 1985, SCAND J GASTROENTERO, V20, P17, DOI 10.3109/00365528509093751; Corder AP, 1996, BRIT J CLIN PRACT, V50, P245; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; Hefle SL, 1996, FOOD TECHNOL-CHICAGO, V50, P86; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; HUNT RH, 1988, SCAND J GASTROENTERO, V23, P34, DOI 10.3109/00365528809099128; ISOLAURI J, 1995, ANN MED, V27, P67, DOI 10.3109/07853899509031939; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; JONES RH, 1990, GUT, V31, P401, DOI 10.1136/gut.31.4.401; Kelso JM, 2000, CLIN EXP ALLERGY, V30, P905, DOI 10.1046/j.1365-2222.2000.00872.x; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLING HJ, 1993, ALLERGY, V48, P9; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; PEDEN NR, 1979, LANCET, V2, P199; Penston JG, 1996, ALIMENT PHARM THERAP, V10, P83; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64, DOI 10.1016/S0016-5085(85)80133-5; Richardson P, 1998, DRUGS, V56, P307, DOI 10.2165/00003495-199856030-00002; SAMLOFF IM, 1989, GASTROENTEROLOGY, V96, P586, DOI 10.1016/S0016-5085(89)80054-X; SHARMA BK, 1984, GUT, V25, P957, DOI 10.1136/gut.25.9.957; Taylor SL, 2001, J ALLERGY CLIN IMMUN, V107, P765, DOI 10.1067/mai.2001.114241; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171; Yagami T, 2002, INT ARCH ALLERGY IMM, V128, P271, DOI 10.1159/000063859; Yanagisawa K, 1997, J BIOCHEM-TOKYO, V121, P95; 2003, MED LETT DRUGS THER, V45, P61	35	157	161	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					656	+		10.1096/fj.04-3170fje	http://dx.doi.org/10.1096/fj.04-3170fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671152				2022-12-28	WOS:000226576600005
J	D'Amelio, P; Grimaldi, A; Pescarmona, GP; Tamone, C; Roato, I; Isaia, G				D'Amelio, P; Grimaldi, A; Pescarmona, GP; Tamone, C; Roato, I; Isaia, G			Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis	FASEB JOURNAL			English	Article						TNF-alpha; RANKL; cytokines	T-CELLS; PRECURSORS; REPLACEMENT; INDUCTION; MONOCYTES; CYTOKINES; CULTURE	Osteoclasts are cells involved in bone reabsorbing and hence in postmenopausal bone loss. There is no evidence of increased in vitro spontaneous osteoclast formation in postmenopausal osteoporosis. The aim of our study was to evaluate spontaneous osteoclastogenesis in osteoporosis. Bone mineral density, markers of bone turnover, and cultures of peripheral blood mononuclear cells (PBMC) on dentine slices with or without the addition of 1,25-OH vitamin D-3 ([10(-8) M]) were obtained from 18 osteoporotic women and 15 controls. To verify cytokine production by PBMC cultures, supernatants were collected on days 3 and 6 and tested for TNF-alpha and RANKL. The data obtained were compared between patients and controls by one-way ANOVA and correlated by Pearson's coefficient. We found a significant increase in osteoclast formation and bone reabsorbing activity in patients with respect to controls; in addition, the production of TNF-alpha and RANKL is significantly higher in patients. Furthermore, osteoclast number is inversely correlated with bone mineral density and directly with RANKL in culture supernatants. Our data demonstrated an increased spontaneous osteoclastogenesis in women affected by postmenopausal osteoporosis: this increase may be explained by the higher production of TNF-alpha and RANKL by PBMC cultures of osteoporotic patients.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Univ Turin, Dept Genet Biol & Biochem Res, I-10126 Turin, Italy; Univ Turin, Ctr Med Expt CeRMS, Dept Med Oncol, I-10126 Turin, Italy	University of Turin; University of Turin; University of Turin	D'Amelio, P (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	patriziadamelio@netscape.net	D'AMELIO, PATRIZIA/K-3042-2016	D'AMELIO, PATRIZIA/0000-0002-4467-8337; PESCARMONA, GIAN PIERO/0000-0003-2143-8901				Bernard-Poenaru O, 2001, OSTEOPOROSIS INT, V12, P769, DOI 10.1007/s001980170054; BERNSTEIN MJ, 1984, JAMA-J AM MED ASSOC, V252, P799; Cohen-Solal ME, 1998, J CLIN ENDOCR METAB, V83, P1687, DOI 10.1210/jc.83.5.1687; Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood-2004-02-0474; Eghbali-Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215; Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097-4644(19990101)72:1<67::AID-JCB8>3.0.CO;2-A; HORTON MA, 1985, CANCER RES, V45, P5663; Itonaga I, 1999, BIOCHEM BIOPH RES CO, V264, P590, DOI 10.1006/bbrc.1999.1545; Jevon M, 2003, SCAND J RHEUMATOL, V32, P95, DOI 10.1080/03009740310000102; Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#; Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190; Li BB, 2003, BIOL PHARM BULL, V26, P780, DOI 10.1248/bpb.26.780; Massey HM, 1999, BRIT J HAEMATOL, V106, P167; MUNDY GR, 1993, PHYSL PHARM BONE, P185; Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; Romas E, 1997, OSTEOPOROSIS INT, V7, P47, DOI 10.1007/BF03194342; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365-2141.2000.02379.x; Shih C, 1996, ANAT REC, V245, P41, DOI 10.1002/(SICI)1097-0185(199605)245:1<41::AID-AR7>3.0.CO;2-I; World Health Organization, 1994, WHO TECHN REP SER, V843	22	56	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					410	+		10.1096/fj.04-2214fje	http://dx.doi.org/10.1096/fj.04-2214fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15611151	Green Published			2022-12-28	WOS:000226091000011
J	Starace, D; Riccioli, A; D'Alessio, A; Giampietri, C; Petrungaro, S; Galli, R; Filippini, A; Ziparo, E; De Cesaris, P				Starace, D; Riccioli, A; D'Alessio, A; Giampietri, C; Petrungaro, S; Galli, R; Filippini, A; Ziparo, E; De Cesaris, P			Characterization of signaling pathways leading to Fas expression induced by TNF-alpha: pivotal role of NF-kappa B	FASEB JOURNAL			English	Article						sertoli cell; MAPK; apoptosis	TUMOR-NECROSIS-FACTOR; MAMMALIAN MAP KINASE; GERM-CELL APOPTOSIS; SERTOLI-CELLS; TERMINAL KINASE; TRANSDUCTION PATHWAYS; GENE-TRANSCRIPTION; IMMUNE-RESPONSES; ACTIVATION; DEATH	TNF-alpha is known to induce a strong up-regulation of Fas expression in mouse Sertoli cell cultures, leading to their apoptosis triggered by effector FasL-bearing cells. These data suggest that increased Fas expression on the cell surface might be a key event in the pathogenesis of autoimmune orchitis, by inducing a leakage of the blood-tubular barrier as a consequence of Sertoli cell apoptosis. In the present paper, we have investigated the signal transduction mechanisms involved in the regulation of Fas expression induced by TNF-alpha in mouse Sertoli cells. We studied the role of the transcription factor NF-kappaB and of MAPKs in regulating Fas expression. By using Sertoli cells transfected with a NF-kappaB Luc reporter gene, we proved that TNF-alpha activates the IkappaB/ NF-kappaB system. Moreover, the use of the proteasome inhibitor lactacystin led us to demonstrate that NF-kappaB is required for TNF-alpha mediated Fas expression. By using specific inhibitors for each MAPK, we confirmed the pivotal role of the IkappaB/NF-kappaB system by demonstrating that ERKs, p38, and JNK are not involved in Fas up-regulation by TNF-alpha. The comprehension of these pathways could be relevant to the knowledge of the pathogenesis of autoimmune disorders in immune privileged districts of the body.	Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; University of L'Aquila	De Cesaris, P (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy.	paola.decesaris@uniroma1.it	D'Alessio, Alessio/F-3778-2010	D'Alessio, Alessio/0000-0002-3340-2634; riccioli, anna/0000-0002-9792-4933; DE CESARIS, Paola/0000-0002-3802-9103; filippini, antonio/0000-0001-8453-287X; petrungaro, simonetta/0000-0001-7283-4977; Giampietri, Claudia/0000-0002-5025-5365; Ziparo, Elio/0000-0002-8776-3515				Arnold R, 1999, J IMMUNOL, V162, P7140; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Budde LM, 2002, MOL BIOL CELL, V13, P4179, DOI 10.1091/mbc.01-07-0373; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200; D'Alessio A, 2001, P NATL ACAD SCI USA, V98, P3316, DOI 10.1073/pnas.051566098; Darieva Z, 2004, J LEUKOCYTE BIOL, V75, P689, DOI 10.1189/jlb.0603280; De Cesaris P, 1999, J BIOL CHEM, V274, P28978, DOI 10.1074/jbc.274.41.28978; De Cesaris P, 1998, J BIOL CHEM, V273, P7566, DOI 10.1074/jbc.273.13.7566; DE SK, 1993, ENDOCRINOLOGY, V133, P389, DOI 10.1210/en.133.1.389; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; DECESARIS P, 1992, BIOCHEM BIOPH RES CO, V186, P1639; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; Delfino FJ, 1999, J BIOL CHEM, V274, P35607, DOI 10.1074/jbc.274.50.35607; Delfino FJ, 2003, MOL CELL ENDOCRINOL, V201, P1, DOI 10.1016/S0303-7207(03)00005-4; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dym M, 1970, Biology Reprod., V3, P308; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Galdieri M, 1981, J ANDROL, V5, P249; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goransson O, 2004, J NUTR BIOCHEM, V15, P303, DOI 10.1016/j.jnutbio.2004.01.004; GUY GR, 1991, J BIOL CHEM, V266, P14343; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; KOHNO S, 1983, J REPROD IMMUNOL, V5, P339, DOI 10.1016/0165-0378(83)90243-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Lysiak JJ, 2003, BIOL REPROD, V69, P202, DOI 10.1095/biolreprod.102.013318; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marino MW, 1996, J BIOL CHEM, V271, P28624, DOI 10.1074/jbc.271.45.28624; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; PALOMBI F, 1988, BIOL REPROD, V39, P1101, DOI 10.1095/biolreprod39.5.1101; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Pentikainen V, 1999, AM J PHYSIOL-ENDOC M, V276, pE310, DOI 10.1152/ajpendo.1999.276.2.E310; Riccioli A, 2000, J IMMUNOL, V165, P743, DOI 10.4049/jimmunol.165.2.743; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; Ryden M, 2002, J BIOL CHEM, V277, P1085, DOI 10.1074/jbc.M109498200; Stefanini M., 1985, P59; Tamanini A, 2003, VIROLOGY, V307, P228, DOI 10.1016/S0042-6822(02)00078-8; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Waldner H, 1997, J IMMUNOL, V159, P3100; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YULE TD, 1993, ENDOCRINOLOGY, V133, P1098, DOI 10.1210/en.133.3.1098; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang LY, 2004, ENDOCRINOLOGY, V145, P781, DOI 10.1210/en.2003-0987; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	67	28	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					473	+		10.1096/fj.04-2726fje	http://dx.doi.org/10.1096/fj.04-2726fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15601669				2022-12-28	WOS:000226091000014
J	Schwarz, M; Rottgen, P; Takada, Y; Le Gall, F; Knackmuss, S; Bassler, N; Buttner, C; Little, M; Bode, C; Peter, K				Schwarz, M; Rottgen, P; Takada, Y; Le Gall, F; Knackmuss, S; Bassler, N; Buttner, C; Little, M; Bode, C; Peter, K			Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alpha(IIb)beta(3) designed by subtractive selection from naive human phage libraries	FASEB JOURNAL			English	Article						fibrinogen; phage-display	ACUTE CORONARY SYNDROME; GLYCOPROTEIN-IIB-IIIA; INTEGRIN ALPHA(IIB)BETA(3); LIGAND-BINDING; ADHESION RECEPTORS; FIBRINOGEN BINDING; CELL-ADHESION; GPIIB-IIIA; IIB/IIIA; INHIBITORS	Binding of fibrinogen to platelet integrin alpha(II)beta(3) mediates platelet aggregation, and thus inhibition of alpha(IIb)beta(3) represents a powerful therapeutic strategy in cardiovascular medicine. However, the currently used inhibitors of a(IIb)beta(3) demonstrate several adverse effects like thrombocytopenia and bleeding, which are associated with their property to bind to non-activated alpha(IIb)beta(3). To circumvent these problems, we designed blocking single-chain antibody-fragments (scFv) that bind to alpha(IIb)beta(3) exclusively in its activated conformation. Two nave phage libraries were created: a natural phage library, based on human lymphocyte cDNA, and a synthetic library, with randomized V(H)CDR3. We performed serial rounds of subtractive panning with depletion on non-activated and selection on activated aIIbbeta3, which were provided on resting and ADP-stimulated platelets and CHO cells, expressing wild-type or mutated and thereby activated alpha(IIb)beta(3). In contrast to isolated, immobilized targets, as generally used for phage display, this unique cell-based approach for panning allowed the preservation of functional integrin conformation. Thereby, we obtained several scFv-clones that demonstrated exclusive binding to activated platelets and complete inhibition of fibrinogen binding and platelet aggregation. Interestingly, all activation-specific clones contained an RXD pattern in the HCDR3. Binding studies on transiently expressed point mutants and mouse-human domain-switch mutants of alphaIIbbeta3 indicate a binding site similar to fibrinogen. In conclusion, we generated human activation-specific scFvs against alpha(IIb)beta(3), which bind selectively to activated alpha(IIb)beta(3) and thereby potently inhibit fibrinogen binding to alpha(IIb)beta(3) and platelet aggregation.	Univ Freiburg, Dept Cardiol, D-79106 Freiburg, Germany; Scripps Res Inst, La Jolla, CA 92037 USA; Affimed Therapeut AG, D-69120 Heidelberg, Germany; Univ N Carolina, Chapel Hill, NC USA	University of Freiburg; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill	Schwarz, M (corresponding author), Univ Freiburg, Dept Cardiol, Breisacherstr 33, D-79106 Freiburg, Germany.	schwarz@med1.ukl.uni-freiburg.de	/S-2765-2019; Peter, Karlheinz/E-8772-2010	/0000-0002-8040-2258; Peter, Karlheinz/0000-0002-8040-2258; takada, yoshikazu/0000-0001-5481-9589				ABRAMS C, 1994, J BIOL CHEM, V269, P18781; Bennett JS, 2001, ANN NY ACAD SCI, V936, P340; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Billheimer JT, 2002, BLOOD, V99, P3540, DOI 10.1182/blood.V99.10.3540; Borrebaeck CAK, 2002, NAT BIOTECHNOL, V20, P1189, DOI 10.1038/nbt1202-1189; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Chung L, 2004, FASEB J, V18, pA345, DOI 10.1096/fj.03-0586fje; Curtis BR, 2002, BLOOD, V99, P2054, DOI 10.1182/blood.V99.6.2054; Dasgupta H, 2000, AM HEART J, V140, P206, DOI 10.1067/mhj.2000.107554; Dorsam H, 1997, FEBS LETT, V414, P7, DOI 10.1016/S0014-5793(97)00966-6; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Francisco JA, 1997, BLOOD, V89, P4493, DOI 10.1182/blood.V89.12.4493; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; Hamm CW, 2001, LANCET, V358, P1533, DOI 10.1016/S0140-6736(01)06585-0; Holmes MB, 2000, AM J CARDIOL, V85, P491, DOI 10.1016/S0002-9149(99)00778-X; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Kipriyanov SM, 1996, J IMMUNOL METHODS, V196, P51, DOI 10.1016/0022-1759(96)00115-9; Kunicki TJ, 1996, J BIOL CHEM, V271, P20315, DOI 10.1074/jbc.271.34.20315; LERNER RA, 1992, SCIENCE, V258, P1313, DOI 10.1126/science.1455226; Little M, 1999, J IMMUNOL METHODS, V231, P3, DOI 10.1016/S0022-1759(99)00164-7; Madan M, 1999, AM HEART J, V138, pS317, DOI 10.1053/hj.1999.v138.a100465; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Peter K, 1998, BLOOD, V92, P3240, DOI 10.1182/blood.V92.9.3240.421k21_3240_3249; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Peter K, 2000, CIRCULATION, V101, P1158, DOI 10.1161/01.CIR.101.10.1158; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Quinn MJ, 2003, ARTERIOSCL THROM VAS, V23, P945, DOI 10.1161/01.ATV.0000066686.46338.F1; Quinn MJ, 2002, CIRCULATION, V106, P379, DOI 10.1161/01.CIR.0000019581.22812.B2; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schneider DJ, 2000, CARDIOVASC RES, V45, P437, DOI 10.1016/S0008-6363(99)00253-9; Schwarz M, 2004, J PHARMACOL EXP THER, V308, P1002, DOI 10.1124/jpet.103.058883; Schwentker A, 2002, NITRIC OXIDE-BIOL CH, V7, P1, DOI 10.1016/S1089-8603(02)00002-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Tur MK, 2001, BIOTECHNIQUES, V30, P404, DOI 10.2144/01302rr04; Welschof M, 1997, P NATL ACAD SCI USA, V94, P1902, DOI 10.1073/pnas.94.5.1902	40	69	77	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1704	+		10.1096/fj.04-1513fje	http://dx.doi.org/10.1096/fj.04-1513fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15522915				2022-12-28	WOS:000224243200021
J	Pirko, I; Ciric, B; Gamez, J; Bieber, AJ; Warrington, AE; Johnson, AJ; Hanson, DP; Pease, LR; Macura, SI; Rodriguez, M				Pirko, I; Ciric, B; Gamez, J; Bieber, AJ; Warrington, AE; Johnson, AJ; Hanson, DP; Pease, LR; Macura, SI; Rodriguez, M			A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS	FASEB JOURNAL			English	Article						Theiler's murine encephalitis virus; demyelination; in vivo small animal MRI; antibody-mediated remyelination	NERVOUS-SYSTEM REMYELINATION; MONOCLONAL AUTOANTIBODY; MULTIPLE; OLIGODENDROCYTES; MECHANISM; PROGRESS; REPAIR; PDGF	The human monoclonal antibody rHIgM22 enhances remyelination following spinal cord demyelination in a virus-induced murine model of multiple sclerosis. Using three-dimensional T2-weighted in vivo spinal cord magnetic resonance imaging (MRI), we have therefore assessed the extent of spinal cord demyelination, before and after 5 weeks of treatment with rHIgM22, to determine whether antibody enhanced remyelination can be detected by MRI. A significant decrease was seen in T2 high signal lesion volume following antibody treatment. Histologic examination of the spinal cord tissue reveals that this decrease in lesion volume correlates with antibody promoted remyelination. To show that rHIgM22 enters the spinal cord and colocalizes with demyelinating lesions, we used ultrasmall superparamagnetic iron oxide particle ( USPIO)labeled antibodies. This may be considered as additional evidence to the hypothesis that rHIgM22 promotes remyelination by local effects in the lesions, likely by binding to CNS cells. The reduction in high signal T2-weighted lesion volume may be an important outcome measure in future clinical trials in humans.	Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biomed Imaging Resource, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, NMR Core Facil, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	rodriguez@mayo.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Rodriguez, Moses/0000-0001-6328-6497				Asakura K, 1996, J NEUROSCI RES, V43, P273, DOI 10.1002/(SICI)1097-4547(19960201)43:3<273::AID-JNR2>3.0.CO;2-G; Asakura K, 1996, J NEUROIMMUNOL, V65, P11, DOI 10.1016/0165-5728(95)00175-1; Asakura K, 1998, MULT SCLER, V4, P217, DOI 10.1177/135245859800400324; Asakura K, 1998, J NEUROSCI, V18, P7700; Barkhof F, 1997, MULT SCLER, V3, P129, DOI 10.1177/135245859700300212; Bieber A, 2000, Mult Scler, V6 Suppl 2, pS1; Bieber A, 2000, MULT SCLER S2, V6, pS33; Bieber AJ, 2003, ANN NEUROL, V53, P680, DOI 10.1002/ana.10578; Bieber AJ, 2002, GLIA, V37, P241, DOI 10.1002/glia.10033; Bieber AJ, 2001, TRENDS NEUROSCI, V24, pS39, DOI 10.1016/S0166-2236(00)01991-3; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Bruck W, 2003, J NEUROL SCI, V206, P181, DOI 10.1016/s0022-510x(02)00191-0; Ciric B, 2004, J NEUROIMMUNOL, V146, P153, DOI 10.1016/j.jneuroim.2003.11.002; Ciric B, 2001, BLOOD, V97, P321, DOI 10.1182/blood.V97.1.321; Deloire-Grassin MSA, 2000, J NEUROL SCI, V178, P10, DOI 10.1016/S0022-510X(00)00331-2; Duncan ID, 1996, NEUROPATH APPL NEURO, V22, P87, DOI 10.1111/j.1365-2990.1996.tb00852.x; DUNCAN ID, 1992, DEV NEUROSCI-BASEL, V14, P114, DOI 10.1159/000111655; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; Howe CL, 2004, NEUROBIOL DIS, V15, P120, DOI 10.1016/j.nbd.2003.09.002; Lassmann H, 1997, MULT SCLER J, V3, P133, DOI 10.1177/135245859700300213; MCKINNON RD, 1993, GLIA, V7, P245, DOI 10.1002/glia.440070308; MCKINNON RD, 1993, J CELL BIOL, V121, P1397, DOI 10.1083/jcb.121.6.1397; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; Miller DH, 1998, BRAIN, V121, P3, DOI 10.1093/brain/121.1.3; Miller DJ, 1997, J NEUROIMMUNOL, V75, P204, DOI 10.1016/S0165-5728(97)00027-1; Mitsunaga Y, 2002, FASEB J, V16, P1325, DOI 10.1096/fj.01-0994fje; Moore GRW, 2000, NEUROLOGY, V55, P1506, DOI 10.1212/WNL.55.10.1506; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Pavelko KD, 1998, J NEUROSCI, V18, P2498; Pirko I, 2003, CROAT MED J, V44, P463; Pirko I, 2004, FASEB J, V18, P179, DOI 10.1096/fj.02-1124fje; Soldan MMP, 2003, MOL CELL NEUROSCI, V22, P14, DOI 10.1016/S1044-7431(02)00018-0; 't Hart BA, 1998, AM J PATHOL, V153, P649, DOI 10.1016/S0002-9440(10)65606-4; Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820; Warrington AE, 2001, J ALLERGY CLIN IMMUN, V108, pS121, DOI 10.1067/mai.2001.118301	35	77	87	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1577	+		10.1096/fj.04-2026fje	http://dx.doi.org/10.1096/fj.04-2026fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319372				2022-12-28	WOS:000223554900007
J	Terrazzino, S; Berto, F; Dalle Carbonare, M; Fabris, M; Guiotto, A; Bernardini, D; Leon, A				Terrazzino, S; Berto, F; Dalle Carbonare, M; Fabris, M; Guiotto, A; Bernardini, D; Leon, A			Stearoylethanolamide exerts anorexic effects in mice via downregulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression	FASEB JOURNAL			English	Article						N-acylethanolamines; food intake; leptin; peroxisome proliferator-activated receptors; real-time RT-PCR	PROLIFERATOR-ACTIVATED RECEPTORS; ENDOGENOUS CANNABINOID SYSTEM; FATTY-ACID AMIDES; COA DESATURASE-1; ENDOCANNABINOIDS; PALMITOYLETHANOLAMIDE; ANANDAMIDE; CB1; LEPTIN; FOOD	Given the recent demonstration that oleoylethanolamide (OEA), a cannabinoid receptor-inactive N-acylethanolamine, decreases food intake by activating the nuclear receptor PPARalpha ( peroxisome proliferator-activated receptor alpha) in the periphery, we here evaluated the effects of both saturated and unsaturated C18 N-acylethanolamides ( C18: 0; C18: 1; C18: 2) in mice feeding behavior after overnight starvation. Our results show stearoylethanolamide ( SEA, C18: 0) exerts, unlike other unsaturated C18 homologs, a marked dose-dependent anorexic effect evident already at 2 h after its intraperitoneal administration. In addition, oral administration of SEA ( 25 mg/kg) was also effective in reducing food consumption, an effect ascribed to the molecule itself and not to its catabolites. Moreover, although the anorexic response to oral administered SEA was not associated with changes in the levels of various hematochemical parameters ( e. g., glucose, cholesterol, triglycerides, leptin) nor in liver mRNA expression of peroxisome proliferator-activated receptors (PPARs) including PPARa, the anorexic effect of SEA was interestingly accompanied by a reduction in liver stearoyl-CoA desaturase-1 (SCD-1) mRNA expression. As SCD-1 has been recently proposed as a molecular target for the treatment of obesity, the novel observation provided here that SEA reduces food intake in mice in a structurally selective manner, in turn, correlated with downregulation of liver SCD-1 mRNA expression, has the potential of providing new insights on a class of lipid mediators with suitable properties for the pharmacological treatment of over-eating dysfunctions.	Res & Innovat Co, I-35127 Padua, Italy; Univ Padua, Dept Pharmaceut Sci, I-35131 Padua, Italy; Univ Padua, Sch Vet Med, Dept Vet Clin Sci, I-35020 Legnaro, PD, Italy	University of Padua; University of Padua	Terrazzino, S (corresponding author), Res & Innovat Co, Via Svizzera 16, I-35127 Padua, Italy.	info@researchinnovation.com	Berto, Filippo/J-7204-2019; Fabris, Martina/AAC-4814-2019					Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; Capasso R, 2001, BRIT J PHARMACOL, V134, P945, DOI 10.1038/sj.bjp.0704339; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Conti S, 2002, BRIT J PHARMACOL, V135, P181, DOI 10.1038/sj.bjp.0704466; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Cota D, 2003, INT J OBESITY, V27, P289, DOI 10.1038/sj.ijo.0802250; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; De Petrocellis L, 2000, CHEM PHYS LIPIDS, V108, P191, DOI 10.1016/S0009-3084(00)00196-1; De Petrocellis L, 2001, FEBS LETT, V506, P253, DOI 10.1016/S0014-5793(01)02934-9; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; Di Marzo V, 2001, BIOCHEM J, V358, P249, DOI 10.1042/0264-6021:3580249; Facchinetti F, 2002, J NEUROSCI RES, V69, P178, DOI 10.1002/jnr.10295; Farquhar-Smith WP, 2002, PAIN, V97, P11, DOI 10.1016/S0304-3959(01)00419-5; Fride E, 2002, PROSTAG LEUKOTR ESS, V66, P221, DOI 10.1054/plef.2001.0360; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Gomez R, 2002, J NEUROSCI, V22, P9612; Jamshidi N, 2001, BRIT J PHARMACOL, V134, P1151, DOI 10.1038/sj.bjp.0704379; Kakuma T, 2002, BIOCHEM BIOPH RES CO, V297, P1259, DOI 10.1016/S0006-291X(02)02375-6; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; Kunos G, 2000, CHEM PHYS LIPIDS, V108, P159, DOI 10.1016/S0009-3084(00)00194-8; Maccarrone M, 2002, VITAM HORM, V65, P225, DOI 10.1016/S0083-6729(02)65066-6; Maccarrone M, 2002, MOL CELL NEUROSCI, V21, P126, DOI 10.1006/mcne.2002.1164; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Navarro M, 1996, J NEUROCHEM, V67, P1982; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; ROE ET, 1952, J AM CHEM SOC, V74, P3442, DOI 10.1021/ja01133a528; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Trillou CR, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI 10.1152/ajpregu.00545.2002; Vosper H, 2002, PHARMACOL THERAPEUT, V95, P47, DOI 10.1016/S0163-7258(02)00232-2; Williams CM, 2002, PHYSIOL BEHAV, V76, P241, DOI 10.1016/S0031-9384(02)00725-4; WILLIAMS SK, 1999, TIS ENGN INTELL UNIT, V1, P143; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	40	72	76	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1580	+		10.1096/fj.03-1080fje	http://dx.doi.org/10.1096/fj.03-1080fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289450				2022-12-28	WOS:000223554900018
J	Ferri, A; Nencini, M; Casciati, A; Cozzolino, M; Angelini, DF; Longone, P; Spalloni, A; Rotilio, G; Carri, MT				Ferri, A; Nencini, M; Casciati, A; Cozzolino, M; Angelini, DF; Longone, P; Spalloni, A; Rotilio, G; Carri, MT			Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells	FASEB JOURNAL			English	Article						apoptosis; neuroinflammation; non-cell autonomous neuroanal death; ROS; superoxide dsimutase	TRANSGENIC MOUSE MODEL; NF-KAPPA-B; COPPER/ZINC SUPEROXIDE-DISMUTASE; MOTOR-NEURONS; NITRIC-OXIDE; DIFFERENTIAL EXPRESSION; DEPENDENT APOPTOSIS; GLUTAMATE RELEASE; OXIDATIVE STRESS; SPINAL-CORDS	Mutations in the gene coding for the ubiquitous, anti-oxidant enzyme Cu,Zn superoxide dismutase (SOD1) are associated with familial amyotrophic lateral sclerosis (fALS), a fatal disease characterized by selective loss of motor neurons. Expression of a mutant SOD1 typical of fALS patients restricted to either motor neurons or astrocytes is insufficient to generate a pathological phenotype in mouse models, suggesting that a deleterious interplay between different cell types is necessary for the pathogenesis of the disease. In this study, we demonstrate the actual role of a functional cross-talk between glial and neuronal cells expressing fALS mutant G93A-SOD1, where an increase in the production of reactive oxygen species occurs. We show that human glioblastoma cells expressing G93A-SOD1 induce activation of caspase-1, release of cytokines, and activation of apoptotic pathways in cocultured human neuroblastoma cells also expressing G93A-SOD1. Activation of caspase-1 and caspase-3 is observed also in neuroblastoma lines expressing other fALS-SOD1s (G37R, G85R, and I113T) cocultured with glioblastoma lines expressing the corresponding mutant enzymes. These effects are consequent to activation of inflammatory processes in G93A-glioblastoma cells stimulated by cocultured G93A-neuroblastoma. Furthermore, selective death of embryonal spinal motor neurons from G93A-SOD1 transgenic mice is induced by coculture with G93A-glioblastoma and prevented by inhibition of NO synthase. Proinflammatory cytokines, interferon-gamma, and nitric oxide are among the molecular signals exchanged between glial and neuronal cells that generate a functional interplay between the two cell types. This cross-talk may be crucial for the pathogenesis of SOD1-linked fALS but also for the more common sporadic form of the disease, where markers of increased oxidative stress and of glial activation have been found.	CNR, Ist Neurosci, Sez Psicobiol & Psicofarmacol, Rome, Italy; Ctr Neurobiol Sperimental Mondino Tor Vergata S Lu, Lab Neurochim, Rome, Italy; Fdn Santa Lucia, IRCCS, Rome, Italy; Univ Roma Tor Vergata, Dept Biol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Santa Lucia; University of Rome Tor Vergata	Carri, MT (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via della Ric Sci, I-00133 Rome, Italy.	carri@Bio.uniroma2.it	Spalloni, Alida/K-4316-2014; cozzolino, mauro/AAY-2244-2020; Longone, Patrizia/G-8428-2016; Angelini, Daniela F/J-8001-2018; FERRI, ALBERTO/B-7660-2015; Nencini, Monica/ABI-6619-2020; Carri, Maria Teresa/K-5480-2016	Longone, Patrizia/0000-0001-8964-1637; Angelini, Daniela F/0000-0003-4552-9226; FERRI, ALBERTO/0000-0002-4097-0605; COZZOLINO, MAURO/0000-0003-0342-8961; Carri, Maria Teresa/0000-0002-1789-1546; Nencini, Monica/0000-0001-9602-1954; Spalloni, Alida/0000-0002-2661-6677				Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Almer G, 2002, NEUROLOGY, V58, P1277, DOI 10.1212/WNL.58.8.1277; Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.0.CO;2-X; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Beretta S, 2003, NEUROBIOL DIS, V13, P213, DOI 10.1016/S0969-9961(03)00043-3; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Carri M T, 1997, FEBS Lett, V414, P365; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Casciati A, 2002, J NEUROCHEM, V83, P1019, DOI 10.1046/j.1471-4159.2002.01232.x; Cha CI, 2000, BRAIN RES, V853, P156, DOI 10.1016/S0006-8993(99)02302-1; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Ding QX, 2002, J BIOL CHEM, V277, P13935, DOI 10.1074/jbc.M107706200; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferri A, 2000, J NEUROCHEM, V75, P606, DOI 10.1046/j.1471-4159.2000.0750606.x; Fontana G, 2001, NEUROSCIENCE, V106, P183, DOI 10.1016/S0306-4522(01)00272-X; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Gioia C, 2002, J IMMUNOL, V168, P1484, DOI 10.4049/jimmunol.168.3.1484; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kang SJ, 2003, J NEUROSCI, V23, P5455; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Liu DX, 1999, FASEB J, V13, P2318, DOI 10.1096/fasebj.13.15.2318; Luck H, 1963, METHODS ENZYMATIC AN, P885; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; Migheli A, 1997, J NEUROPATH EXP NEUR, V56, P1314, DOI 10.1097/00005072-199712000-00006; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Nguyen MD, 2001, ANN NEUROL, V50, P630, DOI 10.1002/ana.1256; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Plant LD, 2003, J NEUROSCI, V23, P5531; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Rao SD, 2003, J NEUROSCI, V23, P2627; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Roe JA, 2002, FREE RADICAL BIO MED, V32, P169, DOI 10.1016/S0891-5849(01)00778-X; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Schmidt H. H. W., 1996, METHODS NITRIC OXIDE, P491; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Valentine JS, 2002, FREE RADICAL BIO MED, V33, P1314, DOI 10.1016/S0891-5849(02)01080-8; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Yu WH, 2001, J NEUROSCI, V21, P2240, DOI 10.1523/JNEUROSCI.21-07-02240.2001	61	50	54	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1261	+		10.1096/fj.03-1199fje	http://dx.doi.org/10.1096/fj.03-1199fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208263				2022-12-28	WOS:000222327500019
J	Kaneider, NC; Lindner, J; Feistritzer, C; Sturn, DH; Mosheimer, BA; Djanani, AM; Wiedermann, CJ				Kaneider, NC; Lindner, J; Feistritzer, C; Sturn, DH; Mosheimer, BA; Djanani, AM; Wiedermann, CJ			The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor	FASEB JOURNAL			English	Article						Alzheimer disease; G-protein coupled receptors; immunosuppression; leukocytes; sphingosine-1-phosphate receptors	T-CELL CHEMOTAXIS; ALZHEIMERS-DISEASE; MICROGLIA; PEPTIDE; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; 1-PHOSPHATE; NEUTROPHILS; MESSENGER; FIBRILS	Accumulation of inflammatory mononuclear phagocytes in Alzheimer's senile plaques, a hallmark of the innate immune response to beta-amyloid fibrils, can initiate and propagate neurodegeneration characteristic of Alzheimer's disease. Phagocytes migrate toward amyloid beta-protein involving formyl peptide receptor like-1-dependent signaling. Using human peripheral blood monocytes in Boyden chamber micropore filter assays, we show that the amyloid beta-protein- and amyloid beta-precursor protein-induced migration was abrogated by dimethylsphingosine, a sphingosine kinase inhibitor. Amyloid beta-protein stimulated in monocytes the gene expression for sphingosine-1-phosphate receptors 2 and 5, but not 1, 3, and 4. FTY720 that acts as a hingosine-1-phosphate receptor agonist after endogenous phosphorylation by sphingosine kinase, as well as various neuropeptides that are known to be monocyte chemoattractants, dose-dependently inhibited amyloid beta-protein-induced migration. These data demonstrate that the migratory effects of beta-amyloid in human monocytes involve spingosine-1-phosphate signaling. Whereas endogenous neuropeptides may arrest and activate monocytes at sites of high beta-amyloid concentrations, interference with the amyloid beta-protein-dependent sphingosine-1-phosphate pathway in monocytes by FTY720, a novel immunomodulatory drug, suggests that FTY720 may be efficacious in beta-amyloid-related inflammatory diseases.	Univ Innsbruck Hosp, Dept Internal Med, Div Gen Internal Med, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Wiedermann, CJ (corresponding author), Univ Innsbruck, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	Christian.Wiedermann@uibk.ac.at	Wiedermann, Christian J./ABG-9521-2020					Bae YS, 2003, MOL PHARMACOL, V64, P721, DOI 10.1124/mol.64.3.721; Bonaiuto C, 1997, J NEUROIMMUNOL, V77, P51, DOI 10.1016/S0165-5728(97)00054-4; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Cui YH, 2002, J LEUKOCYTE BIOL, V72, P628; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; ElKhoury J, 1996, NATURE, V382, P716; Etminan M, 2003, BMJ-BRIT MED J, V327, P128, DOI 10.1136/bmj.327.7407.128; Fujino M, 2003, J PHARMACOL EXP THER, V305, P70, DOI 10.1124/jpet.102.045658; Giri RK, 2003, J IMMUNOL, V170, P5281, DOI 10.4049/jimmunol.170.10.5281; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; Ikezu T, 2003, J NEUROCHEM, V85, P925, DOI 10.1046/j.1471-4159.2003.01739.x; Kaneider NC, 2003, J VIROL, V77, P5535, DOI 10.1128/JVI.77.9.5535-5539.2003; Kaneider NC, 2002, J BONE MINER RES, V17, P1872, DOI 10.1359/jbmr.2002.17.10.1872; Kveberg L, 2002, EUR J IMMUNOL, V32, P1856, DOI 10.1002/1521-4141(200207)32:7<1856::AID-IMMU1856>3.0.CO;2-B; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lorton D, 1997, MECH AGEING DEV, V94, P199, DOI 10.1016/S0047-6374(96)01847-7; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; McDonald DR, 1997, J NEUROSCI, V17, P2284; MEDA L, 1995, J NEUROIMMUNOL, V59, P29, DOI 10.1016/0165-5728(95)00021-S; Nagahara Y, 2002, BRIT J PHARMACOL, V137, P953, DOI 10.1038/sj.bjp.0704970; Obeid LA, 2002, BBA-MOL CELL BIOL L, V1585, P163, DOI 10.1016/S1388-1981(02)00337-2; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Scarpini E, 2003, LANCET NEUROL, V2, P539, DOI 10.1016/S1474-4422(03)00502-7; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen WP, 2000, BIOCHEM BIOPH RES CO, V272, P276, DOI 10.1006/bbrc.2000.2770; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Sutton E. T., 1999, Journal of Submicroscopic Cytology and Pathology, V31, P313; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	33	37	51	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1309	+		10.1096/fj.03-1050fje	http://dx.doi.org/10.1096/fj.03-1050fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208267				2022-12-28	WOS:000222327500014
J	Chung, TW; Lee, YC; Kim, CH				Chung, TW; Lee, YC; Kim, CH			Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERKs and PI-3K/AKT pathways: Involvement of invasive potential	FASEB JOURNAL			English	Article						hepatitis B virus X protein; extracellular signal-regulated kinase 1/2; phosphatidylinositol 3-kinase; activating protein-1; nuclear factor-kappa B	VIRUS-X-PROTEIN; NF-KAPPA-B; IV COLLAGENASE EXPRESSION; MATRIX METALLOPROTEINASES; PHOSPHATIDYLINOSITOL 3-KINASE; METASTATIC PHENOTYPE; GELATINASE-B; TRANSCRIPTIONAL ACTIVITY; GROWTH-FACTORS; DNA-BINDING	Hepatitis B virus (HBV) X protein (HBx) has been shown to be essential for the development of hepatocellular carcinoma (HCC). Recently, we have found that HBx causes the progression of liver cancer through down-expression of PTEN, known as a tumor suppressor gene ( 1). The prognosis for HCC depends mainly on the clinicopathological characteristic regarding invasion and metastasis. The expression of matrix metalloproteinase (MMP)-9 has been implicated as playing an important role in HCC invasion and metastasis. We previously reported that HBV infection increased the invasiveness of hepatocytes and HCC cells through the transcriptional activation of MMP-9 (2). The HBx was shown to activate the mitogen-activated protein (MAP) kinase and phosphatidylinositol 3-kinase (PI-3K) signal cascade, which is essential for activation of transcription factors such as activating protein (AP)-1 and nuclear factor (NF)-kappaB. In this study, we show that the HBx protein stimulates the activities of the PI-3K-Akt/protein kinase B (PKB) as well as extracellular signal-regulated kinase 1/2 (ERK 1/2) in HBx-transfected cells. Furthermore, we have shown that enhanced expression of MMP-9 in HBx-transfected cells mediated by not only activation of AP-1 transcriptional activity through ERKs pathway but also activation of NF-kappaB transcriptional activity through PI-3K-AKT/PKB pathway, and was associated with the invasive potential. However, treatment with U0126 ( known as the ERKs inhibitor) or wortmannin ( known as the PI-3K inhibitor), but not SB203580 ( known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP-9 induced by HBx in HBx-transfected cells. Seemingly, the invasiveness of HBx-transfected cells was decreased by treating with U0126 or wortmannin, but not SB203580. These results clearly suggest that the HBx contributed to the transcriptional regulation of MMP-9 through the ERKs and PI-3K-AKT/PKB pathway, and increased an invasive potential of cells.	Dongguk Univ, Coll Oriental Med, Natl Res Labs Glycobiol, MOST, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Coll Oriental Med, Dept Biochem & Mol Biol, Kyungju 780714, Kyungbuk, South Korea; Dong A Univ, Fac Biotechnol, Pusan 604714, South Korea	Dongguk University; Dongguk University; Dong A University	Kim, CH (corresponding author), Dongguk Univ, Coll Oriental Med, Natl Res Labs Glycobiol, MOST, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr		Kim, Cheorl-Ho/0000-0002-6323-0714; Chung, Tae-Wook/0000-0001-5243-5020				Abiru S, 2002, HEPATOLOGY, V35, P1117, DOI 10.1053/jhep.2002.32676; Arii S, 1996, HEPATOLOGY, V24, P316; Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Chung TW, 2002, ARCH BIOCHEM BIOPHYS, V408, P147, DOI 10.1016/S0003-9861(02)00522-2; Chung TW, 2003, CANCER RES, V63, P3453; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FINI ME, 1994, J BIOL CHEM, V269, P28620; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GARBISA S, 1987, CANCER RES, V47, P1523; Genersch E, 2000, J CELL SCI, V113, P4319; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hayasaka A, 1996, HEPATOLOGY, V24, P1058; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KOHN EC, 1995, CANCER RES, V55, P1856; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; LENGYEL E, 1995, CANCER RES, V55, P963; LEVY AT, 1991, CANCER RES, V51, P439; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MENZO S, 1993, VIROLOGY, V196, P878, DOI 10.1006/viro.1993.1550; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; NATOLI G, 1994, ONCOGENE, V9, P2837; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Sakamoto Y, 2000, INT J ONCOL, V17, P237; SATO H, 1993, ONCOGENE, V8, P395; Sato T, 2002, CANCER RES, V62, P1025; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; TIOLLAIS P, 1981, SCIENCE, V213, P406, DOI 10.1126/science.6264599; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATANABE H, 1993, J CELL SCI, V104, P991; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427	68	276	303	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1123	+		10.1096/fj.03-1429fje	http://dx.doi.org/10.1096/fj.03-1429fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132991				2022-12-28	WOS:000221883200023
J	De Felice, FG; Vieira, MNN; Meirelles, MNL; Morozova-Roche, LA; Dobson, CM; Ferreira, ST				De Felice, FG; Vieira, MNN; Meirelles, MNL; Morozova-Roche, LA; Dobson, CM; Ferreira, ST			Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure	FASEB JOURNAL			English	Article						systemic amyloidosis; high pressure; oligomers; protofibrils; fibrils	FIBRIL FORMATION; EQUINE LYSOZYME; HIGH-RESOLUTION; WILD-TYPE; PROTEIN; TRANSTHYRETIN; NEUROTOXICITY; PROTOFIBRILS; DISSOCIATION; PORES	Formation of amyloid deposits from the Ile56Thr or Asp67His variants of human lysozyme is a hallmark of autosomal hereditary systemic amyloidosis. It has recently been shown that amyloid fibrils can be formed in vitro from wild-type (WT), I56T, or D67H lysozyme variants upon prolonged incubation at acidic pH and elevated temperatures ( 1). Here, we have used hydrostatic pressure as a tool to generate amyloidogenic states of WT and variant lysozymes at physiological pH. WT or variant lysozyme samples were initially compressed to 3.5 kbar ( at 57degreesC, pH 7.4). Decompression led to the formation of amyloid fibrils, protofibrils, or globular aggregates, as indicated by light scattering, thioflavin T fluorescence, and transmission electron microscopy analysis. Increased 1-anilinonaphthalene-8-sulfonate binding to the proteins was also observed, indicating exposure of hydrophobic surface area. Thus, pressure appears to induce a conformational state of lysozyme that aggregates readily upon decompression. These results support the notion that amyloid aggregation results from the formation of partially unfolded protein conformations and suggest that pressure may be a useful tool for the generation of the amyloidogenic conformations of lysozyme and other proteins.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21944590 Rio De Janeiro, Brazil; Fiocruz MS, Inst Oswaldo Cruz, Dept Ultraestrutura & Biol Celular, BR-21045900 Rio De Janeiro, Brazil; Umea Univ, Dept Med Biochem & Biophys, SE-90741 Umea, Sweden; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Umea University; University of Cambridge	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21944590 Rio De Janeiro, Brazil.	ferreira@bioqmed.ufrj.br	Ferreira, Sergio/AAZ-1576-2020; Morozova-Roche, Ludmilla/AAV-9983-2021; Morozova-Roche, Ludmilla A./AAU-9044-2021; De Felice, Fernanda G/M-1074-2017	Ferreira, Sergio/0000-0001-7160-9866; Morozova-Roche, Ludmilla/0000-0001-5886-2023; Vieira, Marcelo/0000-0003-2178-9218				Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Canet D, 1999, BIOCHEMISTRY-US, V38, P6419, DOI 10.1021/bi983037t; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chamberlain AK, 2001, PROTEIN SCI, V10, P2525, DOI 10.1110/ps.ps.28101; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; Chapeaurouge A, 2001, J BIOL CHEM, V276, P14861, DOI 10.1074/jbc.M009622200; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; CHRYSSOMALLIS GS, 1981, BIOCHEMISTRY-US, V20, P3955, DOI 10.1021/bi00517a002; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; De Felice FG, 2002, CELL MOL NEUROBIOL, V22, P545, DOI 10.1023/A:1021832302524; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2003, NAT REV DRUG DISCOV, V2, P154, DOI 10.1038/nrd1013; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Jonas J, 1998, BIOPHYS J, V75, P445, DOI 10.1016/S0006-3495(98)77532-0; JONAS J, 1994, ANNU REV BIOPH BIOM, V23, P287, DOI 10.1146/annurev.bb.23.060194.001443; Kapurniotu A, 2002, J MOL BIOL, V315, P339, DOI 10.1006/jmbi.2001.5244; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Malisauskas M, 2003, J MOL BIOL, V330, P879, DOI 10.1016/S0022-2836(03)00551-5; Martins SM, 2003, J BIOL CHEM, V278, P50449, DOI 10.1074/jbc.M307354200; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Nash DP, 1997, BIOCHEMISTRY-US, V36, P14375, DOI 10.1021/bi970881v; Noppe W, 1996, J CHROMATOGR A, V719, P327, DOI 10.1016/0021-9673(95)00677-X; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; SAMARASINGHE SD, 1992, BIOCHEMISTRY-US, V31, P7773, DOI 10.1021/bi00149a005; Sasahara K, 2001, PROTEINS, V44, P180, DOI 10.1002/prot.1083; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Spencer A, 1999, PROTEIN EXPRES PURIF, V16, P171, DOI 10.1006/prep.1999.1036; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Webb JN, 2000, BIOTECHNOL PROGR, V16, P630, DOI 10.1021/bp0000499; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	50	66	71	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1099	+		10.1096/fj.03-1072fje	http://dx.doi.org/10.1096/fj.03-1072fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155566				2022-12-28	WOS:000221883200003
J	Nemes, Z; Devreese, B; Steinert, PM; Van Beeumen, J; Fesus, L				Nemes, Z; Devreese, B; Steinert, PM; Van Beeumen, J; Fesus, L			Cross-linking of ubiquitin, HSP27, parkin and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles	FASEB JOURNAL			English	Article						transglutaminase; neurodegeneration; proteasome; neurofibrillary tangles	PAIRED HELICAL FILAMENTS; SODIUM DODECYL-SULFATE; HEAT-SHOCK-PROTEIN; LEWY BODIES; HUNTINGTONS-DISEASE; NEURODEGENERATIVE DISORDERS; PROTEASOME INHIBITION; CEREBROSPINAL-FLUID; TAU-PROTEIN; CELL-DEATH	The accumulation of misfolded proteins in intracellular inclusions is a generic feature of neurodegenerative disorders. Although heavily ubiquitylated, the aggregated proteins are not degraded by the proteasomes. A possible reason for this phenomenon may be a modification of deposited proteins by transglutaminases forming gamma-glutamyl-epsilon-lysine (GGEL) cross-links between distinct proteins. Here, we show that the frequency of GGEL cross-links is an order of magnitude higher in Alzheimer's brain cortex than in age-matched or younger controls. This difference is due to the accumulation of GGEL cross-links in ubiquitin-immunopositive protein particles present in both Alzheimer's brains and those from aged individuals. The highly crosslinked protein aggregates show immunoreactivity to antibodies against tau and neurofilament proteins, and partially also to alpha-synuclein, indicating that these structures are inherent in Alzheimer's neurofibrillary tangles and Lewy bodies. Using mass sequence analysis, we identified the same six pairs of peptide sequences cross-linked in both senile and Alzheimer's specimens: Gln(31) and Gln(190) of HSP27 protein are cross-linked with Lys(29) and Lys(48) of ubiquitin and HSP27 therefore may cross-link two (poly) ubiquitin chains. One lysine residue of parkin and one of alpha-synuclein were also found to be cross-linked. The data suggest that cross-linking of (poly) ubiquitin moieties via HSP27 may have a role in the stabilization of the intraneuronal protein aggregates by interference with the proteasomal elimination of unfolded proteins.	Univ Debrecen, Res Ctr Mol Med, Hungarian Acad Sci, Dept Psychiat, H-4012 Debrecen, Hungary; Univ Debrecen, Res Ctr Mol Med, Hungarian Acad Sci, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary; Univ Debrecen, Res Ctr Mol Med, Hungarian Acad Sci, Signaling & Apoptosis Res Grp, H-4012 Debrecen, Hungary; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	Hungarian Academy of Sciences; University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; Ghent University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Nemes, Z (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Dept Psychiat, Nagyerdei Krt 98, H-4012 Debrecen, Hungary.	znemes@dote.hu	Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041084] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu CT, 2000, MODERN PATHOL, V13, P420, DOI 10.1038/modpathol.3880072; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; Fornai F, 2003, J NEUROSCI, V23, P8955; Franzblau C, 1977, Adv Exp Med Biol, V79, P313; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Grenard P, 2001, J BIOL CHEM, V276, P33066, DOI 10.1074/jbc.M102553200; Grierson AJ, 2001, NEUROSCI LETT, V298, P9, DOI 10.1016/S0304-3940(00)01714-6; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Iseki E, 2002, J NEUROL SCI, V195, P85, DOI 10.1016/S0022-510X(01)00689-X; Ishizawa T, 2003, J NEUROPATH EXP NEUR, V62, P389, DOI 10.1093/jnen/62.4.389; Itoh Y, 1998, J NEUROL SCI, V157, P73, DOI 10.1016/S0022-510X(98)00050-1; Jeitner TM, 2001, J NEUROCHEM, V79, P1109, DOI 10.1046/j.1471-4159.2001.00673.x; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX G, 1988, NEUROSCI LETT, V94, P211, DOI 10.1016/0304-3940(88)90297-2; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; Miller RJ, 2003, TRENDS PHARMACOL SCI, V24, P18, DOI 10.1016/S0165-6147(02)00011-1; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Murthy SNP, 1998, J NEUROCHEM, V71, P2607; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Nemes Z, 2001, NEUROBIOL AGING, V22, P403, DOI 10.1016/S0197-4580(01)00224-X; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P511; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sarvari M, 2002, ANAL BIOCHEM, V311, P187, DOI 10.1016/S0003-2697(02)00422-0; Sarvari M, 2002, DRUG DEVELOP RES, V56, P458, DOI 10.1002/ddr.10098; SELKOE DJ, 1982, SCIENCE, V215, P1243, DOI 10.1126/science.6120571; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; Singer SM, 2002, NEUROCHEM INT, V40, P17, DOI 10.1016/S0197-0186(01)00061-4; Takeda A, 1998, AM J PATHOL, V152, P367; Tanzi RE, 1999, J CLIN INVEST, V104, P1175, DOI 10.1172/JCI8593; Terry Robert D., 1994, P179; Tsuboi Y, 2001, NEUROLOGY, V57, P1675, DOI 10.1212/WNL.57.9.1675; Tucholski J, 1999, J NEUROCHEM, V73, P1871; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VATH JE, 1990, INT J MASS SPECTROM, V100, P287, DOI 10.1016/0168-1176(90)85079-H; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	63	88	105	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1135	+		10.1096/fj.04-1493fje	http://dx.doi.org/10.1096/fj.04-1493fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132984				2022-12-28	WOS:000221883200019
J	Budas, GR; Jovanovic, S; Crawford, RM; Jovanovic, A				Budas, GR; Jovanovic, S; Crawford, RM; Jovanovic, A			Hypoxia-induced preconditioning in adult stimulated cardiomyocytes is mediated by the opening and trafficking of sarcolemmal K(ATP) channels	FASEB JOURNAL			English	Article						ischemia; heart; Kir6.2; SUR2A; cardioprotection	SENSITIVE POTASSIUM CHANNELS; ACTION-POTENTIAL DURATION; CARDIAC-MUSCLE; H9C2 CELLS; MITOCHONDRIAL; ISCHEMIA; HEART; MEMBRANE; KINASE; CARDIOPROTECTION	The opening of sarcolemmal and mitochondrial ATP-sensitive K(+) (K(ATP)) channels in the heart is believed to mediate ischemic preconditioning, a phenomenon whereby brief periods of ischemia/reperfusion protect the heart against myocardial infarction. Here, we have applied digital epifluorescent microscopy, immunoprecipitation and Western blotting, perforated patch clamp electrophysiology, and immunofluorescence/laser confocal microscopy to examine the involvement of K(ATP) channels in cardioprotection afforded by preconditioning. We have shown that adult, stimulated-to-beat, guinea-pig cardiomyocytes survived in sustained hypoxia for similar to17 min. An episode of 5-min-long hypoxia/5-min-long reoxygenation before sustained hypoxia dramatically increased the duration of cellular survival. Experiments with different antagonists of K(ATP) channels, applied at different times during the experimental protocol, suggested that the opening of sarcolemmal K(ATP) channels at the beginning of sustained hypoxia mediate preconditioning. This conclusion was supported by perforated patch clamp experiments that revealed activation of sarcolemmal K(ATP) channels by preconditioning. Immunoprecipitation and Western blotting as well as immunofluorescence and laser confocal microscopy showed that the preconditioning is associated with the increase in K(ATP) channel proteins in sarcolemma. Inhibition of trafficking of K(ATP) channel subunits prevented preconditioning without affecting sensitivity of cardiomyocytes to hypoxia in the absence of preconditioning. We conclude that the preconditioning is mediated by the activation and trafficking of sarcolemmal K(ATP) channels.	Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland	University of Dundee	Jovanovic, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland.	a.jovanovic@dundee.ac.uk	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318	Biotechnology and Biological Sciences Research Council [S18744, C15048] Funding Source: Medline; British Heart Foundation [PG/02/091/14227] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; COHEN MV, 1995, J MOL CELL CARDIOL, V27, P1527, DOI 10.1016/S0022-2828(95)90293-7; Crawford RM, 2003, J BIOL CHEM, V278, P31444, DOI 10.1074/jbc.M303051200; Crawford RM, 2002, EMBO J, V21, P3936, DOI 10.1093/emboj/cdf388; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Das M, 2003, J PHYSIOL-LONDON, V547, P893, DOI 10.1113/jphysiol.2002.035006; Gallagher MM, 2000, CLIN CARDIOL, V23, P530, DOI 10.1002/clc.4960230712; GASSER RNA, 1990, J PHYSIOL-LONDON, V431, P713, DOI 10.1113/jphysiol.1990.sp018356; Gogelein H, 2001, N-S ARCH PHARMACOL, V364, P33, DOI 10.1007/s002100000391; GROSS GJ, 1992, CIRC RES, V70, P223, DOI 10.1161/01.RES.70.2.223; Hamada K, 1998, J MOL CELL CARDIOL, V30, P1369, DOI 10.1006/jmcc.1998.0701; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; Hu KL, 2003, NEURON, V38, P417, DOI 10.1016/S0896-6273(03)00256-3; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic S, 2003, AM J RESP CELL MOL, V28, P363, DOI 10.1165/rcmb.2002-0101OC; Jovanovic S, 2001, INT J MOL MED, V7, P639; Lacza Z, 2003, J MOL CELL CARDIOL, V35, P1339, DOI 10.1016/S0022-2828(03)00249-9; Lascano EC, 2002, MOL CELL BIOCHEM, V236, P53, DOI 10.1023/A:1016198011919; Lhuillier L, 2002, J NEUROPHYSIOL, V88, P954, DOI 10.1152/jn.2002.88.2.954; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Marber MS, 2000, CIRC RES, V86, P926, DOI 10.1161/01.RES.86.9.926; Miki T, 2002, AM J PHYSIOL-ENDOC M, V283, pE1178, DOI 10.1152/ajpendo.00313.2002; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Murriel CL, 2003, ARCH BIOCHEM BIOPHYS, V420, P246, DOI 10.1016/j.abb.2003.08.038; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ovide-Bordeaux S, 2000, J BIOL CHEM, V275, P37291, DOI 10.1074/jbc.M005772200; Ozcan C, 2002, AM J PHYSIOL-HEART C, V282, pH531, DOI 10.1152/ajpheart.00552.2001; Ranki HJ, 2002, J AM COLL CARDIOL, V40, P367, DOI 10.1016/S0735-1097(02)01947-2; Ranki HJ, 2001, J AM COLL CARDIOL, V38, P906, DOI 10.1016/S0735-1097(01)01428-0; Sato T, 2000, CIRCULATION, V101, P2418, DOI 10.1161/01.CIR.101.20.2418; Seharaseyon J, 2000, J MOL CELL CARDIOL, V32, P1923, DOI 10.1006/jmcc.2000.1226; Singh H, 2003, J MOL CELL CARDIOL, V35, P445, DOI 10.1016/S0022-2828(03)00041-5; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Suzuki M, 2003, CIRCULATION, V107, P682, DOI 10.1161/01.CIR.0000055187.67365.81; WILDE AAM, 1994, CARDIOVASC RES, V28, P16, DOI 10.1093/cvr/28.1.16; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	41	77	82	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1046	+		10.1096/fj.04-1602fje	http://dx.doi.org/10.1096/fj.04-1602fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084521	Green Accepted			2022-12-28	WOS:000221108800010
J	Qin, IY; Block, ML; Liu, YX; Bienstock, RJ; Pei, Z; Zhang, W; Wu, XF; Wilson, B; Burka, T; Hong, JS				Qin, IY; Block, ML; Liu, YX; Bienstock, RJ; Pei, Z; Zhang, W; Wu, XF; Wilson, B; Burka, T; Hong, JS			Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress	FASEB JOURNAL			English	Article						dynorphin; pepide; ROS; GGF; Parkinson's disease	PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; TETRAZOLIUM SALT; PEPTIDE; HORMESIS; INFLAMMATION; INHIBITION; NALOXONE; LIPOPOLYSACCHARIDE; NEUROTOXICITY	Inflammation has been increasingly recognized to contribute to the pathogenesis of Parkinson's disease. Several compounds are neuroprotective at femtomolar concentrations through the inhibition of inflammation. However, the mechanisms mediating femtomolar-acting compounds are poorly understood. Here we show that both gly-gly-phe (GGF), a tri-peptide contained in the dynorphin opioid peptide, and naloxone are neuroprotective at femtomolar concentrations against LPS-induced dopaminergic neurotoxicity through the reduction of microglial activation. Mechanistic studies demonstrated the critical role of NADPH oxidase in the GGF and naloxone inhibition of microglial activation and associated DA neurotoxicity. Pharmacophore analysis of the neuroprotective dynorphin peptides and naloxone revealed common chemical properties (hydrogen bond acceptor, hydrogen bond donor, positive ionizable, hydrophobic) of these femtomolar-acting compounds. These results support a common high-affinity site of action for several femtomolar-acting compounds, where NADPH oxidase is the critical mechanism governing neuroprotection, suggesting a novel avenue of anti-inflammatory and neuroprotective therapy.	NIEHS, Neuropharmacol Sect, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Chem Sect, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA; Dalian Univ Technol, Dept Biosci & Bioengn, Dalian, Peoples R China; Dalian Med Univ, Clin Hosp 1, Dept Neurol, Dalian, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Dalian University of Technology; Dalian Medical University	Hong, JS (corresponding author), NIEHS, Neuropharmacol Sect, F1-01,POB 12233, Res Triangle Pk, NC 27709 USA.	Hong3@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Bienstock, Rachelle/0000-0001-5228-3610; Block, Michelle/0000-0001-8303-7914	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101411] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Block ML, 2004, FASEB J, V18, P1618, DOI 10.1096/fj.04-1945fje; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Calabrese EJ, 2003, CRIT REV TOXICOL, V33, P355, DOI 10.1080/713611042; Calabrese EJ, 2002, TRENDS PHARMACOL SCI, V23, P331, DOI 10.1016/S0165-6147(02)02034-5; CRAIN SM, 1995, P NATL ACAD SCI USA, V92, P10540, DOI 10.1073/pnas.92.23.10540; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; Fernandez-Espejo E, 2004, MOL NEUROBIOL, V29, P15, DOI 10.1385/MN:29:1:15; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2003, TRENDS PHARMACOL SCI, V24, P395, DOI 10.1016/S0165-6147(03)00176-7; GAO Z, 1996, J CQU, V3, P1; GLADYSHEVA TB, 1989, BIOFIZIKA+, V34, P833; Gozes I, 1999, P NATL ACAD SCI USA, V96, P4143, DOI 10.1073/pnas.96.7.4143; Gozes I, 1999, ANN NY ACAD SCI, V897, P125, DOI 10.1111/j.1749-6632.1999.tb07884.x; Kaiser J, 2003, SCIENCE, V302, P376, DOI 10.1126/science.302.5644.376; LI G, 2005, IN PRESS FASEB J; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2003, METH MOLEC MED, V79, P43; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2001, J PHARMACOL EXP THER, V298, P1133; McGeer PL, 2001, ADV NEUROL, V86, P83; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; QIN L, ANN NY ACAD SCI; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Reglodi D, 2000, ANN NY ACAD SCI, V921, P119; Sazanov L. A., 1992, Biokhimiya, V57, P1443; Sharp BM, 1998, BIOCHEM PHARMACOL, V56, P289, DOI 10.1016/S0006-2952(98)00155-5; Sowa G, 1997, BIOCHEM PHARMACOL, V53, P823, DOI 10.1016/S0006-2952(97)00006-3; Stebbing ARD, 2003, CRIT REV TOXICOL, V33, P463, DOI 10.1080/713611038; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Wilkemeyer MF, 2003, P NATL ACAD SCI USA, V100, P8543, DOI 10.1073/pnas.1331636100; Wilkemeyer MF, 2002, J PHARMACOL EXP THER, V303, P110, DOI 10.1124/jpet.102.036277; WILLIAMSON S A, 1987, Brain Behavior and Immunity, V1, P329, DOI 10.1016/0889-1591(87)90035-3; WILLIAMSON SA, 1988, IMMUNOLOGY, V65, P47; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; WU X, 2005, IN PRESS ANTIOXID RE	40	76	82	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					550	557		10.1096/fj.04-2857com	http://dx.doi.org/10.1096/fj.04-2857com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791005				2022-12-28	WOS:000228865300039
J	Darby, RAJ; Hine, AV				Darby, RAJ; Hine, AV			LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications	FASEB JOURNAL			English	Article						lac repressor protein; protein-DNA interactions; gene therapy; DNA vaccines	HUMAN GENE-THERAPY; PERFORMANCE LIQUID-CHROMATOGRAPHY; REPRESSOR-OPERATOR INTERACTION; ANION-EXCHANGE CHROMATOGRAPHY; PREPARATIVE PURIFICATION; SCALE PRODUCTION; LACTOSE OPERON; ADSORPTION; EXPRESSION; COMPLEXES	Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence-specific zinc finger protein. We present a more generically applicable protein-based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His-tagged Lacl protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (>80% based on recovered starting material, 35-50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity-based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.	Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England	Aston University	Hine, AV (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	a.v.hine@aston.ac.uk		Hine, Anna/0000-0003-4065-831X				Anderson WF, 1998, NATURE, V392, P25; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; Bell CE, 2001, J MOL BIOL, V312, P921, DOI 10.1006/jmbi.2001.5024; BETZ JL, 1976, J MOL BIOL, V105, P293, DOI 10.1016/0022-2836(76)90113-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CARTER BJ, 1999, BIOTECHNOLOGY, P395; CHANDRA G, 1992, ANAL BIOCHEM, V203, P169, DOI 10.1016/0003-2697(92)90060-K; COLOTE S, 1986, ANAL BIOCHEM, V154, P15, DOI 10.1016/0003-2697(86)90488-4; Durland RH, 1998, ADV DRUG DELIVER REV, V30, P33, DOI 10.1016/S0169-409X(97)00105-1; Ferreira GNM, 1999, BIOTECHNOL PROGR, V15, P725, DOI 10.1021/bp990065+; Ferreira GNM, 2000, BIOSEPARATION, V9, P1, DOI 10.1023/A:1008134822673; Fox JL, 1999, NAT BIOTECHNOL, V17, P1153, DOI 10.1038/70689; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GEISLER N, 1976, P NATL ACAD SCI USA, V73, P3103, DOI 10.1073/pnas.73.9.3103; GILBERT W, 1967, P NATL ACAD SCI USA, V58, P2415, DOI 10.1073/pnas.58.6.2415; Giovannini R, 2002, BIOTECHNOL BIOENG, V77, P445, DOI 10.1002/bit.10149; Green AP, 1997, BIOPHARM-APPL T BIO, V10, P52; Grunwald AG, 2001, ANAL BIOCHEM, V296, P138, DOI 10.1006/abio.2001.5197; HORN NA, 1995, HUM GENE THER, V6, P565, DOI 10.1089/hum.1995.6.5-565; Huber CG, 1998, J CHROMATOGR A, V806, P3, DOI 10.1016/S0021-9673(97)01124-2; JOBE A, 1972, J MOL BIOL, V69, P397, DOI 10.1016/0022-2836(72)90253-7; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; Krisky DM, 1998, GENE THER, V5, P1593, DOI 10.1038/sj.gt.3300766; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Lemmens R, 2003, J CHROMATOGR B, V784, P291, DOI 10.1016/S1570-0232(02)00805-X; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Mountain A, 2000, TRENDS BIOTECHNOL, V18, P119, DOI 10.1016/S0167-7799(99)01416-X; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NICK H, 1982, P NATL ACAD SCI-BIOL, V79, P218, DOI 10.1073/pnas.79.2.218; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Oh J, 2002, J VIROL, V76, P1762, DOI 10.1128/JVI.76.4.1762-1768.2002; PFAHL M, 1979, J MOL BIOL, V127, P339, DOI 10.1016/0022-2836(79)90333-4; Prather KJ, 2003, ENZYME MICROB TECH, V33, P865, DOI 10.1016/S0141-0229(03)00205-9; Prazeres DMF, 2004, CHEM ENG PROCESS, V43, P609, DOI 10.1016/j.cep.2003.02.002; Prazeres DMF, 1998, J CHROMATOGR A, V806, P31, DOI 10.1016/S0021-9673(97)01254-5; Prazeres DMF, 1999, TRENDS BIOTECHNOL, V17, P169, DOI 10.1016/S0167-7799(98)01291-8; RENZNIKOFF WS, 1974, P NATL ACAD SCI USA, V71, P2314; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; ROBINSON H, 2000, CLIN MICROBIOL NEWSL, V23, P17; Robinson HL, 1999, NAT MED, V5, P526, DOI 10.1038/8406; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; SADLER JR, 1976, BIOCHEMISTRY-US, V15, P4353, DOI 10.1021/bi00665a001; Sanda MG, 1999, UROLOGY, V53, P260, DOI 10.1016/S0090-4295(98)00539-1; Sandberg LM, 2004, J BIOTECHNOL, V109, P193, DOI 10.1016/j.jbiotec.2003.10.036; Schluep T, 1998, NUCLEIC ACIDS RES, V26, P4524, DOI 10.1093/nar/26.19.4524; SOFER G, 1994, HDB PROCESS CHROMATO; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; Varley DL, 1999, BIOSEPARATION, V8, P209, DOI 10.1023/A:1008015701773; Wils P, 1997, GENE THER, V4, P323, DOI 10.1038/sj.gt.3300388; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; Winters MA, 2003, BIOTECHNOL PROGR, V19, P440, DOI 10.1021/bp020043e; Woodgate J, 2002, BIOTECHNOL BIOENG, V79, P450, DOI 10.1002/bit.10296	53	23	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					801	+		10.1096/fj.04-2812fje	http://dx.doi.org/10.1096/fj.04-2812fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15760969				2022-12-28	WOS:000227901300020
J	Sainson, RCA; Aoto, J; Nakatsu, MN; Holderfield, M; Conn, E; Koller, E; Hughes, CCW				Sainson, RCA; Aoto, J; Nakatsu, MN; Holderfield, M; Conn, E; Koller, E; Hughes, CCW			Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis	FASEB JOURNAL			English	Article						angiogenesis; sprouts; EC	3-DIMENSIONAL FIBRIN MATRICES; TRANSCRIPTION FACTOR; IN-VITRO; GROWTH-FACTOR; MESENCHYMAL TRANSITION; TUMOR ANGIOGENESIS; ACTIVATED NOTCH4; TUBE FORMATION; CYCLE ARREST; MICE LACKING	The requirement for notch signaling during vascular development is well-documented but poorly understood. Embryonic and adult endothelial cells (EC) express notch and notch ligands; however, the necessity for cell-autonomous notch signaling during angiogenesis has not been determined. During angiogenesis, EC display plasticity, whereby a subset of previously quiescent cells loses polarity and becomes migratory. To investigate the role of notch in EC, we have used a three-dimensional in vitro system that models all of the early steps of angiogenesis. We find that newly forming sprouts are composed of specialized tip cells that guide the sprout and trunk cells that proliferate and rearrange to form intercellular lumens. Furthermore, we find that notch acts cell-autonomously to suppress EC proliferation, thereby regulating tube diameter. In addition, when notch signaling is blocked, tip cells divide, and both daughter cells take on a tip cell phenotype, resulting in increased branching through vessel bifurcation. In contrast, notch signaling is not required for re-establishment of EC polarity or for lumen formation. Thus, notch is used reiteratively and cell-autonomously by EC to regulate vessel diameter, to limit branching at the tip of sprouts, and to establish a mature, quiescent phenotype.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92612 USA; ISIS Pharmaceut Inc, Carlsbad, CA USA	University of California System; University of California Irvine; Isis Pharmaceuticals Inc	Hughes, CCW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92612 USA.	cchughes@uci.edu	Hughes, Christopher/F-7510-2010	Nakatsu, Martin/0000-0001-9808-5230; Holderfield, Matthew/0000-0001-8474-3220; Aoto, Jason/0000-0003-0568-634X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060067] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL60067] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitkenhead M, 2002, MICROVASC RES, V63, P159, DOI 10.1006/mvre.2001.2380; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; Bell SE, 2001, J CELL SCI, V114, P2755; Dor Y, 2003, TRENDS CELL BIOL, V13, P131, DOI 10.1016/S0962-8924(03)00022-9; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Fischer A, 2003, TRENDS CARDIOVAS MED, V13, P221, DOI 10.1016/S1050-1738(03)00082-3; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kopan R, 2002, J CELL SCI, V115, P1095; Krebs LT, 2000, GENE DEV, V14, P1343; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; Markwald R, 1996, ACTA ANAT, V156, P173; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Nakajima M, 2003, MECH DEVELOP, V120, P657, DOI 10.1016/S0925-4773(03)00064-9; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; NEHLS V, 1995, HISTOCHEM CELL BIOL, V104, P459, DOI 10.1007/BF01464336; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Parker LH, 2004, NATURE, V428, P754, DOI 10.1038/nature02416; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749-6632.2003.tb03219.x; Shutter JR, 2000, GENE DEV, V14, P1313; Simian M, 2001, DEVELOPMENT, V128, P3117; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sriuranpong V, 2001, CANCER RES, V61, P3200; Sweeney C, 2004, FASEB J, V18, P1421, DOI 10.1096/fj.04-1700fje; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weijzen S, 2002, J IMMUNOL, V169, P4273, DOI 10.4049/jimmunol.169.8.4273; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	57	172	185	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1027	+		10.1096/fj.04-3172fje	http://dx.doi.org/10.1096/fj.04-3172fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15774577				2022-12-28	WOS:000227901300012
J	Ghittoni, R; Patrussi, L; Pirozzi, K; Pellegrini, M; Lazzerini, PE; Capecchi, PL; Pasini, FL; Baldari, CT				Ghittoni, R; Patrussi, L; Pirozzi, K; Pellegrini, M; Lazzerini, PE; Capecchi, PL; Pasini, FL; Baldari, CT			Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases	FASEB JOURNAL			English	Article						statins; lipid rafts; MAP kinase pathways; TCR internalization	COA REDUCTASE INHIBITORS; SMALL G-PROTEINS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; TCR; STATINS; EXPRESSION; KINASE; GERANYLGERANYLATION; INTERNALIZATION	Statins are widely used hypocholesterolemic drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway whose biosynthetic end product is cholesterol. In addition to lowering circulating cholesterol, statins perturb the composition of cell membranes, resulting in disruption of lipid rafts, which function as signaling platforms in immunoreceptor signaling. Furthermore, by inhibiting protein prenylation, a process also dependent on mevalonate, statins block membrane targeting and hence activity of small GTPases, which control multiple pathways triggered by these receptors. T-cell activation is crucially dependent on Ras, Rho and Rab GTPases. Furthermore TCR signaling is orchestrated at lipid rafts, identifying T-cells as potential cellular targets of statins. Here we report that simvastatin suppresses T-cell activation and proliferation as the result of its capacity to inhibit HMG-CoA reductase. T-cell treatment with simvastatin does not affect intracellular cholesterol levels or raft integrity nor, accordingly, the initial tyrosine phosphorylation-dependent cascade. Conversely, inhibition of protein prenylation by simvastatin results in a dramatic impairment in the pathways regulated by small GTPases, including the Ras/MAP kinase pathway, the Rac/stress kinase pathway, and the Rab-dependent pathway of receptor endocytosis. The results identify Ras superfamily GTPases as strategic molecular targets in T-cell immunosuppression by statins.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; Univ Siena, Policlin Le Scotte, Dept Clin Med & Immunol Sci, I-53100 Siena, Italy	University of Siena; University of Siena	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	baldari@unisi.it	Patrussi, Laura/AAD-4332-2020; Laghi Pasini, Franco/P-8994-2016	Laghi Pasini, Franco/0000-0003-0146-4416; Patrussi, Laura/0000-0003-1542-6955; Baldari, Cosima/0000-0002-4414-6744				Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Andre P, 1997, J IMMUNOL, V159, P5253; Bini L, 2003, BIOCHEM J, V369, P301, DOI 10.1042/BJ20020503; Blanco-Colio LM, 2003, KIDNEY INT, V63, P12, DOI 10.1046/j.1523-1755.2003.00744.x; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; D'Oro U, 2002, J IMMUNOL, V169, P6269, DOI 10.4049/jimmunol.169.11.6269; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Essig M, 1998, CIRC RES, V83, P683, DOI 10.1161/01.RES.83.7.683; Eto M, 2002, CIRCULATION, V105, P1756, DOI 10.1161/01.CIR.0000015465.73933.3B; Goldman F, 1996, BLOOD, V88, P4611, DOI 10.1182/blood.V88.12.4611.bloodjournal88124611; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Graham TE, 1998, J IMMUNOL, V161, P6733; Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607; HE HT, 2005, IN PRESS SEMIN IMMUN, V17; Ichimaru N, 2001, ATHEROSCLEROSIS, V158, P417, DOI 10.1016/S0021-9150(01)00438-5; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; Johnson BA, 2003, AM J RESP CRIT CARE, V167, P1271, DOI 10.1164/rccm.200205-410OC; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Libby P, 2003, AM J CARDIOL, V91, p4B, DOI 10.1016/S0002-9149(02)03267-8; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Masamura K, 2003, ARTERIOSCL THROM VAS, V23, P512, DOI 10.1161/01.ATV.0000060461.64771.F0; Massy ZA, 1999, KIDNEY INT, V56, pS80, DOI 10.1038/sj.ki.4495407; Mehra MR, 2002, J AM COLL CARDIOL, V40, P1609, DOI 10.1016/S0735-1097(02)02340-9; Ortego M, 1999, ATHEROSCLEROSIS, V147, P253, DOI 10.1016/S0021-9150(99)00193-8; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Rodman JS, 2000, J CELL SCI, V113, P183; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; van Seventer GA, 1998, TRANSPLANT P, V30, P4270, DOI 10.1016/S0041-1345(98)01410-9; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	49	115	126	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					605	+		10.1096/fj.04-2702fje	http://dx.doi.org/10.1096/fj.04-2702fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677697				2022-12-28	WOS:000226576600001
J	Kaigler, D; Krebsbach, PH; West, ER; Horger, K; Huang, YC; Mooney, DJ				Kaigler, D; Krebsbach, PH; West, ER; Horger, K; Huang, YC; Mooney, DJ			Endothelial cell modulation of bone marrow stromal cell osteogenic potential	FASEB JOURNAL			English	Article						bone development; bone regeneration; osteoprogenitor cells; BMP-2; osteogenic differentiation	POROUS HYDROXYAPATITE; GROWTH-FACTOR; GENE-THERAPY; PROTEIN; MICROVESSELS; EXPRESSION; DEFECTS; MEMBERS; HYPOXIA; COMPLEX	In the context of bone development and regeneration, the intimate association of the vascular endothelium with osteogenic cells suggests that endothelial cells (ECs) may directly regulate the differentiation of osteoprogenitor cells. To investigate this question, bone marrow stromal cells (BMSCs) were cultured: in the presence of EC-conditioned medium, on EC extracellular matrix, and in EC cocultures with and without cell contact. RNA and protein were isolated from ECs and analyzed by reverse transcriptase-polymerase chain reaction and Western blotting, respectively, for expression of bone morphogenetic protein 2 (BMP-2). In animal studies, BMSCs and ECs were cotransplanted into severe combined immunodeficient mice on biodegradable polymer matrices, and histomorphometric analysis was performed to determine the extent of new bone and blood vessel formation. ECs significantly increased BMSC osteogenic differentiation in vitro only when cultured in direct contact. ECs expressed BMP-2, and experiments employing interfering RNA inhibition confirmed its production as contributing to the increased BMSC osteogenic differentiation. In vivo, cotransplantation of ECs with BMSCs resulted in greater bone formation than did transplantation of BMSCs alone. These data suggest that ECs function not only to form the microvasculature that delivers nutrients to developing bone but also to modulate the differentiation of osteoprogenitor cells in vitro and in vivo.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Oral Med Pathol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem & Biomed Engn, Ann Arbor, MI 48109 USA	Harvard University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Harvard Univ, Div Engn & Appl Sci, 29 Oxford St,325 Pierce Hall, Cambridge, MA 02138 USA.	mooneyd@deas.harvard.edu	Krebsbach, Paul H./AAC-4765-2021	Mooney, David/0000-0001-6299-1194	NIDCR NIH HHS [F30 DE05747, R01-DE013835] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F30DE005747, R01DE013835] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534-200206000-00033; BRONCKERS ALJJ, 1987, J HISTOCHEM CYTOCHEM, V35, P825, DOI 10.1177/35.8.3298423; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115; Dong J, 2001, J BIOMED MATER RES, V57, P208, DOI 10.1002/1097-4636(200111)57:2<208::AID-JBM1160>3.0.CO;2-N; FRIEDENSTEIN AJ, 1978, EXP HEMATOL, V6, P440; Fuchs S, 2001, J AM COLL CARDIOL, V37, P1726, DOI 10.1016/S0735-1097(01)01200-1; Gao JZ, 2001, TISSUE ENG, V7, P363, DOI 10.1089/10763270152436427; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; Gysin R, 2002, GENE THER, V9, P991, DOI 10.1038/sj.gt.3301772; JONES AR, 1995, J ORTHOP RES, V13, P553, DOI 10.1002/jor.1100130410; Kaigler D, 2003, TISSUE ENG, V9, P95, DOI 10.1089/107632703762687573; Kon E, 2000, J BIOMED MATER RES, V49, P328; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248; Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401; LATSINIK N V, 1986, Ontogenez, V17, P27; Li WM, 2000, CYTOKINE, V12, P1017, DOI 10.1006/cyto.1999.0678; MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115; Mendes SC, 2002, TISSUE ENG, V8, P911, DOI 10.1089/107632702320934010; MICHIELS C, 1994, EXP CELL RES, V213, P43, DOI 10.1006/excr.1994.1171; Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626; Mooney DJ, 1996, BIOMATERIALS, V17, P1417, DOI 10.1016/0142-9612(96)87284-X; Murphy WL, 2004, J DENT RES, V83, P204, DOI 10.1177/154405910408300304; Nor JE, 2001, LAB INVEST, V81, P453, DOI 10.1038/labinvest.3780253; OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202; OKUMURA M, 1991, BIOMATERIALS, V12, P411, DOI 10.1016/0142-9612(91)90010-8; OWEN M, 1988, J CELL SCI, P63; PATT HM, 1982, EXP HEMATOL, V10, P738; Pelissier P, 2003, PLAST RECONSTR SURG, V111, P1932, DOI 10.1097/01.PRS.0000055044.14093.EA; ROMANA MC, 1990, PLAST RECONSTR SURG, V85, P587, DOI 10.1097/00006534-199004000-00014; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Shang QX, 2001, J CRANIOFAC SURG, V12, P586, DOI 10.1097/00001665-200111000-00017; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; STREETEN EA, 1990, BONE MINER, V10, P85, DOI 10.1016/0169-6009(90)90084-S; URIST MR, 1982, CLIN ORTHOP RELAT R, P219; VILLANUEVA JE, 1990, J BONE MINER RES, V5, P733; Villars F, 2002, AM J PHYSIOL-CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001; Vogelin E, 2002, PLAST RECONSTR SURG, V109, P190; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; YAJIMA H, 1995, J RECONSTR MICROSURG, V11, P201, DOI 10.1055/s-2007-1006533; ZAIDI M, 1993, BONE, V14, P97, DOI 10.1016/8756-3282(93)90234-2	46	196	209	5	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					665	+		10.1096/fj.04-2529fje	http://dx.doi.org/10.1096/fj.04-2529fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677693	Green Published			2022-12-28	WOS:000226576600002
J	Mizuno, S; Matsumoto, K; Li, MY; Nakamura, T				Mizuno, S; Matsumoto, K; Li, MY; Nakamura, T			HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis	FASEB JOURNAL			English	Article						c-Met; HGF supplement therapy; resolution of fibrosis; chronic respiratory failure; myofibroblast cell death	HEPATOCYTE GROWTH-FACTOR; PULMONARY-FIBROSIS; FACTOR SUPPRESSES; EPITHELIAL-CELLS; GENE-EXPRESSION; RENAL FIBROSIS; BLEOMYCIN; ACTIVATION; PROLIFERATION; LOCALIZATION	Pulmonary fibrosis is characterized by a loss of lung epithelial cells, replaced by interstitial myofibroblasts to deposit extracellular matrix (ECM) proteins. Previous studies demonstrated that hepatocyte growth factor (HGF) improved lung fibrosis in murine models, whereas molecular mechanisms whereby HGF improved lung fibrosis have yet to be fully understood. When MRC-5 human lung fibroblasts were treated with transforming growth factor-beta1, the cells underwent phenotypic change similar to myofibroblasts and this was associated with upregulation of c-Met/HGF receptor expression. For the myofibroblast-like cells, HGF increased activities of MMP-2/-9, predominant enzymes for breakdown of fibronectin (FN). Under such conditions, HGF induced caspase-dependent apoptosis, linked with a decrease in a FN central cell binding (CCB) domain involved in FAK phosphorylation. When MMI270 ( a broad-spectrum MMP inhibitor) was added together with HGF, decreases in FN-CCB domain expression and FAK phosphorylation by HGF were restored, and these events were associated with an inhibition of HGF-induced apoptosis, suggesting that increased activities of MMPs underlie the major mechanism of HGF-mediated apoptosis in myofibroblasts. In bleomycin-treated mice, c-Met expression was found on interstitial myofibroblasts and HGF increased apoptosis in culture of myofibroblasts isolated from bleomycin-treated murine lungs. Furthermore, administration of recombinant HGF to bleomycin-treated mice increased lung MMP activities and enhanced myofibroblast apoptosis, while in vivo MMI270 injections together with HGF inhibited such MMP activation, leading to suppressed myofibroblast apoptosis. In conclusion, we identified HGF as a key ligand to elicit myofibroblast apoptosis and ECM degradation, whereas activation of the HGF/c-Met system in fibrotic lungs may be considered a target to attenuate progression of chronic lung disorders.	Osaka Univ, Grad Sch Med, Dept Mol Regenerat Med, Div Mol regenerat Med, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Regenerat Med, Div Mol regenerat Med, Yamadaoka 2-2-B7, Suita, Osaka 5650871, Japan.	nakamura@onbich.med.osaka-u.ac.jp	LI, Ming-Yue/I-2727-2016; Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Bessho K, 2003, AM J PHYSIOL-RENAL, V284, pF1171, DOI 10.1152/ajprenal.00326.2002; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; Fukuda Y, 1998, LAB INVEST, V78, P687; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; HAGIMOTO N, AM J RESP CELL MOL B, V17, P272; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Hattori N, 2004, AM J PATHOL, V164, P1091, DOI 10.1016/S0002-9440(10)63196-3; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hess S, 1999, ENDOCRINOLOGY, V140, P2908, DOI 10.1210/en.140.6.2908; Inoue T, 2002, FASEB J, V16, P268, DOI 10.1096/fj.02-0442fje; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; KATAYAMA M, 1989, EXP CELL RES, V185, P229, DOI 10.1016/0014-4827(89)90051-7; Kosai K, 1999, HEPATOLOGY, V30, P151, DOI 10.1002/hep.510300102; Lane WJ, 2000, BLOOD, V96, P4152; Marchand-Adam S, 2003, AM J RESP CRIT CARE, V168, P1156, DOI 10.1164/rccm.200212-1514OC; Mason RJ, 2002, AM J RESP CELL MOL, V26, P517, DOI 10.1165/ajrcmb.26.5.f239; MATSUDA Y, 1995, J BIOCHEM-TOKYO, V118, P643, DOI 10.1093/oxfordjournals.jbchem.a124958; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Mizuno S, 2004, AM J PHYSIOL-RENAL, V286, pF134, DOI 10.1152/ajprenal.00199.2003; Mizuno S, 2000, KIDNEY INT, V57, P937; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Ohmichi H, 1996, AM J PHYSIOL-LUNG C, V270, pL1031, DOI 10.1152/ajplung.1996.270.6.L1031; Ohmichi H, 1998, DEVELOPMENT, V125, P1315; OHTA K, 1995, AM J RESP CRIT CARE, V152, P1659, DOI 10.1164/ajrccm.152.5.7582311; Ozaki I, 2002, J HEPATOL, V36, P169, DOI 10.1016/S0168-8278(01)00245-8; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; PHAN SH, 1991, J CLIN INVEST, V87, P148, DOI 10.1172/JCI114964; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; Sakamaki Y, 2002, AM J RESP CELL MOL, V26, P525, DOI 10.1165/ajrcmb.26.5.4714; Taniyama Y, 2000, CIRCULATION, V102, P246, DOI 10.1161/01.CIR.102.2.246; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Umeda Y, 2004, LAB INVEST, V84, P836, DOI 10.1038/labinvest.3700098; Yaekashiwa M, 1997, AM J RESP CRIT CARE, V156, P1937, DOI 10.1164/ajrccm.156.6.9611057; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhang HY, 1997, J IMMUNOL, V158, P1392; Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720; ZHANG K, 1994, AM J PATHOL, V145, P114; ZHANG K, 1995, AM J PATHOL, V147, P352	47	139	151	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					580	+		10.1096/fj.04-1535fje	http://dx.doi.org/10.1096/fj.04-1535fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665032				2022-12-28	WOS:000226576600016
J	Nishimura, H; Fujimoto, A; Tamura, N; Yajima, T; Wajjwalku, W; Yoshikai, Y				Nishimura, H; Fujimoto, A; Tamura, N; Yajima, T; Wajjwalku, W; Yoshikai, Y			A novel autoregulatory mechanism for transcriptional activation of the IL-15 gene by a nonsecretable isoform of IL-15 generated by alternative splicing	FASEB JOURNAL			English	Article							GROWTH-FACTOR RECEPTORS; RETRACTED ARTICLE. SEE; NUCLEAR TRANSLOCATION; ALPHA-CHAIN; NATURAL-KILLER; SIGNAL PEPTIDE; BETA-CHAIN; INTERLEUKIN-15; EXPRESSION; CYTOKINE	There are several isoforms of interleukin (IL) - 15 generated by alternating splicing. We reported previously that alternative IL-15 transgenic (Tg) mice expressing an IL-15 cDNA isoform encoding nonsecretable IL-15 protein had an impaired ability to produce IL-15. In this study, we found that expression of endogenous IL-15 mRNA but not tumor necrosis factor alpha mRNA was severely impaired in response to lipopolysaccharide, not only in macrophages from alternative IL-15 Tg mice but also in RAW264.7 cells that had been transfected with alternative IL-15 together with IL-15 receptor alpha (IL-15Ralpha). IL-15 promoter activity was suppressed in the transfected cells. Although nuclear factor-kappaB activation was not impaired, the binding activity of nuclear extracts to the interferon-stimulated response element of the IL-15 promoter region was reduced in RAW264.7 cells, which had been cotransfected with alternative IL-15 and IL-15Ralpha. IL-15 was mainly colocalized with IL-15Ralpha at the cytoplasmic membrane of RAW264.7 cells, which had been cotransfected with normal IL-15, whereas nonsecretable IL-15 was colocalized with IL-15Ralpha in nucleus after cotransfection with alternative IL-15 and IL-15Ralpha. These results suggest that nonsecretable IL-15 generated by alternative splicing suppresses further IL-15 gene transcription, implying a novel autocrine regulatory mechanism for cytokine gene expression by alternative splicing.	Kyushu Univ, Med Inst Bioregulat, Div Host Def, Higashi Ku, Fukuoka 8128582, Japan; Nagoya Univ, Sch Med, Res Inst Dis Mech & Control, Lab Host Def & Germfree Life, Nagoya, Aichi 466, Japan	Kyushu University; Nagoya University	Nishimura, H (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Host Def, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nishihit@bioreg.kyushu-u.ac.jp						ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Akira S, 2003, J INFECT DIS, V187, pS356, DOI 10.1086/374749; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; Bamford RN, 1998, J IMMUNOL, V160, P4418; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; CURTIS BM, 1990, J IMMUNOL, V144, P1295; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kriventseva EV, 2003, TRENDS GENET, V19, P124, DOI 10.1016/S0168-9525(03)00023-4; Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Mariner JM, 2002, J IMMUNOL, V168, P5667, DOI 10.4049/jimmunol.168.11.5667; Mariner JM, 2001, J IMMUNOL, V166, P2602, DOI 10.4049/jimmunol.166.4.2602; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nishimura H, 1998, J IMMUNOL, V160, P936; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Onu A, 1997, J IMMUNOL, V158, P255; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; RAKOWICZSZULCZYNSKA EM, 1988, CANCER RES, V48, P7200; Srinivasan R, 2000, CANCER RES, V60, P1483; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Washizu J, 1998, IMMUNOGENETICS, V48, P1, DOI 10.1007/s002510050393; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262	44	41	56	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					19	28		10.1096/fj.04-2633com	http://dx.doi.org/10.1096/fj.04-2633com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629891				2022-12-28	WOS:000226576600038
J	Krymskaya, VP; Goncharova, EA; Ammit, AJ; Lim, PN; Goncharov, DA; Eszterhas, A; Panettieri, RA				Krymskaya, VP; Goncharova, EA; Ammit, AJ; Lim, PN; Goncharov, DA; Eszterhas, A; Panettieri, RA			Src is necessary and sufficient for human airway smooth muscle cell proliferation and migration	FASEB JOURNAL			English	Article						asthma; airway remodeling; COPD	PROTEIN-KINASE PATHWAY; TYROSINE KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; C-SRC; ACTIVATION; FAMILY; STIMULATION; HOMEOSTASIS; MECHANISMS	Airway smooth muscle (ASM) hypertrophy and hyperplasia, important pathological features in chronic severe asthma, likely contribute to irreversible airflow obstruction. Despite considerable research effort, the precise cellular mechanisms that modulate ASM growth remain unknown. Src, a nonreceptor tyrosine kinase proto-oncogene, reportedly modulates cell proliferative responses to growth factors, contractile agonists, and inflammatory mediators. Here, we show that Src activation is required for human ASM mitogenesis and motility. Platelet-derived growth factor ( PDGF), epidermal growth factor (EGF), and thrombin induce rapid activation of Src, and inhibition of Src induces a concentration-dependent abrogation of PDGF-, EGF-, and thrombin-induced ASM cell proliferation. Src immunoprecipitates had associated phosphatidylinositol 3-kinase, or PI3K, activation in response to PDGF and thrombin but not EGF. Further, Src activation is both necessary and sufficient for the stimulation of DNA synthesis as demonstrated by dominant negative Src inhibition of PDGF-, EGF-, and thrombin-induced DNA synthesis. Human ASM cell migration was also attenuated by transfection of cells with dominant negative Src. Further, expression of constitutively active Src promoted cell migration. Collectively, these data demonstrate that Src modulates human ASM cell proliferation and migration, suggesting that Src may play an important role in promoting ASM cell growth and migration that occur in airway remodeling found in asthma and chronic obstructive pulmonary disease, or COPD.	Univ Penn, Pulm Allergy & Crit Care Div, Dept Med, Philadelphia, PA 19104 USA; Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	University of Pennsylvania; University of Sydney	Krymskaya, VP (corresponding author), Univ Penn, Pulm Allergy & Crit Care Div, Dept Med, 421 Curie Blvd,BRB II III, Philadelphia, PA 19104 USA.	krymskay@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019	Ammit, Alaina/0000-0003-0555-2544	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067663, R01HL064063, R01HL055301, R01HL071106, P50HL067663] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071106, HL55301, HL67663, HL071106, R01 HL064063, R01 HL055301, P01 HL067663, P50 HL067663, HL64063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ammit AJ, 1999, AM J RESP CELL MOL, V21, P719, DOI 10.1165/ajrcmb.21.6.3731; Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; Amrani Y, 1997, AM J PHYSIOL-LUNG C, V273, pL1020, DOI 10.1152/ajplung.1997.273.5.L1020; Billington CK, 2003, RESP RES, V4; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Condliffe A M, 2000, Respir Res, V1, P24, DOI 10.1186/rr8; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hershenson MB, 1999, AM J RESP CELL MOL, V21, P651, DOI 10.1165/ajrcmb.21.6.f168; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Krymskaya VP, 2001, AM J PHYSIOL-LUNG C, V280, pL1009, DOI 10.1152/ajplung.2001.280.5.L1009; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V276, pL246, DOI 10.1152/ajplung.1999.276.2.L246; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Orsini MJ, 1999, AM J PHYSIOL-LUNG C, V277, pL479, DOI 10.1152/ajplung.1999.277.3.L479; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Sayeski PP, 2003, EXP CELL RES, V287, P339, DOI 10.1016/S0014-4827(03)00154-X; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsang F, 2002, BIOCHEM BIOPH RES CO, V293, P72, DOI 10.1016/S0006-291X(02)00170-5; Weber DS, 2004, CIRC RES, V94, P1219, DOI 10.1161/01.RES.0000126848.54740.4A; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V281, pC709, DOI 10.1152/ajpcell.2001.281.2.C709	36	70	76	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					428	+		10.1096/fj.04-2869fje	http://dx.doi.org/10.1096/fj.04-2869fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15746183				2022-12-28	WOS:000226091000009
J	Cerpa, WF; Barria, MI; Chacon, MA; Suazo, M; Gonzalez, M; Opazo, C; Bush, AI; Inestrosa, NC				Cerpa, WF; Barria, MI; Chacon, MA; Suazo, M; Gonzalez, M; Opazo, C; Bush, AI; Inestrosa, NC			The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu2+ neurotoxicity in vivo	FASEB JOURNAL			English	Article						water maze; intracerebral injection	ALZHEIMERS-DISEASE; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; NEURITE OUTGROWTH; OXIDATIVE STRESS; SCIATIC-NERVE; APP; PEROXYNITRITE; REDUCTION	The amyloid precursor protein (APP) contains a Cu binding domain (CuBD) localized between amino acids 135 and 156 (APP(135-156)), which can reduce Cu2+ to Cu1+ in vitro. The physiological function of this APP domain has not yet being established; nevertheless several studies support the notion that the CuBD of APP is involved in Cu homeostasis. We used APP synthetic peptides to evaluate their protective properties against Cu2+ neurotoxicity in a bilateral intra-hippocampal injection model. We found that human APP135-156 protects against Cu2+-induced neurotoxic effects, such as, impairment of spatial memory, neuronal cell loss, and astrogliosis. APP135-156 lacking two histidine residues showed protection against Cu2+; however, APP135-156 mutated in cysteine 144, a key residue in the reduction of Cu2+ to Cu1+, did not protect against Cu2+ neurotoxicity. In accordance with recent reports, the CuBD of the Caenorhabditis elegans, APL-1 protected against Cu2+ neurotoxicity in vivo. We also found that Cu2+ neurotoxicity is associated with an increase in nitrotyrosine immunofluorescence as well as with a decrease in Cu2+ uptake. The CuBD of APP therefore may play a role in the detoxification of brain Cu.	Pontificia Univ Catolica Chile, FONDAP, Biomed Ctr,Gac Ciencias Biol, Ctr Regulac Celular & Patol Joaquin V Luco, Santiago, Chile; Univ Chile, Inst Nutr & Tecnol Alimentos, Santiago 11, Chile; Mental Hlth Res Inst Victoria, Parkville, Vic 3010, Australia; Harvard Univ, Genet & Aging Res Unit, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA	Pontificia Universidad Catolica de Chile; Universidad de Chile; Harvard University; Massachusetts General Hospital	Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, FONDAP, Biomed Ctr,Gac Ciencias Biol, Ctr Regulac Celular & Patol Joaquin V Luco, Alameda 340, Santiago, Chile.	ninestr@genes.bio.puc.cl	Bush, Ashley/Y-2457-2019; Cerpa, Waldo/GSI-5204-2022; Gonzalez, Mauricio/I-2772-2013; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Cerpa, Waldo/0000-0001-7344-0144; Bush, Ashley I/0000-0001-8259-9069; Opazo, Carlos/0000-0003-3473-7548; Barria, Maria/0000-0001-6225-5971; Gonzalez Canales, Mauricio Alejandro/0000-0002-1592-9758				ALVAREZ J, 1992, NEUROSCI LETT, V144, P130, DOI 10.1016/0304-3940(92)90733-N; ALVAREZ J, 1995, EUR J NEUROSCI, V7, P152, DOI 10.1111/j.1460-9568.1995.tb01029.x; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Chacon MA, 2003, MOL PSYCHIATR, V8, P853, DOI [10.1038/sj.mp.4001400, 10.1038/sj.mp.4001414]; Chacon MA, 2003, J NEUROCHEM, V87, P195, DOI 10.1046/j.1471-4159.2003.01985.x; Cote S.L., 1993, IMMUNOCYTOCHEMISTRY; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; MANDEL RJ, 1989, EXP NEUROL, V104, P208, DOI 10.1016/0014-4886(89)90031-9; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Moreno RD, 1996, BRAIN RES, V718, P13, DOI 10.1016/0006-8993(95)01555-8; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ruiz FH, 1999, J NEUROCHEM, V73, P1288, DOI 10.1046/j.1471-4159.1999.0731288.x; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tohgi H, 1999, NEUROSCI LETT, V269, P52, DOI 10.1016/S0304-3940(99)00406-1; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	42	31	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1701	+		10.1096/fj.03-1349fje	http://dx.doi.org/10.1096/fj.03-1349fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345692				2022-12-28	WOS:000224243200045
J	Kim, S; Jeon, BS; Heo, C; Im, PS; Ahn, TB; Seo, JH; Kim, HS; Park, CH; Choi, SH; Cho, SH; Lee, WJ; Suh, YH				Kim, S; Jeon, BS; Heo, C; Im, PS; Ahn, TB; Seo, JH; Kim, HS; Park, CH; Choi, SH; Cho, SH; Lee, WJ; Suh, YH			alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocytes in Parkinson's disease	FASEB JOURNAL			English	Article						glucocorticoid receptor; reactive oxygen species; GC	DEXAMETHASONE-INDUCED APOPTOSIS; BLOOD MONONUCLEAR-CELLS; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; NEURONAL CELLS; WILD-TYPE; DEATH; PROTEIN; SYSTEM	Though the etiology of Parkinson's disease (PD) remains unclear, alpha-synuclein (alpha-SN) is regarded as a major causative agent of PD. Several lines of evidence indicate that immunological abnormalities are associated with PD for unknown reasons. The present study was performed to assess whether peripheral blood mononuclear cells (PBMCs) show altered alpha-SN expression in PD patients and to identify its functions, which may be related to peripheral immune abnormalities in PD. alpha-SN was found to be expressed more in 151 idiopathic PD (IPD) patients than in 101 healthy controls, who nevertheless showed as age-dependent increases. By in vitro transfection, alpha-SN expression was shown to be correlated with glucocorticoid sensitive apoptosis, possibly caused by the enhanced expression of glucocorticoid receptor (GR), caspase activations (caspase-8, caspase-9), CD95 up-regulation, and reactive oxygen species (ROS) production. An understanding of the correlation between alpha-SN levels and apoptosis in the presence of the coordinated involvement of multiple processes would provide an insight into the molecular basis of the disease. The present study provides a clue that the alpha-SN may be one of the primary causes of the immune abnormalities observed in PD and offers new targets for pharmacotherapeutic intervention.	Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia &, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Neurol, Clin Res Inst, Seoul 10799, South Korea; Seoul Natl Univ Hosp, MRC, Seoul 10799, South Korea; Kyung Hee Univ Hosp, Dept Neurol, Seoul 130702, South Korea; Seoul Natl Univ, Coll Med, Dept Anat, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Kyung Hee University; Kyung Hee University Hospital; Seoul National University (SNU)	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia &, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Kim, Hye Sun/J-2752-2012; Jeon, Beom Seok/J-2788-2012; Suh, Yoo-Hun/J-2761-2012; Lee, Wang Jae/J-5586-2012					Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Bas J, 2001, J NEUROIMMUNOL, V113, P146, DOI 10.1016/S0165-5728(00)00422-7; Bessler H, 1999, BIOMED PHARMACOTHER, V53, P141, DOI 10.1016/S0753-3322(99)80079-1; BORHI R, 2000, NEUROSCI LETT, V287, P65; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; COHEN JJ, 1984, J IMMUNOL, V132, P38; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Czonkowska A, 2002, MED SCI MONITOR, V8, P165; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; ELANAF OM, 1998, FEBS LETT, V440, P71; Ferrer I, 2000, NEUROPATH APPL NEURO, V26, P424, DOI 10.1046/j.1365-2990.2000.00267.x; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; GALVIN JE, 2001, EXPETL NEUROL, V168, P147; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Glasson B. I., 2000, SCIENCE, V290, P985; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; GOEDERT M, 1998, MOL PSYCHIATR, V8, P871; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hasegawa Y, 2000, ACTA NEUROL SCAND, V101, P159, DOI 10.1034/j.1600-0404.2000.101003159.x; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V237, P611, DOI 10.1006/bbrc.1997.6978; Hashimoto M, 1999, BRAIN PATHOL, V9, P707; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hisanaga K, 2001, ARCH NEUROL-CHICAGO, V58, P1580, DOI 10.1001/archneur.58.10.1580; Hong L, 1998, NEUROREPORT, V9, P1239, DOI 10.1097/00001756-199804200-00051; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Ko LW, 2000, J NEUROCHEM, V75, P2546, DOI 10.1046/j.1471-4159.2000.0752546.x; Kobayashi H, 2003, BRAIN, V126, P32, DOI 10.1093/brain/awg010; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lev N, 2003, PROG NEURO-PSYCHOPH, V27, P245, DOI 10.1016/S0278-5846(03)00019-8; Marchetti MC, 2003, BLOOD, V101, P585, DOI 10.1182/blood-2002-06-1779; MIGLIORATI G, 1993, BLOOD, V81, P1352; Mizuno Y, 1998, ANN NEUROL, V44, pS99, DOI 10.1002/ana.410440715; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143; Newton CJ, 2001, J ENDOCRINOL, V169, P249, DOI 10.1677/joe.0.1690249; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Robertson NM, 1997, CANCER RES, V57, P43; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Sanner SM, 2002, STEROIDS, V67, P715, DOI 10.1016/S0039-128X(02)00024-7; Schmidt M, 1999, J IMMUNOL, V163, P3484; Schmidt M, 2001, J IMMUNOL, V166, P1344, DOI 10.4049/jimmunol.166.2.1344; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sherer TB, 2002, J NEUROSCI, V22, P7006; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P14, DOI 10.1007/PL00007400; Wandinger KP, 1999, J NEUROIMMUNOL, V98, P214, DOI 10.1016/S0165-5728(99)00093-4; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zourlidou A, 2003, NEUROSCI LETT, V340, P234, DOI 10.1016/S0304-3940(03)00081-8	66	65	67	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1615	+		10.1096/fj.04-1917fje	http://dx.doi.org/10.1096/fj.04-1917fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289452				2022-12-28	WOS:000223554900020
J	Tzavara, ET; Bymaster, FP; Davis, RJ; Wade, MR; Perry, KW; Wess, J; McKinzie, DL; Felder, C; Nomikos, GG				Tzavara, ET; Bymaster, FP; Davis, RJ; Wade, MR; Perry, KW; Wess, J; McKinzie, DL; Felder, C; Nomikos, GG			M-4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies	FASEB JOURNAL			English	Article						acetylcholine; microdialysis; dopamine; psychostimulants	VENTRAL TEGMENTAL AREA; STRIATAL DOPAMINE; SUBSTANTIA-NIGRA; ACETYLCHOLINE-RELEASE; GLUTAMATE RECEPTORS; NUCLEUS-ACCUMBENS; MESSENGER-RNAS; GABA RELEASE; STIMULATION; MODULATION	Dopaminergic dysfunction is an important pathogenetic factor for brain pathologies such as Parkinson's disease, ADHD, schizophrenia, and addiction as well as for metabolic disorders and anorexia. Dopaminergic neurons projecting from the midbrain to forebrain regions, such as the nucleus accumbens and the prefrontal cortex, regulate motor and cognitive functions and coordinate the patterned response of the organism to sensory, affective, and rewarding stimuli. In this study, we showed that dopaminergic neurotransmission is highly dependent on M-4 cholinergic muscarinic receptor function. Using in vivo microdialysis, we found elevated dopamine (DA) basal values and enhanced DA response to psychostimulants in the nucleus accumbens of M-4 knockout mice. We also demonstrated impaired homeostatic control of cholinergic activity that leads to increased basal acetylcholine efflux in the midbrain of these animals. Thus, loss of M-4 muscarinic receptor control of cholinergic function effectuates a state of dopaminergic hyperexcitability. This may be responsible for pathological conditions, in which appetitive motivation as well as affective and cognitive processing is impaired. We propose that M-4 receptor agonists could represent an innovative strategy for the treatment of pathologies associated with hyperdopaminergia.	Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA; NIDDKD, Bioorgan Chem Lab, Bethesda, MD 20892 USA	Eli Lilly; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Nomikos, GG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, DC0510, Indianapolis, IN 46285 USA.	gnomikos@lilly.com		Felder, Christian/0000-0003-1134-8881	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basile AS, 2002, P NATL ACAD SCI USA, V99, P11452, DOI 10.1073/pnas.162371899; BERNARD V, 1992, J NEUROSCI, V12, P3591; Bodick NC, 1997, ARCH NEUROL-CHICAGO, V54, P465, DOI 10.1001/archneur.1997.00550160091022; Bymaster FP, 2002, CNS NEUROL DISORD-DR, V1, P163, DOI 10.2174/1568007024606249; Calabresi P, 2000, TRENDS NEUROSCI, V23, P120, DOI 10.1016/S0166-2236(99)01501-5; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Chapman CA, 1997, NEUROSCIENCE, V76, P177; DAMSMA G, 1988, LIFE SCI, V43, P1161, DOI 10.1016/0024-3205(88)90475-4; DEBELLEROCHE J, 1978, BRAIN RES, V142, P53, DOI 10.1016/0006-8993(78)90176-2; DICHIARA G, 1994, TRENDS NEUROSCI, V17, P228, DOI 10.1016/0166-2236(94)90005-1; Felder CC, 2001, LIFE SCI, V68, P2605, DOI 10.1016/S0024-3205(01)01059-1; Fink-Jensen A, 1998, NEUROREPORT, V9, P3481, DOI 10.1097/00001756-199810260-00027; Forster GL, 2000, EUR J NEUROSCI, V12, P3596, DOI 10.1046/j.1460-9568.2000.00250.x; Forster GL, 2003, EUR J NEUROSCI, V17, P751, DOI 10.1046/j.1460-9568.2003.02511.x; Forster GL, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0001.2002; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Garzon M, 2000, J COMP NEUROL, V419, P32, DOI 10.1002/(SICI)1096-9861(20000327)419:1<32::AID-CNE2>3.0.CO;2-O; Gerber DJ, 2001, P NATL ACAD SCI USA, V98, P15312, DOI 10.1073/pnas.261583798; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Heidbreder CA, 1996, SYNAPSE, V24, P182, DOI 10.1002/(SICI)1098-2396(199610)24:2<182::AID-SYN10>3.0.CO;2-0; Iannazzo L, 2000, NEUROSCI LETT, V287, P129, DOI 10.1016/S0304-3940(00)01163-0; Ince E, 1997, SYNAPSE, V27, P357, DOI 10.1002/(SICI)1098-2396(199712)27:4<357::AID-SYN9>3.0.CO;2-B; Izurieta-Sanchez P, 2000, EUR J PHARMACOL, V399, P151, DOI 10.1016/S0014-2999(00)00353-8; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; Jones CK, 2000, J PHARMACOL EXP THER, V294, P1017; KAYADJANIAN H, 1994, NEUROSCIENCE, V63, P989, DOI 10.1016/0306-4522(94)90567-3; Kitai ST, 1999, CURR OPIN NEUROBIOL, V9, P690, DOI 10.1016/S0959-4388(99)00040-9; LEHMANN J, 1983, NEUROSCIENCE, V10, P1105, DOI 10.1016/0306-4522(83)90102-1; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; Lokwan SJA, 1999, NEUROSCIENCE, V92, P245, DOI 10.1016/S0306-4522(98)00748-9; Maviel T, 2003, NEUROSCIENCE, V120, P1049, DOI 10.1016/S0306-4522(03)00403-2; McGinty JF, 1999, ANN NY ACAD SCI, V877, P129, DOI 10.1111/j.1749-6632.1999.tb09265.x; OAKMAN SA, 1995, J NEUROSCI, V15, P5859; Perry KW, 1997, J NEURAL TRANSM, V104, P953, DOI 10.1007/BF01285563; RAITERI M, 1984, J PHARMACOL EXP THER, V228, P209; Rasmussen T, 2000, EUR J PHARMACOL, V402, P241, DOI 10.1016/S0014-2999(00)00442-8; Roth MT, 1996, NEUROREPORT, V7, P3069, DOI 10.1097/00001756-199611250-00055; Shannon HE, 2000, SCHIZOPHR RES, V42, P249, DOI 10.1016/S0920-9964(99)00138-3; Shippenberg TS, 1999, PSYCHOPHARMACOLOGY, V147, P33, DOI 10.1007/s002130051138; Smolders I, 1997, J NEUROCHEM, V68, P1942; Stanhope KJ, 2001, J PHARMACOL EXP THER, V299, P782; Sugaya K, 1997, MOL BRAIN RES, V50, P305, DOI 10.1016/S0169-328X(97)00199-X; Tandon R, 1999, BRIT J PSYCHIAT, V174, P7, DOI 10.1192/S0007125000293586; Tzavaral ET, 2003, MOL PSYCHIATR, V8, P673, DOI 10.1038/sj.mp.4001270; VILARO MT, 1994, MOL BRAIN RES, V21, P30, DOI 10.1016/0169-328X(94)90375-1; WEINER DM, 1990, P NATL ACAD SCI USA, V87, P7050, DOI 10.1073/pnas.87.18.7050; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Westerink BHC, 1996, J NEUROSCI, V16, P2605; XU M, 1989, BRAIN RES, V495, P232, DOI 10.1016/0006-8993(89)90217-5; Yan Z, 2001, NEUROSCIENCE, V103, P1017, DOI 10.1016/S0306-4522(01)00039-2; YEOMANS JS, 1995, NEUROPSYCHOPHARMACOL, V12, P3, DOI 10.1016/0893-133X(94)00054-4; Zhang WL, 2002, J NEUROSCI, V22, P6347	54	121	130	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1410	+		10.1096/fj.04-1575fje	http://dx.doi.org/10.1096/fj.04-1575fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231726				2022-12-28	WOS:000222979200020
J	Bauer, DE; Harris, MH; Plas, DR; Lum, JJ; Hammerman, PS; Rathmell, JC; Riley, JL; Thompson, CB				Bauer, DE; Harris, MH; Plas, DR; Lum, JJ; Hammerman, PS; Rathmell, JC; Riley, JL; Thompson, CB			Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand	FASEB JOURNAL			English	Article						growth factor; interleukin-3; glucose metabolism; cell size	FACTOR-INDEPENDENT SURVIVAL; GLUCOSE-METABOLISM; CARBOHYDRATE-METABOLISM; KINASE; GROWTH; LYMPHOCYTES; ACTIVATION; AKT; PHYTOHAEMAGGLUTININ; EXPRESSION	The relationship between growth factor-dependent cell growth and proliferation and the up-regulation of cellular metabolism required to support these processes remains poorly defined. Here, we demonstrate that cell growth, proliferation, and glucose metabolism are coordinately regulated by interleukin-3 (IL-3) in cytokine-dependent cells. Surprisingly, glycolytic activity is stimulated to a greater extent than would be expected based on the rate of cell growth or proliferation. IL-3 signaling exerts a direct effect on glycolytic commitment independent of cell growth control. These results are not restricted to IL-3 as the cytokines IL-7 and IL-2 have similar effects on glucose metabolism when assayed in factor-dependent cell lines or primary lymphocytes, respectively. Growth factor stimulation leads cells to consume less oxygen and produce more lactate per glucose, indicative of conversion from oxidative to glycolytic metabolism. The enforced rate of glucose metabolism is in excess of that required to support cell growth; accordingly, if extracellular glucose is reduced, cells retain the ability to grow and proliferate by derepressing oxidative metabolism. These data suggest that the high rate of glycolysis observed in response to growth factor stimulation is a primary effect rather than a homeostatic response to increased cell growth.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu		Lum, Julian/0000-0002-5624-3541; Riley, James/0000-0002-1057-576X	NCI NIH HHS [R01 CA105463, K01 CA091905, K01 CA91905-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA091905, R01CA105463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; COOPER EH, 1963, BRIT J HAEMATOL, V9, P101, DOI 10.1111/j.1365-2141.1963.tb05446.x; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; CULVENOR JG, 1976, BIOCHIM BIOPHYS ACTA, V437, P354, DOI 10.1016/0304-4165(76)90005-2; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; GUPPY M, 1995, BRIT J HAEMATOL, V91, P752, DOI 10.1111/j.1365-2141.1995.tb05381.x; Guthridge MA, 1998, STEM CELLS, V16, P301, DOI 10.1002/stem.160301; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEDESKOV CJ, 1968, BIOCHEM J, V110, P373, DOI 10.1042/bj1100373; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; Koebmann BJ, 2002, J BACTERIOL, V184, P3909, DOI 10.1128/JB.184.14.3909-3916.2002; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krauss S, 2000, FASEB J, V14, P2581, DOI 10.1096/fj.00-0064com; KUTCHAI H, 1984, AM J PHYSIOL, V247, P107; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Parry RV, 2003, J IMMUNOL, V171, P166, DOI 10.4049/jimmunol.171.1.166; Peuchen S, 1996, NEUROSCIENCE, V71, P855, DOI 10.1016/0306-4522(95)00480-7; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Riley JL, 2001, J IMMUNOL, V166, P4943, DOI 10.4049/jimmunol.166.8.4943; ROOS D, 1970, BIOCHIM BIOPHYS ACTA, V222, P565, DOI 10.1016/0304-4165(70)90182-0; SAGONE AL, 1974, CELL IMMUNOL, V14, P443, DOI 10.1016/0008-8749(74)90195-6; Salway J.G., 2017, METABOLISM GLANCE; SAPICO V, 1970, J BIOL CHEM, V245, P3252; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VOET D, 2002, FUNDAMENTALS BIOCHEM; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; WILSON JE, 1989, PREP BIOCHEM, V19, P13, DOI 10.1080/10826068908544893	40	130	137	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1303	+		10.1096/fj.03-1001fje	http://dx.doi.org/10.1096/fj.03-1001fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180958	Green Accepted			2022-12-28	WOS:000222327500028
J	Bonten, EJ; Wang, DN; Toy, JN; Mann, L; Mignardot, A; Yogalingam, G; d'Azzo, A				Bonten, EJ; Wang, DN; Toy, JN; Mann, L; Mignardot, A; Yogalingam, G; d'Azzo, A			Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis	FASEB JOURNAL			English	Article						lysosomal storage diseases; reticuloendothelial system; PPCA	HUMAN ALPHA-GLUCOSIDASE; PROTECTIVE PROTEIN; INSECT CELLS; MOUSE MODEL; GAUCHER-DISEASE; MURINE MODEL; BONE-MARROW; NEURAMINIDASE; EXPRESSION; MUTATIONS	Lysosomal storage diseases (LSDs) are monogenic disorders of metabolism caused by deficiency of hydrolytic enzymes. In several LSDs, cells of the reticuloendothelial (RE) system are the primary targets of the disease. Exogenous administration of recombinant enzymes overproduced in mammalian cells has proved effective for treating the systemic phenotype in nonneuropathic patients with LSDs. However, for the treatment of diseases with primary involvement of the RE system, the production of the therapeutic enzyme in insect cells could be an alternative and advantageous method because glycoproteins expressed in insect cells carry carbohydrates of the pauci-mannose or core-type. These recombinant enzymes are in principle already poised to be internalized by cells that express mannose receptors, including macrophages. Here, we demonstrate that three baculovirus-expressed enzymes, protective protein/cathepsin A (PPCA), neuraminidase (Neu1), and beta-glucosidase, were readily taken up and restored lysosomal function in enzyme-deficient mouse macrophages. The capacity of recombinant PPCA and Neu1 to clear the lysosomal storage in target cells was assessed in PPCA(-/-) mice, a model of galactosialidosis. Intravenously injected PPCA(-/-) mice efficiently internalized the corrective enzymes in resident macrophages of many organs. In addition, treated mice showed overall clearance of lysosomal storage in the most affected systemic organs, kidney, liver, and spleen. Our results suggest that ERT with baculovirus-expressed enzymes might be an effective treatment for nonneuropathic patients with galactosialidosis and possibly for others with LSDs that primarily involve the RE system.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	d'Azzo, A (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Mail Stop 331,332 N Lauderdale St, Memphis, TN 38105 USA.	alessandra.dazzo@stjude.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060950] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52025] Funding Source: Medline; NIGMS NIH HHS [GM-60950] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; Altmann F, 1997, GLYCOCONJUGATE J, V14, P643, DOI 10.1023/A:1018548812675; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; Bijvoet AGA, 1998, HUM MOL GENET, V7, P1815, DOI 10.1093/hmg/7.11.1815; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bonten EJ, 2000, J BIOL CHEM, V275, P37657, DOI 10.1074/jbc.M007380200; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; Bonten EJ, 2000, HUM MOL GENET, V9, P2715, DOI 10.1093/hmg/9.18.2715; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; d'Azzo A., 2002, WILEY ENCY MOL MED, P2624; DIEHL AME, 1999, SCHIFFS DIS LIVER, V1, P39; Downs-Kelly E, 2000, J MOL NEUROSCI, V15, P251, DOI 10.1385/JMN:15:3:251; Dunder U, 2000, FASEB J, V14, P361, DOI 10.1096/fasebj.14.2.361; GALBRAITH D, 2002, BIOPROCESSING J, V1, P47; Galjaard H., 1980, GENETIC METABOLIC DI; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; Grabowski GA, 1998, BLOOD REV, V12, P115, DOI 10.1016/S0268-960X(98)90023-6; Jarvis DL, 1998, CURR OPIN BIOTECH, V9, P528, DOI 10.1016/S0958-1669(98)80041-4; Kakkis ED, 2001, MOL GENET METAB, V72, P199, DOI 10.1006/mgme.2000.3140; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; Liu YJ, 1998, P NATL ACAD SCI USA, V95, P2503, DOI 10.1073/pnas.95.5.2503; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Miranda SRP, 2000, GENE THER, V7, P1768, DOI 10.1038/sj.gt.3301300; NEUFELD EF, 1970, SCIENCE, V169, P141, DOI 10.1126/science.169.3941.141; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; ONO T, 1990, ANAL BIOCHEM, V187, P324, DOI 10.1016/0003-2697(90)90464-K; Paku S, 2001, AM J PATHOL, V158, P1313, DOI 10.1016/S0002-9440(10)64082-5; PARK CM, 1991, ACTA RADIOL, V32, P34; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; RAO MS, 1991, AM J PATHOL, V139, P1111; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; Sands MS, 2001, J BIOL CHEM, V276, P43160, DOI 10.1074/jbc.M107778200; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; SKLAR MD, 1985, J CELL PHYSIOL, V125, P403, DOI 10.1002/jcp.1041250307; Sly W S, 1978, Prog Clin Biol Res, V23, P547; Takahashi K, 1998, CELL TISSUE RES, V292, P311, DOI 10.1007/s004410051062; Van den Hout H, 2000, LANCET, V356, P397, DOI 10.1016/S0140-6736(00)02533-2; Van den Hout JMP, 2001, J INHERIT METAB DIS, V24, P266, DOI 10.1023/A:1010383421286; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Yu WH, 2000, MOL GENET METAB, V71, P573, DOI 10.1006/mgme.2000.3095; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	45	37	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					971	+		10.1096/fj.03-0941fje	http://dx.doi.org/10.1096/fj.03-0941fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084520				2022-12-28	WOS:000221108800009
J	Basoni, C; Nobles, M; Grimshaw, A; Desgranges, C; Davies, D; Perretti, M; Kramer, IM; Genot, E				Basoni, C; Nobles, M; Grimshaw, A; Desgranges, C; Davies, D; Perretti, M; Kramer, IM; Genot, E			Inhibitory control of TGF-beta 1 on the activation of Rap1, CD11b, and transendothelial migration of leukocytes	FASEB JOURNAL			English	Article						monocytes; endothelium; integrins; Epac; atherosclerosis	GROWTH-FACTOR-BETA; CELL-LINE U-937; VASCULAR ENDOTHELIUM; ADHESION MOLECULE-1; MAC-1 CD11B/CD18; HUMAN PLATELETS; HUMAN MONOCYTES; INTEGRIN MAC-1; LIPID LESIONS; SMALL GTPASE	beta 2-Integrins are a family of dimeric adhesion molecules expressed on leukocytes. Their capacity to bind ligand is regulated by their state of activation. CD11b, an alpha M beta 2 integrin, is implicated in a number of physiological and pathological events such as inflammation, thrombosis, or atherosclerosis. The GTPase Rap1 is essential for its activation and could therefore play a strategic role in the regulation of leukocyte functioning. Because low levels of circulating TGF-beta have been linked with severe atherosclerosis, we have assessed the role of this cytokine in the regulation of Rap1 and CD11b activation in differentiated U937 cells and in human peripheral blood monocytes. TGF-beta 1 caused a significant reduction in the expression of CD11b but not in the expression of other integrins tested. More importantly, TGF-beta 1 greatly reduced the capacity of PMA or chemokines to activate CD11b and Rap 1, a phenomenon paralleled by a loss of the Epac transcript and a reduction in 8-pCPT-2'-O-Me-cAMP-mediated activation of Rap1. This inhibition diminished the capacity of monocytes to migrate across a monolayer of endothelial cells. The inhibitory effect of TGF-beta 1 on Rap1 activity may exert a general protective influence against aberrant transendothelial migration, thereby holding inflammatory responses in check.	INSERM, U441, F-33600 Pessac, France; European Inst Chem & Biol, Mol & Cellular Biol Sect, F-33600 Pessac, France; UCL, Rayne Inst, Dept Med, London WC1E 6BT, England; Univ London Imperial Coll Sci & Technol, Kennedy Inst, London W8 8LH, England; Canc Res UK, London WC2A 3PX, England; Barts & London Queen Marys Sch Med & Dent, Dept Biochem Pharmacol, London E1 2AD, England	Institut National de la Sante et de la Recherche Medicale (Inserm); University of London; King's College London; University College London; Imperial College London; University of Oxford; Cancer Research UK; University of London; Queen Mary University London	Kramer, IM (corresponding author), Univ Bordeaux 1, INSERM, European Inst Chem & Biol, U441, Ave Fac, F-33405 Talence, France.	i.kramer@iecb.u-bordeaux.fr	Genot, Elisabeth/G-8031-2014	Davies, Derek/0000-0002-6977-4181				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fantuzzi L, 1999, BLOOD, V94, P875, DOI 10.1182/blood.V94.3.875.415k28_875_883; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GAMBLE JR, 1993, J IMMUNOL, V150, P4494; GOMPERTS BD, 2002, SIGNAL TRANSDUCTION; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Grainger DJ, 2000, J CELL SCI, V113, P2355; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; GRAINGER DJ, 1995, CLIN CHIM ACTA, V235, P11, DOI 10.1016/0009-8981(94)05995-4; Grainger DJ, 2000, CYTOKINE GROWTH F R, V11, P133, DOI 10.1016/S1359-6101(99)00037-4; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KELSEY SM, 1992, LEUKEMIA RES, V16, P427, DOI 10.1016/0145-2126(92)90167-6; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; MEERSCHAERT J, 1995, J IMMUNOL, V154, P4099; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; OLSSON I, 1983, CANCER RES, V43, P5862; OLSSON IL, 1982, CANCER RES, V42, P3928; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Smith WB, 1996, J IMMUNOL, V157, P360; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tachimoto H, 2000, J IMMUNOL, V165, P2748, DOI 10.4049/jimmunol.165.5.2748; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Wheller SK, 1997, EUR J PHARMACOL, V331, P65, DOI 10.1016/S0014-2999(97)01015-7; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; Zicha D, 1999, J CELL SCI, V112, P447	54	32	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					822	+		10.1096/fj.04-3085fje	http://dx.doi.org/10.1096/fj.04-3085fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746186				2022-12-28	WOS:000227901300027
J	Reid, B; Song, B; McCaig, CD; Zhao, M				Reid, B; Song, B; McCaig, CD; Zhao, M			Wound healing in rat cornea: the role of electric currents	FASEB JOURNAL			English	Article						cornea epithelium; vibrating probe; electric field	CHLORIDE TRANSPORT; DIRECTED MIGRATION; EPITHELIAL-CELLS; FROG CORNEA; FIELDS; STIMULATION; SODIUM; REGENERATION; ORIENTATION; INHIBITION	Human corneal epithelial cells respond rapidly following injury to restore the integrity of the ocular surface. What stimulates and guides cells to move into the wound to heal? One candidate is the wound-induced electric field. Using vibrating probe techniques, we provide detailed temporal and spatial mapping of endogenous electric currents at rat corneal wounds. We find Cl- and Na+ are the major components of electric currents in rat corneal wounds. Na+ is the major component of ionic transport in the resting (nonwounded) rat cornea and of the wound center leakage current, whereas Cl- is a more important component of the endogenous electrical current at the wound edges. Enhancing or decreasing Cl- flow with clinically approved pharmacological agents such as aminophylline, ascorbic acid, or furosemide increased or decreased endogenous wound electric currents, respectively. These changes in wound currents correlated directly with the rate of wound healing in vivo. Thus, pharmacologically enhancing or decreasing wound-induced electric currents increased and decreased wound healing rate, respectively. This may have wide-reaching and novel therapeutic potential in the management of wound healing and may help explain some mechanistic aspects of the effects of some clinically used agents.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk	McCaig, Colin/B-1774-2010; Song, Bing/AAB-4755-2021	Song, Bing/0000-0001-9356-2333	Wellcome Trust [068012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altizer AM, 2002, J EXP ZOOL, V293, P467, DOI 10.1002/jez.10141; BECKER RO, 1972, NATURE, V235, P109, DOI 10.1038/235109a0; BORGENS RB, 1977, P NATL ACAD SCI USA, V74, P4528, DOI 10.1073/pnas.74.10.4528; BORGENS RB, 1984, J EXP ZOOL, V231, P249, DOI 10.1002/jez.1402310209; CANDIA OA, 1968, BIOCHIM BIOPHYS ACTA, V163, P262, DOI 10.1016/0005-2736(68)90105-3; CHIANG M, 1991, DEV BIOL, V146, P377, DOI 10.1016/0012-1606(91)90239-Y; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; FOULDS IS, 1983, BRIT J DERMATOL, V109, P515, DOI 10.1111/j.1365-2133.1983.tb07673.x; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; Illingworth C. M., 1980, Clinical Physics and Physiological Measurement, V1, P87, DOI 10.1088/0143-0815/1/1/007; JAFFE LF, 1979, J EXP ZOOL, V209, P115, DOI 10.1002/jez.1402090114; KLYCE SD, 1972, J PHYSIOL-LONDON, V226, P407, DOI 10.1113/jphysiol.1972.sp009991; KLYCE SD, 1977, J PHYSIOL-LONDON, V266, P777, DOI 10.1113/jphysiol.1977.sp011793; KLYCE SD, 1975, AM J PHYSIOL, V228, P1446, DOI 10.1152/ajplegacy.1975.228.5.1446; MAURICE DM, 1967, EXP EYE RES, V6, P138, DOI 10.1016/S0014-4835(67)80065-4; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; MCGAHAN MC, 1982, BIOCHIM BIOPHYS ACTA, V689, P385, DOI 10.1016/0005-2736(82)90273-5; Nishimura KY, 1996, J CELL SCI, V109, P199; Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070-2153(03)58001-2; Nuccitelli R., 1988, ADV CELL BIOL, V2, P213, DOI DOI 10.1016/S1569-2558(08)60435-X; Ojingwa JC, 2003, J INVEST DERMATOL, V121, P1, DOI 10.1046/j.1523-1747.2003.12454.x; PATARCA R, 1983, AM J PHYSIOL, V245, pF660, DOI 10.1152/ajprenal.1983.245.6.F660; Robinson KR, 2003, BIOESSAYS, V25, P759, DOI 10.1002/bies.10307; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; SOONG HK, 1990, INVEST OPHTH VIS SCI, V31, P2278; Sta Iglesia Drina D., 1998, Wound Repair and Regeneration, V6, P531; VANDERHEYDEN C, 1975, EXP EYE RES, V20, P89, DOI 10.1016/0014-4835(75)90111-6; WIGHAM CG, 1994, PFLUG ARCH EUR J PHY, V428, P577, DOI 10.1007/BF00374580; WOLOSIN JM, 1991, AM J PHYSIOL, V261, pC857, DOI 10.1152/ajpcell.1991.261.5.C857; ZADUNAISKY JA, 1973, EXP EYE RES, V15, P577, DOI 10.1016/0014-4835(73)90069-9; ZADUNAISKY JA, 1966, AM J PHYSIOL, V211, P506, DOI 10.1152/ajplegacy.1966.211.2.506; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1996, INVEST OPHTH VIS SCI, V37, P2548; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942	36	128	135	2	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					379	386		10.1096/fj.04-2325com	http://dx.doi.org/10.1096/fj.04-2325com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746181	Green Accepted			2022-12-28	WOS:000227901300038
J	Wang, Q; Woltjer, RL; Cimino, PJ; Pan, C; Montine, KS; Zhang, J; Montine, TJ				Wang, Q; Woltjer, RL; Cimino, PJ; Pan, C; Montine, KS; Zhang, J; Montine, TJ			Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein	FASEB JOURNAL			English	Article						neurodegeneration; laser capture microdissection; liquid chromatography mass spectrometry	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ALPHA-SYNUCLEIN; LESIONS	We performed proteomic analysis of neurofibrillary tangles (NFTs) obtained by laser capture microdissection from pyramidal neurons in hippocampal sector CA1 in patients with Alzheimer disease (AD) using liquid chromatography (LC)-mass spectrometry (MS)/MS. We discovered a total of 155 proteins in laser captured NFT's, 72 of which were identified by multiple unique peptides. Of these 72 proteins, 63 had previously unknown association with NFTs; one of these was glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We validated by immunohistochemistry that GAPDH colocalized with the majority of NFTs as well as plaque-like structures in AD brain and was coimmunoprecipitated by antibodies to abnormal forms of tau in AD, but not tau from AD temporal cortex. Characterization of GAPDH showed that it, along with phosphorylated tau and A beta peptides, was present in detergent-insoluble fractions from AD temporal cortex but not from age-matched controls. These data are the first proteomic investigation of NFTs. Moreover, our results validate this approach by demonstrating that GAPDH, a glycolytic and microtubule binding protein, not only co-localized to NFTs and immunoprecipitated with PHF-tau, but also is one of the few proteins known to undergo conversion to a detergent-insoluble form in AD.	Univ Washington, Harborview Med Ctr, Sch Med,Dept Pathol, Div Neuropathol, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Montine, TJ (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med,Dept Pathol, Div Neuropathol, Box 359660, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Cimino, P.J./0000-0003-0441-4502; Montine, Kathleen/0000-0003-2110-8363	NIA NIH HHS [AG22040, AG05144, AG05136, AG24011] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005136, P50AG005144, K01AG022040, R01AG024011] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Caligiuri G, 1999, ATHEROSCLEROSIS, V145, P301, DOI 10.1016/S0021-9150(99)00081-7; Fend F, 1999, AM J PATHOL, V154, P61, DOI 10.1016/S0002-9440(10)65251-0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Levy-Lahad E, 1998, J GERIATR PSYCH NEUR, V11, P42, DOI 10.1177/089198879801100202; Lia LJ, 2004, J BIOL CHEM, V279, P37061, DOI 10.1074/jbc.M403672200; LOWE JS, 2002, GREENFIELDS NEUROPAT, V2, P325; Mazzola JL, 2003, J NEUROSCI RES, V71, P279, DOI 10.1002/jnr.10484; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; ZHANG J, IN PRESS NEUROBIOL A; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200	16	152	160	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					869	+		10.1096/fj.04-3210fje	http://dx.doi.org/10.1096/fj.04-3210fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746184				2022-12-28	WOS:000227901300030
J	Dan, Z; Popov, Y; Patsenker, E; Preimel, D; Liu, C; Wang, XD; Seitz, HK; Schuppan, D; Stickel, F				Dan, Z; Popov, Y; Patsenker, E; Preimel, D; Liu, C; Wang, XD; Seitz, HK; Schuppan, D; Stickel, F			Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential	FASEB JOURNAL			English	Article						alcoholic liver disease; cytochrome P4502E1; hypervitaminosis A; mitochondrial damage; vitamin A	ETHANOL-INDUCED APOPTOSIS; BETA-CAROTENE; VITAMIN-A; PERMEABILITY TRANSITION; CYTOCHROME P-4502E1; ACID CONCENTRATION; RAT HEPATOCYTES; LIVER-INJURY; C-JUN; CARCINOGENESIS	Chronic alcohol consumption depletes hepatic vitamin A stores. However, vitamin A supplementation is hepatotoxic,which is further potentiated by concomitant alcohol consumption. It was suggested that polar retinol metabolites generated by alcohol-inducible cytochrome P4502E1 aggravate liver damage. However, experimental evidence supporting this hypothesis is lacking. To elucidate the effects of polar retinol metabolites on cultured HepG2 cells and primary rat hepatocytes, polar retinol metabolites were extracted from liver tissues of rats fed either an alcoholic or isocaloric control Lieber-DeCarli diet. Cell toxicity assays included morphology assessment, trypan blue exclusion test,and LDH/AST leakage. Staining for DAPI and acridine orange, FACS analysis, and Western blot for cleaved caspase-9 and-3 were used to detect apoptosis. Polar retinol metabolites caused marked cytotoxicity in a concentration- and time-dependent manner in both cell types reflected by morphological changes, a dramatic increase in trypan blue positive cells, and LDH/AST leakage. Toxicity was due to apoptosis, as demonstrated by a time-dependent increase of sub-G1 cellular events,a rapid loss of mitochondrial membrane potential, and a time-dependent activation of caspase-9 and-3. No toxicity was found with equivalent doses of the control extract from nonalcoholic rats. We demonstrate that polar retinol metabolites cause marked hepatocyte death through the induction of apoptosis.	Univ Heidelberg, Salem Med Ctr, Dept Med, Lab Alcohol Res & Liver Dis, D-69121 Heidelberg, Germany; Univ Erlangen Nuremberg, Dept Med 1, Lab Liver Res, Erlangen, Germany; Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gastroenterol, Wuhan 430074, Peoples R China; Tufts Univ, Human Nutr Res Ctr Aging, Nutr & Canc Biol Lab, Boston, MA 02111 USA	Ruprecht Karls University Heidelberg; University of Erlangen Nuremberg; Huazhong University of Science & Technology; Tufts University; United States Department of Agriculture (USDA)	Stickel, F (corresponding author), Univ Heidelberg, Salem Med Ctr, Dept Med, Lab Alcohol Res & Liver Dis, Zeppelinstr 11-33, D-69121 Heidelberg, Germany.	felix.stickel@stadtmission-hd.de	Popov, Yury V./A-7781-2008	Popov, Yury V./0000-0001-7973-942X				Adachi M, 2002, FREE RADICAL BIO MED, V32, P487, DOI 10.1016/S0891-5849(02)00740-2; Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; Badger TM, 2003, ALCOHOL CLIN EXP RES, V27, P336, DOI 10.1097/01.ALC.0000052583.87673.37; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Chung JG, 2001, CARCINOGENESIS, V22, P1213, DOI 10.1093/carcin/22.8.1213; Chung JY, 2002, ONCOGENE, V21, P1539, DOI 10.1038/sj.onc.1205023; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Crabb DW, 2001, ALCOHOL CLIN EXP RES, V25, p207S, DOI 10.1097/00000374-200105051-00034; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; Eguchi Y, 1997, CANCER RES, V57, P1835; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; Higuchi H, 2001, HEPATOLOGY, V34, P320, DOI 10.1053/jhep.2001.26380; Kessova IG, 2001, ALCOHOL CLIN EXP RES, V25, P1368, DOI 10.1111/j.1530-0277.2001.tb02360.x; LEO MA, 1992, HEPATOLOGY, V15, P883, DOI 10.1002/hep.1840150522; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Leo MA, 1997, AM J CLIN NUTR, V66, P1461, DOI 10.1093/ajcn/66.6.1461; Lieber CS, 1999, ALCOHOL CLIN EXP RES, V23, P991, DOI 10.1111/j.1530-0277.1999.tb04217.x; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Liu C, 2002, ALCOHOL CLIN EXP RES, V26, P1703, DOI 10.1097/01.ALC.0000037135.09289.69; Liu C, 2001, GASTROENTEROLOGY, V120, P179, DOI 10.1053/gast.2001.20877; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MINUK GY, 1988, HEPATOLOGY, V8, P272, DOI 10.1002/hep.1840080214; Neuman MG, 2002, ALCOHOL, V28, P117, DOI 10.1016/S0741-8329(02)00243-4; Neuman MG, 1999, CLIN BIOCHEM, V32, P547, DOI 10.1016/S0009-9120(99)00054-5; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pastorino JG, 1999, BIOCHEM BIOPH RES CO, V265, P405, DOI 10.1006/bbrc.1999.1696; Patek AJ, 1939, J CLIN INVEST, V18, P609, DOI 10.1172/JCI101075; RUSSELL RM, 1974, NEW ENGL J MED, V291, P435, DOI 10.1056/NEJM197408292910903; SEGLEN PO, 1979, J TOXICOL ENV HEALTH, V5, P551, DOI 10.1080/15287397909529766; Seitz H. K., 2002, Nutritional toxicology, P122; Stickel F, 2003, ALIMENT PHARM THER, V18, P357, DOI 10.1046/j.1365-2036.2003.01660.x; Stickel F, 2002, GUT, V51, P132, DOI 10.1136/gut.51.1.132; Wang XD, 1998, HEPATOLOGY, V28, P744, DOI 10.1002/hep.510280321; WORNER TM, 1988, AM J CLIN NUTR, V48, P1431, DOI 10.1093/ajcn/48.6.1431; Wu DF, 1999, ALCOHOL CLIN EXP RES, V23, P67	38	49	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					845	+		10.1096/fj.04-2809fje	http://dx.doi.org/10.1096/fj.04-2809fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15731294				2022-12-28	WOS:000227591900005
J	Turner, NA; O'Regan, DJ; Ball, SG; Porter, KE				Turner, NA; O'Regan, DJ; Ball, SG; Porter, KE			Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels	FASEB JOURNAL			English	Article						statins; signal transduction pathways; matrix metalloproteinase-9	HMG-COA REDUCTASE; IV COLLAGENASE EXPRESSION; ARTERY BYPASS GRAFTS; NITRIC-OXIDE; MATRIX-METALLOPROTEINASE-9 EXPRESSION; DEGRADING METALLOPROTEINASES; NEOINTIMA FORMATION; MONONUCLEAR-CELLS; CAROTID-ARTERY; IN-VIVO	Increased matrix metalloproteinase-9 (MMP-9) expression is associated with intimal hyperplasia in saphenous vein (SV) bypass grafts. Recent evidence suggests that HMG-CoA reductase inhibitors (statins) can prevent the progression of vein graft failure. Here we investigated whether statins inhibited MMP-9 secretion from cultured human SV smooth muscle cells (SMC) and examined the underlying mechanisms. SV-SMC from different patients were exposed to phorbol ester (TPA) or PDGF-BB plus interleukin- 1 alpha (IL-1). MMP-9 secretion and mRNA expression were analyzed using gelatin zymography and RT-PCR, respectively. Specific signal transduction pathways were investigated by immunoblotting and pharmacological inhibition. Simvastatin reduced TPA- and PDGF/IL-1-induced MMP-9 secretion and mRNA levels, effects reversed by geranylgeranyl pyrophosphate and mimicked by inhibiting Rho geranylgeranylation or Rho-kinase ( ROCK). MMP-9 secretion induced by PDGF/IL-1 was mediated via the ERK, p38 MAPK, and NF kappa B pathways, whereas that induced by TPA was mediated specifically via the ERK pathway. Simvastatin failed to inhibit activation of these signaling pathways. Moreover, simvastatin did not affect MMP-9 mRNA stability. Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England; Leeds Gen Infirm, Yorkshire Heart Ctr, Dept Cardiac Surg, Leeds, W Yorkshire, England	University of Leeds; Leeds General Infirmary; University of Leeds	Porter, KE (corresponding author), Univ Leeds, Inst Cardiovasc Res, Worsley Bldg, Leeds LS2 9JT, W Yorkshire, England.	medkep@leeds.ac.uk		Turner, Neil/0000-0002-4957-5433				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Amin ARMR, 2003, GENES CELLS, V8, P515, DOI 10.1046/j.1365-2443.2003.00652.x; ANGELINI GD, 1989, EUR HEART J, V10, P273, DOI 10.1093/oxfordjournals.eurheartj.a059476; Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; Campeau L, 1997, NEW ENGL J MED, V336, P153; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; Chong PH, 2002, ANN PHARMACOTHER, V36, P1907, DOI 10.1345/aph.1C116; Christenson JT, 2001, AM J CARDIOL, V88, P896, DOI 10.1016/S0002-9149(01)01901-4; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20; Doggrell SA, 2001, EXPERT OPIN INV DRUG, V10, P1755, DOI 10.1517/13543784.10.9.1755; Dotani MI, 2000, AM J CARDIOL, V86, P1128, DOI 10.1016/S0002-9149(00)01172-3; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Flaker GC, 1999, J AM COLL CARDIOL, V34, P106, DOI 10.1016/S0735-1097(99)00145-X; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; George SJ, 1997, CARDIOVASC RES, V33, P447, DOI 10.1016/S0008-6363(96)00211-8; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607; Igarashi M, 1997, BRIT J PHARMACOL, V120, P1172, DOI 10.1038/sj.bjp.0701018; Indolfi C, 2000, J AM COLL CARDIOL, V35, P214, DOI 10.1016/S0735-1097(99)00526-4; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Kamiyama Masumi, 2003, J Atheroscler Thromb, V10, P117; Kraynack NC, 2002, AM J PHYSIOL-LUNG C, V283, pL604, DOI 10.1152/ajplung.00459.2001; Leville CD, 2000, J SURG RES, V90, P183, DOI 10.1006/jsre.2000.5887; Luan ZX, 2003, ARTERIOSCL THROM VAS, V23, P769, DOI 10.1161/01.ATV.0000068646.76823.AE; Negre-Aminou P, 2001, BIOCHEM PHARMACOL, V61, P991, DOI 10.1016/S0006-2952(01)00566-4; Noa M, 2001, PHARMACOL RES, V43, P31, DOI 10.1006/phrs.2000.0736; Ortego M, 1999, ATHEROSCLEROSIS, V147, P253, DOI 10.1016/S0021-9150(99)00193-8; Ortego M, 2002, EUR J PHARMACOL, V448, P113, DOI 10.1016/S0014-2999(02)01938-6; PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41; Porter KE, 2004, CARDIOVASC RES, V61, P745, DOI 10.1016/j.cardiores.2003.11.032; Porter KE, 2002, J VASC SURG, V36, P150, DOI 10.1067/mva.2002.122029; Porter KE, 2002, BIOCHEM SOC T, V30, P120, DOI 10.1042/bst0300120; Porter KE, 1998, BRIT J SURG, V85, P1373; Porter KE, 1999, EUR J VASC ENDOVASC, V17, P404, DOI 10.1053/ejvs.1998.0761; Sessa WC, 2001, TRENDS MOL MED, V7, P189, DOI 10.1016/S1471-4914(01)01985-2; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; Southgate KM, 1999, ARTERIOSCL THROM VAS, V19, P1640, DOI 10.1161/01.ATV.19.7.1640; Suma H, 1999, Ann Thorac Cardiovasc Surg, V5, P141; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Turner NA, 2003, CARDIOVASC RES, V57, P784, DOI 10.1016/S0008-6363(02)00729-0; Turner NA, 2001, CELL SIGNAL, V13, P269, DOI 10.1016/S0898-6568(01)00135-8; Viedt C, 2003, BASIC RES CARDIOL, V98, P353, DOI 10.1007/s00395-003-0437-4; von Haehling S, 2003, HEART FAIL REV, V8, P99, DOI 10.1023/A:1022103222857; Wang IK, 2000, ONCOLOGY-BASEL, V59, P245, DOI 10.1159/000012168; Werba JP, 2003, ANN THORAC SURG, V76, P2132, DOI 10.1016/S0003-4975(03)00820-8; Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000; Yamakawa Tadashi, 2003, J Atheroscler Thromb, V10, P37	53	122	134	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					804	+		10.1096/fj.04-2852fje	http://dx.doi.org/10.1096/fj.04-2852fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15728660				2022-12-28	WOS:000227591900007
J	Del Bas, JM; Fernandez-Larrea, J; Blay, M; Ardevol, A; Salvado, MJ; Arola, L; Blade, C				Del Bas, JM; Fernandez-Larrea, J; Blay, M; Ardevol, A; Salvado, MJ; Arola, L; Blade, C			Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats	FASEB JOURNAL			English	Article						red wine; cholesterol; triglycerides; microarrays; lipoprotein lipase; apoB	LOW-DENSITY-LIPOPROTEIN; SMALL HETERODIMER PARTNER; APOLIPOPROTEIN A-II; ORPHAN NUCLEAR RECEPTOR; FARNESOID-X-RECEPTOR; TRIGLYCERIDE-RICH LIPOPROTEINS; BILE-ACID SYNTHESIS; RED WINE; C-III; PLASMA-LIPIDS	Moderate consumption of red wine reduces risk of death from cardiovascular disease. The polyphenols in red wine are ultimately responsible for this effect, exerting antiatherogenic actions through their antioxidant capacities and modulating intracellular signaling pathways and transcriptional activities. Lipoprotein metabolism is crucial in atherogenesis, and liver is the principal organ controlling lipoprotein homeostasis. This study was intended to identify the primary effects of procyanidins, the most abundant polyphenols in red wine, on both plasma lipoprotein profile and the expression of genes controlling lipoprotein homeostasis in the liver. We show that procyanidins lowered plasma triglyceride, free fatty acids, apolipoprotein B ( apoB), LDL-cholesterol and nonHDL: nonLDL-cholesterol levels and slightly increased HDL-cholesterol. Liver mRNA levels of small heterodimer partner ( SHP), cholesterol 7alpha-hydroxylase (CYP7A1), and cholesterol biosynthetic enzymes increased, whereas those of apoAII, apoCI, and apoCIII decreased. Lipoprotein lipase (LPL) mRNA levels increased in muscle and decreased in adipose tissue. In conclusion, procyanidins improve the atherosclerotic risk index in the postprandial state, inducing in the liver the overexpression of CYP7A1 ( suggesting an increase of cholesterol elimination via bile acids) and SHP, a nuclear receptor emerging as a key regulator of lipid homeostasis at the transcriptional level. These results could explain, at least in part, the beneficial long-term effects associated with moderate red wine consumption.	Univ Rovira & Virgili, CeRTA, Dept Bioquim & Biotecnol, Tarragona 43005, Spain	Universitat Rovira i Virgili	Blade, C (corresponding author), Univ Rovira & Virgili, CeRTA, Dept Bioquim & Biotecnol, Pl Imperial Tarraco 1, Tarragona 43005, Spain.	mcbs@astor.urv.es	del Bas, Josep M/K-2327-2014; Blay, Mayte Dr/B-1680-2009; del Bas, Josep Maria/K-9310-2019; Salvado, M. Josepa/B-6062-2015; Arola, Lluís/C-6074-2011; Ardévol, Anna/AAO-6194-2021	del Bas, Josep M/0000-0002-0700-2004; Blay, Mayte Dr/0000-0002-6256-9847; del Bas, Josep Maria/0000-0002-0700-2004; Salvado, M. Josepa/0000-0003-3883-3326; Arola, Lluís/0000-0003-2767-1974; Ardévol, Anna/0000-0003-0156-7538; Blade, Cinta/0000-0003-2838-2402; Fernandez-Larrea, Juan Bautista/0000-0001-8007-8040				AaltoSetala K, 1996, J LIPID RES, V37, P1802; Auger C, 2002, J NUTR, V132, P1207, DOI 10.1093/jn/132.6.1207; Aviram M, 2002, ANN NY ACAD SCI, V957, P146, DOI 10.1111/j.1749-6632.2002.tb02913.x; Bagchi DB, 2003, MUTAT RES-FUND MOL M, V523, P87, DOI 10.1016/S0027-5107(02)00324-X; BarrettConnor E, 1997, MATURITAS, V27, P261, DOI 10.1016/S0378-5122(97)00041-8; BATESON MC, 1978, BRIT J CLIN PHARMACO, V5, P249, DOI 10.1111/j.1365-2125.1978.tb01632.x; Bays H, 2003, EXPERT OPIN PHARMACO, V4, P1901, DOI 10.1517/14656566.4.11.1901; Blanco-Vaca F, 2001, J LIPID RES, V42, P1727; Boisfer E, 1999, J BIOL CHEM, V274, P11564, DOI 10.1074/jbc.274.17.11564; Borradaile NM, 2003, DIABETES, V52, P2554, DOI 10.2337/diabetes.52.10.2554; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Buchwald H, 2001, ATHEROSCLEROSIS, V154, P221, DOI 10.1016/S0021-9150(00)00467-6; CARULLI N, 1981, J CLIN PHARMACOL, V21, P436, DOI 10.1002/j.1552-4604.1981.tb01746.x; Cascon E, 2001, LIPIDS, V36, P383, DOI 10.1007/s11745-001-0732-6; Chiang JYL, 2004, J HEPATOL, V40, P539, DOI 10.1016/j.jhep.2003.11.006; Cui J, 2003, J BIOL CHEM, V278, P10214, DOI 10.1074/jbc.M209323200; Davis RA, 2002, J LIPID RES, V43, P533; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; DELLAGLI M, IN PRESS CARDIOVASC; DRAEGER B, 1985, METHOD ENZYMAT AN, P148; Duran-Sandoval D, 2004, DIABETES, V53, P890, DOI 10.2337/diabetes.53.4.890; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANKEL EN, 1995, J AGR FOOD CHEM, V43, P890, DOI 10.1021/jf00052a008; Fremont L, 2000, LIPIDS, V35, P991, DOI 10.1007/s11745-000-0610-2; FUHRMAN B, 1995, AM J CLIN NUTR, V61, P549, DOI 10.1093/ajcn/61.3.549; GIBSON DM, 2002, METABOLIC REGULATION, P87; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gottardis MM, 1996, CANCER RES, V56, P5566; Haubenwallner S, 1995, J LIPID RES, V36, P2541; Hui TY, 2002, J LIPID RES, V43, P785; Hung CCC, 2003, DIABETES, V52, P1288, DOI 10.2337/diabetes.52.5.1288; Iijima K, 2000, CIRCULATION, V101, P805, DOI 10.1161/01.CIR.101.7.805; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; IKEWAKI K, 1995, ARTERIOSCL THROM VAS, V15, P306, DOI 10.1161/01.ATV.15.3.306; Ikewaki K, 1996, J LIPID RES, V37, P399; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jong MC, 1996, J CLIN INVEST, V98, P2259, DOI 10.1172/JCI119036; Jong MC, 1998, J CLIN INVEST, V101, P145, DOI 10.1172/JCI791; KANNER J, 1994, J AGR FOOD CHEM, V42, P64, DOI 10.1021/jf00037a010; Kassam A, 2001, MOL CELL ENDOCRINOL, V176, P49, DOI 10.1016/S0303-7207(01)00475-0; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KERSCHER L, 1985, METHOD ENZYMAT AN, P154; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; Lai KD, 2003, J BIOL CHEM, V278, P36418, DOI 10.1074/jbc.M303913200; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lew JL, 2004, J BIOL CHEM, V279, P8856, DOI 10.1074/jbc.M306422200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Mann Laura B, 2004, Pathophysiology, V10, P105, DOI 10.1016/j.pathophys.2003.10.011; Marcoux C, 2001, METABOLISM, V50, P112, DOI 10.1053/meta.2001.19452; Miyake JH, 2002, ARTERIOSCL THROM VAS, V22, P121, DOI 10.1161/hq0102.102588; Mohan R, 2003, CURR TOP MED CHEM, V3, P1637, DOI 10.2174/1568026033451709; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nigdikar SV, 1998, AM J CLIN NUTR, V68, P258, DOI 10.1093/ajcn/68.2.258; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Pal S, 2004, INT J OBESITY, V28, P324, DOI 10.1038/sj.ijo.0802577; Pal S, 2003, J NUTR, V133, P700, DOI 10.1093/jn/133.3.700; Pandak WM, 2001, GASTROENTEROLOGY, V120, P1801, DOI 10.1053/gast.2001.24833; Pandak WM, 2001, AM J PHYSIOL-GASTR L, V281, pG878, DOI 10.1152/ajpgi.2001.281.4.G878; Pinent M, 2004, ENDOCRINOLOGY, V145, P4985, DOI 10.1210/en.2004-0764; Plonne D, 2001, J LIPID RES, V42, P1865; Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8; Redinger RN, 2003, J LAB CLIN MED, V142, P7, DOI 10.1016/S0022-2143(03)00088-X; Redinger RN, 2003, AM J SURG, V185, P168, DOI 10.1016/S0002-9610(02)01212-6; RENAUD S, 1993, ANN NY ACAD SCI, V686, P299, DOI 10.1111/j.1749-6632.1993.tb39191.x; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Roig P, 1999, LIFE SCI, V64, P1517, DOI 10.1016/S0024-3205(99)00088-0; Rosenkranz S, 2002, FASEB J, V16, P1958, DOI 10.1096/fj.02-0207fje; Shachter NS, 2001, CURR OPIN LIPIDOL, V12, P297, DOI 10.1097/00041433-200106000-00009; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; STOCKS J, 1979, LANCET, V2, P667; Truelsen T, 1998, STROKE, V29, P2467, DOI 10.1161/01.STR.29.12.2467; Urizar NL, 2003, ANNU REV NUTR, V23, P303, DOI 10.1146/annurev.nutr.23.011702.073102; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; Valsa A. K., 1998, Indian Journal of Physiology and Pharmacology, V42, P286; van't Hooft FM, 2001, CIRCULATION, V104, P1223, DOI 10.1161/hc3601.095709; Vinson JA, 2001, ATHEROSCLEROSIS, V156, P67, DOI 10.1016/S0021-9150(00)00625-0; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; Wang DQH, 2003, AM J PHYSIOL-GASTR L, V285, pG494, DOI 10.1152/ajpgi.00156.2003; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Weng W, 1996, P NATL ACAD SCI USA, V93, P14788, DOI 10.1073/pnas.93.25.14788; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Yamakoshi J, 2002, FOOD CHEM TOXICOL, V40, P599, DOI 10.1016/S0278-6915(02)00006-6; Yee WL, 2002, MOL CELL BIOCHEM, V229, P85, DOI 10.1023/A:1017920527201	92	154	160	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					479	+		10.1096/fj.04-3095fje	http://dx.doi.org/10.1096/fj.04-3095fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15637110				2022-12-28	WOS:000226576600030
J	Nieddu, E; Melchiori, A; Pescarolo, MP; Bagnasco, L; Biasotti, B; Licheri, B; Malacarne, D; Tortolina, L; Castagnino, N; Pasa, S; Cimoli, G; Avignolo, C; Ponassi, R; Balbi, C; Patrone, E; D'Arrigo, C; Barboro, P; Vasile, F; Orecchia, P; Carnemolla, B; Damonte, G; Millo, E; Palomba, D; Fassina, G; Mazzei, M; Parodi, S				Nieddu, E; Melchiori, A; Pescarolo, MP; Bagnasco, L; Biasotti, B; Licheri, B; Malacarne, D; Tortolina, L; Castagnino, N; Pasa, S; Cimoli, G; Avignolo, C; Ponassi, R; Balbi, C; Patrone, E; D'Arrigo, C; Barboro, P; Vasile, F; Orecchia, P; Carnemolla, B; Damonte, G; Millo, E; Palomba, D; Fassina, G; Mazzei, M; Parodi, S			Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc	FASEB JOURNAL			English	Article						D-peptides; protein-protein contacts; growth inhibition; structural studies	SECONDARY STRUCTURE; CELL-GROWTH; DNA; INTERNALIZATION; RECOGNITION; COMPLEX; DOMAIN	Our work is focused in the broad area of strategies and efforts to inhibit protein - protein interactions. The possible strategies in this field are definitely much more varied than in the case of ATP-pocket inhibitors. In our previous work ( 10), we reported that a retro-inverso ( RI) form of Helix1 (H1) of c-Myc, linked to an RI-internalization sequence arising from the third alpha-helix of Antennapedia (Int) was endowed with an antiproliferative and proapoptotic activity toward the cancer cell lines MCF-7 and HCT-116. The activity apparently was dependent upon the presence of the Myc motif. In this work, by ala-scan mapping of the H1 portion of our molecules with Daa, we found two amino acids necessary for antiproliferative activity: D-Lys in 4 and D-Arg in 5 ( numbers refer to L-forms). In the natural hetero-dimer, these two side chains project to the outside of the four alpha-helix bundle. Moreover, we were able to obtain three peptides more active than the original lead. They strongly reduced cell proliferation and survival (RI-Int-VV-H1-E2A, S6A, F8A; RI-Int-VV-H1-S6A, F8A, R11A; RI-Int-VV-H1-S6A, F8A, Q13A): after 8 days at 10 muM total cell number was similar to 1% of the number of cells initially seeded. In these more potent molecules, the ablated side chains project to the inside in the corresponding natural four alpha-helix bundle. In the present work, we also investigated the behavior of our molecules at the biochemical level. Using both a circular dichroism (CD) and a fluorescence anisotropy approach, we noted that side chains projecting at the interior of the four alpha-helix bundle are needed for inducing the partial unfolding of Myc-H2, without an opening of the leucine zipper. Side chains projecting at the outside are not required for this biochemical effect. However, antiproliferative activity had the opposite requirements: side chains projecting at the outside of the bundle were essential, and, on the contrary, ablation of one side chain at a time projecting at the inside increased rather than decreased biological activity. We conclude that our active molecules probably interfere at the level of a protein - protein interaction between Myc-Max and a third protein of the transcription complex. Finally, CD and nuclear magnetic resonance (NMR) data, plus dynamic simulations, suggest a prevalent random coil conformation of the H1 portion of our molecules, at least in diluted solutions. The introduction of a kink ( substitution with proline in positions 5 or 7) led to an important reduction of biological activity. We have also synthesized a longer peptido-mimetic molecule (RI-Int-H1-S6A, F8A-loop-H2) with the intent of obtaining a wider zone of interaction and a stronger interference at the level of the higher-order structure (enhanceosome). RI-Int-H1-S6A, F8A-loop-H2 was less active rather than more active in respect to RI-Int-VV-H1-S6A, F8A, apparently because it has a clear bent to form a - sheet ( CD and NMR data).	Univ Genoa, Dept Pharmaceut Sci, I-16132 Genoa, Italy; Natl Canc Inst, Expt Oncol Lab, Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; Inst Study Macromol, Genoa Sect, Genoa, Italy; Univ Genoa, Dept Biophys Sci & Technol, Genoa, Italy; Natl Canc Inst, Cell Biol Lab, Genoa, Italy; Inst Giannina Gaslini, Genoa, Italy; Ctr Excellence Biomed Res, Dept Expt Med, Biochem Sect, Genoa, Italy; Xeptagen SpA, Naples, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa	Nieddu, E (corresponding author), Univ Genoa, Dept Pharmaceut Sci, I-16132 Genoa, Italy.	erika.nieddu@unige.it	Millo, Enrico/K-3218-2018; orecchia, paola/AAH-3509-2019; Fassina, Giorgio/I-7127-2012; Barboro, Paola/AAE-7144-2019	Millo, Enrico/0000-0002-4019-0051; Fassina, Giorgio/0000-0003-1845-2657; Barboro, Paola/0000-0001-9074-9290; D'Arrigo, Cristina/0000-0002-5352-5287; orecchia, paola/0000-0003-0556-9784; VASILE, FRANCESCA/0000-0002-3926-8261				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BHATIA K, 1994, BLOOD, V84, P883; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cimoli G, 2001, TUMORI J, V87, pS20; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Giorello L, 1998, CANCER RES, V58, P3654; GREENFIELD N, 1967, BIOCHEMISTRY-US, V6, P1630, DOI 10.1021/bi00858a009; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Jean-Francois N, 2003, J MOL BIOL, V326, P1577, DOI 10.1016/S0022-2836(03)00029-9; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; KURT W, 2003, ENCY HUMAN GENOME, P457; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pescarolo MP, 2001, FASEB J, V15, P31; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095	24	20	22	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					632	+		10.1096/fj.04-2369fje	http://dx.doi.org/10.1096/fj.04-2369fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671156				2022-12-28	WOS:000226576600006
J	Sellers, KW; Sun, CW; Diez-Freire, C; Waki, H; Morisseau, C; Falck, JR; Hammock, BD; Paton, JF; Raizada, MK				Sellers, KW; Sun, CW; Diez-Freire, C; Waki, H; Morisseau, C; Falck, JR; Hammock, BD; Paton, JF; Raizada, MK			Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat	FASEB JOURNAL			English	Article						brain stem; baroreceptor reflex; central nervous system	ANGIOTENSIN-II; EPOXYEICOSATRIENOIC ACIDS; BARORECEPTOR REFLEX; CORONARY-ARTERIES; ARACHIDONIC-ACID; IN-VIVO; INHIBITION; ACTIVATION; EXPRESSION	The role of soluble epoxide hydrolase (sEH) in the central control of blood pressure ( BP) has not been elucidated in spite of peripheral sEH overexpression being linked to hypertension. Thus, our objective was to investigate the involvement of brain sEH in BP control. sEH expression in the hypothalamus and brain stem, two cardioregulatory brain areas, was increased in the spontaneously hypertensive rat (SHR) compared to the Wistar Kyoto (WKY) rat. Inhibition of the enzyme by intracerebroventricular (icv) delivery of AUDA further increased both BP and heart rate (HR) by 32 +/- 6 mmHg and 54 +/- 10 bpm, respectively, ( P< 0.05) in the SHR. Analysis of waveform telemetry data revealed a decrease in spontaneous baroreceptor reflex gain following sEH inhibition, indicating the sustained increase in BP may be due to a decrease in baroreceptor reflex function. The hypertensive effect of sEH inhibition is likely a result of an increase in epoxyeicosatrienoic acid (EET)-mediated generation of ROS. This view is supported by the following: 1) Inhibition of EET formation attenuates AUDA-induced increase in BP; 2) delivery of an EET agonist increases BP and HR in the WKY rat, and 3) inhibition of NAD(P)H oxidase by gp91ds-tat prevents AUDA-induced increases in BP and HR. Finally, electrophysiological studies demonstrate that AUDA increased neuronal firing rate exclusively in the SHR, an effect completely abolished by gp91ds-tat. These observations suggest that EETs and sEH inhibition are involved in increasing BP in the SHR. We suggest that an increased expression of sEH is a futile central nervous system response in protection against hypertension.	Univ Florida, Coll Med, McKnight Brain Inst, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA; Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Calif Davis, Ctr Canc, Davis, CA 95616 USA; Dept Entomol, Davis, CA USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	State University System of Florida; University of Florida; University of Bristol; University of California System; University of California Davis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Raizada, MK (corresponding author), Univ Florida, Coll Med, McKnight Brain Inst, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA.	mraizada@phys.med.ufl.edu	Paton, Julian/AAM-2121-2020; Sun, Chengwen/AAC-4522-2019	Sun, Chengwen/0000-0001-5889-8448; Falck, John/0000-0002-9219-7845; Paton, Julian/0000-0001-7410-2913; Waki, Hidefumi/0000-0002-4278-2077	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033610, R01HL056921, R37HL033610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, P30ES005707, R37ES002710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56921, HL33610] Funding Source: Medline; NIEHS NIH HHS [P30 ES05707, R37 ES02710, P42 ES04699] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brand-Schieber E, 2000, J PHYSIOL PHARMACOL, V51, P655; Campbell WB, 2002, AM J PHYSIOL-HEART C, V282, pH1656, DOI 10.1152/ajpheart.00597.2001; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Coleman JE, 2003, PHYSIOL GENOMICS, V12, P221, DOI 10.1152/physiolgenomics.00135.2002; Falck JR, 2003, AM J PHYSIOL-HEART C, V284, pH337, DOI 10.1152/ajpheart.00831.2001; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Fornage M, 2002, HYPERTENSION, V40, P485, DOI 10.1161/01.HYP.0000032278.75806.68; FROHLICH ED, 1988, J HYPERTENS, V6, pS2, DOI 10.1097/00004872-198812040-00002; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86, DOI 10.1161/01.HYP.5.1.86; GRANT DF, 1993, J BIOL CHEM, V268, P17628; Imig JD, 2002, HYPERTENSION, V39, P690, DOI 10.1161/hy0202.103788; Lindpaintner K, 1994, Curr Opin Nephrol Hypertens, V3, P30, DOI 10.1097/00041552-199401000-00004; Lohmeier TE, 2004, HYPERTENSION, V43, P306, DOI 10.1161/01.HYP.0000111837.73693.9b; LOUIS WJ, 1990, J CARDIOVASC PHARM, V16, pS1, DOI 10.1097/00005344-199006167-00002; Okuda T, 2002, BIOCHEM BIOPH RES CO, V296, P537, DOI 10.1016/S0006-291X(02)00902-6; Oosting J, 1997, J HYPERTENS, V15, P391, DOI 10.1097/00004872-199715040-00010; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; RAIZADA MK, 1995, ADV EXP MED BIOL, V377, P331; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Sinal CJ, 2000, J BIOL CHEM, V275, P40504, DOI 10.1074/jbc.M008106200; Sun CW, 2003, J NEUROPHYSIOL, V90, P3155, DOI 10.1152/jn.00222.2003; Thrasher TN, 2002, AM J PHYSIOL-REG I, V282, pR1044, DOI 10.1152/ajpregu.00431.2001; TRIPPODO NC, 1981, CIRC RES, V48, P309, DOI 10.1161/01.RES.48.3.309; Waki H, 2003, J PHYSIOL-LONDON, V546, P233, DOI 10.1113/jphysiol.2002.030270; Yang H, 2004, HYPERTENSION, V43, P324, DOI 10.1161/01.HYP.0000113045.12850.cd; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	28	51	56	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					626	+		10.1096/fj.04-3128fje	http://dx.doi.org/10.1096/fj.04-3128fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15659536				2022-12-28	WOS:000226576600019
J	Oliveira, HCF; Cosso, RG; Alberici, LC; Maciel, EN; Salerno, AG; Dorighello, GG; Velho, JA; de Faria, EC; Vercesi, AE				Oliveira, HCF; Cosso, RG; Alberici, LC; Maciel, EN; Salerno, AG; Dorighello, GG; Velho, JA; de Faria, EC; Vercesi, AE			Oxidative stress in atherosclerosis-prone mouse is due to low antioxidant capacity of mitochondria	FASEB JOURNAL			English	Article						hypercholesterolemia; LDL receptor; reactive oxygen species; mitochondria permeability transition; pyridine nucleotide oxidation	LOW-DENSITY-LIPOPROTEIN; PERMEABILITY TRANSITION; CHOLESTEROL-SYNTHESIS; PYRIDINE-NUCLEOTIDES; LIVER-MITOCHONDRIA; RECEPTOR; ATHEROGENESIS; STATE; FLUORESCENCE; GENERATION	Atherosclerotic disease remains a leading cause of death in westernized societies, and reactive oxygen species (ROS) play a pivotal role in atherogenesis. Mitochondria are the main intracellular sites of ROS generation and are also targets for oxidative damage. Here, we show that mitochondria from atherosclerosis-prone, hypercholesterolemic low-density lipoprotein (LDL) receptor knockout mice have oxidative phosphorylation efficiency similar to that from control mice but have a higher net production of ROS and susceptibility to develop membrane permeability transition. Increased ROS production was observed in mitochondria isolated from several tissues, including liver, heart, and brain, and in intact mononuclear cells from spleen. In contrast to control mitochondria, knockout mouse mitochondria did not sustain a reduced state of matrix NADPH, the main source of antioxidant defense against ROS. Experiments in vivo showed faster liver secretion rates and de novo synthesis of triglycerides and cholesterol in knockout than in control mice, suggesting that increased lipogenesis depleted the reducing equivalents from NADPH and generated a state of oxidative stress in hypercholesterolemic knockout mice. These data provide the first evidence of how oxidative stress is generated in LDL receptor defective cells and could explain the increased LDL oxidation, cell death, and atherogenesis seen in familiar hypercholesterolemia.	Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil; Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Fisiol & Biofis, BR-13083970 Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Estadual de Campinas	Vercesi, AE (corresponding author), Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil.	anibal@unicamp.br	Dorighello, Gabriel G/J-8708-2013; Salerno, Alessandro G/A-7891-2013; Alberici, Luciane C/J-3013-2015; Oliveira, Helena C. F./C-1343-2013; Vercesi, Aníbal E/C-8767-2012	Dorighello, Gabriel G/0000-0001-6566-4244; Salerno, Alessandro G/0000-0002-7688-5904; Alberici, Luciane C/0000-0002-7464-9385; Oliveira, Helena C. F./0000-0003-0119-6992; Cotta de Faria, Eliana/0000-0002-5208-1274; Vercesi, Anibal Eugenio/0000-0001-6671-7125				Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; DIETSCHY JM, 1984, J LIPID RES, V25, P1469; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gaylor JL, 2002, BIOCHEM BIOPH RES CO, V292, P1139, DOI 10.1006/bbrc.2001.2008; Gille L, 2001, ARCH BIOCHEM BIOPHYS, V388, P34, DOI 10.1006/abbi.2000.2257; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; LAMB DJ, 1992, ATHEROSCLEROSIS, V92, P187, DOI 10.1016/0021-9150(92)90277-N; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; RICCHELLI F, 1995, EUR J BIOCHEM, V233, P165, DOI 10.1111/j.1432-1033.1995.165_1.x; Skulachev VP, 2000, FREE RADICAL BIO MED, V29, P1056, DOI 10.1016/S0891-5849(00)00291-4; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STOKES J, 1987, CIRCULATION, V75, P65; VERCESI AE, 1987, ARCH BIOCHEM BIOPHYS, V252, P171, DOI 10.1016/0003-9861(87)90021-X; VINOGRADOV AD, 1972, J BIOENERG, V3, P203, DOI 10.1007/BF01515968; Voyiaziakis E, 1998, J LIPID RES, V39, P313; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Zago EB, 2000, FEBS LETT, V478, P29, DOI 10.1016/S0014-5793(00)01815-9	27	87	91	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					278	+		10.1096/fj.04-2095fje	http://dx.doi.org/10.1096/fj.04-2095fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15569776				2022-12-28	WOS:000225482100004
J	Usmani, OS; Belvisi, MG; Patel, HJ; Crispino, N; Birrell, MA; Korbonits, M; Korbonits, D; Barnes, PJ				Usmani, OS; Belvisi, MG; Patel, HJ; Crispino, N; Birrell, MA; Korbonits, M; Korbonits, D; Barnes, PJ			Theobromine inhibits sensory nerve activation and cough	FASEB JOURNAL			English	Article						vagus; methylxanthines	XANTHINE DERIVATIVE 1H-PURINE-2,6-DIONE; ANTITUSSIVE PROPERTIES; GUINEA-PIGS; CAPSAICIN; REFLEX; ASTHMA; THEOPHYLLINE; CONDUCTANCE; SENSITIVITY; CHALLENGE	Cough is a common and protective reflex, but persistent coughing is debilitating and impairs quality of life. Antitussive treatment using opioids is limited by unacceptable side effects, and there is a great need for more effective remedies. The present study demonstrates that theobromine, a methylxanthine derivative present in cocoa, effectively inhibits citric acid-induced cough in guinea-pigs in vivo. Furthermore, in a randomized, double-blind, placebo-controlled study in man, theobromine suppresses capsaicin-induced cough with no adverse effects. We also demonstrate that theobromine directly inhibits capsaicin-induced sensory nerve depolarization of guinea-pig and human vagus nerve suggestive of an inhibitory effect on afferent nerve activation. These data indicate the actions of theobromine appear to be peripherally mediated. We conclude theobromine is a novel and promising treatment, which may form the basis for a new class of antitussive drugs.	Univ London Imperial Coll Sci Technol & Med, Dept Airway Dis, Resp Pharmacol Grp, Natl Heart & Lung Inst, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England; Chinoin Co Ltd, Budapest, Hungary; St Bartholomews Hosp, Dept Endocrinol, London, England	Imperial College London; Imperial College London; Sanofi-Aventis; University of London; Queen Mary University London	Belvisi, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Airway Dis, Resp Pharmacol Grp, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	m.belvisi@imperial.ac.uk	Belvisi, Maria G/A-3055-2009	Korbonits, Marta/0000-0002-4101-9432; Barnes, Peter/0000-0002-5122-4018				BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; Birrell MA, 2002, BRIT J PHARMACOL, V136, P620, DOI 10.1038/sj.bjp.0704758; Cherry Donald K, 2003, Adv Data, P1; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; Eccles R, 1996, PULM PHARMACOL THER, V9, P293, DOI 10.1006/pulp.1996.0038; Fox AJ, 1997, J CLIN INVEST, V99, P513, DOI 10.1172/JCI119187; French CT, 2002, CHEST, V121, P1123, DOI 10.1378/chest.121.4.1123; Fujimura M, 1996, EUR RESPIR J, V9, P1624, DOI 10.1183/09031936.96.09081624; FULLER RW, 1998, J APPL PHYSIOL, V65, P1125; KALIX P, 1979, BRAIN RES, V162, P159, DOI 10.1016/0006-8993(79)90766-2; KAMEI J, 1995, METHOD FIND EXP CLIN, V17, P193; KARLSSON JA, 1993, THORAX, V48, P396, DOI 10.1136/thx.48.4.396; Klinger M, 2002, CELL SIGNAL, V14, P99, DOI 10.1016/S0898-6568(01)00235-2; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; Lalloo UG, 1998, EUR RESPIR J, V11, P702; LAUDE EA, 1993, PULM PHARMACOL, V6, P171, DOI 10.1006/pulp.1993.1023; MIDGREN B, 1992, AM REV RESPIR DIS, V146, P347, DOI 10.1164/ajrccm/146.2.347; Mikus EG, 1997, ARZNEIMITTEL-FORSCH, V47, P1358; Mikus EG, 1997, ARZNEIMITTEL-FORSCH, V47, P395; MORICE AH, 1992, EUR RESPIR J, V5, P841; Morice AH, 1996, PULM PHARMACOL THER, V9, P281, DOI 10.1006/pulp.1996.0036; Mumford GK, 1996, EUR J CLIN PHARMACOL, V51, P319, DOI 10.1007/s002280050205; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; Patel HJ, 2003, BRIT J PHARMACOL, V140, P261, DOI 10.1038/sj.bjp.0705435; Pavesi L, 2001, CHEST, V120, P1121, DOI 10.1378/chest.120.4.1121; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; SAANO V, 1993, J PHARM PHARMACOL, V45, P799, DOI 10.1111/j.2042-7158.1993.tb05688.x; SANTAMBROGIO G, 1987, ANNU REV PHYSIOL, V49, P611, DOI 10.1146/annurev.physiol.49.1.611; Schroder RL, 2000, PFLUG ARCH EUR J PHY, V440, P809, DOI 10.1007/s004240000364; Schroeder K, 2002, BRIT MED J, V324, P329, DOI 10.1136/bmj.324.7333.329; SIMONS FER, 1985, J ALLERGY CLIN IMMUN, V76, P703, DOI 10.1016/0091-6749(85)90674-8; Smith JAM, 1998, BRIT J PHARMACOL, V124, P513, DOI 10.1038/sj.bjp.0701853; Widdicombe J, 2002, PULM PHARMACOL THER, V15, P185, DOI 10.1006/pupt.2002.0354; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193	34	77	87	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					231	+		10.1096/fj.04-1990fje	http://dx.doi.org/10.1096/fj.04-1990fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15548587				2022-12-28	WOS:000225482100012
J	Suchting, S; Heal, P; Tahtis, K; Stewart, LM; Bicknell, R				Suchting, S; Heal, P; Tahtis, K; Stewart, LM; Bicknell, R			Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration	FASEB JOURNAL			English	Article						slits; roundabouts; anti-angiogenesis	TUMOR ANGIOGENESIS; SLIT PROTEINS; NEURONAL MIGRATION; VERTEBRATE SLIT; GUIDANCE; GROWTH; ROUNDABOUT; LIGAND; MORPHOGENESIS; EXPRESSION	Roundabout receptors are molecular guidance molecules that function by interaction with Slit proteins to regulate axon guidance, neuronal migration, and leukocyte chemotaxis. We recently isolated a novel roundabout gene, called Robo4, which is restricted in expression to the endothelium, notably in areas of angiogenesis. The aim of this study was to use the soluble extracellular domain of Robo4 as a probe of function in angiogenesis and endothelial biology. Thus, the soluble extracellular domain of the receptor (Robo4Fc) showed diverse in vivo and in vitro activities including 1) inhibition of angiogenesis in vivo in the rodent subcutaneous sponge model, 2) inhibition of tube formation in the rat aortic ring assay, 3) inhibition of VEGF- and bFGF-stimulated endothelial cell migration, and 4) inhibition of endothelial proliferation. To assess whether Robo4Fc was inhibiting Slit-mediated effects, we determined whether Robo4 and Slit interact. Recombinant Slits-1, -2, and -3 were shown by immunoprecipitation and BiaCore analysis to bind to Robo1 but not Robo4. Further study of the role of Robo4 in angiogenesis appears justified.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Angiogenesis Lab,Canc Res UK, Oxford OX3 9DS, England; St Bartholomews Hosp, Appl Dev Lab, London EC1A 7BE, England	Cancer Research UK; University of Oxford; University of London; Queen Mary University London	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Angiogenesis Lab,Canc Res UK, Oxford OX3 9DS, England.	roy.bicknell@cancer.org.uk	Stewart, Lauren/HHC-2911-2022	Bicknell, Roy/0000-0002-0941-8919				Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hirata T, 2001, J NEUROSCI, V21, P2373, DOI 10.1523/JNEUROSCI.21-07-02373.2001; Hivert B, 2002, MOL CELL NEUROSCI, V21, P534, DOI 10.1006/mcne.2002.1193; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Huminiecki L, 2000, GENOME RES, V10, P1796, DOI 10.1101/gr.150700; JIRAGE D, 2004, KEYST S ANG NOV BAS; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kramer SG, 2001, SCIENCE, V292, P737, DOI 10.1126/science.1058766; Krebs LT, 2000, GENE DEV, V14, P1343; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Little MH, 2001, AM J PHYSIOL-CELL PH, V281, pC486, DOI 10.1152/ajpcell.2001.281.2.C486; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Ogawa T, 2002, CANCER GENE THER, V9, P633, DOI 10.1038/sj.cgt.7700478; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Patel K, 2001, DEVELOPMENT, V128, P5031; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Shutter JR, 2000, GENE DEV, V14, P1313; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stewart LM, 1999, CANCER IMMUNOL IMMUN, V47, P299, DOI 10.1007/s002620050534; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Williams C, 2000, CURR OPIN BIOTECH, V11, P42, DOI 10.1016/S0958-1669(99)00053-1; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371	43	137	152	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					121	+		10.1096/fj.04-1991fje	http://dx.doi.org/10.1096/fj.04-1991fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15486058				2022-12-28	WOS:000224849900019
J	Maestroni, GJM				Maestroni, GJM			The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein	FASEB JOURNAL			English	Article						innate immunity; dendritic cell precursor; cytokine; CB2 cannabinoid receptor; chemotaxis	IMMUNE-SYSTEM; MIGRATION; TOLERANCE; DIFFERENTIATION; ACTIVATION; PRECURSORS; RECEPTORS; MONOCYTES; IMPACT	The decision-making mechanisms that determine the choice of the appropriate effector immune response to a microbial challenge are poorly understood. The endocannabinoid 2-arachidonoylglycerol (2-AG), injected intradermally in mice together with a soluble protein and a T helper-2 (Th2) priming Toll-like receptors (TLRs) agonist during primary immunization, shifts the memory response to the Th1 type. This effect can be shown by the enhanced hypersensitivity response and by the Th1 pattern of cytokines production that was abolished by the specific cannabinoid receptor CB2 antagonist SR 144528. 2-AG seems to operate during the innate response by increasing the number of dendritic cells (DCs) migrating to the draining lymph nodes. Expression of CB2 mRNA but not of the protein was higher in immature vs. mature DCs. Consistently, in vitro, 2-AG exerted a potent chemotactic activity on both immature and mature DCs. In conclusion, we suggest that, in vivo, the endocannabinoid 2-AG may act as chemotactic substance capable of recruiting DCs and/or their precursors during the innate immune response that, in presence of a TLR agonist, consequently instruct a Th1-shifted adaptive response. As 2-AG may be induced in tissues by various stimuli at concentrations similar to that used in our study, this evidence might be of a wide-ranging pathophysiological relevance.	Ist Cantonale Patol, Ctr Expt Pathol, CH-6601 Locarno, Switzerland		Maestroni, GJM (corresponding author), Ist Cantonale Patol, Ctr Expt Pathol, CH-6601 Locarno, Switzerland.	georges.maestroni@ti.ch	Maestroni, Georges/AAG-9117-2019					Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Ardavin C, 2003, NAT REV IMMUNOL, V3, P582, DOI 10.1038/nri1127; BURSTEIN HJ, 1993, J EXP MED, V177, P457, DOI 10.1084/jem.177.2.457; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Jorda MA, 2002, BLOOD, V99, P2786; Kalia R, 1999, COMPUT SCI ENG, V1, P2; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; Kishimoto S, 2003, J BIOL CHEM, V278, P24469, DOI 10.1074/jbc.M301359200; Klein T W, 2001, Pain Res Manag, V6, P95; Klein TW, 2004, J NEUROIMMUNOL, V147, P91, DOI 10.1016/j.jneuroim.2003.10.019; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Leon B, 2004, BLOOD, V103, P2668, DOI 10.1182/blood-2003-01-0286; Maestroni GJM, 2004, J INVEST DERMATOL, V122, P119, DOI 10.1046/j.0022-202X.2003.22132.x; Maestroni GJM, 2003, J NEUROIMMUNOL, V144, P91, DOI 10.1016/j.jneuroim.2003.08.039; Maestroni GJM, 2000, J IMMUNOL, V165, P6743, DOI 10.4049/jimmunol.165.12.6743; Matias I, 2002, EUR J BIOCHEM, V269, P3771, DOI 10.1046/j.1432-1033.2002.03078.x; Mondino A, 1996, P NATL ACAD SCI USA, V93, P2245, DOI 10.1073/pnas.93.6.2245; Niederhoffer N, 2003, N-S ARCH PHARMACOL, V367, P434, DOI 10.1007/s00210-003-0755-y; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parolaro D, 2002, PROSTAG LEUKOTR ESS, V66, P319, DOI 10.1054/plef.2001.0355; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Qi H, 2003, INFECT IMMUN, V71, P3337, DOI 10.1128/IAI.71.6.3337-3342.2003; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Van Parijs L, 1998, SCIENCE, V280, P243; Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3	27	58	58	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1914	+		10.1096/fj.04-2190fje	http://dx.doi.org/10.1096/fj.04-2190fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385435				2022-12-28	WOS:000224243200019
J	Dougherty, CJ; Kubasiak, LA; Frazier, DP; Li, HF; Xiong, WC; Bishopric, NH; Webster, KA				Dougherty, CJ; Kubasiak, LA; Frazier, DP; Li, HF; Xiong, WC; Bishopric, NH; Webster, KA			Mitochondrial signals initiate the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation	FASEB JOURNAL			English	Article						cardiac myocyte; mitochondria; Pyk2; calcium; Rac-1; ROI; apoptosis	PROTEIN-KINASE; CARDIAC MYOCYTES; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; REGULATED KINASES; REDOX-REGULATION; TYROSINE KINASE; MAP KINASES; APOPTOSIS; DEATH	C-Jun N-terminal kinase (JNK) is part of the mitogen-activated protein kinase ( MAPK) family of signaling pathways that are induced in response to extracellular stimuli. JNK is primarily a stress-response pathway and can be activated by proinflammatory cytokines and growth factors coupled to membrane receptors or through non-receptor pathways by stimuli such as heat shock, UV irradiation, protein synthesis inhibitors, and conditions that elevate the levels of reactive oxygen intermediates (ROI). The molecular initiators of MAPKs by non-receptor stimuli have not been described. Ischemia followed by reperfusion or hypoxia with reoxygenation represents a condition of high oxidative stress where JNK activation is associated with elevated ROI. We show here that the activation of JNK by this condition is initiated in the mitochondria and requires coupled electron transport, ROI generation, and calcium flux. These signals cause the selective, sequential activation of the calcium-dependent, pro-line-rich kinase Pyk2 and the small GTP binding factors Rac-1 and Cdc42. Interruption of these interactions with inactivated dominant negative mutant proteins, blocking calcium flux, or inhibiting electron transport through mitochondrial complexes II, III, or IV prevents JNK activation and results in a proapoptotic phenotype that is characteristic of JNK inhibition in this model of ischemia-reperfusion. The signaling pathway is unique for the reoxygenation stimulus and provides a framework for other non-receptor-mediated pathways of MAPK activation.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Vasc Biol Inst, Miami, FL 33136 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Miami; University of Miami; University of Alabama System; University of Alabama Birmingham	Webster, KA (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,RMSB 6038, Miami, FL 33136 USA.	kwebster@chroma.med.miami.edu		Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044578, R21HL069812, R29HL044578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69812, HL44578, HL07109] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bogoyevitch MA, 2000, J MOL CELL CARDIOL, V32, P1469, DOI 10.1006/jmcc.2000.1187; Caldefie-Chezet F, 2002, CLIN CHIM ACTA, V319, P9, DOI 10.1016/S0009-8981(02)00015-3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Cook SA, 1999, J MOL CELL CARDIOL, V31, P1429, DOI 10.1006/jmcc.1999.0979; Cortassa S, 2003, BIOPHYS J, V84, P2734, DOI 10.1016/S0006-3495(03)75079-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CZAJA MJ, 2003, AM J PHYSIOL, V184, pG875; Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461; Delcamp TJ, 1998, AM J PHYSIOL-HEART C, V275, pH484, DOI 10.1152/ajpheart.1998.275.2.H484; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Floreani M, 2000, BIOCHEM PHARMACOL, V60, P601, DOI 10.1016/S0006-2952(00)00350-6; Gottlieb RA, 2003, ARCH BIOCHEM BIOPHYS, V420, P262, DOI 10.1016/j.abb.2003.07.004; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Inanami O, 1999, ANTIOXID REDOX SIGN, V1, P501, DOI 10.1089/ars.1999.1.4-501; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kam AYF, 2003, J NEUROCHEM, V84, P503, DOI 10.1046/j.1471-4159.2003.01535.x; Kiritoshi S, 2003, DIABETES, V52, P2570, DOI 10.2337/diabetes.52.10.2570; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lukyanetz EA, 2003, ARCH BIOCHEM BIOPHYS, V410, P212, DOI 10.1016/S0003-9861(02)00682-3; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Pantano C, 2003, J BIOL CHEM, V278, P44091, DOI 10.1074/jbc.M308487200; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Seko Y, 1996, CIRC RES, V78, P82, DOI 10.1161/01.RES.78.1.82; Shao ZH, 2002, AM J PHYSIOL-HEART C, V282, pH999, DOI 10.1152/ajpheart.00163.2001; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V281, pH2113, DOI 10.1152/ajpheart.2001.281.5.H2113; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Slepak TI, 2001, J BIOL CHEM, V276, P7575, DOI 10.1074/jbc.M004625200; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; Tahara S, 2001, J AM COLL CARDIOL, V38, P1554, DOI 10.1016/S0735-1097(01)01558-3; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Waypa GB, 2002, CIRC RES, V91, P719, DOI 10.1161/01.RES.0000036751.04896.F1; Webster KA, 1999, J CLIN INVEST, V104, P239; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WEBSTER KA, 1979, J BIOENERG BIOMEMBR, V10, P23; WEBSTER KA, 1993, J MOL CELL CARDIOL, V25, P747, DOI 10.1006/jmcc.1993.1087; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; Wei S, 2001, AM J PHYSIOL-CELL PH, V281, pC1542, DOI 10.1152/ajpcell.2001.281.5.C1542; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	66	83	97	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1060	1070		10.1096/fj.04-1505com	http://dx.doi.org/10.1096/fj.04-1505com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15226266				2022-12-28	WOS:000222979200033
J	Quaranta, MG; Mattioli, B; Giordani, L; Viora, M				Quaranta, MG; Mattioli, B; Giordani, L; Viora, M			HIV-1 Nef equips dendritic cells to reduce survival and function of CD8(+) T cells: a mechanism of immune evasion	FASEB JOURNAL			English	Article						Fas ligand; tumor necrosis factor; AIDS	VIRUS TYPE-1 NEF; FAS LIGAND; DOWN-REGULATION; UP-REGULATION; DC-SIGN; CLASS-I; SIGNALING PATHWAY; INFECTED-CELLS; APOPTOSIS; PROTEIN	The accessory HIV-1 Nef protein is a crucial determinant for viral replication and pathogenesis. During HIV infection, loss of immune control in the setting of a strong and broad HIV-specific T-lymphocyte response, leads to a lethal outcome through AIDS. Moreover, dysfunction of dendritic cells (DCs) may contribute to the immune suppression associated with AIDS progression. We recently demonstrated that exogenous Nef selectively activates immature DCs manipulating their phenotypical, morphological, and functional developmental program. Here, we tracked whether Nef, targeting DCs, could be involved in the dysregulation of CD8(+) T cell responses. We found that Nef inhibits the capacity of DCs to prime alloreactive CD8(+) T cell responses down-regulating their proliferation and functional competence. This coincides with the induction of CD8(+) T cell apoptosis. Nef oversees apoptotic killing of CD8(+) T cells up-regulating TNF-alpha and FasL production by DCs and interfering with the death receptor pathway in CD8(+) T cells and thus activating caspase 8. Our findings suggest that Nef may contribute to the immune evasion associated with HIV-1 infection, subverting DC biology. This may help explain the pleiotropic function that Nef plays during infection and makes this protein an attractive target for preventive and therapeutic intervention.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	viora@iss.it		Quaranta, Maria Giovanna/0000-0002-1077-1488				Accapezzato D, 2003, ANN NY ACAD SCI, V987, P99, DOI 10.1111/j.1749-6632.2003.tb06037.x; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Andrieu M, 2001, AIDS RES HUM RETROV, V17, P1365, DOI 10.1089/08892220152596623; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; Boirivant M, 1998, J CLIN IMMUNOL, V18, P39, DOI 10.1023/A:1023235803948; BROWN CC, 1994, J INFECT DIS, V169, P975, DOI 10.1093/infdis/169.5.975; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Conti L, 2000, J IMMUNOL, V165, P3293, DOI 10.4049/jimmunol.165.6.3293; Cramer LA, 2001, J ACQ IMMUN DEF SYND, V27, P417; Dockrell DH, 1998, J CLIN INVEST, V101, P2394, DOI 10.1172/JCI1171; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Giordani L, 2000, CLIN EXP IMMUNOL, V122, P358, DOI 10.1046/j.1365-2249.2000.01388.x; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenway AL, 2003, J BIOSCIENCES, V28, P323, DOI 10.1007/BF02970151; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hosaka N, 1998, J INFECT DIS, V178, P1030, DOI 10.1086/515700; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; James CO, 2004, J VIROL, V78, P3099, DOI 10.1128/JVI.78.6.3099-3109.2004; Kaiser A, 2003, EUR J IMMUNOL, V33, P162, DOI 10.1002/immu.200390019; KALINKOVICH A, 1992, CLIN EXP IMMUNOL, V89, P351; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; LEWIS DE, 1994, J IMMUNOL, V153, P412; Lichtner M, 2004, AIDS RES HUM RETROV, V20, P175, DOI 10.1089/088922204773004897; Lieberman J, 2002, CURR OPIN IMMUNOL, V14, P478, DOI 10.1016/S0952-7915(02)00366-7; Lu GW, 2002, J IMMUNOL, V168, P1831, DOI 10.4049/jimmunol.168.4.1831; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Mosier DE, 2000, IMMUNOL RES, V21, P253, DOI 10.1385/IR:21:2-3:253; Mueller YM, 2001, IMMUNITY, V15, P871, DOI 10.1016/S1074-7613(01)00246-1; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Quaranta MG, 1999, EXP CELL RES, V250, P112, DOI 10.1006/excr.1999.4494; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497; Raftery MJ, 2001, IMMUNITY, V15, P997, DOI 10.1016/S1074-7613(01)00239-4; Rasola A, 2001, J IMMUNOL, V166, P81, DOI 10.4049/jimmunol.166.1.81; Ross TM, 2001, LEUKEMIA, V15, P332, DOI 10.1038/sj.leu.2402028; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; Suzuki S, 2000, MICROBIOL IMMUNOL, V44, P111, DOI 10.1111/j.1348-0421.2000.tb01254.x; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Teleshova N, 2003, J LEUKOCYTE BIOL, V74, P683, DOI 10.1189/jlb.0403178; Trimble LA, 1998, BLOOD, V91, P585, DOI 10.1182/blood.V91.2.585.585_585_594; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vidalain PO, 2001, IMMUNOBIOLOGY, V204, P629, DOI 10.1078/0171-2985-00102; VIORA M, 1995, CELL IMMUNOL, V163, P289, DOI 10.1006/cimm.1995.1128; VITOLO D, 1993, J IMMUNOL, V151, P1926; Vujanovic NL, 1996, J IMMUNOL, V157, P1117; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Yoon K, 2001, AIDS RES HUM RETROV, V17, P99, DOI 10.1089/08892220150217184	70	30	32	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1459	+		10.1096/fj.04-1633fje	http://dx.doi.org/10.1096/fj.04-1633fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240562				2022-12-28	WOS:000222979200018
J	Jaschke, B; Milz, S; Vogeser, M; Michaelis, C; Vorpahl, M; Schomig, A; Kastrati, A; Wessely, R				Jaschke, B; Milz, S; Vogeser, M; Michaelis, C; Vorpahl, M; Schomig, A; Kastrati, A; Wessely, R			Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drugeluting stents to prevent neointima formation following vascular injury	FASEB JOURNAL			English	Article						restenosis; cell cycle; drug-coated stents	DRUG-ELUTING STENTS; IN-VIVO; DEFICIENT MICE; RAPAMYCIN; ATHEROSCLEROSIS; HYPERPLASIA; P53; PROGRESSION; P27(KIP1); STENOSIS	In-stent restenosis is a hyperproliferative disease which can be successfully treated by drug-eluting stents releasing compounds that exhibit cell-cycle inhibitory properties to inhibit coronary smooth muscle cell (CASMC) proliferation and migration, resembling the key pathomechanisms of in-stent restenosis. Cyclin-dependent kinases (CDK) are key regulators of the eukaryotic cell cycle. CDK activity may be blocked by novel compounds such as flavopiridol. Therefore, CDK inhibitors are attractive drugs to be used for the local prevention of in-stent restenosis. In this study, we demonstrate that flavopiridol leads to potent inhibition of CASMC proliferation and migration. Molecular effects on cell-cycle regulatory mechanisms and distribution were evaluated by post-transcriptional assessment of distinct cyclins and cyclin-dependent kinase inhibitor (CKI) levels and flow cytometry. Cellular necrosis and apoptosis was assessed in CASMC and coronary endothelial cells. Flavopiridol induced a potent antiproliferative effect by cell-cycle inhibition in G(1) and G(2)/M and led to increased protein levels of CKIs p21(cip1) and p27(kip1) as well as p53 in CASMC. Hyperphosphorylation of retinoblastoma protein was abrogated and mitogen-mediated smooth muscle cell migration significantly reduced. No accelerated cytotoxicity or increased apoptosis was detectable. Flavopiridol-coated stents, implanted in rat carotid arteries, led to significant decrease of neointima formation. As proof of principle, our results demonstrate that stents eluting CDK inhibitors such as flavopiridol effectively inhibit neointima formation. Therefore, this new class of therapeutics may be suitable for further clinical investigations on drug-eluting stents to prevent in-stent restenosis.	Deutsch Herzzentrum, D-80636 Munich, Germany; Tech Univ Munich, Med Klin 1, D-8000 Munich, Germany; Univ Munich, Anat Anstalt, D-8000 Munich, Germany; Tech Univ Munich, Inst Expt Onkol & Therapieforsch, D-8000 Munich, Germany; Univ Munich, Klinikum Grosshadern, Inst Klin Chem, D-8000 Munich, Germany	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; University of Munich; Technical University of Munich; University of Munich	Wessely, R (corresponding author), Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	rwessely@dhm.mhn.de	, Kastrati/Y-2389-2019; Milz, Stefan/J-8218-2012	Milz, Stefan/0000-0002-3859-2107				Abizaid A, 2004, J AM COLL CARDIOL, V43, P1118, DOI 10.1016/j.jacc.2004.01.023; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; Braun-Dullaeus RC, 2003, J LAB CLIN MED, V141, P179, DOI 10.1067/mlc.2003.23; Brusselbach S, 1998, INT J CANCER, V77, P146; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; Carlson B, 1999, CANCER RES, V59, P4634; Castro C, 2004, ATHEROSCLEROSIS, V172, P31, DOI 10.1016/j.atherosclerosis.2003.09.003; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; CLOWES AW, 1983, LAB INVEST, V49, P208; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Diez-Juan A, 2003, CIRC RES, V92, P402, DOI 10.1161/01.RES.0000059306.71961.ED; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Grenadier E, 2002, CATHETER CARDIO INTE, V55, P303, DOI 10.1002/ccd.10130; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; Kim KS, 2000, J MED CHEM, V43, P4126, DOI 10.1021/jm000231g; Kitada S, 2000, BLOOD, V96, P393; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Mancini D, 2003, CIRCULATION, V108, P48, DOI 10.1161/01.CIR.0000070421.38604.2B; Marx SO, 2001, CIRCULATION, V104, P852, DOI 10.1161/01.CIR.104.8.852; MILZ S, 1994, J ANAT, V185, P103; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Phillips JW, 2003, CIRCULATION, V107, P2244, DOI 10.1161/01.CIR.0000065604.56839.18; Rectenwald JE, 2000, CIRCULATION, V102, P1697, DOI 10.1161/01.CIR.102.14.1697; Reed SI, 1997, CANCER SURV, V29, P7; Roque M, 2001, LAB INVEST, V81, P895, DOI 10.1038/labinvest.3780298; Ruef J, 1999, CIRCULATION, V100, P659, DOI 10.1161/01.CIR.100.6.659; Sata M, 2003, ARTERIOSCL THROM VAS, V23, P1548, DOI 10.1161/01.ATV.0000089327.48154.32; Schwartz RS, 2002, CIRCULATION, V106, P1867, DOI 10.1161/01.CIR.0000033485.20594.6F; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Sedlacek HH, 2000, DRUGS, V59, P435, DOI 10.2165/00003495-200059030-00004; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sriram V, 2001, CIRCULATION, V103, P2414; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Suzuki T, 2001, CIRCULATION, V104, P1188, DOI 10.1161/hc3601.093987; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Virmani R, 2003, HEART, V89, P133, DOI 10.1136/heart.89.2.133; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wessely R, 1998, CIRCULATION, V98, P450, DOI 10.1161/01.CIR.98.5.450; Wessely R, 2003, HUM MOL GENET, V12, P177, DOI 10.1093/hmg/ddg018; Zhai SP, 2002, BIOMED CHROMATOGR, V16, P379, DOI 10.1002/bmc.166	50	23	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1285	+		10.1096/fj.04-1646fje	http://dx.doi.org/10.1096/fj.04-1646fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180955				2022-12-28	WOS:000222327500008
J	El Jamali, A; Freund, C; Rechner, C; Scheidereit, C; Dietz, R; Bergmann, MW				El Jamali, A; Freund, C; Rechner, C; Scheidereit, C; Dietz, R; Bergmann, MW			Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3 beta	FASEB JOURNAL			English	Article						cardiac hypertrophy; heart failure; CRE-dependent transcription	ELEMENT-BINDING PROTEIN; NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; CARDIAC MYOCYTE APOPTOSIS; CAMP-RESPONSIVE ELEMENT; CYCLIC-AMP; BETA(2)-ADRENERGIC RECEPTORS; TRANSCRIPTION FACTOR; MEDIATED INDUCTION; ANGIOTENSIN-II	In vivo, left ventricular remodeling after myocardial infarction involves hypertrophy generally attributed to increased cardiac workload. We hypothesized that hypoxia/reoxygenation directly induces cardiomyocyte hypertrophy and studied several participating kinases and transcription factors in isolated cardiomyocytes. Hypoxia for 6 h followed by 42 h reoxygenation induced cardiomyocyte hypertrophy assessed by H-3 leucine incorporation and immunohistochemistry. Inhibition of reactive oxygen species (ROS), serine/threonine kinase AKT, and ERK abolished reoxygenation-induced hypertrophy. In addition, a beta2-adrenergic receptor (beta2-AR) antagonist, as well as Gi inhibitor pertussis toxin, blocked reoxygenation- induced hypertrophy. Hypoxia for 6 h increased transcription factors CREB, NF-kappaB, and GATA DNA binding activities. However, only CREB DNA-binding was sustained during reoxygenation. Inhibition of PI3-kinase, ERK, and PKA abrogated reoxygenation- induced CREB DNA-binding without affecting CREB serine-133 phosphorylation. These same pathways were found to regulate hypoxia/reoxygenation-induced GSK3beta kinase activity and CREB serine-129 de-phosphorylation. GSK3beta mutants resistant to phosphorylation blocked the stimulation of CRE-dependent transcription induced by hypoxia/reoxygenation. Transfection of cardiomyocytes with a dominant-negative mutant of CREB abrogated hypoxia/reoxygenation-induced hypertrophy. We suggest that hypoxia/reoxygenation induces cardiomyocyte hypertrophy through CREB activation. Inactivation of GSK3beta by hypoxia/reoxygenation, possibly integrating PI3-kinase and ERK pathways downstream of beta2-AR and ROS, is a prerequisite for CRE-dependent transcription. Transient hypoxia may contribute to cardiac hypertrophy in ischemic heart disease independent of cardiac workload.	HELIOS Klin, Franz Volhard Clin, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Franz-Volhard Clinical Research Center; Helios Kliniken; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bergmann, MW (corresponding author), Franz Volhard Clin, Charite Campus Buch,Wiltbergstr 50, D-13125 Berlin, Germany.	M.Bergmann@mdc-berlin.de						Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bergmann M, 2000, AM J RESP CELL MOL, V22, P582, DOI 10.1165/ajrcmb.22.5.3889; Bergmann MW, 2001, J MOL CELL CARDIOL, V33, P1223, DOI 10.1006/jmcc.2001.1385; Bleeke T, 2004, CIRC RES, V94, P37, DOI 10.1161/01.RES.0000109412.80157.7D; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Funakoshi Y, 2002, J BIOL CHEM, V277, P18710, DOI 10.1074/jbc.M110430200; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Haq S, 2003, P NATL ACAD SCI USA, V100, P4610, DOI 10.1073/pnas.0835895100; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Kwon SH, 2003, J MOL CELL CARDIOL, V35, P615, DOI 10.1016/S0022-2828(03)00084-1; Matsui T, 2001, CIRCULATION, V104, P330; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Muller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; OGAWA Y, 1995, J MOL MED-JMM, V73, P457; Oishi Y, 2003, HYPERTENSION, V41, P814, DOI 10.1161/01.HYP.0000048340.53100.43; Purcell NH, 2001, P NATL ACAD SCI USA, V98, P6668, DOI 10.1073/pnas.111155798; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; Schafer M, 2003, FASEB J, V17, P449, DOI 10.1096/fj.02-0398fje; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tomita H, 2003, CIRC RES, V93, P12, DOI 10.1161/01.RES.0000079794.57578.F1; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xuan YT, 1999, CIRC RES, V84, P1095, DOI 10.1161/01.RES.84.9.1095; Yaoita H, 2002, CIRCULATION, V105, P975, DOI 10.1161/hc0802.104503	49	50	52	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1096	+		10.1096/fj.03-1054fje	http://dx.doi.org/10.1096/fj.03-1054fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155564				2022-12-28	WOS:000221883200005
J	Siler, U; Barella, L; Spitzer V; Schnorr, J; Lein, M; Goralczyk, R; Wertz, K				Siler, U; Barella, L; Spitzer, V; Schnorr, J; Lein, M; Goralczyk, R; Wertz, K			Lycopene and Vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model	FASEB JOURNAL			English	Article						carotenoid; steroid; nutrigenomics; magnetic resonance imaging	PROLIFERATIVE INFLAMMATORY ATROPHY; GROWTH-FACTORS; INTRAEPITHELIAL NEOPLASIA; DIFFERENTIATION PATHWAYS; ANDROGEN RECEPTOR; ALPHA-TOCOPHEROL; VENTRAL PROSTATE; EPITHELIAL-CELLS; BETA-CAROTENE; BRAIN-TUMORS	Epidemiological studies have consistently associated high intakes of lycopene or vitamin E with a reduced prostate cancer risk. Both compounds were tested in the MatLyLu Dunning prostate cancer model to gain insight into the in vivo action of lycopene and vitamin E. Supplementation for 4 weeks with 200 ppm lycopene, 540 ppm vitamin E, or both led to plasma levels comparable with those in humans. Both compounds also accumulated in tumor tissue. Macroscopic evaluation of the tumors by magnetic resonance imaging showed a significant increase in necrotic area in the vitamin E and the lycopene treatment groups. Microarray analysis of tumor tissues revealed that both compounds regulated local gene expression. Vitamin E reduced androgen signaling without affecting androgen metabolism. Lycopene interfered with local testosterone activation by down-regulating 5-alpha-reductase and consequently reduced steroid target genes expression (cystatin-related protein 1 and 2, prostatic spermine binding protein, prostatic steroid binding protein C1, C2 and C3 chain, probasin). In addition, lycopene down-regulated prostatic IGF-I and IL-6 expression. Based on these findings, we suggest that lycopene and vitamin E contribute to the reduction of prostate cancer by interfering with internal autocrine or paracrine loops of sex steroid hormone and growth factor activation/synthesis and signaling in the prostate.	DSM Nutr Prod Human Nutr & Hlth, Carotenoid Sect, CH-4002 Basel, Switzerland; Humboldt Univ, Charite Univ Hosp, Dept Urol, Berlin, Germany	DSM NV; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wertz, K (corresponding author), DSM Nutr Prod Human Nutr & Hlth, Carotenoid Sect, POB 3255, CH-4002 Basel, Switzerland.	karin.wertz@dsm.com		Siler, Ulrich/0000-0002-2458-2629				ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S; *AM CANC SOC, 2003, CANC FACTS FIG 2003; Bonkhoff H, 1996, PROSTATE, V28, P98; Bostwick DG, 2000, PROSTATE, V43, P286; CARMENA MJ, 1986, CELL BIOCHEM FUNCT, V4, P19, DOI 10.1002/cbf.290040103; Chenevert TL, 1997, CLIN CANCER RES, V3, P1457; Chenevert TL, 2000, JNCI-J NATL CANCER I, V92, P2029, DOI 10.1093/jnci/92.24.2029; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dixon LB, 2001, J NUTR, V131, P1232, DOI 10.1093/jn/131.4.1232; DIXON LB, 1994, NEW ENGL J MED, V330, P1029; Eichholzer M, 1996, INT J CANCER, V66, P145, DOI 10.1002/(SICI)1097-0215(19960410)66:2&lt;145::AID-IJC1&gt;3.0.CO;2-2; FERLAY J, 2000, GLOBOCAN 2000 CANC I; Fleshner N, 1999, J UROLOGY, V161, P1651, DOI 10.1016/S0022-5347(05)68998-7; Friedman EJ, 1997, J UROLOGY, V158, P1585, DOI 10.1016/S0022-5347(01)64284-8; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Gann PH, 1999, CANCER RES, V59, P1225; Geldof AA, 1997, UROLOGY, V49, P795, DOI 10.1016/S0090-4295(96)00576-6; Giovannucci E, 2002, EXP BIOL MED, V227, P852, DOI 10.1177/153537020222701003; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Goralczyk R., 2004, PHYTOCHEM HLTH DIS, P285; Gromadzinska J, 2000, Int J Occup Med Environ Health, V13, P233; Hein DW, 2002, ENVIRON MOL MUTAGEN, V40, P161, DOI 10.1002/em.10103; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; HSING AW, 1990, J NATL CANCER I, V82, P941, DOI 10.1093/jnci/82.11.941; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Huynh H, 2001, J ENDOCRINOL, V171, P109, DOI 10.1677/joe.0.1710109; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; ISAACS JT, 1981, INVEST UROL, V19, P20; ISRAEL K, 1995, NUTR CANCER, V24, P161, DOI 10.1080/01635589509514404; KAISER R, 1972, ELEMENTARE TESTS BEU; Kaplan PJ, 1999, CANCER RES, V59, P2203; Klein EA, 2003, UROL ONCOL-SEMIN ORI, V21, P59, DOI 10.1016/S1078-1439(02)00301-0; Kucuk O, 2002, CANCER METAST REV, V21, P111, DOI 10.1023/A:1020809806121; Labrie F, 2001, FRONT NEUROENDOCRIN, V22, P185, DOI 10.1006/frne.2001.0216; Lein M, 2002, ONCOGENE, V21, P2089, DOI 10.1038/sj.onc.1205267; Lieberman R, 2002, CANCER METAST REV, V21, P297, DOI 10.1023/A:1021267128567; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; PARNES HL, 2004, J UROLOGY, V171, pS75; Parnes Howard L., 2004, Journal of Urology, V171, pS68, DOI 10.1097/01.ju.0000107220.64675.74; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Putzi MJ, 2000, UROLOGY, V56, P828, DOI 10.1016/S0090-4295(00)00776-7; Shimada K, 2003, CARCINOGENESIS, V24, P1067, DOI 10.1093/carcin/bgg058; Smith PC, 2001, PROSTATE, V48, P47; VANKAPPEL A, 2000, THESIS U C BERNARD L; Vogt TM, 2002, AM J EPIDEMIOL, V155, P1023, DOI 10.1093/aje/155.11.1023; Wang XY, 1999, PROG LIPID RES, V38, P309, DOI 10.1016/S0163-7827(99)00008-9; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P7408, DOI 10.1073/pnas.102014399; Zhao M, 1996, BRIT J CANCER, V73, P61, DOI 10.1038/bjc.1996.11	57	135	139	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1019	+		10.1096/fj.03-1116fje	http://dx.doi.org/10.1096/fj.03-1116fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084515				2022-12-28	WOS:000221108800004
J	Salah, Z; Maoz, M; Cohen, I; Pizov, G; Pode, D; Runge, MS; Bar-Shavit, R				Salah, Z; Maoz, M; Cohen, I; Pizov, G; Pode, D; Runge, MS; Bar-Shavit, R			Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression	FASEB JOURNAL			English	Article						PAR1; protease-activated receptor 1; prostate carcinoma; androgen hormone	ENDOTHELIAL GROWTH-FACTOR; PROTEASE-ACTIVATED RECEPTOR-1; TRANSCRIPTION FACTOR AP-2; THROMBIN-RECEPTOR; BINDING-PROTEIN; BREAST-CANCER; CELL-LINES; GENE; TUMOR; EXPRESSION	Human protease-activated receptor-1 (hPar1) plays a role in malignant and physiological invasion processes. We have identified a functional androgen response element ( ARE) located in the hPar1 promoter upstream of the transcription start site at - 1791 to - 1777. Dihydrotestosterone treatment of the prostate cancer cell line LNCaP increased endogenous hPar1 mRNA levels, consistent with the threefold increase in promoter activity of hPar1 - luciferase reporter construct. Specific binding of the hPar1-derived ARE to LNCaP nuclear extracts was demonstrated by electrophoretic mobility shift assay. This binding was abrogated by antiandrogen receptor (anti-AR) antibodies or excess cold oligonucleotide but not by a mutated oligonucleotide. Moreover, using chromatin immunoprecipitation assays, we confirm the in vivo interaction between the AR and ARE domain of the hPar1 promoter. In parallel, we show that hormone ablation therapy markedly reduces the otherwise high hPar1 expression levels in prostate cancer biopsy specimens. We suggest that the hPar1 gene is regulated transcriptionally by androgens, representing one of several target genes effectively reduced during hormone ablation therapy. A major limitation of hormonal deprivation is that it causes only a temporary remission, and the cancer eventually reappears in a more malignant, androgen-independent form. hPar1 is also overexpressed in CL1 cells, an aggressively metastasizing, hormone-independent subclone of LNCaP, and in PC3 prostate adenocarcinoma lacking AR in a mechanism yet to be fully elucidated. These data may imply that hPar1 expression correlates with prostate cancer progression in androgen-dependent and - independent phases and therefore, provides an instrumental, therapeutic target for treatment in prostate cancer.	Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Urol, IL-91120 Jerusalem, Israel; Univ N Carolina, Div Cardiol, Chapel Hill, NC USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bar-Shavit, R (corresponding author), Hadassah Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	barshav@md.huji.ac.il						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arisato T, 2003, CELL MOL LIFE SCI, V60, P1716, DOI 10.1007/s00018-003-3140-6; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Caunt M, 2003, J THROMB HAEMOST, V1, P2097, DOI 10.1046/j.1538-7836.2003.00426.x; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2003, J PATHOL, V200, P47, DOI 10.1002/path.1338; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; FABRE S, 1994, J BIOL CHEM, V269, P5857; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; GHYSELINCK NB, 1993, MOL ENDOCRINOL, V7, P258, DOI 10.1210/me.7.2.258; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; Herkert O, 2001, CIRCULATION, V104, P2826, DOI 10.1161/hc4801.099737; Hobisch A, 1998, CANCER RES, V58, P4640; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jin B, 2001, CLIN ENDOCRINOL, V54, P437, DOI 10.1046/j.1365-2265.2001.01240.x; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Navarro D, 2002, J STEROID BIOCHEM, V81, P191, DOI 10.1016/S0960-0760(02)00064-X; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Prins GS, 1998, J UROLOGY, V159, P641, DOI 10.1016/S0022-5347(01)63692-9; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Rudroff C, 1998, PANCREAS, V16, P189, DOI 10.1097/00006676-199803000-00013; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Visakorpi T, 1999, NAT MED, V5, P264, DOI 10.1038/6472; Wu YX, 1998, BIOCHEM J, V330, P1469, DOI 10.1042/bj3301469; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com	49	29	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					62	72		10.1096/fj.04-2386com	http://dx.doi.org/10.1096/fj.04-2386com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629896				2022-12-28	WOS:000226576600043
J	Obrosova, IG; Mabley, JG; Zsengeller, Z; Charniauskaya, T; Abatan, OI; Groves, JT; Szabo, C				Obrosova, IG; Mabley, JG; Zsengeller, Z; Charniauskaya, T; Abatan, OI; Groves, JT; Szabo, C			Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst	FASEB JOURNAL			English	Article						poly(ADP-ribose) polymerase; streptozotocin-diabetic rats; NOD mice; nerve conduction deficit; tail-flick latency	ALPHA-LIPOIC ACID; NERVE-CONDUCTION-VELOCITY; ENDONEURIAL BLOOD-FLOW; ALDOSE REDUCTASE INHIBITOR; OXIDATIVE STRESS; EPINEURIAL ARTERIOLES; ENDOTHELIAL DYSFUNCTION; PERIPHERAL NEUROPATHY; ANTIOXIDANT TREATMENT; RADICAL SCAVENGER	Nitrosative stress, that is, enhanced peroxynitrite formation, has been documented in both experimental and clinical diabetic neuropathy (DN), but its pathogenetic role remains unexplored. This study evaluated the role for nitrosative stress in two animal models of type 1 diabetes: streptozotocin-diabetic mice and diabetic NOD mice. Control ( C) and streptozotocin-diabetic ( D) mice were treated with and without the potent peroxynitrite decomposition catalyst FP15 (5 mg kg(-1) d(-1)) for 1 wk after 8 wk without treatment. Sciatic nerve nitrotyrosine ( a marker of peroxynitrite-induced injury) and poly( ADP-ribose) immunoreactivities were present in D and absent in C and D+FP15. FP15 treatment corrected sciatic motor and hind-limb digital sensory nerve conduction deficits and sciatic nerve energy state in D, without affecting those variables in C. Nerve glucose and sorbitol pathway intermediate concentrations were similarly elevated in D and D+FP15 vs C. In diabetic NOD mice, a 7-day treatment with either 1 or 3 mg kg(-1) d(-1) FP15 reversed increased tail-flick latency ( a sign of reduced pain sensitivity); the effect of the higher dose was significant as early as 3 days after beginning of the treatment. In conclusion, nitrosative stress plays a major role in DN in, at least, type 1 diabetes. This provides the rationale for development of agents counteracting peroxynitrite formation and promoting peroxynitrite decomposition, and their evaluation in DN.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA; Inotek Pharmaceut Corp, Beverly, MA USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	University of Michigan System; University of Michigan; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Inotek Pharmaceuticals; Princeton University	Obrosova, IG (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	obrosoig@pbrc.edu	Groves, John T./GPP-7588-2022; Szabo, Csaba/D-1882-2013; Szabo, Csaba/ABG-2644-2021	Groves, John T./0000-0002-9944-5899; Zsengeller, Zsuzsanna/0000-0002-4540-5728; Mabley, Jon/0000-0001-9423-6230	NHLBI NIH HHS [HL/DK 71215-01] Funding Source: Medline; NIDDK NIH HHS [DK59809-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ametov AS, 2003, DIABETES CARE, V26, P770, DOI 10.2337/diacare.26.3.770; Boulton AJM, 2004, DIABETES CARE, V27, P1458, DOI 10.2337/diacare.27.6.1458; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131; Cameron NE, 1998, DIABETOLOGIA, V41, P390, DOI 10.1007/s001250050921; Cameron NE, 2001, DIABETOLOGIA, V44, P1161, DOI 10.1007/s001250100626; Cheng C, 2003, DIABETES, V52, P2363, DOI 10.2337/diabetes.52.9.2363; Coppey LJ, 2003, FREE RADICAL RES, V37, P33, DOI 10.1080/1071576021000028442; Coppey LJ, 2001, BRIT J PHARMACOL, V134, P21, DOI 10.1038/sj.bjp.0704216; Coppey LJ, 2001, DIABETES, V50, P1927, DOI 10.2337/diabetes.50.8.1927; Cotter MA, 2003, LIFE SCI, V73, P1813, DOI 10.1016/S0024-3205(03)00508-3; Cuzzocrea S, 2000, ARTHRITIS RHEUM, V43, P320, DOI 10.1002/1529-0131(200002)43:2<320::AID-ANR11>3.0.CO;2-9; El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022; Ellis EA, 2002, NITRIC OXIDE-BIOL CH, V6, P295, DOI 10.1006/niox.2001.0419; Genuth S, 2002, JAMA-J AM MED ASSOC, V287, P2563; Groves J. T., 2004, CYTOCHROME P450 STRU, P1; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; GROVES JT, 1995, J AM CHEM SOC, V117, P9578, DOI 10.1021/ja00142a032; Gupta S, 2002, AM J PHYSIOL-CELL PH, V282, pC560, DOI 10.1152/ajpcell.00343.2001; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hoeldtke RD, 2002, DIABETES, V51, P2817, DOI 10.2337/diabetes.51.9.2817; Hotta N, 2001, DIABETES CARE, V24, P1776, DOI 10.2337/diacare.24.10.1776; Hounsom L, 1998, DIABETOLOGIA, V41, P839, DOI 10.1007/s001250050996; Hounsom L, 2001, DIABETOLOGIA, V44, P424, DOI 10.1007/s001250051638; KARASU C, 1995, DIABETOLOGIA, V38, P129, DOI 10.1007/s001250050262; KARMELI F, 1995, GUT, V37, P386, DOI 10.1136/gut.37.3.386; Kato N, 2000, DIABETES RES CLIN PR, V50, P77, DOI 10.1016/S0168-8227(00)00164-9; Klotz LO, 2002, FREE RADICAL BIO MED, V33, P737, DOI 10.1016/S0891-5849(02)00892-4; Lee JB, 1997, BIOORG MED CHEM LETT, V7, P2913, DOI 10.1016/S0960-894X(97)10109-3; Lee JB, 1998, J AM CHEM SOC, V120, P7493, DOI 10.1021/ja980507y; Li F, 2004, DIABETOLOGIA, V47, P710, DOI 10.1007/s00125-004-1356-0; Love A, 1996, EUR J PHARMACOL, V314, P33, DOI 10.1016/S0014-2999(96)00528-6; Mabley JG, 2002, MOL MED, V8, P581, DOI 10.1007/BF03402168; MAITRA I, 1995, FREE RADICAL BIO MED, V18, P823, DOI 10.1016/0891-5849(94)00195-P; Marla SS, 1997, P NATL ACAD SCI USA, V94, P14243, DOI 10.1073/pnas.94.26.14243; Minchenko AG, 2003, FASEB J, V17, P1514, DOI 10.1096/fj.03-0013fje; Mizisin AP, 2001, J NEUROPATH EXP NEUR, V60, P953, DOI 10.1093/jnen/60.10.953; Moro MA, 1998, FREE RADICAL RES, V28, P193, DOI 10.3109/10715769809065804; NAGAMATSU M, 1995, DIABETES CARE, V18, P1160, DOI 10.2337/diacare.18.8.1160; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Nassar T, 2002, EUR J PHARMACOL, V436, P111, DOI 10.1016/S0014-2999(01)01566-7; Obrosova IG, 1999, DIABETOLOGIA, V42, P1187, DOI 10.1007/s001250051290; Obrosova IG, 2003, DIABETES, V52, P864, DOI 10.2337/diabetes.52.3.864; Obrosova IG, 2002, INT REV NEUROBIOL, V50, P3; Obrosova IG, 2001, FASEB J, V15, P123, DOI 10.1096/fj.01-0603fje; Obrosova IG, 2004, DIABETES, V53, P711, DOI 10.2337/diabetes.53.3.711; OBROSOVA IG, 2003, DIABETES S2, V3, P439; Obrosova Irina G, 2003, Curr Diab Rep, V3, P439, DOI 10.1007/s11892-003-0005-1; Obrosova LG, 2004, DIABETES, V53, pA213; Pacher P, 2003, CIRCULATION, V107, P896, DOI 10.1161/01.CIR.0000048192.52098.DD; Packer L, 2001, NUTRITION, V17, P888, DOI 10.1016/S0899-9007(01)00658-X; Price SA, 2004, DIABETES, V53, P1851, DOI 10.2337/diabetes.53.7.1851; Purves T, 2001, FASEB J, V15, P2508, DOI 10.1096/fj.01-0253hyp; Sagara M, 1996, DIABETOLOGIA, V39, P263; Santilli F, 2004, HORM METAB RES, V36, P319, DOI 10.1055/s-2004-814489; Sayers NM, 2003, DIABETES, V52, P2372, DOI 10.2337/diabetes.52.9.2372; Schmeichel AM, 2003, DIABETES, V52, P165, DOI 10.2337/diabetes.52.1.165; Schmidt RE, 2003, AM J PATHOL, V163, P2077, DOI 10.1016/S0002-9440(10)63565-1; Shimanovich R, 2001, ARCH BIOCHEM BIOPHYS, V387, P307, DOI 10.1006/abbi.2000.2247; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; Stevens MJ, 2000, DIABETES, V49, P1006, DOI 10.2337/diabetes.49.6.1006; Szabo C, 2002, MOL MED, V8, P571, DOI 10.1007/BF03402167; Thornalley PJ, 2002, INT REV NEUROBIOL, V50, P37; VanDam PS, 1996, EUR J CLIN INVEST, V26, P1143, DOI 10.1046/j.1365-2362.1996.510601.x; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Ziegler D, 2004, DIABETIC MED, V21, P114, DOI 10.1111/j.1464-5491.2004.01109.x; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5	68	126	131	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					401	+		10.1096/fj.04-1913fje	http://dx.doi.org/10.1096/fj.04-1913fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15611153	Green Published			2022-12-28	WOS:000226091000010
J	Jurek, D; Udilova, N; Jozkowicz, A; Nohl, H; Marian, B; Schulte-Hermann, R				Jurek, D; Udilova, N; Jozkowicz, A; Nohl, H; Marian, B; Schulte-Hermann, R			Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells	FASEB JOURNAL			English	Article						colon carcinogenesis; dietary fat; fatty acid hydroperoxides; cyclooxygenase-2	PROTEIN-KINASE-C; INTESTINAL POLYPOSIS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; PROSTATE-CANCER; UP-REGULATION; COLON-CANCER; CARCINOGENESIS; BREAST; RISK	Fatty acid hydroperoxides arise from unsaturated fatty acids in the presence of oxygen and elevated temperature during processing of food. Here we have studied their effects on gene expression in colorectal tumor cells using linoleic acid hydroperoxide (LOOH) as a model compound. Its addition to the medium of LT97 human adenoma cells and SW480 human carcinoma cells enhanced the production of intracellular hydrogen peroxide. Furthermore, in both cell lines, increases in VEGF mRNA and protein were observed. Unoxidized linoleic acid had little or no activity. Concomitantly, COX-2 expression was up-regulated. In the LT97 cells, the COX inhibitors SC58560 and SC58236 completely prevented the VEGF induction, suggesting that the effect was dependent on prostaglandin synthesis. In vivo prostaglandin-mediated induction of VEGF secretion is known to be essential for the growth of adenomatous polyps and their progression to carcinomas. Therefore, our results for the first time implicate dietary lipid hydroperoxide as a key risk factor in colon carcinogenesis.	Med Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Vet Univ Vienna, Res Inst Pharmacol & Toxicol, Vienna, Austria; Jagiellonian Univ, Fac Biotechnol, Krakow, Poland	Medical University of Vienna; University of Veterinary Medicine Vienna; Jagiellonian University	Marian, B (corresponding author), Med Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	brigitte.marian@meduniwien.ac.at	Rohr-Udilova, Nataliya/J-6751-2015	Rohr-Udilova, Nataliya/0000-0003-2432-3632				Bartsch H, 1999, CARCINOGENESIS, V20, P2209, DOI 10.1093/carcin/20.12.2209; Bartsch H, 2002, CANCER DETECT PREV, V26, P308, DOI 10.1016/S0361-090X(02)00093-4; Bird RP, 2000, TOXICOL LETT, V112, P395, DOI 10.1016/S0378-4274(99)00261-1; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEDMAN E, 1989, CANCER RES, V49, P544; Furstenberger G, 2002, PROSTAG OTH LIPID M, V68-9, P235, DOI 10.1016/S0090-6980(02)00033-3; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; HIETANEN E, 1994, EUR J CLIN NUTR, V48, P575; Jiang WG, 2003, PROSTAG LEUKOTR ESS, V69, P275, DOI 10.1016/S0952-3278(03)00110-8; Jozkowicz A, 2001, CARDIOVASC RES, V51, P773, DOI 10.1016/S0008-6363(01)00344-3; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; Kanazawa K, 1998, BBA-LIPID LIPID MET, V1393, P349, DOI 10.1016/S0005-2760(98)00089-7; Kanner J, 2001, FREE RADICAL BIO MED, V31, P1388, DOI 10.1016/S0891-5849(01)00718-3; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Liu ZH, 2001, INT J ONCOL, V19, P1009; Mason Joel B, 2002, Semin Gastrointest Dis, V13, P143; Matsuyama M, 2004, INT J ONCOL, V24, P821; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Paul S, 1997, CRIT REV FOOD SCI, V37, P635, DOI 10.1080/10408399709527793; Rao CV, 2001, CANCER RES, V61, P1927; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Rota C, 1997, BIOCHEM J, V328, P565, DOI 10.1042/bj3280565; Schulte-Hermann R, 1999, TOXICOLOGY, P179; Seno H, 2002, CANCER RES, V62, P506; SNYDERWINE EG, 2002, MUTAT RES, V506, P215; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stamp DH, 2002, MED HYPOTHESES, V59, P398, DOI 10.1016/S0306-9877(02)00125-1; Stolze K, 2000, FREE RADICAL BIO MED, V29, P1005, DOI 10.1016/S0891-5849(00)00401-9; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Udilova N, 2003, FOOD CHEM TOXICOL, V41, P1481, DOI 10.1016/S0278-6915(03)00164-9; Urata Y, 2002, FREE RADICAL BIO MED, V32, P688, DOI 10.1016/S0891-5849(01)00823-1; WEINSTEIN IB, 1991, ENVIRON HEALTH PERSP, V93, P175, DOI 10.2307/3431186; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; Winer I, 2002, MELANOMA RES, V12, P429, DOI 10.1097/00008390-200209000-00003; Yoshimura R, 2003, J UROLOGY, V170, P1994, DOI 10.1097/01.ju.0000080296.54262.c8; Zhu JW, 2002, WORLD J GASTROENTERO, V8, P153, DOI 10.3748/wjg.v8.i1.153	40	30	30	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					97	+		10.1096/fj.04-2111fje	http://dx.doi.org/10.1096/fj.04-2111fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522906				2022-12-28	WOS:000225482100028
J	Lecca, MR; Wagner, U; Patrignani, A; Berger, EG; Hennet, T				Lecca, MR; Wagner, U; Patrignani, A; Berger, EG; Hennet, T			Genome-wide analysis of the unfolded protein response in fibroblasts from congenital disorders of glycosylation type-I patients	FASEB JOURNAL			English	Article						disease; stress; oligonucleotide array; transcriptome	ENDOPLASMIC-RETICULUM STRESS; ER-ASSOCIATED DEGRADATION; MOLECULAR CHAPERONE; GENE-EXPRESSION; TRANSCRIPTIONAL INDUCTION; MISFOLDED GLYCOPROTEINS; TRANSMEMBRANE PROTEIN; MAMMALIAN-CELLS; KINASE-ACTIVITY; REQUIRES	Congenital disorders of glycosylation (CDG) are a family of diseases characterized by defects of N-linked glycosylation. In CDG-I, several genetic defects cause a shortage of dolichol-linked oligosaccharides, which leads to underglycosylation of nascent glycoproteins. N-linked glycosylation is important for proper folding and trafficking of glycoproteins. Inhibition of glycosylation results in the buildup of misfolded proteins in the endoplasmic reticulum, which induces a protective reaction known as the unfolded protein response (UPR). To investigate whether UPR components are induced in CDG, we have performed a transcriptome analysis of primary fibroblasts from unaffected control subjects and from CDG-I patients using oligonucleotide gene expression arrays. The stress imposed by CDG was also compared with the stress induced by tunicamycin and glucose deprivation. Whereas tunicamycin elicited a strong transcriptional response typical for the UPR, CDG fibroblasts displayed a qualitatively similar yet moderate induction of genes encoding components of the UPR. Among these genes, the PERK kinase inhibitor DNAJC3/P58(IPK) gene showed the highest induction throughout all CDG-I types tested. This was paralleled by elevated expression of genes involved in amino acid biosynthesis and transport, which defined a new component of the cellular response to glycosylation stress.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Funct Genom Ctr Zurich, Zurich, Switzerland	University of Zurich	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	thennet@access.unizh.ch		Partigiani, Andrea/0000-0001-8019-3911				Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; Aebi M, 1999, Glycoconj J, V16, P669; Baek JY, 2003, BIOCHEM J, V373, P191, DOI 10.1042/BJ20030144; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERGER EG, 1993, J CELL BIOCHEM, V52, P275, DOI 10.1002/jcb.240520304; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gill A, 2002, J BIOL CHEM, V277, P44747, DOI 10.1074/jbc.M205001200; Grubenmann CE, 2002, HUM MOL GENET, V11, P2331, DOI 10.1093/hmg/11.19.2331; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Imbach T, 2000, HUM GENET, V106, P538, DOI 10.1007/s004390050022; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim BI, 2000, MAX PLANCK SERIES, V1, P105; Klebl B, 2001, BIOCHEM BIOPH RES CO, V286, P714, DOI 10.1006/bbrc.2001.5457; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; MORI K, 1993, CELL, V74, P743; Mote PL, 1998, MECH AGEING DEV, V104, P149, DOI 10.1016/S0047-6374(98)00064-5; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200	46	41	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2004	18	14					240	+		10.1096/fj.04-2397fje	http://dx.doi.org/10.1096/fj.04-2397fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15545299				2022-12-28	WOS:000225482100019
J	Yang, M; Huang, HC; Li, JZ; Li, DX; Wang, HY				Yang, M; Huang, HC; Li, JZ; Li, DX; Wang, HY			Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation	FASEB JOURNAL			English	Article						CTGF; TGF beta 1; Smad	FACTOR-BETA; TGF-BETA; FACTOR CTGF; EXPRESSION; FIBROSIS; CELLS; FIBRONECTIN; MECHANISM	Renal myofibroblasts play a crucial role in the accumulation of excess extracellular matrix during renal fibrosis. Both transforming growth factor-beta1 (TGFbeta1) and connective tissue growth factor (CTGF) are important profibrotic growth factors, which interact in the pathogenesis of fibrosis. In this study, we demonstrate that CTGF alone has no influence on myofibroblast transformation and fibronectin secretion in kidney interstitial fibroblasts, whereas incubation of CTGF in combination with TGFbeta1 enhanced TGFbeta1 responses, including myofibroblast activation, de novo expression of alpha-SMA, and extracellular accumulation of fibronectin. CTGF induced tryrosine phosphorylation of the cytoplasmic domain of the low-density lipoprotein receptor-associated protein (LRP) in fibroblasts, and the LRP-antagonist, receptor-associated protein (RAP) inhibited CTGF-induced tryrosine phosphorylation of LRP. Inhibition of LRP signaling reduced CTGF-mediated synergistic induction of alpha-SMA protein. Furthermore, the potentiating action of CTGF was neither dependent on modulation of TGFbeta1-induced Smad2 phosphorylation and its association with Smad4, nor did it result from nuclear accumulation of activated Smad2. When TGFbeta1-pretreated fibroblasts were incubated with CTGF, activation of ERK1/2 MAPK signaling was observed. Inhibition of ERK activation by the MEK1 inhibitor PD98059 was associated with a reduction of CTGF-promoted alpha-SMA protein expression. Our in vitro studies provide evidence that CTGF potentiates TGFbeta1-mediated myofibroblast differentiation and activates differentiated myofibroblasts.	Peking Univ, Hosp 1, Div Nephrol, Beijing 100034, Peoples R China; Peking Univ, Inst Nephrol, Beijing 100034, Peoples R China; FibroGen Inc, San Francisco, CA USA	Peking University; Peking University; FibroGen	Huang, HC (corresponding author), Peking Univ, Hosp 1, Div Nephrol, 8 Xi Shi Ku St, Beijing 100034, Peoples R China.	haichang@bjmu.edu.cn						Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Bakin AV, 2002, J CELL SCI, V115, P3193; Becker GJ, 2000, CURR OPIN NEPHROL HY, V9, P133, DOI 10.1097/00041552-200003000-00006; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; De Heer E, 2000, NEPHROL DIAL TRANSPL, V15, P72, DOI 10.1093/ndt/15.suppl_6.72; Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010; Doolittle F, 2002, ENVIRON MICROBIOL, V4, P10, DOI 10.1046/j.1462-2920.2002.gtfb00257.x; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; ElNahas AM, 1996, KIDNEY INT, V49, pS23; Evans RA, 2003, EXP CELL RES, V282, P90, DOI 10.1016/S0014-4827(02)00015-0; Fogo AB, 2000, CURR OPIN NEPHROL HY, V9, P241, DOI 10.1097/00041552-200005000-00006; Folger PA, 2001, INVEST OPHTH VIS SCI, V42, P2534; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9; Goldschmeding R, 2000, NEPHROL DIAL TRANSPL, V15, P296, DOI 10.1093/ndt/15.3.296; Gore-Hyer E, 2002, AM J PHYSIOL-RENAL, V283, pF707, DOI 10.1152/ajprenal.00007.2002; Goumenos DS, 2001, NEPHRON, V87, P240, DOI 10.1159/000045921; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Grupp C, 2001, KIDNEY INT, V59, P543, DOI 10.1046/j.1523-1755.2001.059002543.x; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Inkinen K, 2003, CONNECT TISSUE RES, V44, P19, DOI 10.1080/03008200390151918; Inoue T, 2002, FASEB J, V16, P268, DOI 10.1096/fj.02-0442fje; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Klahr S, 2001, SEMIN NEPHROL, V21, P133, DOI 10.1053/snep.2001.20942; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; MuchanetaKubara EC, 1997, NEPHROL DIAL TRANSPL, V12, P904, DOI 10.1093/ndt/12.5.904; Pan LH, 2001, EUR RESPIR J, V17, P1220, DOI 10.1183/09031936.01.00074101; Paradis V, 2002, LAB INVEST, V82, P767, DOI 10.1097/01.LAB.0000017365.18894.D3; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Tang WW, 1997, KIDNEY INT, V51, P926, DOI 10.1038/ki.1997.131; Twigg SM, 2002, ENDOCRINOLOGY, V143, P1260, DOI 10.1210/en.143.4.1260; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Walker GA, 2001, CURR TOP DEV BIOL, V51, P91, DOI 10.1016/S0070-2153(01)51003-0; Yang JW, 2003, J AM SOC NEPHROL, V14, P3167, DOI 10.1097/01.ASN.0000099373.33259.B2; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Yokoi H, 2002, AM J PHYSIOL-RENAL, V282, pF933, DOI 10.1152/ajprenal.00122.2001; Zeisberg M, 2001, CURR OPIN NEPHROL HY, V10, P315, DOI 10.1097/00041552-200105000-00004; ZHANG K, 1994, AM J PATHOL, V145, P114	46	83	96	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1920	+		10.1096/fj.04-2357fje	http://dx.doi.org/10.1096/fj.04-2357fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15469966				2022-12-28	WOS:000224849900026
J	Golpon, HA; Fadok, VA; Taraseviciene-Stewart, L; Scerbavicius, R; Sauer, C; Welte, T; Henson, PM; Voelkel, NF				Golpon, HA; Fadok, VA; Taraseviciene-Stewart, L; Scerbavicius, R; Sauer, C; Welte, T; Henson, PM; Voelkel, NF			Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth	FASEB JOURNAL			English	Article						apoptosis; endothelial cells; epithelial cells	IN-VITRO; GENE-EXPRESSION; ENDOTHELIAL-CELLS; MACROPHAGES; PHOSPHATIDYLSERINE; LUNG; INHIBITION; CLEARANCE; PROLIFERATION; RECOGNITION	Removal of apoptotic cells by neighboring viable cells or professional phagocytes is essential for the maintenance of tissue homeostastis. Here we show that the phagocytosis of apoptotic Jurkat T cells by mouse epithelial cells (HC-11) and peritoneal macrophages leads to the secretion of growth and survival factors. We characterized VEGF as one of these factors which subsequently promote the proliferation of endothelial cells. Further we demonstrate that the phagocytosis of apoptotic bodies inhibits both spontanous and UV-irradiation-induced apoptosis in endothelial and epithelial cells. These effects were not observed when phagocytes had been exposed to viable or necrotic Jurkat T cells. We conclude that phagocytosis of apoptotic cells leads to secretion of growth and survival factors by phagocytes that represents a new form of life-promoting cell-cell interaction.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Pulm Hypertens Ctr, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, Denver, CO 80206 USA; Univ Magdeburg, Immunol Res Ctr, D-39120 Magdeburg, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Otto von Guericke University	Voelkel, NF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Pulm Hypertens Ctr, 4200 E 9th Ave, Denver, CO 80262 USA.	norbert.voelkel@uchsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060195, R01HL066554] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60195, HL 66554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aarbiou J, 2004, AM J RESP CELL MOL, V30, P193, DOI 10.1165/rcmb.2002-0267OC; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hu B, 2000, J IMMUNOL, V165, P2124, DOI 10.4049/jimmunol.165.4.2124; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Kaplan F, 2000, MOL GENET METAB, V71, P321, DOI 10.1006/mgme.2000.3040; KUNISAKI Y, 2004, IN PRESS BLOOD; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; Licht R, 1999, J IMMUNOL METHODS, V223, P237, DOI 10.1016/S0022-1759(98)00212-9; McDonald PP, 1999, J IMMUNOL, V163, P6164; Morimoto K, 2001, AM J RESP CELL MOL, V24, P608, DOI 10.1165/ajrcmb.24.5.4292; Ramanathan MD, 2003, EXP BIOL MED, V228, P697, DOI 10.1177/153537020322800608; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; Reiter I, 1999, J IMMUNOL, V163, P1730; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Segura I, 2002, FASEB J, V16, DOI 10.1096/fj.01-0819com; Simamura E, 2001, TISSUE CELL, V33, P161; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang Q, 2002, AM J RESP CRIT CARE, V166, P872, DOI 10.1164/rccm.2201007; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; Wright L, 1998, AM J RESP CRIT CARE, V157, P219, DOI 10.1164/ajrccm.157.1.9704003; [No title captured]	39	162	170	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1716	+		10.1096/fj.04-1853fje	http://dx.doi.org/10.1096/fj.04-1853fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345697				2022-12-28	WOS:000224243200050
J	Tam, J; Rosenberg, L; Maysinger, D				Tam, J; Rosenberg, L; Maysinger, D			INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice	FASEB JOURNAL			English	Article						dorsal root ganglia; diabetic neuropathy; STAT	GLUCAGON-LIKE PEPTIDE-1; NEOGENESIS-ASSOCIATED PROTEIN; GROWTH-FACTOR; PERIPHERAL-NERVE; NEURITE OUTGROWTH; ISLET-NEOGENESIS; NEUROTROPHIC FACTOR; CELL REGENERATION; AXONAL-TRANSPORT; GENE-EXPRESSION	INGAP peptide comprises the core active sequence of Islet Neogenesis Associated Protein ( INGAP), a pancreatic cytokine that can induce new islet formation and restore euglycemia in diabetic rodents. The ability of INGAP peptide in vitro to enhance nerve growth from sensory ganglia suggests its potential utility in peripheral nerve disorders. In this study, INGAP peptide was administered alone or in combination with insulin to streptozotocin-induced diabetic mice exhibiting signs of peripheral neuropathy. Following a 2-wk treatment period, thermal hypoalgesia in diabetic mice was significantly improved in groups that received INGAP peptide, without development of hyperalgesia. Explanted dorsal root ganglia (DRG) from these groups showed enhanced nerve outgrowth and evidence of increased mitochondrial activity. Western blotting experiments revealed attenuation of neurofilament hyperphosphorylation, up-regulation of alpha-tubulin and actin, and increased phosphorylation of the transcription factor STAT3 in DRG. These findings suggest that INGAP peptide can activate some of the signaling pathways implicated in nerve regeneration in sensory ganglia, thereby providing a means of improvement of nociceptive dysfunction in the peripheral nervous system.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Maysinger, D (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	dusica.maysinger@mcgill.ca	Maysinger, Dusica/GYU-6332-2022	Tam, Joseph/0000-0002-3864-7008				Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Agresti C, 1996, EUR J NEUROSCI, V8, P1106, DOI 10.1111/j.1460-9568.1996.tb01278.x; Akahori Y, 1997, NEUROREPORT, V8, P2265, DOI 10.1097/00001756-199707070-00034; Akkina SK, 2001, EXP NEUROL, V167, P173, DOI 10.1006/exnr.2000.7547; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Apfel SC, 1999, DIABETES OBES METAB, V1, P3, DOI 10.1046/j.1463-1326.1999.00006.x; Apfel SC, 2000, JAMA-J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; Averill S, 2002, J NEUROSCI, V22, P7493; BERTELLI JA, 1995, J NEUROSCI METH, V58, P151, DOI 10.1016/0165-0270(94)00169-H; Bilsland J, 1999, J NEUROSCI METH, V92, P75, DOI 10.1016/S0165-0270(99)00099-0; BISBY MA, 1980, EXP NEUROL, V69, P74, DOI 10.1016/0014-4886(80)90144-2; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Calcutt NA, 2003, J CLIN INVEST, V111, P507, DOI 10.1172/JCI200315792; Christianson JA, 2003, J PAIN, V4, P493, DOI 10.1016/j.jpain.2003.07.002; DIAMOND J, 1987, P NATL ACAD SCI USA, V84, P6596, DOI 10.1073/pnas.84.18.6596; DIAMOND J, 1992, J NEUROSCI, V12, P1467; DIAMOND J, 1992, J NEUROSCI, V12, P1454; Dodge ME, 2002, BRAIN RES, V953, P144, DOI 10.1016/S0006-8993(02)03279-1; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Dyck P.J., 1999, DIABETIC NEUROPATHY, V2nd ed.; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; FERNYHOUGH P, 1993, BRAIN RES, V607, P117, DOI 10.1016/0006-8993(93)91496-F; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; Flores LE, 2003, J ENDOCRINOL, V177, P243, DOI 10.1677/joe.0.1770243; Fox A, 1999, PAIN, V81, P307, DOI 10.1016/S0304-3959(99)00024-X; Gabra BH, 2002, EUR J PHARMACOL, V457, P115, DOI 10.1016/S0014-2999(02)02658-4; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Gold G, 1998, DIABETES, V47, pA253; Grandis M, 2001, MUSCLE NERVE, V24, P622, DOI 10.1002/mus.1047; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Havel PJ, 1998, AM J PHYSIOL-REG I, V274, pR1482, DOI 10.1152/ajpregu.1998.274.5.R1482; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; ISHII DN, 1985, INT J NEUROSCI, V26, P109, DOI 10.3109/00207458508985610; Kerekes N, 1997, BRAIN RES, V754, P131, DOI 10.1016/S0006-8993(97)00056-5; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; KOLB H, 1987, DIABETES METAB REV, V3, P751, DOI 10.1002/dmr.5610030308; Kolta MG, 1996, NEUROPEPTIDES, V30, P335, DOI 10.1016/S0143-4179(96)90022-0; Kunioku H, 2001, NEUROSCI LETT, V309, P13, DOI 10.1016/S0304-3940(01)02012-2; LIEBERMAN AR, 1976, PERIPHERAL NERVE, P188; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Liu RY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-17-j0003.2001; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; LONGO FM, 1986, MUSCLE NERVE, V9, P385, DOI 10.1002/mus.880090502; Middlemas A, 2003, BRAIN, V126, P1671, DOI 10.1093/brain/awg150; Mizisin AP, 1999, J PERIPHER NERV SYST, V4, P211; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Peterziel H, 2002, J CELL BIOL, V159, P157, DOI 10.1083/jcb.200203115; Pierson CR, 2003, J NEUROPATH EXP NEUR, V62, P260, DOI 10.1093/jnen/62.3.260; Pierson CR, 2002, J NEUROPATH EXP NEUR, V61, P857, DOI 10.1093/jnen/61.10.857; PITTENGER GL, 1992, ADV EXP MED BIOL, V321, P123; Rafaeloff R, 1997, J CLIN INVEST, V99, P2100, DOI 10.1172/JCI119383; Rosenberg L, 1996, DIABETOLOGIA, V39, P256; Rosenberg L, 2000, DIABETES, V49, pA256; Rosenberg L, 1998, MICROSC RES TECHNIQ, V43, P337, DOI 10.1002/(SICI)1097-0029(19981115)43:4<337::AID-JEMT8>3.0.CO;2-U; ROSENBERG L, 2004, IN PRESS ANN SURG; Schifitto G, 2001, NEUROLOGY, V57, P1313, DOI 10.1212/WNL.57.7.1313; Schwaiger FW, 2000, EUR J NEUROSCI, V12, P1165, DOI 10.1046/j.1460-9568.2000.00005.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sima AAF, 1999, DIABETOLOGIA, V42, P773, DOI 10.1007/s001250051227; Smith DS, 1997, J NEUROSCI, V17, P646; Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896-6273(00)81003-X; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stromberg H, 2000, BRAIN RES, V853, P105, DOI 10.1016/S0006-8993(99)02260-X; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; Sun Y, 2002, BIOCHEM BIOPH RES CO, V295, P532, DOI 10.1016/S0006-291X(02)00706-4; Tam J, 2002, BIOCHEM BIOPH RES CO, V291, P649, DOI 10.1006/bbrc.2002.6497; Taylor-Fishwick DA, 2003, BBA-MOL BASIS DIS, V1638, P83, DOI 10.1016/S0925-4439(03)00042-5; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; Unno M, 2002, DIABETES, V51, pS478, DOI 10.2337/diabetes.51.2007.S478; Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8; Veeranna, 1998, J NEUROSCI, V18, P4008; Wellmer A, 2001, J PERIPHER NERV SYST, V6, P204, DOI 10.1046/j.1529-8027.2001.01019.x; Woolfe G, 1944, J PHARMACOL EXP THER, V80, P300; Yasuda H, 2003, PROG NEUROBIOL, V69, P229, DOI 10.1016/S0301-0082(03)00034-0; Zhuang HX, 1997, J PHARMACOL EXP THER, V283, P366	83	28	30	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1767	+		10.1096/fj.04-1894fje	http://dx.doi.org/10.1096/fj.04-1894fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345684				2022-12-28	WOS:000224243200037
J	Zhu, YM; Stolz, DB; Guo, FL; Ross, MA; Watkins, SC; Tan, BJ; Qi, RZ; Manser, E; Li, QT; Bay, BH; Teo, TS; Duan, W				Zhu, YM; Stolz, DB; Guo, FL; Ross, MA; Watkins, SC; Tan, BJ; Qi, RZ; Manser, E; Li, QT; Bay, BH; Teo, TS; Duan, W			Signaling via a novel integral plasma membrane pool of a serine/threonine protein kinase PRK1 in mammalian cells	FASEB JOURNAL			English	Article						PKN; RhoA; protein kinase C; androgen receptor; prostate cancer; neurite retraction	RHO-GTPASES; LYSOPHOSPHATIDIC ACID; ANDROGEN RECEPTOR; DIFFERENTIAL LOCALIZATION; PROSTATE-CANCER; PHOSPHORYLATION; ACTIVATION; DOMAIN; PKN; MECHANISMS	Mammalian serine/threonine protein kinases, except for TGF-beta receptor kinase family, are intracellular proteins. PRK1/PKN is a member of the protein kinase C superfamily of serine/threonine kinases and is one of the first identified effectors for RhoA GTPase. However, the role of PRK1 in mediating signaling downstream of activated RhoA is largely unknown. Here, we present evidence that identifies a novel plasma membrane pool of PRK1. This integral membrane form of PRK1 is catalytically active. The phosphorylation of serine(377) of PRK1 is required for its integration into membranes. This integration is essential for PRK1 to function as a Rho effector as only the integral plasma membrane PRK1 is able to initiate RhoA-mediated and ligand-dependent transcriptional activation of the androgen receptor in human epithelial cells and to mediate RhoA-induced neurite retraction in mouse neuronal cells. These results indicate that RhoA signals via the integral membrane pool of its effectors in its immediate vicinity at the plasma membrane, thus establishing a new paradigm in mammalian cell signaling.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 117597, Singapore; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Ctr Biol Imaging, Pittsburgh, PA 15261 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Inst Mol & Cell Biol, Singapore 117609, Singapore	National University of Singapore; National University of Singapore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Duan, W (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, MD4 Annex,Room 02-05,8 Med Dr, Singapore 117597, Singapore.	bchduanw@nus.edu.sg	Watkins, Simon/ABG-2590-2021; Manser, Edward/ABD-2301-2020; Duan, Wei/A-5181-2015	Watkins, Simon/0000-0003-4092-1552; Duan, Wei/0000-0001-5782-9184; Qi, Robert Zhong/0000-0001-5596-8172				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Benard V, 2002, METHOD ENZYMOL, V345, P349; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bowie JU, 2001, CURR OPIN STRUC BIOL, V11, P397, DOI 10.1016/S0959-440X(00)00223-2; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Cronauer MV, 2003, INT J ONCOL, V23, P1095; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; GARAVITO RM, 2003, BIOPHYS J, V32, P183; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; Kranenburg O, 1997, J CELL SCI, V110, P2417; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Manser E, 2002, DEV CELL, V3, P323, DOI 10.1016/S1534-5807(02)00268-X; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; OKAMOTO T, 1999, CURRENT PROTOCOLS S, V3; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; Pryde JG, 1998, METH MOL B, V88, P23; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sayas CL, 2002, BBA-MOL CELL BIOL L, V1582, P144, DOI 10.1016/S1388-1981(02)00149-X; Shotton DM, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P26; SILVIUS JR, 1992, ANNU REV BIOPH BIOM, V21, P323, DOI 10.1146/annurev.bb.21.060192.001543; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	43	19	21	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1722	+		10.1096/fj.04-1876fje	http://dx.doi.org/10.1096/fj.04-1876fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15375078				2022-12-28	WOS:000224243200023
J	Chavakis, T; Cines, DB; Rhee, JS; Liang, OD; Schubert, U; Hammes, HP; Higazi, AA; Nawroth, PP; Preissner, KT; Bdeir, K				Chavakis, T; Cines, DB; Rhee, JS; Liang, OD; Schubert, U; Hammes, HP; Higazi, AA; Nawroth, PP; Preissner, KT; Bdeir, K			Regulation of neovascularization by human neutrophil peptides (aleph-defensins): a link between inflammation and angiogenesis	FASEB JOURNAL			English	Article						integrin; adhesion; fibronectin; endothelial; apoptosis	ACTIVATED HUMAN NEUTROPHILS; MOLECULAR-WEIGHT KININOGEN; LOW-DENSITY-LIPOPROTEIN; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; VASCULAR CELLS; INTEGRIN; BINDING; FIBRONECTIN; RECEPTOR	Angiogenesis, the growth of new blood vessels, is a complex biological process that is orchestrated by several growth factors and components of the extracellular matrix, including fibronectin (FN) and its receptor the integrin alpha5beta1. Angiogenesis is a critical part of inflammation and wound repair, but the mechanism by which vascular proliferation and migration is regulated by inflammatory cells is not completely understood. We have previously shown that human neutrophil peptides (HNPs), also known as alpha-defensins, which are secreted in high concentrations when neutrophils are activated, bind specifically to FN in the extracellular matrix and inhibit plasminogen activation. Therefore, we asked whether HNPs act as a link between inflammation and angiogenesis. alpha5beta1-Mediated endothelial cell adhesion and migration to FN, both under control conditions and under stimulation by vascular endothelial growth factor (VEGF), were inhibited specifically and in a dose-dependent manner by HNPs, whereas endothelial cell adhesion and migration to other components of the extracellular matrix, such as vitronectin, collagen, or fibrinogen/fibrin were not. Consistent with this finding, HNPs bound to and promoted the binding of fibronectin to alpha5beta1 integrin in arginineglycine-aspartic acid (RGD)-independent manner. HNPs also completely inhibited VEGF-induced proliferation and induced apoptosis of endothelial cells in a dose-dependent manner. Moreover, HNPs inhibited capillary tube formation in three-dimensional fibrin-matrices as well as neovascularization in vivo in the chicken chorioallantoic membrane assay. Taken together, these data indicate that HNPs can regulate angiogenesis by affecting endothelial cell adhesion and migration in an FN-dependent manner as well as endothelial cell proliferation. These findings provide new insight into the role of inflammatory cells in angiogenesis and might provide a platform for developing a novel class of anti-angiogenesis drugs.	Univ Heidelberg, Dept Internal Med 1, D-69120 Heidelberg, Germany; Univ Giessen, Inst Biochem, Giessen, Germany; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; Univ Clin Mannheim, Dept Internal Med, Mannheim, Germany	Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; University of Pennsylvania; Ruprecht Karls University Heidelberg	Chavakis, T (corresponding author), Univ Heidelberg, Dept Internal Med 1, INF 410, D-69120 Heidelberg, Germany.	triantafyllos.chavakis@med.uni-heidelberg	Hammes, Hans-Peter/S-3719-2019; Chavakis, Triantafyllos/ABE-8845-2020		NHLBI NIH HHS [HL58107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010664] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Fakhri N, 2003, BIOL CHEM, V384, P423, DOI 10.1515/BC.2003.048; AUSPRUNK DH, 1975, AM J PATHOL, V79, P597; Barnathan ES, 1997, AM J PATHOL, V150, P1009; Bdeir K, 1999, BLOOD, V94, P2007; Breier G, 1997, THROMB HAEMOSTASIS, V78, P678; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 2002, J CLIN INVEST, V109, P693, DOI 10.1172/JCI200215218; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Higazi AA, 2000, BLOOD, V96, P1393; Higazi AAR, 1997, BLOOD, V89, P4290, DOI 10.1182/blood.V89.12.4290; Higazi AAR, 1996, J BIOL CHEM, V271, P17650, DOI 10.1074/jbc.271.30.17650; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lee S, 2002, J CLIN INVEST, V110, P1105, DOI 10.1172/JCI200215755; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Levy O, 1996, EUR J HAEMATOL, V56, P263; Mizukawa N, 2000, ANTICANCER RES, V20, P1125; Nassar T, 2002, BLOOD, V100, P4026, DOI 10.1182/blood-2002-04-1080; NYGAARD SD, 1993, AM J RESP CELL MOL, V8, P193, DOI 10.1165/ajrcmb/8.2.193; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scapini P, 2002, J IMMUNOL, V168, P5798, DOI 10.4049/jimmunol.168.11.5798; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3; Webb NJA, 1998, CYTOKINE, V10, P254, DOI 10.1006/cyto.1997.0297; YANG JT, 1993, DEVELOPMENT, V119, P1093	39	108	118	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1306	+		10.1096/fj.03-1009fje	http://dx.doi.org/10.1096/fj.03-1009fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208269				2022-12-28	WOS:000222327500015
J	Marriott, HM; Ali, F; Read, RC; Mitchell, TJ; Whyte, MKB; Dockrell, DH				Marriott, HM; Ali, F; Read, RC; Mitchell, TJ; Whyte, MKB; Dockrell, DH			Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection	FASEB JOURNAL			English	Article						programmed cell death; human; monocytes	PERMEABILITY TRANSITION PORE; NADPH PHAGOCYTE OXIDASE; MYCOBACTERIUM-TUBERCULOSIS; STREPTOCOCCUS-PNEUMONIAE; MURINE MACROPHAGES; IN-VITRO; EXPERIMENTAL SALMONELLOSIS; PERITONEAL-MACROPHAGES; ANTIMICROBIAL ACTIONS; ALVEOLAR MACROPHAGES	Macrophages are resistant to constitutive apoptosis, but infectious stimuli can induce either microbial or host-mediated macrophage apoptosis. Phagocytosis and killing of opsonized pneumococci by macrophages are potent stimuli for host-mediated apoptosis, but the link between pneumococcal killing and apoptosis induction remains undefined. We now show phagocytosis of pneumococci by differentiated human monocyte-derived macrophages (MDM) results in up-regulation of inducible nitric oxide synthase ( iNOS) and increased production of NO and reactive nitrogen species. NO accumulation in macrophages initiates an apoptotic program that involves NO-dependent mitochondrial membrane permeabilization, Mcl-1 downregulation, and caspase activation and results in nuclear condensation and fragmentation. An inhibitor of mitochondrial permeability transition, bongkrekic acid, decreases pneumococcal-associated macrophage apoptosis. Conversely, inhibition of NO production using iNOS inhibitors decreases bacterial killing and shifts the cell death program from apoptosis to necrosis. Pneumolysin contributes to both NO production and apoptosis induction. After initial microbial killing, NO accumulation switches the macrophage phenotype from an activated cell to a cell susceptible to apoptosis. These results illustrate important roles for NO in the integration of host defense and regulation of inflammation in human macrophages.	Univ Sheffield, Sch Med & Biomed Sci, Div Genom Med, Sheffield, S Yorkshire, England; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow, Lanark, Scotland	University of Sheffield; University of Glasgow	Dockrell, DH (corresponding author), Univ Sheffield, Sch Med, Div Genom Med, F Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	d.h.dockrell@sheffield.ac.uk	Whyte, Moira/E-6210-2010	Marriott, Helen/0000-0003-1070-0054; Read, Robert/0000-0002-4297-6728; Dockrell, David/0000-0002-2718-4861; Mitchell, Timothy/0000-0002-8309-5556				Ali F, 2003, J INFECT DIS, V188, P1119, DOI 10.1086/378675; Banick PD, 1997, J CELL PHYSIOL, V172, P12, DOI 10.1002/(SICI)1097-4652(199707)172:1<12::AID-JCP2>3.0.CO;2-G; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bergeron Y, 1999, ANTIMICROB AGENTS CH, V43, P2283, DOI 10.1128/AAC.43.9.2283; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Braun JS, 1999, INFECT IMMUN, V67, P3750, DOI 10.1128/IAI.67.8.3750-3756.1999; Braun JS, 2002, J CLIN INVEST, V109, P19; Broillet MC, 2001, FEBS LETT, V491, P227, DOI 10.1016/S0014-5793(01)02206-2; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Coakley RJ, 2002, BLOOD, V100, P3383, DOI 10.1182/blood.V100.9.3383; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; Dockrell DH, 2003, J IMMUNOL, V171, P5380, DOI 10.4049/jimmunol.171.10.5380; Dockrell DH, 2001, J INFECT DIS, V184, P713, DOI 10.1086/323084; DUMAREY CH, 1994, J LEUKOCYTE BIOL, V56, P36, DOI 10.1002/jlb.56.1.36; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gordon SB, 2000, INFECT IMMUN, V68, P2286, DOI 10.1128/IAI.68.4.2286-2293.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; Hortelano S, 2003, J IMMUNOL, V171, P6059, DOI 10.4049/jimmunol.171.11.6059; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; Oddo M, 1998, J IMMUNOL, V160, P5448; Orman KL, 1998, J INFECT DIS, V178, P1649, DOI 10.1086/314526; REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836; Rijneveld AW, 2002, J INFECT DIS, V185, P91, DOI 10.1086/338122; Rojas M, 1997, J IMMUNOL, V159, P1352; Sato E, 2000, J BIOL CHEM, V275, P10826, DOI 10.1074/jbc.275.15.10826; Schaible UE, 2003, NAT MED, V9, P1039, DOI 10.1038/nm906; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; Sly LM, 2003, J IMMUNOL, V170, P430, DOI 10.4049/jimmunol.170.1.430; Stevanin TM, 2002, INFECT IMMUN, V70, P4399, DOI 10.1128/IAI.70.8.4399-4405.2002; Suzuki N, 2002, J BIOL CHEM, V277, P47, DOI 10.1074/jbc.M108195200; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; Ulett GC, 2003, J INFECT DIS, V188, P1049, DOI 10.1086/378202; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; Webb JL, 2001, INFECT IMMUN, V69, P6391, DOI 10.1128/IAI.69.10.6391-6400.2001; WEINBERG JB, 1995, BLOOD, V86, P1184; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zanella B, 2002, BIOCHEM BIOPH RES CO, V290, P1010, DOI 10.1006/bbrc.2001.6284; Zhang X, 2002, J BIOL CHEM, V277, P48472, DOI 10.1074/jbc.M209130200; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	63	96	101	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1126	+		10.1096/fj.03-1450fje	http://dx.doi.org/10.1096/fj.03-1450fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132983				2022-12-28	WOS:000221883200018
J	Wang, WG; Graeler, MH; Goetzl, EJ				Wang, WG; Graeler, MH; Goetzl, EJ			Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4(+)25(+) regulatory T Cells	FASEB JOURNAL			English	Article						lysophospholipids; G proteins; cytokines; chemokines; proliferation	LYSOPHOSPHATIDIC ACID; CUTTING EDGE; RECEPTORS; GROWTH; SUPPRESSION; LYMPHOCYTES; EXPRESSION; CHEMOTAXIS	Sphingosine 1-phosphate (S1P) evokes T cell chemotaxis at 1-100 nM and inhibits chemotaxis to chemokines at 300 nM-1 uM through their predominant S1P(1) G protein-coupled receptor (R). Mouse CD4(+)25(+) regulatory T cells now are shown to express the same pattern of S1P(1) > S1P(4) >> other S1P Rs as other CD4 T cells. CD4(+)25(+) T cell suppression of H-3-thymidine uptake and IL-2 generation by CD4(+)25(-)T cells stimulated with anti-T cell receptor antibodies without S1P was enhanced significantly by S1P at normal blood and lymph concentrations. These levels of S1P also enhanced IL-10 generation by CD4(+)25(+) T cells by up to threefold compared with that without S1P but decreased IL-10 from CD4(+)25-T cells. That IL-10 from CD4+25+ T cells incubated with S1P mediates suppressive activity was demonstrated by prevention with neutralizing anti-IL-10 or anti-IL-10 receptor antibodies. Extracellular fluid S1P thus is required for optimal activity of CD4(+)25(+) T cells.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, UB8B,Box 0711 533 Parnassus & 4th, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; GRALER MH, 2004, FASEB J; Idzko M, 2002, FASEB J, V16, P625, DOI 10.1096/fj.01-0625fje; Kveberg L, 2002, EUR J IMMUNOL, V32, P1856, DOI 10.1002/1521-4141(200207)32:7<1856::AID-IMMU1856>3.0.CO;2-B; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shevach EM, 2001, ADV EXP MED BIOL, V490, P21; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Sundstedt A, 2003, J IMMUNOL, V170, P1240, DOI 10.4049/jimmunol.170.3.1240; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317; Zheng YH, 2000, FASEB J, V14, P2387	22	38	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1043	+		10.1096/fj.04-1555fje	http://dx.doi.org/10.1096/fj.04-1555fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084513				2022-12-28	WOS:000221108800002
J	Park, JB				Park, JB			N-Coumaroyldopamine and N-caffeoyldopamine increase cAMP via beta 2-adrenoceptors in myelocytic U937 cells	FASEB JOURNAL			English	Article						phytochemical; cardiac disease; beta-adrenoceptor agonist; cocoa	CONSTITUENTS; AGONIST; U937; COUMAROYLTYRAMINE; IDENTIFICATION; ANTIPLATELET; AGGREGATION; POLYPHENOLS; INHIBITION; CHOCOLATE	N-Caffeoyldopamine is a phytochemical found in various plants, including cocoa (Theobroma cacao L.). N-caffeoyldopamine and its natural analogs (N-cinnamoyldopamine, N-coumaroyldopamine, N-feruloyldopamine, and N-sinapoyldopamine) were synthesized and investigated to determine their potency as P-adrenoceptor agonists, because they have chemical structural moieties found in P-adrenoceptor agonists. Among the compounds tested in this study, N-coumaroyldopamine and N-caffeoyldopamine were the two most potent compounds, able to increase cAMP at the concentrations <0.05 mu M in U937 cells. The decreasing order of potency was N-coumaroyldopamine > N-caffeoyldopamine > N-feruloyldopamine > N-sinapoyldopamine > N-cinnamoyldopamine. Using beta 2-specific antagonists (butoxamine and ICI 118551), N-coumaroyldopamine and N-caffeoyldopamine were found to increase cAMP via beta 2-adrenoceptors in U937 cells. In producing cAMP in U937 cells, N-coumaroyldopamine and N-caffeoyldopamine were as potent as several well-known beta 2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol). These results indicate that N-coumaroyldopamine and N-caffeoyldopamine are potent compounds able to increase cAMP via beta 2-adrenoceptors in U937 cells, and may have potential effects on human health.	ARS, Phytonutrients Lab, BHNRC, USDA, Beltsville, MD 20705 USA	United States Department of Agriculture (USDA)	Park, JB (corresponding author), ARS, Phytonutrients Lab, BHNRC, USDA, Bldg 307C,Rm 131, Beltsville, MD 20705 USA.	parkj@ars.usda.gov						Albericio F, 1997, METHOD ENZYMOL, V289, P104; Alemanno L, 2003, ANN BOT-LONDON, V92, P613, DOI 10.1093/aob/mcg177; Astrup A, 2000, ENDOCRINE, V13, P207, DOI 10.1385/ENDO:13:2:207; Back K, 2001, PLANT CELL PHYSIOL, V42, P475, DOI 10.1093/pcp/pce060; Betti L, 2002, J MED CHEM, V45, P3603, DOI 10.1021/jm011077g; Blue DR, 2004, BJU INT, V93, P162, DOI 10.1111/j.1464-410X.2004.04577.x; Bradberry J Chris, 2004, J Am Pharm Assoc (2003), V44, pS37, DOI 10.1331/154434504322904596; BRIGHTLING CE, 1993, J LEUKOCYTE BIOL, V53, P559, DOI 10.1002/jlb.53.5.559; Calzada BC, 2001, PHARMACOL RES, V44, P195, DOI 10.1006/phrs.2001.0857; Cheer Susan M, 2002, Am J Respir Med, V1, P285; Cutillo F, 2003, PHYTOCHEMISTRY, V64, P1381, DOI 10.1016/S0031-9422(03)00511-9; Danesch Ulrich C, 2004, Altern Med Rev, V9, P54; GRANKVIST K, 1977, BIOCHEM J, V162, P19, DOI 10.1042/bj1620019; Ishide T, 2002, CURR MED RES OPIN, V18, P407, DOI 10.1185/030079902125001119; Kondo K, 1996, LANCET, V348, P1514, DOI 10.1016/S0140-6736(05)65927-2; Koshimizu T, 2002, BIOL PHARM BULL, V25, P401, DOI 10.1248/bpb.25.401; Kris-Etherton PM, 2000, AM J CLIN NUTR, V72, P1059; LARSSON PT, 1992, THROMB HAEMOSTASIS, V68, P687; Leineweber K, 2004, ANN MED, V36, P64, DOI 10.1080/17431380410032544; LIGGETT SB, 1989, EUR J PHARMACOL, V163, P171, DOI 10.1016/0014-2999(89)90414-7; Lo WL, 2003, NAT PROD RES, V17, P91, DOI 10.1080/1478641031000103669; Lohse MJ, 2004, TRENDS MOL MED, V10, P55, DOI 10.1016/j.molmed.2003.12.004; Makino T, 2001, BIOL PHARM BULL, V24, P1206, DOI 10.1248/bpb.24.1206; MENCIAHUERTA JM, 1991, INT ARCH ALLER A IMM, V94, P91, DOI 10.1159/000235334; Metra M, 2001, Am J Cardiovasc Drugs, V1, P3, DOI 10.2165/00129784-200101010-00001; Miller A L, 1998, Altern Med Rev, V3, P422; NOSAL R, 1992, THROMB RES, V68, P333, DOI 10.1016/0049-3848(92)90092-O; Park JB, 2002, BIOCHEM BIOPH RES CO, V292, P1104, DOI 10.1006/bbrc.2002.6752; Rein D, 2000, AM J CLIN NUTR, V72, P30; Salpeter SR, 2004, DRUG AGING, V21, P405, DOI 10.2165/00002512-200421060-00005; Sanbongi C, 1997, CELL IMMUNOL, V177, P129, DOI 10.1006/cimm.1997.1109; Schmidt A, 1999, J BIOL CHEM, V274, P4273, DOI 10.1074/jbc.274.7.4273; Small KM, 2001, TRENDS PHARMACOL SCI, V22, P471, DOI 10.1016/S0165-6147(00)01758-2; Toda N, 2003, PHARMACOL THERAPEUT, V100, P215, DOI 10.1016/j.pharmthera.2003.09.001; van der Woude Hanneke J, 2002, Am J Respir Med, V1, P55; Visioli F, 2000, CARDIOVASC RES, V47, P419, DOI 10.1016/S0008-6363(00)00053-5; Waldeck B, 2002, EUR J PHARMACOL, V445, P1, DOI 10.1016/S0014-2999(02)01728-4; Wallukat G, 2002, HERZ, V27, P683, DOI 10.1007/s00059-002-2434-z; Wang SS, 2004, LIFE SCI, V74, P2467, DOI 10.1016/j.lfs.2003.03.005; Weisburger JH, 2001, EXP BIOL MED, V226, P891, DOI 10.1177/153537020122601003; Wu PL, 2003, J NAT PROD, V66, P996, DOI 10.1021/np0301238; YAMAMOTO I, 1991, PHARMACOL BIOCHEM BE, V40, P465; Yang YL, 2002, J NAT PROD, V65, P1462, DOI 10.1021/np020191e	43	27	27	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					497	502		10.1096/fj.04-2782com	http://dx.doi.org/10.1096/fj.04-2782com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15790999				2022-12-28	WOS:000228865300033
J	Camps, J; Ponsa, I; Ribas, M; Prat, E; Egozcue, J; Peinado, MA; Miro, R				Camps, J; Ponsa, I; Ribas, M; Prat, E; Egozcue, J; Peinado, MA; Miro, R			Comprehensive measurement of chromosomal instability in cancer cells: combination of fluorescence in situ hybridization and cytokinesis-block micronucleus assay	FASEB JOURNAL			English	Article						colorectal cancer; genetic instability; aneuploidy; nondisjunction; chromosomal rearrangements	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-LYMPHOCYTES; CYTOGENETIC CHARACTERIZATION; NUCLEOPLASMIC BRIDGES; EVOLUTION; TUMORS; LINES	Most tumors show abnormal karyotypes involving either chromosome rearrangements and/or aneuploidies. The aim of our study is to measure the rate of both structural and numerical chromosome instability in two colorectal cancer cell lines: HCT116, and SW480 and its single subclones. To determine structural instability, we measured the nonclonal chromosome alterations of the last cell division by means of multicolor-fluorescence in situ hybridization (FISH). To quantify numerical instability, we used centromere-specific DNA probes to simultaneously detect chromosome loss and nondisjunctional events in binucleated cells obtained by cytokinesis-block micronucleus assay (CBMN). After clonal episodes, the structural chromosome instability rate increased significantly, confirming the large contribution of structural rearrangements to the heterogeneity of cancer cells. On the other hand, the aneuploidy rate was high and conserved in both the parental SW480 cell line and its subclones. The ability to differentiate chromosome loss and nondisjunction by the CBMN assay allowed us to conclude that no significant differences were detected among these events. Analysis of nucleoplasmic bridges, micronuclei, and nuclear blebs also demonstrated the differences among the structural instability rates of the parental cell line and its subclones. Overall, our results demonstrate the prevalence of structural over numerical chromosome instability in the subclones when comparing them with their parental cell line, confirming the contribution of ongoing chromosomal reorganizations in the generation of tumor cell heterogeneity.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Lab Citogenet, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, E-08193 Barcelona, Spain; Hosp Duran & Reynals, Inst Rec Oncol, IDIBELL, Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals	Camps, J (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Lab Citogenet, E-08193 Barcelona, Spain.	Jordi.Camps@uab.es	Peinado, Miguel A./A-5591-2008; Camps, Jordi/AAG-3080-2020	Peinado, Miguel A./0000-0002-4090-793X; Camps, Jordi/0000-0002-3165-3640; Ponsa, Immaculada/0000-0003-3436-1907; miro, rosa/0000-0003-2508-5074				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Camps J, 2004, ONCOL REP, V11, P1215; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fabarius A, 2003, CANCER GENET CYTOGEN, V143, P59, DOI 10.1016/S0165-4608(03)00003-7; Fenech M, 2002, DRUG DISCOV TODAY, V7, P1128, DOI 10.1016/S1359-6446(02)02502-3; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2003, MUTAT RES-GEN TOX EN, V534, P65, DOI 10.1016/S1383-5718(02)00249-8; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Gutierrez Norma C, 2003, Hematol J, V4, P67, DOI 10.1038/sj.thj.6200226; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; Masramon L, 2000, CANCER GENET CYTOGEN, V121, P17, DOI 10.1016/S0165-4608(00)00219-3; Mitelman F, 1995, INT SYSTEM HUMAN CYT; NORPPA H, 1993, MUTAGENESIS, V8, P519, DOI 10.1093/mutage/8.6.519; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ponsa I, 2001, RADIAT RES, V155, P424, DOI 10.1667/0033-7587(2001)155[0424:NDACLI]2.0.CO;2; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Ribas M, 2002, FASEB J, V16, P289, DOI 10.1096/fj.02-0425fje; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Thomas P, 2003, MUTAGENESIS, V18, P187, DOI 10.1093/mutage/18.2.187; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; WEIER HUG, 1991, HUM GENET, V87, P489	30	38	39	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					828	+		10.1096/fj.04-2276fje	http://dx.doi.org/10.1096/fj.04-2276fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15760839				2022-12-28	WOS:000227901300021
J	Castino, R; Isidoro, C; Murphy, D				Castino, R; Isidoro, C; Murphy, D			Autophagy-dependent cell survival and cell death in an autosomal dominant familial neurohypophyseal diabetes insipidus in vitro model	FASEB JOURNAL			English	Article						vasopressin; apoptosis; dopamine; adFNDI	ENDOSOMAL-LYSOSOMAL SYSTEM; HYPOTHALAMIC NEURONS; APOPTOSIS; INHIBITION; HEREDITARY; MECHANISMS; RELEASE; GENE; POLYGLUTAMINE; EXPANSIONS	Mutations in the human gene encoding the antidiuretic hormone vasopressin (VP) cause autosomal dominant familial neurohypophyseal diabetes insipidus (adFNDI), a rare inherited disorder that presents as polydipsia and polyuria as a consequence of a loss of secretion of VP from posterior pituitary nerve terminals. Work from our laboratories has shown that adFNDI, like other neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's, is associated with autophagy. We have recently shown that the activation of autophagy in mouse neuroblastoma Neuro2a cells after adenoviral vector-mediated delivery of an adFNDI mutant VP transgene (Cys67stop) is a cell survival mechanism; its inhibition induces apoptosis. We now show that expression of Cys67stop sensitizes Neuro2a cells to the lethal effects of dopamine. This mode of cell death exhibits features typically associated with classical apoptosis. Yet inhibition of autophagy reversed these effects and rescued cell viability. We propose that autophagy-mediated cell death is a "two-hit" process: Following the cellular stress of the accumulation of a misfolded mutant protein, autophagy is prosurvival. However, a second insult triggers an autophagy-dependent apoptosis.	Henry Wellcome Labs Integrat Neurosci & Endocrino, Mol Neuroendocrinol Res Grp, Bristol BS1 3NY, Avon, England; Amedeo Avogadro Univ, Dept Med Sci, Lab Mol Pathol, Novara, Italy	University of Bristol; University of Eastern Piedmont Amedeo Avogadro	Murphy, D (corresponding author), Henry Wellcome Labs Integrat Neurosci & Endocrino, Mol Neuroendocrinol Res Grp, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	d.murphy@bristol.ac.uk	Murphy, David/C-3967-2012; Isidoro, Ciro/J-6063-2016	Murphy, David/0000-0003-2946-0353; Isidoro, Ciro/0000-0002-5494-3034	Biotechnology and Biological Sciences Research Council [S18346] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; Castino R, 2002, INT J CANCER, V97, P775, DOI 10.1002/ijc.10139; CASTINO R, 2005, FASEB J EXPRESS, DOI DOI 10.1096/F4.04-3162FJE; Cataldo AM, 1996, J NEUROSCI, V16, P186; Chen C, 2000, BIOCHEM BIOPH RES CO, V270, P816, DOI 10.1006/bbrc.2000.2520; Chen Quan, 2001, ScientificWorldJournal, V1, P142, DOI 10.1100/tsw.2001.233; Christensen JH, 2004, CLIN ENDOCRINOL, V60, P125, DOI 10.1111/j.1365-2265.2004.01953.x; Christensen JH, 2004, EUR J HUM GENET, V12, P44, DOI 10.1038/sj.ejhg.5201086; Christensen JH, 2003, APMIS, V111, P92; CUEVO AM, 2004, TRENDS CELL BIOL, V14, P70; Davies J, 2002, J NEUROENDOCRINOL, V14, P629, DOI 10.1046/j.1365-2826.2002.00822.x; de Bree FM, 2000, FEBS LETT, V475, P175, DOI 10.1016/S0014-5793(00)01623-9; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; Harding TC, 1997, J NEUROCHEM, V69, P2620; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; Jellinger K. A., 2000, Journal of Neural Transmission Supplement, V60, P21; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Jellinger KA, 2000, J NEURAL TRANSM-SUPP, P95; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Lim MLR, 2002, J BIOMED SCI, V9, P488, DOI 10.1159/000064722; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Munafo DB, 2001, J CELL SCI, V114, P3619; NAGAI I, 1984, ACTA ENDOCRINOL-COP, V105, P318, DOI 10.1530/acta.0.1050318; NAGASAKI H, 1995, J CLIN ENDOCR METAB, V80, P1352, DOI 10.1210/jc.80.4.1352; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; REEVES WB, 1992, WILLIAMS TXB ENDOCRI, P311; Russell TA, 2003, J CLIN INVEST, V112, P1697, DOI 10.1172/JCI200318616; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Sharman G, 2004, PROG BIOPHYS MOL BIO, V84, P151, DOI 10.1016/j.pbiomolbio.2003.11.005; Si-Hoe SL, 2000, FASEB J, V14, P1680; Waller S, 1996, ENDOCRINOLOGY, V137, P5068, DOI 10.1210/en.137.11.5068; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	49	43	45	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1024	+		10.1096/fj.04-3163fje	http://dx.doi.org/10.1096/fj.04-3163fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15781608				2022-12-28	WOS:000227901300010
J	Maertens, G; Vercammen, J; Debyser, Z; Engelborghs, Y				Maertens, G; Vercammen, J; Debyser, Z; Engelborghs, Y			Measuring protein-protein interactions inside living cells using single color fluorescence correlation spectroscopy. Application to human immunodeficiency virus type I integrase and LEDGF/p75	FASEB JOURNAL			English	Article						HIV-1 integrase; microscopy; intracellular diffusion; GFP; FCS	AMINO-ACID-RESIDUES; HIV-1 INTEGRASE; 2-PHOTON EXCITATION; NONDIVIDING CELLS; DNA INTEGRATION; PREINTEGRATION COMPLEXES; TRANSLATIONAL DIFFUSION; CORRELATION MICROSCOPY; NUCLEAR-LOCALIZATION; CROSS-CORRELATION	Recently we described the interaction of human immunodeficiency virus type 1 (HIV-1)(1) integrase (IN) with a cellular protein, lens epithelium-derived growth factor/transcription coactivator p75 (LEDGF/p75). We now present the study of the diffusion behavior of the three independent domains of IN and LEDGF/p75 using fluorescence correlation microscopy (FCM). We show that diffusion in the cell of the different enhanced green fluorescent protein (EGFP) fusion proteins is described by two components with different fractions and that the average parameters in the nucleus are comparable with those in the cytoplasm. In addition, we demonstrate that specific interaction between EGFP-fused HIV-1 IN and LEDGF/p75 results in a shift in diffusion coefficient (D). The opposite shift was observed in an IN-deletion mutant that does not exhibit LEDGF/p75 binding or in a LEDGF/p75 knock-down experiment using siRNA. We thus demonstrate that protein-protein interactions can be studied in living cells, using single-color FCM (scFCM).	Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Engelborghs, Y (corresponding author), Katholieke Univ Leuven, Lab Biomol Dynam, Celestijnenlaan 200D, B-3001 Louvain, Belgium.	Yves.Engelborghs@fys.kuleuven.ac.be	Maertens, Goedele/D-8628-2015	Maertens, Goedele/0000-0002-1963-8026				Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Bacia K, 2002, BIOPHYS J, V83, P1184, DOI 10.1016/S0006-3495(02)75242-9; Billinton N, 2001, ANAL BIOCHEM, V291, P175, DOI 10.1006/abio.2000.5006; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Brown P. O., 1997, P161; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; CHEREPANOV P, 2004, J BIOL CHEM, V14, P14; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; Engelman A, 2003, CURR TOP MICROBIOL, V281, P209; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gallop MA, 1997, CURR OPIN CHEM BIOL, V1, P94, DOI 10.1016/S1367-5931(97)80114-7; Hess ST, 2003, BIOPHYS J, V85, P2566, DOI 10.1016/S0006-3495(03)74679-7; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Kim SA, 2004, P NATL ACAD SCI USA, V101, P105, DOI 10.1073/pnas.2436461100; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; LLANO M, 2004, J BIOL CHEM, V8, P8; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Moreau K, 2004, VIROLOGY, V318, P566, DOI 10.1016/j.virol.2003.09.037; Moreau K, 2003, EUR J BIOCHEM, V270, P4426, DOI 10.1046/j.1432-1033.2003.03833.x; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043; QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185; Rauer B, 1996, BIOPHYS CHEM, V58, P3, DOI 10.1016/0301-4622(95)00080-1; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Ruan QQ, 2002, BIOPHYS J, V83, P3177, DOI 10.1016/S0006-3495(02)75320-4; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; Turlure F, 2004, FRONT BIOSCI-LANDMRK, V9, P3187, DOI 10.2741/1472; Van Craenenbroeck  E, 2000, J MOL RECOGNIT, V13, P93, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<93::AID-JMR492>3.0.CO;2-6; Vodicka Marie A., 2001, Somatic Cell and Molecular Genetics, V26, P35, DOI 10.1023/A:1021022629126; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; Wang ZF, 2004, J BIOMED OPT, V9, P395, DOI 10.1117/1.1646416; Woodward CL, 2003, J VIROL, V77, P4516, DOI 10.1128/JVI.77.8.4516-4527.2003	58	36	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1039	+		10.1096/fj.04-3373fje	http://dx.doi.org/10.1096/fj.04-3373fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788449				2022-12-28	WOS:000227901300003
J	Devchand, PR; Schmidt, BA; Primo, VC; Zhang, QY; Arnaout, MA; Serhan, CN; Nikolic, B				Devchand, PR; Schmidt, BA; Primo, VC; Zhang, QY; Arnaout, MA; Serhan, CN; Nikolic, B			A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils	FASEB JOURNAL			English	Article						eicosanoids; lipoxin; LXA(4) receptor; complex inflammatory diseases	DISEASE; ASPIRIN; INFLAMMATION; TRAFFICKING; RECRUITMENT; INHIBITION; A(4)	Lipoxin A(4) (LXA(4)) and aspirin-triggered 15-epi-LXA(4) are potent endogenous lipid mediators thought to define the inflammatory set-point. We used single prophylactic administrations of a synthetic aspirin-triggered lipoxin A(4) signal mimetic, ATLa, to probe dynamics of early host-donor interactions in a mouse model for the inflammation-associated multifactorial disease of allogeneic bone marrow transplant (BMT) - induced graft-vs.-host disease (GvHD). We first demonstrated that both host and donor are responsive to the ATLa signals. The simple and restricted regimen of a single prophylactic administration of ATLa [ 100 ng/mL to donor cells or 1 mu g (similar to 50 mu g/kg) i. v. to host] was sufficient to delay death. Clinical indicators of weight, skin lesions, diarrhea and eye inflammation were monitored. Histological analyses on day 45 post-BMT showed that the degree of cellular trafficking, particularly neutrophil infiltrate, and protection of end-organ target pathology are different, depending on whether the host or donor was treated with ATLa. Taken together, these results chart some ATLa protective effects on GvHD cellular dynamics over time and identify a previously unrecognized effect of host neutrophils in the early phase post-BMT as important determinants in the dynamics of GvHD onset and progression.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Renal, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Serhan, CN (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Thorn Bldg Med Res,75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu; bnikolic@partners.org			NIAMS NIH HHS [K01-AR02219] Funding Source: Medline; NIDDK NIH HHS [K08-DK59919, P01-DK50305] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059919, P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R29GM038765, R37GM038765] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blazar BR, 1997, IMMUNOL REV, V157, P79, DOI 10.1111/j.1600-065X.1997.tb00976.x; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gewirtz AT, 2002, J IMMUNOL, V168, P5260, DOI 10.4049/jimmunol.168.10.5260; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kim YM, 2003, J CLIN INVEST, V111, P659, DOI 10.1172/JCI200316950; Leonard MO, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015795.74094.91; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nikolic B, 1997, CURR OPIN IMMUNOL, V9, P634, DOI 10.1016/S0952-7915(97)80042-8; Nikolic B, 2000, J CLIN INVEST, V105, P1289, DOI 10.1172/JCI7894; Perretti M, 2004, J LEUKOCYTE BIOL, V76, P25, DOI 10.1189/jlb.1103552; Qiu FH, 2001, FASEB J, V15, P2736, DOI 10.1096/fj.01-0576fje; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Souza MHLP, 2003, AM J PHYSIOL-GASTR L, V285, pG54, DOI 10.1152/ajpgi.00525.2002; Wallace JL, 2003, TRENDS PHARMACOL SCI, V24, P323, DOI 10.1016/S0165-6147(03)00166-4	21	24	27	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					203	210		10.1096/fj.04-2565com	http://dx.doi.org/10.1096/fj.04-2565com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677343				2022-12-28	WOS:000227591900024
J	Ohyagi, Y; Asahara, H; Chui, DH; Tsuruta, Y; Sakae, N; Miyoshi, K; Yamada, T; Kikuchi, H; Taniwaki, T; Murai, H; Ikezoe, K; Furuya, H; Kawarabayashi, T; Shoji, M; Checler, F; Iwaki, T; Makifuchi, T; Takeda, K; Kira, JI; Tabira, T				Ohyagi, Y; Asahara, H; Chui, DH; Tsuruta, Y; Sakae, N; Miyoshi, K; Yamada, T; Kikuchi, H; Taniwaki, T; Murai, H; Ikezoe, K; Furuya, H; Kawarabayashi, T; Shoji, M; Checler, F; Iwaki, T; Makifuchi, T; Takeda, K; Kira, JI; Tabira, T			Intracellular A beta 42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease	FASEB JOURNAL			English	Article									Kyushu Univ, Dept Neurol, Grad Sch Med Sci,Neurol Inst, Higashi-ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Neuropathol, Grad Sch Med Sci, Neurol Inst, Fukuoka, Japan; NCNP, Natl Inst Neurosci, Div Demyelinating Dis & Aging, Tokyo, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Neurol, Okayama, Japan; Inst Pharmacol Mol & Cellulaire, Valbonne, France; Natl Saigata Hosp, Dept Clin Res, Niigata, Japan; Natl Inst Longev Sci, Aichi, Japan	Kyushu University; Kyushu University; National Center for Neurology & Psychiatry - Japan; Okayama University; UDICE-French Research Universities; Universite Cote d'Azur	Ohyagi, Y (corresponding author), Kyushu Univ, Dept Neurol, Grad Sch Med Sci,Neurol Inst, Higashi-ku, 311 Maidashi, Fukuoka 8128582, Japan.	ohyagi@neuro.med.kyushu-u.ac.jp	Checler, Frederic/C-1241-2009	Checler, Frederic/0000-0003-2098-1750; Shoji, Mikio/0000-0003-1027-1712					0	210	228	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					255	257		10.1096/fj.04-2637fje	http://dx.doi.org/10.1096/fj.04-2637fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15548589				2022-12-28	WOS:000227591900029
J	Chung, TW; Moon, SK; Chang, YC; Ko, JH; Lee, YC; Cho, G; Kim, SH; Kim, JG; Kim, CH				Chung, TW; Moon, SK; Chang, YC; Ko, JH; Lee, YC; Cho, G; Kim, SH; Kim, JG; Kim, CH			Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism	FASEB JOURNAL			English	Article						hepatocellular carcinoma; tumor regression; Euonymus alatus; MMP-9; NF-kappa B; CAPE; xenograft	NF-KAPPA-B; MATRIX-METALLOPROTEINASE INHIBITOR; ACTIVATED PROTEIN-KINASE; PHENETHYL ESTER; HEPATOCELLULAR-CARCINOMA; TUMOR ANGIOGENESIS; BINDING-ACTIVITY; EXPRESSION; CANCER; MATRIX-METALLOPROTEINASE-9	Our previous studies have clearly shown that the angiogenic enzymes, matrix metalloproteinase (MMP) -2/9, are directly involved in human hepatic tumorigenesis and metastasis and suggest that the MMP-2/9 inhibitors, which have dual inhibitory activities on enzyme activity and transcription, represent the best candidates for achieving tumor regression. Many anti-cancer drugs have strong cellular cytotoxicity and side effects, indicating that strong anti-cancer drugs that have no or minimal cytotoxicity and side effects need to be developed. The specific aim of the present study was to develop powerful anti-cancer drugs with specific tumor regression and anti-metastatic potential having the dual inhibitory activities of specific MMP-2 and -9 enzyme activities and gene transcription at the molecular level. Caffeic acid (CA), a strong and selective MMP-9 activity and transcription inhibitor, was isolated from the plant Euonymus alatus and its derivative, caffeic acid phenethyl ester (CAPE), was synthesized. CA and CAPE selectively inhibited MMP-2 and -9 but not -1, -3, -7, or cathepsin K. Treatment of HepG2 cells with CA (100 mug/mL) and CAPE (5 mug/mL) suppressed phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression by inhibiting the function of NF-kappaB, but not AP-1. We confirmed that CA and CAPE suppressed the growth of HepG2 tumor xenografts in nude mice in vivo. The subcutaneous and oral administrations of CA and CAPE significantly reduced the liver metastasis. These results confirm the therapeutic potential of the compounds and suggest that the anti-metastatic and anti-tumor effects of CA and CAPE are mediated through the selective suppression of MMP-9 enzyme activity and transcriptional down-regulation by the dual inhibition of NF-kappaB as well as MMP-9 catalytic activity.	Dongguk Univ, Natl Res Lab Glycobiol, Coll Oriental Med, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Dept Biochem & Mol Biol, Coll Oriental Med, Kyungju 780714, Kyungbuk, South Korea; Daegu Catholic Univ, Dept Pathol, Coll Med, Taegu, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon, South Korea; Dong A Univ, Fac Biotechnol, Pusan, South Korea; Korea Basic Sci Res Inst, Proteome Anal Team, Taejon, South Korea; Kyungpook Natl Univ, Dept Microbiol, Taegu, South Korea	Dongguk University; Dongguk University; Catholic University of Daegu; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Dong A University; Korea Basic Science Institute (KBSI); Kyungpook National University	Kim, CH (corresponding author), Dongguk Univ, Natl Res Lab Glycobiol, Coll Oriental Med, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr	Ko, Jae-Hyeon/I-4133-2019	Ko, Jae-Hyeon/0000-0001-7766-2385; Chung, Tae-Wook/0000-0001-5243-5020; Kim, Cheorl-Ho/0000-0002-6323-0714				Abiru S, 2002, HEPATOLOGY, V35, P1117, DOI 10.1053/jhep.2002.32676; Arai K, 2003, GLIA, V43, P254, DOI 10.1002/glia.10255; Arii S, 1996, HEPATOLOGY, V24, P316; Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Cha BY, 2003, J ETHNOPHARMACOL, V85, P163, DOI 10.1016/S0378-8741(02)00373-2; CHAN WS, 1995, ANTICANCER RES, V15, P703; Chung TW, 2002, ARCH BIOCHEM BIOPHYS, V408, P147, DOI 10.1016/S0003-9861(02)00522-2; Chung TW, 2003, CANCER RES, V63, P3453; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Demeule M, 2000, BBA-PROTEIN STRUCT M, V1478, P51, DOI 10.1016/S0167-4838(00)00009-1; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Fernandez MA, 1998, J PHARM PHARMACOL, V50, P1183, DOI 10.1111/j.2042-7158.1998.tb03332.x; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRENKEL K, 1993, CANCER RES, V53, P1255; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gatto C, 1999, CLIN CANCER RES, V5, P3603; GRUNBERGER D, 1988, EXPERIENTIA, V44, P230, DOI 10.1007/BF01941717; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hah N, 2003, BIOCHEM BIOPH RES CO, V305, P428, DOI 10.1016/S0006-291X(03)00788-5; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003; Kaegi E, 1998, CAN MED ASSOC J, V158, P1033; KASHIWADA Y, 1995, J NAT PRODUCTS, V58, P392, DOI 10.1021/np50117a007; Katori H, 2002, CANCER LETT, V178, P151, DOI 10.1016/S0304-3835(01)00837-0; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KOHN EC, 1995, CANCER RES, V55, P1856; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; Lozonschi L, 1999, CANCER RES, V59, P1252; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Maekawa R, 1999, CANCER RES, V59, P1231; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; Michaluart P, 1999, CANCER RES, V59, P2347; Mirzoeva OK, 1996, FEBS LETT, V396, P266, DOI 10.1016/0014-5793(96)01111-8; Nagaoka T, 2003, BIOL PHARM BULL, V26, P638; Nagaoka T, 2002, BIOORGAN MED CHEM, V10, P3351, DOI 10.1016/S0968-0896(02)00138-4; Nardini M, 2001, FREE RADICAL BIO MED, V30, P722, DOI 10.1016/S0891-5849(00)00515-3; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PLOEMEN JHTM, 1993, FOOD CHEM TOXICOL, V31, P475, DOI 10.1016/0278-6915(93)90106-9; Sakamoto Y, 2000, INT J ONCOL, V17, P237; Sato T, 2002, CANCER RES, V62, P1025; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Shahidi F., 1995, FOOD PHENOLICS SOURC; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Sugita K, 1999, IDrugs, V2, P327; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; TANAKA T, 1993, CARCINOGENESIS, V14, P1321, DOI 10.1093/carcin/14.7.1321; Tonn JC, 1999, INT J CANCER, V80, P764, DOI 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J; Vieira O, 1998, BIOCHEM PHARMACOL, V55, P333, DOI 10.1016/S0006-2952(97)00470-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wojtowicz-Praga S, 1999, Drugs R D, V1, P117, DOI 10.2165/00126839-199901020-00001; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	65	306	323	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1670	1681		10.1096/fj.04-2126com	http://dx.doi.org/10.1096/fj.04-2126com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522912				2022-12-28	WOS:000225482100035
J	Golan-Mashiach, M; Dazard, JE; Gerecht-Nir, S; Amariglio, N; Fisher, T; Jacob-Hirsch, J; Bielorai, B; Osenberg, S; Barad, O; Getz, G; Toren, A; Rechavi, G; Itskovitz-Eldor, J; Domany, E; Givol, D				Golan-Mashiach, M; Dazard, JE; Gerecht-Nir, S; Amariglio, N; Fisher, T; Jacob-Hirsch, J; Bielorai, B; Osenberg, S; Barad, O; Getz, G; Toren, A; Rechavi, G; Itskovitz-Eldor, J; Domany, E; Givol, D			Design principle of gene expression used by human stem cells: implication for pluripotency	FASEB JOURNAL			English	Article						differentiation; self-renewal; microarray; clustering	HEMATOPOIETIC STEM; MOLECULAR SIGNATURE; ES CELLS; DIFFERENTIATION; MOUSE; MAINTENANCE; LINES; P63; MORPHOGENESIS; KERATINOCYTES	Human embryonic stem cells (ESC) are undifferentiated and are endowed with the capacities of self-renewal and pluripotential differentiation. Adult stem cells renew their own tissue, but whether they can transdifferentiate to other tissues is still controversial. To understand the genetic program that underlies the pluripotency of stem cells, we compared the transcription profile of ESC with that of progenitor/stem cells of human hematopoietic and keratinocytic origins, along with their mature cells to be viewed as snapshots along tissue differentiation. ESC gene profiles show higher complexity with significantly more highly expressed genes than adult cells. We hypothesize that ESC use a strategy of expressing genes that represent various differentiation pathways and selection of only a few for continuous expression upon differentiation to a particular target. Such a strategy may be necessary for the pluripotency of ESC. The progenitors of either hematopoietic or keratinocytic cells also follow the same design principle. Using advanced clustering, we show that many of the ESC expressed genes are turned off in the progenitors/stem cells followed by a further down-regulation in adult tissues. Concomitantly, genes specific to the target tissue are up-regulated toward mature cells of skin or blood.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Case Western Reserve Univ, Dept Epidemiol & Biostat, Sch Med, Cleveland, OH 44106 USA; Tel Aviv Univ, Dept Pediat Hematol Oncol, Chaim Sheba Med Ctr, IL-52621 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-52621 Tel Aviv, Israel; Technion Israel Inst Technol, Fac Med, Rambam Med Ctr, Dept Obstet & Gynecol, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rambam Med Ctr, Biotechnol Interdisciplinary Unit, Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Case Western Reserve University; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	david.givol@weizmann.ac.il	DOMANY, EYTAN/K-1560-2012					Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Blanchard F, 2002, MOL BIOL CELL, V13, P1536, DOI 10.1091/mbc.02-02-0010; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Handgretinger R, 2003, ANN NY ACAD SCI, V996, P141, DOI 10.1111/j.1749-6632.2003.tb03242.x; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sakuma R, 2002, GENES CELLS, V7, P401, DOI 10.1046/j.1365-2443.2002.00528.x; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sokal R.R., 2012, BIOMETRY; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tosh D, 2002, NAT REV MOL CELL BIO, V3, P187, DOI 10.1038/nrm761; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; Vanhoutteghem A, 2004, P NATL ACAD SCI USA, V101, P3468, DOI 10.1073/pnas.0400268101; Xu CH, 1999, DEVELOPMENT, V126, P483; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; YANAI I, 2004, BIOINFORMATICS  0930, DOI DOI 10.1093/BIOINFORMATICS/BTI042; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012	50	59	61	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					147	149		10.1096/fj.04-2417fje	http://dx.doi.org/10.1096/fj.04-2417fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15498892	Green Submitted			2022-12-28	WOS:000224849900010
J	Suganami, T; Mukoyama, M; Mori, K; Yokoi, H; Koshikawa, M; Sawai, K; Hidaka, S; Ebihara, K; Tanaka, T; Sugawara, A; Kawachi, H; Vinson, C; Ogawa, Y; Nakao, K				Suganami, T; Mukoyama, M; Mori, K; Yokoi, H; Koshikawa, M; Sawai, K; Hidaka, S; Ebihara, K; Tanaka, T; Sugawara, A; Kawachi, H; Vinson, C; Ogawa, Y; Nakao, K			Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy	FASEB JOURNAL			English	Article						lipoatrophic diabetes; TGF-beta 1; podocytes; proteinuria; transgenic mice	MICE OVEREXPRESSING LEPTIN; MATRIX GENE-EXPRESSION; GROWTH-FACTOR-BETA; TGF-BETA; PANCREAS TRANSPLANTATION; EXTRACELLULAR-MATRIX; INSULIN SENSITIVITY; GLUCOSE-METABOLISM; HYPERTENSIVE-RATS; TRANSGENIC MICE	Diabetic nephropathy is the leading cause of end-stage renal disease, for which effective therapy to prevent the progression at advanced stages remains to be established. There is also a long debate whether diabetic glomerular injury is reversible or not. Lipoatrophic diabetes, a syndrome caused by paucity of adipose tissue, is characterized by severe insulin resistance, dyslipidemia, and fatty liver. Here, we show that a genetic model of lipoatrophic diabetes (A-ZIP/F-1 mice) manifests a typical renal injury observed in human diabetic nephropathy that is associated with glomerular hypertrophy, diffuse and pronounced mesangial widening, accumulation of extracellular matrix proteins, podocyte damage, and overt proteinuria. By crossing A-ZIP/F-1 mice with transgenic mice overexpressing an adipocyte-derived hormone leptin, we also reveal that leptin completely prevents the development of hyperglycemia and nephropathy in A-ZIP/F-1 mice. Furthermore, continuous leptin administration to A-ZIP/F-1 mice by minipump beginning at 40 weeks of age significantly alleviates the glomerular injury and proteinuria. These findings demonstrate the therapeutic usefulness of leptin at least for a certain type of diabetic nephropathy. The model presented here will serve as a novel tool to analyze the molecular mechanism underlying not only the progression but also the regression of diabetic nephropathy.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Niigata Univ, Dept Cell Biol, Inst Nephrol, Grad Sch Med & Dent Sci, Niigata, Japan	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Niigata University	Mukoyama, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	muko@kuhp.kyoto-u.ac.jp	SUGANAMI, Takayoshi/A-9475-2016; Mori, Kiyoshi/N-1267-2014; Yokoi, Hideki/AAV-9038-2021; Yokoi, Hideki/R-1289-2016	Mori, Kiyoshi/0000-0002-7285-8351; Yokoi, Hideki/0000-0001-8343-9737; Yokoi, Hideki/0000-0001-8343-9737; Ogawa, Yoshihiro/0000-0002-0834-2836	NATIONAL CANCER INSTITUTE [ZIABC005271, Z01BC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUNA GM, 1983, LANCET, V2, P1274; Aizawa-Abe M, 2000, J CLIN INVEST, V105, P1243, DOI 10.1172/JCI8341; Andreelli F, 2000, J CLIN ENDOCR METAB, V85, P715, DOI 10.1210/jc.85.2.715; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Chen S, 2003, BIOCHEM BIOPH RES CO, V300, P16, DOI 10.1016/S0006-291X(02)02708-0; Doublier S, 2003, DIABETES, V52, P1023, DOI 10.2337/diabetes.52.4.1023; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Fioretto P, 1998, NEW ENGL J MED, V339, P69, DOI 10.1056/NEJM199807093390202; GOLDSTEIN BJ, 1994, SYNDROME EXTREME INS; Ikejima K, 2002, GASTROENTEROLOGY, V122, P1399, DOI 10.1053/gast.2002.32995; Kawachi H, 2000, KIDNEY INT, V57, P1949, DOI 10.1046/j.1523-1755.2000.00044.x; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Koop K, 2003, J AM SOC NEPHROL, V14, P2063, DOI 10.1097/01.ASN.0000078803.53165.C9; Kopp JB, 1996, LAB INVEST, V74, P991; Masuzaki H, 1999, DIABETES, V48, P1615, DOI 10.2337/diabetes.48.8.1615; Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447; Miyanaga F, 2003, DIABETOLOGIA, V46, P1329, DOI 10.1007/s00125-003-1193-6; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; ORLOFF MJ, 1986, DIABETES, V35, P347, DOI 10.2337/diabetes.35.3.347; Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; Sawai K, 2003, J AM SOC NEPHROL, V14, P1154, DOI 10.1097/01.ASN.0000060576.61218.3D; Saxena NK, 2003, J CELL BIOCHEM, V89, P311, DOI 10.1002/jcb.10494; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; Suganami T, 2003, HYPERTENSION, V42, P1183, DOI 10.1161/01.HYP.0000101689.64849.97; Suganami T, 2001, J HYPERTENS, V19, P1095, DOI 10.1097/00004872-200106000-00015; Suganami T, 2001, J AM SOC NEPHROL, V12, P2652, DOI 10.1681/ASN.V12122652; WAJCHENBERG BL, 1983, ACTA DIABETOL LAT, V20, P1, DOI 10.1007/BF02629124; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; Wolf G, 1999, KIDNEY INT, V56, P860, DOI 10.1046/j.1523-1755.1999.00626.x; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yaoita E, 2002, AM J PATHOL, V161, P1597, DOI 10.1016/S0002-9440(10)64438-0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	39	46	49	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					127	+		10.1096/fj.04-2183fje	http://dx.doi.org/10.1096/fj.04-2183fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15496495				2022-12-28	WOS:000224849900014
J	Borkow, G; Gabbay, J				Borkow, G; Gabbay, J			Putting copper into action: copper-impregnated products with potent biocidal activities	FASEB JOURNAL			English	Article						HIV-1; filters; fabrics; dust mites; athlete's foot	PLASMA-MEMBRANE; TINEA-PEDIS; METAL-IONS; VIRUS; INACTIVATION; HIV-1; RISK; TRANSMISSION; TRANSFUSION; MECHANISMS	Copper ions, either alone or in copper complexes, have been used for centuries to disinfect liquids, solids, and human tissue. Today copper is used as a water purifier, algaecide, fungicide, nematocide, molluscicide, and antibacterial and antifouling agent. Copper also displays potent antiviral activity. We hypothesized that introducing copper into clothing, bedding, and other articles would provide them with biocidal properties. A durable platform technology has been developed that introduces copper into cotton fibers, latex, and other polymeric materials. This study demonstrates the broad-spectrum antimicrobial ( antibacterial, antiviral, antifungal) and antimite activities of copper-impregnated fibers and polyester products. This technology enabled the production of antiviral gloves and filters (which deactivate HIV-1 and other viruses), antibacterial self-sterilizing fabrics (which kill antibiotic-resistant bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci), antifungal socks (which alleviate symptoms of athlete's foot), and anti-dust mite mattress covers (which reduce mite-related allergies). These products did not have skin-sensitizing properties, as determined by guine pig maximization and rabbit skin irritation tests. Our study demonstrates the potential use of copper in new applications. These applications address medical issues of the greatest importance, such as viral transmissions; nosocomial, or healthcare-associated, infections; and the spread of antibiotic-resistant bacteria.	Cupron Inc, New York, NY 10165 USA		Borkow, G (corresponding author), Hameyasdim 44, IL-76910 Kfar Gibton, Israel.	gadi@cupron.com	Borkow, Gadi/W-4294-2019					[Anonymous], 1999, [No title captured], Patent No. 5871816; [Anonymous], DISINFECTION STERILI; AUGER P, 1993, MYCOSES, V36, P35, DOI 10.1111/j.1439-0507.1993.tb00685.x; Avery SV, 1995, BIOCHEM J, V312, P811, DOI 10.1042/bj3120811; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; Bilian X, 2002, BEST PRACT RES CL OB, V16, P155, DOI 10.1053/beog.2002.0267; Borkow G, 1997, BIOCHEMISTRY-US, V36, P3179, DOI 10.1021/bi9624696; Brunton SA, 1999, HOSP PRACT, V34, P67, DOI 10.3810/hp.1999.09.15.165; CERVANTES C, 1994, FEMS MICROBIOL REV, V14, P121, DOI 10.1016/0168-6445(94)90002-7; Cooney JJ, 1999, METHOD ENZYMOL, V310, P637; COONEY TE, 1995, INFECT CONT HOSP EP, V16, P444; CORONEL D, 2000, REANIMATION, V9, P86; CORONEL D, 2001, REANIMATION S, V10, P43; DOLLWET HHA, 1985, TRACE ELEM MED, V2, P80; *FDA, 2003, MIN SAF EFF METH RED; Fowler MG, 2002, J ACQ IMMUN DEF SYND, V30, P230, DOI [10.1097/00042560-200206010-00012, 10.1097/01.QAI.0000018364.28828.14]; FRASER WD, 2001, 211 INCRA HUNT RES C, P43; Goodnough LT, 2003, LANCET, V361, P161, DOI 10.1016/S0140-6736(03)12195-2; HAZEL JR, 1990, PROG LIPID RES, V29, P167, DOI 10.1016/0163-7827(90)90002-3; Hellstern P, 2002, THROMB RES, V107, pS3, DOI 10.1016/S0049-3848(02)00145-7; Hess C, 2002, LANCET, V359, P2230, DOI 10.1016/S0140-6736(02)09291-7; Hostynek Jurij J, 2003, Rev Environ Health, V18, P153; Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438; International Diabetes Federation, 2000, DIAB ATL; JORDAN FTW, 1971, VET REC, V89, P609, DOI 10.1136/vr.89.23.609; KARLSTROM AR, 1991, P NATL ACAD SCI USA, V88, P5552, DOI 10.1073/pnas.88.13.5552; Kim JH, 2000, ARCH BIOCHEM BIOPHYS, V382, P72, DOI 10.1006/abbi.2000.1996; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Lacroix C, 2002, J EUR ACAD DERMATOL, V16, P139, DOI 10.1046/j.1468-3083.2002.00400.x; Louder MK, 1999, METH MOLEC MED, V17, P23, DOI 10.1385/0-89603-369-4:23; MAGNUSSON B, 1980, CONTACT DERMATITIS, V6, P46, DOI 10.1111/j.1600-0536.1980.tb03894.x; Mascola Jr, 1999, METH MOLEC MED, V17, P317, DOI 10.1385/0-89603-369-4:317; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Redd SC, 2002, ENVIRON HEALTH PERSP, V110, P557, DOI 10.1289/ehp.02110s4557; ROBINSON MK, 1989, FOOD CHEM TOXICOL, V27, P479, DOI 10.1016/0278-6915(89)90036-7; RODRIGUEZMONTELONGO L, 1993, BIOCHIM BIOPHYS ACTA, V1144, P77, DOI 10.1016/0005-2728(93)90033-C; Sagripanti JL, 1996, AIDS RES HUM RETROV, V12, P333, DOI 10.1089/aid.1996.12.333; Sagripanti JL, 1997, ANTIMICROB AGENTS CH, V41, P812, DOI 10.1128/AAC.41.4.812; SAGRIPANTI JL, 1993, APPL ENVIRON MICROB, V59, P4374, DOI 10.1128/AEM.59.12.4374-4376.1993; Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X; Skoner D, 2000, J ALLERGY CLIN IMMUN, V105, pS16, DOI 10.1016/S0091-6749(00)90479-2; Snyder E L, 2001, Hematology Am Soc Hematol Educ Program, P433; SPENCER RC, 1994, INTENS CARE MED, V20, pS2, DOI 10.1007/BF01713975; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Stout JE, 1998, INFECT CONT HOSP EP, V19, P911; Strong DM, 2002, TRENDS MOL MED, V8, P355, DOI 10.1016/S1471-4914(02)02361-4; UEDA K, 1980, CHEM-BIOL INTERACT, V29, P145, DOI 10.1016/0009-2797(80)90029-0; YAHAYA MT, 2001, 48 INT COPP RES ASS; Youssefian T, 2002, BLOOD, V99, P4021, DOI 10.1182/blood-2001-12-0191; 2002, DRUG THER B, V40, P67	51	228	261	5	129	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1728	+		10.1096/fj.04-2029fje	http://dx.doi.org/10.1096/fj.04-2029fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345689				2022-12-28	WOS:000224243200042
J	St-Pierre, SJG; Chakkalakal, JV; Kolodziejczyk, SM; Knudson, JC; Jasmin, BJ; Megeney, LA				St-Pierre, SJG; Chakkalakal, JV; Kolodziejczyk, SM; Knudson, JC; Jasmin, BJ; Megeney, LA			Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway	FASEB JOURNAL			English	Article						signaling; corticosteroid; MAPK	DUCHENNE MUSCULAR-DYSTROPHY; N-TERMINAL KINASE; MUSCLE-FIBERS; MDX MOUSE; INCREASED EXPRESSION; DOUBLE-BLIND; IN-VIVO; SKELETAL; DEFLAZACORT; PREDNISONE	Duchenne muscular dystrophy (DMD) is a progressive and ultimately fatal skeletal muscle disease. Currently, the most effective therapy is the administration of a subclass of glucocorticoids, most notably deflazacort. Although deflazacort treatment can attenuate DMD progression, extend ambulation, and maintain muscle strength, the mechanism of its action remains unknown. Prior observations have shown that activation of a JNK1-mediated signal transduction cascade contributes to the progression of the DMD phenotype, in part by phosphorylation and inhibition of a calcineurin sensitive NF-ATc1 transcription factor. Here, we observed that deflazacort treatment restored myocyte viability in muscle cells with constitutive activation of JNK1 and in dystrophic mdx mice. However, deflazacort treatment did not alter JNK1 activity itself, but rather led to an increase in the activity of the calcineurin phosphatase and an up-regulation of NF-ATc1-dependent gene expression. The prophylactic effect of deflazacort treatment was associated with increased expression of NF-ATc1 target genes such as the dystrophin homologue utrophin. Moreover, the muscle sparing effects of deflazacort were completely abolished when used in conjunction with the calcineurin inhibitor cyclosporine. Collectively, these results show that deflazacort attenuates loss of dystrophic myofiber integrity by up-regulating the activity of the phosphatase calcineurin, which in turn negates JNK1 inhibition of NF-ATc1- mediated phosphorylation and nuclear exclusion of NF-ATc1.	Ottawa Gen Hosp, Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Ctr Neuromuscular Dis, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Megeney, LA (corresponding author), Ottawa Gen Hosp, Ottawa Hlth Res Inst, Program Mol Med, Gen Campus, Ottawa, ON K1H 8L6, Canada.	lmegeney@ohri.ca	Chakkalakal, Joe/ABD-2865-2020	Chakkalakal, Joe/0000-0002-8440-7312; Megeney, Lynn/0000-0002-6824-8569				Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; Anderson JE, 2000, CELL TRANSPLANT, V9, P551, DOI 10.1177/096368970000900411; Anderson JE, 1996, MUSCLE NERVE, V19, P1576, DOI 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; BAUMBACH LL, 1989, NEUROLOGY, V39, P465, DOI 10.1212/WNL.39.4.465; Biggar WD, 2001, J PEDIATR-US, V138, P45, DOI 10.1067/mpd.2001.109601; Bonifati MD, 2000, MUSCLE NERVE, V23, P1344, DOI 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.3.CO;2-6; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; Chen RB, 2000, J IMMUNOL, V164, P825, DOI 10.4049/jimmunol.164.2.825; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DESILVA S, 1987, ARCH NEUROL-CHICAGO, V44, P818, DOI 10.1001/archneur.1987.00520200022012; EMERY AEH, 1993, DUCHENNE MUSCULAR DY, P24; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Han ZN, 2002, ARTHRITIS RHEUM, V46, P818, DOI 10.1002/art.10104; Hedin KE, 1997, J IMMUNOL, V159, P5431; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Khanna S, 2003, FASEB J, V17, P1370, DOI 10.1096/fj.02-1108fje; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; MARKHAM A, 1995, DRUGS, V50, P317, DOI 10.2165/00003495-199550020-00008; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; Mesa L E, 1991, Neuromuscul Disord, V1, P261, DOI 10.1016/0960-8966(91)90099-E; METZINGER L, 1995, BRIT J PHARMACOL, V116, P2811, DOI 10.1111/j.1476-5381.1995.tb15930.x; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Oak SA, 2003, J BIOL CHEM, V278, P39287, DOI 10.1074/jbc.M305551200; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Porter JD, 2003, HUM MOL GENET, V12, P1813, DOI 10.1093/hmg/ddg197; Querfurth HW, 2001, MOL CELL NEUROSCI, V17, P793, DOI 10.1006/mcne.2001.0972; SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x	56	68	73	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1937	+		10.1096/fj.04-1859fje	http://dx.doi.org/10.1096/fj.04-1859fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456738				2022-12-28	WOS:000224243200002
J	D'Alessio, M; Cerella, C; Amici, C; Pesce, C; Coppola, S; Fanelli, C; De Nicola, M; Cristofanon, S; Clavarino, G; Bergamaschi, A; Magrini, A; Gualandi, G; Ghibelli, L				D'Alessio, M; Cerella, C; Amici, C; Pesce, C; Coppola, S; Fanelli, C; De Nicola, M; Cristofanon, S; Clavarino, G; Bergamaschi, A; Magrini, A; Gualandi, G; Ghibelli, L			Glutathione depletion up-regulates Bcl-2 in BSO-resistant cells	FASEB JOURNAL			English	Article						apoptosis; oxidative stress; NF-kappa B; chemosensitization	NF-KAPPA-B; BUTHIONINE SULFOXIMINE; CALCIUM HOMEOSTASIS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; APOPTOSIS; EXPRESSION; TRANSCRIPTION; INHIBITION; ACTIVATION	Glutathione depletion by inhibition of its synthesis with buthionine sulfoximine (BSO) is a focus of the current research in antitumor therapy, BSO being used as chemosensitizer. We had previously shown that two human tumor cell lines (U937 and HepG2) survive to treatment with BSO: BSO can elicit an apoptotic response, but the apoptotic process is aborted after cytochrome c release and before caspase activation, suggesting the development of an adaptive response (FASEB J., 1999, 13, 2031- 2036). Here, we investigate the mechanisms of such an adaptation. We found that following BSO, U937 up-regulate Bcl-2 mRNA and protein levels, by a mechanism possibly involving NF-kappaB transcription factor; the increase in protein level is limited by a rapid decay of Bcl-2 in BSO-treated cells, suggesting that redox imbalance speeds up Bcl-2 turnover. BSO-dependent Bcl-2 up-regulation is associated with the ability to survive to BSO. Indeed, 1) its abrogation by CAPE or protein synthesis inhibition sensitizes U937 to BSO; 2) in a panel of four tumor lines, BSO-resistant ( U937, HepG2, and HGB1) but not BSO-sensitive (BL41) cells can up-regulate Bcl-2 following GSH depletion; remarkably, only the latter are chemosensitized by BSO.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Med Sperimentale, I-00133 Rome, Italy; Univ Roma Tor Vergata, Cattedra Med Lavoro, I-00133 Rome, Italy; Univ Tuscia, DABAC, Viterbo, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; Tuscia University	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci 1, I-00133 Rome, Italy.	ghibelli@uniroma2.it	Coppola, Simona/A-6638-2015; Clavarino, Giovanna/M-7174-2014	Coppola, Simona/0000-0001-7851-9409; Clavarino, Giovanna/0000-0003-1778-1352; Cerella, Claudia/0000-0001-9308-8176				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson CP, 1999, EXP CELL RES, V246, P183, DOI 10.1006/excr.1998.4303; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Castello R, 2002, CLIN CHEM, V48, P1288; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Celli A, 1998, AM J PHYSIOL-GASTR L, V275, pG749, DOI 10.1152/ajpgi.1998.275.4.G749; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Rappa G, 2003, EUR J CANCER, V39, P120, DOI 10.1016/S0959-8049(02)00447-1; Reber U, 1998, BIOCHEM PHARMACOL, V55, P349, DOI 10.1016/S0006-2952(97)00480-2; Rimpler MM, 1999, BIOCHEM J, V340, P291, DOI 10.1042/0264-6021:3400291; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Sandau KB, 2000, CELL DEATH DIFFER, V7, P118, DOI 10.1038/sj.cdd.4400615; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Teodori L, 2002, CYTOMETRY, V49, P143, DOI 10.1002/cyto.10172; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Wright SC, 1998, CANCER RES, V58, P5570; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	38	39	40	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1609	+		10.1096/fj.04-1813fje	http://dx.doi.org/10.1096/fj.04-1813fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15289449				2022-12-28	WOS:000223554900017
J	Sengupta, S; Kiziltepe, T; Sasisekharan, R				Sengupta, S; Kiziltepe, T; Sasisekharan, R			A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules	FASEB JOURNAL			English	Article						angiogenesis; tumor model; growth factors; extracellular matrix	GROWTH FACTOR/SCATTER FACTOR; ENDOTHELIAL-CELLS; HEPARAN-SULFATE; REGULATORY ROLE; TUMOR-GROWTH; IN-VITRO; ANGIOGENESIS; CANCER; DIFFERENTIATION; COCULTURE	We have developed a simple yet sensitive dual color fluorescence-based technique for dissecting the tumor-neovascularization relationship and evaluated the susceptibility of each component to therapeutic interventions. Green fluorescent protein (GFP)-expressing melanoma cells were cocultured with endothelial cells on different three-dimensional (3-D) matrices and exposed to multiple growth factors and molecules with established anti-angiogenic or anticancer activities. Cells were fixed and stained with propidium iodide, imaged using a confocal microscope, and stereologically analyzed. Three-dimensionality of the system was tested by depth-coding and pseudocolor 3-D reconstruction in the z-axis. Selective ablation of the tumor cells was affected by the anthracycline antibiotic doxorubicin. Treatment with vascular endothelial growth factor ( VEGF) and hepatocyte growth factor (HGF) promoted the neovascular responses on matrigel and collagen-1 matrices. VEGF-induced angiogenesis was inhibited after treatment with combretastatin and thalidomide. In contrast, HGF exerted a protective effect against these antiangiogenics in a matrigel matrix. However, this effect was lost when the matrix was substituted with collagen, suggesting that the extracellular matrix impinges on cellular function, possibly through an Akt-mediated mechanism. The VEGF-receptor antagonist PTK787 also selectively ablated the VEGF-induced angiogenic effect without inhibiting the HGF-induced response, demonstrating the sensitivity of the system to detect modulation of distinct signal cascades. The current model encompasses the possibility of studying tumor-angiogenesis- matrix interaction on the same platform, expanding the rapid screening of novel molecules in a simulated clinicopathological setting.	MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Biol Engn Div, 16-560,77 Massachusetts Ave, Cambridge, MA 02139 USA.	rams@MIT.edu						Dutt K, 2003, TISSUE ENG, V9, P893, DOI 10.1089/107632703322495547; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; Griffioen AW, 2000, PHARMACOL REV, V52, P237; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; Johnson NA, 2004, FASEB J, V18, P188, DOI 10.1096/fj.03-0097fje; Khodarev NN, 2003, J CELL SCI, V116, P1013, DOI 10.1242/jcs.00281; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Longo N, 2001, BLOOD, V98, P3717, DOI 10.1182/blood.V98.13.3717; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Masiero L, 1997, Angiogenesis, V1, P23, DOI 10.1023/A:1018301031580; NEHLS V, 1995, HISTOCHEM CELL BIOL, V104, P459, DOI 10.1007/BF01464336; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sengupta S, 2003, CANCER RES, V63, P8351; Sengupta S, 2003, CIRCULATION, V107, P2955, DOI 10.1161/01.CIR.0000077501.19266.E5; Sengupta S, 2003, BRIT J PHARMACOL, V139, P219, DOI 10.1038/sj.bjp.0705216; Sengupta S, 2003, ARTERIOSCL THROM VAS, V23, P69, DOI 10.1161/01.ATV.0000048701.86621.D0; Shekhar MPV, 2001, CANCER RES, V61, P1320; St Croix B, 2000, SCIENCE, V289, P1197; Tozer GM, 2002, INT J EXP PATHOL, V83, P21, DOI 10.1046/j.1365-2613.2002.00211.x; Wood JM, 2000, CANCER RES, V60, P2178; Yu JL, 2002, DIFFERENTIATION, V70, P599, DOI 10.1046/j.1432-0436.2002.700913.x; 2003, ANGIOGENESIS INHIBIT	24	8	10	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1565	+		10.1096/fj.04-1934fje	http://dx.doi.org/10.1096/fj.04-1934fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15333517				2022-12-28	WOS:000223554900001
J	Barnham, KJ; Haeffner, F; Ciccotosto, GD; Curtain, CC; Tew, D; Mavros, C; Beyreuther, K; Carrington, D; Masters, CL; Cherny, RA; Cappai, R; Bush, AI				Barnham, KJ; Haeffner, F; Ciccotosto, GD; Curtain, CC; Tew, D; Mavros, C; Beyreuther, K; Carrington, D; Masters, CL; Cherny, RA; Cappai, R; Bush, AI			Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid	FASEB JOURNAL			English	Article						reactive oxygen species; A beta; AD	HYDROGEN-ATOM TRANSFER; METAL-ION REDUCTION; IRON COMPLEXES; CROSS-LINKING; PEPTIDE; COPPER; NEUROTOXICITY; DITYROSINE; PEROXIDE; OXIDATION	Alzheimer's disease ( AD) is characterized by the presence of neurofibrillary tangles and amyloid plaques, which are abnormal protein deposits. The major constituent of the plaques is the neurotoxic beta-amyloid peptide (Abeta); the genetics of familial AD support a direct role for this peptide in AD. Abeta neurotoxicity is linked to hydrogen peroxide formation. A coordinates the redox active transition metals, copper and iron, to catalytically generate reactive oxygen species. The chemical mechanism underlying this process is not well defined. With the use of density functional theory calculations to delineate the chemical mechanisms that drive the catalytic production of H2O2 by Abeta/Cu, tyrosine10 (Y10) was identified as a pivotal residue for this reaction to proceed. The relative stability of tyrosyl radicals facilitates the electron transfers that are required to drive the reaction. Confirming the theoretical results, mutation of the tyrosine residue to alanine inhibited H2O2 production, Cu-induced radicalization, dityrosine cross-linking, and neurotoxicity.	Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Stockholm Univ, AlbaNova Univ Ctr, Dept Phys, SE-10691 Stockholm, Sweden; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Psychiat, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Lab Oxidat Biol,Genet & Aging Res Unit, Charlestown, MA 02129 USA	University of Melbourne; Stockholm University; Monash University; Ruprecht Karls University Heidelberg; Harvard University; Harvard University	Barnham, KJ (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia.	kbarnham@unimelb.edu.au; bush@helix.mgh.harvard.edu	Cappai, Roberto/B-3347-2010; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019	Cappai, Roberto/0000-0002-9505-8496; Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Curtain, Cyril/0000-0001-6955-320X	NATIONAL INSTITUTE ON AGING [R01AG012686] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG12686] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramov AY, 2003, J NEUROSCI, V23, P5088; Atwood CS, 2004, BIOCHEMISTRY-US, V43, P560, DOI 10.1021/bi0358824; Barnham KJ, 2003, J BIOL CHEM, V278, P42959, DOI 10.1074/jbc.M305494200; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Blomberg MRA, 1997, THEOR CHEM ACC, V97, P72, DOI 10.1007/s002140050239; Blomberg MRA, 1999, MOL PHYS, V96, P571, DOI 10.1080/00268979909482994; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Frisch M. J., 1998, GAUSSIAN 98; Goldstein LE, 2000, BIOCHEMISTRY-US, V39, P7266, DOI 10.1021/bi992997s; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hensley K, 1998, J NEUROSCI, V18, P8126; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kato Y, 2000, BIOCHEM BIOPH RES CO, V275, P11, DOI 10.1006/bbrc.2000.3265; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Malencik DA, 1996, ANAL BIOCHEM, V242, P202, DOI 10.1006/abio.1996.0454; Mayer JM, 2002, J AM CHEM SOC, V124, P11142, DOI 10.1021/ja012732c; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Rogers MS, 2003, CURR OPIN CHEM BIOL, V7, P189, DOI 10.1016/S1367-5931(03)00024-3; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Roth JP, 2001, SCIENCE, V294, P2524, DOI 10.1126/science.1066130; *SCHROD LLC, 2003, JAG 4 0 PROGR; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; White AR, 2003, J NEUROSCI RES, V71, P889, DOI 10.1002/jnr.10537; Whittaker JW, 2003, CHEM REV, V103, P2347, DOI 10.1021/cr020425z; Wirstam M, 2003, J AM CHEM SOC, V125, P3980, DOI 10.1021/ja017692r	42	231	235	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1427	+		10.1096/fj.04-1890fje	http://dx.doi.org/10.1096/fj.04-1890fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231727				2022-12-28	WOS:000222979200013
J	Alexakis, C; Mestries, P; Garcia, S; Petit, E; Barbier, V; Papy-Garcia, D; Sagot, MA; Barritault, D; Caruelle, JP; Kern, P				Alexakis, C; Mestries, P; Garcia, S; Petit, E; Barbier, V; Papy-Garcia, D; Sagot, MA; Barritault, D; Caruelle, JP; Kern, P			Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta 1	FASEB JOURNAL			English	Article						regenerating agent; heparan sulfate analog; growth factor; atherosclerosis; fibrosis	MESSENGER-RNA LEVELS; HEPARAN-SULFATE; EXTRACELLULAR-MATRIX; V COLLAGEN; PROLIFERATION; PHENOTYPE; BINDING; ATHEROSCLEROSIS; STIMULATION; ACTIVATION	We have engineered polymers called ReGeneraTing Agents (RGTAs), which mimic the protecting and potentiating properties of heparan sulfates toward heparin-binding growth factors ( HBGF). RGTAs have been shown to optimize cell growth and regulate collagen production in vitro. Here, we studied relationships between RGTA structure and collagen-type expression in aortic smooth muscle cells by using two RGTAs, the carboxylmethylsulfate dextran RG-1503 and the carboxylmethylsulfate dextran with added benzylamide RG-1192. RG-1192 specifically induced a fivefold decrease in collagen III synthesis. This effect was abolished by FGF-2 neutralizing antibody. RG-1192 and FGF-2 acted synergistically to decrease collagen III. RG-1192 was more effective than heparin in this process. RG-1192 increased the pericellular localization of FGF-2 and protected FGF-2 from proteolysis. Surface plasmon resonance analysis indicated a K-d of 15.7 nM for the RG-1192/FGF-2 interaction (10.6 nM for the heparin/FGF-2 interaction). The structurally different RG-1503 ( without benzylamide) did not interact with FGF-2 and worked synergistically with TGF-beta1 to specifically induce a twofold increase in collagen V. RGTAs with different structures exert different modulating effects on the collagen phenotype. Selection of appropriate RGTAs, which had been shown to enhance in vivo tissue repair, may provide a mean of correcting collagen abnormalities in vascular disorders and more generally in fibrotic diseases.	Univ Paris 12, Fac Sci, CNRS, FRE 2412,Lab CRRET, F-94010 Creteil, France; CEA Saclay, Lab Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CEA; UDICE-French Research Universities; Universite Paris Saclay	Kern, P (corresponding author), Univ Paris 12, Fac Sci, CNRS, FRE 2412,Lab CRRET, Ave Gen de Gaulle, F-94010 Creteil, France.	kern@univ-paris12.fr						ADAMS MD, 1995, NATURE, V377, P3; Alexakis C, 2004, GUT, V53, P85, DOI 10.1136/gut.53.1.85; ANG AH, 1990, BIOCHEM J, V265, P461, DOI 10.1042/bj2650461; BENAZZOUG Y, 1995, BIOCHEM PHARMACOL, V49, P847, DOI 10.1016/0006-2952(94)00455-U; BOBIK A, 1993, PHARMACOL REV, V45, P1; Bono F, 1997, BIOCHEM J, V326, P661, DOI 10.1042/bj3260661; CAMPBELL GR, 1988, ARCH PATHOL LAB MED, V112, P977; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P4357; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; de Raucourt E, 1998, J BIOMED MATER RES, V41, P49, DOI 10.1002/(SICI)1097-4636(199807)41:1<49::AID-JBM6>3.0.CO;2-Q; DECROMBRUGGHE B, 1990, ANN NY ACAD SCI, V580, P88, DOI 10.1111/j.1749-6632.1990.tb17921.x; Desgranges P, 1999, FASEB J, V13, P761, DOI 10.1096/fasebj.13.6.761; ELNABOUT R, 1989, MATRIX, V9, P411, DOI 10.1016/S0934-8832(89)80047-2; Escartin Q, 2003, FASEB J, V17, P644, DOI 10.1096/fj.02-0708com; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; Kato S, 1996, AM J PATHOL, V149, P687; Kinsella L, 1998, GLYCOCONJUGATE J, V15, P419, DOI 10.1023/A:1006986104865; Kypreos KE, 1998, J CELL BIOCHEM, V68, P247, DOI 10.1002/(SICI)1097-4644(19980201)68:2<247::AID-JCB11>3.0.CO;2-C; Lafont J, 1998, GROWTH FACTORS, V16, P23, DOI 10.3109/08977199809017489; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; Ledoux D, 2000, J BIOL CHEM, V275, P29383, DOI 10.1074/jbc.M000837200; Logeart D, 1996, J BIOMED MATER RES, V30, P501, DOI 10.1002/(SICI)1097-4636(199604)30:4<501::AID-JBM8>3.0.CO;2-T; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MAJACK RA, 1985, J CELL BIOL, V100, P613, DOI 10.1083/jcb.100.2.613; MAJORS A, 1993, ARTERIOSCLER THROMB, V13, P680, DOI 10.1161/01.ATV.13.5.680; MAJORS AK, 1992, EXP CELL RES, V200, P168, DOI 10.1016/S0014-4827(05)80085-0; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MCCAFFREY TA, 1994, J CELL PHYSIOL, V159, P51, DOI 10.1002/jcp.1041590108; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; Meddahi A, 2002, J BIOMED MATER RES, V62, P525, DOI 10.1002/jbm.10283; Mestries P, 2001, MATRIX BIOL, V20, P171, DOI 10.1016/S0945-053X(01)00131-7; Mestries P, 1998, J BIOMED MATER RES, V42, P286, DOI 10.1002/(SICI)1097-4636(199811)42:2<286::AID-JBM14>3.3.CO;2-F; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Morvan FO, 2004, AM J PATHOL, V164, P739, DOI 10.1016/S0002-9440(10)63161-6; Parekh TV, 1998, CELL GROWTH DIFFER, V9, P423; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; Senni K, 1998, J BIOMED MATER RES, V40, P164, DOI 10.1002/(SICI)1097-4636(199804)40:1<164::AID-JBM19>3.3.CO;2-4; SkaletzRorowski A, 1996, ARTERIOSCL THROM VAS, V16, P1063, DOI 10.1161/01.ATV.16.8.1063; STALLMACH A, 1992, GASTROENTEROLOGY, V102, P1920, DOI 10.1016/0016-5085(92)90314-O; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; Tanaka Y, 1998, P ASSOC AM PHYSICIAN, V110, P118; TARDIEU M, 1992, J CELL PHYSIOL, V150, P194, DOI 10.1002/jcp.1041500126; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Yamauchi H, 2000, FASEB J, V14, P2133	49	32	33	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1147	+		10.1096/fj.03-1126fje	http://dx.doi.org/10.1096/fj.03-1126fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132978				2022-12-28	WOS:000221883200013
J	Jones, SW; Hill, RJ; Krasney, PA; O'Conner, B; Peirce, N; Greenhaff, PL				Jones, SW; Hill, RJ; Krasney, PA; O'Conner, B; Peirce, N; Greenhaff, PL			Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass	FASEB JOURNAL			English	Article						proteolysis; hypertrophy; ubiquitin ligases; calpain; proteasome	UBIQUITIN-PROTEASOME PATHWAY; KAPPA-B PATHWAY; MUSCULAR-DYSTROPHY; PROTEIN BREAKDOWN; CALPAIN SYSTEM; BURN INJURY; HYPERTROPHY; CALCINEURIN; ACTIVATION; TRANSCRIPTION	Skeletal muscle atrophy occurs as a consequence of injury, illness, surgery, and muscle disuse, impacting appreciably on health care costs and patient quality of life, particularly in the absence of appropriate rehabilitation. The molecular mechanisms that regulate muscle mass during atrophy and rehabilitation in humans have not been elucidated, despite several robust candidate pathways being identified. Here, we induced skeletal muscle atrophy in healthy volunteers using two weeks of limb immobilization, and then stimulated the restoration of muscle mass with six weeks of supervised exercise rehabilitation. We determined muscle mass and function and performed targeted gene expression analysis at prescribed time points during immobilization and rehabilitation. For the first time, we have identified novel changes in gene expression following immobilization-induced atrophy and during a program of rehabilitative exercise that restored muscle mass and function. Furthermore, we have shown that exercise performed immediately following immobilization induces profound changes in the expression of a number of genes in favor of the restoration of muscle mass, within 24 h. This information will be of considerable importance to our understanding of how immobilization and contraction stimulate muscle atrophy and hypertrophy, respectively, and to the development of novel therapeutic strategies aimed at maintaining or restoring muscle mass.	Univ Nottingham, Queens Med Ctr, Ctr Integrated Syst Biol & Med, Nottingham NG7 2UH, England; Pfizer Inc, Global Res & Dev, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	University of Nottingham; Pfizer	Jones, SW (corresponding author), Univ Nottingham, Queens Med Ctr, Ctr Integrated Syst Biol & Med, Nottingham NG7 2UH, England.	simonwynjones2003@yahoo.co.uk	Jones, Simon W/AAN-4513-2021; Jones, Simon W/ABB-8625-2020	Jones, Simon W/0000-0001-6785-2310; peirce, nicholas/0000-0002-3272-5060; Greenhaff, Paul/0000-0003-4403-0490				Baghdiguian S, 2001, J MOL MED, V79, P254, DOI 10.1007/s001090100225; Baracos VE, 2001, J PALLIATIVE CARE, V17, P206; BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; DUNN SE, 1999, FASEB J, V15, pA421; Elkin SL, 2000, CLIN SCI, V99, P309, DOI 10.1042/CS20000020; Fang CH, 2000, CLIN SCI, V99, P181, DOI 10.1042/CS20000032; Fang CH, 1998, CLIN SCI, V95, P225, DOI 10.1042/CS19980092; Feasson L, 2002, J PHYSIOL-LONDON, V543, P297, DOI 10.1113/jphysiol.2002.018689; Fischer D, 2000, BIOCHEM BIOPH RES CO, V267, P504, DOI 10.1006/bbrc.1999.1987; FORSBERG NE, 1989, J ANIM SCI, V67, P3313; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; GOLL DE, 1992, BIOCHIMIE, V74, P225, DOI 10.1016/0300-9084(92)90121-T; Goll DE, 1998, CAN J ANIM SCI, V78, P503, DOI 10.4141/A98-081; Hespel P, 2001, J PHYSIOL-LONDON, V536, P625, DOI 10.1111/j.1469-7793.2001.0625c.xd; HIGGINS IJ, 1988, BIOTEC, V2, P3; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Mansoor O, 1998, ANN FR ANESTH, V17, P180, DOI 10.1016/S0750-7658(98)80072-5; Marin O, 2002, BIOCHEMISTRY-US, V41, P618, DOI 10.1021/bi0112309; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; PARR T, 1992, EUR J BIOCHEM, V208, P333, DOI 10.1111/j.1432-1033.1992.tb17191.x; Parr T, 2001, ARCH BIOCHEM BIOPHYS, V395, P1, DOI 10.1006/abbi.2001.2546; Price SR, 2003, INT J BIOCHEM CELL B, V35, P617, DOI 10.1016/S1357-2725(02)00385-0; Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sakamoto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1081, DOI 10.1152/ajpendo.00228.2003; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Sorimachi H, 2000, ADV EXP MED BIOL, V481, P383; SUGITA H, 1980, MUSCLE NERVE, V3, P335, DOI 10.1002/mus.880030410; Suman OE, 2001, J APPL PHYSIOL, V91, P1168, DOI 10.1152/jappl.2001.91.3.1168; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; Tidball JG, 2002, J PHYSIOL-LONDON, V545, P819, DOI 10.1113/jphysiol.2002.024935; Tisdale MJ, 1999, J NUTR, V129, p243S, DOI 10.1093/jn/129.1.243S; Wang W, 1999, J APPL PHYSIOL, V87, P1163, DOI 10.1152/jappl.1999.87.3.1163; Wojtazsewski JFP, 2001, DIABETES, V50, P265, DOI 10.2337/diabetes.50.2.265; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; Zinna EM, 2003, CURR OPIN CLIN NUTR, V6, P87, DOI 10.1097/00075197-200301000-00013	52	265	278	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1025	+		10.1096/fj.03-1228fje	http://dx.doi.org/10.1096/fj.03-1228fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084522				2022-12-28	WOS:000221108800011
J	Harmancey, R; Senard, JM; Pathak, A; Desmoulin, F; Claparols, C; Rouet, P; Smih, F				Harmancey, R; Senard, JM; Pathak, A; Desmoulin, F; Claparols, C; Rouet, P; Smih, F			The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated adrenergic agonist oxidation	FASEB JOURNAL			English	Article						3T3-F442A; human adipocytes; isoprenochrome; NEFA	NITRIC-OXIDE; ADIPOSE-TISSUE; NATRIURETIC PEPTIDES; S-NITROSYLATION; PLASMA-LEVELS; REAL-TIME; EXPRESSION; HYPERTENSION; HYPERTROPHY; MECHANISM	Adipocytes are known to secrete a number of adipokines, but many adipocyte secretions and their functional importance remain to be characterized. This work shows that human white adipocytes and 3T3-F442A-derived adipocytes produce adrenomedullin (AM) and that AM acts in an autocrine/paracrine way on lipid metabolism by extracellular inactivation of isoproterenol, a beta-adrenergic agonist. AM is described as a counter-regulatory factor involved in the control of cardiovascular homeostasis. This peptide is believed to protect the heart from several complications implicated in obesity-linked cardiomorbidity, such as arterial hypertension, cardiac fibrosis, and decreased sinusal variability. The exact source of circulating AM remains a matter of debate, although endothelial and vascular smooth muscle cells seem to be important sites of production. We show that human adipose cells and 3T3-F442A-derived adipocytes express AM receptors and secrete AM. The function of this feature was investigated in 3T3-F442A cell line at the level of lipolysis regulation. AM inhibited beta-adrenergic-stimulated lipolysis by a nitric oxide (NO)-dependent mechanism, inducing a significant decrease in pD2 value for isoproterenol (8.6 +/- 0.2 vs. 9.8 +/- 0.1, P<0.001). This effect is cGMP-independent since it occurred in the presence of the NO-sensitive guanylate cyclase inhibitor ODQ. It is apparently mediated by a novel extracellular mechanism. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) demonstrated that AM-produced NO oxidized isoproterenol to generate its aminochrome, namely isoprenochrome. Isoprenochrome amounts were increased 3.62 +/- 1.13-fold in cell culture media (P<0.05). We describe for the first time that AM downregulates lipolysis in adipocytes through the chemical modification of a beta-agonist.	Univ Toulouse 3, CHU Rangueil, Inst Louis Bugnard, INSERM,U586, F-31059 Toulouse, France; Univ Toulouse 3, CNRS, UMR 5068, F-31062 Toulouse, France; Univ Toulouse 3, Serv Spectrometrie Masse FR 2599, F-31062 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Smih, F (corresponding author), Fac Med Toulouse, Pharmacol Lab, 37 Allees Jules Guesde, F-31073 Toulouse, France.	fatima.smih@toulouse.inserm.fr	desmoulin, franck/AAU-4544-2020; Pathak, Atul/E-7532-2010; Pathak, Atul/ABC-5223-2020; DESMOULIN, Franck/O-1895-2018	desmoulin, franck/0000-0003-0560-6266; Pathak, Atul/0000-0001-6151-0096; DESMOULIN, Franck/0000-0003-0560-6266; Senard, Jean-Michel/0000-0001-7679-1281; Rouet, Philippe/0000-0001-6204-2079				Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337; Aerts JL, 2004, BIOTECHNIQUES, V36, P84, DOI 10.2144/04361ST04; Andersson K, 1999, BRIT J PHARMACOL, V126, P1639, DOI 10.1038/sj.bjp.0702430; Autelitano DJ, 2001, CARDIOVASC RES, V51, P255, DOI 10.1016/S0008-6363(01)00318-2; Buys S, 2003, BRIT J PHARMACOL, V139, P1219, DOI 10.1038/sj.bjp.0705350; Daveu C, 1997, NITRIC OXIDE-BIOL CH, V1, P234, DOI 10.1006/niox.1997.0123; Elizalde M, 2000, J LIPID RES, V41, P1244; Engeli S, 2004, J LIPID RES, V45, P1640, DOI 10.1194/jlr.M300322-JLR200; Estrada C, 1997, BIOCHEM J, V326, P369, DOI 10.1042/bj3260369; Eto T, 2003, REGUL PEPTIDES, V112, P61, DOI 10.1016/S0167-0115(03)00023-5; Fruhbeck G., 2004, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V2, P197, DOI 10.2174/1568016043356255; Fukai N, 2005, AM J PHYSIOL-ENDOC M, V288, pE56, DOI 10.1152/ajpendo.00586.2003; Gaudiot N, 1998, J BIOL CHEM, V273, P13475, DOI 10.1074/jbc.273.22.13475; Gaudiot N, 2000, AM J PHYSIOL-CELL PH, V279, pC1603, DOI 10.1152/ajpcell.2000.279.5.C1603; Hanafy K A, 2001, Med Sci Monit, V7, P801; Hayakawa H, 1999, HYPERTENSION, V33, P689, DOI 10.1161/01.HYP.33.2.689; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Ishihara T, 1999, CLIN NEPHROL, V52, P119; ISHIZAKA Y, 1994, BIOCHEM BIOPH RES CO, V200, P642, DOI 10.1006/bbrc.1994.1496; Kato J, 1999, HYPERTENS RES-CLIN E, V22, P61, DOI 10.1291/hypres.22.61; Kato J, 2002, HYPERTENS RES, V25, P887; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Klatt P, 2000, BIOCHEM J, V351, P485, DOI 10.1042/0264-6021:3510485; Kleinhenz DJ, 2003, FREE RADICAL BIO MED, V34, P856, DOI 10.1016/S0891-5849(02)01438-7; Lemos-Amado F, 2001, RAPID COMMUN MASS SP, V15, P2466, DOI 10.1002/rcm.498; Letizia C, 2001, Ital Heart J Suppl, V2, P1011; Li S, 2003, ARCH BIOCHEM BIOPHYS, V410, P269, DOI 10.1016/S0003-9861(02)00696-3; Li Y, 2003, EUR J ENDOCRINOL, V149, P231, DOI 10.1530/eje.0.1490231; Lukas A, 2003, EUR J CLIN INVEST, V33, P223, DOI 10.1046/j.1365-2362.2003.01139.x; Luodonpaa M, 2001, PEPTIDES, V22, P1859, DOI 10.1016/S0196-9781(01)00505-8; Martinez A, 1999, PEPTIDES, V20, P1471, DOI 10.1016/S0196-9781(99)00158-8; MESSERLI FH, 1981, ARCH INTERN MED, V141, P81, DOI 10.1001/archinte.141.1.81; Minami J, 2000, J CARDIOVASC PHARM, V36, pS83, DOI 10.1097/00005344-200000006-00018; Minamino N, 2002, MICROSC RES TECHNIQ, V57, P28, DOI 10.1002/jemt.10048; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Remiao F, 2003, BIOMED CHROMATOGR, V17, P6, DOI 10.1002/bmc.203; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Sharma AM, 2002, INT J OBESITY, V26, pS5, DOI 10.1038/sj.ijo.0802210; Shimosawa T, 2002, CIRCULATION, V105, P106, DOI 10.1161/hc0102.101399; Shindo T, 2000, CIRCULATION, V101, P2309, DOI 10.1161/01.CIR.101.19.2309; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Tomoda Y, 2001, PEPTIDES, V22, P1783, DOI 10.1016/S0196-9781(01)00519-8; Zhang JJ, 2000, HUM GENE THER, V11, P1817, DOI 10.1089/10430340050129440	47	31	31	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					1045	+		10.1096/fj.04-2868fje	http://dx.doi.org/10.1096/fj.04-2868fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15788445				2022-12-28	WOS:000227901300004
J	Lawrence, KM; Kabir, AMN; Bellahcene, M; Davidson, S; Mesquita, RS; Cao, XB; McCormick, J; Carroll, CJ; Chanalaris, A; Townsend, PA; Hubank, M; Stephanou, A; Knight, RA; Marber, MS; Latchman, DS				Lawrence, KM; Kabir, AMN; Bellahcene, M; Davidson, S; Mesquita, RS; Cao, XB; McCormick, J; Carroll, CJ; Chanalaris, A; Townsend, PA; Hubank, M; Stephanou, A; Knight, RA; Marber, MS; Latchman, DS			Cardioprotection mediated by urocortin is dependent upon PKCF epsilon activation	FASEB JOURNAL			English	Article						ischemia; protein kinase C epsilon; apoptosis; mitochondria	PROTEIN-KINASE-C; CARDIAC MYOCYTES; REPERFUSION INJURY; GENE-EXPRESSION; ISCHEMIC-INJURY; MOUSE HEARTS; DELTA-PKC; LOCALIZATION; PEPTIDES; PROTECTION	Urocortin (Ucn) is an endogenous cardioprotective agent that protects against the damaging effects of ischemia and reperfusion injury in vitro and in vivo. We have found that the mechanism of action of Ucn involves both acute activation of specific target molecules, and using Affymetrix (Santa Clara, CA) gene chip technology, altered gene expression of different end effector molecules. Here, from our gene chip data, we show that after a 24 h exposure to Ucn, there was a specific increase in mRNA and protein levels of the protein kinase C epsilon (PKC epsilon) isozyme in primary rat cardiomyocytes compared with untreated cells and in the Langendorff perfused ex vivo heart. Furthermore, a short 10 min exposure of these cells to Ucn caused a specific translocation/activation of PKC epsilon, in vitro and in the Langendorff perfused ex vivo heart. The importance of the PKC epsilon, isozyme in cardioprotection and its relationship to cardioprotection produced by Ucn was assessed using PKC epsilon-specific inhibitor peptides. The inhibitor peptide, when introduced into cardiomyocytes, caused an increase in apoptotic cell death compared with control peptide after ischemia and reperfusion. When the inhibitor peptide was present with Ucn, the cardioprotective effect of Ucn was lost. This loss of cardioprotection by Ucn was also seen in whole hearts from PKC epsilon, knockout mice. These findings indicate that the cardioprotective effect of Ucn is dependent upon PKC epsilon.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; St Thomas Hosp, Rayne Inst, London SE1 7EH, England; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; Royal Brompton Hospital	Lawrence, KM (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	k.lawrence@ich.ucl.ac.uk	Carroll, Christopher/AAV-8023-2021; Carroll, Christopher/AAJ-6185-2021; Kabir, Arif Md. Rashedul/ABZ-1320-2022; Townsend, Paul/AAF-8234-2020; Hubank, Michael JF/C-1837-2008; marber, michael/AAW-7916-2021; Davidson, Sean M/F-5275-2010; Chanalaris, Anastasios/A-5620-2008	Carroll, Christopher/0000-0002-2814-6955; Kabir, Arif Md. Rashedul/0000-0001-6367-7690; Hubank, Michael JF/0000-0002-2901-0742; Davidson, Sean M/0000-0001-5182-4980; Marber, Michael/0000-0002-3463-7128; Townsend, Paul/0000-0001-8956-9508; Chanalaris, Anastasios/0000-0002-8884-6750				Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Brar BK, 2002, J MOL CELL CARDIOL, V34, P483, DOI 10.1006/jmcc.2002.1529; Brar BK, 1999, MOL CELL ENDOCRINOL, V158, P55, DOI 10.1016/S0303-7207(99)00183-5; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Cross HR, 2002, J MOL CELL CARDIOL, V34, P361, DOI 10.1006/jmcc.2001.1518; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Jin ZQ, 2002, AM J PHYSIOL-HEART C, V282, pH1970, DOI 10.1152/ajpheart.01029.2001; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Latchman DS, 2002, INT J BIOCHEM CELL B, V34, P907, DOI 10.1016/S1357-2725(02)00011-0; Latchman DS, 2001, TRENDS CARDIOVAS MED, V11, P167, DOI 10.1016/S1050-1738(01)00093-7; Lawrence KM, 2003, FASEB J, V17, P2313, DOI 10.1096/fj.02-0832fje; Lawrence KM, 2002, CIRCULATION, V106, P1556, DOI 10.1161/01.CIR.0000028424.02525.AE; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Murriel CL, 2003, ARCH BIOCHEM BIOPHYS, V420, P246, DOI 10.1016/j.abb.2003.08.038; Naruse K, 2000, CIRC RES, V86, P1104; Ohnuma Y, 2002, AM J PHYSIOL-HEART C, V283, pH440, DOI 10.1152/ajpheart.00434.2001; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; Oldenburg O, 2002, CARDIOVASC RES, V55, P429, DOI 10.1016/S0008-6363(02)00439-X; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; PRZYKLENK K, 1995, CIRCULATION, V92, P1546, DOI 10.1161/01.CIR.92.6.1546; SARGENT CA, 1992, J CARDIOVASC PHARM, V20, P251, DOI 10.1097/00005344-199208000-00010; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; Saurin AT, 2002, CARDIOVASC RES, V55, P672, DOI 10.1016/S0008-6363(02)00325-5; Schulman D, 2002, AM J PHYSIOL-HEART C, V283, pH1481, DOI 10.1152/ajpheart.01089.2001; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Wang YG, 1999, CIRC RES, V84, P1156, DOI 10.1161/01.RES.84.10.1156; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023	31	44	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					831	+		10.1096/fj.04-2506fje	http://dx.doi.org/10.1096/fj.04-2506fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764590				2022-12-28	WOS:000227901300019
J	Rotoli, BM; Bussolati, O; Sala, R; Gazzola, GC; Dall'Asta, V				Rotoli, BM; Bussolati, O; Sala, R; Gazzola, GC; Dall'Asta, V			The transport of cationic amino acids in human airway cells: expression of system y(+)L activity and transepithelial delivery of NOS inhibitors	FASEB JOURNAL			English	Article						arginine; cationic amino acid transport; system B-0,B-+; nitric oxide; lysinuric protein intolerance	NITRIC-OXIDE SYNTHASE; L-ARGININE; FUNCTIONAL EXPRESSION; HUMAN ERYTHROCYTES; PROTEIN; IDENTIFICATION; MEMBRANE; LUNG; EPITHELIUM; CLONING	The transport of arginine has been characterized in human airway Calu-3 cells. As assessed with RT-PCR, Calu-3 cells express the genes for several transporters, such as the system y(+)-related SLC7A1, SLC7A2, and SLC7A4; the system y(+)L-related SLC7A6, SLC7A7, and SLC3A2; and the system B-0,B-+-related SLC6A14. In polarized Calu-3 cell monolayers, apical arginine influx has a leucine-sensitive, sodium-dependent component and a leucine- and lysine-resistant sodium-independent fraction. At the basolateral membrane, arginine transport was fully sodium-independent and partially inhibited by leucine provided that sodium was present in the extracellular medium. Moreover, extracellular leucine trans-stimulated arginine efflux from the basolateral membrane in the presence, but not in the absence, of sodium. The transepithelial, apical to basolateral, arginine transport strictly depended on the presence of sodium and was markedly inhibited by apical leucine, but significantly trans-stimulated by the neutral amino acid added at the basolateral side. When added at the apical side, the NOS-inhibitors NMMA and NIL, CAA analogs with a free carboxyl group, markedly inhibited the apical arginine influx and the transepithelial flux of the cationic amino acid. The same compounds trans-stimulated basolateral arginine efflux. None of these effects were observed in the presence of the methyl ester analog NAME. The basolateral medium of Calu-3 cell monolayers, obtained after incubation in the presence of the three inhibitors at the apical side, inhibited the production of NO by activated murine macrophages. The inhibitory effect of the Calu-3 cell conditioned medium was time-dependent and markedly higher with NMMA and NIL than with NAME. Moreover, the NOS-inhibitory effect of the medium was significantly enhanced if NMMA and NIL, at the apical side, and basolateral leucine were simultaneously present during the conditioning procedure. These results indicate that 1) human airway epithelial cells express a functional system y(+)L at the basolateral membrane; 2) in this model, transepithelial arginine transport involves apical influx through system B-0,B-+ and basolateral efflux through system y+L, and 3) the same transporters also perform an efficient transepithelial transport of amino acid-like NOS inhibitors.	Univ Parma, Dipartimento Med Sperimentale, Sez Patol Gen & Clin, I-43100 Parma, Italy	University of Parma	Dall'Asta, V (corresponding author), Univ Parma, Dipartimento Med Sperimentale, Sez Patol Gen & Clin, Via Volturno 39, I-43100 Parma, Italy.	valeria.dallasta@unipr.it	Bussolati, Ovidio/B-7589-2013; Sala, Roberto/B-9736-2013; Dall'Asta, Valeria/M-6698-2015	Bussolati, Ovidio/0000-0002-4301-2939; Sala, Roberto/0000-0002-9167-0020; Dall'Asta, Valeria/0000-0001-8540-0916				BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BAYDOUN AR, 1994, BIOCHEM BIOPH RES CO, V200, P726, DOI 10.1006/bbrc.1994.1511; BOGLE RG, 1992, BRIT J PHARMACOL, V105, P768, DOI 10.1111/j.1476-5381.1992.tb09053.x; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer A, 2000, BIOCHEM J, V349, P787, DOI 10.1042/bj3490787; Dall'Asta V, 2000, AM J PHYSIOL-CELL PH, V279, pC1829, DOI 10.1152/ajpcell.2000.279.6.C1829; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Donnelly LE, 2002, AM J RESP CELL MOL, V26, P144, DOI 10.1165/ajrcmb.26.1.4477; Edwards RM, 1998, J PHARMACOL EXP THER, V285, P1019; Eynott PR, 2002, EUR J PHARMACOL, V452, P123, DOI 10.1016/S0014-2999(02)02237-9; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; Florea BI, 2003, J CONTROL RELEASE, V87, P131, DOI 10.1016/S0168-3659(02)00356-5; Forray MI, 1995, BIOCHEM PHARMACOL, V50, P1963, DOI 10.1016/0006-2952(95)02090-X; Foster KA, 2000, INT J PHARMACEUT, V208, P1, DOI 10.1016/S0378-5173(00)00452-X; Galietta LJV, 1998, AM J PHYSIOL-LUNG C, V275, pL917, DOI 10.1152/ajplung.1998.275.5.L917; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; Gomez FP, 1998, EUR RESPIR J, V12, P865, DOI 10.1183/09031936.98.12040865; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Hatanaka T, 2001, J CLIN INVEST, V107, P1035, DOI 10.1172/JCI12060; Karadag B, 1999, EUR RESPIR J, V13, P1402, DOI 10.1034/j.1399-3003.1999.13f28.x; KHARITONOV SA, 1995, CLIN SCI, V88, P135, DOI 10.1042/cs0880135; KHARITONOV SA, 1995, CHEST, V107, pS156, DOI 10.1378/chest.107.3_Supplement.156S; Kharitonov SA, 1997, THORAX, V52, P1051, DOI 10.1136/thx.52.12.1051; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Mathias NR, 2002, J DRUG TARGET, V10, P31, DOI 10.1080/10611860290007504; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; PARTO K, 1993, CHEST, V104, P1176, DOI 10.1378/chest.104.4.1176; Ribeiro ACM, 1997, CLIN SCI, V93, P57, DOI 10.1042/cs0930057; Rotoli BM, 2004, FEBS LETT, V571, P177, DOI 10.1016/j.febslet.2004.06.086; Sala R, 2002, AM J PHYSIOL-CELL PH, V282, pC134, DOI 10.1152/ajpcell.2002.282.1.C134; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Sapienza MA, 1998, THORAX, V53, P172, DOI 10.1136/thx.53.3.172; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; Sloan JL, 2003, AM J PHYSIOL-LUNG C, V284, pL39, DOI 10.1152/ajplung.00164.2002; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Trapnell BC, 2003, NEW ENGL J MED, V349, P2527, DOI 10.1056/NEJMra023226; Uetani K, 2001, AM J RESP CELL MOL, V24, P720, DOI 10.1165/ajrcmb.24.6.4297; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Zhuang JC, 1997, P NATL ACAD SCI USA, V94, P11875, DOI 10.1073/pnas.94.22.11875	49	23	25	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					810	+		10.1096/fj.04-2924fje	http://dx.doi.org/10.1096/fj.04-2924fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15746185				2022-12-28	WOS:000227901300031
J	Kostadinova, RM; Nawrocki, AR; Frey, FJ; Frey, BM				Kostadinova, RM; Nawrocki, AR; Frey, FJ; Frey, BM			Tumor necrosis factor alpha and phorbol 12-myristate-13acetate down-regulate human 11 beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappa B homodimers and Egr-1	FASEB JOURNAL			English	Article						genomic footprinting; kidney tissue; mineralocorticoid receptor	LIPOPOLYSACCHARIDE TOLERANCE; SALT-SENSITIVITY; ACTIVATION; EXPRESSION; CELLS; SP1; PROMOTER; SUBUNIT; BINDING; GENE	The 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) regulates access of 11beta-hydroxyglucocorticoids to the mineralocorticoid receptor by reducing the hydroxyl group of these steroids at position 11. Previous cell culture studies revealed that tumor necrosis factor-alpha (TNF-alpha) down- regulates 11beta-HSD2 activity. Here, we demonstrate that transgenic mice overexpressing TNF-alpha have decreased mRNA abundance and activity of 11beta-HSD2 in kidney tissue, indicating that this effect may occur also in vivo. The analysis of the transcriptional regulation of 11beta-HSD2 by TNF-alpha and phorbol 12-myristate-13-acetate (PMA) with in vivo genomic footprinting in human colon SW620 cells revealed stimulus-dependent protein-DNA interactions in three promoter regions, kappaB1, Sp1/Egr-1I, and Sp1/Egr-1II. Chromatin immunoprecipitation and electrophoretic mobility shift assays demonstrated the relevance of NF-kappaB binding to kappaB1 and of Egr-1 binding to Sp1/Egr-1 sites for the PMA and TNF-alpha effect. We observed a temporal switch of binding to kappaB1 site from active p65/p50 heterodimers to inactive p50/p50 homodimers. TNF-alpha or PMA treatment for 24 h resulted in accumulation of p50 and decrease of p65 nuclear proteins. Overexpression of p50 inhibited HSD11B2 promoter activity and overexpression of Egr-1 inhibited transactivation of the HSD11B2 promoter by p65/p50. In conclusion, TNF-alpha and PMA down- regulate expression and activity of 11beta-HSD2 most likely by a coordinate binding of p50/p50 and Egr-1 to the HSD11B2 promoter.	Univ Hosp Bern, Dept Hypertens & Nephrol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Dept Clin Res, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Frey, BM (corresponding author), Univ Hosp Bern, Dept Hypertens & Nephrol, Freiburgstr 15, CH-3010 Bern, Switzerland.	brigitte.frey@dkf.unibe.ch						Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Agarwal AK, 1996, MOL CELL ENDOCRINOL, V121, P93, DOI 10.1016/0303-7207(96)03855-5; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; Algarte M, 1999, MOL CELL BIOL, V19, P6140; Atanasov AG, 2003, BIOCHEM BIOPH RES CO, V308, P257, DOI 10.1016/S0006-291X(03)01359-7; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; Cooper MS, 2001, J BONE MINER RES, V16, P1037, DOI 10.1359/jbmr.2001.16.6.1037; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; Goldring CE, 1998, EUR J IMMUNOL, V28, P2960, DOI 10.1002/(SICI)1521-4141(199809)28:09<2960::AID-IMMU2960>3.0.CO;2-B; Grundstrom S, 2004, J BIOL CHEM, V279, P8460, DOI 10.1074/jbc.M312398200; Haudek SB, 2001, J MOL CELL CARDIOL, V33, P1263, DOI 10.1006/jmcc.2001.1388; Heiniger CD, 2003, FASEB J, V17, P917, DOI 10.1096/fj.02-0582fje; Heiniger CD, 2001, FEBS LETT, V507, P351, DOI 10.1016/S0014-5793(01)03004-6; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Knuefermann P, 2002, J BIOL CHEM, V277, P23888, DOI 10.1074/jbc.M202937200; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lovati E, 1999, J CLIN ENDOCR METAB, V84, P3745, DOI 10.1210/jc.84.10.3745; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nawrocki A, 1999, ANAL BIOCHEM, V272, P280, DOI 10.1006/abio.1999.4195; Nawrocki AR, 2002, J BIOL CHEM, V277, P14647, DOI 10.1074/jbc.M111549200; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Quattropani C, 2001, J CLIN INVEST, V108, P1299, DOI 10.1172/JCI200112745; Quinkler M, 2003, J CLIN ENDOCR METAB, V88, P2384, DOI 10.1210/jc.2003-030138; Rabbitt E, 2003, ONCOGENE, V22, P1663, DOI 10.1038/sj.onc.1206293; Schumacher M, 2002, TRANSPLANTATION, V74, P66, DOI 10.1097/00007890-200207150-00012; Stauffer AT, 2002, J BIOL CHEM, V277, P26286, DOI 10.1074/jbc.M201556200; Stewart PM, 1999, VITAM HORM, V57, P249; Takahashi K, 1999, DIGEST DIS SCI, V44, P2516, DOI 10.1023/A:1026699324927; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x	37	44	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					650	+		10.1096/fj.04-2820fje	http://dx.doi.org/10.1096/fj.04-2820fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15659537				2022-12-28	WOS:000226576600020
J	Soboleski, MR; Oaks, J; Halford, WP				Soboleski, MR; Oaks, J; Halford, WP			Green fluorescent protein is a quantitative reporter of gene expression in individual eukaryotic cells	FASEB JOURNAL			English	Article						reporter assay; flow cytometry; TRE promoter; herpes simplex virus ICP0 promoter; adenovirus vector	SIMPLEX-VIRUS TYPE-1; MAMMALIAN-CELLS; TRANSACTIVATOR; GALACTOSIDASE; TAATGARAT; VECTORS; SYSTEM; MARKER; VP16; TOOL	Green fluorescent protein (GFP) has gained widespread use as a tool to visualize spatial and temporal patterns of gene expression in vivo. However, it is not generally accepted that GFP can also be used as a quantitative reporter of gene expression. We report that GFP is a reliable reporter of gene expression in individual eukaryotic cells when fluorescence is measured by flow cytometry. Two pieces of evidence support this conclusion: GFP fluorescence increases in direct proportion to the GFP gene copy number delivered to cells by a replication-defective adenovirus vector, Ad. CMV-GFP, and the intensity of GFP fluorescence is directly proportional to GFP mRNA abundance in cells. This conclusion is further supported by the fact that the induction of GFP gene expression from two inducible promoters (i.e., the TRE and ICP0 promoters) is readily detected by flow cytometric measurement of GFP fluorescent intensity. Collectively, the results presented herein indicate that GFP fluorescence is a reliable and quantitative reporter of underlying differences in gene expression.	Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA	Tulane University	Halford, WP (corresponding author), Dept Vet Mol Biol, 960 Technol Blvd, Bozeman, MT 59718 USA.	halford@montana.edu			NIAID NIH HHS [R01 AI51414, R01 AI051414, R01 AI051414-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051414] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aints A, 1999, J GENE MED, V1, P275; Albano CR, 1998, BIOTECHNOL PROGR, V14, P351, DOI 10.1021/bp970121b; Anderson MT, 1996, P NATL ACAD SCI USA, V93, P8508, DOI 10.1073/pnas.93.16.8508; BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Daelemans D, 2001, J VIROL METHODS, V96, P183, DOI 10.1016/S0166-0934(01)00330-5; Davis AR, 1998, GENE THER, V5, P1148, DOI 10.1038/sj.gt.3300705; Dundr M, 2002, J STRUCT BIOL, V140, P92, DOI 10.1016/S1047-8477(02)00521-X; Elliott G, 1999, J VIROL, V73, P4110, DOI 10.1128/JVI.73.5.4110-4119.1999; Furtado A, 2002, ANAL BIOCHEM, V310, P84, DOI 10.1016/S0003-2697(02)00281-6; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7847, DOI 10.1093/nar/13.21.7847; Galbraith DW, 1995, METHOD CELL BIOL, V50, P3, DOI 10.1016/S0091-679X(08)61018-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; Gu Wei, 1995, Journal of Biomedical Science, V2, P203, DOI 10.1007/BF02253381; Hack NJ, 2000, J NEUROSCI METH, V95, P177, DOI 10.1016/S0165-0270(99)00178-8; Hagenbeek D, 2001, CYTOMETRY, V45, P170, DOI 10.1002/1097-0320(20011101)45:3&lt;170::AID-CYTO1160&gt;3.0.CO;2-Z; Halfhill MD, 2005, METH MOL B, V286, P215; Halford WP, 2004, J VIROL, V78, P10086, DOI 10.1128/JVI.78.18.10086-10095.2004; Halford WP, 2001, J VIROL, V75, P6143, DOI 10.1128/JVI.75.13.6143-6153.2001; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; Jang MH, 2004, P NATL ACAD SCI USA, V101, P6110, DOI 10.1073/pnas.0400969101; Kar-Roy A, 2000, J VIROL METHODS, V84, P127, DOI 10.1016/S0166-0934(99)00122-6; Lissemore JL, 2000, BIOTECHNIQUES, V28, P82, DOI 10.2144/00281st02; Lorenz WW, 1996, J BIOLUM CHEMILUM, V11, P31, DOI 10.1002/(SICI)1099-1271(199601)11:1<31::AID-BIO398>3.0.CO;2-M; Ma L, 2004, P NATL ACAD SCI USA, V101, P9266, DOI 10.1073/pnas.0403201101; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; Shin HS, 2003, BIOTECHNOL PROGR, V19, P152, DOI 10.1021/bp0255614; Srikantha T, 1996, J BACTERIOL, V178, P121, DOI 10.1128/jb.178.1.121-129.1996; STEARNS T, 1995, CURR BIOL, V5, P262, DOI 10.1016/S0960-9822(95)00056-X; Subramanian S, 1996, J BIOTECHNOL, V49, P137, DOI 10.1016/0168-1656(96)01536-2; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	48	101	111	0	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					440	+		10.1096/fj.04-3180fje	http://dx.doi.org/10.1096/fj.04-3180fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15640280	Green Accepted			2022-12-28	WOS:000226576600028
J	Mabley, JG; Pacher, P; Deb, A; Wallace, R; Elder, RH; Szabo, C				Mabley, JG; Pacher, P; Deb, A; Wallace, R; Elder, RH; Szabo, C			Potential role for 8-oxoguanine DNA glycosylase in regulating inflammation	FASEB JOURNAL			English	Article						OGG-1; diabetes; shock; hypersensitivity; DNA repair	ADP-RIBOSE SYNTHETASE; TUMOR-NECROSIS-FACTOR; PEROXYNITRITE DECOMPOSITION CATALYST; DEPENDENT DIABETES-MELLITUS; BASE EXCISION-REPAIR; NITRIC-OXIDE; POLY(ADP-RIBOSE) POLYMERASE; SACCHAROMYCES-CEREVISIAE; NEUTROPHIL RECRUITMENT; ISCHEMIA-REPERFUSION	OGG-1 DNA glycosylase (OGG-1) is an enzyme involved in DNA repair. It excises 7,8-dihydro-8-oxoguanine, which is formed by oxidative damage of guanine. We have investigated the role of OGG-1 in inflammation using three models of inflammation: endotoxic shock, diabetes, and contact hypersensitivity. We found that OGG-1(-/-) mice are resistant to endotoxin ( lipopolysaccharide, LPS)-induced organ dysfunction, neutrophil infiltration and oxidative stress, when compared with the response seen in wild-type controls ( OGG(+/+)). Furthermore, the deletion of the OGG-1 gene was associated with decreased serum cytokine and chemokine levels and prolonged survival after LPS treatment. Type I diabetes was induced by multiple low-dose streptozotocin treatment. OGG-1(-/-) mice were found to have significantly lower blood glucose levels and incidence of diabetes as compared with OGG-1(+/+) mice. Biochemical analysis of the pancreas showed that OGG-1(-/-) mice had greater insulin content, indicative of a greater beta-cell mass coupled with lower levels of the chemokine MIP-1alpha and Th1 cytokines IL-12 and TNF-alpha. Levels of protective Th2 cytokines, IL-4 and IL-10 were significantly higher in the pancreata of OGG-1(-/-) mice as compared with the levels measured in wild-type mice. In the contact hypersensitivity induced by oxazolone, the OGG-1(-/-) mice showed reduced neutrophil accumulation, chemokine, and Th1 and Th2 cytokine levels in the ear tissue. The current studies unveil a role for OGG-1 in the regulation of inflammation.	Univ Brighton, Sch Pharm & Biomol Sci, Brighton BN2 4GJ, E Sussex, England; Inotek Pharmaceut Corp, Beverly, MA USA; NIAAA, NIH, Lab Physiol Studies, Rockville, MD 20852 USA; Christie Hosp NHS Trust, Paterson Inst Canc Res, CR UK Carcinogenesis Grp, Manchester M20 4BX, Lancs, England; Semmelweis Univ, Inst Human Physiol & Clin Expt Res, H-1085 Budapest, Hungary	University of Brighton; Inotek Pharmaceuticals; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Semmelweis University	Mabley, JG (corresponding author), Univ Brighton, Sch Pharm & Biomol Sci, Cockcroft Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.	jgmabley@hotmail.com	Szabo, Csaba/ABG-2644-2021; è-, ä/F-9947-2012; Szabo, Csaba/D-1882-2013; Pacher, Pal/B-6378-2008	Pacher, Pal/0000-0001-7036-8108; Mabley, Jon/0000-0001-9423-6230; Elder, Rhoderick/0000-0003-4614-175X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059266, K23HL071246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000375] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AA999999] Funding Source: Medline; NHLBI NIH HHS [R-01-HL59266, R-01-HL/DK-71246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Andreone TL, 2003, J IMMUNOL, V170, P2113, DOI 10.4049/jimmunol.170.4.2113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardinal JW, 2001, MOL CELL BIOL, V21, P5605, DOI 10.1128/MCB.21.16.5605-5613.2001; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Guzik TJ, 2003, J PHYSIOL PHARMACOL, V54, P469; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hasko G, 2002, MOL MED, V8, P283, DOI 10.1007/BF03402154; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Ishchenko A, 2003, MED SCI MONITOR, V9, pBR16; Karagiozova D, 2003, IMP DAM STRUCT, V1, P1; KARCK U, 1988, J HEPATOL, V7, P352, DOI 10.1016/S0168-8278(88)80008-4; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Lin LH, 2000, J NEUROCHEM, V74, P1098; Liu ZP, 2001, J COMP NEUROL, V432, P35, DOI 10.1002/cne.1087; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Mabley J, 2003, EUR J PHARMACOL, V466, P323, DOI 10.1016/S0014-2999(03)01570-X; Mabley JG, 2003, AM J PHYSIOL-GASTR L, V284, pG138, DOI 10.1152/ajpgi.00060.2002; Mabley JG, 2002, MOL MED, V8, P581, DOI 10.1007/BF03402168; Mabley JG, 2002, J PHARMACOL EXP THER, V300, P876, DOI 10.1124/jpet.300.3.876; Mabley JG, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730457; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Moller P, 2001, FASEB J, V15, P1181, DOI 10.1096/fj.00-0703com; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Phoa N, 2002, CARCINOGENESIS, V23, P469, DOI 10.1093/carcin/23.3.469; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.3.CO;2-M; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Radak Z, 2003, LIFE SCI, V72, P1627, DOI 10.1016/S0024-3205(02)02476-1; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SALERNO A, 1995, IMMUNOLOGY, V84, P404; Salvemini D, 2003, CRIT CARE MED, V31, pS29, DOI 10.1097/00003246-200301001-00005; SCHLAYER HJ, 1988, J HEPATOL, V7, P239, DOI 10.1016/S0168-8278(88)80488-4; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Suarez-Pinzon WL, 2003, DIABETES, V52, P1683, DOI 10.2337/diabetes.52.7.1683; Szabo C, 2002, MOL MED, V8, P571, DOI 10.1007/BF03402167; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; THOMSON JA, 1993, IMMUNOLOGY, V78, P185; Tsuruya K, 2003, DNA REPAIR, V2, P211, DOI 10.1016/S1568-7864(02)00214-8; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; Winter DB, 2003, J IMMUNOL, V170, P5558, DOI 10.4049/jimmunol.170.11.5558; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhou ZX, 2004, AM J PATHOL, V164, P1547, DOI 10.1016/S0002-9440(10)63713-3; Zingarelli B, 1999, GASTROENTEROLOGY, V116, P335, DOI 10.1016/S0016-5085(99)70130-7; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	60	92	93	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					290	+		10.1096/fj.04-2278fje	http://dx.doi.org/10.1096/fj.04-2278fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15677345				2022-12-28	WOS:000226091000026
J	Papadopoulos, MC; Binder, DK; Verkman, AS				Papadopoulos, MC; Binder, DK; Verkman, AS			Enhanced macromolecular diffusion in brain extracellular space in mouse models of vasogenic edema measured by cortical surface photobleaching	FASEB JOURNAL			English	Article						brain swelling; blood brain barrier; brain tumor; fluorescence; FRAP	REACTIVE ASTROCYTES; WATER-CONTENT; INJURY; TUMORS; DEXAMETHASONE; TORTUOSITY; SOLUTE; MICE; MECHANISMS; TRANSPORT	Diffusion of solutes and macromolecules in brain extracellular space (ECS) is important for normal brain function and efficient drug delivery, and is thought to be impaired in edematous brain. Here we measured the diffusion of an inert macromolecular fluorescent marker (FITC-dextran, 70 kDa) in the ECS by fluorescence recovery after photobleaching after staining the exposed cerebral cortex in vivo. In a brain tumor model of vasogenic ( leaky capillary) edema, FITC-dextran diffusion was reduced more than fourfold in hypercellular tumor and surrounding astrogliotic tissue; however, diffusion in brain away from the tumor was similar to30% faster than in normal contralateral brain. The increased diffusion was abolished by dexamethasone pretreatment. Enhanced ECS diffusion was also found in uninjured brain near a region of leaky brain vessels produced by focal cortical freeze injury. In contrast, ECS diffusion was slowed more than sixfold in cytotoxic brain edema caused by anoxia. Diffusion results were related semiquantitatively to ECS volume fraction and matrix viscosity from in vitro photobleaching studies in a model system consisting of silica particles in a fluorescent water/glycerol matrix. Our data provide in vivo evidence for enhanced ECS diffusion in vasogenic brain edema, yet greatly slowed diffusion in cytotoxic edema and in and around tumors.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x; Bastin ME, 1999, NEUROREPORT, V10, P1385, DOI 10.1097/00001756-199905140-00001; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; BOTHE HW, 1984, ACTA NEUROPATHOL, V64, P37, DOI 10.1007/BF00695604; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chen KC, 2000, P NATL ACAD SCI USA, V97, P8306, DOI 10.1073/pnas.150338197; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hrabetova S, 2003, J NEUROSCI, V23, P8351; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; ITO U, 1988, ACTA NEUROCHIR, V90, P35, DOI 10.1007/BF01541264; Ito U, 1990, Adv Neurol, V52, P459; ITO U, 1994, ACTA NEUROCHIR, P361; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; JELSMAN R, 1967, J NEUROSURG, V27, P388, DOI 10.3171/jns.1967.27.5.0388; KAO HP, 1993, J CELL BIOL, V120, P175, DOI 10.1083/jcb.120.1.175; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1994, ACTA NEUROCHIR, P3; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; Kono K, 2001, AM J NEURORADIOL, V22, P1081; Kuroiwa T, 2000, ACT NEUR S, V76, P191; Lu S, 2003, AM J NEURORADIOL, V24, P937; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Netti PA, 2000, CANCER RES, V60, P2497; Nicholson C, 1998, TRENDS NEUROSCI, V21, P207, DOI 10.1016/S0166-2236(98)01261-2; Nicholson C, 2000, PROG BRAIN RES, V125, P129; NICHOLSON C, 1992, CAN J PHYSIOL PHARM, V70, pS314, DOI 10.1139/y92-278; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; PASH MP, 1979, CAN J NEUROL SCI, V6, P423, DOI 10.1017/S0317167100023829; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; Romero IA, 2003, NEUROSCI LETT, V344, P112, DOI 10.1016/S0304-3940(03)00348-3; Rusakov DA, 1998, P NATL ACAD SCI USA, V95, P8975, DOI 10.1073/pnas.95.15.8975; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; Sugahara T, 1999, AM J NEURORADIOL, V20, P1554; Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330, DOI 10.1152/ajpcell.1999.277.2.C330; Vargova L, 2003, GLIA, V42, P77, DOI 10.1002/glia.10204; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; YAMADA K, 1979, J NEUROSURG, V50, P361, DOI 10.3171/jns.1979.50.3.0361	47	37	37	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					425	+		10.1096/fj.04-2834fje	http://dx.doi.org/10.1096/fj.04-2834fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15596484				2022-12-28	WOS:000226091000018
J	Arispe, N; Doh, M; Simakova, O; Kurganov, B; De Maio, A				Arispe, N; Doh, M; Simakova, O; Kurganov, B; De Maio, A			Hsc70 and Hsp70 interact with phosphatidylserine on the surface of PC12 cells resulting in a decrease of viability	FASEB JOURNAL			English	Article						heat shock proteins; polypeptide; lipid bilayer; apoptosis	HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; THERMOTOLERANT CELLS; RIBOSOMAL-SUBUNITS; SELF-ASSOCIATION; SERUM-LEVELS; BINDING; RECEPTOR; EXPRESSION; PEPTIDES	Heat shock proteins ( hsps) are involved in multiple cellular processes during normal and stress conditions, particularly in the folding of polypeptides. A newly recognized property of the members of the Hsp70 family is their ability to interact with lipids, opening ion conductance pathways in artificial membranes, and integrating into natural membranes. The formation of Hsp70 channels in biological membranes and their function is still elusive. In this study, we showed that Hsp70 and Hsc70 display a highly selective interaction with phosphatidylserine moieties on membranes, followed by rapid incorporation into the lipid bilayer. Addition of Hsp70 or Hsc70 into the extracellular medium resulted in a viability decrease of cells beading PS on the exterior surface, such as PC12 cells. This toxic effect is modulated by the presence of ATP or ADP and can be blocked by screening PS moieties with annexin 5. These observations suggest that the presence of Hsp70 in the extracellular medium may be an accelerator of apoptosis since the presence of PS on the surface is an early indicator of this process. These findings may also explain the toxicity observed in cells overexpressing Hsp70s and provide a rational for the tight regulation of Hsp70 expression.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Russian Acad Sci, AN Bach Inst Biochem, Moscow, Russia; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Uniformed Services University of the Health Sciences - USA; Research Center of Biotechnology RAS; Russian Academy of Sciences; Johns Hopkins University	Arispe, N (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	narispe@usuhs.mil	Kurganov, Boris/M-1286-2019	Kurganov, Boris/0000-0002-2930-2286				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; Arispe N, 2000, J BIOL CHEM, V275, P30839, DOI 10.1074/jbc.M005226200; Arispe N, 2002, CELL STRESS CHAPERON, V7, P330, DOI 10.1379/1466-1268(2002)007<0330:LIDTCA>2.0.CO;2; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2003, EXERC IMMUNOL REV, V9, P25; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu-Modak S., 2001, COMP PHOTO, V3, P303; BECK SC, 1994, J BIOL CHEM, V269, P21803; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Cornivelli L, 2003, SHOCK, V20, P320, DOI 10.1097/01.shk.0000082443.66379.d9; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; GUIDON PT, 1986, J CELL PHYSIOL, V128, P239, DOI 10.1002/jcp.1041280215; Kurganov B, 2004, PEPTIDES, V25, P217, DOI 10.1016/j.peptides.2004.01.001; Kurucz I, 1999, CELL STRESS CHAPERON, V4, P139; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TAIT JF, 1989, J BIOL CHEM, V264, P7944; Theodorakis NG, 1999, J BIOL CHEM, V274, P12081, DOI 10.1074/jbc.274.17.12081; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; Zhu JH, 2003, ARTERIOSCL THROM VAS, V23, P1055, DOI 10.1161/01.ATV.0000074899.60898.FD	37	115	121	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					1636	1645		10.1096/fj.04-2088com	http://dx.doi.org/10.1096/fj.04-2088com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15522909				2022-12-28	WOS:000225482100032
J	Niethammer, AG; Wodrich, H; Loeffler, M; Lode, HN; Emmerich, K; Abdollahi, A; Krempien, R; Debus, J; Huber, PE; Reisfeld, RA				Niethammer, AG; Wodrich, H; Loeffler, M; Lode, HN; Emmerich, K; Abdollahi, A; Krempien, R; Debus, J; Huber, PE; Reisfeld, RA			Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy	FASEB JOURNAL			English	Article						vaccine; T cells; cancer; immunology	ORAL DNA VACCINE; PROTECTIVE IMMUNITY; P-GLYCOPROTEIN; MYELOMA CELLS; TUMOR; CANCER; EXPRESSION; PROGRESS; THERAPY; GROWTH	Acquired multidrug resistance (MDR) remains a major challenge in the treatment of cancer with chemotherapeutic drugs. It can be mediated by the up-regulated expression of different proteins within the tumor cell membrane. Here, we used murine multidrug resistance-1 (MDR-1) as a target-antigen for the immunotherapy of cancer. We successfully demonstrated that peripheral T cell tolerance can be broken by oral administration of a DNA vaccine encoding MDR-1 and carried by attenuated Salmonella typhimurium to secondary lymphoid organs. Thus, mice, immunized orally three times at 2-wk intervals and challenged 2 wk thereafter with either MDR-1 expressing CT-26 colon carcinoma cells or MDR-1 expressing Lewis lung carcinoma cells, revealed a significant increase in life span. This was evident, when compared with animals either vaccinated with the empty control vector or challenged with the parental cell lines lacking overexpression of MDR-1. The immune response induced was antigen-specific and CD8(+) T cell-mediated. The presence of the target antigen led to up-regulation of activation markers on CD8(+) T cells and resulted in a strong cytotoxic T cell response as well as lysis of tumor target cells in vitro. We furthermore established the vaccine to be an effective treatment for established multi-drug-resistant tumor metastases, resulting in a significantly increased life span of experimental animals. Absence of CD8(+) T cells due to in vivo depletion led to abrogation of effectiveness. Taken together, our results demonstrate that T cell tolerance against the MDR-1 self-antigen can be broken. It is anticipated that the combination of such an approach with chemotherapy could lead to more effective treatments of cancer.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Heidelberg Med Sch, Dept Radiat Oncol, D-69120 Heidelberg, Germany; Charite Childrens Hosp, Dept Pediat Oncol, Berlin, Germany; Schering AG, D-13342 Berlin, Germany	Scripps Research Institute; Scripps Research Institute; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG	Reisfeld, RA (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Reisfeld@scripps.edu	Wodrich, Harald/P-1777-2019	Wodrich, Harald/0000-0002-4764-1708; Lode, Holger/0000-0002-1201-208X	NATIONAL CANCER INSTITUTE [R01CA083856] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83856] Funding Source: Medline; PHS HHS [T32-A107244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Azuma E, 1997, EUR J HAEMATOL, V59, P14; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Darji A, 2000, FEMS IMMUNOL MED MIC, V27, P341; FERRY DR, 1994, BRIT MED J, V308, P148, DOI 10.1136/bmj.308.6922.148; Ferry DR, 1996, EUR J CANCER, V32A, P1070, DOI 10.1016/0959-8049(96)00091-3; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; Henness S, 2002, INT J RADIAT ONCOL, V54, P895, DOI 10.1016/S0360-3016(02)03037-7; Itoh K, 1991, In Vivo, V5, P647; Jager E, 2000, ONKOLOGIE, V23, P410, DOI 10.1159/000027202; Jager E, 2003, INT J CANCER, V106, P817, DOI 10.1002/ijc.11292; Legrand O, 2001, BLOOD, V97, P502, DOI 10.1182/blood.V97.2.502; Lode HN, 1998, P NATL ACAD SCI USA, V95, P2475, DOI 10.1073/pnas.95.5.2475; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S; MUUL LM, 1987, J IMMUNOL, V138, P989; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; Niethammer AG, 2001, VACCINE, V20, P421, DOI 10.1016/S0264-410X(01)00362-0; Niethammer AG, 2001, CANCER RES, V61, P6178; Reisfeld RA, 2004, INT ARCH ALLERGY IMM, V133, P295, DOI 10.1159/000077009; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 2001, J INTERN MED, V250, P462, DOI 10.1046/j.1365-2796.2001.00911.x; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Shtil AA, 1999, BLOOD, V93, P1831, DOI 10.1182/blood.V93.6.1831.406k38_1831_1837; Shtil AA, 2000, LEUKEMIA LYMPHOMA, V38, P59, DOI 10.3109/10428190009060319; Xiang R, 2001, CLIN CANCER RES, V7, p856S; Yamada A, 2001, CANCER RES, V61, P6459	29	18	26	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					158	+		10.1096/fj.04-2355fje	http://dx.doi.org/10.1096/fj.04-2355fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15498893				2022-12-28	WOS:000224849900011
J	De Felice, FG; Vieira, MNN; Saraiva, LM; Figueroa-Villar, JD; Garcia-Abreu, J; Liu, R; Chang, L; Klein, WL; Ferreira, ST				De Felice, FG; Vieira, MNN; Saraiva, LM; Figueroa-Villar, JD; Garcia-Abreu, J; Liu, R; Chang, L; Klein, WL; Ferreira, ST			Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A beta oligomerization	FASEB JOURNAL			English	Article						amyloid; oligomers; neuroprotection; small molecule inhibitors	LONG-TERM POTENTIATION; REVERSIBLE MEMORY LOSS; FIBRILS IN-VITRO; AMYLOID-BETA; NERVOUS-SYSTEM; PROTEIN; MODEL; NEURODEGENERATION; IMMUNIZATION; AGGREGATION	In the past two decades, a large body of evidence has established a causative role for the beta-amyloid peptide (Abeta) in Alzheimer's disease (AD). However, recent debate has focused on whether amyloid fibrils or soluble oligomers of Abeta are the main neurotoxic species that contribute to neurodegeneration and dementia. Considerable early evidence has indicated that amyloid fibrils are toxic, but some recent studies support the notion that Abeta oligomers are the primary neurotoxins. While this crucial aspect of AD pathogenesis remains controversial, effective therapeutic strategies should ideally target both oligomeric and fibrillar species of Abeta. Here, we describe the anti-amyloidogenic and neuroprotective actions of some di- and tri-substituted aromatic compounds. Inhibition of the formation of soluble Abeta oligomers was monitored using a specific antibody-based assay that discriminates between Abeta oligomers and monomers. Thioflavin T and electron microscopy were used to screen for inhibitors of fibril formation. Taken together, these results led to the identification of compounds that more effectively block Abeta oligomerization than fibrillization. It is significant that such compounds completely blocked the neurotoxicity of Abeta to rat hippocampal neurons in culture. These findings provide a basis for the development of novel small molecule Abeta inhibitors with potential applications in AD.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Anat, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil; Inst Mil Engn, Dept Quim Organ, Rio De Janeiro, Brazil; Northwestern Univ, Dept Neurobiol & Physiol, Cognit Neurol & Alzheimers Dis Ctr, Inst Neurosci, Evanston, IL USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Instituto Militar de Engenharia (IME); Northwestern University	De Felice, FG (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil.	felice@bioqmed.ufrj.br; ferreira@bioqmed.ufrj.br	De Felice, Fernanda G/M-1074-2017; Abreu, Jose G/G-6159-2010; Ferreira, Sergio/AAZ-1576-2020; Saraiva, Ligia M/H-8537-2012; Abreu, Jose G/ABB-1199-2021	Abreu, Jose G/0000-0002-9875-7786; Ferreira, Sergio/0000-0001-7160-9866; Saraiva, Ligia M/0000-0002-0675-129X; Abreu, Jose G/0000-0002-1363-1755				Birmingham K, 2002, NAT MED, V8, P199, DOI 10.1038/nm0302-199b; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chang L, 2003, J MOL NEUROSCI, V20, P305, DOI 10.1385/JMN:20:3:305; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; De Felice FG, 2002, CELL MOL NEUROBIOL, V22, P545, DOI 10.1023/A:1021832302524; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Grace EA, 2002, NEUROSCIENCE, V114, P265, DOI 10.1016/S0306-4522(02)00241-5; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KIM HJ, 2003, FASEB J, V17, P118; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Lin SJ, 2004, BIOORG MED CHEM LETT, V14, P1173, DOI 10.1016/j.bmcl.2003.12.086; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Raghu P, 2002, ARCH BIOCHEM BIOPHYS, V400, P43, DOI 10.1006/abbi.2002.2779; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	42	157	175	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1366	1372		10.1096/fj.04-1764com	http://dx.doi.org/10.1096/fj.04-1764com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333579				2022-12-28	WOS:000224243200055
J	Abdollahi, A; Domhan, S; Jenne, JW; Hallaj, M; Dell' Aqua, G; Mueckenthaler, M; Richter, A; Martin, H; Debus, J; Ansorge, W; Hynynen, K; Huber, PE				Abdollahi, A; Domhan, S; Jenne, JW; Hallaj, M; Dell' Aqua, G; Mueckenthaler, M; Richter, A; Martin, H; Debus, J; Ansorge, W; Hynynen, K; Huber, PE			Apoptosis signals in lymphoblasts induced by focused ultrasound	FASEB JOURNAL			English	Article						FUS; p53; bcl-2	BINDING PROTEIN TAXREB107; IN-VITRO; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNA; PLASMID DNA; CELL-LINES; P53; BREAST; TRANSFECTION	We investigated the effects of focused ultrasound (FUS) on specific molecular signaling and cellular response in three closely related human Tk6 lymphoblast cell lines that differed only in their p53 status. The applied ultrasound parameters fell between the physical dose range, which is safely used in medical diagnostics (peak pressure< 0.1 MPa) and that used for high-energy FUS thermal ablation therapy (peak pressure>10 MPa). Based on cDNA microarrays and protein analysis, we found that FUS at the intermediate peak pressure of 1.5 MPa induced a complex signaling cascade with upregulation of proapoptotic genes [e.g., p53, p21, Thy1 (CD 90)]. Simultaneously, FUS downregulated cellular survival components (e.g., bcl-2, SOD). The p53 status was important for the reaction of the cells to ultrasound. Apoptosis and G(1) arrest were induced primarily in p53+ cells, while p53- cells showed less apoptosis but exhibited G(2) arrest. Likewise, the proliferation of lymphoblasts was much more strongly inhibited in p53+ than in p53- cells. Microarray analysis further demonstrated an upregulation of genes involved in oxidative stress ( e. g., ferritin), suggesting that indirect sonochemical effects via reactive oxygen species play a causative role in the interaction of ultrasound with lymphoblasts. An important characteristic of FUS in therapeutic ultrasound applications is its ability to be administered to the human body in a targeted manner while sparing intermediate tissues. Therefore, our data indicate that this noninvasive, mechanical wave transmission, which is free of ionizing radiation, has the potential to specifically induce localized cell signals and apoptosis.	Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Radiat Oncol, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huber, PE (corresponding author), Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Radiat Oncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.huber@dkfz.de	Ansorge, Wilhelm/AAN-8780-2020					Ashush H, 2000, CANCER RES, V60, P1014; BARNARD GF, 1992, CANCER RES, V52, P3067; BARNETT SB, 1994, ULTRASOUND MED BIOL, V20, P205, DOI 10.1016/0301-5629(94)90060-4; BATAILLE R, 1984, BLOOD, V63, P468; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; CASPARY WJ, 1979, MOL PHARMACOL, V16, P256; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; Debus J, 1999, ULTRASOUND MED BIOL, V25, P301, DOI 10.1016/S0301-5629(98)00143-4; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; DUNN F, 1975, J ACOUST SOC AM, V58, P512, DOI 10.1121/1.380666; EDMONDS PD, 1983, ULTRASOUND MED BIOL, V9, P635, DOI 10.1016/0301-5629(83)90009-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRY WJ, 1955, SCIENCE, V122, P517, DOI 10.1126/science.122.3168.517; Fujita N, 1997, EXP CELL RES, V232, P400, DOI 10.1006/excr.1997.3505; HALDAR S, 1994, CANCER RES, V54, P2095; Hall EJ, 2000, RADIOBIOLOGY RADIOLO, P588; Halliwell B., 1999, FREE RADICAL BIO MED, P936; HENRY JL, 1993, CANCER RES, V53, P1403; Hileman Elizabeth A, 2001, Expert Opin Ther Targets, V5, P697, DOI 10.1517/14728222.5.6.697; Hill CR, 1995, BRIT J RADIOL, V68, P1296, DOI 10.1259/0007-1285-68-816-1296; Honda H, 2002, ULTRASOUND MED BIOL, V28, P673, DOI 10.1016/S0301-5629(02)00509-4; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huber PE, 2003, GENE THER, V10, P1600, DOI 10.1038/sj.gt.3302045; Huber PE, 2000, GENE THER, V7, P1516, DOI 10.1038/sj.gt.3301242; Huber PE, 2001, RADIAT RES, V156, P301, DOI 10.1667/0033-7587(2001)156[0301:TCIVAR]2.0.CO;2; Huber PE, 2001, CANCER RES, V61, P8441; Hynynen K, 2001, RADIOLOGY, V219, P176, DOI 10.1148/radiology.219.1.r01ap02176; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Killeen N, 1997, CURR BIOL, V7, pR774, DOI 10.1016/S0960-9822(06)00402-7; Kim HJ, 1996, HUM GENE THER, V7, P1339, DOI 10.1089/hum.1996.7.11-1339; Lagneaux L, 2002, EXP HEMATOL, V30, P1293, DOI 10.1016/S0301-472X(02)00920-7; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; Miller DL, 1996, ULTRASOUND MED BIOL, V22, P681, DOI 10.1016/0301-5629(95)02077-2; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; MOAN J, 1979, NATURE, V279, P450, DOI 10.1038/279450a0; MORITA T, 1993, AIDS RES HUM RETROV, V9, P115, DOI 10.1089/aid.1993.9.115; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; NACKEN W, 1995, BBA-GENE STRUCT EXPR, V1261, P432, DOI 10.1016/0167-4781(95)00046-J; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pani G, 2000, CANCER RES, V60, P4654; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Richter A, 2002, BIOTECHNIQUES, V33, P620, DOI 10.2144/02333rr05_11834a; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUSLICK KS, 1987, NATURE, V330, P553, DOI 10.1038/330553a0; Tabuchi Y, 2002, BIOCHEM BIOPH RES CO, V290, P498, DOI 10.1006/bbrc.2001.6203; Tata DB, 1997, BIOCHEM BIOPH RES CO, V234, P64, DOI 10.1006/bbrc.1997.6578; Thompson K, 2003, J NEUROSCI RES, V71, P46, DOI 10.1002/jnr.10463; Tyurina YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P413, DOI 10.1006/abbi.1997.0201; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Vykhodtseva N, 2001, ULTRASOUND MED BIOL, V27, P111, DOI 10.1016/S0301-5629(00)00275-1; Xu WX, 2000, BIOCHEM BIOPH RES CO, V278, P318, DOI 10.1006/bbrc.2000.3792; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305	62	55	65	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1413	+		10.1096/fj.04-1601fje	http://dx.doi.org/10.1096/fj.04-1601fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231731				2022-12-28	WOS:000222979200019
J	Hegde, S; Pahne, J; Smola-Hess, S				Hegde, S; Pahne, J; Smola-Hess, S			Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappa B binding activity and CCR7 expression	FASEB JOURNAL			English	Article						antigen presenting cells; cytokines; chemotaxis; nuclear factor-kappa B	TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; BLOOD MONONUCLEAR-CELLS; CHEMOKINE RECEPTOR; IMMUNE-RESPONSE; UP-REGULATION; TNF-ALPHA; C-JUN; IL-6; LIPOPOLYSACCHARIDE	Interleukin-6 (IL-6) is produced during bacterial and viral infections and by various malignant tumors. Here, we describe novel immunosuppressive properties of IL-6 in dendritic cells ( DC). In the presence of GM-CSF, IL-4, and a maturation stimulus, IL-6 skewed monocyte differentiation into phenotypically mature but functionally impaired DC. In DC matured with the toll-like receptor (TLR) 4 stimulus lipopolysaccharide (LPS) or other pro-inflammatory stimuli, IL-6 inhibited CCR7 chemokine receptor up-regulation. As demonstrated for LPS-stimulated DC, IL-6 impaired chemotaxis to CCR7-activating chemokines required for recruiting DC to lymphoid tissues in vivo. Moreover, IL-6 inhibited production of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma inducible protein-10 (IP-10) in DC, and DC-driven allogeneic T cell proliferation in mixed lymphocyte reactions. CCR7 expression was blocked at the transcriptional level. IL-6 led to inhibition of nuclear factor-kappaB (NF-kappaB) binding activity, regulating CCR7 transcription. Neutralization experiments revealed that autocrine IL-10 partially contributed to CCR7 suppression in IL-6-treated DC. Thus IL-6, a cytokine once labeled as "proinflammatory," can mediate immunosuppressive functions, which may involve induction of the classical " anti-inflammatory" cytokine IL-10. Because IL-6 is expressed in response to various pro-inflammatory stimuli in vivo, this mechanism may contribute to down-regulating the immune response initiated by pathogens, in persistent infections or tumors.	Univ Cologne, Inst Virol, D-50935 Cologne, Germany	University of Cologne	Smola-Hess, S (corresponding author), Univ Cologne, Inst Virol, Furst Puckler Str 56, D-50935 Cologne, Germany.	s.smola@uni-koeln.de	Hegde, Subramanya/B-4626-2008					ADERKA D, 1989, J IMMUNOL, V143, P3517; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Allavena P, 1997, ADV EXP MED BIOL, V417, P323; Ardeshna KM, 2002, BRIT J HAEMATOL, V119, P826, DOI 10.1046/j.1365-2141.2002.03869.x; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Baltathakis L, 2001, J CELL BIOCHEM, V83, P281, DOI 10.1002/jcb.1231; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BLAY JY, 1992, CANCER RES, V52, P3317; BOT FJ, 1989, BLOOD, V73, P435; Brossart P, 2000, CANCER RES, V60, P4485; Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805; Buelens C, 1997, EUR J IMMUNOL, V27, P756, DOI 10.1002/eji.1830270326; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HESS S, 1995, J IMMUNOL, V155, P4588; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hess S, 2000, J IMMUNOL, V165, P1939, DOI 10.4049/jimmunol.165.4.1939; Hirano T, 1998, Int Rev Immunol, V16, P249; Hopken UE, 2002, BLOOD, V99, P1109, DOI 10.1182/blood.V99.4.1109; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; La Flamme AC, 2000, J IMMUNOL, V164, P2419, DOI 10.4049/jimmunol.164.5.2419; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Mitani H, 2000, BRIT J HAEMATOL, V109, P288, DOI 10.1046/j.1365-2141.2000.02020.x; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neumann M, 2000, BLOOD, V95, P277; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; Orsini E, 2003, CANCER RES, V63, P4497; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Ratta M, 2002, BLOOD, V100, P230, DOI 10.1182/blood.V100.1.230; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sato K, 1999, J IMMUNOL, V162, P3865; SCHINDLER R, 1990, BLOOD, V75, P40; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Sozzani S, 1998, J IMMUNOL, V161, P1083; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Takayama T, 2001, J IMMUNOL, V166, P7136, DOI 10.4049/jimmunol.166.12.7136; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	57	115	121	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1439	+		10.1096/fj.03-0969fje	http://dx.doi.org/10.1096/fj.03-0969fje			32	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247147				2022-12-28	WOS:000222979200009
J	Warnecke, C; Zaborowska, Z; Kurreck, J; Erdmann, VA; Frei, U; Wiesener, M; Eckardt, KU				Warnecke, C; Zaborowska, Z; Kurreck, J; Erdmann, VA; Frei, U; Wiesener, M; Eckardt, KU			Differentiating the functional role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2 alpha target gene in Hep3B and Kelly cells	FASEB JOURNAL			English	Article						hypoxia-responsive element; EPO; HLF	PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; HIF-ALPHA; EXPRESSION; HIF-1-ALPHA; HOMEOSTASIS; ENHANCER; O-2; VHL; FACTOR-1-ALPHA	Activation of the hypoxia-inducible factor alpha-subunits, HIF-1alpha and HIF-2alpha, seems to be subject to similar regulatory mechanisms, and transgene approaches suggested partial functional redundancy. Here, we used RNA interference to determine the contribution of HIF-1alpha vs. HIF-2alpha to the hypoxic gene induction. Surprisingly, most genes tested were responsive only to the HIF-1alpha siRNA, showing no effect by HIF-2alpha knock-down. The same was found for the activation of reporter genes driven by hypoxia-responsive elements (HREs) from the erythropoietin (EPO), vascular endothelial growth factor, or phosphoglycerate kinase gene. Interestingly, EPO was the only gene investigated that showed responsiveness only to HIF-2alpha knock-down, as observed in Hep3B and Kelly cells. In contrast to the EPO-HRE reporter, the complete EPO enhancer displayed dependency on HIF-2alpha regulation, indicating that additional cis-acting elements confer HIF-2alpha specificity within this region. In 786-0 cells lacking HIF-1alpha protein, the identified HIF-1alpha target genes were regulated by HIF-2alpha. Overexpression of the HIFalpha subunits in different cell lines also led to a loss of target gene specificity. In conclusion, we found a remarkably restricted target gene specificity of the HIFalpha subunits, which can be overcome in cells with perturbations in the pVHL/HIF system and under forced expression.	Free Univ Berlin, Inst Biochem, D-1000 Berlin, Germany; Charite, Virchow Clin, Dept Nephrol & Med Intens Care, Berlin, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Warnecke, C (corresponding author), Univ Erlangen Nurnberg, Med Klin 4, VMD Nephrol Forschungslab, Loschgestr 8 1-2, D-91054 Erlangen, Germany.	christina.warnecke@med4.imed.uni-erlangen.de	Kurreck, Jens/B-7785-2008	Kurreck, Jens/0000-0002-1469-0052				Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Hanze J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI 10.1016/j.bbrc.2003.10.153; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; KOURY ST, 1988, BLOOD, V71, P524; LACOMBE C, 1988, J CLIN INVEST, V81, P620, DOI 10.1172/JCI113363; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell P, 2003, J AM SOC NEPHROL, V14, P2712, DOI 10.1097/01.ASN.0000092792.97122.E0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sowter HM, 2003, CANCER RES, V63, P6130; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wykoff CC, 2000, CANCER RES, V60, P7075; Zhu H, 2002, NEPHROL DIAL TRANSPL, V17, P3, DOI 10.1093/ndt/17.suppl_1.3	44	320	338	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1462	+		10.1096/fj.04-1640fje	http://dx.doi.org/10.1096/fj.04-1640fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240563				2022-12-28	WOS:000222979200017
J	Kevil, CG; Pruitt, H; Kavanagh, TJ; Wilkerson, J; Farin, F; Moellering, D; Darley-Usmar, VM; Bullard, DC; Patel, RP				Kevil, CG; Pruitt, H; Kavanagh, TJ; Wilkerson, J; Farin, F; Moellering, D; Darley-Usmar, VM; Bullard, DC; Patel, RP			Regulation of endothelial glutathione by ICAM-1: implications for inflammation	FASEB JOURNAL			English	Article						intercellular adhesion molecule-1; MAEC; GSH; GCL	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INTERCELLULAR-ADHESION MOLECULE-1; MODIFIER SUBUNIT GENE; FACTOR-KAPPA-B; OXIDATIVE STRESS; ACTIVATOR PROTEIN-1; DEFICIENT MICE; REDOX STATE; IN-VITRO; CELLS	The role of glutathione (GSH) in inflammation is largely discussed from the context of providing reducing equivalents to detoxify reactive oxygen and nitrogen species. Inflammation is now recognized to be an underlying cause of many vascular diseases including atherosclerosis, a disease in which endothelial GSH concentrations are decreased. However, mechanisms that control GSH levels are poorly understood. Key players in the inflammatory process are endothelial adhesion molecules, including intercellular adhesion molecule-1 (ICAM-1). This adhesion molecule is present constitutively and can be induced by a variety of inflammatory stimuli. In this study, using mouse aortic endothelial cells (MAEC) deficient in ICAM-1, we demonstrate a novel interplay between constitutive ICAM-1 and cellular GSH. Deficiency of ICAM-1 was associated with an approximately twofold increase in total GSH content. Inhibiting glutamate-cysteine ligase (GCL), the enzyme that catalyses the rate-limiting step in GSH biosynthesis, prevented the increase in GSH. In addition, the catalytic subunit of GCL was increased (approximate to 1.6-fold) in ICAM-1 deficient relative to wild-type cells, suggesting that constitutive ICAM-1 represses GCL expression. Furthermore, the ratio of reduced (GSH) to oxidized (GSSG) glutathione was also increased suggesting a role for ICAM-1 in modulating cellular redox status. Interestingly, increasing cytosolic GSH in wild-type mouse endothelial cells decreased constitutive ICAM-1, suggesting the presence of an inverse and reciprocal pathway. To test the effects of inducible ICAM-1 on GSH, cells were stimulated with the proinflammatory cytokine TNF-alpha. TNF-alpha stimulated production of ICAM-1, which was however not associated with induction of GSH. In contrast, supplementation of endothelial cells with GSH before TNF-alpha addition, inhibited induction of ICAM-1. These data suggest a novel regulatory pathway between constitutive ICAM-1 and GSH synthesis in the endothelium and are discussed in the context of modulating the inflammatory response.	Louisiana State Univ, Dept Pathol, Shreveport, LA USA; Univ Alabama, Dept Pathol, Birmingham, AL USA; Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA USA; Univ Alabama, Ctr Free Radical Biol, Birmingham, AL USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham	Patel, RP (corresponding author), Univ Alabama, Dept Pathol, 901 19th St S,BMR-2,Room 307, Birmingham, AL 35294 USA.	patel@path.uab.edu	Kevil, Christopher/G-9318-2011; Darley-Usmar, Victor/F-7656-2010	Patel, Rakesh/0000-0002-1526-4303; Darley-Usmar, Victor/0000-0001-8921-7086; Kevil, Christopher/0000-0003-0863-7260; Moellering, Douglas/0000-0003-2040-4187	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010167] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-70146] Funding Source: Medline; NIEHS NIH HHS [R01 ES-10167] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adachi T, 2000, BRIT J PHARMACOL, V129, P1014, DOI 10.1038/sj.bjp.0703127; Ault JG, 2003, EXP CELL RES, V285, P9, DOI 10.1016/S0014-4827(03)00012-0; Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; Diaz D, 2001, TOXICOL LETT, V123, P33, DOI 10.1016/S0378-4274(01)00377-0; Dickinson DA, 2003, BIOL CHEM, V384, P527, DOI 10.1515/BC.2003.061; EGAWA K, 1994, EXPERIENTIA, V50, P958, DOI 10.1007/BF01923487; Greenwood J, 2002, VASC PHARMACOL, V38, P315, DOI 10.1016/S1537-1891(02)00199-4; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Kevil CG, 2001, ACTA PHYSIOL SCAND, V173, P151, DOI 10.1046/j.1365-201X.2001.00901.x; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1442, DOI 10.1152/ajpcell.2001.281.5.C1442; Kobayashi SD, 2003, J LEUKOCYTE BIOL, V73, P315, DOI 10.1189/jlb.1002481; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Moellering D, 1999, FEBS LETT, V448, P292, DOI 10.1016/S0014-5793(99)00371-3; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Moellering DR, 2002, BIOCHEM J, V362, P51, DOI 10.1042/0264-6021:3620051; Nageh MF, 1997, ARTERIOSCL THROM VAS, V17, P1517, DOI 10.1161/01.ATV.17.8.1517; Nakamura S, 2002, CIRCULATION, V105, P2968, DOI 10.1161/01.CIR.0000019739.66514.1E; Nakamura S, 2003, CIRCULATION, V108, P1425, DOI 10.1161/01.CIR.0000091255.63645.98; Okayama N, 1997, AM J PHYSIOL-CELL PH, V273, pC1581, DOI 10.1152/ajpcell.1997.273.5.C1581; Papi A, 2002, FASEB J, V16, P1934, DOI 10.1096/fj.02-0118fje; Patel SS, 1998, CIRCULATION, V97, P75, DOI 10.1161/01.CIR.97.1.75; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Rahman I, 2000, BIOCHEM PHARMACOL, V60, P1041, DOI 10.1016/S0006-2952(00)00392-0; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Thompson SA, 1999, TOXICOL LETT, V110, P1, DOI 10.1016/S0378-4274(99)00133-2; Tsakadze NL, 2002, TRENDS CARDIOVAS MED, V12, P101, DOI 10.1016/S1050-1738(01)00157-8; Wang Q, 2002, AM J RESP CRIT CARE, V166, P872, DOI 10.1164/rccm.2201007; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200; Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001; Zhao XY, 2001, AM J PHYSIOL-LUNG C, V281, pL879, DOI 10.1152/ajplung.2001.281.4.L879	39	50	53	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1321	+		10.1096/fj.03-1401fje	http://dx.doi.org/10.1096/fj.03-1401fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180961				2022-12-28	WOS:000222327500024
J	Garden, GA; Guo, WQ; Jayadev, S; Tun, C; Balcaitis, S; Choi, J; Montine, TJ; Moller, T; Morrison, RS				Garden, GA; Guo, WQ; Jayadev, S; Tun, C; Balcaitis, S; Choi, J; Montine, TJ; Moller, T; Morrison, RS			HIV associated neurodegeneration requires p53 in neurons and microglia	FASEB JOURNAL			English	Article						AIDS; apoptosis; caspase; chemokine receptors; dementia	HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-SUPPRESSOR P53; CELL-DEATH; GLYCOPROTEIN COMPLEX; QUINOLINIC ACID; MOUSE MODEL; APOPTOSIS; ACTIVATION; EXPRESSION; PROTEIN	HIV infection of the central nervous system leads to HIV-associated dementia ( HAD) in a substantial subset of infected individuals. The pathogenesis of neuronal dysfunction in HAD is not well understood, but previous studies have demonstrated evidence for activation of apoptotic pathways. The tumor suppressor transcription factor p53 is an apical mediator of neuronal apoptosis following a variety of injurious stimuli. To determine whether p53 participates in HAD, we exposed cerebrocortical cultures from wild-type and p53 deficient mice to the neurotoxic HIV envelope protein gp120. Using neuron/microglia co-culture of mixed p53 genotype, we observed that both neurons and microglia require p53 for gp120 induced neuronal apoptosis. Additionally, accumulation of p53 protein in neurons was recently reported in postmortem cortical tissue from a small group of HAD patients. Using a much larger cohort of HAD cases, we extend this finding and report that p53 protein also increases in non-neuronal cells, including microglia. Taken together these findings demonstrate a novel role for p53 in the microglial response to gp120. Additionally, these findings, in conjunction with a recent report that monocytes expressing HIV-Tat also secrete neurotoxins that promote p53 activation, suggest that distinct HIV proteins may converge on the p53 pathway to promote neurotoxicity.	Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Div Neuropathol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Garden, GA (corresponding author), Univ Washington, Dept Neurol, Box 356465, Seattle, WA 98195 USA.	gagarden@u.washington.edu	Jayadev, Suman/B-6362-2019; Garden, Gwenn/CAF-9344-2022	Garden, Gwenn/0000-0002-8753-6515	NIMH NIH HHS [U01 MH083545] Funding Source: Medline; NINDS NIH HHS [NS02063, NS45528, NS44337, NS35533] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH083545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044337, R01NS035533, R01NS045528] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; ChengMayer C, 1997, J VIROL, V71, P1657, DOI 10.1128/JVI.71.2.1657-1661.1997; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; de la Monte SM, 1998, LAB INVEST, V78, P401; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Doughty ML, 2000, J NEUROSCI, V20, P3687; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; Genini D, 2001, FASEB J, V15, P5; GIULIAN D, 1995, J NEUROSCI, V15, P7712; Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/S0306-4522(96)00174-1; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Hung CS, 1999, J VIROL, V73, P8216, DOI 10.1128/JVI.73.10.8216-8226.1999; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan-Sciutto KL, 2000, AM J PATHOL, V157, P497, DOI 10.1016/S0002-9440(10)64561-0; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kawahara K, 2001, NEUROSCI LETT, V310, P89, DOI 10.1016/S0304-3940(01)02079-1; Klockel BJ, 2002, CELL DEATH DIFFER, V9, P1063, DOI 10.1038/sj.cdd.4401067; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Kuntz C, 2000, EXP NEUROL, V165, P184, DOI 10.1006/exnr.2000.7464; Letendre SL, 1999, J INFECT DIS, V180, P310, DOI 10.1086/314866; Manes S, 2003, J EXP MED, V198, P1381, DOI 10.1084/jem.20030580; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MATAS D, 2004, CELL DEATH DIFFER; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 1996, J NEUROSCI, V16, P1337; Prudlo J, 2000, BRAIN RES, V879, P183, DOI 10.1016/S0006-8993(00)02745-1; Puig B, 2001, ACTA NEUROPATHOL, V102, P207; Saito N, 2000, J NEUROTRAUM, V17, P173, DOI 10.1089/neu.2000.17.173; Sakhi S, 1997, EXP NEUROL, V145, P81, DOI 10.1006/exnr.1997.6451; Shahbazian MD, 2001, NEUROBIOL DIS, V8, P974, DOI 10.1006/nbdi.2001.0444; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Silva C, 2003, ANN NEUROL, V54, P605, DOI 10.1002/ana.10729; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Su JH, 2000, EXP NEUROL, V163, P9, DOI 10.1006/exnr.2000.7340; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Wang JB, 2002, J INFECT DIS, V185, P885, DOI 10.1086/339522; WESSELINGH SL, 1994, ADV NEUROIMMUNOL, V4, P199, DOI 10.1016/S0960-5428(06)80258-5; Xiang H, 1996, J NEUROSCI, V16, P6753; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yeh MW, 2000, J IMMUNOL, V164, P4265, DOI 10.4049/jimmunol.164.8.4265; Yeung MC, 1998, AIDS, V12, P349, DOI 10.1097/00002030-199804000-00002	56	99	103	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1141	+		10.1096/fj.04-1676fje	http://dx.doi.org/10.1096/fj.04-1676fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155568				2022-12-28	WOS:000221883200001
J	Woischwill, C; Karczewski, P; Bartsch, H; Luther, HP; Kott, M; Haase, H; Morano, I				Woischwill, C; Karczewski, P; Bartsch, H; Luther, HP; Kott, M; Haase, H; Morano, I			Regulation of the human atrial myosin light chain 1 promoter by Ca2+-calmodulin-dependent signaling pathways	FASEB JOURNAL			English	Article						atrial myosin light chain; H9c2; promoter regulation; Ca2+ signaling	CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; MEF2 TRANSCRIPTION FACTOR; CARDIAC-HYPERTROPHY; DEPENDENT ACTIVATION; HUMAN MYOCARDIUM; TRANSGENIC MICE; LIGHT-CHAINS; HEART; EXPRESSION; ISOFORMS	e investigated expression regulation of the human atrial myosin light chain 1 (hALC-1) gene using a cardiomyocyte H9c2 cell line stably transfected with a construct consisting of the human ALC-1 promoter cloned in front of the luciferase gene (H9c2T1). H9c2T1 cells were stimulated with vasopressin, which is known to induce cardiomyocyte hypertrophy and to activate a panel of signaling pathways. Those pathways involved in hALC-1 promoter activity regulation were dissected by using pharmacological inhibitor substances. Stimulation with vasopressin was associated with nuclear NFAT translocation and significantly increased human ALC-1 promoter activity. Inhibition of calcineurin by cyclosporin A blocked the effects of vasopressin on ALC-1 promoter activity to similar to 50%. This suggests that the Ca2+-calmodulin-calcineurin-NFAT pathway is involved in human ALC-1 promoter activation. However, inhibition of multifunctional Ca2+-calmodulin-dependent protein kinases (CaMK) by KN-93 decreased human ALC-1 promoter activity to almost basal levels. CaMK regulation of ALC-1 promoter activity effect could well be mediated by CaMKIV, which accumulated in the nucleus upon vasopressin stimulation. Inhibition of protein kinase C (PKC) isoforms by bisindolylmaleimide had no significant influence on human ALC-1 promoter activity. Thus, our results demonstrate a dominant role of Ca2+-calmodulin-dependent signaling pathways in the regulation of human ALC-1 expression.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Med Berlin Charite, Johannes Muller Inst Physiol, Berlin, Germany; Univ Med Berlin Charite, Med Clin 1, Dept Cardiol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Morano, I (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.	imorano@mdc-berlin.de						ADELAZIZ AI, 2004, J MOL MED; Brostrom MA, 2000, INT J BIOCHEM CELL B, V32, P993, DOI 10.1016/S1357-2725(00)00037-6; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chen WC, 1999, ENDOCRINOLOGY, V140, P1639, DOI 10.1210/en.140.4.1639; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Hagemann D, 2001, MOL CELL BIOCHEM, V220, P69, DOI 10.1023/A:1010899724222; Hoch B, 1998, J CELL BIOCHEM, V68, P259, DOI 10.1002/(SICI)1097-4644(19980201)68:2<259::AID-JCB12>3.0.CO;2-A; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; LOWEY S, 1971, NATURE, V234, P81, DOI 10.1038/234081a0; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; MERCADIER JJ, 1983, CIRC RES, V53, P52, DOI 10.1161/01.RES.53.1.52; MIYANO O, 1992, J BIOL CHEM, V267, P1198; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; Morano M, 1996, J CLIN INVEST, V98, P467, DOI 10.1172/JCI118813; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; PRICE KM, 1980, BIOCHEM J, V191, P571, DOI 10.1042/bj1910571; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ritter O, 1999, J CELL BIOCHEM, V74, P551, DOI 10.1002/(SICI)1097-4644(19990915)74:4<551::AID-JCB5>3.3.CO;2-0; Ritter O, 2002, CIRCULATION, V105, P2265, DOI 10.1161/01.CIR.0000016044.19527.96; ROTTER M, 1991, NUCLEIC ACIDS RES, V19, P1497, DOI 10.1093/nar/19.7.1497; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; SUTSCH G, 1992, CIRC RES, V70, P1035, DOI 10.1161/01.RES.70.5.1035; Tahara A, 1998, CARDIOVASC RES, V38, P198, DOI 10.1016/S0008-6363(97)00324-6; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5	33	11	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					503	511		10.1096/fj.04-2201com	http://dx.doi.org/10.1096/fj.04-2201com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791000				2022-12-28	WOS:000228865300034
J	Salanova, B; Choi, M; Rolle, S; Wellner, M; Scheidereit, C; Luft, FC; Kettritz, R				Salanova, B; Choi, M; Rolle, S; Wellner, M; Scheidereit, C; Luft, FC; Kettritz, R			The effect of fever-like temperatures on neutrophil signaling	FASEB JOURNAL			English	Article						signal transduction; TNF-alpha; apoptosis; NF-kappa B	TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; ADHERENT HUMAN NEUTROPHILS; WHOLE-BODY HYPERTHERMIA; APOPTOSIS IN-VITRO; FACTOR-ALPHA; TNF-ALPHA; TYROSINE PHOSPHORYLATION; ANTIPYRETIC THERAPY	The effect of fever on neutrophils has not been explored. We tested the hypothesis that fever-like temperature spikes affect neutrophil signaling and function. Prior 60 min, 42 degrees C heat exposure inhibited p38 MAPK, ERK, PI3-Kinase/Akt, and NF-kappa B activation in TNF-alpha-challenged suspended neutrophils. Using pharmacological inhibitors and an inhibitory peptide transduced into neutrophils by a HIV-TAT sequence, we found that p38 MAPK and NF-kappa B mediate TNF-alpha-mediated delayed apoptosis in suspended neutrophils. Heat exposure (39-42 degrees C) did not affect constitutive apoptosis but abrogated TNF-alpha-delayed apoptosis in these suspended cells. In contrast, adhesion-dependent functions were not inhibited. Furthermore, we found that heat exposure neither blocked p38 MAPK, ERK, and NF-kappa B activation in neutrophils on fibronectin nor prevented delayed apoptosis by TNF-alpha. when cells interacted with fibronectin. Above and beyond apoptosis, TNF-alpha initiated NF-kappa B-dependent gene transcription. Heat exposure blocked this effect in suspended neutrophils but not in neutrophils on fibronectin. Finally, we show that beta 2-integrins, which are not necessary for TNF-alpha-induced NF-kappa B activation at 37 degrees C, transduce costimulatory signals allowing NF-kappa B activation after heat exposure. The effect could protect circulating neutrophils from TNF-alpha. activation, while not interfering with activation of adherent neutrophils. Fever could make neutrophils more parsimonious.	Max Delbruck Ctr Mol Med, HELIOS Klinikum, Franz Volhard Clin, Dept Nephrol & Hypertens,Med Fac,Charite, Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kettritz, R (corresponding author), Wiltbergstr 50, D-13125 Berlin, Germany.	kettritz@fvk.charite-buch.de		Luft, Friedrich/0000-0002-8635-1199; Kettritz, Ralph/0000-0001-5821-6718				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Aronoff DM, 2001, AM J MED, V111, P304, DOI 10.1016/S0002-9343(01)00834-8; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; Brandts CH, 1997, LANCET, V350, P704, DOI 10.1016/S0140-6736(97)02255-1; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BYNUM GD, 1978, AM J PHYSIOL, V235, pR228, DOI 10.1152/ajpregu.1978.235.5.R228; Castro-Alcaraz S, 2002, J IMMUNOL, V169, P3947, DOI 10.4049/jimmunol.169.7.3947; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; Chu EK, 1997, CRIT CARE MED, V25, P1727, DOI 10.1097/00003246-199710000-00025; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; DRANSFIELD I, 1995, BLOOD, V85, P3264, DOI 10.1182/blood.V85.11.3264.bloodjournal85113264; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Jiang QQ, 2000, INFECT IMMUN, V68, P1265, DOI 10.1128/IAI.68.3.1265-1270.2000; Kettritz R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019411.36000.06; Kettritz R, 2000, J LEUKOCYTE BIOL, V68, P277; Kettritz R, 2004, J BIOL CHEM, V279, P2657, DOI 10.1074/jbc.M309778200; Kettritz R, 2002, KIDNEY INT, V61, P502, DOI 10.1046/j.1523-1755.2002.00161.x; Kettritz R, 1997, J AM SOC NEPHROL, V8, P1091; Kettritz R, 1999, KIDNEY INT, V55, P562, DOI 10.1046/j.1523-1755.1999.00280.x; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; Kluger MJ, 1998, ANN NY ACAD SCI, V856, P224, DOI 10.1111/j.1749-6632.1998.tb08329.x; Kluger MJ, 1996, INFECT DIS CLIN N AM, V10, P1, DOI 10.1016/S0891-5520(05)70282-8; Kozak W, 2000, ANN NY ACAD SCI, V917, P121; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Mackowiak PA, 1997, CLIN INFECT DIS, V25, P119, DOI 10.1086/514520; Mackowiak PA, 1998, ANN NY ACAD SCI, V856, P214, DOI 10.1111/j.1749-6632.1998.tb08328.x; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NATHAN C, 1993, J CELL BIOL, V122, P243, DOI 10.1083/jcb.122.1.243; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Niwa M, 2000, EUR J PHARMACOL, V407, P211, DOI 10.1016/S0014-2999(00)00735-4; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; Ostberg JR, 2001, J IMMUNOL, V167, P2666, DOI 10.4049/jimmunol.167.5.2666; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; Plaisance KI, 2000, ARCH INTERN MED, V160, P449, DOI 10.1001/archinte.160.4.449; Plaisance KI, 2000, PHARMACOTHERAPY, V20, P1417, DOI 10.1592/phco.20.19.1417.34865; RAFIEE P, 1995, J IMMUNOL, V154, P4785; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; RICHTER J, 1995, J IMMUNOL, V154, P4142; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Suzuki K, 2001, J IMMUNOL, V166, P1185, DOI 10.4049/jimmunol.166.2.1185; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; van den Berg JM, 2001, J LEUKOCYTE BIOL, V69, P467; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Wang XY, 1999, J IMMUNOL, V162, P3378; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Wust P, 2002, LANCET ONCOL, V3, P487, DOI 10.1016/S1470-2045(02)00818-5; Yaffe MB, 1999, SURGERY, V126, P248, DOI 10.1016/S0039-6060(99)70162-5; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yan SR, 1997, J IMMUNOL, V158, P1902; Zu YL, 1998, J IMMUNOL, V160, P1982	61	17	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					816	+		10.1096/fj.04-2983fje	http://dx.doi.org/10.1096/fj.04-2983fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15755871				2022-12-28	WOS:000227901300026
J	Wang, ET; Reid, B; Lois, N; Forrester, JV; McCaig, CD; Zhao, M				Wang, ET; Reid, B; Lois, N; Forrester, JV; McCaig, CD; Zhao, M			Electrical inhibition of lens epithelial cell proliferation: an additional factor in secondary cataract?	FASEB JOURNAL			English	Article						posterior capsule opacification; electric fields; lens epithelium; cell cycle	POSTERIOR CAPSULE OPACIFICATION; DIRECTED MIGRATION; SURFACE-CHARGE; FIELDS; GROWTH; CURRENTS; REGENERATION; ORIENTATION; FREQUENCY; CORNEAL	Cataract is the most common cause of blindness but is at least curable by surgery. Unfortunately, many patients gradually develop the complication of posterior capsule opacification (PCO) or secondary cataract. This arises from stimulated cell growth within the lens capsule and can greatly impair vision. It is not fully understood why residual lens epithelial cell growth occurs after surgery. We propose and show that cataract surgery might remove an important inhibitory factor for lens cell growth, namely electric fields. The lens generates a unique pattern of electric currents constantly flowing out from the equator and entering the anterior and posterior poles. We show here that cutting and removing part of the anterior capsule as in cataract surgery significantly decreases the equatorial outward electric currents. Application of electric fields in culture inhibits proliferation of human lens epithelial cells. This inhibitory effect is likely to be mediated through a cell cycle control mechanism that decreases entry of cells into S phase from G1 phase by decreasing the G1-specific cell cycle protein cyclin E and increasing the cyclin-Cdk complex inhibitor p27(kip1). Capsulorrhexis in vivo, which reduced endogenous lens electric fields, significantly increased LEC growth. This, together with our previous findings that electric fields have significant effects on the direction of lens cell migration, points to a controlling mechanism for the aberrant cell growth in posterior capsule opacification. A novel approach to control growth of lens epithelial cells using electric fields combined with other controlling mechanisms may be more effective in the prevention and treatment of this common complication of cataract surgery.	Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk	McCaig, Colin/B-1774-2010		Wellcome Trust [068012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLE DJ, 1992, SURV OPHTHALMOL, V37, P73, DOI 10.1016/0039-6257(92)90073-3; Apple DJ, 2001, OPHTHALMOLOGY, V108, P505, DOI 10.1016/S0161-6420(00)00589-3; AZADNIV M, 1993, RADIAT ENVIRON BIOPH, V32, P73, DOI 10.1007/BF01213133; Bertelmann E, 2001, CURR OPIN OPHTHALMOL, V12, P35, DOI 10.1097/00055735-200102000-00007; Binhi VN, 2000, BBA-GEN SUBJECTS, V1474, P147, DOI 10.1016/S0304-4165(00)00002-7; BRENT TP, 1967, NATURE, V215, P92, DOI 10.1038/215092a0; Candia OA, 2004, EXP EYE RES, V78, P527, DOI 10.1016/j.exer.2003.08.015; Candia OA, 2002, AM J PHYSIOL-CELL PH, V282, pC252, DOI 10.1152/ajpcell.00360.2001; CHU ZW, 1991, ACTA PHARM SINIC, V12, P285; Clark D S, 2000, Curr Opin Ophthalmol, V11, P56, DOI 10.1097/00055735-200002000-00009; Cuzick J, 1998, LANCET, V352, P359, DOI 10.1016/S0140-6736(97)10002-2; ELUL R, 1975, NATURE, V258, P616, DOI 10.1038/258616a0; FITZSIMMONS RJ, 1992, J CELL PHYSIOL, V150, P84, DOI 10.1002/jcp.1041500112; Goldman R, 1996, BIOELECTROMAGNETICS, V17, P450, DOI 10.1002/(SICI)1521-186X(1996)17:6<450::AID-BEM4>3.0.CO;2-2; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Ibaraki N, 1997, NAT MED, V3, P958, DOI 10.1038/nm0997-958; INOUE M, 1985, BIOELECTROMAGNETICS, V6, P293, DOI 10.1002/bem.2250060309; KnightNanan D, 1996, J CATARACT REFR SURG, V22, P730, DOI 10.1016/S0886-3350(96)80312-9; Lois N, 2003, INVEST OPHTH VIS SCI, V44, P3450, DOI 10.1167/iovs.02-1293; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; McCaig CD, 2002, TRENDS NEUROSCI, V25, P354, DOI 10.1016/S0166-2236(02)02174-4; MOISSEIEV J, 1989, J CATARACT REFR SURG, V15, P531, DOI 10.1016/S0886-3350(89)80110-5; NAEGELE RJ, 1991, CANCER BIOCHEM BIOPH, V12, P95; Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070-2153(03)58001-2; Nuccitelli R, 2003, RADIAT PROT DOSIM, V106, P375, DOI 10.1093/oxfordjournals.rpd.a006375; Nuccitelli R., 1988, ADV CELL BIOL, V2, P213, DOI DOI 10.1016/S1569-2558(08)60435-X; PARMELEE JT, 1985, INVEST OPHTH VIS SCI, V26, P1343; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rakic JM, 1997, EXP EYE RES, V64, P67, DOI 10.1006/exer.1996.0179; Ranta P, 1998, OPHTHALMOLOGY, V105, P2127, DOI 10.1016/S0161-6420(98)91138-1; ROBERTSON D, 1981, RADIAT ENVIRON BIOPH, V19, P227, DOI 10.1007/BF01324190; ROBINSON KR, 1983, CURR EYE RES, V2, P843, DOI 10.3109/02713688209020020; Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song B, 2004, J CELL SCI, V117, P4681, DOI 10.1242/jcs.01341; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; Wang E, 2000, EXP EYE RES, V71, P91, DOI 10.1006/exer.2000.0858; Wang ET, 2003, EXP EYE RES, V76, P29, DOI 10.1016/S0014-4835(02)00257-9; Wang ET, 2003, FASEB J, V17, P458, DOI 10.1096/fj.02-0510fje; Wang ET, 2003, INVEST OPHTH VIS SCI, V44, P244, DOI 10.1167/iovs.02-0456; WIND BE, 1988, EXP EYE RES, V46, P117, DOI 10.1016/S0014-4835(88)80070-8; Wormstone IM, 2002, EXP EYE RES, V74, P337, DOI 10.1006/exer.2001.1153; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942	48	28	31	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					842	+		10.1096/fj.04-2733fje	http://dx.doi.org/10.1096/fj.04-2733fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15764648	Green Accepted			2022-12-28	WOS:000227901300018
J	Quintanilla, ME; Tampier, L; Valle-Prieto, A; Sapag, A; Israel, Y				Quintanilla, ME; Tampier, L; Valle-Prieto, A; Sapag, A; Israel, Y			Complex I regulates mutant mitochondrial aldehyde dehydrogenase activity and voluntary ethanol consumption in rats	FASEB JOURNAL			English	Article						alcoholism; penetrance; mitochondria; mtDNA; polymorphism	ALCOHOL-CONSUMPTION; LIVER MITOCHONDRIA; ACETALDEHYDE; METABOLISM; GENES; DEFICIENCY; CHINESE; ALLELE; RISK; POLYMORPHISM	Animals selectively bred for a desirable trait retain wanted genes but exclude genes that may counteract the expression of the former. The possible interactions between selected and excluded genes cannot be readily studied in transgenic or knockout animals but may be addressed by crossing animals bred for opposite traits and studying the F-2 offspring. Ninety-seven percent of Wistar-derived rats selectively bred for their voluntary low-alcohol consumption display a mutated nuclear allele of aldehyde dehydrogenase Aldh2(2) that encodes an enzyme with a low affinity for NAD(+), whereas rats bred for high-alcohol consumption do not present the Aldh2(2) allele. This enzyme is inserted into mitochondria, where NADH-ubiquinone oxidoreductase ( complex I) regenerates NAD(+). The possible influence of complex I on ALDH2 activity and voluntary ethanol intake was investigated. Homozygous Aldh2(2)/Aldh2(2) rats derived from a line of high-drinker F-0 females ( and low-drinker F-0 males) showed a markedly higher ethanol consumption (3.9 +/- 0.5 g . kg(-1) . day(-1)) than homozygous animals derived from a line of low-drinker F-0 females (and high-drinker F-0 males) (1.8 +/- 0.4 g . kg(-1) . day(-1)). Mitochondria of F-2 rats derived from high alcohol-consuming females were more active in oxidizing substrates that generate NADH for complex I than were mitochondria derived from low alcohol-consuming females, leading in the former to higher rates of acetaldehyde metabolism and to a reduced aversion to ethanol. This is the first demonstration that maternally derived genes can either allow or counteract the phenotypic expression of a mutated gene in the context of alcohol abuse or alcoholism.	Univ Chile, Fac Chem & Pharmaceut Sci, Dept Pharmacol & Toxicol Chem, Lab Gene Therapy, RM-8380492 Santiago, Chile; Univ Chile, Fac Med, Program Mol & Clin Pharmacol, Santiago, Chile; Univ Chile, Millennium Inst Adv Studies Cell Biol & Biotechnol, Santiago, Chile; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Universidad de Chile; Universidad de Chile; Universidad de Chile; Jefferson University	Israel, Y (corresponding author), Univ Chile, Fac Chem & Pharmaceut Sci, Dept Pharmacol & Toxicol Chem, Lab Gene Therapy, Olivos 1007, RM-8380492 Santiago, Chile.	Yedy.Israel@jefferson.edu	Sapag, Amalia/I-2574-2013	Sapag, Amalia/0000-0002-7029-2331; Quintanilla, Maria Elena/0000-0002-0278-3219; Israel, Yedy/0000-0003-3468-7966	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010630] Funding Source: NIH RePORTER; NIAAA NIH HHS [R0-1 AA10630] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354; Bai YD, 2004, ANN NY ACAD SCI, V1011, P272, DOI 10.1196/annals.1293.026; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Chen CC, 1999, AM J HUM GENET, V65, P795, DOI 10.1086/302540; Chen YC, 1999, ALCOHOL CLIN EXP RES, V23, P1853, DOI 10.1097/00000374-199912000-00001; COLOMBO G, 1995, PHYSIOL BEHAV, V57, P1181, DOI 10.1016/0031-9384(94)00382-F; ERIKSSON CJP, 1977, ANAL BIOCHEM, V80, P116, DOI 10.1016/0003-2697(77)90631-5; ERIKSSON K, 1971, ANN MED EXP BIOL FEN, V49, P67; GIL DL, 1980, XENOBIOTICA, V10, P7, DOI 10.3109/00498258009033725; Goedde H W, 1987, Alcohol Alcohol Suppl, V1, P47; HANSEN C, 1984, ALCOHOL CLIN EXP RES, V8, P477, DOI 10.1111/j.1530-0277.1984.tb05706.x; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; Harada S, 1996, ALCOHOL CLIN EXP RES, V20, pA293; HASUMURA Y, 1976, J BIOL CHEM, V251, P4908; Heath AC, 1997, PSYCHOL MED, V27, P1381, DOI 10.1017/S0033291797005643; Higuchi S, 1994, Alcohol Alcohol Suppl, V2, P29; Kendler KS, 1997, ARCH GEN PSYCHIAT, V54, P178; Le AD, 2001, ALCOHOL CLIN EXP RES, V25, P1613, DOI 10.1111/j.1530-0277.2001.tb02168.x; Li T K, 1987, Alcohol Alcohol Suppl, V1, P91; Li TK, 2000, J STUD ALCOHOL, V61, P5, DOI 10.15288/jsa.2000.61.5; Lin YP, 2002, MED HYPOTHESES, V59, P204, DOI 10.1016/S0306-9877(02)00253-0; Mansouri A, 1997, J HEPATOL, V27, P96, DOI 10.1016/S0168-8278(97)80286-3; MARDONES J, 1983, NEUROBEH TOXICOL TER, V5, P171; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; MIZOI Y, 1983, PHARMACOL BIOCHEM BE, V18, P127, DOI 10.1016/0091-3057(83)90159-4; Moore JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735; QUINTANILLA ME, 1990, TOXICOLOGY, V63, P113, DOI 10.1016/0300-483X(90)90073-P; Sapag A, 2003, PHARMACOGENETICS, V13, P509, DOI 10.1097/00008571-200308000-00009; Shen YC, 1997, ALCOHOL CLIN EXP RES, V21, P1272, DOI 10.1111/j.1530-0277.1997.tb04448.x; STRACHAN T, 1999, HUM MOL GENET, P59; TENG YS, 1981, BIOCHEM GENET, V19, P107, DOI 10.1007/BF00486141; THOMASSON HR, 1994, ALCOHOL CLIN EXP RES, V18, P640, DOI 10.1111/j.1530-0277.1994.tb00923.x; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; TU GC, 1995, BEHAV GENET, V25, P59, DOI 10.1007/BF02197242; VOGEL F, 1986, HUMAN GENETICS PROBL, P125; XIAO Q, 1995, J CLIN INVEST, V96, P2180, DOI 10.1172/JCI118272; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258	38	13	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					36	42		10.1096/fj.04-2172com	http://dx.doi.org/10.1096/fj.04-2172com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15629893				2022-12-28	WOS:000226576600040
J	Takuma, K; Yao, J; Huang, JM; Xu, HW; Chen, X; Luddy, J; Trillat, AC; Stern, DM; Arancio, O; Yan, SSD				Takuma, K; Yao, J; Huang, JM; Xu, HW; Chen, X; Luddy, J; Trillat, AC; Stern, DM; Arancio, O; Yan, SSD			ABAD enhances A beta-induced cell stress via mitochondrial dysfunction	FASEB JOURNAL			English	Article						amyloid-beta peptide binding alcohol dehydrogenase; mitochondria; glucose utilization; reactive oxygen species; oxidant stress	CYTOCHROME-C-OXIDASE; ALZHEIMERS-DISEASE; PERMEABILITY TRANSITION; IN-VIVO; LIVER-MITOCHONDRIA; LIPID-PEROXIDATION; HEART-MITOCHONDRIA; OXIDATIVE STRESS; TRANSGENIC MICE; CYCLOSPORINE-A	Amyloid-beta peptide (Abeta) binding alcohol dehydrogenase (ABAD), an enzyme present in neuronal mitochondria, is a cofactor facilitating Abeta-induced cell stress. We hypothesized that ABAD provides a direct link between A and cytotoxicity via mitochondrial oxidant stress. Neurons cultured from transgenic (Tg) mice with targeted overexpression of a mutant form of amyloid precursor protein and ABAD (Tg mAPP/ABAD) displayed spontaneous generation of hydrogen peroxide and superoxide anion, and decreased ATP, as well as subsequent release of cytochrome c from mitochondria and induction of caspase-3-like activity followed by DNA fragmentation and loss of cell viability. Generation of reactive oxygen species (ROS) was associated with dysfunction at the level of mitochondrial complex IV ( cytochrome c oxidase, or COX). In neurons cultured from Tg mAPP/ABAD mice, COX activity was selectively decreased, and cyanide, an inhibitor of complex IV, exacerbated leakage of ROS, induction of caspase-3-like activity, and DNA fragmentation. In vivo, Tg mAPP/ABAD mice displayed reduced levels of brain ATP and COX activity, diminished glucose utilization, as well as electrophysiological abnormalities in hippocampal slices compared with Tg mAPP mice. In contrast, neither Tg ABAD mice nor nontransgenic (non-TG) littermates showed similar changes in ATP, COX activity, glucose utilization or electrophysiological properties. Each of the genotypes ( Tg ABAD, Tg mAPP and Tg mAPP/ABAD mice, and non-TG littermates) displayed normal reproductive fitness, development and lifespan ( 1) These findings link ABAD-induced oxidant stress to critical aspects of Alzheimer's disease (AD)-associated cellular dysfunction, suggesting a pivotal role for this enzyme in the pathogenesis of AD.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Kobe, Hyogo 6512180, Japan; Columbia Univ, Taub Inst Res Alzeheimers Dis & Aging Brain, New York, NY 10032 USA; SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; Med Coll Georgia, Deans Off, Augusta, GA 30912 USA; NYU, Sch Med, Nathan Kline Inst, New York, NY 10016 USA	Columbia University; Columbia University; Columbia University; Kobe Gakuin University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University System of Georgia; Augusta University; Nathan Kline Institute for Psychiatric Research; New York University	Yan, SSD (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 650 W 168th St,Black Bldg,Room 17-07, New York, NY 10032 USA.	sdy1@columbia.edu	arancio, ottavio/AAB-7959-2019	arancio, ottavio/0000-0001-6335-164X	NIA NIH HHS [AG17490, AG08702, AG16736] Funding Source: Medline; NINDS NIH HHS [NS42855] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008702, R01AG016736, P01AG017490] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alberts B., 1994, MOL BIOL CELL; Bigl M, 2003, J NEURAL TRANSM, V110, P77, DOI 10.1007/s00702-002-0772-x; Bosetti F, 2002, NEUROBIOL AGING, V23, P371, DOI 10.1016/S0197-4580(01)00314-1; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cardoso SM, 2004, NEUROBIOL AGING, V25, P105, DOI 10.1016/S0197-4580(03)00033-2; Cardoso SM, 2001, FASEB J, V15, P1439, DOI 10.1096/fj.00-0561fje; CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Clark A., 2000, RES PAPERS ED, V15, P25, DOI DOI 10.1080/026715200362934; CROMPTON M, 1988, BIOCHEM J, V255, P357; Du Yan S, 1999, J BIOL CHEM, V274, P2145, DOI 10.1074/jbc.274.4.2145; Eckert A, 2003, BIOCHEM PHARMACOL, V66, P1627, DOI 10.1016/S0006-2952(03)00534-3; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Furuta S, 1997, BBA-GENE STRUCT EXPR, V1350, P317, DOI 10.1016/S0167-4781(96)00171-6; He XY, 2002, MOL BRAIN RES, V99, P46, DOI 10.1016/S0169-328X(02)00102-X; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hoffman JM, 2000, J NUCL MED, V41, P1920; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; IMBERTI R, 1995, J RES COMMUN CHEM PA, V78, P27; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Mattson MP, 2001, J MOL NEUROSCI, V17, P205, DOI 10.1385/JMN:17:2:205; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Ofman R, 2003, AM J HUM GENET, V72, P1300, DOI 10.1086/375116; PARKER WD, 1994, NEUROLOGY, V44, P1086, DOI 10.1212/WNL.44.6.1086; Parks JK, 2001, J NEUROCHEM, V76, P1050, DOI 10.1046/j.1471-4159.2001.00112.x; Petrone A, 2003, EMBO J, V22, P4121, DOI 10.1093/emboj/cdg399; Salim S, 2000, TOXICOLOGY, V144, P163, DOI 10.1016/S0300-483X(99)00203-6; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120; Smith MA, 1997, J NEUROSCI, V17, P2653; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Villani G, 2000, FREE RADICAL BIO MED, V29, P202, DOI 10.1016/S0891-5849(00)00303-8; Wiedemann FR, 1998, FEBS LETT, V422, P33, DOI 10.1016/S0014-5793(97)01586-X; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1; Yan SD, 1997, NATURE, V389, P689; Yan SD, 2000, BBA-MOL BASIS DIS, V1502, P145, DOI 10.1016/S0925-4439(00)00041-7; Yan SD, 2000, J BIOL CHEM, V275, P27100; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7	47	221	244	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					597	+		10.1096/fj.04-2582fje	http://dx.doi.org/10.1096/fj.04-2582fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665036				2022-12-28	WOS:000226576600015
J	Wang, X; Zhang, JL; Kim, HP; Wang, Y; Choi, AMK; Ryter, SW				Wang, X; Zhang, JL; Kim, HP; Wang, Y; Choi, AMK; Ryter, SW			Bcl-XL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation	FASEB JOURNAL			English	Article						caspase-8; DISC; hypoxia; reoxygenation	CYTOCHROME-C RELEASE; CELL-DEATH; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; MITOCHONDRIAL-MEMBRANE; FAMILY PROTEINS; GOLGI-COMPLEX; UP-REGULATION; BH3 DOMAIN; BAX	Hypoxia/reoxygenation (H/R) causes cellular injury and death. The cell death pathways induced by H/R remain incompletely understood. H/R can induce Bid and Bax mitochondrial translocation and cytochrome c release. Using mouse lung endothelial cells (MLEC), we examined the role of Bcl-X-L, an anti-apoptotic Bcl-2-related protein, in H/R-induced cell death. The expression of Bcl-X-L protected MLEC against H/R-induced cell death by blocking Bax and Bid translocation and inhibiting mitochondrial cytochrome c release. Bcl-X-L expression inhibited caspase-8 cleavage and death-inducing signal complex (DISC) formation in plasma membrane. By isolating mitochondrial, nuclear, and Golgi fractions, we found that H/ R induced DISC formation in these organelles. Bcl-X-L expression inhibited DISC formation in the nuclear and Golgi fractions relative to LacZ-infected controls. In contrast, DISC formation was elevated in the mitochondrial fraction of Bcl-X-L-infected cells. GRASP65, a Golgi-associated protein, physically associated with Fas and caspase-8; Bcl-X-L expression decreased these associations. Bcl-X-L expression also up-regulated FLIP, a caspase-8 inhibitor. In conclusion, Bcl-X-L may inactivate caspase-8 by decreasing DISC formation in the plasma membrane, nucleus, and Golgi complex while diverting DISC formation to the mitochondria. The inhibitory effects of Bcl-X-L on DISC formation may play significant roles in protecting endothelial cells from H/R-induced cell death.	Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ryter, SW (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, 3435 5th Ave,MUN NW 628, Pittsburgh, PA 15213 USA.	Ryters@upmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R01HL060234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL60234, R01-HL55330] Funding Source: Medline; NIAID NIH HHS [R01-AI42365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], [No title captured]; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Brunelle JK, 2002, APOPTOSIS, V7, P475, DOI 10.1023/A:1020668923852; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Cao XX, 2002, MOL MED, V8, P869, DOI 10.1007/BF03402093; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clerici C, 2000, J APPL PHYSIOL, V88, P1890, DOI 10.1152/jappl.2000.88.5.1890; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gollapudi S, 2003, INT J ONCOL, V22, P597; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Haynes AP, 2002, BRIT J HAEMATOL, V118, P488, DOI 10.1046/j.1365-2141.2002.03643.x; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Igbavboa U, 2003, J BIOL CHEM, V278, P17150, DOI 10.1074/jbc.M301150200; Jeremias I, 2000, CIRCULATION, V102, P915; Jiang JG, 2001, J BIOL CHEM, V276, P25049, DOI 10.1074/jbc.M101611200; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim HP, 2004, FASEB J, V18, P1080, DOI 10.1096/fj.03-1391com; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Plesnila N, 2002, EUR SURG RES, V34, P37, DOI 10.1159/000048885; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Tang ZL, 2002, MOL CELL BIOCHEM, V234, P211, DOI 10.1023/A:1015930927407; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Wang X, 2004, J BIOL CHEM, V279, P5237, DOI 10.1074/jbc.M309271200; Wu CR, 2003, STROKE, V34, P1803, DOI 10.1161/01.STR.0000077255.15597.69; YANG J, 1997, SCIENCE, V275, P1132; Yoshimura S, 2001, J CELL SCI, V114, P4105	42	35	46	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1826	1833		10.1096/fj.04-2047com	http://dx.doi.org/10.1096/fj.04-2047com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576486				2022-12-28	WOS:000226091000033
J	Kriem, B; Sponne, I; Fifre, A; Malaplate-Armand, C; Lozac'h-Pillot, K; Koziel, V; Yen-Potin, FT; Bihain, B; Oster, T; Olivier, JL; Pillot, T				Kriem, B; Sponne, I; Fifre, A; Malaplate-Armand, C; Lozac'h-Pillot, K; Koziel, V; Yen-Potin, FT; Bihain, B; Oster, T; Olivier, JL; Pillot, T			Cytosolic phospholipase A(2) mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide	FASEB JOURNAL			English	Article						Alzheimer's disease; arachidonic acid	CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; A-BETA; A(2) CPLA(2); CELL-DEATH; MEMBRANE; ACTIVATION; IMMUNOREACTIVITY; TRANSLOCATION; A-BETA(1-42)	Recent data have revealed that soluble oligomeric forms of amyloid peptide (Abeta) may be the proximate effectors of the neuronal injury and death occurring in Alzheimer's disease (AD). However, the molecular mechanisms associated with the neuronal cell death induced by the nonfibrillar Abeta remain to be elucidated. In this study, we investigated the role of the cytosolic Ca2+-dependent phospholipase A(2) (cPLA(2)), and its associated metabolic pathway, i.e., the arachidonic acid (AA) cascade, in the apoptotic cell death induced by soluble oligomers of Abeta. The treatment of rat cortical neurons with low concentrations of soluble Abeta (1-40) or Abeta (1-42) peptide resulted in an early calcium-dependent release of AA associated with a transient relocalization of cPLA(2). Both cPLA(2) antisense oligonucleotides and a selective inhibitor of cPLA2 activity abolished the release of AA from neurons and also protected cells against apoptosis induced by Abeta. Furthermore, inhibitors of the PKC, p38, and MEK/ERK pathways that are involved in cPLA(2) phosphorylation and activation reduced Abeta-induced cell death. Finally, we demonstrate that inhibitors of cyclooxygenase-2 reduced the Abeta-induced cell death by 55%. Our studies suggest a novel neuronal response of soluble oligomers of Abeta, which occurs through a cPLA(2) signaling cascade and an AA-dependent death pathway. This may prove to be crucial in AD processes and could provide important targets for drug development.	Univ Nancy 1, Fac Med, INSERM, EMI 0014, F-54505 Vandoeuvre Les Nancy, France; Lab Med & Therapeut Mol, F-54505 Vandoeuvre Les Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Pillot, T (corresponding author), Univ Nancy 1, Fac Med, INSERM, EMI 0014, 9 Ave Foret Haye, F-54505 Vandoeuvre Les Nancy, France.	Thierry.Pillot@medecine.uhp-nancy.fr	Yen, Frances T/G-9175-2014; Olivier, Jean luc/AAQ-2721-2021	Yen, Frances T/0000-0001-8740-4304; 				Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Arai K, 2001, EUR J NEUROSCI, V13, P2319, DOI 10.1046/j.0953-816x.2001.01623.x; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Drouet B, 2000, CELL MOL LIFE SCI, V57, P705, DOI 10.1007/s000180050035; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Estus S, 1997, J NEUROSCI, V17, P7736; Evans JH, 2004, MOL BIOL CELL, V15, P371, DOI 10.1091/mbc.e03-05-0338; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; Farooqui AA, 1990, DEMENTIA, V1, P208, DOI DOI 10.1159/000107144; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Klapisz E, 1999, EUR J BIOCHEM, V265, P957, DOI 10.1046/j.1432-1327.1999.00797.x; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kramer RM, 1996, J LIPID MEDIAT CELL, V14, P3, DOI 10.1016/0929-7855(96)01501-5; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Li Q, 1997, J BIOL CHEM, V272, P2404, DOI 10.1074/jbc.272.4.2404; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MCCLURE RJ, 1994, ANN NY ACAD SCI, V747, P110; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pettegrew JW, 2001, NEUROCHEM RES, V26, P771, DOI 10.1023/A:1011603916962; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Sponne I, 2003, J BIOL CHEM, V278, P3437, DOI 10.1074/jbc.M206745200; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Stephenson DT, 1996, NEUROBIOL DIS, V3, P51, DOI 10.1006/nbdi.1996.0005; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; VIAL D, 1995, J NEUROCHEM, V64, P2765; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	43	113	114	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					85	+		10.1096/fj.04-1807fje	http://dx.doi.org/10.1096/fj.04-1807fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15486059				2022-12-28	WOS:000224849900020
J	Scovassi, AI				Scovassi, AI			Mitochondrial poly(ADP-ribosylation): from old data to new perspectives	FASEB JOURNAL			English	Review						mitochondria; cell death; ROS; cytoplasmic enzyme; poly(ADP-ribosylate)	RAT-LIVER MITOCHONDRIA; ADP-RIBOSYLATION; CELL-DEATH; POLYMERASE; NUCLEAR; DNA; ACTIVATION; APOPTOSIS; MEMBRANE; REPAIR	Poly( ADP-ribosylation) is involved in DNA repair and replication, transcription, and cell death. For a long time, only one poly(ADP-ribosylating) enzyme was known, named ADPRT/PARP (EC 2.4.2.30). The recent discovery of a family of PARPs has provided a high degree of complexity in the field. Moreover, the finding that poly(ADP-ribosylation) is not confined to the nucleus but is also carried out by cytoplasmic enzymes supports the idea that it could regulate proteins localized in different cellular compartments. In this respect, a reappraisal of the literature on mitochondrial poly( ADP-ribosylation) could be useful, as well as a discussion of its relevance regarding the current "hot" view of poly(ADP-ribosylation) as a mediator of cell death.	CNR, Ist Genet Mol, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Scovassi, AI (corresponding author), Via Abbiategrasso 207, I-27100 Pavia, Italy.	scovassi@igm.cnr.it	Scovassi, Anna Ivana/F-2458-2010	Scovassi, Anna Ivana/0000-0003-3484-9881				Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BERTAZZONI U, 1977, EUR J BIOCHEM, V81, P237, DOI 10.1111/j.1432-1033.1977.tb11945.x; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; BURZIO LO, 1981, BIOCHEM BIOPH RES CO, V103, P369, DOI 10.1016/0006-291X(81)91702-2; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Druzhyna N, 2000, DIABETES, V49, P1849, DOI 10.2337/diabetes.49.11.1849; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Klaidman LK, 2003, CURR MED CHEM, V10, P2669, DOI 10.2174/0929867033456323; KUN E, 1975, P NATL ACAD SCI USA, V72, P1436, DOI 10.1073/pnas.72.4.1436; MASMOUDI A, 1988, J NEUROCHEM, V51, P188, DOI 10.1111/j.1471-4159.1988.tb04854.x; MASMOUDI A, 1987, BIOCHEMISTRY-US, V26, P1965, DOI 10.1021/bi00381a027; Meyer RG, 2003, GENE, V314, P181, DOI 10.1016/S0378-1119(03)00738-8; Mosgoeller W, 1996, J CELL SCI, V109, P409; Purrello VS, 2002, MECH AGEING DEV, V123, P511, DOI 10.1016/S0047-6374(01)00354-2; RICHTER C, 1983, P NATL ACAD SCI-BIOL, V80, P3188, DOI 10.1073/pnas.80.11.3188; Scovassi AI, 2003, EUR J HISTOCHEM, V47, P185; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WARNSING P, 1986, THESIS U PAVIA ITALY; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	27	50	51	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1487	1488		10.1096/fj.04-1841rev	http://dx.doi.org/10.1096/fj.04-1841rev			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466356				2022-12-28	WOS:000224849900031
J	Saenz, DA; Goldin, AP; Minces, L; Chianelli, M; Sarmiento, MAK; Rosenstein, RE				Saenz, DA; Goldin, AP; Minces, L; Chianelli, M; Sarmiento, MAK; Rosenstein, RE			Effect of melatonin on the retinal glutamate/glutamine cycle in the golden hamster retina	FASEB JOURNAL			English	Article						glutamine synthetase; L-glutamine influx; glutaminase	AMINO-ACID-TRANSPORT; GLUTAMINE-SYNTHETASE; GANGLION-CELLS; RABBIT RETINA; NEUROHORMONE MELATONIN; NEURONAL DEGENERATION; SYNAPTIC TRANSMISSION; CIRCADIAN REGULATION; RECEPTORS; SYSTEM	Glutamate is the main excitatory neurotransmitter in the retina, but it is neurotoxic when present in excessive amounts. The metabolic dependence of glutamatergic neurons upon glia via the glutamate/glutamine cycle to provide the precursor for neurotransmitter glutamate is well established. Since melatonin has been shown to be neuroprotective in several systems, in the present report, its effect on the glutamate/glutamine cycle activity was examined in the golden hamster retina. Melatonin (0.1-10 nM) significantly increased retinal glutamine synthetase activity but it did not affect L-glutamine release. A characterization of the hamster retinal L-glutamine uptake mechanism was performed. This mechanism was partly Na+-dependent, and it was significantly inhibited by 2-aminobicyclo (2, 2, 1) heptane 2-carboxylic acid (BCH, a selective antagonists for the L-type system) and by alpha-(methylamino)-isobutyric acid ( MeAIB, substrate characteristic for the A -type transporter) suggesting the coexistence of these transport systems in the hamster retina. Melatonin (0.1-10 nM) significantly increased total glutamine uptake as well as the BCH and the MeAIB-insensitive transporters activity. On the other hand, melatonin significantly decreased retinal glutaminase activity. On the basis of these results, it might be presumed that hamster retinal glutamate/glutamine cycle activity is regulated by physiological concentrations of melatonin. Furthermore, these findings suggest that a treatment with melatonin could be considered as a new approach to handling glutamate-mediated neuronal degeneration.	Univ Buenos Aires, Fac Med, Dept Bioquim Humana, Lab Neuroquim Retiniana & Oftalmol Expt,Conicet, RA-1121 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Rosenstein, RE (corresponding author), Univ Buenos Aires, Fac Med, Dept Bioquim Humana, Lab Neuroquim Retiniana & Oftalmol Expt,Conicet, Paraguay 2155,5P, RA-1121 Buenos Aires, DF, Argentina.	ruthr@fmed.uba.ar		Goldin, Andrea/0000-0002-6402-0890				Acuna Castroviejo Dario, 2002, Curr Top Med Chem, V2, P133; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; BESHARSE JC, 1983, SCIENCE, V219, P1341, DOI 10.1126/science.6828862; BLOOMFIELD SA, 1985, J NEUROPHYSIOL, V53, P699, DOI 10.1152/jn.1985.53.3.699; BLOOMFIELD SA, 1985, J NEUROPHYSIOL, V53, P714, DOI 10.1152/jn.1985.53.3.714; Bode BP, 2001, J NUTR, V131, p2475S, DOI 10.1093/jn/131.9.2475S; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Celebi S, 2002, EUR J OPHTHALMOL, V12, P77, DOI 10.1177/112067210201200201; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DAVID P, 1988, EXP EYE RES, V46, P657, DOI 10.1016/S0014-4835(88)80054-X; Deitmer JW, 2003, J NEUROCHEM, V87, P127, DOI 10.1046/j.1471-4159.2003.01981.x; DUBOCOVICH ML, 1988, FASEB J, V2, P2765, DOI 10.1096/fasebj.2.12.2842214; DUBOCOVICH ML, 1983, NATURE, V204, P183; Espinar A, 2000, J PINEAL RES, V28, P81, DOI 10.1034/j.1600-079X.2001.280203.x; FAILLACE MP, 1995, NEUROREPORT, V6, P2093, DOI 10.1097/00001756-199510010-00033; Faillace MP, 1996, J NEUROCHEM, V67, P623; FAILLACE MP, 1994, J NEUROCHEM, V62, P1995; Faillace MP, 1995, NEUROREPORT, V7, P141, DOI 10.1097/00001756-199512290-00034; Faillace MP, 1996, BRAIN RES, V711, P112, DOI 10.1016/0006-8993(95)01405-5; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; Gu SM, 2001, J BIOL CHEM, V276, P24137, DOI 10.1074/jbc.M009003200; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Heckel T, 2003, NEUROCHEM INT, V43, P289, DOI 10.1016/S0197-0186(03)00014-7; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KVAMME E, 1985, METHOD ENZYMOL, V113, P241; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; LOUZADAJUNIOR P, 1992, J NEUROCHEM, V59, P358, DOI 10.1111/j.1471-4159.1992.tb08912.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY SC, 1987, PROG NEUROBIOL, V28, P55, DOI 10.1016/0301-0082(87)90005-0; MASSEY SC, 1988, J PHYSIOL-LONDON, V405, P635, DOI 10.1113/jphysiol.1988.sp017353; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Morgan J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1524; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; Nagaraja TN, 1996, J NEUROCHEM, V66, P1665; Otis TS, 1998, J NEUROSCI, V18, P7099; PANG SF, 1991, NEUROENDOCRINOLOGY, V53, P2, DOI 10.1159/000125787; Pappolla MA, 1997, J NEUROSCI, V17, P1683; PATEL AJ, 1983, DEV BRAIN RES, V10, P83, DOI 10.1016/0165-3806(83)90123-2; PIERCE ME, 1985, J GEN PHYSIOL, V86, P671, DOI 10.1085/jgp.86.5.671; Poitry S, 2000, J NEUROSCI, V20, P1809; Rauen T, 2000, NEUROCHEM INT, V37, P179, DOI 10.1016/S0197-0186(00)00021-8; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; RIEPE RE, 1977, NATURE, V268, P654, DOI 10.1038/268654a0; ROSNER M, 1992, RES COMMUN CHEM PATH, V77, P299; Saenz DA, 2002, J NEUROCHEM, V80, P512, DOI 10.1046/j.0022-3042.2001.00723.x; Saenz DA, 2002, J PINEAL RES, V33, P31, DOI 10.1034/j.1600-079X.2002.01880.x; SARKAR PK, 1983, MOL CELL BIOCHEM, V53-4, P233; SARTHY PV, 1983, J NEUROSCI, V3, P2532; SARTHY PV, 1978, J CELL BIOL, V78, P675, DOI 10.1083/jcb.78.3.675; Shaked I, 2002, J NEUROCHEM, V83, P574, DOI 10.1046/j.1471-4159.2002.01168.x; Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x; Tanaka K, 2000, NEUROSCI RES, V37, P15, DOI 10.1016/S0168-0102(00)00104-8; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; Tosini G, 2003, J NEUROENDOCRINOL, V15, P364, DOI 10.1046/j.1365-2826.2003.00973.x; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; VivienRoels B, 1997, GEN COMP ENDOCR, V106, P85, DOI 10.1006/gcen.1996.6853; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; ZAWILSKA JB, 1992, NEUROCHEM INT, V20, P23, DOI 10.1016/0197-0186(92)90122-8	63	21	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1912	+		10.1096/fj.04-2062fje	http://dx.doi.org/10.1096/fj.04-2062fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15448109				2022-12-28	WOS:000224243200010
J	Crean, JK; Furlong, F; Finlay, D; Mitchell, D; Conway, B; Brady, HR; Godson, C; Martin, F				Crean, JK; Furlong, F; Finlay, D; Mitchell, D; Conway, B; Brady, HR; Godson, C; Martin, F			Connective tissue growth factor [CTGF]/CCN2 stimulates mesangial cell migration through integrated dissolution of focal adhesion complexes and activation of cell polarization	FASEB JOURNAL			English	Article						protein kinase C zeta; Rho; focal adhesion kinase; SHP-2; actin disassembly	TYROSINE-PHOSPHATASE SHP-2; PROTEIN-KINASE-C; VASCULAR ENDOTHELIAL-CELLS; FACTOR INDUCES APOPTOSIS; IN-VITRO; CDC42; RHO; EXPRESSION; FAMILY; FAK	Connective tissue growth factor [CTGF]/CCN2 is a prototypic member of the CCN family of regulatory proteins. CTGF expression is up-regulated in a number of fibrotic diseases, including diabetic nephropathy, where it is believed to act as a downstream mediator of TGF-function; however, the exact mechanisms whereby CTGF mediates its effects remain unclear. Here, we describe the role of CTGF in cell migration and actin disassembly in human mesangial cells, a primary target in the development of renal glomerulosclerosis. The addition of CTGF to primary mesangial cells induced cell migration and cytoskeletal rearrangement but had no effect on cell proliferation. Cytoskeletal rearrangement was associated with a loss of focal adhesions, involving tyrosine dephosphorylation of focal adhesion kinase and paxillin, increased activity of the protein tyrosine phosphatase SHP-2, with a concomitant decrease in RhoA and Rac1 activity. Conversely, Cdc42 activity was increased by CTGF. These functional responses were associated with the phosphorylation and translocation of protein kinase C-zeta to the leading edge of migrating cells. Inhibition of CTGF-induced protein kinase C-zeta activity with a myristolated PKC-zeta inhibitor prevented cell migration. Moreover, transient transfection of human mesangial cells with a PKC-zeta kinase inactive mutant ( dominant negative) expression vector also led to a decrease in CTGF-induced migration compared with wild-type. Furthermore, CTGF stimulated phosphorylation and activation of GSK-3beta. These data highlight for the first time an integrated mechanism whereby CTGF regulates cell migration through facilitative actin cytoskeleton disassembly, which is mediated by dephosphorylation of focal adhesion kinase and paxillin, loss of RhoA activity, activation of Cdc42, and phosphorylation of PKC-zeta and GSK-3beta. These changes indicate that the initial stages of CTGF mediated mesangial cell migration are similar to those involved in the process of cell polarization. These findings begin to shed mechanistic light on the renal diabetic milieu, where increased CTGF expression in the glomerulus contributes to cellular dysfunction.	Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Univ Coll Dublin, Mater Misericordiae Hosp, Dept Pharmacol, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Dublin Mol Med Ctr, Dublin 4, Ireland; Queens Univ Belfast, Inst Clin Sci, Dept Med, Belfast, Antrim, North Ireland	Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Trinity College Dublin; University College Dublin; Queens University Belfast	Crean, JK (corresponding author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Med & Therapeut, Dublin 4, Ireland.	john.crean@ucd.ie		/0000-0002-4337-6177; Furlong, Fiona/0000-0002-9206-2297; Godson, Catherine/0000-0003-0655-1041				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRADY HR, 1992, KIDNEY INT, V42, P480, DOI 10.1038/ki.1992.312; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brill S, 1996, MOL CELL BIOL, V16, P4869; Cary LA, 1996, J CELL SCI, V109, P1787; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Cortes P, 2000, KIDNEY INT, V58, P2452, DOI 10.1046/j.1523-1755.2000.00428.x; Cortes P, 2002, CLIN EXP PHARMACOL P, V29, P149, DOI 10.1046/j.1440-1681.2002.03615.x; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Dlugosz JA, 2002, AM J PHYSIOL-RENAL, V282, pF151, DOI 10.1152/ajprenal.0055.2001; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Harwood A, 2003, NAT CELL BIOL, V5, P275, DOI 10.1038/ncb0403-275; Hishikawa K, 2000, EUR J PHARMACOL, V392, P19, DOI 10.1016/S0014-2999(00)00115-1; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; ILLC D, 1995, NATURE, V377, P539; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kubota S, 2000, FEBS LETT, V474, P58, DOI 10.1016/S0014-5793(00)01573-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; MacGillivray M, 2003, J BIOL CHEM, V278, P27190, DOI 10.1074/jbc.M213083200; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nishida T, 1998, BIOCHEM BIOPH RES CO, V247, P905, DOI 10.1006/bbrc.1998.8895; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Roberts LA, 2003, J CELL PHYSIOL, V196, P196, DOI 10.1002/jcp.10303; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Tzima E, 2003, J BIOL CHEM, V278, P31020, DOI 10.1074/jbc.M301179200; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whiteside CI, 2002, AM J PHYSIOL-RENAL, V282, pF975, DOI 10.1152/ajprenal.00014.2002; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Yokoi H, 2001, AM J KIDNEY DIS, V38, pS134, DOI 10.1053/ajkd.2001.27422; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZHOU XP, 1995, LAB INVEST, V73, P372	60	65	70	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1541	+		10.1096/fj.04-1546fje	http://dx.doi.org/10.1096/fj.04-1546fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319369				2022-12-28	WOS:000223554900014
J	Matsusue, K; Peters, JM; Gonzalez, FJ				Matsusue, K; Peters, JM; Gonzalez, FJ			PPAR beta/delta potentiates PPAR gamma-stimulated adipocyte differentiation	FASEB JOURNAL			English	Article						peroxisome proliferator-activated receptor	ACTIVATED-RECEPTOR-DELTA; ADIPOSE DIFFERENTIATION; BROWN ADIPOCYTES; GENE-EXPRESSION; PERILIPIN-A; INSULIN; ADIPOGENESIS; MACROPHAGES; PROTEIN; TRANSCRIPTION	It is well established that peroxisome proliferator-activated receptor-gamma (PPARgamma) has a critical role in modulating adipocyte differentiation based on gain-of-function and loss-of-function experiments. However, recent gain-of-function experiments suggest that PPARbeta may also have a role in mediating adipocyte differentiation. Because ligands for PPARs can activate more than one receptor isoform, the specific role of PPARbeta in adipocyte differentiation was examined using PPARbeta-null adipocytes. Wild-type adipocytes accumulate lipids in response to differentiation signaling induced from standard differentiation medium, and this effect is significantly reduced in PPARbeta-null adipocytes. The addition of the PPARbeta ligand L165041 to the standard differentiation medium causes enhanced adipocyte differentiation and lipid accumulation, and this effect is diminished in adipocytes lacking expression of PPARbeta. Treatment of wild-type adipocytes with the PPARgamma ligand troglitazone causes accelerated adipocyte differentiation and lipid accumulation, and this effect is marginally reduced in PPARbeta-null adipocytes. Expression patterns of mRNA markers of early and late adipocyte differentiation are consistent with the morphological and biochemical differences observed. Results from these studies demonstrate that in the absence of PPARbeta expression, adipocyte differentiation is significantly impaired, providing loss-of-function evidence supporting a role for this receptor in adipocyte differentiation. These results also demonstrate that L165041-stimulated adipocyte differentiation and lipid accumulation is mediated by PPARbeta. In addition, as the ability of troglitazone to induce adipocyte differentiation is also impaired in PPARbeta null adipocytes, this suggests that both PPARbeta and PPARgamma isoforms are required to facilitate maximal lipid accumulation and differentiation during adipogenesis.	NCI, LAb Metab, Bethesda, MD 20892 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Gonzalez, FJ (corresponding author), NCI, LAb Metab, Bldg 37,Room 3106, Bethesda, MD 20892 USA.	fjgonz@helix.nih.gov	Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [R01CA097999, R01CA089607] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89607, CA97999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Inoue Y, 2004, J BIOL CHEM, V279, P2480, DOI 10.1074/jbc.M311015200; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; SHIMIZU Y, 1994, J BIOCHEM-TOKYO, V115, P1069, DOI 10.1093/oxfordjournals.jbchem.a124459; TANG YL, 1994, J BIOL CHEM, V269, P6011; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X	30	79	90	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1477	+		10.1096/fj.04-1944fje	http://dx.doi.org/10.1096/fj.04-1944fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247146				2022-12-28	WOS:000222979200001
J	Papadopoulos, MC; Manley, GT; Krishna, S; Verkman, AS				Papadopoulos, MC; Manley, GT; Krishna, S; Verkman, AS			Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema	FASEB JOURNAL			English	Article						AQP4; astrocyte; knockout mice; water transport	FULMINANT HEPATIC-FAILURE; WATER CHANNELS; RAT-BRAIN; MESSENGER-RNA; INJURY; EXPRESSION; MICE; MODEL; PATHOPHYSIOLOGY; HYPONATREMIA	Aquaporin-4 (AQP4) is the major water channel in the brain, expressed predominantly in astroglial cell membranes. Initial studies in AQP4-deficient mice showed reduced cellular brain edema following water intoxication and ischemic stroke. We hypothesized that AQP4 deletion would have the opposite effect (increased brain swelling) in vasogenic (noncellular) edema because of impaired removal of excess brain water through glial limitans and ependymal barriers. In support of this hypothesis, we found higher intracranial pressure (ICP, 52 +/- 6 vs. 26 +/- 3 cm H2O) and brain water content (81.2 +/- 0.1 vs. 80.4 +/- 0.1%) in AQP4-deficient mice after continuous intraparenchymal fluid infusion. In a freeze-injury model of vasogenic brain edema, AQP4-deficient mice had remarkably worse clinical outcome, higher ICP (22 +/- 4 vs. 9 +/- 1 cm H2O), and greater brain water content (80.9 +/- 0.1 vs. 79.4 +/- 0.1%). In a brain tumor edema model involving stereotactic implantation of melanoma cells, tumor growth was comparable in wildtype and AQP4-deficient mice. However, AQP4-deficient mice had higher ICP (39 +/- 4 vs. 19 +/- 5 cm H2O at seven days postimplantation) and corresponding accelerated neurological deterioration. Thus, AQP4-mediated transcellular water movement is crucial for fluid clearance in vasogenic brain edema, suggesting AQP4 activation and/or up-regulation as a novel therapeutic option in vasogenic brain edema.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; St George Hosp, Sch Med, Dept Cellular & Mol Sci, London SW17 0RE, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; St Georges University London	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176; Krishna, Sanjeev/0000-0003-0066-0634	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT NJ, 2004, IN PRESS NEUROCHEM I; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Aoki K, 2003, ACTA NEUROPATHOL, V106, P121, DOI 10.1007/s00401-003-0709-y; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; BLAKEMORE WF, 1972, J NEUROCYTOL, V1, P69, DOI 10.1007/BF01098647; Blei AT, 2001, METAB BRAIN DIS, V16, P85, DOI 10.1023/A:1011670713730; BONDAREFF W, 1973, AM J ANAT, V136, P277, DOI 10.1002/aja.1001360303; Brightman MW, 2002, J NEUROCYTOL, V31, P595, DOI 10.1023/A:1025783326667; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; KAYE AH, 1986, CANCER RES, V46, P1367; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1994, ACTA NEUROCHIR, P3; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARMAROU A, 1994, AM J PHYSIOL, V267, pH514, DOI 10.1152/ajpheart.1994.267.2.H514; Marples D, 1999, AM J PHYSIOL-RENAL, V276, pF331, DOI 10.1152/ajprenal.1999.276.3.F331; Matkowskyj KA, 1999, AM J PHYSIOL-GASTR L, V277, pG455, DOI 10.1152/ajpgi.1999.277.2.G455; Nielsen S, 1997, J NEUROSCI, V17, P171; OURY TD, 1993, J BIOL CHEM, V268, P15394; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Sampson JH, 2000, P NATL ACAD SCI USA, V97, P7503, DOI 10.1073/pnas.130166597; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Thapar K, 2001, BRAIN TUMORS ENCY AP, P189; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Verkman AS, 2002, ANN MED, V34, P192, DOI 10.1080/713782138; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531	41	581	648	1	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1291	+		10.1096/fj.04-1723fje	http://dx.doi.org/10.1096/fj.04-1723fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208268				2022-12-28	WOS:000222327500006
J	Warner, TD; Mitchell, JA				Warner, TD; Mitchell, JA			Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic	FASEB JOURNAL			English	Review						cyclooxygenase-2; nonsteroidal anti-inflammatory; drugs; rofecoxib; celecoxib; thrombosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARDIOVASCULAR THROMBOTIC EVENTS; SELECTIVE COX-2 INHIBITOR; MUCOSAL PROSTAGLANDIN E-2; ACTIVATED RECEPTOR-GAMMA; TRANSGENIC MOUSE MODEL; DOUBLE-BLIND; GASTROINTESTINAL TOXICITY; THROMBOEMBOLIC EVENTS; ALZHEIMERS-DISEASE	The beneficial actions of nonsteroidal anti-inflammatory drugs ( NSAIDs) have been linked to their ability to inhibit inducible COX-2 at sites of inflammation, and their side effects ( e. g., gastric damage) to inhibition of constitutive COX-1. Selective inhibitors of COX-2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. Although clinical data indicate that COX-2 selectivity is associated with a reduction in severe gastrointestinal events, they also reveal there are roles for constitutive COX-2 within tissues such as the brain, kidney, pancreas, intestine, and blood vessels. We now better understand the roles of COX-1 and COX-2 in functions as disparate as the perception of pain and the progression of cancers. Clinical use of COX-2-selective compounds has ignited strong debates regarding potential side effects, most notably those within the cardiovascular system such as myocardial infarctions, strokes, and elevation in blood pressure. This review will discuss how the latest studies help us understand the roles of COX-1 and COX-2 and what clinically proven benefits the newer generation of COX-2-selective inhibitors offer.	Barts & London Queen Marys Sch Med & Dent, Barts & London, William Harvey Res Inst, London EC1M 6BQ, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Royal Brompton Hosp, Unit Crit Care Med, London, England	University of London; Queen Mary University London; Imperial College London; Royal Brompton Hospital	Warner, TD (corresponding author), Barts & London Queen Marys Sch Med & Dent, Barts & London, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	t.d.warner@qmul.ac.uk	Mitchell, Jane A/A-1991-2009; Warner, Timothy D/A-1980-2009	Warner, Timothy D/0000-0003-3988-4408				Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Alsalameh S, 2003, ALIMENT PHARM THER, V17, P489, DOI 10.1046/j.1365-2036.2003.01460.x; Altman R, 2002, CIRCULATION, V106, P191, DOI 10.1161/01.CIR.0000021599.56755.A1; Altorki NK, 2003, J CLIN ONCOL, V21, P2645, DOI 10.1200/JCO.2003.07.127; Araki Y, 2003, CANCER RES, V63, P728; Baatar D, 2002, AM J PATHOL, V160, P963, DOI 10.1016/S0002-9440(10)64918-8; Bae SH, 2001, CLIN CANCER RES, V7, P1410; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Bavbek S, 1999, J ASTHMA, V36, P657, DOI 10.3109/02770909909055417; Becerra CR, 2003, INT J CANCER, V105, P868, DOI 10.1002/ijc.11164; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Blomqvist S, 2001, ECOL STU AN, V148, P211; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623-200401000-00017; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Buvanendran A, 2003, JAMA-J AM MED ASSOC, V290, P2411, DOI 10.1001/jama.290.18.2411; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Chan FKL, 2002, NEW ENGL J MED, V347, P2104, DOI 10.1056/NEJMoa021907; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A; Chiolero Arnaud, 2002, Expert Opin Drug Saf, V1, P45, DOI 10.1517/14740338.1.1.45; Chow LWC, 2003, J STEROID BIOCHEM, V86, P443, DOI 10.1016/S0960-0760(03)00355-8; Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462; Crane CH, 2003, AM J CLIN ONCOL-CANC, V26, pS81, DOI 10.1097/00000421-200308002-00009; Curhan GC, 2002, ARCH INTERN MED, V162, P2204, DOI 10.1001/archinte.162.19.2204; Daniels SE, 2002, OBSTET GYNECOL, V100, P350, DOI 10.1016/S0029-7844(02)02085-9; Daniels SE, 2002, J AM DENT ASSOC, V133, P611, DOI 10.14219/jada.archive.2002.0237; Dilger K, 2002, J CLIN PHARMACOL, V42, P985; Dinchuk JE, 2003, IMMUNOL LETT, V86, P121, DOI 10.1016/S0165-2478(02)00268-7; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Einhorn TA, 1999, SPINE, V24, P2193; Elder CL, 2001, AM J SPORT MED, V29, P801, DOI 10.1177/03635465010290062101; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fenwick SW, 2003, GASTROENTEROLOGY, V125, P716, DOI 10.1016/S0016-5085(03)01061-8; Fiala M, 2002, EUR J CLIN INVEST, V32, P360, DOI 10.1046/j.1365-2362.2002.00994.x; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Fujita M, 2000, J GASTROEN HEPATOL, V15, P1277, DOI 10.1046/j.1440-1746.2000.02399.x; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goldstein JL, 2003, ALIMENT PHARM THER, V18, P125, DOI 10.1046/j.1365-2036.2003.01650.x; Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736-0266(02)00079-7; Greenberg HE, 2000, J CLIN PHARMACOL, V40, P1509; Gretzer B, 2001, BRIT J PHARMACOL, V132, P1565, DOI 10.1038/sj.bjp.0703955; Hallak A, 2003, DIGEST DIS SCI, V48, P1998, DOI 10.1023/A:1026130623186; HARA S, 1994, J BIOL CHEM, V269, P19897; Hoozemans JJM, 2002, J NEUROPATH EXP NEUR, V61, P678, DOI 10.1093/jnen/61.8.678; Hunt RH, 2003, AM J GASTROENTEROL, V98, P1725, DOI 10.1016/S0002-9270(03)00449-0; Hunt RH, 2003, ALIMENT PHARM THER, V17, P201, DOI 10.1046/j.1365-2036.2003.01407.x; Hwang DY, 2002, FASEB J, V16, DOI 10.1096/fj.01-0732com; Ibuki T, 2003, J NEUROCHEM, V86, P318, DOI 10.1046/j.1471-4159.2003.01848.x; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kaur BS, 2002, GASTROENTEROLOGY, V123, P60, DOI 10.1053/gast.2002.34244; Khan AA, 2002, CLIN PHARMACOL THER, V72, P44, DOI 10.1067/mcp.2002.125560; Kis B, 2003, J CEREBR BLOOD F MET, V23, P1287, DOI 10.1097/01.WCB.0000090681.07515.81; Kitahara M, 2002, J AM SOC NEPHROL, V13, P1261, DOI 10.1681/ASN.V1351261; Kniss DA, 1999, J SOC GYNECOL INVEST, V6, P285, DOI 10.1177/107155769900600602; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Korita D, 2002, J CLIN ENDOCR METAB, V87, P5209, DOI 10.1210/jc.2002-020531; Krishnan K, 2001, CANCER EPIDEM BIOMAR, V10, P447; Laulederkind SJF, 2002, LAB INVEST, V82, P919, DOI 10.1097/01.LAB.0000020407.98665.98; Launer LJ, 2003, DRUGS, V63, P731, DOI 10.2165/00003495-200363080-00001; Layton D, 2003, RHEUMATOLOGY, V42, P1342, DOI 10.1093/rheumatology/keg379; Layton D, 2003, RHEUMATOLOGY, V42, P1354, DOI 10.1093/rheumatology/keg401; Lazarus M, 2002, ENDOCRINOLOGY, V143, P2410, DOI 10.1210/en.143.6.2410; Leese PT, 2000, J CLIN PHARMACOL, V40, P124, DOI 10.1177/00912700022008766; Leung AT, 2002, CURR MED RES OPIN, V18, P49, DOI 10.1185/030079902125000282; Lisse JR, 2003, ANN INTERN MED, V139, P539, DOI 10.7326/0003-4819-139-7-200310070-00005; Long J, 2002, J BONE JOINT SURG AM, V84A, P1763, DOI 10.2106/00004623-200210000-00004; MacDonald TM, 2003, LANCET, V361, P573, DOI 10.1016/S0140-6736(03)12509-3; Makarowski W, 2002, OSTEOARTHR CARTILAGE, V10, P290, DOI 10.1053/joca.2001.0510; Malmstrom K, 2003, GYNECOL OBSTET INVES, V56, P65, DOI 10.1159/000072735; Malmstrom K, 2002, CLIN THER, V24, P1549, DOI 10.1016/S0149-2918(02)80059-5; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; Marrache AM, 2002, J IMMUNOL, V169, P6474, DOI 10.4049/jimmunol.169.11.6474; Martin-Garcia C, 2003, J INVEST ALLERG CLIN, V13, P20; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McCartney SA, 1999, ALIMENT PHARM THERAP, V13, P1115; Mitchell JA, 1999, BRIT J PHARMACOL, V128, P1121, DOI 10.1038/sj.bjp.0702897; Morrison BW, 1999, CLIN THER, V21, P943, DOI 10.1016/S0149-2918(99)80016-2; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Nagatsuka I, 2002, INT J CANCER, V100, P515, DOI 10.1002/ijc.10508; Nash GF, 2002, LANCET ONCOL, V3, P425, DOI 10.1016/S1470-2045(02)00789-1; Ouellet M, 2001, P NATL ACAD SCI USA, V98, P14583, DOI 10.1073/pnas.251543298; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pall M, 2001, HUM REPROD, V16, P1323, DOI 10.1093/humrep/16.7.1323; Patrignani P, 2003, EXPERT OPIN PHARMACO, V4, P265, DOI 10.1517/eoph.4.2.265.21085; Phillips RKS, 2002, GUT, V50, P857, DOI 10.1136/gut.50.6.857; Quiralte J, 2002, ANN ALLERG ASTHMA IM, V89, P63, DOI 10.1016/S1081-1206(10)61912-6; Rahme E, 2002, ARCH INTERN MED, V162, P1111, DOI 10.1001/archinte.162.10.1111; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Reicin AS, 2002, AM J CARDIOL, V89, P204, DOI 10.1016/S0002-9149(01)02201-9; Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558; Rinder HM, 2002, J CLIN PHARMACOL, V42, P881, DOI 10.1177/009127002401102795; Rordorf C, 2003, ALIMENT PHARM THER, V18, P533, DOI 10.1046/j.1365-2036.2003.01691.x; Rossat J, 1999, CLIN PHARMACOL THER, V66, P76, DOI 10.1016/S0009-9236(99)70056-1; Sabino MAC, 2002, CANCER RES, V62, P7343; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Sample D, 2002, CANCER EPIDEM BIOMAR, V11, P275; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sarkar S, 2003, GASTROENTEROLOGY, V124, P18, DOI 10.1053/gast.2003.50022; Saukkonen K, 2001, CLIN CANCER RES, V7, P1923; Schade S, 2002, BIOCHEM PHARMACOL, V64, P1227, DOI 10.1016/S0006-2952(02)01290-X; Schuller HM, 2002, J CANCER RES CLIN, V128, P525, DOI 10.1007/s00432-002-0365-y; Schwartz JI, 1999, CLIN PHARMACOL THER, V65, P653, DOI 10.1016/S0009-9236(99)90087-5; Seibert K, 1997, ADV EXP MED BIOL, V400, P167; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sheng HM, 2001, CANCER RES, V61, P2670; Sikes DH, 2002, EUR J GASTROEN HEPAT, V14, P1101, DOI 10.1097/00042737-200210000-00011; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Simmons DL, 1999, P NATL ACAD SCI USA, V96, P3275, DOI 10.1073/pnas.96.6.3275; Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963; Singh G, 2003, J RHEUMATOL, V30, P714; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Solomon DH, 2003, CIRCULATION, V107, P1303, DOI 10.1161/01.CIR.0000054612.26458.B2; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Svensson CI, 2002, ANNU REV PHARMACOL, V42, P553, DOI 10.1146/annurev.pharmtox.42.092401.143905; Swan SK, 2000, ANN INTERN MED, V133, P1, DOI 10.7326/0003-4819-133-1-200007040-00002; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Talley JJ, 2000, J MED CHEM, V43, P775, DOI 10.1021/jm990577v; Taylor MT, 2000, CANCER RES, V60, P6607; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tomita M, 2002, BONE, V30, P159, DOI 10.1016/S8756-3282(01)00688-3; Tucker ON, 1999, CANCER RES, V59, P987; Urade Y, 2002, PROSTAG OTH LIPID M, V68-9, P375, DOI 10.1016/S0090-6980(02)00042-4; van Ryn J, 2000, CURR MED CHEM, V7, P1145, DOI 10.2174/0929867003374255; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; Wang LH, 2002, PROSTAG OTH LIPID M, V68-9, P409, DOI 10.1016/S0090-6980(02)00045-X; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Watanabe K, 2002, PROSTAG OTH LIPID M, V68-9, P401, DOI 10.1016/S0090-6980(02)00044-8; Watson DJ, 2002, ARCH INTERN MED, V162, P1105, DOI 10.1001/archinte.162.10.1105; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Whelton A, 2000, ARCH INTERN MED, V160, P1465, DOI 10.1001/archinte.160.10.1465; Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002-9149(02)02661-9; Whelton A, 2001, Am J Ther, V8, P85, DOI 10.1097/00045391-200103000-00003; White WB, 2002, AM J CARDIOL, V89, P425, DOI 10.1016/S0002-9149(01)02265-2; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Widlansky ME, 2003, HYPERTENSION, V42, P310, DOI 10.1161/01.HYP.0000084603.93510.28; Wight NJ, 2001, GASTROENTEROLOGY, V120, P867, DOI 10.1053/gast.2001.22432; Wilgus TA, 2003, WOUND REPAIR REGEN, V11, P25, DOI 10.1046/j.1524-475X.2003.11106.x; Wilner KD, 2002, J CLIN PHARMACOL, V42, P1027; Winchester SK, 2002, ENDOCRINOLOGY, V143, P2593, DOI 10.1210/en.143.7.2593; Woessner KM, 2002, ARTHRITIS RHEUM, V46, P2201, DOI 10.1002/art.10426; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Xiang ZM, 2002, NEUROBIOL AGING, V23, P327, DOI 10.1016/S0197-4580(01)00282-2; Xu SY, 2000, BBA-PROTEIN STRUCT M, V1482, P298, DOI 10.1016/S0167-4838(00)00163-1; Yaksh TL, 2001, J NEUROSCI, V21, P5847, DOI 10.1523/JNEUROSCI.21-16-05847.2001; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Zacher J, 2002, CURR MED RES OPIN, V18, P229, DOI 10.1185/030079902125000796; Zhang XP, 2000, EXP CELL RES, V254, P232, DOI 10.1006/excr.1999.4758; Zimmermann KC, 1998, MOL PHARMACOL, V54, P536, DOI 10.1124/mol.54.3.536	158	456	506	0	44	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					790	804		10.1096/fj.03-0645rev	http://dx.doi.org/10.1096/fj.03-0645rev			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15117884				2022-12-28	WOS:000221883200028
J	Sambamurti, K; Kinsey, R; Maloney, B; Ge, YW; Lahiri, DK				Sambamurti, K; Kinsey, R; Maloney, B; Ge, YW; Lahiri, DK			Gene structure and organization of the human beta-secretase (BACE) promoter	FASEB JOURNAL			English	Article						dementia; aging; genomic; Alzheimer's disease; amyloid	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; EXPRESSION; IDENTIFICATION; SITE; CYTOKINES; CLEAVAGE; CLONING	The first step in the generation of the amyloid-beta peptide (Abeta) deposited in the brains of patients with Alzheimer's disease ( AD) is the processing of the larger Abeta precursor protein (APP) by an integral membrane aspartyl protease named the beta-site APP-cleaving enzyme (BACE). We present the genomic organization of the BACE gene. BACE mRNAs are synthesized as nine exons and eight introns from a 30.6 kb region of chromosome 11q23.2-11q23.3. Regulation of BACE may play an important role in regulating the levels of Abeta produced and is therefore likely to play an important role in AD. Herein, we report the cloning and detailed analysis of 3765 nucleotides of the promoter region of BACE and 364 nucleotides of the 5' untranslated region of the BACE mRNA (5' UTR). Characteristic "CAAT" and "TATA" boxes are absent within 1.5 kb of the transcription start site (TSS). The promoter region and 5' UTR contain multiple transcription factor binding sites, such as activator protein (AP) 1, AP2, cAMP response element binding protein ( CREB), estrogen responsive element ( ERE), glucocorticoid responsive element (GRE), "GC" box, nuclear factor (NF)-kappaB, signal transducer and activator of transcription ( STAT) 1, stimulating protein (SP) 1, metal-regulatory elements, and possible Zeste binding sites. Limited interspecies similarity was observed between the human sequence and corresponding genomic DNA from the rat and mouse sequences, but several transcription factor-binding sites are conserved. Thus, the BACE gene contains basal regulatory elements, inducible features and sites for regulated activity by various transcription factors. These results identify the important regions for functional analysis of the binding domains and neuron-specific expression ( 1). Such a study will allow us to further examine the possible role of changes in the promoter of BACE in AD pathogenesis.	Med Univ S Carolina, Charleston, SC 29425 USA; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Medical University of South Carolina; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Lahiri, DK (corresponding author), 791 N Union Dr, Indianapolis, IN 46206 USA.	dlahiri@iupui.edu	Lahiri, Debomoy/AAZ-3322-2020; Sambamurti, Kumar/A-1620-2012; Maloney, Bryan J/C-4924-2011	Sambamurti, Kumar/0000-0001-9507-9214; Maloney, Bryan J/0000-0003-2364-9649	NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER; NIA NIH HHS [AG18379, AG18884] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; GE YW, 2004, FASEB J         0401, DOI DOI 10.1096/FJ.03-1739FJE; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Huang XQ, 1996, GENOMICS, V33, P21, DOI 10.1006/geno.1996.0155; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; LAHIRI DK, 1995, MOL BRAIN RES, V32, P233, DOI 10.1016/0169-328X(95)00078-7; Lange-Dohna C, 2003, J NEUROSCI RES, V73, P73, DOI 10.1002/jnr.10639; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Satoh J, 2000, NEUROPATHOLOGY, V20, P289, DOI 10.1046/j.1440-1789.2000.00349.x; SCHUG J, TESS TRANSCRIPTION E; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vattemi G, 2003, EXP NEUROL, V179, P150, DOI 10.1016/S0014-4886(02)00025-0; Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407	41	150	157	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1034	+		10.1096/fj.03-1378fje	http://dx.doi.org/10.1096/fj.03-1378fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059975				2022-12-28	WOS:000221108800026
J	Brunn, GJ; Bungum, MK; Johnson, GB; Platt, JL				Brunn, GJ; Bungum, MK; Johnson, GB; Platt, JL			Conditional signaling by Toll-like receptor 4	FASEB JOURNAL			English	Article						sepsis; inflammatory response syndrome; extracellular matrix; heparan sulfate	INFLAMMATORY RESPONSE SYNDROME; NF-KAPPA-B; HEPARAN-SULFATE; ENDOTHELIAL-CELLS; IMMUNE-SYSTEM; DENDRITIC CELLS; DROSOPHILA TOLL; ACTIVATION; EXPRESSION; OLIGOSACCHARIDES	Signaling through Toll-like receptor 4 (TLR4) is thought to initiate innate and adaptive immune responses. Signaling of TLR4 is usually studied using isolated cells, which are activated by subnanomolar concentrations of lipopolysaccharide (LPS). However, in normal tissues, cells bearing TLR4 reside in microenvironments containing large amounts of endogenous substances that can stimulate the receptor. We developed an in vitro model system using the human cell line HEK 293 and an in vivo model using mice that have normal or that lack TLR4 receptors to study how TLR4 functions in such microenvironments. Here we report that signaling through TLR4 is strongly inhibited by intact extracellular matrix and that inhibition is abrogated and endogenous agonist(s) are liberated when the matrix is degraded. Thus, release from inhibition rather than direct stimulation by agonists such as LPS is the critical first event by which TLR4 initiates immune responses.	Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Pediat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Platt, JL (corresponding author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW,2-66 Med Sci Bldg, Rochester, MN 55905 USA.	platt.jeffrey@mayo.edu	Johnson, Geoffrey B/AAG-2729-2021; Eckhardt, Erik/G-1567-2010; Platt, Jeffrey/AHB-0480-2022	Johnson, Geoffrey B/0000-0002-4866-1401; Platt, Jeffrey/0000-0002-4915-0419; Johnson, Geoffrey/0000-0002-9781-4072	NHLBI NIH HHS [HL46810] Funding Source: Medline; NIAID NIH HHS [AI53733] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053733] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; BONIFACINO JS, 1998, CURRENT PROTOCOLS CE, pCH10; Boulday G, 2001, CIRC RES, V88, P430; Conrad H E, 2001, Methods Mol Biol, V171, P347; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dunn D L, 2000, Surg Infect (Larchmt), V1, P227, DOI 10.1089/109629600750018150; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Ihrcke NS, 1996, J CELL PHYSIOL, V168, P625, DOI 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.3.CO;2-A; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kishore SP, 2005, FEBS LETT, V579, P699, DOI 10.1016/j.febslet.2004.12.047; Magor BG, 2001, DEV COMP IMMUNOL, V25, P651, DOI 10.1016/S0145-305X(01)00029-5; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Paterson RL, 2000, J ROY COLL SURG EDIN, V45, P178; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Saadi S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0690hyp; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863	30	97	110	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					872	+		10.1096/fj.04-3211fje	http://dx.doi.org/10.1096/fj.04-3211fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15738005				2022-12-28	WOS:000227591900001
J	Elbling, L; Weiss, RM; Teufelhofer, O; Uhl, M; Knasmueller, S; Schulte-Hermann, R; Berger, W; Mickshe, M				Elbling, L; Weiss, RM; Teufelhofer, O; Uhl, M; Knasmueller, S; Schulte-Hermann, R; Berger, W; Mickshe, M			Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities	FASEB JOURNAL			English	Article						oxidative stress; DNA damage; monocytic cell lines; H(2)O(2); EGCG	COLON ADENOCARCINOMA CELLS; HYDROGEN-PEROXIDE; DNA-DAMAGE; EPIGALLOCATECHIN GALLATE; POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; CANCER CHEMOPREVENTION; GROWTH-INHIBITION; OXIDATIVE DAMAGE; REACTIVE OXYGEN; CELLULAR-DNA	Green tea is the most widely consumed beverage. It has attained high reputation as a health-promoting dietary component ascribed to the antioxidant activity of(-)-epigallocatechin-3-gallate(EGCG), its main polyphenolic constituent. Evidence is increasing that tea constituents can be cell damaging and pro-oxidant themselves. These effects were suggested to be due to spontaneous H(2)O(2) generation by polyphenols in solution. In the present study, we investigated the oxidant and antioxidant properties of green tea extracts(GTE) and of EGCG by means of the rodent macrophage-like RAW 264.7 and human promyelocytic leukemic HL60 cell lines. The results obtained show that both under cell-free conditions and in the presence of cells the oxidant activities of GTE and EGCG exceeded those of spontaneously generated H(2)O(2)(FOX assay). Increase of intracellular oxidative stress was indicated by 2',7'-dichlorofluorescin probing,and the enhanced genotoxicity was demonstrated by the alkaline comet assay and by the micronucleus assay(cytokinesis block). Time-and dose-dependent induction of cell death was monitored by trypan blue exclusion, MTT assay,and Hoechst staining. Furthermore,in our systems in vitro,EGCG neither directly scavenges H(2)O(2) nor mediates other antioxidant activities but rather increased H(2)O(2)-induced oxidative stress and DNA damage. In conclusion, our data suggest that detailed mechanistic studies on the effects of GTE and EGCG should be performed in vivo before excessive intake and/or topical application of green tea products can be recommended to healthy and/or diseased persons.	Med Univ Vienna, Inst Canc Res, Div Appl & Expt Oncol, Clin Internal Med 1, A-1090 Vienna, Austria; Med Univ Vienna, Inst Canc Res, Div Oncol Toxicol, Clin Internal Med 1, A-1090 Vienna, Austria; Med Univ Vienna, Inst Canc Res, Environm Toxicol Grp, Clin Internal Med 1, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Elbling, L (corresponding author), Med Univ Vienna, Inst Canc Res, Div Appl & Expt Oncol, Clin Internal Med 1, Borschkegasse 8A, A-1090 Vienna, Austria.	elbling.leonilla@meduniwien.ac.at	Knasmueller, Siegfried/P-4347-2014	Knasmueller, Siegfried/0000-0002-1638-4438; Berger, Walter/0000-0003-0014-1658				Anderson RF, 2001, CARCINOGENESIS, V22, P1189, DOI 10.1093/carcin/22.8.1189; August DA, 1999, CANCER EPIDEM BIOMAR, V8, P709; Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Bertram B, 2003, MUTAT RES-GEN TOX EN, V534, P77, DOI 10.1016/S1383-5718(02)00245-0; Chai PC, 2003, BIOCHEM BIOPH RES CO, V304, P650, DOI 10.1016/S0006-291X(03)00655-7; Chen C, 2003, CARCINOGENESIS, V24, P1369, DOI 10.1093/carcin/bgg091; Chen JJ, 2004, BJU INT, V93, P1082, DOI 10.1111/j.1464-410X.2004.04785.x; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Deguchi H, 2002, INT J ONCOL, V21, P1301; Dhawan A, 2002, MUTAT RES-GEN TOX EN, V515, P39, DOI 10.1016/S1383-5718(01)00347-3; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; Frei B, 2003, J NUTR, V133, p3275S, DOI 10.1093/jn/133.10.3275S; Funatogawa K, 2004, MICROBIOL IMMUNOL, V48, P251, DOI 10.1111/j.1348-0421.2004.tb03521.x; Furukawa A, 2003, BIOCHEM PHARMACOL, V66, P1769, DOI 10.1016/S0006-2952(03)00541-0; GANOUSIS LG, 1992, MOL PHARMACOL, V42, P1118; Guo Q, 1999, BBA-GEN SUBJECTS, V1427, P13, DOI 10.1016/S0304-4165(98)00168-8; Helma C, 2000, MUTAT RES-GEN TOX EN, V466, P9, DOI 10.1016/S1383-5718(99)00232-6; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Hong J, 2003, BIOCHEM BIOPH RES CO, V310, P222, DOI 10.1016/j.bbrc.2003.09.007; Hong J, 2002, CANCER RES, V62, P7241; Johnson MK, 2000, MUTAT RES-DNA REPAIR, V459, P211, DOI 10.1016/S0921-8777(99)00074-9; Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167; Kannan K, 2004, FREE RADICAL BIO MED, V36, P423, DOI 10.1016/j.freeradbiomed.2003.09.012; Kitano K, 1997, BIOPHYS CHEM, V65, P157, DOI 10.1016/S0301-4622(96)02254-5; Kondo K, 1999, FREE RADICAL BIO MED, V27, P855, DOI 10.1016/S0891-5849(99)00133-1; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; Lambert JD, 2003, J NUTR, V133, P4172, DOI 10.1093/jn/133.12.4172; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; Lee MJ, 2004, CANCER EPIDEM BIOMAR, V13, P132, DOI 10.1158/1055-9965.EPI-03-0040; Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4; Long LH, 2000, BIOCHEM BIOPH RES CO, V273, P50, DOI 10.1006/bbrc.2000.2895; Lu H, 2003, DRUG METAB DISPOS, V31, P572, DOI 10.1124/dmd.31.5.572; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Mannisto P T, 1992, Prog Drug Res, V39, P291; Meng XF, 2002, CHEM RES TOXICOL, V15, P1042, DOI 10.1021/tx010184a; Moyers SB, 2004, NUTR REV, V62, P204, DOI [10.1301/nr.2004.may.204-211, 10.1111/j.1753-4887.2004.tb00041.x]; Murakami A, 2003, MUTAT RES-FUND MOL M, V523, P151, DOI 10.1016/S0027-5107(02)00331-7; Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168; NAKAYAMA T, 1994, CANCER RES, V54, pS1991; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; ROTHE G, 1994, METHOD ENZYMOL, V233, P539; Roy M, 2003, MUTAT RES-FUND MOL M, V523, P33, DOI 10.1016/S0027-5107(02)00319-6; Saeki K, 2002, BIOCHEM J, V368, P705, DOI 10.1042/BJ20020101; Sakagami H, 2001, ANTICANCER RES, V21, P2633; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Stanner SA, 2004, PUBLIC HEALTH NUTR, V7, P407, DOI 10.1079/PHN2003543; Stone JR, 2004, ARCH BIOCHEM BIOPHYS, V422, P119, DOI 10.1016/j.abb.2003.12.029; Sugisawa A, 2004, MUTAT RES-GEN TOX EN, V559, P97, DOI 10.1016/j.mrgentox.2004.01.002; Teufelhofer O, 2003, TOXICOL SCI, V76, P376, DOI 10.1093/toxsci/kfg234; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tobi SE, 2002, INT J CANCER, V102, P439, DOI 10.1002/ijc.10730; Wei HC, 1999, FREE RADICAL BIO MED, V26, P1427, DOI 10.1016/S0891-5849(99)00005-2; Whiteside MA, 2004, NUTR REV, V62, P142, DOI 10.1111/j.1753-4887.2004.tb00036.x; Yamamoto T, 2003, J PHARMACOL EXP THER, V307, P230, DOI 10.1124/jpet.103.054676; Yamamoto T, 2004, J PHARMACOL EXP THER, V308, P317, DOI 10.1124/jpet.103.058891; Yang CS, 1999, CANCER EPIDEM BIOMAR, V8, P83; Yang CS, 1998, CANCER EPIDEM BIOMAR, V7, P351; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035; Yen GC, 2004, FREE RADICAL RES, V38, P193, DOI 10.1080/10715760310001638001; Zhu NQ, 2000, J AGR FOOD CHEM, V48, P979, DOI 10.1021/jf991188c	68	226	240	2	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					807	+		10.1096/fj.04-2915fje	http://dx.doi.org/10.1096/fj.04-2915fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15738004				2022-12-28	WOS:000227591900002
J	Offer, T; Ho, E; Traber, MG; Bruno, RS; Kuypers, FA; Ames, BN				Offer, T; Ho, E; Traber, MG; Bruno, RS; Kuypers, FA; Ames, BN			A simple assay for frequency of chromosome breaks and loss (micronuclei) by flow cytometry of human reticulocytes	FASEB JOURNAL			English	Article						DNA damage; double-strand breaks; transferrin; CD71; mutation; smoking	HUMAN-LYMPHOCYTES; CYTOGENETIC DAMAGE; C677T POLYMORPHISM; PERIPHERAL-BLOOD; CIGARETTE-SMOKE; GENETIC-DAMAGE; FOLIC-ACID; ERYTHROCYTES; ENUMERATION; POPULATIONS	Exposure to environmental stress, such as radiation, poor nutrition, or smoking, can cause hazardous lesions in DNA, including double-strand breaks. In red blood cells, a DNA fragment or lagging chromosome forms a micronucleus when left behind after the main nucleus is extruded to form the mature reticulocyte during erythropoiesis. Reticulocytes with micronuclei in human peripheral blood are not generally available for analysis because the spleen removes aberrant cells. We have developed a simple and rapid method to isolate and analyze immature reticulocytes in the peripheral blood for the presence of micronuclei before these cells are removed by the spleen. This method applies single-laser flow-cytometry to measure micronuclei in an enriched transferrin-positive reticulocyte population. Abramsson-Zetterberg et al. (Abramsson-Zetterberg, L., Zetterberg, G., Bergqvist, M., and Grawe, J. Environ. Mol. Mutagen. 36, 22 - 31, 2000) have described a method to measure micronuclei in an enriched reticulocyte population using a dual-laser flow cytometry. Unlike the beads used in their magnetic-immunoseparation procedures, the beads used in this study do not require a prelabeling step and are compatible with the flow cell, sparing the need to release the cells from the beads and avoiding the potentially confounding DNase-treatment step. Dertinger et al. ( Dertinger, S. D., Torous, D. K., Hall, N. E., Murante, F. G., Gleason, S. E., Miller, R. K., and Tometsko, C. R. Mutat. Res. 515, 3 - 14, 2002; Dertinger, S. D., Chen, Y., Miller, R. K., Brewer, K. J., Smudzin, T., Torous, D. K., Hall, N. E., Olvany, K. A., Murante, F. G., and Tometsko, C. R. ( 2003) Mutat. Res. 542, 77 - 87, 2003) further improved the scoring of micronuclei to enable the use of benchtop instruments in analyzing samples of unenriched reticulocyte-populations. The present method is distinct from flow cytometric assays, such as reported by Dertinger et al., which enable scoring of limited numbers of reticulocytes per sample and require lengthy data acquisition times. We assessed DNA damage in smokers using this novel flow-cytometry based micronuclei-assay. The results show that this assay can effectively detect micronuclei in human blood samples. This method, unlike available micronuclei assays, allows rapid evaluation of a large number of cells and therefore should prove to be useful in monitoring of human populations for genetic damage.	Childrens Hosp, Oakland Res Inst, Nutr Genom Ctr, Oakland, CA 94609 USA; Oregon State Univ, Dept Nutr & Food Management, Corvallis, OR 97331 USA; Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; Oregon State University; Oregon State University	Ames, BN (corresponding author), Childrens Hosp, Oakland Res Inst, Nutr Genom Ctr, 747 52nd St, Oakland, CA 94609 USA.	bames@chori.org	Traber, Maret G./ABI-2511-2020; Bruno, Richard/K-1930-2012	Traber, Maret G./0000-0002-2892-4024; Bruno, Richard/0000-0002-6772-2038	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K05AT001323] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD000222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NCCIH NIH HHS [K05 AT001323-01] Funding Source: Medline; NIDDK NIH HHS [DK59576] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210] Funding Source: Medline; NIMHD NIH HHS [P60-MD00222-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Abramsson-Zetterberg L, 2000, ENVIRON MOL MUTAGEN, V36, P22, DOI 10.1002/1098-2280(2000)36:1<22::AID-EM4>3.0.CO;2-U; Ames BN, 2004, ARCH BIOCHEM BIOPHYS, V423, P227, DOI 10.1016/j.abb.2003.11.002; Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; Balansky RM, 2000, CARCINOGENESIS, V21, P1677, DOI 10.1093/carcin/21.9.1677; Bonassi S, 2003, MUTAT RES-REV MUTAT, V543, P155, DOI 10.1016/S1383-5742(03)00013-9; Crott JW, 2001, CANCER EPIDEM BIOMAR, V10, P1089; D'Agostini F, 2001, INT J ONCOL, V18, P607; DARCY PF, 1988, ICH FDA REDBOOK GUID; Dertinger SD, 2003, MUTAT RES-GEN TOX EN, V542, P77, DOI 10.1016/j.mrgentox.2003.08.004; Dertinger SD, 2002, MUTAT RES-GEN TOX EN, V515, P3, DOI 10.1016/S1383-5718(02)00009-8; Dertinger SD, 1996, MUTAT RES-GENET TOX, V371, P283, DOI 10.1016/S0165-1218(96)90117-2; EVERSON RB, 1988, JNCI-J NATL CANCER I, V80, P525, DOI 10.1093/jnci/80.7.525; Fenech M, 1997, ENVIRON MOL MUTAGEN, V30, P112, DOI 10.1002/(SICI)1098-2280(1997)30:2<112::AID-EM3>3.0.CO;2-P; Fenech M, 2002, DRUG DISCOV TODAY, V7, P1128, DOI 10.1016/S1359-6446(02)02502-3; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2002, FOOD CHEM TOXICOL, V40, P1113, DOI 10.1016/S0278-6915(02)00028-5; Ishikawa H, 2003, J OCCUP HEALTH, V45, P179, DOI 10.1539/joh.45.179; Izzotti A, 2001, CANCER RES, V61, P2472; Kimura M, 2004, J NUTR, V134, P48, DOI 10.1093/jn/134.1.48; Kirsch-Volders M, 2001, MUTAGENESIS, V16, P51, DOI 10.1093/mutage/16.1.51; LARRAMENDY ML, 1991, MUTAT RES, V259, P189, DOI 10.1016/0165-1218(91)90052-N; MACGREGOR JT, 1990, PROG CLIN BIOL RES, V347, P139; MacGregor JT, 1997, MUTAT RES-FUND MOL M, V377, P125, DOI 10.1016/S0027-5107(97)00070-5; MAVOURNIN KH, 1990, MUTAT RES, V239, P29, DOI 10.1016/0165-1110(90)90030-F; Norppa H, 2003, MUTAGENESIS, V18, P221, DOI 10.1093/mutage/18.3.221; Schneider M, 2001, FREE RADICAL RES, V34, P209, DOI 10.1080/10715760100300201; SMITH DF, 1990, CANCER RES, V50, P5049; TUCKER JD, 1993, MUTAT RES, V301, P19, DOI 10.1016/0165-7992(93)90051-V; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; XUE KX, 1992, INT J CANCER, V50, P702, DOI 10.1002/ijc.2910500506	30	28	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					485	+		10.1096/fj.04-2729fje	http://dx.doi.org/10.1096/fj.04-2729fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15601670				2022-12-28	WOS:000226091000015
J	Lynch, RG				Lynch, RG			Surfactant and RDS in premature infants	FASEB JOURNAL			English	Editorial Material																		AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; CLEMENTS JA, 1956, AM J PHYSIOL, V187, P592; GRUENWALD P, 1956, Bull N Y Acad Med, V32, P689; PATTLE RE, 1955, NATURE, V175, P1125, DOI 10.1038/1751125b0	4	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1624	1624		10.1096/fasebj.18.13.1624	http://dx.doi.org/10.1096/fasebj.18.13.1624			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466362				2022-12-28	WOS:000224849900037
J	Leinninger, GM; Backus, C; Uhler, MD; Lentz, SI; Feldman, EL				Leinninger, GM; Backus, C; Uhler, MD; Lentz, SI; Feldman, EL			Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons	FASEB JOURNAL			English	Article						insulin-like growth factor; dorsal root ganglia neurons; apoptosis; glucose; CREB; FKHR	PROTEIN-KINASE; SKELETAL-MUSCLE; APOPTOSIS; PHOSPHORYLATION; DEATH; EXPRESSION; RECEPTOR; SURVIVAL; GLUCOSE; BCL-2	Insulin-like growth factor-I (IGF-I) protects neurons of the peripheral nervous system from apoptosis, but the underlying signaling pathways are not well understood. We studied IGF-I mediated signaling in embryonic dorsal root ganglia (DRG) neurons. DRG neurons express IGF-I receptors (IGF-IR), and IGF-I activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. High glucose exposure induces apoptosis, which is inhibited by IGF-I through the PI3K/Akt pathway. IGF-I stimulation of the PI3K/Akt pathway phosphorylates three known Akt effectors: the survival transcription factor cyclic AMP response element binding protein ( CREB) and the pro-apoptotic effector proteins glycogen synthase kinase-3 (GSK-3) and forkhead ( FKHR). IGF-I regulates survival at the nuclear level through accumulation of phospho-Akt in DRG neuronal nuclei, increased CREB-mediated transcription, and nuclear exclusion of FKHR. High glucose increases expression of the pro-apoptotic Bcl protein Bim ( a transcriptional target of FKHR). However, IGF-I does not regulate Bim or anti-apoptotic Bcl-xL protein expression levels, which suggests that IGF-I neuroprotection is not through regulation of their expression. High glucose also induces loss of the initiator caspase-9 and increases caspase-3 cleavage, effects blocked by IGF-I. These data suggest that IGF-I prevents apoptosis in DRG neurons by regulating PI3K/Akt pathway effectors, including GSK-3, CREB, and FKHR, and by blocking caspase activation.	Univ Michigan, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Mental Hlth Res Inst, Ann Arbor, MI USA; Univ Michigan, MDRTC morphol & Image Anal Core, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol 4414, Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Lentz, Stephen/0000-0003-1686-7998; Feldman, Eva/0000-0002-9162-2694	NHGRI NIH HHS [HG02367] Funding Source: Medline; NIDDK NIH HHS [DK063340] Funding Source: Medline; NINDS NIH HHS [NS38849, NS43023, NS36778] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK063340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036778, F31NS043023, R01NS038849] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EICHLER ME, 1989, BRAIN RES, V482, P340, DOI 10.1016/0006-8993(89)91197-9; Federici M, 1998, DIABETES, V47, P87, DOI 10.2337/diabetes.47.1.87; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gao WQ, 1999, J NEUROBIOL, V39, P142, DOI 10.1002/(SICI)1097-4695(199904)39:1<142::AID-NEU11>3.0.CO;2-H; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hetman M, 2000, J NEUROSCI, V20, P2567; Jones DM, 2003, J NEUROCHEM, V86, P1116, DOI 10.1046/j.1471-4159.2003.01925.x; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KORINKOVA P, 1976, ACTA HISTOCHEM, V56, P47; Leinninger GM, 2003, MED INTELL UNIT, P158; LEWIS ME, 1993, EXP NEUROL, V124, P73, DOI 10.1006/exnr.1993.1177; Linseman DA, 2002, J NEUROSCI, V22, P9287; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Mayfield J, 1998, AM FAM PHYSICIAN, V58, P1355; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McDonald ES, 2002, NEUROBIOL DIS, V9, P220, DOI 10.1006/nbdi.2001.0468; Medina-Kauwe LK, 2001, GENE THER, V8, P1753, DOI 10.1038/sj.gt.3301583; MU XJ, 1993, J NEUROSCI, V13, P4029; Parrizas M, 1997, J BIOL CHEM, V272, P154; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Rabinovsky ED, 2002, FASEB J, V16, P53, DOI 10.1096/fj.02-0183fje; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; Walton M, 1999, J NEUROCHEM, V73, P1836; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225	40	133	139	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1544	+		10.1096/fj.04-1581fje	http://dx.doi.org/10.1096/fj.04-1581fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319368	Green Submitted			2022-12-28	WOS:000223554900013
J	Ramana, KV; Bhatnagar, A; Srivastava, SK				Ramana, KV; Bhatnagar, A; Srivastava, SK			Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells	FASEB JOURNAL			English	Article						PKC activity; NF-kappa B; monocyte and adhesion molecules	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; GENE-TRANSCRIPTION; OXIDATIVE STRESS; INDUCED ICAM-1; NITRIC-OXIDE; ACTIVATION; MECHANISMS; GLUCOCORTICOIDS	Increased expression of adhesion molecules by the activated endothelium is a critical feature of vascular inflammation associated with several disease states such as atherosclerosis. However, mechanisms regulating the endothelial induction of adhesion molecules are not entirely clear. Herein we report that inhibition of the polyol pathway enzyme aldose reductase (AR) prevents the increase in ICAM-1 and VCAM-1 in human umbilical vein endothelial cells (HUVECs) and decreases monocyte adhesion to these cells. In TNF-alpha-stimulated HUVECs, treatment with AR inhibitors sorbinil and tolrestat diminished NF-kappaB activity, phosphorylation and degradation of Ikappa-Balpha, and the nuclear translocation of NF-kappaB. Inhibition of AR abrogated TNF-alpha-induced activation and membrane translocation of PKC, and antisense ablation of AR prevented both TNF-alpha-induced PKC and NF-kappaB activation. However, inhibition of AR did not prevent phorbol ester-induced activation of PKC or NF-kappaB, indicating that inhibition of AR does prevents events upstream of PKC activation. These results identify a novel regulator of endothelial activation and suggest that AR is an obligatory mediator of TNF-alpha signaling leading to an increase in the expression of adhesion molecules and increased binding of monocytes to the endothelium.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Louisville, Dept Med, Louisville, KY 40292 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Louisville	Srivastava, SK (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 6-644,Basic Sci Bldg, Galveston, TX 77555 USA.	ssrivast@utmb.edu	Ramana, Kota/C-5460-2012	Ramana, Kota/0000-0001-6502-7800	NEI NIH HHS [EY01677] Funding Source: Medline; NHLBI NIH HHS [HL55477] Funding Source: Medline; NIDDK NIH HHS [DK36118] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001677] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COUFFINHAL T, 1994, CIRC RES, V74, P225, DOI 10.1161/01.RES.74.2.225; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; DIESHER TA, 1993, FEBS LETT, V331, P285; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011; Kang JS, 2003, FEBS LETT, V550, P89, DOI 10.1016/S0014-5793(03)00827-5; Krasinski K, 2001, CIRCULATION, V104, P1754, DOI 10.1161/hc4001.098046; Krull M, 1999, J IMMUNOL, V162, P4834; LANE TA, 1990, BIOCHEM BIOPH RES CO, V172, P1273, DOI 10.1016/0006-291X(90)91587-I; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LIBBY P, 1998, BIOL VESSEL WALL COM, P2893; Liden J, 2000, BIOCHEM BIOPH RES CO, V273, P1008, DOI 10.1006/bbrc.2000.3079; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lockyer JM, 1998, CIRC RES, V82, P314, DOI 10.1161/01.RES.82.3.314; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; LUSIS AJ, 2001, CELL, V104, P503; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; MAURI N, 1993, J CLIN INVEST, V92, P1866; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Min W, 1997, J IMMUNOL, V159, P3508; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Rahman A, 1999, MOL PHARMACOL, V55, P575; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Shinmura K, 2002, CIRC RES, V91, P240, DOI 10.1161/01.RES.0000029970.97247.57; Simoncini T, 2000, CIRC RES, V87, P19, DOI 10.1161/01.RES.87.1.19; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; Vielma SA, 2003, CIRC RES, V92, P1130, DOI 10.1161/01.RES.0000074001.46892.1C; WAGNER N, 1993, J IMMUNOL, V150, P4887; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21; Yamawaki H, 2003, CIRCULATION, V108, P1619, DOI 10.1161/01.CIR.0000089373.49941.C4; Zhang F, 2002, ATHEROSCLEROSIS, V161, P381, DOI 10.1016/S0021-9150(01)00672-4; Zhang LF, 2003, CIRCULATION, V108, P472, DOI 10.1161/01.CIR.0000080378.96063.23; Zhang SL, 1999, KIDNEY INT, V55, P454, DOI 10.1046/j.1523-1755.1999.00271.x; Zhang WJ, 2003, FREE RADICAL BIO MED, V34, P674, DOI 10.1016/S0891-5849(02)01375-8	58	68	78	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1209	1218		10.1096/fj.04-1650com	http://dx.doi.org/10.1096/fj.04-1650com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15284221				2022-12-28	WOS:000223554900036
J	Saxena, NK; Titus, MA; Ding, XK; Floyd, J; Srinivasan, S; Sitaraman, SV; Anania, FA				Saxena, NK; Titus, MA; Ding, XK; Floyd, J; Srinivasan, S; Sitaraman, SV; Anania, FA			Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation	FASEB JOURNAL			English	Article						nonalcoholic steohepatitis (NASH); liver fibrosis; proliferation; MAP kinase; PI-3 kinase	SIGNALING PATHWAYS; LIVER FIBROSIS; GROWTH-FACTOR; RECEPTOR; EXPRESSION; PROLIFERATION; ACTIVATION; RAT; FIBROGENESIS; SURVIVAL	A key feature in the molecular pathogenesis of liver fibrosis requires maintenance of the activated hepatic stellate cell (HSC) phenotype by both proliferation and inhibition of apoptosis. We provide evidence that leptin is a potent HSC mitogen and dramatically inhibits stellate cell apoptosis. Leptin proved to be as potent an HSC mitogen as platelet-derived growth factor ( PDGF) as assessed by bromodeoxyuridine ( BrdU) incorporation in isolated primary HSCs; data using fluorescent propidium iodide ( PI) uptake revealed that leptin, like PDGF, increased HSC populations in the S- and G(2)/M-phases of the cell cycle. Leptin resulted in a robust increase in cyclin D1 expression. Using the chemical inhibitor of Janus kinase 2 (Jak2) activity, AG 490, and overexpression of the suppressor of cytokine signaling 3 (SOCS-3), we show that blockade of leptin receptor (Ob-Rb) phosphorylation blocks leptin-induced HSC proliferation. Leptin-associated phosphorylation of both extracellular regulated kinase (p44/p42, Erk) and Akt is also prohibited. Further, the PI-3 kinase inhibitor LY294002 and MAPK inhibitor PD98059 were found to significantly reduce leptin-induced HSC proliferation, thereby indicating that leptin induced HSC proliferation is Akt- and Erk-dependent. Akt was also protective against HSC apoptosis. Leptin abolished both cycloheximide-induced and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, demonstrated by reduced caspase-3 activity, HSC-TUNEL staining, and DNA fragmentation. We conclude that leptin acts as a direct hepatic stellate cell survival agonist. Importantly, we have demonstrated that leptin-induced HSC proliferation and survival by Ob-Rb phosphorylation are both Erk- and Akt- dependent.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA	Emory University; University System of Maryland; University of Maryland Baltimore	Anania, FA (corresponding author), Room 248,615 Michael St, Atlanta, GA 30322 USA.	fanania@emory.edu	Srinivasan, Shanthi/A-6133-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062092, R03DK064644, K08DK002802, R56DK062092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA012933] Funding Source: NIH RePORTER; NIAAA NIH HHS [R21 AA012933-01, R21 AA012933, AA 12933] Funding Source: Medline; NIDDK NIH HHS [R01 DK062092-03, DK 064644, K08 DK002802, R01 DK062092, R03 DK064644, DK 062092, R56 DK062092, DK 022802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Alessenko AV, 1997, FEBS LETT, V416, P113, DOI 10.1016/S0014-5793(97)01161-7; ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burysek L, 2002, J BIOL CHEM, V277, P33509, DOI 10.1074/jbc.M201941200; CASINI A, 1993, GASTROENTEROLOGY, V105, P245, DOI 10.1016/0016-5085(93)90033-9; Contos MJ, 2002, ADV ANAT PATHOL, V9, P37, DOI 10.1097/00125480-200201000-00005; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Diehl AM, 1999, SEMIN LIVER DIS, V19, P221, DOI 10.1055/s-2007-1007111; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Friedman SL, 1999, SEMIN LIVER DIS, V19, P129, DOI 10.1055/s-2007-1007105; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gores GJ, 2001, HEPATOLOGY, V34, P3, DOI 10.1053/jhep.2001.25173; Honda H, 2002, HEPATOLOGY, V36, P12, DOI 10.1053/jhep.2002.33684; Ikejima K, 2002, GASTROENTEROLOGY, V122, P1399, DOI 10.1053/gast.2002.32995; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kloek C, 2002, J BIOL CHEM, V277, P41547, DOI 10.1074/jbc.M205148200; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leclercq IA, 2002, J HEPATOL, V37, P206, DOI 10.1016/S0168-8278(02)00102-2; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Myers MG, 2004, RECENT PROG HORM RES, V59, P287, DOI 10.1210/rp.59.1.287; Ormerod MG, 1998, LEUKEMIA, V12, P1013, DOI 10.1038/sj.leu.2401061; Pinzani M, 1996, AM J PATHOL, V148, P785; Potter JJ, 1998, BIOCHEM BIOPH RES CO, V244, P178, DOI 10.1006/bbrc.1997.8193; Saile B, 1997, AM J PATHOL, V151, P1265; SAXENA NK, 2002, J HEPATOL, V37, P206; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Taimr P, 2003, HEPATOLOGY, V37, P87, DOI 10.1053/jhep.2003.50002; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Trim N, 2000, AM J PATHOL, V156, P1235, DOI 10.1016/S0002-9440(10)64994-2; Vecchione C, 2002, DIABETES, V51, P168, DOI 10.2337/diabetes.51.1.168; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	51	171	192	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1612	+		10.1096/fj.04-1847fje	http://dx.doi.org/10.1096/fj.04-1847fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319373	Green Accepted			2022-12-28	WOS:000223554900008
J	Rudnick, J; Puttmann, B; Tesch, PA; Alkner, B; Schoser, BGH; Salanova, M; Kirsch, K; Gunga, HC; Schiffl, G; Luck, G; Blottner, D				Rudnick, J; Puttmann, B; Tesch, PA; Alkner, B; Schoser, BGH; Salanova, M; Kirsch, K; Gunga, HC; Schiffl, G; Luck, G; Blottner, D			Differential expression of nitric oxide synthases (NOS 1-3) in human skeletal muscle following exercise countermeasure during 12 weeks of bed rest	FASEB JOURNAL			English	Article						skeletal muscle atrophy; caveolin; human spaceflight	OXIDATIVE STRESS; INOS EXPRESSION; GENE-EXPRESSION; SMOOTH-MUSCLE; DYSTROPHIN; ISOFORM; SARCOLEMMA; STRENGTH; LOCALIZATION; ADAPTATIONS	Adaptive changes of major body systems in astronauts during spaceflight can be simulated by strict anti-orthostatic head-down tilt (HDT) bed rest (BR), a ground-based microgravity (muG) model that provides a meaningful opportunity to study atrophy mechanisms and possible countermeasures under controlled experimental conditions. As nitric oxide (NO) signaling is linked to muscle activity, we investigated altered expression of the three major isoforms of nitric oxide synthase (NOS 1-3) at cellular compartments during prolonged HDT BR without (control group) and with resistance exercise interventions (exercise group) using a flywheel ergometer (FWE). Atrophy detected in mixed (fast-slow) m. vastus lateralis (VL) and slow-type m. soleus (SOL) myofiber Types I and II (minus 35-40% of myofiber cross-sectional area) was prevented by FWE training. Concomitant to muscle atrophy, reduced NOS 1 protein and immunostaining was found in VL not in SOL biopsies. In trained VL, NOS 1 protein and immunostaining at myofibers II were significantly increased at the end of BR. Exercise altered NOS 2/caveolin 3 co-immunostaining patterns of subsarcolemmal focal accumulations in VL or SOL myofibers, which suggests reorganization of sarcolemmal microdomains. In trained VL, increased capillary-to-fiber (C/F) ratio and NOS 3 protein content were documented. Activity-linked NO signaling may be widespread in skeletal muscle cellular compartments that may be directly or indirectly impacted by adequate exercise countermeasure protocols to offset the negative effects induced by disuse, immobilization, or extended exposure to microgravity.	Charite Univ Med Berlin, Dept Anat, D-14195 Berlin, Germany; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; Univ Munich, Friedrich Baur Inst, Dept Neurol, Munich, Germany; CBF, Dept Physiol, Berlin, Germany; Ctr Space Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Karolinska Institutet; University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Blottner, D (corresponding author), Charite Univ Med Berlin, Dept Anat, Campus Benjamin Franklin,Konigin-Luise-Str 15, D-14195 Berlin, Germany.	dieter.blottner@charite.de	Alkner, Björn/AHC-5835-2022; Schoser, Benedikt/AAH-6286-2020	Blottner, Dieter/0000-0003-0355-3340; Schoser, Benedikt/0000-0002-2757-8131				ADAMS GR, 1993, J APPL PHYSIOL, V74, P911, DOI 10.1152/jappl.1993.74.2.911; Adams V, 2002, CARDIOVASC RES, V54, P95, DOI 10.1016/S0008-6363(02)00228-6; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Alkner BA, 2004, ACTA PHYSIOL SCAND, V181, P345, DOI 10.1111/j.1365-201X.2004.01293.x; Alkner BA, 2003, EUR J APPL PHYSIOL, V90, P44, DOI 10.1007/s00421-003-0850-2; ANDERSEN JL, 1994, ACTA PHYSIOL SCAND, V150, P21, DOI 10.1111/j.1748-1716.1994.tb09655.x; Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Balon TW, 1997, J APPL PHYSIOL, V82, P359, DOI 10.1152/jappl.1997.82.1.359; Bamman MM, 1998, J APPL PHYSIOL, V84, P157, DOI 10.1152/jappl.1998.84.1.157; BERG HE, 1994, AVIAT SPACE ENVIR MD, V65, P752; Berg HE, 1998, ACTA ASTRONAUT, V42, P219, DOI 10.1016/S0094-5765(98)00119-2; BERGSTROM J, 1967, ACTA PHYSIOL SCAND, V71, P140, DOI 10.1111/j.1748-1716.1967.tb03720.x; BLOTTNER D, 1995, HISTOCHEM CELL BIOL, V103, P379, DOI 10.1007/BF01457813; Bode-Boger S M, 1994, J Cardiovasc Risk, V1, P173; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; Booth FW, 1997, INT J SPORTS MED, V18, pS265, DOI 10.1055/s-2007-972723; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; Buckwalter JB, 2003, J APPL PHYSIOL, V94, P935, DOI 10.1152/japplphysiol.00378.2002; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; CONVERTINO VA, 1981, AVIAT SPACE ENVIR MD, V52, P251; Delp MD, 2000, AM J PHYSIOL-HEART C, V278, pH1866, DOI 10.1152/ajpheart.2000.278.6.H1866; Desplanches D, 1997, INT J SPORTS MED, V18, pS259, DOI 10.1055/s-2007-972722; Droppert P M, 1993, J Br Interplanet Soc, V46, P83; Edgerton VR, 2001, J EXP BIOL, V204, P3217; Edgerton VR, 2000, J APPL PHYSIOL, V89, P1224, DOI 10.1152/jappl.2000.89.3.1224; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ferrando AA, 1996, AM J PHYSIOL-ENDOC M, V270, pE627, DOI 10.1152/ajpendo.1996.270.4.E627; Fitts RH, 2001, J EXP BIOL, V204, P3201; Fluck M, 1999, AM J PHYSIOL-CELL PH, V277, pC152, DOI 10.1152/ajpcell.1999.277.1.C152; Fluck M, 2003, REV PHYSIOL BIOCH P, V146, P159, DOI 10.1007/s10254-002-0004-7; Frandsen U, 1996, BIOCHEM BIOPH RES CO, V227, P88, DOI 10.1006/bbrc.1996.1472; Fraysse B, 2003, FASEB J, V17, P1916, DOI 10.1096/fj.02-1012fje; Fujii Y, 1998, J APPL PHYSIOL, V85, P2330, DOI 10.1152/jappl.1998.85.6.2330; Gath I, 1999, BIOCHEM J, V340, P723, DOI 10.1042/0264-6021:3400723; Gordon SE, 2001, J APPL PHYSIOL, V90, P1174, DOI 10.1152/jappl.2001.90.3.1174; Hortobagyi T, 2000, J PHYSIOL-LONDON, V524, P293, DOI 10.1111/j.1469-7793.2000.00293.x; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Hudlicka O, 1998, MICROCIRCULATION, V5, P7; Joyner MJ, 1997, J APPL PHYSIOL, V83, P1785, DOI 10.1152/jappl.1997.83.6.1785; Jungersten L, 1997, J APPL PHYSIOL, V82, P760, DOI 10.1152/jappl.1997.82.3.760; Kandarian SC, 2002, EXERC SPORT SCI REV, V30, P111, DOI 10.1097/00003677-200207000-00004; Kingwell BA, 2000, CLIN EXP PHARMACOL P, V27, P239, DOI 10.1046/j.1440-1681.2000.03232.x; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KONDO H, 1993, FEBS LETT, V326, P189, DOI 10.1016/0014-5793(93)81788-2; Koryak Y, 1998, EUR J APPL PHYSIOL O, V78, P128, DOI 10.1007/s004210050397; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Lambertz D, 2001, J APPL PHYSIOL, V90, P179, DOI 10.1152/jappl.2001.90.1.179; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; LeBlanc A, 1997, INT J SPORTS MED, V18, pS283, DOI 10.1055/s-2007-972726; LEBLANC AD, 1992, J APPL PHYSIOL, V73, P2172, DOI 10.1152/jappl.1992.73.5.2172; LEE KH, 1994, J BIOL CHEM, V269, P14371; LLOYD PG, 2001, REV PHYSL BIOCH PHAR, V281, pH2528; Louboutin JP, 2001, MOL MED, V7, P355, DOI 10.1007/BF03402218; LUTHI JM, 1986, INT J SPORTS MED, V7, P123, DOI 10.1055/s-2008-1025748; Ma J, 2003, J APPL PHYSIOL, V94, P83, DOI 10.1152/japplphysiol.00294.2002; Malyshev I Y, 2000, Med Sci Monit, V6, P480; MATHIEUCOSTELLO O, 1993, ADV EXP MED BIOL, V345, P661; Maxwell AJ, 1998, CIRCULATION, V98, P369, DOI 10.1161/01.CIR.98.4.369; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Park CS, 1996, LIFE SCI, V59, P219, DOI 10.1016/0024-3205(96)00287-1; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Pohl U, 1999, NEWS PHYSIOL SCI, V14, P74; REID MB, 1998, PATHOPHYSIOL, V5, P113; Richmonds CR, 1999, MECH AGEING DEV, V109, P177, DOI 10.1016/S0047-6374(99)00035-4; Riede UN, 1998, J AM COLL CARDIOL, V32, P964, DOI 10.1016/S0735-1097(98)00335-0; Roberts CK, 1999, AM J PHYSIOL-ENDOC M, V277, pE390, DOI 10.1152/ajpendo.1999.277.2.E390; SALE DG, 1988, MED SCI SPORT EXER, V20, pS135, DOI 10.1249/00005768-198810001-00009; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; Schoser BGH, 1997, NEUROSCI LETT, V231, P163, DOI 10.1016/S0304-3940(97)00554-5; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; SHEN WQ, 1995, MED SCI SPORT EXER, V27, P1125; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Tatchum-Talom R, 2000, AM J PHYSIOL-HEART C, V279, pH1757, DOI 10.1152/ajpheart.2000.279.4.H1757; Thomas GD, 2003, CIRC RES, V92, P554, DOI 10.1161/01.RES.0000061570.83105.52; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; Trappe SW, 2001, J APPL PHYSIOL, V91, P57, DOI 10.1152/jappl.2001.91.1.57; Vassilakopoulos T, 2003, AM J PHYSIOL-LUNG C, V284, pL452, DOI 10.1152/ajplung.00270.2002; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Wang MX, 2001, NITRIC OXIDE-BIOL CH, V5, P219, DOI 10.1006/niox.2001.0348; WEINDRUCH R, 1995, J GERONTOL A-BIOL, V50, P157; Williamson DL, 2001, J APPL PHYSIOL, V91, P1955, DOI 10.1152/jappl.2001.91.5.1955	89	72	83	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1228	+		10.1096/fj.03-0792fje	http://dx.doi.org/10.1096/fj.03-0792fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180967				2022-12-28	WOS:000222327500039
J	Huang, Y; Hickey, RP; Yeh, JL; Liu, DG; Dadak, A; Young, LH; Johnson, RS; Giordano, FJ				Huang, Y; Hickey, RP; Yeh, JL; Liu, DG; Dadak, A; Young, LH; Johnson, RS; Giordano, FJ			Cardiac myocyte-specific HIF-1 alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart	FASEB JOURNAL			English	Article						hypoxia; cardiac muscle; contraction; gene expression	SERCA2 GENE-EXPRESSION; HYPOXIA; ANGIOGENESIS; HYPERTROPHY; ISCHEMIA; MYOCARDIUM; ACTIVATION; PATHWAY; VEGF	At a resting pulse rate the heart consumes almost twice-as much oxygen per gram tissue as the brain and more than 43 times more than resting skeletal muscle ( 1). Unlike skeletal muscle, cardiac muscle cannot sustain anaerobic metabolism. Balancing oxygen demand with availability is crucial to cardiac function and survival, and regulated gene expression is a critical element of maintaining this balance. We investigated the role of the hypoxia-inducible transcription factor HIF-1alpha in maintaining this balance under normoxic conditions. Cardiac myocyte-specific HIF-1alpha gene deletion in the hearts of genetically engineered mice caused reductions in contractility, vascularization, high-energy phosphate content, and lactate production. This was accompanied by altered calcium flux and altered expression of genes involved in calcium handling, angiogenesis, and glucose metabolism. These findings support a central role for HIF-1alpha in coordinating energy availability and utilization in the heart and have implications for disease states in which cardiac oxygen delivery is impaired. Heart muscle requires a constant supply of oxygen. When oxygen supply does not match myocardial demand cardiac contractile dysfunction occurs, and prolongation of this mismatch leads to apoptosis and necrosis. Coordination of oxygen supply and myocardial demand involves immediate adaptations, such as coronary vasodilatation, and longer-term adaptations that include altered patterns of gene expression ( 2 - 4). How the expression of multiple genes is coordinated with oxygen availability in the heart and the impact of oxygen-dependent gene expression on cardiac function are insufficiently understood. Further elucidating these relationships may help clarify the molecular pathology of various cardiovascular disease states, including ischemic cardiomyopathy and myocardial hibernation ( 5, 6).	Yale Univ, Dept Med, New Haven, CT 06520 USA; Univ Calif San Diego, Dept Biol, San Diego, CA 92103 USA	Yale University; University of California System; University of California San Diego	Giordano, FJ (corresponding author), BCMM 436C,295 Congress Ave, New Haven, CT 06510 USA.	Frank.Giordano@yale.edu	Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Dadak, Agnes/0000-0002-0948-4764	NHLBI NIH HHS [R01 HL64001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064001] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; ANVERSA P, 1990, PROG CARDIOVASC DIS, V33, P49, DOI 10.1016/0033-0620(90)90039-5; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen J, 1998, DEVELOPMENT, V125, P1943; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Cramer T, 2003, CELL CYCLE, V2, P192, DOI 10.4161/cc.2.3.402; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; *GENZ, HIF 1A GEN THER BYP; GIORDANO F, 1996, CIRCULATION; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; Giordano FJ, 2001, CURR OPIN GENET DEV, V11, P35, DOI 10.1016/S0959-437X(00)00153-2; Hartong R, 1996, J MOL CELL CARDIOL, V28, P2467, DOI 10.1006/jmcc.1996.0239; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Lyn D, 2000, PHYSIOL GENOMICS, V2, P93, DOI 10.1152/physiolgenomics.2000.2.3.93; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minchenko A, 2000, MOL CELL BIOCHEM, V208, P53, DOI 10.1023/A:1007042729486; Nielsen JN, 2003, J APPL PHYSIOL, V94, P631, DOI 10.1152/japplphysiol.00642.2002; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pfander D, 2003, J CELL SCI, V116, P1819, DOI 10.1242/jcs.00385; Porter MJ, 2003, AM J PHYSIOL-CELL PH, V285, pC39, DOI 10.1152/ajpcell.00461.2002; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; Sakai S, 2000, CIRCULATION, V101, P2849, DOI 10.1161/01.CIR.101.24.2849; Schipani E, 2001, GENE DEV, V15, P2865; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002; Simkhovich BZ, 2003, CARDIOVASC RES, V59, P450, DOI 10.1016/S0008-6363(03)00399-7; Simkhovich BZ, 2003, CARDIOVASC PATHOL, V12, P180, DOI 10.1016/S1054-8807(03)00038-3; Tian R, 2001, CIRCULATION, V103, P2961, DOI 10.1161/01.CIR.103.24.2961; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; West, 1991, PHYSL BASIS MED PRAC	38	164	173	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1138	+		10.1096/fj.04-1510fje	http://dx.doi.org/10.1096/fj.04-1510fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132980				2022-12-28	WOS:000221883200015
J	Wegener, JW; Schulla, V; Lee, TS; Koller, A; Feil, S; Feil, R; Kleppisch, T; Klugbauer, N; Moosmang, S; Welling, A; Hofmann, F				Wegener, JW; Schulla, V; Lee, TS; Koller, A; Feil, S; Feil, R; Kleppisch, T; Klugbauer, N; Moosmang, S; Welling, A; Hofmann, F			An essential role of Ca(v)1.2 L-type calcium channel for urinary bladder function	FASEB JOURNAL			English	Article						contraction; detrusor muscle; smooth muscle; protein kinase C; tamoxifendependent cre recombinase	DETRUSOR SMOOTH-MUSCLE; GUINEA-PIG DETRUSOR; PROTEIN-KINASE-C; MUSCARINIC RECEPTOR STIMULATION; CA2+ CHANNEL; INDUCED CONTRACTION; MICE LACKING; RHO-KINASE; BAY K-8644; ACETYLCHOLINE	Mice deficient in the smooth muscle Ca(v)1.2 calcium channel (SMACKO, smooth muscle alpha(1c)-subunit calcium channel knockout) have a severely reduced micturition and an increased bladder mass. L-type calcium current, protein, and spontaneous contractile activity were absent in the bladder of SMACKO mice. K+ and carbachol (CCh)-induced contractions were reduced to 10-fold in detrusor muscles from SMACKO mice. The dihydropyridine isradipine inhibited K+- and CCh-induced contractions of muscles from CTR but had no effect in muscles from SMACKO mice. CCh-induced contraction was blocked by removing extracellular Ca2+ but was unaffected by the PLC inhibitor U73122 or depletion of intracellular Ca2+ stores by thapsigargin. In muscles from CTR and SMACKO mice, CCh-induced contraction was partially inhibited by the Rho-kinase inhibitor Y27632. These results show that the Ca(v)1.2 Ca2+ channel is essential for normal bladder function. The Rho-kinase and Ca2+-release pathways cannot compensate the lack of the L-type Ca2+ channel.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Wegener, JW (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	Wegener@ipt.med.tu-muenchen.de	Feil, Robert/B-8918-2014; Welling, Andrea/K-6674-2017; Feil, Susanne/AAF-7032-2019	Feil, Robert/0000-0002-7335-4841; Welling, Andrea/0000-0002-5364-4980; Wegener, Jorg/0000-0002-8129-1537				An JY, 2002, BRIT J PHARMACOL, V137, P1001, DOI 10.1038/sj.bjp.0704954; ANDERSSON KE, 1991, J UROLOGY, V146, P1156, DOI 10.1016/S0022-5347(17)38030-8; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; BO X, 1990, BRIT J PHARMACOL, V101, P494, DOI 10.1111/j.1476-5381.1990.tb12736.x; Bolton TB, 1999, ANNU REV PHYSIOL, V61, P85, DOI 10.1146/annurev.physiol.61.1.85; Callaghan B, 2004, CIRC RES, V94, P626, DOI 10.1161/01.RES.0000118248.17466.B7; Chambers P, 1996, EXP PHYSIOL, V81, P553, DOI 10.1113/expphysiol.1996.sp003958; Choppin A, 2001, BRIT J PHARMACOL, V133, P1035, DOI 10.1038/sj.bjp.0704165; Chow KY, 2003, NEUROUROL URODYNAM, V22, P77, DOI 10.1002/nau.10081; Curtis TM, 2001, J PHYSIOL-LONDON, V532, P609, DOI 10.1111/j.1469-7793.2001.0609e.x; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Eglen RM, 1996, PHARMACOL REV, V48, P531; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Fetscher C, 2002, BRIT J PHARMACOL, V136, P641, DOI 10.1038/sj.bjp.0704781; FOVAEUS M, 1987, J UROLOGY, V137, P798, DOI 10.1016/S0022-5347(17)44214-5; Hirasawa M, 2003, P NATL ACAD SCI USA, V100, P6139, DOI 10.1073/pnas.0936131100; IACOVOU JW, 1990, J UROLOGY, V144, P775, DOI 10.1016/S0022-5347(17)39590-3; Jezior JR, 2001, BRIT J PHARMACOL, V134, P78, DOI 10.1038/sj.bjp.0704241; Jin XC, 2002, GASTROENTEROLOGY, V123, P827, DOI 10.1053/gast.2002.35388; KAMISHIMA T, 1992, AM J PHYSIOL, V263, pC69, DOI 10.1152/ajpcell.1992.263.1.C69; King JA, 1998, GEN PHARMACOL, V30, P131, DOI 10.1016/S0306-3623(97)00032-3; Klugbauer N, 2002, EUR J PHARMACOL, V447, P279, DOI 10.1016/S0014-2999(02)01850-2; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; MAGGI CA, 1989, BRIT J PHARMACOL, V98, P1021, DOI 10.1111/j.1476-5381.1989.tb14634.x; Masters JG, 1999, BRIT J PHARMACOL, V127, P996, DOI 10.1038/sj.bjp.0702640; Matsui M, 2000, P NATL ACAD SCI USA, V97, P9579, DOI 10.1073/pnas.97.17.9579; Matsui M, 2002, J NEUROSCI, V22, P10627; Mimata H, 1997, Int J Urol, V4, P591, DOI 10.1111/j.1442-2042.1997.tb00315.x; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Sakurada S, 2003, CIRC RES, V93, P548, DOI 10.1161/01.RES.0000090998.08629.60; Schneider T, 2004, J PHARMACOL EXP THER, V308, P47, DOI 10.1124/jpet.103.058248; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Seisenberger C, 2000, J BIOL CHEM, V275, P39193, DOI 10.1074/jbc.M006467200; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SIBLEY GNA, 1984, J PHYSIOL-LONDON, V354, P431, DOI 10.1113/jphysiol.1984.sp015386; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UCHIDA W, 1994, N-S ARCH PHARMACOL, V350, P398; Wellman GC, 2003, CELL CALCIUM, V34, P211, DOI 10.1016/S0143-4160(03)00124-6; Wess J, 2003, TRENDS PHARMACOL SCI, V24, P414, DOI 10.1016/S0165-6147(03)00195-0; Wibberley A, 2003, BRIT J PHARMACOL, V138, P757, DOI 10.1038/sj.bjp.0705109; Wu C, 2002, J PHYSIOL-LONDON, V538, P357, DOI 10.1113/jphysiol.2001.013191; Wu C, 1999, J UROLOGY, V162, P1840, DOI 10.1016/S0022-5347(05)68248-1	44	91	97	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1159	+		10.1096/fj.04-1516fje	http://dx.doi.org/10.1096/fj.04-1516fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15132976				2022-12-28	WOS:000221883200011
J	Kageyama, Y; Koshiji, M; To, KKW; Tian, YM; Ratcliffe, PJ; Huang, LE				Kageyama, Y; Koshiji, M; To, KKW; Tian, YM; Ratcliffe, PJ; Huang, LE			Leu-574 of human HIF-1a is a molecular determinant of prolyl hydroxylation	FASEB JOURNAL			English	Article						hypoxia; prolyl-4-hydroxylases; transcription factor	HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; ARNT TRANSCRIPTION FACTOR; STRUCTURAL BASIS; FACTOR 1-ALPHA; GENE-EXPRESSION; ALPHA-SUBUNIT; HIF-1-ALPHA; VHL	Hypoxia-inducible factor (HIF)-1alpha, a master regulator of oxygen homeostasis, regulates genes crucial for cell growth and survival. In normoxia, HIF-1alpha is constantly degraded via the ubiquitin-proteasome pathway. The von Hippel-Lindau (VHL) E3 ubiquitin ligase binds HIF-1alpha through specific recognition of hydroxylated Pro-402 or Pro-564, both of which are modified by the oxygen-dependent HIF prolyl hydroxylases (PHDs/HPHs). Despite the identification of a conserved Leu-X-X-Leu-Ala-Pro motif, the molecular requirement of HIF-1alpha for PHDs/HPHs binding remains elusive. Recently, we demonstrated that Leu-574 of human HIF-1alpha-10 residues downstream of Pro-564-is essential for VHL recognition. We show here that the role of Leu-574 is to recruit PHD2/HPH2 for Pro-564 hydroxylation. An antibody specific for hydroxylated Pro-564 has been used to determine the hydroxylation status; mutation or deletion of Leu-574 results in a significant decrease in the ratio of the hydroxylated HIF-1alpha to the total amount. The nine-residue spacing between Pro-564 and Leu-574 is not obligatory for prolyl hydroxylation. Furthermore, mutation of Leu-574 disrupts the binding of PHD2/HPH2, a key prolyl hydroxylase for oxygen-dependent proteolysis of HIF-1alpha. Hence, our findings indicate that Leu-574 is essential for recruiting PHD2/HPH2, thereby providing a molecular basis for modulating HIF-1alpha activity.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Henry wellcome Bldg Genom Med, Oxford OX3 7BN, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oxford	Huang, LE (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA.	huange@mail.nih.gov	To, Kenneth K W/M-4500-2013	To, Kenneth K W/0000-0003-2755-0283; Huang, Eric/0000-0002-6444-1708; Ratcliffe, Peter/0000-0002-2853-806X	DIVISION OF BASIC SCIENCES - NCI [Z01BC010424] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Huang LE, 2002, J BIOL CHEM, V277, P41750, DOI 10.1074/jbc.M207280200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pereira T, 2003, J BIOL CHEM, V278, P6816, DOI 10.1074/jbc.M209297200; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	43	59	60	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1028	+		10.1096/fj.03-1233fje	http://dx.doi.org/10.1096/fj.03-1233fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084514				2022-12-28	WOS:000221108800003
J	Layland, J; Cave, AC; Warren, C; Grieve, DJ; Sparks, E; Kentish, JC; Solaro, RJ; Shah, AM				Layland, J; Cave, AC; Warren, C; Grieve, DJ; Sparks, E; Kentish, JC; Solaro, RJ; Shah, AM			Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I	FASEB JOURNAL			English	Article						myocardial contractility; myofilament Ca2+ responsiveness	CALCIUM SENSITIVITY; VENTRICULAR MYOCYTES; MYOFILAMENT RESPONSE; NITRIC-OXIDE; PHOSPHORYLATION; CA2+; RELAXATION; ACTIVATION; PROTEINS; HEARTS	Gram negative endotoxemia is associated with an intrinsic impairment of cardiomyocyte contraction, in part due to a reduction in myofilament Ca2+ responsiveness. Endotoxemic rat hearts show increased cardiac troponin I (cTnI) phosphorylation at serines 23 and 24, residues required for the protein kinase A (PKA)-dependent reduction of myofilament Ca2+ sensitivity after beta-adrenoceptor stimulation. To investigate the functional significance of increased TnI phosphorylation in endotoxemia, we studied the contractile effects of systemic bacterial lipopolysaccharide (LPS) treatment in transgenic mice (TG) with cardiac-specific replacement of cTnI by slow skeletal TnI (ssTnI, which lacks the PKA phosphorylation sites) and matched nontransgenic littermates (NTG) on a CD1 background. In wild-type CD1 mice treated with LPS (6 mg/kg ip), after 16-18 h there was a significant reduction in the maximum rates of left ventricular pressure development and pressure decline in isolated Langendorff-perfused hearts compared with saline-treated controls and a decrease in isolated myocyte unloaded sarcomere shortening from 6.1 +/- 0.2 to 3.9 +/- 0.2% (1 Hz, 32 degrees C, P<0.05). Similarly, in NTG myocytes, endotoxemia reduced myocyte shortening by 42% from 6.7 0.2 to 3.9 +/- 0.1% (P<0.05) with no change in intracellular Ca2+ transients. However, in the TG group, LPS reduced myocyte shortening by only 13% from 7.5 +/- 0.2 to 6.5 +/- 0.2% (P<0.05). LPS treatment significantly reduced the positive inotropic effect of isoproterenol in NTG myocytes but not in TG myocytes, even though isoproterenol-induced increases in Ca2+ transient amplitude were similar in both groups. Only LPS-treated NTG hearts showed a significant increase in cTnI phosphorylation. Investigation of the sarcomere shortening-Ca2+ relationship in Triton-skinned cardiomyocytes revealed a significant reduction in myofilament Ca2+ sensitivity after LPS treatment in NTG myocytes, an effect that was substantially attenuated in TG myocytes. In conclusion, the replacement of cTnI with ssTnI in the heart provides significant protection against endotoxemia-induced cardiac contractile dysfunction, most probably by preserving myofilament Ca2+ responsiveness due to prevention of phosphorylation of TnI at PKA-sensitive sites.	Kings Coll London, GKT Sch Med, Dept Cardiol, Div Cardiovasc, London SE5 9PJ, England; Univ Illinois, Chicago, IL USA	University of London; King's College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shah, AM (corresponding author), Kings Coll London, GKT Sch Med, Dept Cardiol, Div Cardiovasc, Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk	Warren, Gordon/A-9794-2008; Grieve, David/F-5035-2010	Warren, Gordon/0000-0002-7073-8524; Shah, Ajay/0000-0002-6547-0631	NHLBI NIH HHS [R37 HL-22231] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DG, 1985, J MOL CELL CARDIOL, V17, P821, DOI 10.1016/S0022-2828(85)80097-3; BLUMENTHAL DK, 1978, J BIOL CHEM, V253, P334; CAPOGROSSI MC, 1986, J GEN PHYSIOL, V88, P589, DOI 10.1085/jgp.88.5.589; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47; Grocott-Mason RM, 1998, INTENS CARE MED, V24, P286, DOI 10.1007/s001340050570; Kaye DM, 1999, BIOCHEM BIOPH RES CO, V256, P398, DOI 10.1006/bbrc.1999.0346; KENTISH JC, 1991, PFLUG ARCH EUR J PHY, V419, P310, DOI 10.1007/BF00371112; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Khadour FH, 2002, AM J PHYSIOL-HEART C, V283, pH1108, DOI 10.1152/ajpheart.00549.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Layland J, 2002, J PHYSIOL-LONDON, V540, P457, DOI 10.1113/jphysiol.2001.014126; Layland J, 2004, J PHYSIOL-LONDON, V556, P835, DOI 10.1113/jphysiol.2004.061176; Lim CC, 2001, AM J PHYSIOL-HEART C, V281, pH969, DOI 10.1152/ajpheart.2001.281.2.H969; LINCOLN TM, 1978, J BIOL CHEM, V253, P337; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pena JR, 2004, CARDIOVASC RES, V61, P756, DOI 10.1016/j.cardiores.2003.12.019; PFITZER G, 1982, FEBS LETT, V149, P171, DOI 10.1016/0014-5793(82)81095-8; Powers FM, 1998, J MOL CELL CARDIOL, V30, P967, DOI 10.1006/jmcc.1998.0661; Rigby SL, 1998, AM J PHYSIOL-HEART C, V274, pH580, DOI 10.1152/ajpheart.1998.274.2.H580; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; SOLARO RJ, 2001, HDB PHYSL, P264; STAHL TJ, 1990, AM J PHYSIOL, V258, pH625, DOI 10.1152/ajpheart.1990.258.3.H625; Tavernier B, 2001, FASEB J, V15, P294, DOI 10.1096/fj.00-0433fje; Tavernier B, 2001, AM J RESP CRIT CARE, V163, P362, DOI 10.1164/ajrccm.163.2.2002128; Tavernier B, 1998, CARDIOVASC RES, V38, P472, DOI 10.1016/S0008-6363(98)00028-5; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Wu LL, 2001, AM J PHYSIOL-REG I, V281, pR408, DOI 10.1152/ajpregu.2001.281.2.R408; Yasuda S, 1997, CIRC RES, V81, P1011; YATES LD, 1983, J MOL BIOL, V168, P123, DOI 10.1016/S0022-2836(83)80326-X; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; ZHONG JM, 1997, AM J PHYSIOL-HEART C, V273, pH2312	36	126	128	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1137	+		10.1096/fj.04-2519fje	http://dx.doi.org/10.1096/fj.04-2519fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15601671				2022-12-28	WOS:000228865300006
J	Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM				Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM			Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways	FASEB JOURNAL			English	Article						neuroprotection; mitogen-activated protein kinase; phosphatidyl inositol-3 kinase; NO synthase	MICE OVEREXPRESSING ERYTHROPOIETIN; ARTERY-OCCLUSION; RETINAL DEGENERATION; NEURONAL APOPTOSIS; NITRIC-OXIDE; CELL-DEATH; INJURY; KINASE; NEUROPROTECTION; EXPRESSION	Apart from its hematopoietic function, erythropoietin (Epo) exerts neuroprotective functions in brain hypoxia and ischemia. To examine the mechanisms mediating Epo's neuroprotective activity in vivo, we made use of our transgenic mouse line tg21 that constitutively expresses human Epo in brain without inducing excessive erythrocytosis. We show that human Epo is expressed in tg21 brains and that cortical and striatal neurons carry the Epo receptor. After middle cerebral artery occlusion, human Epo potently protected brains of tg21 mice against ischemic injury, both when severe (90 min) and mild (30 min) ischemia was imposed. Histochemical studies revealed that Epo induced an activation of JAK-2, ERK-1/-2, and Akt pathways in the ischemic brain. This activation was associated with elevated Bcl-X-L and decreased NO synthase-1 and -2 levels in neurons. Intracerebroventricular injections of selective inhibitors of ERK-1/-2 (PD98059) or Akt (wortmannin) pathways revealed that both ERK-1/-2 and Akt were required for Epo's neuroprotective function, antagonization of either pathway completely abolishing tissue protection. On the other hand, ERK-1/-2 and Akt blockade did not reverse the neuronal NO synthase-1/-2 inhibition, indicating that Epo down-regulates these NO synthases in an ERK-1/-2 and Akt independent manner. On the basis of our data, the dual activation of ERK-1/-2 and Akt is crucial for Epo's neuroprotective activity.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich	Kilic, E (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	ertugrul.kilic@usz.ch	Hermann, Dirk/GZB-9350-2022; Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk M./AAT-3652-2021; Soliz, Jorge/AAA-9752-2022; Kilic, Ertugrul/W-4563-2018	Hermann, Dirk M./0000-0003-0198-3152; Kilic, Ertugrul/0000-0001-6494-8923; Soliz, Jorge/0000-0002-2335-5862; Bassetti, Claudio/0000-0002-4535-0245; Gassmann, Max/0000-0003-2750-8878				Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2005, SEMIN CELL DEV BIOL, V16, P531, DOI 10.1016/j.semcdb.2005.03.004; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hermann DM, 2001, NEUROBIOL DIS, V8, P655, DOI 10.1006/nbdi.2001.0399; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Hudson JQ, 2002, PHARMACOTHERAPY, V22, p141S, DOI 10.1592/phco.22.14.141S.33397; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Macdougall Iain C, 2003, Curr Hematol Rep, V2, P459; Maeda K, 1999, NEUROBIOL DIS, V6, P101, DOI 10.1006/nbdi.1998.0235; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Wang YM, 2005, BRAIN, V128, P52, DOI 10.1093/brain/awh325; Wenger RH, 1998, INT J MOL MED, V2, P317; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011	37	239	269	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2026	+		10.1096/fj.05-3941fje	http://dx.doi.org/10.1096/fj.05-3941fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	15556972				2022-12-28	WOS:000232991100027
J	Nunes, AF; Saraiva, MJ; Sousa, MM				Nunes, AF; Saraiva, MJ; Sousa, MM			Transthyretin knockouts are a new mouse model for increased neuropeptide Y	FASEB JOURNAL			English	Article						lipoprotein lipase; peptidylglycine alpha-amidating monooxygenase; peripheral nerve; depression	VASOACTIVE INTESTINAL POLYPEPTIDE; DORSAL-ROOT GANGLIA; MESSENGER-RNA; LIPOPROTEIN-LIPASE; EXPRESSION; PEPTIDE; CELLS; MONOOXYGENASE; RECEPTOR; BEHAVIOR	Transthyretin (TTR) has access to the brain and nerve through the blood and cerebrospinal fluid. To investigate TTR function in nervous system homeostasis, differential gene expression in wild-type (WT) and TTR knockout ( KO) mice was assessed. Peptidylglycine alpha-amidating monooxygenase (PAM), the rate-limiting enzyme in neuropeptide maturation, is overexpressed in the peripheral (PNS) and central nervous system (CNS) of TTR KOs that, consequently, display increased neuropeptide Y (NPY) levels. NPY acts on energy homeostasis by increasing white adipose tissue lipoprotein lipase (LPL) and decreasing thermogenesis; accordingly, we show increased LPL expression and activity in white adipose tissue, PNS, and CNS as well as decreased body temperature in TTR KOs. Associated to increased NPY levels, TTR KOs display increased carbohydrate consumption and preference. In neuronal cells, absence of TTR is related to increased PAM activity, NPY levels and LPL expression, reinforcing that TTR is involved in neuropeptide maturation and that increased NPY correlates with LPL overexpression in the nervous system. Furthermore, we provide molecular insights to the reduced depressive behavior of TTR KOs, as NPY is anti-depressant. Our findings demonstrate that TTR KOs are a model for increased NPY and that TTR plays a role in nervous system physiology.	Inst Mol & Cellular Biol, Mol Neurobiol Grp, P-4150180 Oporto, Portugal; Univ Porto, ICBAS, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Sousa, MM (corresponding author), Inst Mol & Cellular Biol, Mol Neurobiol Grp, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	msousa@ibmc.up.pt	Sousa, Monica/K-4367-2013; Saraiva, Maria João/K-3907-2013	Sousa, Monica/0000-0002-4524-2260; Saraiva, Maria João/0000-0002-3360-6899				BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; Chen XL, 1997, AM J PHYSIOL-HEART C, V273, pH1737, DOI 10.1152/ajpheart.1997.273.4.H1737; Cougnon-Aptel N, 1999, NEUROSCI LETT, V259, P45, DOI 10.1016/S0304-3940(98)00900-8; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; ERNSTROM U, 1995, FEBS LETT, V360, P177, DOI 10.1016/0014-5793(95)00095-Q; ESTEBAN J, 1989, LIFE SCI, V45, P2395, DOI 10.1016/0024-3205(89)90002-7; FORD TA, 1993, J MOL NEUROSCI, V4, P97, DOI 10.1007/BF02782122; Fraboulet S, 1996, ENDOCRINOLOGY, V137, P5493, DOI 10.1210/en.137.12.5493; Heilig M, 2004, NEUROPEPTIDES, V38, P213, DOI 10.1016/j.npep.2004.05.002; HEILIG M, 1988, EUR J PHARMACOL, V147, P465, DOI 10.1016/0014-2999(88)90182-3; Herzog H, 2003, EUR J PHARMACOL, V480, P21, DOI 10.1016/j.ejphar.2003.08.089; Hiruma H, 2000, BRAIN RES, V883, P184, DOI 10.1016/S0006-8993(00)02892-4; Huey PU, 2002, J LIPID RES, V43, P19; Huey PU, 1998, J LIPID RES, V39, P2135; Inui A, 1998, P ASSOC AM PHYSICIAN, V110, P171; Kohno K, 1997, AM J PATHOL, V150, P1497; Liz MA, 2004, J BIOL CHEM, V279, P21431, DOI 10.1074/jbc.M402212200; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; Pedrazzini T, 2003, CELL MOL LIFE SCI, V60, P350, DOI 10.1007/s000180300029; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; PULFORD D, 2002, SOC NEUR 32 ANN M WA; RAZ A, 1969, J BIOL CHEM, V244, P3230; Redrobe JP, 2002, NEUROPSYCHOPHARMACOL, V26, P615, DOI 10.1016/S0893-133X(01)00403-1; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Saegusa T, 2003, J VET MED SCI, V65, P1365, DOI 10.1292/jvms.65.1365; Serot JM, 1997, J NEUROL NEUROSUR PS, V63, P506, DOI 10.1136/jnnp.63.4.506; Shi TJS, 1999, NEUROSCIENCE, V93, P741; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; Sousa JC, 2004, J NEUROCHEM, V88, P1052, DOI 10.1046/j.1471-4159.2003.02309.x; Sousa MM, 2003, PROG NEUROBIOL, V71, P385, DOI 10.1016/j.pneurobio.2003.11.002; Sousa MM, 2000, J LIPID RES, V41, P58; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; SPINDEL ER, 1987, GEN COMP ENDOCR, V67, P67, DOI 10.1016/0016-6480(87)90206-1; STENFORS C, 1989, J NEUROSCI RES, V24, P445, DOI 10.1002/jnr.490240315; Stogner KA, 2000, EUR J PHARMACOL, V387, pR9, DOI 10.1016/S0014-2999(99)00800-6; Sunman JA, 2004, MOL CARCINOGEN, V41, P231, DOI 10.1002/mc.20060; THEODORSSONNORHEIM E, 1987, LIFE SCI, V41, P845, DOI 10.1016/0024-3205(87)90177-9; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Thorsell A, 2000, P NATL ACAD SCI USA, V97, P12852, DOI 10.1073/pnas.220232997; Valenzuela RF, 2000, J NEUROL SCI, V173, P140, DOI 10.1016/S0022-510X(99)00316-0; Vasquez PAJ, 2000, BEHAV BRAIN RES, V111, P115, DOI 10.1016/S0166-4328(00)00142-X; White DM, 1996, NEUROSCIENCE, V73, P881, DOI 10.1016/0306-4522(96)00055-3; WIDDOWSON PS, 1992, J NEUROCHEM, V59, P73, DOI 10.1111/j.1471-4159.1992.tb08877.x; WIDERLOV E, 1988, J PSYCHIATR RES, V22, P69, DOI 10.1016/0022-3956(88)90030-1; ZACHRISSON O, 1995, NEUROSCI LETT, V194, P89, DOI 10.1016/0304-3940(95)11735-F	45	64	70	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					166	+		10.1096/fj.05-4106fje	http://dx.doi.org/10.1096/fj.05-4106fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16263939				2022-12-28	WOS:000234053100022
J	Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R				Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R			Control of ion transport in mammalian airways by protease activated receptors type 2 (PAR-2)	FASEB JOURNAL			English	Article						airway epithelium; trypsin; tryptase	CYSTIC-FIBROSIS MOUSE; CL-SECRETION; INFLAMMATION; INHIBITION; MODULATION; EXPRESSION; EPITHELIUM; CHANNELS	Protease-activated receptors (PARs) are widely distributed in human airways. They couple to G-proteins and are activated after proteolytic cleavage of the N terminus of the receptor. Evidence is growing that PAR subtype 2 plays a pivotal role in inflammatory airway diseases, such as allergic asthma or bronchitis. However, nothing is known about the effects of PAR-2 on electrolyte transport in the native airways. PAR-2 is expressed in airway epithelial cells, where they are activated by mast cell tryptase, neutrophil proteinase 3, or trypsin. Recent studies produced conflicting results about the functional consequence of PAR-2 stimulation. Here we report that stimulation of PAR-2 receptors in mouse and human airways leads to a change in electrolyte transport and a shift from absorption to secretion. Although PAR-2 appears to be expressed on both sides of the epithelium, only basolateral stimulation results in inhibition of amiloride sensitive Na+ conductance and stimulation of both luminal Cl- channels and basolateral K+ channels. The present data indicate that these changes occur through activation of phospholipase C and increase in intracellular Ca2+, which activates basolateral SK4 K+ channels and luminal Ca2+-dependent Cl- channels. In addition, the present data suggest a PAR-2 mediated release of prostaglandin E2, which may contribute to the secretory response. In conclusion, these results provide further evidence for a role of PAR-2 in inflammatory airway disease: stimulation of these receptors may cause accumulation of airway surface liquid, which, however, may help to flush noxious stimuli away from the affected airways.	Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany; Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Heidelberg Univ, Kinderklin 3, Mukoviszidose Zentrum, Heidelberg, Germany	University of Regensburg; University of Queensland; Ruprecht Karls University Heidelberg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu.au	Markovich, Daniel/F-7884-2012; Mall, Marcus A./AAA-1498-2022; Schreiber, Robert/Q-7550-2019	Mall, Marcus A./0000-0002-4057-2199; Kunzelmann, Karl/0000-0002-4583-7037				Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Cicala C, 2001, BRIT J PHARMACOL, V132, P1229, DOI 10.1038/sj.bjp.0703934; Cocks TM, 2001, PULM PHARMACOL THER, V14, P183, DOI 10.1006/pupt.2001.0285; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; KAWABATA A, 2004, IN PRESS J PHARM EXP; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; KOSLOWSKY T, 1994, PFLUG ARCH EUR J PHY, V428, P597, DOI 10.1007/BF00374583; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; Lan RS, 2004, AM J PHYSIOL-LUNG C, V286, pL388, DOI 10.1152/ajplung.00286.2003; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mall M, 2003, PEDIATR RES, V53, P608, DOI 10.1203/01.PDR.0000057204.51420.DC; Mall M, 2000, AM J RESP CELL MOL, V23, P283, DOI 10.1165/ajrcmb.23.3.4060; MALL M, 2002, AM J PHYSIOL, V282, P200; Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Oceandy D, 2003, J MEMBRANE BIOL, V192, P159, DOI 10.1007/s00232-002-1072-y; Oceandy D, 2002, HUM MOL GENET, V11, P1059, DOI 10.1093/hmg/11.9.1059; Reed DE, 2003, J PHYSIOL-LONDON, V547, P531, DOI 10.1113/jphysiol.2002.032011; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Risse PA, 2004, LIFE SCI, V75, P991, DOI 10.1016/j.lfs.2004.02.008; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Vergnolle N, 2004, BRIT J PHARMACOL, V141, P1264, DOI 10.1038/sj.bjp.0705750; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	38	89	90	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					969	+		10.1096/fj.04-2469fje	http://dx.doi.org/10.1096/fj.04-2469fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15809358				2022-12-28	WOS:000228865300031
J	Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M				Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M			5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking	FASEB JOURNAL			English	Article; Proceedings Paper	8th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases	SEP, 2003	Chicago, IL			eicosanoids; mesothelioma	CANCER-THERAPY; MALIGNANT MESOTHELIOMA; LEUKOTRIENE SYNTHESIS; CELL-SURVIVAL; EXPRESSION; PROTEIN; CYCLOOXYGENASE-2; OVEREXPRESSION; BIOSYNTHESIS; LINES	5-Lipoxygenase (5-LO) promotes cancer cell proliferation and survival by unclear mechanisms. Here, we show that 5-LO expression and activity were induced by genotoxic agents in a p53-independent manner and antagonized p53- or genotoxic drug-induced apoptosis in a variety of cancer cells. 5-LO inhibited p53- governed transactivation of the pro-apoptotic genes bax and pig3 but not of p21(WAF1/CIP1) or mdm2. This may be explained by 5-LO capability to inhibit the binding of p53 to promyelocytic leukemia protein (PML) and p53 subnuclear relocalization into PML-nuclear bodies in response to genotoxic stress. Interestingly, 5-LO activity appears to be involved in nuclear retention and inactivation of wild-type p53 in malignant mesothelioma cells. In these cells, genetic or pharmacological inhibition of 5-LO enabled suppression of in vitro tumorigenicity by low doses of chemotherapeutic drugs. Together, these results uncover novel functions of 5-LO and contribute to the understanding of 5-LO involvement in tumor progression. Moreover, they provide a rationale to the therapeutic use of 5-LO inhibitors to enhance cancer chemosensitivity in selected tumors.	Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, I-60131 Ancona, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Rome, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Dept Biomed Sci, Chieti, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Aging Res Ctr, Chieti, Italy; NCI, Neural Dev Grp, Mouse Canc Genet Program, Frederick, MD 21701 USA	Marche Polytechnic University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Catalano, A (corresponding author), Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, Via Ranieri, I-60131 Ancona, Italy.	catgfp@yahoo.it	Soddu, Silvia/K-2467-2018; Procopio, Antonio Domenico/AAB-2451-2021; Soddu, Silvia/ABH-6774-2020; Romano, Mario/I-7986-2012	Soddu, Silvia/0000-0001-8526-0044; Procopio, Antonio Domenico/0000-0001-6897-8724; Soddu, Silvia/0000-0001-8526-0044; Romano, Mario/0000-0001-8512-1458				Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Catalano A, 2004, CRIT REV ONCOL HEMAT, V50, P101, DOI 10.1016/j.critrevonc.2003.10.001; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; GIACCIA AJ, 1998, GENE DEV, V14, P2015; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; Hong SH, 1999, CANCER RES, V59, P2223; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Prives C, 1999, J PATHOL, V187, P112; REID GK, 1990, J BIOL CHEM, V265, P19818; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Vivo C, 2003, BRIT J CANCER, V88, P388, DOI 10.1038/sj.bjc.6600736; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	35	102	104	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1740	+		10.1096/fj.04-2258fje	http://dx.doi.org/10.1096/fj.04-2258fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15375079	Green Published			2022-12-28	WOS:000224243200022
